,CID,name,smiles,7.1,8.1,8.2,8.5,8.6,8.7
0,50001,"1-[4-[[(4S)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]-4-propan-2-ylpiperazine",CC(C)N1CCN(CC1)C2=CC=C(C=C2)OC[C@H]3COC(O3)(CN4C=NC=N4)C5=C(C=C(C=C5)Cl)Cl,,,,,,
1,50002,"5-Phenacylideneimidazolidine-2,4-dione",C1=CC=C(C=C1)C(=O)C=C2C(=O)NC(=O)N2,,,,,,
2,50003,CID 50003,C1=CC(=CC=C1C(=O)C=C2C(=O)NC(=O)N2)Cl,,,,,,
3,50004,CID 50004,C1=CC(=CC=C1C(=O)C=C2C(=O)NC(=O)N2)Br,,,,,,
4,50005,2-Isopropoxyethyl carbamate,CC(C)OCCOC(=O)N,,,,,,
5,50006,"1,5-Dimethylhexyl acetate",CC(C)CCCC(C)OC(=O)C,,,,,,
6,50007,"1,4-Dimethylheptylamine",CCCC(C)CCC(C)N,,,,,,
7,50008,Isobutyl (hydroxymethyl)carbamate,CC(C)COC(=O)NCO,,,,,,
8,50009,"CARBONIC ACID, BUTYL-p-IODOBENZYL ESTER",CCCCOC(=O)OCC1=CC=C(C=C1)I,,,,,,
9,50010,"Carbonic acid, hexyl benzyl ester",CCCCCCOC(=O)OCC1=CC=CC=C1,,,,,,
10,50011,Hexyl m-iodobenzyl carbonate,CCCCCCOC(=O)OCC1=CC(=CC=C1)I,,,,,,
11,50012,p-Iodobenzyl hexanoate,CCCCCC(=O)OCC1=CC=C(C=C1)I,,,,,,
12,50013,"OCTANOIC ACID, p-IODOBENZYL ESTER",CCCCCCCC(=O)OCC1=CC=C(C=C1)I,,,,,,
13,50014,"CARBAMIC ACID, (p-IODOBENZYL)-, HEXYL ESTER",CCCCCCOC(=O)NCC1=CC=C(C=C1)I,,,,,,
14,50015,"Hexanoic acid, 6-((((4-iodophenyl)methoxy)carbonyl)amino)-",C1=CC(=CC=C1COC(=O)NCCCCCC(=O)O)I,,,,,,
15,50016,CID 50016,CC(=O)N(C)C1=C(C(=C(C(=C1I)C(=O)NCC(=O)NC2=C(C(=C(C(=C2I)C(=O)[O-])I)C(=O)NCCO)I)I)C(=O)NC)I.[Na+],,,,,,
16,50017,CID 50017,CCCC(CCCCCCCCC=CS(=O)(=O)[O-])S(=O)(=O)[O-].[Na+].[Na+],,,,,,
17,50018,CID 50018,CCCC(CCCCCCCCC=CS(=O)(=O)O)S(=O)(=O)O,,,,,,
18,50019,Manganous dicarbonate,C(=O)([O-])[O-].C(=O)([O-])[O-].[Mn+2],,,,,,
19,50020,"4-Ethoxybenzene-1,3-diamine sulfate",CCOC1=C(C=C(C=C1)N)N.OS(=O)(=O)O,,,,,,
20,50021,4-Methoxy-5-nitro-1H-imidazole,COC1=C(NC=N1)[N+](=O)[O-],,,,,,
21,50022,CID 50022,CCCCCCCCCCCCCCS(=O)(=O)[O-].[Na+],,,,,,
22,50023,1-Tetradecanesulfonic acid,CCCCCCCCCCCCCCS(=O)(=O)O,,,,,,
23,50024,"2-Butenoic acid, 3,7-dimethyl-6-octen-1-yl ester",CC=CC(=O)OCCC(C)CCC=C(C)C,,,,,,
24,50025,CID 50025,C1=CC=C2C(=C1)C3=C4C(=C2COS(=O)(=O)[O-])C=CC5=CC=CC(=C54)C=C3.[Na+],,,,,,
25,50026,6-Sulfooxymethylbenzo(a)pyrene,C1=CC=C2C(=C1)C3=C4C(=C2COS(=O)(=O)O)C=CC5=CC=CC(=C54)C=C3,,,,,['6-Sulfooxymethylbenzo(a)pyrene is a known human metabolite of 6-hydroxymethylbenzo[a]pyrene.'],
26,50027,CID 50027,CCCCN=C(C1=CC=C(C=C1)OC)S,,,,,,
27,50028,CID 50028,CC(C)CN=C(C1=CC=C(C=C1)Cl)S,,,,,,
28,50029,CID 50029,COC1=CC=CC=C1C(=NC2CCCCC2)S,,,,,,
29,50030,"[(4,6-Dichloropyridin-2-yl)oxy]acetic acid",C1=C(C=C(N=C1OCC(=O)O)Cl)Cl,,,,,,
30,50031,"(+)-alpha-Cyano-3-phenoxybenzyl (+)-cis-3-(2-chloro-3,3,3-trifluoroprop-1-en-1-yl)-2,2-dimethylcyclopropane carboxylate",CC1([C@@H]([C@@H]1C(=O)OC(C#N)C2=CC(=CC=C2)OC3=CC=CC=C3)C=C(C(F)(F)F)Cl)C,,,,,,
31,50032,o-Methoxycarbanilic acid 2-(dimethylamino)ethyl ester hydrochloride,C[NH+](C)CCOC(=O)NC1=CC=CC=C1OC.[Cl-],,,,,,
32,50033,2-(dimethylamino)ethyl N-(2-methoxyphenyl)carbamate,CN(C)CCOC(=O)NC1=CC=CC=C1OC,,,,,,
33,50034,m-Methoxycarbanilic acid 2-(dimethylamino)ethyl ester hydrochloride,C[NH+](C)CCOC(=O)NC1=CC(=CC=C1)OC.[Cl-],,,,,,
34,50035,2-(dimethylamino)ethyl N-(3-methoxyphenyl)carbamate,CN(C)CCOC(=O)NC1=CC(=CC=C1)OC,,,,,,
35,50036,p-Methoxycarbanilic acid 2-(dimethylamino)ethyl ester hydrochloride,C[NH+](C)CCOC(=O)NC1=CC=C(C=C1)OC.[Cl-],,,,,,
36,50037,2-dimethylaminoethyl N-(4-methoxyphenyl)carbamate,CN(C)CCOC(=O)NC1=CC=C(C=C1)OC,,,,,,
37,50038,2-(Dimethylamino)ethyl m-ethoxycarbanilate hydrochloride,CCOC1=CC=CC(=C1)NC(=O)OCC[NH+](C)C.[Cl-],,,,,,
38,50039,2-dimethylaminoethyl N-(3-ethoxyphenyl)carbamate,CCOC1=CC=CC(=C1)NC(=O)OCCN(C)C,,,,,,
39,50040,2-(Dimethylamino)ethyl p-ethoxycarbanilate hydrochloride,CCOC1=CC=C(C=C1)NC(=O)OCC[NH+](C)C.[Cl-],,,,,,
40,50041,2-dimethylaminoethyl N-(4-ethoxyphenyl)carbamate,CCOC1=CC=C(C=C1)NC(=O)OCCN(C)C,,,,,,
41,50042,o-Propoxycarbanilic acid 2-(dimethylamino)ethyl ester hydrochloride,CCCOC1=CC=CC=C1NC(=O)OCC[NH+](C)C.[Cl-],,,,,,
42,50043,2-dimethylaminoethyl N-(2-propoxyphenyl)carbamate,CCCOC1=CC=CC=C1NC(=O)OCCN(C)C,,,,,,
43,50044,m-Propoxycarbanilic acid 2-(dimethylamino)ethyl ester hydrochloride,CCCOC1=CC=CC(=C1)NC(=O)OCC[NH+](C)C.[Cl-],,,,,,
44,50045,2-dimethylaminoethyl N-(3-propoxyphenyl)carbamate,CCCOC1=CC=CC(=C1)NC(=O)OCCN(C)C,,,,,,
45,50046,p-Propoxycarbanilic acid 2-(dimethylamino)ethyl ester hydrochloride,CCCOC1=CC=C(C=C1)NC(=O)OCC[NH+](C)C.[Cl-],,,,,,
46,50047,2-dimethylaminoethyl N-(4-propoxyphenyl)carbamate,CCCOC1=CC=C(C=C1)NC(=O)OCCN(C)C,,,,,,
47,50048,2-(Dimethylamino)ethyl o-butoxycarbanilate hydrochloride,CCCCOC1=CC=CC=C1NC(=O)OCC[NH+](C)C.[Cl-],,,,,,
48,50049,2-dimethylaminoethyl N-(2-butoxyphenyl)carbamate,CCCCOC1=CC=CC=C1NC(=O)OCCN(C)C,,,,,,
49,50050,2-(Dimethylamino)ethyl m-butoxycarbanilate hydrochloride,CCCCOC1=CC=CC(=C1)NC(=O)OCC[NH+](C)C.[Cl-],,,,,,
50,50051,2-dimethylaminoethyl N-(3-butoxyphenyl)carbamate,CCCCOC1=CC=CC(=C1)NC(=O)OCCN(C)C,,,,,,
51,50052,2-(Dimethylamino)ethyl p-butoxycarbanilate hydrochloride,CCCCOC1=CC=C(C=C1)NC(=O)OCC[NH+](C)C.[Cl-],,,,,,
52,50053,2-dimethylaminoethyl N-(4-butoxyphenyl)carbamate,CCCCOC1=CC=C(C=C1)NC(=O)OCCN(C)C,,,,,,
53,50054,o-Pentyloxycarbanilic acid 2-(dimethylamino)ethyl ester hydrochloride,CCCCCOC1=CC=CC=C1NC(=O)OCC[NH+](C)C.[Cl-],,,,,,
54,50055,2-dimethylaminoethyl N-(2-pentoxyphenyl)carbamate,CCCCCOC1=CC=CC=C1NC(=O)OCCN(C)C,,,,,,
55,50056,m-Pentyloxycarbanilic acid 2-(dimethylamino)ethyl ester hydrochloride,CCCCCOC1=CC=CC(=C1)NC(=O)OCC[NH+](C)C.[Cl-],,,,,,
56,50057,2-dimethylaminoethyl N-(3-pentoxyphenyl)carbamate,CCCCCOC1=CC=CC(=C1)NC(=O)OCCN(C)C,,,,,,
57,50058,p-Pentyloxycarbanilic acid 2-(dimethylamino)ethyl ester hydrochloride,CCCCCOC1=CC=C(C=C1)NC(=O)OCC[NH+](C)C.[Cl-],,,,,,
58,50059,2-dimethylaminoethyl N-(4-pentoxyphenyl)carbamate,CCCCCOC1=CC=C(C=C1)NC(=O)OCCN(C)C,,,,,,
59,50060,2-(Dimethylamino)ethyl o-(hexyloxy)carbanilate hydrochloride,CCCCCCOC1=CC=CC=C1NC(=O)OCC[NH+](C)C.[Cl-],,,,,,
60,50061,2-dimethylaminoethyl N-(2-hexoxyphenyl)carbamate,CCCCCCOC1=CC=CC=C1NC(=O)OCCN(C)C,,,,,,
61,50062,2-(Dimethylamino)ethyl m-(hexyloxy)carbanilate hydrochloride,CCCCCCOC1=CC=CC(=C1)NC(=O)OCC[NH+](C)C.[Cl-],,,,,,
62,50063,2-dimethylaminoethyl N-(3-hexoxyphenyl)carbamate,CCCCCCOC1=CC=CC(=C1)NC(=O)OCCN(C)C,,,,,,
63,50064,2-(Dimethylamino)ethyl o-(heptyloxy)carbanilate hydrochloride,CCCCCCCOC1=CC=CC=C1NC(=O)OCC[NH+](C)C.[Cl-],,,,,,
64,50065,2-dimethylaminoethyl N-(2-heptoxyphenyl)carbamate,CCCCCCCOC1=CC=CC=C1NC(=O)OCCN(C)C,,,,,,
65,50066,"CARBANILIC ACID, m-HEPTYLOXY-, 2-(DIMETHYLAMINO)ETHYL ESTER, HYDROCHLORIDE",CCCCCCCOC1=CC=CC(=C1)NC(=O)OCC[NH+](C)C.[Cl-],,,,,,
66,50067,2-dimethylaminoethyl N-(3-heptoxyphenyl)carbamate,CCCCCCCOC1=CC=CC(=C1)NC(=O)OCCN(C)C,,,,,,
67,50068,2-(Dimethylamino)ethyl p-heptyloxycarbanilate hydrochloride,CCCCCCCOC1=CC=C(C=C1)NC(=O)OCC[NH+](C)C.[Cl-],,,,,,
68,50069,2-dimethylaminoethyl N-(4-heptoxyphenyl)carbamate,CCCCCCCOC1=CC=C(C=C1)NC(=O)OCCN(C)C,,,,,,
69,50070,o-Octyloxycarbanilic acid 2-(dimethylamino)ethyl ester hydrochloride,CCCCCCCCOC1=CC=CC=C1NC(=O)OCC[NH+](C)C.[Cl-],,,,,,
70,50071,2-dimethylaminoethyl N-(2-octoxyphenyl)carbamate,CCCCCCCCOC1=CC=CC=C1NC(=O)OCCN(C)C,,,,,,
71,50072,m-Octyloxycarbanilic acid 2-(dimethylamino)ethyl ester hydrochloride,CCCCCCCCOC1=CC=CC(=C1)NC(=O)OCC[NH+](C)C.[Cl-],,,,,,
72,50073,2-dimethylaminoethyl N-(3-octoxyphenyl)carbamate,CCCCCCCCOC1=CC=CC(=C1)NC(=O)OCCN(C)C,,,,,,
73,50074,p-Octyloxycarbanilic acid 2-(dimethylamino)ethyl ester hydrochloride,CCCCCCCCOC1=CC=C(C=C1)NC(=O)OCC[NH+](C)C.[Cl-],,,,,,
74,50075,2-dimethylaminoethyl N-(4-octoxyphenyl)carbamate,CCCCCCCCOC1=CC=C(C=C1)NC(=O)OCCN(C)C,,,,,,
75,50076,o-Nonyloxycarbanilic acid 2-(dimethylamino)ethyl ester hydrochloride,CCCCCCCCCOC1=CC=CC=C1NC(=O)OCC[NH+](C)C.[Cl-],,,,,,
76,50077,2-dimethylaminoethyl N-(2-nonoxyphenyl)carbamate,CCCCCCCCCOC1=CC=CC=C1NC(=O)OCCN(C)C,,,,,,
77,50078,m-Nonyloxycarbanilic acid 2-(dimethylamino)ethyl ester hydrochloride,CCCCCCCCCOC1=CC=CC(=C1)NC(=O)OCC[NH+](C)C.[Cl-],,,,,,
78,50079,2-dimethylaminoethyl N-(3-nonoxyphenyl)carbamate,CCCCCCCCCOC1=CC=CC(=C1)NC(=O)OCCN(C)C,,,,,,
79,50080,p-Nonyloxycarbanilic acid 2-(dimethylamino)ethyl ester hydrochloride,CCCCCCCCCOC1=CC=C(C=C1)NC(=O)OCC[NH+](C)C.[Cl-],,,,,,
80,50081,2-(dimethylamino)ethyl N-(4-nonoxyphenyl)carbamate,CCCCCCCCCOC1=CC=C(C=C1)NC(=O)OCCN(C)C,,,,,,
81,50082,2-(Dimethylamino)ethyl o-decyloxycarbanilate hydrochloride,CCCCCCCCCCOC1=CC=CC=C1NC(=O)OCC[NH+](C)C.[Cl-],,,,,,
82,50083,2-dimethylaminoethyl N-(2-decoxyphenyl)carbamate,CCCCCCCCCCOC1=CC=CC=C1NC(=O)OCCN(C)C,,,,,,
83,50084,2-(Dimethylamino)ethyl m-decyloxycarbanilate hydrochloride,CCCCCCCCCCOC1=CC=CC(=C1)NC(=O)OCC[NH+](C)C.[Cl-],,,,,,
84,50085,2-(dimethylamino)ethyl N-(3-decoxyphenyl)carbamate,CCCCCCCCCCOC1=CC=CC(=C1)NC(=O)OCCN(C)C,,,,,,
85,50086,2-(Dimethylamino)ethyl p-decyloxycarbanilate hydrochloride,CCCCCCCCCCOC1=CC=C(C=C1)NC(=O)OCC[NH+](C)C.[Cl-],,,,,,
86,50087,2-dimethylaminoethyl N-(4-decoxyphenyl)carbamate,CCCCCCCCCCOC1=CC=C(C=C1)NC(=O)OCCN(C)C,,,,,,
87,50088,Bepridil hydrochloride,CC(C)COCC(CN(CC1=CC=CC=C1)C2=CC=CC=C2)N3CCCC3.Cl,,,"['Agents used for the treatment or prevention of cardiac arrhythmias. They may affect the polarization-repolarization phase of the action potential, its excitability or refractoriness, or impulse conduction or membrane responsiveness within cardiac fibers. Anti-arrhythmia agents are often classed into four main groups according to their mechanism of action: sodium channel blockade, beta-adrenergic blockade, repolarization prolongation, or calcium channel blockade. (See all compounds classified as Anti-Arrhythmia Agents.)', 'A class of drugs that act by selective inhibition of calcium influx through cellular membranes. (See all compounds classified as Calcium Channel Blockers.)', 'Drugs used in the treatment of acute or chronic vascular HYPERTENSION regardless of pharmacological mechanism. Among the antihypertensive agents are DIURETICS; (especially DIURETICS, THIAZIDE); ADRENERGIC BETA-ANTAGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; GANGLIONIC BLOCKERS; and VASODILATOR AGENTS. (See all compounds classified as Antihypertensive Agents.)', 'Drugs used to cause dilation of the blood vessels. (See all compounds classified as Vasodilator Agents.)']",,,
88,50089,Dihydrohymenovin,CC1CC2C(CC3(C1CC(OC3O)O)C)C(C(=O)O2)C,,,,,,
89,50090,"(E)-isopentyl 3,7-dimethylocta-2,6-dienoate",CC(C)CCOC(=O)C=C(C)CCC=C(C)C,,,,,,
90,50091,2-(Dimethylamino)ethyl o-ethoxycarbanilate hydrochloride,CCOC1=CC=CC=C1NC(=O)OCC[NH+](C)C.[Cl-],,,,,,
91,50092,2-dimethylaminoethyl N-(2-ethoxyphenyl)carbamate,CCOC1=CC=CC=C1NC(=O)OCCN(C)C,,,,,,
92,50093,"BENZ(a)ANTHRACENE, 7,12-DIMETHYL-2-FLUORO-",CC1=C2C=CC3=C(C2=C(C4=CC=CC=C14)C)C=C(C=C3)F,,,,,,
93,50094,"BENZ(a)ANTHRACENE, 7,12-DIMETHYL-1-FLUORO-",CC1=C2C=CC3=C(C2=C(C4=CC=CC=C14)C)C(=CC=C3)F,,,,,,
94,50095,"ANDROSTA-1,4-DIEN-3-ONE, 17,17-BIS(METHYLTHIO)-9-FLUORO-11-HYDROXY-, (11-beta)-",C[C@]12C[C@@H]([C@]3([C@H]([C@@H]1CCC2(SC)SC)CCC4=CC(=O)C=C[C@@]43C)F)O,,,,,,
95,50096,"(3R,4R)-7,12-Dimethyl-3,4-dihydrobenzo(a)anthracene-3,4-diol",CC1=C2C=CC3=C(C2=C(C4=CC=CC=C14)C)C=C[C@H]([C@@H]3O)O,,,,,,
96,50097,"BENZ(a)ANTHRACENE, 10,11-DIHYDRO-10,11-DIHYDROXY-7,12-DIMETHYL-, (E)-",CC1=C2C=CC3=CC=CC=C3C2=C(C4=C1C=C[C@@H]([C@H]4O)O)C,,,,,,
97,50098,"4-Methyl-2,3-dinitrophenol",CC1=C(C(=C(C=C1)O)[N+](=O)[O-])[N+](=O)[O-],,,,,,
98,50099,"2,2',3,4',6-Pentachlorobiphenyl",C1=CC(=C(C=C1Cl)Cl)C2=C(C=CC(=C2Cl)Cl)Cl,,,,,,
99,50100,"2,2',3,4',5-Pentachlorobiphenyl",C1=CC(=C(C=C1Cl)Cl)C2=C(C(=CC(=C2)Cl)Cl)Cl,,,,,,
100,50101,"2,3',4,5,5'-Pentachlorobiphenyl",C1=C(C=C(C=C1Cl)Cl)C2=CC(=C(C=C2Cl)Cl)Cl,,,,,,
101,50102,"2,2',3,3',4,5,6-Heptachlorobiphenyl",C1=CC(=C(C(=C1)Cl)Cl)C2=C(C(=C(C(=C2Cl)Cl)Cl)Cl)Cl,,,,,,
102,50103,"2,2',3,3',4,5,5',6-Octachlorobiphenyl",C1=C(C=C(C(=C1C2=C(C(=C(C(=C2Cl)Cl)Cl)Cl)Cl)Cl)Cl)Cl,,,,,,
103,50104,CID 50104,CCCCCCCCC=CCCCCCCCCC(=O)OC(C)(C)C(C(C)C)OC(=O)CCCCCCCC=CCCCCCCCC,,,,,,
104,50105,"Azetidine, 1-(3,4,5-trimethoxythiobenzoyl)-",COC1=CC(=CC(=C1OC)OC)C(=S)N2CCC2,,,,,,
105,50106,"2,6-Diethylquinoline",CCC1=CC2=C(C=C1)N=C(C=C2)CC,,,,,,
106,50107,Proglinazine-ethyl,CCOC(=O)CNC1=NC(=NC(=N1)Cl)NC(C)C,,,,,,
107,50108,Isosulfan blue,CCN(CC)C1=CC=C(C=C1)C(=C2C=CC(=[N+](CC)CC)C=C2)C3=C(C=CC(=C3)S(=O)(=O)[O-])S(=O)(=O)[O-].[Na+],,,['Chemicals and substances that impart color including soluble dyes and insoluble pigments. They are used in INKS; PAINTS; and as INDICATORS AND REAGENTS. (See all compounds classified as Coloring Agents.)'],"['Following subcutaneous administration, isosulfan blue injection 1% binds to serum proteins and is picked up by the lymphatic vessels. Thus, the lymphatic vessels are delineated by the blue dye.', 'It is not known whether this drug is excreted in human milk.', 'Up to 10% of the subcutaneously administered dose of isosulfan blue injection 1% is excreted unchanged in the urine in 24 hours in humans.']",,
108,50109,"1,3-Benzenediamine, 4-chloro-, sulfate (1:1)",C1=CC(=C(C=C1N)N)Cl.OS(=O)(=O)O,,,,,,
109,50110,CID 50110,C1=CC(=N)C(=N)C=C1N(O)O.OS(=O)(=O)O,,,,,,
110,50111,CID 50111,C1=CC(=N)C(=CC1=N)N(O)O.OS(=O)(=O)O,,,,,,
111,50112,"[(2R,3S,4S,5R,6R)-2-[(2R,3S,4S,5S,6S)-2-[2-[[6-amino-2-[3-amino-1-[(2,3-diamino-3-oxopropyl)amino]-3-oxopropyl]-5-methylpyrimidine-4-carbonyl]amino]-3-[[3-hydroxy-5-[[3-hydroxy-1-oxo-1-[2-[4-[4-[3-[[(1S)-1-phenylethyl]amino]propylcarbamoyl]-1,3-thiazol-2-yl]-1,3-thiazol-2-yl]ethylamino]butan-2-yl]amino]-4-methyl-5-oxopentan-2-yl]amino]-1-(1H-imidazol-5-yl)-3-oxopropoxy]-4,5-dihydroxy-6-(hydroxymethyl)oxan-3-yl]oxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl] carbamate",CC1=C(N=C(N=C1N)C(CC(=O)N)NCC(C(=O)N)N)C(=O)NC(C(C2=CN=CN2)O[C@H]3[C@H]([C@H]([C@@H]([C@@H](O3)CO)O)O)O[C@@H]4[C@H]([C@H]([C@@H]([C@H](O4)CO)O)OC(=O)N)O)C(=O)NC(C)C(C(C)C(=O)NC(C(C)O)C(=O)NCCC5=NC(=CS5)C6=NC(=CS6)C(=O)NCCCN[C@@H](C)C7=CC=CC=C7)O,,,,,,
112,50113,"DIBENZ(a,h)ANTHRACENE, 1,2,7,8-TETRAHYDRO-",C1CC2=C(C=C1)C=CC3=C2C=C4C=CC5=CC=CCC5=C4C3,,,,,,
113,50114,N-((1-Ethyl-2-pyrrolidinyl)methyl)-2-methoxy-5-((dimethylsulfamoyl)amino)benzamide,CCN1CCCC1CNC(=O)C2=C(C=CC(=C2)NS(=O)(=O)N(C)C)OC,,,,,,
114,50115,"Benzamide, N-((1-ethyl-2-pyrrolidinyl)methyl)-2-methoxy-4-methyl-5-((methylsulfonyl)amino)-",CCN1CCCC1CNC(=O)C2=C(C=C(C(=C2)NS(=O)(=O)C)C)OC,,,,,,
115,50116,3-(2-ethyl-6H-benzo[c][1]benzothiepin-11-ylidene)propyl-dimethylazanium;chloride,CCC1=CC2=C(C=C1)SCC3=CC=CC=C3C2=CCC[NH+](C)C.[Cl-],,,,,,
116,50117,"3-(2-ethyl-6H-benzo[c][1]benzothiepin-11-ylidene)-N,N-dimethylpropan-1-amine",CCC1=CC2=C(C=C1)SCC3=CC=CC=C3C2=CCCN(C)C,,,,,,
117,50118,CID 50118,CC(C)C1=CC2=C(C=C1)SCC3=CC=CC=C3C2=CCC[NH+](C)C.[Cl-],,,,,,
118,50119,CID 50119,CC(C)C1=CC2=C(C=C1)SCC3=CC=CC=C3C2=CCCN(C)C,,,,,,
119,50120,CID 50120,CCCCC1=CC2=C(C=C1)SCC3=CC=CC=C3C2=CCC[NH+](C)C.[Cl-],,,,,,
120,50121,CID 50121,CCCCC1=CC2=C(C=C1)SCC3=CC=CC=C3C2=CCCN(C)C,,,,,,
121,50122,CID 50122,CC1=C2C(=CC=C1)C(=CCC[NH+](C)C)C3=CC=CC=C3CS2.[Cl-],,,,,,
122,50123,CID 50123,CC1=C2C(=CC=C1)C(=CCCN(C)C)C3=CC=CC=C3CS2,,,,,,
123,50124,"3-(2,9-dichloro-6H-benzo[c][1]benzothiepin-11-ylidene)propyl-dimethylazanium;chloride",C[NH+](C)CCC=C1C2=C(CSC3=C1C=C(C=C3)Cl)C=CC(=C2)Cl.[Cl-],,,,,,
124,50125,"3-(2,9-dichloro-6H-benzo[c][1]benzothiepin-11-ylidene)-N,N-dimethylpropan-1-amine",CN(C)CCC=C1C2=C(CSC3=C1C=C(C=C3)Cl)C=CC(=C2)Cl,,,,,,
125,50126,"5H-Dibenzo(a,d)cyclohepten-5-ol, 10,11-dihydro-3-chloro-5-(3-(dimethylamino)propyl)-, monohydrochloride",C[NH+](C)CCCC1(C2=CC=CC=C2CCC3=C1C=C(C=C3)Cl)O.[Cl-],,,,,,
126,50127,"5-Chloro-2-[3-(dimethylamino)propyl]tricyclo[9.4.0.03,8]pentadeca-1(15),3(8),4,6,11,13-hexaen-2-ol",CN(C)CCCC1(C2=CC=CC=C2CCC3=C1C=C(C=C3)Cl)O,,,,,,
127,50128,"N,N,3-Trimethyl-10,11-dihydro-5H-dibenzo(a,d)cycloheptene-5-propylamine hydrochloride",CC1=CC2=C(CCC3=CC=CC=C3C2CCC[NH+](C)C)C=C1.[Cl-],,,,,,
128,50129,"N,N-dimethyl-3-(5-methyl-2-tricyclo[9.4.0.03,8]pentadeca-1(15),3(8),4,6,11,13-hexaenyl)propan-1-amine",CC1=CC2=C(CCC3=CC=CC=C3C2CCCN(C)C)C=C1,,,,,,
129,50130,"N,N-Dimethyl-5H-dibenzo(a,d)cycloheptene-5-propylamine hydrobromide",C[NH+](C)CCCC1C2=CC=CC=C2C=CC3=CC=CC=C13.[Br-],,,,,,
130,50131,"1-((Octylthio)methyl)pyridinium, chloride",CCCCCCCCSC[N+]1=CC=CC=C1.[Cl-],,,,,,
131,50132,1-(Octylthiomethyl)pyridinium,CCCCCCCCSC[N+]1=CC=CC=C1,,,,,,
132,50133,Ccris 2706,CCCCCCCCSCN1C=C[N+](=C1)C.[Cl-],,,,,,
133,50134,1-Methyl-3-(octylthiomethyl)-1H-imidazole-3-ium,CCCCCCCCSCN1C=C[N+](=C1)C,,,,,,
134,50135,"1H-Imidazolium, 3-((dodecylthio)methyl)-1-methyl-, chloride",CCCCCCCCCCCCSCN1C=C[N+](=C1)C.[Cl-],,,,,,
135,50136,1-Methyl-3-[(dodecylthio)methyl]-1H-imidazol-3-ium,CCCCCCCCCCCCSCN1C=C[N+](=C1)C,,,,,,
136,50137,Pirnabine,CC1CCC2=C(C1)C3=C(C=C(C=C3OC(=O)C)C)OC2(C)C,,,,,,
137,50138,Trioxifene mesylate,COC1=CC=C(C=C1)C2=C(C3=CC=CC=C3CC2)C(=O)C4=CC=C(C=C4)OCCN5CCCC5.CS(=O)(=O)O,,,,,,
138,50139,Trioxifene,COC1=CC=C(C=C1)C2=C(C3=CC=CC=C3CC2)C(=O)C4=CC=C(C=C4)OCCN5CCCC5,,,,,,
139,50140,CID 50140,C1=CC=C2C(=C1)C(=CC(=O)C2=O)[O-].[Na+],,,,,,
140,50141,"1-((Dodecylthio)methyl)pyridinium, chloride",CCCCCCCCCCCCSC[N+]1=CC=CC=C1.[Cl-],,,,,,
141,50142,1-(Dodecylthiomethyl)pyridinium,CCCCCCCCCCCCSC[N+]1=CC=CC=C1,,,,,,
142,50143,"2,4,6-Heptanetriol, 2,6-bis(trifluoromethyl)-1,1,1,7,7,7-hexafluoro-",C(C(CC(C(F)(F)F)(C(F)(F)F)O)O)C(C(F)(F)F)(C(F)(F)F)O,,,,,,
143,50144,"1,3-Butadiene, 1,1,2,3,4-pentachloro-4-(1-methylethoxy)-",CC(C)OC(=C(C(=C(Cl)Cl)Cl)Cl)Cl,,,,,,
144,50145,CID 50145,C1=CC=C2C(=C1)C=CC(=N2)CN=C([NH3+])N.C1=CC=C2C(=C1)C=CC(=N2)CN=C([NH3+])N.[O-]S(=O)(=O)[O-],,,,,,
145,50146,2-Guanidinomethylquinoline,C1=CC=C2C(=C1)C=CC(=N2)CN=C(N)N,,,,,,
146,50147,CID 50147,C1=CC=C2C(=C1)C=CC(=N2)CN=C([NH3+])N.[Cl-],,,,,,
147,50148,2-Guanidinomethylquinoline nitrate,C1=CC=C2C(=C1)C=CC(=N2)C[NH2+]C(=N)N.[N+](=O)([O-])[O-],,,,,,
148,50149,CID 50149,C1C[NH+](CCN1)C2CC3=CC=CC=C3SC4=C2C=C(C=C4O)Cl.C(=CC(=O)[O-])C(=O)O,,,,,,
149,50150,"3-Chloro-5-piperazin-1-yl-5,6-dihydrobenzo[b][1]benzothiepin-1-ol",C1CN(CCN1)C2CC3=CC=CC=C3SC4=C2C=C(C=C4O)Cl,,,,,,
150,50151,CID 50151,CN1CC[NH+](CC1)C2CC3=CC=CC=C3S(=O)C4=C2C=C(C=C4O)Cl.C(=CC(=O)[O-])C(=O)O,,,,,,
151,50152,"3-Chloro-5-(4-methylpiperazin-1-yl)-11-oxo-5,6-dihydrobenzo[b][1]benzothiepin-1-ol",CN1CCN(CC1)C2CC3=CC=CC=C3S(=O)C4=C2C=C(C=C4O)Cl,,,,,,
152,50153,"(1R,3R,alphaR)-Cyfluthrin",CC1([C@H]([C@H]1C(=O)O[C@@H](C#N)C2=CC(=C(C=C2)F)OC3=CC=CC=C3)C=C(Cl)Cl)C,,,,,,
153,50154,"1H-Indole-3-carboxylic acid, 5-(2-(2-(diethylamino)ethoxy)-2-oxoethoxy)-1,2-dimethyl-, 2-(diethylamino)ethyl ester, dicitrate, hemihydrate",CC[NH+](CC)CCOC(=O)COC1=CC2=C(C=C1)N(C(=C2C(=O)OCC[NH+](CC)CC)C)C.C(C(=O)O)C(CC(=O)[O-])(C(=O)O)O.C(C(=O)O)C(CC(=O)[O-])(C(=O)O)O,,,,,,
154,50155,"2-(Diethylamino)ethyl 5-[2-[2-(diethylamino)ethoxy]-2-oxoethoxy]-1,2-dimethylindole-3-carboxylate",CCN(CC)CCOC(=O)COC1=CC2=C(C=C1)N(C(=C2C(=O)OCCN(CC)CC)C)C,,,,,,
155,50156,"1H-Indole-3-carboxylic acid, 5-(2-(2-(diethylamino)ethoxy)-2-oxoethoxy)-2-methyl-1-phenyl-, 2-(diethylamino)ethyl ester, dicitrate",CC[NH+](CC)CCOC(=O)COC1=CC2=C(C=C1)N(C(=C2C(=O)OCC[NH+](CC)CC)C)C3=CC=CC=C3.C(C(=O)O)C(CC(=O)[O-])(C(=O)O)O.C(C(=O)O)C(CC(=O)[O-])(C(=O)O)O,,,,,,
156,50157,2-(Diethylamino)ethyl 5-[2-[2-(diethylamino)ethoxy]-2-oxoethoxy]-2-methyl-1-phenylindole-3-carboxylate,CCN(CC)CCOC(=O)COC1=CC2=C(C=C1)N(C(=C2C(=O)OCCN(CC)CC)C)C3=CC=CC=C3,,,,,,
157,50158,"1H-Indole-3-carboxylic acid, 5-(2-(2-(diethylamino)ethoxy)-2-oxoethoxy)-2-methyl-1-(2-methylphenyl)-, 2-(diethylamino)ethyl ester, dicitrate",CC[NH+](CC)CCOC(=O)COC1=CC2=C(C=C1)N(C(=C2C(=O)OCC[NH+](CC)CC)C)C3=CC=CC=C3C.C(C(=O)O)C(CC(=O)[O-])(C(=O)O)O.C(C(=O)O)C(CC(=O)[O-])(C(=O)O)O,,,,,,
158,50159,2-(Diethylamino)ethyl 5-[2-[2-(diethylamino)ethoxy]-2-oxoethoxy]-2-methyl-1-(2-methylphenyl)indole-3-carboxylate,CCN(CC)CCOC(=O)COC1=CC2=C(C=C1)N(C(=C2C(=O)OCCN(CC)CC)C)C3=CC=CC=C3C,,,,,,
159,50160,"(+/-)-Benzo(A)pyrene-9,10-diol-7,8-epoxide,anti",C1=CC2=C3C(=C1)C=CC4=C3C(=CC5=C4[C@H]([C@@H]([C@H]6[C@@H]5O6)O)O)C=C2,,,,,,
160,50161,Pharmakon1600-01502340,CC1(C(N2[C@H](S1(=O)=O)CC2=O)C(=O)O)C,,,,,,
161,50162,"2,5-Dihydro-3-(hydroxymethyl)-1-methyl-1H-pyrrole-2-ethanol bis(ethylcarbamate)",CCNC(=O)OCCC1C(=CCN1C)COC(=O)NCC,,,,,,
162,50163,Iron(2+) nta,C(C(=O)O)N(CC(=O)[O-])CC(=O)[O-].[Fe+2],,,,"['In cell, Fe2+ is converted to Fe3+ in ferritin, the latter not being absorbed until cell is physiologically ""depleted."" In the blood stream, iron could be quickly oxidized by dissolved oxygen to Fe3+, which complexes with specific Fe-transport beta1-globulin.']",,
163,50164,"(endo,endo,syn)-3-Benzoyl-2,4-diphenyl-9-ethynyl-3-azabicyclo(3.3.1)nonan-9-ol",C#CC1(C2CCCC1C(N(C2C3=CC=CC=C3)C(=O)C4=CC=CC=C4)C5=CC=CC=C5)O,,,,,,
164,50165,"3,5-Dimethylphenylhydroxylamine",CC1=CC(=CC(=C1)NO)C,,,,,,
165,50166,CID 50166,CC(C)(CC1=CC=CC=C1)[NH2+]CC2=CC(=C(C=C2Br)O)OC.C(=CC(=O)[O-])C(=O)O,,,,,,
166,50167,5-Bromo-2-methoxy-4-[[(2-methyl-1-phenylpropan-2-yl)amino]methyl]phenol,CC(C)(CC1=CC=CC=C1)NCC2=CC(=C(C=C2Br)O)OC,,,,,,
167,50168,CID 50168,CC(CC1=CC=CC=C1)[NH2+]CC2=C(C=C(C=C2Br)O)OC.C(=CC(=O)[O-])C(=O)O,,,,,,
168,50169,3-Bromo-5-methoxy-4-[(1-phenylpropan-2-ylamino)methyl]phenol,CC(CC1=CC=CC=C1)NCC2=C(C=C(C=C2Br)O)OC,,,,,,
169,50170,CID 50170,CC(C)(CC1=CC=CC=C1)[NH2+]CC2=C(C=C(C=C2)O)OC.C(=CC(=O)[O-])C(=O)O,,,,,,
170,50171,3-Methoxy-4-[[(2-methyl-1-phenylpropan-2-yl)amino]methyl]phenol,CC(C)(CC1=CC=CC=C1)NCC2=C(C=C(C=C2)O)OC,,,,,,
171,50172,CID 50172,CC(CC1=CC=CC=C1)[NH2+]CC2=C(C(=CC=C2)OC)O.C(=CC(=O)[O-])C(=O)O,,,,,,
172,50173,2-Methoxy-6-[(1-phenylpropan-2-ylamino)methyl]phenol,CC(CC1=CC=CC=C1)NCC2=C(C(=CC=C2)OC)O,,,,,,
173,50174,2-Methoxy-alpha-(phenethylamino)-p-cresol hydrochloride,COC1=C(C=CC(=C1)C[NH2+]CCC2=CC=CC=C2)O.[Cl-],,,,,,
174,50175,2-Methoxy-4-{[(2-phenylethyl)amino]methyl}phenol,COC1=C(C=CC(=C1)CNCCC2=CC=CC=C2)O,,,,,,
175,50176,6-Methoxy-alpha-(phenethylamino)-o-cresol hydrochloride,COC1=CC=CC(=C1O)C[NH2+]CCC2=CC=CC=C2.[Cl-],,,,,,
176,50177,2-Methoxy-6-(((2-phenylethyl)amino)methyl)phenol,COC1=CC=CC(=C1O)CNCCC2=CC=CC=C2,,,,,,
177,50178,alpha-(1-((4-Hydroxy-3-methoxybenzyl)amino)ethyl)benzyl alcohol hydrochloride,CC(C(C1=CC=CC=C1)O)[NH2+]CC2=C(C(=CC=C2)OC)O.[Cl-],,,,,,
178,50179,alpha-(1-((2-Hydroxy-3-methoxybenzyl)amino)ethyl)benzyl alcohol,CC(C(C1=CC=CC=C1)O)NCC2=C(C(=CC=C2)OC)O,,,,,,
179,50180,2-Bromo-6-methoxy-alpha-(phenethylamino)-p-cresol hydrochloride,COC1=C(C(=CC(=C1)C[NH2+]CCC2=CC=CC=C2)Br)O.[Cl-],,,,,,
180,50181,2-Bromo-6-methoxy-4-{[(2-phenylethyl)amino]methyl}phenol,COC1=C(C(=CC(=C1)CNCCC2=CC=CC=C2)Br)O,,,,,,
181,50182,"alpha-(alpha,alpha-Dimethylphenethylamino)-6-methoxy-o-cresol hydrochloride",CC(C)(CC1=CC=CC=C1)[NH2+]CC2=C(C(=CC=C2)OC)O.[Cl-],,,,,,
182,50183,2-Methoxy-6-[[(2-methyl-1-phenylpropan-2-yl)amino]methyl]phenol,CC(C)(CC1=CC=CC=C1)NCC2=C(C(=CC=C2)OC)O,,,,,,
183,50184,4-Bromo-6-methoxy-alpha-(phenethylamino)-o-cresol hydrochloride,COC1=CC(=CC(=C1O)C[NH2+]CCC2=CC=CC=C2)Br.[Cl-],,,,,,
184,50185,4-Bromo-2-methoxy-6-[(2-phenylethylamino)methyl]phenol,COC1=CC(=CC(=C1O)CNCCC2=CC=CC=C2)Br,,,,,,
185,50186,"4-Bromo-alpha-(alpha,alpha-dimethylphenethylamino)-6-methoxy-o-cresol hydrochloride",CC(C)(CC1=CC=CC=C1)[NH2+]CC2=C(C(=CC(=C2)Br)OC)O.[Cl-],,,,,,
186,50187,4-Bromo-2-methoxy-6-[[(2-methyl-1-phenylpropan-2-yl)amino]methyl]phenol,CC(C)(CC1=CC=CC=C1)NCC2=C(C(=CC(=C2)Br)OC)O,,,,,,
187,50188,alpha-(1-((5-Bromo-2-hydroxy-3-methoxybenzyl)amino)ethyl)benzyl alcohol hydrochloride,CC(C(C1=CC=CC=C1)O)[NH2+]CC2=C(C(=CC(=C2)Br)OC)O.[Cl-],,,,,,
188,50189,4-Bromo-2-[[(1-hydroxy-1-phenylpropan-2-yl)amino]methyl]-6-methoxyphenol,CC(C(C1=CC=CC=C1)O)NCC2=C(C(=CC(=C2)Br)OC)O,,,,,,
189,50190,"[(2S,3S,10S,13S,16S,17R)-17-acetyloxy-2,16-bis(4,4-dimethylpiperazin-4-ium-1-yl)-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-yl] acetate;dibromide",CC(=O)O[C@H]1CC2CCC3C([C@]2(C[C@@H]1N4CC[N+](CC4)(C)C)C)CC[C@]5(C3C[C@@H]([C@@H]5OC(=O)C)N6CC[N+](CC6)(C)C)C.[Br-].[Br-],,,,,,
190,50191,"[(2S,3S,10S,13S,16S,17R)-17-acetyloxy-2,16-bis(4,4-dimethylpiperazin-4-ium-1-yl)-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-yl] acetate",CC(=O)O[C@H]1CC2CCC3C([C@]2(C[C@@H]1N4CC[N+](CC4)(C)C)C)CC[C@]5(C3C[C@@H]([C@@H]5OC(=O)C)N6CC[N+](CC6)(C)C)C,,,,,,
191,50192,Pipecuronium,CC(=O)O[C@H]1C[C@@H]2CC[C@@H]3[C@@H]([C@]2(C[C@@H]1N4CC[N+](CC4)(C)C)C)CC[C@]5([C@H]3C[C@@H]([C@@H]5OC(=O)C)N6CC[N+](CC6)(C)C)C,['Used as a muscle relaxant during anesthesia and surgical procedures.'],"['Pipecuronium is a nondepolarizing neuromuscular blocking agent. Neuromuscular blocking agents produce skeletal muscle paralysis by blocking neural transmission at the myoneural junction. The paralysis is selective initially and usually appears in the following muscles consecutively: levator muscles of eyelids, muscles of mastication, limb muscles, abdominal muscles, muscles of the glottis, and finally, the intercostal muscles and the diaphragm. Neuromuscular blocking agents have no clinically significant effect on consciousness or the pain threshold.']","['Drugs that interrupt transmission at the skeletal neuromuscular junction without causing depolarization of the motor end plate. They prevent acetylcholine from triggering muscle contraction and are used as muscle relaxants during electroshock treatments, in convulsive states, and as anesthesia adjuvants. (See all compounds classified as Neuromuscular Nondepolarizing Agents.)', 'Drugs that bind to nicotinic cholinergic receptors (RECEPTORS, NICOTINIC) and block the actions of acetylcholine or cholinergic agonists. Nicotinic antagonists block synaptic transmission at autonomic ganglia, the skeletal neuromuscular junction, and at central nervous system nicotinic synapses. (See all compounds classified as Nicotinic Antagonists.)']",,,"['Distribution Normal renal function: 6.22 (range, 1.34 to 10.66) minutes. Renal function impairment: 4.33 (range, 1.69 to 6.17) minutes. Elimination Normal renal function: 1.7 (range, 0.9 to 2.7) hours. The elimination half-life is not altered by hypothermia and bypass. Renal function impairment: 4 (range, 2 to 8.2) hours. [PharmGKB]']"
192,50193,3-(Butan-2-yl)aniline,CCC(C)C1=CC(=CC=C1)N,,,,,,
193,50194,(E/Z)-ceftizoxime,CON=C(C1=CSC(=N1)N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=CCS3)C(=O)O,,,['Substances that inhibit the growth or reproduction of BACTERIA. (See all compounds classified as Anti-Bacterial Agents.)'],,,
194,50195,CID 50195,CON=C(C1=CN=C(S1)N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=CCS3)C(=O)[O-].[Na+],,,,,,
195,50196,"(6R,7R)-7-[[2-(2-amino-1,3-thiazol-5-yl)-2-methoxyiminoacetyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid",CON=C(C1=CN=C(S1)N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=CCS3)C(=O)O,,,,,,
196,50197,"Pyrene, dichloro-",C1=CC2=C3C(=C1)C(=CC4=C3C(=CC(=C4)Cl)C=C2)Cl,,,,,,
197,50198,"1H-Benzimidazole-2-sulfenamide, N-cyclohexyl-",C1CCC(CC1)NSC2=NC3=CC=CC=C3N2,,,,,,
198,50199,"Carbamic acid, N-methyl-N-nitroso-, phenyl ester",CN(C(=O)OC1=CC=CC=C1)N=O,,,,,,
199,50200,Mollicellin C,CC1=CC(=C(C2=C1C(=O)OC3=C(O2)C(=C(C(=C3O)OC)C(=O)C=C(C)C)C)C=O)O,,,,,,
200,50201,Mollicellin E,CC1=C2C(=C(C(=C1Cl)O)C=O)OC3=C(C(=C(C(=C3C)C(=O)C=C(C)C)OC)O)OC2=O,,,,,,
201,50202,1-Nitrophenanthrene,C1=CC=C2C(=C1)C=CC3=C2C=CC=C3[N+](=O)[O-],,,,,,
202,50203,"Bis(1,3-dichloro-2-propyl)-2,3-dichloro-1-propyl phosphate",C(C(CCl)Cl)OP(=O)(OC(CCl)CCl)OC(CCl)CCl,,,,,,
203,50204,Apyramide,CC1=C(C2=C(N1C(=O)C3=CC=C(C=C3)Cl)C=CC(=C2)OC)CC(=O)OC4=CC=C(C=C4)NC(=O)C,,,,,,
204,50205,"Benzamide, N-((3-(2-(3,4-dihydroxyphenyl)ethyl)-3,4-dihydro-4-oxo-2-quinazolinyl)methyl)-",C1=CC=C(C=C1)C(=O)NCC2=NC3=CC=CC=C3C(=O)N2CCC4=CC(=C(C=C4)O)O,,,,,,
205,50206,"Benzamide, N-((8-bromo-3-(2-(3,4-dihydroxyphenyl)ethyl)-4-oxo-3,4-dihydro-2-quinazolinyl)methyl)-",C1=CC=C(C=C1)C(=O)NCC2=NC3=C(C=CC=C3Br)C(=O)N2CCC4=CC(=C(C=C4)O)O,,,,,,
206,50207,Noboritomycin A,CCOC(=O)C1[C@@H](CC(O1)C2([C@@H](C(C3(O2)C(C=CC4(O3)[C@@H](C[C@@H]([C@H](O4)C(C)C(=O)[C@@H](C)C([C@H](C)CC(C)C5=C(C(=C(C=C5)C)O)C(=O)O)O)C)C)O)C)OC)C)O,,,,,,
207,50208,Noboritomycin-B,CCC1=C(C(=C(C=C1)C(C)C[C@@H](C)C([C@H](C)C(=O)C(C)[C@@H]2[C@H](C[C@H](C3(O2)C=CC(C4(O3)C([C@H](C(O4)(C)C5C[C@H](C(O5)C(=O)OCC)O)OC)C)O)C)C)O)C(=O)O)O,,,,,,
208,50209,"(11-beta)-17,17-Bis(ethylthio)-9-fluoro-11-hydroxyandrosta-1,4-dien-3-one",CCSC1(CC[C@@H]2[C@@]1(C[C@@H]([C@]3([C@H]2CCC4=CC(=O)C=C[C@@]43C)F)O)C)SCC,,,,,,
209,50210,Fenpirithrin,CC1(C(C1C(=O)OC(C#N)C2=NC(=CC=C2)OC3=CC=CC=C3)C=C(Cl)Cl)C,,,,,,
210,50211,"HYDANTOIN, 5-(p-BUTOXYPHENYL)-5-METHYL-",CCCCOC1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C,,,,,,
211,50212,Methyl 2-(2-benzylideneheptylideneamino)benzoate,CCCCCC(=CC1=CC=CC=C1)C=NC2=CC=CC=C2C(=O)OC,,,,,,
212,50213,CID 50213,CC(=CCCCC(C)(C)O)CC1=CCC2=CC=CC=C21.[Cl-],,,,,,
213,50214,CID 50214,CC(=CCCCC(C)(C)O)CC1=CCC2=CC=CC=C21,,,,,,
214,50215,Bis(6-methyl-3-cyclohexenemethyl) adipate,CC1CC=CCC1COC(=O)CCCCC(=O)OCC2CC=CCC2C,,,,,,
215,50216,Prenyl salicylate,CC(=CCOC(=O)C1=CC=CC=C1O)C,,,,,,
216,50217,CID 50217,CC1=CC(=C(C=C1N=NC2=CC=C(C=C2)S(=O)(=O)[O-])OC)N=NC3=CC=C(C=C3)OC.[Na+],,,,,,
217,50218,Acid Orange 156 parent,CC1=CC(=C(C=C1N=NC2=CC=C(C=C2)S(=O)(=O)O)OC)N=NC3=CC=C(C=C3)OC,,,,,,
218,50219,"Triphenyleno[1,12-bcd]thiophene",C1=CC=C2C3=C4C(=CC=C3)SC5=CC=CC(=C54)C2=C1,,,,,,
219,50220,"10,11-Dihydrobenzo[f]tetraphene-10,11-diol",C1=CC=C2C(=C1)C3=CC=CC=C3C4=C2C=C5C=C[C@@H](C(C5=C4)O)O,,,,,,
220,50221,Enciprazine hydrochloride,COC1=CC=CC=C1N2CCN(CC2)CC(COC3=CC(=C(C(=C3)OC)OC)OC)O.Cl.Cl,,,,,,
221,50222,Enciprazine,COC1=CC=CC=C1N2CCN(CC2)CC(COC3=CC(=C(C(=C3)OC)OC)OC)O,,,,,,
222,50223,"Allylamine, N-ethyl-2-methyl-N-nitroso-",CCN(C(C)C=C)N=O,,,,,,
223,50224,Buserelin acetate,CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC3=CNC4=CC=CC=C43)NC(=O)[C@H](CC5=CN=CN5)NC(=O)[C@@H]6CCC(=O)N6.CC(=O)O,,,"['Compounds which increase the capacity to conceive in females. (See all compounds classified as Fertility Agents, Female.)']",,,
224,50225,Buserelin,CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC3=CNC4=CC=CC=C43)NC(=O)[C@H](CC5=CN=CN5)NC(=O)[C@@H]6CCC(=O)N6,"['Buserelin may be used in the treatment of hormone-responsive cancers such as prostate cancer or breast cancer, estrogen-dependent conditions (such as endometriosis or uterine fibroids), and in assisted reproduction.']","['The substitution of glycine in position 6 by D-serine, and that of glycinamide in position 10 by ethylamide, leads to a nonapeptide with a greatly enhanced LHRH effect. The effects of buserelin on FSH and LH release are 20 to 170 times greater than those of LHRH. Buserelin also has a longer duration of action than natural LHRH. Investigations in healthy adult males and females have demonstrated that the increase in plasma LH and FSH levels persist for at least 7 hours and that a return to basal values requires about 24 hours. Clinical inhibition of gonadotropin release, and subsequent reduction of serum testosterone or estradiol to castration level, was found when large pharmacologic doses (50-500 mcg SC/day or 300-1200 mcg IN/day) were administered for periods greater than 1 to 3 months. Chronic administration of such doses of buserelin results in sustained inhibition of gonadotropin production, suppression of ovarian and testicular steroidogenesis and, ultimately, reduced circulating levels of gonadotropin and gonadal steroids. These effects form the basis for buserelin use in patients with hormone-dependent metastatic carcinoma of the prostate gland as well as in patients with endometriosis.']","['Compounds which increase the capacity to conceive in females. (See all compounds classified as Fertility Agents, Female.)']","['Buserelin is water soluble and readily absorbed after subcutaneous injection (70% bioavailable). However, bioavailability after oral absorption. When administered correctly via the nasal route, it may be absorbed in the nasal mucosa to achieve sufficient plasma levels.', 'Buserelin and its inactive metabolites are excreted via the renal and biliary routes. In man it is excreted in urine at 50% in its intact form.', 'Buserelin circulates in serum predominantly in intact active form. Preferred accumulation is preferentially in the liver and kidneys as well as in the anterior pituitary lobe, the biological target organ.']","['It is metabolized and subsequently inactivated by peptidase (pyroglutamyl peptidase and chymotrypsin-like endopeptidase) in the liver and kidneys as well as in the gastrointestinal tract. In the pituitary gland, it is inactivated by membrane-located enzymes.']","['The elimination half-life is approximately 50 to 80 minutes following intravenous administration, 80 minutes after subcutaneous administration and approximately 1 to 2 hours after intranasal administration.']"
225,50226,"1,1'-(Tetrachloroethylidene)bis(chlorobenzene)",C1=CC(=CC(=C1)Cl)C(C2=CC(=CC=C2)Cl)(C(Cl)(Cl)Cl)Cl,,,,,,
226,50227,"Ethanaminium, N,N-diethyl-N-methyl-2-oxo-2-((2,4,6-trimethylphenyl)amino)-, iodide",CC[N+](C)(CC)CC(=O)NC1=C(C=C(C=C1C)C)C.[I-],,,,,,
227,50228,"Ammonium, diethylmethyl(((2,4,6-trimethylphenyl)carbamoyl)methyl)-",CC[N+](C)(CC)CC(=O)NC1=C(C=C(C=C1C)C)C,,,,,,
228,50229,"2-Oxo-N,N,N-triethyl-2-((2,4,6-trimethylphenyl)amino)ethanaminium iodide",CC[N+](CC)(CC)CC(=O)NC1=C(C=C(C=C1C)C)C.[I-],,,,,,
229,50230,1-Phenylethyl 2-chloroacetoacetate,CC(C1=CC=CC=C1)OC(=O)C(C(=O)C)Cl,,,,,,
230,50231,"BENZYLAMINE, alpha,N-DIMETHYL-N-NITROSO-",CC(C1=CC=CC=C1)N(C)N=O,,,,,,
231,50232,"BENZYLAMINE, N-NITROSO-alpha,alpha,N-TRIMETHYL-",CC(C)(C1=CC=CC=C1)N(C)N=O,,,,,,
232,50233,2-(4-Methylphenyl)butanoic acid,CCC(C1=CC=C(C=C1)C)C(=O)O,,,,,,
233,50234,Somantadine,CC(C)(CC12CC3CC(C1)CC(C3)C2)N,,,,,,
234,50235,"Cycloheptylamine, N,N-dimethyl-4,4-diphenyl-, hydrochloride",C[NH+](C)C1CCCC(CC1)(C2=CC=CC=C2)C3=CC=CC=C3.[Cl-],,,,,,
235,50236,"N,N-dimethyl-4,4-diphenylcycloheptan-1-amine",CN(C)C1CCCC(CC1)(C2=CC=CC=C2)C3=CC=CC=C3,,,,,,
236,50237,CID 50237,C1CC(CCC(C1)(C2=CC=CC=C2)C3=CC=CC=C3)[NH3+].C(=CC(=O)[O-])C(=O)O,,,,,,
237,50238,"4,4-Diphenylcycloheptan-1-amine",C1CC(CCC(C1)(C2=CC=CC=C2)C3=CC=CC=C3)N,,,,,,
238,50239,CID 50239,C[NH2+]C1CCCC(CC1)(C2=CC=CC=C2)C3=CC=CC=C3.C(=CC(=O)[O-])C(=O)O,,,,,,
239,50240,"N-methyl-4,4-diphenylcycloheptan-1-amine",CNC1CCCC(CC1)(C2=CC=CC=C2)C3=CC=CC=C3,,,,,,
240,50241,Dec-6-enyl acetate,CCCC=CCCCCCOC(=O)C,,,,,,
241,50242,"Acridinium, 3-amino-10-methyl-9-(p-(p-((1-methylpyridinium-4-yl)amino)benzamido)anilino)-, dichloride",C[N+]1=CC=C(C=C1)NC2=CC=C(C=C2)C(=O)NC3=CC=C(C=C3)NC4=C5C=CC(=CC5=[N+](C6=CC=CC=C64)C)N.[Cl-].[Cl-],,,,,,
242,50243,3-Amino-10-methyl-9-((4-((4-((1-methylpyridinium-4-yl)amino)benzoyl)amino)phenyl)amino)acridinium,C[N+]1=CC=C(C=C1)NC2=CC=C(C=C2)C(=O)NC3=CC=C(C=C3)NC4=C5C=CC(=CC5=[N+](C6=CC=CC=C64)C)N,,,,,,
243,50244,"Acridinium, 3-amino-10-methyl-9-(p-((p-((1-methylpyridinium-4-yl)amino)phenyl)sulfonamido)anilino)-, diperchlorate",C[N+]1=CC=C(C=C1)NC2=CC=C(C=C2)S(=O)(=O)NC3=CC=C(C=C3)NC4=C5C=CC(=CC5=[N+](C6=CC=CC=C64)C)N.[O-]Cl(=O)(=O)=O.[O-]Cl(=O)(=O)=O,,,,,,
244,50245,N-[4-[(3-amino-10-methylacridin-10-ium-9-yl)amino]phenyl]-4-[(1-methylpyridin-1-ium-4-yl)amino]benzenesulfonamide,C[N+]1=CC=C(C=C1)NC2=CC=C(C=C2)S(=O)(=O)NC3=CC=C(C=C3)NC4=C5C=CC(=CC5=[N+](C6=CC=CC=C64)C)N,,,,,,
245,50246,"Acridinium, 2-amino-10-methyl-9-(p-((p-((1-methylpyridinium-3-yl)carbamoyl)phenyl)carbamoyl)anilino)-, dichloride",C[N+]1=CC=CC(=C1)NC(=O)C2=CC=C(C=C2)NC(=O)C3=CC=C(C=C3)NC4=C5C=C(C=CC5=[N+](C6=CC=CC=C64)C)N.[Cl-].[Cl-],,,,,,
246,50247,4-[(2-amino-10-methylacridin-10-ium-9-yl)amino]-N-[4-[(1-methylpyridin-1-ium-3-yl)carbamoyl]phenyl]benzamide,C[N+]1=CC=CC(=C1)NC(=O)C2=CC=C(C=C2)NC(=O)C3=CC=C(C=C3)NC4=C5C=C(C=CC5=[N+](C6=CC=CC=C64)C)N,,,,,,
247,50248,Triclabendazole,CSC1=NC2=CC(=C(C=C2N1)Cl)OC3=C(C(=CC=C3)Cl)Cl,['This drug is indicated for the treatment of fascioliasis in patients aged 6 years old and above.'],['Triclabendazole and its metabolites are active against both the immature and mature worms of _Fasciola hepatica_ and _Fasciola gigantica_ helminths.  **Effect on QT interval**  This drug may prolong the cardiac QT interval. Monitor ECG in patients with a history of QT prolongation or who are taking medications known to prolong the QT interval.'],"['Agents used to treat cestode, trematode, or other flatworm infestations in man or animals. (See all compounds classified as Antiplatyhelmintic Agents.)']","['After a single oral dose of 10 mg/kg triclabendazole with a 560-kcal meal to patients diagnosed with fascioliasis, mean peak plasma concentrations (Cmax) for triclabendazole, the sulfoxide, and sulfone metabolites were 1.16, 38.6, and 2.29 μmol/L, respectively. The area under the curve (AUC) for triclabendazole, the sulfoxide and sulfone metabolites were 5.72, 386, and 30.5 μmol∙h/L, respectively.  After the oral administration of a single dose of triclabendazole at 10 mg/kg with a 560 calorie meal to patients with fascioliasis, the median Tmax for the parent compound as well as the active sulfoxide metabolite was 3 to 4 hours.  **Effect of Food** Cmax and AUC of triclabendazole and sulfoxide metabolite increased about 2-3 times when triclabendazole was administered as a single dose at 10 mg/kg with a meal containing approximately 560 calories. Additionally, the sulfoxide metabolite Tmax increased from 2 hours in fasting subjects to 4 hours in fed subjects.', 'No data regarding excretion is available in humans. In animals, triclabendazole is primarily excreted by the biliary tract in the feces (90%), together with the sulfoxide and sulfone metabolite. Less than 10% of an oral dose is found excreted in the urine.', 'The apparent volume of distribution (Vd) of the sulfoxide metabolite in fed patients is about 1 L/kg.']","['Based on in vitro studies, triclabendazole is mainly metabolized by CYP1A2 enzyme (approximately 64%) into its active _sulfoxide_ metabolite and to a lesser extent by CYP2C9, CYP2C19, CYP2D6, CYP3A, and FMO (flavin containing monooxygenase). This sulfoxide metabolite is further metabolized mainly by CYP2C9 to the active sulfone metabolite, and to a smaller extent by CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2D6, and CYP3A4, _in vitro_.']","['The plasma elimination half-life (t1/2) of triclabendazole, the sulfoxide and sulfone metabolites in human is about 8, 14, and 11 hours, respectively.']"
248,50249,"1,2,4,7,9-Pentabromo-dibenzofuran",C1=C(C=C(C2=C1OC3=C2C(=C(C=C3Br)Br)Br)Br)Br,,,,,,
249,50250,Oxantel embonate,CN1CCCN=C1C=CC2=CC(=CC=C2)O.C1=CC=C2C(=C1)C=C(C(=C2CC3=C(C(=CC4=CC=CC=C43)C(=O)O)O)O)C(=O)O,,,['Substances used in the treatment or control of nematode infestations. They are used also in veterinary practice. (See all compounds classified as Antinematodal Agents.)'],,,
250,50251,"1,3-Naphthalenediol, 4,4'-methylenedi-",C1=CC=C2C(=C1)C(=CC(=C2CC3=C(C=C(C4=CC=CC=C43)O)O)O)O,,,,,,
251,50252,"2,7-Naphthalenediol, 1,1'-methylenedi-",C1=CC(=CC2=C1C=CC(=C2CC3=C(C=CC4=C3C=C(C=C4)O)O)O)O,,,,,,
252,50253,"1,3-Naphthalenediol, 4,4'-methylenedi-, tetraacetate",CC(=O)OC1=CC(=C(C2=CC=CC=C21)CC3=C(C=C(C4=CC=CC=C43)OC(=O)C)OC(=O)C)OC(=O)C,,,,,,
253,50254,"2-Naphthoic acid, 4,4'-methylenebis(3-acetoxy-",CC(=O)OC1=C(C2=CC=CC=C2C=C1C(=O)O)CC3=C(C(=CC4=CC=CC=C43)C(=O)O)OC(=O)C,,,,,,
254,50255,3-Chloro-5-nitrobenzotrifluoride,C1=C(C=C(C=C1[N+](=O)[O-])Cl)C(F)(F)F,,,,,,
255,50256,"Ethanone, 1-(2,3-dihydro-1,1,2,6-tetramethyl-3-(1-methylethyl)-1H-inden-5-yl)-, trans-",C[C@@H]1[C@H](C2=C(C1(C)C)C=C(C(=C2)C(=O)C)C)C(C)C,,,,,,
256,50257,"N-[2-[(2-Bromo-4,6-dinitrophenyl)azo]-5-[(2-cyanoethyl)-2-propenylamino]-4-methoxyphenyl]acetamide",CC(=O)NC1=CC(=C(C=C1N=NC2=C(C=C(C=C2Br)[N+](=O)[O-])[N+](=O)[O-])OC)N(CCC#N)CC=C,,,,,,
257,50258,Piroctone olamine,CC1=CC(=O)N(C(=C1)CC(C)CC(C)(C)C)O.C(CO)N,,,,,,
258,50259,Piroctone,CC1=CC(=O)N(C(=C1)CC(C)CC(C)(C)C)O,,,,,,
259,50260,"N-(3,4-dimethyl-2,6-dinitrophenyl)-N-pentan-3-ylnitrous amide",CCC(CC)N(C1=C(C=C(C(=C1[N+](=O)[O-])C)C)[N+](=O)[O-])N=O,,,,,,
260,50261,"Carbamothioic acid, dipropyl-, S-propyl ester, mixt. with 2,2-dichloro-N,N-di-2-propenylacetamide",CCCN(CCC)C(=O)SCCC.C=CCN(CC=C)C(=O)C(Cl)Cl,,,,,,
261,50262,Tioclorim,CSC1=C(N=C(N=C1Cl)N)N,,,,,,
262,50263,"Carbamic acid, (2-(heptyloxy)phenyl)-, 1-methyl-2-(1-piperidinyl)ethyl ester hydrochloride",CCCCCCCOC1=CC=CC=C1NC(=O)OC(C)C[NH+]2CCCCC2.[Cl-],,,,,,
263,50264,N-[2-(Heptyloxy)phenyl]carbamic acid 1-methyl-2-piperidinoethyl ester,CCCCCCCOC1=CC=CC=C1NC(=O)OC(C)CN2CCCCC2,,,,,,
264,50265,Carbisocaine,CCCCCCCOC1=CC=CC=C1NC(=O)OC(C)C[NH+](CC)CC.[Cl-],,,"['Drugs that block nerve conduction when applied locally to nerve tissue in appropriate concentrations. They act on any part of the nervous system and on every type of nerve fiber. In contact with a nerve trunk, these anesthetics can cause both sensory and motor paralysis in the innervated area. Their action is completely reversible. (From Gilman AG, et. al., Goodman and Gilman&apos;s The Pharmacological Basis of Therapeutics, 8th ed) Nearly all local anesthetics act by reducing the tendency of voltage-dependent sodium channels to activate. (See all compounds classified as Anesthetics, Local.)']",,,
265,50266,Carbizocaine,CCCCCCCOC1=CC=CC=C1NC(=O)OC(C)CN(CC)CC,,,"['Drugs that block nerve conduction when applied locally to nerve tissue in appropriate concentrations. They act on any part of the nervous system and on every type of nerve fiber. In contact with a nerve trunk, these anesthetics can cause both sensory and motor paralysis in the innervated area. Their action is completely reversible. (From Gilman AG, et. al., Goodman and Gilman&apos;s The Pharmacological Basis of Therapeutics, 8th ed) Nearly all local anesthetics act by reducing the tendency of voltage-dependent sodium channels to activate. (See all compounds classified as Anesthetics, Local.)']",,,
266,50267,"Carbamic acid, (2-(pentyloxy)phenyl)-, 3-(1-pyrrolidinyl)propyl ester, monohydrochloride",CCCCCOC1=CC=CC=C1NC(=O)OCCC[NH+]2CCCC2.[Cl-],,,,,,
267,50268,3-pyrrolidin-1-ylpropyl N-(2-pentoxyphenyl)carbamate,CCCCCOC1=CC=CC=C1NC(=O)OCCCN2CCCC2,,,,,,
268,50269,"Carbamic acid, (2-(hexyloxy)phenyl)-, 3-(1-pyrrolidinyl)propyl ester, monohydrochloride",CCCCCCOC1=CC=CC=C1NC(=O)OCCC[NH+]2CCCC2.[Cl-],,,,,,
269,50270,3-pyrrolidin-1-ylpropyl N-(2-hexoxyphenyl)carbamate,CCCCCCOC1=CC=CC=C1NC(=O)OCCCN2CCCC2,,,,,,
270,50271,"Carbamic acid, (2-(heptyloxy)phenyl)-, 3-(1-pyrrolidinyl)propyl ester, ethanedioate (1:1)",CCCCCCCOC1=CC=CC=C1NC(=O)OCCC[NH+]2CCCC2.C(=O)(C(=O)[O-])O,,,,,,
271,50272,"Carbamic acid, [2-(heptyloxy)phenyl]-, 3-(1-pyrrolidinyl)propyl ester",CCCCCCCOC1=CC=CC=C1NC(=O)OCCCN2CCCC2,,,,,,
272,50273,"CARBANILIC ACID, o-(OCTYLOXY)-, 3-(1-PYRROLIDINYL)PROPYL ESTER, OXALATE (1:1)",CCCCCCCCOC1=CC=CC=C1NC(=O)OCCC.C(=O)(C(=O)[O-])O,,,,,,
273,50274,propyl N-(2-octoxyphenyl)carbamate,CCCCCCCCOC1=CC=CC=C1NC(=O)OCCC,,,,,,
274,50275,"Carbamic acid, (2-(pentyloxy)phenyl)-, 3-(hexahydro-1H-azepin-1-yl)propyl ester hydrochloride",CCCCCOC1=CC=CC=C1NC(=O)OCCC[NH+]2CCCCCC2.[Cl-],,,,,,
275,50276,3-(azepan-1-yl)propyl N-(2-pentoxyphenyl)carbamate,CCCCCOC1=CC=CC=C1NC(=O)OCCCN2CCCCCC2,,,,,,
276,50277,"Carbanilic acid, o-(nonyloxy)-, 3-(hexahydro-1H-azepin-1-yl)propyl ester, hydrochloride",CCCCCCCCCOC1=CC=CC=C1NC(=O)OCCC[NH+]2CCCCCC2.[Cl-],,,,,,
277,50278,3-(azepan-1-yl)propyl N-(2-nonoxyphenyl)carbamate,CCCCCCCCCOC1=CC=CC=C1NC(=O)OCCCN2CCCCCC2,,,,,,
278,50279,"Acetamide, N-(2-(5-methoxy-2-methyl-3-indolyl)ethyl)-",CC1=C(C2=C(N1)C=CC(=C2)OC)CCNC(=O)C,,,,,,
279,50280,"1-[2,3-Bis(2-oxopropoxy)propoxy]propan-2-one",CC(=O)COCC(COCC(=O)C)OCC(=O)C,,,,,,
280,50281,N-Methyl-5-phenylazoindoline,CN1CCC2=C1C=CC(=C2)N=NC3=CC=CC=C3,,,,,,
281,50282,Pyrene-2-carbaldehyde,C1=CC2=C3C(=C1)C=CC4=C3C(=CC(=C4)C=O)C=C2,,,,,,
282,50283,CID 50283,CC(=NNS(=O)(=O)C1=CC=C(C=C1)NC(=NC2=CC=C(C=C2)S(=O)(=O)NN=C(C)C)S)C,,,,,,
283,50284,CID 50284,CCCC(=C1CC1C2=C(C(=O)C3=CC=CC=C3N2)C)C,,,,,,
284,50285,"Carbanilic acid, 2-methyl-4-(pentyloxy)-, 2-(dimethylamino)ethyl ester",CCCCCOC1=CC(=C(C=C1)NC(=O)OCCN(C)C)C,,,,,,
285,50286,Myristalkonium saccharinate,CCCCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1.C1=CC=C2C(=C1)C(=NS2(=O)=O)[O-],,,,,,
286,50287,Tiotidine,CN=C(NCCSCC1=CSC(=N1)N=C(N)N)NC#N,,,"['Drugs that selectively bind to but do not activate histamine H2 receptors, thereby blocking the actions of histamine. Their clinically most important action is the inhibition of acid secretion in the treatment of gastrointestinal ulcers. Smooth muscle may also be affected. Some drugs in this class have strong effects in the central nervous system, but these actions are not well understood. (See all compounds classified as Histamine H2 Antagonists.)']",,,
287,50288,Ipexidine mesylate,CCCCCCNC(=O)NC(=NCCCN1CCN(CC1)CCCN=C(N)NC(=O)NCCCCCC)N.CS(=O)(=O)O.CS(=O)(=O)O,,,,,,
288,50289,Ipexidine,CCCCCCNC(=O)NC(=NCCCN1CCN(CC1)CCCN=C(N)NC(=O)NCCCCCC)N,,,,,,
289,50290,"3-Nitro-1,2-bis(2-(diethylamino)ethoxy)anthraquinone dihydrochloride",CC[NH+](CC)CCOC1=C(C=C2C(=C1OCC[NH+](CC)CC)C(=O)C3=CC=CC=C3C2=O)[N+](=O)[O-].[Cl-].[Cl-],,,,,,
290,50291,"1,2-Bis[2-(diethylamino)ethoxy]-3-nitroanthracene-9,10-dione",CCN(CC)CCOC1=C(C=C2C(=C1OCCN(CC)CC)C(=O)C3=CC=CC=C3C2=O)[N+](=O)[O-],,,,,,
291,50292,"Acetanilide, 2-bromo-4'-(3-carbamoylpropyl)-",CC(=O)NC1=C(C=C(C=C1)CCCC(=O)N)Br,,,,,,
292,50293,2-Chloro-5-(trichloromethyl)pyridine,C1=CC(=NC=C1C(Cl)(Cl)Cl)Cl,,,,,,
293,50294,Nedocromil,CCCC1=C2C(=CC3=C1OC(=CC3=O)C(=O)O)C(=O)C=C(N2CC)C(=O)O,['For the treatment of mild to moderate asthma'],['Nedocromil is a anti-inflammatory agent and can be administered directly to the bronchial mucosa. It has significant inhibitory effect on allergen-induced early and late asthmatic reactions and on bronchial hyperresponsiveness.'],"['Compounds that prevent the release of inflammatory mediators from MAST CELLS. (See all compounds classified as Mast Cell Stabilizers.)', 'Drugs that are used to treat asthma. (See all compounds classified as Anti-Asthmatic Agents.)', 'Agents that are used to treat allergic reactions. Most of these drugs act by preventing the release of inflammatory mediators or inhibiting the actions of released mediators on their target cells. (From AMA Drug Evaluations Annual, 1994, p475) (See all compounds classified as Anti-Allergic Agents.)', 'Substances that reduce or suppress INFLAMMATION. (See all compounds classified as Anti-Inflammatory Agents.)']","['Low', 'It is not metabolized and is eliminated primarily unchanged in urine (70%) and feces (30%).']",['Nedocromil is not metabolized after IV administration and is excreted unchanged.'],['~3.3 hours']
294,50295,Nedocromil sodium,CCCC1=C2C(=CC3=C1OC(=CC3=O)C(=O)[O-])C(=O)C=C(N2CC)C(=O)[O-].[Na+].[Na+],,,"['Agents that are used to treat allergic reactions. Most of these drugs act by preventing the release of inflammatory mediators or inhibiting the actions of released mediators on their target cells. (From AMA Drug Evaluations Annual, 1994, p475) (See all compounds classified as Anti-Allergic Agents.)', 'Drugs that are used to treat asthma. (See all compounds classified as Anti-Asthmatic Agents.)', 'Substances that reduce or suppress INFLAMMATION. (See all compounds classified as Anti-Inflammatory Agents.)', 'Compounds that prevent the release of inflammatory mediators from MAST CELLS. (See all compounds classified as Mast Cell Stabilizers.)']",,,
295,50296,"1,2,3,4,4a,9b-Hexahydrodibenzothiophene",C1CCC2C(C1)C3=CC=CC=C3S2,,,,,,
296,50297,Methyl 2-methyl-1-(methylthio)butyl disulfide,CCC(C)C(SC)SSC,,,,,,
297,50298,"4H-(1)Benzothiopyrano(4,3-c)pyrazole-3-carboxamide, N-(2-(dimethylamino)ethyl)-1-phenyl-",CN(C)CCNC(=O)C1=NN(C2=C1CSC3=CC=CC=C32)C4=CC=CC=C4,,,,,,
298,50299,"4H-(1)Benzothiopyrano(4,3-c)pyrazole-3-carboxamide, N-(2-(dimethylamino)ethyl)-6-fluoro-1-phenyl-, dihydrate",CN(C)CCNC(=O)C1=NN(C2=C1CSC3=C2C=CC=C3F)C4=CC=CC=C4.O.O,,,,,,
299,50300,"N-[2-(dimethylamino)ethyl]-6-fluoro-1-phenyl-4H-thiochromeno[4,3-c]pyrazole-3-carboxamide",CN(C)CCNC(=O)C1=NN(C2=C1CSC3=C2C=CC=C3F)C4=CC=CC=C4,,,,,,
300,50301,"4H-(1)Benzothiopyrano(4,3-c)pyrazole-3-carboxamide, N-(2-(diethylamino)ethyl)-1-phenyl-",CCN(CC)CCNC(=O)C1=NN(C2=C1CSC3=CC=CC=C32)C4=CC=CC=C4,,,,,,
301,50302,"4H-(1)Benzothiopyrano(4,3-c)pyrazole-3-carboxamide, N-(2-(diethylamino)ethyl)-1-phenyl-6-trifluoromethyl-",CCN(CC)CCNC(=O)C1=NN(C2=C1CSC3=C2C=CC=C3C(F)(F)F)C4=CC=CC=C4,,,,,,
302,50303,"4H-(1)Benzothiopyrano(4,3-c)pyrazole-3-carboxamide, 6-fluoro-N-(3-morpholinopropyl)-1-phenyl-",C1COCCN1CCCNC(=O)C2=NN(C3=C2CSC4=C3C=CC=C4F)C5=CC=CC=C5,,,,,,
303,50304,"4H-(1)Benzothiopyrano(4,3-c)pyrazole-3-carboxamide, N-((1-ethyl-2-pyrrolidinyl)methyl)-1-phenyl-",CCN1CCCC1CNC(=O)C2=NN(C3=C2CSC4=CC=CC=C43)C5=CC=CC=C5,,,,,,
304,50305,"4H-(1)Benzothiopyrano(4,3-c)pyrazole-3-carboxamide, N-(2-(diethylamino)ethyl)-1-phenyl-, 5,5-dioxide",CCN(CC)CCNC(=O)C1=NN(C2=C1CS(=O)(=O)C3=CC=CC=C32)C4=CC=CC=C4,,,,,,
305,50306,"4H-(1)Benzothiopyrano(4,3-c)pyrazole-3-carboxamide, N-(3-morpholinopropyl)-1-phenyl-, 5,5'-dioxide",C1COCCN1CCCNC(=O)C2=NN(C3=C2CS(=O)(=O)C4=CC=CC=C43)C5=CC=CC=C5,,,,,,
306,50307,"4H-(1)BENZOTHIOPYRANO(3,4-d)ISOXAZOLE-3-CARBOXAMIDE, N-(2-(DIETHYLAMINO)ETHYL)-",CCN(CC)CCNC(=O)C1=NOC2=CSC3=CC=CCC3=C21,,,,,,
307,50308,"CHROMONE, 7-METHOXY-2-(3-(4-(o-METHOXYPHENYL)-1-PIPERAZINYL)PROPYL)-3-METHYL-",CC1=C(OC2=C(C1=O)C=CC(=C2)OC)CCCN3CCN(CC3)C4=CC=CC=C4OC,,,,,,
308,50309,"Chromone, 3-methyl-2-(3-(4-phenyl-1-piperazinyl)propyl)-",CC1=C(OC2=CC=CC=C2C1=O)CCCN3CCN(CC3)C4=CC=CC=C4,,,,,,
309,50310,"Chromone, 7-fluoro-3-methyl-2-(3-(4-phenyl-1-piperazinyl)propyl)-",CC1=C(OC2=C(C1=O)C=CC(=C2)F)CCCN3CCN(CC3)C4=CC=CC=C4,,,,,,
310,50311,Nitrosobis(2-chloropropyl)amine,CC(CN(CC(C)Cl)N=O)Cl,,,,,,
311,50312,Fiacitabine,C1=C(C(=NC(=O)N1[C@H]2[C@H]([C@@H]([C@H](O2)CO)O)F)N)I,,,"['Agents used in the prophylaxis or therapy of VIRUS DISEASES. Some of the ways they may act include preventing viral replication by inhibiting viral DNA polymerase; binding to specific cell-surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking late stages of virus assembly. (See all compounds classified as Antiviral Agents.)', 'Substances that inhibit or prevent the proliferation of NEOPLASMS. (See all compounds classified as Antineoplastic Agents.)']",,,
312,50313,Fialuridine,C1=C(C(=O)NC(=O)N1[C@H]2[C@H]([C@@H]([C@H](O2)CO)O)F)I,,,"['Agents used in the prophylaxis or therapy of VIRUS DISEASES. Some of the ways they may act include preventing viral replication by inhibiting viral DNA polymerase; binding to specific cell-surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking late stages of virus assembly. (See all compounds classified as Antiviral Agents.)', 'Compounds that inhibit cell production of DNA or RNA. (See all compounds classified as Nucleic Acid Synthesis Inhibitors.)']",,,
313,50314,"2-Imidazolidinone, (2-chlorophenyl)hydrazone, monohydrochloride",C1C[NH+]=C(N1)NNC2=CC=CC=C2Cl.[Cl-],,,,,,
314,50315,2-Imidazolidinone (2-chlorophenyl)hydrazone,C1CN=C(N1)NNC2=CC=CC=C2Cl,,,,,,
315,50316,"1,1,2,2-Cyclohex-4-enetetracarbonitrile, 4,5-dimethyl-",CC1=C(CC(C(C1)(C#N)C#N)(C#N)C#N)C,,,,,,
316,50317,"1-(10,11-Dihydro-5H-dibenzo(a,d)cyclohepten-5-yl)-2-methyl-3-methylaminoazetidine",CC1C(CN1C2C3=CC=CC=C3CCC4=CC=CC=C24)NC,,,,,,
317,50318,"1-(3-Methoxy-10,11-dihydroxy-5H-dibenzo(a,d)cyclohepten-5-yl)-3-(methylamino)azetidine",CNC1CN(C1)C2C3=CC=CC=C3CCC4=C2C=C(C=C4)OC,,,,,,
318,50319,1-benzhydryl-N-methylazetidin-3-amine,CNC1CN(C1)C(C2=CC=CC=C2)C3=CC=CC=C3,,,,,,
319,50320,"Iodine, bis(acetato-O)(2-methoxyphenyl)-",CC(=O)OI(C1=CC=CC=C1OC)OC(=O)C,,,,,,
320,50321,"8-Chloro-10-methylamino-10,11-dihydrodibenzo(b,f)thiepin hydrochloride",C[NH2+]C1CC2=CC=CC=C2SC3=C1C=C(C=C3)Cl.[Cl-],,,,,,
321,50322,"3-chloro-N-methyl-5,6-dihydrobenzo[b][1]benzothiepin-5-amine",CNC1CC2=CC=CC=C2SC3=C1C=C(C=C3)Cl,,,,,,
322,50323,"S-(8-Chloro-10,11-dihydrodibenzo(b,f)thiepin-10-yl)isothiuronium chloride monohydrate",C1C(C2=C(C=CC(=C2)Cl)SC3=CC=CC=C31)SC(=[NH2+])N.[Cl-],,,,,,
323,50324,"(3-Chloro-5,6-dihydrobenzo[b][1]benzothiepin-5-yl) carbamimidothioate",C1C(C2=C(C=CC(=C2)Cl)SC3=CC=CC=C31)SC(=N)N,,,,,,
324,50325,"Ethanamine, 2-((8-chloro-10,11-dihydrodibenzo(b,f)thiepin-10-yl)thio)-N,N-dimethyl-, hydrochloride",C[NH+](C)CCSC1CC2=CC=CC=C2SC3=C1C=C(C=C3)Cl.[Cl-],,,,,,
325,50326,"2-[(3-chloro-5,6-dihydrobenzo[b][1]benzothiepin-5-yl)sulfanyl]-N,N-dimethylethanamine",CN(C)CCSC1CC2=CC=CC=C2SC3=C1C=C(C=C3)Cl,,,,,,
326,50327,CID 50327,C1C(C2=C(C=CC(=C2)Cl)SC3=CC=CC=C31)[NH3+].C(=CC(=O)[O-])C(=O)O,,,,,,
327,50328,"Dibenzo[b,f]thiepin-10-amine, 8-chloro-10,11-dihydro-",C1C(C2=C(C=CC(=C2)Cl)SC3=CC=CC=C31)N,,,,,,
328,50329,"2,3'-Dimethyl-4-aminobiphenyl hydrochloride",CC1=CC(=CC=C1)C2=C(C=C(C=C2)[NH3+])C.[Cl-],,,,,,
329,50330,"(1,1'-Biphenyl)-4-amine, 2,3'-dimethyl-",CC1=CC(=CC=C1)C2=C(C=C(C=C2)N)C,,,,,,
330,50331,"Naphthalene-1,2-diol-3,4-epoxide, syn",C1=CC=C2C3C(O3)[C@H](C(C2=C1)O)O,,,,,,
331,50332,"Naphthalene-1,2-diol-3,4-epoxide, anti",C1=CC=C2[C@@H]3[C@@H](O3)[C@H]([C@@H](C2=C1)O)O,,,,,,
332,50333,CID 50333,CN1CC[NH+](CC1)C2=CC3=C(C=C(C=C3)O)SC4=C2C=C(C=C4)Cl.C(=CC(=O)[O-])C(=O)O,,,,,,
333,50334,3-Chloro-5-(4-methylpiperazin-1-yl)benzo[b][1]benzothiepin-9-ol,CN1CCN(CC1)C2=CC3=C(C=C(C=C3)O)SC4=C2C=C(C=C4)Cl,,,,,,
334,50335,"Diethylamine, 2-chloro-2'-iodo-",C(CCl)NCCI,,,,,,
335,50336,9-(p-(Ethylamino)anilino)acridine hydrochloride,CC[NH2+]C1=CC=C(C=C1)NC2=C3C=CC=CC3=NC4=CC=CC=C42.[Cl-],,,,,,
336,50337,"ACRIDINE, 9-(p-(ETHYLAMINO)ANILINO)-",CCNC1=CC=C(C=C1)NC2=C3C=CC=CC3=NC4=CC=CC=C42,,,,,,
337,50338,9-(p-(Propylamino)anilino)acridine hydrochloride,CCC[NH2+]C1=CC=C(C=C1)NC2=C3C=CC=CC3=NC4=CC=CC=C42.[Cl-],,,,,,
338,50339,"ACRIDINE, 9-(p-(PROPYLAMINO)ANILINO)-",CCCNC1=CC=C(C=C1)NC2=C3C=CC=CC3=NC4=CC=CC=C42,,,,,,
339,50340,9-(p-(Hexylamino)anilino)acridine hydrochloride,CCCCCC[NH2+]C1=CC=C(C=C1)NC2=C3C=CC=CC3=NC4=CC=CC=C42.[Cl-],,,,,,
340,50341,9-(p-(Hexylamino)anilino)acridine,CCCCCCNC1=CC=C(C=C1)NC2=C3C=CC=CC3=NC4=CC=CC=C42,,,,,,
341,50342,"Hexanesulfonamide, N-(4-(acridin-9-ylamino)-3-methoxyphenyl)-, methanesulfonate",CCCCCCS(=O)(=O)NC1=CC(=C(C=C1)[NH2+]C2=C3C=CC=CC3=NC4=CC=CC=C42)OC.CS(=O)(=O)[O-],,,,,,
342,50343,N-[4-(acridin-9-ylamino)-3-methoxyphenyl]hexane-1-sulfonamide,CCCCCCS(=O)(=O)NC1=CC(=C(C=C1)NC2=C3C=CC=CC3=NC4=CC=CC=C42)OC,,,,,,
343,50344,"4-Acridinecarboxamide, 9-((2-methoxy-4-((propylsulfonyl)amino)phenyl)amino)-, hydrochloride",CCCS(=O)(=O)NC1=CC(=C(C=C1)[NH2+]C2=C3C=CC=C(C3=NC4=CC=CC=C42)C(=O)N)OC.[Cl-],,,,,,
344,50345,9-[2-Methoxy-4-(propylsulfonylamino)anilino]acridine-4-carboxamide,CCCS(=O)(=O)NC1=CC(=C(C=C1)NC2=C3C=CC=C(C3=NC4=CC=CC=C42)C(=O)N)OC,,,,,,
345,50346,"4-Acridinecarboxamide, 9-((4-((butylsulfonyl)amino)-2-methoxyphenyl)amino)-, hydrochloride",CCCCS(=O)(=O)NC1=CC(=C(C=C1)[NH2+]C2=C3C=CC=C(C3=NC4=CC=CC=C42)C(=O)N)OC.[Cl-],,,,,,
346,50347,N-[4-[(4-Carbamoylacridin-9-yl)amino]-3-methoxyphenyl]-1-butanesulfonamide,CCCCS(=O)(=O)NC1=CC(=C(C=C1)NC2=C3C=CC=C(C3=NC4=CC=CC=C42)C(=O)N)OC,,,,,,
347,50348,"4-Acridinecarboxamide, 9-((2-methoxy-4-((pentylsulfonyl)amino)phenyl)amino)-, hydrochloride",CCCCCS(=O)(=O)NC1=CC(=C(C=C1)[NH2+]C2=C3C=CC=C(C3=NC4=CC=CC=C42)C(=O)N)OC.[Cl-],,,,,,
348,50349,9-[2-Methoxy-4-(pentylsulfonylamino)anilino]acridine-4-carboxamide,CCCCCS(=O)(=O)NC1=CC(=C(C=C1)NC2=C3C=CC=C(C3=NC4=CC=CC=C42)C(=O)N)OC,,,,,,
349,50350,2-Acetamidophenethyl Alcohol,CC(=O)NC1=CC=CC=C1CCO,,,,,,
350,50351,"BENZ(a)ANTHRACENE-12-METHANOL, 3,4-DIHYDRO-3,4-DIHYDROXY-7-METHYL-, (E)-",CC1=C2C=CC3=C(C2=C(C4=CC=CC=C14)CO)C=C[C@H]([C@@H]3O)O,,,,,,
351,50352,"Benz(a)anthracene-3,4-diol, 3,4-dihydro-7-(hydroxymethyl)-12-methyl-",CC1=C2C3=C(C=CC2=C(C4=CC=CC=C14)CO)[C@H]([C@@H](C=C3)O)O,,,,,,
352,50353,"(E)-3,4-Dihydroxy-3,4-dihydrobenz(a)anthracene-7,12-dimethanol",C1=CC=C2C(=C1)C(=C3C=CC4=C(C3=C2CO)C=C[C@H]([C@@H]4O)O)CO,,,,,,
353,50354,"2-Nitronaphtho(2,1-b)furan",C1=CC=C2C(=C1)C=CC3=C2C=C(O3)[N+](=O)[O-],,,,,,
354,50355,CID 50355,CCOC(=O)C=C(C)C=CC=CCC1=CC2=C(C=C1)C(CCC2(C)C)(C)C,,,,,,
355,50356,9-(p-(Butylamino)anilino)acridine hydrochloride,CCCCNC1=CC=C(C=C1)[NH2+]C2=C3C=CC=CC3=NC4=CC=CC=C42.[Cl-],,,,,,
356,50357,"ACRIDINE, 9-(p-(BUTYLAMINO)ANILINO)-",CCCCNC1=CC=C(C=C1)NC2=C3C=CC=CC3=NC4=CC=CC=C42,,,,,,
357,50358,"Ethanamine, 2-((1,1-dimethylbutyl)dithio)-, hydrochloride",CCCC(C)(C)SSCC[NH3+].[Cl-],,,,,,
358,50359,2-(2-Methylpentan-2-yldisulfanyl)ethanamine,CCCC(C)(C)SSCCN,,,,,,
359,50360,3-Methyl-4-nitrobiphenyl,CC1=C(C=CC(=C1)C2=CC=CC=C2)[N+](=O)[O-],,,,,,
360,50361,"L-LYSINE, MONO(alpha-METHYL-4-(2-THIENYLCARBONYL)BENZENEACETATE)",CC(C1=CC=C(C=C1)C(=O)C2=CC=CS2)C(=O)[O-].C(CC[NH3+])C[C@@H](C(=O)O)N,,,,,,
361,50362,3-((p-(Dimethylamino)phenyl)azo)benzaldehyde,CN(C)C1=CC=C(C=C1)N=NC2=CC=CC(=C2)C=O,,,,,,
362,50363,"BENZYL ALCOHOL, m-((p-AMINOPHENYL)AZO)-",C1=CC(=CC(=C1)N=NC2=CC=C(C=C2)N)CO,,,,,,
363,50364,3-((p-Methylaminophenyl)azo)benzyl alcohol,CNC1=CC=C(C=C1)N=NC2=CC=CC(=C2)CO,,,,,,
364,50365,N-Methyl-4-(m-tolylazo)acetanilide,CC1=CC(=CC=C1)N=NC2=CC=C(C=C2)N(C)C(=O)C,,,,,,
365,50366,"BENZOIC ACID, m-((p-METHYLAMINOPHENYL)AZO)-",CNC1=CC=C(C=C1)N=NC2=CC=CC(=C2)C(=O)O,,,,,,
366,50367,Buprofezin,CC(C)N1C(=NC(C)(C)C)SCN(C1=O)C2=CC=CC=C2,,,"['Pesticides designed to control insects that are harmful to man. The insects may be directly harmful, as those acting as disease vectors, or indirectly harmful, as destroyers of crops, food products, or textile fabrics. (See all compounds classified as Insecticides.)']","['(14)C-buprofezin (radiochemical purity >97%) administered by gavage to 5 rats/sex/dose at 10 and 100 mg/kg; in males, 90-91% of dose eliminated by 48 hr (20-21% in urine, 69-71% in feces); in females, 87-89% of dose eliminated by 48 hr (13-14% in urine, 73-76% in feces); elimination faster in males during 1st 24 hr, but equalized by 48 hr; <1% of dose remained in body by 7 days; > or =30% of male dose and > or =38% of female dose recovered in bile at 24 hr; chromatography of urine, bile, and feces indicated extensive conjugation; bile cannulation of 3M/3F revealed that fecal metabolites were likely of bile origin.', '[(14)C-phenyl]-buprofezin (2 or 22.5 mCi/mmol; >97% radiochemical purity) suspended in 1 mL of olive oil was administered by gavage to fasted /rats/ at 10 and 100 mg/kg (number of animals varied with the experiment); over 90% of administered dose was excreted by 48 hr at both concentrations; by 96 hr at both concentrations, 70-74% of dose excreted in feces (though a delay at the high dose relative to the low dose was noted through 24 hr), 21-25% in urine, very low amounts excreted as expired (14)C-CO2; at 10 mg/kg, 12% of the parent compound was excreted into the feces; Cmax in blood occurred at 9 hr for both doses after which concentrations declined biphasically (t1/2 =13 and 60 hr); peak levels of radiolabel occurred in tissues at 5-9 hr post dose, after which tissue levels decreased biphasically with a t1/2 of 3.5-15 hr and 15-72 hr for the 2 phases; by 96 hr tissue residue levels were low.', 'Male rats /were/ fed diet containing buprofezin at 200 or 1000 ppm for up to 24 weeks; 3/dose were sacrificed on days 2 and 4 and on weeks 1, 2, 4, 8, 12, 16, and 24; buprofezin levels measured by gas-liquid chromatography after extraction from blood, brain, liver, kidney, adipose tissue, and muscle; detection limit: 0.1 ppm; 200 ppm: only adipose tissue attained levels high enough to consistently detect, remaining stable between 4 days and 24 weeks at a mean concentration of 0.43-1.10 ppm; an occasional animal showed detectable levels in liver, while kidney, muscle, and brain never showed detectable levels; 1000 ppm: adipose tissue peaked at 10.53 ppm on day 4, declining to 3.40 ppm at 24 weeks; liver retained a stable concentration of 0.21-0.96 over the entire period; kidneys were near or below the detection limit for 8 weeks and undetectable thereafter; brain was near or below the detection limit for 1 week and undetectable thereafter; muscle was near or below the detection limit for 2 weeks and undetectable thereafter (no measurement at 4 weeks); test article thus did not accumulate in any tissue at either concentration.']","['[(14)C-phenyl]-buprofezin (2 or 22.5 mCi/mmol; >97% radiochemical purity) suspended in 1 mL of olive oil was administered by gavage to fasted /rats/ at 10 and 100 mg/kg (number of animals varied with the experiment); ... metabolite studies revealed hydroxylation of the phenyl ring, oxidation of sulfur, and cleavage of the thiadiazin ring, with evidence of glucuronic and sulfuric conjugation.', '/In/ ruminants: 2-tert-butylimino-5-(4-hydroxyphenyl)-3-isopropyl-1,3,5- thiadiazinan-4-one (BF2) was the major residue identified in liver and kidney (residue in fat and muscle were < or =0.020 ppm) and N-(4-hydroxyphenyl)acetamide (BF23) was the major residue identified in milk from the ruminant metabolism study (all other residue were <10% total radioactive residue (TRR); 3.5x maximum theoretical dietary burden (MTDB)). ...The residues of concern in milk are buprofezin and BF23; ... the residues of concern in ruminant tissues are buprofezin and BF2.']",
367,50368,"2-Tert-butylimino-5-(4-hydroxyphenyl)-3-propan-2-yl-1,3,5-thiadiazinan-4-one",CC(C)N1C(=NC(C)(C)C)SCN(C1=O)C2=CC=C(C=C2)O,,,,,,
368,50369,2-(6-Methoxynaphthalen-2-yl)-2-methylpropanoic acid,CC(C)(C1=CC2=C(C=C1)C=C(C=C2)OC)C(=O)O,,,,,,
369,50370,2-ethoxy-N-[(4-methylphenyl)methyl]benzamide,CCOC1=CC=CC=C1C(=O)NCC2=CC=C(C=C2)C,,,,,,
370,50371,2-Ethoxy-N-(1-phenylbutyl)benzamide,CCCC(C1=CC=CC=C1)NC(=O)C2=CC=CC=C2OCC,,,,,,
371,50372,Propyl 3-benzoyloxy-8-methyl-8-azoniabicyclo[3.2.1]octane-2-carboxylate;chloride,CCCOC(=O)C1C2CCC([NH+]2C)CC1OC(=O)C3=CC=CC=C3.[Cl-],,,,,,
372,50373,3-Benzoyloxy-8-methyl-8-aza-bicyclo[3.2.1]octane-2-carboxylic acid propyl ester,CCCOC(=O)C1C2CCC(N2C)CC1OC(=O)C3=CC=CC=C3,,,,,,
373,50374,Ethyl 2-oxo-5-(2-propynyloxymethyl)tetrahydro-3-furanacetate,CCOC(=O)CC1CC(OC1=O)COCC#C,,,,,,
374,50375,"HEPTANOIC ACID, ESTER with DIETHYL (2,2,2-TRICHLORO-1-HYDROXYETHYL)PHOSPHONATE",CCCCCCC(=O)OP(=C(C(Cl)(Cl)Cl)O)(OCC)OCC,,,,,,
375,50376,"Phosphonic acid, (2,2,2-trichloro-1-hydroxyethyl)-, diethyl ester, hexanoate",CCCCCC(=O)OC(C(Cl)(Cl)Cl)P(=O)(OCC)OCC,,,,,,
376,50377,(alpha-Ethyl-p-phenylbenzyl)hydrazine hydrochloride,CCC(C1=CC=C(C=C1)C2=CC=CC=C2)N[NH3+].[Cl-],,,,,,
377,50378,1-(4-Phenylphenyl)propylhydrazine,CCC(C1=CC=C(C=C1)C2=CC=CC=C2)NN,,,,,,
378,50379,"Hydrazine, 1-(2-hydroxyethyl)-2-(5-methyl-3-isoxazolylcarbonyl)-",CC1=CC(=NO1)C(=O)NNCCO,,,,,,
379,50380,1-(alpha-Methylbenzyl)hydrazine hemisulfate,CC(C1=CC=CC=C1)NN.CC(C1=CC=CC=C1)NN.OS(=O)(=O)O,,,,,,
380,50381,1-(3-Phenylpropyl)hydrazine hydrogen sulfate,C1=CC=C(C=C1)CCCN[NH3+].OS(=O)(=O)[O-],,,,,,
381,50382,"3,7-Diazaadamantan-9-one, 1,5-bis(3,4-dimethoxyphenyl)-",COC1=C(C=C(C=C1)C23CN4CC(C2=O)(CN(C3)C4)C5=CC(=C(C=C5)OC)OC)OC,,,,,,
382,50383,"3,7-DIAZAADAMANTAN-9-ONE, 1,5-BIS(m-METHOXYPHENYL)-",COC1=CC=CC(=C1)C23CN4CC(C2=O)(CN(C3)C4)C5=CC(=CC=C5)OC,,,,,,
383,50384,"3,7-DIAZAADAMANTAN-9-ONE, 1,5-BIS(o-METHOXYPHENYL)-",COC1=CC=CC=C1C23CN4CC(C2=O)(CN(C3)C4)C5=CC=CC=C5OC,,,,,,
384,50385,"3,7-DIAZAADAMANTAN-9-ONE, 1,5-BIS(p-METHOXYPHENYL)-",COC1=CC=C(C=C1)C23CN4CC(C2=O)(CN(C3)C4)C5=CC=C(C=C5)OC,,,,,,
385,50386,"Cinnoline-3-acetic acid, 6,7-dimethyl-4-hydroxy-",CC1=CC2=C(C=C1C)NN=C(C2=O)CC(=O)O,,,,,,
386,50387,"2,4,6-Cycloheptatriene-1-acetic acid, 2-(morpholinoethyl) ester, hydrochloride",C1COCC[NH+]1CCOC(=O)CC2C=CC=CC=C2.[Cl-],,,,,,
387,50388,"2,4,6-Cycloheptatrien-1-ylacetic acid 2-morpholinoethyl ester",C1COCCN1CCOC(=O)CC2C=CC=CC=C2,,,,,,
388,50389,"2,4,6-Cycloheptatriene-1-acetic acid, 3-morpholinopropyl ester, hydrochloride",C1COCC[NH+]1CCCOC(=O)CC2C=CC=CC=C2.[Cl-],,,,,,
389,50390,"3-Morpholin-4-ylpropyl 2-cyclohepta-2,4,6-trien-1-ylacetate",C1COCCN1CCCOC(=O)CC2C=CC=CC=C2,,,,,,
390,50391,"2,4,6-Cycloheptatriene-1-acetic acid, 2-piperidinoethyl ester, hydrochloride",C1CC[NH+](CC1)CCOC(=O)CC2C=CC=CC=C2.[Cl-],,,,,,
391,50392,"2-Piperidin-1-ylethyl 2-cyclohepta-2,4,6-trien-1-ylacetate",C1CCN(CC1)CCOC(=O)CC2C=CC=CC=C2,,,,,,
392,50393,"2,4,6-Cycloheptatriene-1-acetic acid, 3-(piperidinopropyl) ester, hydrochloride",C1CC[NH+](CC1)CCCOC(=O)CC2C=CC=CC=C2.[Cl-],,,,,,
393,50394,"3-Piperidin-1-ylpropyl 2-cyclohepta-2,4,6-trien-1-ylacetate",C1CCN(CC1)CCCOC(=O)CC2C=CC=CC=C2,,,,,,
394,50395,"2,4,6-Cycloheptatriene-1-acetic acid, 2-(1-pyrrolidinyl)ethyl ester, hydrochloride",C1CC[NH+](C1)CCOC(=O)CC2C=CC=CC=C2.[Cl-],,,,,,
395,50396,"2-Pyrrolidin-1-ylethyl 2-cyclohepta-2,4,6-trien-1-ylacetate",C1CCN(C1)CCOC(=O)CC2C=CC=CC=C2,,,,,,
396,50397,2-Bromobicyclo(2.2.2)octane-2-carboxamide,C1CC2CCC1CC2(C(=O)N)Br,,,,,,
397,50398,2-Methylbicyclo(2.2.2)octane-2-carboxamide,CC1(CC2CCC1CC2)C(=O)N,,,,,,
398,50399,5-exo-Methylbicyclo(2.2.2)oct-2-ene-5-endo-carboxamide,CC1(CC2CCC1C=C2)C(=O)N,,,,,,
399,50400,5-Propylbicyclo[2.2.2]oct-2-ene-5-carboxamide,CCCC1(CC2CCC1C=C2)C(=O)N,,,,,,
400,50401,"Carbamic acid, (2-(1-ethylpropoxy)ethyl) ester",CCC(CC)OCCOC(=O)N,,,,,,
401,50402,CID 50402,C(CS)N=C(S)S,,,,,,
402,50403,(2-(1-Methylbutoxy)ethyl)carbamate,CCCC(C)OCCOC(=O)N,,,,,,
403,50404,(2-(2-Methylbutoxy)ethyl)carbamate,CCC(C)COCCOC(=O)N,,,,,,
404,50405,"Carbamic acid, (2-(3-methylbutoxy)ethyl) ester",CC(C)CCOCCOC(=O)N,,,,,,
405,50406,(2-(1-Methylpropoxy)ethyl)carbamate,CCC(C)OCCOC(=O)N,,,,,,
406,50407,"Carbamic acid, (2-pentoxyethyl) ester",CCCCCOCCOC(=O)N,,,,,,
407,50408,"Carbamic acid, (2-propoxyethyl) ester",CCCOCCOC(=O)N,,,,,,
408,50409,Methyl (3-(p-benzyl-alpha-methylbenzyl))carbazate hydrochloride,CC(C1=CC=C(C=C1)CC2=CC=CC=C2)[NH2+]NC(=O)OC.[Cl-],,,,,,
409,50410,methyl N-[1-(4-benzylphenyl)ethylamino]carbamate,CC(C1=CC=C(C=C1)CC2=CC=CC=C2)NNC(=O)OC,,,,,,
410,50411,"Carbazic acid, 3-benzyl-, methyl ester",COC(=O)NNCC1=CC=CC=C1,,,,,,
411,50412,"CARBAZIC ACID, 3-(p-BUTOXYBENZYL)-, ETHYL ESTER",CCCCOC1=CC=C(C=C1)CNNC(=O)OCC,,,,,,
412,50413,Ethyl 3-(p-chloro-alpha-methylbenzyl)carbazate,CCOC(=O)NNC(C)C1=CC=C(C=C1)Cl,,,,,,
413,50414,Ethyl 3-(alpha-ethylbenzyl)carbazate,CCC(C1=CC=CC=C1)NNC(=O)OCC,,,,,,
414,50415,Ethyl 3-(p-methoxy-alpha-methylbenzyl)carbazate,CCOC(=O)NNC(C)C1=CC=C(C=C1)OC,,,,,,
415,50416,tert-Butyl (3-alpha-methylbenzyl)carbazate,CC(C1=CC=CC=C1)NNC(=O)OC(C)(C)C,,,,,,
416,50417,1-Methyl-4-ethyl-2-(alpha-methylbenzyl)bicarbamate,CCOC(=O)NN(C(C)C1=CC=CC=C1)C(=O)OC,,,,,,
417,50418,2-Chloroethyl 3-phenethylcarbazate hydrochloride,C1=CC=C(C=C1)CC[NH2+]NC(=O)OCCCl.[Cl-],,,,,,
418,50419,2-chloroethyl N-(2-phenylethylamino)carbamate,C1=CC=C(C=C1)CCNNC(=O)OCCCl,,,,,,
419,50420,Ethyl 3-phenethylcarbazate,CCOC(=O)NNCCC1=CC=CC=C1,,,,,,
420,50421,"Carbazic acid, 3-phenethyl-, methyl ester",COC(=O)NNCCC1=CC=CC=C1,,,,,,
421,50422,CID 50422,CN(C)CCCN=C(C1=CC(=C(C=C1)OC)OC)S,,,,,,
422,50423,CID 50423,CN(C)CCCN=C(C1=CC(=C(C(=C1)OC)OC)OC)S,,,,,,
423,50424,CID 50424,CC(C)COC1=CC=C(C=C1)C(=NCCN2CCOCC2)S,,,,,,
424,50425,CID 50425,CC(C)COC1=CC=C(C=C1)C(=NCCN2CCCCC2)S,,,,,,
425,50426,CID 50426,CC(C)COC1=CC=C(C=C1)C(=NCCN2CCCC2)S,,,,,,
426,50427,CID 50427,CC(C)CCOC1=CC=C(C=C1)C(=NCCN2CCOCC2)S,,,,,,
427,50428,CID 50428,CCCOC1=CC=C(C=C1)C(=NCCN2CCOCC2)S,,,,,,
428,50429,CID 50429,CCCOC1=CC=C(C=C1)C(=NCCN2CCCCC2)S,,,,,,
429,50430,"1H-1-Benzazepine, 2,5-dihydro-7,8-dimethyl-2,5-dioxo-4-(piperidinomethyl)-",CC1=CC2=C(C=C1C)NC(=O)C=C(C2=O)CN3CCCCC3,,,,,,
430,50431,"5-Aminomethyl-6,7,8,9-tetrahydro-5H-benzocycloheptene-5-amine",C1CCC(C2=CC=CC=C2C1)(CN)N,,,,,,
431,50432,"3H-1,4-Benzodiazepine, 7-chloro-2-(N-methoxymethyl-N-methylamino)-5-phenyl-, 4-oxide",CN(COC)C1=NC2=C(C=C(C=C2)Cl)C(=[N+](C1)[O-])C3=CC=CC=C3,,,,,,
432,50433,"Benzofuran, 6-(2,4-dichlorobenzoyl)-4,7-dimethoxy-2,3-dimethyl-",CC1=C(OC2=C(C(=CC(=C12)OC)C(=O)C3=C(C=C(C=C3)Cl)Cl)OC)C,,,,,,
433,50434,2-Methoxy-3-piperidinomethylanthraquinone,COC1=CC2=C(C=C1CC3CCCNC3)C(=O)C4=CC=CC=C4C2=O,,,,,,
434,50435,"Barbituric acid, 5-allyl-5-piperonyl-",C=CCC1(C(=O)NC(=O)NC1=O)CC2=CC3=C(C=C2)OCO3,,,,,,
435,50436,CID 50436,CCC1(C(=NC(=NC1=O)S)[O-])C2=CCCCC2.[Na+],,,,,,
436,50437,CID 50437,CCC1(C(=O)NC(=NC1=O)S)C2=CCCCC2,,,,,,
437,50438,"Barbituric acid, 5-ethyl-5-piperonyl-",CCC1(C(=O)NC(=O)NC1=O)CC2=CC3=C(C=C2)OCO3,,,,,,
438,50439,CID 50439,CCN(CC)CCN=C(C1=CC=C(C=C1)Cl)S,,,,,,
439,50440,CID 50440,CCN(CC)CCCN=C(C1=CC=C(C=C1)Cl)S,,,,,,
440,50441,CID 50441,CCN(CC)CCN=C(C1=CC(=C(C(=C1)OC)OC)OC)S,,,,,,
441,50442,CID 50442,CCN(CC)CCCN=C(C1=CC(=C(C(=C1)OCC)OCC)OCC)S,,,,,,
442,50443,CID 50443,CCN(CC)CCN=C(C1=CC(=C(C=C1)OC)OC)S,,,,,,
443,50444,"Benzeneacetic acid, alpha-amino-, propyl ester, hydrochloride, (+-)-",CCCOC(=O)C(C1=CC=CC=C1)[NH3+].[Cl-],,,,,,
444,50445,Propyl amino(phenyl)acetate,CCCOC(=O)C(C1=CC=CC=C1)N,,,,,,
445,50446,"Glycine, 2-phenyl-, pentyl ester, hydrochloride, D,L-",CCCCCOC(=O)C(C1=CC=CC=C1)[NH3+].[Cl-],,,,,,
446,50447,Pentyl 2-amino-2-phenylacetate,CCCCCOC(=O)C(C1=CC=CC=C1)N,,,,,,
447,50448,"Glycine, 2-phenyl-, hexyl ester, hydrochloride, D,L-",CCCCCCOC(=O)C(C1=CC=CC=C1)[NH3+].[Cl-],,,,,,
448,50449,Hexyl 2-amino-2-phenylacetate,CCCCCCOC(=O)C(C1=CC=CC=C1)N,,,,,,
449,50450,"Glycine, 2-phenyl-, octyl ester, hydrochloride, D,L-",CCCCCCCCOC(=O)C(C1=CC=CC=C1)[NH3+].[Cl-],,,,,,
450,50451,(R)-alpha-Aminobenzeneacetic acid octyl ester,CCCCCCCCOC(=O)C(C1=CC=CC=C1)N,,,,,,
451,50452,"Glycine, 2-phenyl-, nonyl ester, hydrochloride, D,L-",CCCCCCCCCOC(=O)C(C1=CC=CC=C1)[NH3+].[Cl-],,,,,,
452,50453,Nonyl 2-amino-2-phenylacetate,CCCCCCCCCOC(=O)C(C1=CC=CC=C1)N,,,,,,
453,50454,Fenoctimine sulfate,CCCCCCCCN=CN1CCC(CC1)C(C2=CC=CC=C2)C3=CC=CC=C3.CCCCCCCCN=CN1CCC(CC1)C(C2=CC=CC=C2)C3=CC=CC=C3.O.OS(=O)(=O)O.OS(=O)(=O)O,,,,,,
454,50455,Fenoctimine,CCCCCCCCN=CN1CCC(CC1)C(C2=CC=CC=C2)C3=CC=CC=C3,,,,,,
455,50456,CID 50456,CC(=[NH+]C1=NC2=CC=CC=C2C=C1)S.[Cl-],,,,,,
456,50457,CID 50457,CC(=NC1=NC2=CC=CC=C2C=C1)S,,,,,,
457,50458,"3,4,5-trimethoxy-N-[4-[C-methyl-N-(2-morpholin-4-ylethoxy)carbonimidoyl]phenyl]benzamide",CC(=NOCCN1CCOCC1)C2=CC=C(C=C2)NC(=O)C3=CC(=C(C(=C3)OC)OC)OC,,,,,,
458,50459,beta-Phenylpropyl-trimethylammonium iodide,CC(C[N+](C)(C)C)C1=CC=CC=C1.[I-],,,,,,
459,50460,Trimethyl(2-phenylpropyl)azanium,CC(C[N+](C)(C)C)C1=CC=CC=C1,,,,,,
460,50461,Trimethyl(1-methyl-3-phenylpropyl)ammonium iodide,CC(CCC1=CC=CC=C1)[N+](C)(C)C.[I-],,,,,,
461,50462,Trimethyl(4-phenylbutan-2-yl)azanium,CC(CCC1=CC=CC=C1)[N+](C)(C)C,,,,,,
462,50463,Diproteverine,CCOC1=C(C=C(C=C1)CC2=NCCC3=CC(=C(C=C32)OC(C)C)OC(C)C)OCC,,,,,,
463,50464,Antibiotic XK 62-3,CC1(COC(C(C1NC)O)OC2C(CC(C(C2O)OC3C(CCC(O3)CN)N)NC)N)O,,,,,,
464,50465,Fluroxypyr,C(C(=O)O)OC1=NC(=C(C(=C1Cl)N)Cl)F,,,"['Pesticides used to destroy unwanted vegetation, especially various types of weeds, grasses (POACEAE), and woody plants. Some plants develop HERBICIDE RESISTANCE. (See all compounds classified as Herbicides.)']","['Fluroxypyr is absorbed rapidly and excreted primarily in the urine via the kidney.', 'Fluroxypyr (14)C-methylheptyl ester (95.8 % a.i. unlabeled; radiochemical purity 99%; labeled on the methylheptanol portion of the molecule) or (14)C-methylheptanol (98.9% unlabeled; radiochemical purity 97.5%) showed the principal route of excretion being expired (14)CO2, which contained 61% and 63% of the radioactivity for the fluroxypyr methylheptyl ester and methylheptanol balance groups, respectively. The urine contained 30% and 27% and the feces contained 5% and 7% of the administered dose for the fluroxypyr methylheptyl ester and methylheptanol groups, respectively. Each was extensively absorbed and rapidly eliminated. Approximately 52% and 54% of the administered fluroxypyr methylheptyl ester and methylheptanol, respectively, was absorbed and expired as (14)CO2 within 12 hr post dose, and an additional 18% of the administered dose was excreted in the urine within 12 hr post dose. Based on the percentage of the dose in the expired (14)CO2, urine, and tissues, 90% of the dose was absorbed by the rats in each case. Once absorbed, both were extensively metabolized and rapidly expired as (14)CO2 and eliminated in the urine with a half-life of 6 hours. Half-lives for the elimination phase were 18.2 and 17.4 hr for fluroxypyr methylheptyl ester and Methylheptanol, respectively. Data indicate that the fluroxypyr methylheptyl ester bond is readily hydrolyzed and that the methylheptyl ester portion of fluroxypyr is bioequivalent to Methylheptanol. /Fluroxypyr-1-methylheptyl ester/', 'In rats, following oral administration, fluroxypyr is not metabolized, but is rapidly excreted unchanged, principally in the urine.']","['... The aim of these studies was to determine the transdermal metabolism of three related compounds [the herbicide, fluroxypyr methylheptyl ester (FPMH), fluroxypyr methyl ester (FPM), and fluroxypyr (FP)] during penetration through human and /F344 male/ rat skin in vitro ... Both FPM and FPMH were completely metabolized during their passage through human and rat skin in vitro. The only metabolite produced was that of the hydrolysis product, FP, with no parent ester penetrating through the skin. The extent of FP formation within the skin was directly correlated to the degree of stratum corneum reservoir formation. The larger the stratum corneum reservoir, the lower the levels of FP recovered from within the skin. This suggests that as the ester partitioned out of the SC it was immediately hydrolyzed to FP, which could then pass freely through the remainder of the epidermis and dermis. Similar metabolic profiles were observed for the transdermal metabolism of FPM and FPMH in previously frozen rat skin, indicating the robust nature of the esterase enzymes involved. In conclusion, systemic exposure after skin contact with FPM or FPMH is likely to be to the acid metabolite, FP, only and not to the parent ester. In addition, the rate and extent of percutaneous absorption will be a major determinant of cutaneous metabolism. /Fluroxypyr-1-methylheptyl ester/', '... With fluroxypyr acid, most of the administered dose is excreted as the fluroxypyr, without the formation of significant metabolites. The pattern with fluroxypyr-MHE is quite different: there is extensive metabolism resulting in the formation of about 20-22 metabolites, with a substantial proportion of the administered dose excreted in expired air - indicating complete mineralization - and most of the remaining dose excreted as urinary metabolites. /Fluroxypyr-1-methylheptyl ester/', 'Eight male Fischer 344 rats/group were treated orally by gavage with either 17.7 mg/kg of 1-methylheptanol-1-(14)C (B930-93, radiochemical purity: 97.5%, specific activity: 24.2 mCi/mmol) or 50.0 mg/kg of Fluroxypyr 1-methylheptyl-1-(14)C ester (B930-96, radiochemical purity: 99%, specific activity: 25.3 mCi/mmol). Five animals/group were included in a pharmacokinetic study in which plasma samples were drawn from an indwelling catheter at 10, 20 , 30, 45 min and 1, 1.5, 2, 3, 5, 7, 10, 12, 24, 48 hr post-dose. The 3 remaining animals/group were included in an excretion balance study in which urine, cage wash and CO2 samples were collected at 12, 24, 36, and 48 hr post-dose and fecal samples were collected at 24 and 48 hr. The pharmacokinetic parameters and excretion profiles for both test materials are very similar. The study results indicate that the metabolic profile of the methylheptanol moiety of fluroxypyr methylheptyl ester is quite similar to that of methylheptanol itself. /Fluroxypyr-1-methylheptyl ester/', 'Five substudies were performed in which CD rats were dosed orally by gavage with 50 mg/kg in single or multiple daily doses of (14)C-Dowco 433 MHE (lot no. 6-HD-0113-39a, specific activity: 61.8 uCi/mg, radiochemical purity: 99%) mixed with non-radiolabeled Dowco 433 MHE (lot no. EMJ 211178) with a final specific activity of 0.937 uCi/mg and a radiochemical purity of 98%. The dosing material was mixed in olive oil and administered at a volume of 2.5 mL/kg. The radiolabel was located on the pyridinyl ring. In Study A (excretion study), 3 animals/sex were dosed for 7 days, followed by 5 days of sample collection. In Study B (plasma analysis), one group of 3 animals/sex received a single dose, followed by 5 days of sample collection. A second group of 3 animals/sex were dosed daily for 7 days, followed by 5 days of sample collection. In Study C (tissue distribution), 5 animals/sex were dosed daily for 7 days, followed by serial sacrifices of 1 animal/sex/time at 1, 7, 24, 72, and 168 hr after the last dose. In Study D (whole body autoradiography), 6 males were dosed daily for 7 days, followed by serial sacrifices of 1 animal/sex/time at 1, 7, 24, 72, and 168 hr after the last dose. In Study E (biliary excretion), two animals/sex received a single dose, followed by 2 days of sample collection. In the excretion study, approximately 92% of the administered dose was ultimately excreted in the urine with no difference between the sexes. Between 90 and 96% of the first administered dose was excreted within 24 hr. In the bile duct cannulated rats, only 60 to 64% of the administered dose was recovered in the urine within the 48 hr post-dose with 26 to 29% of the dose recovered in the feces. Only 0.7% of the dose was recovered in the bile. /It was concluded/ that the absence of bile in the gastrointestinal tract resulted in reduced absorption of the test material and thereby reduced the excretion observed in the urine. Peak plasma concentration levels of radiolabeling were observed within the 1st hr post-dose after a single dose and within the first two hr post-dose after multiple doses. The radiolabel within the tissues was largely localized within the kidneys, gastrointestinal tract, and blood with a progressive diminution of the concentrations in these sites over the 7 day sample collection period. The clarity of the autoradiographic pictures was too poor to make any more than a very general characterization of the distribution. More than 93% of the excreted radiolabel was identified as Dowco 433. Metabolic transformation of the test material was largely by ester hydrolysis. /Fluroxypyr-1-methylheptyl ester/', 'Three fasted male Wistar rats/group were dosed orally by gavage with 20 or 200 mg/kg or intravenously through an implanted jugular cannula with 20 mg/kg of (14)C-Dowco 433 (ref. no. GHD-1030-44a, radiochemical purity: >99%, specific activity: 22.7 mCi/mmol). The radiolabel was sited at the 2 and 6 positions of the pyridinyl ring. The dosing preparation was prepared by diluting this radiolabeled material with unlabeled Dowco 433 (ref. no. 230-75-42/43, purity: 99.5%) such that each animal received 5 uCi/dose. The dose was administered in an aqueous NaOH vehicle (pH adjusted to 6.5). Samples of heparinized blood were collected at specified time intervals (up to 48 hr for the oral treatments and up to 24 hr post-dose for the iv treatment). Urine was collected at 6, 12, 24, and 48 (except for iv treatment) hr post-dose. Feces were recovered at 24 hr intervals after dosing. Urinary excretion was the major route of elimination, accounting for 88 to 94% of the administered radioactivity. Residual radioactivity in the tissues was quite minimal at 24 or 48 hr post-dose. The absorption half- life was determined to be 1.3 hr. Plasma concentration-time demonstrated a biphasic profile with a fast elimination half-life of 4.2 min and a terminal elimination half-life of 6.4 hr. The AUC (ug hr/g) values were 22.26, 864.43, and 58.72 for the oral 20 mg/kg, the oral 200 mg/kg, and the iv 20 mg/kg treatments, respectively. This disproportionate increase in the AUC value for the 200 mg/kg treatment in comparison to that of the 20 mg/kg treatment (38.8 times greater) was attributed to a saturation of the excretion pathway at the higher dosing level. The test material was largely recovered in the urine unmetabolized.']","['In a study with (14)C-fluroxypyr-MHE in rats, ... a plasma half-life of 18.2 hr and a urinary half-life of 6 hr /was reported/. /Fluroxypyr-1-methylheptyl ester/']"
465,50466,"2-Benzyl-8-phenyl-1,2,3,4-tetrahydroisoquinoline hydrochloride",C1C[NH+](CC2=C1C=CC=C2C3=CC=CC=C3)CC4=CC=CC=C4.[Cl-],,,,,,
466,50467,"2-benzyl-8-phenyl-3,4-dihydro-1H-isoquinoline",C1CN(CC2=C1C=CC=C2C3=CC=CC=C3)CC4=CC=CC=C4,,,,,,
467,50468,"2-Benzyl-3-methyl-8-phenyl-1,2,3,4-tetrahydroisoquinoline hydrochloride",CC1CC2=C(C[NH+]1CC3=CC=CC=C3)C(=CC=C2)C4=CC=CC=C4.[Cl-],,,,,,
468,50469,"2-Benzyl-3-methyl-8-phenyl-1,2,3,4-tetrahydroisoquinoline",CC1CC2=C(CN1CC3=CC=CC=C3)C(=CC=C2)C4=CC=CC=C4,,,,,,
469,50470,"8-Phenyl-1,2,3,4-tetrahydroisoquinoline hydrochloride",C1C[NH2+]CC2=C1C=CC=C2C3=CC=CC=C3.[Cl-],,,,,,
470,50471,"8-Phenyl-1,2,3,4-tetrahydroisoquinoline",C1CNCC2=C1C=CC=C2C3=CC=CC=C3,,,,,,
471,50472,"3-Methyl-8-phenyl-1,2,3,4-tetrahydroisoquinoline hydrochloride",CC1CC2=C(C[NH2+]1)C(=CC=C2)C3=CC=CC=C3.[Cl-],,,,,,
472,50473,"3-Methyl-8-phenyl-1,2,3,4-tetrahydroisoquinoline",CC1CC2=C(CN1)C(=CC=C2)C3=CC=CC=C3,,,,,,
473,50474,CID 50474,COC(=O)CCC=C=CC[C@H]1[C@H](C[C@H](C1C=C[C@H](COC2=CC=CC=C2)O)O)O,,,,,,
474,50475,"Carbazic acid, 3-phenethyl-, (2-hydroxyethyl) ester",C1=CC=C(C=C1)CCNNC(=O)OCCO,,,,,,
475,50476,"alpha-Ethyl-3-(formamido)-2,4,6-triiodohydrocinnamic acid",CCC(CC1=C(C(=C(C=C1I)I)NC=O)I)C(=O)O,,,,,,
476,50477,CID 50477,CCCCCC(=O)NC1=C(C=C(C(=C1I)CC(CC)C(=O)[O-])I)I.[Na+],,,,,,
477,50478,"2-[[3-(Hexanoylamino)-2,4,6-triiodophenyl]methyl]butanoic acid",CCCCCC(=O)NC1=C(C=C(C(=C1I)CC(CC)C(=O)O)I)I,,,,,,
478,50479,CID 50479,CCC(CC1=C(C(=C(C=C1I)I)NC(=O)CC)I)C(=O)[O-].[Na+],,,,,,
479,50480,"2-[[2,4,6-Triiodo-3-(propanoylamino)phenyl]methyl]butanoic acid",CCC(CC1=C(C(=C(C=C1I)I)NC(=O)CC)I)C(=O)O,,,,,,
480,50481,CID 50481,CCCCC(=O)NC1=C(C=C(C(=C1I)CC(CC)C(=O)[O-])I)I.[Na+],,,,,,
481,50482,"2-[[2,4,6-Triiodo-3-(pentanoylamino)phenyl]methyl]butanoic acid",CCCCC(=O)NC1=C(C=C(C(=C1I)CC(CC)C(=O)O)I)I,,,,,,
482,50483,"Indole, 5-acetyl-3-morpholinomethyl-, monohydrate",CC(=O)C1=CC2=C(C=C1)NC=C2CN3CCOCC3.O,,,,,,
483,50484,1-[3-(morpholin-4-ylmethyl)-1H-indol-5-yl]ethanone,CC(=O)C1=CC2=C(C=C1)NC=C2CN3CCOCC3,,,,,,
484,50485,"Indole, 5-acetyl-3-piperidinomethyl-",CC(=O)C1=CC2=C(C=C1)NC=C2CN3CCCCC3,,,,,,
485,50486,CID 50486,CN1CCN(CC1)CCCC2=C3C(=CC=C2)N=C4C(=NC(=O)NC4=O)N3.Cl.Cl,,,,,,
486,50487,CID 50487,CN1CCN(CC1)CCCC2=C3C(=CC=C2)N=C4C(=NC(=O)NC4=O)N3,,,,,,
487,50488,"Phosphonic acid, (2,2,2-trichloro-1-hydroxyethyl)-, diethyl ester, isobutyrate",CCOP(=O)(C(C(Cl)(Cl)Cl)OC(=O)C(C)C)OCC,,,,,,
488,50489,"4-(p-Methoxybenzyl)-6,7-methylenedioxyisoquinoline methanesulfonate",COC1=CC=C(C=C1)CC2=C[NH+]=CC3=CC4=C(C=C32)OCO4.CS(=O)(=O)[O-],,,,,,
489,50490,"8-[(4-Methoxyphenyl)methyl]-[1,3]dioxolo[4,5-g]isoquinoline",COC1=CC=C(C=C1)CC2=CN=CC3=CC4=C(C=C32)OCO4,,,,,,
490,50491,Pivoxil sulbactam,CC1(C(N2C(S1(=O)=O)CC2=O)C(=O)OCOC(=O)C(C)(C)C)C,,,,,,
491,50492,CID 50492,CC1(C(N2C(S1(=O)=O)CC2=O)C(=O)[O-])C.[Na+],,,,,,
492,50493,Aminophenazone hemibarbital,CCC1(C(=O)NC(=O)NC1=O)CC.CC1=C(C(=O)N(N1C)C2=CC=CC=C2)N(C)C.CC1=C(C(=O)N(N1C)C2=CC=CC=C2)N(C)C,,,,,,
493,50494,3-Amino-4-cyclohexylaminocoumarin,C1CCC(CC1)NC2=C(C(=O)OC3=CC=CC=C32)N,,,,,,
494,50495,3-Amino-4-dipropylaminocoumarin,CCCN(CCC)C1=C(C(=O)OC2=CC=CC=C21)N,,,,,,
495,50496,"Coumarin, 3-amino-4-(4-phenyl-1-piperazinyl)-",C1CN(CCN1C2=CC=CC=C2)C3=C(C(=O)OC4=CC=CC=C43)N,,,,,,
496,50497,"5-Benzofuranol, 2-chloro-4-(dimethylaminomethyl)-3-phenyl-",CN(C)CC1=C(C=CC2=C1C(=C(O2)Cl)C3=CC=CC=C3)O,,,,,,
497,50498,3-Chloro-4-(diethylaminomethyl)-2-phenyl-5-benzofuranol hydrochloride,CC[NH+](CC)CC1=C(C=CC2=C1C(=C(O2)C3=CC=CC=C3)Cl)O.[Cl-],,,,,,
498,50499,3-Chloro-4-(diethylaminomethyl)-2-phenyl-1-benzofuran-5-ol,CCN(CC)CC1=C(C=CC2=C1C(=C(O2)C3=CC=CC=C3)Cl)O,,,,,,
499,50500,"5-Benzofuranol, 3-chloro-2-phenyl-4-(piperidinomethyl)-",C1CCN(CC1)CC2=C(C=CC3=C2C(=C(O3)C4=CC=CC=C4)Cl)O,,,,,,
500,50501,"5-Benzofuranol, 3-chloro-4-(morpholinomethyl)-2-phenyl-",C1COCCN1CC2=C(C=CC3=C2C(=C(O3)C4=CC=CC=C4)Cl)O,,,,,,
501,50502,"5-Benzofuranol, 3-chloro-2-phenyl-4-((4-phenyl-1-piperazinyl)methyl)-",C1CN(CCN1CC2=C(C=CC3=C2C(=C(O3)C4=CC=CC=C4)Cl)O)C5=CC=CC=C5,,,,,,
502,50503,"5-Benzofuranol, 4-bromo-6-(dimethylaminomethyl)-2-phenyl-",CN(C)CC1=CC2=C(C=C(O2)C3=CC=CC=C3)C(=C1O)Br,,,,,,
503,50504,"5-Benzofuranol, 4-bromo-2-phenyl-6-piperidinomethyl-",C1CCN(CC1)CC2=CC3=C(C=C(O3)C4=CC=CC=C4)C(=C2O)Br,,,,,,
504,50505,"5-Benzofuranol, 4-bromo-6-(morpholinomethyl)-2-phenyl-",C1COCCN1CC2=CC3=C(C=C(O3)C4=CC=CC=C4)C(=C2O)Br,,,,,,
505,50506,4-Bromo-2-phenyl-6-((4-phenyl-1-piperazinyl)methyl)-5-benzofuranol,C1CN(CCN1CC2=CC3=C(C=C(O3)C4=CC=CC=C4)C(=C2O)Br)C5=CC=CC=C5,,,,,,
506,50507,"2,4-Dibromo-6-(diethylaminomethyl)-3-phenyl-5-benzofuranol hydrochloride",CC[NH+](CC)CC1=CC2=C(C(=C(O2)Br)C3=CC=CC=C3)C(=C1O)Br.[Cl-],,,,,,
507,50508,"2,4-Dibromo-6-(diethylaminomethyl)-3-phenyl-1-benzofuran-5-ol",CCN(CC)CC1=CC2=C(C(=C(O2)Br)C3=CC=CC=C3)C(=C1O)Br,,,,,,
508,50509,"5-Benzofuranol, 2,4-dibromo-3-phenyl-6-(piperidinomethyl)-",C1CCN(CC1)CC2=CC3=C(C(=C(O3)Br)C4=CC=CC=C4)C(=C2O)Br,,,,,,
509,50510,"5-Benzofuranol, 2,4-dibromo-6-(morpholinomethyl)-3-phenyl-",C1COCCN1CC2=CC3=C(C(=C(O3)Br)C4=CC=CC=C4)C(=C2O)Br,,,,,,
510,50511,"5-Benzofuranol, 2,4-dibromo-3-phenyl-6-((4-phenyl-1-piperazinyl)methyl)-",C1CN(CCN1CC2=CC3=C(C(=C(O3)Br)C4=CC=CC=C4)C(=C2O)Br)C5=CC=CC=C5,,,,,,
511,50512,"6-Benzofuranol, 7-(benzylaminomethyl)-2,5-dibromo-3-phenyl-",C1=CC=C(C=C1)CNCC2=C3C(=CC(=C2O)Br)C(=C(O3)Br)C4=CC=CC=C4,,,,,,
512,50513,"Glycine, N-(N-(3-amino-3,3-diphosphonopropyl)glycyl)-, dihydrate",C(CNCC(=O)NCC(=O)O)C(N)(P(=O)(O)O)P(=O)(O)O.O.O,,,,,,
513,50514,"2-[[2-[(3-Amino-3,3-diphosphonopropyl)amino]acetyl]amino]acetic acid",C(CNCC(=O)NCC(=O)O)C(N)(P(=O)(O)O)P(=O)(O)O,,,,,,
514,50515,Amonafide,CN(C)CCN1C(=O)C2=CC=CC3=CC(=CC(=C32)C1=O)N,"['Investigated for use/treatment in breast cancer, ovarian cancer, and prostate cancer.']",,"['Agents used in the prophylaxis or therapy of VIRUS DISEASES. Some of the ways they may act include preventing viral replication by inhibiting viral DNA polymerase; binding to specific cell-surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking late stages of virus assembly. (See all compounds classified as Antiviral Agents.)', 'Substances that inhibit or prevent the proliferation of NEOPLASMS. (See all compounds classified as Antineoplastic Agents.)', 'Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. (See all compounds classified as Enzyme Inhibitors.)', 'Agents that are capable of inserting themselves between the successive bases in DNA, thus kinking, uncoiling or otherwise deforming it and therefore preventing its proper functioning. They are used in the study of DNA. (See all compounds classified as Intercalating Agents.)']",,,
515,50516,Fluvalinate,CC(C)C(C(=O)OC(C#N)C1=CC(=CC=C1)OC2=CC=CC=C2)NC3=C(C=C(C=C3)C(F)(F)F)Cl,,,"['Pesticides designed to control insects that are harmful to man. The insects may be directly harmful, as those acting as disease vectors, or indirectly harmful, as destroyers of crops, food products, or textile fabrics. (See all compounds classified as Insecticides.)']","['/Pyrethroids/ readily penetrate insect cuticle as shown by topical LD50 to Periplaneta (cockroach) ... /Pyrethroids/', 'When radioactive pyrethroid is administered orally to mammals, it is absorbed from intestinal tract of the animals and distributed in every tissue examined. Excretion of radioactivity in rats administered trans-isomer: dosage: 500 mg/kg; interval 20 days; urine 36%; feces 64%; total 100%. /Pyrethroids/', 'Although limited absorption may account for the low toxicity of some pyrethroids, rapid biodegradation by mammalian liver enzymes (ester hydrolysis and oxidation) is probably the major factor responsible. Most pyrethroid metabolites are promptly excreted, at least in part, by the kidney. /Pyrethroids/', 'When fluvalinate labeled with (14)C in the acid moiety was admin to rats at 1 mg/kg, (14)C was rapidly excreted into urine (9 to 19%) and feces (75 to 88%) within 4 days after admin. The major (14)C component (45% of the fecal (14)C) was the parent cmpd. Liver showed relatively higher (14)C tissue residue than other tissues, indicating that the (14)C tissue residues from fluvalinate are somewhat different from those of other pyrethroids having the same alcohol moiety ... The major urinary metabolites are anilino acid, its hydroxymethyl derivative, its glycine conjugate, haloaniline, and sulfate conjugate of hydroxyhaloaniline. On the other hand, the major fecal metabolites are anilino acid, its amide derivative, and several conjugates of anilino acid with  several endogenous components ...', 'When (14)C-acid-fluvalinate was admin to rhesus monkeys at 1 mg/kg, the (14)C was excreted into urine (37%) and feces (55%) within 5 days after admin.']","['The metabolic pathways for the breakdown of the pyrethroids vary little between mammalian species but vary somewhat with structure. ... Essentially, pyrethrum and allethrin are broken down mainly by oxidation of the isobutenyl side chain of the acid moiety and of the unsaturated side chain of the alcohol moiety with ester hydrolysis playing and important part, whereas for the other pyrethroids ester hydrolysis predominates. /Pyrethrum and pyrethroids/', 'The relative resistance of mammals to the pyrethroids is almost wholly attributable to their ability to hydrolyze the pyrethroids rapidly to their inactive acid and alcohol components, since direct injection into the mammalian CNS leads to a susceptibility similar to that seen in insects. Some additional resistance of homeothermic organisms can also be attributed to the negative temperature coefficient of action of the pyrethroids, which are thus less toxic at mammalian body temperatures, but the major effect is metabolic. Metabolic disposal of the pyrethroids is very rapid, which means that toxicity is high by the intravenous route, moderate by slower oral absorption, and often unmeasureably low by dermal absorption. /Pyrethroids/', 'Fastest breakdown is seen with primary alcohol esters of trans-substituted acids since they undergo rapid hydrolytic and oxidative attack. For all secondary alcohol esters and for primary alcohol cis-substituted cyclopropanecarboxylates, oxidative attack is predominant. /Pyrethroids/', 'Pyrethroids are generally metabolized in mammals through ester hydrolysis, oxidation, and conjugation, and there is no tendency to accumulate in tissues. In the environment, synthetic pyrethroids are fairly rapidly degraded in soil and in plants. Ester hydrolysis and oxidation at various sites on the molecule are the major degradation processes. /Pyrethroids/', 'For more Metabolism/Metabolites (Complete) data for FLUVALINATE (8 total), please visit the HSDB record page.']",['The elimination half-lives for mammals ranges from 6 to 12 hours.']
516,50517,1-(p-Allyloxyphenyl)-3-benzyl-2-phenylguanidine hydrobromide,C=CCOC1=CC=C(C=C1)[NH2+]C(=NCC2=CC=CC=C2)NC3=CC=CC=C3.[Br-],,,,,,
517,50518,2-Benzyl-1-phenyl-3-(4-prop-2-enoxyphenyl)guanidine,C=CCOC1=CC=C(C=C1)NC(=NCC2=CC=CC=C2)NC3=CC=CC=C3,,,,,,
518,50519,1-(p-Allyloxyphenyl)-3-benzyl-2-(p-tolyl)guanidine hydrobromide,CC1=CC=C(C=C1)NC(=NCC2=CC=CC=C2)[NH2+]C3=CC=C(C=C3)OCC=C.[Br-],,,,,,
519,50520,2-Benzyl-1-(4-methylphenyl)-3-(4-prop-2-enoxyphenyl)guanidine,CC1=CC=C(C=C1)NC(=NCC2=CC=CC=C2)NC3=CC=C(C=C3)OCC=C,,,,,,
520,50521,1-(p-Allyloxyphenyl)-3-benzyl-2-(p-methoxyphenyl)guanidine hydrobromide,COC1=CC=C(C=C1)NC(=NCC2=CC=CC=C2)[NH2+]C3=CC=C(C=C3)OCC=C.[Br-],,,,,,
521,50522,2-Benzyl-1-(4-methoxyphenyl)-3-(4-prop-2-enoxyphenyl)guanidine,COC1=CC=C(C=C1)NC(=NCC2=CC=CC=C2)NC3=CC=C(C=C3)OCC=C,,,,,,
522,50523,"GUANIDINE, 1-(p-ALLYLOXYPHENYL)-3-BENZYL-2-(p-ETHOXYPHENYL)-, HYDROBROMIDE",CCOC1=CC=C(C=C1)NC(=NCC2=CC=CC=C2)[NH2+]C3=CC=C(C=C3)OCC=C.[Br-],,,,,,
523,50524,2-Benzyl-1-(4-ethoxyphenyl)-3-(4-prop-2-enoxyphenyl)guanidine,CCOC1=CC=C(C=C1)NC(=NCC2=CC=CC=C2)NC3=CC=C(C=C3)OCC=C,,,,,,
524,50525,1-(p-Allyloxyphenyl)-3-benzyl-2-(p-chlorophenyl)guanidine hydrobromide,C=CCOC1=CC=C(C=C1)[NH2+]C(=NCC2=CC=CC=C2)NC3=CC=C(C=C3)Cl.[Br-],,,,,,
525,50526,2-Benzyl-1-(4-chlorophenyl)-3-(4-prop-2-enoxyphenyl)guanidine,C=CCOC1=CC=C(C=C1)NC(=NCC2=CC=CC=C2)NC3=CC=C(C=C3)Cl,,,,,,
526,50527,1-(p-Allyloxyphenyl)-3-(p-chlorophenethyl)-2-phenylguanidine hydrobromide,C=CCOC1=CC=C(C=C1)N=C([NH2+]CCC2=CC=C(C=C2)Cl)NC3=CC=CC=C3.[Br-],,,,,,
527,50528,2-[2-(4-Chlorophenyl)ethyl]-1-phenyl-3-(4-prop-2-enoxyphenyl)guanidine,C=CCOC1=CC=C(C=C1)NC(=NCCC2=CC=C(C=C2)Cl)NC3=CC=CC=C3,,,,,,
528,50529,1-(p-Allyloxyphenyl)-3-(p-chlorophenethyl)-2-(p-tolyl)guanidine hydrobromide,CC1=CC=C(C=C1)NC(=NCCC2=CC=C(C=C2)Cl)[NH2+]C3=CC=C(C=C3)OCC=C.[Br-],,,,,,
529,50530,2-[2-(4-Chlorophenyl)ethyl]-1-(4-methylphenyl)-3-(4-prop-2-enoxyphenyl)guanidine,CC1=CC=C(C=C1)NC(=NCCC2=CC=C(C=C2)Cl)NC3=CC=C(C=C3)OCC=C,,,,,,
530,50531,"Guanidine, 1-(p-allyloxyphenyl)-3-(p-chlorophenethyl)-2-(p-chlorophenyl)-, hydrobromide",C=CCOC1=CC=C(C=C1)[NH2+]C(=NCCC2=CC=C(C=C2)Cl)NC3=CC=C(C=C3)Cl.[Br-],,,,,,
531,50532,1-(4-Chlorophenyl)-2-[2-(4-chlorophenyl)ethyl]-3-(4-prop-2-enoxyphenyl)guanidine,C=CCOC1=CC=C(C=C1)NC(=NCCC2=CC=C(C=C2)Cl)NC3=CC=C(C=C3)Cl,,,,,,
532,50533,"Guanidine, 1-(p-allyloxyphenyl)-3-(p-bromophenyl)-2-(p-chlorophenethyl)-, hydrobromide",C=CCOC1=CC=C(C=C1)[NH2+]C(=NCCC2=CC=C(C=C2)Cl)NC3=CC=C(C=C3)Br.[Br-],,,,,,
533,50534,1-(4-Bromophenyl)-2-[2-(4-chlorophenyl)ethyl]-3-(4-prop-2-enoxyphenyl)guanidine,C=CCOC1=CC=C(C=C1)NC(=NCCC2=CC=C(C=C2)Cl)NC3=CC=C(C=C3)Br,,,,,,
534,50535,CID 50535,CC(=CC(=O)OC)NC(C1=CC=C(C=C1)O)C(=O)[O-].[K+],,,,,,
535,50536,2-(4-Hydroxyphenyl)-2-[(4-methoxy-4-oxobut-2-en-2-yl)amino]acetic acid,CC(=CC(=O)OC)NC(C1=CC=C(C=C1)O)C(=O)O,,,,,,
536,50537,"Methanesulfonic acid--2-(3,4-dichlorophenyl)-3-[(propan-2-yl)amino]bicyclo[2.2.2]octan-2-ol (1/1)",CC(C)N[C@H]1C2CCC([C@@]1(C3=CC(=C(C=C3)Cl)Cl)O)CC2.CS(=O)(=O)O,,,,,,
537,50538,"(2S,3S)-2-(3,4-dichlorophenyl)-3-(propan-2-ylamino)bicyclo[2.2.2]octan-2-ol",CC(C)N[C@H]1C2CCC([C@@]1(C3=CC(=C(C=C3)Cl)Cl)O)CC2,,,,,,
538,50539,"2,4,6-Cycloheptatrien-1-one, 3,4-dimethoxy-2-hydroxy-",COC1=CC=CC(=O)C(=C1OC)O,,,,,,
539,50540,"2-Methyl-2-butene-1,1,1-D3",[2H]C([2H])([2H])/C(=C/C)/C,,,,,,
540,50541,"2-Methyl-2-pentene-1,1,1-D3 (trans)",[2H]C([2H])([2H])/C(=C/CC)/C,,,,,,
541,50542,"2,4-Dimethyl-2-pentene-1,1,1-D3 (trans)",[2H]C([2H])([2H])/C(=C/C(C)C)/C,,,,,,
542,50543,1-Methoxy-2-methylbut-1-ene,CCC(=COC)C,,,,,,
543,50544,"1,2,6,7,8-Pentachlorodibenzofuran",C1=CC(=C(C2=C1OC3=C(C(=C(C=C23)Cl)Cl)Cl)Cl)Cl,,,,,,
544,50545,CID 50545,C[C@@H](C(=O)O)NC(=O)CNCCC(N)(P(=O)(O)O)P(=O)(O)O.O.O,,,,,,
545,50546,"N-(N-(3-Amino-3,3-diphosphonopropyl)glycyl)alanine",C[C@@H](C(=O)O)NC(=O)CNCCC(N)(P(=O)(O)O)P(=O)(O)O,,,,,,
546,50547,"Ether, benzyl thymyl",CC1=CC(=C(C=C1)C(C)C)OCC2=CC=CC=C2,,,,,,
547,50548,CID 50548,C1=CC=C(C=C1)C=C2C(=O)N(C(=N2)S)C3=CC(=CC=C3)I,,,,,,
548,50549,CID 50549,C1=CC=C(C(=C1)C=C2C(=O)N(C(=N2)S)C3=CC(=CC=C3)I)Cl,,,,,,
549,50550,CID 50550,C1=CC(=CC(=C1)Cl)C=C2C(=O)N(C(=N2)S)C3=CC(=CC=C3)I,,,,,,
550,50551,CID 50551,C1=CC(=CC(=C1)I)N2C(=O)C(=CC3=CC=C(C=C3)Cl)N=C2S,,,,,,
551,50552,CID 50552,CC1=CC=CC=C1C=C2C(=O)N(C(=N2)S)C3=CC(=CC=C3)I,,,,,,
552,50553,CID 50553,CC1=CC(=CC=C1)C=C2C(=O)N(C(=N2)S)C3=CC(=CC=C3)I,,,,,,
553,50554,CID 50554,CC1=CC=C(C=C1)C=C2C(=O)N(C(=N2)S)C3=CC(=CC=C3)I,,,,,,
554,50555,CID 50555,COC1=CC=CC=C1C=C2C(=O)N(C(=N2)S)C3=CC(=CC=C3)I,,,,,,
555,50556,CID 50556,COC1=CC=CC(=C1)C=C2C(=O)N(C(=N2)S)C3=CC(=CC=C3)I,,,,,,
556,50557,CID 50557,COC1=CC=C(C=C1)C=C2C(=O)N(C(=N2)S)C3=CC(=CC=C3)I,,,,,,
557,50558,CID 50558,C1=CC=C(C(=C1)C=C2C(=O)N(C(=N2)S)C3=CC(=CC=C3)I)[N+](=O)[O-],,,,,,
558,50559,CID 50559,C1=CC(=CC(=C1)I)N2C(=O)C(=CC3=CC=C(C=C3)[N+](=O)[O-])N=C2S,,,,,,
559,50560,"2-Ethyl-4-methylpentyl (2,4,5-trichlorophenoxy)acetate",CCC(CC(C)C)COC(=O)COC1=CC(=C(C=C1Cl)Cl)Cl,,,,,,
560,50561,"Ethanone, 2-((4,5-dihydro-1H-imidazol-2-yl)(5-(1-methylethyl)-1,3,4-thiadiazol-2-yl)amino)-1-phenyl-, monohydriodide",CC(C)C1=NN=C(S1)[NH+](CC(=O)C2=CC=CC=C2)C3=NCCN3.[I-],,,,,,
561,50562,"2-[4,5-dihydro-1H-imidazol-2-yl-(5-propan-2-yl-1,3,4-thiadiazol-2-yl)amino]-1-phenylethanone",CC(C)C1=NN=C(S1)N(CC(=O)C2=CC=CC=C2)C3=NCCN3,,,,,,
562,50563,"Ethanone, 2-((4,5-dihydro-1H-imidazol-2-yl)(5-methyl-1,3,4-thiadazol-2-yl)amino)-1-(4-methoxyphenyl)-, monohydriodide",CC1=NN=C(S1)[NH+](CC(=O)C2=CC=C(C=C2)OC)C3=NCCN3.[I-],,,,,,
563,50564,"2-[4,5-dihydro-1H-imidazol-2-yl-(5-methyl-1,3,4-thiadiazol-2-yl)amino]-1-(4-methoxyphenyl)ethanone",CC1=NN=C(S1)N(CC(=O)C2=CC=C(C=C2)OC)C3=NCCN3,,,,,,
564,50565,"Ethanone, 2-((4,5-dihydro-1H-imidazol-2-yl)(5-(1-methylethyl)-1,3,4-thiadiazol-2-yl)amino)-1-(4-methoxyphenyl)-, monohydriodide",CC(C)C1=NN=C(S1)[NH+](CC(=O)C2=CC=C(C=C2)OC)C3=NCCN3.[I-],,,,,,
565,50566,"2-[4,5-dihydro-1H-imidazol-2-yl-(5-propan-2-yl-1,3,4-thiadiazol-2-yl)amino]-1-(4-methoxyphenyl)ethanone",CC(C)C1=NN=C(S1)N(CC(=O)C2=CC=C(C=C2)OC)C3=NCCN3,,,,,,
566,50567,"Ethanone, 2-((4,5-dihydro-1H-imidazol-2-yl)(5-(2-methylpropyl)-1,3,4-thiadiazol-2-yl)amino)-1-(4-methoxyphenyl)-, monohydriodide",CC(C)CC1=NN=C(S1)[NH+](CC(=O)C2=CC=C(C=C2)OC)C3=NCCN3.[I-],,,,,,
567,50568,"2-[4,5-dihydro-1H-imidazol-2-yl-[5-(2-methylpropyl)-1,3,4-thiadiazol-2-yl]amino]-1-(4-methoxyphenyl)ethanone",CC(C)CC1=NN=C(S1)N(CC(=O)C2=CC=C(C=C2)OC)C3=NCCN3,,,,,,
568,50569,"ACETIC ACID, TRIFLUORO-, 2-(5-PHENYL-3-as-TRIAZINYL)HYDRAZIDE",C1=CC=C(C=C1)C2=CN=NC(=N2)NNC(=O)C(F)(F)F,,,,,,
569,50570,"ACETIC ACID, 2-(5-PHENYL-3-as-TRIAZINYL)HYDRAZIDE",CC(=O)NNC1=NC(=CN=N1)C2=CC=CC=C2,,,,,,
570,50571,"GLYCINE, 2-(5-PHENYL-3-as-TRIAZINYL)HYDRAZIDE, DIHYDROBROMIDE, HYDRATE",C1=CC=C(C=C1)C2=CN=NC(=N2)C(C(=O)N[NH3+])[NH3+].[Br-].[Br-],,,,,,
571,50572,"2-Amino-2-(5-phenyl-1,2,4-triazin-3-yl)acetohydrazide",C1=CC=C(C=C1)C2=CN=NC(=N2)C(C(=O)NN)N,,,,,,
572,50573,CID 50573,CC(C(=O)N[NH+]=C1NN=CC(=N1)C2=CC=C(C=C2)Cl)[NH3+].[Br-].[Br-],,,,,,
573,50574,"2-amino-N'-[5-(4-chlorophenyl)-1,2,4-triazin-3-yl]propanehydrazide",CC(C(=O)NNC1=NC(=CN=N1)C2=CC=C(C=C2)Cl)N,,,,,,
574,50575,"Cinchonan-9-ol, (9S)-, mono(alpha-hydroxybenzeneacetate) (salt)",C=CC1C[NH+]2CCC1CC2C(C3=CC=NC4=CC=CC=C34)O.C1=CC=C(C=C1)C(C(=O)[O-])O,,,,,,
575,50576,3-[Butyl[4-[(4-nitrophenyl)azo]phenyl]amino]propiononitrile,CCCCN(CCC#N)C1=CC=C(C=C1)N=NC2=CC=C(C=C2)[N+](=O)[O-],,,,,,
576,50577,Diethylnitrosopyridine,CCC1=CC(=C(N=C1)N=O)CC,,,,,,
577,50578,"Malononitrile, (5-nitrofurfurylidene)-",C1=C(OC(=C1)[N+](=O)[O-])C=C(C#N)C#N,,,,,,
578,50579,"Carbamic acid, (2-(pentyloxy)phenyl)-, 3-(1-piperidinyl)propyl ester, monohydrochloride",CCCCCOC1=CC=CC=C1NC(=O)OCCC[NH+]2CCCCC2.[Cl-],,,,,,
579,50580,(2-Pentoxyphenyl)carbamic acid 3-piperidinopropyl ester,CCCCCOC1=CC=CC=C1NC(=O)OCCCN2CCCCC2,,,,,,
580,50581,o-(Nonyloxy)carbanilic acid 3-piperidinopropyl ester hydrochloride,CCCCCCCCCOC1=CC=CC=C1NC(=O)OCCC[NH+]2CCCCC2.[Cl-],,,,,,
581,50582,(2-(Nonyloxy)phenyl)carbamic acid 3-piperidinopropyl ester,CCCCCCCCCOC1=CC=CC=C1NC(=O)OCCCN2CCCCC2,,,,,,
582,50583,"1'-Phenyl(1,3'-bipyrrolidine)-2,2',5,5'-tetrone",C1CC(=O)N(C1=O)C2CC(=O)N(C2=O)C3=CC=CC=C3,,,,,,
583,50584,"(1,3'-BIPYRROLIDINE)-2,2',5,5'-TETRONE, 1'-(m-TOLYL)-",CC1=CC(=CC=C1)N2C(=O)CC(C2=O)N3C(=O)CCC3=O,,,,,,
584,50585,"1'-(2,6-Xylyl)(1,3'-bipyrrolidine)-2,2',5,5'-tetrone",CC1=C(C(=CC=C1)C)N2C(=O)CC(C2=O)N3C(=O)CCC3=O,,,,,,
585,50586,"Benzoic acid, 4-(3-(2-methyl-4-oxo-3(4H)-quinazolinyl)-2,6-dioxo-1-piperidinyl)-",CC1=NC2=CC=CC=C2C(=O)N1C3CCC(=O)N(C3=O)C4=CC=C(C=C4)C(=O)O,,,,,,
586,50587,Thymopoietin pentapeptide,CC(C)C(C(=O)NC(CC1=CC=C(C=C1)O)C(=O)O)NC(=O)C(CC(=O)O)NC(=O)C(CCCCN)NC(=O)C(CCCN=C(N)N)N,,,"['Substances that augment, stimulate, activate, potentiate, or modulate the immune response at either the cellular or humoral level. The classical agents (Freund&apos;s adjuvant, BCG, Corynebacterium parvum, et al.) contain bacterial antigens. Some are endogenous (e.g., histamine, interferon, transfer factor, tuftsin, interleukin-1). Their mode of action is either non-specific, resulting in increased immune responsiveness to a wide variety of antigens, or antigen-specific, i.e., affecting a restricted type of immune response to a narrow group of antigens. The therapeutic efficacy of many biological response modifiers is related to their antigen-specific immunoadjuvanticity. (See all compounds classified as Adjuvants, Immunologic.)']",,,
587,50588,CID 50588,CC(=NNC1=NN=C(C=C1)N2CCOCC2)CC(=O)OC(C)(C)C,,,,,,
588,50589,"5-[2-(4-Carboxyphenyl)hydrazinylidene]-6-oxo-5,6-dihydronaphthalene-2-carboxylic acid",C1=CC(=CC=C1C(=O)O)N=NC2=C(C=CC3=C2C=CC(=C3)C(=O)O)O,,,,,,
589,50590,Cyprofuram,C1CC1C(=O)N(C2CCOC2=O)C3=CC(=CC=C3)Cl,,,,,,
590,50591,1H-Indol-3-ol,C1=CC=C2C(=C1)C(=CN2)O,,,,,['Indoxyl is a known human metabolite of indole.'],
591,50592,Tungsten antimonate,[O-][Sb](=O)([O-])[O-].[W],,,,,,
592,50593,CID 50593,CC(C(=O)O)OC1=CC(=C(C=C1Cl)Cl)Cl.CC(C(=O)O)OC1=CC(=C(C=C1Cl)Cl)Cl.O.[AlH3],,,,,,
593,50594,"6-Oxo-5-(2-phenylhydrazinylidene)-5,6-dihydronaphthalene-2-carboxylic acid",C1=CC=C(C=C1)N=NC2=C(C=CC3=C2C=CC(=C3)C(=O)O)O,,,,,,
594,50595,"6-Oxo-5-[2-(4-sulfophenyl)hydrazinylidene]-5,6-dihydronaphthalene-2-carboxylic acid",C1=CC(=CC=C1N=NC2=C(C=CC3=C2C=CC(=C3)C(=O)O)O)S(=O)(=O)O,,,,,,
595,50596,4-[(2-Hydroxy-6-sulfo-1-naphthyl)azo]benzoic acid,C1=CC(=CC=C1C(=O)O)N=NC2=C(C=CC3=C2C=CC(=C3)S(=O)(=O)O)O,,,,,,
596,50597,CID 50597,C(=CC=CCl)C=CCl,,,,,,
597,50598,Dimethylcarbamyl diethylthiocarbamyl sulfide,CCN(CC)C(=S)SC(=O)N(C)C,,,,,,
598,50599,CID 50599,C1C[C@@H](O[C@@H]1CO)N2C=NC3=C2NC=NC3=O,,,,,,
599,50600,CID 50600,C1=NC2=C(N1COCCO)N=C(N=C2[O-])N.[Na+],,,,,,
600,50601,"9,10-Anthracenedione, 1,4-bis(dimethylamino)-5,8-dihydroxy-",CN(C)C1=C2C(=C(C=C1)N(C)C)C(=O)C3=C(C=CC(=C3C2=O)O)O,,,,,,
601,50602,"1,4-Dihydroxy-5,8-bis(2-phenylethylamino)anthraquinone",C1=CC=C(C=C1)CCNC2=C3C(=C(C=C2)NCCC4=CC=CC=C4)C(=O)C5=C(C=CC(=C5C3=O)O)O,,,,,,
602,50603,3-Carboxymethylbenzanthrone,C1=CC=C2C(=C1)C3=C4C(=C(C=C3)SCC(=O)O)C=CC=C4C2=O,,,,,,
603,50604,3-(Ethoxycarbonylmethylthio)benzanthrone,CCOC(=O)CSC1=C2C=CC=C3C2=C(C=C1)C4=CC=CC=C4C3=O,,,,,,
604,50605,"7H-BENZ(de)ANTHRACEN-7-ONE, 3,9-DIHYDROXY-",C1=CC2=C(C=CC3=C2C(=C1)C(=O)C4=C3C=CC(=C4)O)O,,,,,,
605,50606,"7H-BENZ(de)ANTHRACEN-7-ONE, 3-p-TOLUIDINO-",CC1=CC=C(C=C1)NC2=C3C=CC=C4C3=C(C=C2)C5=CC=CC=C5C4=O,,,,,,
606,50607,3-Octen-1-ol-acetate,CCCCC=CCCOC(=O)C,,,,,,
607,50608,3-Octenoic acid methyl ester,CCCCC=CCC(=O)OC,,,,,,
608,50609,Decyl 4-hydroxybenzoate,CCCCCCCCCCOC(=O)C1=CC=C(C=C1)O,,,,,,
609,50610,"1,2,4,6,8-Pentachlorodibenzofuran",C1=C(C=C(C2=C1C3=C(O2)C(=CC(=C3Cl)Cl)Cl)Cl)Cl,,,,,,
610,50611,"1,2,3,4,6,8,9-Heptachlorodibenzofuran",C1=C(C2=C(C3=C(O2)C(=C(C(=C3Cl)Cl)Cl)Cl)C(=C1Cl)Cl)Cl,,,,,,
611,50612,"1,2,4,6,8,9-Hexachlorodibenzofuran",C1=C(C2=C(C3=C(O2)C(=CC(=C3Cl)Cl)Cl)C(=C1Cl)Cl)Cl,,,,,,
612,50613,"1,2,3,4,6,8-Hexachlorodibenzofuran",C1=C(C=C(C2=C1C3=C(O2)C(=C(C(=C3Cl)Cl)Cl)Cl)Cl)Cl,,,,,,
613,50614,"(7S)-7-[[4-(2-amino-1-carboxy-2-oxoethylidene)-1,3-dithietane-2-carbonyl]amino]-7-methoxy-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid",CN1C(=NN=N1)SCC2=C(N3C([C@@](C3=O)(NC(=O)C4SC(=C(C(=O)N)C(=O)O)S4)OC)SC2)C(=O)O,,,,,,
614,50615,"(E)-2-(o-Chlorophenyl)-3-(dimethylaminomethyl)bicyclo(2.2.2)octane, hydrochloride",C[NH+](C)C[C@@H]1C2CCC(C1C3=CC=CC=C3Cl)CC2.[Cl-],,,,,,
615,50616,"1-[(2R)-3-(2-chlorophenyl)-2-bicyclo[2.2.2]octanyl]-N,N-dimethylmethanamine",CN(C)C[C@@H]1C2CCC(C1C3=CC=CC=C3Cl)CC2,,,,,,
616,50617,"(E)-2-(Dimethylaminomethyl)-3-(p-fluorophenyl)bicyclo(2.2.2)octane, hydrochloride",C[NH+](C)C[C@@H]1C2CCC(C1C3=CC=C(C=C3)F)CC2.[Cl-],,,,,,
617,50618,"1-[(2R)-3-(4-fluorophenyl)-2-bicyclo[2.2.2]octanyl]-N,N-dimethylmethanamine",CN(C)C[C@@H]1C2CCC(C1C3=CC=C(C=C3)F)CC2,,,,,,
618,50619,"(E)-2-(p-Bromophenyl)-3-(methylaminomethyl)bicyclo(2.2.2)octane, hydrochloride",C[NH2+]C[C@@H]1C2CCC(C1C3=CC=C(C=C3)Br)CC2.[Cl-],,,,,,
619,50620,1-[3-(4-bromophenyl)-2-bicyclo[2.2.2]octanyl]-N-methylmethanamine,CNCC1C2CCC(C1C3=CC=C(C=C3)Br)CC2,,,,,,
620,50621,"cis-2-(p-Chlorophenyl)-3-dimethylaminomethylbicyclo(2.2.2)octane, hydrochloride",C[NH+](C)C[C@H]1[C@H](C2CCC1CC2)C3=CC=C(C=C3)Cl.[Cl-],,,,,,
621,50622,"1-[(2R,3S)-3-(4-chlorophenyl)-2-bicyclo[2.2.2]octanyl]-N,N-dimethylmethanamine",CN(C)C[C@H]1[C@H](C2CCC1CC2)C3=CC=C(C=C3)Cl,,,,,,
622,50623,6-Benzoyl-3-chloro-2-nitrobenzoic acid,C1=CC=C(C=C1)C(=O)C2=C(C(=C(C=C2)Cl)[N+](=O)[O-])C(=O)O,,,,,,
623,50624,CID 50624,CC1=C(SC(=N1)SCC2=C(N3[C@@H]([C@@H](C3=O)NC(=O)C(=NOC)C4=CSC(=N4)N)SC2)C(=O)[O-])CC(=O)[O-].[Na+].[Na+],,,,,,
624,50625,"Cefodizime,(S)",CC1=C(SC(=N1)SCC2=C(N3[C@@H]([C@@H](C3=O)NC(=O)C(=NOC)C4=CSC(=N4)N)SC2)C(=O)O)CC(=O)O,,,,,,
625,50626,6-Chloro-alpha-((dibutylamino)methyl)-1-naphthalenemethanol,CCCCN(CCCC)CC(C1=CC=CC2=C1C=CC(=C2)Cl)O,,,,,,
626,50627,"1,2,6-Trichlorodibenzo-p-dioxin",C1=CC2=C(C(=C1)Cl)OC3=C(O2)C(=C(C=C3)Cl)Cl,,,,,,
627,50628,"Acetamide, N-(ethoxyethyl)-N-ethyl-",CCN(CCOCC)C(=O)C,,,,,,
628,50629,"Benzyl alcohol, 2,5-dimethoxy-alpha-methyl-alpha-(methylaminomethyl)-, hydrochloride",CC(C[NH2+]C)(C1=C(C=CC(=C1)OC)OC)O.[Cl-],,,,,,
629,50630,"2-(2,5-Dimethoxyphenyl)-1-(methylamino)propan-2-ol",CC(CNC)(C1=C(C=CC(=C1)OC)OC)O,,,,,,
630,50631,"Benzyl alcohol, 2,5-dimethoxy-alpha-(dimethylaminomethyl)-alpha-methyl-, hydrochloride",CC(C[NH+](C)C)(C1=C(C=CC(=C1)OC)OC)O.[Cl-],,,,,,
631,50632,"2-(2,5-Dimethoxyphenyl)-1-(dimethylamino)propan-2-ol",CC(CN(C)C)(C1=C(C=CC(=C1)OC)OC)O,,,,,,
632,50633,p-Aminobenzoic acid 3-piperidinopropyl ester hydrochloride,C1CC[NH+](CC1)CCCOC(=O)C2=CC=C(C=C2)N.[Cl-],,,,,,
633,50634,3-Piperidin-1-ylpropyl 4-aminobenzoate,C1CCN(CC1)CCCOC(=O)C2=CC=C(C=C2)N,,,,,,
634,50635,"p-Aminobenzoic acid, (2,2-dimethyl-(2-isopentylamino))ethyl ester, hydrochloride",CC(C)CC[NH2+]C(C)(C)COC(=O)C1=CC=C(C=C1)N.[Cl-],,,,,,
635,50636,[2-Methyl-2-(3-methylbutylamino)propyl] 4-aminobenzoate,CC(C)CCNC(C)(C)COC(=O)C1=CC=C(C=C1)N,,,,,,
636,50637,p-Aminobenzoic acid 3-(3-methylpiperidino)propyl ester hydrochloride,CC1CCC[NH+](C1)CCCOC(=O)C2=CC=C(C=C2)N.[Cl-],,,,,,
637,50638,3-(3-Methylpiperidin-1-yl)propyl 4-aminobenzoate,CC1CCCN(C1)CCCOC(=O)C2=CC=C(C=C2)N,,,,,,
638,50639,"Benzoic acid, p-amino-, 1,1-dimethyl-2-(isopentylamino)ethyl ester, hydrochloride",CC(C)CC[NH2+]CC(C)(C)OC(=O)C1=CC=C(C=C1)N.[Cl-],,,,,,
639,50640,[2-Methyl-1-(3-methylbutylamino)propan-2-yl] 4-aminobenzoate,CC(C)CCNCC(C)(C)OC(=O)C1=CC=C(C=C1)N,,,,,,
640,50641,"4-Biphenylcarboxylic acid, 4'-methoxy-, 3-(2-methylpiperidino)propyl ester, hydrochloride",CC1CCCC[NH+]1CCCOC(=O)C2=CC=C(C=C2)C3=CC=C(C=C3)OC.[Cl-],,,,,,
641,50642,3-(2-Methylpiperidin-1-yl)propyl 4-(4-methoxyphenyl)benzoate,CC1CCCCN1CCCOC(=O)C2=CC=C(C=C2)C3=CC=C(C=C3)OC,,,,,,
642,50643,"p-Aminobenzoic acid, 2-cyclohexylamino-2,2-dimethylethyl ester, hydrochloride",CC(C)(COC(=O)C1=CC=C(C=C1)N)[NH2+]C2CCCCC2.[Cl-],,,,,,
643,50644,"BENZOIC ACID, p-AMINO-, (2-CYCLOHEXYLAMINO-2,2-DIMETHYL)ETHYL ESTER",CC(C)(COC(=O)C1=CC=C(C=C1)N)NC2CCCCC2,,,,,,
644,50645,"2-(1-Morpholinoethyl)-1,4-benzodioxane",CC(C1COC2=CC=CC=C2O1)N3CCOCC3,,,,,,
645,50646,"Barbituric acid, 5-((2,2-dimethylpropionyl)methyl)-5-isopentyl-",CC(C)CCC1(C(=O)NC(=O)NC1=O)CC(=O)C(C)(C)C,,,,,,
646,50647,CID 50647,C1=CC=C(C=C1)C[NH+](CCCl)CC=CC2=CC=CC=C2.[Cl-],,,,,,
647,50648,CID 50648,C1=CC=C(C=C1)CN(CCCl)CC=CC2=CC=CC=C2,,,,,,
648,50649,1-(2-(N-(2-Chloroethyl)-N-ethylamino)ethyl)-1H-benzotriazole hydrochloride,CC[NH+](CCN1C2=CC=CC=C2N=N1)CCCl.[Cl-],,,,,,
649,50650,2-(benzotriazol-1-yl)-N-(2-chloroethyl)-N-ethylethanamine,CCN(CCN1C2=CC=CC=C2N=N1)CCCl,,,,,,
650,50651,"Carbamic acid, dimethyl-, 5-(dimethylamino)-2-(3-pyridylazo)phenyl ester, methiodide",C[N+]1=CC=CC(=C1)N=NC2=C(C=C(C=C2)N(C)C)OC(=O)N(C)C.[I-],,,,,,
651,50652,"[5-(dimethylamino)-2-[(1-methylpyridin-1-ium-3-yl)diazenyl]phenyl] N,N-dimethylcarbamate",C[N+]1=CC=CC(=C1)N=NC2=C(C=C(C=C2)N(C)C)OC(=O)N(C)C,,,,,,
652,50653,"Barbituric acid, 5-allyl-5-((2,2-dimethylpropionyl)methyl)-",CC(C)(C)C(=O)CC1(C(=O)NC(=O)NC1=O)CC=C,,,,,,
653,50654,4-(p-Hydroxyanilino)benzaldehyde,C1=CC(=CC=C1C=O)NC2=CC=C(C=C2)O,,,,,,
654,50655,"Benzimidazole, 1-(2-(diethylamino)ethyl)-2-(2-piperidinoethyl)-, hydrochloride",CC[NH+](CC)CCN1C2=CC=CC=C2N=C1CCN3CCCCC3.[Cl-],,,,,,
655,50656,"N,N-diethyl-2-[2-(2-piperidin-1-ylethyl)benzimidazol-1-yl]ethanamine",CCN(CC)CCN1C2=CC=CC=C2N=C1CCN3CCCCC3,,,,,,
656,50657,4-(Furan-2-yl)but-2-enoic acid,C1=COC(=C1)CC=CC(=O)O,,,,,,
657,50658,"2-IMIDAZOLIN-4-ONE, 1-BENZOYL-2-(ACETAMIDO-tert-BUTYL)THIO-",CC(C)(C)CC(=O)NSC1=NC(=O)CN1C(=O)C2=CC=CC=C2,,,,,,
658,50659,"Benzimidazole, 1-((2-diethylaminoethyl)-2-(pyrrolidin-1-yl)ethyl)-, hydrochloride",CCN(CC)CC[N+]1(C=NC2=CC=CC=C21)CCN3CCCC3.[Cl-],,,,,,
659,50660,"N,N-diethyl-2-[1-(2-pyrrolidin-1-ylethyl)benzimidazol-1-ium-1-yl]ethanamine",CCN(CC)CC[N+]1(C=NC2=CC=CC=C21)CCN3CCCC3,,,,,,
660,50661,Azabicyclooctanol methyl bromide diphenylacetate,C[N+]12CCCC(C1)C(C2)OC(=O)C(C3=CC=CC=C3)C4=CC=CC=C4.[Br-],,,,,,
661,50662,1-Methyl-1-azoniabicyclo[3.2.1]octan-6-ol diphenylacetate,C[N+]12CCCC(C1)C(C2)OC(=O)C(C3=CC=CC=C3)C4=CC=CC=C4,,,,,,
662,50663,1-Azabicyclo(3.2.1)octan-6-OL 9-fluorenecarboxylate hydrochloride,C1CC2C[NH+](C1)CC2OC(=O)C3C4=CC=CC=C4C5=CC=CC=C35.[Cl-],,,,,,
663,50664,9H-Fluorene-9-carboxylic acid 1-azabicyclo[3.2.1]octan-6-yl ester,C1CC2CN(C1)CC2OC(=O)C3C4=CC=CC=C4C5=CC=CC=C35,,,,,,
664,50665,6-Diphenylacetoxy-1-azabicyclo(3.2.1)octane hydrochloride,C1CC2C[NH+](C1)CC2OC(=O)C(C3=CC=CC=C3)C4=CC=CC=C4.[Cl-],,,,,,
665,50666,1-Azabicyclo[3.2.1]octan-6-ol diphenylacetate,C1CC2CN(C1)CC2OC(=O)C(C3=CC=CC=C3)C4=CC=CC=C4,,,,,,
666,50667,"Ammonium, ((3-hydroxy-2-pyridyl)methyl)trimethyl-, bromide, (p-bromophenyl)methylcarbamate",CN(C1=CC=C(C=C1)Br)C(=O)OC2=C(N=CC=C2)C[N+](C)(C)C.[Br-],,,,,,
667,50668,[3-[(4-Bromophenyl)-methylcarbamoyl]oxypyridin-2-yl]methyl-trimethylazanium,CN(C1=CC=C(C=C1)Br)C(=O)OC2=C(N=CC=C2)C[N+](C)(C)C,,,,,,
668,50669,cis-(Cyclopropylenebis(2-carbonyloxyethyl))bis(trimethylammonium) diiodide,C[N+](C)(C)C(=O)OCC[C@H]1C[C@H]1CCOC(=O)[N+](C)(C)C.[I-].[I-],,,,,,
669,50670,"trimethyl-[2-[(1R,2S)-2-[2-(trimethylazaniumyl)carbonyloxyethyl]cyclopropyl]ethoxycarbonyl]azanium",C[N+](C)(C)C(=O)OCC[C@H]1C[C@H]1CCOC(=O)[N+](C)(C)C,,,,,,
670,50671,trans-(Cyclopropylenebis(2-carbonyloxyethyl))bis(trimethylammonium) diiodide,C[N+](C)(C)C(=O)OCC[C@@H]1C[C@H]1CCOC(=O)[N+](C)(C)C.[I-].[I-],,,,,,
671,50672,"trimethyl-[2-[(1S,2S)-2-[2-(trimethylazaniumyl)carbonyloxyethyl]cyclopropyl]ethoxycarbonyl]azanium",C[N+](C)(C)C(=O)OCC[C@@H]1C[C@H]1CCOC(=O)[N+](C)(C)C,,,,,,
672,50673,"Barbituric acid, 5-ethyl-5-(1-(isopentyloxy)vinyl)-",CCC1(C(=O)NC(=O)NC1=O)C(=C)OCCC(C)C,,,,,,
673,50674,N-Methyl-N-phenylcarbamic acid (2-(diethylamino)methyl-3-pyridyl)ester hydrochloride,CC[NH+](CC)CC1=C(C=CC=N1)OC(=O)N(C)C2=CC=CC=C2.[Cl-],,,,,,
674,50675,[2-(diethylaminomethyl)pyridin-3-yl] N-methyl-N-phenylcarbamate,CCN(CC)CC1=C(C=CC=N1)OC(=O)N(C)C2=CC=CC=C2,,,,,,
675,50676,"1-Ethyl-4-(1-(1,4-benzodioxan-2-yl)ethyl)piperazine",CCN1CCN(CC1)C(C)C2COC3=CC=CC=C3O2,,,,,,
676,50677,"BARBITURIC ACID, 5,5-DIETHYL-1-(p-TOLYL)-",CCC1(C(=O)NC(=O)N(C1=O)C2=CC=C(C=C2)C)CC,,,,,,
677,50678,"Barbituric acid, 5-((2,2-dimethylpropionyl)methyl)-5-ethyl-",CCC1(C(=O)NC(=O)NC1=O)CC(=O)C(C)(C)C,,,,,,
678,50679,p-Aminobenzoic acid 2-((1-ethylpropyl)amino)propyl ester hydrochloride,CCC(CC)[NH2+]C(C)COC(=O)C1=CC=C(C=C1)N.[Cl-],,,,,,
679,50680,p-Aminobenzoic acid 2-(3-pentylamino)-1-propyl ester,CCC(CC)NC(C)COC(=O)C1=CC=C(C=C1)N,,,,,,
680,50681,"Carbamic acid, 2,4-dichlorophenyl-, pyrrolidinyl ester",C1CCN(C1)OC(=O)NC2=C(C=C(C=C2)Cl)Cl,,,,,,
681,50682,1-(2-(N-Benzyl-N-(2-chloroethyl)amino)ethyl)-1H-benzotriazole hydrochloride,C1=CC=C(C=C1)C[NH+](CCN2C3=CC=CC=C3N=N2)CCCl.[Cl-],,,,,,
682,50683,2-(benzotriazol-1-yl)-N-benzyl-N-(2-chloroethyl)ethanamine,C1=CC=C(C=C1)CN(CCN2C3=CC=CC=C3N=N2)CCCl,,,,,,
683,50684,"Benzylamine, N-(2-benzimidazolylmethyl)-N-(2-chloroethyl)-, hydrochloride",C1=CC=C(C=C1)C[NH+](CCCl)CC2=NC3=CC=CC=C3N2.[Cl-],,,,,,
684,50685,N-(1H-benzimidazol-2-ylmethyl)-N-benzyl-2-chloroethanamine,C1=CC=C(C=C1)CN(CCCl)CC2=NC3=CC=CC=C3N2,,,,,,
685,50686,p-Aminobenzoic acid 3-(3-ethoxycarbonylpiperidino)propyl ester hydrochloride,CCOC(=O)C1CCC[NH+](C1)CCCOC(=O)C2=CC=C(C=C2)N.[Cl-],,,,,,
686,50687,Ethyl 1-[3-(4-aminobenzoyl)oxypropyl]piperidine-3-carboxylate,CCOC(=O)C1CCCN(C1)CCCOC(=O)C2=CC=C(C=C2)N,,,,,,
687,50688,p-Aminobenzoic acid 2-((4-methylcyclohexyl)amino)ethyl ester hydrochloride,CC1CCC(CC1)[NH2+]CCOC(=O)C2=CC=C(C=C2)N.[Cl-],,,,,,
688,50689,2-[(4-Methylcyclohexyl)amino]ethyl 4-aminobenzoate,CC1CCC(CC1)NCCOC(=O)C2=CC=C(C=C2)N,,,,,,
689,50690,CID 50690,CC(=CCCC(=CCCC(=CCN(CC1=CC2=C(C=C1)OCO2)CC3=CC4=C(C=C3)OCO4)C)C)C,,,,,,
690,50691,CID 50691,C(CF)C(C(=O)[O-])O.[Na+],,,,,,
691,50692,4-Fluoro-2-hydroxybutanoic acid,C(CF)C(C(=O)O)O,,,,,,
692,50693,m-Aminobenzoic acid 2-(2-piperidyl)ethyl ester hydrochloride,C1CC[NH2+]C(C1)CCOC(=O)C2=CC(=CC=C2)N.[Cl-],,,,,,
693,50694,2-Piperidin-2-ylethyl 3-aminobenzoate,C1CCNC(C1)CCOC(=O)C2=CC(=CC=C2)N,,,,,,
694,50695,o-Aminobenzoic acid 2-(2-piperidyl)ethyl ester hydrochloride,C1CC[NH2+]C(C1)CCOC(=O)C2=CC=CC=C2N.[Cl-],,,,,,
695,50696,beta-2-Piperidylethyl-p-aminobenzoate hydrochloride,C1CC[NH2+]C(C1)CCOC(=O)C2=CC=C(C=C2)N.[Cl-],,,,,,
696,50697,2-Piperidin-2-ylethyl 4-aminobenzoate,C1CCNC(C1)CCOC(=O)C2=CC=C(C=C2)N,,,,,,
697,50698,m-Aminobenzoic acid (2-methyl-2-(propylamino))propyl ester hydrochloride,CCC[NH2+]C(C)(C)COC(=O)C1=CC(=CC=C1)N.[Cl-],,,,,,
698,50699,[2-Methyl-2-(propylamino)propyl] 3-aminobenzoate,CCCNC(C)(C)COC(=O)C1=CC(=CC=C1)N,,,,,,
699,50700,p-Aminobenzoic acid (2-methyl-2-(propylamino))propyl ester hydrochloride,CCC[NH2+]C(C)(C)COC(=O)C1=CC=C(C=C1)N.[Cl-],,,,,,
700,50701,[2-Methyl-2-(propylamino)propyl] 4-aminobenzoate,CCCNC(C)(C)COC(=O)C1=CC=C(C=C1)N,,,,,,
701,50702,p-Aminobenzoic acid (2-methyl-2-(pentylamino))propyl ester hydrochloride,CCCCC[NH2+]C(C)(C)COC(=O)C1=CC=C(C=C1)N.[Cl-],,,,,,
702,50703,[2-Methyl-2-(pentylamino)propyl] 4-aminobenzoate,CCCCCNC(C)(C)COC(=O)C1=CC=C(C=C1)N,,,,,,
703,50704,p-Aminobenzoic acid 2-((1-propylbutyl)amino)ethyl ester hydrochloride,CCCC(CCC)[NH2+]CCOC(=O)C1=CC=C(C=C1)N.[Cl-],,,,,,
704,50705,2-(Heptan-4-ylamino)ethyl 4-aminobenzoate,CCCC(CCC)NCCOC(=O)C1=CC=C(C=C1)N,,,,,,
705,50706,"Benzoic acid, (3-dimethylamino-1-(3-pyridyl))propyl ester, hydrochloride",C[NH+](C)CCC(C1=CN=CC=C1)OC(=O)C2=CC=CC=C2.[Cl-],,,,,,
706,50707,[3-(Dimethylamino)-1-pyridin-3-ylpropyl] benzoate,CN(C)CCC(C1=CN=CC=C1)OC(=O)C2=CC=CC=C2,,,,,,
707,50708,"Benzoic acid, p-amino-, 1-methyl-2-((4-methylcyclohexyl)amino)ethyl ester hydrochloride",CC1CCC(CC1)[NH2+]CC(C)OC(=O)C2=CC=C(C=C2)N.[Cl-],,,,,,
708,50709,1-[(4-Methylcyclohexyl)amino]propan-2-yl 4-aminobenzoate,CC1CCC(CC1)NCC(C)OC(=O)C2=CC=C(C=C2)N,,,,,,
709,50710,"Benzoic acid, p-amino-, 1-methyl-2-((1-propylbutyl)amino)ethyl ester, hydrochloride",CCCC(CCC)[NH2+]CC(C)OC(=O)C1=CC=C(C=C1)N.[Cl-],,,,,,
710,50711,p-Aminobenzoic acid 1-(4-heptylamino)-2-propyl ester,CCCC(CCC)NCC(C)OC(=O)C1=CC=C(C=C1)N,,,,,,
711,50712,p-Aminobenzoic acid 2-((1-propylbutyl)amino)propyl ester hydrochloride,CCCC(CCC)[NH2+]C(C)COC(=O)C1=CC=C(C=C1)N.[Cl-],,,,,,
712,50713,p-Aminobenzoic acid 2-(4-heptylamino)-1-propyl ester,CCCC(CCC)NC(C)COC(=O)C1=CC=C(C=C1)N,,,,,,
713,50714,p-Aminobenzoic acid 2-(N-methyl-N-phenethylamino)ethyl ester hydrochloride,C[NH+](CCC1=CC=CC=C1)CCOC(=O)C2=CC=C(C=C2)N.[Cl-],,,,,,
714,50715,2-[Methyl(2-phenylethyl)amino]ethyl 4-aminobenzoate,CN(CCC1=CC=CC=C1)CCOC(=O)C2=CC=C(C=C2)N,,,,,,
715,50716,"Benzoic acid, p-amino-, 2-((3,3,5-trimethylcyclohexyl)amino)ethyl ester, hydrochloride",CC1CC(CC(C1)(C)C)[NH2+]CCOC(=O)C2=CC=C(C=C2)N.[Cl-],,,,,,
716,50717,"2-[(3,3,5-Trimethylcyclohexyl)amino]ethyl 4-aminobenzoate",CC1CC(CC(C1)(C)C)NCCOC(=O)C2=CC=C(C=C2)N,,,,,,
717,50718,"Benzoic acid, p-amino-, 2-(N-methyl-N-(1-methylheptyl)amino)ethyl ester, hydrochloride",CCCCCCC(C)[NH+](C)CCOC(=O)C1=CC=C(C=C1)N.[Cl-],,,,,,
718,50719,2-[Methyl(octan-2-yl)amino]ethyl 4-aminobenzoate,CCCCCCC(C)N(C)CCOC(=O)C1=CC=C(C=C1)N,,,,,,
719,50720,p-Aminobenzoic acid 2-((1-methyloctyl)amino)ethyl ester hydrochloride,CCCCCCCC(C)[NH2+]CCOC(=O)C1=CC=C(C=C1)N.[Cl-],,,,,,
720,50721,2-(Nonan-2-ylamino)ethyl 4-aminobenzoate,CCCCCCCC(C)NCCOC(=O)C1=CC=C(C=C1)N,,,,,,
721,50722,p-Aminobenzoic acid 2-(1-propylbutylamino)butyl ester hydrochloride,CCCC(CCC)[NH2+]C(CC)COC(=O)C1=CC=C(C=C1)N.[Cl-],,,,,,
722,50723,2-(Heptan-4-ylamino)butyl 4-aminobenzoate,CCCC(CCC)NC(CC)COC(=O)C1=CC=C(C=C1)N,,,,,,
723,50724,p-Aminobenzoic acid 3-(N-methyl-N-phenethylamino)propyl ester hydrochloride,C[NH+](CCCOC(=O)C1=CC=C(C=C1)N)CCC2=CC=CC=C2.[Cl-],,,,,,
724,50725,3-[Methyl(2-phenylethyl)amino]propyl 4-aminobenzoate,CN(CCCOC(=O)C1=CC=C(C=C1)N)CCC2=CC=CC=C2,,,,,,
725,50726,"Benzoic acid, p-amino-, 2-(N-methyl-N-(3-phenylpropyl)amino)ethyl ester, hydrochloride",C[NH+](CCCC1=CC=CC=C1)CCOC(=O)C2=CC=C(C=C2)N.[Cl-],,,,,,
726,50727,2-[Methyl(3-phenylpropyl)amino]ethyl 4-aminobenzoate,CN(CCCC1=CC=CC=C1)CCOC(=O)C2=CC=C(C=C2)N,,,,,,
727,50728,p-Aminobenzoic acid 2-((1-methylnonyl)amino)ethyl ester hydrochloride,CCCCCCCCC(C)[NH2+]CCOC(=O)C1=CC=C(C=C1)N.[Cl-],,,,,,
728,50729,2-(Decan-2-ylamino)ethyl 4-aminobenzoate,CCCCCCCCC(C)NCCOC(=O)C1=CC=C(C=C1)N,,,,,,
729,50730,"Benzoic acid, p-amino-, 3-(N-methyl-N-(3-phenylpropyl)amino)propyl ester, hydrochloride",C[NH+](CCCC1=CC=CC=C1)CCCOC(=O)C2=CC=C(C=C2)N.[Cl-],,,,,,
730,50731,3-[Methyl(3-phenylpropyl)amino]propyl 4-aminobenzoate,CN(CCCC1=CC=CC=C1)CCCOC(=O)C2=CC=C(C=C2)N,,,,,,
731,50732,p-Butoxybenzoic acid (bis(dimethylaminomethyl)phenethyl)methyl ester hydrochloride,CCCCOC1=CC=C(C=C1)C(=O)OC(CCC2=CC=CC=C2)(C[NH+](C)C)CN(C)C.[Cl-],,,,,,
732,50733,"Benzoic acid, 4-butoxy-, 1,1-bis((dimethylamino)methyl)-3-phenylpropyl ester",CCCCOC1=CC=C(C=C1)C(=O)OC(CCC2=CC=CC=C2)(CN(C)C)CN(C)C,,,,,,
733,50734,"3-(2-Anilinoethyl)-8-propionyl-3,8-diazabicyclo(3.2.1)octane hydrochloride",CCC(=O)N1C2CCC1CN(C2)CC[NH2+]C3=CC=CC=C3.[Cl-],,,,,,
734,50735,m-Aminobenzoic acid (2-(ethylamino)-2-methyl)propyl ester hydrogen sulfate,CC[NH2+]C(C)(C)COC(=O)C1=CC(=CC=C1)N.OS(=O)(=O)[O-],,,,,,
735,50736,[2-(Ethylamino)-2-methylpropyl] 3-aminobenzoate,CCNC(C)(C)COC(=O)C1=CC(=CC=C1)N,,,,,,
736,50737,p-Aminobenzoic acid (2-(ethylamino)-2-methyl)propyl ester hydrochloride,CC[NH2+]C(C)(C)COC(=O)C1=CC=C(C=C1)N.[Cl-],,,,,,
737,50738,[2-(Ethylamino)-2-methylpropyl] 4-aminobenzoate,CCNC(C)(C)COC(=O)C1=CC=C(C=C1)N,,,,,,
738,50739,p-Aminobenzoic acid (2-(isopropylamino)-1-methyl)ethyl ester hydrochloride,CC(C)[NH2+]CC(C)OC(=O)C1=CC=C(C=C1)N.[Cl-],,,,,,
739,50740,1-(Propan-2-ylamino)propan-2-yl 4-aminobenzoate,CC(C)NCC(C)OC(=O)C1=CC=C(C=C1)N,,,,,,
740,50741,p-Aminobenzoic acid 2-((1-methylbutyl)amino)ethyl ester hydrochloride,CCCC(C)[NH2+]CCOC(=O)C1=CC=C(C=C1)N.[Cl-],,,,,,
741,50742,2-(Pentan-2-ylamino)ethyl 4-aminobenzoate,CCCC(C)NCCOC(=O)C1=CC=C(C=C1)N,,,,,,
742,50743,"Benzoic acid, m-amino-, (2-(isopropylamino)-2-methyl)propyl ester, hydrogen sulfate",CC(C)[NH2+]C(C)(C)COC(=O)C1=CC=C(C=C1)N.OS(=O)(=O)[O-],,,,,,
743,50744,[2-Methyl-2-(propan-2-ylamino)propyl] 4-aminobenzoate,CC(C)NC(C)(C)COC(=O)C1=CC=C(C=C1)N,,,,,,
744,50745,p-Aminobenzoic acid (2-(isopropylamino)-2-methyl)propyl ester hydrochloride,CC(C)[NH2+]C(C)(C)COC(=O)C1=CC=C(C=C1)N.[Cl-],,,,,,
745,50746,p-Aminobenzoic acid 2-(isopropylamino)butyl ester hydrochloride,CCC(COC(=O)C1=CC=C(C=C1)N)[NH2+]C(C)C.[Cl-],,,,,,
746,50747,2-(Propan-2-ylamino)butyl 4-aminobenzoate,CCC(COC(=O)C1=CC=C(C=C1)N)NC(C)C,,,,,,
747,50748,p-Aminobenzoic acid (2-(isopentylamino)-1-methyl)ethyl ester hydrochloride,CC(C)CC[NH2+]CC(C)OC(=O)C1=CC=C(C=C1)N.[Cl-],,,,,,
748,50749,1-(3-Methylbutylamino)propan-2-yl 4-aminobenzoate,CC(C)CCNCC(C)OC(=O)C1=CC=C(C=C1)N,,,,,,
749,50750,3-Amino-4-ethoxybenzoic acid 2-(diethylamino)ethyl ester hydrochloride,CC[NH+](CC)CCOC(=O)C1=CC(=C(C=C1)OCC)N.[Cl-],,,,,,
750,50751,"Benzoic acid, 3-amino-4-ethoxy-, 2-(diethylamino)ethyl ester",CCN(CC)CCOC(=O)C1=CC(=C(C=C1)OCC)N,,,,,,
751,50752,p-Aminobenzoic acid 2-(1-ethylpropylamino)butyl ester hydrochloride,CCC(CC)[NH2+]C(CC)COC(=O)C1=CC=C(C=C1)N.[Cl-],,,,,,
752,50753,2-(Pentan-3-ylamino)butyl 4-aminobenzoate,CCC(CC)NC(CC)COC(=O)C1=CC=C(C=C1)N,,,,,,
753,50754,p-Aminobenzoic acid 2-((1-methylhexyl)amino)ethyl ester hydrochloride,CCCCCC(C)[NH2+]CCOC(=O)C1=CC=C(C=C1)N.[Cl-],,,,,,
754,50755,2-(Heptan-2-ylamino)ethyl 4-aminobenzoate,CCCCCC(C)NCCOC(=O)C1=CC=C(C=C1)N,,,,,,
755,50756,p-Aminobenzoic acid 2-((2-ethylhexyl)amino)ethyl ester hydrochloride,CCCCC(CC)C[NH2+]CCOC(=O)C1=CC=C(C=C1)N.[Cl-],,,,,,
756,50757,2-(2-Ethylhexylamino)ethyl 4-aminobenzoate,CCCCC(CC)CNCCOC(=O)C1=CC=C(C=C1)N,,,,,,
757,50758,"Benzoic acid, p-amino-, (2-(1-ethylbutylamino)-2-methyl)propyl ester, hydrochloride",CCCC(CC)[NH2+]C(C)(C)COC(=O)C1=CC=C(C=C1)N.[Cl-],,,,,,
758,50759,[2-(Hexan-3-ylamino)-2-methylpropyl] 4-aminobenzoate,CCCC(CC)NC(C)(C)COC(=O)C1=CC=C(C=C1)N,,,,,,
759,50760,p-Aminobenzoic acid 2-((1-methylheptyl)amino)ethyl ester hydrochloride,CCCCCCC(C)[NH2+]CCOC(=O)C1=CC=C(C=C1)N.[Cl-],,,,,,
760,50761,p-Aminobenzoic acid 2-(1-methylheptylamino)ethyl ester sulfamate,CCCCCCC(C)[NH2+]CCOC(=O)C1=CC=C(C=C1)N.NS(=O)(=O)[O-],,,,,,
761,50762,"Benzoic acid, p-amino-, 2-((1-isobutyl-3-methylbutyl)amino)ethyl ester, hydrochloride",CC(C)CC(CC(C)C)[NH2+]CCOC(=O)C1=CC=C(C=C1)N.[Cl-],,,,,,
762,50763,"2-(2,6-Dimethylheptan-4-ylamino)ethyl 4-aminobenzoate",CC(C)CC(CC(C)C)NCCOC(=O)C1=CC=C(C=C1)N,,,,,,
763,50764,"Benzoic acid, p-amino-, 1,1-dimethyl-2-((1-methylhexyl)amino)ethyl ester, hydrochloride",CCCCCC(C)[NH2+]CC(C)(C)OC(=O)C1=CC=C(C=C1)N.[Cl-],,,,,,
764,50765,[1-(Heptan-2-ylamino)-2-methylpropan-2-yl] 4-aminobenzoate,CCCCCC(C)NCC(C)(C)OC(=O)C1=CC=C(C=C1)N,,,,,,
765,50766,"Benzoic acid, p-amino-, (2-(2-ethylhexylamino)-2-methyl)propyl ester, hydrochloride",CCCCC(CC)C[NH2+]C(C)(C)COC(=O)C1=CC=C(C=C1)N.[Cl-],,,,,,
766,50767,[2-(2-Ethylhexylamino)-2-methylpropyl] 4-aminobenzoate,CCCCC(CC)CNC(C)(C)COC(=O)C1=CC=C(C=C1)N,,,,,,
767,50768,"Benzoic acid, p-amino-, 2-(N-ethyl-N-(1-methylheptyl)amino)ethyl ester, hydrochloride",CCCCCCC(C)[NH+](CC)CCOC(=O)C1=CC=C(C=C1)N.[Cl-],,,,,,
768,50769,2-[Ethyl(octan-2-yl)amino]ethyl 4-aminobenzoate,CCCCCCC(C)N(CC)CCOC(=O)C1=CC=C(C=C1)N,,,,,,
769,50770,"Benzoic acid, p-amino-, 1,1-dimethyl-2-(isopropylamino)ethyl ester, hydrochloride",CC(C)[NH2+]CC(C)(C)OC(=O)C1=CC=C(C=C1)N.[Cl-],,,,,,
770,50771,[2-Methyl-1-(propan-2-ylamino)propan-2-yl] 4-aminobenzoate,CC(C)NCC(C)(C)OC(=O)C1=CC=C(C=C1)N,,,,,,
771,50772,p-Aminobenzoic acid 2-(cyclopentylamino)propyl ester hydrochloride,CC(COC(=O)C1=CC=C(C=C1)N)[NH2+]C2CCCC2.[Cl-],,,,,,
772,50773,2-(Cyclopentylamino)propyl 4-aminobenzoate,CC(COC(=O)C1=CC=C(C=C1)N)NC2CCCC2,,,,,,
773,50774,"Benzoic acid, p-amino-, (2-(cyclopentylamino)-1-methyl)ethyl ester, hydrochloride",CC(C[NH2+]C1CCCC1)OC(=O)C2=CC=C(C=C2)N.[Cl-],,,,,,
774,50775,1-(Cyclopentylamino)propan-2-yl 4-aminobenzoate,CC(CNC1CCCC1)OC(=O)C2=CC=C(C=C2)N,,,,,,
775,50776,"p-Aminobenzoic acid 2-((1,3-dimethylbutyl)amino)ethyl ester hydrochloride",CC(C)CC(C)[NH2+]CCOC(=O)C1=CC=C(C=C1)N.[Cl-],,,,,,
776,50777,2-(4-Methylpentan-2-ylamino)ethyl 4-aminobenzoate,CC(C)CC(C)NCCOC(=O)C1=CC=C(C=C1)N,,,,,,
777,50778,"Benzoic acid, p-amino-, (2-((1-ethylpropyl)amino)-1-methyl)ethyl ester, hydrochloride",CCC(CC)[NH2+]CC(C)OC(=O)C1=CC=C(C=C1)N.[Cl-],,,,,,
778,50779,p-Aminobenzoic acid 1-(3-pentylamino)-2-propyl ester,CCC(CC)NCC(C)OC(=O)C1=CC=C(C=C1)N,,,,,,
779,50780,p-Aminobenzoic acid (2-(isobutylamino)-2-methyl)propyl ester hydrochloride,CC(C)C[NH2+]C(C)(C)COC(=O)C1=CC=C(C=C1)N.[Cl-],,,,,,
780,50781,[2-Methyl-2-(2-methylpropylamino)propyl] 4-aminobenzoate,CC(C)CNC(C)(C)COC(=O)C1=CC=C(C=C1)N,,,,,,
781,50782,p-Aminobenzoic acid 2-(N-cyclohexyl-N-methylamino)ethyl ester hydrochloride,C[NH+](CCOC(=O)C1=CC=C(C=C1)N)C2CCCCC2.[Cl-],,,,,,
782,50783,2-[Cyclohexyl(methyl)amino]ethyl 4-aminobenzoate,CN(CCOC(=O)C1=CC=C(C=C1)N)C2CCCCC2,,,,,,
783,50784,p-Aminobenzoic acid 2-(cyclopentylamino)butyl ester hydrochloride,CCC(COC(=O)C1=CC=C(C=C1)N)[NH2+]C2CCCC2.[Cl-],,,,,,
784,50785,2-(Cyclopentylamino)butyl 4-aminobenzoate,CCC(COC(=O)C1=CC=C(C=C1)N)NC2CCCC2,,,,,,
785,50786,"Benzoic acid, p-amino-, 2-(cyclopentylamino)-1,1-dimethylethyl ester, hydrochloride",CC(C)(C[NH2+]C1CCCC1)OC(=O)C2=CC=C(C=C2)N.[Cl-],,,,,,
786,50787,[1-(Cyclopentylamino)-2-methylpropan-2-yl] 4-aminobenzoate,CC(C)(CNC1CCCC1)OC(=O)C2=CC=C(C=C2)N,,,,,,
787,50788,"Benzoic acid, p-amino-, (2-((1,3-dimethylbutyl)amino)-1-methyl)ethyl ester, hydrochloride",CC(C)CC(C)[NH2+]CC(C)OC(=O)C1=CC=C(C=C1)N.[Cl-],,,,,,
788,50789,1-(4-Methylpentan-2-ylamino)propan-2-yl 4-aminobenzoate,CC(C)CC(C)NCC(C)OC(=O)C1=CC=C(C=C1)N,,,,,,
789,50790,"Benzoic acid, p-amino-, 1,1-dimethyl-2-((1-ethylpropyl)amino)ethyl ester, hydrochloride",CCC(CC)[NH2+]CC(C)(C)OC(=O)C1=CC=C(C=C1)N.[Cl-],,,,,,
790,50791,[2-Methyl-1-(pentan-3-ylamino)propan-2-yl] 4-aminobenzoate,CCC(CC)NCC(C)(C)OC(=O)C1=CC=C(C=C1)N,,,,,,
791,50792,p-Aminobenzoic acid 2-(N-cyclohexyl-N-ethylamino)ethyl ester hydrochloride,CC[NH+](CCOC(=O)C1=CC=C(C=C1)N)C2CCCCC2.[Cl-],,,,,,
792,50793,2-[Cyclohexyl(ethyl)amino]ethyl 4-aminobenzoate,CCN(CCOC(=O)C1=CC=C(C=C1)N)C2CCCCC2,,,,,,
793,50794,p-Aminobenzoic acid (2-(hexylamino)-2-methyl)propyl ester hydrochloride,CCCCCC[NH2+]C(C)(C)COC(=O)C1=CC=C(C=C1)N.[Cl-],,,,,,
794,50795,[2-(Hexylamino)-2-methylpropyl] 4-aminobenzoate,CCCCCCNC(C)(C)COC(=O)C1=CC=C(C=C1)N,,,,,,
795,50796,"BENZOIC ACID, p-AMINO-, 3-(DIBUTYLAMINO)PROPYL ESTER, SUCCINATE",CCCC[NH+](CCCC)CCCOC(=O)C1=CC=C(C=C1)N.C(CC(=O)[O-])C(=O)O,,,,,,
796,50797,p-Aminobenzoic acid (2-(heptylamino)-2-methyl)propyl ester hydrochloride,CCCCCCC[NH2+]C(C)(C)COC(=O)C1=CC=C(C=C1)N.[Cl-],,,,,,
797,50798,[2-(Heptylamino)-2-methylpropyl] 4-aminobenzoate,CCCCCCCNC(C)(C)COC(=O)C1=CC=C(C=C1)N,,,,,,
798,50799,"Benzoic acid, p-amino-, 1,1-dimethyl-2-((1-methylheptyl)amino)ethyl ester, hydrochloride",CCCCCCC(C)[NH2+]CC(C)(C)OC(=O)C1=CC=C(C=C1)N.[Cl-],,,,,,
799,50800,"p-Aminobenzoic acid 2-(2-octylamino)-1,1-dimethylethyl ester",CCCCCCC(C)NCC(C)(C)OC(=O)C1=CC=C(C=C1)N,,,,,,
800,50801,p-Aminobenzoic acid (2-(decylamino)-2-methyl)propyl ester hydrochloride,CCCCCCCCCC[NH2+]C(C)(C)COC(=O)C1=CC=C(C=C1)N.[Cl-],,,,,,
801,50802,[2-(Decylamino)-2-methylpropyl] 4-aminobenzoate,CCCCCCCCCCNC(C)(C)COC(=O)C1=CC=C(C=C1)N,,,,,,
802,50803,"Carbamic acid, dimethyl-, (2-((dimethylamino)methyl)-3-pyridyl) ester, hydrochloride",C[NH+](C)CC1=C(C=CC=N1)OC(=O)N(C)C.[Cl-],,,,,,
803,50804,p-Aminobenzoic acid 2-(butylamino)ethyl ester hydrochloride,CCCC[NH2+]CCOC(=O)C1=CC=C(C=C1)N.[Cl-],,,,,,
804,50805,2-(Butylamino)ethyl 4-aminobenzoate,CCCCNCCOC(=O)C1=CC=C(C=C1)N,,,,,,
805,50806,p-Aminobenzoic acid 2-(cyclohexylamino)ethyl ester hydrochloride,C1CCC(CC1)[NH2+]CCOC(=O)C2=CC=C(C=C2)N.[Cl-],,,,,,
806,50807,2-(Cyclohexylamino)ethyl 4-aminobenzoate,C1CCC(CC1)NCCOC(=O)C2=CC=C(C=C2)N,,,,,,
807,50808,p-Aminobenzoic acid (2-(butylamino)-2-methyl)propyl ester hydrochloride,CCCC[NH2+]C(C)(C)COC(=O)C1=CC=C(C=C1)N.[Cl-],,,,,,
808,50809,[2-(Butylamino)-2-methylpropyl] 4-aminobenzoate,CCCCNC(C)(C)COC(=O)C1=CC=C(C=C1)N,,,,,,
809,50810,m-Aminobenzoic acid (2-(butylamino)-2-methyl)propyl ester hydrochloride,CCCC[NH2+]C(C)(C)COC(=O)C1=CC(=CC=C1)N.[Cl-],,,,,,
810,50811,[2-(Butylamino)-2-methylpropyl] 3-aminobenzoate,CCCCNC(C)(C)COC(=O)C1=CC(=CC=C1)N,,,,,,
811,50812,2-(Cyclohexylamino)propyl 4-aminobenzoate,CC(COC(=O)C1=CC=C(C=C1)N)NC2CCCCC2,,,,,,
812,50813,p-Aminobenzoic acid (2-(cyclohexylamino)-1-methyl)ethyl ester hydrochloride,CC(C[NH2+]C1CCCCC1)OC(=O)C2=CC=C(C=C2)N.[Cl-],,,,,,
813,50814,p-Aminobenzoic acid 1-cyclohexylamino-2-propyl ester,CC(CNC1CCCCC1)OC(=O)C2=CC=C(C=C2)N,,,,,,
814,50815,p-Aminobenzoic acid (2-(cyclohexylamino)-1-methyl)ethyl ester glycolate,CC(C[NH2+]C1CCCCC1)OC(=O)C2=CC=C(C=C2)N.C(C(=O)[O-])O,,,,,,
815,50816,p-Aminobenzoic acid 2-(cyclobutylamino)propyl ester hydrochloride,CC(COC(=O)C1=CC=C(C=C1)N)[NH2+]C2CCC2.[Cl-],,,,,,
816,50817,2-(Cyclobutylamino)propyl 4-aminobenzoate,CC(COC(=O)C1=CC=C(C=C1)N)NC2CCC2,,,,,,
817,50818,p-Aminobenzoic acid 2-(N-benzyl-N-methylamino)ethyl ester hydrochloride,C[NH+](CCOC(=O)C1=CC=C(C=C1)N)CC2=CC=CC=C2.[Cl-],,,,,,
818,50819,2-[Benzyl(methyl)amino]ethyl 4-aminobenzoate,CN(CCOC(=O)C1=CC=C(C=C1)N)CC2=CC=CC=C2,,,,,,
819,50820,p-Aminobenzoic acid 2-(cyclohexylamino)butyl ester hydrochloride,CCC(COC(=O)C1=CC=C(C=C1)N)[NH2+]C2CCCCC2.[Cl-],,,,,,
820,50821,2-(Cyclohexylamino)butyl 4-aminobenzoate,CCC(COC(=O)C1=CC=C(C=C1)N)NC2CCCCC2,,,,,,
821,50822,p-Aminobenzoic acid 2-(cyclohexylamino)butyl ester glycolate,CCC(COC(=O)C1=CC=C(C=C1)N)[NH2+]C2CCCCC2.C(C(=O)[O-])O,,,,,,
822,50823,"Benzoic acid, p-amino-, 2-(cyclohexylamino)-1,1-dimethylethyl ester, hydrochloride",CC(C)(C[NH2+]C1CCCCC1)OC(=O)C2=CC=C(C=C2)N.[Cl-],,,,,,
823,50824,[1-(Cyclohexylamino)-2-methylpropan-2-yl] 4-aminobenzoate,CC(C)(CNC1CCCCC1)OC(=O)C2=CC=C(C=C2)N,,,,,,
824,50825,p-Aminobenzoic acid 3-(N-benzyl-N-methylamino)propyl ester hydrochloride,C[NH+](CCCOC(=O)C1=CC=C(C=C1)N)CC2=CC=CC=C2.[Cl-],,,,,,
825,50826,3-[Benzyl(methyl)amino]propyl 4-aminobenzoate,CN(CCCOC(=O)C1=CC=C(C=C1)N)CC2=CC=CC=C2,,,,,,
826,50827,Ethylaminopropyldiphenylaminocarbinol hydrochloride,CC[NH2+]CCCOCN(C1=CC=CC=C1)C2=CC=CC=C2.[Cl-],,,,,,
827,50828,N-[3-(ethylamino)propoxymethyl]-N-phenylaniline,CCNCCCOCN(C1=CC=CC=C1)C2=CC=CC=C2,,,,,,
828,50829,p-Aminobenzoic acid 2-((1-butylpentyl)amino)ethyl ester hydrochloride,CCCCC(CCCC)[NH2+]CCOC(=O)C1=CC=C(C=C1)N.[Cl-],,,,,,
829,50830,2-(Nonan-5-ylamino)ethyl 4-aminobenzoate,CCCCC(CCCC)NCCOC(=O)C1=CC=C(C=C1)N,,,,,,
830,50831,"Benzoic acid, p-amino-, (2-((1-butylpentyl)amino)-1-methyl)ethyl ester, hydrochloride",CCCCC(CCCC)[NH2+]CC(C)OC(=O)C1=CC=C(C=C1)N.[Cl-],,,,,,
831,50832,1-(Nonan-5-ylamino)propan-2-yl 4-aminobenzoate,CCCCC(CCCC)NCC(C)OC(=O)C1=CC=C(C=C1)N,,,,,,
832,50833,p-Aminobenzoic acid 2-((1-butylpentyl)amino)propyl ester hydrochloride,CCCCC(CCCC)[NH2+]C(C)COC(=O)C1=CC=C(C=C1)N.[Cl-],,,,,,
833,50834,2-(Nonan-5-ylamino)propyl 4-aminobenzoate,CCCCC(CCCC)NC(C)COC(=O)C1=CC=C(C=C1)N,,,,,,
834,50835,p-Aminobenzoic acid 2-(1-methylheptylamino)ethyl ester glycolate,CCCCCCC(C)[NH2+]CCOC(=O)C1=CC=C(C=C1)N.C(C(=O)[O-])O,,,,,,
835,50836,"CAMPHORIC ACID, BIS(2-(DIETHYLAMINO)ETHYL) ESTER, HYDROCHLORIDE, d,l-",CC[NH+](CC)CCOC(=O)C1(CCC(C1(C)C)C(=O)OCCN(CC)CC)C.[Cl-],,,,,,
836,50837,"Bis[2-(diethylamino)ethyl] 1,2,2-trimethylcyclopentane-1,3-dicarboxylate",CCN(CC)CCOC(=O)C1CCC(C1(C)C)(C)C(=O)OCCN(CC)CC,,,,,,
837,50838,2-Phenylacetic acid (2-morpholinoethyl) ester hydrochloride hydrate,C1COCC[NH+]1CCOC(CC2=CC=CC=C2)O.[Cl-],,,,,,
838,50839,1-(2-Morpholin-4-ylethoxy)-2-phenylethanol,C1COCCN1CCOC(CC2=CC=CC=C2)O,,,,,,
839,50840,"2,7-Dimethyl-3,6-dimethyldiamino-10-methylacridinium chloride hydrochloride",CC1=CC2=CC3=C(C=C(C(=C3)C)NC)[N+](=C2C=C1[NH2+]C)C.[Cl-].[Cl-],,,,,,
840,50841,"Acridan-9-carboxylic acid, 10-methyl-, 2-(diethylamino)ethyl ester, hydrochloride",CC[NH+](CC)CCOC(=O)C1C2=CC=CC=C2N(C3=CC=CC=C13)C.[Cl-],,,,,,
841,50842,2-(diethylamino)ethyl 10-methyl-9H-acridine-9-carboxylate,CCN(CC)CCOC(=O)C1C2=CC=CC=C2N(C3=CC=CC=C13)C,,,,,,
842,50843,(2-Chloroethyl)ethylmethyl(naphthylmethyl)ammonium methyl sulfate,CC[N+](C)(CCCl)CC1=CC=CC2=CC=CC=C21.OS(=O)(=O)[O-],,,,,,
843,50844,2-Chloroethyl-ethyl-methyl-(naphthalen-1-ylmethyl)azanium,CC[N+](C)(CCCl)CC1=CC=CC2=CC=CC=C21,,,,,,
844,50845,"(2-(3,5-Xylyloxy)ethyl)hydrazine hydrochloride",CC1=CC(=CC(=C1)OCCN[NH3+])C.[Cl-],,,,,,
845,50846,"2-(3,5-Dimethylphenoxy)ethylhydrazine",CC1=CC(=CC(=C1)OCCNN)C,,,,,,
846,50847,"(2-(3,4,5-Trimethoxyphenoxy)ethyl)hydrazine hydrochloride",COC1=CC(=CC(=C1OC)OC)OCCN[NH3+].[Cl-],,,,,,
847,50848,"2-(3,4,5-Trimethoxyphenoxy)ethylhydrazine",COC1=CC(=CC(=C1OC)OC)OCCNN,,,,,,
848,50849,(2-o-Tolyloxyethyl)hydrazine hydrochloride,CC1=CC=CC=C1OCCN[NH3+].[Cl-],,,,,,
849,50850,CID 50850,C1=CC=C(C=C1)OCCCN[NH3+].C(=CC(=O)[O-])C(=O)O,,,,,,
850,50851,1-(3-Phenoxypropyl)hydrazine,C1=CC=C(C=C1)OCCCNN,,,,,,
851,50852,CID 50852,CSC1=CC=C(C=C1)OCCN[NH3+].C(=CC(=O)[O-])C(=O)O,,,,,,
852,50853,2-(4-Methylsulfanylphenoxy)ethylhydrazine,CSC1=CC=C(C=C1)OCCNN,,,,,,
853,50854,CID 50854,CC(CSC1=CC=CC=C1)N[NH3+].C(=CC(=O)[O-])C(=O)O,,,,,,
854,50855,1-Phenylsulfanylpropan-2-ylhydrazine,CC(CSC1=CC=CC=C1)NN,,,,,,
855,50856,((1-Phenoxymethyl)propyl)hydrazine hydrochloride,CCC(COC1=CC=CC=C1)N[NH3+].[Cl-],,,,,,
856,50857,1-Phenoxybutan-2-ylhydrazine,CCC(COC1=CC=CC=C1)NN,,,,,,
857,50858,CID 50858,CC(COC1=CC=C(C=C1)SC)N[NH3+].C(=CC(=O)[O-])C(=O)O,,,,,,
858,50859,1-(4-Methylsulfanylphenoxy)propan-2-ylhydrazine,CC(COC1=CC=C(C=C1)SC)NN,,,,,,
859,50860,CID 50860,C1=CC=C(C=C1)SCCCCN[NH3+].C(=CC(=O)[O-])C(=O)O,,,,,,
860,50861,4-Phenylsulfanylbutylhydrazine,C1=CC=C(C=C1)SCCCCNN,,,,,,
861,50862,CID 50862,CCCC(COC1=CC=CC=C1)N[NH3+].C(=CC(=O)[O-])C(=O)O,,,,,,
862,50863,1-Phenoxypentan-2-ylhydrazine,CCCC(COC1=CC=CC=C1)NN,,,,,,
863,50864,CID 50864,C1=CC=C(C=C1)OCCCCCN[NH3+].C(=CC(=O)[O-])C(=O)O,,,,,,
864,50865,5-Phenoxypentylhydrazine,C1=CC=C(C=C1)OCCCCCNN,,,,,,
865,50866,CID 50866,C1=CC=C2C(=C1)C=CC=C2OCCN[NH3+].C(=CC(=O)[O-])C(=O)O,,,,,,
866,50867,2-Naphthalen-1-yloxyethylhydrazine,C1=CC=C2C(=C1)C=CC=C2OCCNN,,,,,,
867,50868,CID 50868,C1=CC=C(C=C1)OCCCCCCN[NH3+].C(=CC(=O)[O-])C(=O)O,,,,,,
868,50869,6-Phenoxyhexylhydrazine,C1=CC=C(C=C1)OCCCCCCNN,,,,,,
869,50870,(2-(p-Nitrophenoxy)ethyl)hydrazine hydrochloride,C1=CC(=CC=C1[N+](=O)[O-])OCCN[NH3+].[Cl-],,,,,,
870,50871,2-(4-Nitrophenoxy)ethylhydrazine,C1=CC(=CC=C1[N+](=O)[O-])OCCNN,,,,,,
871,50872,CID 50872,C1=CC=C(C=C1)OCCCCN[NH3+].C(=CC(=O)[O-])C(=O)O,,,,,,
872,50873,4-Phenoxybutylhydrazine,C1=CC=C(C=C1)OCCCCNN,,,,,,
873,50874,"3-Chloro-5-(3-dimethylaminopropyl)-5H-dibenzo(a,d)cyclohepten-5-ol hydrogen phosphate",C[NH+](C)CCCC1(C2=CC=CC=C2C=CC3=C1C=C(C=C3)Cl)O.OP(=O)(O)[O-],,,,,,
874,50875,"5-Chloro-2-[3-(dimethylamino)propyl]tricyclo[9.4.0.03,8]pentadeca-1(15),3(8),4,6,9,11,13-heptaen-2-ol",CN(C)CCCC1(C2=CC=CC=C2C=CC3=C1C=C(C=C3)Cl)O,,,,,,
875,50876,CID 50876,C[NH+]1C2CCC1CC(C2)OC(=O)C(=CC3=CC=CC=C3)C4=CC(=CC=C4)N.[Cl-],,,,,,
876,50877,CID 50877,CN1C2CCC1CC(C2)OC(=O)C(=CC3=CC=CC=C3)C4=CC(=CC=C4)N,,,,,,
877,50878,"Chromone, 2,3-dimethyl-7-methoxy-8-(4-methyl-1-piperazinyl)methyl-, hydrochloride",CC1=C(OC2=C(C1=O)C=CC(=C2CN3CC[NH+](CC3)C)OC)C.[Cl-],,,,,,
878,50879,"7-Methoxy-2,3-dimethyl-8-[(4-methylpiperazin-1-yl)methyl]chromen-4-one",CC1=C(OC2=C(C1=O)C=CC(=C2CN3CCN(CC3)C)OC)C,,,,,,
879,50880,"Nicotinic acid, 3-(2-methylpiperidino)propyl ester, hydrochloride",CC1CCCC[NH+]1CCCOC(=O)C2=CN=CC=C2.[Cl-],,,,,,
880,50881,"Nicotinic acid, 3-(2,6-dimethylpiperidino)propyl ester, hydrochloride",CC1CCCC([NH+]1CCCOC(=O)C2=CN=CC=C2)C.[Cl-],,,,,,
881,50882,"3-(2,6-Dimethylpiperidin-1-yl)propyl pyridine-3-carboxylate",CC1CCCC(N1CCCOC(=O)C2=CN=CC=C2)C,,,,,,
882,50883,"alpha,alpha-Di(dimethylaminomethyl)-gamma-phenylpropyl carbanilate hydrochloride",C[NH+](C)CC(CCC1=CC=CC=C1)(CN(C)C)OC(=O)NC2=CC=CC=C2.[Cl-],,,,,,
883,50884,"Carbanilic acid, 1,1-bis((dimethylamino)methyl)-3-phenylpropyl ester",CN(C)CC(CCC1=CC=CC=C1)(CN(C)C)OC(=O)NC2=CC=CC=C2,,,,,,
884,50885,"Formamide, N,N-bis(2-chloroethyl)-, hydrochloride",C(CCl)[NH+](CCCl)C=O.[Cl-],,,,,,
885,50886,p-Aminobenzoic acid 2-((1-methylheptyl)amino)ethyl ester acetate,CCCCCCC(C)[NH2+]CCOC(=O)C1=CC=C(C=C1)N.CC(=O)[O-],,,,,,
886,50887,"Benzoic acid, p-amino-, 2-(1-isobutyl-3-methylbutylamino)butyl ester, hydrochloride",CCC(COC(=O)C1=CC=C(C=C1)N)[NH2+]C(CC(C)C)CC(C)C.[Cl-],,,,,,
887,50888,"2-(2,6-Dimethylheptan-4-ylamino)butyl 4-aminobenzoate",CCC(COC(=O)C1=CC=C(C=C1)N)NC(CC(C)C)CC(C)C,,,,,,
888,50889,p-Aminobenzoic acid 2-((1-ethylpropyl)amino)ethyl ester hydrochloride,CCC(CC)[NH2+]CCOC(=O)C1=CC=C(C=C1)N.[Cl-],,,,,,
889,50890,2-(Pentan-3-ylamino)ethyl 4-aminobenzoate,CCC(CC)NCCOC(=O)C1=CC=C(C=C1)N,,,,,,
890,50891,"2,3,3',4,4',5'-Hexachlorobiphenyl",C1=CC(=C(C(=C1C2=CC(=C(C(=C2)Cl)Cl)Cl)Cl)Cl)Cl,,,,,,
891,50892,"2,3,3',4,5,5',6-Heptachlorobiphenyl",C1=C(C=C(C=C1Cl)Cl)C2=C(C(=C(C(=C2Cl)Cl)Cl)Cl)Cl,,,,,,
892,50893,Diacetolol hydrochloride,CC(C)NCC(COC1=C(C=C(C=C1)NC(=O)C)C(=O)C)O.Cl,,,,,,
893,50894,Diacetolol,CC(C)NCC(COC1=C(C=C(C=C1)NC(=O)C)C(=O)C)O,,,,,,
894,50895,Haloxyfop,CC(C(=O)O)OC1=CC=C(C=C1)OC2=C(C=C(C=N2)C(F)(F)F)Cl,,,,,,
895,50896,Haloxyfop-methyl,CC(C(=O)OC)OC1=CC=C(C=C1)OC2=C(C=C(C=N2)C(F)(F)F)Cl,,,,,,
896,50897,Fluazifop-butyl,CCCCOC(=O)C(C)OC1=CC=C(C=C1)OC2=NC=C(C=C2)C(F)(F)F,,,"['Pesticides used to destroy unwanted vegetation, especially various types of weeds, grasses (POACEAE), and woody plants. Some plants develop HERBICIDE RESISTANCE. (See all compounds classified as Herbicides.)']",,"['In plants, fluazifop-butyl is rapidly hydrolyzed to fluazifop.']",
897,50898,p-Aminobenzoic acid 2-(1-isobutyl-3-methylbutylamino)butyl ester glycolate,CCC(COC(=O)C1=CC=C(C=C1)N)[NH2+]C(CC(C)C)CC(C)C.C(C(=O)[O-])O,,,,,,
898,50899,"Benzoic acid, p-amino-, 2-((1-isobutyl-3-methylbutyl)amino)propyl ester, glycolate",CC(C)CC(CC(C)C)[NH2+]C(C)COC(=O)C1=CC=C(C=C1)N.C(C(=O)[O-])O,,,,,,
899,50900,"2-(2,6-Dimethylheptan-4-ylamino)propyl 4-aminobenzoate",CC(C)CC(CC(C)C)NC(C)COC(=O)C1=CC=C(C=C1)N,,,,,,
900,50901,"Benzoic acid, p-amino-, 2-((1-isobutyl-3-methylbutyl)amino)propyl ester, hydrochloride",CC(C)CC(CC(C)C)[NH2+]C(C)COC(=O)C1=CC=C(C=C1)N.[Cl-],,,,,,
901,50902,"Acetic acid, 2,2-diphenyl-2-ethoxy-, (1-ethyl-3-pyrrolidinyl)methyl ester, citrate",CC[NH+]1CCC(C1)COC(=O)C(C2=CC=CC=C2)(C3=CC=CC=C3)OCC.C(C(=O)O)C(CC(=O)[O-])(C(=O)O)O,,,,,,
902,50903,"(1-Ethylpyrrolidin-3-yl)methyl 2-ethoxy-2,2-diphenylacetate",CCN1CCC(C1)COC(=O)C(C2=CC=CC=C2)(C3=CC=CC=C3)OCC,,,,,,
903,50904,CID 50904,C1COC[C@@]23[C@@H]1[C@H](CC4=C2C=C(C=C4)O)N(CC3)CC5CC5.C1COC[C@@]23[C@@H]1[C@H](CC4=C2C=C(C=C4)O)N(CC3)CC5CC5.[C@@H]([C@H](C(=O)O)O)(C(=O)O)O,,,,,,
904,50905,"(1S,9S,10R)-17-(cyclopropylmethyl)-13-oxa-17-azatetracyclo[7.5.3.01,10.02,7]heptadeca-2(7),3,5-trien-4-ol",C1COC[C@@]23[C@@H]1[C@H](CC4=C2C=C(C=C4)O)N(CC3)CC5CC5,,,,,,
905,50906,CID 50906,CN(C)C1=C(C2=NC3=C(C=CC(=C3C=O)N(C)C)C=C2C=C1)C=NN(CCCl)CCCl,,,,,,
906,50907,"Acridine-4-carboxaldehyde, 3,6-bis(dimethylamino)-5-((p-((bis(2-chloroethyl))amino)phenyl)iminomethyl)-",CN(C)C1=C(C2=NC3=C(C=CC(=C3C=O)N(C)C)C=C2C=C1)C=NC4=CC=C(C=C4)N(CCCl)CCCl,,,,,,
907,50908,"Ethanaminium, 2-(3-(1,3,3a,4,7,7a-hexahydro-1,3-dioxo-4,7-methano-2H-isoindol-2-yl)phenoxy)-N,N,N-triethyl-, iodide",CC[N+](CC)(CC)CCOC1=CC=CC(=C1)N2C(=O)C3C4CC(C3C2=O)C=C4.[I-],,,,,,
908,50909,"2-[3-(3,5-Dioxo-4-azatricyclo[5.2.1.02,6]dec-8-en-4-yl)phenoxy]ethyl-triethylazanium",CC[N+](CC)(CC)CCOC1=CC=CC(=C1)N2C(=O)C3C4CC(C3C2=O)C=C4,,,,,,
909,50910,"N,N-Diethyl-4-(1,3-dioxo-1,3,3a,4,7,7a-hexahydro-4,7-methano-2H-isoindol-2-yl)benzamide",CCN(CC)C(=O)C1=CC=C(C=C1)N2C(=O)C3C4CC(C3C2=O)C=C4,,,,,,
910,50911,"Benzoic acid, 4-(1,3-dioxo-1,3,3a,4,7,7a-hexahydro-4,7-methano-2H-isoindol-2-yl)-, 2-(diethylamino)ethyl ester, monohydrochloride",CC[NH+](CC)CCOC(=O)C1=CC=C(C=C1)N2C(=O)C3C4CC(C3C2=O)C=C4.[Cl-],,,,,,
911,50912,"2-(Diethylamino)ethyl 4-(3,5-dioxo-4-azatricyclo[5.2.1.02,6]dec-8-en-4-yl)benzoate",CCN(CC)CCOC(=O)C1=CC=C(C=C1)N2C(=O)C3C4CC(C3C2=O)C=C4,,,,,,
912,50913,"Benzoic acid, 3-(1,3-dioxo-1,3,3a,4,7,7a-hexahydro-4,7-methano-2H-isoindol-2-yl)-, (diethylamino)methyl ester",CCN(CC)COC(=O)C1=CC(=CC=C1)N2C(=O)C3C4CC(C3C2=O)C=C4,,,,,,
913,50914,"Benzoic acid, dichloro-3,4-dihydroxy-",C1=C(C(=C(C(=C1Cl)O)O)Cl)C(=O)O,,,,,,
914,50915,"(E)-2-(p-Bromophenyl)-3-(dimethylaminomethyl)bicyclo(2.2.2)octane, hydrochloride",C[NH+](C)C[C@@H]1C2CCC(C1C3=CC=C(C=C3)Br)CC2.[Cl-],,,,,,
915,50916,"1-[(2R)-3-(4-bromophenyl)-2-bicyclo[2.2.2]octanyl]-N,N-dimethylmethanamine",CN(C)C[C@@H]1C2CCC(C1C3=CC=C(C=C3)Br)CC2,,,,,,
916,50917,"Quinuclidinium, 6-(hydroxy(6-methoxy-4-quinolinyl)methyl)-1-methyl-3-vinyl-, iodide",C[N+]12CCC(C[C@@H]1[C@H](C3=C4C=C(C=CC4=NC=C3)OC)O)C(C2)C=C.[I-],,,,,,
917,50918,"2,3,6,7-Tetrabromonaphthalene",C1=C2C=C(C(=CC2=CC(=C1Br)Br)Br)Br,,,,,,
918,50919,"4-hydroxy-7-methoxy-3,4-dihydro-2H-1,4-benzoxazin-3-one",COC1=CC2=C(C=C1)N(C(=O)CO2)O,,,,,,
919,50920,"4-Hydroxy-6-methoxy-2H-1,4-benzoxazin-3(4H)-one",COC1=CC2=C(C=C1)OCC(=O)N2O,,,,,,
920,50921,Amidantel hydrochloride,C[NH+](C)C(=C)NC1=CC=C(C=C1)NC(=O)COC.[Cl-],,,,,,
921,50922,N-[4-[1-(dimethylamino)ethenylamino]phenyl]-2-methoxyacetamide,CN(C)C(=C)NC1=CC=C(C=C1)NC(=O)COC,,,,,,
922,50923,"Benzanilide, 3-(bis(2-chloroethyl)amino)-",C1=CC=C(C=C1)NC(=O)C2=CC(=CC=C2)N(CCCl)CCCl,,,,,,
923,50924,"Benzoic acid, 3-(bis(2-chloroethyl)amino)-4-chloro-",C1=CC(=C(C=C1C(=O)O)N(CCCl)CCCl)Cl,,,,,,
924,50925,"1,4-Bis((2-(dimethylamino)ethyl)amino)-9,10-anthracenedione",CN(C)CCNC1=C2C(=C(C=C1)NCCN(C)C)C(=O)C3=CC=CC=C3C2=O,,,,,,
925,50926,Cesium;potassium;dihydroxide,[OH-].[OH-].[K+].[Cs+],,,,,,
926,50927,CID 50927,CCCCC(C)(C)[C@@H](C=CC1[C@H](CC(=O)[C@H]1CC=CCCCC(=O)O)C)O,,,,,,
927,50928,"2-(3,4-Dimethoxyphenyl)-1,3-dithiolane",COC1=C(C=C(C=C1)C2SCCS2)OC,,,,,,
928,50929,CID 50929,CC1=C(OC2=C(C(=O)C=CC2=C1O)C[NH+]3CCOCC3)C.[Cl-],,,,,,
929,50930,CID 50930,CC1=C(OC2=C(C(=O)C=CC2=C1O)CN3CCOCC3)C,,,,,,
930,50931,CID 50931,CCC1=C(OC2=C(C(=O)C=CC2=C1O)C[NH2+]C)CC.[Cl-],,,,,,
931,50932,CID 50932,CCC1=C(OC2=C(C(=O)C=CC2=C1O)CNC)CC,,,,,,
932,50933,"Oxalic acid, 2-pentyl-1-imidazolyl ester",CCCCCC1=NC=CN1OC(=O)C(=O)O,,,,,,
933,50934,"Oxalic acid, 2-octyl-1-imidazolyl ester",CCCCCCCCC1=NC=CN1OC(=O)C(=O)O,,,,,,
934,50935,CID 50935,CC[NH+](CC)CCOC(=O)C=CCC1=CC=C(C=C1)C2=CC=CC=C2.[Cl-],,,,,,
935,50936,CID 50936,CCN(CC)CCOC(=O)C=CCC1=CC=C(C=C1)C2=CC=CC=C2,,,,,,
936,50937,2-Piperidinomethyl-4-methyl-1-tetralone hydrochloride,CC1CC(C(=O)C2=CC=CC=C12)C[NH+]3CCCCC3.[Cl-],,,,,,
937,50938,"4-methyl-2-(piperidin-1-ylmethyl)-3,4-dihydro-2H-naphthalen-1-one",CC1CC(C(=O)C2=CC=CC=C12)CN3CCCCC3,,,,,,
938,50939,CID 50939,CC[NH+](CC)C=CCC(C)Cl.[Cl-],,,,,,
939,50940,CID 50940,CCN(CC)C=CCC(C)Cl,,,,,,
940,50941,"8-Ethoxy-2,6-dimethyloct-2-ene",CCOCCC(C)CCC=C(C)C,,,,,,
941,50942,Doxofylline,CN1C2=C(C(=O)N(C1=O)C)N(C=N2)CC3OCCO3,"['Indicated for the treatment of chronic obstructive pulmonary disease (COPD), bronchial asthma and pulmonary disease with spastic bronchial component.']","['Doxofylline is a methylxanthine bronchodilator with potent bronchodilator activity comparable to that of theophylline. In animal studies, doxofylline demonstrated to attenuate bronchoconstriction, inflammatory actions and the release of thromboxane A2 (TXA2) when challenged with platelet-activating factor.   Doxofylline does not demonstrate direct inhibition of any histone deacetylase (HDAC) enzymes or known PDE enzyme isoforms and did not act as an antagonist at A2 or A2 receptors. The affinity for adenosine A1, A2A and A2B receptors are reported to be all higher than 100 µM. It only displays an inhibitory action against PDE2A1 and antagonism at adenosine A(2A) at high concentrations. A study demonstrated that doxofylline interacts with β2-adrenoceptors to induce blood vessel relaxation and airway smooth muscle relaxation. In dog studies, doxofylline decreased airway responsiveness at a dose that did not affect heart rate and respiratory rate.']","['Agents that suppress cough. They act centrally on the medullary cough center. EXPECTORANTS, also used in the treatment of cough, act locally. (See all compounds classified as Antitussive Agents.)', 'Agents that cause an increase in the expansion of a bronchus or bronchial tubes. (See all compounds classified as Bronchodilator Agents.)', 'Compounds which inhibit or antagonize the biosynthesis or actions of phosphodiesterases. (See all compounds classified as Phosphodiesterase Inhibitors.)']","['After repeated administrations doxofylline reaches the steady-state in about 4 days. Following oral administration of 400 mg doxofylline twice daily for 5 days in adults with chronic bronchitis, the peak plasma concentrations (Cmax) at steady state ranged from 5.78 to 20.76 mcg/mL. The time to reach maximum concentration (Tmax) was 1.19 ± 0.19 hours. The absolute bioavailability of doxofylline in healthy subjects was 63 ± 25%.', 'Less than 4% of an orally administered dose is excreted unchanged in the urine due to extensive hepatic metabolism.', 'Doxofylline demonstrates a short distribution phase following intravenous administration of 100 mg given in adults with chronic bronchitis. As methylxanthines are distributed to all body compartments, doxofylline may be detected in breast milk and placenta.', 'Following oral administration of 400 mg doxofylline twice daily for 5 days, the total clearance was 555.2 ± 180.6 mL/min.']",['Doxofylline is thought to undergo hepatic metabolism which accounts for 90% of total drug clearance. β-hydroxymethyltheophylline was detected in the serum and urine after oral administration of 400 mg given in healthy subjects. The circulating metabolite was devoid of any significant pharmacological activity.'],"['Following administration of a single intravenous dose of 100 mg over 10 minutes in adults with chronic bronchitis, the elimination half life of doxofylline was 1.83 ± 0.37 hours. Following oral administration of 400 mg twice daily for 5 days in adults with chronic bronchitis, the mean elimination half life was 7.01 ± 0.80 hours.']"
942,50943,"N-Butyl-3,4,5-trimethoxybenzamide",CCCCNC(=O)C1=CC(=C(C(=C1)OC)OC)OC,,,,,,
943,50944,"Benzoic acid, 5-methoxy-2-sulfamoyl-, methyl ester",COC1=CC(=C(C=C1)S(=O)(=O)N)C(=O)OC,,,,,,
944,50945,"Benzoic acid, 5-ethoxy-2-sulfamoyl-, methyl ester",CCOC1=CC(=C(C=C1)S(=O)(=O)N)C(=O)OC,,,,,,
945,50946,"Benzoic acid, 5-propoxy-2-sulfamoyl-, methyl ester",CCCOC1=CC(=C(C=C1)S(=O)(=O)N)C(=O)OC,,,,,,
946,50947,5-Butoxy-2-sulfamoylbenzoic acid methyl ester,CCCCOC1=CC(=C(C=C1)S(=O)(=O)N)C(=O)OC,,,,,,
947,50948,"Benzoic acid, 5-pentyloxy-2-sulfamoyl-, methyl ester",CCCCCOC1=CC(=C(C=C1)S(=O)(=O)N)C(=O)OC,,,,,,
948,50949,"Benzoic acid, 5-isobutoxy-2-sulfamoyl-, methyl ester",CC(C)COC1=CC(=C(C=C1)S(=O)(=O)N)C(=O)OC,,,,,,
949,50950,"Benzoic acid, 5-isopentyloxy-2-sulfamoyl-, methyl ester",CC(C)CCOC1=CC(=C(C=C1)S(=O)(=O)N)C(=O)OC,,,,,,
950,50951,5-Nitro-2-sulfamoylbenzoic acid methyl ester,COC(=O)C1=C(C=CC(=C1)[N+](=O)[O-])S(=O)(=O)N,,,,,,
951,50952,"Benzanilide, 2'-acetyl-3-(bis(2-chloroethyl)amino)-4-methyl-",CC1=C(C=C(C=C1)C(=O)NC2=CC=CC=C2C(=O)C)N(CCCl)CCCl,,,,,,
952,50953,"Benzanilide, 3'-acetyl-3-(bis(2-chloroethyl)amino)-4-methyl-",CC1=C(C=C(C=C1)C(=O)NC2=CC=CC(=C2)C(=O)C)N(CCCl)CCCl,,,,,,
953,50954,"Benzanilide, 4'-acetyl-3-(bis(2-chloroethyl)amino)-4-methyl-",CC1=C(C=C(C=C1)C(=O)NC2=CC=C(C=C2)C(=O)C)N(CCCl)CCCl,,,,,,
954,50955,"Benzanilide, 3-(bis(2-chloroethyl)amino)-2'-(bromoacetyl)-4-methyl-",CC1=C(C=C(C=C1)C(=O)NC2=CC=CC=C2C(=O)CBr)N(CCCl)CCCl,,,,,,
955,50956,"Benzanilide, 3-(bis(2-chloroethyl)amino)-3'-(bromoacetyl)-4-methyl-",CC1=C(C=C(C=C1)C(=O)NC2=CC=CC(=C2)C(=O)CBr)N(CCCl)CCCl,,,,,,
956,50957,"Benzanilide, 3-(bis(2-chloroethyl)amino)-4'-(bromoacetyl)-4-methyl-",CC1=C(C=C(C=C1)C(=O)NC2=CC=C(C=C2)C(=O)CBr)N(CCCl)CCCl,,,,,,
957,50958,1-Nitrobenzo(a)pyrene,C1=CC=C2C3=C4C(=CC2=C1)C=CC5=C4C(=C(C=C5)[N+](=O)[O-])C=C3,,,['Chemical agents that increase the rate of genetic mutation by interfering with the function of nucleic acids. A clastogen is a specific mutagen that causes breaks in chromosomes. (See all compounds classified as Mutagens.)'],,"['1- and 3-nitrobenzo[a]pyrene (1- and 3-nitro-BaP) are environmental pollutants and are S9-mediated mutagens in the Chinese hamster ovary (CHO) cell/hypoxanthine-guanine phosphoribosyl transferase assay. In this study, the pathways leading to the mutagenic activation of these compounds in CHO cells were examined. The microsomal metabolites of 1- and 3-nitro-BaP, the 1- and 3-nitro-BaP trans-7,8-dihydroxy-7,8-dihydrodiols (trans-7,8-dihydrodiols) and the 1- and 3-nitro-BaP trans-9,10-dihydrodiols, were isolated and tested for mutagenicity. At the concentrations assayed, both trans-9,10-dihydrodiols were non-mutagenic with and without S9 activation. In contrast, the trans-7,8-dihydrodiols of 1- and 3-nitro-BaP were direct-acting mutagens and these responses were similar in magnitude to the S9-mediated mutagenicities of the parent nitro-BaPs. S9 increased the mutagenic responses of the trans-7,8-dihydrodiols approximately 20-fold. Inhibition of epoxide hydrolase decreased the S9-mediated mutagenicity of 1-nitro-BaP by half, but doubled the S9-mediated mutagenicity of 3-nitro-BaP. These results suggest that in CHO cells: (i) the major route of mutagenic activation of 1- and 3-nitro-BaP involves S9-generated derivatives of the trans-7,8-dihydrodiols, e.g. bay-region diol epoxides; (ii) reactive nitroarene oxides may contribute to mutation induction by 3-nitro-BaP; and (iii) metabolic routes involving trans-9,10-dihydrodiol formation result in detoxification.', 'The environmental pollutants 1- and 3-nitrobenzo[a]pyrene (1- and 3-NBaP) are metabolized by mammalian microsomes through ring oxidation to 1-NBaP trans-7,8-dihydrodiol and 3-NBaP trans-7,8-dihydrodiol, and by nitroreduction to 1- and 3-aminobenzo[a]pyrene. To determine if these compounds are tumorigenic, 1- and 3-NBaP, along with several of their metabolites and the parent benzo[a]pyrene (BaP) and its trans-7,8-dihydrodiol metabolite, were tested in the neonatal CD-1 mouse bioassay. Male mice were administered i.p. injections at a total dose of 100 or 400 nmol per mouse on 1, 8 and 15 days after birth. While the liver tumor incidences for BaP, BaP trans-7,8-dihydrodiol, and the positive control 6-nitrochrysene (6-NC) were significantly higher than in the solvent control animals, all the other tested compounds exhibited no tumorigenicity. The frequency of Ha- and Ki-ras mutations in liver tumors of mice treated with BaP, BaP trans-7,8-dihydrodiol, and 6-NC were higher than in the few liver tumors isolated from control mice or mice treated with the NBaPs or their metabolites. Since 1- and 3-NBaP and their metabolites are potent mutagens in the Salmonella assay and moderate mutagens in the Chinese hamster ovary (CHO) mammalian mutagenicity assay, our results indicate that the in vitro mutagenicity of these compounds does not correlate with their tumorigenicity.', 'The compounds 1-, 3-, and 6-nitrobenzo[a]pyrene (nitro-BaP) are environmental pollutants and have been shown to be potent bacterial mutagens. The anaerobic metabolism of these isomeric nitro-BaPs was investigated by the incubation of rat intestinal microflora with each isomer for 48 hr. Aliquots were removed at several time intervals, extracted, fractionated by high-pressure liquid chromatography (HPLC), and the radioactivity determined. Metabolites were identified by comparison of their chromatographic, ultraviolet-visible absorption, and mass spectral properties with those of authentic standards. The order of the extent of nitroreduction for these isomers was 3-nitro-BaP greater than 6-nitro-BaP greater than 1-nitro-BaP. After 48 hr of exposure, 84% of the added 3-nitro-BaP was present as 3-amino-BaP, 51% of the 6-nitro-BaP was metabolized to 6-amino-BaP, and 1-nitro-BaP was reduced to 1-amino-BaP (13%) and 1-nitroso-BaP (4%). The order of the extent of microbial nitroreduction for these nitro-BaP isomers is different from the predictions based on electronic and steric hindrance effects. These results suggest that intestinal microflora nitroreductases exhibit a markedly high degree of substrate specificity toward nitro-BaPs that affects the extent of nitroreduction.', '1-,3- and 6-Nitrobenzo[a]pyrene (nitro-BaP), which are prototypes of nitro polycyclic aromatic hydrocarbons (nitro-PAHs) derived from a carcinogenic parent PAH, benzo[a]pyrene, are environmental contaminants and potent bacterial mutagens. In this study, the aerobic and hypoxic metabolism of 1-nitro-BaP by rat liver microsomes was studied. Aerobic metabolism of 1-nitro-BaP yielded 1-nitro-BaP trans-7,8- and 9,10-dihydrodiol, while metabolism under hypoxic conditions yielded 1-amino-BaP. The metabolites formed from aerobic metabolism of 1-nitro-BaP and 1-nitro-BaP trans-9,10-dihydrodiol by liver microsomes of untreated rats and rats pretreated with 3-methylcholanthrene and phenobarbital were quantified. Comparison of these results with those obtained with BaP and BaP trans-9,10-dihydrodiol indicates that nitro substitution at the 1-position of BaP markedly affects the regioselectivity of the P-450-containing enzymes. 1-Nitro-BaP and the three metabolites were potent mutagens in Salmonella typhimurium TA98, both in the absence and in the presence of an exogenous metabolic activation system (S9). The direct and S9-mediated mutagenicities of 1-nitro-BaP and the two dihydrodiols were decreased in the nitroreductase-deficient strain TA98NR, while TA98/1,8-DNP6, an O-acetylase-deficient strain, was less sensitive to the two dihydrodiols, both with and without S9, and 1-nitro-BaP with S9. 1-Amino-BaP was equally mutagenic in all three tester strains. These observations indicate that: the metabolism of 1-nitro-BaP involves several pathways leading to mutagenic activation; the major activation pathways of 1-nitro-BaP involve nitroreduction; nitroreduction followed by O-acetylation is the major activation pathway of 1-nitro-BaP trans-7,8- and 9,10-dihydrodiol; and 1-amino-BaP is a potent direct-acting mutagen.', 'Metabolism of 1-nitrobenzo(a)pyrene (1-nitro-BaP) by rat liver microsomes yielded 1-nitro-BaP trans-7,8-dihydrodiol, 1-nitro-BaP trans-9,10-dihydrodiol and 1-nitro-BaP 7,8,9,10-tetrahydrotetrol. Formation of these metabolites suggests that a vicinal 7,8,9,10-dihydrodiol-epoxide is a metabolite of 1-nitro-BaP. (This study may be related to carcinogenesis.)']",
958,50959,"2,8-Dimethyldibenzothiophene",CC1=CC2=C(C=C1)SC3=C2C=C(C=C3)C,,,,,,
959,50960,"2,4,8-Trimethyldibenzothiophene",CC1=CC2=C(C=C1)SC3=C(C=C(C=C23)C)C,,,,,,
960,50961,3-Nitrobenzo(a)pyrene,C1=CC=C2C3=C4C(=CC2=C1)C=CC5=C(C=CC(=C54)C=C3)[N+](=O)[O-],,,['Chemical agents that increase the rate of genetic mutation by interfering with the function of nucleic acids. A clastogen is a specific mutagen that causes breaks in chromosomes. (See all compounds classified as Mutagens.)'],,"['1- and 3-nitrobenzo[a]pyrene (1- and 3-nitro-BaP) are environmental pollutants and are S9-mediated mutagens in the Chinese hamster ovary (CHO) cell/hypoxanthine-guanine phosphoribosyl transferase assay. In this study, the pathways leading to the mutagenic activation of these compounds in CHO cells were examined. The microsomal metabolites of 1- and 3-nitro-BaP, the 1- and 3-nitro-BaP trans-7,8-dihydroxy-7,8-dihydrodiols (trans-7,8-dihydrodiols) and the 1- and 3-nitro-BaP trans-9,10-dihydrodiols, were isolated and tested for mutagenicity. At the concentrations assayed, both trans-9,10-dihydrodiols were non-mutagenic with and without S9 activation. In contrast, the trans-7,8-dihydrodiols of 1- and 3-nitro-BaP were direct-acting mutagens and these responses were similar in magnitude to the S9-mediated mutagenicities of the parent nitro-BaPs. S9 increased the mutagenic responses of the trans-7,8-dihydrodiols approximately 20-fold. Inhibition of epoxide hydrolase decreased the S9-mediated mutagenicity of 1-nitro-BaP by half, but doubled the S9-mediated mutagenicity of 3-nitro-BaP. These results suggest that in CHO cells: (i) the major route of mutagenic activation of 1- and 3-nitro-BaP involves S9-generated derivatives of the trans-7,8-dihydrodiols, e.g. bay-region diol epoxides; (ii) reactive nitroarene oxides may contribute to mutation induction by 3-nitro-BaP; and (iii) metabolic routes involving trans-9,10-dihydrodiol formation result in detoxification.', 'The environmental pollutants 1- and 3-nitrobenzo[a]pyrene (1- and 3-NBaP) are metabolized by mammalian microsomes through ring oxidation to 1-NBaP trans-7,8-dihydrodiol and 3-NBaP trans-7,8-dihydrodiol, and by nitroreduction to 1- and 3-aminobenzo[a]pyrene. To determine if these compounds are tumorigenic, 1- and 3-NBaP, along with several of their metabolites and the parent benzo[a]pyrene (BaP) and its trans-7,8-dihydrodiol metabolite, were tested in the neonatal CD-1 mouse bioassay. Male mice were administered i.p. injections at a total dose of 100 or 400 nmol per mouse on 1, 8 and 15 days after birth. While the liver tumor incidences for BaP, BaP trans-7,8-dihydrodiol, and the positive control 6-nitrochrysene (6-NC) were significantly higher than in the solvent control animals, all the other tested compounds exhibited no tumorigenicity. The frequency of Ha- and Ki-ras mutations in liver tumors of mice treated with BaP, BaP trans-7,8-dihydrodiol, and 6-NC were higher than in the few liver tumors isolated from control mice or mice treated with the NBaPs or their metabolites. Since 1- and 3-NBaP and their metabolites are potent mutagens in the Salmonella assay and moderate mutagens in the Chinese hamster ovary (CHO) mammalian mutagenicity assay, our results indicate that the in vitro mutagenicity of these compounds does not correlate with their tumorigenicity.', 'The compounds 1-, 3-, and 6-nitrobenzo[a]pyrene (nitro-BaP) are environmental pollutants and have been shown to be potent bacterial mutagens. The anaerobic metabolism of these isomeric nitro-BaPs was investigated by the incubation of rat intestinal microflora with each isomer for 48 hr. Aliquots were removed at several time intervals, extracted, fractionated by high-pressure liquid chromatography (HPLC), and the radioactivity determined. Metabolites were identified by comparison of their chromatographic, ultraviolet-visible absorption, and mass spectral properties with those of authentic standards. The order of the extent of nitroreduction for these isomers was 3-nitro-BaP greater than 6-nitro-BaP greater than 1-nitro-BaP. After 48 hr of exposure, 84% of the added 3-nitro-BaP was present as 3-amino-BaP, 51% of the 6-nitro-BaP was metabolized to 6-amino-BaP, and 1-nitro-BaP was reduced to 1-amino-BaP (13%) and 1-nitroso-BaP (4%). The order of the extent of microbial nitroreduction for these nitro-BaP isomers is different from the predictions based on electronic and steric hindrance effects. These results suggest that intestinal microflora nitroreductases exhibit a markedly high degree of substrate specificity toward nitro-BaPs that affects the extent of nitroreduction.']",
961,50962,"CRESOL, alpha,alpha'-(DIMETHYLPHENYLENE)DI-",CC1=CC(=C(C=C1CC2=CC=CC=C2O)CC3=CC=CC=C3O)C,,,,,,
962,50963,Cimetidine hydrochloride,CC1=C(N=CN1)CSCCNC(=NC)NC#N.Cl,,,"['Drugs and compounds which inhibit or antagonize the biosynthesis or actions of CYTOCHROME P-450 CYP1A2. (See all compounds classified as Cytochrome P-450 CYP1A2 Inhibitors.)', 'Various agents with different action mechanisms used to treat or ameliorate PEPTIC ULCER or irritation of the gastrointestinal tract. This has included ANTIBIOTICS to treat HELICOBACTER INFECTIONS; HISTAMINE H2 ANTAGONISTS to reduce GASTRIC ACID secretion; and ANTACIDS for symptomatic relief. (See all compounds classified as Anti-Ulcer Agents.)', 'Drugs that selectively bind to but do not activate histamine H2 receptors, thereby blocking the actions of histamine. Their clinically most important action is the inhibition of acid secretion in the treatment of gastrointestinal ulcers. Smooth muscle may also be affected. Some drugs in this class have strong effects in the central nervous system, but these actions are not well understood. (See all compounds classified as Histamine H2 Antagonists.)']",,,
963,50964,"1H-2-Benzopyran-1-methanamine, 3,4-dihydro-6,7-dimethoxy-N-methyl-N-(phenylmethyl)-, hydrochloride",C[N+](C)(CC1=CC=CC=C1)C2C3=CC(=C(C=C3CCO2)OC)OC.[Cl-],,,,,,
964,50965,"benzyl-(6,7-dimethoxy-3,4-dihydro-1H-isochromen-1-yl)-dimethylazanium",C[N+](C)(CC1=CC=CC=C1)C2C3=CC(=C(C=C3CCO2)OC)OC,,,,,,
965,50966,"1-Butanone, 4-(((3,4-dihydro-6,7-dimethoxy-1H-2-benzopyran-1-yl)methyl)methylamino)-1-(4-fluorophenyl)-",CC(C1C2=CC(=C(C=C2CCO1)OC)OC)NCCCC(=O)C3=CC=C(C=C3)F,,,,,,
966,50967,"1H-2-Benzopyran-1-methanamine, N,N-diethyl-3,4-dihydro-6,7-dimethoxy-, hydrochloride",CC[N+](C)(CC)C1C2=CC(=C(C=C2CCO1)OC)OC.[Cl-],,,,,,
967,50968,"(6,7-dimethoxy-3,4-dihydro-1H-isochromen-1-yl)-diethyl-methylazanium",CC[N+](C)(CC)C1C2=CC(=C(C=C2CCO1)OC)OC,,,,,,
968,50969,"3,7-Dimethyl-8-hydroxy-6-methoxyisochroman",CC1CC2=CC(=C(C(=C2CO1)O)C)OC,,,,,,
969,50970,"Ethanone, 2-(diethylamino)-1-(2-(4-fluorophenyl)-1H-indol-3-YL)-",CCN(CC)CC(=O)C1=C(NC2=CC=CC=C21)C3=CC=C(C=C3)F,,,,,,
970,50971,Einecs 274-314-3,CC(C)NCC(COC1C2=CC=CC=C2C(=O)N1C3=CC=CC=C3)O.C(CC(=O)O)C(=O)O,,,,,,
971,50972,Nofecainide,CC(C)NCC(COC1C2=CC=CC=C2C(=O)N1C3=CC=CC=C3)O,,,,,,
972,50973,"Acetic acid, 2-((acetoxymethyl)nitrosamino)ethyl ester",CC(=O)OCCN(COC(=O)C)N=O,,,,,,
973,50974,"Acetic acid, 4-((acetoxymethyl)nitrosamino)propyl ester",CC(=O)OCCCN(COC(=O)C)N=O,,,,,,
974,50975,"Acetic acid, 4-((acetoxymethyl)nitrosamino)butyl ester",CC(=O)OCCCCN(COC(=O)C)N=O,,,,,,
975,50976,Mcmamn,CC(=O)OCN(CC(=O)OC)N=O,,,,,,
976,50977,"beta-ALANINE, N-(HYDROXYMETHYL)-N-NITROSO-, METHYL ESTER, ACETATE",CC(=O)OCN(CCC(=O)OC)N=O,,,,,,
977,50978,"Butyric acid, ((hydroxymethyl)nitrosamino)-, methyl ester, acetate",CC(=O)OCN(CCCC(=O)OC)N=O,,,,,,
978,50979,"(S)-[(2R,5R)-5-ethenyl-1-oxido-1-azoniabicyclo[2.2.2]octan-2-yl]-(6-methoxyquinolin-4-yl)methanol",COC1=CC2=C(C=CN=C2C=C1)[C@@H]([C@H]3CC4CC[N+]3(C[C@@H]4C=C)[O-])O,,,,,,
979,50980,Flucythrinate,CC(C)C(C1=CC=C(C=C1)OC(F)F)C(=O)OC(C#N)C2=CC(=CC=C2)OC3=CC=CC=C3,,,,"['Flucythrinate is rapidly metabolized by ester cleavage and oxidation. When radio-labeled flucythrinate was administered orally to rats, 15 to 24% was eliminated in the urine and 37 to 65.6% was eliminated in the feces during the first 24 hours. Within 8 days, 95.8 to 100% of the dose was eliminated in either urine or feces. A large amount of the chemical recovered in the feces was unaltered flucythrinate, suggesting that this portion passed through the gut without being absorbed into the bloodstream. Metabolites of flucythrinate are considered to be of no toxicological significance.', 'In rats, following oral administration, 60-70% is eliminated within 24 hours, and >95% within 8 days, in the feces and urine. In the feces, the parent compound makes up most of the material excreted, but in the urine and in tissue, several metabolites are present. The major route of degradation is through hydrolysis, with subsequent hydroxylation of the hydrolysis products.', 'Pyrethrins are absorbed through intact skin when applied topically. When animals were exposed to aerosols of pyrethrins with piperonyl butoxide being released into the air, little or none of the combination was systemically absorbed. /Pyrethrins/', 'Although limited absorption may account for the low toxicity of some pyrethroids, rapid biodegradation by mammalian liver enzymes (ester hydrolysis and oxidation) is probably the major factor responsible. Most pyrethroid metabolites are promptly excreted, at least in part, by the kidney. /Pyrethroids/']","['Flucythrinate is rapidly metabolized by ester cleavage and oxidation.', 'The metabolic pathways for the breakdown of the pyrethroids vary little between mammalian species but vary somewhat with structure. ... Essentially, pyrethrum and allethrin are broken down mainly by oxidation of the isobutenyl side chain of the acid moiety and of the unsaturated side chain of the alcohol moiety with ester hydrolysis playing and important part, whereas for the other pyrethroids ester hydrolysis predominates. /Pyrethrum and pyrethroids/', 'The relative resistance of mammals to the pyrethroids is almost wholly attributable to their ability to hydrolyze the pyrethroids rapidly to their inactive acid and alcohol components, since direct injection into the mammalian CNS leads to a susceptibility similar to that seen in insects. Some additional resistance of homeothermic organisms can also be attributed to the negative temperature coefficient of action of the pyrethroids, which are thus less toxic at mammalian body temperatures, but the major effect is metabolic. Metabolic disposal of the pyrethroids is very rapid, which means that toxicity is high by the intravenous route, moderate by slower oral absorption, and often unmeasureably low by dermal absorption. /Pyrethroids/', 'Pyrethrins are reportedly inactivated in the GI tract following ingestion. In animals, pyrethrins are rapidly metabolized to water soluble, inactive compounds. /Pyrethrins/', 'Synthetic pyrethroids are generally metabolized in mammals through ester hydrolysis, oxidation, and conjugation, and there is no tendency to accumulate in tissues. In the environment, synthetic pyrethroids are fairly rapidly degraded in soil and in plants. Ester hydrolysis and oxidation at various sites on the molecule are the major degradation processes. /Synthetic pyrethroids/']",
980,50981,Pimonidazole,C1CCN(CC1)CC(CN2C=CN=C2[N+](=O)[O-])O,,,['Drugs used to potentiate the effectiveness of radiation therapy in destroying unwanted cells. (See all compounds classified as Radiation-Sensitizing Agents.)'],,,
981,50982,CID 50982,COC(CC1C(=O)NC(=O)NC1=O)C[Hg].[OH-].[Na+],,,,,,
982,50983,"[2-Methoxy-3-(2,4,6-trioxo-1,3-diazinan-5-yl)propyl]mercury",COC(CC1C(=O)NC(=O)NC1=O)C[Hg],,,,,,
983,50984,"(2-(3,4-Methylenedioxyphenoxy)ethyl)hydrazine hydrochloride",C1OC2=C(O1)C=C(C=C2)OCCN[NH3+].[Cl-],,,,,,
984,50985,"2-(1,3-Benzodioxol-5-yloxy)ethylhydrazine",C1OC2=C(O1)C=C(C=C2)OCCNN,,,,,,
985,50986,CID 50986,CC(CSC1=CC=C(C=C1)OC)N[NH3+].C(=CC(=O)[O-])C(=O)O,,,,,,
986,50987,1-(4-Methoxyphenyl)sulfanylpropan-2-ylhydrazine,CC(CSC1=CC=C(C=C1)OC)NN,,,,,,
987,50988,CID 50988,CCCC1=CC(=C(C=C1)OCCN[NH3+])OC.C(=CC(=O)[O-])C(=O)O,,,,,,
988,50989,2-(2-Methoxy-4-propylphenoxy)ethylhydrazine,CCCC1=CC(=C(C=C1)OCCNN)OC,,,,,,
989,50990,"N-Benzyl-N-(2-chloroethyl)-N',N'-diethylethylenediamine hydrochloride",CCN(CC)CC[NH+](CCCl)CC1=CC=CC=C1.[Cl-],,,,,,
990,50991,"N'-benzyl-N'-(2-chloroethyl)-N,N-diethylethane-1,2-diamine",CCN(CC)CCN(CCCl)CC1=CC=CC=C1,,,,,,
991,50992,N-(2-Morpholinoethyl)dibenzylamine hydrochloride,C1COCC[NH+]1CCN(CC2=CC=CC=C2)CC3=CC=CC=C3.[Cl-],,,,,,
992,50993,Dibenzyl[2-(morpholin-4-YL)ethyl]amine,C1COCCN1CCN(CC2=CC=CC=C2)CC3=CC=CC=C3,,,,,,
993,50994,"5H-Dibenzo(a,d)cycloheptene, 10,11-dihydro-5-(1-methyl-3-pyrrolidinylmethylene)-, oxalate",C[NH+]1CCC(C1)C=C2C3=CC=CC=C3CCC4=CC=CC=C42.C(=O)(C(=O)[O-])O,,,,,,
994,50995,"1-Methyl-3-(2-tricyclo[9.4.0.03,8]pentadeca-1(15),3,5,7,11,13-hexaenylidenemethyl)pyrrolidine",CN1CCC(C1)C=C2C3=CC=CC=C3CCC4=CC=CC=C42,,,,,,
995,50996,"5H-Dibenzo(a,d)cycloheptene, 10,11-dihydro-5-(1-methyl-3-pyrrolidinylmethyl)-, oxalate",C[NH+]1CCC(C1)CC2C3=CC=CC=C3CCC4=CC=CC=C24.C(=O)(C(=O)[O-])O,,,,,,
996,50997,"1-Methyl-3-(2-tricyclo[9.4.0.03,8]pentadeca-1(15),3,5,7,11,13-hexaenylmethyl)pyrrolidine",CN1CCC(C1)CC2C3=CC=CC=C3CCC4=CC=CC=C24,,,,,,
997,50998,7-Methoxy-3-methyl-8-(4-methyl-1-piperazinyl)methylflavone hydrochloride,CC1=C(OC2=C(C1=O)C=CC(=C2CN3CC[NH+](CC3)C)OC)C4=CC=CC=C4.[Cl-],,,,,,
998,50999,7-Methoxy-3-methyl-8-[(4-methylpiperazin-1-yl)methyl]-2-phenylchromen-4-one,CC1=C(OC2=C(C1=O)C=CC(=C2CN3CCN(CC3)C)OC)C4=CC=CC=C4,,,,,,
999,51000,"N-(2-Chloroethyl)-N,N',N'-tribenzylethylenediamine hydrochloride",C1=CC=C(C=C1)C[NH+](CCN(CC2=CC=CC=C2)CC3=CC=CC=C3)CCCl.[Cl-],,,,,,
1000,51001,"N,N',N'-tribenzyl-N-(2-chloroethyl)ethane-1,2-diamine",C1=CC=C(C=C1)CN(CCN(CC2=CC=CC=C2)CC3=CC=CC=C3)CCCl,,,,,,
1001,51002,CID 51002,COC1=CC=C(C=C1)SCCN[NH3+].C(=CC(=O)[O-])C(=O)O,,,,,,
1002,51003,2-(4-Methoxyphenyl)sulfanylethylhydrazine,COC1=CC=C(C=C1)SCCNN,,,,,,
1003,51004,(2-(p-Methoxyphenoxy)ethyl)hydrazine hydrochloride,COC1=CC=C(C=C1)OCCN[NH3+].[Cl-],,,,,,
1004,51005,2-(4-Methoxyphenoxy)ethylhydrazine,COC1=CC=C(C=C1)OCCNN,,,,,,
1005,51006,CID 51006,COC1=CC(=CC=C1)OCCN[NH3+].C(=CC(=O)[O-])C(=O)O,,,,,,
1006,51007,2-(3-Methoxyphenoxy)ethylhydrazine,COC1=CC(=CC=C1)OCCNN,,,,,,
1007,51008,CID 51008,CC(COC1=CC=C(C=C1)OC)N[NH3+].C(=CC(=O)[O-])C(=O)O,,,,,,
1008,51009,1-(4-Methoxyphenoxy)propan-2-ylhydrazine,CC(COC1=CC=C(C=C1)OC)NN,,,,,,
1009,51010,(1-(o-Methoxyphenoxymethyl)ethyl)hydrazine hydrochloride,CC(COC1=CC=CC=C1OC)N[NH3+].[Cl-],,,,,,
1010,51011,1-(2-Methoxyphenoxy)propan-2-ylhydrazine,CC(COC1=CC=CC=C1OC)NN,,,,,,
1011,51012,"Chloromethyl 2,4-dichlorobenzoate",C1=CC(=C(C=C1Cl)Cl)C(=O)OCCl,,,,,,
1012,51013,4-Amino-3-(4-chlorophenyl)butanoate;chloride,C1=CC(=CC=C1C(CC(=O)[O-])CN)Cl.[Cl-],,,,,,
1013,51014,"BENZ(a)ANTHRACENE-8,9-DIOL, 8,9-DIHYDRO-12-(HYDROXYMETHYL)-7-METHYL-, trans-",CC1=C2C=CC3=CC=CC=C3C2=C(C4=C1[C@@H]([C@H](C=C4)O)O)CO,,,,,,
1014,51015,CID 51015,C[C@H]1[C@@H]2CC[C@H](C[C@H]2C3=C(N1)C=C(C=C3OC(=O)C)O[C@@H](C)CCCC4=CC=CC=C4)O.Cl,,,,,,
1015,51016,CID 51016,C[C@H]1[C@@H]2CC[C@H](C[C@H]2C3=C(N1)C=C(C=C3OC(=O)C)O[C@@H](C)CCCC4=CC=CC=C4)O,,,,,,
1016,51017,"BENZ(a)ANTHRACENE-8,9-DIOL, 8,9-DIHYDRO-7-(HYDROXYMETHYL)-12-METHYL-, trans-",CC1=C2C=C[C@@H]([C@H](C2=C(C3=C1C4=CC=CC=C4C=C3)CO)O)O,,,,,,
1017,51018,3-Fluoranthenemethanol,C1=CC=C2C(=C1)C3=C4C2=CC=CC4=C(C=C3)CO,,,,,,
1018,51019,"ACETAMIDE, 2-(2-(2-(o-METHOXYPHENOXY)ETHOXY)ETHOXY)-",COC1=CC=CC=C1OCCOCCOCC(=O)N,,,,,,
1019,51020,2-(2-(2-(o-Methoxyphenoxy)ethoxy)ethoxy)ethylamine hydrochloride,COC1=CC=CC=C1OCCOCCOCC[NH3+].[Cl-],,,,,,
1020,51021,2-[2-[2-(2-Methoxyphenoxy)ethoxy]ethoxy]ethanamine,COC1=CC=CC=C1OCCOCCOCCN,,,,,,
1021,51022,"ANILINE, N-(2-(2-(2-(o-METHOXYPHENOXY)ETHOXY)ETHOXY)ETHYL)-",COC1=CC=CC=C1OCCOCCOCCNC2=CC=CC=C2,,,,,,
1022,51023,Chloro(difluoro)methane;dichloro(fluoro)methane,C(F)(F)Cl.C(F)(Cl)Cl,,,,,,
1023,51024,CID 51024,CCC(C)[C@@H]1[C@H](CC[C@@]2(O1)CC3C[C@H](O2)CC=C([C@H]([C@H](C=CC=C4CO[C@H]5[C@@]4([C@@H](C=C([C@H]5O)C)C(=O)O3)O)C)O[C@H]6C[C@@H]([C@H]([C@@H](O6)C)OC7C[C@@H]([C@H]([C@@H](O7)C)O)OC)OC)C)C.C[C@H]1CC[C@]2(CC3C[C@H](O2)CC=C([C@H]([C@H](C=CC=C4CO[C@H]5[C@@]4([C@@H](C=C([C@H]5O)C)C(=O)O3)O)C)O[C@H]6C[C@@H]([C@H]([C@@H](O6)C)OC7C[C@@H]([C@H]([C@@H](O7)C)O)OC)OC)C)O[C@@H]1C(C)C,,,,,,
1024,51025,CID 51025,CCC(C)[C@@H]1[C@H](CC[C@@]2(O1)CC3C[C@H](O2)CC=C([C@H]([C@H](C=CC=C4CO[C@H]5[C@@]4([C@@H](C=C([C@H]5O)C)C(=O)O3)O)C)O[C@H]6C[C@@H]([C@H]([C@@H](O6)C)OC7C[C@@H]([C@H]([C@@H](O7)C)O)OC)OC)C)C,,,,,,
1025,51026,CID 51026,C[C@H]1CC[C@]2(CC3C[C@H](O2)CC=C([C@H]([C@H](C=CC=C4CO[C@H]5[C@@]4([C@@H](C=C([C@H]5O)C)C(=O)O3)O)C)O[C@H]6C[C@@H]([C@H](C(O6)C)OC7C[C@@H]([C@H](C(O7)C)O)OC)OC)C)O[C@@H]1C(C)C,,,,,,
1026,51027,"2-(Methacryloyloxy)ethyl 1,3-dioxo-1,3-dihydroisobenzofuran-5-carboxylate",CC(=C)C(=O)OCCOC(=O)C1=CC2=C(C=C1)C(=O)OC2=O,,,,,,
1027,51028,"2,2-Diphenyl-4'-nitroacetanilide",C1=CC=C(C=C1)C(C2=CC=CC=C2)C(=O)NC3=CC=C(C=C3)[N+](=O)[O-],,,,,,
1028,51029,CID 51029,C1CC[NH+](CC1)CC(=O)NC=C2NC3=CC=CC=C3S2.[Cl-],,,,,,
1029,51030,"N-(3H-1,3-benzothiazol-2-ylidenemethyl)-2-piperidin-1-ylacetamide",C1CCN(CC1)CC(=O)NC=C2NC3=CC=CC=C3S2,,,,,,
1030,51031,"3-Benzofurancarboxylic acid, 6-(dimethylaminomethyl)-5-hydroxy-2-methyl-, ethyl ester",CCOC(=O)C1=C(OC2=C1C=C(C(=C2)CN(C)C)O)C,,,,,,
1031,51032,"2,3-Dimethyl-4-(m-methoxybenzylideneamino)-1-phenyl-3-pyrazolin-5-one",CC1=C(C(=O)N(N1C)C2=CC=CC=C2)N=CC3=CC(=CC=C3)OC,,,,,,
1032,51033,4-((p-Isopentyloxybenzylidene)amino)-3-methylbenzophenone,CC1=C(C=CC(=C1)C(=O)C2=CC=CC=C2)N=CC3=CC=C(C=C3)OCCC(C)C,,,,,,
1033,51034,4-((m-Isopentyloxybenzylidene)amino)-3-methylbenzophenone,CC1=C(C=CC(=C1)C(=O)C2=CC=CC=C2)N=CC3=CC(=CC=C3)OCCC(C)C,,,,,,
1034,51035,"Benzenamine, 2,6-dinitro-3-methyl-(9CI)",CC1=C(C(=C(C=C1)[N+](=O)[O-])N)[N+](=O)[O-],,,,,,
1035,51036,7-N-(p-Hydroxyphenyl)-mitomycin C,CC1=C(C(=O)C2=C(C1=O)N3CC4C([C@@]3([C@@H]2COC(=O)N)OC)N4)NC5=CC=C(C=C5)O,,,,,,
1036,51037,2-Tridecyl-2-imidazoline hydrochloride,CCCCCCCCCCCCCC1=[NH+]CCN1.[Cl-],,,,,,
1037,51038,Cefaclor hydrate,C1C(=C(N2[C@H](S1)[C@@H](C2=O)NC(=O)[C@@H](C3=CC=CC=C3)N)C(=O)O)Cl.O,,,['Substances that inhibit the growth or reproduction of BACTERIA. (See all compounds classified as Anti-Bacterial Agents.)'],,,
1038,51039,Cefaclor,C1C(=C(N2[C@H](S1)[C@@H](C2=O)NC(=O)[C@@H](C3=CC=CC=C3)N)C(=O)O)Cl,"['For the treatment of certain infections caused by bacteria such as pneumonia and ear, lung, skin, throat, and urinary tract infections.']","['Cefaclor is a second generation cephalosporin antibiotic with a spectrum resembling first-generation cephalosporins. <i>In vitro</i> tests demonstrate that the bactericidal action of the cephalosporins results from inhibition of cell-wall synthesis. As indicated by _in vitro_ and _in vivo_ clinical studies, cefaclor was shown to be effective against most strains of Gram positive aerobes - Staphylococci (including coagulase-positive, coagulase-negative, and penicillinase-producing strains), <i>Streptococcus pneumoniae</i>, <i>Streptococcus pyogenes</i> (group A &szlig;-hemolytic streptococci), as well as Gram-negative aerobes - <i>Escherichia coli</i>, <i>Haemophilus influenzae</i> (including &szlig;-lactamase-producing ampicillin-resistant strains), <i>Klebsiella sp</i>, and <i>Proteus mirabilis</i>.']",['Substances that inhibit the growth or reproduction of BACTERIA. (See all compounds classified as Anti-Bacterial Agents.)'],"['Well absorbed after oral administration, independent of food intake.', 'Approximately 60% to 85% of the drug is excreted unchanged in the urine within 8 hours, the greater portion being excreted within the first 2 hours.']",['No appreciable biotransformation in liver (approximately 60% to 85% of the drug is excreted unchanged in the urine within 8 hours).'],['0.6-0.9 hour']
1039,51040,Avobenzone,CC(C)(C)C1=CC=C(C=C1)C(=O)CC(=O)C2=CC=C(C=C2)OC,"['Sun protection factor, added in the sunscreen products for its wide spectrum ultraviolet absorption properties.']",,['Chemical or physical agents that protect the skin from sunburn and erythema by absorbing or blocking ultraviolet radiation. (See all compounds classified as Sunscreening Agents.)'],"['Solvents used in sunscreen products affect the stability and binding of the drug to the skin; in general, alcoholic solvents allow for the most rapid and deepest epidermal penetration of sunscreens. It appears that sunscreen agents are absorbed by the intact epidermis to varying degrees. /Sunscreens/']",,
1040,51041,"2,2',4,5-Tetrachlorobiphenyl",C1=CC=C(C(=C1)C2=CC(=C(C=C2Cl)Cl)Cl)Cl,,,,,,
1041,51042,"2,3',4',5'-Tetrachlorobiphenyl",C1=CC=C(C(=C1)C2=CC(=C(C(=C2)Cl)Cl)Cl)Cl,,,,,,
1042,51043,"3,4,4',5-Tetrachlorobiphenyl",C1=CC(=CC=C1C2=CC(=C(C(=C2)Cl)Cl)Cl)Cl,,,,,,
1043,51044,Bucindolol hydrochloride,CC(C)(CC1=CNC2=CC=CC=C21)NCC(COC3=CC=CC=C3C#N)O.Cl,,,"['Drugs that bind to but do not activate beta-adrenergic receptors thereby blocking the actions of beta-adrenergic agonists. Adrenergic beta-antagonists are used for treatment of hypertension, cardiac arrhythmias, angina pectoris, glaucoma, migraine headaches, and anxiety. (See all compounds classified as Adrenergic beta-Antagonists.)', 'Drugs that mimic the effects of stimulating postganglionic adrenergic sympathetic nerves. Included here are drugs that directly stimulate adrenergic receptors and drugs that act indirectly by provoking the release of adrenergic transmitters. (See all compounds classified as Sympathomimetics.)', 'Drugs used to cause dilation of the blood vessels. (See all compounds classified as Vasodilator Agents.)', 'Drugs that bind to and block the activation of ADRENERGIC ALPHA-1 RECEPTORS. (See all compounds classified as Adrenergic alpha-1 Receptor Antagonists.)']",,,
1044,51045,Bucindolol,CC(C)(CC1=CNC2=CC=CC=C21)NCC(COC3=CC=CC=C3C#N)O,,,"['Drugs that bind to but do not activate beta-adrenergic receptors thereby blocking the actions of beta-adrenergic agonists. Adrenergic beta-antagonists are used for treatment of hypertension, cardiac arrhythmias, angina pectoris, glaucoma, migraine headaches, and anxiety. (See all compounds classified as Adrenergic beta-Antagonists.)', 'Drugs that mimic the effects of stimulating postganglionic adrenergic sympathetic nerves. Included here are drugs that directly stimulate adrenergic receptors and drugs that act indirectly by provoking the release of adrenergic transmitters. (See all compounds classified as Sympathomimetics.)', 'Drugs that bind to and block the activation of ADRENERGIC ALPHA-1 RECEPTORS. (See all compounds classified as Adrenergic alpha-1 Receptor Antagonists.)', 'Drugs used to cause dilation of the blood vessels. (See all compounds classified as Vasodilator Agents.)']",,,
1045,51046,CID 51046,CN1C(=C(NC2=CC=CC=N2)O)C(=O)C3=C(S1(=O)=O)C=C(S3)Cl,,,,,,
1046,51047,Lortalamine,CN1CC[C@]23C(C1)C(CC(=O)N2)C4=C(O3)C=CC(=C4)Cl,,,,,,
1047,51048,"2-Isoindolineacetamide, N-(3,4-dihydro-4-oxo-3-quinazolinylmethyl)-1,3-dioxo-, trihydrochloride",C1=CC=C2C(=C1)C(=O)N(C2=O)CC(=O)[NH2+]C[NH+]3C=[NH+]C4=CC=CC=C4C3=O.[Cl-].[Cl-].[Cl-],,,,,,
1048,51049,"2-(1,3-dioxoisoindol-2-yl)-N-[(4-oxoquinazolin-3-yl)methyl]acetamide",C1=CC=C2C(=C1)C(=O)N(C2=O)CC(=O)NCN3C=NC4=CC=CC=C4C3=O,,,,,,
1049,51050,"Acetamide, N-(3,4-dihydro-4-oxo-3-quinazolinylmethyl)-2-(N-methylanilino)-, trihydrochloride",C[NH+](CC(=O)NC[NH+]1C=[NH+]C2=CC=CC=C2C1=O)C3=CC=CC=C3.[Cl-].[Cl-].[Cl-],,,,,,
1050,51051,2-(N-methylanilino)-N-[(4-oxoquinazolin-3-yl)methyl]acetamide,CN(CC(=O)NCN1C=NC2=CC=CC=C2C1=O)C3=CC=CC=C3,,,,,,
1051,51052,"Acetamide, N-(3,4-dihydro-4-oxo-3-quinazolinylmethyl)-2-(N-ethylanilino)-, trihydrochloride",CC[NH+](CC(=O)NC[NH+]1C=[NH+]C2=CC=CC=C2C1=O)C3=CC=CC=C3.[Cl-].[Cl-].[Cl-],,,,,,
1052,51053,2-(N-ethylanilino)-N-[(4-oxoquinazolin-3-yl)methyl]acetamide,CCN(CC(=O)NCN1C=NC2=CC=CC=C2C1=O)C3=CC=CC=C3,,,,,,
1053,51054,CID 51054,CC1=C(N2C=CC=CC2=C1)CC[NH3+].C(=CC(=O)[O-])C(=O)O,,,,,,
1054,51055,"3-Indolizineethanamine, 2-methyl-",CC1=C(N2C=CC=CC2=C1)CCN,,,,,,
1055,51056,CID 51056,CC1=C(N2C=CC=CC2=C1)CC[NH2+]C.C(=CC(=O)[O-])C(=O)O,,,,,,
1056,51057,N-methyl-2-(2-methylindolizin-3-yl)ethanamine,CC1=C(N2C=CC=CC2=C1)CCNC,,,,,,
1057,51058,CID 51058,CC1=C(N2C=CC=CC2=C1)CC[NH+](C)C.C(=CC(=O)[O-])C(=O)O,,,,,,
1058,51059,"N,N-dimethyl-2-(2-methylindolizin-3-yl)ethanamine",CC1=C(N2C=CC=CC2=C1)CCN(C)C,,,,,,
1059,51060,CID 51060,CC[NH2+]CCC1=C(C=C2N1C=CC=C2)C.C(=CC(=O)[O-])C(=O)O,,,,,,
1060,51061,N-ethyl-2-(2-methylindolizin-3-yl)ethanamine,CCNCCC1=C(C=C2N1C=CC=C2)C,,,,,,
1061,51062,CID 51062,CC[NH+](CC)CCC1=C(C=C2N1C=CC=C2)C.C(=CC(=O)[O-])C(=O)O,,,,,,
1062,51063,"N,N-diethyl-2-(2-methylindolizin-3-yl)ethanamine",CCN(CC)CCC1=C(C=C2N1C=CC=C2)C,,,,,,
1063,51064,CID 51064,CC1=C(N2CCCCC2=C1)CC[NH3+].C(=CC(=O)[O-])C(=O)O,,,,,,
1064,51065,"3-Indolizineethanamine, 5,6,7,8-tetrahydro-2-methyl-",CC1=C(N2CCCCC2=C1)CCN,,,,,,
1065,51066,CID 51066,CC[NH2+]CCC1=C(C=C2N1CCCC2)C.C(=CC(=O)[O-])C(=O)O,,,,,,
1066,51067,"N-ethyl-2-(2-methyl-5,6,7,8-tetrahydroindolizin-3-yl)ethanamine",CCNCCC1=C(C=C2N1CCCC2)C,,,,,,
1067,51068,CID 51068,CC1=C(N2CCCCC2=C1)CC[NH2+]C.C(=CC(=O)[O-])C(=O)O,,,,,,
1068,51069,"N-methyl-2-(2-methyl-5,6,7,8-tetrahydroindolizin-3-yl)ethanamine",CC1=C(N2CCCCC2=C1)CCNC,,,,,,
1069,51070,CID 51070,CC[NH+](CC)CCC1=C(C=C2N1CCCC2)C.C(=CC(=O)[O-])C(=O)O,,,,,,
1070,51071,"N,N-diethyl-2-(2-methyl-5,6,7,8-tetrahydroindolizin-3-yl)ethanamine",CCN(CC)CCC1=C(C=C2N1CCCC2)C,,,,,,
1071,51072,CID 51072,CC1=C(N2CCCCC2=C1)CC[NH+](C)C.C(=CC(=O)[O-])C(=O)O,,,,,,
1072,51073,"N,N-dimethyl-2-(2-methyl-5,6,7,8-tetrahydroindolizin-3-yl)ethanamine",CC1=C(N2CCCCC2=C1)CCN(C)C,,,,,,
1073,51074,"2,3,3',4',5-Pentachlorobiphenyl",C1=CC(=C(C=C1C2=C(C(=CC(=C2)Cl)Cl)Cl)Cl)Cl,,,,,,
1074,51075,"2,3,3',4,5-Pentachlorobiphenyl",C1=CC(=CC(=C1)Cl)C2=CC(=C(C(=C2Cl)Cl)Cl)Cl,,,,,,
1075,51076,"Acetamide, 2-chloro-N-(2-ethoxyethyl)-N-(3-methylphenyl)-",CCOCCN(C1=CC=CC(=C1)C)C(=O)CCl,,,,,,
1076,51077,"DIBENZ(a,h)ANTHRACENE, 1,2,3,4-TETRAHYDRO-3,4-DIHYDROXY-, (E)-",C1CC2=C(C=CC3=CC4=C(C=CC5=CC=CC=C54)C=C23)[C@@H]([C@H]1O)O,,,,,,
1077,51078,1-Ethyl-1H-indole-3-thiol,CCN1C=C(C2=CC=CC=C21)S,,,,,,
1078,51079,"1H-Indole, 3-(ethenylthio)-1-ethyl-",CCN1C=C(C2=CC=CC=C21)SC=C,,,,,,
1079,51080,"1H-Indole, 3-(ethenylthio)-",C=CSC1=CNC2=CC=CC=C21,,,,,,
1080,51081,Pefloxacin,CCN1C=C(C(=O)C2=CC(=C(C=C21)N3CCN(CC3)C)F)C(=O)O,['For the treatment of uncomplicated gonococcal urethritis in males and for gram-negative-bacterial infections in the gastrointestinal system and the genitourinary tract.'],"['Pefloxacin is a fluoroquinolone antibiotic. Flouroquinolones such as pefloxacin possess excellent activity against gram-negative aerobic bacteria such as <i>E.coli</i> and <i>Neisseria gonorrhoea</i> as well as gram-positive bacteria including <i>S. pneumoniae</i> and <i>Staphylococcus aureus</i>. They also posses effective activity against shigella, salmonella, campylobacter, gonococcal organisms, and multi drug resistant pseudomonas and enterobacter.']","['Compounds that inhibit the activity of DNA TOPOISOMERASE II. Included in this category are a variety of ANTINEOPLASTIC AGENTS which target the eukaryotic form of topoisomerase II and ANTIBACTERIAL AGENTS which target the prokaryotic form of topoisomerase II. (See all compounds classified as Topoisomerase II Inhibitors.)', 'Substances that inhibit the growth or reproduction of BACTERIA. (See all compounds classified as Anti-Bacterial Agents.)', 'Drugs and compounds which inhibit or antagonize the biosynthesis or actions of CYTOCHROME P-450 CYP1A2. (See all compounds classified as Cytochrome P-450 CYP1A2 Inhibitors.)']",['Well absorbed by the oral route.'],['Hepatic. Primary metabolites are pefloxacin N-oxide and norfloxacin.'],['8.6 hours']
1081,51082,Mitoxantrone hydrochloride,C1=CC(=C2C(=C1NCCNCCO)C(=O)C3=C(C=CC(=C3C2=O)O)O)NCCNCCO.Cl.Cl,,,"['Substances that inhibit or prevent the proliferation of NEOPLASMS. (See all compounds classified as Antineoplastic Agents.)', 'Compounds that inhibit the activity of DNA TOPOISOMERASE II. Included in this category are a variety of ANTINEOPLASTIC AGENTS which target the eukaryotic form of topoisomerase II and ANTIBACTERIAL AGENTS which target the prokaryotic form of topoisomerase II. (See all compounds classified as Topoisomerase II Inhibitors.)', 'Compounds capable of relieving pain without the loss of CONSCIOUSNESS. (See all compounds classified as Analgesics.)']","['An optimum procedure was established for preparing mitoxantrone albumin microspheres (DHAQ-BSA-MS) with emulsion-heating solidification. The morphology, diameters, drug loading, release characteristics, stability and its distribution in vivo of the drug-loaded albumin microspheres were studied. The results showed that the surface was regular, the average diameter was 0.99 micron, mean surface diameter was 1.24 microns and mean volume diameter was 1.44 microns, apparent drug loading was 2.558 +/- 0.101 micrograms.mg-1 (n = 5), effective drug loading was 1.503% +/- 0.127% (n = 5), embedding ratio was 92.82% +/- 6.48% (n = 5), and the release characteristics were in accord with ""biphase kinetics equation"": 1 - Q = 0.6428e-0.2132t + 0.3988e-0.00150t (gamma 1 = -0.9951, gamma 2 = -0.9982); T1/2 alpha = 3.250 h, T1/2 beta = 461.7 h. The stability of the drug-loaded albumin microspheres was good after three months storage at room temperature. The results determined by HPLC showed that the drug accumulated about 77.6% +/- 1.38% of the dose in the liver 20 minutes after intravenous injection to mice. This indicates that DHAQ-BSA-MS showed remarkable targeting for liver, and it seems to have important value for increasing the antihepatoma effect and decreasing the toxicity of mitoxantrone.', '... /Pharmacokinetics/ 1,4 dihydroxy 5,8 bis((2 ((2 hydroxyethyl)amino)ethyl)amino) 9,10 an6 thracenedione hydrochloride (I; NSC 301739; mitoxantrone hydrochloride) were determined in 6 metastatic cancer patients who each received 100 200 mCi, one to 3 mg/sq m of I in 12 ml of normal saline solution as an IV bolus over 15 min. Plasma clearance of I followed a biphasic pattern with a harmonic mean initial half life of 13.7 min and a terminal half life of 37.4 hr. Recovery of unchanged drug in the urine was 6.8% at 24 hr and 7.3% at 72 hr, while the corresponding recovery of total radioactivity was 9.4% and 11.3%. The apparent volume of distribution of I was about 13.8 + 2.9 liters/kg. Total clearance was 238.7 ml/kg/hr, twice the creatinine clearance.', '... Pharmacokinetic studies in humans and animals with mitoxantrone hydrochloride (Novantrone) are /discussed/ Intravenously administered novantrone disappears from the plasma of humans and animals with multiexponential kinetics and with a terminal half life ranging from 38 hr to several days. It is rapidly cleared from the plasma by extensive sequestration into the tissues; however, redistribution back into the plasma and elimination from the body are slow processes, In both animals and humans, novantroneis metabolized to the mono and dicarboxylic acid derivatives, as well as the glucuronide conjugates of these acids. Following IV administration, it is unchanged novantrone that binds to most tissues. Elimination is slow and predominantly via the kidney. Interaction studies with doxorubicin (II) indicate that prior administration of doxorubicin may prolong the half life of novantrone but that concurrent administration may not involve problems after the first dose.', 'Uptake of weak acid and weak base chemotherapeutic drugs by tumors is greatly influenced by the tumor extracellular/interstitial pH (pH(e)), the intracellular pH (pH(i)) maintained by the tumor cells, and by the ionization properties of the drug itself. The acid-outside plasmalemmal pH gradient in tumors acts to exclude weak base drugs like the anthracyclines, anthraquinones, and vinca alkaloids from the cells, leading to a substantial degree of ""physiological drug resistance"" in tumors. We have induced acute metabolic alkalosis in C3H tumor-bearing C3H/hen mice, by gavage and by intraperitoneal (i.p.) administration of NaHCO(3). (31)P magnetic resonance spectroscopic measurements of 3-aminopropylphosphonate show increases of up to 0.6 pH units in tumor pH(e), and 0.2 to 0.3 pH units in hind leg tissue pH(e), within 2 hours of i.p. administration of NaHCO(3). Theoretical calculations of mitoxantrone uptake into tumor and normal (hind leg) tissue at the measured pH(e) and pH(i) values indicate that a gain in therapeutic index of up to 3.3-fold is possible with NaHCO(3) pretreatment. Treatment of C3H tumor-bearing mice with 12 mg/kg mitoxantrone resulted in a tumor growth delay of 9 days, whereas combined NaHCO(3)--mitoxantrone therapy resulted in an enhancement of the TGD to 16 days.']","['... Pharmacokinetic studies in humans and animals with mitoxantrone hydrochloride (Novantrone) are /discussed/ Intravenously administered novantrone disappears from the plasma of humans and animals with multiexponential kinetics and with a terminal half life ranging from 38 hr to several days. It is rapidly cleared from the plasma by extensive sequestration into the tissues; however, redistribution back into the plasma and elimination from the body are slow processes, In both animals and humans, novantroneis metabolized to the mono and dicarboxylic acid derivatives, as well as the glucuronide conjugates of these acids. Following IV administration, it is unchanged novantrone that binds to most tissues. Elimination is slow and predominantly via the kidney. Interaction studies with doxorubicin (II) indicate that prior administration of doxorubicin may prolong the half life of novantrone but that concurrent administration may not involve problems after the first dose.']",
1082,51083,"Aziridine, 1-((4-chlorophenoxy)acetyl)-",C1CN1C(=O)COC2=CC=C(C=C2)Cl,,,,,,
1083,51084,N-Benzyl-N-(alpha-acetoxybenzyl)nitrosamine,CC(=O)OC(C1=CC=CC=C1)N(CC2=CC=CC=C2)N=O,,,,,,
1084,51085,"2-Butanone, 4-(4-hydroxy-1-piperidinyl)-3-((4-hydroxy-1-piperidinyl)methyl)-",CC(=O)C(CN1CCC(CC1)O)CN2CCC(CC2)O,,,,,,
1085,51086,"5-[(4-Chloro-2-nitrophenyl)azo]-1-ethyl-1,2-dihydro-6-hydroxy-4-methyl-2-oxo-3-pyridinecarbonitrile",CCN1C(=C(C(=C(C1=O)N=NC2=C(C=C(C=C2)Cl)[N+](=O)[O-])C)C#N)O,,,,,,
1086,51087,Itazigrel,COC1=CC=C(C=C1)C2=C(SC(=N2)C(F)(F)F)C3=CC=C(C=C3)OC,,,,,,
1087,51088,"1-Hexanethiol, 2,6-diamino-, dihydrochloride, (L)-",C(CC[NH3+])CC(CS)[NH3+].[Cl-].[Cl-],,,,,,
1088,51089,Lysinethiol,C(CCN)CC(CS)N,,,,,,
1089,51090,"ACETIC ACID, 2-(5-(3,4-DICHLOROPHENYL)-3-as-TRIAZINYL)HYDRAZIDE",CC(=O)NNC1=NC(=CN=N1)C2=CC(=C(C=C2)Cl)Cl,,,,,,
1090,51091,"ACETIC ACID, TRIFLUORO-, 2-(5-(4-CHLOROPHENYL)-3-as-TRIAZINYL)HYDRAZIDE",C1=CC(=CC=C1C2=CN=NC(=N2)NNC(=O)C(F)(F)F)Cl,,,,,,
1091,51092,"ACETIC ACID, TRIFLUORO-, 2-(5-(3-CHLOROPHENYL)-3-as-TRIAZINYL)HYDRAZIDE",C1=CC(=CC(=C1)Cl)C2=CN=NC(=N2)NNC(=O)C(F)(F)F,,,,,,
1092,51093,CID 51093,CC(C(=O)N[NH+]=C1NN=CC(=N1)C2=CC(=CC=C2)Cl)[NH3+].[Br-].[Br-],,,,,,
1093,51094,"2-amino-N'-[5-(3-chlorophenyl)-1,2,4-triazin-3-yl]propanehydrazide",CC(C(=O)NNC1=NC(=CN=N1)C2=CC(=CC=C2)Cl)N,,,,,,
1094,51095,"3-(Chloroacetylhydrazino)-5-phenyl-1,2,4-triazine",C1=CC=C(C=C1)C2=CN=NC(=N2)NNC(=O)CCl,,,,,,
1095,51096,"ACETIC ACID, DICHLORO-, 2-(5-PHENYL-3-as-TRIAZINYL)HYDRAZIDE",C1=CC=C(C=C1)C2=CN=NC(=N2)NNC(=O)C(Cl)Cl,,,,,,
1096,51097,"3-(Phenylacetylhydrazino)-5-phenyl-1,2,4-triazine, hydrochloride",C1=CC=C(C=C1)CC(=O)N[NH2+]C2=NC(=CN=N2)C3=CC=CC=C3.[Cl-],,,,,,
1097,51098,"2-phenyl-N'-(5-phenyl-1,2,4-triazin-3-yl)acetohydrazide",C1=CC=C(C=C1)CC(=O)NNC2=NC(=CN=N2)C3=CC=CC=C3,,,,,,
1098,51099,"3-(Isobutyrylhydrazino)-5-phenyl-1,2,4-triazine, hydrochloride",CC(C)C(=O)N[NH2+]C1=NC(=CN=N1)C2=CC=CC=C2.[Cl-],,,,,,
1099,51100,"2-methyl-N'-(5-phenyl-1,2,4-triazin-3-yl)propanehydrazide",CC(C)C(=O)NNC1=NC(=CN=N1)C2=CC=CC=C2,,,,,,
1100,51101,CID 51101,CCCCCC(=O)N[NH+]=C1NN=CC(=N1)C2=CC=CC=C2.[Cl-],,,,,,
1101,51102,"N'-(5-phenyl-1,2,4-triazin-3-yl)hexanehydrazide",CCCCCC(=O)NNC1=NC(=CN=N1)C2=CC=CC=C2,,,,,,
1102,51103,"3-(Trichloroacetylhydrazino)-5-(4-chlorophenyl)-1,2,4-triazine, hydrochloride",C1=CC(=CC=C1C2=CN=NC(=N2)[NH2+]NC(=O)C(Cl)(Cl)Cl)Cl.[Cl-],,,,,,
1103,51104,"2,2,2-trichloro-N'-[5-(4-chlorophenyl)-1,2,4-triazin-3-yl]acetohydrazide",C1=CC(=CC=C1C2=CN=NC(=N2)NNC(=O)C(Cl)(Cl)Cl)Cl,,,,,,
1104,51105,"ACETIC ACID, PHENYL-, 2-(5-(p-TOLYL)-3-as-TRIAZINYL)HYDRAZIDE",CC1=CC=C(C=C1)C2=CN=NC(=N2)NNC(=O)CC3=CC=CC=C3,,,,,,
1105,51106,Daurisoline,CN1CCC2=CC(=C(C=C2[C@H]1CC3=CC=C(C=C3)OC4=C(C=CC(=C4)C[C@@H]5C6=CC(=C(C=C6CCN5C)OC)O)O)OC)OC,,,,,,
1106,51107,"Methanaminium, N,N,N-trimethyl-, 2-naphthalenecarbodithioate",C[N+](C)(C)C.C1=CC=C2C=C(C=CC2=C1)C(=S)[S-],,,,,,
1107,51108,Naphthalene-2-carbodithioic acid,C1=CC=C2C=C(C=CC2=C1)C(=S)S,,,,,,
1108,51109,"Carbamic acid, ((N-nitrosobenzylamino)methyl)-, ethyl ester",CCOC(=O)NCN(CC1=CC=CC=C1)N=O,,,,,,
1109,51110,"Carbamic acid, ((methylnitrosamino)methyl)-, methyl ester",CN(CNC(=O)OC)N=O,,,,,,
1110,51111,"Carbamic acid, ((methylnitrosamino)methyl)-, ethyl ester",CCOC(=O)NCN(C)N=O,,,,,,
1111,51112,"Carbamic acid, ((methylnitrosamino)methyl)-, benzyl ester",CN(CNC(=O)OCC1=CC=CC=C1)N=O,,,,,,
1112,51113,CID 51113,CC(=NNC(=NCC=C)S)C1=CC=CC=N1,,,,,,
1113,51114,2-Methyl-N-nitrosothiazolidine,CC1N(CCS1)N=O,,,,,,
1114,51115,"2,3-Dimethoxypropyl 2-(trimethylazaniumyl)ethyl phosphate",C[N+](C)(C)CCOP(=O)([O-])OCC(COC)OC,,,,,,
1115,51116,"2-[2,3-Dimethoxypropoxy(hydroxy)phosphoryl]oxyethyl-trimethylazanium",C[N+](C)(C)CCOP(=O)(O)OCC(COC)OC,,,,,,
1116,51117,9-Methylbenzo(a)pyrene,CC1=CC2=C3C=CC4=CC=CC5=C4C3=C(C=C5)C=C2C=C1,,,,,,
1117,51118,"Carbamic acid, (bis(1-aziridinyl)phosphinyl)-, cyclohexyl ester",C1CCC(CC1)OC(=O)NP(=O)(N2CC2)N3CC3,,,,,,
1118,51119,"1,4,9-Trichlorodibenzofuran",C1=CC2=C(C(=C1)Cl)C3=C(C=CC(=C3O2)Cl)Cl,,,,,,
1119,51120,"1,9-Dichlorodibenzofuran",C1=CC2=C(C(=C1)Cl)C3=C(O2)C=CC=C3Cl,,,,,,
1120,51121,"1,3,4,6,9-Pentachlorodibenzofuran",C1=CC(=C2C(=C1Cl)C3=C(O2)C(=C(C=C3Cl)Cl)Cl)Cl,,,,,,
1121,51122,"1,3,4,7-Tetrachlorodibenzofuran",C1=CC2=C(C=C1Cl)OC3=C2C(=CC(=C3Cl)Cl)Cl,,,,,,
1122,51123,"1,2,6,9-Tetrachlorodibenzofuran",C1=CC(=C(C2=C1OC3=C(C=CC(=C23)Cl)Cl)Cl)Cl,,,,,,
1123,51124,"1,4,6,9-Tetrachlorodibenzofuran",C1=CC(=C2C(=C1Cl)C3=C(C=CC(=C3O2)Cl)Cl)Cl,,,,,,
1124,51125,"1,3,4,7,9-Pentachlorodibenzofuran",C1=C(C=C(C2=C1OC3=C2C(=CC(=C3Cl)Cl)Cl)Cl)Cl,,,,,,
1125,51126,"1,3,6,7,8-Pentachlorodibenzofuran",C1=C(C=C(C2=C1OC3=C(C(=C(C=C23)Cl)Cl)Cl)Cl)Cl,,,,,,
1126,51127,"1,2,8,9-Tetrachlorodibenzofuran",C1=CC(=C(C2=C1OC3=C2C(=C(C=C3)Cl)Cl)Cl)Cl,,,,,,
1127,51128,"1,2,4,8,9-Pentachlorodibenzofuran",C1=CC(=C(C2=C1OC3=C2C(=C(C=C3Cl)Cl)Cl)Cl)Cl,,,,,,
1128,51129,"1,2,3,4,6,7,9-Heptachlorodibenzofuran",C1=C(C2=C(C(=C1Cl)Cl)OC3=C2C(=C(C(=C3Cl)Cl)Cl)Cl)Cl,,,,,,
1129,51130,"1,2,3,4,7,8-Hexachlorodibenzofuran",C1=C2C(=CC(=C1Cl)Cl)OC3=C2C(=C(C(=C3Cl)Cl)Cl)Cl,,,,,,
1130,51131,"BUTYRIC ACID, 4-CHLORO-, 2-(5-(4-CHLOROPHENYL)-3-as-TRIAZINYL)HYDRAZIDE",C1=CC(=CC=C1C2=CN=NC(=N2)NNC(=O)CCCCl)Cl,,,,,,
1131,51132,2-Methoxypropyl acetate,CC(COC(=O)C)OC,,,,,,
1132,51133,N-(2-Naphthyl) glycine hydrazide dihydrochloride,C1=CC=C2C=C(C=CC2=C1)[NH2+]CC(=O)N[NH3+].[Cl-].[Cl-],,,,,,
1133,51134,N-(2-Naphthyl)glycine hydrazide,C1=CC=C2C=C(C=CC2=C1)NCC(=O)NN,,,,,,
1134,51135,N-Octylthiomethyl-3-methylpyridinium chloride,CCCCCCCCSC[N+]1=CC=CC(=C1)C.[Cl-],,,,,,
1135,51136,1-(Octylthiomethyl)-3-methylpyridinium,CCCCCCCCSC[N+]1=CC=CC(=C1)C,,,,,,
1136,51137,3-Methyl-n-dodecylthiomethylpyridinium chloride,CCCCCCCCCCCCSC[N+]1=CC=CC(=C1)C.[Cl-],,,,,,
1137,51138,3-Methyl-1-[(dodecylthio)methyl]pyridin-1-ium,CCCCCCCCCCCCSC[N+]1=CC=CC(=C1)C,,,,,,
1138,51139,"N-Octylthiomethyl-3,5-dimethylpyridinium chloride",CCCCCCCCSC[N+]1=CC(=CC(=C1)C)C.[Cl-],,,,,,
1139,51140,"1-(Octylthiomethyl)-3,5-dimethylpyridinium",CCCCCCCCSC[N+]1=CC(=CC(=C1)C)C,,,,,,
1140,51141,"N-Dodecylthiomethyl-3,5-dimethylpyridinium chloride",CCCCCCCCCCCCSC[N+]1=CC(=CC(=C1)C)C.[Cl-],,,,,,
1141,51142,"1-(Dodecylthiomethyl)-3,5-dimethylpyridinium",CCCCCCCCCCCCSC[N+]1=CC(=CC(=C1)C)C,,,,,,
1142,51143,Pentadecyl ethyleneglycol monoether,CCCCCCCCCCCCCCCOCCO,,,,,,
1143,51144,2-Undecan-6-yloxyethanol,CCCCCC(CCCCC)OCCO,,,,,,
1144,51145,2-Pentadecan-8-yloxyethanol,CCCCCCCC(CCCCCCC)OCCO,,,,,,
1145,51146,"2-(1,1-Dipropylbutoxy)ethanol",CCCC(CCC)(CCC)OCCO,,,,,,
1146,51147,2-[(6-Pentylundecan-6-yl)oxy]ethan-1-ol,CCCCCC(CCCCC)(CCCCC)OCCO,,,,,,
1147,51148,2-(1-Hexylcyclohexyloxy)ethanol,CCCCCCC1(CCCCC1)OCCO,,,,,,
1148,51149,2-(1-Decylcyclohexyloxy)ethanol,CCCCCCCCCCC1(CCCCC1)OCCO,,,,,,
1149,51150,"1,4-Bis((2-((2-hydroxyethyl)amino)ethyl)amino)-9,10-anthracenedione diacetate",CC(=O)[O-].CC(=O)[O-].C1=CC=C2C(=C1)C(=O)C3=C(C=CC(=C3C2=O)NCC[NH2+]CCO)NCC[NH2+]CCO,,,"['Substances that inhibit or prevent the proliferation of NEOPLASMS. (See all compounds classified as Antineoplastic Agents.)', 'Agents that are capable of inserting themselves between the successive bases in DNA, thus kinking, uncoiling or otherwise deforming it and therefore preventing its proper functioning. They are used in the study of DNA. (See all compounds classified as Intercalating Agents.)']",,,
1150,51151,"1,4-Dihydroxy-5,8-bis(2-((2-hydroxyethyl)amino)ethylamino)-9,10-anthracenedione diacetate",CC(=O)[O-].CC(=O)[O-].C1=CC(=C2C(=C1NCC[NH2+]CCO)C(=O)C3=C(C=CC(=C3C2=O)O)O)NCC[NH2+]CCO,,,"['Substances that inhibit or prevent the proliferation of NEOPLASMS. (See all compounds classified as Antineoplastic Agents.)', 'Compounds that inhibit the activity of DNA TOPOISOMERASE II. Included in this category are a variety of ANTINEOPLASTIC AGENTS which target the eukaryotic form of topoisomerase II and ANTIBACTERIAL AGENTS which target the prokaryotic form of topoisomerase II. (See all compounds classified as Topoisomerase II Inhibitors.)', 'Compounds capable of relieving pain without the loss of CONSCIOUSNESS. (See all compounds classified as Analgesics.)']",,,
1151,51152,"Acetic acid, (isopropylnitrosoamino)methyl ester",CC(C)N(COC(=O)C)N=O,,,,,,
1152,51153,"Acetic acid, (isobutylnitrosoamino)methyl ester",CC(C)CN(COC(=O)C)N=O,,,,,,
1153,51154,Tetraethylene glycol diheptanoate,CCCCCCC(=O)OCCOCCOCCOCCOC(=O)CCCCCC,,,,,,
1154,51155,"2-Imidazoline, 2-methyl-1-(3,4,5-trimethoxythiobenzoyl)-",CC1=NCCN1C(=S)C2=CC(=C(C(=C2)OC)OC)OC,,,,,,
1155,51156,"Acetic acid, (2,6-dimethoxy-4-(4-morpholinylthioxomethyl)phenoxy)-, ethyl ester",CCOC(=O)COC1=C(C=C(C=C1OC)C(=S)N2CCOCC2)OC,,,,,,
1156,51157,"2-(2-(Cyclohexylmethylphenylsilyl)ethoxy)-N,N-diethylethanamine",CCN(CC)CCOCC[Si](C)(C1CCCCC1)C2=CC=CC=C2,,,,,,
1157,51158,"Ethanamine, N,N-diethyl-2-(2-(methyldiphenylsilyl)ethoxy)-",CCN(CC)CCOCC[Si](C)(C1=CC=CC=C1)C2=CC=CC=C2,,,,,,
1158,51159,"2-(2-((4-Chlorophenyl)methylphenylsilyl)ethoxy)-N,N-diethylethanamine",CCN(CC)CCOCC[Si](C)(C1=CC=CC=C1)C2=CC=C(C=C2)Cl,,,,,,
1159,51160,"ISONIPECOTIC ACID, 4-(p-HYDROXYPHENYL)-1-METHYL-, ETHYL ESTER, HYDROCHLORIDE",CCOC(=O)C1(CC[NH+](CC1)C)C2=CC=C(C=C2)O.[Cl-],,,,,,
1160,51161,4-Hydroxymeperidine,CCOC(=O)C1(CCN(CC1)C)C2=CC=C(C=C2)O,,,,,,
1161,51162,"Isoquinoline, 1,2-dihydro-2-benzoyl-1-(1-(3-(4-methyl-l-piperazinyl)propyl)-3-indolyl)-",CN1CCN(CC1)CCCN2C=C(C3=CC=CC=C32)C4C5=CC=CC=C5C=CN4C(=O)C6=CC=CC=C6,,,,,,
1162,51163,"Indole, 5-(3-indolyl)-3-(aminoethyl)-, hydrochloride",C1=CC=C2C(=C1)C(=CN2)C3=CC4=C(C=C3)NC=C4CCN.Cl,,,,,,
1163,51164,5-(3-Indolyl)tryptamine,C1=CC=C2C(=C1)C(=CN2)C3=CC4=C(C=C3)NC=C4CCN,,,,,,
1164,51165,alpha-(Epoxyethyl)-p-methoxybenzyl alcohol,COC1=CC=C(C=C1)C(C2CO2)O,,,,,,
1165,51166,Octenidine hydrochloride,CCCCCCCCN=C1C=CN(C=C1)CCCCCCCCCCN2C=CC(=NCCCCCCCC)C=C2.Cl.Cl,,,"['Substances that prevent infectious agents or organisms from spreading or kill infectious agents in order to prevent the spread of infection. (See all compounds classified as Anti-Infective Agents.)', 'Substances used on humans and other animals that destroy harmful microorganisms or inhibit their activity. They are distinguished from DISINFECTANTS, which are used on inanimate objects. (See all compounds classified as Anti-Infective Agents, Local.)']",,,
1166,51167,Octenidine,CCCCCCCCN=C1C=CN(C=C1)CCCCCCCCCCN2C=CC(=NCCCCCCCC)C=C2,,,"['Substances that prevent infectious agents or organisms from spreading or kill infectious agents in order to prevent the spread of infection. (See all compounds classified as Anti-Infective Agents.)', 'Substances used on humans and other animals that destroy harmful microorganisms or inhibit their activity. They are distinguished from DISINFECTANTS, which are used on inanimate objects. (See all compounds classified as Anti-Infective Agents, Local.)']",,,
1167,51168,"3,2'-Dimethyl-4-nitrosobiphenyl",CC1=CC=CC=C1C2=CC(=C(C=C2)N=O)C,,,,,,
1168,51169,N-Acetyl-N-hydroxy-o-toluidine,CC1=CC=CC=C1N(C(=O)C)O,,,,,,
1169,51170,"Biphenyl, 2'-methyl-4-nitroso-",CC1=CC=CC=C1C2=CC=C(C=C2)N=O,,,,,,
1170,51171,"Acetohydroxamic acid, N-(2'-methylbiphenyl-4-YL)-",CC1=CC=CC=C1C2=CC=C(C=C2)N(C(=O)C)O,,,,,,
1171,51172,"N-(3,2'-Dimethylbiphenyl-4-yl)acetohydroxamic acid",CC1=CC=CC=C1C2=CC(=C(C=C2)N(C(=O)C)O)C,,,,,,
1172,51173,Flurofamide,C1=CC(=CC=C1C(=O)NP(=O)(N)N)F,,,,,,
1173,51174,Flutroline,C1CN(CC2=C1N(C3=C2C=C(C=C3)F)C4=CC=C(C=C4)F)CCCC(C5=CC=C(C=C5)F)O,,,,,,
1174,51175,CID 51175,C[NH+]1CC2CC(C1)CN(C2)C(=O)C3=CC(=C(C(=C3)OC)OC)OC.C(=CC(=O)[O-])C(=O)O,,,,,,
1175,51176,"(7-Methyl-3,7-diazabicyclo[3.3.1]nonan-3-yl)-(3,4,5-trimethoxyphenyl)methanone",CN1CC2CC(C1)CN(C2)C(=O)C3=CC(=C(C(=C3)OC)OC)OC,,,,,,
1176,51177,CID 51177,C[NH+]1CC2CC(C1)CN(C2)C(=O)C3=CC(=C(C=C3)Cl)Cl.C(=CC(=O)[O-])C(=O)O,,,,,,
1177,51178,"(3,4-Dichlorophenyl)-(7-methyl-3,7-diazabicyclo[3.3.1]nonan-3-yl)methanone",CN1CC2CC(C1)CN(C2)C(=O)C3=CC(=C(C=C3)Cl)Cl,,,,,,
1178,51179,"3-Benzoyl-7-butyl-3,7-diazabicyclo(3.3.1)nonane hydrochloride",CCCC[NH+]1CC2CC(C1)CN(C2)C(=O)C3=CC=CC=C3.[Cl-],,,,,,
1179,51180,"(7-Butyl-3,7-diazabicyclo[3.3.1]nonan-3-yl)-phenylmethanone",CCCCN1CC2CC(C1)CN(C2)C(=O)C3=CC=CC=C3,,,,,,
1180,51181,CID 51181,CCCC[NH+]1CC2CC(C1)CN(C2)C(=O)C3=CC=C(C=C3)OC.C(=CC(=O)[O-])C(=O)O,,,,,,
1181,51182,"(7-Butyl-3,7-diazabicyclo[3.3.1]nonan-3-yl)-(4-methoxyphenyl)methanone",CCCCN1CC2CC(C1)CN(C2)C(=O)C3=CC=C(C=C3)OC,,,,,,
1182,51183,CID 51183,CCCC[NH+]1CC2CC(C1)CN(C2)C(=O)C3=CC=C(C=C3)Cl.C(=CC(=O)[O-])C(=O)O,,,,,,
1183,51184,"(7-Butyl-3,7-diazabicyclo[3.3.1]nonan-3-yl)-(4-chlorophenyl)methanone",CCCCN1CC2CC(C1)CN(C2)C(=O)C3=CC=C(C=C3)Cl,,,,,,
1184,51185,CID 51185,CCCC[NH+]1CC2CC(C1)CN(C2)C(=O)C3=CC(=C(C=C3)Cl)Cl.C(=CC(=O)[O-])C(=O)O,,,,,,
1185,51186,"(7-Butyl-3,7-diazabicyclo[3.3.1]nonan-3-yl)-(3,4-dichlorophenyl)methanone",CCCCN1CC2CC(C1)CN(C2)C(=O)C3=CC(=C(C=C3)Cl)Cl,,,,,,
1186,51187,CID 51187,C[NH+]1CC2CC(C1)CN(C2)C(=O)C3=CC=CC=C3.C(=CC(=O)[O-])C(=O)O,,,,,,
1187,51188,"(7-Methyl-3,7-diazabicyclo[3.3.1]nonan-3-yl)-phenylmethanone",CN1CC2CC(C1)CN(C2)C(=O)C3=CC=CC=C3,,,,,,
1188,51189,CID 51189,C[NH+]1CC2CC(C1)CN(C2)C(=O)C3=CC=C(C=C3)OC.C(=CC(=O)[O-])C(=O)O,,,,,,
1189,51190,"(4-Methoxyphenyl)-(7-methyl-3,7-diazabicyclo[3.3.1]nonan-3-yl)methanone",CN1CC2CC(C1)CN(C2)C(=O)C3=CC=C(C=C3)OC,,,,,,
1190,51191,Dichloron,CCOP(=S)(OCC)OC1=NC(=C(C=C1Cl)Cl)Cl.COP(=O)(OC)OC=C(Cl)Cl,,,,,,
1191,51192,"Naphthalene-1,5-dicarbaldehyde",C1=CC(=C2C=CC=C(C2=C1)C=O)C=O,,,,,,
1192,51193,"Butyric acid, 2-acetamido-4-(vinylthio)-, methyl ester",CC(=O)NC(CCSC=C)C(=O)OC,,,,,,
1193,51194,CID 51194,CC[C@H]1CC(=O)[C@H]2[C@@]34[C@@H]1[C@H](CC5=C3C(=C(C=C5)OC)O2)N(CC4)CC6CC6,,,,,,
1194,51195,"1,2,6,7,9-Pentachlorodibenzofuran",C1=CC(=C(C2=C1OC3=C2C(=CC(=C3Cl)Cl)Cl)Cl)Cl,,,,,,
1195,51196,O-Desmethylquinidine,C=CC1CN2CCC1CC2[C@@H](C3=C4C=C(C=CC4=NC=C3)O)O,,,,,,
1196,51197,CID 51197,C[N+](C)(C)CCOC(=O)C=CC1=CNC2=CC=CC=C21.[I-],,,,,,
1197,51198,CID 51198,C[N+](C)(C)CCOC(=O)C=CC1=CNC2=CC=CC=C21,,,,,,
1198,51199,Nafimidone hydrochloride,C1=CC=C2C=C(C=CC2=C1)C(=O)CN3C=CN=C3.Cl,,,,,,
1199,51200,Nafimidone,C1=CC=C2C=C(C=CC2=C1)C(=O)CN3C=CN=C3,,,,,,
1200,51201,1-(2-Cyclohexylphenoxy)-1-(2-imidazolinyl)ethane hydrochloride,C1CCC(CC1)C2=CC=CC=C2OCCC3=NCC[NH2+]3.[Cl-],,,,,,
1201,51202,"2-[2-(2-cyclohexylphenoxy)ethyl]-4,5-dihydro-1H-imidazole",C1CCC(CC1)C2=CC=CC=C2OCCC3=NCCN3,,,,,,
1202,51203,1-(2-Cyclohexylphenoxy)-1-(5-methyl-2-imidazolinyl)ethane hydrochloride,CC1CN=C([NH2+]1)CCOC2=CC=CC=C2C3CCCCC3.[Cl-],,,,,,
1203,51204,2-[2-(2-Cyclohexylphenoxy)ethyl]-4-methyl-2-imidazoline,CC1CN=C(N1)CCOC2=CC=CC=C2C3CCCCC3,,,,,,
1204,51205,1-(4-Cyclohexylphenoxy)-1-(5-methyl-2-imidazolinyl)ethane hydrochloride,CC1CN=C([NH2+]1)CCOC2=CC=C(C=C2)C3CCCCC3.[Cl-],,,,,,
1205,51206,"2-[2-(4-cyclohexylphenoxy)ethyl]-5-methyl-4,5-dihydro-1H-imidazole",CC1CN=C(N1)CCOC2=CC=C(C=C2)C3CCCCC3,,,,,,
1206,51207,CID 51207,CC(=O)C1=CC2=C(C=C1)SC3=C(CC2N4CCN(CC4)CCO)C=CC(=C3)F.C(=CC(=O)O)C(=O)O.C(=CC(=O)O)C(=O)O,,,,,,
1207,51208,"1-[9-Fluoro-5-[4-(2-hydroxyethyl)piperazin-1-yl]-5,6-dihydrobenzo[b][1]benzothiepin-3-yl]ethanone",CC(=O)C1=CC2=C(C=C1)SC3=C(CC2N4CCN(CC4)CCO)C=CC(=C3)F,,,,,,
1208,51209,CID 51209,CN1CCN(CC1)C2CC3=C(C=C(C=C3)F)SC4=C2C=C(C=C4)O.C(=CC(=O)[O-])C(=O)[O-],,,,,,
1209,51210,"7-Fluoro-11-(4-methylpiperazin-1-yl)-10,11-dihydrodibenzo[b,f]thiepin-2-ol",CN1CCN(CC1)C2CC3=C(C=C(C=C3)F)SC4=C2C=C(C=C4)O,,,,,,
1210,51211,"BENZIMIDAZOLEMETHANOL, alpha-(p-CHLOROPHENYL)-, HYDROCHLORIDE",C1=CC=C2C(=C1)NC=[N+]2C(C3=CC=C(C=C3)Cl)O.[Cl-],,,,,,
1211,51212,3H-benzimidazol-1-ium-1-yl-(4-chlorophenyl)methanol,C1=CC=C2C(=C1)NC=[N+]2C(C3=CC=C(C=C3)Cl)O,,,,,,
1212,51213,1-Methyl-S-(3-methylthiophosphoryl)imidazolium,C[N+]1=CN(C=C1)P(=O)([O-])SC,,,,,,
1213,51214,(3-Methylimidazol-3-ium-1-yl)-methylsulfanylphosphinic acid,C[N+]1=CN(C=C1)P(=O)(O)SC,,,,,,
1214,51215,"Acetohydroxamic acid, N-(7-iodo-2-fluorenyl)-",CC(=O)N(C1=CC2=C(C=C1)C3=C(C2)C=C(C=C3)I)O,,,,,,
1215,51216,"2-Chloro-5-(methylthio)-4,6-pyrimidinediamine",CSC1=C(N=C(N=C1N)Cl)N,,,,,,
1216,51217,"Benzoic acid, 4-(((tetrahydro-5-ethyl-3-methyl-5-phenyl-2,4,6-trioxo-1(2H)-pyrimidinyl)acetyl)amino)-",CCC1(C(=O)N(C(=O)N(C1=O)CC(=O)NC2=CC=C(C=C2)C(=O)O)C)C3=CC=CC=C3,,,,,,
1217,51218,"Benzoic acid, 2-(((tetrahydro-5-ethyl-3-methyl-5-phenyl-2,4,6-trioxo-1(2H)-pyrimidinyl)acetyl)amino)-",CCC1(C(=O)N(C(=O)N(C1=O)CC(=O)NC2=CC=CC=C2C(=O)O)C)C3=CC=CC=C3,,,,,,
1218,51219,"Benzoic acid, 2,2'-((dihydro-5,5-diethyl-2,4,6-trioxo-1,3(2H,4H)-pyrimidinediyl)bis((1-oxo-2,1-ethanediyl)imino))bis-",CCC1(C(=O)N(C(=O)N(C1=O)CC(=O)NC2=CC=CC=C2C(=O)O)CC(=O)NC3=CC=CC=C3C(=O)O)CC,,,,,,
1219,51220,"3-(4-Chlorophenyl)-5,5-dimethylimidazolidine-2,4-dione",CC1(C(=O)N(C(=O)N1)C2=CC=C(C=C2)Cl)C,,,,,,
1220,51221,Versiconol acetate,CC(=O)OCCC(CO)C1=C(C=C2C(=C1O)C(=O)C3=C(C2=O)C=C(C=C3O)O)O,,,,,,
1221,51222,Pirazolac,C1=CC(=CC=C1C2=CN(N=C2CC(=O)O)C3=CC=C(C=C3)F)Cl,,,,,,
1222,51223,Vidarabine sodium phosphate,C1=NC(=C2C(=N1)N(C=N2)[C@H]3[C@H]([C@@H]([C@H](O3)COP(=O)([O-])[O-])O)O)N.[Na+].[Na+],,,,,,
1223,51224,CID 51224,C[NH+]1CC2CC(C1)CN(C2)C(=O)C3=CC=C(C=C3)Cl.C(=CC(=O)[O-])C(=O)O,,,,,,
1224,51225,"3-(4-Chlorobenzoyl)-7-methyl-3,7-diazabicyclo[3.3.1]nonane",CN1CC2CC(C1)CN(C2)C(=O)C3=CC=C(C=C3)Cl,,,,,,
1225,51226,"Butanoic acid, 3-methyl-, 4-((acetyloxy)methyl)-7-formyl-1,3,4,7a-tetrahydro-1-hydroxycyclopenta(c)pyran-4-yl ester",CC(C)CC(=O)OC1(COC(C2C1=CC=C2C=O)O)COC(=O)C,,,,,,
1226,51227,3-[(3-Methylbutyl)nitrosoamino]-2-butanone,CC(C)CCN(C(C)C(=O)C)N=O,,,,,,
1227,51228,"N-(3,4-dichlorophenyl)-N-[2-(dimethylamino)cyclopentyl]propanamide",CCC(=O)N(C1CCCC1N(C)C)C2=CC(=C(C=C2)Cl)Cl,,,,,,
1228,51229,"Acridinium, 1,2,3,4-tetrahydro-9,10-dimethyl-, methyl sulfate",CC1=C2CCCCC2=[N+](C3=CC=CC=C13)C.COS(=O)(=O)[O-],,,,,,
1229,51230,"9,10-Dimethyl-1,2,3,4-tetrahydroacridin-10-ium",CC1=C2CCCCC2=[N+](C3=CC=CC=C13)C,,,,,,
1230,51231,"Guanidine, 1-cyclohexyl-2-(2-methyl-4-quinolyl)-3-(1,3,4-thiadiazol-2-YL)-",CC1=NC2=CC=CC=C2C(=C1)NC(=NC3CCCCC3)NC4=NN=CS4,,,,,,
1231,51232,"GUANIDINE, 1-tert-BUTYL-2-(2-METHYL-4-QUINOLYL)-3-(2-THIAZOLYL)-",CC1=NC2=CC=CC=C2C(=C1)NC(=NC(C)(C)C)NC3=NC=CS3,,,,,,
1232,51233,"GUANIDINE, 1-tert-BUTYL-2-(2-METHYL-4-QUINOLYL)-3-(4-METHYL-2-THIAZOLYL)-",CC1=NC2=CC=CC=C2C(=C1)NC(=NC(C)(C)C)NC3=NC(=CS3)C,,,,,,
1233,51234,"Guanidine, 1-butyl-2-(2-methyl-4-quinolyl)-3-(2-thiazolyl)-",CCCCN=C(NC1=CC(=NC2=CC=CC=C21)C)NC3=NC=CS3,,,,,,
1234,51235,"Guanidine, 1-isobutyl-2-(2-methyl-4-quinolyl)-3-(2-thiazolyl)-",CC1=NC2=CC=CC=C2C(=C1)NC(=NCC(C)C)NC3=NC=CS3,,,,,,
1235,51236,1-sec-Butyl-2-(2-methyl-4-quinolyl)-3-(2-thiazolyl)guanidine,CCC(C)N=C(NC1=CC(=NC2=CC=CC=C21)C)NC3=NC=CS3,,,,,,
1236,51237,"Guanidine, 1-(2,2-dimethylpropyl)-2-(2-methyl-4-quinolyl)-3-(2-thiazolyl)-",CC1=NC2=CC=CC=C2C(=C1)NC(=NCC(C)(C)C)NC3=NC=CS3,,,,,,
1237,51238,1-Cyclopropyl-2-(2-methyl-4-quinolyl)-3-(2-thiazolyl)guanidine dinitrate,CC1=NC2=CC=CC=C2C(=C1)N=C([NH2+]C3CC3)[NH2+]C4=NC=CS4.[N+](=O)([O-])[O-].[N+](=O)([O-])[O-],,,,,,
1238,51239,"2-Cyclopropyl-1-(2-methylquinolin-4-yl)-3-(1,3-thiazol-2-yl)guanidine",CC1=NC2=CC=CC=C2C(=C1)NC(=NC3CC3)NC4=NC=CS4,,,,,,
1239,51240,"Guanidine, 1-cyclopentyl-2-(2-methyl-4-quinolyl)-3-(2-thiazolyl)-",CC1=NC2=CC=CC=C2C(=C1)NC(=NC3CCCC3)NC4=NC=CS4,,,,,,
1240,51241,"Guanidine, 1-(1-methylcyclopentyl)-2-(2-methyl-4-quinolyl)-3-(2-thiazolyl)-",CC1=NC2=CC=CC=C2C(=C1)NC(=NC3(CCCC3)C)NC4=NC=CS4,,,,,,
1241,51242,"N-tert-Butyl-N''-(2,3-dihydro-1,3-thiazol-2-yl)-N'-(2-methylquinolin-4(1H)-ylidene)guanidine",CC1=NC2=CC=CC=C2C(=C1)NC(=NC3NC=CS3)NC(C)(C)C,,,,,,
1242,51243,1-tert-Butyl-2-(2-ethoxy-4-quinolyl)-3-(2-thiazolyl)guanidine dinitrate,CCOC1=NC2=CC=CC=C2C(=C1)NC(=[NH+]C(C)(C)C)[NH2+]C3=NC=CS3.[N+](=O)([O-])[O-].[N+](=O)([O-])[O-],,,,,,
1243,51244,"2-Tert-butyl-1-(2-ethoxyquinolin-4-yl)-3-(1,3-thiazol-2-yl)guanidine",CCOC1=NC2=CC=CC=C2C(=C1)NC(=NC(C)(C)C)NC3=NC=CS3,,,,,,
1244,51245,"GUANIDINE, 1-tert-BUTYL-2-(2-PROPYL-4-QUINOLYL)-3-(2-THIAZOLYL)-",CCCC1=NC2=CC=CC=C2C(=C1)NC(=NC(C)(C)C)NC3=NC=CS3,,,,,,
1245,51246,1-tert-Butyl-2-(2-isobutyl-4-quinolyl)-3-(2-thiazolyl)guanidine,CC(C)CC1=NC2=CC=CC=C2C(=C1)NC(=NC(C)(C)C)NC3=NC=CS3,,,,,,
1246,51247,1-tert-Pentyl-2-(2-methyl-4-quinolyl)-3-(2-thiazolyl)guanidine,CCC(C)(C)N(C1=NC=CS1)C(=NC2=CC(=NC3=CC=CC=C32)C)N,,,,,,
1247,51248,"Guanidine, 1-ethyl-2-(2-methyl-4-quinolyl)-3-(2-thiazolyl)-",CCN=C(NC1=CC(=NC2=CC=CC=C21)C)NC3=NC=CS3,,,,,,
1248,51249,CID 51249,C1C(C(C(C1O)C=CC(COC2=CSC=C2)O)CC=CCCCC(=O)O)O,,,,,,
1249,51250,CID 51250,CC(CCCC1([C@H](CCC(=CCO)CO1)O)C)C(=O)CC=C(C)C,,,,,,
1250,51251,6-trans Leukotriene B4,CCCCCC=CC[C@H](C=CC=CC=C[C@H](CCCC(=O)O)O)O,,,,,,
1251,51252,"9,10-Dihydro-10-methyl-9-(2-(4-morpholinyl)-2-cyclohexen-1-yl)acridine",CN1C2=CC=CC=C2C(C3=CC=CC=C31)C4CCCC=C4N5CCOCC5,,,,,,
1252,51253,"9,10-Dihydro-10-methyl-9-(2-(1-piperidinyl)-2-cyclohexen-1-yl)acridine",CN1C2=CC=CC=C2C(C3=CC=CC=C31)C4CCCC=C4N5CCCCC5,,,,,,
1253,51254,8-Fluorobenzo[a]pyrene,C1=CC2=C3C(=C1)C=CC4=C3C(=CC5=C4C=CC(=C5)F)C=C2,,,,,,
1254,51255,9-Fluorobenzo[a]pyrene,C1=CC2=C3C(=C1)C=CC4=C5C=C(C=CC5=CC(=C43)C=C2)F,,,,,,
1255,51256,"10-Fluoro-7,12-dimethylbenz(a)anthracene",CC1=C2C=CC(=CC2=C(C3=C1C=CC4=CC=CC=C43)C)F,,,,,,
1256,51257,1-Cyanocycloheptyl acetate,CC(=O)OC1(CCCCCC1)C#N,,,,,,
1257,51258,"Pentakis(2,2,2-trifluoroethoxy)phosphorane",C(C(F)(F)F)OP(OCC(F)(F)F)(OCC(F)(F)F)(OCC(F)(F)F)OCC(F)(F)F,,,,,,
1258,51259,2-Bromo-2'-fluoro-N-methyldiethylamine hydrochloride,C[NH+](CCF)CCBr.[Cl-],,,,,,
1259,51260,N-(2-bromoethyl)-2-fluoro-N-methylethanamine,CN(CCF)CCBr,,,,,,
1260,51261,2-Bromo-2'-iododiethylamine hydrochloride,C(CBr)[NH2+]CCI.[Cl-],,,,,,
1261,51262,2-bromo-N-(2-iodoethyl)ethanamine,C(CBr)NCCI,,,,,,
1262,51263,Alfentanil,CCC(=O)N(C1=CC=CC=C1)C2(CCN(CC2)CCN3C(=O)N(N=N3)CC)COC,['For the management of postoperative pain and the maintenance of general anesthesia.'],"[""Alfentanil is a synthetic opioid analgesic. Alfentanil interacts predominately with the opioid mu-receptor. These mu-binding sites are discretely distributed in the human brain, spinal cord, and other tissues. In clinical settings, alfentanil exerts its principal pharmacologic effects on the central nervous system. Its primary actions of therapeutic value are analgesia and sedation. Alfentanil may increase the patient's tolerance for pain and decrease the perception of suffering, although the presence of the pain itself may still be recognized. In addition to analgesia, alterations in mood, euphoria and dysphoria, and drowsiness commonly occur. Alfentanil depresses the respiratory centers, depresses the cough reflex, and constricts the pupils.""]","['Compounds with activity like OPIATE ALKALOIDS, acting at OPIOID RECEPTORS. Properties include induction of ANALGESIA or NARCOSIS. (See all compounds classified as Analgesics, Opioid.)', 'Ultrashort-acting anesthetics that are used for induction. Loss of consciousness is rapid and induction is pleasant, but there is no muscle relaxation and reflexes frequently are not reduced adequately. Repeated administration results in accumulation and prolongs the recovery time. Since these agents have little if any analgesic activity, they are seldom used alone except in brief minor procedures. (From AMA Drug Evaluations Annual, 1994, p174) (See all compounds classified as Anesthetics, Intravenous.)', 'Agents that induce NARCOSIS. Narcotics include agents that cause somnolence or induced sleep (STUPOR); natural or synthetic derivatives of OPIUM or MORPHINE or any substance that has such effects. They are potent inducers of ANALGESIA and OPIOID-RELATED DISORDERS. (See all compounds classified as Narcotics.)']","['For intravenous injection or infusion only.', 'Only 1.0% of the dose is excreted as unchanged drug; urinary excretion is the major route of elimination of metabolites.', '0.4 to 1 L/kg', '5 mL/kg/min', 'The distribution and elimination kinetics of alfentanil, a new short-acting analgesic, were studied in five surgical patients. Its behavior, following a bolus injection of 120 micrograms/ml, was compatible with a three-compartment open-model distribution. The disappearance of the drug from plasma was rapid (t 1/2 pi = 3.5 +/- 1.3 minutes, t 1/2 alpha = 16.8 +/- 6.4 minutes) with 96.4% of the drug eliminated from plasma in 1 hour, indicating extensive transfer to the remote peripheral compartment. This was followed by a slower elimination phase with a t 1/2 beta of 94 +/- 38 minutes. Total volume of distribution was 1.03 +/- 0.50 L/kg. Total plasma clearance was 456 +/- 155 ml/min. The short analgesic effect of this drug might be attributed to the rapid displacement of the drug from the central and intermediate compartments to the remote peripheral compartment. Approximately 25% of the injected dose was present in the remote peripheral compartment 30 to 60 minutes after alfentanil administration. As the return of drug from this peripheral to the central compartment is slower than the elimination rate of the drug, it could be the rate-limiting step in the elimination of alfentanil from the body.', 'The in vitro plasma protein binding and distribution in blood of fentanyl and three analogues were studied in rats, dogs and healthy volunteers. In human plasma, 84.4% of fentanyl was bound, 92.5% of sufentanil, 92.1% of alfentanil and 93.6% of lofentanil. Plasma protein binding of the four analgesics was independent of their concentration over the whole therapeutic range. Plasma protein binding of alfentanil was much less pH dependent than that of the three other analgesics. Attention was drawn to the possible contribution of the ""acute phase"" protein alpha 1-acid glycoprotein (alpha 1-AGP), of lipoproteins and of blood cells to the binding of fentanyl and its analogs in blood.', 'The influence of the pH of the incubation medium on the cellular accumulation of tritiated fentanyl, lofentanil, and alfentanil was investigated in isolated guinea pig atria. Fentanyl and lofentanil accumulated in atrial tissue up to about 30- and 50-fold, respectively. The amount of drug bound when equilibrium was attained was found to be dependent upon the pH of the medium. By plotting binding equilibria v. pH of the bath, curves were obtained which resembled titration curves. Half-maximal binding was attained at pH values close to the pKa values of fentanyl and lofentanil. Alfentanil was found to accumulate less. The uptake by the tissue was strongly proportional to the extracellular concentration. Atria equilibrated with fentanyl at pH 8.5 released the compound rapidly when exposed to a pH of 7.0, even in the continuous presence of fentanyl in the bath. The consequences of the findings for in vivo conditions are discussed with respect to a possible augmentation of the actions of fentanyl by respiratory acidosis.', 'Alfentanil has an apparent volume of distribution of 0.4 to 1 L/kg, with an average plasma clearance of 5 mL/kg/min. Plasma protein binding of alfentanil is approximately 92%.', 'For more Absorption, Distribution and Excretion (Complete) data for Alfentanil (19 total), please visit the HSDB record page.']","['The liver is the major site of biotransformation.', 'Alfentanil was rapidly metabolized into a large number of metabolites with oxidative O-demethylation and oxidative N-dealkylation at the piperidine nitrogen as the major metabolic pathways.', 'The liver is the major site of biotransformation.', 'Alfentanil has known human metabolites that include 2-(4-ethyl-5-oxo-1,2,3,4-tetrazol-1-yl)acetaldehyde, N-phenylpropionamide, and Noralfentanil.']","['90-111 minutes', 'After iv injection, alfentanil is distributed in the body according to a two or three compartment model. When given to young and middle-aged patients for various surgical procedures, alfentanil has an elimination half-life of 70-99 minutes independent of the dose or route of administration.', 'The pharmacokinetics of alfentanil can be described as a three-compartment model with sequential distribution half-lives of 1 and 14 minutes. Alfentanil has a terminal elimination half-life of 90 to 111 minutes.', 'The aim of this study was to compare the pharmacokinetics of fentanyl, alfentanil, and sufentanil in isoflurane-anesthetized cats. Six adult cats were used. Anesthesia was induced and maintained with isoflurane in oxygen. End-tidal isoflurane concentration was set at 2% and adjusted as required due to spontaneous movement. Fentanyl (10 ug/kg), alfentanil (100 ug/kg), or sufentanil (1 ug/kg) was administered intravenously as a bolus, on separate days. Blood samples were collected immediately before and for 8 hr following drug administration. Plasma drug concentration was determined using liquid chromatography/mass spectrometry. Compartment models were fitted to concentration-time data. A 3-compartment model best fitted the concentration-time data for all drugs, except for 1 cat in the sufentanil group (excluded from analysis). ... The terminal half-life (min) [median (range)] /was/ 144 (118-501) for alfentanil ... .', 'Alfentanil has an immediate onset of action and plasma levels decay according to a 3- compartment model with sequential half-lives of 1 minute for the fast distribution phase, 12 minutes for the redistribution phase and 90 minutes for the terminal elimination phase.', 'For more Biological Half-Life (Complete) data for Alfentanil (6 total), please visit the HSDB record page.']"
1263,51264,CID 51264,CCCCOC1=NC2=CC=CC=C2C(=C1)C=NOCC[NH+](CC)CC.[Cl-],,,,,,
1264,51265,CID 51265,CCCCOC1=NC2=CC=CC=C2C(=C1)C=NOCCN(CC)CC,,,,,,
1265,51266,CID 51266,CC[NH+](CC)CCON=CC1=CC(=NC2=CC=CC=C21)OC3CCCCC3.[Cl-],,,,,,
1266,51267,CID 51267,CCN(CC)CCON=CC1=CC(=NC2=CC=CC=C21)OC3CCCCC3,,,,,,
1267,51268,CID 51268,CCCC1=NC2=CC=CC=C2C(=C1)C=NOCC[NH+](CC)CC.[Cl-],,,,,,
1268,51269,CID 51269,CCCC1=NC2=CC=CC=C2C(=C1)C=NOCCN(CC)CC,,,,,,
1269,51270,CID 51270,CCCCC1=NC2=CC=CC=C2C(=C1)C=NOCC[NH+](CC)CC.[Cl-],,,,,,
1270,51271,CID 51271,CCCCC1=NC2=CC=CC=C2C(=C1)C=NOCCN(CC)CC,,,,,,
1271,51272,"ALLOPHANIC ACID, 2-(o-BROMOPHENYL)-, ETHYL ESTER",CCOC(=O)N(C1=CC=CC=C1Br)C(=O)N,,,,,,
1272,51273,"ALLOPHANIC ACID, 2-(alpha,alpha,alpha-TRIFLUORO-o-TOLYL)-, ETHYL ESTER",CCOC(=O)N(C1=CC=CC=C1C(F)(F)F)C(=O)N,,,,,,
1273,51274,CID 51274,C1=CC=C(C(=C1)C=C2C(=O)N(C(=N2)S)C3=CC(=CC=C3)Cl)Cl,,,,,,
1274,51275,CID 51275,C1=CC(=CC(=C1)Cl)N2C(=O)C(=CC3=CC=C(C=C3)Cl)N=C2S,,,,,,
1275,51276,CID 51276,CC1=CC=CC=C1C=C2C(=O)N(C(=N2)S)C3=CC(=CC=C3)Cl,,,,,,
1276,51277,CID 51277,CC1=CC(=CC=C1)C=C2C(=O)N(C(=N2)S)C3=CC(=CC=C3)Cl,,,,,,
1277,51278,CID 51278,CC1=CC=C(C=C1)C=C2C(=O)N(C(=N2)S)C3=CC(=CC=C3)Cl,,,,,,
1278,51279,CID 51279,COC1=CC=CC=C1C=C2C(=O)N(C(=N2)S)C3=CC(=CC=C3)Cl,,,,,,
1279,51280,CID 51280,COC1=CC=CC(=C1)C=C2C(=O)N(C(=N2)S)C3=CC(=CC=C3)Cl,,,,,,
1280,51281,"1H-Imidazole-1-ethanol, 2-dodecyl-4,5-dihydro-, hydrochloride (1:1)",CCCCCCCCCCCCC1=NCCN1CCO.Cl,,,,,,
1281,51282,"2-Dodecyl-4,5-dihydro-1H-imidazole-1-ethanol",CCCCCCCCCCCCC1=NCCN1CCO,,,,,,
1282,51283,DL-Alanine-15N,CC(C(=O)O)[15NH2],,,,,,
1283,51284,CID 51284,C1=CC(=CC(=C1)Cl)N2C(=O)C(=CC3=CC=C(C=C3)[N+](=O)[O-])N=C2S,,,,,,
1284,51285,11-methyl-11H-benzo[a]fluorene,CC1C2=CC=CC=C2C3=C1C4=CC=CC=C4C=C3,,,,,,
1285,51286,2-Chlorobenzoic acid 4-benzoyl-1-methyl-4-piperidinyl ester conjugate monoacid,CC1CC(CCN1)(C(=O)C2=CC=CC=C2)OC(=O)C3=CC=CC=C3Cl,,,,,,
1286,51287,"Benzoic acid, 2-bromo-, 4-benzoyl-1-methyl-4-piperidinyl ester, conjugate monoacid",CC1CC(CCN1)(C(=O)C2=CC=CC=C2)OC(=O)C3=CC=CC=C3Br,,,,,,
1287,51288,"Benzoic acid, 4-hydroxy-, 4-benzoyl-1-methyl-4-piperidinyl ester, conjugate monoacid",CN1CCC(CC1)(C(=O)C2=CC=CC=C2)OC(=O)C3=CC=C(C=C3)O,,,,,,
1288,51289,"Benzoic acid, 4-methoxy-, 4-benzoyl-1-methyl-4-piperidinyl ester, conjugate monoacid",CN1CCC(CC1)(C(=O)C2=CC=CC=C2)OC(=O)C3=CC=C(C=C3)OC,,,,,,
1289,51290,"Benzoic acid, 4-amino-2-chloro-, 4-benzoyl-1-methyl-4-piperidinyl ester, conjugate monoacid",CN1CCC(CC1)(C(=O)C2=CC=CC=C2)OC(=O)C3=C(C=C(C=C3)N)Cl,,,,,,
1290,51291,N'-Nitrosoanatabine,C1C=CCN([C@@H]1C2=CN=CC=C2)N=O,,,,,,
1291,51292,N-Trifluoroacetyldemecolcine,CN([C@H]1CCC2=CC(=C(C(=C2C3=CC=C(C(=O)C=C13)OC)OC)OC)OC)C(=O)C(F)(F)F,,,,,,
1292,51293,"N,N-Dimethyl-2-((2,6-dimethyl-4-pyrimidinyl)oxy)ethanamine hydrochloride",CC1=CC(=NC(=N1)C)OCC[NH+](C)C.[Cl-],,,,,,
1293,51294,"2-((2,6-Dimethylpyrimidin-4-yl)oxy)-N,N-dimethylethanamine",CC1=CC(=NC(=N1)C)OCCN(C)C,,,,,,
1294,51295,"N,N-Diethyl-2-((2,6-dimethyl-4-pyrimidinyl)oxy)ethanamine hydrochloride",CC[NH+](CC)CCOC1=NC(=NC(=C1)C)C.[Cl-],,,,,,
1295,51296,"2-(2,6-dimethylpyrimidin-4-yl)oxy-N,N-diethylethanamine",CCN(CC)CCOC1=NC(=NC(=C1)C)C,,,,,,
1296,51297,"BENZOIC ACID, 2-(p-BROMOPHENYL)HYDRAZIDE",C1=CC=C(C=C1)C(=O)NNC2=CC=C(C=C2)Br,,,,,,
1297,51298,(m-Methoxybenzyl)trimethylammonium bromide,C[N+](C)(C)CC1=CC(=CC=C1)OC.[Br-],,,,,,
1298,51299,(3-Methoxybenzyl)trimethylaminium,C[N+](C)(C)CC1=CC(=CC=C1)OC,,,,,,
1299,51300,(m-Bromobenzyl)trimethylammonium bromide,C[N+](C)(C)CC1=CC(=CC=C1)Br.[Br-],,,,,,
1300,51301,(3-Bromobenzyl)trimethylaminium,C[N+](C)(C)CC1=CC(=CC=C1)Br,,,,,,
1301,51302,"N'-Cyclohexyl-N,N-dimethyl-1,3-propanediamine",CN(C)CCCNC1CCCCC1,,,,,,
1302,51303,"(5-benzylfuran-3-yl)methyl (1S,3R)-2,2-dimethyl-3-[(2-oxothiolan-3-ylidene)methyl]cyclopropane-1-carboxylate",CC1([C@@H]([C@@H]1C(=O)OCC2=COC(=C2)CC3=CC=CC=C3)C=C4CCSC4=O)C,,,,,,
1303,51304,CID 51304,C1=C(C(=O)C1=O)[O-].[Na+],,,,,,
1304,51305,"1a,11b-Dihydro-1H-tetrapheno[5,6-b]azirene",C1=CC=C2C=C3C4=CC=CC=C4C5C(C3=CC2=C1)N5,,,,,,
1305,51306,"1a,11b-Dihydro-11-methylbenz(3,4)anthra(1,2-b)azirine",CC1=C2C3C(N3)C4=CC=CC=C4C2=CC5=CC=CC=C15,,,,,,
1306,51307,"[(2R,3R,5R,6S,8R,10R,17R)-8-acetyloxy-5,7-dihydroxy-6,16,18-trimethoxy-13-(methoxymethyl)-11-methyl-11-azoniahexacyclo[7.7.2.12,5.01,10.03,8.013,17]nonadecan-4-yl] benzoate;bromide",CC(=O)O[C@@]12[C@@H]3[C@@H](C[C@@](C3OC(=O)C4=CC=CC=C4)([C@H](C1O)OC)O)C56[C@@H]7C(C2[C@H]5[NH+](CC7(CCC6OC)COC)C)OC.[Br-],,,,,,
1307,51308,CID 51308,CC(=O)O[C@@]12[C@@H]3C(C[C@@](C3OC(=O)C4=CC=CC=C4)([C@H](C1O)OC)O)C56[C@@H]7C(C2[C@H]5N(CC7(CCC6OC)COC)C)OC,,,,,,
1308,51309,"[(2R,3R,5R,6S,8R,10R,17S)-11-ethyl-5,7,8,14-tetrahydroxy-6,16,18-trimethoxy-13-(methoxymethyl)-11-azoniahexacyclo[7.7.2.12,5.01,10.03,8.013,17]nonadecan-4-yl] benzoate;bromide",CC[NH+]1CC2([C@H]3C(C4[C@@H]1C3([C@@H]5C[C@@]6([C@H](C([C@]4([C@H]5C6OC(=O)C7=CC=CC=C7)O)O)OC)O)C(CC2O)OC)OC)COC.[Br-],,,,,,
1309,51310,CID 51310,CCN1CC2([C@H]3C(C4[C@@H]1C3(C(CC2O)OC)C5C[C@@]6([C@H](C([C@]4([C@H]5C6OC(=O)C7=CC=CC=C7)O)O)OC)O)OC)COC,,,,,,
1310,51311,"[(2S,3S,5R,6R,8R,10R,17S)-3,7,8,14-tetrahydroxy-6,16,18-trimethoxy-13-(methoxymethyl)-11-methyl-11-azoniahexacyclo[7.7.2.12,5.01,10.03,8.013,17]nonadecan-4-yl] benzoate;bromide",C[NH+]1CC2([C@H]3C(C4[C@@H]1C3([C@@H]5C[C@@H]6[C@H](C([C@]4([C@]5(C6OC(=O)C7=CC=CC=C7)O)O)O)OC)C(CC2O)OC)OC)COC.[Br-],,,,,,
1311,51312,"[(2S,3S,5R,6R,8R,10R,17S)-3,7,8,14-tetrahydroxy-6,16,18-trimethoxy-13-(methoxymethyl)-11-methyl-11-azahexacyclo[7.7.2.12,5.01,10.03,8.013,17]nonadecan-4-yl] benzoate",CN1CC2([C@H]3C(C4[C@@H]1C3([C@@H]5C[C@@H]6[C@H](C([C@]4([C@]5(C6OC(=O)C7=CC=CC=C7)O)O)O)OC)C(CC2O)OC)OC)COC,,,,,,
1312,51313,"[(2R,3R,5R,6S,8R,10R,17R)-5,7,8-trihydroxy-6,16,18-trimethoxy-13-(methoxymethyl)-11-methyl-11-azoniahexacyclo[7.7.2.12,5.01,10.03,8.013,17]nonadecan-4-yl] benzoate;bromide",C[NH+]1CC2(CCC(C34[C@@H]2C(C([C@H]31)[C@@]5([C@@H]6[C@H]4C[C@@](C6OC(=O)C7=CC=CC=C7)([C@H](C5O)OC)O)O)OC)OC)COC.[Br-],,,,,,
1313,51314,"[(2R,3R,5R,6S,8R,10R,17R)-5,7,8-trihydroxy-6,16,18-trimethoxy-13-(methoxymethyl)-11-methyl-11-azahexacyclo[7.7.2.12,5.01,10.03,8.013,17]nonadecan-4-yl] benzoate",CN1CC2(CCC(C34[C@@H]2C(C([C@H]31)[C@@]5([C@@H]6[C@H]4C[C@@](C6OC(=O)C7=CC=CC=C7)([C@H](C5O)OC)O)O)OC)OC)COC,,,,,,
1314,51315,Mesaconitine hydrobromide,CC(=O)O[C@@]12[C@@H]3[C@@H](C[C@@](C3OC(=O)C4=CC=CC=C4)([C@H](C1O)OC)O)C56[C@@H]7C(C2[C@H]5[NH+](CC7(C(CC6OC)O)COC)C)OC.[Br-],,,,,,
1315,51316,5-(Acetoxymethyl)chrysene,CC(=O)OCC1=CC2=CC=CC=C2C3=C1C4=CC=CC=C4C=C3,,,,,,
1316,51317,"5-Chrysenecarboxylic acid, methyl ester",COC(=O)C1=CC2=CC=CC=C2C3=C1C4=CC=CC=C4C=C3,,,,,,
1317,51318,"1,2,3,4-Tetrahydro-5-chrysenemethanol",C1CCC2=C(C1)C=CC3=C2C(=CC4=CC=CC=C34)CO,,,,,,
1318,51319,"1,2,3,4-Tetrahydro-5-chrysenecarboxylic acid methyl ester",COC(=O)C1=CC2=CC=CC=C2C3=C1C4=C(CCCC4)C=C3,,,,,,
1319,51320,"5H-CHRYSENO(4,5-bcd)PYRAN-5-ONE",C1=CC=C2C3=C4C(=CC2=C1)C(=O)OC5=CC=CC(=C54)C=C3,,,,,,
1320,51321,"3,4-Dihydrochrysene",C1CC2=C(C=C1)C=CC3=C2C=CC4=CC=CC=C43,,,,,,
1321,51322,Bisantrene (dihydrochloride),C1CN=C(N1)NN=CC2=C3C=CC=CC3=C(C4=CC=CC=C42)C=NNC5=NCCN5.Cl.Cl,,,,,,
1322,51323,Bisantreno,C1CN=C(N1)NN=CC2=C3C=CC=CC3=C(C4=CC=CC=C42)C=NNC5=NCCN5,,,"['Chemical substances, produced by microorganisms, inhibiting or preventing the proliferation of neoplasms. (See all compounds classified as Antibiotics, Antineoplastic.)']",,,
1323,51324,"1,1,4,4-Tetramethyl-6-[1-(4-methylphenyl)prop-1-en-2-yl]-2,3-dihydronaphthalene",CC1=CC=C(C=C1)C=C(C)C2=CC3=C(C=C2)C(CCC3(C)C)(C)C,,,,,,
1324,51325,CID 51325,C[Si](C)(C)SC(=NC1=CC=CC=C1)S,,,,,,
1325,51326,CID 51326,CC1=CC=C(C=C1)N=C(S)S[Si](C)(C)C,,,,,,
1326,51327,CID 51327,C[Si](C)(C)SC(=NC1=CC(=CC=C1)Cl)S,,,,,,
1327,51328,CID 51328,COC1=CC=CC=C1N=C(S)S[Si](C)(C)C,,,,,,
1328,51329,"Benzene, ethenyl-, tetrachloro deriv.",C=CC1=CC(=C(C(=C1Cl)Cl)Cl)Cl,,,,,,
1329,51330,"Allyl 3,5,5-trimethylhexanoate",CC(CC(=O)OCC=C)CC(C)(C)C,,,,,,
1330,51331,"4,17-Dimethyltrilostane",C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C)O)CCC45[C@@]3(C[C@H](C(=O)[C@]4(O5)C)C#N)C,,,,,,
1331,51332,"Butyric acid, 2-((9-methoxy-7-methyl-5-oxo-3a,4,4a,8,9,9a-hexahydro-5H-furo(3,2-g)(1)benzopyran-4-yl)oxy)-, 2-(diethylamino)ethyl ester, hydrochloride",CCC(C(=O)OCC[NH+](CC)CC)OC1C2C=COC2C(C3C1C(=O)C=C(O3)C)OC.[Cl-],,,,,,
1332,51333,"2-(Diethylamino)ethyl 2-[(9-methoxy-7-methyl-5-oxo-3a,4,4a,8a,9,9a-hexahydrofuro[3,2-g]chromen-4-yl)oxy]butanoate",CCC(C(=O)OCCN(CC)CC)OC1C2C=COC2C(C3C1C(=O)C=C(O3)C)OC,,,,,,
1333,51334,"1H-NAPHTHO(2,1-b)PYRAN-1-ONE, 3-(ETHYLAMINO)-",CCNC1=CC(=O)C2=C(O1)C=CC3=CC=CC=C32,,,,,,
1334,51335,"1H-NAPHTHO(2,1-b)PYRAN-1-ONE, 3-(ISOPROPYLAMINO)-",CC(C)NC1=CC(=O)C2=C(O1)C=CC3=CC=CC=C32,,,,,,
1335,51336,7-Fluorobenzo[a]pyrene,C1=CC2=C3C(=C1)C=CC4=C3C(=CC5=C4C=CC=C5F)C=C2,,,,,,
1336,51337,"Acetic acid, 2-(4-(4-chlorobenzyl)-2-methylphenoxy)-, ethyl ester",CCOC(=O)COC1=C(C=C(C=C1)CC2=CC=C(C=C2)Cl)C,,,,,,
1337,51338,(+-)-Ethyl 2-(4-(4-chlorobenzyl)phenoxy)-2-methylcaproate,CCCCC(C)(C(=O)OCC)OC1=CC=C(C=C1)CC2=CC=C(C=C2)Cl,,,,,,
1338,51339,2-Acetamidoethyl 2-[4-[(4-chlorophenyl)methyl]phenoxy]-2-methylbutanoate,CCC(C)(C(=O)OCCNC(=O)C)OC1=CC=C(C=C1)CC2=CC=C(C=C2)Cl,,,,,,
1339,51340,2-(4-(4-Chlorobenzyl)phenoxy)-2-methylbutanol,CCC(C)(CO)OC1=CC=C(C=C1)CC2=CC=C(C=C2)Cl,,,,,,
1340,51341,2-(4-(4-Chlorobenzyl)phenoxy)-2-methylbutanoic acid,CCC(C)(C(=O)O)OC1=CC=C(C=C1)CC2=CC=C(C=C2)Cl,,,,,,
1341,51342,CID 51342,CCC(C)(C(=O)[O-])OC1=CC=C(C=C1)CC2=CC=C(C=C2)Cl.[Na+],,,,,,
1342,51343,(+-)-2-(4-(4-Chlorobenzyl)phenoxy)-2-methylbutyric acid 3-pyridinylmethylamine,CCC(C)(C(=O)[O-])OC1=CC=C(C=C1)CC2=CC=C(C=C2)Cl.C1=CC(=CN=C1)C[NH3+],,,,,,
1343,51344,(+-)-Methyl 2-(4-(4-chlorobenzyl)phenoxy)-2-methylbutyrate,CCC(C)(C(=O)OC)OC1=CC=C(C=C1)CC2=CC=C(C=C2)Cl,,,,,,
1344,51345,(+-)-Propyl 2-(4-(4-chlorobenzyl)phenoxy)-2-methylbutyrate,CCCOC(=O)C(C)(CC)OC1=CC=C(C=C1)CC2=CC=C(C=C2)Cl,,,,,,
1345,51346,(+-)-2-(4-((4-Chlorophenyl)methyl)phenoxy)-2-methylbutanoic acid butyl ester,CCCCOC(=O)C(C)(CC)OC1=CC=C(C=C1)CC2=CC=C(C=C2)Cl,,,,,,
1346,51347,"Acetic acid, 2-(2-(4-chlorobenzyl)phenoxy)-, ethyl ester",CCOC(=O)COC1=CC=CC=C1CC2=CC=C(C=C2)Cl,,,,,,
1347,51348,Beclobrate,CCC(C)(C(=O)OCC)OC1=CC=C(C=C1)CC2=CC=C(C=C2)Cl,,,['Substances that lower the levels of certain LIPIDS in the BLOOD. They are used to treat HYPERLIPIDEMIAS. (See all compounds classified as Hypolipidemic Agents.)'],,,
1348,51349,CID 51349,CC(=NN=C(N(C)C)S)C1=CC=CC=N1,,,,,,
1349,51350,CID 51350,CC(=NN=C(N(C)C1CCCCC1)S)C2=CC=CC=N2,,,,,,
1350,51351,CID 51351,CC(=NN=C(N1CCCCCC1)S)C2=CC=CC=N2,,,,,,
1351,51352,CID 51352,CC(=NN=C(N1CC2CCC(C1)CC2)S)C3=CC=CC=N3,,,,,,
1352,51353,"1,1,7,7-Tetrachloroheptane",C(CCC(Cl)Cl)CCC(Cl)Cl,,,,,,
1353,51354,"But-2-enedioic acid;17-methyl-6,14,17-triazatetracyclo[12.4.0.02,6.08,13]octadeca-2,4,8,10,12-pentaene",CN1CCN2C(C1)C3=CC=CN3CC4=CC=CC=C42.C(=CC(=O)O)C(=O)O,,,,,,
1354,51355,Aptazapine,CN1CCN2C(C1)C3=CC=CN3CC4=CC=CC=C42,['Investigated for the treatment of depression.'],,,,,
1355,51356,"4-Benzofurancarboxylic acid, 5-hydroxy-, acetate",CC(=O)OC1=C(C2=C(C=C1)OC=C2)C(=O)O,,,,,,
1356,51357,"4-Benzofurancarboxylic acid, 5-hydroxy-2-methyl-, acetate",CC1=CC2=C(O1)C=CC(=C2C(=O)O)OC(=O)C,,,,,,
1357,51358,"6-Benzofurancarboxylic acid, 5-hydroxy-2-methyl-, acetate",CC1=CC2=CC(=C(C=C2O1)C(=O)O)OC(=O)C,,,,,,
1358,51359,"6-Benzofurancarboxylic acid, 2,3-dimethyl-5-hydroxy-, acetate",CC1=C(OC2=CC(=C(C=C12)OC(=O)C)C(=O)O)C,,,,,,
1359,51360,"6-Benzofurancarboxylic acid, 2,3-dimethyl-7-hydroxy-4-methoxy-, acetate",CC1=C(OC2=C(C(=CC(=C12)OC)C(=O)O)OC(=O)C)C,,,,,,
1360,51361,"3-Benzofurancarboxylic acid, 4-hydroxy-2-methyl-, acetate",CC1=C(C2=C(O1)C=CC=C2OC(=O)C)C(=O)O,,,,,,
1361,51362,CID 51362,CCN(CC)C(=NN=C(C)C1=CC=CC=N1)S,,,,,,
1362,51363,CID 51363,CCCN(C(=NN=O)N)[N+](=O)[O-],,,,,,
1363,51364,"Carbonic acid, trithio-, bis(2-((2,1,3-benzothia(S(sup IV))diazol-4-yl)methylamino)ethyl)ester",CN(CCSC(=S)SCCN(C)C1=CC=CC2=NSN=C21)C3=CC=CC4=NSN=C43,,,,,,
1364,51365,"Phenanthren, tetramethyl-",CC1=CC2=C(C=C1)C(=CC3=C(C=C(C=C23)C)C)C,,,,,,
1365,51366,"N-Hydroxy-N,N'-diacetylbenzidine",CC(=O)NC1=CC=C(C=C1)C2=CC=C(C=C2)N(C(=O)C)O,,,,,,
1366,51367,N-Hydroxy-N'-acetylbenzidine,CC(=O)NC1=CC=C(C=C1)C2=CC=C(C=C2)NO,,,,,,
1367,51368,N-[4-Chloro-2-[(2-chloro-4-nitrophenyl)azo]-5-[(2-hydroxypropyl)amino]phenyl]acetamide,CC(CNC1=C(C=C(C(=C1)NC(=O)C)N=NC2=C(C=C(C=C2)[N+](=O)[O-])Cl)Cl)O,,,,,,
1368,51369,Benalaxyl,CC1=C(C(=CC=C1)C)N(C(C)C(=O)OC)C(=O)CC2=CC=CC=C2,,,,,,
1369,51370,7-O-Methylepinogarol,CC1(CC(C2=C(C3=C(C=C2C1)C(=O)C4=C5C(=CC(=C4C3=O)O)C6(C(C(C(C(O5)O6)O)N(C)C)O)C)O)OC)O,,,,,,
1370,51371,2-Cyano-3-ethoxyprop-2-enoic acid,CCOC=C(C#N)C(=O)O,,,,,,
1371,51372,"anti-10,11-Dihydroxy-8,9-epoxy-7-methyl-8,9,10,11-tetrahydrobenz(a)anthracene",CC1=C2C=CC3=CC=CC=C3C2=CC4=C1[C@H]5[C@H](O5)[C@H]([C@@H]4O)O,,,,,,
1372,51373,"1,2,4,9-Tetrachlorodibenzo-P-dioxin",C1=CC2=C(C(=C1)Cl)OC3=C(O2)C(=CC(=C3Cl)Cl)Cl,,,,,,
1373,51374,"1,2,7,9-Tetrachlorodibenzo-P-dioxin",C1=CC(=C(C2=C1OC3=C(O2)C(=CC(=C3)Cl)Cl)Cl)Cl,,,,,,
1374,51375,"1,3,6,9-Tetrachlorodibenzo-P-dioxin",C1=CC(=C2C(=C1Cl)OC3=C(O2)C(=CC(=C3)Cl)Cl)Cl,,,,,,
1375,51376,"1,2,3,6-Tetrachlorodibenzo-P-dioxin",C1=CC2=C(C(=C1)Cl)OC3=CC(=C(C(=C3O2)Cl)Cl)Cl,,,,,,
1376,51377,"1,2,3,9-Tetrachlorodibenzo-P-dioxin",C1=CC2=C(C(=C1)Cl)OC3=C(C(=C(C=C3O2)Cl)Cl)Cl,,,,,,
1377,51378,"1,2,4,6-Tetrachlorodibenzo-P-dioxin",C1=CC2=C(C(=C1)Cl)OC3=C(O2)C(=C(C=C3Cl)Cl)Cl,,,,,,
1378,51379,"1,2,4,7-Tetrachlorodibenzo-P-dioxin",C1=CC2=C(C=C1Cl)OC3=C(O2)C(=C(C=C3Cl)Cl)Cl,,,,,,
1379,51380,"1,2,4,8-Tetrachlorodibenzo-P-dioxin",C1=CC2=C(C=C1Cl)OC3=C(O2)C(=CC(=C3Cl)Cl)Cl,,,,,,
1380,51381,2-Ethoxybenzyl alcohol,CCOC1=CC=CC=C1CO,,,,,,
1381,51382,"(3-Phenoxyphenyl)methyl 2,2-dimethyl-3-(2-chloro-3,3,3-trifluoro-1-propenyl)cyclopropanecarboxylate",CC1(C(C1C(=O)OCC2=CC(=CC=C2)OC3=CC=CC=C3)C=C(C(F)(F)F)Cl)C,,,,,,
1382,51383,N-Hydroxy-N-(4-phenoxyphenyl)acetamide,CC(=O)N(C1=CC=C(C=C1)OC2=CC=CC=C2)O,,,,,,
1383,51384,"BENZ(c)ACRIDIN-7-AMINE, 5,6-DIMETHYL-",CC1=C(C2=C(C3=CC=CC=C3N=C2C4=CC=CC=C14)N)C,,,,,,
1384,51385,"8-Nitro-2,3,7-trichlorodibenzo-p-dioxin",C1=C(C(=CC2=C1OC3=CC(=C(C=C3O2)Cl)Cl)Cl)[N+](=O)[O-],,,,,,
1385,51386,CID 51386,C(=C(N)O)(C(=O)N)N=O,,,,,,
1386,51387,"7-Nitro-2,3-dichlorodibenzo-p-dioxin",C1=CC2=C(C=C1[N+](=O)[O-])OC3=CC(=C(C=C3O2)Cl)Cl,,,,,,
1387,51388,"BENZ(a)ANTHRACENE-10,11-DIOL, 10,11-DIHYDRO-7-(HYDROXYMETHYL)-12-METHYL-, trans-",CC1=C2C(=C(C3=C1[C@@H]([C@H](C=C3)O)O)CO)C=CC4=CC=CC=C42,,,,,,
1388,51389,"1,1-Didodecylimidazolidin-1-ium chloride",CCCCCCCCCCCC[N+]1(CCNC1)CCCCCCCCCCCC.[Cl-],,,,,,
1389,51390,"1,1-Didodecylimidazolidin-1-ium",CCCCCCCCCCCC[N+]1(CCNC1)CCCCCCCCCCCC,,,,,,
1390,51391,"Dodecanamide, N-(3-(dimethylamino)propyl)-, monohydrochloride",CCCCCCCCCCCC(=O)NCCCN(C)C.Cl,,,,,,
1391,51392,N-[3-(dimethylamino)propyl]dodecanamide,CCCCCCCCCCCC(=O)NCCCN(C)C,,,,,,
1392,51393,Lauryl isoquinolinium chloride,CCCCCCCCCCCC[N+]1=CC2=CC=CC=C2C=C1.[Cl-],,,,,,
1393,51394,"ANILINE, 5-CHLORO-2-((p-CHLOROPHENYL)THIO)-N-(3-(DIMETHYLAMINO)PROPYL)-",CN(C)CCCNC1=C(C=CC(=C1)Cl)SC2=CC=C(C=C2)Cl,,,,,,
1394,51395,Photothidiazuron,C1=CC=C(C=C1)NC(=O)NC2=NSN=C2,,,,,,
1395,51396,"Acetic acid, (4-chlorophenoxy)-, 2-(hexahydro-1H-azepin-1-yl)ethyl ester, hydrochloride",C1CCC[NH+](CC1)CCOC(=O)COC2=CC=C(C=C2)Cl.[Cl-],,,,,,
1396,51397,2-(Azepan-1-yl)ethyl 2-(4-chlorophenoxy)acetate,C1CCCN(CC1)CCOC(=O)COC2=CC=C(C=C2)Cl,,,,,,
1397,51398,"Acetic acid, (4-chlorophenoxy)-, 3-(hexahydro-1H-azepin-1-yl)propyl ester, hydrochloride",C1CCC[NH+](CC1)CCCOC(=O)COC2=CC=C(C=C2)Cl.[Cl-],,,,,,
1398,51399,3-(Azepan-1-yl)propyl 2-(4-chlorophenoxy)acetate,C1CCCN(CC1)CCCOC(=O)COC2=CC=C(C=C2)Cl,,,,,,
1399,51400,7-(p-(9-Acridinylamino)phenyl)heptanamide methanesulfonate,CS(=O)(=O)[O-].C1=CC=C2C(=C1)C(=C3C=CC=CC3=N2)[NH2+]C4=CC=C(C=C4)CCCCCCC(=O)N,,,,,,
1400,51401,7-[4-(Acridin-9-ylamino)phenyl]heptanamide,C1=CC=C2C(=C1)C(=C3C=CC=CC3=N2)NC4=CC=C(C=C4)CCCCCCC(=O)N,,,,,,
1401,51402,4'-(9-Acridinylamino)-3'-methoxy-1-heptanesulfonanilide methanesulfonate,CCCCCCCS(=O)(=O)NC1=CC(=C(C=C1)[NH2+]C2=C3C=CC=CC3=NC4=CC=CC=C42)OC.CS(=O)(=O)[O-],,,,,,
1402,51403,N-[4-(acridin-9-ylamino)-3-methoxyphenyl]heptane-1-sulfonamide,CCCCCCCS(=O)(=O)NC1=CC(=C(C=C1)NC2=C3C=CC=CC3=NC4=CC=CC=C42)OC,,,,,,
1403,51404,4'-(9-Acridinylamino)-3'-methoxy-1-octanesulfonanilide methanesulfonate,CCCCCCCCS(=O)(=O)NC1=CC(=C(C=C1)[NH2+]C2=C3C=CC=CC3=NC4=CC=CC=C42)OC.CS(=O)(=O)[O-],,,,,,
1404,51405,N-[4-(acridin-9-ylamino)-3-methoxyphenyl]octane-1-sulfonamide,CCCCCCCCS(=O)(=O)NC1=CC(=C(C=C1)NC2=C3C=CC=CC3=NC4=CC=CC=C42)OC,,,,,,
1405,51406,"N,N'-Dinitrosopyridinol carbamate",CN(C(=O)OCC1=NC(=CC=C1)COC(=O)N(C)N=O)N=O,,,,,,
1406,51407,"1-Butanesulfonanilide, 4'-(3-acetamido-9-acridinylamino)-3'-methoxy-, hydrochloride",CCCCS(=O)(=O)NC1=CC(=C(C=C1)NC2=C3C=CC(=CC3=[NH+]C4=CC=CC=C42)NC(=O)C)OC.[Cl-].[Cl-],,,,,,
1407,51408,N-[4-[[3-(Acetylamino)acridin-9-yl]amino]-3-methoxyphenyl]-1-butanesulfonamide,CCCCS(=O)(=O)NC1=CC(=C(C=C1)NC2=C3C=CC(=CC3=NC4=CC=CC=C42)NC(=O)C)OC,,,,,,
1408,51409,"1-Hexanesulfonanilide, 4'-(3-acetamido-9-acridinylamino)-3'-methoxy-, hydrochloride, dihydrate",CCCCCCS(=O)(=O)NC1=CC(=C(C=C1)[NH2+]C2=C3C=C(C=CC3=NC4=CC=CC=C42)NC(=O)C)OC.[Cl-],,,,,,
1409,51410,N-[9-[4-(hexylsulfonylamino)-2-methoxyanilino]acridin-2-yl]acetamide,CCCCCCS(=O)(=O)NC1=CC(=C(C=C1)NC2=C3C=C(C=CC3=NC4=CC=CC=C42)NC(=O)C)OC,,,,,,
1410,51411,"1-Heptanesulfonanilide, 4'-(3-acetamido-9-acridinylamino)-3'-methoxy-, hydrochloride, dihydrate",CCCCCCCS(=O)(=O)NC1=CC(=C(C=C1)[NH2+]C2=C3C=CC(=CC3=NC4=CC=CC=C42)NC(=O)C)OC.[Cl-],,,,,,
1411,51412,N-[9-[4-(heptylsulfonylamino)-2-methoxyanilino]acridin-3-yl]acetamide,CCCCCCCS(=O)(=O)NC1=CC(=C(C=C1)NC2=C3C=CC(=CC3=NC4=CC=CC=C42)NC(=O)C)OC,,,,,,
1412,51413,"1-Butanesulfonanilide, 3'-methoxy-4'-(4-methoxy-9-acridinylamino)-, hydrochloride",CCCCS(=O)(=O)NC1=CC(=C(C=C1)[NH2+]C2=C3C=CC=C(C3=NC4=CC=CC=C42)OC)OC.[Cl-],,,,,,
1413,51414,N-[3-Methoxy-4-[(4-methoxyacridin-9-yl)amino]phenyl]-1-butanesulfonamide,CCCCS(=O)(=O)NC1=CC(=C(C=C1)NC2=C3C=CC=C(C3=NC4=CC=CC=C42)OC)OC,,,,,,
1414,51415,"4'-(Benzo(b)(1,8)naphthyridin-5-ylamino)-3'-methoxy-1-butanesulfonanilide HCl dihydrate",CCCCS(=O)(=O)NC1=CC(=C(C=C1)[NH2+]C2=C3C=CC=NC3=NC4=CC=CC=C42)OC.[Cl-],,,,,,
1415,51416,"N-[4-[[Benzo[b][1,8]naphthyridin-5-yl]amino]-3-methoxyphenyl]-1-butanesulfonamide",CCCCS(=O)(=O)NC1=CC(=C(C=C1)NC2=C3C=CC=NC3=NC4=CC=CC=C42)OC,,,,,,
1416,51417,"4'-(Benzo(b)(1,8)naphthyridin-5-ylamino)-3'-methoxy-1-hexanesulfonanilide HCl hemihydrate",CCCCCCS(=O)(=O)NC1=CC(=C(C=C1)[NH2+]C2=C3C=CC=NC3=NC4=CC=CC=C42)OC.[Cl-],,,,,,
1417,51418,"N-[4-(benzo[b][1,8]naphthyridin-5-ylamino)-3-methoxyphenyl]hexane-1-sulfonamide",CCCCCCS(=O)(=O)NC1=CC(=C(C=C1)NC2=C3C=CC=NC3=NC4=CC=CC=C42)OC,,,,,,
1418,51419,"1-Heptanesulfonanilide, 4'-(benzo(b)(1,8)naphthyridin-5-ylamino)-3'-methoxy-, hydrochloride",CCCCCCCS(=O)(=O)NC1=CC(=C(C=C1)[NH2+]C2=C3C=CC=NC3=NC4=CC=CC=C42)OC.[Cl-],,,,,,
1419,51420,"N-[4-(benzo[b][1,8]naphthyridin-5-ylamino)-3-methoxyphenyl]heptane-1-sulfonamide",CCCCCCCS(=O)(=O)NC1=CC(=C(C=C1)NC2=C3C=CC=NC3=NC4=CC=CC=C42)OC,,,,,,
1420,51421,3'-Methoxy-4'-(3-nitro-9-acridinylamino)-1-butanesulfonanilide hydrochloride,CCCCS(=O)(=O)NC1=CC(=C(C=C1)[NH2+]C2=C3C=CC(=CC3=NC4=CC=CC=C42)[N+](=O)[O-])OC.[Cl-],,,,,,
1421,51422,CID 51422,CCCCS(=O)(=O)N=C1C=CC(=NC2=C3C=CC(=CC3=NC4=CC=CC=C42)N(O)O)C(=C1)OC,,,,,,
1422,51423,3'-Methoxy-4'-(3-nitro-9-acridinylamino)-1-hexanesulfonanilide hydrochloride,CCCCCCS(=O)(=O)NC1=CC(=C(C=C1)[NH2+]C2=C3C=C(C=CC3=NC4=CC=CC=C42)[N+](=O)[O-])OC.[Cl-],,,,,,
1423,51424,CID 51424,CCCCCCS(=O)(=O)N=C1C=CC(=NC2=C3C=C(C=CC3=NC4=CC=CC=C42)N(O)O)C(=C1)OC,,,,,,
1424,51425,3'-Methoxy-4'-(3-nitro-9-acridinylamino)-1-heptanesulfonanilide hydrochloride,CCCCCCCS(=O)(=O)NC1=CC(=C(C=C1)[NH2+]C2=C3C=CC(=CC3=NC4=CC=CC=C42)[N+](=O)[O-])OC.[Cl-],,,,,,
1425,51426,CID 51426,CCCCCCCS(=O)(=O)N=C1C=CC(=NC2=C3C=CC(=CC3=NC4=CC=CC=C42)N(O)O)C(=C1)OC,,,,,,
1426,51427,"1-Hexanesulfonanilide, 4'-(4-carbamoyl-9-acridinylamino)-3'-methoxy-, hydrochloride",CCCCCCS(=O)(=O)NC1=CC(=C(C=C1)[NH2+]C2=C3C(=NC4=CC=CC=C42)C=CC=C3C(=O)N)OC.[Cl-],,,,,,
1427,51428,9-[4-(Hexylsulfonylamino)-2-methoxyanilino]acridine-1-carboxamide,CCCCCCS(=O)(=O)NC1=CC(=C(C=C1)NC2=C3C(=NC4=CC=CC=C42)C=CC=C3C(=O)N)OC,,,,,,
1428,51429,"1-Heptanesulfonanilide, 4'-(4-carbamoyl-9-acridinylamino)-3'-methoxy-, hydrochloride",CCCCCCCS(=O)(=O)NC1=CC(=C(C=C1)[NH2+]C2=C3C=CC=C(C3=NC4=CC=CC=C42)C(=O)N)OC.[Cl-],,,,,,
1429,51430,9-[4-(Heptylsulfonylamino)-2-methoxyanilino]acridine-4-carboxamide,CCCCCCCS(=O)(=O)NC1=CC(=C(C=C1)NC2=C3C=CC=C(C3=NC4=CC=CC=C42)C(=O)N)OC,,,,,,
1430,51431,"Acetic acid, (p-(3-oxo-1-indanyl)phenyl)-",C1C(C2=CC=CC=C2C1=O)C3=CC=C(C=C3)CC(=O)O,,,,,,
1431,51432,3-Allyl-5-methyl-3-(2-pyridyl)dihydro-2(3H)-furanone,CC1CC(C(=O)O1)(CC=C)C2=CC=CC=N2,,,,,,
1432,51433,5-Methyl-3-propyl-3-(2-pyridyl)dihydro-2(3H)-furanone,CCCC1(CC(OC1=O)C)C2=CC=CC=N2,,,,,,
1433,51434,3-Isopropyl-5-methyl-3-(2-pyridyl)dihydro-2(3H)-furanone,CC1CC(C(=O)O1)(C2=CC=CC=N2)C(C)C,,,,,,
1434,51435,6-(4-Piperidinophenyl)hexylamine succinate,C1CC[NH+](CC1)C2=CC=C(C=C2)CCCCCCN.C(CC(=O)[O-])C(=O)O,,,,,,
1435,51436,6-(4-Piperidin-1-ylphenyl)hexan-1-amine,C1CCN(CC1)C2=CC=C(C=C2)CCCCCCN,,,,,,
1436,51437,Methylphosphonic acid (2-(bis(1-methylethyl)amino)ethyl) ethyl ester,CCOP(=O)(C)OCCN(C(C)C)C(C)C,,,,,,
1437,51438,Mono-n-butylammonium tetrafluoroborate,[B-](F)(F)(F)F.CCCC[NH3+],,,,,,
1438,51439,"2,2',4,4',5,5'-Hexachlorodiphenyl ether",C1=C(C(=CC(=C1Cl)Cl)Cl)OC2=CC(=C(C=C2Cl)Cl)Cl,,,,,,
1439,51440,"4-(4-Fluorophenyl)-5-(2-(4-phenyl-1-piperazinyl)ethyl)-1,3-dioxol-2-one dihydrochloride",C1CN(CCN1CCC2=C(OC(=O)O2)C3=CC=C(C=C3)F)C4=CC=CC=C4.Cl.Cl,,,,,,
1440,51441,Fludoxopone,C1CN(CCN1CCC2=C(OC(=O)O2)C3=CC=C(C=C3)F)C4=CC=CC=C4,,,,,,
1441,51442,"1,3-Dioxol-2-one, 4-phenyl-5-(2-(4-phenyl-1-piperazinyl)ethyl)-, dihydrochloride",C1CN(CCN1CCC2=C(OC(=O)O2)C3=CC=CC=C3)C4=CC=CC=C4.Cl.Cl,,,,,,
1442,51443,"4-Phenyl-5-[2-(4-phenylpiperazin-1-yl)ethyl]-1,3-dioxol-2-one",C1CN(CCN1CCC2=C(OC(=O)O2)C3=CC=CC=C3)C4=CC=CC=C4,,,,,,
1443,51444,"4-(4-Chlorophenyl)-5-[2-(4-phenyl-1-piperazinyl)ethyl]-1,3-dioxol-2-one dihydrochloride",C1CN(CCN1CCC2=C(OC(=O)O2)C3=CC=C(C=C3)Cl)C4=CC=CC=C4.Cl.Cl,,,,,,
1444,51445,Clodoxopone,C1CN(CCN1CCC2=C(OC(=O)O2)C3=CC=C(C=C3)Cl)C4=CC=CC=C4,,,,,,
1445,51446,"1,3-Dioxol-2-one, 5-(2-(4-(2,5-dichlorophenyl)-1-piperazinyl)ethyl)-4-(4-fluorophenyl)-, hydrochloride",C1CN(CC[NH+]1CCC2=C(OC(=O)O2)C3=CC=C(C=C3)F)C4=C(C=CC(=C4)Cl)Cl.[Cl-],,,,,,
1446,51447,"4-[2-[4-(2,5-Dichlorophenyl)piperazin-1-yl]ethyl]-5-(4-fluorophenyl)-1,3-dioxol-2-one",C1CN(CCN1CCC2=C(OC(=O)O2)C3=CC=C(C=C3)F)C4=C(C=CC(=C4)Cl)Cl,,,,,,
1447,51448,"1,3-Dioxol-2-one, 5-(2-(4-(3,4-dichlorophenyl)-1-piperazinyl)ethyl)-4-(4-fluorophenyl)-, hydrochloride",C1CN(CC[NH+]1CCC2=C(OC(=O)O2)C3=CC=C(C=C3)F)C4=CC(=C(C=C4)Cl)Cl.[Cl-],,,,,,
1448,51449,"4-[2-[4-(3,4-Dichlorophenyl)piperazin-1-yl]ethyl]-5-(4-fluorophenyl)-1,3-dioxol-2-one",C1CN(CCN1CCC2=C(OC(=O)O2)C3=CC=C(C=C3)F)C4=CC(=C(C=C4)Cl)Cl,,,,,,
1449,51450,"1,3-Dioxol-2-one, 4-(4-fluorophenyl)-5-(2-(4-(3-trifluoromethylphenyl)-1-piperazinyl)ethyl)-, hydrochloride",C1CN(CC[NH+]1CCC2=C(OC(=O)O2)C3=CC=C(C=C3)F)C4=CC=CC(=C4)C(F)(F)F.[Cl-],,,,,,
1450,51451,"4-(4-Fluorophenyl)-5-[2-[4-[3-(trifluoromethyl)phenyl]piperazin-1-yl]ethyl]-1,3-dioxol-2-one",C1CN(CCN1CCC2=C(OC(=O)O2)C3=CC=C(C=C3)F)C4=CC=CC(=C4)C(F)(F)F,,,,,,
1451,51452,"1,3-Dioxol-2-one, 5-(2-(4-(3-chlorophenyl)-1-piperazinyl)ethyl)-4-(4-fluorophenyl)-, dihydrochloride",C1CN(CCN1CCC2=C(OC(=O)O2)C3=CC=C(C=C3)F)C4=CC(=CC=C4)Cl.Cl.Cl,,,,,,
1452,51453,"4-[2-[4-(3-Chlorophenyl)piperazin-1-yl]ethyl]-5-(4-fluorophenyl)-1,3-dioxol-2-one",C1CN(CCN1CCC2=C(OC(=O)O2)C3=CC=C(C=C3)F)C4=CC(=CC=C4)Cl,,,,,,
1453,51454,"1,2,3,6,7-Pentachlorodibenzo-p-dioxin",C1=CC(=C(C2=C1OC3=C(C(=C(C=C3O2)Cl)Cl)Cl)Cl)Cl,,,,,,
1454,51455,"1,2,3,6,8-Pentachlorodibenzo-p-dioxin",C1=C(C=C(C2=C1OC3=C(C(=C(C=C3O2)Cl)Cl)Cl)Cl)Cl,,,,,,
1455,51456,"1,2,3,7,9-Pentachlorodibenzo-p-dioxin",C1=C(C=C(C2=C1OC3=CC(=C(C(=C3O2)Cl)Cl)Cl)Cl)Cl,,,,,,
1456,51457,"1,2,3,8,9-Pentachlorodibenzo-p-dioxin",C1=CC(=C(C2=C1OC3=CC(=C(C(=C3O2)Cl)Cl)Cl)Cl)Cl,,,,,,
1457,51458,"BENZ(a)ANTHRACENE-3,4-DIOL, 7,12-DIMETHYL-",CC1=C2C=CC3=C(C2=C(C4=CC=CC=C14)C)C=CC(=C3O)O,,,,,"['BENZ(a)ANTHRACENE-3,4-DIOL, 7,12-DIMETHYL- is a known human metabolite of 7,12 Dimethylbenzanthracene.']",
1458,51459,3-Methyl-2-phenylchromen-4-one,CC1=C(OC2=CC=CC=C2C1=O)C3=CC=CC=C3,,,,,,
1459,51460,"CARBONIC ACID, o-CARBOXYPHENYL PROPYL ESTER",CCCOC(=O)OC1=CC=CC=C1C(=O)O,,,,,,
1460,51461,"CARBONIC ACID, PENTYL ESTER, ESTER with SALICYLIC ACID",CCCCCOC(=O)OC1=CC=CC=C1C(=O)O,,,,,,
1461,51462,"1,3,6,8-Tetrachlorodibenzofuran",C1=C(C=C(C2=C1C3=C(O2)C=C(C=C3Cl)Cl)Cl)Cl,,,,,,
1462,51463,"1,2,4,6-Tetrachlorodibenzofuran",C1=CC2=C(C(=C1)Cl)OC3=C2C(=C(C=C3Cl)Cl)Cl,,,,,,
1463,51464,"1,2,4,7,9-Pentachlorodibenzofuran",C1=C(C=C(C2=C1OC3=C2C(=C(C=C3Cl)Cl)Cl)Cl)Cl,,,,,,
1464,51465,"1,3,4,6,7,8-Hexachlorodibenzofuran",C1=C2C3=C(C(=C(C=C3Cl)Cl)Cl)OC2=C(C(=C1Cl)Cl)Cl,,,,,,
1465,51466,"1,2,4,6,8-Pentachlorodibenzo-p-dioxin",C1=C(C=C(C2=C1OC3=C(O2)C(=CC(=C3Cl)Cl)Cl)Cl)Cl,,,,,,
1466,51467,"2H-1,4-Benzoxazin-3(4H)-one, 4-(acetyloxy)-7-methoxy-",CC(=O)ON1C(=O)COC2=C1C=CC(=C2)OC,,,,,,
1467,51468,CID 51468,CC(=NOCC(=O)N(CCN1CCOCC1)C2=CC=CC=C2)C3=CC=C(C=C3)N,,,,,,
1468,51469,alpha-(3-(m-Methoxyphenyl)-3-propylpyrrolidinylmethyl)benzyl alcohol,CCCC1(CCN(C1)CC(C2=CC=CC=C2)O)C3=CC(=CC=C3)OC,,,,,,
1469,51470,CID 51470,CC(C[NH+]1CCN(CC1)C(=O)C=CC2=CC(=C(C(=C2)OC)OC)OC)(C3=CC=CC=C3)O.[Cl-],,,,,,
1470,51471,CID 51471,CC(CN1CCN(CC1)C(=O)C=CC2=CC(=C(C(=C2)OC)OC)OC)(C3=CC=CC=C3)O,,,,,,
1471,51472,"Ammonium, hexamethylenebis(1-methyl-3-(2-methylspiro(5.5)undecyl)propyl)bis(dimethyl-, dibromide, trihydrate",CC1CCCC2(C1CCC(C)[N+](C)(C)CCCCCC[N+](C)(C)C(C)CCC3C(CCCC34CCCCC4)C)CCCCC2.[Br-].[Br-],,,,,,
1472,51473,6-[Dimethyl-[4-(4-methylspiro[5.5]undecan-5-yl)butan-2-yl]azaniumyl]hexyl-dimethyl-[4-(4-methylspiro[5.5]undecan-5-yl)butan-2-yl]azanium,CC1CCCC2(C1CCC(C)[N+](C)(C)CCCCCC[N+](C)(C)C(C)CCC3C(CCCC34CCCCC4)C)CCCCC2,,,,,,
1473,51474,CID 51474,CCCOC1=CC=C(C=C1)C(=NCCN2CCCC2)S,,,,,,
1474,51475,CID 51475,CC(C)OC1=CC=C(C=C1)C(=NCCN2CCCC2)S,,,,,,
1475,51476,"1H-1-Benzazepine, 2,5-dihydro-7,8-dimethyl-2,5-dioxo-4-(4-methyl-1-piperazinomethyl)-",CC1=CC2=C(C=C1C)NC(=O)C=C(C2=O)CN3CCN(CC3)C,,,,,,
1476,51477,CID 51477,CC(C)CCOC1=CC=C(C=C1)C(=NCCN2CCCC2)S,,,,,,
1477,51478,"Carbamic acid, propyl-, diester with (2-butoxy-3-methoxyphenethyl)iminodiethanol, malonate, hydrate",CCCCOC1=C(C=CC=C1OC)CC[NH+](CCOC(=O)NCCC)CCOC(=O)NCCC.C(C(=O)O)C(=O)[O-],,,,,,
1478,51479,2-[2-(2-butoxy-3-methoxyphenyl)ethyl-[2-(propylcarbamoyloxy)ethyl]amino]ethyl N-propylcarbamate,CCCCOC1=C(C=CC=C1OC)CCN(CCOC(=O)NCCC)CCOC(=O)NCCC,,,,,,
1479,51480,Naphthopyrin,CC1=C(C(=O)N(N1C)C2=CC=CC=C2)NC3=CC4=CC=CC=C4C=C3,,,,,,
1480,51481,"12H-Dibenzo(a,d)cyclooctene, 5,6,7-trihydro-12-(1-methyl-2-piperidyl)ethylidene-, hydrochloride",C[NH+]1CCCCC1CC=C2C3=CC=CC=C3CCCC4=CC=CC=C42.[Cl-],,,,,,
1481,51482,"1-Methyl-2-[2-(2-tricyclo[10.4.0.03,8]hexadeca-1(16),3,5,7,12,14-hexaenylidene)ethyl]piperidine",CN1CCCCC1CC=C2C3=CC=CC=C3CCCC4=CC=CC=C42,,,,,,
1482,51483,CID 51483,C1CC[NH+](C1)CCN2C(=O)CC3=C(C=C(C=C3)Cl)C(=N2)C4=CC=CC=C4.C(=CC(=O)[O-])C(=O)O,,,,,,
1483,51484,"8-chloro-1-phenyl-3-(2-pyrrolidin-1-ylethyl)-5H-2,3-benzodiazepin-4-one",C1CCN(C1)CCN2C(=O)CC3=C(C=C(C=C3)Cl)C(=N2)C4=CC=CC=C4,,,,,,
1484,51485,"alpha-(1-(N-Propyl-N-(4-(3,4,5-trimethoxybenzoyloxy)butyl))ethyl)benzyl alcohol",CCCN(CCCCO)C(C)C(C1=CC=CC=C1)OC(=O)C2=CC(=C(C(=C2)OC)OC)OC,,,,,,
1485,51486,"Carbamic acid, ethyl-, diester with (2-butoxy-3-methoxyphenethyl)iminodiethanol, malonate, hydrate",CCCCOC1=C(C=CC=C1OC)CC[NH+](CCOC(=O)NCC)CCOC(=O)NCC.C(C(=O)O)C(=O)[O-],,,,,,
1486,51487,2-[2-(2-butoxy-3-methoxyphenyl)ethyl-[2-(ethylcarbamoyloxy)ethyl]amino]ethyl N-ethylcarbamate,CCCCOC1=C(C=CC=C1OC)CCN(CCOC(=O)NCC)CCOC(=O)NCC,,,,,,
1487,51488,"Ammonium, hexamethylenebis(1-methyl-3-(2,6,6-trimethyl-1-cyclohexen-1-yl)propyl)bis(dimethyl-, dibromide, hydrate",CC1=C(C(CCC1)(C)C)CC(C)C[N+](C)(C)CCCCCC[N+](C)(C)CCC(C)C2=C(CCCC2(C)C)C.[Br-].[Br-],,,,,,
1488,51489,"6-[Dimethyl-[2-methyl-3-(2,6,6-trimethylcyclohexen-1-yl)propyl]azaniumyl]hexyl-dimethyl-[3-(2,6,6-trimethylcyclohexen-1-yl)butyl]azanium",CC1=C(C(CCC1)(C)C)CC(C)C[N+](C)(C)CCCCCC[N+](C)(C)CCC(C)C2=C(CCCC2(C)C)C,,,,,,
1489,51490,"Ammonium, hexamethylenebis(1-methyl-3-(2,2,3,6-tetramethylcyclohexyl)propyl)bis(dimethyl-, dibromide, hydrate",CC1CCC(C(C1CCC(C)[N+](C)(C)CCCCCC[N+](C)(C)C(C)CCC2C(CCC(C2(C)C)C)C)(C)C)C.[Br-].[Br-],,,,,,
1490,51491,"6-[Dimethyl-[4-(2,2,3,6-tetramethylcyclohexyl)butan-2-yl]azaniumyl]hexyl-dimethyl-[4-(2,2,3,6-tetramethylcyclohexyl)butan-2-yl]azanium",CC1CCC(C(C1CCC(C)[N+](C)(C)CCCCCC[N+](C)(C)C(C)CCC2C(CCC(C2(C)C)C)C)(C)C)C,,,,,,
1491,51492,"Ethylenebis(dimethyl(1-methyl-3-(2,2,6-trimethylcyclohexyl)propyl)ammonium bromide)",CC1CCCC(C1CCC(C)[N+](C)(C)CC[N+](C)(C)C(C)CCC2C(CCCC2(C)C)C)(C)C.[Br-].[Br-],,,,,,
1492,51493,"2-[Dimethyl-[4-(2,2,6-trimethylcyclohexyl)butan-2-yl]azaniumyl]ethyl-dimethyl-[4-(2,2,6-trimethylcyclohexyl)butan-2-yl]azanium",CC1CCCC(C1CCC(C)[N+](C)(C)CC[N+](C)(C)C(C)CCC2C(CCCC2(C)C)C)(C)C,,,,,,
1493,51494,"Ammonium, ethylenebis(1-methyl-3-(2,6,6-trimethyl-1-cyclohexen-1-yl)propyl)bis(dimethyl-, dibromide, hydrate",CC1=C(C(CCC1)(C)C)CCC(C)[N+](C)(C)CC[N+](C)(C)C(C)CCC2=C(CCCC2(C)C)C.[Br-].[Br-],,,,,,
1494,51495,"2-[Dimethyl-[4-(2,6,6-trimethylcyclohexen-1-yl)butan-2-yl]azaniumyl]ethyl-dimethyl-[4-(2,6,6-trimethylcyclohexen-1-yl)butan-2-yl]azanium",CC1=C(C(CCC1)(C)C)CCC(C)[N+](C)(C)CC[N+](C)(C)C(C)CCC2=C(CCCC2(C)C)C,,,,,,
1495,51496,"Ammonium, dipropyl((3-hydroxy-2-pyridyl)methyl)methyl-, bromide, dimethylcarbamate (ester), hydrate",CCC[N+](C)(CCC)CC1=C(C=CC=N1)OC(=O)N(C)C.[Br-],,,,,,
1496,51497,[3-(Dimethylcarbamoyloxy)pyridin-2-yl]methyl-methyl-dipropylazanium,CCC[N+](C)(CCC)CC1=C(C=CC=N1)OC(=O)N(C)C,,,,,,
1497,51498,CID 51498,C1CC2=CC=CC=C2N(C1)C=CC=CC=C3C4=CC=CC=C4CC[NH2+]3.[Cl-],,,,,,
1498,51499,CID 51499,C1CC2=CC=CC=C2N(C1)C=CC=CC=C3C4=CC=CC=C4CCN3,,,,,,
1499,51500,"Benzoic acid, p-amino-, 2-(sec-butylamino)-2,2-dimethylethyl ester, hydrochloride",CCC(C)[NH2+]C(C)(C)COC(=O)C1=CC=C(C=C1)N.[Cl-],,,,,,
1500,51501,[2-(Butan-2-ylamino)-2-methylpropyl] 4-aminobenzoate,CCC(C)NC(C)(C)COC(=O)C1=CC=C(C=C1)N,,,,,,
1501,51502,"Benzoic acid, p-(6-(4-(2-chloroethyl)piperazinyl)-2,4-diamino-5-pyrimidinyl)azo-, ethyl ester, hydrochloride, dihydrate",CCOC(=O)C1=CC=C(C=C1)N=NC2=C(N=C(N=C2N3CC[NH+](CC3)CCCl)N)N.[Cl-],,,,,,
1502,51503,"Ethyl 4-[[2,4-diamino-6-[4-(2-chloroethyl)piperazin-1-yl]pyrimidin-5-yl]diazenyl]benzoate",CCOC(=O)C1=CC=C(C=C1)N=NC2=C(N=C(N=C2N3CCN(CC3)CCCl)N)N,,,,,,
1503,51504,"Benzoic acid, p-amino-, (2-((1-isobutyl-3-methyl)butylamino)-1-methyl)ethyl ester, hydrochloride",CC(C)CC(CC(C)C)[NH2+]CC(C)OC(=O)C1=CC=C(C=C1)N.[Cl-],,,,,,
1504,51505,"p-Aminobenzoic acid 1-(2,6-dimethyl-4-heptylamino)-2-propyl ester",CC(C)CC(CC(C)C)NCC(C)OC(=O)C1=CC=C(C=C1)N,,,,,,
1505,51506,"2-(Diphenylcarbamoylsulfanyl)ethyl-diethylazanium;naphthalene-1,5-disulfonate",CC[NH+](CC)CCSC(=O)N(C1=CC=CC=C1)C2=CC=CC=C2.CC[NH+](CC)CCSC(=O)N(C1=CC=CC=C1)C2=CC=CC=C2.C1=CC2=C(C=CC=C2S(=O)(=O)[O-])C(=C1)S(=O)(=O)[O-],,,,,,
1506,51507,"tert-BUTYROPHENONE, 3',4'-DIHYDROXY-",CC(C)(C)C(=O)C1=CC(=C(C=C1)O)O,,,,,,
1507,51508,"Benzoic acid, 3-(aminosulfonyl)-4-(2-(4-chlorophenyl)ethyl)-5-nitro-",C1=CC(=CC=C1CCC2=C(C=C(C=C2S(=O)(=O)N)C(=O)O)[N+](=O)[O-])Cl,,,,,,
1508,51509,"Benzoic acid, 3-(aminosulfonyl)-5-nitro-4-(3-phenylpropyl)-",C1=CC=C(C=C1)CCCC2=C(C=C(C=C2S(=O)(=O)N)C(=O)O)[N+](=O)[O-],,,,,,
1509,51510,"Benzoic acid, 3-amino-5-(aminosulfonyl)-4-(3-phenylpropyl)-",C1=CC=C(C=C1)CCCC2=C(C=C(C=C2S(=O)(=O)N)C(=O)O)N,,,,,,
1510,51511,"1H-Benzimidazole-5-carboxylic acid, 1-methyl-7-((methylamino)sulfonyl)-",CNS(=O)(=O)C1=CC(=CC2=C1N(C=N2)C)C(=O)O,,,,,,
1511,51512,"1H-Benzimidazole-5-carboxylic acid, 1,2-dimethyl-7-((methylamino)sulfonyl)-",CC1=NC2=C(N1C)C(=CC(=C2)C(=O)O)S(=O)(=O)NC,,,,,,
1512,51513,"1H-Benzimidazole-5-carboxylic acid, 2-(2-furanyl)-1-methyl-7-((methylamino)sulfonyl)-",CNS(=O)(=O)C1=CC(=CC2=C1N(C(=N2)C3=CC=CO3)C)C(=O)O,,,,,,
1513,51514,"1H-Benzimidazole-5-carboxylic acid, 7-(aminosulfonyl)-1-(2-(3,4-dimethoxyphenyl)ethyl)-2-(2-furanyl)-",COC1=C(C=C(C=C1)CCN2C3=C(C=C(C=C3S(=O)(=O)N)C(=O)O)N=C2C4=CC=CO4)OC,,,,,,
1514,51515,CID 51515,C=CCN=C(S)SC1=CC=C(C=C1)Cl,,,,,,
1515,51516,"(5S,6R)-6-[2-[(4-amino-4-carboxybutanoyl)amino]-3-(carboxymethylamino)-3-oxopropyl]sulfanyl-5-hydroxyicosa-7,9,11,14-tetraenoic acid",CCCCCC=CCC=CC=CC=C[C@H]([C@H](CCCC(=O)O)O)SCC(C(=O)NCC(=O)O)NC(=O)CCC(C(=O)O)N,,,,,,
1516,51517,Testosterone propionate with methyltestosterone (1:14),CCC(=O)O[C@]1(CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CCC4=CC(=O)CC[C@]34C)C)C.C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)CCC4=CC(=O)CC[C@]34C,,,,,,
1517,51518,"[(8R,9S,10R,13S,14S,17S)-10,13,17-trimethyl-3-oxo-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-17-yl] propanoate",CCC(=O)O[C@]1(CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CCC4=CC(=O)CC[C@]34C)C)C,,,,,,
1518,51519,"(8R,10R,13S,14S,17S)-17-hydroxy-10,13-dimethyl-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-3-one",C[C@]12CCC3[C@H]([C@@H]1CC[C@@H]2O)CCC4=CC(=O)CC[C@]34C,,,,,,
1519,51520,"2,5-Dimethyl-dithiane",CC1CSC(CS1)C,,,,,,
1520,51521,"GUANIDINE, 1-tert-BUTYL-2-(4-PYRIDYL)-3-(2-THIAZOLYL)-",CC(C)(C)N=C(NC1=CC=NC=C1)NC2=NC=CS2,,,,,,
1521,51522,"Guanidine, 2-(4-pyridyl)-1-(2-thiazolyl)-3-(1,1,3-trimethylbutyl)-",CC(C)CC(C)(C)N=C(NC1=CC=NC=C1)NC2=NC=CS2,,,,,,
1522,51523,1-tert-Butyl-2-(2-methyl-4-pyridyl)-3-(2-thiazolyl)guanidine dinitrate,CC1=NC=CC(=C1)N=C([NH2+]C2=NC=CS2)[NH2+]C(C)(C)C.[N+](=O)([O-])[O-].[N+](=O)([O-])[O-],,,,,,
1523,51524,"2-Tert-butyl-1-(2-methylpyridin-4-yl)-3-(1,3-thiazol-2-yl)guanidine",CC1=NC=CC(=C1)NC(=NC(C)(C)C)NC2=NC=CS2,,,,,,
1524,51525,1-Pentyl-2-(2-methyl-4-quinolyl)-3-(2-thiazolyl)guanidine dinitrate,CCCCC[NH+](C1=NC=CS1)C(=[NH+]C2=CC(=NC3=CC=CC=C32)C)N.[N+](=O)([O-])[O-].[N+](=O)([O-])[O-],,,,,,
1525,51526,"2-(2-Methylquinolin-4-yl)-1-pentyl-1-(1,3-thiazol-2-yl)guanidine",CCCCCN(C1=NC=CS1)C(=NC2=CC(=NC3=CC=CC=C32)C)N,,,,,,
1526,51527,"GUANIDINE, 1-tert-BUTYL-2-(2-METHYL-4-QUINOLYL)-",CC1=NC2=CC=CC=C2C(=C1)NC(=NC(C)(C)C)N,,,,,,
1527,51528,"GUANIDINE, 1-tert-BUTYL-3-(2-HYDROXYETHYL)-2-(2-METHYL-4-QUINOLYL)-",CC1=NC2=CC=CC=C2C(=C1)NC(=NCCO)NC(C)(C)C,,,,,,
1528,51529,1-tert-Butyl-2-(2-methyl-4-quinolyl)-3-phenylguanidine,CC1=NC2=CC=CC=C2C(=C1)NC(=NC(C)(C)C)NC3=CC=CC=C3,,,,,,
1529,51530,"Guanidine, 1-cyclohexyl-2-(2-methyl-4-quinolyl)-3-phenyl-",CC1=NC2=CC=CC=C2C(=C1)NC(=NC3CCCCC3)NC4=CC=CC=C4,,,,,,
1530,51531,"1,2-Epoxy-1,2,3,4-tetrahydrochrysene",C1CC2=C(C=CC3=C2C=CC4=CC=CC=C43)C5C1O5,,,,,,
1531,51532,Methyl (alpha-methyl-p-phenoxybenzyl)carbazate hydrobromide,CC(C1=CC=C(C=C1)OC2=CC=CC=C2)[NH2+]NC(=O)OC.[Br-],,,,,,
1532,51533,methyl N-[1-(4-phenoxyphenyl)ethylamino]carbamate,CC(C1=CC=C(C=C1)OC2=CC=CC=C2)NNC(=O)OC,,,,,,
1533,51534,Methyl alpha-methyl-p-(phenylsulfonyl)benzylcarbazate,CC(C1=CC=C(C=C1)S(=O)(=O)C2=CC=CC=C2)NNC(=O)OC,,,,,,
1534,51535,"2,4,6-Cycloheptatriene-1-acetic acid, 2-(4-methylpiperazinyl)ethyl ester, hydrochloride",C[NH+]1CCN(CC1)CCOC(=O)CC2C=CC=CC=C2.[Cl-],,,,,,
1535,51536,"2-(4-Methylpiperazin-1-yl)ethyl 2-cyclohepta-2,4,6-trien-1-ylacetate",CN1CCN(CC1)CCOC(=O)CC2C=CC=CC=C2,,,,,,
1536,51537,"2,4,6-Cycloheptatriene-1-acetic acid, 3-(4-methylpiperazin-1-yl)propyl ester, hydrochloride",C[NH+]1CCN(CC1)CCCOC(=O)CC2C=CC=CC=C2.[Cl-],,,,,,
1537,51538,"3-(4-Methylpiperazin-1-yl)propyl 2-cyclohepta-2,4,6-trien-1-ylacetate",CN1CCN(CC1)CCCOC(=O)CC2C=CC=CC=C2,,,,,,
1538,51539,"2-Naphthalenesulfonic acid, compd. with 3-(dimethylamino)-2-methyl-1-phenyl-1-(phenylmethyl)propyl propanoate (1:1)",CCC(=O)OC(CC1=CC=CC=C1)(C2=CC=CC=C2)C(C)C[NH+](C)C.C1=CC=C2C=C(C=CC2=C1)S(=O)(=O)[O-],,,,,,
1539,51540,"4-Hydroxy-alpha-(1-(N-(4-hydroxybutyl)amino)ethyl)benzyl alcohol 3,4,5-trimethoxybenzoate",CC(C(C1=CC=C(C=C1)O)OC(=O)C2=CC(=C(C(=C2)OC)OC)OC)NCCCCO,,,,,,
1540,51541,"2-[(4-Hydroxybutyl)(propyl)amino]-1-(4-hydroxyphenyl)propyl 3,4,5-trimethoxybenzoate",CCCN(CCCCO)C(C)C(C1=CC=C(C=C1)O)OC(=O)C2=CC(=C(C(=C2)OC)OC)OC,,,,,,
1541,51542,"Carbamic acid, dimethyl-, 5-(dimethylamino)-2-(p-(dimethylamino)phenylazo)phenyl ester, methiodide",CN(C)C1=CC(=C(C=C1)N=NC2=CC=C(C=C2)[N+](C)(C)C)OC(=O)N(C)C.[I-],,,,,,
1542,51543,[4-[[4-(Dimethylamino)-2-(dimethylcarbamoyloxy)phenyl]diazenyl]phenyl]-trimethylazanium,CN(C)C1=CC(=C(C=C1)N=NC2=CC=C(C=C2)[N+](C)(C)C)OC(=O)N(C)C,,,,,,
1543,51544,"syn-Chrysene-1,2-diol-3,4-epoxide",C1=CC=C2C(=C1)C=CC3=C2C=CC4=C3[C@H]5[C@H](O5)[C@H]([C@@H]4O)O,,,,,,
1544,51545,"Chrysenediol, 3,4-epoxy-1,2,3,4-tetrahydro-, (+)-(E)-",C1=CC=C2C(=C1)C=CC3=C2C=CC4=C3[C@@H]5[C@@H](O5)[C@H]([C@@H]4O)O,,,,,,
1545,51546,"2-Benzofuranmethanol, 5-chloro-3-phenyl-, carbanilate",C1=CC=C(C=C1)C2=C(OC3=C2C=C(C=C3)Cl)COC(=O)NC4=CC=CC=C4,,,,,,
1546,51547,"2-Benzofuranmethanol, 5-bromo-3-phenyl-, carbanilate",C1=CC=C(C=C1)C2=C(OC3=C2C=C(C=C3)Br)COC(=O)NC4=CC=CC=C4,,,,,,
1547,51548,CID 51548,C1=CC=C(C=C1)C2=C(OC3=C2C=CC(=C3)Cl)C=NNC(=O)C4=CC=NC=C4,,,,,,
1548,51549,CID 51549,C1=CC=C(C=C1)C2=C(OC3=C2C=C(C=C3)Br)C=NNC(=O)C4=CC=NC=C4,,,,,,
1549,51550,Sulotroban,C1=CC=C(C=C1)S(=O)(=O)NCCC2=CC=C(C=C2)OCC(=O)O,,,"['Agents used for the treatment or prevention of cardiac arrhythmias. They may affect the polarization-repolarization phase of the action potential, its excitability or refractoriness, or impulse conduction or membrane responsiveness within cardiac fibers. Anti-arrhythmia agents are often classed into four main groups according to their mechanism of action: sodium channel blockade, beta-adrenergic blockade, repolarization prolongation, or calcium channel blockade. (See all compounds classified as Anti-Arrhythmia Agents.)', 'Fibrinolysin or agents that convert plasminogen to FIBRINOLYSIN. (See all compounds classified as Fibrinolytic Agents.)', 'Drugs or agents which antagonize or impair any mechanism leading to blood platelet aggregation, whether during the phases of activation and shape change or following the dense-granule release reaction and stimulation of the prostaglandin-thromboxane system. (See all compounds classified as Platelet Aggregation Inhibitors.)']",,,
1550,51551,"1-(Furan-3-yl)-6-hydroxy-4,8-dimethylnonan-1-one",CC(C)CC(CC(C)CCC(=O)C1=COC=C1)O,,,,,,
1551,51552,"Cinchoninic acid, 2-(10-(3-(dimethylamino)propyl)-2-phenothiazinyl)-6-methyl-, ethyl ester, hydrochloride",CCOC(=O)C1=CC(=NC2=C1C=C(C=C2)C)C3=CC4=C(C=C3)SC5=CC=CC=C5N4CCC[NH+](C)C.[Cl-],,,,,,
1552,51553,Ethyl 2-[10-[3-(dimethylamino)propyl]phenothiazin-2-yl]-6-methylquinoline-4-carboxylate,CCOC(=O)C1=CC(=NC2=C1C=C(C=C2)C)C3=CC4=C(C=C3)SC5=CC=CC=C5N4CCCN(C)C,,,,,,
1553,51554,"Cinchoninic acid, 6-chloro-2-(10-(3-(dimethylamino)propyl)-2-phenothiazinyl)-, ethyl ester, hydrochloride",CCOC(=O)C1=CC(=NC2=C1C=C(C=C2)Cl)C3=CC4=C(C=C3)SC5=CC=CC=C5N4CCC[NH+](C)C.[Cl-],,,,,,
1554,51555,Ethyl 6-chloro-2-[10-[3-(dimethylamino)propyl]phenothiazin-2-yl]quinoline-4-carboxylate,CCOC(=O)C1=CC(=NC2=C1C=C(C=C2)Cl)C3=CC4=C(C=C3)SC5=CC=CC=C5N4CCCN(C)C,,,,,,
1555,51556,Fomesafen,CS(=O)(=O)NC(=O)C1=C(C=CC(=C1)OC2=C(C=C(C=C2)C(F)(F)F)Cl)[N+](=O)[O-],,,,,"['Metabolism of fomesafen was accompanied by a transient accumulation of a metabolite identified as (N-(4-(4-(trifluoromethyl)phenoxy)-2-methanamidephenyl)acetamide) using liquid chromatography-mass spectrometry, thus indicating a metabolic pathway involving /of the nitro group and acetylation of the resultant amino group/.']",
1556,51557,"1,2,3,4-Tetrahydro-1,2-epoxyanthracene",C1CC2=CC3=CC=CC=C3C=C2C4C1O4,,,,,,
1557,51558,17-Hydroxy-6-methylestr-4-en-3-one,CC1CC2C(CCC3(C2CC[C@@H]3O)C)C4C1=CC(=O)CC4,,,,,,
1558,51559,"Malononitrile, (2,2-diphenylethylidene)-",C1=CC=C(C=C1)C(C=C(C#N)C#N)C2=CC=CC=C2,,,,,,
1559,51560,"3-(2-Benzofuranyl)-2,2-dimethyl-3-ethylpropionic acid",CCC(C1=CC2=CC=CC=C2O1)C(C)(C)C(=O)O,,,,,,
1560,51561,"1,5-Dioxaspiro(5.5)undecane-3-methanol, 3-((4,6-bis(1-aziridinyl)-1,3,5-triazin-2-yl)amino)-",C1CCC2(CC1)OCC(CO2)(CO)NC3=NC(=NC(=N3)N4CC4)N5CC5,,,,,,
1561,51562,"1,3-Dioxane-5-methanol, 5-((4,6-bis(1-aziridinyl)-1,3,5-triazin-2-yl)amino)-2-phenyl-",C1CN1C2=NC(=NC(=N2)NC3(COC(OC3)C4=CC=CC=C4)CO)N5CC5,,,,,,
1562,51563,"1,3-Dioxane-5-methanol, 5-((4,6-bis(1-aziridinyl)-1,3,5-triazin-2-yl)amino)-2-(3,4-dimethylphenyl)-",CC1=C(C=C(C=C1)C2OCC(CO2)(CO)NC3=NC(=NC(=N3)N4CC4)N5CC5)C,,,,,,
1563,51564,N-benzoyl-N-(3-chloro-4-fluorophenyl)phenylalanine,C1=CC=C(C=C1)CC(C(=O)O)N(C2=CC(=C(C=C2)F)Cl)C(=O)C3=CC=CC=C3,,,,,,
1564,51565,"2-amino-N-[(1S,2R,3R,4S,5S,6R)-4-amino-3-[(2R,3R,6S)-3-amino-6-(1-aminoethyl)oxan-2-yl]oxy-2,5-dihydroxy-6-methoxycyclohexyl]-N-methylacetamide;sulfuric acid",CC([C@@H]1CC[C@H]([C@H](O1)O[C@@H]2[C@H]([C@@H]([C@@H]([C@H]([C@H]2O)N(C)C(=O)CN)OC)O)N)N)N.OS(=O)(=O)O.OS(=O)(=O)O,,,,,,
1565,51566,CID 51566,CC([C@@H]1CC[C@H]([C@H](O1)OC2[C@H]([C@@H](C([C@H](C2O)N(C)C(=O)CN)OC)O)N)N)N,,,,,,
1566,51567,Viroxime,CC(C)S(=O)(=O)N1C2=C(C=CC(=C2)C(=NO)C3=CC=CC=C3)N=C1N,,,['Agents used in the prophylaxis or therapy of VIRUS DISEASES. Some of the ways they may act include preventing viral replication by inhibiting viral DNA polymerase; binding to specific cell-surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking late stages of virus assembly. (See all compounds classified as Antiviral Agents.)'],,,
1567,51568,"1,1'-Dihexyl-4,4'-bipyridinium diiodide",CCCCCC[N+]1=CC=C(C=C1)C2=CC=[N+](C=C2)CCCCCC.[I-].[I-],,,,,,
1568,51569,"m-CRESOL, 6-tert-BUTYL-4-NITRO-",CC1=CC(=C(C=C1[N+](=O)[O-])C(C)(C)C)O,,,,,,
1569,51570,"Tetrabenzo(a,e,klm,s)picene",C1=CC=C2C(=C1)C=CC3=CC4=C5C6=C(C=C4)C=C7C=CC8=CC=CC=C8C7=C6C9=CC=CC=C9C5=C32,,,,,,
1570,51571,"Tetrabenzo(a,c,m,o)naphtho(1,2,3,4-rst)pentaphene",C1=CC=C2C(=C1)C3=CC=CC=C3C4=C2C=C5C=CC6=CC7=C(C8=CC=CC=C8C9=CC=CC=C97)C1=C6C5=C4C2=CC=CC=C21,,,,,,
1571,51572,"Tetranaphtho(3,2,1-de:1',2',3'-jk:3'',2'',1''-op:1''',2''',3'''-uv)pentacene",C1=CC=C2C(=C1)C=C3C=CC4=CC5=CC=CC=C5C6=C4C3=C2C7=CC8=C(C=C76)C9=C1C(=CC2=CC=CC=C29)C=CC2=CC3=CC=CC=C3C8=C21,,,,,,
1572,51573,CID 51573,CC1=C(C=CC(=C1)OCC2=NN=C(O2)S)Cl,,,,,,
1573,51574,Chlozolinate,CCOC(=O)C1(C(=O)N(C(=O)O1)C2=CC(=CC(=C2)Cl)Cl)C,,,,,,
1574,51575,"Indole, 1-(2-diethylaminoethyl)-",CCN(CC)CCN1C=CC2=CC=CC=C21,,,,,,
1575,51576,Acifran,CC1(C(=O)C=C(O1)C(=O)O)C2=CC=CC=C2,,,,,,
1576,51577,"1-(2-Hydroxyethyl)-2-(hydroxymethyl)piperidine-3,4,5-triol",C1C(C(C(C(N1CCO)CO)O)O)O,,,,,,
1577,51578,"2-Quinuclidinemethanol, alpha-(6-hydroxy-4-quinolyl)-5-vinyl-, hydrochloride",C=CC1C[NH+]2CCC1CC2C(C3=C4C=C(C=CC4=NC=C3)O)O.[Cl-],,,,,,
1578,51579,"(8alpha,9R)-Cinchonan-6',9-diol",C=CC1CN2CCC1CC2C(C3=C4C=C(C=CC4=NC=C3)O)O,,,,,,
1579,51580,"(8R)-7,8-dihydrobenzo[n]triphenylene-7,8-diol",C1=CC=C2C=C3C(=CC2=C1)C4=CC=CC=C4C5=C3[C@H](C(C=C5)O)O,,,,,,
1580,51581,"trans-3,4-Dihydrobenzo(b)triphenylene-3,4-diol",C1=CC=C2C=C3C4=CC=CC=C4C5=C(C3=CC2=C1)C=C[C@H](C5O)O,,,,,,
1581,51582,"Acetic acid, ((2,3,5,6-tetramethylphenyl)thio)-, ethyl ester",CCOC(=O)CSC1=C(C(=CC(=C1C)C)C)C,,,,,,
1582,51583,"2-(2,3,5,6-Tetramethylphenoxy)butyric acid ethyl ester",CCC(C(=O)OCC)OC1=C(C(=CC(=C1C)C)C)C,,,,,,
1583,51584,"2-((2,3,5,6-Tetramethylphenyl)thio)butyric acid ethyl ester",CCC(C(=O)OCC)SC1=C(C(=CC(=C1C)C)C)C,,,,,,
1584,51585,"Acetic acid, ((2,3,5,6-tetramethylphenyl)thio)-",CC1=CC(=C(C(=C1C)SCC(=O)O)C)C,,,,,,
1585,51586,"2-(2,3,5,6-Tetramethylphenoxy)butyric acid",CCC(C(=O)O)OC1=C(C(=CC(=C1C)C)C)C,,,,,,
1586,51587,"2-((2,3,5,6-Tetramethylphenyl)thio)butyric acid",CCC(C(=O)O)SC1=C(C(=CC(=C1C)C)C)C,,,,,,
1587,51588,"Butyric acid, 4-(2,3,5,6-tetramethylphenoxy)-",CC1=CC(=C(C(=C1C)OCCCC(=O)O)C)C,,,,,,
1588,51589,"Butyric acid, 4-((2,3,5,6-tetramethylphenyl)thio)-",CC1=CC(=C(C(=C1C)SCCCC(=O)O)C)C,,,,,,
1589,51590,5-Benzamido-2-methyl-trans-decahydroisoquinoline,CN1CC[C@H]2[C@H](C1)CCCC2NC(=O)C3=CC=CC=C3,,,,,,
1590,51591,trans-4-Chloro-N-(2-methyldecahydroisoquinol-5-yl)benzamide,CN1CC[C@@H]2[C@@H](C1)CCCC2NC(=O)C3=CC=C(C=C3)Cl,,,,,,
1591,51592,"trans-2,4-Dichloro-N-(2-methyldecahydroisoquinol-5-yl)benzamide",CN1CC[C@@H]2[C@@H](C1)CCCC2NC(=O)C3=C(C=C(C=C3)Cl)Cl,,,,,,
1592,51593,"trans-3,4-Dichloro-N-(2-methyldecahydroisoquinol-5-yl)benzamide",CN1CC[C@@H]2[C@@H](C1)CCCC2NC(=O)C3=CC(=C(C=C3)Cl)Cl,,,,,,
1593,51594,trans-N-(2-Methyldecahydroisoquinol-5-yl)-4-trifluoromethylbenzamide,CN1CC[C@H]2[C@H](C1)CCCC2NC(=O)C3=CC=C(C=C3)C(F)(F)F,,,,,,
1594,51595,trans-N-(2-Methyldecahydroisoquinol-5-yl)-4-nitrobenzamide,CN1CC[C@H]2[C@H](C1)CCCC2NC(=O)C3=CC=C(C=C3)[N+](=O)[O-],,,,,,
1595,51596,trans-4-Methoxy-N-(2-methyldecahydroisoquinol-5-yl)benzamide,CN1CC[C@@H]2[C@@H](C1)CCCC2NC(=O)C3=CC=C(C=C3)OC,,,,,,
1596,51597,trans-4-Methyl-N-(2-methyldecahydroisoquinol-5-yl)benzamide,CC1=CC=C(C=C1)C(=O)NC2CCC[C@H]3[C@H]2CCN(C3)C,,,,,,
1597,51598,trans-3-Chloro-N-(2-methyldecahydroisoquinol-5-yl)benzamide,CN1CC[C@H]2[C@H](C1)CCCC2NC(=O)C3=CC(=CC=C3)Cl,,,,,,
1598,51599,trans-4-Fluoro-N-(2-methyldecahydroisoquinol-5-yl)benzamide,CN1CC[C@@H]2[C@@H](C1)CCCC2NC(=O)C3=CC=C(C=C3)F,,,,,,
1599,51600,CID 51600,[C]1[C][C][C][C]1.[C]1[C][C][C][C]1.[C]1[C][C][C][C]1.[C]1[C][C][C][C]1.O.Cl[Nb]Cl.Cl[Nb]Cl,,,,,,
1600,51601,Niobium dichloride,Cl[Nb]Cl,,,,,,
1601,51602,CID 51602,C=1=C=C=C=C1,,,,,,
1602,51603,Brocrinat,C1=CC=C(C(=C1)C2=NOC3=C2C=CC(=C3Br)OCC(=O)O)F,,,,,,
1603,51604,"7,8-Dihydroxy-9,10-epoxy-7,8-dihydrobenzo(a)pyrene",C1=CC2=C3C(=C1)C=CC4=C3C(=CC5=C4C6=C(O6)C(C5O)O)C=C2,,,,,,
1604,51605,Fenoxycarb,CCOC(=O)NCCOC1=CC=C(C=C1)OC2=CC=CC=C2,,,"['Pesticides designed to control insects that are harmful to man. The insects may be directly harmful, as those acting as disease vectors, or indirectly harmful, as destroyers of crops, food products, or textile fabrics. (See all compounds classified as Insecticides.)']","['About ninety percent of a dose of fenoxycarb fed to rats was excreted within 96 hours. No residues were found in the animals organs.', '... Rambouillet sheep... were dosed daily with a placebo or with fenoxycarb at 0.69 or 1.38 mg/kg/day, representing ten (10x) and 20 times (20x) the maximum amounts of fenoxycarb in forage or hay treated at recommended levels for fire ant control. ... Means of hepatic fenoxycarb residues in the rams followed a statistically significant (P < or = 0.05) dose-related pattern. No fenoxycarb was detected (detection limit of 5 ppb) in any neonatal liver, despite the presence of hepatic fenoxycarb residues in the treated ewes, indicating that transplacental transport of fenoxycarb was minimal. No fenoxycarb was detected in any lamb liver at 28 days, although both the colostrum and the milk of exposed ewes were found to contain fenoxycarb at levels proportional to the treatments. ...']",,
1605,51606,CID 51606,C[C@@H]1C[C@H](C[C@@H]([C@@H]1O[C@@H]2CCCCO2)N)O[C@H]3C[C@@](CC4=C3C(=C5C(=C4O)C(=O)C6=C(C5=O)C(=CC=C6)OC)O)(C(=O)CO)O,,,,,,
1606,51607,"1,2,9,10-Tetramethoxy-6a-alpha-aporphine 6-oxide",C[N+]1(CCC2=CC(=C(C3=C2[C@@H]1CC4=CC(=C(C=C43)OC)OC)OC)OC)[O-],,,,,,
1607,51608,"1,2,3,4-Tetrahydro-1,1-dimethyl-4,6-isoquinolinediol hydrochloride",CC1(C2=C(C=C(C=C2)O)C(C[NH2+]1)O)C.[Cl-],,,,,,
1608,51609,"1,1-dimethyl-3,4-dihydro-2H-isoquinoline-4,6-diol",CC1(C2=C(C=C(C=C2)O)C(CN1)O)C,,,,,,
1609,51610,"1,2,3,4-Tetrahydro-1-(3,4-dimethoxyphenyl)-4,6-isoquinolinediol hydrochloride",COC1=C(C=C(C=C1)C2C3=C(C=C(C=C3)O)C(C[NH2+]2)O)OC.[Cl-],,,,,,
1610,51611,"1-(3,4-Dimethoxyphenyl)-1,2,3,4-tetrahydroisoquinoline-4,6-diol",COC1=C(C=C(C=C1)C2C3=C(C=C(C=C3)O)C(CN2)O)OC,,,,,,
1611,51612,"1,2,3,4-Tetrahydro-1-(4-methoxyphenyl)-4,6-isoquinolinediol hydrochloride",COC1=CC=C(C=C1)C2C3=C(C=C(C=C3)O)C(C[NH2+]2)O.[Cl-],,,,,,
1612,51613,"1-(4-Methoxyphenyl)-1,2,3,4-tetrahydroisoquinoline-4,6-diol",COC1=CC=C(C=C1)C2C3=C(C=C(C=C3)O)C(CN2)O,,,,,,
1613,51614,"4,6-Isoquinolinediol, 1,2,3,4-tetrahydro-1-(3,4,5-trimethoxyphenyl)-, hydrochloride, hydrate (3:3:1)",COC1=CC(=CC(=C1OC)OC)C2C3=C(C=C(C=C3)O)C(C[NH2+]2)O.[Cl-],,,,,,
1614,51615,"1,2,3,4-Tetrahydro-1-(3,4,5-trimethoxyphenyl)-4,6-isoquinolinediol",COC1=CC(=CC(=C1OC)OC)C2C3=C(C=C(C=C3)O)C(CN2)O,,,,,,
1615,51616,"1-Naphthalenol, 2-(9,10-dihydro-10-methyl-9-acridinyl)-",CN1C2=CC=CC=C2C(C3=CC=CC=C31)C4=C(C5=CC=CC=C5C=C4)O,,,,,,
1616,51617,"N-((((((5,5-Dimethyl-1,3,2-dioxaphosphorinan-2-yl)(1,1-dimethylethyl)amino)thio)methylamino)carbonyl)oxy)ethanimidothioic acid methyl ester P-sulfide",CC(=NOC(=O)N(C)SN(C(C)(C)C)P1(=S)OCC(CO1)(C)C)SC,,,,,,
1617,51618,"Benzylamine, N-(2-bromoallyl)-",C=C(CNCC1=CC=CC=C1)Br,,,,,,
1618,51619,"[(7S,11S,12R,13S,14R,15R,16R,17S,18S)-2,15,17,32-tetrahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-1'-(2-methylpropyl)-6,23-dioxospiro[8,33-dioxa-24,27,29-triazapentacyclo[23.6.1.14,7.05,31.026,30]tritriaconta-1(31),2,4,9,19,21,25(32),26,29-nonaene-28,4'-piperidine]-13-yl] acetate",C[C@H]1C=CC=C(C(=O)NC2=C(C3=C(C4=C(C(=C3O)C)O[C@@](C4=O)(OC=C[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)C5=NC6(CCN(CC6)CC(C)C)N=C25)O)C,,,,,,
1619,51620,"2,4,5,6-Tetraphenyl-1,3,5-dioxaphosphorinane 5-oxide",C1=CC=C(C=C1)C2OC(P(=O)(C(O2)C3=CC=CC=C3)C4=CC=CC=C4)C5=CC=CC=C5,,,,,,
1620,51621,Methyl 3-sec-butyl-3-methylglycidate,CCC(C)C1(C(O1)C(=O)OC)C,,,,,,
1621,51622,N-(7-Nitro-9H-fluoren-2-yl)acetamide,CC(=O)NC1=CC2=C(C=C1)C3=C(C2)C=C(C=C3)[N+](=O)[O-],,,,,,
1622,51623,CID 51623,C[NH+](C)C1CCC2=CC=CC=C2C(C1)OC3=CC=C(C=C3)[N+](=O)[O-].C(=CC(=O)[O-])C(=O)O,,,,,,
1623,51624,"N,N-dimethyl-5-(4-nitrophenoxy)-6,7,8,9-tetrahydro-5H-benzo[7]annulen-7-amine",CN(C)C1CCC2=CC=CC=C2C(C1)OC3=CC=C(C=C3)[N+](=O)[O-],,,,,,
1624,51625,"4,5-Dihydroxy-1-(5-nitro-2-thiazolyl)-2-imidazolidinone",C1=C(SC(=N1)N2C(C(NC2=O)O)O)[N+](=O)[O-],,,,,,
1625,51626,5-Hydroxyniridazole,C1C(N(C(=O)N1)C2=NC=C(S2)[N+](=O)[O-])O,,,,,,
1626,51627,"[(8S,10R,11S,13S,14S,17R)-11-hydroxy-10,13-dimethyl-3-oxo-17-(2-propanoyloxyacetyl)-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-17-yl] butanoate",CCCC(=O)O[C@@]1(CC[C@@H]2[C@@]1(C[C@@H](C3[C@H]2CCC4=CC(=O)CC[C@]34C)O)C)C(=O)COC(=O)CC,,,,,,
1627,51628,"Benzamide, N-(2-(3,4,6,7,12,12a-hexahydropyrazino(1',2':1,6)pyrido(3,4-b)indol-2(1H)-yl)ethyl)-4-methoxy-",COC1=CC=C(C=C1)C(=O)NCCN2CCN3CC4=C(CC3C2)C5=CC=CC=C5N4,,,,,,
1628,51629,"Benzamide, 4-chloro-N-(2-(3,4,6,7,12,12a-hexahydropyrazino(1',2':1,6)pyrido(3,4-b)indol-2(1H)-yl)ethyl)-",C1CN2CC3=C(CC2CN1CCNC(=O)C4=CC=C(C=C4)Cl)C5=CC=CC=C5N3,,,,,,
1629,51630,"Benzamide, 4-(2-(3,4,6,7,12,12a-hexahydropyrazino(1',2':1,6)pyrido(3,4-b)indol-2(1H)-yl)ethyl)-4-methyl-",CC1=CC=C(C=C1)C(=O)NCCN2CCN3CC4=C(CC3C2)C5=CC=CC=C5N4,,,,,,
1630,51631,"N-(2-(3,4,6,7,12,12a-Hexahydropyrazino(1',2':1,6)pyrido(3,4-b)indol-2(1H)-yl)ethyl)benzamide",C1CN2CC3=C(CC2CN1CCNC(=O)C4=CC=CC=C4)C5=CC=CC=C5N3,,,,,,
1631,51632,"Benzamide, N-(2-(3,4,6,7,12,12a-hexahydropyrazino(1',2':1,6)pyrido(3,4-b)indol-2(1H)-yl)ethyl)-4-(methylsulfonyl)-",CS(=O)(=O)C1=CC=C(C=C1)C(=O)NCCN2CCN3CC4=C(CC3C2)C5=CC=CC=C5N4,,,,,,
1632,51633,"Benzamide, 4-fluoro-N-(2-(3,4,6,7,12,12a-hexahydropyrazino(1',2':1,6)pyrido(3,4-b)indol-2(1H)-yl)ethyl)-",C1CN2CC3=C(CC2CN1CCNC(=O)C4=CC=C(C=C4)F)C5=CC=CC=C5N3,,,,,,
1633,51634,Miglustat,CCCCN1C[C@@H]([C@H]([C@@H]([C@H]1CO)O)O)O,"[""For the treatment of adult patients with mild to moderate type 1 (nonneuropathic) Gaucher's disease for whom enzyme replacement therapy is not a therapeutic option (e.g. due to constraints such as allergy, hypersensitivity, or poor venous access). Now approved in some countries for the treatment of progressive neurological symptoms in adult and pediatric patients with Niemann-Pick disease type C (NP-C).""]","[""Miglustat, an N-alkylated imino sugar, is a synthetic analogue of D-glucose. Miglustat is an inhibitor of the enzyme glucosylceramide synthase, which is a glucosyl transferase enzyme responsible for catalyzing the formation of glucosylceramide (glucocerebroside). Glucosylceramide is a substrate for the endogenous glucocerebrosidase, an enzyme that is deficient in Gaucher's disease. The accumulation of glucosylceramide due to the absence of glucocerebrosidase results in the storage of this material in the lysosomes of tissue macrophages, leading to widespread pathology due to infiltration of lipid-engorged macrophages in the viscera, lymph nodes, and bone marrow. This results in secondary hematologic consequences including sever anemia and thrombocytopenia, in addition to the characteristic progressive hepatosplenomegaly, as well as skeletal complications including osteonecrosis and osteopenia with secondary pathological fractures.""]","['Agents used to treat AIDS and/or stop the spread of the HIV infection. These do not include drugs used to treat symptoms or opportunistic infections associated with AIDS. (See all compounds classified as Anti-HIV Agents.)', 'Compounds that inhibit or block the activity of GLYCOSIDE HYDROLASES such as ALPHA-AMYLASES and ALPHA-GLUCOSIDASES. (See all compounds classified as Glycoside Hydrolase Inhibitors.)', 'Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. (See all compounds classified as Enzyme Inhibitors.)']",['Mean oral bioavailability is 97%.'],['There is no evidence that miglustat is metabolized in humans.'],['The effective half-life of miglustat is approximately 6 to 7 hours.']
1634,51635,"1(2H)-Naphthalenone, 3,4-dihydro-2-((dimethylamino)methyl)-6-methoxy-, hydrochloride",C[NH+](C)CC1CCC2=C(C1=O)C=CC(=C2)OC.[Cl-],,,,,,
1635,51636,"2-[(dimethylamino)methyl]-6-methoxy-3,4-dihydro-2H-naphthalen-1-one",CN(C)CC1CCC2=C(C1=O)C=CC(=C2)OC,,,,,,
1636,51637,CID 51637,CC1=CC(=C(C(=C1)C)C=C(C(=O)NN)N(C)C)C,,,,,,
1637,51638,CID 51638,CC1=CC(=C(C(=C1)C)C=C(C(=O)NN)NCCC2=CC=CC=C2)C,,,,,,
1638,51639,CID 51639,CC1=CC(=C(C(=C1)C)C=C(C(=O)NN)NC(C)CC2=CC=CC=C2)C,,,,,,
1639,51640,CID 51640,CC1=CC(=C(C(=C1)C)C=C(C(=O)NN)N(C)CC(C)C2=CC=CC=C2)C,,,,,,
1640,51641,CID 51641,CC1=CC(=C(C(=C1C)C=C(C(=O)NN)NC)C)C,,,,,,
1641,51642,CID 51642,CCNC(=CC1=C(C(=CC(=C1C)C)C)C)C(=O)NN,,,,,,
1642,51643,CID 51643,CCCNC(=CC1=C(C(=CC(=C1C)C)C)C)C(=O)NN,,,,,,
1643,51644,CID 51644,CC1=CC(=C(C(=C1C)C=C(C(=O)NN)N(C)C)C)C,,,,,,
1644,51645,CID 51645,CC1=CC(=C(C(=C1C)C=C(C(=O)N[NH3+])NCC(C)C2=CC=CC=C2)C)C.[Cl-],,,,,,
1645,51646,CID 51646,CC1=CC(=C(C(=C1C)C=C(C(=O)NN)NCC(C)C2=CC=CC=C2)C)C,,,,,,
1646,51647,CID 51647,CC1=CC(=C(C(=C1C)C=C(C(=O)NN)N(C)CC(C)C2=CC=CC=C2)C)C,,,,,,
1647,51648,CID 51648,CC1=CC(=C(C(=C1C)C=NNC(=O)CCN(C)C(C)CC2=CC=CC=C2)C)C,,,,,,
1648,51649,CID 51649,CN(C)C(C=O)NN=CC1=CC2=CC=CC=C2O1,,,,,,
1649,51650,CID 51650,C1=CC=C(C=C1)CCNC(=CC2=CC3=CC=CC=C3O2)C(=O)NN,,,,,,
1650,51651,CID 51651,CC(CNC(=CC1=CC2=CC=CC=C2O1)C(=O)N[NH3+])C3=CC=CC=C3.[Cl-],,,,,,
1651,51652,CID 51652,CC(CNC(=CC1=CC2=CC=CC=C2O1)C(=O)NN)C3=CC=CC=C3,,,,,,
1652,51653,CID 51653,CC(CN(C)C(=CC1=CC2=CC=CC=C2O1)C(=O)NN)C3=CC=CC=C3,,,,,,
1653,51654,CID 51654,CN(C)C(=CC1=CC2=CC=CC=C2C=C1)C(=O)NN,,,,,,
1654,51655,CID 51655,CC(CNC(=CC1=CC2=CC=CC=C2C=C1)C(=O)N[NH3+])C3=CC=CC=C3.[Cl-],,,,,,
1655,51656,CID 51656,CC(CNC(=CC1=CC2=CC=CC=C2C=C1)C(=O)NN)C3=CC=CC=C3,,,,,,
1656,51657,CID 51657,CNC(=CC1=CC2=CC=CC=C2C=C1)C(=O)NN,,,,,,
1657,51658,CID 51658,CCCNC(=CC1=CC2=CC=CC=C2C=C1)C(=O)NN,,,,,,
1658,51659,2-[Methyl(2-phenylpropyl)amino]-3-naphthalen-2-ylprop-2-enehydrazide,CC(CN(C)C(=CC1=CC2=CC=CC=C2C=C1)C(=O)NN)C3=CC=CC=C3,,,,,,
1659,51660,CID 51660,CC(CC1=CC=CC=C1)N(C)CCC(=O)NN=CC2=CC3=CC=CC=C3C=C2,,,,,,
1660,51661,N-(3-(3-Indolyl)propyl)isonicotinamide hydrochloride hydrate,C1=CC=C2C(=C1)C(=CN2)CCCNC(=O)C3=CC=NC=C3.[Cl-],,,,,,
1661,51662,N-[3-(1H-indol-3-yl)propyl]pyridine-4-carboxamide,C1=CC=C2C(=C1)C(=CN2)CCCNC(=O)C3=CC=NC=C3,,,,,,
1662,51663,"BENZAMIDE, N-(3-(3-INDOLYL)PROPYL)-m-NITRO-",C1=CC=C2C(=C1)C(=CN2)CCCNC(=O)C3=CC(=CC=C3)[N+](=O)[O-],,,,,,
1663,51664,"Isonicotinamide, N-(3-(5-methoxy-3-indolyl)propyl)-",COC1=CC2=C(C=C1)NC=C2CCCNC(=O)C3=CC=NC=C3,,,,,,
1664,51665,1-(Tert-butylamino)-3-(3-methyl-2-nitrophenoxy)propan-2-ol,CC1=C(C(=CC=C1)OCC(CNC(C)(C)C)O)[N+](=O)[O-],,,,,,
1665,51666,"BENZ(a)ANTHRACENE, 1,2-DIHYDRO-7,12-DIMETHYL-",CC1=C2C=CC3=C(C2=C(C4=CC=CC=C14)C)CCC=C3,,,,,,
1666,51667,CID 51667,BC#N.BC#N.C(CN)N,,,,,,
1667,51668,"2H-1-Benzopyran-3-carboxylic acid, 7-amino-2-oxo-, ethyl ester",CCOC(=O)C1=CC2=C(C=C(C=C2)N)OC1=O,,,,,,
1668,51669,4-[3-(3-Ethenylpiperidin-4-yl)propyl]-6-methoxyquinoline,COC1=CC2=C(C=CN=C2C=C1)CCCC3CCNCC3C=C,,,,,,
1669,51670,2-[2-[[5-(2-aminopropan-2-yl)furan-2-yl]methylsulfanyl]ethylamino]-5-[(6-methylpyridin-3-yl)methyl]-1H-pyrimidin-6-one;trihydrochloride,CC1=NC=C(C=C1)CC2=CN=C(NC2=O)NCCSCC3=CC=C(O3)C(C)(C)N.Cl.Cl.Cl,,,,,,
1670,51671,2-[2-[[5-(2-aminopropan-2-yl)furan-2-yl]methylsulfanyl]ethylamino]-5-[(6-methylpyridin-3-yl)methyl]-1H-pyrimidin-6-one,CC1=NC=C(C=C1)CC2=CN=C(NC2=O)NCCSCC3=CC=C(O3)C(C)(C)N,,,,,,
1671,51672,"Acetic acid, 2-(mercaptomethylthio)-, methyl ester, S-ester with O-heptyl methylphosphonothioate",CCCCCCCOP(=O)(C)SCSCC(=O)OC,,,,,,
1672,51673,"Acetic acid, 2-(mercaptomethylthio)-, methyl ester, S-ester with O-pentyl methylphosphonothioate",CCCCCOP(=O)(C)SCSCC(=O)OC,,,,,,
1673,51674,"Acetic acid, 2-(mercaptomethylthio)-, methyl ester, S-ester with O-hexyl methylphosphonothioate",CCCCCCOP(=O)(C)SCSCC(=O)OC,,,,,,
1674,51675,"Acetic acid, 2-(mercaptomethylthio)-, methyl ester, S-ester with O-octyl methylphosphonothioate",CCCCCCCCOP(=O)(C)SCSCC(=O)OC,,,,,,
1675,51676,"2,5-Diphenyl-1,3,5,2-dioxaphosphaborinane",B1(OCP(CO1)C2=CC=CC=C2)C3=CC=CC=C3,,,,,,
1676,51677,"N-Acetyl-3,3'-dichlorobenzidine",CC(=O)NC1=C(C=C(C=C1)C2=CC(=C(C=C2)N)Cl)Cl,,,,,,
1677,51678,Demethyldeacetylmoxisylyte,CC1=CC(=C(C=C1O)C(C)C)OCCNC,,,,,,
1678,51679,"Carbamic acid, ((methylnitrosamino)methyl)-, isopropyl ester",CC(C)OC(=O)NCN(C)N=O,,,,,,
1679,51680,"3-ACRIDINECARBAMIC ACID, 9-(p-(METHYLSULFONAMIDO)ANILINO)-, METHYL ESTER",COC(=O)NC1=CC=CC2=NC3=CC=CC=C3C(=C21)NC4=CC=C(C=C4)NS(=O)(=O)C,,,,,,
1680,51681,CID 51681,CC(C)OC1=C(OC2=C(C1=O)C=C(C=C2)C(=O)[O-])C3=CC=C(C=C3)OC.[Na+],,,,,,
1681,51682,2-(4-Methoxyphenyl)-4-oxo-3-propan-2-yloxychromene-6-carboxylic acid,CC(C)OC1=C(OC2=C(C1=O)C=C(C=C2)C(=O)O)C3=CC=C(C=C3)OC,,,,,,
1682,51683,Swainsonine,C1C[C@H]([C@@H]2[C@@H]([C@@H](CN2C1)O)O)O,,,"['Substances that augment, stimulate, activate, potentiate, or modulate the immune response at either the cellular or humoral level. The classical agents (Freund&apos;s adjuvant, BCG, Corynebacterium parvum, et al.) contain bacterial antigens. Some are endogenous (e.g., histamine, interferon, transfer factor, tuftsin, interleukin-1). Their mode of action is either non-specific, resulting in increased immune responsiveness to a wide variety of antigens, or antigen-specific, i.e., affecting a restricted type of immune response to a narrow group of antigens. The therapeutic efficacy of many biological response modifiers is related to their antigen-specific immunoadjuvanticity. (See all compounds classified as Adjuvants, Immunologic.)', 'Agents obtained from higher plants that have demonstrable cytostatic or antineoplastic activity. (See all compounds classified as Antineoplastic Agents, Phytogenic.)', 'Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. (See all compounds classified as Enzyme Inhibitors.)']",,,
1683,51684,"2-BENZOXAZOLINONE, 6-(o-CHLOROBENZOYL)-",C1=CC=C(C(=C1)C(=O)C2=CC3=C(C=C2)NC(=O)O3)Cl,,,,,,
1684,51685,CID 51685,COC1=CC=CC=C1N2C(=O)C(=CC3=CC=CC=C3Cl)N=C2S,,,,,,
1685,51686,CID 51686,CCOC1=CC=CC=C1N2C(=O)C(=CC3=CC=CC=C3Cl)N=C2S,,,,,,
1686,51687,CID 51687,COC1=CC=CC(=C1)N2C(=O)C(=CC3=CC=CC=C3Cl)N=C2S,,,,,,
1687,51688,CID 51688,CCOC1=CC=CC(=C1)N2C(=O)C(=CC3=CC=CC=C3Cl)N=C2S,,,,,,
1688,51689,CID 51689,COC1=CC=CC=C1N2C(=O)C(=CC3=CC(=CC=C3)Cl)N=C2S,,,,,,
1689,51690,CID 51690,CCOC1=CC=CC=C1N2C(=O)C(=CC3=CC(=CC=C3)Cl)N=C2S,,,,,,
1690,51691,CID 51691,COC1=CC=CC(=C1)N2C(=O)C(=CC3=CC(=CC=C3)Cl)N=C2S,,,,,,
1691,51692,CID 51692,CCOC1=CC=CC(=C1)N2C(=O)C(=CC3=CC(=CC=C3)Cl)N=C2S,,,,,,
1692,51693,CID 51693,CC1=CC=C(C=C1)C=C2C(=O)N(C(=N2)S)C3=CC=CC=C3OC,,,,,,
1693,51694,CID 51694,CCOC1=CC=CC=C1N2C(=O)C(=CC3=CC=C(C=C3)C)N=C2S,,,,,,
1694,51695,CID 51695,CC1=CC=C(C=C1)C=C2C(=O)N(C(=N2)S)C3=CC(=CC=C3)OC,,,,,,
1695,51696,CID 51696,CCOC1=CC=CC(=C1)N2C(=O)C(=CC3=CC=C(C=C3)C)N=C2S,,,,,,
1696,51697,CID 51697,COC1=CC=CC=C1N2C(=O)C(=CC3=CC=C(C=C3)[N+](=O)[O-])N=C2S,,,,,,
1697,51698,CID 51698,CCOC1=CC=CC=C1N2C(=O)C(=CC3=CC=C(C=C3)[N+](=O)[O-])N=C2S,,,,,,
1698,51699,CID 51699,COC1=CC=CC(=C1)N2C(=O)C(=CC3=CC=C(C=C3)[N+](=O)[O-])N=C2S,,,,,,
1699,51700,CID 51700,CCOC1=CC=CC(=C1)N2C(=O)C(=CC3=CC=C(C=C3)[N+](=O)[O-])N=C2S,,,,,,
1700,51701,Darodipine,CCOC(=O)C1=C(NC(=C(C1C2=CC=CC3=NON=C32)C(=O)OCC)C)C,,,['A class of drugs that act by selective inhibition of calcium influx through cellular membranes. (See all compounds classified as Calcium Channel Blockers.)'],,,
1701,51702,"3-(1-Ethyl-1,2,3,6-tetrahydro-4-pyridinyl)-1H-indole hydrochloride",CC[NH+]1CCC(=CC1)C2=CNC3=CC=CC=C32.[Cl-],,,,,,
1702,51703,"3-(1-ethyl-1,2,3,6-tetrahydropyridin-4-yl)-1H-indole",CCN1CCC(=CC1)C2=CNC3=CC=CC=C32,,,,,,
1703,51704,"5-Chloro-3-(1-ethyl-1,2,3,6-tetrahydro-4-pyridinyl)-1H-indole hydrochloride",CC[NH+]1CCC(=CC1)C2=CNC3=C2C=C(C=C3)Cl.[Cl-],,,,,,
1704,51705,"5-chloro-3-(1-ethyl-3,6-dihydro-2H-pyridin-4-yl)-1H-indole",CCN1CCC(=CC1)C2=CNC3=C2C=C(C=C3)Cl,,,,,,
1705,51706,"5-Chloro-3-(1-(cyclopropylmethyl)-1,2,3,6-tetrahydro-4-pyridinyl)-1H-indole hydrochloride",C1CC1C[NH+]2CCC(=CC2)N3C=CC4=C3C=CC(=C4)Cl.[Cl-],,,,,,
1706,51707,"5-chloro-1-[1-(cyclopropylmethyl)-3,6-dihydro-2H-pyridin-4-yl]indole",C1CC1CN2CCC(=CC2)N3C=CC4=C3C=CC(=C4)Cl,,,,,,
1707,51708,"3-[2-[4-(2-Methylphenyl)pyrazin-1-yl]ethyl]-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyridine",CC1=CC=CC=C1N2C=CN(C=C2)CCC3=NN=C4N3CCCC4,,,,,,
1708,51709,N-((4-Phenylbenzoyl)methyl)imidazole,C1=CC=C(C=C1)C2=CC=C(C=C2)C(=O)CN3C=CN=C3,,,,,,
1709,51710,Oxmetidine,CC1=C(N=CN1)CSCCNC2=NC=C(C(=O)N2)CC3=CC4=C(C=C3)OCO4,,,"['Drugs that selectively bind to but do not activate histamine H2 receptors, thereby blocking the actions of histamine. Their clinically most important action is the inhibition of acid secretion in the treatment of gastrointestinal ulcers. Smooth muscle may also be affected. Some drugs in this class have strong effects in the central nervous system, but these actions are not well understood. (See all compounds classified as Histamine H2 Antagonists.)', 'Various agents with different action mechanisms used to treat or ameliorate PEPTIC ULCER or irritation of the gastrointestinal tract. This has included ANTIBIOTICS to treat HELICOBACTER INFECTIONS; HISTAMINE H2 ANTAGONISTS to reduce GASTRIC ACID secretion; and ANTACIDS for symptomatic relief. (See all compounds classified as Anti-Ulcer Agents.)']",,,
1710,51711,Pramiracetam sulfate,CC(C)N(CCNC(=O)CN1CCCC1=O)C(C)C.OS(=O)(=O)O,,,,,,
1711,51712,Pramiracetam,CC(C)N(CCNC(=O)CN1CCCC1=O)C(C)C,,,,,,
1712,51713,CID 51713,C[C@@H]1CCC[C@@H](N1CC[NH2+]C(=N)[NH3+])C.[O-]S(=O)(=O)[O-],,,,,,
1713,51714,"2-[2-[(2S,6R)-2,6-dimethylpiperidin-1-yl]ethyl]guanidine",C[C@@H]1CCC[C@@H](N1CCN=C(N)N)C,,,,,,
1714,51715,CID 51715,C[C@H]1[C@H]([C@@H]([C@@H]([C@H](O1)NC2=CC=C(C=C2)C(=O)[O-])O)O)O.[Na+],,,,,,
1715,51716,"4-[[(2S,3S,4S,5S,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]amino]benzoic acid",C[C@H]1[C@H]([C@@H]([C@@H]([C@H](O1)NC2=CC=C(C=C2)C(=O)O)O)O)O,,,,,,
1716,51717,Eltenac,C1=CC(=C(C(=C1)Cl)NC2=CSC=C2CC(=O)O)Cl,,,"['Anti-inflammatory agents that are non-steroidal in nature. In addition to anti-inflammatory actions, they have analgesic, antipyretic, and platelet-inhibitory actions. They act by blocking the synthesis of prostaglandins by inhibiting cyclooxygenase, which converts arachidonic acid to cyclic endoperoxides, precursors of prostaglandins. Inhibition of prostaglandin synthesis accounts for their analgesic, antipyretic, and platelet-inhibitory actions; other mechanisms may contribute to their anti-inflammatory effects. (See all compounds classified as Anti-Inflammatory Agents, Non-Steroidal.)']",,,
1717,51718,"(R-(R*,S*))-1-Cyclohexyl-3-((2-hydroxy-1-methyl-2-phenylethyl)amino)propan-1-one hydrochloride",C[C@@H]([C@@H](C1=CC=CC=C1)O)NCCC(=O)C2CCCCC2.Cl,,,['Agents that have a strengthening effect on the heart or that can increase cardiac output. They may be CARDIAC GLYCOSIDES; SYMPATHOMIMETICS; or other drugs. They are used after MYOCARDIAL INFARCT; CARDIAC SURGICAL PROCEDURES; in SHOCK; or in congestive heart failure (HEART FAILURE). (See all compounds classified as Cardiotonic Agents.)'],,,
1718,51719,Alifedrine,C[C@@H]([C@@H](C1=CC=CC=C1)O)NCCC(=O)C2CCCCC2,,,['Agents that have a strengthening effect on the heart or that can increase cardiac output. They may be CARDIAC GLYCOSIDES; SYMPATHOMIMETICS; or other drugs. They are used after MYOCARDIAL INFARCT; CARDIAC SURGICAL PROCEDURES; in SHOCK; or in congestive heart failure (HEART FAILURE). (See all compounds classified as Cardiotonic Agents.)'],,,
1719,51720,"1,2,3,7,8,9-Hexachlorodibenzofuran",C1=C2C(=C(C(=C1Cl)Cl)Cl)C3=C(C(=C(C=C3O2)Cl)Cl)Cl,,,,,,
1720,51721,"1H-Indole-1-acetic acid, 2,3-dihydro-5,7-dimethyl-3,3-diphenyl-2-oxo-, ethyl ester",CCOC(=O)CN1C2=C(C=C(C=C2C(C1=O)(C3=CC=CC=C3)C4=CC=CC=C4)C)C,,,,,,
1721,51722,"Indoline-1-acetic acid, 5-chloro-3,3-diphenyl-2-oxo-",C1=CC=C(C=C1)C2(C3=C(C=CC(=C3)Cl)N(C2=O)CC(=O)O)C4=CC=CC=C4,,,,,,
1722,51723,"1H-Indole-1-acetic acid, 2,3-dihydro-3,3-diphenyl-5-methyl-2-oxo-",CC1=CC2=C(C=C1)N(C(=O)C2(C3=CC=CC=C3)C4=CC=CC=C4)CC(=O)O,,,,,,
1723,51724,"5-Methoxy-3,3-diphenyl-2-oxoindoline-1-acetohydroxamic acid",COC1=CC2=C(C=C1)N(C(=O)C2(C3=CC=CC=C3)C4=CC=CC=C4)CC(=O)NO,,,,,,
1724,51725,"Acetic acid, (2-benzoyl-4-methylphenoxy)-, ethyl ester",CCOC(=O)COC1=C(C=C(C=C1)C)C(=O)C2=CC=CC=C2,,,,,,
1725,51726,"5-Ethyl-5-(1,3-dimethyl-1-butenyl)barbituric acid",CCC1(C(=O)NC(=O)NC1=O)C(=CC(C)C)C,,,,,,
1726,51727,"BENZOIC ACID, p-AMINO-, PHOSPHATE",C1=CC(=CC=C1C(=O)O)[NH3+].OP(=O)(O)[O-],,,,,,
1727,51728,"Benzo(1,2-b:3,4-b')dipyrrole-3,8-dimethanaminium, 1,6-dihydro-2,7-bis(ethoxycarbonyl)-N,N,N,N',N',N'-hexamethyl-, bis(methylsulfate)",CCOC(=O)C1=C(C2=C(N1)C3=C(C=C2)NC(=C3C[N+](C)(C)C)C(=O)OCC)C[N+](C)(C)C.COS(=O)(=O)[O-].COS(=O)(=O)[O-],,,,,,
1728,51729,"[2,7-Bis(ethoxycarbonyl)-3-[(trimethylazaniumyl)methyl]-1,6-dihydropyrrolo[2,3-e]indol-8-yl]methyl-trimethylazanium",CCOC(=O)C1=C(C2=C(N1)C3=C(C=C2)NC(=C3C[N+](C)(C)C)C(=O)OCC)C[N+](C)(C)C,,,,,,
1729,51730,"Carbanilic acid, p-(hexyloxy)-, 2-(hexahydro-1H-azepin-1-yl)ethyl ester, hydrochloride",CCCCCCOC1=CC=C(C=C1)NC(=O)OCC[NH+]2CCCCCC2.[Cl-],,,,,,
1730,51731,2-(azepan-1-yl)ethyl N-(4-hexoxyphenyl)carbamate,CCCCCCOC1=CC=C(C=C1)NC(=O)OCCN2CCCCCC2,,,,,,
1731,51732,2-(Dimethylamino)ethyl p-(hexyloxy)carbanilate hydrochloride,CCCCCCOC1=CC=C(C=C1)NC(=O)OCC[NH+](C)C.[Cl-],,,,,,
1732,51733,2-dimethylaminoethyl N-(4-hexoxyphenyl)carbamate,CCCCCCOC1=CC=C(C=C1)NC(=O)OCCN(C)C,,,,,,
1733,51734,CID 51734,CCCCN=C(C(=NC1=NN=C(O1)S(=O)(=O)N)S)S,,,,,,
1734,51735,"N-Cyclohexyl-N'-(5-sulfamoyl-1,3,4-thiadiazole-2-yl)oxamide",C1CCC(CC1)NC(=O)C(=O)NC2=NN=C(S2)S(=O)(=O)N,,,,,,
1735,51736,"Manganate, tetrachloro-, bis(3,4,5-trimethoxyphenethylammonium)",COC1=CC(=CC(=C1OC)OC)CCNCCC2=CC(=C(C(=C2)OC)OC)OC.COC1=CC(=CC(=C1OC)OC)CCNCCC2=CC(=C(C(=C2)OC)OC)OC.Cl[Mn](Cl)(Cl)Cl,,,,,,
1736,51737,"2-(3,4,5-trimethoxyphenyl)-N-[2-(3,4,5-trimethoxyphenyl)ethyl]ethanamine",COC1=CC(=CC(=C1OC)OC)CCNCCC2=CC(=C(C(=C2)OC)OC)OC,,,,,,
1737,51738,Mangantetrachlorid,Cl[Mn](Cl)(Cl)Cl,,,,,,
1738,51739,"BENZO(c)PHENANTHRENE, 1,2-DIHYDRO-",C1CC2=C(C=C1)C=CC3=C2C4=CC=CC=C4C=C3,,,,,,
1739,51740,"ISOTHIOHYDANTOIN, 1-ACETYL-2-(ACETAMIDO-tert-BUTYL)-",CC(=O)NCC(C)(C)SC1=NC(=O)CN1C(=O)C,,,,,,
1740,51741,"GLYCINE, 2-(m-(BIS(2-CHLOROETHYL)AMINO)PHENYL)-",C1=CC(=CC(=C1)N(CCCl)CCCl)C(C(=O)O)N,,,,,,
1741,51742,"2-(2,6-Dichlorobenzyloxy)-2-(2,4-dichlorophenyl)acetic acid",C1=CC(=C(C(=C1)Cl)COC(C2=C(C=C(C=C2)Cl)Cl)C(=O)O)Cl,,,,,,
1742,51743,beta-Acetylmandeloyloxy-beta-phenylethyl dimethylamine,CC(=O)C(C1=CC=CC=C1)(C(=O)OC(CN(C)C)C2=CC=CC=C2)O,,,,,,
1743,51744,CID 51744,COC(=O)CCC=C=CC[C@H]1[C@@H]([C@H](CC1=O)O)C=C[C@H](COC2=CC=CC=C2)O,,,,,,
1744,51745,"CRESOL, 2,5-DICHLORO-alpha-(2,4-XYLYL)-",CC1=CC(=C(C=C1)CC2=C(C(=CC(=C2)Cl)O)Cl)C,,,,,,
1745,51746,CID 51746,C[NH+](C)CCC=C1C2=CC=CC=C2CSC3=C1C=C(C=C3)O.[Cl-],,,,,,
1746,51747,CID 51747,CN(C)CCC=C1C2=CC=CC=C2CSC3=C1C=C(C=C3)O,,,,,,
1747,51748,"S-(6,11-Dihydrodibenzo(b,e)thiepin-11-yl)isothiourea hydrochloride",C1C2=CC=CC=C2C(C3=CC=CC=C3S1)SC(=[NH2+])N.[Cl-],,,,,,
1748,51749,"6,11-Dihydrobenzo[c][1]benzothiepin-11-yl carbamimidothioate",C1C2=CC=CC=C2C(C3=CC=CC=C3S1)SC(=N)N,,,,,,
1749,51750,3-Dimethylaminopropyl 2-(4-aminophenylthiomethyl)benzoate dihydrochloride monohydrate,C[NH+](C)CCCOC(=O)C1=CC=CC=C1CSC2=CC=C(C=C2)[NH3+].[Cl-].[Cl-],,,,,,
1750,51751,3-(Dimethylamino)propyl 2-[(4-aminophenyl)sulfanylmethyl]benzoate,CN(C)CCCOC(=O)C1=CC=CC=C1CSC2=CC=C(C=C2)N,,,,,,
1751,51752,"Ethanamine, 2-((6,11-dihydrodibenzo(b,e)thiepin-11-yl)thio)-N,N-dimethyl-, hydrochloride",C[NH+](C)CCSC1C2=CC=CC=C2CSC3=CC=CC=C13.[Cl-],,,,,,
1752,51753,"2-(6,11-dihydrobenzo[c][1]benzothiepin-11-ylsulfanyl)-N,N-dimethylethanamine",CN(C)CCSC1C2=CC=CC=C2CSC3=CC=CC=C13,,,,,,
1753,51754,Fenticonazole nitrate,C1=CC=C(C=C1)SC2=CC=C(C=C2)COC(CN3C=CN=C3)C4=C(C=C(C=C4)Cl)Cl.[N+](=O)(O)[O-],,,"['Substances that destroy fungi by suppressing their ability to grow or reproduce. They differ from FUNGICIDES, INDUSTRIAL because they defend against fungi present in human or animal tissues. (See all compounds classified as Antifungal Agents.)']",,,
1754,51755,Fenticonazole,C1=CC=C(C=C1)SC2=CC=C(C=C2)COC(CN3C=CN=C3)C4=C(C=C(C=C4)Cl)Cl,,,"['Substances that destroy fungi by suppressing their ability to grow or reproduce. They differ from FUNGICIDES, INDUSTRIAL because they defend against fungi present in human or animal tissues. (See all compounds classified as Antifungal Agents.)']",,,
1755,51756,"3,4-Dihydro-6,7-dimethoxy-1-((4,5-dimethoxy-2-iodo)benzyl)isoquinoline hydrochloride",COC1=C(C=C2C(=C1)CC[NH+]=C2CC3=CC(=C(C=C3I)OC)OC)OC.[Cl-],,,,,,
1756,51757,"1-(2-Iodo-4,5-dimethoxybenzyl)-3,4-dihydro-6,7-dimethoxyisoquinoline",COC1=C(C=C2C(=C1)CCN=C2CC3=CC(=C(C=C3I)OC)OC)OC,,,,,,
1757,51758,2-Methylthiane,CC1CCCCS1,,,,,,
1758,51759,"6,9-Difluoro-11-hydroxy-16-methyl-17-[(methylsulfanyl)carbonyl]-3-oxoandrosta-1,4-dien-17-yl propanoate",CCC(=O)O[C@@]1([C@@H](CC2[C@@]1(C[C@@H]([C@]3(C2C[C@@H](C4=CC(=O)C=CC43C)F)F)O)C)C)C(=O)SC,,,,,,
1759,51760,2-[Di(propan-2-yl)amino]ethylsulfanyl-methylphosphinic acid,CC(C)N(CCSP(=O)(C)O)C(C)C,,,,,,
1760,51761,"FORMALDEHYDE, mixt. with GUAIACOL",COC1=CC=CC=C1O.C=O,,,,,,
1761,51762,"N-(3,4-dimethyl-2,6-dinitrophenyl)-N-pentan-3-ylnitramide",CCC(CC)N(C1=C(C=C(C(=C1[N+](=O)[O-])C)C)[N+](=O)[O-])[N+](=O)[O-],,,,,,
1762,51763,Apraclonidine hydrochloride,C1CN=C(N1)NC2=C(C=C(C=C2Cl)N)Cl.Cl,,,['Compounds that bind to and activate ADRENERGIC ALPHA-2 RECEPTORS. (See all compounds classified as Adrenergic alpha-2 Receptor Agonists.)'],,,
1763,51764,"Benzamide, 3,5-dibromo-2,6-dimethoxy-N-(1-ethyl-2-pyrrolidinylmethyl)-, (R)-(+)-",CCN1CCC[C@@H]1CNC(=O)C2=C(C(=CC(=C2OC)Br)Br)OC,,,,,,
1764,51765,"(S)-(-)-2-((3,5-Dibromo-2,6-dimethoxybenzamido)methyl)-1-ethylpyrrolidine hydrochloride",CC[NH+]1CCC[C@H]1CNC(=O)C2=C(C(=CC(=C2OC)Br)Br)OC.[Cl-],,,,,,
1765,51766,"3,5-dibromo-N-[[(2S)-1-ethylpyrrolidin-2-yl]methyl]-2,6-dimethoxybenzamide",CCN1CCC[C@H]1CNC(=O)C2=C(C(=CC(=C2OC)Br)Br)OC,,,,,,
1766,51767,"(R)-(+)-2-((3-Bromo-2,6-dimethoxybenzamido)methyl)-1-ethylpyrrolidine hydrochloride",CC[NH+]1CCC[C@@H]1CNC(=O)C2=C(C=CC(=C2OC)Br)OC.[Cl-],,,,,,
1767,51768,"3-bromo-N-[[(2S)-1-ethylpyrrolidin-2-yl]methyl]-2,6-dimethoxy-benzamide",CCN1CCC[C@@H]1CNC(=O)C2=C(C=CC(=C2OC)Br)OC,,,,,,
1768,51769,"10-Amino-2-chloro-10,11-dihydrodibenzo(b,f)thiepin S-oxide methanesulfonate",CS(=O)(=O)[O-].C1C(C2=CC=CC=C2S(=O)C3=C1C=C(C=C3)Cl)[NH3+],,,,,,
1769,51770,CID 51770,C1C(C2=CC=CC=C2[S+](C3=C1C=C(C=C3)Cl)O)N,,,,,,
1770,51771,"2-(3-(Acetyloxy)-1-oxopropoxy)-N,N,N-trimethylethanaminium iodide",CC(=O)OCCC(=O)OCC[N+](C)(C)C.[I-],,,,,,
1771,51772,2-(3-Acetyloxypropanoyloxy)ethyl-trimethylazanium,CC(=O)OCCC(=O)OCC[N+](C)(C)C,,,,,,
1772,51773,"2-(3-(Acetyloxy)-1-oxobutoxy)-N,N,N-trimethylethanaminium iodide",CC(CC(=O)OCC[N+](C)(C)C)OC(=O)C.[I-],,,,,,
1773,51774,2-(3-Acetyloxybutanoyloxy)ethyl-trimethylazanium,CC(CC(=O)OCC[N+](C)(C)C)OC(=O)C,,,,,,
1774,51775,"2-(1-Oxo-2-((1-oxohexyl)oxy)propoxy)-N,N,N-trimethylethanaminium iodide",CCCCCC(=O)OC(C)C(=O)OCC[N+](C)(C)C.[I-],,,,,,
1775,51776,2-(2-Hexanoyloxypropanoyloxy)ethyl-trimethylazanium,CCCCCC(=O)OC(C)C(=O)OCC[N+](C)(C)C,,,,,,
1776,51777,2-(1-Oxo-2-((1-oxoheptyl)oxy)propoxy)ethanaminium iodide,CCCCCCC(=O)OC(C)C(=O)OCC[NH3+].[I-],,,,,,
1777,51778,[1-(2-Aminoethoxy)-1-oxopropan-2-yl] heptanoate,CCCCCCC(=O)OC(C)C(=O)OCCN,,,,,,
1778,51779,"2-(1-Oxo-2-((1-oxooctyl)oxy)propoxy)-N,N,N-trimethylethanaminium iodide",CCCCCCCC(=O)OC(C)C(=O)OCC[N+](C)(C)C.[I-],,,,,,
1779,51780,Trimethyl-[2-(2-octanoyloxypropanoyloxy)ethyl]azanium,CCCCCCCC(=O)OC(C)C(=O)OCC[N+](C)(C)C,,,,,,
1780,51781,CID 51781,C[N+]1(CC[C@]23[C@@H]4C(=O)CC[C@]2([C@@H]1CC5=C3C(=C(C=C5)O)O4)O)CC6CC6.[Br-],,,,,,
1781,51782,CID 51782,C[N+]1(CC[C@]23[C@@H]4C(=O)CC[C@]2([C@@H]1CC5=C3C(=C(C=C5)O)O4)O)CC6CC6,,,,,,
1782,51783,"6a-alpha-APORPHINE, 1,2,9,10-TETRAMETHOXY-, PHOSPHATE, dl-",C[NH+]1CCC2=CC(=C(C3=C2[C@@H]1CC4=CC(=C(C=C43)OC)OC)OC)OC.OP(=O)(O)[O-],,,,,,
1783,51784,CID 51784,C1C([C@@H](C(C1O)CC=CCC=CC(=O)O)C=C[C@H](COC2=CC(=CC=C2)Cl)O)O,,,,,,
1784,51785,CID 51785,COC(=O)CCCC=CCC1[C@H](C(CC1O)O)C=CC(COC2=CC=CC(=C2)C(F)(F)F)O,,,,,,
1785,51786,CID 51786,COC(=O)CCCC=CCC1[C@H](C(CC1O)O)C=C[C@H](C#CC2=CC(=CC=C2)Cl)O,,,,,,
1786,51787,CID 51787,COC(=O)CCCC=CCC1[C@H](C(CC1O)O)C=C[C@H](C#CC2=CC=C(C=C2)Cl)O,,,,,,
1787,51788,CID 51788,COC(=O)CCCC=CCC1[C@H](C(CC1O)O)C=C[C@H](C2=CC3=CC=CC=C3S2)O,,,,,,
1788,51789,CID 51789,COC(=O)CCCC=CCC1[C@H](C(CC1O)O)C=C[C@H](C2=CC3=CC=CC=C3O2)O,,,,,,
1789,51790,CID 51790,COC(=O)CCCC=CCC1[C@H](C(CC1O)O)C=C[C@H](CSC2=CCCCC2)O,,,,,,
1790,51791,CID 51791,C1C([C@@H](C(C1O)CC=CCCCC(=O)O)C=C[C@H](COC2=CC=CC(=C2)C(F)(F)F)O)O,,,,,,
1791,51792,"14-hydroxy-13-methyl-17-(6-oxopyran-3-yl)-3-[(2R,5S)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-1,2,3,6,7,8,9,11,12,15,16,17-dodecahydrocyclopenta[a]phenanthrene-10-carbaldehyde",CC12CCC3C(C1(CCC2C4=COC(=O)C=C4)O)CCC5=CC(CCC35C=O)O[C@H]6C(C([C@@H](C(O6)CO)O)O)O,,,,,,
1792,51793,Vinylbutonate,CCCC(=O)OC(=C(Cl)Cl)P(=O)(OC)OC,,,,,,
1793,51794,Metronidazole phosphate,CC1=NC=C(N1CCOP(=O)(O)O)[N+](=O)[O-],,,"['Substances that inhibit the growth or reproduction of BACTERIA. (See all compounds classified as Anti-Bacterial Agents.)', 'Substances that are destructive to protozoans. (See all compounds classified as Antiprotozoal Agents.)', 'Substances that prevent infectious agents or organisms from spreading or kill infectious agents in order to prevent the spread of infection. (See all compounds classified as Anti-Infective Agents.)']",,,
1794,51795,"Benzofuran, 2-mesityl-3-(p-anisoyl)-",CC1=CC(=C(C(=C1)C)C2=C(C3=CC=CC=C3O2)C(=O)C4=CC=C(C=C4)OC)C,,,,,,
1795,51796,p-Hydroxyphenyl 2-mesitylbenzofuran-4-yl ketone,CC1=CC(=C(C(=C1)C)C2=CC3=C(C=CC=C3O2)C(=O)C4=CC=C(C=C4)O)C,,,,,,
1796,51797,p-Hydroxyphenyl 2-mesitylbenzofuran-3-yl ketone,CC1=CC(=C(C(=C1)C)C2=C(C3=CC=CC=C3O2)C(=O)C4=CC=C(C=C4)O)C,,,,,,
1797,51798,"3,5-Diiodo-4-hydroxyphenyl 2-mesityl-3-benzofuranyl ketone",CC1=CC(=C(C(=C1)C)C2=C(C3=CC=CC=C3O2)C(=O)C4=CC(=C(C(=C4)I)O)I)C,,,,,,
1798,51799,"3,5-Dibromo-4-hydroxyphenyl 2-mesityl-3-benzofuranyl ketone",CC1=CC(=C(C(=C1)C)C2=C(C3=CC=CC=C3O2)C(=O)C4=CC(=C(C(=C4)Br)O)Br)C,,,,,,
1799,51800,"(6R,7R)-7-[[2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-3-[(2-methyl-5,6-dioxo-1H-1,2,4-triazin-3-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid",CN1C(=NC(=O)C(=O)N1)SCC2=C(N3[C@@H]([C@@H](C3=O)NC(=O)C(=NOC)C4=CSC(=N4)N)SC2)C(=O)O,,,,,,
1800,51801,4-Propyl-1-(bis(2-chloroethyl)amino)-2-heptyn-4-ol hydrochloride,CCCC(CCC)(C#CC[NH+](CCCl)CCCl)O.[Cl-],,,,,,
1801,51802,1-[Bis(2-chloroethyl)amino]-4-propylhept-2-yn-4-ol,CCCC(CCC)(C#CCN(CCCl)CCCl)O,,,,,,
1802,51803,Copper p-anisate,COC1=CC=C(C=C1)C(=O)[O-].COC1=CC=C(C=C1)C(=O)[O-].[Cu+2],,,,,,
1803,51804,4-(N-Butylnitrosamino)-4-hydroxybutyric acid lactone,CCCCN(C1CCC(=O)O1)N=O,,,,,,
1804,51805,Hydrazine Selenate,NN.O[Se](=O)(=O)O,,,,,,
1805,51806,3-Ethylheptane,CCCCC(CC)CC,,,,,,
1806,51807,"1H-Indole-3-acetic acid, 1-(4-chlorobenzoyl)-5-methoxy-2-methyl-, 3-((4-(benzoylamino)-5-(dipropylamino)-1,5-dioxopentyl)oxy)propyl ester, (+-)-",CCCN(CCC)C(=O)C(CCC(=O)OCCCOC(=O)CC1=C(N(C2=C1C=C(C=C2)OC)C(=O)C3=CC=C(C=C3)Cl)C)NC(=O)C4=CC=CC=C4,,,,,,
1807,51808,Disodium ZINC edetate,C(CN(CC(=O)[O-])CC(=O)[O-])N(CC(=O)[O-])CC(=O)[O-].[Na+].[Na+].[Zn+2],,,,,,
1808,51809,"1H-Indole-3-acetic acid, 1-(4-chlorobenzoyl)-5-methoxy-2-methyl-, 2-(4-(4-(benzoylamino)-5-(dipropylamino)-1,5-dioxopentyl)-1-piperazinyl)ethyl ester, (+-)-, ethanedioate (1:1)",CCCN(CCC)C(=O)C(CCC(=O)N1CC[NH+](CC1)CCOC(=O)CC2=C(N(C3=C2C=C(C=C3)OC)C(=O)C4=CC=C(C=C4)Cl)C)NC(=O)C5=CC=CC=C5.C(=O)(C(=O)[O-])O,,,,,,
1809,51810,2-[4-[4-Benzamido-5-(dipropylamino)-5-oxopentanoyl]piperazin-1-yl]ethyl 2-[1-(4-chlorobenzoyl)-5-methoxy-2-methylindol-3-yl]acetate,CCCN(CCC)C(=O)C(CCC(=O)N1CCN(CC1)CCOC(=O)CC2=C(N(C3=C2C=C(C=C3)OC)C(=O)C4=CC=C(C=C4)Cl)C)NC(=O)C5=CC=CC=C5,,,,,,
1810,51811,"1H-Indole-3-acetic acid, 1-(4-chlorobenzoyl)-5-methoxy-2-methyl-, 3-((4-(benzoylamino)-5-(dipropylamino)-1,5-dioxopentyl)amino)propyl ester, (+-)-",CCCN(CCC)C(=O)C(CCC(=O)NCCCOC(=O)CC1=C(N(C2=C1C=C(C=C2)OC)C(=O)C3=CC=C(C=C3)Cl)C)NC(=O)C4=CC=CC=C4,,,,,,
1811,51812,"1H-Indole-3-acetic acid, 1-(4-chlorobenzoyl)-5-methoxy-2-methyl-, 3-(4-(2-hydroxyethyl)-1-piperazinyl)propyl ester, ethanedioate (1:2) (salt)",CC1=C(C2=C(N1C(=O)C3=CC=C(C=C3)Cl)C=CC(=C2)OC)CC(=O)OCCCN4CCN(CC4)CCO.C(=O)(C(=O)O)O.C(=O)(C(=O)O)O,,,,,,
1812,51813,3-[4-(2-Hydroxyethyl)piperazin-1-yl]propyl 2-[1-(4-chlorobenzoyl)-5-methoxy-2-methylindol-3-yl]acetate,CC1=C(C2=C(N1C(=O)C3=CC=C(C=C3)Cl)C=CC(=C2)OC)CC(=O)OCCCN4CCN(CC4)CCO,,,,,,
1813,51814,9-Cyclohexyl-2-n-propoxy-9H-adenine,CCCOC1=NC(=C2C(=N1)N(C=N2)C3CCCCC3)N,,,,,,
1814,51815,"Malononitrile, (piperidinomethylene)-",C1CCN(CC1)C=C(C#N)C#N,,,,,,
1815,51816,"Malononitrile, (1-pyrrolidinylmethylene)-",C1CCN(C1)C=C(C#N)C#N,,,,,,
1816,51817,2-Nonynenitrile,CCCCCCC#CC#N,,,,,,
1817,51818,BENZ(c)ACRIDINE-7-METHANOL,C1=CC=C2C(=C1)C=CC3=C(C4=CC=CC=C4N=C32)CO,,,,,['BENZ(c)ACRIDINE-7-METHANOL is a known human metabolite of 7-methylbenz(c)acridine.'],
1818,51819,CID 51819,C1CS(=O)(=O)C2=C(C=C(C=C2)Cl)C(=O)C1=C(NC3=CC(=C(C=C3)Cl)Cl)[O-].[Na+],,,,,,
1819,51820,CID 51820,C1CS(=O)(=O)C2=C(C=C(C=C2)Cl)C(=O)C1=C(NC3=CC(=C(C=C3)Cl)Cl)O,,,,,,
1820,51821,"2,3',4,5'-Tetrachlorobiphenyl",C1=CC(=C(C=C1Cl)Cl)C2=CC(=CC(=C2)Cl)Cl,,,,,,
1821,51822,"2,2',3,4,6'-Pentachlorobiphenyl",C1=CC(=C(C(=C1)Cl)C2=C(C(=C(C=C2)Cl)Cl)Cl)Cl,,,,,,
1822,51823,"1,4-Bis(p-phenoxyanilino)anthraquinone",C1=CC=C(C=C1)OC2=CC=C(C=C2)NC3=C4C(=C(C=C3)NC5=CC=C(C=C5)OC6=CC=CC=C6)C(=O)C7=CC=CC=C7C4=O,,,,,,
1823,51824,"Ethanone, 1-(1-chloro-3-adamantyl)-2-hydroxy-",C1C2CC3(CC1CC(C2)(C3)Cl)C(=O)CO,,,,,,
1824,51825,"Ethanone, 1-(1-bromo-3-adamantyl)-2-hydroxy-",C1C2CC3(CC1CC(C2)(C3)Br)C(=O)CO,,,,,,
1825,51826,"Ethanone, 2-hydroxy-1-(1-iodo-3-adamantyl)-",C1C2CC3(CC1CC(C2)(C3)I)C(=O)CO,,,,,,
1826,51827,"Ethanone, 2-hydroxy-1-(1-phenyl-3-adamantyl)-",C1C2CC3(CC1CC(C2)(C3)C(=O)CO)C4=CC=CC=C4,,,,,,
1827,51828,"Ethanone, 1-(1-bromo-3-adamantyl)-2-ethoxy-",CCOCC(=O)C12CC3CC(C1)CC(C3)(C2)Br,,,,,,
1828,51829,CID 51829,C1C2CC3(CC1CC(C2)(C3)I)C(=NO)CO,,,,,,
1829,51830,"3-ADAMANTANECARBOXYLIC ACID, m-TOLYL ESTER",CC1=CC(=CC=C1)OC(=O)C23CC4CC(C2)CC(C4)C3,,,,,,
1830,51831,CID 51831,CCCCCCCCC(C)C1=CC=C(C=C1)S(=O)(=O)[O-].[Na+],,,,,,
1831,51832,9-(4-Sulfophenyl)decane,CCCCCCCCC(C)C1=CC=C(C=C1)S(=O)(=O)O,,,,,,
1832,51833,CID 51833,CCCCCC(CCCC)C1=CC=C(C=C1)S(=O)(=O)[O-].[Na+],,,,,,
1833,51834,4-(1-Butylhexyl)benzenesulfonic acid,CCCCCC(CCCC)C1=CC=C(C=C1)S(=O)(=O)O,,,,,,
1834,51835,"2(3H)-Benzoxazolone, 3-acetyl-5-bromo-",CC(=O)N1C2=C(C=CC(=C2)Br)OC1=O,,,,,,
1835,51836,5-Chloro-3-(phenyl-1-piperidinylmethyl)-2(3H)-benzoxazolone,C1CCN(CC1)C(C2=CC=CC=C2)N3C4=C(C=CC(=C4)Cl)OC3=O,,,,,,
1836,51837,2-(Dibutylamino)-2-phenylacetic acid ethyl ester hydrochloride,CCCC[NH+](CCCC)C(C1=CC=CC=C1)C(=O)OCC.[Cl-],,,,,,
1837,51838,Ethyl 2-(dibutylamino)-2-phenylacetate,CCCCN(CCCC)C(C1=CC=CC=C1)C(=O)OCC,,,,,,
1838,51839,2-(Dibutylamino)-2-phenylacetic acid hydrochloride,CCCC[NH+](CCCC)C(C1=CC=CC=C1)C(=O)O.[Cl-],,,,,,
1839,51840,2-(Dibutylamino)-2-phenylacetic acid,CCCCN(CCCC)C(C1=CC=CC=C1)C(=O)O,,,,,,
1840,51841,"2,4-Dichlorophenylsulfinylacetic acid",C1=CC(=C(C=C1Cl)Cl)S(=O)CC(=O)O,,,,,,
1841,51842,2-(2-(Diethylamino)ethoxy)-2-phenylacetic acid ethyl ester hydrochloride,CC[NH+](CC)CCOC(C1=CC=CC=C1)C(=O)OCC.[Cl-],,,,,,
1842,51843,Ethyl 2-[2-(diethylamino)ethoxy]-2-phenylacetate,CCN(CC)CCOC(C1=CC=CC=C1)C(=O)OCC,,,,,,
1843,51844,CID 51844,COC(=O)C(=C1C(=O)C(=C(O1)O)C2=CC=CC=C2)C3=CC=CC=C3,,,,,,
1844,51845,"2-(3,5-Diiodo-4-hydroxyphenoxy)-2-(3,5-diiodophenyl)acetic acid aminodiethanol",C1=C(C=C(C=C1I)I)C(C(=O)O)OC2=CC(=C(C(=C2)I)O)I.C(CO)NCCO,,,,,,
1845,51846,"2-(3,5-Diiodophenyl)-2-(4-hydroxy-3,5-diiodophenoxy)acetic acid",C1=C(C=C(C=C1I)I)C(C(=O)O)OC2=CC(=C(C(=C2)I)O)I,,,,,,
1846,51847,"5-(Diethylamino)-1-pentyl 2,2-diphenylacetate hydrochloride",CC[NH+](CC)CCCCCOC(=O)C(C1=CC=CC=C1)C2=CC=CC=C2.[Cl-],,,,,,
1847,51848,"5-(Diethylamino)pentyl 2,2-diphenylacetate",CCN(CC)CCCCCOC(=O)C(C1=CC=CC=C1)C2=CC=CC=C2,,,,,,
1848,51849,(1-Imino-2-phenyl)ethylthioacetic acid hydrochloride,C1=CC=C(C=C1)CC(=[NH2+])SCC(=O)O.[Cl-],,,,,,
1849,51850,2-(2-Phenylethanimidoyl)sulfanylacetic acid,C1=CC=C(C=C1)CC(=N)SCC(=O)O,,,,,,
1850,51851,"ACETIC ACID, (p-((4-METHYL-9-ACRIDINYL)AMINO)PHENYL)-, HEMIHYDRATE",CC1=CC=CC2=C(C3=CC=CC=C3N=C12)NC4=CC=C(C=C4)CC(=O)O.CC1=CC=CC2=C(C3=CC=CC=C3N=C12)NC4=CC=C(C=C4)CC(=O)O.O,,,,,,
1851,51852,2-[4-[(4-Methylacridin-9-yl)amino]phenyl]acetic acid,CC1=CC=CC2=C(C3=CC=CC=C3N=C12)NC4=CC=C(C=C4)CC(=O)O,,,,,,
1852,51853,2-(alpha-Methyl-m-trifluoromethylphenethylamino)acetic acid hydrazide,CC(CC1=CC(=CC=C1)C(F)(F)F)NCC(=O)NN,,,,,,
1853,51854,"ACETIC ACID, PHENOXY-, p-BROMOPHENACYL ESTER",C1=CC=C(C=C1)OCC(=O)OCC(=O)C2=CC=C(C=C2)Br,,,,,,
1854,51855,"3,4-Di(acetylthiomethyl)-5-hydroxy-6-methylpyridine hydrobromide",CC1=[NH+]C=C(C(=C1O)CSC(=O)C)CSC(=O)C.[Br-],,,,,,
1855,51856,"3-Pyridinol, 4,5-bis(acetylthiomethyl)-2-methyl-",CC1=NC=C(C(=C1O)CSC(=O)C)CSC(=O)C,,,,,,
1856,51857,"N-(1,4-Dimethylpentyl)-acetoacetamide",CC(C)CCC(C)NC(=O)CC(=O)C,,,,,,
1857,51858,"1'-Acetonaphthone, 4'-(acetonyloxy)-2-chloro-",CC(=O)COC1=CC=C(C2=CC=CC=C21)C(=O)CCl,,,,,,
1858,51859,"3-(4-Acetyl-1-naphthyloxy)-1,2-propanediol",CC(=O)C1=CC=C(C2=CC=CC=C21)OCC(CO)O,,,,,,
1859,51860,1-(4-Ethoxyacetyl-1-naphthyloxy)-2-propanol,CCOCC(=O)C1=CC=C(C2=CC=CC=C21)OCC(C)O,,,,,,
1860,51861,"3-Butanol, 1-(4-acetyl-1-naphthyloxy)-",CC(CCOC1=CC=C(C2=CC=CC=C21)C(=O)C)O,,,,,,
1861,51862,4-(4-Acetyl-1-naphthyloxy)-2-butyn-1-ol,CC(=O)C1=CC=C(C2=CC=CC=C21)OCC#CCO,,,,,,
1862,51863,"2-Propanol, 1-(4-hydroxyacetyl-1-naphthyloxy)-",CC(COC1=CC=C(C2=CC=CC=C21)C(=O)CO)O,,,,,,
1863,51864,"1'-Acetonaphthone, 2-methoxy-4'-(2-oxobutoxy)-",CCC(=O)COC1=CC=C(C2=CC=CC=C21)C(=O)COC,,,,,,
1864,51865,"1'-Acetonaphthone, 4'-(2-oxobutoxy)-",CCC(=O)COC1=CC=C(C2=CC=CC=C21)C(=O)C,,,,,,
1865,51866,CID 51866,CCCN=C(S)SC1=CC=CC=C1,,,,,,
1866,51867,"Dibenzyl toluene-2,4-dicarbamate",CC1=C(C=C(C=C1)NC(=O)OCC2=CC=CC=C2)NC(=O)OCC3=CC=CC=C3,,,,,,
1867,51868,CID 51868,CCCCSC(=O)NC=CNC(=O)SCCCC,,,,,,
1868,51869,S-dodecyl N-[2-(dodecylsulfanylcarbonylamino)ethenyl]carbamothioate,CCCCCCCCCCCCSC(=O)NC=CNC(=O)SCCCCCCCCCCCC,,,,,,
1869,51870,CID 51870,C1=CC=C(C=C1)SC(=O)NC=CNC(=O)SC2=CC=CC=C2,,,,,,
1870,51871,S-(2-methylphenyl) N-[2-[(2-methylphenyl)sulfanylcarbonylamino]ethenyl]carbamothioate,CC1=CC=CC=C1SC(=O)NC=CNC(=O)SC2=CC=CC=C2C,,,,,,
1871,51872,CID 51872,C1=CC(=C(C=C1Cl)Cl)OC(=O)NC=CNC(=O)OC2=C(C=C(C=C2)Cl)Cl,,,,,,
1872,51873,CID 51873,CCCCC(CC)COC(=O)NC=CNC(=O)OCC(CC)CCCC,,,,,,
1873,51874,(4-nitrophenyl)methyl N-[2-[(4-nitrophenyl)methoxycarbonylamino]ethenyl]carbamate,C1=CC(=CC=C1COC(=O)NC=CNC(=O)OCC2=CC=C(C=C2)[N+](=O)[O-])[N+](=O)[O-],,,,,,
1874,51875,CID 51875,C1=CC=C(C=C1)NNC2=CC=C(C=C2)OC(=O)N=CC=NC(=O)OC3=CC=C(C=C3)N=NC4=CC=CC=C4,,,,,,
1875,51876,CID 51876,C1=CN=CC=C1CCCOC(=O)NC=CNC(=O)OCCCC2=CC=NC=C2,,,,,,
1876,51877,"(2,4,5-trichlorophenyl) N-[2-[(2,4,5-trichlorophenoxy)carbonylamino]ethenyl]carbamate",C1=C(C(=CC(=C1Cl)Cl)Cl)OC(=O)NC=CNC(=O)OC2=CC(=C(C=C2Cl)Cl)Cl,,,,,,
1877,51878,"(2,4,6-triiodophenyl) N-[2-[(2,4,6-triiodophenoxy)carbonylamino]ethenyl]carbamate",C1=C(C=C(C(=C1I)OC(=O)NC=CNC(=O)OC2=C(C=C(C=C2I)I)I)I)I,,,,,,
1878,51879,CID 51879,CCCCCCCCCCCCCCCCCC(=O)OC(=O)NC=CNC(=O)OC(=O)CCCCCCCCCCCCCCCCC,,,,,,
1879,51880,CID 51880,C(C(=O)OC(=O)NC=CNC(=O)OC(=O)CI)I,,,,,,
1880,51881,CID 51881,C(CI)C(=O)OC(=O)NC=CNC(=O)OC(=O)CCI,,,,,,
1881,51882,CID 51882,C1=CC=C(C=C1)OCC(=O)OC(=O)NC=CNC(=O)OC(=O)COC2=CC=CC=C2,,,,,,
1882,51883,"2-[(2,2,2-Trichloroacetyl)oxycarbonylamino]ethenylcarbamoyl 2,2,2-trichloroacetate",C(=CNC(=O)OC(=O)C(Cl)(Cl)Cl)NC(=O)OC(=O)C(Cl)(Cl)Cl,,,,,,
1883,51884,dodecyl N-[2-(dodecoxycarbonylamino)ethenyl]carbamate,CCCCCCCCCCCCOC(=O)NC=CNC(=O)OCCCCCCCCCCCC,,,,,,
1884,51885,prop-2-ynyl N-[2-(prop-2-ynoxycarbonylamino)ethenyl]carbamate,C#CCOC(=O)NC=CNC(=O)OCC#C,,,,,,
1885,51886,"Carbanilic acid, 1-carboxyethyl ester",CC(C(=O)O)OC(=O)NC1=CC=CC=C1,,,,,,
1886,51887,CID 51887,C1=CC=NC(=C1)C(=C(C2=CC=CC=N2)OC(=O)NC3=CC=C(C=C3)Cl)OC(=O)NC4=CC=C(C=C4)Cl,,,,,,
1887,51888,m-Chlorocarbanilic acid 2-(diethylamino)ethyl ester hydrochloride,CC[NH+](CC)CCOC(=O)NC1=CC(=CC=C1)Cl.[Cl-],,,,,,
1888,51889,2-(Diethylamino)ethyl 3-chlorophenylcarbamate,CCN(CC)CCOC(=O)NC1=CC(=CC=C1)Cl,,,,,,
1889,51890,CID 51890,C1=CC(=CC=C1NC(=O)OCC(=CI)I)Cl,,,,,,
1890,51891,"p-Chlorocarbanilic acid 2,2,2-trichloroacetimidoylamino ester",C1=CC(=CC=C1NC(=O)ON=C(C(Cl)(Cl)Cl)N)Cl,,,,,,
1891,51892,3-(Dibutylamino)-2-hydroxypropyl carbanilate hydrochloride,CCCC[NH+](CCCC)CC(COC(=O)NC1=CC=CC=C1)O.[Cl-],,,,,,
1892,51893,[3-(dibutylamino)-2-hydroxypropyl] N-phenylcarbamate,CCCCN(CCCC)CC(COC(=O)NC1=CC=CC=C1)O,,,,,,
1893,51894,"Carbanilic acid, 2,5-dichloro-, 2-mercaptoethyl ester",C1=CC(=C(C=C1Cl)NC(=O)OCCS)Cl,,,,,,
1894,51895,3-(Diisobutylamino)-2-hydroxypropyl carbanilate hydrochloride,CC(C)C[NH+](CC(C)C)CC(COC(=O)NC1=CC=CC=C1)O.[Cl-],,,,,,
1895,51896,[3-[bis(2-methylpropyl)amino]-2-hydroxypropyl] N-phenylcarbamate,CC(C)CN(CC(C)C)CC(COC(=O)NC1=CC=CC=C1)O,,,,,,
1896,51897,N-Methyl-N-(o-tolyl)carbamic acid isopropyl ester,CC1=CC=CC=C1N(C)C(=O)OC(C)C,,,,,,
1897,51898,3-(Dipropylamino)-2-hydroxypropyl carbanilate hydrochloride,CCC[NH+](CCC)CC(COC(=O)NC1=CC=CC=C1)O.[Cl-],,,,,,
1898,51899,[3-(dipropylamino)-2-hydroxypropyl] N-phenylcarbamate,CCCN(CCC)CC(COC(=O)NC1=CC=CC=C1)O,,,,,,
1899,51900,CID 51900,CNC(=O)OC1=CC=CC(=C1)N=C(S)SC,,,,,,
1900,51901,CID 51901,C1=CC(=CC(=C1)[N+](=O)[O-])N=C(S)SCC(=O)O,,,,,,
1901,51902,CID 51902,C1=CC(=CC=C1N=C(S)SCC(=O)O)[N+](=O)[O-],,,,,,
1902,51903,p-Ethoxycarbanilic acid isopropyl ester,CCOC1=CC=C(C=C1)NC(=O)OC(C)C,,,,,,
1903,51904,"p-Ethoxycarbanilic acid 2,2,2-trichloroacetimidoylamino ester",CCOC1=CC=C(C=C1)NC(=O)ON=C(C(Cl)(Cl)Cl)N,,,,,,
1904,51905,"CARBANILIC ACID, m-HYDROXY-, ALLYL ESTER",C=CCOC(=O)NC1=CC(=CC=C1)O,,,,,,
1905,51906,"CARBANILIC ACID, m-HYDROXY-, ISOPENTYL ESTER",CC(C)CCOC(=O)NC1=CC(=CC=C1)O,,,,,,
1906,51907,Isopropyl N-isopentyl-N-phenylcarbamate,CC(C)CCN(C1=CC=CC=C1)C(=O)OC(C)C,,,,,,
1907,51908,"CARBANILIC ACID, p-METHOXY-, 2-MERCAPTOETHYL ESTER",COC1=CC=C(C=C1)NC(=O)OCCS,,,,,,
1908,51909,"CARBANILIC ACID, (p-METHOXY)THIO-, S-(2-HYDROXYETHYL) ESTER",COC1=CC=C(C=C1)NC(=O)SCCO,,,,,,
1909,51910,"CARBANILIC ACID, p-METHYL-, 4-THIOCYANATO-2-BUTYNYL ESTER",CC1=CC=C(C=C1)NC(=O)OCC#CCSC#N,,,,,,
1910,51911,"Carbanilic acid, 4-thiocyanato-2-butynyl ester",CC#CCOC(=O)NC1=CC=C(C=C1)SC#N,,,,,,
1911,51912,CID 51912,CC[NH+](CC)CCOC(=NC1=CC=CC=C1)S.[Cl-],,,,,,
1912,51913,CID 51913,CCN(CC)CCOC(=NC1=CC=CC=C1)S,,,,,,
1913,51914,CID 51914,CC1=CC=CC=C1C(C2=CC=CC=C2)OCCON(C)CC(=NO)[NH3+].C(=CC(=O)[O-])C(=O)O,,,,,,
1914,51915,CID 51915,CC1=CC=CC=C1C(C2=CC=CC=C2)OCCON(C)CC(=NO)N,,,,,,
1915,51916,2-Phenyl-2-piperidinoacetamide hydrochloride,C1CC[NH+](CC1)C(C2=CC=CC=C2)C(=O)N.[Cl-],,,,,,
1916,51917,2-Phenyl-2-piperidinoacetamide,C1CCN(CC1)C(C2=CC=CC=C2)C(=O)N,,,,,,
1917,51918,"ACETAMIDE, 2-(p-TOLYLTHIO)-",CC1=CC=C(C=C1)SCC(=O)N,,,,,,
1918,51919,2-(p-Nitrophenyl)acetamide O-benzoyl oxime,C1=CC=C(C=C1)C(=O)ON=C(CC2=CC=C(C=C2)[N+](=O)[O-])N,,,,,,
1919,51920,"Acetanilide, 4'-(N-(6-amino-1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl)carbamoyl)-",CC(=O)NC1=CC=C(C=C1)C(=O)NC2=C(N(C(=O)N(C2=O)C)C)N,,,,,,
1920,51921,"Acetanilide, 2',4'-bis(2-chloroacetamido)-",CC(=O)NC1=C(C=C(C=C1)NC(=O)CCl)NC(=O)CCl,,,,,,
1921,51922,"ACETANILIDE, 2',4'-BIS(alpha-IODOACETAMIDO)-",CC(=O)NC1=C(C=C(C=C1)NC(=O)CI)NC(=O)CI,,,,,,
1922,51923,"2',4'-Dibromo-2-iodoacetanilide",C1=CC(=C(C=C1Br)Br)NC(=O)CI,,,,,,
1923,51924,"2',6'-Dichloro-2-methylaminoacetanilide",CNCC(=O)NC1=C(C=CC=C1Cl)Cl,,,,,,
1924,51925,"2',6'-Dichloro-2-pyrrolidinoacetanilide",C1CC(NC1)CC(=O)NC2=C(C=CC=C2Cl)Cl,,,,,,
1925,51926,CID 51926,CC(=O)N(C1NC(CS1)C=NNC2=C(C=C(C=C2)[N+](=O)[O-])[N+](=O)[O-])C3=CC=CC=C3,,,,,,
1926,51927,"Acetanilide, 2-iodo-2',4',6'-trichloro-",C1=C(C=C(C(=C1Cl)NC(=O)CI)Cl)Cl,,,,,,
1927,51928,(p-Aminophenyl)acetic acid isopentyl ester hydrochloride,CC(C)CCOC(=O)CC1=CC=C(C=C1)[NH3+].[Cl-],,,,,,
1928,51929,3-Methylbutyl 2-(4-aminophenyl)acetate,CC(C)CCOC(=O)CC1=CC=C(C=C1)N,,,,,,
1929,51930,2-Amino-2-phenylacetic acid 3-pentyl ester hydrochloride,CCC(CC)OC(=O)C(C1=CC=CC=C1)[NH3+].[Cl-],,,,,,
1930,51931,Pentan-3-yl 2-amino-2-phenylacetate,CCC(CC)OC(=O)C(C1=CC=CC=C1)N,,,,,,
1931,51932,2-Benzimidazolylsulfonylacetic acid,C1=CC=C2C(=C1)NC(=N2)S(=O)(=O)CC(=O)O,,,,,,
1932,51933,Methyl 2-chloroethylthioacetate,COC(=O)CSCCCl,,,,,,
1933,51934,"Acetic acid, ((2-chloro-1-naphthyl)oxy)-",C1=CC=C2C(=C1)C=CC(=C2OCC(=O)O)Cl,,,,,,
1934,51935,(p-Nitrophenyl)trimethylammonium iodide,C[N+](C)(C)C1=CC=C(C=C1)[N+](=O)[O-].[I-],,,,,,
1935,51936,"AMMONIUM, OCTADECYLTRIMETHYL-, p-CHLOROPHENYLSULFONATE",CCCCCCCCCCCCCCCCCC[N+](C)(C)C.C1=CC(=CC=C1S(=O)(=O)[O-])Cl,,,,,,
1936,51937,Octadecyltrimethylammonium tetrafluoroborate,[B-](F)(F)(F)F.CCCCCCCCCCCCCCCCCC[N+](C)(C)C,,,,,,
1937,51938,"Ammonium, bicarbamoylditrimethylenebis((p-chlorobenzyl)diethyl-, dichloride",CC[N+](CC)(CCCNC(=O)C(=O)NCCC[N+](CC)(CC)CC1=CC=C(C=C1)Cl)CC2=CC=C(C=C2)Cl.[Cl-].[Cl-],,,,,,
1938,51939,(4-Chlorophenyl)methyl-[3-[[2-[3-[(4-chlorophenyl)methyl-diethylazaniumyl]propylamino]-2-oxoacetyl]amino]propyl]-diethylazanium,CC[N+](CC)(CCCNC(=O)C(=O)NCCC[N+](CC)(CC)CC1=CC=C(C=C1)Cl)CC2=CC=C(C=C2)Cl,,,,,,
1939,51940,CID 51940,C[N+](C)(C)CC=NO.[I-],,,,,,
1940,51941,2-Hydroxyiminoethyl(trimethyl)azanium,C[N+](C)(C)CC=NO,,,,,,
1941,51942,"Ammonium, tetramethyl-, benzothiazole-2-mercaptide",C[N+](C)(C)C.C1=CC=C2C(=C1)N=C(S2)[S-],,,,,,
1942,51943,Tetrapropargylammonium bromide,C#CC[N+](CC#C)(CC#C)CC#C.[Br-],,,,,,
1943,51944,Tetrapropargyl ammonium,C#CC[N+](CC#C)(CC#C)CC#C,,,,,,
1944,51945,"AMMONIUM, (p-TOLYL)TRIETHYL-, IODIDE",CC[N+](CC)(CC)C1=CC=C(C=C1)C.[I-],,,,,,
1945,51946,"Benzenaminium, N,N,N-triethyl-4-methyl-",CC[N+](CC)(CC)C1=CC=C(C=C1)C,,,,,,
1946,51947,"Ammonium, (2-(3,4,5-trimethoxybenzamido)ethyl)trimethyl-, bromide",C[N+](C)(C)CCNC(=O)C1=CC(=C(C(=C1)OC)OC)OC.[Br-],,,,,,
1947,51948,"Trimethyl-[2-[(3,4,5-trimethoxybenzoyl)amino]ethyl]azanium",C[N+](C)(C)CCNC(=O)C1=CC(=C(C(=C1)OC)OC)OC,,,,,,
1948,51949,"2,4,6-Tris(beta-trimethylammoniumethyl)-s-trioxane trichloride",C[N+](C)(C)CCC1OC(OC(O1)CC[N+](C)(C)C)CC[N+](C)(C)C.[Cl-].[Cl-].[Cl-],,,,,,
1949,51950,"2-[4,6-Bis[2-(trimethylazaniumyl)ethyl]-1,3,5-trioxan-2-yl]ethyl-trimethylazanium",C[N+](C)(C)CCC1OC(OC(O1)CC[N+](C)(C)C)CC[N+](C)(C)C,,,,,,
1950,51951,"2,4-Bis(2-methylphenoxy)aniline",CC1=CC=CC=C1OC2=CC(=C(C=C2)N)OC3=CC=CC=C3C,,,,,,
1951,51952,"N,p-Bis(phenylthiomethyl)-N-methylaniline",CN(CSC1=CC=CC=C1)C2=CC=C(C=C2)CSC3=CC=CC=C3,,,,,,
1952,51953,"N-(1,2-Dichloro-2,2-diphenylethylidene)-4-(methylsulfonyl)aniline",CS(=O)(=O)C1=CC=C(C=C1)N=C(C(C2=CC=CC=C2)(C3=CC=CC=C3)Cl)Cl,,,,,,
1953,51954,"Aniline, N-(1,2-dichloro-2,2-diphenylethylidene)-4-nitro-",C1=CC=C(C=C1)C(C2=CC=CC=C2)(C(=NC3=CC=C(C=C3)[N+](=O)[O-])Cl)Cl,,,,,,
1954,51955,"ANILINE, N,N-DIMETHYL-p-(N-(2-METHOXYETHYL)FORMIMIDOYL)-",CN(C)C1=CC=C(C=C1)C=NCCOC,,,,,,
1955,51956,"N-Sulfinyl-2,4,5-trichloroaniline",C1=C(C(=CC(=C1Cl)Cl)Cl)N=S=O,,,,,,
1956,51957,"p-ANISALDEHYDE, 2-CHLOROMETHYL-",COC1=CC(=C(C=C1)C=O)CCl,,,,,,
1957,51958,CID 51958,COC1=CC=C(C=C1)C(=NO)[NH3+].[I-],,,,,,
1958,51959,2-Hydrazinylidene-1-(4-methoxyphenyl)ethanone,COC1=CC=C(C=C1)C(=O)C=NN,,,,,,
1959,51960,"9-Acetyl-1,7,8-anthracenetriol",CC(=O)C1=C2C(=CC3=C1C(=C(C=C3)O)O)C=CC=C2O,,,,,,
1960,51961,"Ammonium, tetramethyl-, dibromochloride",C[N+](C)(C)C.[Cl-](Br)Br,,,,,,
1961,51962,CID 51962,[Cl-](Br)Br,,,,,,
1962,51963,1-(4-Methoxyacetyl-1-naphthyloxy)-2-propanol-,CC(COC1=CC=C(C2=CC=CC=C21)C(=O)COC)O,,,,,,
1963,51964,Copper disodium ethylenediaminetetraacetate,C(CN(CC(=O)[O-])CC(=O)[O-])N(CC(=O)[O-])CC(=O)[O-].[Na+].[Na+].[Cu+2],,,,,,
1964,51965,Disodium manganese ethylenediaminetetraacetate,C(CN(CC(=O)[O-])CC(=O)[O-])N(CC(=O)[O-])CC(=O)[O-].[Na+].[Na+].[Mn+2],,,,,,
1965,51966,"2,2-Dimethyl-4-(chloromethyl)-1,3-dioxa-2-silacyclopentane",C[Si]1(OCC(O1)CCl)C,,,,,,
1966,51967,"1,1'-Dipropyl-4,4'-bipyridinium dichloride",CCC[N+]1=CC=C(C=C1)C2=CC=[N+](C=C2)CCC.[Cl-].[Cl-],,,,,,
1967,51968,CID 51968,CCCCC(CC=C[C@@H]1[C@H](C(=O)CC1O)CC=CCCCC(=O)OC)(C=C)O,,,,,,
1968,51969,1-(4-chloro-2-nitrophenyl)-N-phenylmethanimine oxide,C1=CC=C(C=C1)[N+](=CC2=C(C=C(C=C2)Cl)[N+](=O)[O-])[O-],,,,,,
1969,51970,"ANILINE, N-(((p-CHLOROPHENYL)THIO)METHYL)-m-NITRO-",C1=CC(=CC(=C1)[N+](=O)[O-])NCSC2=CC=C(C=C2)Cl,,,,,,
1970,51971,9-(4-Methylanilino)-acridine,CC1=CC=C(C=C1)NC2=C3C=CC=CC3=NC4=CC=CC=C42,,,,,,
1971,51972,4'-(9-Acridinylamino)acetophenone,CC(=O)C1=CC=C(C=C1)NC2=C3C=CC=CC3=NC4=CC=CC=C42,,,,,,
1972,51973,1-(4-Acetyl-1-naphthyloxy)-2-hexanone,CCCCC(=O)COC1=CC=C(C2=CC=CC=C21)C(=O)C,,,,,,
1973,51974,1-(4-Acetyl-1-naphthyloxy)-2-pentanone,CCCC(=O)COC1=CC=C(C2=CC=CC=C21)C(=O)C,,,,,,
1974,51975,1-(4-Acetyl-1-naphthyloxy)-3-pentanone,CCC(=O)CCOC1=CC=C(C2=CC=CC=C21)C(=O)C,,,,,,
1975,51976,"2'-Acetonaphthone, 6'-(2-oxopropoxy)-",CC(=O)COC1=CC2=C(C=C1)C=C(C=C2)C(=O)C,,,,,,
1976,51977,[4-[Cyano(4-fluorophenyl)methyl]phenyl]ammonium chloride,C1=CC(=CC=C1C(C#N)C2=CC=C(C=C2)F)[NH3+].[Cl-],,,,,,
1977,51978,4-Amino-alpha-(4-fluorophenyl)benzeneacetonitrile,C1=CC(=CC=C1C(C#N)C2=CC=C(C=C2)F)N,,,,,,
1978,51979,(p-Aminophenyl)(p-anisyl)acetonitrile hydrochloride,COC1=CC=C(C=C1)C(C#N)C2=CC=C(C=C2)[NH3+].[Cl-],,,,,,
1979,51980,2-(4-Aminophenyl)-2-(4-methoxyphenyl)acetonitrile,COC1=CC=C(C=C1)C(C#N)C2=CC=C(C=C2)N,,,,,,
1980,51981,"ACETONITRILE, (p-AMINOPHENYL)(p-TOLYL)-, HYDROCHLORIDE",CC1=CC=C(C=C1)C(C#N)C2=CC=C(C=C2)[NH3+].[Cl-],,,,,,
1981,51982,4-Amino-alpha-(4-methylphenyl)benzeneacetonitrile,CC1=CC=C(C=C1)C(C#N)C2=CC=C(C=C2)N,,,,,,
1982,51983,"Acetoacetonitrile, 4-(N-methylanilino)-2-phenyl-",CN(CC(=O)C(C#N)C1=CC=CC=C1)C2=CC=CC=C2,,,,,,
1983,51984,"(1,1,3-Trimethylbutylamino)acetonitrile hydrochloride",CC(C)CC(C)(C)[NH2+]CC#N.[Cl-],,,,,,
1984,51985,"2-(2,4-Dimethylpentan-2-ylamino)acetonitrile",CC(C)CC(C)(C)NCC#N,,,,,,
1985,51986,"3-[4-(N-hydroxy-C-methylcarbonimidoyl)phenoxy]propane-1,2-diol",CC(=NO)C1=CC=C(C=C1)OCC(CO)O,,,,,,
1986,51987,"o-ACETOTOLUIDIDE, 2-IODO-",CC1=CC=CC=C1NC(=O)CI,,,,,,
1987,51988,"Acetylenedicarboxamide, hemihydrate",C(#CC(=O)N)C(=O)N.C(#CC(=O)N)C(=O)N.O,,,,,,
1988,51989,"Acridine, 3-chloro-9-(4-hydroxy-3-piperidinomethylanilino)-7-methoxy-, 10-oxide",COC1=CC2=C(C=C1)N(C3=C(C2=NC4=CC(=C(C=C4)O)CN5CCCCC5)C=CC(=C3)Cl)O,,,,,,
1989,51990,"Acridine, 1,2,3,4-tetrahydro-5-chloro-9-(3-(dipropylamino)propylamino)-",CCCN(CCC)CCCNC1=C2CCCCC2=NC3=C1C=CC=C3Cl,,,,,,
1990,51991,4-Methoxyacridin-9-ol,COC1=CC=CC2=C1NC3=CC=CC=C3C2=O,,,,,,
1991,51992,"7-Methoxy-1,2,3,4-tetrahydro-9(9ah)-acridinone",COC1=CC2=C(C=C1)N=C3CCCCC3C2=O,,,,,,
1992,51993,Ethyl 3-butylsulfonylprop-2-enoate,CCCCS(=O)(=O)C=CC(=O)OCC,,,,,,
1993,51994,Ethyl 3-ethylsulfonylprop-2-enoate,CCOC(=O)C=CS(=O)(=O)CC,,,,,,
1994,51995,CID 51995,C(=CI)C(=O)[O-].[Na+],,,,,,
1995,51996,3-Iodoprop-2-enoic acid,C(=CI)C(=O)O,,,,,,
1996,51997,3-Phenylsulfanyl-acrylic acid ethyl ester-S-oxide,CCOC(=O)C=CS(=O)C1=CC=CC=C1,,,,,,
1997,51998,"7H-ADENINE, N-(p-FLUOROPHENYL)-",C1=CC(=CC=C1NC2=NC=NC3=C2NC=N3)F,,,,,,
1998,51999,CID 51999,C1=NC2=NC=NC2=C(N1)[NH3+].[I-],,,,,,
1999,52000,"7H-ADENINE, N-(o-METHOXYPHENYL)-",COC1=CC=CC=C1NC2=NC=NC3=C2NC=N3,,,,,,
2000,52001,Dimethylhexadecyl(4-chloro-2-butynyl)ammonium chloride,CCCCCCCCCCCCCCCC[N+](C)(C)CC#CCCl.[Cl-],,,,,,
2001,52002,4-Chlorobut-2-ynyl-hexadecyl-dimethylazanium,CCCCCCCCCCCCCCCC[N+](C)(C)CC#CCCl,,,,,,
2002,52003,(p-Chloro-alpha-cyanobenzyl)trimethylammonium iodide,C[N+](C)(C)C(C#N)C1=CC=C(C=C1)Cl.[I-],,,,,,
2003,52004,[(4-Chlorophenyl)-cyanomethyl]-trimethylazanium,C[N+](C)(C)C(C#N)C1=CC=C(C=C1)Cl,,,,,,
2004,52005,2-(p-Chlorophenylsulfonyl)ethyltrimethylammonium bromide,C[N+](C)(C)CCS(=O)(=O)C1=CC=C(C=C1)Cl.[Br-],,,,,,
2005,52006,2-(4-Chlorophenyl)sulfonylethyl-trimethylazanium,C[N+](C)(C)CCS(=O)(=O)C1=CC=C(C=C1)Cl,,,,,,
2006,52007,(3-(3-(p-Chlorophenyl)-1-ureido)propyl)trimethylammonium iodide,C[N+](C)(C)CCCNC(=O)NC1=CC=C(C=C1)Cl.[I-],,,,,,
2007,52008,3-[(4-Chlorophenyl)carbamoylamino]propyl-trimethylazanium,C[N+](C)(C)CCCNC(=O)NC1=CC=C(C=C1)Cl,,,,,,
2008,52009,(Cyclopropylmethyl)trimethylammonium iodide,C[N+](C)(C)CC1CC1.[I-],,,,,,
2009,52010,"N,N,N-Trimethylcyclopropanemethanaminium",C[N+](C)(C)CC1CC1,,,,,,
2010,52011,"(3,4-Dichlorophenylcarbamoylmethyl)diethylmethylammonium iodide",CC[N+](C)(CC)CC(=O)NC1=CC(=C(C=C1)Cl)Cl.[I-],,,,,,
2011,52012,"[2-(3,4-Dichloroanilino)-2-oxoethyl]-diethyl-methylazanium",CC[N+](C)(CC)CC(=O)NC1=CC(=C(C=C1)Cl)Cl,,,,,,
2012,52013,"Ammonium, (2-(2,2-dicyano-1-hydroxyvinyloxy)ethyl)trimethyl-, hydroxide, inner salt",C[N+](C)(C)CCOC(=O)C(=C=[N-])C#N,,,,,,
2013,52014,"2-(2,2-Dicyano-1-hydroxyethenoxy)ethyl-trimethylazanium",C[N+](C)(C)CCOC(=C(C#N)C#N)O,,,,,,
2014,52015,"Ammonium, diethyl(2-hydroxyethyl)methyl-, iodide, 2-phenylvalerate",CCCC(C1=CC=CC=C1)C(=O)OCC[N+](C)(CC)CC.[I-],,,,,,
2015,52016,Diethyl-methyl-[2-(2-phenylpentanoyloxy)ethyl]azanium,CCCC(C1=CC=CC=C1)C(=O)OCC[N+](C)(CC)CC,,,,,,
2016,52017,CID 52017,CC[N+](C)(CC)CC(=C(C)O)N=O.[I-],,,,,,
2017,52018,CID 52018,CC[N+](C)(CC)CC(=C(C)O)N=O,,,,,,
2018,52019,"Ammonium, diethyl(3-hydroxypropyl)methyl-, iodide, 2-phenylbutyrate",CCC(C1=CC=CC=C1)C(=O)OCCC[N+](C)(CC)CC.[I-],,,,,,
2019,52020,Diethyl-methyl-[3-(2-phenylbutanoyloxy)propyl]azanium,CCC(C1=CC=CC=C1)C(=O)OCCC[N+](C)(CC)CC,,,,,,
2020,52021,"Diethyl(3-hydroxy-1,3,3-triphenylpropyl)methylammonium chloride hemihydrate",CC[N+](C)(CC)C(CC(C1=CC=CC=C1)(C2=CC=CC=C2)O)C3=CC=CC=C3.[Cl-],,,,,,
2021,52022,"Diethyl-(3-hydroxy-1,3,3-triphenylpropyl)-methylazanium",CC[N+](C)(CC)C(CC(C1=CC=CC=C1)(C2=CC=CC=C2)O)C3=CC=CC=C3,,,,,,
2022,52023,Diethylmethyl(2-(4-methyl-1-oxo-2H-phthalazin-yl)ethyl)ammonium iodide,CC[N+](C)(CC)CCN1C(=O)C2=CC=CC=C2C(=N1)C.[I-],,,,,,
2023,52024,Diethyl-methyl-[2-(4-methyl-1-oxophthalazin-2-yl)ethyl]azanium,CC[N+](C)(CC)CCN1C(=O)C2=CC=CC=C2C(=N1)C,,,,,,
2024,52025,Diethylmethyl(m-tolyl)ammonium iodide,CC[N+](C)(CC)C1=CC=CC(=C1)C.[I-],,,,,,
2025,52026,Diethyl-methyl-(3-methylphenyl)azanium,CC[N+](C)(CC)C1=CC=CC(=C1)C,,,,,,
2026,52027,Dimethyloctadecyl(5-hydroxy-4-oxo-2-pyranylmethyl)ammonium iodide,CCCCCCCCCCCCCCCCCC[N+](C)(C)CC1=CC(=O)C(=CO1)O.[I-],,,,,,
2027,52028,(5-Hydroxy-4-oxopyran-2-yl)methyl-dimethyl-octadecylazanium,CCCCCCCCCCCCCCCCCC[N+](C)(C)CC1=CC(=O)C(=CO1)O,,,,,,
2028,52029,"(3-(2,4-Dioxo-3-oxazolidinyl)propyl)trimethylammonium iodide",C[N+](C)(C)CCCN1C(=O)COC1=O.[I-],,,,,,
2029,52030,"3-(2,4-Dioxo-1,3-oxazolidin-3-yl)propyl-trimethylazanium",C[N+](C)(C)CCCN1C(=O)COC1=O,,,,,,
2030,52031,"(2,2-Diphenyl-5-methyl-5-dioxanylmethyl)trimethylammonium bromide",CC1(COC(OC1)(C2=CC=CC=C2)C3=CC=CC=C3)C[N+](C)(C)C.[Br-],,,,,,
2031,52032,"Trimethyl-[(5-methyl-2,2-diphenyl-1,3-dioxan-5-yl)methyl]azanium",CC1(COC(OC1)(C2=CC=CC=C2)C3=CC=CC=C3)C[N+](C)(C)C,,,,,,
2032,52033,"N-Dodecylbenzyl-N,N,N-trimethylammonium hexafluorophosphate",CCCCCCCCCCCCC1=CC=C(C=C1)C[N+](C)(C)C.F[P-](F)(F)(F)(F)F,,,,,,
2033,52034,P-laurylbenzyltrimethylammonium,CCCCCCCCCCCCC1=CC=C(C=C1)C[N+](C)(C)C,,,,,,
2034,52035,(N-Ethylcarbaniloylmethyl)diethylmethylammonium iodide,CCN(C1=CC=CC=C1)C(=O)C[N+](C)(CC)CC.[I-],,,,,,
2035,52036,diethyl-[2-(N-ethylanilino)-2-oxoethyl]-methylazanium,CCN(C1=CC=CC=C1)C(=O)C[N+](C)(CC)CC,,,,,,
2036,52037,(2-Furfurylcarbamoylmethyl)diethylmethylammonium iodide,CC[N+](C)(CC)CC(=O)NCC1=CC=CO1.[I-],,,,,,
2037,52038,Diethyl-[2-(furan-2-ylmethylamino)-2-oxoethyl]-methylazanium,CC[N+](C)(CC)CC(=O)NCC1=CC=CO1,,,,,,
2038,52039,Furtrethonium bromide,C[N+](C)(C)CC1=CC=CO1.[Br-],,,['Drugs that bind to and activate cholinergic receptors. (See all compounds classified as Cholinergic Agonists.)'],,,
2039,52040,(2-Hexynylene)bis(triethylammonium) diiodide,CC[N+](CC)(CC)CCCC#CC[N+](CC)(CC)CC.[I-].[I-],,,,,,
2040,52041,Triethyl-[6-(triethylazaniumyl)hex-2-ynyl]azanium,CC[N+](CC)(CC)CCCC#CC[N+](CC)(CC)CC,,,,,,
2041,52042,"Ammonium, (beta-benzoyloxyphenethyl)trimethyl-, iodide",C[N+](C)(C)CC(C1=CC=CC=C1)OC(=O)C2=CC=CC=C2.[I-],,,,,,
2042,52043,"beta-Benzoxy-N,N,N-trimethylbenzeneethanaminium",C[N+](C)(C)CC(C1=CC=CC=C1)OC(=O)C2=CC=CC=C2,,,,,,
2043,52044,"Ammonium, (3-lactamidopropyl)trimethyl-, iodide",CC(C(=O)NCCC[N+](C)(C)C)O.[I-],,,,,,
2044,52045,3-(2-Hydroxypropanoylamino)propyl-trimethylazanium,CC(C(=O)NCCC[N+](C)(C)C)O,,,,,,
2045,52046,"Acetamide, N-(chlorofluoren-2-YL)-2,2,2-trifluoro-",C1C2=CC=CC=C2C3=C1C(=C(C=C3)NC(=O)C(F)(F)F)Cl,,,,,,
2046,52047,"Acetamide, N-(2-chloro-3-fluoranthenyl)-",CC(=O)NC1=C(C=C2C3=CC=CC=C3C4=CC=CC1=C42)Cl,,,,,,
2047,52048,"Acetamide, 2-chloro-N-(2-(2-pyridyl)ethyl)-",C1=CC=NC(=C1)CCNC(=O)CCl,,,,,,
2048,52049,"N-(2,7-Dichlorofluoren-4-yl)acetamide",CC(=O)NC1=CC(=CC2=C1C3=C(C2)C=C(C=C3)Cl)Cl,,,,,,
2049,52050,"2-iodo-N,N-dimethylacetamide",CN(C)C(=O)CI,,,,,,
2050,52051,"N,N-Dimethyl-2-(alpha-methyl-M-trifluoromethylphenethylamino)acetamide",CC(CC1=CC(=CC=C1)C(F)(F)F)NCC(=O)N(C)C,,,,,,
2051,52052,"Acetamide, N,N-dipropyl-2-iodo-",CCCN(CCC)C(=O)CI,,,,,,
2052,52053,"Acetamide, N,N-(2,2'-dipyridyl)-",CC(=O)N(C1=CC=CC=N1)C2=CC=CC=N2,,,,,,
2053,52054,"Acetamide, 2-iodo-N-(2-(2-pyridyl)ethyl)-, monohydrate",C1=CC=NC(=C1)CCNC(=O)CI.O,,,,,,
2054,52055,2-iodo-N-(2-pyridin-2-ylethyl)acetamide,C1=CC=NC(=C1)CCNC(=O)CI,,,,,,
2055,52056,CID 52056,CC(C)CC1(C(=NC(=NC1=O)S)[O-])C(C)C=C.[Na+],,,,,,
2056,52057,CID 52057,CC(C)CC1(C(=O)NC(=NC1=O)S)C(C)C=C,,,,,,
2057,52058,CID 52058,CCCC1(C(=O)NC(=NC1=O)[O-])C(C)SCC(C)C.[Na+],,,,,,
2058,52059,"5-[1-(2-Methylpropylsulfanyl)ethyl]-5-propyl-1,3-diazinane-2,4,6-trione",CCCC1(C(=O)NC(=O)NC1=O)C(C)SCC(C)C,,,,,,
2059,52060,CID 52060,C1=CC=NC(=C1)C=C2C(=O)NC(=NC2=O)S,,,,,,
2060,52061,N-[[2-chloro-4-(dimethylamino)phenyl]methylidene]hydroxylamine,CN(C)C1=CC(=C(C=C1)C=NO)Cl,,,,,,
2061,52062,"N-[(2,4-dichlorophenyl)methylideneamino]-1,3-benzothiazol-2-amine",C1=CC=C2C(=C1)N=C(S2)NN=CC3=C(C=C(C=C3)Cl)Cl,,,,,,
2062,52063,CID 52063,CC[NH+](CC)CCOC1=CC=C(C=C1)C=NNC2=NC3C(N2C)C(=O)N(C(=O)N3C)C.[Cl-],,,,,,
2063,52064,CID 52064,CCN(CC)CCOC1=CC=C(C=C1)C=NNC2=NC3C(N2C)C(=O)N(C(=O)N3C)C,,,,,,
2064,52065,"2-[4-[2-[(3,4-Dimethoxyphenyl)methylidene]hydrazinyl]phenyl]ethene-1,1,2-tricarbonitrile",COC1=C(C=C(C=C1)C=NNC2=CC=C(C=C2)C(=C(C#N)C#N)C#N)OC,,,,,,
2065,52066,4-[(Hydroxyimino)methyl]-2-iodo-6-methoxyphenol,COC1=C(C(=CC(=C1)C=NO)I)O,,,,,,
2066,52067,[(4-Hydroxy-3-iodo-5-methoxyphenyl)methylideneamino]urea,COC1=C(C(=CC(=C1)C=NNC(=O)N)I)O,,,,,,
2067,52068,"2,4,6-Trichloro-3-hydroxybenzaldehyde",C1=C(C(=C(C(=C1Cl)O)Cl)C=O)Cl,,,,,,
2068,52069,"2,4,6-Trichloro-3-(hydroxyiminomethyl)phenol",C1=C(C(=C(C(=C1Cl)O)Cl)C=NO)Cl,,,,,,
2069,52070,"8-[2-[(4-methoxyphenyl)methylidene]hydrazinyl]-1,3-dimethyl-7H-purine-2,6-dione",CN1C2=C(C(=O)N(C1=O)C)NC(=N2)NN=CC3=CC=C(C=C3)OC,,,,,,
2070,52071,CID 52071,C1=CC(=CC(=C1)C(F)(F)F)C=N[O-].[Na+],,,,,,
2071,52072,CID 52072,C1=CC(=CC(=C1)C(F)(F)F)C=N[O-],,,,,,
2072,52073,CID 52073,C1=CC=C(C(=C1)C=N[O-])C(F)(F)F.[Na+],,,,,,
2073,52074,CID 52074,C1=CC=C(C(=C1)C=N[O-])C(F)(F)F,,,,,,
2074,52075,CID 52075,C1=CC(=CC=C1C=N[O-])C(F)(F)F.[Na+],,,,,,
2075,52076,N-oxido-1-[4-(trifluoromethyl)phenyl]methanimine,C1=CC(=CC=C1C=N[O-])C(F)(F)F,,,,,,
2076,52077,"Benzamide, 5-acetamido-2-allyloxy-4-ethyl-",CCC1=CC(=C(C=C1NC(=O)C)C(=O)N)OCC=C,,,,,,
2077,52078,"Benzamide, 5-acetamido-N-butyl-2-(prop-2-ynyl)-",CCCCNC(=O)C1=C(C=CC(=C1)NC(=O)C)CC#C,,,,,,
2078,52079,"Benzamide, 5-acetamido-N-propyl-2-(prop-2-ynyl)-",CCCNC(=O)C1=C(C=CC(=C1)NC(=O)C)CC#C,,,,,,
2079,52080,"N-Allyl-N-cyclohexyl-3,4,5-trimethoxybenzamide",COC1=CC(=CC(=C1OC)OC)C(=O)N(CC=C)C2CCCCC2,,,,,,
2080,52081,"N-Allyl-N-(2,4-cyclopentadien-1-yl)-3,4,5-trimethoxybenzamide",COC1=CC(=CC(=C1OC)OC)C(=O)N(CC=C)C2C=CC=C2,,,,,,
2081,52082,"N-Allyl-3,4-dimethoxybenzamide",COC1=C(C=C(C=C1)C(=O)NCC=C)OC,,,,,,
2082,52083,"N-Allyl-N-phenyl-3,4,5-trimethoxybenzamide",COC1=CC(=CC(=C1OC)OC)C(=O)N(CC=C)C2=CC=CC=C2,,,,,,
2083,52084,"Benzamide, 2-butoxy-N-(2-(diethylamino)ethyl)-",CCCCOC1=CC=CC=C1C(=O)NCCN(CC)CC,,,,,,
2084,52085,"Benzamide, 2-butoxy-6-methyl-N-(2-(pyrrolidinyl)ethyl)-",CCCCOC1=CC=CC(=C1C(=O)NCCN2CCCC2)C,,,,,,
2085,52086,"Benzamide, 3-butoxy-N-(2-(pyrrolidinyl)ethyl)-",CCCCOC1=CC=CC(=C1)C(=O)NCCN2CCCC2,,,,,,
2086,52087,"Benzamide, 4-butoxy-N-(2-(pyrrolidinyl)ethyl)-",CCCCOC1=CC=C(C=C1)C(=O)NCCN2CCCC2,,,,,,
2087,52088,"Benzamide, 2-butoxy-N-(3-(pyrrolidinyl)propyl)-",CCCCOC1=CC=CC=C1C(=O)NCCCN2CCCC2,,,,,,
2088,52089,"Benzamide, N,N-diallyl-3,4,5-trimethoxy-",COC1=CC(=CC(=C1OC)OC)C(=O)N(CC=C)CC=C,,,,,,
2089,52090,"3,4-Dichloro-N-(2,2,2-trichloro-1-hydroxyethyl)benzamide",C1=CC(=C(C=C1C(=O)NC(C(Cl)(Cl)Cl)O)Cl)Cl,,,,,,
2090,52091,"N-(beta-Dimethylaminoethyl)-3,4,5-trimethoxybenzamide hydrochloride",C[NH+](C)CCNC(=O)C1=CC(=C(C(=C1)OC)OC)OC.[Cl-],,,,,,
2091,52092,"N-[2-(Dimethylamino)ethyl]-3,4,5-trimethoxybenzamide",CN(C)CCNC(=O)C1=CC(=C(C(=C1)OC)OC)OC,,,,,,
2092,52093,"Benzamide, 2,6-dimethyl-N-(2-(pyrrolidinyl)ethyl)-",CC1=CC(=C(C=C1)C(=O)NCCN2CCCC2)C,,,,,,
2093,52094,"Benzamide, 2-ethoxy-N-(2-(pyrrolidinyl)ethyl)-",CCOC1=CC=CC=C1C(=O)NCCN2CCCC2,,,,,,
2094,52095,"Benzamide, 2-methoxy-N-(2-(pyrrolidinyl)ethyl)-",COC1=CC=CC=C1C(=O)NCCN2CCCC2,,,,,,
2095,52096,"Benzamide, N-((4-methyl-3-pyridyl)methyl)-",CC1=C(C=NC=C1)CNC(=O)C2=CC=CC=C2,,,,,,
2096,52097,"Benzamide, 2-propoxy-N-(2-(pyrrolidinyl)ethyl)-",CCCOC1=CC=CC=C1C(=O)NCCN2CCCC2,,,,,,
2097,52098,"Benzamidine, N,N'-bis(L-carboxyisobutylmethyl)-",CC(C)C[C@@H](C(=O)O)NC(=N[C@@H](CC(C)C)C(=O)O)C1=CC=CC=C1,,,,,,
2098,52099,"N,N-Diethyl-1,4a,6a-trimethyl-2-oxohexadecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide",CCN(CC)C(=O)[C@H]1CCC2C1(CCC3C2CC[C@@H]4C3(CCC(=O)N4C)C)C,,,,,,
2099,52100,"Acridine, 3-chloro-9-(4-(diethylamino)-1-(4-methoxyphenyl)butylamino)-7-methoxy-, dihydrochloride, hydrate",CC[NH+](CC)CCCC(C1=CC=C(C=C1)OC)[NH2+]C2=C3C=C(C=CC3=NC4=C2C=CC(=C4)Cl)OC.[Cl-].[Cl-],,,,,,
2100,52101,"N-(6-chloro-2-methoxyacridin-9-yl)-N',N'-diethyl-1-(4-methoxyphenyl)butane-1,4-diamine",CCN(CC)CCCC(C1=CC=C(C=C1)OC)NC2=C3C=C(C=CC3=NC4=C2C=CC(=C4)Cl)OC,,,,,,
2101,52102,Dicyclohexylethylmethylammonium iodide,CC[N+](C)(C1CCCCC1)C2CCCCC2.[I-],,,,,,
2102,52103,Dicyclohexyl-ethyl-methylazanium,CC[N+](C)(C1CCCCC1)C2CCCCC2,,,,,,
2103,52104,"Adipamide, N,N'-bis(3-chlorophenyl)-",C1=CC(=CC(=C1)Cl)NC(=O)CCCCC(=O)NC2=CC(=CC=C2)Cl,,,,,,
2104,52105,"L-N-Benzyloxycarbonyl-3,3-dimethylalanine 1,2-dibromoethyl ester",CC(C)[C@@H](C(=O)OC(CBr)Br)NC(=O)OCC1=CC=CC=C1,,,,,,
2105,52106,"L-N-Benzyloxycarbonyl-3,3-dimethylalanine 2-propynyl ester",CC(C)C(C(=O)OCC#C)NC(=O)OCC1=CC=CC=C1,,,,,,
2106,52107,"Alanine, N-benzyloxycarbonyl-3-vinyloxycarbonyl-, vinyl ester, L-",C=COC(=O)C[C@@H](C(=O)OC=C)NC(=O)OCC1=CC=CC=C1,,,,,,
2107,52108,2-(5-(Bis-(2-chloroethyl)amino)-2-benzimidazolyl)alanine,CC(C1=NC2=C(N1)C=C(C=C2)N(CCCl)CCCl)(C(=O)O)N,,,,,,
2108,52109,2-(5-(Bis(2-chloroethyl)amino)-1-methyl-2-benzimidazolyl)alanine,CC(C1=NC2=C(N1C)C=CC(=C2)N(CCCl)CCCl)(C(=O)O)N,,,,,,
2109,52110,CID 52110,C1=CC=C(C=C1)C[C@@H](C(=O)O)NC(=O)C=CC2=CC=CC=C2.O,,,,,,
2110,52111,Cinnamoyl-(trans)-L-phenylalanine,C1=CC=C(C=C1)C[C@@H](C(=O)O)NC(=O)C=CC2=CC=CC=C2,,,,,,
2111,52112,"ALLYLAMINE, compd. with 4-DICYANOVINYL-2-IODO-6-METHOXYPHENOL",COC1=C(C(=CC(=C1)C=C(C#N)C#N)I)O.C=CCN,,,,,,
2112,52113,2-[(4-Hydroxy-3-iodo-5-methoxyphenyl)methylene]malononitrile,COC1=C(C(=CC(=C1)C=C(C#N)C#N)I)O,,,,,,
2113,52114,Allyldimethylphenylammonium iodide,C[N+](C)(CC=C)C1=CC=CC=C1.[I-],,,,,,
2114,52115,"N-Allyl-N,N-dimethylanilinium",C[N+](C)(CC=C)C1=CC=CC=C1,,,,,,
2115,52116,"Ammonium, (p-benzoquinon-2,5-ylenebis(iminotrimethylene))bis(butyldiethyl-, dibromide",CCCC[N+](CC)(CC)CCCNC1=CC(=O)C(=CC1=O)NCCC[N+](CC)(CC)CCCC.[Br-].[Br-],,,,,,
2116,52117,"Butyl-[3-[[4-[3-[butyl(diethyl)azaniumyl]propylamino]-3,6-dioxocyclohexa-1,4-dien-1-yl]amino]propyl]-diethylazanium",CCCC[N+](CC)(CC)CCCNC1=CC(=O)C(=CC1=O)NCCC[N+](CC)(CC)CCCC,,,,,,
2117,52118,"Ammonium, (p-benzoquinon-2,5-ylenebis(iminotrimethylene))bis(diethyl(o-methoxybenzyl)-, dichloride",CC[N+](CC)(CCCNC1=CC(=O)C(=CC1=O)NCCC[N+](CC)(CC)CC2=CC=CC=C2OC)CC3=CC=CC=C3OC.[Cl-].[Cl-],,,,,,
2118,52119,"3-[[4-[3-[Diethyl-[(2-methoxyphenyl)methyl]azaniumyl]propylamino]-3,6-dioxocyclohexa-1,4-dien-1-yl]amino]propyl-diethyl-[(2-methoxyphenyl)methyl]azanium",CC[N+](CC)(CCCNC1=CC(=O)C(=CC1=O)NCCC[N+](CC)(CC)CC2=CC=CC=C2OC)CC3=CC=CC=C3OC,,,,,,
2119,52120,"Ammonium, (p-benzoquinon-2,5-ylenebis(iminotrimethylene))bis(dimethylethyl-, dibromide",CC[N+](C)(C)CCCNC1=CC(=O)C(=CC1=O)NCCC[N+](C)(C)CC.[Br-].[Br-],,,,,,
2120,52121,"Ethyl-[3-[[4-[3-[ethyl(dimethyl)azaniumyl]propylamino]-3,6-dioxocyclohexa-1,4-dien-1-yl]amino]propyl]-dimethylazanium",CC[N+](C)(C)CCCNC1=CC(=O)C(=CC1=O)NCCC[N+](C)(C)CC,,,,,,
2121,52122,"(alpha-Benzoylbenzyl)methyl(2-morpholinoethyl)(2-pyridyl)ammonium, iodide",C[N+](CCN1CCOCC1)(C2=CC=CC=N2)C(C3=CC=CC=C3)C(=O)C4=CC=CC=C4.[I-],,,,,,
2122,52123,"Methyl-(2-morpholin-4-ylethyl)-(2-oxo-1,2-diphenylethyl)-pyridin-2-ylazanium",C[N+](CCN1CCOCC1)(C2=CC=CC=N2)C(C3=CC=CC=C3)C(=O)C4=CC=CC=C4,,,,,,
2123,52124,CID 52124,CCCCCCCOC(=O)C[N+](C)(C)CC=C(C)CC1=CC=CC=C1.[Cl-],,,,,,
2124,52125,CID 52125,CCCCCCCOC(=O)C[N+](C)(C)CC=C(C)CC1=CC=CC=C1,,,,,,
2125,52126,"Ammonium, benzyltriethyl-, acetate",CC[N+](CC)(CC)CC1=CC=CC=C1.CC(=O)[O-],,,,,,
2126,52127,Benzyltriethylammonium cyanoacetate,CC[N+](CC)(CC)CC1=CC=CC=C1.C(C#N)C(=O)[O-],,,,,,
2127,52128,"Ammonium, benzyltriethyl-, 2,4-dichlorobenzoate",CC[N+](CC)(CC)CC1=CC=CC=C1.C1=CC(=C(C=C1Cl)Cl)C(=O)[O-],,,,,,
2128,52129,"Ammonium, benzyltriethyl-, 2,4-dichlorophenoxyacetate",CC[N+](CC)(CC)CC1=CC=CC=C1.C1=CC(=C(C=C1Cl)Cl)OCC(=O)[O-],,,,,,
2129,52130,Benzyltriethylammonium pentachlorophenate,CC[N+](CC)(CC)CC1=CC=CC=C1.C1(=C(C(=C(C(=C1Cl)Cl)Cl)Cl)Cl)[O-],,,,,,
2130,52131,"Ammonium, benzyltriethyl-, 2,4,5-trichlorophenate",CC[N+](CC)(CC)CC1=CC=CC=C1.C1=C(C(=CC(=C1Cl)Cl)Cl)[O-],,,,,,
2131,52132,"Ammonium, benzyltriethyl-, 2,4,5-trichlorophenoxyacetate",CC[N+](CC)(CC)CC1=CC=CC=C1.C1=C(C(=CC(=C1Cl)Cl)Cl)OCC(=O)[O-],,,,,,
2132,52133,"Benzenemethanaminium, N,N,N-trimethyl-, carbonate (2:1)",C[N+](C)(C)CC1=CC=CC=C1.C[N+](C)(C)CC1=CC=CC=C1.C(=O)([O-])[O-],,,,,,
2133,52134,"Ammonium, benzyltrimethyl-, 2,4-dichlorophenoxyacetate",C[N+](C)(C)CC1=CC=CC=C1.C1=CC(=C(C=C1Cl)Cl)OCC(=O)[O-],,,,,,
2134,52135,"Benzyltrimethylammonium 2,4,5-trichlorophenoxyacetate",C[N+](C)(C)CC1=CC=CC=C1.C1=C(C(=CC(=C1Cl)Cl)Cl)OCC(=O)[O-],,,,,,
2135,52136,(o-Bromobenzyl)trimethylammonium bromide,C[N+](C)(C)CC1=CC=CC=C1Br.[Br-],,,,,,
2136,52137,(2-Bromophenyl)methyl-trimethylazanium,C[N+](C)(C)CC1=CC=CC=C1Br,,,,,,
2137,52138,"Ammonium, (2-bromoethyl)decyldimethyl-, bromide",CCCCCCCCCC[N+](C)(C)CCBr.[Br-],,,,,,
2138,52139,2-Bromoethyl-decyl-dimethylazanium,CCCCCCCCCC[N+](C)(C)CCBr,,,,,,
2139,52140,"Ammonium, (3-(((butylimino)methylene)amino)propyl)trimethyl-, iodide",CCCCN=C=NCCC[N+](C)(C)C.[I-],,,,,,
2140,52141,CID 52141,CCCCN=C=NCCC[N+](C)(C)C,,,,,,
2141,52142,(2-Butynylene)bis(triethylammonium) dichloride,CC[N+](CC)(CC)CC#CC[N+](CC)(CC)CC.[Cl-].[Cl-],,,,,,
2142,52143,Triethyl-[4-(triethylazaniumyl)but-2-ynyl]azanium,CC[N+](CC)(CC)CC#CC[N+](CC)(CC)CC,,,,,,
2143,52144,(Phenylcarbamoylmethyl)diethylmethyl ammonium iodide,CC[N+](C)(CC)CC(=O)NC1=CC=CC=C1.[I-],,,,,,
2144,52145,Methyllidocaine,CC[N+](C)(CC)CC(=O)NC1=CC=CC=C1,,,,,,
2145,52146,"Methyl 4-(3-(diethylamino)propionylamino)salicylate, methiodide",CC[N+](C)(CC)CCC(=O)NC1=CC(=C(C=C1)C(=O)OC)O.[I-],,,,,,
2146,52147,Diethyl-[3-(3-hydroxy-4-methoxycarbonylanilino)-3-oxopropyl]-methylazanium,CC[N+](C)(CC)CCC(=O)NC1=CC(=C(C=C1)C(=O)OC)O,,,,,,
2147,52148,"Ethyl 4-(3-dimethylaminopropionylamino)salicylate, methiodide",CCOC(=O)C1=C(C=C(C=C1)NC(=O)CC[N+](C)(C)C)O.[I-],,,,,,
2148,52149,[3-(4-Ethoxycarbonyl-3-hydroxyanilino)-3-oxopropyl]-trimethylazanium,CCOC(=O)C1=C(C=C(C=C1)NC(=O)CC[N+](C)(C)C)O,,,,,,
2149,52150,"Methyl 4-(3-(dimethylamino)propionylamino)salicylate, methiodide",C[N+](C)(C)CCC(=O)NC1=CC(=C(C=C1)C(=O)OC)O.[I-],,,,,,
2150,52151,[3-(3-Hydroxy-4-methoxycarbonylanilino)-3-oxopropyl]-trimethylazanium,C[N+](C)(C)CCC(=O)NC1=CC(=C(C=C1)C(=O)OC)O,,,,,,
2151,52152,"2-(Diethylaminoethyl) 4-(2-diethylaminoacetylamino)salicylate, bismethiodide",CC[N+](C)(CC)CCOC(=O)C1=C(C=C(C=C1)NC(=O)C[N+](C)(CC)CC)O.[I-].[I-],,,,,,
2152,52153,2-[4-[[2-[Diethyl(methyl)azaniumyl]acetyl]amino]-2-hydroxybenzoyl]oxyethyl-diethyl-methylazanium,CC[N+](C)(CC)CCOC(=O)C1=C(C=C(C=C1)NC(=O)C[N+](C)(CC)CC)O,,,,,,
2153,52154,"Ethyl 4-(2-diethylaminoacetylamino)salicylate, methiodide",CC[N+](C)(CC)CC(=O)NC1=CC(=C(C=C1)C(=O)OCC)O.[I-],,,,,,
2154,52155,[2-(4-Ethoxycarbonyl-3-hydroxyanilino)-2-oxoethyl]-diethyl-methylazanium,CC[N+](C)(CC)CC(=O)NC1=CC(=C(C=C1)C(=O)OCC)O,,,,,,
2155,52156,3-Isobutyl-3-phenyl-2-azetidinone,CC(C)CC1(CNC1=O)C2=CC=CC=C2,,,,,,
2156,52157,3-Phenyl-3-propyl-2-azetidinone,CCCC1(CNC1=O)C2=CC=CC=C2,,,,,,
2157,52158,"1-AZIRIDINECARBOXAMIDE, N-(p-CHLOROPHENYL)-2-METHYL-",CC1CN1C(=O)NC2=CC=C(C=C2)Cl,,,,,,
2158,52159,1-(Methylcarbamoyl)-2-methylaziridine,CC1CN1C(=O)NC,,,,,,
2159,52160,"AZIRIDINE, 2,3-DIMETHYL-compd. with p-NITROBENZOATE",CC1C(N1)C.C1=CC(=CC=C1C(=O)O)[N+](=O)[O-],,,,,,
2160,52161,"2,3-Dimethylaziridine",CC1C(N1)C,,,,,,
2161,52162,CID 52162,C1CN1C(=O)C=CC(=O)N2CC2,,,,,,
2162,52163,3-(2-(Furyl)ethyl)-3-methyl-3-azoniabicyclo(3.2.2)nonane iodide,C[N+]1(CC2CCC(C1)CC2)CCC3=CC=CO3.[I-],,,,,,
2163,52164,3-[2-(2-Furanyl)ethyl]-3-methyl-3-azoniabicyclo[3.2.2]nonane,C[N+]1(CC2CCC(C1)CC2)CCC3=CC=CO3,,,,,,
2164,52165,1-Azabicyclo(3.3.1)nonanyl phenyl-2-thienylglycolate methobromide,C[N+]12CCCC(C1)CC(C2)OC(=O)C(C3=CC=CC=C3)(C4=CC=CS4)O.[Br-],,,,,,
2165,52166,1-Methyl-1-azoniabicyclo[3.3.1]nonan-3-ol 2-phenyl-2-(2-thienyl)-2-hydroxyacetate,C[N+]12CCCC(C1)CC(C2)OC(=O)C(C3=CC=CC=C3)(C4=CC=CS4)O,,,,,,
2166,52167,Helenalin extract,CC1CC2C(C(C3(C1C=CC3=O)C)O)C(=C)C(=O)O2,,,,,,
2167,52168,5-Allyl-1-benzyl-5-isopropyl barbituric acid,CC(C)C1(C(=O)NC(=O)N(C1=O)CC2=CC=CC=C2)CC=C,,,,,,
2168,52169,1-Benzyl-5-allyl-5-phenylbarbituric acid,C=CCC1(C(=O)NC(=O)N(C1=O)CC2=CC=CC=C2)C3=CC=CC=C3,,,,,,
2169,52170,CID 52170,CCCCSC(C)C1(C(=NC(=NC1=O)S)[O-])CC=C.[Na+],,,,,,
2170,52171,CID 52171,CCCCSC(C)C1(C(=O)NC(=NC1=O)S)CC=C,,,,,,
2171,52172,1-Benzyl-5-ethyl-5-isoamyl barbituric acid,CCC1(C(=O)NC(=O)N(C1=O)CC2=CC=CC=C2)CCC(C)C,,,,,,
2172,52173,"Barbituric acid, 5-(3,3-dimethylallyl)-1,3-diphenyl-",CC(=CCC1C(=O)N(C(=O)N(C1=O)C2=CC=CC=C2)C3=CC=CC=C3)C,,,,,,
2173,52174,"Barbituric acid, 1,3-diphenyl-5-dodecyl-",CCCCCCCCCCCCC1C(=O)N(C(=O)N(C1=O)C2=CC=CC=C2)C3=CC=CC=C3,,,,,,
2174,52175,"Barbituric acid, 1,3-diphenyl-5-dodecyl-2-thio-",CCCCCCCCCCCCC1C(=O)N(C(=S)N(C1=O)C2=CC=CC=C2)C3=CC=CC=C3,,,,,,
2175,52176,"Barbituric acid, 1,3-diphenyl-5-pentyl-2-thio-",CCCCCC1C(=O)N(C(=S)N(C1=O)C2=CC=CC=C2)C3=CC=CC=C3,,,,,,
2176,52177,CID 52177,CCC(C)CC1(C(=NC(=NC1=O)S)[O-])CC.[Na+],,,,,,
2177,52178,CID 52178,CCC(C)CC1(C(=O)NC(=NC1=O)S)CC,,,,,,
2178,52179,CID 52179,CCCCCC1(C(=NC(=NC1=O)S)[O-])CC.[Na+],,,,,,
2179,52180,CID 52180,CCCCCC1(C(=O)NC(=NC1=O)S)CC,,,,,,
2180,52181,CID 52181,CCSCC1(C(=O)NC(=NC1=O)[O-])C(C)C.[Na+],,,,,,
2181,52182,"5-(Ethylsulfanylmethyl)-5-propan-2-yl-1,3-diazinane-2,4,6-trione",CCSCC1(C(=O)NC(=O)NC1=O)C(C)C,,,,,,
2182,52183,CID 52183,CCSCC1(C(=O)NC(=NC1=O)[O-])C.[Na+],,,,,,
2183,52184,"5-(Ethylsulfanylmethyl)-5-methyl-1,3-diazinane-2,4,6-trione",CCSCC1(C(=O)NC(=O)NC1=O)C,,,,,,
2184,52185,CID 52185,CCCC1(C(=O)NC(=NC1=O)[O-])CSCC.[Na+],,,,,,
2185,52186,"5-(Ethylsulfanylmethyl)-5-propyl-1,3-diazinane-2,4,6-trione",CCCC1(C(=O)NC(=O)NC1=O)CSCC,,,,,,
2186,52187,CID 52187,C1(=O)C(C(=O)NC(=O)N1)(NN=C(N)S)O.O,,,,,,
2187,52188,CID 52188,C1(=O)C(C(=O)NC(=O)N1)(NN=C(N)S)O,,,,,,
2188,52189,CID 52189,COC1=CC(=CC2=C(N=C(NC2=O)S)O)C=C(C1=O)I,,,,,,
2189,52190,CID 52190,CC(C)CC1(C(=O)NC(=NC1=O)[O-])C(C)C=C.[Na+],,,,,,
2190,52191,"5-But-3-en-2-yl-5-(2-methylpropyl)-1,3-diazinane-2,4,6-trione",CC(C)CC1(C(=O)NC(=O)NC1=O)C(C)C=C,,,,,,
2191,52192,CID 52192,CC(C)CC1(C(=O)NC(=NC1=O)[O-])CC(=C)C.[Na+],,,,,,
2192,52193,"5-(2-Methylprop-2-enyl)-5-(2-methylpropyl)-1,3-diazinane-2,4,6-trione",CC(C)CC1(C(=O)NC(=O)NC1=O)CC(=C)C,,,,,,
2193,52194,Indecainide hydrochloride,CC(C)NCCCC1(C2=CC=CC=C2C3=CC=CC=C31)C(=O)N.Cl,,,,,,
2194,52195,Indecainide,CC(C)NCCCC1(C2=CC=CC=C2C3=CC=CC=C31)C(=O)N,['For the treatment of life-threatening dysrhythmias and sustained ventricular tachycardia.'],['Indecainide is a rarely used antidysrhythmic. Indecainide has local anesthetic activity and belongs to the membrane stabilizing (Class 1) group of antiarrhythmic agents; it has electrophysiologic effects characteristic of the IC class of antiarrhythmics.'],,['Nearly complete following oral administration.'],,
2195,52196,CID 52196,COC1=CC(=CC2=C(N=C(NC2=O)S)O)C=CC1=O,,,,,,
2196,52197,CID 52197,CCC1(C(=O)NC(=NC1=O)[O-])CSCC.[Na+],,,,,,
2197,52198,5-Ethyl-5-((ethylthio)methyl)barbituric acid,CCC1(C(=O)NC(=O)NC1=O)CSCC,,,,,,
2198,52199,CID 52199,CCC1(C(=O)NC(=NC1=O)[O-])CSC(C)C.[Na+],,,,,,
2199,52200,"5-Ethyl-5-(propan-2-ylsulfanylmethyl)-1,3-diazinane-2,4,6-trione",CCC1(C(=O)NC(=O)NC1=O)CSC(C)C,,,,,,
2200,52201,CID 52201,CCSCC1(C(=O)NC(=NC1=O)[O-])CC(C)C.[Na+],,,,,,
2201,52202,5-[(Ethylmercapto)methyl]-5-isobutylbarbituric acid,CCSCC1(C(=O)NC(=O)NC1=O)CC(C)C,,,,,,
2202,52203,3-Allyl-2-amino-1-ethylbenzimidazole bromide,CCN1C2=CC=CC=C2[N+](=C1N)CC=C.[Br-],,,,,,
2203,52204,1-Ethyl-3-prop-2-enylbenzimidazol-3-ium-2-amine,CCN1C2=CC=CC=C2[N+](=C1N)CC=C,,,,,,
2204,52205,Einecs 277-568-3,CC[N+]1=C(NC2=C1C=CC(=C2)[NH3+])C.[Cl-].[Cl-],,,,,,
2205,52206,1-ethyl-2-methyl-3H-benzimidazol-1-ium-5-amine,CC[N+]1=C(NC2=C1C=CC(=C2)N)C,,,,,,
2206,52207,2-Amino-1-ethyl-3-(2-propynyl)benzimidazole bromide,CCN1C2=CC=CC=C2[N+](=C1N)CC#C.[Br-],,,,,,
2207,52208,1-Ethyl-3-prop-2-ynylbenzimidazol-3-ium-2-amine,CCN1C2=CC=CC=C2[N+](=C1N)CC#C,,,,,,
2208,52209,"Benzimidazole, 2,2'-(2-butynylenedithio)DI-",C1=CC=C2C(=C1)NC(=N2)SCC#CCSC3=NC4=CC=CC=C4N3,,,,,,
2209,52210,"Benzimidazole, 5,6-dimethyl-2-mercaptomethyl-",CC1=CC2=C(C=C1C)N=C(N2)CS,,,,,,
2210,52211,4-Ethoxy-N-(2-(1-pyrrolidinyl)ethyl)benzamidine dihydrochloride hydrate,CCOC1=CC=C(C=C1)C(=[NH+]CC[NH+]2CCCC2)N.[Cl-].[Cl-],,,,,,
2211,52212,4-Ethoxy-N-[2-(1-pyrrolidinyl)ethyl]benzamidine,CCOC1=CC=C(C=C1)C(=NCCN2CCCC2)N,,,,,,
2212,52213,4-Methoxy-N-(2-(1-pyrrolidinyl)ethyl)benzamidine dihydrochloride hydrate,COC1=CC=C(C=C1)C(=[NH+]CC[NH+]2CCCC2)N.[Cl-].[Cl-],,,,,,
2213,52214,4-Methoxy-N-[2-(1-pyrrolidinyl)ethyl]benzamidine,COC1=CC=C(C=C1)C(=NCCN2CCCC2)N,,,,,,
2214,52215,"BENZANILIDE, 2'-CHLORO-N-(p-CHLOROPHENYL)-",C1=CC=C(C=C1)C(=O)N(C2=CC=C(C=C2)Cl)C3=CC=CC=C3Cl,,,,,,
2215,52216,"Benzanilide, 2',3,4,5'-tetrachloro-",C1=CC(=C(C=C1C(=O)NC2=C(C=CC(=C2)Cl)Cl)Cl)Cl,,,,,,
2216,52217,"BENZO(rst)PENTAPHENE, 1,2-DIHYDRO-",C1CC2=C(C=C1)C=C3C=CC4=CC5=CC=CC=C5C6=C4C3=C2C=C6,,,,,,
2217,52218,"DIBENZO(b,def)CHRYSENE, 3,4-DIHYDRO-",C1CC2=C(C=C1)C=C3C=CC4=C5C3=C2C=CC5=CC6=CC=CC=C46,,,,,,
2218,52219,"BENZO(rst)PENTAPHENE-3,4-DIOL, 3,4-DIHYDRO-, E-",C1=CC=C2C3=C4C(=CC2=C1)C=CC5=CC6=C(C=C[C@H]([C@@H]6O)O)C(=C54)C=C3,,,,,,
2219,52220,"DIBENZO(b,def)CHRYSENE-1,2-DIOL, 1,2-DIHYDRO-, E-",C1=CC=C2C3=C4C(=CC2=C1)C=CC5=C4C(=CC6=C5C=C[C@H]([C@@H]6O)O)C=C3,,,,,,
2220,52221,"2-Piperidino-p-acetophenetidide, hydrochloride",CCOC1=CC=C(C=C1)NC(=O)C[NH+]2CCCCC2.[Cl-],,,,,,
2221,52222,N-(4-Ethoxyphenyl)-2-piperidinoacetamide,CCOC1=CC=C(C=C1)NC(=O)CN2CCCCC2,,,,,,
2222,52223,CID 52223,COC1=C2C(=C(C=C1)C(=O)CCC(=O)[O-])CCO2.[Na+],,,,,,
2223,52224,"4-(7-Methoxy-2,3-dihydro-1-benzofuran-4-yl)-4-oxobutanoic acid",COC1=C2C(=C(C=C1)C(=O)CCC(=O)O)CCO2,,,,,,
2224,52225,CID 52225,CC1=C(OC2=C(C=CC(=C12)C(=O)CCC(=O)[O-])OC)C.[Na+],,,,,,
2225,52226,"4-(7-Methoxy-2,3-dimethyl-1-benzofuran-4-yl)-4-oxobutanoic acid",CC1=C(OC2=C(C=CC(=C12)C(=O)CCC(=O)O)OC)C,,,,,,
2226,52227,CID 52227,CC1=C(OC2=C1C=CC(=C2OC)C(=O)CCC(=O)[O-])C.[Na+],,,,,,
2227,52228,"4-(7-Methoxy-2,3-dimethyl-1-benzofuran-6-yl)-4-oxobutanoic acid",CC1=C(OC2=C1C=CC(=C2OC)C(=O)CCC(=O)O)C,,,,,,
2228,52229,CID 52229,CCC1=C(C2=C(C=CC(=C2O1)OC)C(=O)CCC(=O)[O-])C.[Na+],,,,,,
2229,52230,4-(2-Ethyl-7-methoxy-3-methyl-1-benzofuran-4-yl)-4-oxobutanoic acid,CCC1=C(C2=C(C=CC(=C2O1)OC)C(=O)CCC(=O)O)C,,,,,,
2230,52231,CID 52231,CC1=CC2=C(C=CC(=C2O1)OC)C(=O)CCC(=O)[O-].[Na+],,,,,,
2231,52232,4-(7-Methoxy-2-methyl-1-benzofuran-4-yl)-4-oxobutanoic acid,CC1=CC2=C(C=CC(=C2O1)OC)C(=O)CCC(=O)O,,,,,,
2232,52233,CID 52233,COC1=C2C(=C(C=C1)C(=O)CCC(=O)[O-])C=CO2.[Na+],,,,,,
2233,52234,4-(7-Methoxy-1-benzofuran-4-yl)-4-oxobutanoic acid,COC1=C2C(=C(C=C1)C(=O)CCC(=O)O)C=CO2,,,,,,
2234,52235,CID 52235,COC1=C2C(=CC(=C1)C(=O)CCC(=O)[O-])C=CO2.[Na+],,,,,,
2235,52236,4-(7-Methoxy-1-benzofuran-5-yl)-4-oxobutanoic acid,COC1=C2C(=CC(=C1)C(=O)CCC(=O)O)C=CO2,,,,,,
2236,52237,"3-Acetamido-2,5-dimethylbenzoic acid",CC1=CC(=C(C(=C1)NC(=O)C)C)C(=O)O,,,,,,
2237,52238,CID 52238,C1=CC(=CC=C1C(=O)O)N=C(N)N=C([NH3+])N.[Cl-],,,,,,
2238,52239,4-(3-Carbamimidoylguanidino)benzoic acid,C1=CC(=CC=C1C(=O)O)N=C(N)N=C(N)N,,,,,,
2239,52240,CID 52240,C1=CC(=CC=C1C(=O)O)NC(=O)N=C([NH3+])N.[Cl-],,,,,,
2240,52241,4-(Diaminomethylidenecarbamoylamino)benzoic acid,C1=CC(=CC=C1C(=O)O)NC(=O)N=C(N)N,,,,,,
2241,52242,"p-Aminobenzoic acid 2-(1-(1-cyclohexyl)ethylamino)-1,1-dimethylethyl ester",CC(C1CCCCC1)NCC(C)(C)OC(=O)C2=CC=C(C=C2)N,,,,,,
2242,52243,"p-Aminobenzoic acid 2-(1-(1-cyclohexyl)ethylamino)-2,2-dimethylethyl ester",CC(C1CCCCC1)NC(C)(C)COC(=O)C2=CC=C(C=C2)N,,,,,,
2243,52244,"Benzoic acid, p-amino-, 2-(2-(2-(2-(2-(diethylamino)ethoxy)ethoxy)ethoxy)ethoxy)ethyl ester, hydrochloride",CC[NH+](CC)CCOCCOCCOCCOCCOC(=O)C1=CC=C(C=C1)N.[Cl-],,,,,,
2244,52245,2-[2-[2-[2-[2-(Diethylamino)ethoxy]ethoxy]ethoxy]ethoxy]ethyl 4-aminobenzoate,CCN(CC)CCOCCOCCOCCOCCOC(=O)C1=CC=C(C=C1)N,,,,,,
2245,52246,"Benzoic acid, p-amino-, 2-(2-(2-(2-(diethylamino)ethoxy)ethoxy)ethoxy)ethyl ester, hydrochloride",CC[NH+](CC)CCOCCOCCOCCOC(=O)C1=CC=C(C=C1)N.[Cl-],,,,,,
2246,52247,2-[2-[2-[2-(Diethylamino)ethoxy]ethoxy]ethoxy]ethyl 4-aminobenzoate,CCN(CC)CCOCCOCCOCCOC(=O)C1=CC=C(C=C1)N,,,,,,
2247,52248,"Benzoic acid, p-amino-, 2-(2-(2-(diethylamino)ethoxy)ethoxy)ethyl ester, hydrochloride",CC[NH+](CC)CCOCCOCCOC(=O)C1=CC=C(C=C1)N.[Cl-],,,,,,
2248,52249,2-[2-[2-(Diethylamino)ethoxy]ethoxy]ethyl 4-aminobenzoate,CCN(CC)CCOCCOCCOC(=O)C1=CC=C(C=C1)N,,,,,,
2249,52250,"BENZOIC ACID, p-AMINO-, 2-(2-(DIETHYLAMINO)ETHOXY)ETHYL ESTER, HYDROCHLORIDE",CC[NH+](CC)CCOCCOC(=O)C1=CC=C(C=C1)N.[Cl-],,,,,,
2250,52251,2-[2-(Diethylamino)ethoxy]ethyl 4-aminobenzoate,CCN(CC)CCOCCOC(=O)C1=CC=C(C=C1)N,,,,,,
2251,52252,2-(5-(Bis-(2-chloroethyl)amino)-1-phenyl-2-benzimidazolyl)alanine,CC(C1=NC2=C(N1C3=CC=CC=C3)C=CC(=C2)N(CCCl)CCCl)(C(=O)O)N,,,,,,
2252,52253,"p-Aminobenzoic acid 2-(4,6-dimethyl-4-heptylamino)-1-propyl ester",CCCC(C)(CC(C)C)NC(C)COC(=O)C1=CC=C(C=C1)N,,,,,,
2253,52254,"Benzoic acid, p-amino-, 3-(N-methyl-N-(4-phenylbutyl)amino)propyl ester, hydrochloride",C[NH+](CCCCC1=CC=CC=C1)CCCOC(=O)C2=CC=C(C=C2)N.[Cl-],,,,,,
2254,52255,3-[Methyl(4-phenylbutyl)amino]propyl 4-aminobenzoate,CN(CCCCC1=CC=CC=C1)CCCOC(=O)C2=CC=C(C=C2)N,,,,,,
2255,52256,"BENZOIC ACID, m-BROMO-, BENZOYLHYDRAZIDE",C1=CC=C(C=C1)C(=O)NNC(=O)C2=CC(=CC=C2)Br,,,,,,
2256,52257,"BENZOIC ACID, o-BUTOXY-, 2-(PYRROLIDINYL)ETHYL ESTER",CCCCOC1=CC=CC=C1C(=O)OCCN2CCCC2,,,,,,
2257,52258,"2,4-Dichlorobenzoic acid 2-(diethylamino)propyl ester hydrochloride",CC[NH+](CC)C(C)COC(=O)C1=C(C=C(C=C1)Cl)Cl.[Cl-],,,,,,
2258,52259,"2-(Diethylamino)propyl 2,4-dichlorobenzoate",CCN(CC)C(C)COC(=O)C1=C(C=C(C=C1)Cl)Cl,,,,,,
2259,52260,"Benzoic acid, 5-(diethylamino)pentyl ester, hydrochloride",CC[NH+](CC)CCCCCOC(=O)C1=CC=CC=C1.[Cl-],,,,,,
2260,52261,5-(Diethylamino)pentyl benzoate,CCN(CC)CCCCCOC(=O)C1=CC=CC=C1,,,,,,
2261,52262,"Benzoic acid, 2,5-dimethoxy-4-(4-piperonylpiperazin-1-yl-carbonyl)-, ethyl ester, methanesulfonate",CCOC(=O)C1=C(C=C(C(=C1)OC)C(=O)N2CC[NH+](CC2)CC3=CC4=C(C=C3)OCO4)OC.CS(=O)(=O)[O-],,,,,,
2262,52263,"Ethyl 4-[4-(1,3-benzodioxol-5-ylmethyl)piperazine-1-carbonyl]-2,5-dimethoxybenzoate",CCOC(=O)C1=C(C=C(C(=C1)OC)C(=O)N2CCN(CC2)CC3=CC4=C(C=C3)OCO4)OC,,,,,,
2263,52264,"BENZOIC ACID, o-ETHOXY-, 2-DIETHYLAMINO-1-PHENYLETHYL ESTER, HYDROCHLORIDE",CC[NH+](CC)CC(C1=CC=CC=C1)OC(=O)C2=CC=CC=C2OCC.[Cl-],,,,,,
2264,52265,alpha-[(Diethylamino)methyl]benzyl alcohol o-ethoxybenzoate,CCN(CC)CC(C1=CC=CC=C1)OC(=O)C2=CC=CC=C2OCC,,,,,,
2265,52266,"BENZOIC ACID, m-(ETHYLSULFAMOYL)-, COPPER SALT (2:1), DIHYDRATE",CCNS(=O)(=O)C1=CC=CC(=C1)C(=O)[O-].CCNS(=O)(=O)C1=CC=CC(=C1)C(=O)[O-].[Cu+2],,,,,,
2266,52267,3-(N-Ethylsulfamoyl)benzoic acid,CCNS(=O)(=O)C1=CC=CC(=C1)C(=O)O,,,,,,
2267,52268,"Benzoic acid, p-(3-hydroxy-5-hydroxymethyl-2-methyl-4-pyridylmethyl)amino-, 2-diethylaminoethyl ester, dihydrochloride",CC[NH+](CC)CCOC(=O)C1=CC=C(C=C1)NCC2=C(C(=[NH+]C=C2CO)C)O.[Cl-].[Cl-],,,,,,
2268,52269,2-(Diethylamino)ethyl 4-[[3-hydroxy-5-(hydroxymethyl)-2-methylpyridin-4-yl]methylamino]benzoate,CCN(CC)CCOC(=O)C1=CC=C(C=C1)NCC2=C(C(=NC=C2CO)C)O,,,,,,
2269,52270,p-(o-Methoxybenzylidene)aminobenzoic acid ethyl ester,CCOC(=O)C1=CC=C(C=C1)N=CC2=CC=CC=C2OC,,,,,,
2270,52271,Ethyl 4-(m-nitrobenzylidene)aminobenzoate,CCOC(=O)C1=CC=C(C=C1)N=CC2=CC(=CC=C2)[N+](=O)[O-],,,,,,
2271,52272,"Benzoic acid, 3-[[(phenylamino)carbonyl]amino]-",C1=CC=C(C=C1)NC(=O)NC2=CC=CC(=C2)C(=O)O,,,,,,
2272,52273,"2,5-Dimethyl-4-nitrobenzonitrile",CC1=CC(=C(C=C1[N+](=O)[O-])C)C#N,,,,,,
2273,52274,"BENZO(b)PHENAZINE-2-CARBOXYLIC ACID, 5,12-DIHYDRO-, ETHYL ESTER",CCOC(=O)C1=CC2=C(C=C1)NC3=CC4=CC=CC=C4C=C3N2,,,,,,
2274,52275,"2H-1-Benzopyran-6-carboxylic acid, 3-glyoxyloyl-2-oxo-, ethyl ester",CCOC(=O)C1=CC2=C(C=C1)OC(=O)C(=C2)C(=O)C=O,,,,,,
2275,52276,"2H-1-Benzopyran-3-carboxylic acid, 6-nitro-2-oxo-, morpholinoethyl ester, hydrochloride",C1COCC[NH+]1CCOC(=O)C2=CC3=C(C=CC(=C3)[N+](=O)[O-])OC2=O.[Cl-],,,,,,
2276,52277,2-Morpholin-4-ylethyl 6-nitro-2-oxochromene-3-carboxylate,C1COCCN1CCOC(=O)C2=CC3=C(C=CC(=C3)[N+](=O)[O-])OC2=O,,,,,,
2277,52278,"Benzothiazole, 2-(bis(methylsulfonyl)amino)-",CS(=O)(=O)N(C1=NC2=CC=CC=C2S1)S(=O)(=O)C,,,,,,
2278,52279,"Benzothiazole, 2-(4-chloro-2-butynylthio)-",C1=CC=C2C(=C1)N=C(S2)SCC#CCCl,,,,,,
2279,52280,"Benzothiazole, 2-pentylthio-",CCCCCSC1=NC2=CC=CC=C2S1,,,,,,
2280,52281,"2-Benzothiazolethiol, 6-nitro-, sodium salt",C1=CC2=C(C=C1[N+](=O)[O-])SC(=N2)[S-].[Na+],,,,,,
2281,52282,3-(p-Hydroxyanilinomethyl)-benzothiazoline-2-thione hydrochloride,C1=CC=C2C(=C1)[NH+](C(=S)S2)CNC3=CC=C(C=C3)O.[Cl-],,,,,,
2282,52283,"3-[(4-Hydroxyanilino)methyl]-1,3-benzothiazole-2-thione",C1=CC=C2C(=C1)N(C(=S)S2)CNC3=CC=C(C=C3)O,,,,,,
2283,52284,"1,2-Bis(2-benzoxazolyl)cyclohexane",C1CCC(C(C1)C2=NC3=CC=CC=C3O2)C4=NC5=CC=CC=C5O4,,,,,,
2284,52285,"Benzoxazole, 2-diphenylmethyl-",C1=CC=C(C=C1)C(C2=CC=CC=C2)C3=NC4=CC=CC=C4O3,,,,,,
2285,52286,"Benzoxazole, 2-(1-ethylpropyl)-",CCC(CC)C1=NC2=CC=CC=C2O1,,,,,,
2286,52287,CID 52287,C1=CC(=C2C(=C1)OC(=N2)S)O,,,,,,
2287,52288,"Benzoxazolium, 2-[2-(acetylphenylamino)ethenyl]-3-ethyl-, iodide",CC[N+]1=C(OC2=CC=CC=C21)C=CN(C3=CC=CC=C3)C(=O)C.[I-],,,,,,
2288,52289,2-[2-(Acetylphenylamino)ethenyl]-3-ethylbenzoxazolium,CC[N+]1=C(OC2=CC=CC=C21)C=CN(C3=CC=CC=C3)C(=O)C,,,,,,
2289,52290,2-(benzothiazol-2-ylthio)-N'-benzylideneacetohydrazide,C1=CC=C(C=C1)C=NNC(=O)CSC2=NC3=CC=CC=C3S2,,,,,,
2290,52291,"1-Propanol, 2-bromo-3-chloro-",C(C(CCl)Br)O,,,,,,
2291,52292,"Benzoic acid, p-amino-, 2,2-dimethyl-2-(1-methylhexyl)aminoethyl ester, hydrochloride",CCCCCC(C)[NH2+]C(C)(C)COC(=O)C1=CC=C(C=C1)N.[Cl-],,,,,,
2292,52293,[2-(Heptan-2-ylamino)-2-methylpropyl] 4-aminobenzoate,CCCCCC(C)NC(C)(C)COC(=O)C1=CC=C(C=C1)N,,,,,,
2293,52294,"BENZOIC ACID, o-BUTOXY-, 2-(DIETHYLAMINO)ETHYL ESTER",CCCCOC1=CC=CC=C1C(=O)OCCN(CC)CC,,,,,,
2294,52295,2-(Morpholine-4-carbonyl)benzoic acid,C1COCCN1C(=O)C2=CC=CC=C2C(=O)O,,,,,,
2295,52296,4-((6-(Diethylamino)hexyl)amino)-6-methoxybenzothiazole oxalate,CC[NH+](CC)CCCCCCNC1=C2C(=CC(=C1)OC)SC=N2.C(=O)(C(=O)[O-])O,,,,,,
2296,52297,"N',N'-diethyl-N-(6-methoxy-1,3-benzothiazol-4-yl)hexane-1,6-diamine",CCN(CC)CCCCCCNC1=C2C(=CC(=C1)OC)SC=N2,,,,,,
2297,52298,"1,2-Bis(ethylsulfonyl)ethene",CCS(=O)(=O)C=CS(=O)(=O)CC,,,,,,
2298,52299,CID 52299,CC[NH+](C)CCN(CC1=CC(=CC=C1)Br)C2=CC=CC=N2.C(=CC(=O)[O-])C(=O)O,,,,,,
2299,52300,"N'-[(3-bromophenyl)methyl]-N-ethyl-N-methyl-N'-pyridin-2-ylethane-1,2-diamine",CCN(C)CCN(CC1=CC(=CC=C1)Br)C2=CC=CC=N2,,,,,,
2300,52301,"ETHYLENEDIAMINE, N-(5H-DIBENZO(a,d)CYCLOHEPTEN-5-YL)-N,N'-DIMETHYL-",CNCCN(C)C1C2=CC=CC=C2C=CC3=CC=CC=C13,,,,,,
2301,52302,"N,N'-Diethylthiomethyl-N,N'-dimethylethylenediamine dihydrochloride",CCSC[NH+](C)CC[NH+](C)CSCC.[Cl-].[Cl-],,,,,,
2302,52303,"N,N'-bis(ethylsulfanylmethyl)-N,N'-dimethylethane-1,2-diamine",CCSCN(C)CCN(C)CSCC,,,,,,
2303,52304,1-(2-Butoxyethenoxy)butane,CCCCOC=COCCCC,,,,,,
2304,52305,2-Methylaminofluorene hydrochloride,C[NH2+]C1=CC2=C(C=C1)C3=CC=CC=C3C2.[Cl-],,,,,,
2305,52306,"Fluorene-2,7-diamine, 1,3,6,8-tetrabromo-",C1C2=C(C(=C(C=C2C3=CC(=C(C(=C31)Br)N)Br)Br)N)Br,,,,,,
2306,52307,1-Fluorenemethanol,C1C2=CC=CC=C2C3=CC=CC(=C31)CO,,,,,,
2307,52308,"1,3-Dibromo-7-nitro-2-fluorenol",C1C2=C(C=CC(=C2)[N+](=O)[O-])C3=CC(=C(C(=C31)Br)O)Br,,,,,,
2308,52309,"Formamide, N-(1,3-dibromo-7-nitrofluoren-2-YL)-",C1C2=C(C=CC(=C2)[N+](=O)[O-])C3=CC(=C(C(=C31)Br)NC=O)Br,,,,,,
2309,52310,alpha-((Aminooxy)methyl)benzyl alcohol hydrochloride,C1=CC=C(C=C1)C(CO[NH3+])O.[Cl-],,,,,,
2310,52311,alpha-(Aminooxymethyl)benzyl alcohol,C1=CC=C(C=C1)C(CON)O,,,,,,
2311,52312,"BENZYL ALCOHOL, p-CHLORO-alpha-(BENZYLETHYLAMINO)METHYL-",CCN(CC1=CC=CC=C1)CC(C2=CC=C(C=C2)Cl)O,,,,,,
2312,52313,alpha-4-Dimethyl-alpha-(1-methylcyclopropyl)benzyl alcohol,CC1=CC=C(C=C1)C(C)(C2(CC2)C)O,,,,,,
2313,52314,4-Fluoro-alpha-methyl-alpha-(1-methylcyclopropyl)benzyl alcohol,CC1(CC1)C(C)(C2=CC=C(C=C2)F)O,,,,,,
2314,52315,"N,N-Diallyl-2-methoxy-5-nitrobenzylammonium chloride",COC1=C(C=C(C=C1)[N+](=O)[O-])C[NH+](CC=C)CC=C.[Cl-],,,,,,
2315,52316,N-[(2-methoxy-5-nitrophenyl)methyl]-N-prop-2-enylprop-2-en-1-amine,COC1=C(C=C(C=C1)[N+](=O)[O-])CN(CC=C)CC=C,,,,,,
2316,52317,"Benzylamine, 2,4-dichloro-N-(2-ethoxyethyl)-",CCOCCNCC1=C(C=C(C=C1)Cl)Cl,,,,,,
2317,52318,"Benzylamine, 3,4-dichloro-N-(2-ethoxyethyl)-",CCOCCNCC1=CC(=C(C=C1)Cl)Cl,,,,,,
2318,52319,"2,4-Dichlorobenzylamine hydrochloride",C1=CC(=C(C=C1Cl)Cl)C[NH3+].[Cl-],,,,,,
2319,52320,"alpha,N,N-Triethyl-p-methylbenzylamine hydrochloride",CCC(C1=CC=C(C=C1)C)[NH+](CC)CC.[Cl-],,,,,,
2320,52321,"N,N-diethyl-1-(4-methylphenyl)propan-1-amine",CCC(C1=CC=C(C=C1)C)N(CC)CC,,,,,,
2321,52322,"Benzylamine, 2,4,6-trinitro-",C1=C(C=C(C(=C1[N+](=O)[O-])CN)[N+](=O)[O-])[N+](=O)[O-],,,,,,
2322,52323,N-(2-(Ethylthio)ethyl)-p-chlorobenzylidenimine,CCSCCN=CC1=CC=C(C=C1)Cl,,,,,,
2323,52324,"6-Isopropyl-8-methylbicyclo(2.2.2)oct-5-ene-2,3-dicarboxylic anhydride",CC1CC2C3C(C1C=C2C(C)C)C(=O)OC3=O,,,,,,
2324,52325,CID 52325,C1=CC=C(C=C1)C(=O)C2=CC=C(C=C2)N=C(N)N=C([NH3+])N.[Cl-],,,,,,
2325,52326,2-(4-Benzoylphenyl)-1-(diaminomethylidene)guanidine,C1=CC=C(C=C1)C(=O)C2=CC=C(C=C2)N=C(N)N=C(N)N,,,,,,
2326,52327,CID 52327,B(C1=CC(=CC=C1)N=C(N)N=C([NH3+])N)(O)O.[Cl-],,,,,,
2327,52328,[3-[[Amino-(diaminomethylideneamino)methylidene]amino]phenyl]boronic acid,B(C1=CC(=CC=C1)N=C(N)N=C(N)N)(O)O,,,,,,
2328,52329,p-Methoxyphenylbiguanide dihydroiodide,COC1=CC=C(C=C1)[NH+]=C(N)[NH+]=C(N)N.[I-].[I-],,,,,,
2329,52330,"4-Biphenylamine, 3,2',4',6'-tetramethyl-",CC1=CC(=C(C(=C1)C)C2=CC(=C(C=C2)N)C)C,,,,,,
2330,52331,"4-Biphenylamine, 3,2',5'-trimethyl-",CC1=CC(=C(C=C1)C)C2=CC(=C(C=C2)N)C,,,,,,
2331,52332,5-Chloro-2-hydroxy-3-biphenylcarboxylic acid 2-(diisopropylamino)ethyl ester hydrochloride,CC(C)[NH+](CCOC(=O)C1=CC(=CC(=C1O)C2=CC=CC=C2)Cl)C(C)C.[Cl-],,,,,,
2332,52333,2-[Di(propan-2-yl)amino]ethyl 5-chloro-2-hydroxy-3-phenylbenzoate,CC(C)N(CCOC(=O)C1=CC(=CC(=C1O)C2=CC=CC=C2)Cl)C(C)C,,,,,,
2333,52334,"4-Biphenylcarboxylic acid, 3-(2-methylpiperidino)propyl ester, hydrochloride",CC1CCCC[NH+]1CCCOC(=O)C2=CC=C(C=C2)C3=CC=CC=C3.[Cl-],,,,,,
2334,52335,4-Amino-3-hydroxybiphenyl sulfate,C1=CC=C(C=C1)C2=CC(=C(C=C2)[NH3+])O.OS(=O)(=O)[O-],,,,,,
2335,52336,"1,1,5,5-Tetraethyl-3-(p-diethylaminophenyl)-2,4-dithiobiuret",CCN(CC)C1=CC=C(C=C1)N(C(=S)N(CC)CC)C(=S)N(CC)CC,,,,,,
2336,52337,CID 52337,CC(=O)O[C@H]1CC[C@]2([C@@H](C1)CC[C@@H]3[C@@H]2CC[C@]4([C@@]3(CC[C@@H]4C5=CSC(=N5)[NH3+])O)C)C.[Cl-],,,,,,
2337,52338,CID 52338,CC(=O)O[C@H]1CC[C@]2([C@@H](C1)CC[C@@H]3C2CC[C@]4([C@@]3(CC[C@@H]4C5=CSC(=N5)N)O)C)C,,,,,,
2338,52339,Naboctate,CCCCCCCC(C)C1=CC2=C(C3=C(CCC(C3)C)C(O2)(C)C)C(=C1)OC(=O)CCCN(CC)CC,,,,,,
2339,52340,"Benzylamine, N,N-dimethyl-, hexafluoroarsenate (1-)",C[NH+](C)CC1=CC=CC=C1.F[As-](F)(F)(F)(F)F,,,,,,
2340,52341,3-(Diethylamino)propyl 2-phenylbutyrate hydrochloride,CCC(C1=CC=CC=C1)C(=O)OCCC[NH+](CC)CC.[Cl-],,,,,,
2341,52342,3-(Diethylamino)propyl 2-phenylbutanoate,CCC(C1=CC=CC=C1)C(=O)OCCCN(CC)CC,,,,,,
2342,52343,"BUTYRIC ACID, 4-(p-TRIFLUOROACETAMIDOPHENYL)-, METHYL ESTER",COC(=O)CCCC1=CC=C(C=C1)NC(=O)C(F)(F)F,,,,,,
2343,52344,"Butyronitrile, 4-anilino-",C1=CC=C(C=C1)NCCCC#N,,,,,,
2344,52345,2-Benzyl-3-oxo-2-phenylbutyronitrile,CC(=O)C(CC1=CC=CC=C1)(C#N)C2=CC=CC=C2,,,,,,
2345,52346,"Butyronitrile, 2-carbamoyl-",CCC(C#N)C(=O)N,,,,,,
2346,52347,"Butyronitrile, 4-(dibutylamino)-, picrate",CCCC[NH+](CCCC)CCCC#N.C1=C(C=C(C(=C1[N+](=O)[O-])[O-])[N+](=O)[O-])[N+](=O)[O-],,,,,,
2347,52348,4-(Dibutylamino)butyronitrile,CCCCN(CCCC)CCCC#N,,,,,,
2348,52349,3-Amino-2-(2-(diisopropylamino)ethoxy)butyrophenone dihydrochloride,CC(C)[NH+](CCOC(C(C)[NH3+])C(=O)C1=CC=CC=C1)C(C)C.[Cl-].[Cl-],,,,,,
2349,52350,3-Amino-2-[2-[di(propan-2-yl)amino]ethoxy]-1-phenylbutan-1-one,CC(C)N(CCOC(C(C)N)C(=O)C1=CC=CC=C1)C(C)C,,,,,,
2350,52351,2-Bromo-2-methyl-4'-(p-nitrophenyl)butyrophenone,CCC(C)(C(=O)C1=CC=C(C=C1)C2=CC=C(C=C2)[N+](=O)[O-])Br,,,,,,
2351,52352,8-(Cycloheptyloxy)caffeine,CN1C2=C(N=C1OC3CCCCCC3)N(C(=O)N(C2=O)C)C,,,,,,
2352,52353,"Caffeine, 8-(cyclopentylmethyl)-",CN1C(=NC2=C1C(=O)N(C(=O)N2C)C)CC3CCCC3,,,,,,
2353,52354,8-(Cyclopentyloxy)caffeine,CN1C2=C(N=C1OC3CCCC3)N(C(=O)N(C2=O)C)C,,,,,,
2354,52355,"8-((3,4-Dihydro-2H-pyran-2-yl)oxy)caffeine",CN1C2=C(N=C1OC3CCC=CO3)N(C(=O)N(C2=O)C)C,,,,,,
2355,52356,"Caffeine, 8-(isopentylthio)-",CC(C)CCSC1=NC2=C(N1C)C(=O)N(C(=O)N2C)C,,,,,,
2356,52357,8-((3-Methylcyclohexyl)oxy)caffeine,CC1CCCC(C1)OC2=NC3=C(N2C)C(=O)N(C(=O)N3C)C,,,,,,
2357,52358,8-((cis-4-Methylcyclohexyl)oxy)caffeine,CC1CCC(CC1)OC2=NC3=C(N2C)C(=O)N(C(=O)N3C)C,,,,,,
2358,52359,"Caffeine, 8-(nonylthio)-",CCCCCCCCCSC1=NC2=C(N1C)C(=O)N(C(=O)N2C)C,,,,,,
2359,52360,"3,7-Dihydro-8-(1-propenyl)-1,3,7-trimethyl-1H-purine-2,6-dione",CC=CC1=NC2=C(N1C)C(=O)N(C(=O)N2C)C,,,,,,
2360,52361,N-(1-Benzyl-2-hydroxyethyl)carbamic acid benzyl ester,C1=CC=C(C=C1)CC(CO)NC(=O)OCC2=CC=CC=C2,,,,,,
2361,52362,"Carbamic acid, bis(diphenyldithio-, butynylene ester",C1=CC=C(C=C1)N(C2=CC=CC=C2)C(=S)SCC#CCSC(=S)N(C3=CC=CC=C3)C4=CC=CC=C4,,,,,,
2362,52363,CID 52363,CCOC(=NC(=O)C1=CC=C(C=C1)Br)S,,,,,,
2363,52364,"CARBAMIC ACID, DIETHYL-, p-ACETYLPHENYL ESTER",CCN(CC)C(=O)OC1=CC=C(C=C1)C(=O)C,,,,,,
2364,52365,CID 52365,CCN(CC)CCCCCN=C(S)S,,,,,,
2365,52366,"Benzenemethanol, alpha-ethyl-, carbamate",CCC(C1=CC=CC=C1)OC(=O)N,,,,,,
2366,52367,"Carbamic acid, ethylenebis((2-cyanoethyl)dithio-, disodium salt",C(CN(CCN(CCC#N)C(=S)[S-])C(=S)[S-])C#N.[Na+].[Na+],,,,,,
2367,52368,2-Cyanoethyl-[2-[2-cyanoethyl(dithiocarboxy)amino]ethyl]carbamodithioic acid,C(CN(CCN(CCC#N)C(=S)S)C(=S)S)C#N,,,,,,
2368,52369,CID 52369,CCCCCCCN=C(OCC)S,,,,,,
2369,52370,N-(1-Naphthyl)thiocarbamic acid S-(2-hydroxyethyl) ester,C1=CC=C2C(=C1)C=CC=C2NC(=O)SCCO,,,,,,
2370,52371,"N-[1-(7-bicyclo[4.2.0]octa-1,3,5-trienyl)hexylidene]hydroxylamine",CCCCCC(=NO)C1CC2=CC=CC=C12,,,,,,
2371,52372,"Ketone, 5-indolinyl methyl, hydriodide",CC(=O)C1=C2CC[NH2+]C2=CC=C1.[I-],,,,,,
2372,52373,"Ketone, indol-1-YL ethyl",CCC(=O)N1C=CC2=CC=CC=C21,,,,,,
2373,52374,(alpha-Methyl-m-trifluoromethylphenethylaminomethyl) piperidino ketone,CC(CC1=CC(=CC=C1)C(F)(F)F)NCC(=O)N2CCCCC2,,,,,,
2374,52375,4-Oxo-4-(3-propan-2-yloxypropylamino)but-2-enoic acid,CC(C)OCCCNC(=O)C=CC(=O)O,,,,,,
2375,52376,"Maleimide, 2,3-dichloro-N-decyl-",CCCCCCCC(C(CN1C(=O)C=CC1=O)Cl)Cl,,,,,,
2376,52377,"Malonic acid, acetamido(7-amino-3-indolylmethyl)-, diethyl ester",CCOC(=O)C(C(=O)OCC)NC(=O)CCC1=CNC2=C1C=CC=C2N,,,,,,
2377,52378,"Malonic acid, (3-bromo-4-hydroxybenzylidene)-",C1=CC(=C(C=C1C=C(C(=O)O)C(=O)O)Br)O,,,,,,
2378,52379,"Malonic acid, (3,5-dichloro-4-hydroxybenzylidene)-",C1=C(C=C(C(=C1Cl)O)Cl)C=C(C(=O)O)C(=O)O,,,,,,
2379,52380,"2-(3,5-Diiodo-4-(4-hydroxy-3-iodophenoxy)benzyl)malonic acid",C1=CC(=C(C=C1OC2=C(C=C(C=C2I)CC(C(=O)O)C(=O)O)I)I)O,,,,,,
2380,52381,"Malonic acid, oxo-, diethyl ester, dimethylhydrazone",CCOC(=O)C(=NN(C)C)C(=O)OCC,,,,,,
2381,52382,"MALONONITRILE, 4-CHLORO-3-NITROBENZYLIDENE-, compd. with TRIBUTYLPHOSPHINE",CCCCP(CCCC)CCCC.C1=CC(=C(C=C1C=C(C#N)C#N)[N+](=O)[O-])Cl,,,,,,
2382,52383,"Malononitrile, (1-ethynylcyclohexyl)-",C1CCC(CC1)C#CC(C#N)C#N,,,,,,
2383,52384,"MALONONITRILE, 2-(4-HYDROXY-3-IODO-5-METHOXYBENZYLIDENE)-compd. with MORPHOLINE",COC1=C(C(=CC(=C1)C=C(C#N)C#N)I)O.C1COCCN1,,,,,,
2384,52385,"Malononitrile, 4-hydroxy-3-iodo-5-methoxybenzylidene-, compd. with tributylphosphine",CCCCP(CCCC)CCCC.COC1=C(C(=CC(=C1)C=C(C#N)C#N)I)O,,,,,,
2385,52386,3-Methoxypropylammonium 4-dicyanovinyl-6-iodo-2-methoxyphenoxide,COCCCN.COC1=C(C(=CC(=C1)C=C(C#N)C#N)I)O,,,,,,
2386,52387,"MALONONITRILE, 2-METHOXYBENZYLIDENE-, compd. with TRIBUTYLPHOSPHINE",CCCCP(CCCC)CCCC.COC1=CC=CC=C1C=C(C#N)C#N,,,,,,
2387,52388,2-Cyano-3-methyl-4-phenylbutyronitrile,CC(CC1=CC=CC=C1)C(C#N)C#N,,,,,,
2388,52389,"Malononitrile, (7-oxo-14-dispiro(5.1.5.1)tetradecanylidene)-",C1CCC2(CC1)C(=C(C#N)C#N)C3(C2=O)CCCCC3,,,,,,
2389,52390,"Malonic acid, (3-chloro-4-hydroxybenzylidene)-",C1=CC(=C(C=C1C=C(C(=O)O)C(=O)O)Cl)O,,,,,,
2390,52391,"Mandelic acid, alpha-cyclohexyl-, 1-methyl-3-pyrrolidinylmethyl ester, hydrochloride",C[NH+]1CCC(C1)COC(=O)C(C2CCCCC2)(C3=CC=CC=C3)O.[Cl-],,,,,,
2391,52392,(1-Methylpyrrolidin-3-yl)methyl 2-cyclohexyl-2-hydroxy-2-phenylacetate,CN1CCC(C1)COC(=O)C(C2CCCCC2)(C3=CC=CC=C3)O,,,,,,
2392,52393,"Butyrophenone, 2-(piperidinomethyl)-4'-propoxy-, hydrochloride",CCCOC1=CC=C(C=C1)C(=O)C(CC)C[NH+]2CCCCC2.[Cl-],,,,,,
2393,52394,2-(Piperidin-1-ylmethyl)-1-(4-propoxyphenyl)butan-1-one,CCCOC1=CC=C(C=C1)C(=O)C(CC)CN2CCCCC2,,,,,,
2394,52395,"CARBAMIC ACID, tert-BUTYL-, m-(3,3-DIISOPROPYLUREIDO)PHENYL ESTER",CC(C)N(C(C)C)C(=O)NC1=CC(=CC=C1)OC(=O)NC(C)(C)C,,,,,,
2395,52396,"CARBAMIC ACID, N-(p-CHLOROBENZENESULFONYL), ETHYL ESTER, CYCLOHEXYLAMINE SALT",CCOC(=O)N=S(=O)(C1=CC=C(C=C1)Cl)[O-].C1CCC(CC1)[NH3+],,,,,,
2396,52397,4-chloro-N-ethoxycarbonylbenzenesulfonimidic acid,CCOC(=O)N=S(=O)(C1=CC=C(C=C1)Cl)O,,,,,,
2397,52398,Tri(diisobutylcarbinyl) borate,B(OC(C(C)CC)C(C)CC)(OC(C(C)CC)C(C)CC)OC(C(C)CC)C(C)CC,,,,,,
2398,52399,"Boric acid, tris(2,2,2-trichloro-1,1-dimethylethyl) ester",B(OC(C)(C)C(Cl)(Cl)Cl)(OC(C)(C)C(Cl)(Cl)Cl)OC(C)(C)C(Cl)(Cl)Cl,,,,,,
2399,52400,"2,3-Dimethylbuta-1,3-dienyl-(4-nitrophenyl)diazene",CC(=C)C(=CN=NC1=CC=C(C=C1)[N+](=O)[O-])C,,,,,,
2400,52401,"Butane, 1,4-bis(decylsulfonyl)-",CCCCCCCCCCS(=O)(=O)CCCCS(=O)(=O)CCCCCCCCCC,,,,,,
2401,52402,2-((p-Dimethylaminobenzylidene)amino)-1-butanol,CCC(CO)N=CC1=CC=C(C=C1)N(C)C,,,,,,
2402,52403,"N-(4,4-dimethoxybutan-2-ylideneamino)-N-methylmethanamine",CC(=NN(C)C)CC(OC)OC,,,,,,
2403,52404,"2-Butanone, 1-(1-naphthyloxy)-",CCC(=O)COC1=CC=CC2=CC=CC=C21,,,,,,
2404,52405,"[2,3-Diiodo-4-(2-iodoacetyl)oxybut-2-enyl] 2-iodoacetate",C(C(=C(COC(=O)CI)I)I)OC(=O)CI,,,,,,
2405,52406,CID 52406,CC(=O)OCC(=C(COC(=O)C)I)I,,,,,,
2406,52407,N-Benzyl-2-chloro-2-ethylbutyramide,CCC(CC)(C(=O)NCC1=CC=CC=C1)Cl,,,,,,
2407,52408,3-Hydroxy-N-(alpha-methyl-m-trifluoromethylphenethyl)butyramide,CC(CC1=CC(=CC=C1)C(F)(F)F)NC(=O)CC(C)O,,,,,,
2408,52409,"2-(p-(9-Acridinylamino)phenoxy)butyric acid, dihydrate",CCC(C(=O)O)OC1=CC=C(C=C1)NC2=C3C=CC=CC3=[NH+]C4=CC=CC=C42.[Cl-],,,,,,
2409,52410,2-[4-(Acridin-9-ylamino)phenoxy]butanoic acid,CCC(C(=O)O)OC1=CC=C(C=C1)NC2=C3C=CC=CC3=NC4=CC=CC=C42,,,,,,
2410,52411,"BUTYRIC ACID, beta-AMINO-beta-UREIDO-, ETHYL ESTER",CCOC(=O)CC(C)(N)NC(=O)N,,,,,,
2411,52412,Ethyl 2-(9-anthracenylmethylene)-3-oxobutanoate,CCOC(=O)C(=CC1=C2C=CC=CC2=CC3=CC=CC=C31)C(=O)C,,,,,,
2412,52413,2-Chloro-2-methylbutyric acid,CCC(C)(C(=O)O)Cl,,,,,,
2413,52414,"2-Cyano-3,3-diphenylbutyric acid ethyl ester",CCOC(=O)C(C#N)C(C)(C1=CC=CC=C1)C2=CC=CC=C2,,,,,,
2414,52415,Dicarboxydine,C1=CC(=C(C=C1C2=CC(=C(C=C2)OCCCC(=O)O)N)N)OCCCC(=O)O,,,,,,
2415,52416,"2,2-Diphenyl-4-mercaptobutyric acid",C1=CC=C(C=C1)C(CCS)(C2=CC=CC=C2)C(=O)O,,,,,,
2416,52417,"4-(3-Hydroxy-5-hydroxymethyl-2-methyl-4-pyridyl)methylaminobutyric acid, hydrochloride",CC1=NC=C(C(=C1O)C[NH2+]CCCC(=O)O)CO.[Cl-],,,,,,
2417,52418,4-[[(5-(Hydroxymethyl)-2-methyl-3-hydroxypyridin-4-yl)methyl]amino]butyric acid,CC1=NC=C(C(=C1O)CNCCCC(=O)O)CO,,,,,,
2418,52419,"Butyric acid, 4-(p-(9-(3-methylaminoacridinyl)amino)phenyl)-, hydrochloride, hemihydrate",C[NH2+]C1=CC2=NC3=CC=CC=C3C(=C2C=C1)NC4=CC=C(C=C4)CCCC(=O)O.[Cl-],,,,,,
2419,52420,4-[4-[[3-(Methylamino)acridin-9-yl]amino]phenyl]butanoic acid,CNC1=CC2=NC3=CC=CC=C3C(=C2C=C1)NC4=CC=C(C=C4)CCCC(=O)O,,,,,,
2420,52421,"[2-[(8S,9S,10R,11S,13S,14S,17R)-17-ethoxycarbonyloxy-11-hydroxy-10,13-dimethyl-3-oxo-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-17-yl]-2-oxoethyl] propanoate",CCC(=O)OCC(=O)C1(CCC2C1(CC(C3C2CCC4=CC(=O)C=CC34C)O)C)OC(=O)OCC,,,,,,
2421,52422,"N,N'-Diphenyl-N'-carboxymethylurea",C1=CC=C(C=C1)NC(=O)N(CC(=O)O)C2=CC=CC=C2,,,,,,
2422,52423,CID 52423,C(=NN=C(S)[S-])(N)S.[K+],,,,,,
2423,52424,CID 52424,C(=NN=C(S)S)(N)S,,,,,,
2424,52425,"Carbazole-2-carbonitrile, 5,6,7,8-tetrahydro-1-methyl-",CC1=C(C=CC2=C1NC3=C2CCCC3)C#N,,,,,,
2425,52426,"CARBONIC ACID, DIESTER with 4'-HYDROXYACETOPHENONE",CC(=O)C1=CC=C(C=C1)OC(=O)OC2=CC=C(C=C2)C(=O)C,,,,,,
2426,52427,p-Xylylenebis(O-methylxanthate),COC(=S)SCC1=CC=C(C=C1)CSC(=S)OC,,,,,,
2427,52428,"5-(2-(N-(2-Chloroethyl)-N-ethylamino)ethoxy)carvacrol 1,5-naphthalenedisulfonate",CC[NH+](CCOC1=C(C=C(C(=C1)C)O)C(C)C)CCCl.C1=CC2=C(C=CC=C2S(=O)(=O)[O-])C(=C1)S(=O)(=O)O,,,,,,
2428,52429,4-[2-[2-Chloroethyl(ethyl)amino]ethoxy]-2-methyl-5-propan-2-ylphenol,CCN(CCOC1=C(C=C(C(=C1)C)O)C(C)C)CCCl,,,,,,
2429,52430,"5-(2-((2-Chloroethyl)ethylamino)ethoxy)carvacrol 3,4,5-trimethoxybenzylate hydrochloride",CC[NH+](CCOC1=C(C=C(C(=C1)C)OC(=O)C2=CC(=C(C(=C2)OC)OC)OC)C(C)C)CCCl.[Cl-],,,,,,
2430,52431,"[4-[2-[2-Chloroethyl(ethyl)amino]ethoxy]-2-methyl-5-propan-2-ylphenyl] 3,4,5-trimethoxybenzoate",CCN(CCOC1=C(C=C(C(=C1)C)OC(=O)C2=CC(=C(C(=C2)OC)OC)OC)C(C)C)CCCl,,,,,,
2431,52432,"5-(2-(N,N-Dimethylamino)ethoxy)carvacrol benzylate hydrochloride",CC1=CC(=C(C=C1OC(=O)C2=CC=CC=C2)C(C)C)OCC[NH+](C)C.[Cl-],,,,,,
2432,52433,[4-[2-(Dimethylamino)ethoxy]-2-methyl-5-propan-2-ylphenyl] benzoate,CC1=CC(=C(C=C1OC(=O)C2=CC=CC=C2)C(C)C)OCCN(C)C,,,,,,
2433,52434,"5-(2-(N,N-Dimethylamino)ethoxy)carvacrol p-bromobenzylate hydrochloride",CC1=CC(=C(C=C1OC(=O)C2=CC=C(C=C2)Br)C(C)C)OCC[NH+](C)C.[Cl-],,,,,,
2434,52435,[4-[2-(Dimethylamino)ethoxy]-2-methyl-5-propan-2-ylphenyl] 4-bromobenzoate,CC1=CC(=C(C=C1OC(=O)C2=CC=C(C=C2)Br)C(C)C)OCCN(C)C,,,,,,
2435,52436,"5-(2-(N,N-Dimethylamino)ethoxy)carvacrol 2-nitrobenzylate hydrochloride",CC1=CC(=C(C=C1OC(=O)C2=CC=CC=C2[N+](=O)[O-])C(C)C)OCC[NH+](C)C.[Cl-],,,,,,
2436,52437,[4-[2-(Dimethylamino)ethoxy]-2-methyl-5-propan-2-ylphenyl] 2-nitrobenzoate,CC1=CC(=C(C=C1OC(=O)C2=CC=CC=C2[N+](=O)[O-])C(C)C)OCCN(C)C,,,,,,
2437,52438,"2,3-Dimethyl-7-methoxy-8-morpholinochromone hydrochloride",CC1=C(OC2=C(C1=O)C=CC(=C2[NH+]3CCOCC3)OC)C.[Cl-],,,,,,
2438,52439,"7-Methoxy-2,3-dimethyl-8-morpholin-4-ylchromen-4-one",CC1=C(OC2=C(C1=O)C=CC(=C2N3CCOCC3)OC)C,,,,,,
2439,52440,"trans-1,2,3,4-Tetrahydrochrysene-1,2-diol",C1CC2=C(C=CC3=C2C=CC4=CC=CC=C43)[C@H]([C@@H]1O)O,,,,,,
2440,52441,Cinchonidine ethiodide,CC[N+]12CCC(C[C@@H]1[C@H](C3=CC=NC4=CC=CC=C34)O)C(C2)C=C.[I-],,,,,,
2441,52442,(S)-[(2R)-5-ethenyl-1-ethyl-1-azoniabicyclo[2.2.2]octan-2-yl]-quinolin-4-ylmethanol,CC[N+]12CCC(C[C@@H]1[C@H](C3=CC=NC4=CC=CC=C34)O)C(C2)C=C,,,,,,
2442,52443,"Quinuclidinium, 6-(hydroxy(6-methoxy-4-quinolinyl)methyl)-1-ethyl-3-vinyl-, iodide",CC[N+]12CCC(C[C@@H]1[C@H](C3=C4C=C(C=CC4=NC=C3)OC)O)C(C2)C=C.[I-],,,,,,
2443,52444,"BENZO(a)PYRENE-7,8-DIOL, DIACETATE (ester), (E)-",CC(=O)OC1=C(C2=C(C=C1)C3=C4C(=C2)C=CC5=C4C(=CC=C5)C=C3)OC(=O)C,,,,,,
2444,52445,N-Nitrosocimetidine,CC1=C(N=CN1)CSCCN=C(NC#N)N(C)N=O,,,,,,
2445,52446,"Methanesulfonic acid--1-(8-hydroxy-3,6,11-trimethyl-1,2,3,4,5,6-hexahydro-2,6-methano-3-benzazocin-11-yl)octan-3-one (1/1)",CCCCCC(=O)CCC1(C2CC3=C(C1(CCN2C)C)C=C(C=C3)O)C.CS(=O)(=O)O,,,,,,
2446,52447,"1-(8-Hydroxy-3,6,11-trimethyl-1,2,3,4,5,6-hexahydro-2,6-methano-3-benzazocin-11-yl)octan-3-one",CCCCCC(=O)CCC1(C2CC3=C(C1(CCN2C)C)C=C(C=C3)O)C,,,,,,
2447,52448,CID 52448,COC(=O)C=C(C(=O)OC)OC1=C(C=C(C=C1)Cl)Cl,,,,,,
2448,52449,5-(2-(N-(2-Chloroethyl)-N-ethylamino)ethoxy)carvacryl benzylate hydrochloride,CC[NH+](CCOC1=C(C=C(C(=C1)C)OC(=O)C2=CC=CC=C2)C(C)C)CCCl.[Cl-],,,,,,
2449,52450,[4-[2-[2-Chloroethyl(ethyl)amino]ethoxy]-2-methyl-5-propan-2-ylphenyl] benzoate,CCN(CCOC1=C(C=C(C(=C1)C)OC(=O)C2=CC=CC=C2)C(C)C)CCCl,,,,,,
2450,52451,2-(Benzylthio)-3-phenylpropenamide,C1=CC=C(C=C1)CSC(=CC2=CC=CC=C2)C(=O)N,,,,,,
2451,52452,"N-methyl-3-(3,4,5-trimethoxyphenyl)prop-2-enamide",CNC(=O)C=CC1=CC(=C(C(=C1)OC)OC)OC,,,,,,
2452,52453,CID 52453,CC1=CC=C(C=C1)SC(=CC2=CC=CC=C2)C(=O)N,,,,,,
2453,52454,CID 52454,CC[NH+](CC)CCCC(C)OC(=O)C=CC1=CC=CC=C1.[Cl-],,,,,,
2454,52455,5-(Diethylamino)pentan-2-yl 3-phenylprop-2-enoate,CCN(CC)CCCC(C)OC(=O)C=CC1=CC=CC=C1,,,,,,
2455,52456,CID 52456,C[NH+](C)CCOC(=O)C(=CC1=CC=C(C=C1)OC)C2=CC=C(C=C2)OC.[Cl-],,,,,,
2456,52457,"2-(Dimethylamino)ethyl 2,3-bis(4-methoxyphenyl)prop-2-enoate",CN(C)CCOC(=O)C(=CC1=CC=C(C=C1)OC)C2=CC=C(C=C2)OC,,,,,,
2457,52458,CID 52458,C[NH+](C)CCOC(=O)C(=CC1=CC=C(C=C1)OC)C2=CC=C(C=C2)[N+](=O)[O-].[Cl-],,,,,,
2458,52459,2-(Dimethylamino)ethyl 3-(4-methoxyphenyl)-2-(4-nitrophenyl)prop-2-enoate,CN(C)CCOC(=O)C(=CC1=CC=C(C=C1)OC)C2=CC=C(C=C2)[N+](=O)[O-],,,,,,
2459,52460,CID 52460,C[NH+](C)CCOC(=O)C(=CC1=CC=CC=C1)C2=CC=C(C=C2)OC.[Cl-],,,,,,
2460,52461,2-(Dimethylamino)ethyl 2-(4-methoxyphenyl)-3-phenylprop-2-enoate,CN(C)CCOC(=O)C(=CC1=CC=CC=C1)C2=CC=C(C=C2)OC,,,,,,
2461,52462,CID 52462,C[NH+](C)CCOC(=O)C(=CC1=CC=C(C=C1)OC)C2=CC=CC=C2.[Cl-],,,,,,
2462,52463,2-(Dimethylamino)ethyl 3-(4-methoxyphenyl)-2-phenylprop-2-enoate,CN(C)CCOC(=O)C(=CC1=CC=C(C=C1)OC)C2=CC=CC=C2,,,,,,
2463,52464,CID 52464,C[NH+](C)CCOC(=O)C(=CC1=CC=CC=C1)C2=CC=C(C=C2)[N+](=O)[O-].[Cl-],,,,,,
2464,52465,CID 52465,CN(C)CCOC(=O)C(=CC1=CC=CC=C1)C2=CC=C(C=C2)[N+](=O)[O-],,,,,,
2465,52466,CID 52466,C[NH+](C)CCOC(=O)C(=CC1=CC=C(C=C1)[N+](=O)[O-])C2=CC=CC=C2.[Cl-],,,,,,
2466,52467,CID 52467,CN(C)CCOC(=O)C(=CC1=CC=C(C=C1)[N+](=O)[O-])C2=CC=CC=C2,,,,,,
2467,52468,CID 52468,C[NH+](C)CCOC(=O)C(=CC1=CC=CC=C1)C2=CC=CC=C2.[Cl-],,,,,,
2468,52469,"2-(Dimethylamino)ethyl 2,3-diphenylprop-2-enoate",CN(C)CCOC(=O)C(=CC1=CC=CC=C1)C2=CC=CC=C2,,,,,,
2469,52470,"CINNAMONITRILE, beta-ACETAMIDOMETHYL-alpha-CYANO-p-(METHYLTHIO)-",CC(=O)NCC(=C(C#N)C#N)C1=CC=C(C=C1)SC,,,,,,
2470,52471,CID 52471,CCC1=C(C(=CC=C1)CC)C2=C(OC3=CC=CC=C3C2=O)O,,,,,,
2471,52472,CID 52472,CC1=C(C(=CC=C1)C2=C(OC3=CC=CC=C3C2=O)O)C,,,,,,
2472,52473,CID 52473,CC1=CC(=C(C=C1)C2=C(OC3=CC=CC=C3C2=O)O)C,,,,,,
2473,52474,CID 52474,CC1=CC(=C(C=C1)C)C2=C(OC3=CC=CC=C3C2=O)O,,,,,,
2474,52475,CID 52475,CC1=C(C(=CC=C1)C)C2=C(OC3=CC=CC=C3C2=O)O,,,,,,
2475,52476,CID 52476,CC1=C(C=C(C=C1)C2=C(OC3=CC=CC=C3C2=O)O)C,,,,,,
2476,52477,CID 52477,CCC1=CC=CC=C1C2=C(OC3=CC=CC=C3C2=O)O,,,,,,
2477,52478,CID 52478,CC(C)C1=CC=CC=C1C2=C(OC3=CC=CC=C3C2=O)O,,,,,,
2478,52479,CID 52479,C1=CC=C2C=C(C=CC2=C1)C3=C(OC4=CC=CC=C4C3=O)O,,,,,,
2479,52480,CID 52480,CC1=CC(=CC=C1)C2=C(OC3=CC=CC=C3C2=O)O,,,,,,
2480,52481,CID 52481,CC1=CC=CC=C1C2=C(OC3=CC=CC=C3C2=O)O,,,,,,
2481,52482,CID 52482,CC1=CC=C(C=C1)C2=C(OC3=CC=CC=C3C2=O)O,,,,,,
2482,52483,"o-CRESOL, 6-CHLORO-4-NITROSO-",CC1=CC(=CC(=C1O)Cl)N=O,,,,,,
2483,52484,CID 52484,CC[NH+](CC)CC1=C(C=CC(=C1)NC2=C3C=CC(=CC3=NC=C2)C)O.[Cl-],,,,,,
2484,52485,2-(Diethylaminomethyl)-4-[(7-methylquinolin-4-yl)amino]phenol,CCN(CC)CC1=C(C=CC(=C1)NC2=C3C=CC(=CC3=NC=C2)C)O,,,,,,
2485,52486,"o-CRESOL, alpha,alpha'-(HEXAMETHYLENEDINITRILO)BIS(4-CHLORO-",C1=CC(=C(C=C1Cl)CN=CCCCCC=NCC2=C(C=CC(=C2)Cl)O)O,,,,,,
2486,52487,"3-{2-[(Anthracen-1-yl)methylidene]hydrazinyl}-1H-1lambda~6~-thiophene-1,1-dione",C1=CC=C2C=C3C(=CC2=C1)C=CC=C3C=NNC4=CS(=O)(=O)C=C4,,,,,,
2487,52488,"Anthra(1,9-cd)pyrazol-6-one, 2-(9-(anthraquinonylamino)-7-oxo-7H-benz(de)anthracen-3-yl)-",C1=CC=C2C(=C1)C3=NN(C4=CC=CC(=C43)C2=O)C5=C6C=CC=C7C6=C(C=C5)C8=C(C7=O)C=C(C=C8)NC9=CC=CC1=C9C(=O)C2=CC=CC=C2C1=O,,,,,,
2488,52489,"ANTHRA(1,9-cd)PYRAZOL-6-ONE, 2-(7-OXO-7H-BENZ(de)ANTHRACEN-1-YL)-",C1=CC=C2C(=C1)C3=C(C=CC4=C3C(=CC=C4)C2=O)N5C6=CC=CC7=C6C(=N5)C8=CC=CC=C8C7=O,,,,,,
2489,52490,"Anthraquinone, 1-amino-2-bromo-4-(2-(2-hydroxyethyl)sulfonyl-4-methylphenylamino)-",CC1=CC(=C(C=C1)NC2=CC(=C(C3=C2C(=O)C4=CC=CC=C4C3=O)N)Br)S(=O)(=O)CCO,,,,,,
2490,52491,"ANTHRAQUINONE, 1,4-BIS(p-HYDROXYANILINO)-5,8-DIHYDROXY-",C1=CC(=CC=C1NC2=C3C(=C(C=C2)NC4=CC=C(C=C4)O)C(=O)C5=C(C=CC(=C5C3=O)O)O)O,,,,,,
2491,52492,"ANTHRAQUINONE, 1-(7-OXO-7H-BENZ(de)ANTHRACEN-2-YLAMINO)-",C1=CC=C2C(=C1)C3=C4C(=CC(=C3)NC5=CC=CC6=C5C(=O)C7=CC=CC=C7C6=O)C=CC=C4C2=O,,,,,,
2492,52493,"Anthraquinone, 1-(2,4,6-trimethylphenylamino)-",CC1=CC(=C(C(=C1)C)NC2=CC=CC3=C2C(=O)C4=CC=CC=C4C3=O)C,,,,,,
2493,52494,"9,10-Dihydro-9-anthroic acid 2-(diethylamino)propyl ester hydrochloride",CC[NH+](CC)C(C)COC(=O)C1C2=CC=CC=C2CC3=CC=CC=C13.[Cl-],,,,,,
2494,52495,"2-(Diethylamino)propyl 9,10-dihydroanthracene-9-carboxylate",CCN(CC)C(C)COC(=O)C1C2=CC=CC=C2CC3=CC=CC=C13,,,,,,
2495,52496,CID 52496,CC1CCCC(N1N=C(C2=C(N(N(C2=O)C3=CC=CC=C3)C)C)S)C,,,,,,
2496,52497,CID 52497,CC1CCN(CC1)C(=NC2=C(N(N(C2=O)C3=CC=CC=C3)C)C)S,,,,,,
2497,52498,CID 52498,CC1=C(C(=O)N(N1C)C2=CC=CC=C2)N=C(N3CCOCC3)S,,,,,,
2498,52499,Ocoteine,CN1CCC2=C3[C@@H]1CC4=CC(=C(C=C4C3=C5C(=C2OC)OCO5)OC)OC,,,,,,
2499,52500,N-alpha-Tosyl-L-arginine trihydrate,CC1=CC=C(C=C1)S(=O)(=O)N[C@@H](CCCN=C(N)N)C(=O)O.O.O.O,,,,,,
2500,52501,Tos-Arg-OH,CC1=CC=C(C=C1)S(=O)(=O)N[C@@H](CCCN=C(N)N)C(=O)O,,,,,,
2501,52502,"ARSINE, (p-AMINOPHENYL)OXO-, DIHYDRATE",C1=CC(=CC=C1N)[As]=O.O.O,,,,,,
2502,52503,Butyl(isopropyl)arsinic acid,CCCC[As](=O)(C(C)C)O,,,,,,
2503,52504,"3-(2,4-Dichlorophenoxy)-2-hydroxypropyl-o-chlorophenyl arsinic acid",C1=CC=C(C(=C1)Cl)[As](=O)(CC(COC2=C(C=C(C=C2)Cl)Cl)O)O,,,,,,
2504,52505,"ARSINE OXIDE, (p-CHLOROPHENYL)HYDROXYMETHYL-",C[As](=O)(C1=CC=C(C=C1)Cl)O,,,,,,
2505,52506,"Arsine oxide, hydroxyisobutylisopropyl-",CC(C)C[As](=O)(C(C)C)O,,,,,,
2506,52507,"Atropine, sulfate (2:1), dihydrate",CN1C2CCC1CC(C2)OC(=O)C(CO)C3=CC=CC=C3.CN1C2CCC1CC(C2)OC(=O)C(CO)C3=CC=CC=C3.O.O.OS(=O)(=O)O,,,"['Agents used for the treatment or prevention of cardiac arrhythmias. They may affect the polarization-repolarization phase of the action potential, its excitability or refractoriness, or impulse conduction or membrane responsiveness within cardiac fibers. Anti-arrhythmia agents are often classed into four main groups according to their mechanism of action: sodium channel blockade, beta-adrenergic blockade, repolarization prolongation, or calcium channel blockade. (See all compounds classified as Anti-Arrhythmia Agents.)', 'Agents that are administered in association with anesthetics to increase effectiveness, improve delivery, or decrease required dosage. (See all compounds classified as Adjuvants, Anesthesia.)', 'Agents that inhibit the actions of the parasympathetic nervous system. The major group of drugs used therapeutically for this purpose is the MUSCARINIC ANTAGONISTS. (See all compounds classified as Parasympatholytics.)', 'Agents that cause an increase in the expansion of a bronchus or bronchial tubes. (See all compounds classified as Bronchodilator Agents.)', 'Drugs that bind to but do not activate MUSCARINIC RECEPTORS, thereby blocking the actions of endogenous ACETYLCHOLINE or exogenous agonists. Muscarinic antagonists have widespread effects including actions on the iris and ciliary muscle of the eye, the heart and blood vessels, secretions of the respiratory tract, GI system, and salivary glands, GI motility, urinary bladder tone, and the central nervous system. (See all compounds classified as Muscarinic Antagonists.)', 'Agents that dilate the pupil. They may be either sympathomimetics or parasympatholytics. (See all compounds classified as Mydriatics.)']",,,
2507,52508,CID 52508,C1CC2C[C@@H]1[C@H]3[C@@H]2CN(C3)NC(=O)C4=CC(=C(C=C4)Cl)S(=O)(=O)N,,,"['Agents that inhibit SODIUM-POTASSIUM-CHLORIDE SYMPORTERS which are concentrated in the thick ascending limb at the junction of the LOOP OF HENLE and KIDNEY TUBULES, DISTAL. They act as DIURETICS. Excess use is associated with HYPOKALEMIA and HYPERGLYCEMIA. (See all compounds classified as Sodium Potassium Chloride Symporter Inhibitors.)']",,,
2508,52509,Cinchonine ethiodide,CC[N+]12CCC(CC1[C@@H](C3=CC=NC4=CC=CC=C34)O)C(C2)C=C.[I-],,,,,,
2509,52510,(R)-(5-ethenyl-1-ethyl-1-azoniabicyclo[2.2.2]octan-2-yl)-quinolin-4-ylmethanol,CC[N+]12CCC(CC1[C@@H](C3=CC=NC4=CC=CC=C34)O)C(C2)C=C,,,,,,
2510,52511,"Ethylquinidinium, iodide",CC[N+]12CCC(C[C@@H]1[C@H](C3=C4C=C(C=CC4=NC=C3)OC)O)[C@H](C2)C=C.[I-],,,,,,
2511,52512,"(S)-[(2R,5R)-5-ethenyl-1-ethyl-1-azoniabicyclo[2.2.2]octan-2-yl]-(6-methoxyquinolin-4-yl)methanol",CC[N+]12CCC(C[C@@H]1[C@H](C3=C4C=C(C=CC4=NC=C3)OC)O)[C@H](C2)C=C,,,,,,
2512,52513,Cinchonidine methiodide,C[N+]12CCC(C[C@@H]1[C@H](C3=CC=NC4=CC=CC=C34)O)C(C2)C=C.[I-],,,,,,
2513,52514,(S)-(5-ethenyl-1-methyl-1-azoniabicyclo[2.2.2]octan-2-yl)-quinolin-4-ylmethanol,C[N+]12CCC(CC1[C@H](C3=CC=NC4=CC=CC=C34)O)C(C2)C=C,,,,,,
2514,52515,(9S)-9-Hydroxy-1-methylcinchonan-1-ium iodide,C[N+]12CCC(CC1[C@@H](C3=CC=NC4=CC=CC=C34)O)C(C2)C=C.[I-],,,,,,
2515,52516,(R)-(5-ethenyl-1-methyl-1-azoniabicyclo[2.2.2]octan-2-yl)-quinolin-4-ylmethanol,C[N+]12CCC(CC1[C@@H](C3=CC=NC4=CC=CC=C34)O)C(C2)C=C,,,,,,
2516,52517,CID 52517,CC[NH+](CC)CCCCCOC(=O)C=CCC1CCC2C(C1)OCO2.[Cl-],,,,,,
2517,52518,CID 52518,CCN(CC)CCCCCOC(=O)C=CCC1CCC2C(C1)OCO2,,,,,,
2518,52519,"3-Methylcyclobutane-1,2-dicarboxylic acid",CC1CC(C1C(=O)O)C(=O)O,,,,,,
2519,52520,"4-(m-Chlorophenyl)-2,3-diphenyl-1,2,4-oxadiazolidin-5-one",C1=CC=C(C=C1)C2N(OC(=O)N2C3=CC(=CC=C3)Cl)C4=CC=CC=C4,,,,,,
2520,52521,"1-OXASPIRO(2,5)OCTANE-2-CARBOXYLIC ACID, tert-BUTYL ESTER",CC(C)(C)OC(=O)C1CCCC2(O1)CC2,,,,,,
2521,52522,"1,4-OXATHIANE compd. with MERCURIC CHLORIDE",C1CSCCO1.Cl[Hg]Cl,,,,,,
2522,52523,"1,3-Cyclobutanediol, 2,2,4,4-tetramethyl-, bis(trichloroacetate)",CC1(C(C(C1OC(=O)C(Cl)(Cl)Cl)(C)C)OC(=O)C(Cl)(Cl)Cl)C,,,,,,
2523,52524,"1,3-Cyclobutanedione, 2,2,4,4-tetramethyl-, disemicarbazone",CC1(C(=NNC(=O)N)C(C1=NNC(=O)N)(C)C)C,,,,,,
2524,52525,"Cyclohept(b)indole, 5,6,7,8,9,10-hexahydro-10-(3-(dimethylamino)propyl)-2-fluoro-, hydrochloride",C[NH+](C)CCCC1CCCCC2=C1C3=C(N2)C=CC(=C3)F.[Cl-],,,,,,
2525,52526,"3-(2-fluoro-5,6,7,8,9,10-hexahydrocyclohepta[b]indol-10-yl)-N,N-dimethylpropan-1-amine",CN(C)CCCC1CCCCC2=C1C3=C(N2)C=CC(=C3)F,,,,,,
2526,52527,"Cyclohept(b)indole, 5,6,7,8,9,10-hexahydro-5-(3-(dimethylamino)propyl)-, hydrochloride",C[NH+](C)CCCN1C2=C(CCCCC2)C3=CC=CC=C31.[Cl-],,,,,,
2527,52528,"N,N-dimethyl-3-(7,8,9,10-tetrahydro-6H-cyclohepta[b]indol-5-yl)propan-1-amine",CN(C)CCCN1C2=C(CCCCC2)C3=CC=CC=C31,,,,,,
2528,52529,"2-(3-Chloro-4-hydroxyiminocyclohexa-2,5-dien-1-ylidene)-2-(4-methoxyphenyl)acetonitrile",COC1=CC=C(C=C1)C(=C2C=CC(=NO)C(=C2)Cl)C#N,,,,,,
2529,52530,CID 52530,CC1=CC(=C(C#N)C2=CC=C(C=C2)OC)C=CC1=NO,,,,,,
2530,52531,"3-p-Chlorophenyl-1,1-dimethylguanidine hydroiodide trihydrate",CN(C)C(=N)[NH2+]C1=CC=C(C=C1)Cl.[I-],,,,,,
2531,52532,"2-(4-Chlorophenyl)-1,1-dimethylguanidine",CN(C)C(=NC1=CC=C(C=C1)Cl)N,,,,,,
2532,52533,CID 52533,C1=CC=C(C=C1)C(C2=CC=CC=C2)OCCN=C([NH3+])N.C(=CC(=O)[O-])C(=O)O,,,,,,
2533,52534,"Guanidine, (2-benzhydryloxyethyl)-",C1=CC=C(C=C1)C(C2=CC=CC=C2)OCCN=C(N)N,,,,,,
2534,52535,CID 52535,C1C(NC2=CC=CC=C21)CC[NH2+]C(=N)[NH3+].[O-]S(=O)(=O)[O-],,,,,,
2535,52536,"2-[2-(2,3-dihydro-1H-indol-2-yl)ethyl]guanidine",C1C(NC2=CC=CC=C21)CCN=C(N)N,,,,,,
2536,52537,"Heptadecanamide, 16-methyl-N-(3-morpholinopropyl)-, lactate",CC(C)CCCCCCCCCCCCCCC(=O)NCCC[NH+]1CCOCC1.CC(C(=O)[O-])O,,,,,,
2537,52538,Isostearamidopropyl morpholine,CC(C)CCCCCCCCCCCCCCC(=O)NCCCN1CCOCC1,,,,,,
2538,52539,"Heptane, hexyldiazeno-",CCCCCCCN=NCCCCCC,,,,,,
2539,52540,"Heptanoic acid, 7-(N,N-diethylthiocarbamoylthio)-",CCN(CC)C(=S)SCCCCCCC(=O)O,,,,,,
2540,52541,"2,6-Dimethyl-2,3,5,6-tetrabromo-4-heptanone",CC(C)(C(C(=O)C(C(C)(C)Br)Br)Br)Br,,,,,,
2541,52542,Cimoxatone,COCC1CN(C(=O)O1)C2=CC=C(C=C2)OCC3=CC(=CC=C3)C#N,,,"['A chemically heterogeneous group of drugs that have in common the ability to block oxidative deamination of naturally occurring monoamines. (From Gilman, et al., Goodman and Gilman&apos;s The Pharmacological Basis of Therapeutics, 8th ed, p414) (See all compounds classified as Monoamine Oxidase Inhibitors.)']",,,
2542,52543,CID 52543,CC1(C(=NN=C(N)S)C(C1=NN=C(N)S)(C)C)C,,,,,,
2543,52544,CID 52544,C(CCl)N=NC(=N)[NH3+].[Cl-],,,,,,
2544,52545,1-(2-Chloroethylimino)guanidine,C(CCl)N=NC(=N)N,,,,,,
2545,52546,"Indole, 3-(5-(dimethylamino)pentyl)-, adipinate",C[NH+](C)CCCCCC1=CNC2=CC=CC=C21.C(CCC(=O)[O-])CC(=O)O,,,,,,
2546,52547,"5-(1H-indol-3-yl)-N,N-dimethylpentan-1-amine",CN(C)CCCCCC1=CNC2=CC=CC=C21,,,,,,
2547,52548,3-(3-(Dimethylamino)propyl)indole hydrochloride,C[NH+](C)CCCC1=CNC2=CC=CC=C21.[Cl-],,,,,,
2548,52549,"3-(1H-indol-3-yl)-N,N-dimethylpropan-1-amine",CN(C)CCCC1=CNC2=CC=CC=C21,,,,,,
2549,52550,"Indole-2,3-dione, 5,6-dimethyl-",CC1=CC2=C(C=C1C)NC(=O)C2=O,,,,,,
2550,52551,3-(N-2-Ethoxyethylformimidoyl)indole,CCOCCN=CC1=CNC2=CC=CC=C21,,,,,,
2551,52552,Einecs 277-615-8,C1=CC=C2C(=C1)C(=CN2)C(=N)CCO,,,,,,
2552,52553,"Indole, 3-(2-(2-mercaptoethyl)aminoethyl)-, hydrochloride",C1=CC=C2C(=C1)C(=CN2)CC[NH2+]CCS.[Cl-],,,,,,
2553,52554,2-{[2-(1H-indol-3-yl)ethyl]amino}ethanethiol,C1=CC=C2C(=C1)C(=CN2)CCNCCS,,,,,,
2554,52555,3-(2-(4-Methoxybenzylamino)ethyl)indole monohydrochloride,COC1=CC=C(C=C1)C[NH2+]CCC2=CNC3=CC=CC=C32.[Cl-],,,,,,
2555,52556,2-(1H-indol-3-yl)-N-(4-methoxybenzyl)ethanamine,COC1=CC=C(C=C1)CNCCC2=CNC3=CC=CC=C32,,,,,,
2556,52557,Methyl alpha-acetamido-1-methyl-3-indolepropionate,CC(=O)NC(CC1=CN(C2=CC=CC=C21)C)C(=O)OC,,,,,,
2557,52558,"3-Indolepropionic acid, 5-chloro-2-methyl-",CC1=C(C2=C(N1)C=CC(=C2)Cl)CCC(=O)O,,,,,,
2558,52559,"3-Indolepropionic acid, 2,5-dimethyl-",CC1=CC2=C(C=C1)NC(=C2CCC(=O)O)C,,,,,,
2559,52560,"Ethyl 2,5-dimethyl-3-indolepropionate",CCOC(=O)CCC1=C(NC2=C1C=C(C=C2)C)C,,,,,,
2560,52561,"2-Methyl-2,3,3a,7a-tetrahydro-3-indolepropionic acid",CC1C(C2C=CC=CC2N1)CCC(=O)O,,,,,,
2561,52562,"Indole, 3-(N-(3-pyridyl)formimidoyl)-",C1=CC=C2C(=C1)C(=CN2)C=NC3=CN=CC=C3,,,,,,
2562,52563,"Indole, 3-(N-(4-pyridyl)formimidoyl)-",C1=CC=C2C(=C1)C(=CN2)C=NC3=CC=NC=C3,,,,,,
2563,52564,"1-Indolinecarboxaldehyde, 6-nitro-",C1CN(C2=C1C=CC(=C2)[N+](=O)[O-])C=O,,,,,,
2564,52565,"5-(m-Chlorophenyl)carbamoyloxytryptamine, hydrochloride",C1=CC(=CC(=C1)Cl)NC(=O)OC2=CC3=C(C=C2)NC=C3CC[NH3+].[Cl-],,,,,,
2565,52566,[3-(2-aminoethyl)-1H-indol-5-yl] N-(3-chlorophenyl)carbamate,C1=CC(=CC(=C1)Cl)NC(=O)OC2=CC3=C(C=C2)NC=C3CCN,,,,,,
2566,52567,"5-Diethylcarbamoyloxytryptamine, acetate",CCN(CC)C(=O)OC1=CC2=C(C=C1)NC=C2CC[NH3+].CC(=O)[O-],,,,,,
2567,52568,3-(2-aminoethyl)-1H-indol-5-yl diethylcarbamate,CCN(CC)C(=O)OC1=CC2=C(C=C1)NC=C2CCN,,,,,,
2568,52569,5-Methylcarbamoyloxytryptamine hydrochloride,CNC(=O)OC1=CC2=C(C=C1)NC=C2CC[NH3+].[Cl-],,,,,,
2569,52570,[3-(2-aminoethyl)-1H-indol-5-yl] N-methylcarbamate,CNC(=O)OC1=CC2=C(C=C1)NC=C2CCN,,,,,,
2570,52571,"5-Phenylcarbamoyloxytryptamine, hydrochloride",C1=CC=C(C=C1)NC(=O)OC2=CC3=C(C=C2)NC=C3CC[NH3+].[Cl-],,,,,,
2571,52572,3-(2-aminoethyl)-1H-indol-5-yl phenylcarbamate,C1=CC=C(C=C1)NC(=O)OC2=CC3=C(C=C2)NC=C3CCN,,,,,,
2572,52573,"Isoindoline, 2-(diethylaminoethyl)-",CCN(CC)CCN1CC2=CC=CC=C2C1,,,,,,
2573,52574,N-Isopropylisoindoline hydrochloride,CC(C)[NH+]1CC2=CC=CC=C2C1.[Cl-],,,,,,
2574,52575,2-Isopropylisoindoline,CC(C)N1CC2=CC=CC=C2C1,,,,,,
2575,52576,"2-(3-(4-Methyl-1-piperazinyl)propyl)-3a,4,7,7a-tetrahydroisoindoline",CN1CCN(CC1)CCCN2CC3CC=CCC3C2,,,,,,
2576,52577,"3a,4,7,7a-Tetrahydro-2-(diethylaminoethyl)isoindoline",CCN(CC)CCN1CC2CC=CCC2C1,,,,,,
2577,52578,"2-(2-(Diethylmethylammonio)ethyl)-2-methyl-3a,4,7,7a-tetrahydroisoindolinium diiodide",CC[N+](C)(CC)CC[N+]1(CC2CC=CCC2C1)C.[I-].[I-],,,,,,
2578,52579,"Diethyl-methyl-[2-(2-methyl-1,3,3a,4,7,7a-hexahydroisoindol-2-ium-2-yl)ethyl]azanium",CC[N+](C)(CC)CC[N+]1(CC2CC=CCC2C1)C,,,,,,
2579,52580,CID 52580,CCCCCCC(=N)C1=C2C(=CC(=C1O)O)C(=C(C(=C2O)C3=C(C4=C(C(=C(C=C4C(=C3C)C(C)C)O)O)C(=N)CCCCCC)O)C)C(C)C,,,,,,
2580,52581,"2,7-Naphthalenedisulfonic acid, 4-(4-chloro-6-ethylphenylamino-2-s-triazinylamino)-5-hydroxy-6-(4-methyl-2-sulfophenylazo)-, trisodium salt",CCN(C1=CC=CC=C1)C2=NC(=NC(=N2)NC3=C4C(=CC(=C3)S(=O)(=O)[O-])C=C(C(=C4O)N=NC5=C(C=C(C=C5)C)S(=O)(=O)[O-])S(=O)(=O)[O-])Cl.[Na+].[Na+].[Na+],,,,,,
2581,52582,"5-((4-Chloro-6-(ethyl(phenyl)amino)-1,3,5-triazin-2-yl)amino)-4-hydroxy-3-((4-methyl-2-sulfophenyl)diazenyl)-2,7-naphthalenedisulfonic acid",CCN(C1=CC=CC=C1)C2=NC(=NC(=N2)NC3=C4C(=CC(=C3)S(=O)(=O)O)C=C(C(=C4O)N=NC5=C(C=C(C=C5)C)S(=O)(=O)O)S(=O)(=O)O)Cl,,,,,,
2582,52583,"2-[6-[(4,6-Dichloro-s-triazin-2-yl)methylamino]-1-hydroxy-3-sulfo-2-naphthylazo]-1,5-naphthalenedisulfonic acid",C1=CC2=C(C=CC(=C2S(=O)(=O)O)N=NC3=C(C=C4C=C(C=CC4=C3O)NCC5=NC(=NC(=N5)Cl)Cl)S(=O)(=O)O)C(=C1)S(=O)(=O)O,,,,,,
2583,52584,"2-Naphthalenesulfonic acid, 5,6'-iminobis(1-hydroxy-",C1=CC2=C(C=CC(=C2O)S(=O)(=O)O)C(=C1)NC3=CC4=C(C=C3)C(=C(C=C4)S(=O)(=O)O)O,,,,,,
2584,52585,"Naphtho(1,2-e:5,6-e')bis(1,3)oxazine, 3,9-bis(2-chloropropyl)-2,3,4,8,9,10-hexahydro-",CC(CN1CC2=C(C=CC3=C2C=CC4=C3CN(CO4)CC(C)Cl)OC1)Cl,,,,,,
2585,52586,"NAPHTHO(1,2-e:5,6-e')BIS(1,3)OXAZINE, 2,3,4,8,9,10-HEXAHYDRO-3,9-DICYCLOHEXYL-",C1CCC(CC1)N2CC3=C(C=CC4=C3C=CC5=C4CN(CO5)C6CCCCC6)OC2,,,,,,
2586,52587,"trans-1-Dimethylamino-1,2,3,4-tetrahydro-2-naphthol benzoate hydrochloride",C[NH+](C)C1[C@H](CCC2=CC=CC=C12)OC(=O)C3=CC=CC=C3.[Cl-],,,,,,
2587,52588,"[(2S)-1-(dimethylamino)-1,2,3,4-tetrahydronaphthalen-2-yl] benzoate",CN(C)C1[C@H](CCC2=CC=CC=C12)OC(=O)C3=CC=CC=C3,,,,,,
2588,52589,"1,4-Naphthoquinone, 2-benzylthio-3-chloro-",C1=CC=C(C=C1)CSC2=C(C(=O)C3=CC=CC=C3C2=O)Cl,,,,,,
2589,52590,"1,4-Naphthoquinone, 2-(1,1-bis(hydroxymethyl)-2-hydroxyethylamino)-",C1=CC=C2C(=C1)C(=O)C=C(C2=O)NC(CO)(CO)CO,,,,,,
2590,52591,"2-Chloro-3-(2-hydroxyethyl)-1,4-naphthoquinone",C1=CC=C2C(=C1)C(=O)C(=C(C2=O)Cl)CCO,,,,,,
2591,52592,"1,4-Naphthoquinone, 3-chloro-2-isopentylamino-",CC(C)CCNC1=C(C(=O)C2=CC=CC=C2C1=O)Cl,,,,,,
2592,52593,CID 52593,C1=CC=C2C(=C1)C=CC3=C2N(C(=CC=CC=CC=C4C(=O)N(C(=S)S4)CCCS(=O)(=O)[O-])S3)CCCS(=O)(=O)[O-].[Na+].[Na+],,,,,,
2593,52594,CID 52594,C1=CC=C2C(=C1)C=CC3=C2N(C(=CC=CC=CC=C4C(=O)N(C(=S)S4)CCCS(=O)(=O)O)S3)CCCS(=O)(=O)O,,,,,,
2594,52595,(4-(5-((Aminoiminomethyl)amino)-2-benzofuranyl)phenyl)guanidine,C1=CC(=CC=C1C2=COC3=C2C=C(C=C3)N=CNN)N=C(N)N,,,,,,
2595,52596,CID 52596,C1=CC2=C(C=C1C(=N)N)OC(=C2)C=CC3=CC4=C(O3)C=CC(=C4)C(=N)N,,,,,,
2596,52597,CID 52597,C1=CC2=C(C=C1C(=N)N)OC(=C2)C=CC3=CC4=C(O3)C=C(C=C4)C(=N)N,,,,,,
2597,52598,2-[2-(5-Carbamimidoyl-3-methyl-1-benzofuran-2-yl)ethenyl]-3-methyl-1-benzofuran-5-carboximidamide,CC1=C(OC2=C1C=C(C=C2)C(=N)N)C=CC3=C(C4=C(O3)C=CC(=C4)C(=N)N)C,,,,,,
2598,52599,"2-[6-(5-Carbamimidoyl-1-benzofuran-2-yl)hexa-1,3,5-trienyl]-1-benzofuran-5-carboximidamide",C1=CC2=C(C=C1C(=N)N)C=C(O2)C=CC=CC=CC3=CC4=C(O3)C=CC(=C4)C(=N)N,,,,,,
2599,52600,2-[2-(5-carbamimidoyl-1-benzofuran-2-yl)ethenyl]-1H-indole-6-carboximidamide,C1=CC2=C(C=C1C(=N)N)NC(=C2)C=CC3=CC4=C(O3)C=CC(=C4)C(=N)N,,,,,,
2600,52601,"1H-Indole-6-carboximidamide, 2-(4-(3-(aminoiminomethyl)phenoxy)phenyl)-",C1=CC(=CC(=C1)OC2=CC=C(C=C2)C3=CC4=C(N3)C=C(C=C4)C(=N)N)C(=N)N,,,,,,
2601,52602,CID 52602,C1=CC(=CC=C1C=CC2=CC3=C(N2)C=C(C=C3)C(=N)N)OC4=CC=C(C=C4)C(=N)N,,,,,,
2602,52603,"1H-Indole, 6-(4,5-dihydro-1H-imidazol-2-yl)-2-(4-(4-(4,5-dihydro-1H-imidazol-2-yl)phenoxy)phenyl)-",C1CN=C(N1)C2=CC=C(C=C2)OC3=CC=C(C=C3)C4=CC5=C(N4)C=C(C=C5)C6=NCCN6,,,,,,
2603,52604,"6-(4,5-dihydro-1H-imidazol-2-yl)-2-[2-[4-[4-(4,5-dihydro-1H-imidazol-2-yl)phenoxy]phenyl]ethenyl]-1H-indole",C1CN=C(N1)C2=CC=C(C=C2)OC3=CC=C(C=C3)C=CC4=CC5=C(N4)C=C(C=C5)C6=NCCN6,,,,,,
2604,52605,CID 52605,C1=CC(=CC=C1C=CC2=CC3=C(O2)C=CC(=C3)C(=N)N)C(=N)N,,,,,,
2605,52606,"2-[4-(4-Carbamimidoylphenyl)buta-1,3-dienyl]-1-benzofuran-5-carboximidamide",C1=CC(=CC=C1C=CC=CC2=CC3=C(O2)C=CC(=C3)C(=N)N)C(=N)N,,,,,,
2606,52607,CID 52607,C1=CC(=CC=C1C=CC=CC=CC2=CC3=C(O2)C=CC(=C3)C(=N)N)C(=N)N,,,,,,
2607,52608,CID 52608,C1=CC(=CC=C1C=CC2=CC3=C(O2)C=CC(=C3)C(=N)N)OC4=CC=C(C=C4)C(=N)N,,,,,,
2608,52609,"5-Benzofurancarboximidamide, 2-(4-(3-(4-(aminoiminomethyl)phenyl)-1-triazenyl)phenyl)-",C1=CC(=CC=C1C2=CC3=C(O2)C=CC(=C3)C(=N)N)N=NNC4=CC=C(C=C4)C(=N)N,,,,,,
2609,52610,2-Phenacylisoquinolinium chloride,C1=CC=C(C=C1)C(=O)C[N+]2=CC3=CC=CC=C3C=C2.[Cl-],,,,,,
2610,52611,2-(2-Oxo-2-phenylethyl)isoquinolinium,C1=CC=C(C=C1)C(=O)C[N+]2=CC3=CC=CC=C3C=C2,,,,,,
2611,52612,"Isothiazolidine, 2-cyclohexyl-, 1,1-dioxide",C1CCC(CC1)N2CCCS2(=O)=O,,,,,,
2612,52613,"Isothiazolidine, 2-dodecyl-, 1,1-dioxide",CCCCCCCCCCCCN1CCCS1(=O)=O,,,,,,
2613,52614,"ISOTHIAZOLIDINE, 2-(p-METHOXYPHENYL)-, 1,1-DIOXIDE",COC1=CC=C(C=C1)N2CCCS2(=O)=O,,,,,,
2614,52615,"Isothiazolidine, 2-(3-pentyl)-, 1,1-dioxide",CCC(CC)N1CCCS1(=O)=O,,,,,,
2615,52616,"Isothiazolidine, 2-(2,4,4-trimethyl-2-pentyl)-, 1,1-dioxide",CC(C)(C)CC(C)(C)N1CCCS1(=O)=O,,,,,,
2616,52617,"1,5-Diisothiocyanatonaphthalene",C1=CC2=C(C=CC=C2N=C=S)C(=C1)N=C=S,,,,,,
2617,52618,"Phosphonic acid, (2,2,2-trichloro-1-hydroxyethyl)-, diethyl ester, isovalerate",CCOP(=O)(C(C(Cl)(Cl)Cl)OC(=O)CC(C)C)OCC,,,,,,
2618,52619,CID 52619,CC1C[C@@H]2[C@H](C([C@]3(O2)CCC4[C@@H](C3C)C(C5C4CC=C6C5(CCC(C6)O)C)O)C)NC1,,,,,,
2619,52620,"3-Benzyl-7-methyl-3,7-diazabicyclo(3.3.1)nonane methane sulfonate",C[NH+]1CC2CC(C1)CN(C2)CC3=CC=CC=C3.CS(O)(O)[O-],,,,,,
2620,52621,"3-Benzyl-7-methyl-3,7-diazabicyclo[3.3.1]nonane",CN1CC2CC(C1)CN(C2)CC3=CC=CC=C3,,,,,,
2621,52622,3-(Dimethylamino)-1-phenyl-1-propanol phenylcarbamate hydrochloride,C[NH+](C)CCC(C1=CC=CC=C1)OC(=O)NC2=CC=CC=C2.[Cl-],,,,,,
2622,52623,[3-(dimethylamino)-1-phenylpropyl] N-phenylcarbamate,CN(C)CCC(C1=CC=CC=C1)OC(=O)NC2=CC=CC=C2,,,,,,
2623,52624,"Isoindolinium, hexahydro-2-(2-(diethylmethylammonio)ethyl)-2-methyl-, diiodide",CC[N+](C)(CC)CC[N+]1(CC2CCCCC2C1)C.[I-].[I-],,,,,,
2624,52625,"Diethyl-methyl-[2-(2-methyl-1,3,3a,4,5,6,7,7a-octahydroisoindol-2-ium-2-yl)ethyl]azanium",CC[N+](C)(CC)CC[N+]1(CC2CCCCC2C1)C,,,,,,
2625,52626,"Isonipecotamide, 1-(2-(10,11-dihydrodibenzo(a,d)cyclohepten-5-ylidene)ethyl)-4-piperidino-, dihydrochloride",C1CC[NH+](CC1)C2(CC[NH+](CC2)CC=C3C4=CC=CC=C4C=CC5=CC=CC=C53)C(=O)N.[Cl-].[Cl-],,,,,,
2626,52627,"4-Piperidin-1-yl-1-[2-(2-tricyclo[9.4.0.03,8]pentadeca-1(15),3,5,7,9,11,13-heptaenylidene)ethyl]piperidine-4-carboxamide",C1CCN(CC1)C2(CCN(CC2)CC=C3C4=CC=CC=C4C=CC5=CC=CC=C53)C(=O)N,,,,,,
2627,52628,"Isonipecotic acid, 1-(3-(2-chloro-10-phenothiazinyl)propyl)-, hydrochloride",CCOC(=O)C1CCN(CC1)CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)Cl.Cl,,,,,,
2628,52629,Ethyl 1-[3-(2-chlorophenothiazin-10-yl)propyl]piperidine-4-carboxylate,CCOC(=O)C1CCN(CC1)CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)Cl,,,,,,
2629,52630,3-(2-(Methylamino)ethyl)indole sulfosalicylate,CNCCC1=CNC2=CC=CC=C21.C1=CC(=C(C=C1S(=O)(=O)O)C(=O)O)O,,,,,,
2630,52631,"1-Naphthalenecarbamic acid (2,2,2-trichloroacetimidoylamino) ester",C1=CC=C2C(=C1)C=CC=C2NC(=O)ON=C(C(Cl)(Cl)Cl)N,,,,,,
2631,52632,CID 52632,C1=CC(=O)C(=NN=C2C(=CC3=C(C2=O)C(=CC(=C3)S(=O)(=O)O)NC4=NC(=NC(=N4)Cl)Cl)S(=O)(=O)O)C=C1N(O)O,,,,,,
2632,52633,CID 52633,CC=CCC(C[NH2+]CC[NH+]1CCOCC1)C2=CC=CC3=CC=CC=C32.[Cl-].[Cl-],,,,,,
2633,52634,N-(2-morpholin-4-ylethyl)-2-naphthalen-1-ylhex-4-en-1-amine,CC=CCC(CNCCN1CCOCC1)C2=CC=CC3=CC=CC=C32,,,,,,
2634,52635,"1-NAPHTHOIC ACID, (o-BROMOBENZOYL)HYDRAZIDE",C1=CC=C2C(=C1)C=CC=C2C(=O)NNC(=O)C3=CC=CC=C3Br,,,,,,
2635,52636,1-(p-Methoxybenzoyl)-2-(1-naphthoyl)hydrazine,COC1=CC=C(C=C1)C(=O)N=NC(=O)C2=CC=CC3=CC=CC=C32,,,,,,
2636,52637,"Octamethylenedicarbonyldimethylenebis(1,2,3,4-tetrahydroisoquinoline)",C1CNC(C2=CC=CC=C21)CC(=O)CCCCCCCCC(=O)CC3C4=CC=CC=C4CCN3,,,,,,
2637,52638,"(1-(p-Methoxybenzoyl)-2-phenylethylene)di(1,2,3,4-tetrahydroisoquinoline)",COC1=CC=C(C=C1)C(=O)C(C2C3=CC=CC=C3CCN2)C(C4C5=CC=CC=C5CCN4)C6=CC=CC=C6,,,,,,
2638,52639,"1H-Indole, 6-(4,5-dihydro-1H-imidazol-2-yl)-2-(4-(3-(4,5-dihydro-1H-imidazol-2-yl)phenoxy)phenyl)-",C1CN=C(N1)C2=CC(=CC=C2)OC3=CC=C(C=C3)C4=CC5=C(N4)C=C(C=C5)C6=NCCN6,,,,,,
2639,52640,"(5S,6R)-6-[2-amino-3-(carboxymethylamino)-3-oxopropyl]sulfanyl-5-hydroxyicosa-7,9,11,14-tetraenoic acid",CCCCCC=CCC=CC=CC=C[C@H]([C@H](CCCC(=O)O)O)SCC(C(=O)NCC(=O)O)N,,,,,,
2640,52641,"1,3-Dioxo-alpha-(4-hydroxy-3-nitrobenzyl)-2-isoindolineacetic acid",C1=CC=C2C(=C1)C(=O)N(C2=O)C(CC3=CC(=C(C=C3)O)[N+](=O)[O-])C(=O)O,,,,,,
2641,52642,"Formamidine, N-((dibenzylamino)thio)-N'-(2,4-xylyl)-",CC1=CC(=C(C=C1)N=CNSN(CC2=CC=CC=C2)CC3=CC=CC=C3)C,,,,,,
2642,52643,CID 52643,C1=CC=C(C=C1)SC(=O)C=CC(=O)SC2=CC=CC=C2,,,,,,
2643,52644,1-(furan-2-yl)-N-[(5-nitrofuran-2-yl)methylideneamino]methanimine,C1=COC(=C1)C=NN=CC2=CC=C(O2)[N+](=O)[O-],,,,,,
2644,52645,CID 52645,C1=CC=C(C(=C1)C=NN=CC2=CC=C(O2)[N+](=O)[O-])[N+](=O)[O-],,,,,,
2645,52646,"2(5H)-Furanone, 3-acetyl-4-(4-hydroxy-3-methoxyphenyl)-",CC(=O)C1=C(COC1=O)C2=CC(=C(C=C2)O)OC,,,,,,
2646,52647,3-[(4-Phenylmethoxyphenyl)methylidene]oxolan-2-one,C1COC(=O)C1=CC2=CC=C(C=C2)OCC3=CC=CC=C3,,,,,,
2647,52648,"[(2,4-Diethyl-2,5-dimethyloxolan-3-ylidene)amino]urea",CCC1C(OC(C1=NNC(=O)N)(C)CC)C,,,,,,
2648,52649,"2-Furanpropanethiol, tetrahydro-S-(2-diethylaminoethyl)-beta-(1-naphthyl)-, oxalate",CC[NH+](CC)CCSCC(CC1CCCO1)C2=CC=CC3=CC=CC=C32.C(=O)(C(=O)[O-])O,,,,,,
2649,52650,"N,N-diethyl-2-[2-naphthalen-1-yl-3-(oxolan-2-yl)propyl]sulfanylethanamine",CCN(CC)CCSCC(CC1CCCO1)C2=CC=CC3=CC=CC=C32,,,,,,
2650,52651,"2-(2,4-Dinitrophenoxymethyl)tetrahydrofuran",C1CC(OC1)COC2=C(C=C(C=C2)[N+](=O)[O-])[N+](=O)[O-],,,,,,
2651,52652,"FURFURYLAMINE, alpha-BENZYL-N-ETHYL-",CCNC(CC1=CC=CC=C1)C2=CC=CO2,,,,,,
2652,52653,Dinaphthalen-2-yl but-2-enedioate,C1=CC=C2C=C(C=CC2=C1)OC(=O)C=CC(=O)OC3=CC4=CC=CC=C4C=C3,,,,,,
2653,52654,"8-Azabicyclo(4.3.0)nonane, 8-(3-morpholinopropyl)-",C1CCC2CN(CC2C1)CCCN3CCOCC3,,,,,,
2654,52655,alpha-Benzyl-alpha-(2-thienyl)-3-azabicyclo(3.2.2)nonane-3-propanol hydrochloride,C1CC2CCC1C[NH+](C2)CCC(CC3=CC=CC=C3)(C4=CC=CS4)O.[Cl-],,,,,,
2655,52656,4-(3-Azabicyclo[3.2.2]nonan-3-yl)-1-phenyl-2-(2-thienyl)butan-2-ol,C1CC2CCC1CN(C2)CCC(CC3=CC=CC=C3)(C4=CC=CS4)O,,,,,,
2656,52657,alpha-(p-Butylphenyl)-alpha-phenyl-3-azabicyclo(3.2.2)nonane-3-propanol hydrochloride,CCCCC1=CC=C(C=C1)C(CC[NH+]2CC3CCC(C2)CC3)(C4=CC=CC=C4)O.[Cl-],,,,,,
2657,52658,alpha-(4-Butylphenyl)-alpha-phenyl-3-azabicyclo[3.2.2]nonane-3-propan-1-ol,CCCCC1=CC=C(C=C1)C(CCN2CC3CCC(C2)CC3)(C4=CC=CC=C4)O,,,,,,
2658,52659,alpha-Cyclohexyl-alpha-phenyl-3-azabicyclo(4.2.1)nonane-3-propanol hydrochloride,C1CCC(CC1)C(CC[NH+]2CCC3CCC(C3)C2)(C4=CC=CC=C4)O.[Cl-],,,,,,
2659,52660,alpha-Cyclohexyl-alpha-phenyl-3-azabicyclo[4.2.1]nonane-3-propan-1-ol,C1CCC(CC1)C(CCN2CCC3CCC(C3)C2)(C4=CC=CC=C4)O,,,,,,
2660,52661,Azabicyclononanol diphenylacetate hydrochloride,C1CC2CCC([NH+](C1)C2)OC(=O)C(C3=CC=CC=C3)C4=CC=CC=C4.[Cl-],,,,,,
2661,52662,1-Azabicyclo[3.3.1]nonan-2-ol diphenylacetate,C1CC2CCC(N(C1)C2)OC(=O)C(C3=CC=CC=C3)C4=CC=CC=C4,,,,,,
2662,52663,2-Methyl-azabicyclononanol diphenylacetate hydrochloride,CC1(CCC2CCC[NH+]1C2)OC(=O)C(C3=CC=CC=C3)C4=CC=CC=C4.[Cl-],,,,,,
2663,52664,2-Methyl-1-azabicyclo[3.3.1]nonan-2-ol diphenylacetate,CC1(CCC2CCCN1C2)OC(=O)C(C3=CC=CC=C3)C4=CC=CC=C4,,,,,,
2664,52665,9-tert-Butyl-3-(dimethylamino)-3-azaspiro(5.5)undecane hydrochloride,CC(C)(C)C1CCC2(CC1)CCN(CC2)[NH+](C)C.[Cl-],,,,,,
2665,52666,9-tert-Butyl-3-(dimethylamino)-3-azaspiro[5.5]undecane,CC(C)(C)C1CCC2(CC1)CCN(CC2)N(C)C,,,,,,
2666,52667,CID 52667,C1CCC2(CC1)CC[NH+](CC2)CCCC(=NO)C3=CC=C(C=C3)F.[Cl-],,,,,,
2667,52668,CID 52668,C1CCC2(CC1)CCN(CC2)CCCC(=NO)C3=CC=C(C=C3)F,,,,,,
2668,52669,"5-AZA-2,8,9-TRIOXA-1-SILABICYCLO(3.3.3)UNDECANE, 1-(p-ISOPROPYLPHENYL)-",CC(C)C1=CC=C(C=C1)[Si]23OCCN(CCO2)CCO3,,,,,,
2669,52670,"Methyl 2-cyano-7-(2-cyano-3-methoxy-3-oxo-1-phenylprop-1-enyl)iminohepta-3,5-dienoate",COC(=O)C(C=CC=CC=NC(=C(C#N)C(=O)OC)C1=CC=CC=C1)C#N,,,,,,
2670,52671,N-(azepan-1-yl)-1-(4-chloro-3-nitrophenyl)methanimine,C1CCCN(CC1)N=CC2=CC(=C(C=C2)Cl)[N+](=O)[O-],,,,,,
2671,52672,"AZETIDINE, 3-AMINO-1-(10,11-DIHYDRO-5H-DIBENZ(a,d)CYCLOHEPTEN-5-YL)-",C1CC2=CC=CC=C2C(C3=CC=CC=C31)N4CC(C4)N,,,,,,
2672,52673,"AZETIDINE, 3-BENZYLAMINO-1-(10,11-DIHYDRO-5H-DIBENZO(a,d)CYCLOHEPTEN-5-YL)-",C1CC2=CC=CC=C2C(C3=CC=CC=C31)N4CC(C4)NCC5=CC=CC=C5,,,,,,
2673,52674,"AZETIDINE, 3-tert-BUTYLAMINO-1-(10,11-DIHYDRO-5H-DIBENZO(a,d)CYCLOHEPTEN-5-YL)-",CC(C)(C)NC1CN(C1)C2C3=CC=CC=C3CCC4=CC=CC=C24,,,,,,
2674,52675,"1-(3-Chloro-10,11-dihydro-5H-dibenzo(a,d)cyclohepten-5-yl)-3-dimethylaminoazetidine",CN(C)C1CN(C1)C2C3=CC=CC=C3CCC4=C2C=C(C=C4)Cl,,,,,,
2675,52676,"1-(3-Chloro-10,11-dihydro-5H-dibenzo(a,d)cyclohepten-5-yl)-3-methylaminoazetidine",CNC1CN(C1)C2C3=CC=CC=C3CCC4=C2C=C(C=C4)Cl,,,,,,
2676,52677,"AZETIDINE, 3-CYCLOHEXYLAMINO-1-(10,11-DIHYDRO-5H-DIBENZO(a,d)CYCLOHEPTEN-5-YL)-",C1CCC(CC1)NC2CN(C2)C3C4=CC=CC=C4CCC5=CC=CC=C35,,,,,,
2677,52678,"1-(Dibenzo(a,e)cyclopropa(c)cyclohept-6-yl)-3-(methylamino)azetidine",CNC1CN(C1)C2C3=CC=CC=C3C4CC4C5=CC=CC=C25,,,,,,
2678,52679,"1-(10,11-Dihydro-5H-dibenzo(a,d)cyclohepten-5-yl)-3-aminomethylazetidine",C1CC2=CC=CC=C2C(C3=CC=CC=C31)N4CC(C4)CN,,,,,,
2679,52680,"AZETIDINE, 1-(10,11-DIHYDRO-5H-DIBENZO(a,d)CYCLOHEPTEN-5-YL)-3-(DIMETHYLAMINO)-",CN(C)C1CN(C1)C2C3=CC=CC=C3CCC4=CC=CC=C24,,,,,,
2680,52681,"AZETIDINE, 1-(10,11-DIHYDRO-5H-DIBENZO(a,d)CYCLOHEPTEN-5-YL)-3-ETHYLAMINO-",CCNC1CN(C1)C2C3=CC=CC=C3CCC4=CC=CC=C24,,,,,,
2681,52682,"AZETIDINE, 1-(10,11-DIHYDRO-5H-DIBENZO(a,d)CYCLOHEPTEN-5-YL)-3-(2-PROPYLAMINO)-",CC(C)NC1CN(C1)C2C3=CC=CC=C3CCC4=CC=CC=C24,,,,,,
2682,52683,3-(p-Aminophenyl)-3-ethyl-2-azetidinone,CCC1(CNC1=O)C2=CC=C(C=C2)N,,,,,,
2683,52684,3-Benzyl-3-ethyl-2-azetidinone,CCC1(CNC1=O)CC2=CC=CC=C2,,,,,,
2684,52685,3-Cyclohexyl-3-ethyl-2-azetidinone,CCC1(CNC1=O)C2CCCCC2,,,,,,
2685,52686,"2,2'-Bis(8-benzyliminomethyl-4-isopropyl-3-methyl-1,6,7-trihydroxynaphthalene)",CC1=C(C2=CC(=C(C(=C2C(=C1C3=C(C4=C(C(=C(C=C4C(=C3C)C(C)C)O)O)C(=N)CC5=CC=CC=C5)O)O)C(=N)CC6=CC=CC=C6)O)O)C(C)C,,,,,,
2686,52687,N-Nitrosothiazolidine,C1CSCN1N=O,,,,,,
2687,52688,2-Methyl-3-(methylhydroxyphosphinyl)alanine,CC(CP(=O)(C)O)(C(=O)O)N,,,,,,
2688,52689,3-Amino-3-phosphonobutyric acid,CC(CC(=O)O)(N)P(=O)(O)O,,,,,,
2689,52690,"1-(Dibenzo(a,e)cyclopropa(c)cyclohept-6-yl)-3-(dimethylamino)-azetidine",CN(C)C1CN(C1)C2C3=CC=CC=C3C4CC4C5=CC=CC=C25,,,,,,
2690,52691,CID 52691,CC#CCC(C)[C@H](C=CC1[C@@H](C[C@H]2[C@@H]1CC(=CCCCC(=O)O)C2)O)O,,,,,,
2691,52692,"(2Z)-1,7,7-trimethyl-N-(prop-2-yn-1-yloxy)bicyclo[2.2.1]heptan-2-imine",CC1(C2CCC1(C(=NOCC#C)C2)C)C,,,,,,
2692,52693,2-Chloroindan-1-one,C1C(C(=O)C2=CC=CC=C21)Cl,,,,,,
2693,52694,(1S)-2-bromo-1-phenylethanol,C1=CC=C(C=C1)[C@@H](CBr)O,,,,,,
2694,52695,2-Chloro-1-(4-methylphenyl)-2-phenylethanone,CC1=CC=C(C=C1)C(=O)C(C2=CC=CC=C2)Cl,,,,,,
2695,52696,2-Bromo-1-phenylbutan-1-one,CCC(C(=O)C1=CC=CC=C1)Br,,,,,,
2696,52697,2-Chloro-1-phenylbutan-1-one,CCC(C(=O)C1=CC=CC=C1)Cl,,,,,,
2697,52698,"Diethylamine, 2-chloro-2'-iodo-N-methyl-",CN(CCCl)CCI,,,,,,
2698,52699,2-Heptanamidoacetohydroxamic acid,CCCCCCC(=O)NCC(=O)NO,,,,,,
2699,52700,2-Hexanamidoacetohydroxamic acid,CCCCCC(=O)NCC(=O)NO,,,,,,
2700,52701,"Acetohydroxamic acid, 2-(4-methylvaleramido)-",CC(C)CCC(=O)NCC(=O)NO,,,,,,
2701,52702,"Acetohydroxamic acid, 2-(cyclohexanecarboxamido)-",C1CCC(CC1)C(=O)NCC(=O)NO,,,,,,
2702,52703,CID 52703,CC(=C1C[NH+]2CCC1CC2CO)C3=C4C=C(C=CC4=[NH+]C=C3)OCCO.[Cl-].[Cl-],,,,,,
2703,52704,CID 52704,CC(=C1CN2CCC1CC2CO)C3=C4C=C(C=CC4=NC=C3)OCCO,,,,,,
2704,52705,trans-Chloro(2-(3-bromopropionamido)cyclohexyl)mercury,C1CC[C@H]([C@@H](C1)NC(=O)CCBr)[Hg]Cl,,,,,,
2705,52706,trans-Chloro(2-hexanamidocyclohexyl)mercury,CCCCCC(=O)N[C@@H]1CCCC[C@H]1[Hg]Cl,,,,,,
2706,52707,Chloro(2-(3-methoxypropionamido)cyclohexyl)mercury,COCCC(=O)NC1CCCCC1[Hg]Cl,,,,,,
2707,52708,"1-(1-Ethynylcyclohexyloxy)-2,2,2-tribromoethanol",C#CC1(CCCCC1)OC(C(Br)(Br)Br)O,,,,,,
2708,52709,2-(alpha-Methyl-m-trifluoromethylphenethylamino)ethanol acetate,CC(CC1=CC(=CC=C1)C(F)(F)F)NCCOC(=O)C,,,,,,
2709,52710,CID 52710,C1=CC=C(C(=C1)C(=O)OCCNCCC2=CC(=CC=C2)C(F)(F)F)N,,,,,,
2710,52711,N-(2-Hydroxyethyl)-alpha-methyl-m-trifluoromethylphenethylamine p-aminobenzoate,CC(CC1=CC(=CC=C1)C(F)(F)F)NCCOC(=O)C2=CC=C(C=C2)N,,,,,,
2711,52712,2-(alpha-Methyl-m-trifluoromethylphenethylamino)ethanol chloroacetate,CC(CC1=CC(=CC=C1)C(F)(F)F)NCCOC(=O)CCl,,,,,,
2712,52713,N-(2-Hydroxyethyl)-alpha-methyl-m-trifluoromethylphenethylamine o-chlorobenzoate,CC(CC1=CC(=CC=C1)C(F)(F)F)NCCOC(=O)C2=CC=CC=C2Cl,,,,,,
2713,52714,N-(2-Hydroxyethyl)-alpha-methyl-m-trifluoromethylphenethylamine p-chlorobenzoate,CC(CC1=CC(=CC=C1)C(F)(F)F)NCCOC(=O)C2=CC=C(C=C2)Cl,,,,,,
2714,52715,N-(2-Hydroxyethyl)-alpha-methyl-m-trifluoromethylphenethylamine p-chlorophenoxyacetate,CC(CC1=CC(=CC=C1)C(F)(F)F)NCCOC(=O)COC2=CC=C(C=C2)Cl,,,,,,
2715,52716,N-(2-Hydroxyethyl)-alpha-methyl-m-trifluoromethylphenethylamine p-chlorophenylacetate,CC(CC1=CC(=CC=C1)C(F)(F)F)NCCOC(=O)CC2=CC=C(C=C2)Cl,,,,,,
2716,52717,2-(alpha-Methyl-m-trifluoromethylphenethylamino)ethanol cyclopropylcarboxylate,CC(CC1=CC(=CC=C1)C(F)(F)F)NCCOC(=O)C2CC2,,,,,,
2717,52718,2-(alpha-Methyl-m-trifluoromethylphenethylamino)ethanol 2-cyclopropyl-2-phenylacetate,CC(CC1=CC(=CC=C1)C(F)(F)F)NCCOC(=O)C(C2CC2)C3=CC=CC=C3,,,,,,
2718,52719,N-(2-Hydroxyethyl)-alpha-methyl-m-trifluoromethylphenethylamine p-fluorobenzoate,CC(CC1=CC(=CC=C1)C(F)(F)F)NCCOC(=O)C2=CC=C(C=C2)F,,,,,,
2719,52720,N-(2-Hydroxyethyl)-alpha-methyl-m-trifluoromethylphenethylamine o-hydroxybenzoate,CC(CC1=CC(=CC=C1)C(F)(F)F)NCCOC(=O)C2=CC=CC=C2O,,,,,,
2720,52721,N-(2-Hydroxyethyl)-alpha-methyl-m-trifluoromethylphenethylamine p-isobutylbenzoate,CC(C)CC1=CC=C(C=C1)C(=O)OCCNC(C)CC2=CC(=CC=C2)C(F)(F)F,,,,,,
2721,52722,CID 52722,CC=C(C)C(=O)OCCNC(C)CC1=CC(=CC=C1)C(F)(F)F,,,,,,
2722,52723,2-(alpha-Methyl-m-trifluoromethylphenethylamino)ethanol 1-naphthylcarboxylate,CC(CC1=CC(=CC=C1)C(F)(F)F)NCCOC(=O)C2=CC=CC3=CC=CC=C32,,,,,,
2723,52724,2-(alpha-Methyl-m-trifluoromethylphenethylamino)ethanol 2-naphthylcarboxylate,CC(CC1=CC(=CC=C1)C(F)(F)F)NCCOC(=O)C2=CC3=CC=CC=C3C=C2,,,,,,
2724,52725,N-(2-Hydroxyethyl)-alpha-methyl-m-trifluoromethylphenethylamine p-nitrobenzoate,CC(CC1=CC(=CC=C1)C(F)(F)F)NCCOC(=O)C2=CC=C(C=C2)[N+](=O)[O-],,,,,,
2725,52726,2-(alpha-Methyl-m-trifluoromethylphenethylamino)ethanol phenylacetate,CC(CC1=CC(=CC=C1)C(F)(F)F)NCCOC(=O)CC2=CC=CC=C2,,,,,,
2726,52727,N-(2-Hydroxyethyl)-alpha-methyl-m-trifluoromethylphenethylamine 2-phenylbutyrate,CCC(C1=CC=CC=C1)C(=O)OCCNC(C)CC2=CC(=CC=C2)C(F)(F)F,,,,,,
2727,52728,CID 52728,CC(CC1=CC(=CC=C1)C(F)(F)F)NCCOC(=O)C=CC2=CC=CC=C2,,,,,,
2728,52729,2-(alpha-Methyl-m-trifluoromethylphenethylamino)ethanol propionate,CCC(=O)OCCNC(C)CC1=CC(=CC=C1)C(F)(F)F,,,,,,
2729,52730,2-(alpha-Methyl-m-trifluoromethylphenethylamino)ethanol p-toluate,CC1=CC=C(C=C1)C(=O)OCCNC(C)CC2=CC(=CC=C2)C(F)(F)F,,,,,,
2730,52731,N-(2-Hydroxyethyl)-alpha-methyl-m-trifluoromethylphenethylamine m-trifluoromethylbenzoate,CC(CC1=CC(=CC=C1)C(F)(F)F)NCCOC(=O)C2=CC(=CC=C2)C(F)(F)F,,,,,,
2731,52732,"Ethanol, 2-(alpha-methyl-m-trifluoromethylphenethylamino)-, 3,4,5-trimethoxybenzoate",CC(CC1=CC(=CC=C1)C(F)(F)F)NCCOC(=O)C2=CC(=C(C(=C2)OC)OC)OC,,,,,,
2732,52733,N-Thenylidene-2-aminoethanol,C1=CSC(=C1)C=NCCO,,,,,,
2733,52734,"Ethenetricarbonitrile, (1-benzyl-2-pyrrolyl)-",C1=CC=C(C=C1)CN2C=CC=C2C(=C(C#N)C#N)C#N,,,,,,
2734,52735,"Ether, bis(2,6-dichlorobenzyl)",C1=CC(=C(C(=C1)Cl)COCC2=C(C=CC=C2Cl)Cl)Cl,,,,,,
2735,52736,"Ether, bis(4,4'-thiocyanatomethylphenyl)",C1=CC(=CC=C1CSC#N)OC2=CC=C(C=C2)CSC#N,,,,,,
2736,52737,p-Cyclohexyloxy-alpha-phenylethylallylamine,CC(C1=CC=C(C=C1)OC2CCCCC2)NCC=C,,,,,,
2737,52738,"DIBENZ(a,h)ACRIDINE, 8-ETHYL-",CCC1=CC=CC2=C1C3=NC4=C(C=C3C=C2)C5=CC=CC=C5C=C4,,,,,,
2738,52739,"5H-Dibenzo(a,d)cycloheptene, 10,11-dihydro-5-(3-dimethylaminobutylidene)-, hydrochloride",CC(CC=C1C2=CC=CC=C2CCC3=CC=CC=C31)[NH+](C)C.[Cl-],,,,,,
2739,52740,"10,11-Dihydro-5-[3-methyl-3-(dimethylamino)propylidene]-5H-dibenzo[a,d]cycloheptene",CC(CC=C1C2=CC=CC=C2CCC3=CC=CC=C31)N(C)C,,,,,,
2740,52741,"11H-Dibenzo(b,e)(1,4)dioxepin-7-carboxylic acid, 3,8-dihydroxy-1-pentoxymethyl-6-pentyl-11-oxo-",CCCCCC1=C(C(=CC2=C1OC3=CC(=CC(=C3C(=O)O2)COCCCCC)O)O)C(=O)O,,,,,,
2741,52742,"2,6-diacetyl-7,9-dihydroxy-8-methyl-9bH-dibenzofuran-1,3-dione",CC1=C(C2=C(C(=C1O)C(=O)C)OC3=CC(=O)C(C(=O)C32)C(=O)C)O,,,,,,
2742,52743,"DIBENZO(b,d)PYRAN-1-DIAZONIUM, 6-OXO-, TETRAFLUOROBORATE(1-)",[B-](F)(F)(F)F.C1=CC=C2C(=C1)C3=C(C=CC=C3OC2=O)[N+]#N,,,,,,
2743,52744,6-Oxobenzo[c]chromene-1-diazonium,C1=CC=C2C(=C1)C3=C(C=CC=C3OC2=O)[N+]#N,,,,,,
2744,52745,"5H-Dibenzo(b,g)(1,4)thiazocine, 6,7-dihydro-5-(3-diethylaminopropyl)-, 12,12-dioxide",CCN(CC)CCCN1CCC2=CC=CC=C2S(=O)(=O)C3=CC=CC=C31,,,,,,
2745,52746,"5H-Dibenzo(b,g)(1,4)thiazocine, 6,7-dihydro-5-(3-piperidinopropyl)-, 12,12-dioxide",C1CCN(CC1)CCCN2CCC3=CC=CC=C3S(=O)(=O)C4=CC=CC=C42,,,,,,
2746,52747,"5H-Dibenzo(b,g)(1,4)thiazocine, 6,7-dihydro-5-(3-pyrrolidinylpropyl)-, 12,12-dioxide",C1CCN(C1)CCCN2CCC3=CC=CC=C3S(=O)(=O)C4=CC=CC=C42,,,,,,
2747,52748,"2-Methoxy-11-(3-(methylamino)-1-azetidinyl)dibenzo(b,e)thiepin",CNC1CN(C1)C2C3=CC=CC=C3CSC4=C2C=C(C=C4)OC,,,,,,
2748,52749,"1,6-Dithiocyanatomannitol",C(C(C(C(C(CN=C=S)O)O)O)O)N=C=S,,,,,,
2749,52750,"1,6-Dithiocyanato-2,3,4,5-tetraacetylmannitol",CC(=O)OC(CN=C=S)C(C(C(CN=C=S)OC(=O)C)OC(=O)C)OC(=O)C,,,,,,
2750,52751,Dianilinomercury,C1=CC=C(C=C1)[NH-].C1=CC=C(C=C1)[NH-].[Hg+2],,,,,,
2751,52752,Bis(2-nitrobutoxy)methane,CCC(COCOCC(CC)[N+](=O)[O-])[N+](=O)[O-],,,,,,
2752,52753,"Methane, bis(pentachlorobenzylthio)-",C(C1=C(C(=C(C(=C1Cl)Cl)Cl)Cl)Cl)SCSCC2=C(C(=C(C(=C2Cl)Cl)Cl)Cl)Cl,,,,,,
2753,52754,"N-(4-chlorophenyl)-N',N'-dimethylmethanediamine",CN(C)CNC1=CC=C(C=C1)Cl,,,,,,
2754,52755,"Methanediamine, dichloro-N,N-dimethyl-N'-phenyl-",CN(C)C(NC1=CC=CC=C1)(Cl)Cl,,,,,,
2755,52756,2-(1H-Imidazol-1-yl)-1-(1-naphthalenyl)ethanone monohydrochloride,C1=CC=C2C(=C1)C=CC=C2C(=O)C[NH+]3C=CN=C3.[Cl-],,,,,,
2756,52757,2-Imidazol-1-yl-1-naphthalen-1-ylethanone,C1=CC=C2C(=C1)C=CC=C2C(=O)CN3C=CN=C3,,,,,,
2757,52758,"Acetophenone, 2-(1-imidazolyl)-4'-phenethyl-",C1=CC=C(C=C1)CCC2=CC=C(C=C2)C(=O)CN3C=CN=C3,,,,,,
2758,52759,"2-(1-Imidazolyl)-2',3',5',6'-tetramethylacetophenone",CC1=CC(=C(C(=C1C)C(=O)CN2C=CN=C2)C)C,,,,,,
2759,52760,"Acetophenone, 2-(1-imidazolyl)-2',3',4',5',6'-pentamethyl-",CC1=C(C(=C(C(=C1C)C)C(=O)CN2C=CN=C2)C)C,,,,,,
2760,52761,"4'-Bromo-2-(1-imidazolyl)-2',3',5',6'-tetramethylacetophenone",CC1=C(C(=C(C(=C1C(=O)CN2C=CN=C2)C)C)Br)C,,,,,,
2761,52762,"Acetophenone, 2-(1-imidazolyl)-4'-(methylthio)-",CSC1=CC=C(C=C1)C(=O)CN2C=CN=C2,,,,,,
2762,52763,"Acetophenone, 4'-(ethylthio)-2-(1-imidazolyl)-",CCSC1=CC=C(C=C1)C(=O)CN2C=CN=C2,,,,,,
2763,52764,2-(1-Imidazolyl)-4'-(propylthio)acetophenone,CCCSC1=CC=C(C=C1)C(=O)CN2C=CN=C2,,,,,,
2764,52765,"Acetophenone, 2-(1-imidazolyl)-4'-(isopropylthio)-",CC(C)SC1=CC=C(C=C1)C(=O)CN2C=CN=C2,,,,,,
2765,52766,"Acetophenone, 4'-(butylthio)-2-(1-imidazolyl)-",CCCCSC1=CC=C(C=C1)C(=O)CN2C=CN=C2,,,,,,
2766,52767,2-(1-Imidazolyl)-4'-(isopentylthio)acetophenone,CC(C)CCSC1=CC=C(C=C1)C(=O)CN2C=CN=C2,,,,,,
2767,52768,"Acetophenone, 2-(1-imidazolyl)-2'-(phenylthio)-",C1=CC=C(C=C1)SC2=CC=CC=C2C(=O)CN3C=CN=C3,,,,,,
2768,52769,2-(1-Imidazolyl)-3'-(phenylthio)acetophenone,C1=CC=C(C=C1)SC2=CC=CC(=C2)C(=O)CN3C=CN=C3,,,,,,
2769,52770,2-(1-Imidazolyl)-4'-(phenylthio)acetophenone,C1=CC=C(C=C1)SC2=CC=C(C=C2)C(=O)CN3C=CN=C3,,,,,,
2770,52771,"1-Propanol, 1-(p-phenethylphenyl)-2-(1-imidazolyl)-2-methyl-, hydrochloride",CC(C)(C(C1=CC=C(C=C1)CCC2=CC=CC=C2)O)[NH+]3C=CN=C3.[Cl-],,,,,,
2771,52772,2-Imidazol-1-yl-2-methyl-1-[4-(2-phenylethyl)phenyl]propan-1-ol,CC(C)(C(C1=CC=C(C=C1)CCC2=CC=CC=C2)O)N3C=CN=C3,,,,,,
2772,52773,N-(2-(2-Biphenylyl)-2-hydroxyethyl)imidazole hydrochloride,C1=CC=C(C=C1)C2=CC=CC=C2C(C[NH+]3C=CN=C3)O.[Cl-],,,,,,
2773,52774,2-Imidazol-1-yl-1-(2-phenylphenyl)ethanol,C1=CC=C(C=C1)C2=CC=CC=C2C(CN3C=CN=C3)O,,,,,,
2774,52775,N-(2-(3-Biphenylyl)-2-hydroxyethyl)imidazole hydrochloride,C1=CC=C(C=C1)C2=CC(=CC=C2)C(C[NH+]3C=CN=C3)O.[Cl-],,,,,,
2775,52776,1-(Biphenyl-3-yl)-2-(1h-imidazol-1-yl)ethanol,C1=CC=C(C=C1)C2=CC(=CC=C2)C(CN3C=CN=C3)O,,,,,,
2776,52777,N-((4-Hydroxybenzoyl)methyl)imidazole hydrochloride,C1=CC(=CC=C1C(=O)C[NH+]2C=CN=C2)O.[Cl-],,,,,,
2777,52778,1-(4-Hydroxyphenyl)-2-imidazol-1-ylethanone,C1=CC(=CC=C1C(=O)CN2C=CN=C2)O,,,,,,
2778,52779,"N-(3,4-Dihydroxyphenacyl)imidazole hydrochloride",C1=CC(=C(C=C1C(=O)C[NH+]2C=CN=C2)O)O.[Cl-],,,,,,
2779,52780,"1-(3,4-Dihydroxyphenyl)-2-(1-imidazolyl)ethanone",C1=CC(=C(C=C1C(=O)CN2C=CN=C2)O)O,,,,,,
2780,52781,CID 52781,CC(=O)NC1=CC=CC=C1C(=O)O.[OH-].[Na+].[Hg],,,,,,
2781,52782,2-(alpha-Methyl-m-trifluoromethylphenethylamino)ethanol phenylpropionate,CC(CC1=CC(=CC=C1)C(F)(F)F)NCCOC(=O)CCC2=CC=CC=C2,,,,,,
2782,52783,"5-(2-(1-Methyl-2-piperidyl)ethyl)-dibenzo(a,d)(1,4)cyclooctadiene",CN1CCCCC1CCC2CCC3=CC=CC=C3CC4=CC=CC=C24,,,,,,
2783,52784,CID 52784,C[NH+]1CCC(C1)C=C2CCC3=CC=CC=C3CC4=CC=CC=C24.[Cl-],,,,,,
2784,52785,CID 52785,CN1CCC(C1)C=C2CCC3=CC=CC=C3CC4=CC=CC=C24,,,,,,
2785,52786,"Mercury, chloro(N-phenylformamido)-",C1=CC=C(C=C1)N(C=O)[Hg]Cl,,,,,,
2786,52787,"Mercury(1+), chloro-",Cl[Hg+],,,,,,
2787,52788,2-Hydrazinopropane hydrochloride,CC(C)N[NH3+].[Cl-],,,,,,
2788,52789,1-Isopropylhydrazine,CC(C)NN,,,,,,
2789,52790,"HYDRAZINE, 1-(m-METHOXYBENZOYL)-2-(1-NAPHTHOYL)-",COC1=CC=CC(=C1)C(=O)NNC(=O)C2=CC=CC3=CC=CC=C32,,,,,,
2790,52791,1-Phenyl-2-propylhydrazine hydrochloride,CCC[NH2+]NC1=CC=CC=C1.[Cl-],,,,,,
2791,52792,Phenylhydrazinopropan,CCCNNC1=CC=CC=C1,,,,,,
2792,52793,CID 52793,CC1=CN=C(N=C1NN)N[NH3+].[Cl-],,,,,,
2793,52794,"2,4-Dihydrazinyl-5-methylpyrimidine",CC1=CN=C(N=C1NN)NN,,,,,,
2794,52795,CID 52795,CC1=CC(=NC(=N1)N[NH3+])NN.[Cl-],,,,,,
2795,52796,(2-Hydrazinyl-6-methylpyrimidin-4-yl)hydrazine,CC1=CC(=NC(=N1)NN)NN,,,,,,
2796,52797,"Hydrazine, pentyl-, sulfate",CCCCCN[NH3+].OS(=O)(=O)[O-],,,,,,
2797,52798,CID 52798,CCCNNC1=CC=CC=C1.CS(=O)(=O)[O-].[Na+],,,,,,
2798,52799,"Hydrazine, propyl-, sulfate",CCCN[NH3+].OS(=O)(=O)[O-],,,,,,
2799,52800,CID 52800,C1=CN=C(N=C1NN)N[NH3+].[Cl-],,,,,,
2800,52801,"2,4-Dihydrazinopyrimidine",C1=CN=C(N=C1NN)NN,,,,,,
2801,52802,CID 52802,C1=C(N=C(N=C1NN)N[NH3+])NN.[Cl-],,,,,,
2802,52803,"(2,6-Dihydrazinylpyrimidin-4-yl)hydrazine",C1=C(N=C(N=C1NN)NN)NN,,,,,,
2803,52804,(alpha-Methyl-m-trifluoromethylphenethylamino)trimethylammonium iodide,CC(CC1=CC(=CC=C1)C(F)(F)F)N[N+](C)(C)C.[I-],,,,,,
2804,52805,Trimethyl-[1-[3-(trifluoromethyl)phenyl]propan-2-ylamino]azanium,CC(CC1=CC(=CC=C1)C(F)(F)F)N[N+](C)(C)C,,,,,,
2805,52806,CID 52806,CC(=N[N+](C)(C)C)C1=C(C=C(C=C1)O)O.[I-],,,,,,
2806,52807,CID 52807,CC(=N[N+](C)(C)C)C1=C(C=C(C=C1)O)O,,,,,,
2807,52808,"Propionamide, 3-(3,4-dimethoxyphenyl)-3-methyl-",CC(CC(=O)N)C1=CC(=C(C=C1)OC)OC,,,,,,
2808,52809,"N-(2-Hydroxy-2-propyl)-3,4-methylenedioxyhydrocinnamamide",CC(CO)NC(=O)CCC1=CC2=C(C=C1)OCO2,,,,,,
2809,52810,CID 52810,C1=CC(=CC=C1CCC(=O)NN=C([NH3+])N)C=O.[Cl-],,,,,,
2810,52811,N-(diaminomethylideneamino)-3-(4-formylphenyl)propanamide,C1=CC(=CC=C1CCC(=O)NN=C(N)N)C=O,,,,,,
2811,52812,"IMIDAZOLIDINE, 2-(4-(BIS(2-CHLOROETHYL)AMINO)-o-TOLYL)-1,3-BIS(o-METHOXYBENZYL)-",CC1=C(C=CC(=C1)N(CCCl)CCCl)C2N(CCN2CC3=CC=CC=C3OC)CC4=CC=CC=C4OC,,,,,,
2812,52813,"IMIDAZOLIDINE, 2-(p-CHLOROPHENYL)-1,3-DIPHENYL-",C1CN(C(N1C2=CC=CC=C2)C3=CC=C(C=C3)Cl)C4=CC=CC=C4,,,,,,
2813,52814,"Imidazolidine, 1,3-dibutyl-2-propyl-",CCCCN1CCN(C1CCC)CCCC,,,,,,
2814,52815,"2-(2,4-Dichlorophenyl)-1,3-diphenylimidazolidine",C1CN(C(N1C2=CC=CC=C2)C3=C(C=C(C=C3)Cl)Cl)C4=CC=CC=C4,,,,,,
2815,52816,"1,3-Diethyl-2-phenylimidazolidine",CCN1CCN(C1C2=CC=CC=C2)CC,,,,,,
2816,52817,"2-(3-Nitrophenyl)-1,3-diphenylimidazolidine",C1CN(C(N1C2=CC=CC=C2)C3=CC(=CC=C3)[N+](=O)[O-])C4=CC=CC=C4,,,,,,
2817,52818,"N-[4,5-Dihydro-1-methyl-5-[(4-nitrophenyl)methylene]-4-oxo-1H-imidazol-2-yl]acetamide",CC(=O)NC1=NC(=O)C(=CC2=CC=C(C=C2)[N+](=O)[O-])N1C,,,,,,
2818,52819,CID 52819,CC(C)N[NH3+].CS(=O)(=O)[O-].[Na+],,,,,,
2819,52820,CID 52820,NN.F[SnH](F)F,,,,,,
2820,52821,(2-(1-(p-Chlorophenyl)-1-silacyclohexyloxy)ethyl)diethylmethylammonium iodide,CC[N+](C)(CC)CCO[Si]1(CCCCC1)C2=CC=C(C=C2)Cl.[I-],,,,,,
2821,52822,2-[1-(4-Chlorophenyl)silinan-1-yl]oxyethyl-diethyl-methylazanium,CC[N+](C)(CC)CCO[Si]1(CCCCC1)C2=CC=C(C=C2)Cl,,,,,,
2822,52823,"Butyrophenone, 4'-fluoro-4-(spiro(benzofuran-3(2H),4'-piperidin)-1'-YL)-",C1CN(CCC12COC3=CC=CC=C23)CCCC(=O)C4=CC=C(C=C4)F,,,,,,
2823,52824,"Butyrophenone, 4'-fluoro-4-(7-methoxyspiro(benzofuran-3(2H),4'-piperidin)-1'-yl)-, hydrochloride",COC1=CC=CC2=C1OCC23CC[NH+](CC3)CCCC(=O)C4=CC=C(C=C4)F.[Cl-],,,,,,
2824,52825,"1-(4-fluorophenyl)-4-(7-methoxyspiro[2H-1-benzofuran-3,4'-piperidine]-1'-yl)butan-1-one",COC1=CC=CC2=C1OCC23CCN(CC3)CCCC(=O)C4=CC=C(C=C4)F,,,,,,
2825,52826,"Butyrophenone, 4'-fluoro-4-(2-methoxyspiro(benzofuran-3(2H),4'-piperidin)-1'-yl)-, oxalate, hemihydrate",COC1C2(CC[NH+](CC2)CCCC(=O)C3=CC=C(C=C3)F)C4=CC=CC=C4O1.C(=O)(C(=O)[O-])O,,,,,,
2826,52827,"1-(4-fluorophenyl)-4-(2-methoxyspiro[2H-1-benzofuran-3,4'-piperidine]-1'-yl)butan-1-one",COC1C2(CCN(CC2)CCCC(=O)C3=CC=C(C=C3)F)C4=CC=CC=C4O1,,,,,,
2827,52828,"BUTYROPHENONE, 4'-FLUORO-4-(4-(o-HYDROXYPHENYL)-4-HYDROXYMETHYLPIPERIDINO)-",C1CN(CCC1(CO)C2=CC=CC=C2O)CCCC(=O)C3=CC=C(C=C3)F,,,,,,
2828,52829,"Butyrophenone, 4'-fluoro-4-(4-(2-hydroxy-3-methoxyphenyl)-4-(hydroxymethyl)piperidino)-",COC1=CC=CC(=C1O)C2(CCN(CC2)CCCC(=O)C3=CC=C(C=C3)F)CO,,,,,,
2829,52830,CID 52830,C1=CC(=C(C(=C1)Cl)C=NN=C(N)S)F,,,,,,
2830,52831,CID 52831,CCCCCCCCOC1=CC=C(C=C1)C=NN=C(N)S,,,,,,
2831,52832,CID 52832,C#CCOC1=CC=CC=C1C=NN=C(N)S,,,,,,
2832,52833,"Phenol, 2,6-dichloro-4-octyl-",CCCCCCCCC1=CC(=C(C(=C1)Cl)O)Cl,,,,,,
2833,52834,"1,2-Bis(hexadecylsulfonyl)ethane",CCCCCCCCCCCCCCCCS(=O)(=O)CCS(=O)(=O)CCCCCCCCCCCCCCCC,,,,,,
2834,52835,"Ethane, 1,2-bis(tetradecylsulfonyl)-",CCCCCCCCCCCCCCS(=O)(=O)CCS(=O)(=O)CCCCCCCCCCCCCC,,,,,,
2835,52836,N-(p-Ethoxyphenylformimidoyl)dimethylamine p-toluenesulfonate,CCOC1=CC=C(C=C1)C(=N)[NH+](C)C.CC1=CC=C(C=C1)S(=O)(=O)[O-],,,,,,
2836,52837,"4-ethoxy-N,N-dimethylbenzenecarboximidamide",CCOC1=CC=C(C=C1)C(=N)N(C)C,,,,,,
2837,52838,"m-DIOXAN-5-AMINE, 5-BENZYLAMINOMETHYL-2-PHENYL-",C1C(COC(O1)C2=CC=CC=C2)(CNCC3=CC=CC=C3)N,,,,,,
2838,52839,"m-DIOXAN-5-AMINE, 2-(p-CHLOROPHENYL)-",C1C(COC(O1)C2=CC=C(C=C2)Cl)N,,,,,,
2839,52840,"m-DIOXAN-5-AMINE, 2-(p-CHLOROPHENYL)-5-ETHYL-",CCC1(COC(OC1)C2=CC=C(C=C2)Cl)N,,,,,,
2840,52841,"5-Benzylideneamino-5-methyl-1,3-dioxane",CC1(COCOC1)N=CC2=CC=CC=C2,,,,,,
2841,52842,"2,2-Dibenzyl-4-diethylaminomethyl-1,3-dioxolane hydrochloride",CC[NH+](CC)CC1COC(O1)(CC2=CC=CC=C2)CC3=CC=CC=C3.[Cl-],,,,,,
2842,52843,"N-[(2,2-dibenzyl-1,3-dioxolan-4-yl)methyl]-N-ethylethanamine",CCN(CC)CC1COC(O1)(CC2=CC=CC=C2)CC3=CC=CC=C3,,,,,,
2843,52844,"4-Diethylaminomethyl-2,2-diphenyl-1,3-dioxolane hydrochloride",CC[NH+](CC)CC1COC(O1)(C2=CC=CC=C2)C3=CC=CC=C3.[Cl-],,,,,,
2844,52845,"N-[(2,2-diphenyl-1,3-dioxolan-4-yl)methyl]-N-ethylethanamine",CCN(CC)CC1COC(O1)(C2=CC=CC=C2)C3=CC=CC=C3,,,,,,
2845,52846,"2,2-Dimethyl-4-((pentachlorophenylthio)methyl)-1,3-dioxolane",CC1(OCC(O1)CSC2=C(C(=C(C(=C2Cl)Cl)Cl)Cl)Cl)C,,,,,,
2846,52847,Cyclamen aldehyde propyleneglycol acetal,CC1COC(O1)C(C)CC2=CC=C(C=C2)C(C)C,,,,,,
2847,52848,"2-(p-Chlorophenyl)-1,3-dioxolane-4-methanol",C1C(OC(O1)C2=CC=C(C=C2)Cl)CO,,,,,,
2848,52849,"Dipentylamine, tetrafluoroborate(1-)",[B-](F)(F)(F)F.CCCCC[NH2+]CCCCC,,,,,,
2849,52850,"15,18-Dithiadotriacontane",CCCCCCCCCCCCCCSCCSCCCCCCCCCCCCCC,,,,,,
2850,52851,"11,17-Dithiaheptacosane",CCCCCCCCCCSCCCCCSCCCCCCCCCC,,,,,,
2851,52852,"2-(1-(Dibutoxyphosphinyl)butoxy)-1,3,2-dithiaphospholane",CCCCOP(=O)(C(CCC)OP1SCCS1)OCCCC,,,,,,
2852,52853,"1,3,2-Dithiaphospholane, 2-(dibutylamino)-",CCCCN(CCCC)P1SCCS1,,,,,,
2853,52854,"Pyridoxin-4,5-dimethylenedisulfid hydrochlorid [German]",CC1=[NH+]C=C2CSSCC2=C1O.[Cl-],,,,,,
2854,52855,"7-Methyl-1,4-dihydrodithiino[4,5-c]pyridin-8-ol",CC1=NC=C2CSSCC2=C1O,,,,,,
2855,52856,"2-(4-Methylphenyl)-1,3-dioxan-5-ol",CC1=CC=C(C=C1)C2OCC(CO2)O,,,,,,
2856,52857,"1,2-Bis(dodecylsulfonyl)ethane",CCCCCCCCCCCCS(=O)(=O)CCS(=O)(=O)CCCCCCCCCCCC,,,,,,
2857,52858,"Dibutyltin;2,4,5-trichlorophenol;hydrate",CCCC[Sn]CCCC.CCCC[Sn]CCCC.C1=C(C(=CC(=C1Cl)Cl)Cl)O.C1=C(C(=CC(=C1Cl)Cl)Cl)O.O,,,,,,
2858,52859,10-Fluorobenzo(a)pyrene,C1=CC2=C3C(=C1)C=CC4=C5C(=CC(=C43)C=C2)C=CC=C5F,,,,,,
2859,52860,"1,2-Bis(decylsulfonyl)ethane",CCCCCCCCCCS(=O)(=O)CCS(=O)(=O)CCCCCCCCCC,,,,,,
2860,52861,1-Methyl-2-methylthiobenzimidazole hydrochloride,C[N+]1=C(NC2=CC=CC=C21)SC.[Cl-],,,,,,
2861,52862,3-methyl-2-methylsulfanyl-1H-benzimidazol-3-ium,C[N+]1=C(NC2=CC=CC=C21)SC,,,,,,
2862,52863,"1-Methyl-2-methylthio-5,6-dimethoxybenzimidazole hydrochloride",C[N+]1=C(NC2=CC(=C(C=C21)OC)OC)SC.[Cl-],,,,,,
2863,52864,"5,6-dimethoxy-3-methyl-2-methylsulfanyl-1H-benzimidazol-3-ium",C[N+]1=C(NC2=CC(=C(C=C21)OC)OC)SC,,,,,,
2864,52865,"Benzimidazole, 5,6-dimethoxy-2-((3-dimethylaminopropyl)thio)-",CN(C)CCCSC1=NC2=CC(=C(C=C2N1)OC)OC,,,,,,
2865,52866,3-Ethoxy-2-nitropyridine,CCOC1=C(N=CC=C1)[N+](=O)[O-],,,,,,
2866,52867,"N,N'-Bis(m-chlorobenzylidene)-1,6-hexanediamine",C1=CC(=CC(=C1)Cl)C=NCCCCCCN=CC2=CC(=CC=C2)Cl,,,,,,
2867,52868,"1,6-Hexanediamine, N,N'-di-o-veratrylidene-",C1OC2=CC=CC(=C2O1)C=NCCCCCCN=CC3=C4C(=CC=C3)OCO4,,,,,,
2868,52869,2-(Diethylamino)ethyl 2-ethylhexanoate hydrochloride,CCCCC(CC)C(=O)OCC[NH+](CC)CC.[Cl-],,,,,,
2869,52870,2-(Diethylamino)ethyl 2-ethylhexanoate,CCCCC(CC)C(=O)OCCN(CC)CC,,,,,,
2870,52871,2-(Diethylamino)ethyl 5-methyl-2-phenylhexanoate hydrochloride,CC[NH+](CC)CCOC(=O)C(CCC(C)C)C1=CC=CC=C1.[Cl-],,,,,,
2871,52872,2-(Diethylamino)ethyl 5-methyl-2-phenylhexanoate,CCN(CC)CCOC(=O)C(CCC(C)C)C1=CC=CC=C1,,,,,,
2872,52873,6-Naphthalen-1-yl-4-oxohex-5-enoic acid,C1=CC=C2C(=C1)C=CC=C2C=CC(=O)CCC(=O)O,,,,,,
2873,52874,6-(3-Nitrophenyl)-4-oxohex-5-enoic acid,C1=CC(=CC(=C1)[N+](=O)[O-])C=CC(=O)CCC(=O)O,,,,,,
2874,52875,"1-(4-Chloro-1,3-benzodioxol-5-yl)-5,5-dimethylhex-1-en-3-ol",CC(C)(C)CC(C=CC1=C(C2=C(C=C1)OCO2)Cl)O,,,,,,
2875,52876,"1,3-Dichloro-5,5-di(p-tolyl)hydantoin",CC1=CC=C(C=C1)C2(C(=O)N(C(=O)N2Cl)Cl)C3=CC=C(C=C3)C,,,,,,
2876,52877,"5-Cyclohexyl-3-[2-(diethylamino)ethyl]-5-(2-methylpropyl)imidazolidine-2,4-dione",CCN(CC)CCN1C(=O)C(NC1=O)(CC(C)C)C2CCCCC2,,,,,,
2877,52878,"5-Cyclohexyl-3-[2-(diethylamino)ethyl]-5-methylimidazolidine-2,4-dione",CCN(CC)CCN1C(=O)C(NC1=O)(C)C2CCCCC2,,,,,,
2878,52879,"5-Cyclohexyl-3-[2-(diethylamino)ethyl]-5-(thiolan-3-yl)imidazolidine-2,4-dione",CCN(CC)CCN1C(=O)C(NC1=O)(C2CCCCC2)C3CCSC3,,,,,,
2879,52880,"5-Cyclohexyl-5-(thiolan-3-yl)imidazolidine-2,4-dione",C1CCC(CC1)C2(C(=O)NC(=O)N2)C3CCSC3,,,,,,
2880,52881,"5,5-Dicyclohexylhydantoin",C1CCC(CC1)C2(C(=O)NC(=O)N2)C3CCCCC3,,,,,,
2881,52882,"5,5-Dicyclohexyl-3-[2-(diethylamino)ethyl]imidazolidine-2,4-dione",CCN(CC)CCN1C(=O)C(NC1=O)(C2CCCCC2)C3CCCCC3,,,,,,
2882,52883,"5,5-Dicyclohexyl-3-[3-(diethylamino)propyl]imidazolidine-2,4-dione",CCN(CC)CCCN1C(=O)C(NC1=O)(C2CCCCC2)C3CCCCC3,,,,,,
2883,52884,"HYDRAZINE, 1-(m-FLUOROBENZOYL)-2-(1-NAPHTHOYL)-",C1=CC=C2C(=C1)C=CC=C2C(=O)NNC(=O)C3=CC(=CC=C3)F,,,,,,
2884,52885,"HYDRAZINE, 1-(p-FLUOROBENZOYL)-2-(1-NAPHTHOYL)-",C1=CC=C2C(=C1)C=CC=C2C(=O)NNC(=O)C3=CC=C(C=C3)F,,,,,,
2885,52886,"2-Imidazoline, 1-(N-benzyl-N-phenylaminomethyl)-",C1CN(C=N1)CN(CC2=CC=CC=C2)C3=CC=CC=C3,,,,,,
2886,52887,"2-Imidazoline, 4,4-dimethyl-1-isopropyl-2-nonyl-",CCCCCCCCCC1=NC(CN1C(C)C)(C)C,,,,,,
2887,52888,"2-Imidazoline, 4,4-dimethyl-1-isopropyl-2-undecyl-",CCCCCCCCCCCC1=NC(CN1C(C)C)(C)C,,,,,,
2888,52889,"2-Imidazoline, 4,4-dimethyl-2-nonyl-1-phenyl-",CCCCCCCCCC1=NC(CN1C2=CC=CC=C2)(C)C,,,,,,
2889,52890,"2-Imidazoline-1-ethanol, 4,4-dimethyl-2-nonyl-",CCCCCCCCCC1=NC(CN1CCO)(C)C,,,,,,
2890,52891,"2-IMIDAZOLINE-1-ETHANOL, 2-NONYL-beta,beta,4,4-TETRAMETHYL-",CCCCCCCCCC1=NC(CN1C(C)(C)CO)(C)C,,,,,,
2891,52892,"2-Imidazoline-1-ethanol, 2-nonyl-alpha,4,4-trimethyl-",CCCCCCCCCC1=NC(CN1CC(C)O)(C)C,,,,,,
2892,52893,"2-IMIDAZOLINE-1-ETHANOL, alpha,4,4-TRIMETHYL-2-UNDECYL-",CCCCCCCCCCCC1=NC(CN1CC(C)O)(C)C,,,,,,
2893,52894,2-(3-Indolylmethyl)imidazoline hydrochloride,C1CN=C([NH2+]1)CC2=CNC3=CC=CC=C32.[Cl-],,,,,,
2894,52895,2-Phenacylthio-2-imidazolinium chloride,C1CN=C(N1)SCC(=O)C2=CC=CC=C2.[Cl-],,,,,,
2895,52896,"2-(4,5-dihydro-1H-imidazol-2-ylthio)-1-phenylethanone",C1CN=C(N1)SCC(=O)C2=CC=CC=C2,,,,,,
2896,52897,"5,7-Dimethyl-3-indoleacetic acid",CC1=CC(=C2C(=C1)C(=CN2)CC(=O)O)C,,,,,,
2897,52898,5-Methoxy-2-methyltryptamine hydrochloride,CC1=C(C2=C(N1)C=CC(=C2)OC)CC[NH3+].[Cl-],,,,,,
2898,52899,2-(5-Methoxy-2-methyl-1H-indol-3-yl)ethanamine,CC1=C(C2=C(N1)C=CC(=C2)OC)CCN,,,,,,
2899,52900,"Indole-2-carbohydrazide, 5-benzyloxy-N,N-dimethyl-",CN(C)NC(=O)C1=CC2=C(N1)C=CC(=C2)OCC3=CC=CC=C3,,,,,,
2900,52901,"5-Acetyl-2-carbethoxy-N,N-dimethyltryptamine hydrochloride",CCOC(=O)C1=C(C2=C(N1)C=CC(=C2)C(=O)C)CCN(C)C.Cl,,,,,,
2901,52902,ethyl 5-acetyl-3-[2-(dimethylamino)ethyl]-1H-indole-2-carboxylate,CCOC(=O)C1=C(C2=C(N1)C=CC(=C2)C(=O)C)CCN(C)C,,,,,,
2902,52903,CID 52903,CN1CCC(C1)OC(=O)N2C=CC3=CC=CC=C32,,,,,,
2903,52904,"4-(indol-3-ylidenemethyl)-N,N-dimethylaniline",CN(C)C1=CC=C(C=C1)C=C2C=NC3=CC=CC=C32,,,,,,
2904,52905,3-(4-(Dimethylamino)butyl)indole hydrochloride,C[NH+](C)CCCCC1=CNC2=CC=CC=C21.[Cl-],,,,,,
2905,52906,3-(4-Dimethylaminobutyl) indole,CN(C)CCCCC1=CNC2=CC=CC=C21,,,,,,
2906,52907,"2H-Naphtho(1,2-d)triazole-6,8-disulfonic acid, 2-(4'-amino-1,1'-biphenyl-4-yl)-, dipotassium salt",C1=CC(=CC=C1C2=CC=C(C=C2)N3N=C4C=CC5=C(C4=N3)C=C(C=C5S(=O)(=O)[O-])S(=O)(=O)[O-])N.[K+].[K+],,,,,,
2907,52908,"2-[4-(4-Aminophenyl)phenyl]benzo[e]benzotriazole-6,8-disulfonic acid",C1=CC(=CC=C1C2=CC=C(C=C2)N3N=C4C=CC5=C(C4=N3)C=C(C=C5S(=O)(=O)O)S(=O)(=O)O)N,,,,,,
2908,52909,"2H-Naphtho(1,2-d)triazole-6,8-disulfonic acid, 2-(4'-amino-3'-sulfo-1,1'-biphenyl-4-yl)-, tripotassium salt",C1=CC(=CC=C1C2=CC(=C(C=C2)N)S(=O)(=O)[O-])N3N=C4C=CC5=C(C4=N3)C=C(C=C5S(=O)(=O)[O-])S(=O)(=O)[O-].[K+].[K+].[K+],,,,,,
2909,52910,"2-[4-(4-Amino-3-sulfophenyl)phenyl]benzo[e]benzotriazole-6,8-disulfonic acid",C1=CC(=CC=C1C2=CC(=C(C=C2)N)S(=O)(=O)O)N3N=C4C=CC5=C(C4=N3)C=C(C=C5S(=O)(=O)O)S(=O)(=O)O,,,,,,
2910,52911,"N-Heptyl-6-methoxy-1,2,3,4-tetrahydro-1-naphthylamine hydrochloride",CCCCCCC[NH2+]C1CCCC2=C1C=CC(=C2)OC.[Cl-],,,,,,
2911,52912,4-(Ethylthio)nicotinic acid hydrobromide,CCSC1=C(C=[NH+]C=C1)C(=O)O.[Br-],,,,,,
2912,52913,4-Ethylsulfanylpyridine-3-carboxylic acid,CCSC1=C(C=NC=C1)C(=O)O,,,,,,
2913,52914,"9-(p-(9-Acridinylamino)phenyl)nonanamide, methanesulfonate, hydrate",CS(=O)(=O)[O-].C1=CC=C2C(=C1)C(=C3C=CC=CC3=N2)[NH2+]C4=CC=C(C=C4)CCCCCCCCC(=O)N,,,,,,
2914,52915,9-[4-(Acridin-9-ylamino)phenyl]nonanamide,C1=CC=C2C(=C1)C(=C3C=CC=CC3=N2)NC4=CC=C(C=C4)CCCCCCCCC(=O)N,,,,,,
2915,52916,"Nonanamide, N-purin-6-YL-",CCCCCCCCC(=O)NC1=NC=NC2=C1NC=N2,,,,,,
2916,52917,"2-Norbornanamine, N-(4-chlorobenzhydryl)-, hydrochloride",C1CC2CC1CC2[NH2+]C(C3=CC=CC=C3)C4=CC=C(C=C4)Cl.[Cl-],,,,,,
2917,52918,N-[(4-chlorophenyl)-phenylmethyl]bicyclo[2.2.1]heptan-2-amine,C1CC2CC1CC2NC(C3=CC=CC=C3)C4=CC=C(C=C4)Cl,,,,,,
2918,52919,Haloperidol decanoate,CCCCCCCCCC(=O)OC1(CCN(CC1)CCCC(=O)C2=CC=C(C=C2)F)C3=CC=C(C=C3)Cl,,,"['Agents that control agitated psychotic behavior, alleviate acute psychotic states, reduce psychotic symptoms, and exert a quieting effect. They are used in SCHIZOPHRENIA; senile dementia; transient psychosis following surgery; or MYOCARDIAL INFARCTION; etc. These drugs are often referred to as neuroleptics alluding to the tendency to produce neurological side effects, but not all antipsychotics are likely to produce such effects. Many of these drugs may also be effective against nausea, emesis, and pruritus. (See all compounds classified as Antipsychotic Agents.)']",,,
2919,52920,"5,5-Dicyclohexyl-3-[2-(dimethylamino)ethyl]imidazolidine-2,4-dione",CN(C)CCN1C(=O)C(NC1=O)(C2CCCCC2)C3CCCCC3,,,,,,
2920,52921,2-(Diethylamino)ethyl 2-phenylnonanoate hydrochloride,CCCCCCCC(C1=CC=CC=C1)C(=O)OCC[NH+](CC)CC.[Cl-],,,,,,
2921,52922,2-(Diethylamino)ethyl 2-phenylnonanoate,CCCCCCCC(C1=CC=CC=C1)C(=O)OCCN(CC)CC,,,,,,
2922,52923,CID 52923,CCCC(=C1C(=O)CC(CC1=O)CC(C)SCC)NOCC,,,,,,
2923,52924,"Butyramide, 2-amino-N-(((4-chloro-2-(o-chlorobenzoyl)phenyl)methylcarbamoyl)methyl)-3-methyl-, hydrochloride, hydrate (2:1:2)",CC(C)C(C(=O)NCC(=O)N(C)C1=C(C=C(C=C1)Cl)C(=O)C2=CC=CC=C2Cl)[NH3+].[Cl-],,,,,,
2924,52925,2-amino-N-[2-[4-chloro-2-(2-chlorobenzoyl)-N-methylanilino]-2-oxoethyl]-3-methylbutanamide,CC(C)C(C(=O)NCC(=O)N(C)C1=C(C=C(C=C1)Cl)C(=O)C2=CC=CC=C2Cl)N,,,,,,
2925,52926,"7H-Isoquino(2,1-d)(1,4)benzodiazepin-8-ium, 6,7,9,10-tetrahydro-2-chloro-12,13-dimethoxy-7-ethyl-6-oxo-, bromide",CCC1C(=O)NC2=C(C=C(C=C2)Cl)C3=[N+]1CCC4=CC(=C(C=C43)OC)OC.[Br-],,,,,,
2926,52927,"2-Chloro-7-ethyl-12,13-dimethoxy-5,7,9,10-tetrahydroisoquinolino[2,1-d][1,4]benzodiazepin-8-ium-6-one",CCC1C(=O)NC2=C(C=C(C=C2)Cl)C3=[N+]1CCC4=CC(=C(C=C43)OC)OC,,,,,,
2927,52928,"4-amino-5-(2-bromoethenyl)-1-[(2R,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one",C1[C@@H](O[C@@H](C1O)CO)N2C=C(C(=NC2=O)N)C=CBr,,,,,,
2928,52929,Ethyl 5-methoxy-2-sulfamoylbenzoate,CCOC(=O)C1=C(C=CC(=C1)OC)S(=O)(=O)N,,,,,,
2929,52930,"Benzoic acid, 5-methoxy-2-sulfamoyl-, propyl ester",CCCOC(=O)C1=C(C=CC(=C1)OC)S(=O)(=O)N,,,,,,
2930,52931,Butyl 5-methoxy-2-sulfamoylbenzoate,CCCCOC(=O)C1=C(C=CC(=C1)OC)S(=O)(=O)N,,,,,,
2931,52932,"Benzoic acid, 2-(dimethylsulfamoyl)-5-methoxy-, methyl ester",CN(C)S(=O)(=O)C1=C(C=C(C=C1)OC)C(=O)OC,,,,,,
2932,52933,"Benzoic acid, 2-(dimethylsulfamoyl)-5-methoxy-, isopropyl ester",CC(C)OC(=O)C1=C(C=CC(=C1)OC)S(=O)(=O)N(C)C,,,,,,
2933,52934,"Benzoic acid, 5-methoxy-2-sulfamoyl-, isopropyl ester",CC(C)OC(=O)C1=C(C=CC(=C1)OC)S(=O)(=O)N,,,,,,
2934,52935,"Benzoic acid, 5-propoxy-2-sulfamoyl-, isopropyl ester",CCCOC1=CC(=C(C=C1)S(=O)(=O)N)C(=O)OC(C)C,,,,,,
2935,52936,"5-BENZOFURANOL, 3-(p-CHLOROPHENYL)-4-DIMETHYLAMINOMETHYL-2-METHYL-",CC1=C(C2=C(O1)C=CC(=C2CN(C)C)O)C3=CC=C(C=C3)Cl,,,,,,
2936,52937,"6-Benzofuranol, 3-(p-chlorophenyl)-7-dimethylaminomethyl-2-methyl-, hydrochloride",CC1=C(C2=C(O1)C(=C(C=C2)O)C[NH+](C)C)C3=CC=C(C=C3)Cl.[Cl-],,,,,,
2937,52938,2-Methyl-3-(p-chlorophenyl)-6-hydroxy-7-dimethylaminomethylbenzofuran,CC1=C(C2=C(O1)C(=C(C=C2)O)CN(C)C)C3=CC=C(C=C3)Cl,,,,,,
2938,52939,"Benzoic acid, 5-butoxy-2-sulfamoyl-, isopropyl ester",CCCCOC1=CC(=C(C=C1)S(=O)(=O)N)C(=O)OC(C)C,,,,,,
2939,52940,Methyl 8-methyl-3-phenyl-8-azabicyclo[3.2.1]octane-2-carboxylate,CN1C2CCC1C(C(C2)C3=CC=CC=C3)C(=O)OC,,,,,,
2940,52941,"Acridine, 3,6-diamino-4,5-diiodo-",C1=CC(=C(C2=NC3=C(C=CC(=C3I)N)C=C21)I)N,,,,,,
2941,52942,"Iron, (ethanedioato(2-)-O,O')bis(pyridine 1-oxide-O)-, (T-4)-",C1=CC=[N+](C=C1)[O-].C1=CC=[N+](C=C1)[O-].C(=O)(C(=O)[O-])[O-].[Fe+2],,,,,,
2942,52943,"2-Isoindolineacetamide, 1,3-dioxo-N-ethyl-",CCNC(=O)CN1C(=O)C2=CC=CC=C2C1=O,,,,,,
2943,52944,"2-Isoindolineacetamide, 1-3-dioxo-N-propyl-",CCCNC(=O)CN1C(=O)C2=CC=CC=C2C1=O,,,,,,
2944,52945,"2-Isoindolineacetamide, N-butyl-1,3-dioxo-",CCCCNC(=O)CN1C(=O)C2=CC=CC=C2C1=O,,,,,,
2945,52946,"1,3-Dioxo-N-diethyl-2-isoindolineacetamide",CCN(CC)C(=O)CN1C(=O)C2=CC=CC=C2C1=O,,,,,,
2946,52947,"2-Isoindolinebutyramide, 1,3-dioxo-N-methyl-",CNC(=O)CCCN1C(=O)C2=CC=CC=C2C1=O,,,,,,
2947,52948,"2-Isoindolinebutyramide, 1,3-dioxo-N-butyl-",CCCCNC(=O)CCCN1C(=O)C2=CC=CC=C2C1=O,,,,,,
2948,52949,"Arsonic acid, (4-((4-chlorobenzoyl)amino)phenyl)-",C1=CC(=CC=C1C(=O)NC2=CC=C(C=C2)[As](=O)(O)O)Cl,,,,,,
2949,52950,"Arsonic acid, (4-((dichloroacetyl)amino)phenyl)-",C1=CC(=CC=C1NC(=O)C(Cl)Cl)[As](=O)(O)O,,,,,,
2950,52951,"Arsonic acid, (4-((3-chloro-1-oxopropyl)amino)phenyl)-",C1=CC(=CC=C1NC(=O)CCCl)[As](=O)(O)O,,,,,,
2951,52952,"Arsonic acid, (4-((4-chloro-1-oxobutyl)amino)phenyl)-",C1=CC(=CC=C1NC(=O)CCCCl)[As](=O)(O)O,,,,,,
2952,52953,"Arsonic acid, (4-((2,4-dichlorobenzoyl)amino)phenyl)-",C1=CC(=CC=C1NC(=O)C2=C(C=C(C=C2)Cl)Cl)[As](=O)(O)O,,,,,,
2953,52954,"Arsonic acid, (4-(((4-chlorophenyl)acetyl)amino)phenyl)-",C1=CC(=CC=C1CC(=O)NC2=CC=C(C=C2)[As](=O)(O)O)Cl,,,,,,
2954,52955,"3(2H)-Benzoxazolecarboxylic acid, 6-bromo-2-oxo-, ethyl ester",CCOC(=O)N1C2=C(C=C(C=C2)Br)OC1=O,,,,,,
2955,52956,"N-(5-Sulfamoyl-1,3,4-thiadiazol-2-yl)oxamide",C1(=NN=C(S1)S(=O)(=O)N)NC(=O)C(=O)N,,,,,,
2956,52957,"N-Propyl-N'-(5-sulfamoyl-1,3,4-thiadiazole-2-yl)oxamide",CCCNC(=O)C(=O)NC1=NN=C(S1)S(=O)(=O)N,,,,,,
2957,52958,"N-Isopropyl-N'-(5-sulfamoyl-1,3,4-thiadiazol-2-yl)oxamide",CC(C)NC(=O)C(=O)NC1=NN=C(S1)S(=O)(=O)N,,,,,,
2958,52959,"N-Butyl-N'-(5-sulfamoyl-1,3,4-thiadiazole-2-yl)oxamide",CCCCNC(=O)C(=O)NC1=NN=C(S1)S(=O)(=O)N,,,,,,
2959,52960,"1,2,3,4-Tetrahydro-8-(o-methoxyphenyl)isoquinoline hydrochloride",COC1=CC=CC=C1C2=CC=CC3=C2C[NH2+]CC3.[Cl-],,,,,,
2960,52961,"8-(2-Methoxyphenyl)-1,2,3,4-tetrahydroisoquinoline",COC1=CC=CC=C1C2=CC=CC3=C2CNCC3,,,,,,
2961,52962,"1,2,3,4-Tetrahydro-8-(o-methoxyphenyl)-2-methylisoquinoline hydrochloride",C[NH+]1CCC2=C(C1)C(=CC=C2)C3=CC=CC=C3OC.[Cl-],,,,,,
2962,52963,"8-(2-methoxyphenyl)-2-methyl-3,4-dihydro-1H-isoquinoline",CN1CCC2=C(C1)C(=CC=C2)C3=CC=CC=C3OC,,,,,,
2963,52964,"1,2,3,4-Tetrahydro-8-(m-methoxyphenyl)-2-methylisoquinoline hydrochloride",C[NH+]1CCC2=C(C1)C(=CC=C2)C3=CC(=CC=C3)OC.[Cl-],,,,,,
2964,52965,"8-(3-methoxyphenyl)-2-methyl-3,4-dihydro-1H-isoquinoline",CN1CCC2=C(C1)C(=CC=C2)C3=CC(=CC=C3)OC,,,,,,
2965,52966,CID 52966,CC1=CC(=C2C(=C1C)N=C3C(=NC(=O)NC3=O)N2)CCC[NH+](C)C.[Cl-],,,,,,
2966,52967,CID 52967,CC1=CC(=C2C(=C1C)N=C3C(=NC(=O)NC3=O)N2)CCCN(C)C,,,,,,
2967,52968,CID 52968,C[NH+](C)CCCC1=C2C(=CC=C1)N=C3C(=NC(=O)NC3=O)N2.[Cl-],,,,,,
2968,52969,CID 52969,CN(C)CCCC1=C2C(=CC=C1)N=C3C(=NC(=O)NC3=O)N2,,,,,,
2969,52970,"5-Acetyl-N,N-dimethyltryptamine hydrochloride",CC(=O)C1=CC2=C(C=C1)NC=C2CCN(C)C.Cl,,,,,,
2970,52971,"Ethanone, 1-[3-[2-(dimethylamino)ethyl]-1H-indol-5-yl]-",CC(=O)C1=CC2=C(C=C1)NC=C2CCN(C)C,,,,,,
2971,52972,(1-(p-Trifluoromethyl)benzyl)hydrazine hydrochloride,C1=CC(=CC=C1CN[NH3+])C(F)(F)F.[Cl-],,,,,,
2972,52973,(4-(Trifluoromethyl)benzyl)hydrazine,C1=CC(=CC=C1CNN)C(F)(F)F,,,,,,
2973,52974,"6,7-Dimethoxy-4-(p-(dimethylamino)benzyl)isoquinoline hydrobromide",C[NH+](C)C1=CC=C(C=C1)CC2=CN=CC3=CC(=C(C=C32)OC)OC.[Br-],,,,,,
2974,52975,"4-((6,7-Dimethoxyisoquinolin-4-yl)methyl)-N,N-dimethylaniline",CN(C)C1=CC=C(C=C1)CC2=CN=CC3=CC(=C(C=C32)OC)OC,,,,,,
2975,52976,Nonyl boric acid,B(O)(O)OCCCCCCCCC,,,,,,
2976,52977,"Ammonium, diethyl((N-(3-hydroxy-2-pyridyl)methyl-N-phenylamino)ethyl)methyl-, bromide, dimethylcarbamate (ester), methanoate",CC[N+](C)(CC)CC[NH+](CC1=C(C=CC=N1)OC(=O)N(C)C)C2=CC=CC=C2.C[O-].[Br-],,,,,,
2977,52978,2-[N-[[3-(dimethylcarbamoyloxy)pyridin-2-yl]methyl]anilino]ethyl-diethyl-methylazanium,CC[N+](C)(CC)CCN(CC1=C(C=CC=N1)OC(=O)N(C)C)C2=CC=CC=C2,,,,,,
2978,52979,p-Aminobenzoic acid (2-(sec-butylamino)-1-methyl)ethyl ester hydrochloride,CCC(C)[NH2+]CC(C)OC(=O)C1=CC=C(C=C1)N.[Cl-],,,,,,
2979,52980,1-(Butan-2-ylamino)propan-2-yl 4-aminobenzoate,CCC(C)NCC(C)OC(=O)C1=CC=C(C=C1)N,,,,,,
2980,52981,"6-Azabicyclo(3.2.1)octane, 6,7-dimethyl-1-(m-hydroxyphenyl)-, 3-pyridinecarboxylate (ester), hydrochloride",CC1C2(CCCC(C2)[NH+]1C)C3=CC(=CC=C3)OC(=O)C4=CN=CC=C4.[Br-],,,,,,
2981,52982,"3-(6,7-Dimethyl-6-azabicyclo[3.2.1]octan-1-yl)phenol 3-pyridinecarboxylate",CC1C2(CCCC(C2)N1C)C3=CC(=CC=C3)OC(=O)C4=CN=CC=C4,,,,,,
2982,52983,CID 52983,COC1=C(C(=C(C2=C1C=CO2)OC)OCC[NH+]3CCOCC3)C(=O)C=CC4=CC(=CC=C4)O.C(=CC(=O)[O-])C(=O)O,,,,,,
2983,52984,CID 52984,COC1=C(C(=C(C2=C1C=CO2)OC)OCCN3CCOCC3)C(=O)C=CC4=CC(=CC=C4)O,,,,,,
2984,52985,CID 52985,C1=CC(=CC=C1C=CC(=O)NCCO)[N+](=O)[O-].O,,,,,,
2985,52986,CID 52986,C1=CC(=CC=C1C=CC(=O)NCCO)[N+](=O)[O-],,,,,,
2986,52987,CID 52987,CC1=CC(=CC=C1)C=CC(=O)NCCO.O,,,,,,
2987,52988,N-(2-hydroxyethyl)-3-(3-methylphenyl)prop-2-enamide,CC1=CC(=CC=C1)C=CC(=O)NCCO,,,,,,
2988,52989,"1,3-Dioxa-9-azaspiro(5.5)undecane, 5-ethyl-9-(3-(p-fluorobenzoyl)propyl)-, hydrochloride",CCC1COCOC12CC[NH+](CC2)CCCC(=O)C3=CC=C(C=C3)F.[Cl-],,,,,,
2989,52990,"4-(5-Ethyl-1,3-dioxa-9-azaspiro[5.5]undecan-9-yl)-1-(4-fluorophenyl)butan-1-one",CCC1COCOC12CCN(CC2)CCCC(=O)C3=CC=C(C=C3)F,,,,,,
2990,52991,"1,3-Dioxa-9-azaspiro(5.5)undecane, 5-ethyl-9-(3-(fluorobenzoyl)propyl)-2-(m-fluorophenyl)-",CCC1COC(OC12CC[NH+](CC2)CCCC(=O)C3=CC=C(C=C3)F)C4=CC(=CC=C4)F.[Cl-],,,,,,
2991,52992,"4-[5-Ethyl-2-(3-fluorophenyl)-1,3-dioxa-9-azaspiro[5.5]undecan-9-yl]-1-(4-fluorophenyl)butan-1-one",CCC1COC(OC12CCN(CC2)CCCC(=O)C3=CC=C(C=C3)F)C4=CC(=CC=C4)F,,,,,,
2992,52993,"Butyrophenone, 4-(2-(p-chlorophenyl)-5-ethyl-1,3-dioxa-9-azaspiro(5.5)undec-9-yl)-4'-fluoro-, hydrochloride, hydrate",CCC1COC(OC12CC[NH+](CC2)CCCC(=O)C3=CC=C(C=C3)F)C4=CC=C(C=C4)Cl.[Cl-],,,,,,
2993,52994,"4-[2-(4-Chlorophenyl)-5-ethyl-1,3-dioxa-9-azaspiro[5.5]undecan-9-yl]-1-(4-fluorophenyl)butan-1-one",CCC1COC(OC12CCN(CC2)CCCC(=O)C3=CC=C(C=C3)F)C4=CC=C(C=C4)Cl,,,,,,
2994,52995,"9,10-Anthracenedicarboxylic acid, 9,10-dihydro-, bis(2-(diethylamino)ethyl) ester, hydrochloride",CC[NH+](CC)CCOC(=O)C1C2=CC=CC=C2C(C3=CC=CC=C13)C(=O)OCCN(CC)CC.[Cl-],,,,,,
2995,52996,"Bis[2-(diethylamino)ethyl] 9,10-dihydroanthracene-9,10-dicarboxylate",CCN(CC)CCOC(=O)C1C2=CC=CC=C2C(C3=CC=CC=C13)C(=O)OCCN(CC)CC,,,,,,
2996,52997,Sulfometuron-methyl,CC1=CC(=NC(=N1)NC(=O)NS(=O)(=O)C2=CC=CC=C2C(=O)OC)C,,,"['Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. (See all compounds classified as Enzyme Inhibitors.)', 'Pesticides used to destroy unwanted vegetation, especially various types of weeds, grasses (POACEAE), and woody plants. Some plants develop HERBICIDE RESISTANCE. (See all compounds classified as Herbicides.)']","['... Sulfometuron methyl was rapidly metabolized and excreted by goats, a representative ruminant animal. The majority of dosed (14)C-labeled sulfometuron methyl, 94-99%, was excreted in urine and feces. Less than 1% was excreted in milk. Major residues in urine and feces consisted of both sulfometuron methyl and (hydroxymethyl)-pyrimidine sulfometuron methyl (HM-SM). The major metabolite in milk was also HM-SM. Less than 10% (<0.01 ppm) of total (14)C labeled residues in milk was the parent herbicide, indicating that sulfometuron methyl accumulation in milk was below detectable limits of 0.03 ppm. In the same study, accumulation of (14)C-labeled residues in meat and fat were also below detectable limits.']",['Major residues in urine and feces consisted of both sulfometuron methyl and (hydroxymethyl)-pyrimidine sulfometuron methyl (HM-SM). The major metabolite in milk was also HM-SM ...'],"['Half-lives of /sulfometuron methyl/ in rats ranged from 28 - 48 hours with doses of 16mg/kg and 3000 mg/kg, respectively, and therefore did not accumulate.']"
2997,52998,Sulfometuron,CC1=CC(=NC(=N1)NC(=O)NS(=O)(=O)C2=CC=CC=C2C(=O)O)C,,,,,,
2998,52999,Metsulfuron-methyl,CC1=NC(=NC(=N1)OC)NC(=O)NS(=O)(=O)C2=CC=CC=C2C(=O)OC,,,,"['Overall recovery of metsulfuron methyl among the treatment groups was acceptable (about 91.6-103.8%). The primary route of excretion /in rats/ was via the urine which accounted for approximately 71-95% (78-96% if cage wash radioactivity is considered) among the various treatment groups. Fecal elimination was 4.8-13.3%. Excretion was almost complete within 48 ours. Based on time course urinary and fecal excretion data, elimination half-lives (males and females) were estimated to be 13-16 hours for Group I (single low dose), 9-12 hours for Group II (21 day dietary exposure), and 23-29 hours for Group III single high dose) which affirmed notable alteration of absorption and/or excretion processes in the high-dose group. Tissue burdens were minimal (generally <0.1% to 1%) regardless of exposure protocol; the gastrointestinal tract, carcass, and skin had the highest concentrations of radioactivity. For the single or repeated low dose groups, the tissue content was generally >0.03 ppm. In the high-dose group, females had somewhat higher tissue burdens (ranging from 0.8 ppm in brain to 7.1 ppm in liver and 8.0 ppm in kidneys) than did males (0.1 ppm in blood to 1.6 ppm in liver and 2.6 ppm in kidneys). No evidence for sequestration of the test article or its biotransformation products.', 'In mammals, following oral administration, metsulfuron-methyl is excreted predominantly unchanged. The methoxycarbonyl and sulfonylurea groups are only partly degraded, by O-demethylation and hydroxylation.']","['Four metabolites and parent were recovered in both urine and feces /of rats/ in all treatment groups. Parent compound accounted for most of the urinary and fecal radioactivity (77-90% and 1.8-6.2% of the administered dose, respectively). Metabolite I was consistent with (methyl 2-((amino)sulfonyl)benzoate); Metabolite II - (2-((amino)sulfonyl)benzoic acid); and Metabolite III was consistent with (methyl 2-((((amino)carbonyl)amino)sulfonyl)benzoate). Metab. I and II appeared to result from sequential hydrolysis reactions terminating in the formation of saccharin while metab. III was formed by cleavage of the two ring structures. Total metabolites (in urine + feces of each group) accounted for approximately 5.4-8.2% of the administered dose. The metabolite profiles were qualitatively similar for urine and feces in that parent compound and the four metabolites (saccharin, metabolites I, II, and III) were found in both matrices.', '(Phenyl-(U)-(14)C)sulfometuron-methyl was metabolized in excised wheat seedlings (sensitive to sulfometuron-methyl) to (14)C methyl 2-(((((4-hydroxymethyl)-6-methylpyrimindin-2-yl)amino)carbonyl)amino sulfonyl)benzoate and its carbohydrate conjugate. This metabolic pathway is consistent with sulfometuron-methyl metabolism in tolerant species such as Bermuda grass. Sulfometuron-methyl was metabolized at a slower rate than metsulfuron-methyl in wheat. When plants were exposed to (14)C methyl-4-hydroxy-2(((((4-methoxy-6-methyl-1,3,5-triazin-2- yl-) amino)carbonyl)amino)-sulfonyl)benzoate and (14)C methyl 2-(((((4-hydroxymethyl)-6-methylpyrimindin-2-yl) amino)carbonyl)amino)sulfonyl)benzoate (the primary hydroxylated wheat metabolites of metsulfuron-methyl and sulfometuron-methyl, respectively), the rate of glucose conjugation of methyl-4-hydroxy-2(((((4-methoxy-6-methyl- 1,3,5-triazin-2-yl-)amino)carbonyl)amino)-sulfonyl)benzoate was much faster than the rate of glucose conjugation of methyl 2-(((((4-hydroxymethyl)-6- methylpyrimindin-2- yl)amino)carbonyl)amino)sulfonyl)benzoate. Along with their parent cmpd, both methyl 2-(((((4-hydroxymethyl)-6- methylpyrimindin-2- yl)amino)carbonyl)amino)sulfonyl)benzoate and methyl-4-hydroxy-2(((((4-methoxy-6-methyl-1,3,5-triazin-2- yl- )amino)carbonyl)amino)-sulfonyl)benzoate are potent inhibitors of wild mustard acetolactate synthase. These results indicate that wheat intolerance to sulfometuron-methyl (but tolerance to the structurally closed related metsulfon-methyl) reflects not only a reduced ability to hydroxylate the parent molecule but also a reduced ability to conjugate the primary toxic metabolite to a nontoxic moiety.', 'In mammals, following oral administration, metsulfuron-methyl is excreted predominantly unchanged. The methoxycarbonyl and sulfonylurea groups are only partly degraded, by O-demethylation and hydroxylation.']","['Based on time course urinary and fecal excretion data /in rats/, elimination half-lives (males and females) were estimated to be 13-16 hours for Group I (single low dose), 9-12 hours for Group II (21 day dietary exposure), and 23-29 hours for Group III single high dose) ...']"
2999,53000,Dazoxiben hydrochloride,C1=CC(=CC=C1C(=O)O)OCCN2C=CN=C2.Cl,,,['Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. (See all compounds classified as Enzyme Inhibitors.)'],,,
3000,53001,Dazoxiben,C1=CC(=CC=C1C(=O)O)OCCN2C=CN=C2,,,['Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. (See all compounds classified as Enzyme Inhibitors.)'],,,
3001,53002,"N,N-Diethyl-5-nitro-3-phenyl-2-benzofuranmethylamine hydrochloride",CC[NH+](CC)CC1=C(C2=C(O1)C=CC(=C2)[N+](=O)[O-])C3=CC=CC=C3.[Cl-],,,,,,
3002,53003,N-ethyl-N-[(5-nitro-3-phenyl-1-benzofuran-2-yl)methyl]ethanamine,CCN(CC)CC1=C(C2=C(O1)C=CC(=C2)[N+](=O)[O-])C3=CC=CC=C3,,,,,,
3003,53004,"BENZOFURAN, 3-(p-CHLOROPHENYL)-2,6-BIS((4-PHENYL-1-PIPERAZINYL)METHYL)-",C1CN(CCN1CC2=CC3=C(C=C2)C(=C(O3)CN4CCN(CC4)C5=CC=CC=C5)C6=CC=C(C=C6)Cl)C7=CC=CC=C7,,,,,,
3004,53005,"5-Benzofuranol, 4-(dimethylaminomethyl)-3-phenyl-2-((4-phenyl-1-piperazinyl)methyl)-",CN(C)CC1=C(C=CC2=C1C(=C(O2)CN3CCN(CC3)C4=CC=CC=C4)C5=CC=CC=C5)O,,,,,,
3005,53006,"5-Benzofuranol, 2,4-bis((4-phenyl-1-piperazinyl)methyl)-3-phenyl-",C1CN(CCN1CC2=C(C=CC3=C2C(=C(O3)CN4CCN(CC4)C5=CC=CC=C5)C6=CC=CC=C6)O)C7=CC=CC=C7,,,,,,
3006,53007,"5-Benzofuranol, 3-phenyl-2-((4-phenyl-1-piperazinyl)methyl)-4-piperidinomethyl-, hemihydrate",C1CCN(CC1)CC2=C(C=CC3=C2C(=C(O3)CN4CCN(CC4)C5=CC=CC=C5)C6=CC=CC=C6)O.O,,,,,,
3007,53008,3-Phenyl-2-[(4-phenylpiperazin-1-yl)methyl]-4-(piperidin-1-ylmethyl)-1-benzofuran-5-ol,C1CCN(CC1)CC2=C(C=CC3=C2C(=C(O3)CN4CCN(CC4)C5=CC=CC=C5)C6=CC=CC=C6)O,,,,,,
3008,53009,"1,2-Dimethyl-1,2,3,4-tetrahydropicene",CC1CCC2=C(C1C)C3=C(C=C2)C4=C(C=C3)C5=CC=CC=C5C=C4,,,,,,
3009,53010,"3,4,7-Trimethyl-1,2,3,4-tetrahydrochrysene",CC1CCC2=C(C1C)C3=C(C=C2)C4=CC=CC(=C4C=C3)C,,,,,,
3010,53011,"4-[[4-(4-Chlorophenyl)-5-(2-methoxy-2-oxoethyl)-1,3-thiazol-2-yl]amino]-4-oxobut-2-enoic acid",COC(=O)CC1=C(N=C(S1)NC(=O)C=CC(=O)O)C2=CC=C(C=C2)Cl,,,,,,
3011,53012,CID 53012,C1=CC(=CC=C1C2=C(SC(=N2)NC(=O)C=CC(=O)O)CC(=O)O)Cl,,,,,,
3012,53013,"2-((5-(2-Chloroethyl)-4-methyl-2-thiazolyl)thio)-N,N-diethylethanamine hydrochloride",CC[NH+](CC)CCSC1=NC(=C(S1)CCCl)C.[Cl-],,,,,,
3013,53014,"2-[[5-(2-chloroethyl)-4-methyl-1,3-thiazol-2-yl]sulfanyl]-N,N-diethylethanamine",CCN(CC)CCSC1=NC(=C(S1)CCCl)C,,,,,,
3014,53015,"BENZIMIDAZOLE, 1-(p-CHLOROBENZYL)-2-METHYL-, HYDROCHLORIDE",CC1=[N+](C2=CC=CC=C2N1)CC3=CC=C(C=C3)Cl.[Cl-],,,,,,
3015,53016,3-[(4-chlorophenyl)methyl]-2-methyl-1H-benzimidazol-3-ium,CC1=[N+](C2=CC=CC=C2N1)CC3=CC=C(C=C3)Cl,,,,,,
3016,53017,CID 53017,CC(=NNC1=CC=C(C=C1)Br)Cl,,,,,,
3017,53018,Nicotinoyl bromide 4-nitrophenylhydrazone,C1=CC(=CN=C1)C(=NNC2=CC=C(C=C2)[N+](=O)[O-])Br,,,,,,
3018,53019,"BENZOIC ACID, m-IODO-, 2-PHENYLHYDRAZIDE",C1=CC=C(C=C1)NNC(=O)C2=CC(=CC=C2)I,,,,,,
3019,53020,"BUTYRIC ACID, 2-(p-BROMOPHENYL)HYDRAZIDE",CCCC(=O)NNC1=CC=C(C=C1)Br,,,,,,
3020,53021,"ISOVALERIC ACID, 2-(p-BROMOPHENYL)HYDRAZIDE",CC(C)CC(=O)NNC1=CC=C(C=C1)Br,,,,,,
3021,53022,"Furo(2',3':5,6)cyclohepta(1,2-c)pyran-2(3H)-one, decahydro-5,7-dimethoxy-4a,9-dimethyl-3-methylene-, (3aR-(3a-alpha,4a-beta,5-alpha,7-beta,8a-alpha,9-alpha,10-alpha))-",C[C@@H]1CC2[C@H](C[C@]3([C@H]1C[C@@H](O[C@H]3OC)OC)C)C(=C)C(=O)O2,,,,,,
3022,53023,"Acetyl chloride 2,4-dinitrophenylhydrazone",CC(=NNC1=C(C=C(C=C1)[N+](=O)[O-])[N+](=O)[O-])Cl,,,,,,
3023,53024,Cefotetan disodium,CN1C(=NN=N1)SCC2=C(N3[C@@H]([C@@](C3=O)(NC(=O)C4SC(=C(C(=O)N)C(=O)[O-])S4)OC)SC2)C(=O)[O-].[Na+].[Na+],,,['Substances that inhibit the growth or reproduction of BACTERIA. (See all compounds classified as Anti-Bacterial Agents.)'],,,
3024,53025,Cefotetan,CN1C(=NN=N1)SCC2=C(N3[C@@H]([C@@](C3=O)(NC(=O)C4SC(=C(C(=O)N)C(=O)O)S4)OC)SC2)C(=O)O,['For prophylaxis and treatment of bacterial infections.'],['Cefotetan is a semisynthetic cephamycin antibiotic that is administered intravenously or intramuscularly. The drug is highly resistant to a broad spectrum of beta-lactamases and is active against a wide range of both aerobic and anaerobic gram-positive and gram-negative microorganisms.'],['Substances that inhibit the growth or reproduction of BACTERIA. (See all compounds classified as Anti-Bacterial Agents.)'],"['No active metabolites of cefotetan have been detected; however, small amounts (less than 7%) of cefotetan in plasma and urine may be converted to its tautomer, which has antimicrobial activity similar to the parent drug. In normal patients, from 51% to 81% of an administered dose of Cefotetan is excreted unchanged by the kidneys over a 24 hour period, which results in high and prolonged urinary concentrations.', '10.4 L [elderly patients (greater than 65 years) with normal renal function]', '1.8 +/- 0.1 L/h [elderly patients with normal renal function (.65 years)]']","['No active metabolites of cefotetan have been detected; however, small amounts (less than 7%) of cefotetan in plasma and urine may be converted to its tautomer, which has antimicrobial activity similar to the parent drug.']","['In volunteers with reduced renal function, the plasma half-life of cefotetan is prolonged']"
3025,53026,CID 53026,CC1CC(=NC2=CC=CC=C2N1)S,,,,,,
3026,53027,N-(2-Methyl-2-(methylthio)propionyl)-L-cysteine,CC(C)(C(=O)N[C@@H](CS)C(=O)O)SC,,,,,,
3027,53028,"Isoquinolinium, 3,4-dihydro-6,7-dimethoxy-1-((4,5-dimethoxy-2-iodophenyl)methyl)-2-methyl-, iodide",C[N+]1=C(C2=CC(=C(C=C2CC1)OC)OC)CC3=CC(=C(C=C3I)OC)OC.[I-],,,,,,
3028,53029,"1-[(2-Iodo-4,5-dimethoxyphenyl)methyl]-6,7-dimethoxy-2-methyl-3,4-dihydroisoquinolin-2-ium",C[N+]1=C(C2=CC(=C(C=C2CC1)OC)OC)CC3=CC(=C(C=C3I)OC)OC,,,,,,
3029,53030,"Isonipecotic acid, 1-(2-fluoroethyl)-4-phenyl-, ethyl ester, hydrochloride",CCOC(=O)C1(CC[NH+](CC1)CCF)C2=CC=CC=C2.[Cl-],,,,,,
3030,53031,Ethyl 1-(2-fluoroethyl)-4-phenylpiperidine-4-carboxylate,CCOC(=O)C1(CCN(CC1)CCF)C2=CC=CC=C2,,,,,,
3031,53032,"Imipenem Monohydrate, Antibiotic for Culture Media Use Only",C[C@@H]([C@@H]1[C@H]2CC(=C(N2C1=O)C(=O)O)SCCN=CN)O.O,,,,,,
3032,53033,B(e)P diol epoxide-1,C1=CC2=C3C(=C1)[C@@H]4[C@@H](O4)C5=C3C(=CC6=C5[C@@H]([C@H](C=C6)O)O)C=C2,,,,,,
3033,53034,N-[4-[3-(5-nitrofuran-2-yl)prop-2-enoyl]phenyl]acetamide,CC(=O)NC1=CC=C(C=C1)C(=O)C=CC2=CC=C(O2)[N+](=O)[O-],,,,,,
3034,53035,"2,3,4',5-Tetrachlorobiphenyl",C1=CC(=CC=C1C2=C(C(=CC(=C2)Cl)Cl)Cl)Cl,,,,,,
3035,53036,"2,3,4,4',5-Pentachlorobiphenyl",C1=CC(=CC=C1C2=CC(=C(C(=C2Cl)Cl)Cl)Cl)Cl,,,,,,
3036,53037,"2,3,3',5,5',6-Hexachlorobiphenyl",C1=C(C=C(C=C1Cl)Cl)C2=C(C(=CC(=C2Cl)Cl)Cl)Cl,,,,,,
3037,53038,"2,2',3,4,4',5,6-Heptachlorobiphenyl",C1=CC(=C(C=C1Cl)Cl)C2=C(C(=C(C(=C2Cl)Cl)Cl)Cl)Cl,,,,,,
3038,53039,"2,3,3',4,4',5',6-Heptachlorobiphenyl",C1=C(C=C(C(=C1Cl)Cl)Cl)C2=C(C(=C(C=C2Cl)Cl)Cl)Cl,,,,,,
3039,53040,"Acetic acid, 2-(o-(((4-isopropyl-2-methyl-5-oxo-1-phenyl-3-pyrazolin-3-yl)methyl)carbamoyl)phenyl)-",CC(C)C1=C(N(N(C1=O)C2=CC=CC=C2)C)CNC(=O)C3=CC=CC=C3CC(=O)O,,,,,,
3040,53041,"Formamide, N-(2-adamantyl)-, hydrochloride",C1C2CC3CC1CC(C2)C3NC=O.Cl,,,,,,
3041,53042,"Formamide, N-(2-adamantyl)",C1C2CC3CC1CC(C2)C3NC=O,,,,,,
3042,53043,"2-Adamantanecarbamic acid, ethyl ester, hydrochloride",CCOC(=O)NC1C2CC3CC(C2)CC1C3.Cl,,,,,,
3043,53044,ethyl N-(2-adamantyl)carbamate,CCOC(=O)NC1C2CC3CC(C2)CC1C3,,,,,,
3044,53045,"Benzamide, N-(2-adamantyl)-, hydrochloride",C1C2CC3CC1CC(C2)C3NC(=O)C4=CC=CC=C4.Cl,,,,,,
3045,53046,N-(2-adamantyl)benzamide,C1C2CC3CC1CC(C2)C3NC(=O)C4=CC=CC=C4,,,,,,
3046,53047,"Benzamide, N-(2-adamantyl)-N-methyl-, hydrochloride",CN(C1C2CC3CC(C2)CC1C3)C(=O)C4=CC=CC=C4.Cl,,,,,,
3047,53048,N-(Adamantan-2-yl)-N-methylbenzamide,CN(C1C2CC3CC(C2)CC1C3)C(=O)C4=CC=CC=C4,,,,,,
3048,53049,"Chromone, 6-ethyl-7-methoxy-3-(2-methyl-4-thiazolyl)-",CCC1=CC2=C(C=C1OC)OC=C(C2=O)C3=CSC(=N3)C,,,,,,
3049,53050,5-Phenyl-1-(phenylmethyl)-2-imidazolidinone,C1C(N(C(=O)N1)CC2=CC=CC=C2)C3=CC=CC=C3,,,,,,
3050,53051,Aphos,CC(=O)OC(C(Cl)(Cl)Cl)P(=O)(OC1=CC=CC=C1)OC2=CC=CC=C2,,,,,,
3051,53052,"Ethanamine, N,N-diethyl-2-(2-(2-methyl-5-nitro-1H-imidazol-1-yl)ethoxy)-, 2-hydroxy-1,2,3-propanetricarboxylate (1:1)",CC[NH+](CC)CCOCCN1C(=NC=C1[N+](=O)[O-])C.C(C(=O)O)C(CC(=O)O)(C(=O)[O-])O,,,,,,
3052,53053,"Ethanamine, N,N-diethyl-2-(2-(2-methyl-5-nitro-1H-imidazol-1-yl)ethoxy)-",CCN(CC)CCOCCN1C(=NC=C1[N+](=O)[O-])C,,,,,,
3053,53054,1-[Bis(4-chlorophenyl)methoxy-(4-chlorophenyl)methyl]-4-chlorobenzene,C1=CC(=CC=C1C(C2=CC=C(C=C2)Cl)OC(C3=CC=C(C=C3)Cl)C4=CC=C(C=C4)Cl)Cl,,,,,,
3054,53055,"Carbamic acid, ((N-nitrosobenzylamino)methyl)-, isopropyl ester",CC(C)OC(=O)NCN(CC1=CC=CC=C1)N=O,,,,,,
3055,53056,CID 53056,CN1C(=NC(=O)C(=O)N1)SCC2=C(N3[C@@H]([C@@H](C3=O)NC(=O)C(=NOC)C4=CSC(=N4)N)SC2)C(=O)[O-].[Na+],,,,,,
3056,53057,"Acetic acid, (2,4,6-triiodophenoxy)-",C1=C(C=C(C(=C1I)OCC(=O)O)I)I,,,,,,
3057,53058,CID 53058,C1=CC=C(C(=C1)C=C2C(=O)N(C(=N2)S)C3=CC=CC=C3Cl)Cl,,,,,,
3058,53059,CID 53059,C1=CC=C(C(=C1)N2C(=O)C(=CC3=CC(=CC=C3)Cl)N=C2S)Cl,,,,,,
3059,53060,CID 53060,C1=CC=C(C(=C1)N2C(=O)C(=CC3=CC=C(C=C3)Cl)N=C2S)Cl,,,,,,
3060,53061,CID 53061,COC1=CC=CC(=C1)C=C2C(=O)N(C(=N2)S)C3=CC=CC=C3Cl,,,,,,
3061,53062,CID 53062,C1=CC=C(C(=C1)N2C(=O)C(=CC3=CC(=CC=C3)[N+](=O)[O-])N=C2S)Cl,,,,,,
3062,53063,CID 53063,C1=CC=C(C(=C1)N2C(=O)C(=CC3=CC=C(C=C3)[N+](=O)[O-])N=C2S)Cl,,,,,,
3063,53064,CID 53064,CC1=CC=CC=C1C=C2C(=O)N(C(=N2)S)C3=CC=CC=C3Cl,,,,,,
3064,53065,CID 53065,CC1=CC(=CC=C1)C=C2C(=O)N(C(=N2)S)C3=CC=CC=C3Cl,,,,,,
3065,53066,"Benzoic acid, 3,4,5-trimethoxy-, (1,4,5,6-tetrahydro-5,5-diethyl-4,6-dioxo-1-(2-(4-morpholinyl)ethyl)-3-pyridinyl)methyl ester",CCC1(C=C(C(=O)N(C1=O)CCN2CCOCC2)COC(=O)C3=CC(=C(C(=C3)OC)OC)OC)CC,,,,,,
3066,53067,"1,2,9,10-Tetramethoxy-6a-alpha-aporphine-3-methanol hydrochloride",C[NH+]1CCC2=C(C(=C(C3=C2[C@@H]1CC4=CC(=C(C=C43)OC)OC)OC)OC)CO.[Cl-],,,,,,
3067,53068,"[(6aS)-1,2,9,10-tetramethoxy-6-methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinolin-3-yl]methanol",CN1CCC2=C(C(=C(C3=C2[C@@H]1CC4=CC(=C(C=C43)OC)OC)OC)OC)CO,,,,,,
3068,53069,"Benzamide, N-((1,2,9,10-tetramethoxy-6a-alpha-aporphin-3-yl)methyl)-, hydrochloride",C[NH+]1CCC2=C(C(=C(C3=C2[C@@H]1CC4=CC(=C(C=C43)OC)OC)OC)OC)CNC(=O)C5=CC=CC=C5.[Cl-],,,,,,
3069,53070,"Benzamide, N-((5,6,6a,7-tetrahydro-1,2,9,10-tetramethoxy-6-methyl-4H-dibenzo(de,g)quinolin-3-yl)methyl)-, (S)-",CN1CCC2=C(C(=C(C3=C2[C@@H]1CC4=CC(=C(C=C43)OC)OC)OC)OC)CNC(=O)C5=CC=CC=C5,,,,,,
3070,53071,CID 53071,COC1=CC=CC=C1C=C2C(=O)N(C(=N2)S)C3=CC=CC=C3Cl,,,,,,
3071,53072,"6a,7-Didehydro-7-methyl-1,2,9,10-tetramethoxyaporphine hydrochloride",CC1=C2C3=C(C4=CC(=C(C=C14)OC)OC)C(=C(C=C3CC[NH+]2C)OC)OC.[Cl-],,,,,,
3072,53073,"1,2,9,10-Tetramethoxy-6,7-dimethyl-5,6-dihydro-4h-dibenzo[de,g]quinoline",CC1=C2C3=C(C4=CC(=C(C=C14)OC)OC)C(=C(C=C3CCN2C)OC)OC,,,,,,
3073,53074,"1,3,5,2-Dioxaphosphaborinane, 2,5-diphenyl-, 5-sulfide",B1(OCP(=S)(CO1)C2=CC=CC=C2)C3=CC=CC=C3,,,,,,
3074,53075,CID 53075,CC(=C)C(=O)C(=CC(=O)[O-])OC.[Na+],,,,,,
3075,53076,Picenadol hydrochloride,CCC[C@@]1(CCN(C[C@@H]1C)C)C2=CC(=CC=C2)O.Cl,,,,,,
3076,53077,Picenadol,CCC[C@@]1(CCN(C[C@@H]1C)C)C2=CC(=CC=C2)O,,,,,,
3077,53078,CID 53078,C1=CC=C(C=C1)C2=C(C(=C3C(=CC(=O)C(=C3O2)O)O)O)O,,,,,,
3078,53079,Bromobutide,CC(C)(C)C(C(=O)NC(C)(C)C1=CC=CC=C1)Br,,,,,,
3079,53080,Ascorbic acid methylglyoxal acetal,CC(=O)C1OC2=C(O1)C(=O)OC2C(CO)O,,,,,,
3080,53081,Oftanol C,CCOP(=S)(NC(C)C)OC1=CC=CC=C1C(=O)OC(C)C.C1C=CCC2C1C(=O)N(C2=O)SC(Cl)(Cl)Cl,,,,,,
3081,53082,2-[2-[2-Chloroethyl(nitroso)carbamoyl]hydrazinyl]-3-phenylpropanoic acid,C1=CC=C(C=C1)CC(C(=O)O)NNC(=O)N(CCCl)N=O,,,,,,
3082,53083,Undec-5-en-3-yne,CCCCCC=CC#CCC,,,,,,
3083,53084,Recainam,CC1=C(C(=CC=C1)C)NC(=O)NCCCNC(C)C,,,"['Agents used for the treatment or prevention of cardiac arrhythmias. They may affect the polarization-repolarization phase of the action potential, its excitability or refractoriness, or impulse conduction or membrane responsiveness within cardiac fibers. Anti-arrhythmia agents are often classed into four main groups according to their mechanism of action: sodium channel blockade, beta-adrenergic blockade, repolarization prolongation, or calcium channel blockade. (See all compounds classified as Anti-Arrhythmia Agents.)']",,,
3084,53085,N-(2-(Dimethylamino)ethyl)-N-(3-phenyl-1-indolyl)acetamide hydrochloride,CC(=O)N(CC[NH+](C)C)N1C=C(C2=CC=CC=C21)C3=CC=CC=C3.[Cl-],,,,,,
3085,53086,N-[2-(dimethylamino)ethyl]-N-(3-phenylindol-1-yl)acetamide,CC(=O)N(CCN(C)C)N1C=C(C2=CC=CC=C21)C3=CC=CC=C3,,,,,,
3086,53087,"Indole, 1-((3-(4-benzyl-1-piperazinyl)propyl)methylamino)-3-phenyl-, dihydrochloride",CN(CCCN1CCN(CC1)CC2=CC=CC=C2)N3C=C(C4=CC=CC=C43)C5=CC=CC=C5.Cl.Cl,,,,,,
3087,53088,N-[3-(4-benzylpiperazin-1-yl)propyl]-N-methyl-3-phenylindol-1-amine,CN(CCCN1CCN(CC1)CC2=CC=CC=C2)N3C=C(C4=CC=CC=C43)C5=CC=CC=C5,,,,,,
3088,53089,1-(Bis(2-(dimethylamino)ethyl)amino)-3-phenylindole dihydrochloride hydrate,C[NH+](C)CCN(CC[NH+](C)C)N1C=C(C2=CC=CC=C21)C3=CC=CC=C3.[Cl-].[Cl-],,,,,,
3089,53090,"N'-[2-(dimethylamino)ethyl]-N,N-dimethyl-N'-(3-phenylindol-1-yl)ethane-1,2-diamine",CN(C)CCN(CCN(C)C)N1C=C(C2=CC=CC=C21)C3=CC=CC=C3,,,,,,
3090,53091,1-(Bis(2-(dimethylamino)ethyl)amino)-5-chloro-3-phenylindole dihydrochloride,C[NH+](C)CCN(CC[NH+](C)C)N1C=C(C2=C1C=CC(=C2)Cl)C3=CC=CC=C3.[Cl-].[Cl-],,,,,,
3091,53092,"N'-(5-chloro-3-phenylindol-1-yl)-N'-[2-(dimethylamino)ethyl]-N,N-dimethylethane-1,2-diamine",CN(C)CCN(CCN(C)C)N1C=C(C2=C1C=CC(=C2)Cl)C3=CC=CC=C3,,,,,,
3092,53093,"Ammonium, (N-(3-phenyl-1-indolyl)iminodiethylene)bis(diethylmethyl-, diiodide",CC[N+](C)(CC)CCN(CC[N+](C)(CC)CC)N1C=C(C2=CC=CC=C21)C3=CC=CC=C3.[I-].[I-],,,,,,
3093,53094,2-[2-[Diethyl(methyl)azaniumyl]ethyl-(3-phenylindol-1-yl)amino]ethyl-diethyl-methylazanium,CC[N+](C)(CC)CCN(CC[N+](C)(CC)CC)N1C=C(C2=CC=CC=C21)C3=CC=CC=C3,,,,,,
3094,53095,1-(Bis(2-(diethylamino)ethyl)amino)-5-fluoro-3-phenylindole dihydrochloride,CC[NH+](CC)CCN(CC[NH+](CC)CC)N1C=C(C2=C1C=CC(=C2)F)C3=CC=CC=C3.[Cl-].[Cl-],,,,,,
3095,53096,"N'-[2-(diethylamino)ethyl]-N,N-diethyl-N'-(5-fluoro-3-phenylindol-1-yl)ethane-1,2-diamine",CCN(CC)CCN(CCN(CC)CC)N1C=C(C2=C1C=CC(=C2)F)C3=CC=CC=C3,,,,,,
3096,53097,1-(Bis(2-(diethylamino)ethyl)amino)-5-methyl-3-phenylindole dihydrochloride,CC[NH+](CC)CCN(CC[NH+](CC)CC)N1C=C(C2=C1C=CC(=C2)C)C3=CC=CC=C3.[Cl-].[Cl-],,,,,,
3097,53098,"N'-[2-(diethylamino)ethyl]-N,N-diethyl-N'-(5-methyl-3-phenylindol-1-yl)ethane-1,2-diamine",CCN(CC)CCN(CCN(CC)CC)N1C=C(C2=C1C=CC(=C2)C)C3=CC=CC=C3,,,,,,
3098,53099,"Indole, 1-(bis(2-(diethylamino)ethyl)amino)-3-(p-chlorophenyl)-5-methyl-, dihydrochloride",CC[NH+](CC)CCN(CC[NH+](CC)CC)N1C=C(C2=C1C=CC(=C2)C)C3=CC=C(C=C3)Cl.[Cl-].[Cl-],,,,,,
3099,53100,"N'-[3-(4-chlorophenyl)-5-methylindol-1-yl]-N'-[2-(diethylamino)ethyl]-N,N-diethylethane-1,2-diamine",CCN(CC)CCN(CCN(CC)CC)N1C=C(C2=C1C=CC(=C2)C)C3=CC=C(C=C3)Cl,,,,,,
3100,53101,"Indole, 1-(bis(2-(diethylamino)ethyl)amino)-5-chloro-3-(p-tolyl)-, dihydrochloride",CC[NH+](CC)CCN(CC[NH+](CC)CC)N1C=C(C2=C1C=CC(=C2)Cl)C3=CC=C(C=C3)C.[Cl-].[Cl-],,,,,,
3101,53102,"N'-[5-chloro-3-(4-methylphenyl)indol-1-yl]-N'-[2-(diethylamino)ethyl]-N,N-diethylethane-1,2-diamine",CCN(CC)CCN(CCN(CC)CC)N1C=C(C2=C1C=CC(=C2)Cl)C3=CC=C(C=C3)C,,,,,,
3102,53103,"Indole, 1-(bis(3-(dimethylamino)propyl)amino)-5-methyl-3-phenyl-, dihydrochloride",CC1=CC2=C(C=C1)N(C=C2C3=CC=CC=C3)N(CCC[NH+](C)C)CCC[NH+](C)C.[Cl-].[Cl-],,,,,,
3103,53104,"N'-[3-(dimethylamino)propyl]-N,N-dimethyl-N'-(5-methyl-3-phenylindol-1-yl)propane-1,3-diamine",CC1=CC2=C(C=C1)N(C=C2C3=CC=CC=C3)N(CCCN(C)C)CCCN(C)C,,,,,,
3104,53105,1-(2-(Dimethylamino)ethylamino)-3-phenylindole hydrochloride,C[NH+](C)CCNN1C=C(C2=CC=CC=C21)C3=CC=CC=C3.[Cl-],,,,,,
3105,53106,"N',N'-dimethyl-N-(3-phenylindol-1-yl)ethane-1,2-diamine",CN(C)CCNN1C=C(C2=CC=CC=C21)C3=CC=CC=C3,,,,,,
3106,53107,"Indole, 1-((2-(dimethylamino)ethyl)methylamino)-5-methyl-3-phenyl-, hydrochloride",CC1=CC2=C(C=C1)N(C=C2C3=CC=CC=C3)N(C)CC[NH+](C)C.[Cl-],,,,,,
3107,53108,"N,N,N'-trimethyl-N'-(5-methyl-3-phenylindol-1-yl)ethane-1,2-diamine",CC1=CC2=C(C=C1)N(C=C2C3=CC=CC=C3)N(C)CCN(C)C,,,,,,
3108,53109,2-(((4-Chlorophenyl)methylene)amino)benzoic acid 6-methoxy-2-methyl-4-quinolinyl ester,CC1=CC(=C2C=C(C=CC2=N1)OC)OC(=O)C3=CC=CC=C3N=CC4=CC=C(C=C4)Cl,,,,,,
3109,53110,"2-(((4-(Acetylamino)phenyl)methylene)amino)benzoic acid, 2,7-dimethyl-4-quinolinyl ester",CC1=CC2=NC(=CC(=C2C=C1)OC(=O)C3=CC=CC=C3N=CC4=CC=C(C=C4)NC(=O)C)C,,,,,,
3110,53111,2-(((4-(Acetylamino)phenyl)methylene)amino)benzoic acid 6-chloro-2-methyl-4-quinolinyl ester,CC1=CC(=C2C=C(C=CC2=N1)Cl)OC(=O)C3=CC=CC=C3N=CC4=CC=C(C=C4)NC(=O)C,,,,,,
3111,53112,"2-(((4-(Dimethylamino)phenyl)methylene)amino)benzoic acid 2,6-dimethyl-4-quinolinyl ester",CC1=CC2=C(C=C(N=C2C=C1)C)OC(=O)C3=CC=CC=C3N=CC4=CC=C(C=C4)N(C)C,,,,,,
3112,53113,"2-(((4-Chlorophenyl)methylene)amino)benzoic acid 2,6-dimethyl-4-quinolinyl ester",CC1=CC2=C(C=C(N=C2C=C1)C)OC(=O)C3=CC=CC=C3N=CC4=CC=C(C=C4)Cl,,,,,,
3113,53114,"Acetic acid, 2-(mercaptomethylthio)-, methyl ester, S-ester with O-methyl methylphosphonothioate",COC(=O)CSCSP(=O)(C)OC,,,,,,
3114,53115,"Acetic acid, 2-(mercaptomethylthio)-, methyl ester, S-ester with O-ethyl methylphosphonothioate",CCOP(=O)(C)SCSCC(=O)OC,,,,,,
3115,53116,Ethyl 2-(mercaptomethylthio)acetate S-ester with O-ethyl methylphosphonothioate,CCOC(=O)CSCSP(=O)(C)OCC,,,,,,
3116,53117,"Acetic acid, 2-(mercaptomethylthio)-, isobutyl ester, S-ester with O-ethyl methylphosphonothioate",CCOP(=O)(C)SCSCC(=O)OCC(C)C,,,,,,
3117,53118,"Acetic acid, 2-(mercaptomethylthio)-, methyl ester, S-ester with O-propyl methylphosphonothioate",CCCOP(=O)(C)SCSCC(=O)OC,,,,,,
3118,53119,"Acetic acid, 2-(mercaptomethylthio)-, methyl ester, S-ester with O-butyl methylphosphonothioate",CCCCOP(=O)(C)SCSCC(=O)OC,,,,,,
3119,53120,Methyl2-[[methyl(2-methylpropoxy)phosphoryl]sulfanylmethylsulfanyl]acetate,CC(C)COP(=O)(C)SCSCC(=O)OC,,,,,,
3120,53121,"Acetic acid, 2-(mercaptomethylthio)-, isobutyl ester, S-ester with O-isobutyl methylphosphonothioate",CC(C)COC(=O)CSCSP(=O)(C)OCC(C)C,,,,,,
3121,53122,"Acetanilide, 2-(diethylamino)-4'-nitro-",CCN(CC)CC(=O)NC1=CC=C(C=C1)[N+](=O)[O-],,,,,,
3122,53123,"4'-Chloro-2-(diethylamino)acetanilide, hydrochloride",CC[NH+](CC)CC(=O)NC1=CC=C(C=C1)Cl.[Cl-],,,,,,
3123,53124,N-(4-chlorophenyl)-2-(diethylamino)acetamide,CCN(CC)CC(=O)NC1=CC=C(C=C1)Cl,,,,,,
3124,53125,2-(Diethylamino)-4'-nitroacetanilide hydrochloride,CC[NH+](CC)CC(=O)NC1=CC=C(C=C1)[N+](=O)[O-].[Cl-],,,,,,
3125,53126,4'-Chloro-2-(diethylamino)-N-methylacetanilide hydrochloride,CC[NH+](CC)CC(=O)N(C)C1=CC=C(C=C1)Cl.[Cl-],,,,,,
3126,53127,N-(4-chlorophenyl)-2-(diethylamino)-N-methylacetamide,CCN(CC)CC(=O)N(C)C1=CC=C(C=C1)Cl,,,,,,
3127,53128,"butyl (2R)-2-[[(2S)-2-[[(2R)-2-[3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxypropanoyl]amino]propanoyl]amino]-5-amino-5-oxopentanoate",CCCCOC(=O)[C@@H](CCC(=O)N)NC(=O)[C@H](C)NC(=O)[C@@H](C)OC1C(C(OC(C1O)CO)O)NC(=O)C,,,,,,
3128,53129,CID 53129,CC1=CC(=O)C(=CN1)C(=O)NC(C2=CC=C(C=C2)O)C(=O)N[C@H]3[C@@H]4N(C3=O)C(=C(CS4)CSC5=NN=NN5C)C(=O)[O-].[Na+],,,,,,
3129,53130,"(6R,7R)-7-[[2-[(4-hydroxy-6-methyl-pyridine-3-carbonyl)amino]-2-(4-hydroxyphenyl)acetyl]amino]-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid",CC1=CC(=O)C(=CN1)C(=O)NC(C2=CC=C(C=C2)O)C(=O)N[C@H]3[C@@H]4N(C3=O)C(=C(CS4)CSC5=NN=NN5C)C(=O)O,,,,,,
3130,53131,"7,7-Dimethyl-4-(2-phenylmethoxyethyl)bicyclo(3.1.1)hept-3-ene",CC1(C2CC=C(C1C2)CCOCC3=CC=CC=C3)C,,,,,,
3131,53132,Azanium;boranylformate,BC(=O)[O-].[NH4+],,,,,,
3132,53133,CID 53133,CCC(CC1=CC=C(C=C1)OC)C(=CC)C2=CC=C(C=C2)OC,,,,,,
3133,53134,CID 53134,CCC(=C(CC)C1=CC=C(C=C1)OCC)CC2=CC=C(C=C2)OCC,,,,,,
3134,53135,1-[2-Ethyl-3-(4-methoxyphenyl)pent-2-enyl]-4-methoxybenzene,CCC(=C(CC)C1=CC=C(C=C1)OC)CC2=CC=C(C=C2)OC,,,,,,
3135,53136,"Ammonium, (2-(2-chloroethoxy)ethyl)trimethyl-, perchlorate",C[N+](C)(C)CCOCCCl.[O-]Cl(=O)(=O)=O,,,,,,
3136,53137,O-(2-Chloroethyl)choline,C[N+](C)(C)CCOCCCl,,,,,,
3137,53138,O-(2-Bromoethyl)choline bromide,C[N+](C)(C)CCOCCBr.[Br-],,,,,,
3138,53139,O-(2-Bromoethyl)choline,C[N+](C)(C)CCOCCBr,,,,,,
3139,53140,O-(2-Iodoethyl)choline iodide,C[N+](C)(C)CCOCCI.[I-],,,,,,
3140,53141,O-(2-Iodoethyl)choline,C[N+](C)(C)CCOCCI,,,,,,
3141,53142,2-Hydroxy-5-(hydroxymethyl)benzaldehyde,C1=CC(=C(C=C1CO)C=O)O,,,,,,
3142,53143,"Iron, bis(benzenamine)(ethanedioato(2-)-O,O')-",C1=CC=C(C=C1)N.C1=CC=C(C=C1)N.C(=O)(C(=O)[O-])[O-].[Fe+2],,,,,,
3143,53144,"3,6-Dichlorodibenzofuran",C1=CC2=C(C(=C1)Cl)OC3=C2C=CC(=C3)Cl,,,,,,
3144,53145,N-Ethyl-N-formylhydrazine,CCN(C=O)N,,,,,,
3145,53146,N-Nitroso-propyl-(alpha-hydroperoxypropyl)amine,CCCN(C(CC)OO)N=O,,,,,,
3146,53147,N-Ethyl-N-(alpha-hydroperoxyethyl)nitrosamine,CCN(C(C)OO)N=O,,,,,,
3147,53148,"Dimethylamine, 1-(hydroperoxy)-N-nitroso-",CN(COO)N=O,,,,,,
3148,53149,Chloracetophon,COP(=O)(C(C(Cl)(Cl)Cl)OC(=O)CCl)OC,,,,,,
3149,53150,1-[Methyl(nitroso)amino]butyl acetate,CCCC(N(C)N=O)OC(=O)C,,,,,,
3150,53151,"Ethylamine, N-(hydroperoxymethyl)-N-nitroso-",CCN(COO)N=O,,,,,,
3151,53152,"3-(2H-1,3-benzodioxol-5-yl)-N,N-dimethylprop-2-enamide",CN(C)C(=O)C=CC1=CC2=C(C=C1)OCO2,,,,,,
3152,53153,"[(7R,8S)-7,11-dimethoxy-5,12-dimethyl-10,13-dioxo-2,5-diazatetracyclo[7.4.0.02,7.04,6]trideca-1(9),11-dien-8-yl]methyl carbamate",CC1=C(C(=O)C2=C(C1=O)N3CC4C([C@@]3([C@@H]2COC(=O)N)OC)N4C)OC,,,,,,
3153,53154,4-Chlorodibenzofuran,C1=CC=C2C(=C1)C3=C(O2)C(=CC=C3)Cl,,,,,,
3154,53155,"1,6-Dichlorodibenzofuran",C1=CC2=C(C(=C1)Cl)OC3=C2C(=CC=C3)Cl,,,,,,
3155,53156,"2,7-Dichlorodibenzofuran",C1=CC2=C(C=C1Cl)OC3=C2C=C(C=C3)Cl,,,,,,
3156,53157,CID 53157,CC(=NNC(=NC)S)C1=CC=CC=N1,,,,,,
3157,53158,CID 53158,CCCCN=C(NN=C(C)C1=CC=CC=N1)S,,,,,,
3158,53159,1-Phenyl-3-(1-pyridin-2-ylethylideneamino)urea,CC(=NNC(=O)NC1=CC=CC=C1)C2=CC=CC=N2,,,,,,
3159,53160,"5-Phenyl-2,4,6-trimethyl-1,3,5-dioxaphosphorinane 5-oxide",CC1OC(P(=O)(C(O1)C)C2=CC=CC=C2)C,,,,,,
3160,53161,"Ammonium, (methylenebis(indole-3,5-diylmethylene))bis(trimethyl-, bismethanesulfate",C[N+](C)(C)CC1=CC2=C(C=C1)NC=C2CC3=CNC4=C3C=C(C=C4)C[N+](C)(C)C.COS(=O)(=O)[O-].COS(=O)(=O)[O-],,,,,,
3161,53162,trimethyl-[[3-[[5-[(trimethylazaniumyl)methyl]-1H-indol-3-yl]methyl]-1H-indol-5-yl]methyl]azanium,C[N+](C)(C)CC1=CC2=C(C=C1)NC=C2CC3=CNC4=C3C=C(C=C4)C[N+](C)(C)C,,,,,,
3162,53163,"Ammonium, (sulfonylbis(indole-3,5-diylmethylene))bis(trimethyl-, bismethanesulfate",C[N+](C)(C)CC1=CC2=C(C=C1)NC=C2S(=O)(=O)C3=CNC4=C3C=C(C=C4)C[N+](C)(C)C.COS(=O)(=O)[O-].COS(=O)(=O)[O-],,,,,,
3163,53164,trimethyl-[[3-[[5-[(trimethylazaniumyl)methyl]-1H-indol-3-yl]sulfonyl]-1H-indol-5-yl]methyl]azanium,C[N+](C)(C)CC1=CC2=C(C=C1)NC=C2S(=O)(=O)C3=CNC4=C3C=C(C=C4)C[N+](C)(C)C,,,,,,
3164,53165,"IRON, (ETHANEDIOATO(2-)-O,O')BIS(1-PHENYLPIPERAZINE-N(sup 1),N(sup 4))-",C1CN(CCN1)C2=CC=CC=C2.C1CN(CCN1)C2=CC=CC=C2.C(=O)(C(=O)[O-])[O-].[Fe+2],,,,,,
3165,53166,"IRON, (ETHANEDIOATO(2-)-O,O')BIS(1-METHYLPIPERAZINE-N(sup 1),N(sup 4))-",CN1CCNCC1.CN1CCNCC1.C(=O)(C(=O)[O-])[O-].[Fe+2],,,,,,
3166,53167,1-Methylpiperazine,CN1CCNCC1,,,,,,
3167,53168,"Iron, bis(o-phenylenediamine)oxalato-",C1=CC=C(C(=C1)N)N.C1=CC=C(C(=C1)N)N.C(=O)(C(=O)[O-])[O-].[Fe+2],,,,,,
3168,53169,"Benzenepropanoic acid, silver(+1) salt",C1=CC=C(C=C1)CCC(=O)[O-].[Ag+],,,,,,
3169,53170,"Acetamide, N-(2,5-dimethyl-1H-pyrrol-1-YL)-2-(1-naphthalenyloxy)-",CC1=CC=C(N1NC(=O)COC2=CC=CC3=CC=CC=C32)C,,,,,,
3170,53171,"Acetamide, N-(2,5-dimethyl-1H-pyrrol-1-YL)-2-(2-naphthalenyloxy)-",CC1=CC=C(N1NC(=O)COC2=CC3=CC=CC=C3C=C2)C,,,,,,
3171,53172,"1,3-Bis(isocyanatomethyl)cyclohexane",C1CC(CC(C1)CN=C=O)CN=C=O,,,,,,
3172,53173,"Benzamide, N-(2-(3,4,6,7,12,12a-hexahydropyrazino(1',2':1,6)pyrido(3,4-b)indol-2(1H)-yl)ethyl)-4-nitro-",C1CN2CC3=C(CC2CN1CCNC(=O)C4=CC=C(C=C4)[N+](=O)[O-])C5=CC=CC=C5N3,,,,,,
3173,53174,Albendazole sulfone,CCCS(=O)(=O)C1=CC2=C(C=C1)N=C(N2)NC(=O)OC,,,['Agents that kill parasitic worms. They are used therapeutically in the treatment of HELMINTHIASIS in man and animal. (See all compounds classified as Anthelmintics.)'],,,
3174,53175,"Benzenamine, 3-isothiocyanato-",C1=CC(=CC(=C1)N=C=S)N,,,,,,
3175,53176,"1,2,3,6,8,9-Hexachlorodibenzofuran",C1=C2C(=C(C(=C1Cl)Cl)Cl)C3=C(O2)C(=CC(=C3Cl)Cl)Cl,,,,,,
3176,53177,"(1)BENZOPYRANO(3,4-d)IMIDAZOL-4(1H)-ONE",C1=CC=C2C(=C1)C3=C(C(=O)O2)NC=N3,,,,,,
3177,53178,"2-Phenoxy-1-(3,4-dimethoxyphenyl)propan-1,3-diol",COC1=C(C=C(C=C1)C(C(CO)OC2=CC=CC=C2)O)OC,,,,,,
3178,53179,"2-(2,4-Dichlorophenoxy)-1-(3,4-dimethoxyphenyl)propane-1,3-diol",COC1=C(C=C(C=C1)C(C(CO)OC2=C(C=C(C=C2)Cl)Cl)O)OC,,,,,,
3179,53180,"Estra-1,3,5(10)-triene-3,17-diol, (17-beta)-, 17-((4-(4-(bis(2-chloroethyl)amino)phenyl)-1-oxobutoxy)acetate)",CC12CCC3C(C1CC[C@@H]2OC(=O)COC(=O)CCCC4=CC=C(C=C4)N(CCCl)CCCl)CCC5=C3C=CC(=C5)O,,,,,,
3180,53181,"[(17S)-17-[2-[4-[4-[bis(2-chloroethyl)amino]phenyl]butanoyloxy]acetyl]oxy-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-3-yl] benzoate",CC12CCC3C(C1CC[C@@H]2OC(=O)COC(=O)CCCC4=CC=C(C=C4)N(CCCl)CCCl)CCC5=C3C=CC(=C5)OC(=O)C6=CC=CC=C6,,,,,,
3181,53182,"alpha-(3,3-Diphenylpropyl)-1-naphthaleneacetic acid",C1=CC=C(C=C1)C(CCC(C2=CC=CC3=CC=CC=C32)C(=O)O)C4=CC=CC=C4,,,,,,
3182,53183,"Acetic acid, (4-(2-hydroxy-4-methoxybenzoyl)phenoxy)-",COC1=CC(=C(C=C1)C(=O)C2=CC=C(C=C2)OCC(=O)O)O,,,,,,
3183,53184,"Acetic acid, (4-(2,4-dimethoxybenzoyl)phenoxy)-",COC1=CC(=C(C=C1)C(=O)C2=CC=C(C=C2)OCC(=O)O)OC,,,,,,
3184,53185,"Acetic acid, (5-methoxy-2-(4-methoxybenzoyl)phenoxy)-",COC1=CC=C(C=C1)C(=O)C2=C(C=C(C=C2)OC)OCC(=O)O,,,,,,
3185,53186,"Acetamide, N-(5-(2,4-dimethoxybenzoyl)-2-methoxyphenyl)-",CC(=O)NC1=C(C=CC(=C1)C(=O)C2=C(C=C(C=C2)OC)OC)OC,,,,,,
3186,53187,CID 53187,C1=CC=C(C=C1)C=C(C#N)C2=CC=CC=C2C(=O)O,,,,,,
3187,53188,CID 53188,C1=CC=C(C(=C1)C=C(C#N)C2=CC=CC=C2C(=O)O)Cl,,,,,,
3188,53189,CID 53189,C1=CC=C(C(=C1)C(=CC2=C(C=C(C=C2)Cl)Cl)C#N)C(=O)O,,,,,,
3189,53190,CID 53190,C1=CC=C(C(=C1)C(=CC2=CC(=C(C=C2)Cl)Cl)C#N)C(=O)O,,,,,,
3190,53191,"Acetamide, 2-chloro-N-(2-hydroxyethyl)-N-((5-methyl-2-furanyl)methyl)-",CC1=CC=C(O1)CN(CCO)C(=O)CCl,,,,,,
3191,53192,"Acetamide, 2-chloro-N-((5-chloro-2-furanyl)methyl)-N-methyl-",CN(CC1=CC=C(O1)Cl)C(=O)CCl,,,,,,
3192,53193,"Acetamide, 2-chloro-N-((5-chloro-2-furanyl)methyl)-N-ethyl-",CCN(CC1=CC=C(O1)Cl)C(=O)CCl,,,,,,
3193,53194,"Acetamide, 2-chloro-N-((5-chloro-2-furanyl)methyl)-N-(1-methylethyl)-",CC(C)N(CC1=CC=C(O1)Cl)C(=O)CCl,,,,,,
3194,53195,"Acetamide, 2-chloro-N-((5-chloro-2-furanyl)methyl)-N-(2-hydroxyethyl)-",C1=C(OC(=C1)Cl)CN(CCO)C(=O)CCl,,,,,,
3195,53196,"Acetamide, 2-chloro-N-ethyl-N-((5-(methoxymethyl)-2-furanyl)methyl)-",CCN(CC1=CC=C(O1)COC)C(=O)CCl,,,,,,
3196,53197,"Acetamide, 2-chloro-N-(2-hydroxyethyl)-N-((5-(methoxymethyl)-2-furanyl)methyl)-",COCC1=CC=C(O1)CN(CCO)C(=O)CCl,,,,,,
3197,53198,"Acetamide, 2-chloro-N-((5-(4-chlorophenoxy)-2-furanyl)methyl)-N-(1-methylethyl)-",CC(C)N(CC1=CC(=CO1)OC2=CC=C(C=C2)Cl)C(=O)CCl,,,,,,
3198,53199,"11-Amino-12,13-dimethoxy-5,9,10,14b-tetrahydroisoquino(2,1-d)(1,4)benzodiazepin-6(7H)-one",COC1=C(C(=C2CCN3CC(=O)NC4=CC=CC=C4C3C2=C1)N)OC,,,,,,
3199,53200,"12,13-Dimethoxy-7-isopropyl-5,9,10,14b-tetrahydroisoquino(2,1-d)(1,4)benzodiazepin-6(7H)-one",CC(C)C1C(=O)NC2=CC=CC=C2C3N1CCC4=CC(=C(C=C34)OC)OC,,,,,,
3200,53201,"3,4,5-Trimethoxybenzoic acid trans-4-guanidinocyclohexyl ester monohydrochloride",COC1=CC(=CC(=C1OC)OC)C(=O)OC2CCC(CC2)[NH+]=C(N)N.[Cl-],,,,,,
3201,53202,"[4-(Diaminomethylideneamino)cyclohexyl] 3,4,5-trimethoxybenzoate",COC1=CC(=CC(=C1OC)OC)C(=O)OC2CCC(CC2)N=C(N)N,,,,,,
3202,53203,"3,4,5-Trimethoxybenzoic acid 1-amidino-3-piperidyl ester monohydrochloride",COC1=CC(=CC(=C1OC)OC)C(=O)OC2CCC[NH+](C2)C(=N)N.[Cl-],,,,,,
3203,53204,"(1-Carbamimidoylpiperidin-3-yl) 3,4,5-trimethoxybenzoate",COC1=CC(=CC(=C1OC)OC)C(=O)OC2CCCN(C2)C(=N)N,,,,,,
3204,53205,"3,4,5-Trimethoxybenzoic acid 2-guanidinoethyl ester monohydrochloride",COC1=CC(=CC(=C1OC)OC)C(=O)OCC[NH2+]C(=N)N.[Cl-],,,,,,
3205,53206,"2-(Diaminomethylideneamino)ethyl 3,4,5-trimethoxybenzoate",COC1=CC(=CC(=C1OC)OC)C(=O)OCCN=C(N)N,,,,,,
3206,53207,"3,4,5-Trimethoxybenzoic acid 3-guanidinopropyl ester monohydrochloride",COC1=CC(=CC(=C1OC)OC)C(=O)OCCC[NH2+]C(=N)N.[Cl-],,,,,,
3207,53208,"3-(Diaminomethylideneamino)propyl 3,4,5-trimethoxybenzoate",COC1=CC(=CC(=C1OC)OC)C(=O)OCCCN=C(N)N,,,,,,
3208,53209,"3,4,5-Trimethoxybenzoic acid 4-guanidinobutyl ester sulfate (2:1)",COC1=CC(=CC(=C1OC)OC)C(=O)OCCCC[NH+]=C(N)N.COC1=CC(=CC(=C1OC)OC)C(=O)OCCCC[NH+]=C(N)N.[O-]S(=O)(=O)[O-],,,,,,
3209,53210,"4-(Diaminomethylideneamino)butyl 3,4,5-trimethoxybenzoate",COC1=CC(=CC(=C1OC)OC)C(=O)OCCCCN=C(N)N,,,,,,
3210,53211,"3,4,5-Trimethoxybenzoic acid 5-guanidinopentyl ester sulfate (2:1)",COC1=CC(=CC(=C1OC)OC)C(=O)OCCCCC[NH+]=C(N)N.COC1=CC(=CC(=C1OC)OC)C(=O)OCCCCC[NH+]=C(N)N.[O-]S(=O)(=O)[O-],,,,,,
3211,53212,"5-(Diaminomethylideneamino)pentyl 3,4,5-trimethoxybenzoate",COC1=CC(=CC(=C1OC)OC)C(=O)OCCCCCN=C(N)N,,,,,,
3212,53213,"3,4,5-Trimethoxybenzoic acid 6-guanidinohexyl ester sulfate (2:1)",COC1=CC(=CC(=C1OC)OC)C(=O)OCCCCCC[NH+]=C(N)N.COC1=CC(=CC(=C1OC)OC)C(=O)OCCCCCC[NH+]=C(N)N.[O-]S(=O)(=O)[O-],,,,,,
3213,53214,"6-(Diaminomethylideneamino)hexyl 3,4,5-trimethoxybenzoate",COC1=CC(=CC(=C1OC)OC)C(=O)OCCCCCCN=C(N)N,,,,,,
3214,53215,"3,4,5-Trimethoxybenzoic acid 4-(3-methylguanidino)butyl ester sulfate (2:1)",C[NH+]=C(N)NCCCCOC(=O)C1=CC(=C(C(=C1)OC)OC)OC.C[NH+]=C(N)NCCCCOC(=O)C1=CC(=C(C(=C1)OC)OC)OC.[O-]S(=O)(=O)[O-],,,,,,
3215,53216,"4-[(N'-methylcarbamimidoyl)amino]butyl 3,4,5-trimethoxybenzoate",CN=C(N)NCCCCOC(=O)C1=CC(=C(C(=C1)OC)OC)OC,,,,,,
3216,53217,1-(2-Nitro-4-propyloxyphenyl)-3-carbomethoxy-S-methylisothiourea,CCCOC1=CC(=C(C=C1)N=CSCNC(=O)OC)[N+](=O)[O-],,,,,,
3217,53218,"Ethylamine, 2-((6-allyl-7-chloro-1,4-benzodioxan-5-yl)oxy)-N-methyl-, hydrochloride",C[NH2+]CCOC1=C2C(=CC(=C1CC=C)Cl)OCCO2.[Cl-],,,,,,
3218,53219,"2-[(7-chloro-6-prop-2-enyl-2,3-dihydro-1,4-benzodioxin-5-yl)oxy]-N-methylethanamine",CNCCOC1=C2C(=CC(=C1CC=C)Cl)OCCO2,,,,,,
3219,53220,"1-(2,6-Dichloro-3,4,5-trimethoxyphenyl)ethanone",CC(=O)C1=C(C(=C(C(=C1Cl)OC)OC)OC)Cl,,,,,,
3220,53221,"Methyl 2,6-dichloro-3,4,5-trimethoxybenzoate",COC1=C(C(=C(C(=C1OC)Cl)C(=O)OC)Cl)OC,,,,,,
3221,53222,"1-(2,6-Dichloro-4-hydroxy-3,5-dimethoxyphenyl)propan-2-one",CC(=O)CC1=C(C(=C(C(=C1Cl)OC)O)OC)Cl,,,,,,
3222,53223,"Benzeneacetic acid, 2,6-dichloro-alpha,4-dihydroxy-3,5-dimethoxy-",COC1=C(C(=C(C(=C1Cl)C(C(=O)O)O)Cl)OC)O,,,,,,
3223,53224,"Benzenemethanol, 2,6-dichloro-3,4,5-trimethoxy-alpha-methyl-",CC(C1=C(C(=C(C(=C1Cl)OC)OC)OC)Cl)O,,,,,,
3224,53225,"Benzeneacetic acid, 2,6-dichloro-3,4,5-trimethoxy-, methyl ester",COC1=C(C(=C(C(=C1OC)Cl)CC(=O)OC)Cl)OC,,,,,,
3225,53226,"2-Propanone, 1-(2,6-dichloro-3,4,5-trimethoxyphenyl)-",CC(=O)CC1=C(C(=C(C(=C1Cl)OC)OC)OC)Cl,,,,,,
3226,53227,"Benzeneacetic acid, 2,6-dichloro-alpha-hydroxy-3,4,5-trimethoxy-, methyl ester",COC1=C(C(=C(C(=C1OC)Cl)C(C(=O)OC)O)Cl)OC,,,,,,
3227,53228,"BENZYL ALCOHOL, o-(5-(m-METHOXYPHENYL)-s-TRIAZOL-3-YL)-",COC1=CC=CC(=C1)C2=NNC(=N2)C3=CC=CC=C3CO,,,,,,
3228,53229,"1,3,6-Trinitropyrene",C1=CC2=C3C(=C(C=C2[N+](=O)[O-])[N+](=O)[O-])C=CC4=C(C=CC1=C43)[N+](=O)[O-],,,,,,
3229,53230,"1,3-Dinitropyrene",C1=CC2=C3C(=C1)C=CC4=C(C=C(C(=C43)C=C2)[N+](=O)[O-])[N+](=O)[O-],,,"['Substances that increase the risk of NEOPLASMS in humans or animals. Both genotoxic chemicals, which affect DNA directly, and nongenotoxic chemicals, which induce neoplasms by other mechanism, are included. (See all compounds classified as Carcinogens.)', 'Chemical agents that increase the rate of genetic mutation by interfering with the function of nucleic acids. A clastogen is a specific mutagen that causes breaks in chromosomes. (See all compounds classified as Mutagens.)']",,,
3230,53231,"Acetamide, N,N-diethyl-2-(2,6-xylidino)-",CCN(CC)C(=O)CNC1=C(C=CC=C1C)C,,,,,,
3231,53232,Lovastatin,CC[C@H](C)C(=O)O[C@H]1C[C@H](C=C2[C@H]1[C@H]([C@H](C=C2)C)CC[C@@H]3C[C@H](CC(=O)O3)O)C,"['Lovastatin is indicated to reduce the risk of myocardial infarction, unstable angina, and the need for coronary revascularization procedures in individuals without symptomatic cardiovascular disease, average to moderately elevated total-C and LDL-C, and below average HDL-C. It is indicated as an intervention alternative in individuals presenting dyslipidemia at risk of developing atherosclerotic vascular disease. The administration of this agent should be accompanied by the implementation of a fat and cholesterol-restricted diet.  Therapy with lipid-altering agents should be a component of multiple risk factor intervention in those individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Lovastatin is indicated as an adjunct to diet for the reduction of elevated total-C and LDL-C levels in patients with primary hypercholesterolemia (Types IIa and IIb2), when the response to diet restricted in saturated fat and cholesterol and to other nonpharmacological measures alone has been inadequate.  Lovastatin is also indicated to slow the progression of coronary atherosclerosis in patients with coronary heart disease as part of a treatment strategy to lower total-C and LDL-C to target levels.  Lovastatin is indicated as an adjunct to diet to reduce total-C, LDL-C and apolipoprotein B levels in adolescent boys and girls with Heterozygous Familial Hypercholesterolemia (HeFH) who are at least one year post-menarche, 10 to 17 years of age, with HeFH if after an adequate trial of diet therapy the following findings are present: LDL-C remains greater than 189 mg/dL or LDL-C remains greater than 160 mg/dL and there is a positive family history of premature cardiovascular disease or two or more other CVD risk factors are present in the adolescent patient.  Before administering lovastatin, it is important to rule out the presence of secondary causes of hypercholesterolemia and a lipid profile should be performed.  Prescribing of statin medications is considered standard practice following any cardiovascular events and for people with a moderate to high risk of development of CVD. Statin-indicated conditions include diabetes mellitus, clinical atherosclerosis (including myocardial infarction, acute coronary syndromes, stable angina, documented coronary artery disease, stroke, trans ischemic attack (TIA), documented carotid disease, peripheral artery disease, and claudication), abdominal aortic aneurysm, chronic kidney disease, and severely elevated LDL-C levels.']","['Lovastatin is an oral antilipemic agent which reversibly inhibits HMG-CoA reductase. It is used to lower total cholesterol, low density lipoprotein-cholesterol (LDL-C), apolipoprotein B (apoB), non-high density lipoprotein-cholesterol (non-HDL-C), and trigleride (TG) plasma concentrations while increasing HDL-C concentrations. High LDL-C, low HDL-C and high TG concentrations in the plasma are associated with increased risk of atherosclerosis and cardiovascular disease. The total cholesterol to HDL-C ratio is a strong predictor of coronary artery disease and high ratios are associated with higher risk of disease. Increased levels of HDL-C are associated with lower cardiovascular risk. By decreasing LDL-C and TG and increasing HDL-C, lovastatin reduces the risk of cardiovascular morbidity and mortality.  Elevated cholesterol levels, and in particular, elevated low-density lipoprotein (LDL) levels, are an important risk factor for the development of CVD. Use of statins to target and reduce LDL levels has been shown in a number of landmark studies to significantly reduce the risk of development of CVD and all-cause mortality. Statins are considered a cost-effective treatment option for CVD due to their evidence of reducing all-cause mortality including fatal and non-fatal CVD as well as the need for surgical revascularization or angioplasty following a heart attack. Evidence has shown that even for low-risk individuals (with <10% risk of a major vascular event occurring within 5 years) statins cause a 20%-22% relative reduction in major cardiovascular events (heart attack, stroke, coronary revascularization, and coronary death) for every 1 mmol/L reduction in LDL without any significant side effects or risks. Clinical studies have shown that lovastatin reduces LDL-C and total cholesterol by 25-40%. The 50% inhibitory dose is known to be of 46 mcg/kg which is translated into a reduction of approximately 30% of plasma cholesterol.  **Myopathy/Rhabdomyolysis**  Lovastatin, like other inhibitors of HMG-CoA reductase, occasionally causes myopathy manifested as muscle pain, tenderness or weakness with creatine kinase (CK) above ten times the upper limit of normal (ULN). Myopathy sometimes takes the form of rhabdomyolysis with or without acute renal failure secondary to myoglobinuria, and rare fatalities have occurred. The risk of myopathy is dose-related and is increased by high levels of HMG-CoA reductase inhibitory activity in plasma. In a clinical study (EXCEL) in which patients were carefully monitored and some interacting drugs were excluded, there was one case of myopathy among 4933 patients randomized to lovastatin 20 to 40 mg daily for 48 weeks, and 4 among 1649 patients randomized to 80 mg daily.  Predisposing factors for myopathy include advanced age (≥65 years), female gender, uncontrolled hypothyroidism, and renal impairment. Chinese patients may also be at increased risk for myopathy. In most cases, muscle symptoms and CK increases resolved when treatment was promptly discontinued.  The risk of myopathy during treatment with lovastatin may be increased with concurrent administration of interacting drugs such as [fenofibrate], [niacin], [gemfibrozil], [cyclosporine], and strong inhibitors of the CYP3A4 enzyme.  Cases of myopathy, including rhabdomyolysis, have been reported with HMG-CoA reductase inhibitors coadministered with [colchicine], and caution should therefore be exercised when prescribing these two medications together.  Real-world data from observational studies has suggested that 10-15% of people taking statins may experience muscle aches at some point during treatment.  **Liver Dysfunction**  Persistent increases (to more than 3 times the upper limit of normal) in serum transaminases occurred in 1.9% of adult patients who received lovastatin for at least one year in early clinical trials. When the drug was interrupted or discontinued in these patients, the transaminase levels usually fell slowly to pretreatment levels. The increases usually appeared 3 to 12 months after the start of therapy with lovastatin, and were not associated with jaundice or other clinical signs or symptoms. In the EXCEL study, the incidence of persistent increases in serum transaminases over 48 weeks was 0.1% for placebo, 0.1% at 20 mg/day, 0.9% at 40 mg/day, and 1.5% at 80 mg/day in patients on lovastatin. However, in post-marketing experience with lovastatin, symptomatic liver disease has been reported rarely at all dosages.']","['Substances used to lower plasma cholesterol levels. (See all compounds classified as Anticholesteremic Agents.)', 'Compounds that inhibit HYDROXYMETHYLGLUTARYL COA REDUCTASES. They have been shown to directly lower CHOLESTEROL synthesis. (See all compounds classified as Hydroxymethylglutaryl-CoA Reductase Inhibitors.)']","['Lovastatin Cmax was found to be 3.013ng/mL with a Tmax of 3.36 hours.  Plasma concentrations of total radioactivity (lovastatin plus 14C-metabolites) peaked at 2 hours and declined rapidly to about 10% of peak by 24 hours postdose. Absorption of lovastatin, estimated relative to an intravenous reference dose, in each of four animal species tested, averaged about 30% of an oral dose. In animal studies, after oral dosing, lovastatin had high selectivity for the liver, where it achieved substantially higher concentrations than in non-target tissues. Lovastatin undergoes extensive first-pass extraction in the liver, its primary site of action, with subsequent excretion of drug equivalents in the bile. As a consequence of extensive hepatic extraction of lovastatin, the availability of drug to the general circulation is low and variable. In a single dose study in four hypercholesterolemic patients, it was estimated that less than 5% of an oral dose of lovastatin reaches the general circulation as active inhibitors. Following administration of lovastatin tablets the coefficient of variation, based on between-subject variability, was approximately 40% for the area under the curve (AUC) of total inhibitory activity in the general circulation.  The peak concentrations of lovastatin when a dose of 10-40 mg is administered are reported to range from 1.04-4.03 ng/ml and an AUC of 14-53 ng.h/ml. This indicates that lovastatin presents a dose-dependent pharmacokinetic profile. When lovastatin was given under fasting conditions, plasma concentrations of both active and total inhibitors were on average about two-thirds those found when lovastatin was administered immediately after a standard test meal.  Genetic differences in the OATP1B1 (Organic-Anion-Transporting Polypeptide 1B1) hepatic transporter encoded by the SCLCO1B1 gene (Solute Carrier Organic Anion Transporter family member 1B1) have been shown to impact lovastatin pharmacokinetics. Evidence from pharmacogenetic studies of the c.521T>C single nucleotide polymorphism (SNP) showed that lovastatin Cmax and AUC were 340 and 286% higher, respectively, for individuals homozygous for 521CC compared to homozygous 521TT individuals. The 521CC genotype is also associated with a marked increase in the risk of developing myopathy, likely secondary to increased systemic exposure. Other statin drugs impacted by this polymorphism include [rosuvastatin], [pitavastatin], [atorvastatin], [simvastatin], and [pravastatin].  While specific dosage instructions are not included in the available product monographs for lovastatin, individuals with the above-mentioned c.521CC OATP1B1 genotype should be monitored for development of adverse effects from increased exposure to the drug, such as muscle pain and risk of rhabdomyolysis, particularly at higher doses.', 'Following an oral dose of 14C-labeled lovastatin to man, 10% of the dose was excreted in urine and 83% in feces. The latter represents absorbed drug excreted in bile, together with unabsorbed drug.', 'Lovastatin is able to cross the blood-brain barrier and placenta.', '/MILK/ It is not known whether lovastatin is excreted in human milk.', 'Following an oral dose of (14)C-labeled lovastatin in man, 10% of the dose was excreted in urine and 83% in feces. The latter represents absorbed drug equivalents excreted in bile, as well as any unabsorbed drug. Plasma concentrations of total radioactivity (lovastatin plus (14)C-metabolites) peaked at 2 hours and declined rapidly to about 10% of peak by 24 hours postdose. Absorption of lovastatin, estimated relative to an intravenous reference dose, in each of four animal species tested, averaged about 30% of an oral dose. In animal studies, after oral dosing, lovastatin had high selectivity for the liver, where it achieved substantially higher concentrations than in non-target tissues. Lovastatin undergoes extensive first-pass extraction in the liver, its primary site of action, with subsequent excretion of drug equivalents in the bile. As a consequence of extensive hepatic extraction of lovastatin, the availability of drug to the general circulation is low and variable. In a single dose study in four hypercholesterolemic patients, it was estimated that less than 5% of an oral dose of lovastatin reaches the general circulation as active inhibitors. Following administration of lovastatin tablets the coefficient of variation, based on between-subject variability, was approximately 40% for the area under the curve (AUC) of total inhibitory activity in the general circulation.', 'Both lovastatin and its beta-hydroxyacid metabolite are highly bound (> 95%) to human plasma proteins. Animal studies demonstrated that lovastatin crosses the blood-brain and placental barriers.', 'Peak plasma concentrations of both active and total inhibitors were attained within 2 to 4 hours of dose administration.']","[""Lovastatin is given as a lactone prodrug and thus, in order to produce its mechanism of action, it is required to be converted to the active beta-hydroxy form. This drug activation process does not seem to be related to CYP isoenzyme activity but rather to be controlled by the activity of serum paraoxonase.  Lovastatin is metabolized by the microsomal hepatic enzyme system (Cytochrome P-450 isoform 3A4). The major active metabolites present in human plasma are the β-hydroxy acid of lovastatin, its 6'-hydroxy, 6'-hydroxymethyl, and 6'-exomethylene derivatives. The uptake of lovastatin by the liver is enhanced by the activity of OATP1B1."", ""Lovastatin is metabolized by the microsomal hepatic enzyme system (Cytochrome P-450 isoform 3A4). The major active metabolites present in human plasma are the beta-hydroxy acid of lovastatin, its 6'-hydroxy, 6'-hydroxymethyl, and 6'-exomethylene derivatives."", ""The major active metabolites present in human plasma are the beta-hydroxyacid of lovastatin, its 6'-hydroxy derivative, and two additional metabolites."", ""Lovastatin has known human metabolites that include 3-Hydroxylovastatin and 6'beta-Hydroxylovastatin.""]",['Lovastatin half-life is reported to be of 13.37 hours. The elimination half-life of the hydroxy acid form of lovastatin is reported to be of 0.7-3 hours.']
3232,53233,1-(p-Phenylphenethyl)hydrazine hydrochloride,C1=CC=C(C=C1)C2=CC=C(C=C2)CCN[NH3+].[Cl-],,,,,,
3233,53234,2-(4-Phenylphenyl)ethylhydrazine,C1=CC=C(C=C1)C2=CC=C(C=C2)CCNN,,,,,,
3234,53235,1-(p-Phenylbenzyl)hydrazine hydrochloride,C1=CC=C(C=C1)C2=CC=C(C=C2)CN[NH3+].[Cl-],,,,,,
3235,53236,Biphenyl-4-ylmethyl-hydrazine,C1=CC=C(C=C1)C2=CC=C(C=C2)CNN,,,,,,
3236,53237,(alpha-Methyl-p-phenylbenzyl)hydrazine hydrochloride,CC(C1=CC=C(C=C1)C2=CC=CC=C2)N[NH3+].[Cl-],,,,,,
3237,53238,CID 53238,CC(C1=CC=C(C=C1)C2=CC=CC=C2)NN,,,,,,
3238,53239,(alpha-Methyl-p-phenoxybenzyl)hydrazine hydrochloride,CC(C1=CC=C(C=C1)OC2=CC=CC=C2)N[NH3+].[Cl-],,,,,,
3239,53240,1-(4-Phenoxyphenyl)ethylhydrazine,CC(C1=CC=C(C=C1)OC2=CC=CC=C2)NN,,,,,,
3240,53241,1-(p-Methoxy-alpha-methylbenzyl)hydrazine,CC(C1=CC=C(C=C1)OC)N[NH3+].C(=O)(C(=O)[O-])O,,,,,,
3241,53242,1-(1-(4-Methoxyphenyl)ethyl)hydrazine,CC(C1=CC=C(C=C1)OC)NN,,,,,,
3242,53243,1-(p-Fluoro-alpha-methylbenzyl)hydrazine oxalate,CC(C1=CC=C(C=C1)F)N[NH3+].C(=O)(C(=O)[O-])O,,,,,,
3243,53244,alpha-Methyl-4-fluorobenzylhydrazine,CC(C1=CC=C(C=C1)F)NN,,,,,,
3244,53245,(alpha-Ethylbenzyl)hydrazine oxalate,CCC(C1=CC=CC=C1)N[NH3+].C(=O)(C(=O)[O-])O,,,,,,
3245,53246,(p-Ethoxy-alpha-methylbenzyl)hydrazine oxalate,CCOC1=CC=C(C=C1)C(C)N[NH3+].C(=O)(C(=O)[O-])O,,,,,,
3246,53247,1-(4-Ethoxyphenyl)ethylhydrazine,CCOC1=CC=C(C=C1)C(C)NN,,,,,,
3247,53248,1-(4-Hydroxybutyryl)-2-(alpha-methylphenethyl)hydrazine hydrochloride,CC(CC1=CC=CC=C1)[NH2+]NC(=O)CCCO.[Cl-],,,,,,
3248,53249,4-hydroxy-N'-(1-phenylpropan-2-yl)butanehydrazide,CC(CC1=CC=CC=C1)NNC(=O)CCCO,,,,,,
3249,53250,"1-Methyl-1'-pentyl-4,4'-bipyridinium diiodide",CCCCC[N+]1=CC=C(C=C1)C2=CC=[N+](C=C2)C.[I-].[I-],,,,,,
3250,53251,"1-Methyl-1'-pentyl-4,4'-bipyridinium",CCCCC[N+]1=CC=C(C=C1)C2=CC=[N+](C=C2)C,,,,,,
3251,53252,CID 53252,COC1=C(C(=C(C=C1)C=CCC(=O)N2CC[NH+](CC2)CC=CC3=CC=CC=C3)OC)OC.C(=CC(=O)[O-])C(=O)O,,,,,,
3252,53253,CID 53253,COC1=C(C(=C(C=C1)C=CCC(=O)N2CCN(CC2)CC=CC3=CC=CC=C3)OC)OC,,,,,,
3253,53254,CID 53254,COC1=C(C(=C(C=C1)C=CCC(=O)N2CC[NH+](CC2)CC(=O)N3CCCCCC3)OC)OC.C(=CC(=O)[O-])C(=O)O,,,,,,
3254,53255,CID 53255,COC1=C(C(=C(C=C1)C=CCC(=O)N2CCN(CC2)CC(=O)N3CCCCCC3)OC)OC,,,,,,
3255,53256,CID 53256,COC1=C(C(=C(C=C1)C=CCC(=O)N2CC[NH+](CC2)CC(=O)N3CCOCC3)OC)OC.C(=CC(=O)[O-])C(=O)O,,,,,,
3256,53257,CID 53257,COC1=C(C(=C(C=C1)C=CCC(=O)N2CCN(CC2)CC(=O)N3CCOCC3)OC)OC,,,,,,
3257,53258,CID 53258,COC1=C(C(=C(C=C1)C=CCC(=O)N2CC[NH+](CC2)CC(=O)N3CCCC3)OC)OC.C(=CC(=O)[O-])C(=O)O.N,,,,,,
3258,53259,CID 53259,COC1=C(C(=C(C=C1)C=CCC(=O)N2CCN(CC2)CC(=O)N3CCCC3)OC)OC,,,,,,
3259,53260,(beta-(2-Pyridyl)ethyl)isoquinoline,C1=CC=C2C(=C1)C=CN=C2CCC3=CC=CC=N3,,,,,,
3260,53261,"2-[4-(Methylthio)phenoxy]-1-(3,4-dimethoxyphenyl)-1,3-propanediol",COC1=C(C=C(C=C1)C(C(CO)OC2=CC=C(C=C2)SC)O)OC,,,,,,
3261,53262,"5-Nitro-3-(1,2,3,6-tetrahydro-4-pyridinyl)-1H-indole hydrochloride",C1C[NH2+]CC=C1C2=CNC3=C2C=C(C=C3)[N+](=O)[O-].[Cl-],,,,,,
3262,53263,"5-nitro-3-(1,2,3,6-tetrahydropyridin-4-yl)-1H-indole",C1CNCC=C1C2=CNC3=C2C=C(C=C3)[N+](=O)[O-],,,,,,
3263,53264,B(c)PH diol epoxide-1,C1=CC=C2C(=C1)C=CC3=C2C4=C(C=C3)[C@@H]([C@H]([C@H]5[C@@H]4O5)O)O,,,,,,
3264,53265,"Isoquinolinium, 1,2,3,4-tetrahydro-7-hydroxy-1-((4-hydroxyphenyl)methyl)-6-methoxy-2,2-dimethyl-, chloride, (R)-",C[N+]1(CCC2=CC(=C(C=C2[C@H]1CC3=CC=C(C=C3)O)O)OC)C.[Cl-],,,,,,
3265,53266,Magnocurarine,C[N+]1(CCC2=CC(=C(C=C2[C@H]1CC3=CC=C(C=C3)O)O)OC)C,,,,,,
3266,53267,4-Hydroxy-3-chloro-1-butene,C=CC(CO)Cl,,,,,,
3267,53268,"N-(1,2,3,5,6,7-Hexahydro-s-indacen-1-yl)acetamide",CC(=O)NC1CCC2=C1C=C3CCCC3=C2,,,,,,
3268,53269,"Acetamide, N-(1,2,3,5,6,7-hexahydro-s-indacen-1-yl)-2-((1-methylethyl)(phenylmethyl)amino)-, monohydrochloride, hydrate",CC(C)[NH+](CC1=CC=CC=C1)CC(=O)NC2CCC3=C2C=C4CCCC4=C3.[Cl-],,,,,,
3269,53270,"2-[benzyl(propan-2-yl)amino]-N-(1,2,3,5,6,7-hexahydro-s-indacen-1-yl)acetamide",CC(C)N(CC1=CC=CC=C1)CC(=O)NC2CCC3=C2C=C4CCCC4=C3,,,,,,
3270,53271,Butantrone,CCCC(=O)C1C2=C(C(=CC=C2)O)C(=O)C3=C1C=CC=C3O,,,,,,
3271,53272,"2-INDOLINONE, 5-BROMO-1-(DIETHYLAMINOMETHYL)-3,3-DI-p-TOLYL-",CCN(CC)CN1C2=C(C=C(C=C2)Br)C(C1=O)(C3=CC=C(C=C3)C)C4=CC=C(C=C4)C,,,,,,
3272,53273,"2-INDOLINONE, 5-BROMO-3,3-DI-p-TOLYL-1-(MORPHOLINOMETHYL)-",CC1=CC=C(C=C1)C2(C3=C(C=CC(=C3)Br)N(C2=O)CN4CCOCC4)C5=CC=C(C=C5)C,,,,,,
3273,53274,CID 53274,C1CC2CCC1CN(C2)C(=NN=CC3=CC=CC=N3)S,,,,,,
3274,53275,Ethyl 2-amino-6-(4-fluorobenzylamino)pyridin-3-ylcarbamate maleate,CCOC(=O)NC1=C(N=C(C=C1)NCC2=CC=C(C=C2)F)N.C(=CC(=O)O)C(=O)O,,,['Compounds capable of relieving pain without the loss of CONSCIOUSNESS. (See all compounds classified as Analgesics.)'],,,
3275,53276,Flupirtine,CCOC(=O)NC1=C(N=C(C=C1)NCC2=CC=C(C=C2)F)N,['Investigated for use/treatment in fibromyalgia.'],,['Compounds capable of relieving pain without the loss of CONSCIOUSNESS. (See all compounds classified as Analgesics.)'],"['Bioavailability: 90% (oral), 70% (rectal)', '72% of flupirtine and its metabolites appear in urine and 18% appear in faeces.']",['Hepatic to 2-amino-3-acetylamino-6-(para-fluorobenzylamino) pyridine (which has 20-30% the analgesic potential of its parent compound) and Para-fluorohippuric acid.'],"['6.5 hrs (average), 11.2-16.8 hrs (average 14 hrs) (elderly), 8.7-10.9 hrs (average 9.8 hrs) (in those with moderate-level renal impairment).']"
3276,53277,Chaetochromin,CC1C(OC2=C(C1=O)C(=C3C(=C2)C(=C(C=C3O)O)C4=C(C=C(C5=C(C6=C(C=C54)OC(C(C6=O)C)C)O)O)O)O)C,,,,,,
3277,53278,(R)-colchicine,CC(=O)N[C@@H]1CCC2=CC(=C(C(=C2C3=CC=C(C(=O)C=C13)OC)OC)OC)OC,,,,,"['(R)-colchicine has known human metabolites that include 2-demethyicolchicine, 3-demethylcolchicine, and Colchiceine.']",
3278,53279,Morlincain,CC1=C(C(=CC=C1)C)NC(=O)CN2CCOCC2,,,,,,
3279,53280,Dichloromethoxybenzenediol,COC1=C(C(=CC(=C1O)Cl)O)Cl,,,,,,
3280,53281,CID 53281,C1=CC(=C(C(=C1)Cl)NC(=NC(=O)N)N)Cl,,,,,,
3281,53282,2-Amino-10-methylacridinium chloride,C[N+]1=C2C=CC(=CC2=CC3=CC=CC=C31)N.[Cl-],,,,,,
3282,53283,3-Amino-10-methylacridinium chloride,C[N+]1=C2C=C(C=CC2=CC3=CC=CC=C31)N.[Cl-],,,,,,
3283,53284,1-Amino-10-methylacridinium chloride,C[N+]1=C2C=CC=C(C2=CC3=CC=CC=C31)N.[Cl-],,,,,,
3284,53285,1-Amino-10-methylacridinium,C[N+]1=C2C=CC=C(C2=CC3=CC=CC=C31)N,,,,,,
3285,53286,"Ethylamine, 2-(2-propynylthio)-",C#CCSCCN,,,,,,
3286,53287,"Ethylamine, 2-(2-butynylthio)-",CC#CCSCCN,,,,,,
3287,53288,"1,2,3,4,6,7-Hexabromonaphthalene",C1=C2C(=CC(=C1Br)Br)C(=C(C(=C2Br)Br)Br)Br,,,,,,
3288,53289,"1,2,4,6,7-Pentabromonaphthalene",C1=C2C(=CC(=C1Br)Br)C(=C(C=C2Br)Br)Br,,,,,,
3289,53290,"Benzo(a)pyrene-7,8-diol, 7,8-dihydro-7-methyl-, (7S-trans)-",C[C@]1([C@H](C=CC2=C1C=C3C=CC4=C5C3=C2C=CC5=CC=C4)O)O,,,,,,
3290,53291,"1,2,4,6,7,9-Hexachlorodibenzofuran",C1=C(C2=C(C(=C1Cl)Cl)OC3=C2C(=C(C=C3Cl)Cl)Cl)Cl,,,,,,
3291,53292,(3-Chloro-2-hydroxypropyl) 4-acetamidobenzoate,CC(=O)NC1=CC=C(C=C1)C(=O)OCC(CCl)O,,,,,,
3292,53293,9-(p-Iodoanilino)acridine hydrochloride hemihydrate,C1=CC=C2C(=C1)C(=C3C=CC=CC3=N2)[NH2+]C4=CC=C(C=C4)I.[Cl-],,,,,,
3293,53294,N-(4-iodophenyl)acridin-9-amine,C1=CC=C2C(=C1)C(=C3C=CC=CC3=N2)NC4=CC=C(C=C4)I,,,,,,
3294,53295,9-(o-Toluidino)acridine hydrochloride,CC1=CC=CC=C1[NH2+]C2=C3C=CC=CC3=NC4=CC=CC=C42.[Cl-],,,,,,
3295,53296,N-(2-methylphenyl)acridin-9-amine,CC1=CC=CC=C1NC2=C3C=CC=CC3=NC4=CC=CC=C42,,,,,,
3296,53297,9-(m-Toluidino)acridine hydrochloride,CC1=CC(=CC=C1)[NH2+]C2=C3C=CC=CC3=NC4=CC=CC=C42.[Cl-],,,,,,
3297,53298,N-(3-Methylphenyl)-9-acridinamine,CC1=CC(=CC=C1)NC2=C3C=CC=CC3=NC4=CC=CC=C42,,,,,,
3298,53299,2-hydroxy-5-[(1R)-1-hydroxy-2-(4-phenylbutan-2-ylamino)ethyl]benzamide,CC(CCC1=CC=CC=C1)NC[C@@H](C2=CC(=C(C=C2)O)C(=O)N)O,,,,,,
3299,53300,2-hydroxy-5-[(1R)-1-hydroxy-2-(4-phenylbutan-2-ylamino)ethyl]benzamide;hydrochloride,CC(CCC1=CC=CC=C1)NC[C@@H](C2=CC(=C(C=C2)O)C(=O)N)O.Cl,,,,,,
3300,53301,Butylphenyl diphenyl phosphate,CCCCC1=CC=C(C=C1)OP(=O)(OC2=CC=CC=C2)OC3=CC=CC=C3,,,,,,
3301,53302,"DIPYRIDO(1,2-a:3',2'-d)IMIDAZOLE, 2-AMINO-3-METHYL-",CC1=CC2=C(N=C1N)N3C=CC=CC3=N2,,,,,,
3302,53303,"DIPYRIDO(1,2-a:3',2'-d)IMIDAZOLE, 2-AMINO-4-METHYL-",CC1=CC(=NC2=C1N=C3N2C=CC=C3)N,,,,,,
3303,53304,"DIPYRIDO(1,2-a:3',2'-d)IMIDAZOLE, 2-AMINO-7-METHYL-",CC1=CC2=NC3=C(N2C=C1)N=C(C=C3)N,,,,,,
3304,53305,"DIPYRIDO(1,2-a:3',2'-d)IMIDAZOLE, 2-AMINO-8-METHYL-",CC1=CN2C(=NC3=C2N=C(C=C3)N)C=C1,,,,,,
3305,53306,"DIPYRIDO(1,2-a:3',2'-d)IMIDAZOLE, 2-AMINO-9-METHYL-",CC1=CC=CC2=NC3=C(N12)N=C(C=C3)N,,,,,,
3306,53307,"3-[7-chloro-5-(2-fluorophenyl)-2-oxo-3H-1,4-benzodiazepin-1-yl]propanenitrile",C1C(=O)N(C2=C(C=C(C=C2)Cl)C(=N1)C3=CC=CC=C3F)CCC#N,,,,,,
3307,53308,"(5S,6R)-6-(2-amino-2-carboxyethyl)sulfanyl-5-hydroxyicosa-7,9,11,14-tetraenoic acid",CCCCCC=CCC=CC=CC=C[C@H]([C@H](CCCC(=O)O)O)SCC(C(=O)O)N,,,,,,
3308,53309,Diclobutrazol,CC(C)(C)C(C(CC1=C(C=C(C=C1)Cl)Cl)N2C=NC=N2)O,,,,,,
3309,53310,"1-N,3-N-bis(2,3-dihydroxypropyl)-2,4,6-triiodo-5-[(3,4,5,6-tetrahydroxy-2-oxohexanoyl)amino]benzene-1,3-dicarboxamide",C(C(CO)O)NC(=O)C1=C(C(=C(C(=C1I)NC(=O)C(=O)C(C(C(CO)O)O)O)I)C(=O)NCC(CO)O)I,,,,,,
3310,53311,"ACRIDINE, 9-(p-(METHYLSULFONYL)ANILINO)-",CS(=O)(=O)C1=CC=C(C=C1)NC2=C3C=CC=CC3=NC4=CC=CC=C42,,,,,,
3311,53312,"ACRIDINE, 9-(m-NITROANILINO)-",C1=CC=C2C(=C1)C(=C3C=CC=CC3=N2)NC4=CC(=CC=C4)[N+](=O)[O-],,,,,,
3312,53313,"Acridine, 9-(3-pyridylamino)-",C1=CC=C2C(=C1)C(=C3C=CC=CC3=N2)NC4=CN=CC=C4,,,,,,
3313,53314,9-(m-Chloroanilino)acridine methanesulfonate,CS(=O)(=O)[O-].C1=CC=C2C(=C1)C(=C3C=CC=CC3=N2)[NH2+]C4=CC(=CC=C4)Cl,,,,,,
3314,53315,N-(3-Chlorophenyl)acridin-9-amine,C1=CC=C2C(=C1)C(=C3C=CC=CC3=N2)NC4=CC(=CC=C4)Cl,,,,,,
3315,53316,9-(m-Anisidino)acridine methanesulfonate,COC1=CC=CC(=C1)[NH2+]C2=C3C=CC=CC3=NC4=CC=CC=C42.CS(=O)(=O)[O-],,,,,,
3316,53317,N-(3-methoxyphenyl)acridin-9-amine,COC1=CC=CC(=C1)NC2=C3C=CC=CC3=NC4=CC=CC=C42,,,,,,
3317,53318,o-(9-Acridinylamino)benzamide hydrochloride,C1=CC=C2C(=C1)C(=C3C=CC=CC3=[NH+]2)NC4=CC=CC=C4C(=O)N.[Cl-],,,,,,
3318,53319,2-(9-Acridinylamino)benzamide,C1=CC=C2C(=C1)C(=C3C=CC=CC3=N2)NC4=CC=CC=C4C(=O)N,,,,,,
3319,53320,9-(2-Pyridylamino)acridine hydrochloride hemihydrate,C1=CC=C2C(=C1)C(=C3C=CC=CC3=N2)[NH2+]C4=CC=CC=N4.[Cl-],,,,,,
3320,53321,N-pyridin-2-ylacridin-9-amine,C1=CC=C2C(=C1)C(=C3C=CC=CC3=N2)NC4=CC=CC=N4,,,,,,
3321,53322,9-(o-Nitroanilino)acridine hydrochloride,C1=CC=C2C(=C1)C(=C3C=CC=CC3=N2)[NH2+]C4=CC=CC=C4[N+](=O)[O-].[Cl-],,,,,,
3322,53323,N-(2-nitrophenyl)acridin-9-amine,C1=CC=C2C(=C1)C(=C3C=CC=CC3=N2)NC4=CC=CC=C4[N+](=O)[O-],,,,,,
3323,53324,9-(o-Iodoanilino)acridine hydrochloride,C1=CC=C2C(=C1)C(=C3C=CC=CC3=N2)[NH2+]C4=CC=CC=C4I.[Cl-],,,,,,
3324,53325,N-(2-iodophenyl)acridin-9-amine,C1=CC=C2C(=C1)C(=C3C=CC=CC3=N2)NC4=CC=CC=C4I,,,,,,
3325,53326,9-(o-Fluoroanilino)acridine hydrochloride,C1=CC=C2C(=C1)C(=C3C=CC=CC3=N2)[NH2+]C4=CC=CC=C4F.[Cl-],,,,,,
3326,53327,N-(2-Fluorophenyl)-9-acridinamine,C1=CC=C2C(=C1)C(=C3C=CC=CC3=N2)NC4=CC=CC=C4F,,,,,,
3327,53328,9-(o-Anisidino)acridine methanesulfonate,COC1=CC=CC=C1[NH2+]C2=C3C=CC=CC3=NC4=CC=CC=C42.CS(=O)(=O)[O-],,,,,,
3328,53329,N-(2-methoxyphenyl)acridin-9-amine,COC1=CC=CC=C1NC2=C3C=CC=CC3=NC4=CC=CC=C42,,,,,,
3329,53330,9-(o-Ethoxyanilino)acridine hydrochloride,CCOC1=CC=CC=C1[NH2+]C2=C3C=CC=CC3=NC4=CC=CC=C42.[Cl-],,,,,,
3330,53331,N-(2-Ethoxyphenyl)-9-acridinamine,CCOC1=CC=CC=C1NC2=C3C=CC=CC3=NC4=CC=CC=C42,,,,,,
3331,53332,"ACRIDINE, 9-(o-ETHYLANILINO)-, HYDROCHLORIDE",CCC1=CC=CC=C1[NH2+]C2=C3C=CC=CC3=NC4=CC=CC=C42.[Cl-],,,,,,
3332,53333,N-(2-ethylphenyl)acridin-9-amine,CCC1=CC=CC=C1NC2=C3C=CC=CC3=NC4=CC=CC=C42,,,,,,
3333,53334,9-(o-Isopropylanilino)acridine hydrochloride,CC(C)C1=CC=CC=C1[NH2+]C2=C3C=CC=CC3=NC4=CC=CC=C42.[Cl-],,,,,,
3334,53335,N-(2-Isopropylphenyl)-9-acridinamine,CC(C)C1=CC=CC=C1NC2=C3C=CC=CC3=NC4=CC=CC=C42,,,,,,
3335,53336,9-(o-tert-Butylanilino)acridine hydrochloride,CC(C)(C)C1=CC=CC=C1[NH2+]C2=C3C=CC=CC3=NC4=CC=CC=C42.[Cl-],,,,,,
3336,53337,N-(2-tert-Butylphenyl)-9-acridinamine,CC(C)(C)C1=CC=CC=C1NC2=C3C=CC=CC3=NC4=CC=CC=C42,,,,,,
3337,53338,o-(9-Acridinylamino)carbanilic acid methyl ester hydrochloride,COC(=O)NC1=CC=CC=C1[NH2+]C2=C3C=CC=CC3=NC4=CC=CC=C42.[Cl-],,,,,,
3338,53339,methyl N-[2-(acridin-9-ylamino)phenyl]carbamate,COC(=O)NC1=CC=CC=C1NC2=C3C=CC=CC3=NC4=CC=CC=C42,,,,,,
3339,53340,2'-(9-Acridinylamino)acetanilide hydrochloride,CC(=O)NC1=CC=CC=C1[NH2+]C2=C3C=CC=CC3=NC4=CC=CC=C42.[Cl-],,,,,,
3340,53341,N-[2-(acridin-9-ylamino)phenyl]acetamide,CC(=O)NC1=CC=CC=C1NC2=C3C=CC=CC3=NC4=CC=CC=C42,,,,,,
3341,53342,N-(9-Acridinyl)anthranilic acid methyl ester hydrochloride,COC(=O)C1=CC=CC=C1[NH2+]C2=C3C=CC=CC3=NC4=CC=CC=C42.[Cl-],,,,,,
3342,53343,2-(Acridin-9-ylamino)-benzoic acid methyl ester,COC(=O)C1=CC=CC=C1NC2=C3C=CC=CC3=NC4=CC=CC=C42,,,,,,
3343,53344,"BENZONITRILE, p-(9-ACRIDINYLAMINO)-",C1=CC=C2C(=C1)C(=C3C=CC=CC3=N2)NC4=CC=C(C=C4)C#N,,,,,,
3344,53345,"ACRIDINE, 9-(p-BROMOANILINO)-",C1=CC=C2C(=C1)C(=C3C=CC=CC3=N2)NC4=CC=C(C=C4)Br,,,,,,
3345,53346,"ACRIDINE, 9-(m-(METHYLAMINO)ANILINO)-",CNC1=CC(=CC=C1)NC2=C3C=CC=CC3=NC4=CC=CC=C42,,,,,,
3346,53347,"ACRIDINE, 9-(o-AMINOANILINO)-",C1=CC=C2C(=C1)C(=C3C=CC=CC3=N2)NC4=CC=CC=C4N,,,,,,
3347,53348,"3-Heptanone, 4,4-diphenyl-6-piperidino-, hydrochloride",CCC(=O)C(CC(C)[NH+]1CCCCC1)(C2=CC=CC=C2)C3=CC=CC=C3.[Cl-],,,,,,
3348,53349,"Acetone, 2-(6-(2-ethyl-1-imidazolyl)-3-pyridazinyl)hydrazone",CCC1=NC=CN1C2=NN=C(C=C2)NN=C(C)C,,,,,,
3349,53350,"4,4'-(Tetramethylenedioxy)dianiline dihydrochloride",C1=CC(=CC=C1[NH3+])OCCCCOC2=CC=C(C=C2)[NH3+].[Cl-].[Cl-],,,,,,
3350,53351,Diaminodiphenoxybutane,C1=CC(=CC=C1N)OCCCCOC2=CC=C(C=C2)N,,,,,,
3351,53352,"Butyronitrile, 4-((2-cyanoethyl)amino)-",C(CC#N)CNCCC#N,,,,,,
3352,53353,"Benzimidazole, 1-chloromethyl-, hydrochloride",C1=CC=C2C(=C1)NC=[N+]2CCl.[Cl-],,,,,,
3353,53354,3-(chloromethyl)-1H-benzimidazol-3-ium,C1=CC=C2C(=C1)NC=[N+]2CCl,,,,,,
3354,53355,CID 53355,CC(C(=O)[O-])N=C(S)[S-].[Na+].[Na+],,,,,,
3355,53356,CID 53356,CC(C(=O)O)N=C(S)S,,,,,,
3356,53357,CID 53357,C([C@@H](C(=O)[O-])N=C(S)[S-])C(=O)[O-].[Na+].[Na+].[Na+],,,,,,
3357,53358,CID 53358,C([C@@H](C(=O)O)N=C(S)S)C(=O)O,,,,,,
3358,53359,Tolrestat,CN(CC(=O)O)C(=S)C1=CC=CC2=C1C=CC(=C2C(F)(F)F)OC,['For the pharmacological control of certain diabetic complications.'],,['Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. (See all compounds classified as Enzyme Inhibitors.)'],,,
3359,53360,"1,2,3,4-Tetrahydronaphthalene-d12",[2H]C1=C(C(=C2C(=C1[2H])C(C(C(C2([2H])[2H])([2H])[2H])([2H])[2H])([2H])[2H])[2H])[2H],,,,,,
3360,53361,"1-(2-((m-Chloro-alpha-phenylbenzyl)oxy)ethyl)-4-methylhexahydro-1H-1,4-diazepine",CN1CCCN(CC1)CCOC(C2=CC=CC=C2)C3=CC(=CC=C3)Cl,,,,,,
3361,53362,"1H-1,4-Diazepine, hexahydro-1-(3-(diphenylmethoxy)propyl)-4-methyl-",CN1CCCN(CC1)CCCOC(C2=CC=CC=C2)C3=CC=CC=C3,,,,,,
3362,53363,"1H-1,4-Diazepine, hexahydro-1-(2-(diphenylmethoxy)ethyl)-4-isopropyl-",CC(C)N1CCCN(CC1)CCOC(C2=CC=CC=C2)C3=CC=CC=C3,,,,,,
3363,53364,"1-(2-((p-Fluoro-alpha-phenylbenzyl)oxy)ethyl)-4-methylhexahydro-1H-1,4-diazepine",CN1CCCN(CC1)CCOC(C2=CC=CC=C2)C3=CC=C(C=C3)F,,,,,,
3364,53365,"1H-1,4-Diazepine, hexahydro-1-(2-(diphenylmethoxy)ethyl)-4-methyl-",CN1CCCN(CC1)CCOC(C2=CC=CC=C2)C3=CC=CC=C3,,,,,,
3365,53366,"4-Methyl-1-(2-((alpha-(p-tolyl)benzyl)oxy)ethyl)hexahydro-1H-1,4-diazepine",CC1=CC=C(C=C1)C(C2=CC=CC=C2)OCCN3CCCN(CC3)C,,,,,,
3366,53367,CID 53367,CN1CCCN(CC1)CCC(C2=CC=CC=C2)C3=CC=CC=C3Cl,,,,,,
3367,53368,Dimethylcycleanine,C[N+]1(CCC2=CC(=C(C3=C2[C@H]1CC4=CC=C(C=C4)OC5=C6[C@@H](CC7=CC=C(O3)C=C7)[N+](CCC6=CC(=C5OC)OC)(C)C)OC)OC)C.[Br-].[Br-],,,,,,
3368,53369,CID 53369,C[N+]1(CCC2=CC(=C(C3=C2C1CC4=CC=C(C=C4)OC5=C6C(CC7=CC=C(O3)C=C7)[N+](CCC6=CC(=C5OC)OC)(C)C)OC)OC)C,,,,,,
3369,53370,(2S)-1-[(2R)-2-[[(2R)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]propanoyl]pyrrolidine-2-carboxylic acid,CCOC(=O)[C@@H](CCC1=CC=CC=C1)N[C@H](C)C(=O)N2CCC[C@H]2C(=O)O,,,,,,
3370,53371,3-Acetamido-4'-chloro-3-biphenylacetic acid,CC(=O)NC1=C(C=CC(=C1)C2=CC=CC(=C2)CC(=O)O)Cl,,,,,,
3371,53372,5-Amino-3-biphenylacetic acid,C1=CC=C(C=C1)C2=CC(=CC(=C2)CC(=O)O)N,,,,,,
3372,53373,"3-Biphenylacetic acid, 5-amino-4'-methoxy-",COC1=CC=C(C=C1)C2=CC(=CC(=C2)CC(=O)O)N,,,,,,
3373,53374,"3-Biphenylacetic acid, 5-amino-4'-chloro-",C1=CC(=CC=C1C2=CC(=CC(=C2)CC(=O)O)N)Cl,,,,,,
3374,53375,"3-Biphenylacetic acid, 4'-chloro-",C1=CC(=CC(=C1)C2=CC=C(C=C2)Cl)CC(=O)O,,,,,,
3375,53376,"3-Biphenylacetic acid, 5-chloro-",C1=CC=C(C=C1)C2=CC(=CC(=C2)CC(=O)O)Cl,,,,,,
3376,53377,"3-Biphenylacetic acid, 5-chloro-4'-methoxy-",COC1=CC=C(C=C1)C2=CC(=CC(=C2)CC(=O)O)Cl,,,,,,
3377,53378,"3-Biphenylacetic acid, 4',5-dichloro-",C1=CC(=CC=C1C2=CC(=CC(=C2)CC(=O)O)Cl)Cl,,,,,,
3378,53379,"3-Biphenylacetic acid, 5-fluoro-",C1=CC=C(C=C1)C2=CC(=CC(=C2)CC(=O)O)F,,,,,,
3379,53380,4'-Methoxy-alpha-methyl-3-biphenylacetic acid,CC(C1=CC=CC(=C1)C2=CC=C(C=C2)OC)C(=O)O,,,,,,
3380,53381,4'-Chloro-alpha-methyl-3-biphenylacetic acid,CC(C1=CC=CC(=C1)C2=CC=C(C=C2)Cl)C(=O)O,,,,,,
3381,53382,5-Chloro-alpha-methyl-3-biphenylacetic acid,CC(C1=CC(=CC(=C1)C2=CC=CC=C2)Cl)C(=O)O,,,,,,
3382,53383,5-Chloro-4'-methoxy-alpha-methyl-3-biphenylacetic acid,CC(C1=CC(=CC(=C1)C2=CC=C(C=C2)OC)Cl)C(=O)O,,,,,,
3383,53384,"4',5-Dichloro-alpha-methyl-3-biphenylacetic acid",CC(C1=CC(=CC(=C1)C2=CC=C(C=C2)Cl)Cl)C(=O)O,,,,,,
3384,53385,5-Fluoro-alpha-methyl-3-biphenylacetic acid,CC(C1=CC(=CC(=C1)C2=CC=CC=C2)F)C(=O)O,,,,,,
3385,53386,2-[3-(4-Chlorophenyl)-5-fluorophenyl]propanoic acid,CC(C1=CC(=CC(=C1)C2=CC=C(C=C2)Cl)F)C(=O)O,,,,,,
3386,53387,"3-Biphenylacetic acid, 4'-chloro-5-fluoro-",C1=CC(=CC=C1C2=CC(=CC(=C2)CC(=O)O)F)Cl,,,,,,
3387,53388,Rimcazole hydrochloride,C[C@@H]1CN(C[C@@H](N1)C)CCCN2C3=CC=CC=C3C4=CC=CC=C42.Cl.Cl,,,"['Drugs used to prevent SEIZURES or reduce their severity. (See all compounds classified as Anticonvulsants.)', 'Drugs intended to prevent damage to the brain or spinal cord from ischemia, stroke, convulsions, or trauma. Some must be administered before the event, but others may be effective for some time after. They act by a variety of mechanisms, but often directly or indirectly minimize the damage produced by endogenous excitatory amino acids. (See all compounds classified as Neuroprotective Agents.)', 'Agents that control agitated psychotic behavior, alleviate acute psychotic states, reduce psychotic symptoms, and exert a quieting effect. They are used in SCHIZOPHRENIA; senile dementia; transient psychosis following surgery; or MYOCARDIAL INFARCTION; etc. These drugs are often referred to as neuroleptics alluding to the tendency to produce neurological side effects, but not all antipsychotics are likely to produce such effects. Many of these drugs may also be effective against nausea, emesis, and pruritus. (See all compounds classified as Antipsychotic Agents.)']",,,
3388,53389,Rimcazole,C[C@@H]1CN(C[C@@H](N1)C)CCCN2C3=CC=CC=C3C4=CC=CC=C42,,,"['Drugs used to prevent SEIZURES or reduce their severity. (See all compounds classified as Anticonvulsants.)', 'Agents that control agitated psychotic behavior, alleviate acute psychotic states, reduce psychotic symptoms, and exert a quieting effect. They are used in SCHIZOPHRENIA; senile dementia; transient psychosis following surgery; or MYOCARDIAL INFARCTION; etc. These drugs are often referred to as neuroleptics alluding to the tendency to produce neurological side effects, but not all antipsychotics are likely to produce such effects. Many of these drugs may also be effective against nausea, emesis, and pruritus. (See all compounds classified as Antipsychotic Agents.)', 'Drugs intended to prevent damage to the brain or spinal cord from ischemia, stroke, convulsions, or trauma. Some must be administered before the event, but others may be effective for some time after. They act by a variety of mechanisms, but often directly or indirectly minimize the damage produced by endogenous excitatory amino acids. (See all compounds classified as Neuroprotective Agents.)']",,,
3389,53390,"ACETAMIDINE, N-(p-METHOXYPHENYL)-2-PHENYL-",COC1=CC=C(C=C1)N=C(CC2=CC=CC=C2)N,,,,,,
3390,53391,"Benzene, 2,4-diisothiocyanato-1-methoxy-",COC1=C(C=C(C=C1)N=C=S)N=C=S,,,,,,
3391,53392,Pentafluorobenzyl RS-trans-Permethrinate,CC1([C@H]([C@@H]1C(=O)OCC2=C(C(=C(C(=C2F)F)F)F)F)C=C(Cl)Cl)C,,,,,,
3392,53393,N-Nitrosomethylnonylamine,CCCCCCCCCN(C)N=O,,,,,,
3393,53394,Nitrosomethyl-n-decylamine,CCCCCCCCCCN(C)N=O,,,,,,
3394,53395,"N-(4,7-Dimethoxy-6-(2-(isopropylamino)ethoxy)-5-benzofuranyl)acetamide hydroiodide",CC(C)NCCOC1=C(C2=C(C=CO2)C(=C1NC(=O)C)OC)OC.I,,,,,,
3395,53396,"N-[4,7-dimethoxy-6-[2-(propan-2-ylamino)ethoxy]-1-benzofuran-5-yl]acetamide",CC(C)NCCOC1=C(C2=C(C=CO2)C(=C1NC(=O)C)OC)OC,,,,,,
3396,53397,"Acetamide, N-(4,7-dimethoxy-6-(2-(cyclohexylamino)ethoxy)-5-benzofuranyl)-, hydrochloride, hydrate",CC(=O)NC1=C(C2=C(C(=C1OCCNC3CCCCC3)OC)OC=C2)OC.O.Cl,,,,,,
3397,53398,"N-[6-[2-(cyclohexylamino)ethoxy]-4,7-dimethoxy-1-benzofuran-5-yl]acetamide",CC(=O)NC1=C(C2=C(C(=C1OCCNC3CCCCC3)OC)OC=C2)OC,,,,,,
3398,53399,"Acetamide, N-(4,7-dimethoxy-6-(2-morpholinoethoxy)-5-benzofuranyl)-, hydrochloride",CC(=O)NC1=C(C2=C(C(=C1OCCN3CCOCC3)OC)OC=C2)OC.Cl,,,,,,
3399,53400,"N-[4,7-dimethoxy-6-(2-morpholin-4-ylethoxy)-1-benzofuran-5-yl]acetamide",CC(=O)NC1=C(C2=C(C(=C1OCCN3CCOCC3)OC)OC=C2)OC,,,,,,
3400,53401,"Formamide, N-(4,7-dimethoxy-6-(2-piperidinoethoxy)-5-benzofuranyl)-, hydrochloride",COC1=C(C(=C(C2=C1C=CO2)OC)OCC[NH+]3CCCCC3)NC=O.[Cl-],,,,,,
3401,53402,"N-[4,7-dimethoxy-6-(2-piperidin-1-ylethoxy)-1-benzofuran-5-yl]formamide",COC1=C(C(=C(C2=C1C=CO2)OC)OCCN3CCCCC3)NC=O,,,,,,
3402,53403,"N-(4,7-Dimethoxy-6-(2-piperidinoethoxy)-5-benzofuranyl)trifluoroacetamide hydrochloride",COC1=C(C(=C(C2=C1C=CO2)OC)OCCN3CCCCC3)NC(=O)C(F)(F)F.Cl,,,,,,
3403,53404,"N-[4,7-dimethoxy-6-(2-piperidin-1-ylethoxy)-1-benzofuran-5-yl]-2,2,2-trifluoroacetamide",COC1=C(C(=C(C2=C1C=CO2)OC)OCCN3CCCCC3)NC(=O)C(F)(F)F,,,,,,
3404,53405,"Isobutyramide, N-(4,7-dimethoxy-6-(2-piperidinoethoxy)-5-benzofuranyl)-, hydrochloride, hydrate",CC(C)C(=O)NC1=C(C2=C(C(=C1OCC[NH+]3CCCCC3)OC)OC=C2)OC.[Cl-],,,,,,
3405,53406,"N-[4,7-dimethoxy-6-(2-piperidin-1-ylethoxy)-1-benzofuran-5-yl]-2-methylpropanamide",CC(C)C(=O)NC1=C(C2=C(C(=C1OCCN3CCCCC3)OC)OC=C2)OC,,,,,,
3406,53407,"Benzamide, N-(4,7-dimethoxy-6-(2-piperidinoethoxy)-5-benzofuranyl)-, hydrochloride",COC1=C(C(=C(C2=C1C=CO2)OC)OCC[NH+]3CCCCC3)NC(=O)C4=CC=CC=C4.[Cl-],,,,,,
3407,53408,"N-[4,7-Dimethoxy-6-(2-piperidinoethoxy)benzofuran-5-yl]benzamide",COC1=C(C(=C(C2=C1C=CO2)OC)OCCN3CCCCC3)NC(=O)C4=CC=CC=C4,,,,,,
3408,53409,"5-Benzofurancarbamic acid, 4,7-dimethoxy-6-(2-piperidinoethoxy)-, methyl ester, hydrochloride",COC1=C(C(=C(C2=C1C=CO2)OC)OCC[NH+]3CCCCC3)NC(=O)OC.[Cl-],,,,,,
3409,53410,"methyl N-[4,7-dimethoxy-6-(2-piperidin-1-ylethoxy)-1-benzofuran-5-yl]carbamate",COC1=C(C(=C(C2=C1C=CO2)OC)OCCN3CCCCC3)NC(=O)OC,,,,,,
3410,53411,"5-Benzofurancarbamic acid, 4,7-dimethoxy-6-(2-piperidinoethoxy)-, ethyl ester, hydrochloride,hydrate",CCOC(=O)NC1=C(C2=C(C(=C1OCC[NH+]3CCCCC3)OC)OC=C2)OC.[Cl-],,,,,,
3411,53412,"ethyl N-[4,7-dimethoxy-6-(2-piperidin-1-ylethoxy)-1-benzofuran-5-yl]carbamate",CCOC(=O)NC1=C(C2=C(C(=C1OCCN3CCCCC3)OC)OC=C2)OC,,,,,,
3412,53413,"5-Benzofurancarbamic acid, 4,7-dimethoxy-6-(2-piperidinoethoxy)-, isopropyl ester",CC(C)OC(=O)NC1=C(C2=C(C(=C1OCCN3CCCCC3)OC)OC=C2)OC,,,,,,
3413,53414,"5-Benzofurancarbamic acid, 4,7-dimethoxy-6-(2-piperidinoethoxy)-, cyclohexyl ester, oxalate",COC1=C(C(=C(C2=C1C=CO2)OC)OCC[NH+]3CCCCC3)NC(=O)OC4CCCCC4.C(=O)(C(=O)[O-])O,,,,,,
3414,53415,"cyclohexyl N-[4,7-dimethoxy-6-(2-piperidin-1-ylethoxy)-1-benzofuran-5-yl]carbamate",COC1=C(C(=C(C2=C1C=CO2)OC)OCCN3CCCCC3)NC(=O)OC4CCCCC4,,,,,,
3415,53416,"N-(4,7-Dimethoxy-6-(2-(methylamino)ethoxy)-5-benzofuranyl)acetamide hydroiodide",CC(=O)NC1=C(C2=C(C(=C1OCCNC)OC)OC=C2)OC.I,,,,,,
3416,53417,"N-[4,7-dimethoxy-6-[2-(methylamino)ethoxy]-1-benzofuran-5-yl]acetamide",CC(=O)NC1=C(C2=C(C(=C1OCCNC)OC)OC=C2)OC,,,,,,
3417,53418,"N-(4,7-Dimethoxy-6-(2-(ethylamino)ethoxy)-5-benzofuranyl)acetamide oxalate hydrate",CCNCCOC1=C(C2=C(C=CO2)C(=C1NC(=O)C)OC)OC.C(=O)(C(=O)O)O,,,,,,
3418,53419,"N-[6-[2-(ethylamino)ethoxy]-4,7-dimethoxy-1-benzofuran-5-yl]acetamide",CCNCCOC1=C(C2=C(C=CO2)C(=C1NC(=O)C)OC)OC,,,,,,
3419,53420,N-(4-(2-Furyl)-2-thiazolyl)acetamide,CC(=O)NC1=NC(=CS1)C2=CC=CO2,,,,,,
3420,53421,Fostedil,CCOP(=O)(CC1=CC=C(C=C1)C2=NC3=CC=CC=C3S2)OCC,,,['A class of drugs that act by selective inhibition of calcium influx through cellular membranes. (See all compounds classified as Calcium Channel Blockers.)'],,,
3421,53422,alpha-Propoxycarbonyl-dihydroartemisinine,C[C@H]1CC[C@@H]2C(C(O[C@@H]3[C@@]24[C@@H]1CC[C@](O3)(OO4)C)CCCOC(=O)O)C,,,,,,
3422,53423,"7-Bromo-2-nitronaphtho(2,1-b)furan",C1=CC2=C(C=CC3=C2C=C(O3)[N+](=O)[O-])C=C1Br,,,,,,
3423,53424,"2-Nitro-7-methoxynaphtho[2,1-b]furan",COC1=CC2=C(C=C1)C3=C(C=C2)OC(=C3)[N+](=O)[O-],,,"['Chemical agents that increase the rate of genetic mutation by interfering with the function of nucleic acids. A clastogen is a specific mutagen that causes breaks in chromosomes. (See all compounds classified as Mutagens.)', 'Substances that increase the risk of NEOPLASMS in humans or animals. Both genotoxic chemicals, which affect DNA directly, and nongenotoxic chemicals, which induce neoplasms by other mechanism, are included. (See all compounds classified as Carcinogens.)', 'Substances that inhibit or prevent the proliferation of NEOPLASMS. (See all compounds classified as Antineoplastic Agents.)']",,,
3424,53425,"2-Nitro-8-methoxynaphtho(2,1-b)furan",COC1=CC2=C(C=C1)C=CC3=C2C=C(O3)[N+](=O)[O-],,,,,,
3425,53426,"NAPHTHO(2,1-b)FURAN, 5-METHOXY-2-NITRO-",COC1=CC2=C(C=C(O2)[N+](=O)[O-])C3=CC=CC=C31,,,,,,
3426,53427,"NAPHTHO(1,2-b)FURAN, 5-CHLORO-2-NITRO-",C1=CC=C2C(=C1)C(=CC3=C2OC(=C3)[N+](=O)[O-])Cl,,,,,,
3427,53428,"NAPHTHO(1,2-b)FURAN, 5-METHOXY-2-NITRO-",COC1=CC2=C(C3=CC=CC=C31)OC(=C2)[N+](=O)[O-],,,,,,
3428,53429,"8-Methoxy-2-nitronaphtho(2,3-b)furan",COC1=CC=CC2=CC3=C(C=C21)OC(=C3)[N+](=O)[O-],,,,,,
3429,53430,"NAPHTHO(2,3-b)FURAN, 9-BROMO-2-NITRO-",C1=CC=C2C(=C1)C=C3C=C(OC3=C2Br)[N+](=O)[O-],,,,,,
3430,53431,"2,2-Dimethyl-3-hydroxy-1-phenyl-4,4,4-trichloro-1-butanone",CC(C)(C(C(Cl)(Cl)Cl)O)C(=O)C1=CC=CC=C1,,,,,,
3431,53432,Dazepinil,CC1=NC2=CC=CC=C2CC(N1C)C3=CC=CC=C3,,,,,,
3432,53433,"Acetohydroxamic acid, 2-(3-phenylpropionamido)-",C1=CC=C(C=C1)CCC(=O)NCC(=O)NO,,,,,,
3433,53434,"(+)-(1S,2R,3R,4S)-3,4-Dihydroxy-1,2-epoxy-1,2,3,4-tetrahydrobenzo(c)phenanthrene",C1=CC=C2C(=C1)C3=CC=CC=C3C4=C2[C@@H]([C@H]([C@@H]5[C@H]4O5)O)O,,,,,,
3434,53435,"[(7R,8S)-7-methoxy-12-methyl-11-(2-methylpropoxy)-10,13-dioxo-2,5-diazatetracyclo[7.4.0.02,7.04,6]trideca-1(9),11-dien-8-yl]methyl carbamate",CC1=C(C(=O)C2=C(C1=O)N3CC4C([C@@]3([C@@H]2COC(=O)N)OC)N4)OCC(C)C,,,,,,
3435,53436,"[8a-Methoxy-5-methyl-6-(3-methylbutoxy)-4,7-dioxo-1,1a,2,4,7,8,8a,8b-octahydroazireno[2',3':3,4]pyrrolo[1,2-a]indol-8-yl]methyl hydrogen carbonimidate",CC1=C(C(=O)C2=C(C1=O)N3CC4C([C@@]3([C@@H]2COC(=O)N)OC)N4)OCCC(C)C,,,,,,
3436,53437,"[(7R,8S)-7-methoxy-12-methyl-11-octoxy-10,13-dioxo-2,5-diazatetracyclo[7.4.0.02,7.04,6]trideca-1(9),11-dien-8-yl]methyl carbamate",CCCCCCCCOC1=C(C(=O)C2=C(C1=O)[C@H]([C@@]3(N2CC4C3N4)OC)COC(=O)N)C,,,,,,
3437,53438,7-Decyloxy-7-demethoxymitomycin A,CCCCCCCCCCOC1=C(C(=O)C2=C(C1=O)C(C3(N2CC4C3N4)OC)COC(=O)N)C,,,,,,
3438,53439,2-(1-Methyl-2-pyrrolidinyl)-1-phenylethanone,CN1CCCC1CC(=O)C2=CC=CC=C2,,,,,,
3439,53440,2-(1-Methyl-2-pyrrolidinyl)-1-(2-thienyl)ethanone,CN1CCCC1CC(=O)C2=CC=CS2,,,,,,
3440,53441,"5-[(2-Chlorophenyl)methylidene]-3-phenylimidazolidine-2,4-dione",C1=CC=C(C=C1)N2C(=O)C(=CC3=CC=CC=C3Cl)NC2=O,,,,,,
3441,53442,CID 53442,C1=CC=C(C=C1)N2C(=O)C(=CC3=CC=CC=C3Cl)N=C2[SeH],,,,,,
3442,53443,CID 53443,CC1=CC=C(C=C1)N2C(=O)C(=CC3=CC=CC=C3Cl)NC2=O,,,,,,
3443,53444,CID 53444,CC1=CC=C(C=C1)N2C(=O)C(=CC3=CC=CC=C3Cl)N=C2[SeH],,,,,,
3444,53445,"5-[(3-Chlorophenyl)methylidene]-3-phenylimidazolidine-2,4-dione",C1=CC=C(C=C1)N2C(=O)C(=CC3=CC(=CC=C3)Cl)NC2=O,,,,,,
3445,53446,CID 53446,C1=CC=C(C=C1)N2C(=O)C(=CC3=CC(=CC=C3)Cl)N=C2[SeH],,,,,,
3446,53447,CID 53447,CC1=CC=C(C=C1)N2C(=O)C(=CC3=CC(=CC=C3)Cl)NC2=O,,,,,,
3447,53448,CID 53448,CC1=CC=C(C=C1)N2C(=O)C(=CC3=CC(=CC=C3)Cl)N=C2[SeH],,,,,,
3448,53449,"5-[(4-Chlorophenyl)methylidene]-3-phenylimidazolidine-2,4-dione",C1=CC=C(C=C1)N2C(=O)C(=CC3=CC=C(C=C3)Cl)NC2=O,,,,,,
3449,53450,CID 53450,C1=CC=C(C=C1)N2C(=O)C(=CC3=CC=C(C=C3)Cl)N=C2[SeH],,,,,,
3450,53451,CID 53451,CC1=CC=C(C=C1)N2C(=O)C(=CC3=CC=C(C=C3)Cl)NC2=O,,,,,,
3451,53452,CID 53452,CC1=CC=C(C=C1)N2C(=O)C(=CC3=CC=C(C=C3)Cl)N=C2[SeH],,,,,,
3452,53453,"COLCHICINE, N-DEACETYL-N-(p-NITROBENZOYL)-",COC1=CC=C2C(=CC1=O)[C@H](CCC3=CC(=C(C(=C32)OC)OC)OC)NC(=O)C4=CC=C(C=C4)[N+](=O)[O-],,,,,,
3453,53454,"2-(4-Methoxyphenyl)-4-(propan-2-YL)-1H-naphtho[1,2-D]imidazole",CC(C)C1=CC2=CC=CC=C2C3=C1N=C(N3)C4=CC=C(C=C4)OC,,,,,,
3454,53455,1-Diketobutyryl-1-phenyl-2-methyl-2-nitrosohydrazide,CC(=O)C(=O)C(=O)N(C1=CC=CC=C1)N(C)N=O.O,,,,,,
3455,53456,"N-[N-(2,3-dioxobutanoyl)anilino]-N-methylnitrous amide",CC(=O)C(=O)C(=O)N(C1=CC=CC=C1)N(C)N=O,,,,,,
3456,53457,"Benzo(a)heptalen-9(5H)-one, 7-(alpha-L-arabinosylamino)-6,7-dihydro-1,2,3-trimethoxy-10-(methylthio)-, (S)-",COC1=C(C(=C2C(=C1)CCC(C3=CC(=O)C(=CC=C32)SC)NC4C(C(C(CO4)O)O)O)OC)OC,,,,,,
3457,53458,"1,3-Benzodioxole, 5-(4-((2-pyrimidinyl)amino)piperidinomethyl)-",C1CN(CCC1NC2=NC=CC=N2)CC3=CC4=C(C=C3)OCO4,,,,,,
3458,53459,"1,3-Benzodioxole, 5-(4-(N-(2-pyrimidinyl)methylamino)piperidinomethyl)-",CN(C1CCN(CC1)CC2=CC3=C(C=C2)OCO3)C4=NC=CC=N4,,,,,,
3459,53460,"5-((N-(2-(2-Pyrimidinyl)-4-piperidyl)methylamino)methyl)-1,3-benzodioxole",CN(CC1=CC2=C(C=C1)OCO2)C3CCNC(C3)C4=NC=CC=N4,,,,,,
3460,53461,1-(2-(1H-Tetrazol-5-yl)ethyl)-2-naphthalenol,C1=CC=C2C(=C1)C=CC(=C2CCC3=NNN=N3)O,,,,,,
3461,53462,"3-methyl-3H-imidazo[4,5-f]quinolin-2-amine",CN1C2=C(C3=C(C=C2)N=CC=C3)N=C1N,,,,"[""The fate of intravenously injected (14)C-IQ was studied in male NMRI, pregnant NMRI and female C3H mice. Whole-body autoradiograms were characterized by an accumulation of radiolabel in metabolic and excretory organs (liver, kidney, bile, urine, gastric and intestinal contents, salivary glands, nasal mucosa and Harder's gland) and in lymphomyeloid tissues (bone marrow, thymus, spleen and lymph nodes) and endocrine and reproductive tissues (adrenal medulla, pancreatic islets, thyroid, hypophysis, testis, epididymis, seminal vesicles, ampulla and prostate). The liver and kidney cortex were identified as sites of retention of nonextractable radiolabel. IQ crosses the placenta, but no radiolabel was retained in fetal tissues.""]","['The metabolism of 2-amino-3-methylimidazo[4,5-f]quinoline (IQ) was studied in the male rat  using ... 14C and 3H at positions 2 and 5 of the molecule, respectively.  Adult male Fischer 344 rats were administered [2-14C]IQ or [5-3H]IQ by oral gavage at ... 20 or 40 mg/kg bw. Rats were also given [2-14C]IQ in the diet at ... 300 ppm for 2 days and after administration of unlabelled IQ (300 ppm) in the diet  for approximately 6.5 wk for an additional 2 days. In the initial 48 hr following oral  administration of 20 or 40 mg [2-14C]IQ/kg body weight, about 40-50% radioactivity was  recovered in the urine, and about 30-38% radioactivity was recovered in the feces. In the  initial 72 hr following consumption of [2-14C]IQ (300 ppm) in the diet about 26% /of the/ radioactivity  was recovered in the urine and about 61% /of the/ radioactivity was recovered in the feces. Following  cannulation of the bile ducts, rats administered a single dose of [2-14C]IQ (40 mg/kg bw) by oral gavage excreted about 15% of the administered dose in the bile over a period  of 2 days. Urine from rats given [2-14C]IQ contained three main polar metabolites that  included a glucuronide, a sulfate ester and IQ sulfamate, and a number of less polar  metabolites that included IQ, 2-acetylamino-3-methylimidazo[4,5-f]quinoline,  2-aminoimidazo[4,5-f]quinoline and  2-amino-3,6-dihydro-3-methyl-7H-imidazo[4,5-f]quinoline-7-one (7-OH-IQ). Administration of  [2-14C]IQ by oral gavage or in the diet gave the same metabolites, but in different amounts.  In the feces of rats given [2-14C] by oral gavage, IQ-sulfamate was the major metabolite in  the polar fraction. Non-polar metabolites similar to those found in the urine were also  present, but in different amounts. A major, non-polar fecal metabolite, 7-OH-IQ was probably  formed as a result of the activity of the intestinal bacterial flora. In rats given a single  gavage dose of [2-14C]IQ, excretion of metabolites was higher in the urine and lower in the  feces compared with that in animals fed [2-14C]IQ in the diet. One polar metabolite present  in the urine, IQ-sulfamate (39%), was found at considerably higher levels in rats dosed  orally with IQ compared with those fed IQ (less than 6%). Thus, IQ is extensively metabolized  to give a number of polar and non-polar metabolites, the amounts of which depend, in part, on  the mode of dosing.', 'Mixed and pure cultures of human intestinal anaerobic bacteria metabolized IQ to IQ-7-one.', 'Constituents of feed may play a role in the metabolism of IQ. Dietary fibers can bind IQ in vitro, and a high-fat diet increased the capacity of rat liver microsomes to activate IQ.', 'N-Hydroxy-IQ can be esterified by O-acetyltransferase, sulfotransferase and prolyl-tRNA synthetase but at much lower rates than aromatic amines. N-Acetylation of IQ may not be important for DNA binding. Human liver microsomes could activate IQ into a DNA-reactive species. The isozyme involved was tentatively identified as CYP IA2 (p450 IA2). The same enzyme was shown to be responsible for the formation of N-hydroxy-IQ in human hepatic cytosols. Human liver and colon cytosols catalysed the formation of N-hydroxylated IQ into a DNA-binding form, but N-acetylation was not observed under the same conditions. DNA-binding products were also found in human mammary epithelial cells cultured in the presence of IQ. In human fetal liver tissue, cytochrome p450 HFLa was the main activating enzyme of IQ.', '2-Amino-3-methylimidazo(4,5-F)quinoline has known human metabolites that include N-Hydroxy-2-amino-3-methylimidazo[4,5-f]quinoline (N-Hydroxy-IQ).']",
3462,53463,1-Naphthyl-N-ethyl-N-nitrosocarbamate,CCN(C(=O)OC1=CC=CC2=CC=CC=C21)N=O,,,,,,
3463,53464,1-Naphthyl-N-propyl-N-nitrosocarbamate,CCCN(C(=O)OC1=CC=CC2=CC=CC=C21)N=O,,,,,,
3464,53465,1-Naphthyl-N-butyl-N-nitrosocarbamate,CCCCN(C(=O)OC1=CC=CC2=CC=CC=C21)N=O,,,,,,
3465,53466,"BENZALDEHYDE, o-(5-(m-METHOXYPHENYL)-s-TRIAZOL-3-YL)-",COC1=CC=CC(=C1)C2=NN(C=N2)C3=CC=CC=C3C=O,,,,,,
3466,53467,Fluzinamide,CNC(=O)N1CC(C1)OC2=CC=CC(=C2)C(F)(F)F,,,,,,
3467,53468,"Benzoic acid, 3-propionamido-2,4,6-triiodo-",CCC(=O)NC1=C(C=C(C(=C1I)C(=O)O)I)I,,,,,,
3468,53469,Tecloftalam,C1=CC(=C(C(=C1)Cl)Cl)NC(=O)C2=C(C(=C(C(=C2Cl)Cl)Cl)Cl)C(=O)O,,,,,,
3469,53470,N-Hydroxy-4'-fluoro-4-acetylaminobiphenyl,CC(=O)N(C1=CC=C(C=C1)C2=CC=C(C=C2)F)O,,,,,,
3470,53471,"5-Bromo-3-hydroxy-3-(2-oxopropyl)-1,3-dihydro-2H-indol-2-one",CC(=O)CC1(C2=C(C=CC(=C2)Br)NC1=O)O,,,,,,
3471,53472,"Isoquinolinium, 2-amino-, perchlorate",C1=CC=C2C=[N+](C=CC2=C1)N.[O-]Cl(=O)(=O)=O,,,,,,
3472,53473,2-Aminoisoquinolinium,C1=CC=C2C=[N+](C=CC2=C1)N,,,,,,
3473,53474,2-((4-Chlorobenzoyl)amino)-isoquinolinium chloride,C1=CC=C2C=[N+](C=CC2=C1)NC(=O)C3=CC=C(C=C3)Cl.[Cl-],,,,,,
3474,53475,4-chloro-N-isoquinolin-2-ium-2-ylbenzamide,C1=CC=C2C=[N+](C=CC2=C1)NC(=O)C3=CC=C(C=C3)Cl,,,,,,
3475,53476,"Benzaldehyde, 2,6-dichloro-4-hydroxy-3,5-dimethoxy-",COC1=C(C(=C(C(=C1Cl)C=O)Cl)OC)O,,,,,,
3476,53477,2-(2-Aminoacetamido)-2'-(o-chlorobenzoyl)-4'-nitroacetanilide hydrobromide,C1=CC=C(C(=C1)C(=O)C2=C(C=C(C=C2)[N+](=O)[O-])Cl)NC(=O)CNC(=O)C[NH3+].[Br-],,,,,,
3477,53478,2-amino-N-[2-[2-(2-chloro-4-nitrobenzoyl)anilino]-2-oxoethyl]acetamide,C1=CC=C(C(=C1)C(=O)C2=C(C=C(C=C2)[N+](=O)[O-])Cl)NC(=O)CNC(=O)CN,,,,,,
3478,53479,2-Chlorosyringaldehyde,COC1=C(C(=C(C(=C1)C=O)Cl)OC)O,,,,,,
3479,53480,4-Bromocinnamonitrile,C1=CC(=CC=C1C=CC#N)Br,,,,,,
3480,53481,"1,2-Dimethyl-5-(oxiranylmethoxy)-1H-indole-3-carboxylic acid ethyl ester",CCOC(=O)C1=C(N(C2=C1C=C(C=C2)OCC3CO3)C)C,,,,,,
3481,53482,2-Methyl-5-(oxiranylmethoxy)-1-phenyl-1H-indole-3-carboxylic acid ethyl ester,CCOC(=O)C1=C(N(C2=C1C=C(C=C2)OCC3CO3)C4=CC=CC=C4)C,,,,,,
3482,53483,"1H-Indole-3-carboxylic acid, 1,2-dimethyl-5-(2-hydroxy-3-(isopropylamino)propoxy)-, ethyl ester, monohydrochloride",CCOC(=O)C1=C(N(C2=C1C=C(C=C2)OCC(C[NH2+]C(C)C)O)C)C.[Cl-],,,,,,
3483,53484,"Ethyl 5-[2-hydroxy-3-(propan-2-ylamino)propoxy]-1,2-dimethylindole-3-carboxylate",CCOC(=O)C1=C(N(C2=C1C=C(C=C2)OCC(CNC(C)C)O)C)C,,,,,,
3484,53485,"1H-Indole-3-carboxylic acid, 1,2-dimethyl-5-(2-hydroxy-3-(benzylamino)propoxy)-, ethyl ester, monohydrochloride",CCOC(=O)C1=C(N(C2=C1C=C(C=C2)OCC(C[NH2+]CC3=CC=CC=C3)O)C)C.[Cl-],,,,,,
3485,53486,"Ethyl 5-[3-(benzylamino)-2-hydroxypropoxy]-1,2-dimethyl-1h-indole-3-carboxylate",CCOC(=O)C1=C(N(C2=C1C=C(C=C2)OCC(CNCC3=CC=CC=C3)O)C)C,,,,,,
3486,53487,"1H-Indole-3-carboxylic acid, 5-(2-hydroxy-3-(benzylamino)propoxy)-2-methyl-1-phenyl-, ethyl ester, monohydrochloride",CCOC(=O)C1=C(N(C2=C1C=C(C=C2)OCC(C[NH2+]CC3=CC=CC=C3)O)C4=CC=CC=C4)C.[Cl-],,,,,,
3487,53488,Ethyl 5-[3-(benzylamino)-2-hydroxypropoxy]-2-methyl-1-phenylindole-3-carboxylate,CCOC(=O)C1=C(N(C2=C1C=C(C=C2)OCC(CNCC3=CC=CC=C3)O)C4=CC=CC=C4)C,,,,,,
3488,53489,"1H-Indole-3-carboxylic acid, 5-(2-hydroxy-3-(isopropylamino)propoxy)-2-methyl-1-phenyl-, ethyl ester, monohydrochloride",CCOC(=O)C1=C(N(C2=C1C=C(C=C2)OCC(C[NH2+]C(C)C)O)C3=CC=CC=C3)C.[Cl-],,,,,,
3489,53490,Ethyl 5-[2-hydroxy-3-(propan-2-ylamino)propoxy]-2-methyl-1-phenylindole-3-carboxylate,CCOC(=O)C1=C(N(C2=C1C=C(C=C2)OCC(CNC(C)C)O)C3=CC=CC=C3)C,,,,,,
3490,53491,"Naphtho(1,2-b)furan-3-carboxylic acid, 6-(2-hydroxy-3-(isopropylamino)propoxy)-2-methyl-, ethyl ester, monohydrochloride",CCOC(=O)C1=C(OC2=C1C=CC3=C2C=CC=C3OCC(C[NH2+]C(C)C)O)C.[Cl-],,,,,,
3491,53492,Ethyl 6-[2-hydroxy-3-(propan-2-ylamino)propoxy]-2-methylbenzo[g][1]benzofuran-3-carboxylate,CCOC(=O)C1=C(OC2=C1C=CC3=C2C=CC=C3OCC(CNC(C)C)O)C,,,,,,
3492,53493,"Naphtho(1,2-b)furan-3-carboxylic acid, 6-(2-hydroxy-3-(benzylamino)propoxy)-2-methyl-, ethyl ester, monohydrochloride",CCOC(=O)C1=C(OC2=C1C=CC3=C2C=CC=C3OCC(C[NH2+]CC4=CC=CC=C4)O)C.[Cl-],,,,,,
3493,53494,Ethyl 6-[3-(benzylamino)-2-hydroxypropoxy]-2-methylbenzo[g][1]benzofuran-3-carboxylate,CCOC(=O)C1=C(OC2=C1C=CC3=C2C=CC=C3OCC(CNCC4=CC=CC=C4)O)C,,,,,,
3494,53495,"1,5,6,7-Tetrahydro-2-(p-methoxyphenyl)-1-phenyl-4H-indol-4-one",COC1=CC=C(C=C1)C2=CC3=C(N2C4=CC=CC=C4)CCCC3=O,,,,,,
3495,53496,"4H-INDOL-4-ONE, 1,5,6,7-TETRAHYDRO-1-ISOPROPYL-2-(p-METHOXYPHENYL)-",CC(C)N1C2=C(C=C1C3=CC=C(C=C3)OC)C(=O)CCC2,,,,,,
3496,53497,"1,2-Diphenyl-4-(oxiranylmethoxy)-1H-indole",C1C(O1)COC2=CC=CC3=C2C=C(N3C4=CC=CC=C4)C5=CC=CC=C5,,,,,,
3497,53498,2-(p-Methoxyphenyl)-4-(oxiranylmethoxy)-1-phenyl-1H-indole,COC1=CC=C(C=C1)C2=CC3=C(N2C4=CC=CC=C4)C=CC=C3OCC5CO5,,,,,,
3498,53499,"1H-Indole-2-carboxylic acid, 1,3-dimethyl-4-(3-((2-(3,4-dimethoxyphenyl)ethyl)amino)-2-hydroxypropoxy)-, ethyl ester, monohydrochloride",CCOC(=O)C1=C(C2=C(N1C)C=CC=C2OCC(C[NH2+]CCC3=CC(=C(C=C3)OC)OC)O)C.[Cl-],,,,,,
3499,53500,"Ethyl 4-[3-[2-(3,4-dimethoxyphenyl)ethylamino]-2-hydroxypropoxy]-1,3-dimethylindole-2-carboxylate",CCOC(=O)C1=C(C2=C(N1C)C=CC=C2OCC(CNCCC3=CC(=C(C=C3)OC)OC)O)C,,,,,,
3500,53501,"3-Benzofurancarboxylic acid, 5-(2-hydroxy-3-(isopropylamino)propoxy)-2-phenyl-, ethyl ester, hydrochloride",CCOC(=O)C1=C(OC2=C1C=C(C=C2)OCC(C[NH2+]C(C)C)O)C3=CC=CC=C3.[Cl-],,,,,,
3501,53502,Ethyl 5-[2-hydroxy-3-(propan-2-ylamino)propoxy]-2-phenyl-1-benzofuran-3-carboxylate,CCOC(=O)C1=C(OC2=C1C=C(C=C2)OCC(CNC(C)C)O)C3=CC=CC=C3,,,,,,
3502,53503,4-Borono-DL-phenylalanine,B(C1=CC=C(C=C1)CC(C(=O)O)N)(O)O,,,['Drugs used to potentiate the effectiveness of radiation therapy in destroying unwanted cells. (See all compounds classified as Radiation-Sensitizing Agents.)'],,,
3503,53504,Enalaprilat hydrate,C[C@H](C(=O)N1CCC[C@@H]1C(=O)O)N[C@H](CCC2=CC=CC=C2)C(=O)O,,,,,,
3504,53505,Veradoline,CC1C2=CC(=C(C=C2CCN1CCC3=CC=C(C=C3)N)OC)OC,,,,,,
3505,53506,"7-Chloro-2-(dimethylamino)-5-phenyl-3H-1,4-benzodiazepin-3-ol",CN(C)C1=NC2=C(C=C(C=C2)Cl)C(=NC1O)C3=CC=CC=C3,,,,,,
3506,53507,1-((Bis(2-methylpropyl)amino)methyl)-3-(5-nitro-2-thiazolyl)-2-imidazolidinone,CC(C)CN(CC(C)C)CN1CCN(C1=O)C2=NC=C(S2)[N+](=O)[O-],,,,,,
3507,53508,"(5-Benzylfuran-3-yl)methyl 3-but-1-enyl-2,2-dimethylcyclopropane-1-carboxylate",CCC=CC1C(C1(C)C)C(=O)OCC2=COC(=C2)CC3=CC=CC=C3,,,,,,
3508,53509,CID 53509,CC=CC1C(C1(C)C)C(=O)OCC2=COC(=C2)CC3=CC=CC=C3,,,,,,
3509,53510,"Benzeneacetic acid, 4-bromo-alpha-(1-methylethyl)-, cyano(3-phenoxyphenyl)methyl ester",CC(C)C(C1=CC=C(C=C1)Br)C(=O)OC(C#N)C2=CC(=CC=C2)OC3=CC=CC=C3,,,,,,
3510,53511,Levoprotiline,CNC[C@@H](CC12CCC(C3=CC=CC=C31)C4=CC=CC=C24)O,,,"['Mood-stimulating drugs used primarily in the treatment of affective disorders and related conditions. Several MONOAMINE OXIDASE INHIBITORS are useful as antidepressants apparently as a long-term consequence of their modulation of catecholamine levels. The tricyclic compounds useful as antidepressive agents (ANTIDEPRESSIVE AGENTS, TRICYCLIC) also appear to act through brain catecholamine systems. A third group (ANTIDEPRESSIVE AGENTS, SECOND-GENERATION) is a diverse group of drugs including some that act specifically on serotonergic systems. (See all compounds classified as Antidepressive Agents.)']",,,
3511,53512,"[(2S)-3,3-dimethyl-4,4,7-trioxo-4lambda6-thia-1-azabicyclo[3.2.0]heptane-2-carbonyl]oxymethyl (2S)-6-[[(2S)-2-amino-2-phenylacetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate",CC1([C@@H](N2C(S1)C(C2=O)NC(=O)[C@H](C3=CC=CC=C3)N)C(=O)OCOC(=O)[C@H]4C(S(=O)(=O)C5N4C(=O)C5)(C)C)C,,,,,,
3512,53513,CID 53513,C1=CC(=CC=C1C(C(CO)NC(=O)C(=O)NC2=CC=C(C=C2)O)O)[N+](=O)[O-],,,,,,
3513,53514,CID 53514,C1=CC(=CC=C1N=O)OC2=C(C=C(C=C2)N(O)O)[N+](=O)[O-],,,,,,
3514,53515,"Benzenamine, 4-(3-chlorophenoxy)-N-hydroxy-",C1=CC(=CC(=C1)Cl)OC2=CC=C(C=C2)NO,,,,,,
3515,53516,7-Fluoro-3-methoxysulfanyl-1-methylquinolin-4-one,CN1C=C(C(=O)C2=C1C=C(C=C2)F)SOC,,,,,,
3516,53517,"2-Butyl-4,5-dimethylthiazole",CCCCC1=NC(=C(S1)C)C,,,,,,
3517,53518,Quizalofop-ethyl,CCOC(=O)C(C)OC1=CC=C(C=C1)OC2=CN=C3C=C(C=CC3=N2)Cl,,,"['Pesticides used to destroy unwanted vegetation, especially various types of weeds, grasses (POACEAE), and woody plants. Some plants develop HERBICIDE RESISTANCE. (See all compounds classified as Herbicides.)']","['In mammals, following oral admin, the parent is rapidly metabolized; >90% of the dose is eliminated in the urine within 3 days.', 'Selective systemic herbicide, absorbed by the leaves, with translocation throughout the plant, moving in both the xylem & phloem. & accumulation in the meristematic tissue.']",,
3518,53519,CID 53519,CCCC(CCC)C(=O)O.CCCC(CCC)C(=O)[O-].[Na+],,,,,,
3519,53520,Ethylmethylquinoline,CCC1=CC(=NC2=CC=CC=C21)C,,,,,,
3520,53521,5-(m-Bromobenzyl)-3-methylhydantoin,CN1C(=O)C(NC1=O)CC2=CC(=CC=C2)Br,,,,,,
3521,53522,"(6R,7S)-7-[[(2S,3R)-2-[(4-ethyl-2,3-dioxopiperazine-1-carbonyl)amino]-3-hydroxybutanoyl]amino]-7-methoxy-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid",CCN1CCN(C(=O)C1=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@]2([C@@H]3N(C2=O)C(=C(CS3)CSC4=NN=NN4C)C(=O)O)OC,,,,,,
3522,53523,"3-Imidazolidineacetic acid, 2,4-dioxo-5-(m-(trifluoromethyl)benzyl)-, ethyl ester",CCOC(=O)CN1C(=O)C(NC1=O)CC2=CC(=CC=C2)C(F)(F)F,,,,,,
3523,53524,"1,3,8-Trichlorodibenzofuran",C1=CC2=C(C=C1Cl)C3=C(O2)C=C(C=C3Cl)Cl,,,,,,
3524,53525,"O-(2-Diethylaminoethyl)-2',6'-mandeloxylidide",CCN(CC)CCOC(C1=CC=CC=C1)C(=O)NC2=C(C=CC=C2C)C,,,,,,
3525,53526,CID 53526,CC(=CC(=O)C1=CC=C(C=C1)F)N2CCN(CC2)C3=CC=CC=C3,,,,,,
3526,53527,"3-[(3S,5R,10S,11R,13R,14S,17R)-11,14-dihydroxy-3-[(2S,5R)-5-hydroxy-4-methoxy-6-methyloxan-2-yl]oxy-10,13-dimethyl-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthren-17-yl]-2H-furan-5-one",CC1[C@H](C(C[C@H](O1)O[C@H]2CC[C@]3([C@@H](C2)CCC4C3[C@@H](C[C@]5([C@@]4(CC[C@@H]5C6=CC(=O)OC6)O)C)O)C)OC)O,,,,,,
3527,53528,2'-(o-((2-(Diethylamino)ethyl)amino)phenyl)-2-(p-nitrophenyl)acetanilide,CCN(CC)CCNC1=CC=CC=C1C2=CC=CC=C2NC(=O)CC3=CC=C(C=C3)[N+](=O)[O-],,,,,,
3528,53529,6-(p-Chlorobenzoyl)-2-oxo-3-benzoxazolineacetic acid,C1=CC(=CC=C1C(=O)C2=CC3=C(C=C2)N(C(=O)O3)CC(=O)O)Cl,,,,,,
3529,53530,"3-BENZOXAZOLINEACETIC ACID, 6-(o-CHLOROBENZOYL)-2-OXO-",C1=CC=C(C(=C1)C(=O)C2=CC3=C(C=C2)N(C(=O)O3)CC(=O)O)Cl,,,,,,
3530,53531,6-Benzoyl-2-oxo-3-benzoxazolinepropionic acid,C1=CC=C(C=C1)C(=O)C2=CC3=C(C=C2)N(C(=O)O3)CCC(=O)O,,,,,,
3531,53532,6-(p-Chlorobenzoyl)-2-oxo-3-benzoxazolinepropionic acid,C1=CC(=CC=C1C(=O)C2=CC3=C(C=C2)N(C(=O)O3)CCC(=O)O)Cl,,,,,,
3532,53533,6-(p-Methoxybenzoyl)-2-oxo-3-benzoxazolinepropionic acid,COC1=CC=C(C=C1)C(=O)C2=CC3=C(C=C2)N(C(=O)O3)CCC(=O)O,,,,,,
3533,53534,"3-BENZOXAZOLINEPROPIONIC ACID, 6-(o-CHLOROBENZOYL)-2-OXO-",C1=CC=C(C(=C1)C(=O)C2=CC3=C(C=C2)N(C(=O)O3)CCC(=O)O)Cl,,,,,,
3534,53535,"3-Benzoxazolinepropionic acid, 2-oxo-6-(2-thenoyl)-",C1=CSC(=C1)C(=O)C2=CC3=C(C=C2)N(C(=O)O3)CCC(=O)O,,,,,,
3535,53536,6-Benzoyl-alpha-methyl-2-oxo-3-benzoxazolineacetic acid,CC(C(=O)O)N1C2=C(C=C(C=C2)C(=O)C3=CC=CC=C3)OC1=O,,,,,,
3536,53537,6-(p-Chlorobenzoyl)-alpha-methyl-2-oxo-3-benzoxazolineacetic acid,CC(C(=O)O)N1C2=C(C=C(C=C2)C(=O)C3=CC=C(C=C3)Cl)OC1=O,,,,,,
3537,53538,6-(p-Methoxybenzoyl)-alpha-methyl-2-oxo-3-benzoxazolineacetic acid,CC(C(=O)O)N1C2=C(C=C(C=C2)C(=O)C3=CC=C(C=C3)OC)OC1=O,,,,,,
3538,53539,6-(o-Chlorobenzoyl)-alpha-methyl-2-oxo-3-benzoxazolineacetic acid,CC(C(=O)O)N1C2=C(C=C(C=C2)C(=O)C3=CC=CC=C3Cl)OC1=O,,,,,,
3539,53540,alpha-Methyl-2-oxo-6-(2-thenoyl)-3-benzoxazolineacetic acid,CC(C(=O)O)N1C2=C(C=C(C=C2)C(=O)C3=CC=CS3)OC1=O,,,,,,
3540,53541,"2-[nitroso-[4-[(3R,7R,12S)-3,7,12-trihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoyl]amino]acetic acid",CC(CCC(=O)N(CC(=O)O)N=O)C1CCC2C1([C@H](CC3C2[C@@H](CC4C3(CC[C@H](C4)O)C)O)O)C,,,,,,
3541,53542,"2-Naphthalenecarboxamide, N-hydroxy-N-methyl-",CN(C(=O)C1=CC2=CC=CC=C2C=C1)O,,,,,,
3542,53543,CID 53543,C1=CC=C(C=C1)N(CCC(=O)[O-])C(=O)C2=C(C(=C(C=C2I)I)N)I.[Na+],,,,,,
3543,53544,CID 53544,CC1=NC(=CC2=CC=C(C=C2)OC)C(=O)N1C3=NN=C(S3)C,,,,,,
3544,53545,CID 53545,CC1=NC(=CC2=CC=CC=C2O)C(=O)N1C3=NN=C(S3)C,,,,,,
3545,53546,CID 53546,CC1=NC(=CC2=CC(=C(C=C2)O)OC)C(=O)N1C3=NN=C(S3)C,,,,,,
3546,53547,CID 53547,CCC1=NN=C(S1)N2C(=NC(=CC3=CC=CC=C3)C2=O)C,,,,,,
3547,53548,CID 53548,CCC1=NN=C(S1)N2C(=NC(=CC3=CC=C(C=C3)OC)C2=O)C,,,,,,
3548,53549,CID 53549,CCC1=NN=C(S1)N2C(=NC(=CC3=CC(=C(C=C3)O)OC)C2=O)C,,,,,,
3549,53550,CID 53550,CCCC1=NN=C(S1)N2C(=NC(=CC3=CC=C(C=C3)Cl)C2=O)C,,,,,,
3550,53551,CID 53551,CCCC1=NN=C(S1)N2C(=NC(=CC3=CC=C(C=C3)OC)C2=O)C,,,,,,
3551,53552,CID 53552,CCCC1=NN=C(S1)N2C(=NC(=CC3=CC=CC=C3O)C2=O)C,,,,,,
3552,53553,CID 53553,C1CCC(CC1)N(C2CCCCC2)C(=O)C3=CC=C(C=C3)NC(=NC4=CC=CC5=CC=CC=C54)S,,,,,,
3553,53554,Iosulamide sodium,CCN(C1=C(C(=C(C(=C1I)NC(=O)CCS(=O)(=O)CCC(=O)NC2=C(C(=C(C(=C2I)C(=O)[O-])I)N(CC)C(=O)C)I)I)C(=O)[O-])I)C(=O)C.[Na+].[Na+],,,,,,
3554,53555,Dazmegrel,CC1=C(C2=CC=CC=C2N1CCC(=O)O)CN3C=CN=C3,,,"['Drugs used to cause dilation of the blood vessels. (See all compounds classified as Vasodilator Agents.)', 'Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. (See all compounds classified as Enzyme Inhibitors.)', 'Drugs or agents which antagonize or impair any mechanism leading to blood platelet aggregation, whether during the phases of activation and shape change or following the dense-granule release reaction and stimulation of the prostaglandin-thromboxane system. (See all compounds classified as Platelet Aggregation Inhibitors.)']",,,
3555,53556,"Diphenyltris(2,2,2-trifluoroethoxy)phosphorane",C1=CC=C(C=C1)P(C2=CC=CC=C2)(OCC(F)(F)F)(OCC(F)(F)F)OCC(F)(F)F,,,,,,
3556,53557,2-(2-(p-Methoxyphenyl)acetamido)acetohydroxamic acid,COC1=CC=C(C=C1)CC(=O)NCC(=O)NO,,,,,,
3557,53558,N-(2-Chloronicotinoyl)glycine,C1=CC(=C(N=C1)Cl)C(=O)NCC(=O)O,,,,,,
3558,53559,"beta-ALANINE, N-(2-CHLORONICOTINOYL)-",C1=CC(=C(N=C1)Cl)C(=O)NCCC(=O)O,,,,,,
3559,53560,"Alanine, N-(2-chloronicotinoyl)-3-phenyl-",C1=CC=C(C=C1)CC(C(=O)O)NC(=O)C2=C(N=CC=C2)Cl,,,,,,
3560,53561,N-(2-Benzyloxynicotinoyl)glycine,C1=CC=C(C=C1)COC2=C(C=CC=N2)C(=O)NCC(=O)O,,,,,,
3561,53562,N-(2-Hydroxynicotinoyl)glycine,C1=CNC(=O)C(=C1)C(=O)NCC(=O)O,,,,,,
3562,53563,"ACETIC ACID, (m-BENZOYLPHENOXY)-",C1=CC=C(C=C1)C(=O)C2=CC(=CC=C2)OCC(=O)O,,,,,,
3563,53564,2-(3-(p-Methylbenzoyl)-o-tolyloxy)acetic acid,CC1=CC=C(C=C1)C(=O)C2=C(C(=CC=C2)OCC(=O)O)C,,,,,,
3564,53565,2-(3-(p-Chlorobenzoyl)-o-tolyloxy)acetic acid,CC1=C(C=CC=C1OCC(=O)O)C(=O)C2=CC=C(C=C2)Cl,,,,,,
3565,53566,"Benzo(b)thiophene-3-carboxylic acid, 4,5,6,7-tetrahydro-5-methyl-2-(2-piperidinoacetamido)-, ethyl ester",CCOC(=O)C1=C(SC2=C1CC(CC2)C)NC(=O)CN3CCCCC3,,,,,,
3566,53567,"Butyric acid, 4-(2-phenoxynicotinamido)-",C1=CC=C(C=C1)OC2=C(C=CC=N2)C(=O)NCCCC(=O)O,,,,,,
3567,53568,Milacemide hydrochloride,CCCCCNCC(=O)N.Cl,,,,,,
3568,53569,Milacemide,CCCCCNCC(=O)N,,,"['Drugs used to prevent SEIZURES or reduce their severity. (See all compounds classified as Anticonvulsants.)', 'A chemically heterogeneous group of drugs that have in common the ability to block oxidative deamination of naturally occurring monoamines. (From Gilman, et al., Goodman and Gilman&apos;s The Pharmacological Basis of Therapeutics, 8th ed, p414) (See all compounds classified as Monoamine Oxidase Inhibitors.)']",,,
3569,53570,"Acetamide, N,N-dimethyl-2-(2,6-xylidino)-",CC1=C(C(=CC=C1)C)NCC(=O)N(C)C,,,,,,
3570,53571,CID 53571,CN(C1CCCC1N=C(NC2=CC=CC=C2)S)C(=O)C3=CC=CC=C3[N+](=O)[O-],,,,,,
3571,53572,CID 53572,CC1=CC=CC=C1NC(=NC2CCCC2N(C)C(=O)C3=CC=CC=C3[N+](=O)[O-])S,,,,,,
3572,53573,CID 53573,CC1=CC=C(C=C1)NC(=NC2CCCC2N(C)C(=O)C3=CC=CC=C3[N+](=O)[O-])S,,,,,,
3573,53574,CID 53574,CC1=CC(=C(C=C1)C)NC(=NC2CCCC2N(C)C(=O)C3=CC=CC=C3[N+](=O)[O-])S,,,,,,
3574,53575,CID 53575,CC1=CC(=CC(=C1)NC(=NC2CCCC2N(C)C(=O)C3=CC=CC=C3[N+](=O)[O-])S)C,,,,,,
3575,53576,CID 53576,CN(C1CCCC1N=C(NC2=CC=CC=C2OC)S)C(=O)C3=CC=CC=C3[N+](=O)[O-],,,,,,
3576,53577,CID 53577,CN(C1CCCC1N=C(NC2=CC=CC=C2)S)C(=O)C3=CC=C(C=C3)[N+](=O)[O-],,,,,,
3577,53578,CID 53578,CC1=CC(=C(C=C1)C)NC(=NC2CCCC2N(C)C(=O)C3=CC=C(C=C3)[N+](=O)[O-])S,,,,,,
3578,53579,CID 53579,CN(C1CCCC1N=C(NC2=CC=CC=C2OC)S)C(=O)C3=CC=C(C=C3)[N+](=O)[O-],,,,,,
3579,53580,"Dizocilpine maleate, (-)-pound>>(-)-Dizocilpine Maleate",CC12C3=CC=CC=C3CC(N1)C4=CC=CC=C24.C(=CC(=O)O)C(=O)O,,,,,,
3580,53581,"L-Lysine, N6-(7-(acetylamino)-5,6,7,9-tetrahydro-1,2,3-trimethoxy-9-oxobenzo(a)heptalen-10-yl)-methyl ester, (S)-",CC(=O)NC1=C2CC(=O)C(=CC=C2C3=C(C(=C(C=C3CC1)OC)OC)OC)CNCCCC[C@H](C(=O)O)N,,,,,,
3581,53582,"3,4-Dichloro-2-methoxyphenol",COC1=C(C=CC(=C1Cl)Cl)O,,,,,,
3582,53583,N-{3-[(2-Bromoethyl)sulfanyl]-1-methoxy-1-oxopropan-2-yl}ethanimidic acid,CC(=O)NC(CSCCBr)C(=O)OC,,,,,,
3583,53584,N-Carbobenzoxyglycine acetonyl ester,CC(=O)COC(=O)CNC(=O)OCC1=CC=CC=C1,,,,,,
3584,53585,N-Carbobenzoxyglycine methoxymethyl ester,COCOC(=O)CNC(=O)OCC1=CC=CC=C1,,,,,,
3585,53586,N-Carbobenzoxyglycine methoxyethyl ester,COCCOC(=O)CNC(=O)OCC1=CC=CC=C1,,,,,,
3586,53587,N-Tosylglycine vinyl ester,CC1=CC=C(C=C1)S(=O)(=O)NCC(=O)OC=C,,,,,,
3587,53588,(Perfluoro-n-octyl)ethane,CCC(C(C(C(C(C(C(C(F)(F)F)(F)F)(F)F)(F)F)(F)F)(F)F)(F)F)(F)F,,,,,,
3588,53589,CID 53589,C1=CC(=CC=C1N)P(=O)(O)O.C1=CC(=CC=C1NC(=NC(=NCCCCCCN=C(N)N=C(N)NC2=CC=C(C=C2)Cl)N)N)Cl,,,,,,
3589,53590,(4-Aminophenyl)phosphonic acid,C1=CC(=CC=C1N)P(=O)(O)O,,,,,,
3590,53591,2-exo-Piperidino-bornan-3-endo-ol p-aminobenzoate,CC1(C2CCC1(C(C2OC(=O)C3=CC=C(C=C3)N)N4CCCCC4)C)C,,,,,,
3591,53592,1-Nitro-9-(2-dihydroxyethylamino-ethylamino)-acridine hydrochloride,C1=CC=C2C(=C1)C(=C3C(=N2)C=CC=C3[N+](=O)[O-])[NH2+]CC[NH+](CCO)CCO.[Cl-].[Cl-],,,,,,
3592,53593,"9,10-Dihydro-1-nitro-9-[[2-[bis(2-hydroxyethyl)amino]ethyl]imino]acridine",C1=CC=C2C(=C1)C(=C3C(=N2)C=CC=C3[N+](=O)[O-])NCCN(CCO)CCO,,,,,,
3593,53594,"Isoquinoline, 1,2,3,4-tetrahydro-2-((1-butyl-4-phenyl-4-piperidinyl)carbonyl)-6,7-dimethoxy-1-((3,4-dimethoxyphenyl)methyl)-",CCCCN1CCC(CC1)(C2=CC=CC=C2)C(=O)N3CCC4=CC(=C(C=C4C3CC5=CC(=C(C=C5)OC)OC)OC)OC,,,,,,
3594,53595,3-Acetylaconitine,CCN1CC2([C@H]3C(C4[C@@H]1C3([C@@H]5C[C@@]6([C@H](C([C@]4([C@H]5C6OC(=O)C7=CC=CC=C7)OC(=O)C)O)OC)O)C(CC2OC(=O)C)OC)OC)COC,,,,,,
3595,53596,"5-(2-bromoethenyl)-1-[(2R,3S,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidine-2,4-dione",C1=C(C(=O)NC(=O)N1[C@H]2[C@H]([C@@H]([C@H](O2)CO)O)O)C=CBr,,,,,,
3596,53597,Glufosinate-ammonium,CP(=O)(CCC(C(=O)[O-])N)O.[NH4+],,,"['Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. (See all compounds classified as Enzyme Inhibitors.)', 'Pesticides used to destroy unwanted vegetation, especially various types of weeds, grasses (POACEAE), and woody plants. Some plants develop HERBICIDE RESISTANCE. (See all compounds classified as Herbicides.)']",,"['The principal metabolite in urine & feces is 3-[hydroxy(methyl)phosphinoyl]propionic acid.', 'In plants, degradation of glufosinate-ammonium involves deamination, decarboxylation, & finally beta-oxidation to carbon dioxide.']","['...A 65-yr-old male ingested BASTA, which contains 20% w/v of glufosinate ammonium... The   changes in serum glufosinate concn exhibited T-1/2 alpha of 1.84 and T-1/2 beta of 9.59 hr.   /BASTA/']"
3597,53598,"(2,4-Diiodophenoxy)acetic acid",C1=CC(=C(C=C1I)I)OCC(=O)O,,,,,,
3598,53599,N-((4-Nitrobenzoyl)methyl)imidazole hydrochloride,C1=CC(=CC=C1C(=O)C[NH+]2C=CN=C2)[N+](=O)[O-].[Cl-],,,,,,
3599,53600,2-Imidazol-1-yl-1-(4-nitrophenyl)ethanone,C1=CC(=CC=C1C(=O)CN2C=CN=C2)[N+](=O)[O-],,,,,,
3600,53601,N-(4-Aminophenacyl)imidazole hydrochloride,C.C1=CC(=CC=C1C(=O)C[NH+]2C=CN=C2)N.[Cl-],,,,,,
3601,53602,1-(4-Aminophenyl)-2-(1h-imidazol-1-yl)ethanone,C1=CC(=CC=C1C(=O)CN2C=CN=C2)N,,,,,,
3602,53603,N-(4-Acetamidophenacyl)imidazole hydrochloride,CC(=O)NC1=CC=C(C=C1)C(=O)C[NH+]2C=CN=C2.[Cl-],,,,,,
3603,53604,N-[4-(2-imidazol-1-ylacetyl)phenyl]acetamide,CC(=O)NC1=CC=C(C=C1)C(=O)CN2C=CN=C2,,,,,,
3604,53605,N-((4-Phenoxybenzoyl)methyl)imidazole hydrochloride hydrate,C1=CC=C(C=C1)OC2=CC=C(C=C2)C(C[NH+]3C=CN=C3)O.[Cl-],,,,,,
3605,53606,2-Imidazol-1-yl-1-(4-phenoxyphenyl)ethanol,C1=CC=C(C=C1)OC2=CC=C(C=C2)C(CN3C=CN=C3)O,,,,,,
3606,53607,N-((4-tert-Butylbenzoyl)methyl)imidazole hydrochloride,CC(C)(C)C1=CC=C(C=C1)C(=O)C[NH+]2C=CN=C2.[Cl-],,,,,,
3607,53608,1-(4-Tert-butylphenyl)-2-imidazol-1-ylethanone,CC(C)(C)C1=CC=C(C=C1)C(=O)CN2C=CN=C2,,,,,,
3608,53609,N-((4-sec-Butylbenzoyl)methyl)imidazole hydrochloride,CCC(C)C1=CC=C(C=C1)C(=O)C[NH+]2C=CN=C2.[Cl-],,,,,,
3609,53610,1-(4-Butan-2-ylphenyl)-2-imidazol-1-ylethanone,CCC(C)C1=CC=C(C=C1)C(=O)CN2C=CN=C2,,,,,,
3610,53611,N-((2-Phenylbenzoyl)methyl)imidazole hydrochloride,C1=CC=C(C=C1)C2=CC=CC=C2C(=O)C[NH+]3C=CN=C3.[Cl-],,,,,,
3611,53612,2-Imidazol-1-yl-1-(2-phenylphenyl)ethanone,C1=CC=C(C=C1)C2=CC=CC=C2C(=O)CN3C=CN=C3,,,,,,
3612,53613,N-((3-Phenylbenzoyl)methyl)imidazole hydrochloride hemihydrate,C1=CC=C(C=C1)C2=CC(=CC=C2)C(=O)C[NH+]3C=CN=C3.[Cl-],,,,,,
3613,53614,1-(Biphenyl-3-yl)-2-(1h-imidazol-1-yl)ethanone,C1=CC=C(C=C1)C2=CC(=CC=C2)C(=O)CN3C=CN=C3,,,,,,
3614,53615,"4-BIPHENYLMETHANOL, alpha-(1-IMIDAZOLYLMETHYL)-, HYDROCHLORIDE",C1=CC=C(C=C1)C2=CC=C(C=C2)C(C[NH+]3C=CN=C3)O.[Cl-],,,,,,
3615,53616,1-Biphenyl-4-yl-2-imidazol-1-yl-ethanol,C1=CC=C(C=C1)C2=CC=C(C=C2)C(CN3C=CN=C3)O,,,,,,
3616,53617,"1-Propanol, 1-(4-biphenylyl)-2-(1-imidazolyl)-, hydrochloride",CC(C(C1=CC=C(C=C1)C2=CC=CC=C2)O)[NH+]3C=CN=C3.[Cl-],,,,,,
3617,53618,2-Imidazol-1-yl-1-(4-phenylphenyl)propan-1-ol,CC(C(C1=CC=C(C=C1)C2=CC=CC=C2)O)N3C=CN=C3,,,,,,
3618,53619,"4-BIPHENYLMETHANOL, alpha-(2-(1-IMIDAZOLYL)-2-PROPYL)-, HYDROCHLORIDE",CC(C)(C(C1=CC=C(C=C1)C2=CC=CC=C2)O)[NH+]3C=CN=C3.[Cl-],,,,,,
3619,53620,2-Imidazol-1-yl-2-methyl-1-(4-phenylphenyl)propan-1-ol,CC(C)(C(C1=CC=C(C=C1)C2=CC=CC=C2)O)N3C=CN=C3,,,,,,
3620,53621,"1-Propanol, 1-(4-biphenylyl)-3-(1-imidazolyl)-, hydrochloride",C1=CC=C(C=C1)C2=CC=C(C=C2)C(CC[NH+]3C=CN=C3)O.[Cl-],,,,,,
3621,53622,3-Imidazol-1-yl-1-(4-phenylphenyl)propan-1-ol,C1=CC=C(C=C1)C2=CC=C(C=C2)C(CCN3C=CN=C3)O,,,,,,
3622,53623,"1-Propanol, 1-(4-biphenylyl)-2-(1-imidazolylmethyl)-, hydrochloride",CC(C[NH+]1C=CN=C1)C(C2=CC=C(C=C2)C3=CC=CC=C3)O.[Cl-],,,,,,
3623,53624,3-Imidazol-1-yl-2-methyl-1-(4-phenylphenyl)propan-1-ol,CC(CN1C=CN=C1)C(C2=CC=C(C=C2)C3=CC=CC=C3)O,,,,,,
3624,53625,Denzimol hydrochloride,C1=CC=C(C=C1)CCC2=CC=C(C=C2)C(CN3C=CN=C3)O.Cl,,,['Drugs used to prevent SEIZURES or reduce their severity. (See all compounds classified as Anticonvulsants.)'],,,
3625,53626,Denzimol,C1=CC=C(C=C1)CCC2=CC=C(C=C2)C(CN3C=CN=C3)O,,,['Drugs used to prevent SEIZURES or reduce their severity. (See all compounds classified as Anticonvulsants.)'],,,
3626,53627,"1-Propanol, 1-(p-phenethylphenyl)-2-(1-imidazolyl)-, hydrochloride",CC(C1=C(C=CC(=C1)CCC2=CC=CC=C2)CO)[NH+]3C=CN=C3.[Cl-],,,,,,
3627,53628,[2-(1-Imidazol-1-ylethyl)-4-(2-phenylethyl)phenyl]methanol,CC(C1=C(C=CC(=C1)CCC2=CC=CC=C2)CO)N3C=CN=C3,,,,,,
3628,53629,"Carbamic acid, sulfinylbis(methyl-, bis(2,3-dihydro-2,2-dimethyl-7-benzofuranyl) ester",CC1(CC2=C(O1)C(=CC=C2)OC(=O)NCS(=O)CNC(=O)OC3=CC=CC4=C3OC(C4)(C)C)C,,,,,,
3629,53630,"Carbamic acid, ((hexyloxy)sulfinyl)methyl-, 2,3-dihydro-2,2-dimethyl-7-benzofuranyl ester",CCCCCCOS(=O)N(C)C(=O)OC1=CC=CC2=C1OC(C2)(C)C,,,,,,
3630,53631,"((2,6-Xylyl)sulfinyl)methylcarbamic acid 2,3-dihydro-2,2-dimethyl-7-benzofuranyl ester",CC1=C(C(=CC=C1)C)OS(=O)CNC(=O)OC2=CC=CC3=C2OC(C3)(C)C,,,,,,
3631,53632,3-Isopropylphenyl(methyl)(2-methyl-4-t-butylphenylthiosulfinyl)carbamate,CC1=C(C=CC(=C1)C(C)(C)C)SS(=O)CNC(=O)OC2=CC=CC(=C2)C(C)C,,,,,,
3632,53633,"Carbamic acid, ((butylthio)sulfinyl)methyl-, 2,3-dihydro-2,2-dimethyl-7-benzofuranyl ester",CCCCSS(=O)CNC(=O)OC1=CC=CC2=C1OC(C2)(C)C,,,,,,
3633,53634,"5-(Methylthio)-3-(1,2,3,6-tetrahydro-4-pyridinyl)-1H-indole hydrochloride",CSC1=CC2=C(C=C1)NC=C2C3=CC[NH2+]CC3.[Cl-],,,,,,
3634,53635,"5-methylsulfanyl-3-(1,2,3,6-tetrahydropyridin-4-yl)-1H-indole",CSC1=CC2=C(C=C1)NC=C2C3=CCNCC3,,,,,,
3635,53636,"(S)-6,7-Dimethoxy-1-methyl-2-propyl-1,2,3,4-tetrahydroisoquinoline",CCCN1CCC2=CC(=C(C=C2C1C)OC)OC,,,,,,
3636,53637,"(S)-1,2,3,4-Tetrahydro-6,7-dimethoxy-1-methyl-2-(2-methyl-1-oxopropyl)isoquinoline",CC1C2=CC(=C(C=C2CCN1C(=O)C(C)C)OC)OC,,,,,,
3637,53638,1-Nitro-9-(hydroxyethylamino)-acridine hydrochloride,C1=CC=C2C(=C1)C(=C3C(=N2)C=CC=C3[N+](=O)[O-])[NH2+]CCO.[Cl-],,,,,,
3638,53639,"Ethanol, 2-((1-nitro-9-acridinyl)amino)-",C1=CC=C2C(=C1)C(=C3C(=N2)C=CC=C3[N+](=O)[O-])NCCO,,,,,,
3639,53640,"(2R,3R,4R)-4-hydroxy-2-(7-hydroxyheptyl)-3-(4-hydroxy-4-methyloct-1-enyl)cyclopentan-1-one",CCCCC(C)(CC=C[C@H]1[C@@H](CC(=O)[C@@H]1CCCCCCCO)O)O,,,,,,
3640,53641,"(9S,11S)-17-(cyclobutylmethyl)-11-methyl-13-methylidene-17-azatetracyclo[7.5.3.01,10.02,7]heptadeca-2(7),3,5-trien-4-ol;methanesulfonic acid",C[C@H]1CC(=C)CC23C1[C@H](CC4=C2C=C(C=C4)O)N(CC3)CC5CCC5.CS(=O)(=O)O,,,,,,
3641,53642,"(9S,11S)-17-(cyclobutylmethyl)-11-methyl-13-methylidene-17-azatetracyclo[7.5.3.01,10.02,7]heptadeca-2(7),3,5-trien-4-ol",C[C@H]1CC(=C)CC23C1[C@H](CC4=C2C=C(C=C4)O)N(CC3)CC5CCC5,,,,,,
3642,53643,"(6-aRs,10-ars)-4,6,6a,8,9,10a-hexahydro-7-methyl-7H-indolo(3,4-gh)(1,4)benzoxazine HCl",C[NH+]1CCOC2C1CC3=CNC4=CC=CC2=C34.[Cl-],,,,,,
3643,53644,"6-Methyl-3-oxa-6,11-diazatetracyclo[7.6.1.02,7.012,16]hexadeca-1(16),9,12,14-tetraene",CN1CCOC2C1CC3=CNC4=CC=CC2=C34,,,,,,
3644,53645,8-Hydroxyflavone,C1=CC=C(C=C1)C2=CC(=O)C3=C(O2)C(=CC=C3)O,,,,,,
3645,53646,CID 53646,CC(=C(C)C(=O)N)C1=CC(=CC=C1)C(F)(F)F,,,,,,
3646,53647,CID 53647,CC(=C(C)C(=O)NC1CC1)C2=CC(=CC=C2)C(F)(F)F,,,,,,
3647,53648,CID 53648,CC(=C(C)C(=O)NCC=C)C1=CC(=CC=C1)C(F)(F)F,,,,,,
3648,53649,CID 53649,CC(=C(C)C(=O)NCC#C)C1=CC(=CC=C1)C(F)(F)F,,,,,,
3649,53650,CID 53650,CC(=CC(=O)NCC=C)C1=CC=CC=C1,,,,,,
3650,53651,3-Phenyl-n-(prop-2-en-1-yl)prop-2-enamide,C=CCNC(=O)C=CC1=CC=CC=C1,,,,,,
3651,53652,CID 53652,CC(=C(C)C(=O)N)C1=CC=C(C=C1)Cl,,,,,,
3652,53653,"BENZ(c)ACRIDINE-3-beta,4-alpha-DIOL, 3,4-DIHYDRO-, trans-",C1=CC=C2C(=C1)C=C3C=CC4=C(C3=N2)C=C[C@H]([C@@H]4O)O,,,,,,
3653,53654,"2,4-Dimethyl-3-oxazoline",CC1N=C(CO1)C,,,,,,
3654,53655,"(1S,4R,8S,9S,11S,12S,19S)-19-fluoro-11-hydroxy-8-(2-hydroxyacetyl)-6,6,9,13-tetramethyl-5,7-dioxapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one;hydrate",C[C@]12C[C@@H]([C@H]3[C@H](C1C[C@@H]4[C@]2(OC(O4)(C)C)C(=O)CO)C[C@@H](C5=CC(=O)C=CC35C)F)O.C[C@]12C[C@@H]([C@H]3[C@H](C1C[C@@H]4[C@]2(OC(O4)(C)C)C(=O)CO)C[C@@H](C5=CC(=O)C=CC35C)F)O.O,,,,,,
3655,53656,"(1S,4R,8S,9S,11S,12S,19S)-19-fluoro-11-hydroxy-8-(2-hydroxyacetyl)-6,6,9,13-tetramethyl-5,7-dioxapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one",C[C@]12C[C@@H]([C@H]3[C@H](C1C[C@@H]4[C@]2(OC(O4)(C)C)C(=O)CO)C[C@@H](C5=CC(=O)C=CC35C)F)O,,,,,,
3656,53657,N-n-Propyl-N-formylhydrazine,CCCN(C=O)N,,,,,,
3657,53658,boranylformic acid;N-methylmethanamine,BC(=O)O.CNC,,,,,,
3658,53659,"DL-N-(p-(3,3-Dimethyltriazeno)benzoyl)alanine ethyl ester",CCOC(=O)C(C)NC(=O)C1=CC=C(C=C1)N=NN(C)C,,,,,,
3659,53660,"ASPARTIC ACID, N-(p-(3,3-DIMETHYLTRIAZENO)BENZOYL)-, DIETHYL ESTER, DL-",CCOC(=O)CC(C(=O)OCC)NC(=O)C1=CC=C(C=C1)N=NN(C)C,,,,,,
3660,53661,3-Methylnaphthalene-1-carbonitrile,CC1=CC2=CC=CC=C2C(=C1)C#N,,,,,,
3661,53662,1-Nitrosoazepan-4-ol,C1CC(CCN(C1)N=O)O,,,,,,
3662,53663,Hexahydro-1-nitroso-1H-azepin-3-ol,C1CCN(CC(C1)O)N=O,,,,,,
3663,53664,"Mercury, methyl(thioacetamido)-",CC(=S)N[Hg]C,,,,,,
3664,53665,3-Chloro-4-(dichloromethyl)-5-hydroxy-2(5H)-furanone,C1(C(=C(C(=O)O1)Cl)C(Cl)Cl)O,,,"['Substances that increase the risk of NEOPLASMS in humans or animals. Both genotoxic chemicals, which affect DNA directly, and nongenotoxic chemicals, which induce neoplasms by other mechanism, are included. (See all compounds classified as Carcinogens.)', 'Chemical agents that increase the rate of genetic mutation by interfering with the function of nucleic acids. A clastogen is a specific mutagen that causes breaks in chromosomes. (See all compounds classified as Mutagens.)']","['... Radioactivity was rapidly absorbed and excreted near equally in urine (42-54%) and feces (40-51%) 72 hr following oral administration of (14)C-labeled MX at single doses from 0.2 to 20 mg/kg to male and female mice and female rats. A larger percentage (71-73%) of MX-derived radioactivity was excreted in urine after an iv dose (0.2 mg/kg) in both female rats and male mice. Most MX-derived radioactivity was excreted within the first 24 hr postdosing. ... Oral administration produced highest tissue/blood ratios in the following order: forestomach (>100), glandular stomach, intestine, and kidney. Intravenous administration resulted in high, prolonged levels of radioactivity in blood compared to oral dosing. Therefore, MX disposition appears to be dominated by its chemical reactivity with highest concentrations of radioactivity being found at the site of administration.', 'The pharmacokinetics of 3-chloro-4-(dichloromethyl)-5-hydroxy-2(5H)-furanone (MX) was evaluated after a single oral or intravenous administration in the rats using 14C-labelled compound. Twenty to 35% of the dose was absorbed into circulation from the gastrointestinal tract as assessed from the excretion in urine. The mean elimination half-life of the radioactivity in blood (T1/2 k10) was 3.8 hr. Traces of radioactivity remained in the blood for several days. The tissues lining the gastrointestinal and urinary tract, kidneys, stomach, small intestines and urinary bladder contained the highest radioactivity. The activity declined slowest in the kidneys. Urine was the main excretion route. Seventy-seven % of the total amount excreted appeared in urine in 12 hr and 90% in 24 hr. No radioactivity was exhaled in air suggesting that elimination through respiration did not occur. After an intravenous administration of 14C-MX, the T1/2 k10, was much longer, 22.9 hr, and the total elimination half-life (T1/2 beta), 42.1 hr. The results indicate that MX is absorbed from the gastrointestinal tract to a considerable degree and it is excreted in urine very rapidly. A fraction of MX or its metabolites is retained in blood for a longer period of time. The pharmacokinetics of MX does not suggest extensive cumulation of MX in tissues after continuous exposure.', 'In another experiment, a dose of 2 mg/kg (14C)MX was administered to Wistar rats and radioactivity was determined in tissues after 2 and 6 hr. After 2 hr, the highest amount of radioactivity was detected in kidneys, followed by the stomach, ileum, urinary bladder and liver. At 6 hr, the concentration of radioactivity was markedly decreased in kidneys and urinary bladder and to a lesser extent in the gastrointestinal tract.', '... Excretion in urine of  3-chloro-4-(dichloromethyl)-5-hydroxy-2(5H)-furanone (MX) ... was evaluated in male Wistar rats ... dosed by gavage in deionized water at doses between 200 mg/kg and 600 mg/kg, for one animal at a time ...  Urine was collected in metabolism cages up to 72 hr after dosing for chemical analysis of MX in urine. ... Only 0.03-0.07% of the dose (200 mg/kg or 300 mg/kg) was excreted in urine as intact MX...', 'For more Absorption, Distribution and Excretion (Complete) data for 3-CHLORO-4-(DICHLOROMETHYL)-5-HYDROXY-2(5H)-FURANONE (7 total), please visit the HSDB record page.']","['... A larger percentage (71-73%) of MX-derived radioactivity was excreted in urine after an iv dose (0.2 mg/kg) in both female rats and male mice. Most MX-derived radioactivity was excreted within the first 24 hr postdosing. MX was transformed to urinary and biliary metabolites. A major extremely polar urinary metabolite was tentatively identified as 1-hydroxy-1,2,2-ethanetricarboxylic acid. This metabolite is likely transformed from the MX degradation product 2-hydroxy-3-formyl-4-oxo-2-butenoic acid.', '... MX is extensively detoxified in vivo and is unlikely to cause genetic damage in systemic tissues except at relatively high doses where detoxification pathways become saturated...']","['The pharmacokinetics of 3-chloro-4-(dichloromethyl)-5-hydroxy-2(5H)-furanone (MX) was evaluated after a single oral or intravenous administration in the rats using 14C-labelled compound. ... The mean elimination half-life of the radioactivity in blood (T1/2) /following oral administration/ was 3.8 hr. ... After an intravenous administration of 14C-MX, the T1/2 was much longer, 22.9 hr, and the total elimination half-life 42.1 hr.']"
3665,53666,Bis(o-formylphenyl)telluride,C1=CC=C(C(=C1)C=O)[Te]C2=CC=CC=C2C=O,,,,,,
3666,53667,4-Methylnaphthalene-2-carbaldehyde,CC1=CC(=CC2=CC=CC=C12)C=O,,,,,,
3667,53668,"1,2,4-Benzotriazine-3-acetic acid, ethyl ester",CCOC(=O)CC1=NC2=CC=CC=C2N=N1,,,,,,
3668,53669,Fenprinast,CC1(CN2C(=O)C3=C(N=CN3)N(C2=N1)CC4=CC=C(C=C4)Cl)C,,,,,,
3669,53670,CID 53670,CCNP(=S)(OC)OC(=CC(=O)OC(C)C)C.COP(=O)(OC)OC=C(Cl)Cl,,,,,,
3670,53671,"1,2,4-Benzotriazine-3-acetamide",C1=CC=C2C(=C1)N=C(N=N2)CC(=O)N,,,,,,
3671,53672,Fluoroglycofen-ethyl,CCOC(=O)COC(=O)C1=C(C=CC(=C1)OC2=C(C=C(C=C2)C(F)(F)F)Cl)[N+](=O)[O-],,,,,,
3672,53673,N-(4-(2-Furyl)-2-thiazolyl)formamide,C1=COC(=C1)C2=CSC(=N2)NC=O,,,,,,
3673,53674,"KETONE, 7-METHOXYNAPHTHO(2,1-b)FURAN-2-YL METHYL",CC(=O)C1=CC2=C(O1)C=C3C=CC(=CC3=C2)OC,,,,,,
3674,53675,6'-Benzoyloxycincholine,C=CC1CN2CCC1CC2C(C3=C4C=C(C=CC4=NC=C3)OC(=O)C5=CC=CC=C5)O,,,,,,
3675,53676,6-(1-Methyl-2-(4-phenethylpiperazino)ethyl)amino-2-methoxy-benzothiazole oxalate,CC(CN1CCN(CC1)CCC2=CC=CC=C2)NC3=CC4=C(C=C3)N=C(S4)OC.C(=O)(C(=O)O)O.C(=O)(C(=O)O)O,,,,,,
3676,53677,"2-methoxy-N-[1-[4-(2-phenylethyl)piperazin-1-yl]propan-2-yl]-1,3-benzothiazol-6-amine",CC(CN1CCN(CC1)CCC2=CC=CC=C2)NC3=CC4=C(C=C3)N=C(S4)OC,,,,,,
3677,53678,6-(1-Methyl-2-(4-phenethylpiperazino)ethyl)-amino-2-isopropoxy-benzothiazole oxalate hydrate,CC(C)OC1=NC2=C(S1)C=C(C=C2)NC(C)CN3CCN(CC3)CCC4=CC=CC=C4.C(=O)(C(=O)O)O.C(=O)(C(=O)O)O,,,,,,
3678,53679,"N-[1-[4-(2-phenylethyl)piperazin-1-yl]propan-2-yl]-2-propan-2-yloxy-1,3-benzothiazol-6-amine",CC(C)OC1=NC2=C(S1)C=C(C=C2)NC(C)CN3CCN(CC3)CCC4=CC=CC=C4,,,,,,
3679,53680,6-(1-Methyl-2-(4-phenethylpiperazino)ethyl)-amino-2-n-butoxy-benzothiazole oxalate hydrate,CCCCOC1=NC2=C(S1)C=C(C=C2)NC(C)CN3CCN(CC3)CCC4=CC=CC=C4.C(=O)(C(=O)O)O.C(=O)(C(=O)O)O,,,,,,
3680,53681,"2-butoxy-N-[1-[4-(2-phenylethyl)piperazin-1-yl]propan-2-yl]-1,3-benzothiazol-6-amine",CCCCOC1=NC2=C(S1)C=C(C=C2)NC(C)CN3CCN(CC3)CCC4=CC=CC=C4,,,,,,
3681,53682,2-Methoxy-6-(N-(1-methyl-2-(4-phenethylpiperazino)ethyl)-propionamido)-benzothiazole oxalate,CCC(=O)N(C1=CC2=C(C=C1)N=C(S2)OC)C(C)CN3CCN(CC3)CCC4=CC=CC=C4.C(=O)(C(=O)O)O.C(=O)(C(=O)O)O,,,,,,
3682,53683,"N-(2-methoxy-1,3-benzothiazol-6-yl)-N-[1-[4-(2-phenylethyl)piperazin-1-yl]propan-2-yl]propanamide",CCC(=O)N(C1=CC2=C(C=C1)N=C(S2)OC)C(C)CN3CCN(CC3)CCC4=CC=CC=C4,,,,,,
3683,53684,2-(N-(2-Imidazolin-2-yl)-N-(3-indolylmethyl)amino)ethanol hydriodide,C1CNC(=[N+](CCO)CC2=CNC3=CC=CC=C32)N1.[I-],,,,,,
3684,53685,2-hydroxyethyl-imidazolidin-2-ylidene-(1H-indol-3-ylmethyl)azanium,C1CNC(=[N+](CCO)CC2=CNC3=CC=CC=C32)N1,,,,,,
3685,53686,2-(N-(2-Imidazolin-2-yl)-N-(2-phenyl-3-indolylmethyl)amino)ethanol hydriodide,C1CNC(=[N+](CCO)CC2=C(NC3=CC=CC=C32)C4=CC=CC=C4)N1.[I-],,,,,,
3686,53687,2-hydroxyethyl-imidazolidin-2-ylidene-[(2-phenyl-1H-indol-3-yl)methyl]azanium,C1CNC(=[N+](CCO)CC2=C(NC3=CC=CC=C32)C4=CC=CC=C4)N1,,,,,,
3687,53688,1-(N-(2-Imidazolin-2-yl)-N-(2-phenyl-3-indolylmethyl)amino)-1-butanol hydriodide,CCCC([NH+](CC1=C(NC2=CC=CC=C21)C3=CC=CC=C3)C4=NCCN4)O.[I-],,,,,,
3688,53689,1-[N-(2-Imidazolin-2-yl)-N-[(2-phenyl-1H-indol-3-yl)methyl]amino]-1-butanol,CCCC(N(CC1=C(NC2=CC=CC=C21)C3=CC=CC=C3)C4=NCCN4)O,,,,,,
3689,53690,2-(N-(2-Imidazolin-2-yl)-N-(2-(p-methoxyphenyl)-3-indolylmethyl)amino)ethanol hydriodide,COC1=CC=C(C=C1)C2=C(C3=CC=CC=C3N2)C[N+](=C4NCCN4)CCO.[I-],,,,,,
3690,53691,2-hydroxyethyl-imidazolidin-2-ylidene-[[2-(4-methoxyphenyl)-1H-indol-3-yl]methyl]azanium,COC1=CC=C(C=C1)C2=C(C3=CC=CC=C3N2)C[N+](=C4NCCN4)CCO,,,,,,
3691,53692,"1-Butanol, 1-(N-(2-imidazolin-2-yl)-N-(2-(p-methoxyphenyl)-3-indolylmethyl)amino)-, hydriodide",CCCC([NH+](CC1=C(NC2=CC=CC=C21)C3=CC=C(C=C3)OC)C4=NCCN4)O.[I-],,,,,,
3692,53693,1-[N-(2-Imidazolin-2-yl)-N-[[2-(4-methoxyphenyl)-1H-indol-3-yl]methyl]amino]-1-butanol,CCCC(N(CC1=C(NC2=CC=CC=C21)C3=CC=C(C=C3)OC)C4=NCCN4)O,,,,,,
3693,53694,2-(N-(2-Imidazolin-2-yl)-N-(2-(2-pyridyl)-3-indolylmethyl)amino)ethanol hydriodide,C1CNC(=[N+](CCO)CC2=C(NC3=CC=CC=C32)C4=CC=CC=N4)N1.[I-],,,,,,
3694,53695,2-hydroxyethyl-imidazolidin-2-ylidene-[(2-pyridin-2-yl-1H-indol-3-yl)methyl]azanium,C1CNC(=[N+](CCO)CC2=C(NC3=CC=CC=C32)C4=CC=CC=N4)N1,,,,,,
3695,53696,Suproclone,CCC(=O)N1CCN(CC1)C(=O)OC2C3=C(C(=O)N2C4=NC5=C(C=C4)C=CC(=N5)Cl)SCCS3,,,,,,
3696,53697,Cetamolol hydrochloride,CC(C)(C)NCC(COC1=CC=CC=C1OCC(=O)NC)O.Cl,,,,,,
3697,53698,Cetamolol,CC(C)(C)NCC(COC1=CC=CC=C1OCC(=O)NC)O,,,,,,
3698,53699,Flordipine,CCOC(=O)C1=C(N(C(=C(C1C2=CC=CC=C2C(F)(F)F)C(=O)OCC)C)CCN3CCOCC3)C,,,,,,
3699,53700,"2-[(2-Fluorodibenzo[b,f]oxepin-10-yl)sulfanyl]-N-methylethan-1-amine--hydrogen chloride (1/1)",CNCCSC1=CC2=C(C=CC(=C2)F)OC3=CC=CC=C31.Cl,,,,,,
3700,53701,2-(3-fluorobenzo[b][1]benzoxepin-6-yl)sulfanyl-N-methylethanamine,CNCCSC1=CC2=C(C=CC(=C2)F)OC3=CC=CC=C31,,,,,,
3701,53702,Egis 5650;gyki-13504,C1=CC=C(C=C1)C(=C(C2=CC=CC=C2)C(F)(F)F)C3=CC=C(C=C3)OCCNCCO,,,,,,
3702,53703,N-(2-Hydroxymethyl-3-chlorophenyl)anthranilic acid,C1=CC=C(C(=C1)C(=O)O)NC2=C(C(=CC=C2)Cl)CO,,,,,,
3703,53704,N-(2-Methyl-3-chloro-4-hydroxyphenyl)anthranilic acid,CC1=C(C=CC(=C1Cl)O)NC2=CC=CC=C2C(=O)O,,,,,,
3704,53705,Methyl hentriacontanoate,CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC(=O)OC,,,,,,
3705,53706,"Carbamic acid, (2,4,6-trimethylphenyl)-, 2-(diethylamino)ethyl ester, monohydrochloride",CC[NH+](CC)CCOC(=O)NC1=C(C=C(C=C1C)C)C.[Cl-],,,,,,
3706,53707,"2-(diethylamino)ethyl N-(2,4,6-trimethylphenyl)carbamate",CCN(CC)CCOC(=O)NC1=C(C=C(C=C1C)C)C,,,,,,
3707,53708,Enoximone,CC1=C(NC(=O)N1)C(=O)C2=CC=C(C=C2)SC,['For the treatment of congestive heart failure.'],"['Enoximone is a phosphodiesterase inhibitor (type III) that increases the force of contraction of the heart and dilates blood vessels. In June 2005, Myogen announced that they were discontinuing development of enoximone due to negative results. The drug is approved for use in the UK.']","['Agents that have a strengthening effect on the heart or that can increase cardiac output. They may be CARDIAC GLYCOSIDES; SYMPATHOMIMETICS; or other drugs. They are used after MYOCARDIAL INFARCT; CARDIAC SURGICAL PROCEDURES; in SHOCK; or in congestive heart failure (HEART FAILURE). (See all compounds classified as Cardiotonic Agents.)', 'Compounds that specifically inhibit PHOSPHODIESTERASE 3. (See all compounds classified as Phosphodiesterase 3 Inhibitors.)', 'Drugs used to cause dilation of the blood vessels. (See all compounds classified as Vasodilator Agents.)']",['Bioavailabvility is 50% following oral administration.'],['Hepatic oxidation'],['4-10 hours']
3708,53709,"10,11-Dihydro-alpha,8-dimethyl-11-oxo-dibenzo(b,f)thiepin-2-acetic acid",CC1=CC2=C(C=C1)SC3=C(C=C(C=C3)C(C)C(=O)O)C(=O)C2,,,,,,
3709,53710,3-(4-(m-Chlorophenyl)-1-piperazinyl)dihydro-2(3H)-furanone hydrochloride,C1COC(=O)C1[NH+]2CCN(CC2)C3=CC(=CC=C3)Cl.[Cl-],,,,,,
3710,53711,3-[4-(3-Chlorophenyl)piperazin-1-yl]oxolan-2-one,C1COC(=O)C1N2CCN(CC2)C3=CC(=CC=C3)Cl,,,,,,
3711,53712,"N-(5,5-Dimethyl-2-oxotetrahydro-3-furyl)-2,2,2-trifluoroacetamide",CC1(CC(C(=O)O1)NC(=O)C(F)(F)F)C,,,,,,
3712,53713,"N-(5,5-Dimethyl-2-oxotetrahydro-3-furyl)-1-adamantanecarboxamide",CC1(CC(C(=O)O1)NC(=O)C23CC4CC(C2)CC(C4)C3)C,,,,,,
3713,53714,"N-(5,5-dimethyl-2-oxooxolan-3-yl)-3-phenylprop-2-enamide",CC1(CC(C(=O)O1)NC(=O)C=CC2=CC=CC=C2)C,,,,,,
3714,53715,"5,5-Dimethyl-2-oxotetrahydrofuran-3-carbamic acid ethyl ester",CCOC(=O)NC1CC(OC1=O)(C)C,,,,,,
3715,53716,"p-Chloro-N-(5,5-dimethyl-2-oxotetrahydro-3-furyl)benzamide",CC1(CC(C(=O)O1)NC(=O)C2=CC=C(C=C2)Cl)C,,,,,,
3716,53717,"BENZAMIDE, m-CHLORO-N-(5,5-DIMETHYL-2-OXOTETRAHYDRO-3-FURYL)-",CC1(CC(C(=O)O1)NC(=O)C2=CC(=CC=C2)Cl)C,,,,,,
3717,53718,"o-Chloro-N-(5,5-dimethyl-2-oxotetrahydro-3-furyl)benzamide",CC1(CC(C(=O)O1)NC(=O)C2=CC=CC=C2Cl)C,,,,,,
3718,53719,"N-(5,5-dimethyl-2-oxooxolan-3-yl)-4-fluorobenzamide",CC1(CC(C(=O)O1)NC(=O)C2=CC=C(C=C2)F)C,,,,,,
3719,53720,p-Chloro-N-(2-oxotetrahydro-3-furyl)benzamide,C1COC(=O)C1NC(=O)C2=CC=C(C=C2)Cl,,,,,,
3720,53721,p-Bromo-N-(2-oxotetrahydro-3-furyl)benzamide,C1COC(=O)C1NC(=O)C2=CC=C(C=C2)Br,,,,,,
3721,53722,"N-(5,5-Dimethyl-2-oxotetrahydro-3-furyl)isonicotinamide",CC1(CC(C(=O)O1)NC(=O)C2=CC=NC=C2)C,,,,,,
3722,53723,"N-(5,5-Dimethyl-2-oxotetrahydro-3-furyl)indole-3-acetamide",CC1(CC(C(=O)O1)N2C3=CC=CC=C3C=C2CC(=O)N)C,,,,,,
3723,53724,"o-Benzoyl-N-(5,5-dimethyl-2-oxotetrahydro-3-furyl)benzamide",CC1(CC(C(=O)O1)NC(=O)C2=CC=CC=C2C(=O)C3=CC=CC=C3)C,,,,,,
3724,53725,N-Nitrosobis(2-oxobutyl)amine,CCC(=O)CN(CC(=O)CC)N=O,,,,,,
3725,53726,N-Nitroso(2-oxobutyl)(2-oxopropyl)amine,CCC(=O)CN(CC(=O)C)N=O,,,,,,
3726,53727,2-(Dimethylamino)-N-methyl-4'-(phenylthio)acetanilide oxalate,C[NH+](C)CC(=O)N(C)C1=CC=C(C=C1)SC2=CC=CC=C2.C(=O)(C(=O)[O-])O,,,,,,
3727,53728,2-(dimethylamino)-N-methyl-N-(4-phenylsulfanylphenyl)acetamide,CN(C)CC(=O)N(C)C1=CC=C(C=C1)SC2=CC=CC=C2,,,,,,
3728,53729,"Acetanilide, 2-(diethylamino)-4'-(phenylthio)-, oxalate",CC[NH+](CC)CC(=O)NC1=CC=C(C=C1)SC2=CC=CC=C2.C(=O)(C(=O)[O-])O,,,,,,
3729,53730,2-(diethylamino)-N-(4-phenylsulfanylphenyl)acetamide,CCN(CC)CC(=O)NC1=CC=C(C=C1)SC2=CC=CC=C2,,,,,,
3730,53731,4'-(p-Chlorophenylthio)-2-(diethylamino)-acetanilide oxalate,CC[NH+](CC)CC(=O)NC1=CC=C(C=C1)SC2=CC=C(C=C2)Cl.C(=O)(C(=O)[O-])O,,,,,,
3731,53732,N-[4-(4-chlorophenyl)sulfanylphenyl]-2-(diethylamino)acetamide,CCN(CC)CC(=O)NC1=CC=C(C=C1)SC2=CC=C(C=C2)Cl,,,,,,
3732,53733,2'-(p-Chlorophenylthio)-2-(diethylamino)acetanilide oxalate,CC[NH+](CC)CC(=O)NC1=CC=CC=C1SC2=CC=C(C=C2)Cl.C(=O)(C(=O)[O-])O,,,,,,
3733,53734,N-[2-(4-chlorophenyl)sulfanylphenyl]-2-(diethylamino)acetamide,CCN(CC)CC(=O)NC1=CC=CC=C1SC2=CC=C(C=C2)Cl,,,,,,
3734,53735,Oxadixyl,CC1=C(C(=CC=C1)C)N(C(=O)COC)N2CCOC2=O,,,,,,
3735,53736,"2-(3,4-Dimethyl-5,6,7,8-tetrahydro-1-naphthylamino)-2-oxazoline",CC1=CC(=C2CCCCC2=C1C)NC3=NCCO3,,,,,,
3736,53737,"Aniline, N-(2-oxazolin-2-YL)-2,4,5-trimethyl-",CC1=CC(=C(C=C1C)NC2=NCCO2)C,,,,,,
3737,53738,"Benzylamine, 2,6-dimethyl-N-(2-oxazolin-2-YL)-",CC1=C(C(=CC=C1)C)CNC2=NCCO2,,,,,,
3738,53739,"Benzylamine, 2,3-dimethyl-N-(2-oxazolin-2-YL)-",CC1=C(C(=CC=C1)CNC2=NCCO2)C,,,,,,
3739,53740,"1,1,2,3,4-Pentachlorobut-2-ene",C(C(=C(C(Cl)Cl)Cl)Cl)Cl,,,,,,
3740,53741,p-Iodophenyl urethane,CCOC(=O)NC1=CC=C(C=C1)I,,,,,,
3741,53742,"2H-1,4-Benzodiazepin-2-one, 1,3-dihydro-7-chloro-5-phenyl-1-(3-(4-phenyl-1-piperazinyl)propyl)-, monohydrochloride",C1CN(CCN1CCCN2C(=O)CN=C(C3=C2C=CC(=C3)Cl)C4=CC=CC=C4)C5=CC=CC=C5.Cl,,,,,,
3742,53743,"7-Chloro-5-phenyl-1-[3-(4-phenylpiperazino)propyl]-1,3-dihydro-2H-1,4-benzodiazepin-2-one",C1CN(CCN1CCCN2C(=O)CN=C(C3=C2C=CC(=C3)Cl)C4=CC=CC=C4)C5=CC=CC=C5,,,,,,
3743,53744,9-Oxo-10-acridineacetic acid,C1=CC=C2C(=C1)C(=O)C3=CC=CC=C3N2CC(=O)N,,,"['Agents that promote the production and release of interferons. They include mitogens, lipopolysaccharides, and the synthetic polymers Poly A-U and Poly I-C. Viruses, bacteria, and protozoa have been also known to induce interferons. (See all compounds classified as Interferon Inducers.)']",,,
3744,53745,"10(9H)-Acridineacetamide, N-(3-(dimethylamino)propyl)-9-oxo-, monohydrochloride",C[NH+](C)CCCNC(=O)CC1=C2C(=CC=C1)C(=O)C3=CC=CC=C3N2.[Cl-],,,,,,
3745,53746,N-[3-(dimethylamino)propyl]-2-(9-oxo-10H-acridin-4-yl)acetamide,CN(C)CCCNC(=O)CC1=C2C(=CC=C1)C(=O)C3=CC=CC=C3N2,,,,,,
3746,53747,"N-Ethyl-2-(2-methylpiperidino)-N-(1-(2,4-xylyloxy)-2-propyl)acetamide hydrochloride",CCN(C(C)COC1=C(C=C(C=C1)C)C)C(=O)C[NH+]2CCCCC2C.[Cl-],,,,,,
3747,53748,"N-[1-(2,4-dimethylphenoxy)propan-2-yl]-N-ethyl-2-(2-methylpiperidin-1-yl)acetamide",CCN(C(C)COC1=C(C=C(C=C1)C)C)C(=O)CN2CCCCC2C,,,,,,
3748,53749,"N-Ethyl-2-(piperidino)-N-(1-(2,4-xylyloxy)-2-propyl)acetamide hydrochloride",CCN(C(C)COC1=C(C=C(C=C1)C)C)C(=O)C[NH+]2CCCCC2.[Cl-],,,,,,
3749,53750,"N-[1-(2,4-dimethylphenoxy)propan-2-yl]-N-ethyl-2-piperidin-1-ylacetamide",CCN(C(C)COC1=C(C=C(C=C1)C)C)C(=O)CN2CCCCC2,,,,,,
3750,53751,N-(2-Mesityloxyethyl)-N-methyl-2-(2-methylpiperidino)acetamide hydrochloride,CC1CCCC[NH+]1CC(=O)N(C)CCOC2=C(C=C(C=C2C)C)C.[Cl-],,,,,,
3751,53752,"N-methyl-2-(2-methylpiperidin-1-yl)-N-[2-(2,4,6-trimethylphenoxy)ethyl]acetamide",CC1CCCCN1CC(=O)N(C)CCOC2=C(C=C(C=C2C)C)C,,,,,,
3752,53753,2-(Morpholino)-N-methyl-N-(2-mesityloxyethyl)acetamide hydrochloride,CC1=CC(=C(C(=C1)C)OCCN(C)C(=O)C[NH+]2CCOCC2)C.[Cl-],,,,,,
3753,53754,"N-methyl-2-morpholin-4-yl-N-[2-(2,4,6-trimethylphenoxy)ethyl]acetamide",CC1=CC(=C(C(=C1)C)OCCN(C)C(=O)CN2CCOCC2)C,,,,,,
3754,53755,N-Methyl-2-(2-methylpiperidino)-N-(2-phenoxyethyl)acetamide hydrochloride,CC1CCCC[NH+]1CC(=O)N(C)CCOC2=CC=CC=C2.[Cl-],,,,,,
3755,53756,N-methyl-2-(2-methylpiperidin-1-yl)-N-(2-phenoxyethyl)acetamide,CC1CCCCN1CC(=O)N(C)CCOC2=CC=CC=C2,,,,,,
3756,53757,N-Methyl-2-(2-methylpiperidino)-N-(2-(o-tolyloxy)ethyl)-acetamide hydrochloride,CC1CCCC[NH+]1CC(=O)N(C)CCOC2=CC=CC=C2C.[Cl-],,,,,,
3757,53758,N-methyl-N-[2-(2-methylphenoxy)ethyl]-2-(2-methylpiperidin-1-yl)acetamide,CC1CCCCN1CC(=O)N(C)CCOC2=CC=CC=C2C,,,,,,
3758,53759,N-Methyl-N-(2-phenoxyethyl)-2-(piperidino)acetamide hydrochloride,CN(CCOC1=CC=CC=C1)C(=O)C[NH+]2CCCCC2.[Cl-],,,,,,
3759,53760,N-methyl-N-(2-phenoxyethyl)-2-piperidin-1-ylacetamide,CN(CCOC1=CC=CC=C1)C(=O)CN2CCCCC2,,,,,,
3760,53761,N-Methyl-2-(piperidino)-N-(2-(o-tolyloxy)ethyl)acetamide hydrochloride,CC1=CC=CC=C1OCCN(C)C(=O)C[NH+]2CCCCC2.[Cl-],,,,,,
3761,53762,N-methyl-N-[2-(2-methylphenoxy)ethyl]-2-piperidin-1-ylacetamide,CC1=CC=CC=C1OCCN(C)C(=O)CN2CCCCC2,,,,,,
3762,53763,"4'-Butoxy-2-piperidinoacetanilide, hydrochloride",CCCCOC1=CC=C(C=C1)NC(=O)C[NH+]2CCCCC2.[Cl-],,,,,,
3763,53764,N-(4-butoxyphenyl)-2-piperidin-1-ylacetamide,CCCCOC1=CC=C(C=C1)NC(=O)CN2CCCCC2,,,,,,
3764,53765,"2-(Butylamino)-2'-chloroacetanilide, hydrochloride",CCCC[NH2+]CC(=O)NC1=CC=CC=C1Cl.[Cl-],,,,,,
3765,53766,2-(butylamino)-N-(2-chlorophenyl)acetamide,CCCCNCC(=O)NC1=CC=CC=C1Cl,,,,,,
3766,53767,2'-Chloro-2-(2-(diethylamino)ethyl)methylaminoacetanilide dihydrochloride,CC[NH+](CC)CC[NH+](C)CC(=O)NC1=CC=CC=C1Cl.[Cl-].[Cl-],,,,,,
3767,53768,N-(2-chlorophenyl)-2-[2-(diethylamino)ethyl-methylamino]acetamide,CCN(CC)CCN(C)CC(=O)NC1=CC=CC=C1Cl,,,,,,
3768,53769,4'-Chloro-2-(2-(diethylamino)ethyl)methylaminoacetanilide dihydrochloride,CC[NH+](CC)CC[NH+](C)CC(=O)NC1=CC=C(C=C1)Cl.[Cl-].[Cl-],,,,,,
3769,53770,N-(4-chlorophenyl)-2-[2-(diethylamino)ethyl-methylamino]acetamide,CCN(CC)CCN(C)CC(=O)NC1=CC=C(C=C1)Cl,,,,,,
3770,53771,"2'-Chloro-2-(diethylamino)acetanilide, hydrochloride",CC[NH+](CC)CC(=O)NC1=CC=CC=C1Cl.[Cl-],,,,,,
3771,53772,N-[2-Chlorophenyl]-2-(diethylamino)acetamide,CCN(CC)CC(=O)NC1=CC=CC=C1Cl,,,,,,
3772,53773,"2',6'-Dichloro-2-(2-(diethylamino)ethyl)methylaminoacetanilide dihydrochloride",CC[NH+](CC)CC[NH+](C)CC(=O)NC1=C(C=CC=C1Cl)Cl.[Cl-].[Cl-],,,,,,
3773,53774,"N-(2,6-dichlorophenyl)-2-[2-(diethylamino)ethyl-methylamino]acetamide",CCN(CC)CCN(C)CC(=O)NC1=C(C=CC=C1Cl)Cl,,,,,,
3774,53775,"2',6'-Dichloro-2-(dipropylamino)acetanilide, hydrochloride",CCC[NH+](CCC)CC(=O)NC1=C(C=CC=C1Cl)Cl.[Cl-],,,,,,
3775,53776,"N-(2,6-dichlorophenyl)-2-(dipropylamino)acetamide",CCCN(CCC)CC(=O)NC1=C(C=CC=C1Cl)Cl,,,,,,
3776,53777,"2-(Diethylamino)-2',4',6'-trichloroacetanilide, hydrochloride",CC[NH+](CC)CC(=O)NC1=C(C=C(C=C1Cl)Cl)Cl.[Cl-],,,,,,
3777,53778,2-(2-(Diethylamino)ethyl)methylamino-o-acetanisidide dihydrochloride,CC[NH+](CC)CC[NH+](C)CC(=O)NC1=CC=CC=C1OC.[Cl-].[Cl-],,,,,,
3778,53779,2-[2-(diethylamino)ethyl-methylamino]-N-(2-methoxyphenyl)acetamide,CCN(CC)CCN(C)CC(=O)NC1=CC=CC=C1OC,,,,,,
3779,53780,Ethyl 2-(oxepin-2-ylamino)oxyacetate,CCOC(=O)CONC1=CC=CC=CO1,,,,,,
3780,53781,CID 53781,C1C[NH+](CCN1)C2=C3CC(C4=C(C=CC(=C4)Cl)SC3=CC(=C2)F)CCCC(=O)C5=CC=C(C=C5)F.C(=CC(=O)[O-])C(=O)O,,,,,,
3781,53782,"4-(3-Chloro-9-fluoro-7-piperazin-1-yl-5,6-dihydrobenzo[b][1]benzothiepin-5-yl)-1-(4-fluorophenyl)butan-1-one",C1CN(CCN1)C2=C3CC(C4=C(C=CC(=C4)Cl)SC3=CC(=C2)F)CCCC(=O)C5=CC=C(C=C5)F,,,,,,
3782,53783,"1H-1-Benzazepine, 2,3,4,5-tetrahydro-1-((diethylamino)acetyl)-8-fluoro-5-(4-fluorophenyl)-, ethanedioate (1:1)",CC[NH+](CC)CC(=O)N1CCCC(C2=C1C=C(C=C2)F)C3=CC=C(C=C3)F.C(=O)(C(=O)[O-])O,,,,,,
3783,53784,"2,3,4,5-Tetrahydro-1-[(diethylamino)acetyl]-8-fluoro-5-(4-fluorophenyl)-1H-1-benzazepine",CCN(CC)CC(=O)N1CCCC(C2=C1C=C(C=C2)F)C3=CC=C(C=C3)F,,,,,,
3784,53785,"1H-1-Benzazepine, 2,3,4,5-tetrahydro-8-fluoro-5-(4-fluorophenyl)-1-(1-pyrrolidinylacetyl)-, ethanedioate (1:1)",C1CC[NH+](C1)CC(=O)N2CCCC(C3=C2C=C(C=C3)F)C4=CC=C(C=C4)F.C(=O)(C(=O)[O-])O,,,,,,
3785,53786,"1-[8-Fluoro-5-(4-fluorophenyl)-2,3,4,5-tetrahydro-1-benzazepin-1-yl]-2-pyrrolidin-1-ylethanone",C1CCN(C1)CC(=O)N2CCCC(C3=C2C=C(C=C3)F)C4=CC=C(C=C4)F,,,,,,
3786,53787,"1H-1-Benzazepine, 2,3,4,5-tetrahydro-1-(2-(diethylamino)ethyl)-8-fluoro-5-(4-fluorophenyl)-, monohydrochloride",CC[NH+](CC)CCN1CCCC(C2=C1C=C(C=C2)F)C3=CC=C(C=C3)F.[Cl-],,,,,,
3787,53788,"1-[2-(Diethylamino)ethyl]-8-fluoro-5-(4-fluorophenyl)-2,3,4,5-tetrahydro-1H-1-benzazepine",CCN(CC)CCN1CCCC(C2=C1C=C(C=C2)F)C3=CC=C(C=C3)F,,,,,,
3788,53789,"1H-1-Benzazepine, 2,3,4,5-tetrahydro-8-fluoro-5-(4-fluorophenyl)-1-(2-(1-pyrrolidinyl)ethyl)-, hydrochloride, hydrate (2:3:1)",C1CC[NH+](C1)CC[NH+]2CCCC(C3=C2C=C(C=C3)F)C4=CC=C(C=C4)F.[Cl-].[Cl-],,,,,,
3789,53790,"8-Fluoro-5-(4-fluorophenyl)-1-(2-pyrrolidin-1-ylethyl)-2,3,4,5-tetrahydro-1-benzazepine",C1CCN(C1)CCN2CCCC(C3=C2C=C(C=C3)F)C4=CC=C(C=C4)F,,,,,,
3790,53791,"1H-1-Benzazepine, 2,3,4,5-tetrahydro-8-fluoro-5-(4-fluorophenyl)-1-((4-methyl-1-piperazinyl)acetyl)-, dihydrochloride",CN1CCN(CC1)CC(=O)N2CCCC(C3=C2C=C(C=C3)F)C4=CC=C(C=C4)F.Cl.Cl,,,,,,
3791,53792,"2,3,4,5-Tetrahydro-8-fluoro-5-(4-fluorophenyl)-1-[(4-methyl-1-piperazinyl)acetyl]-1H-1-benzazepine",CN1CCN(CC1)CC(=O)N2CCCC(C3=C2C=C(C=C3)F)C4=CC=C(C=C4)F,,,,,,
3792,53793,"1H-1-Benzazepine, 2,3,4,5-tetrahydro-8-fluoro-5-(4-fluorophenyl)-1-((4-(2-hydroxyethyl)-1-piperazinyl)acetyl)-, hydrochloride, hydrate (2:4:1)",C1CC(C2=C(C=C(C=C2)F)N(C1)C(=O)CN3CCN(CC3)CCO)C4=CC=C(C=C4)F.Cl.Cl,,,,,,
3793,53794,"2,3,4,5-Tetrahydro-8-fluoro-5-(4-fluorophenyl)-1-[[4-(2-hydroxyethyl)-1-piperazinyl]acetyl]-1H-1-benzazepine",C1CC(C2=C(C=C(C=C2)F)N(C1)C(=O)CN3CCN(CC3)CCO)C4=CC=C(C=C4)F,,,,,,
3794,53795,"1H-1-Benzazepine, 2,3,4,5-tetrahydro-8-fluoro-5-(4-fluorophenyl)-1-((4-(2-(1-oxopropoxy)ethyl)-1-piperazinyl)acetyl)-, dihydrochloride",CCC(=O)OCCN1CCN(CC1)CC(=O)N2CCCC(C3=C2C=C(C=C3)F)C4=CC=C(C=C4)F.Cl.Cl,,,,,,
3795,53796,"8-Fluoro-5-(4-fluorophenyl)-2,3,4,5-tetrahydro-1-[[4-[2-(1-oxopropoxy)ethyl]-1-piperazinyl]acetyl]-1H-1-benzazepine",CCC(=O)OCCN1CCN(CC1)CC(=O)N2CCCC(C3=C2C=C(C=C3)F)C4=CC=C(C=C4)F,,,,,,
3796,53797,"1H-1-Benzazepine, 2,3,4,5-tetrahydro-8-fluoro-5-(4-fluorophenyl)-1-(2-(4-methyl-1-piperazinyl)ethyl)-, dihydrochloride",CN1CCN(CC1)CCN2CCCC(C3=C2C=C(C=C3)F)C4=CC=C(C=C4)F.Cl.Cl,,,,,,
3797,53798,"8-Fluoro-5-(4-fluorophenyl)-2,3,4,5-tetrahydro-1-[2-(4-methyl-1-piperazinyl)ethyl]-1H-1-benzazepine",CN1CCN(CC1)CCN2CCCC(C3=C2C=C(C=C3)F)C4=CC=C(C=C4)F,,,,,,
3798,53799,"1H-1-Benzazepine, 2,3,4,5-tetrahydro-8-fluoro-5-(4-fluorophenyl)-1-(2-(4-(2-hydroxyethyl)-1-piperazinyl)ethyl)-, dihydrochloride",C1CC(C2=C(C=C(C=C2)F)N(C1)CCN3CCN(CC3)CCO)C4=CC=C(C=C4)F.Cl.Cl,,,,,,
3799,53800,"2,3,4,5-Tetrahydro-8-fluoro-5-(4-fluorophenyl)-1-[2-[4-(2-hydroxyethyl)-1-piperazinyl]ethyl]-1H-1-benzazepine",C1CC(C2=C(C=C(C=C2)F)N(C1)CCN3CCN(CC3)CCO)C4=CC=C(C=C4)F,,,,,,
3800,53801,"1-hydroxy-10,12-dimethoxy-8-methyl-4-[(2R,3R,4S,5R,6R)-3,4,5-trihydroxy-6-methyloxan-2-yl]naphtho[1,2-c]isochromen-6-one",C[C@@H]1[C@@H]([C@@H]([C@H]([C@H](O1)C2=C3C(=C(C=C2)O)C(=CC4=C3OC(=O)C5=C4C(=CC(=C5)C)OC)OC)O)O)O,,,,,,
3801,53802,Toromycin,C[C@@H]1[C@@H]([C@@H]([C@H]([C@H](O1)C2=C3C(=C(C=C2)O)C(=CC4=C3OC(=O)C5=C4C(=CC(=C5)C=C)OC)OC)O)O)O,,,,,,
3802,53803,2-(Butylamino)-N-methyl-N-(2-(o-tolyloxy)ethyl)acetamide hydrochloride,CCCC[NH2+]CC(=O)N(C)CCOC1=CC=CC=C1C.[Cl-],,,,,,
3803,53804,2-(butylamino)-N-methyl-N-[2-(2-methylphenoxy)ethyl]acetamide,CCCCNCC(=O)N(C)CCOC1=CC=CC=C1C,,,,,,
3804,53805,Mononitrosocimetidine,CC1=C(NCN1)CSCCN=C(NC#N)N(C)N=O,,,,,,
3805,53806,"3-Biphenylacetic acid, 4'-chloro-4-methoxy-",COC1=C(C=C(C=C1)C2=CC=C(C=C2)Cl)CC(=O)O,,,,,,
3806,53807,"3-Biphenylacetic acid, 4'-chloro-2-methoxy-",COC1=C(C=CC=C1C2=CC=C(C=C2)Cl)CC(=O)O,,,,,,
3807,53808,"4-Biphenylacetic acid, 4'-chloro-5-methoxy-",COC1=C(C=CC(=C1)C2=CC=C(C=C2)Cl)CC(=O)O,,,,,,
3808,53809,2-(3-Methoxy-2-phenylphenyl)acetic acid,COC1=CC=CC(=C1C2=CC=CC=C2)CC(=O)O,,,,,,
3809,53810,"2-Biphenylacetic acid, 4'-chloro-5-methoxy-",COC1=CC(=C(C=C1)CC(=O)O)C2=CC=C(C=C2)Cl,,,,,,
3810,53811,"2-Biphenylacetic acid, 4'-chloro-4-methoxy-",COC1=CC(=C(C=C1)C2=CC=C(C=C2)Cl)CC(=O)O,,,,,,
3811,53812,"2-Biphenylacetic acid, 4'-chloro-3-methoxy-",COC1=CC=CC(=C1CC(=O)O)C2=CC=C(C=C2)Cl,,,,,,
3812,53813,"3-Biphenylacetic acid, 4'-chloro-6-methoxy-",COC1=C(C=C(C=C1)CC(=O)O)C2=CC=C(C=C2)Cl,,,,,,
3813,53814,"4-Biphenylacetic acid, 4'-chloro-6-methoxy-",COC1=C(C=CC(=C1)CC(=O)O)C2=CC=C(C=C2)Cl,,,,,,
3814,53815,"2,2'-((4-Methoxy-3-nitrobenzyl)imino)diethanol hydrochloride",COC1=C(C=C(C=C1)C[NH+](CCO)CCO)[N+](=O)[O-].[Cl-],,,,,,
3815,53816,"2,2'-[(4-Methoxy-3-nitrobenzyl)imino]diethanol",COC1=C(C=C(C=C1)CN(CCO)CCO)[N+](=O)[O-],,,,,,
3816,53817,"2,2'-((4-Propoxy-3-nitrobenzyl)imino)diethanol hydrochloride",CCCOC1=C(C=C(C=C1)C[NH+](CCO)CCO)[N+](=O)[O-].[Cl-],,,,,,
3817,53818,"2,2'-[(3-Nitro-4-propoxybenzyl)imino]diethanol",CCCOC1=C(C=C(C=C1)CN(CCO)CCO)[N+](=O)[O-],,,,,,
3818,53819,"2,2'-((4-Isobutoxy-3-nitrobenzyl)imino)diethanol hydrochloride",CC(C)COC1=C(C=C(C=C1)C[NH+](CCO)CCO)[N+](=O)[O-].[Cl-],,,,,,
3819,53820,2-[2-Hydroxyethyl-[[4-(2-methylpropoxy)-3-nitrophenyl]methyl]amino]ethanol,CC(C)COC1=C(C=C(C=C1)CN(CCO)CCO)[N+](=O)[O-],,,,,,
3820,53821,"N,N-Bis(2-chloroethyl)-4-methoxy-3-nitro-benzylamine hydrochloride",COC1=C(C=C(C=C1)C[NH+](CCCl)CCCl)[N+](=O)[O-].[Cl-],,,,,,
3821,53822,2-chloro-N-(2-chloroethyl)-N-[(4-methoxy-3-nitrophenyl)methyl]ethanamine,COC1=C(C=C(C=C1)CN(CCCl)CCCl)[N+](=O)[O-],,,,,,
3822,53823,"N,N-Bis(2-chloroethyl)-4-ethoxy-3-nitro-benzylamine hydrochloride",CCOC1=C(C=C(C=C1)C[NH+](CCCl)CCCl)[N+](=O)[O-].[Cl-],,,,,,
3823,53824,2-chloro-N-(2-chloroethyl)-N-[(4-ethoxy-3-nitrophenyl)methyl]ethanamine,CCOC1=C(C=C(C=C1)CN(CCCl)CCCl)[N+](=O)[O-],,,,,,
3824,53825,"N,N-Bis(2-chloroethyl)-4-propoxy-3-nitro-benzylamine hydrochloride",CCCOC1=C(C=C(C=C1)C[NH+](CCCl)CCCl)[N+](=O)[O-].[Cl-],,,,,,
3825,53826,2-chloro-N-(2-chloroethyl)-N-[(3-nitro-4-propoxyphenyl)methyl]ethanamine,CCCOC1=C(C=C(C=C1)CN(CCCl)CCCl)[N+](=O)[O-],,,,,,
3826,53827,"N,N-Bis(2-chloroethyl)-4-butoxy-3-nitro-benzylamine hydrochloride",CCCCOC1=C(C=C(C=C1)C[NH+](CCCl)CCCl)[N+](=O)[O-].[Cl-],,,,,,
3827,53828,N-[(4-butoxy-3-nitrophenyl)methyl]-2-chloro-N-(2-chloroethyl)ethanamine,CCCCOC1=C(C=C(C=C1)CN(CCCl)CCCl)[N+](=O)[O-],,,,,,
3828,53829,"N,N-Bis(2-chloroethyl)-4-isobutoxy-3-nitro-benzylamine hydrochloride",CC(C)COC1=C(C=C(C=C1)C[NH+](CCCl)CCCl)[N+](=O)[O-].[Cl-],,,,,,
3829,53830,2-chloro-N-(2-chloroethyl)-N-[[4-(2-methylpropoxy)-3-nitrophenyl]methyl]ethanamine,CC(C)COC1=C(C=C(C=C1)CN(CCCl)CCCl)[N+](=O)[O-],,,,,,
3830,53831,N-P-Chlorophenyl-M-methoxybenzohydroxamic acid,COC1=CC=CC(=C1)C(=O)N(C2=CC=C(C=C2)Cl)O,,,,,,
3831,53832,"2,5,6-Trimethyl-7-ethylthiohept-1-en-3-yn-5-ol",CCSCC(C)C(C)(C#CC(=C)C)O,,,,,,
3832,53833,"2,5,6-Trimethyl-7-propylthiohept-1-en-3-yn-5-ol",CCCSCC(C)C(C)(C#CC(=C)C)O,,,,,,
3833,53834,"2,5,6-Trimethyl-7-butylthiohept-1-en-3-yn-5-ol",CCCCSCC(C)C(C)(C#CC(=C)C)O,,,,,,
3834,53835,"Acetic acid, ((4-(dimethylamino)-6-methyl-2-pyrimidinyl)thio)-, hydrazide",CC1=CC(=NC(=N1)SCC(=O)NN)N(C)C,,,,,,
3835,53836,"Acetic acid, ((4-(dibutylamino)-6-methyl-2-pyrimidinyl)thio)-, hydrazide",CCCCN(CCCC)C1=NC(=NC(=C1)C)SCC(=O)NN,,,,,,
3836,53837,2-(Pyrrolidinyl)ethyl 2-chloro-6-methylcarbanilate hydrochloride,CC1=C(C(=CC=C1)Cl)NC(=O)OCC[NH+]2CCCC2.[Cl-],,,,,,
3837,53838,2-pyrrolidin-1-ylethyl N-(2-chloro-6-methylphenyl)carbamate,CC1=C(C(=CC=C1)Cl)NC(=O)OCCN2CCCC2,,,,,,
3838,53839,2-Diethylamino-3-methoxy-3-phenylpropyl carbanilate,CCN(CC)C(COC(=O)NC1=CC=CC=C1)C(C2=CC=CC=C2)OC,,,,,,
3839,53840,2-(Dimethylamino)-3-hydroxy-3-phenylpropyl carbanilate,CN(C)C(COC(=O)NC1=CC=CC=C1)C(C2=CC=CC=C2)O,,,,,,
3840,53841,"Carbanilic acid, 2-(N-methyl-N-phenethylamino)ethyl ester",CN(CCC1=CC=CC=C1)CCOC(=O)NC2=CC=CC=C2,,,,,,
3841,53842,"Benzyl 3,3-bis(2-chloroethyl)carbazate",C1=CC=C(C=C1)COC(=O)NN(CCCl)CCCl,,,,,,
3842,53843,"Carbazic acid, 3,3-bis(2-chloroethyl)-, ethyl ester",CCOC(=O)NN(CCCl)CCCl,,,,,,
3843,53844,"Carbazic acid, 3,3-bis(2-chloroethyl)-, phenyl ester",C1=CC=C(C=C1)OC(=O)NN(CCCl)CCCl,,,,,,
3844,53845,"N-(2-(Diethylamino)ethyl)-2-ethoxy-N-(2,6-xylyl)cinchoninamide hydrochloride",CC[NH+](CC)CCN(C1=C(C=CC=C1C)C)C(=O)C2=CC(=NC3=CC=CC=C32)OCC.[Cl-],,,,,,
3845,53846,"N-[2-(diethylamino)ethyl]-N-(2,6-dimethylphenyl)-2-ethoxyquinoline-4-carboxamide",CCN(CC)CCN(C1=C(C=CC=C1C)C)C(=O)C2=CC(=NC3=CC=CC=C32)OCC,,,,,,
3846,53847,CID 53847,CCCCC(=CC1=CC=CC=C1)C(=O)NCCN(CC)CC,,,,,,
3847,53848,2-benzylidene-N-[2-(diethylamino)ethyl]butanamide,CCC(=CC1=CC=CC=C1)C(=O)NCCN(CC)CC,,,,,,
3848,53849,2-(Diethylamino)ethyl 3-(4-ethoxyphenyl)prop-2-enoate,CCN(CC)CCOC(=O)C=CC1=CC=C(C=C1)OCC,,,,,,
3849,53850,2-(Diethylamino)ethyl 2-benzylidenebutanoate,CCC(=CC1=CC=CC=C1)C(=O)OCCN(CC)CC,,,,,,
3850,53851,2-(Diethylamino)ethyl 2-benzylideneheptanoate,CCCCCC(=CC1=CC=CC=C1)C(=O)OCCN(CC)CC,,,,,,
3851,53852,CID 53852,CC[NH+](CC)CCN(C1=C(C=CC=C1C)C)C(=O)C=CC.[Cl-],,,,,,
3852,53853,"Acetamide, 2-((1-benzyl-4-nitro-1H-imidazol-5-YL)thio)-",C1=CC=C(C=C1)CN2C=NC(=C2SCC(=O)N)[N+](=O)[O-],,,,,,
3853,53854,"ACETAMIDE, 2-((1-(p-CHLOROBENZYL)-4-NITRO-1H-IMIDAZOL-5-YL)THIO)-",C1=CC(=CC=C1CN2C=NC(=C2SCC(=O)N)[N+](=O)[O-])Cl,,,,,,
3854,53855,"Acetamide, 2-((1-benzyl-2-methyl-4-nitro-1H-imidazol-5-YL)thio)-",CC1=NC(=C(N1CC2=CC=CC=C2)SCC(=O)N)[N+](=O)[O-],,,,,,
3855,53856,"ACETAMIDE, 2-((1-(p-CHLOROBENZYL)-2-METHYL-4-NITRO-1H-IMIDAZOL-5-YL)THIO)-",CC1=NC(=C(N1CC2=CC=C(C=C2)Cl)SCC(=O)N)[N+](=O)[O-],,,,,,
3856,53857,"Acetonitrile, ((1-benzyl-2-methyl-4-nitro-1H-imidazol-5-YL)thio)-",CC1=NC(=C(N1CC2=CC=CC=C2)SCC#N)[N+](=O)[O-],,,,,,
3857,53858,"ACETONITRILE, ((1-(p-FLUOROBENZYL)-2-METHYL-4-NITRO-1H-IMIDAZOL-5-YL)THIO)-",CC1=NC(=C(N1CC2=CC=C(C=C2)F)SCC#N)[N+](=O)[O-],,,,,,
3858,53859,"ACETONITRILE, ((1-(p-CHLOROBENZYL)-2-METHYL-4-NITRO-1H-IMIDAZOL-5-YL)THIO)-",CC1=NC(=C(N1CC2=CC=C(C=C2)Cl)SCC#N)[N+](=O)[O-],,,,,,
3859,53860,"Acetic acid, ((4-(diethylamino)-6-methyl-2-pyrimidinyl)thio)-, hydrazide",CCN(CC)C1=NC(=NC(=C1)C)SCC(=O)NN,,,,,,
3860,53861,"2-Butoxy-N-(2-(diethylamino)ethyl)-N-(2,6-xylyl)cinchoninamide, hydrochloride",CCCCOC1=NC2=CC=CC=C2C(=C1)C(=O)N(CC[NH+](CC)CC)C3=C(C=CC=C3C)C.[Cl-],,,,,,
3861,53862,"2-butoxy-N-[2-(diethylamino)ethyl]-N-(2,6-dimethylphenyl)quinoline-4-carboxamide",CCCCOC1=NC2=CC=CC=C2C(=C1)C(=O)N(CCN(CC)CC)C3=C(C=CC=C3C)C,,,,,,
3862,53863,"2-(Butylamino)-p-acetophenetidide, hydrochloride",CCCC[NH2+]CC(=O)NC1=CC=C(C=C1)OCC.[Cl-],,,,,,
3863,53864,2-(butylamino)-N-(4-ethoxyphenyl)acetamide,CCCCNCC(=O)NC1=CC=C(C=C1)OCC,,,,,,
3864,53865,"2-(Diethylamino)-2'-ethoxyacetanilide, hydrochloride",CC[NH+](CC)CC(=O)NC1=CC=CC=C1OCC.[Cl-],,,,,,
3865,53866,2-(diethylamino)-N-(2-ethoxyphenyl)acetamide,CCN(CC)CC(=O)NC1=CC=CC=C1OCC,,,,,,
3866,53867,"2-(Diethylamino)-p-acetophenetidide, hydrochloride",CC[NH+](CC)CC(=O)NC1=CC=C(C=C1)OCC.[Cl-],,,,,,
3867,53868,2-(diethylamino)-N-(4-ethoxyphenyl)acetamide,CCN(CC)CC(=O)NC1=CC=C(C=C1)OCC,,,,,,
3868,53869,"Acetanilide, 4'-ethoxy-2-pyrrolidinyl-, hydrochloride",CCOC1=CC=C(C=C1)NC(=O)C[NH+]2CCCC2.[Cl-],,,,,,
3869,53870,N-(4-ethoxyphenyl)-2-(pyrrolidin-1-yl)acetamide,CCOC1=CC=C(C=C1)NC(=O)CN2CCCC2,,,,,,
3870,53871,"2-(Allylamino)-2'-chloro-6'-methylacetanilide, hydrochloride",CC1=C(C(=CC=C1)Cl)NC(=O)C[NH2+]CC=C.[Cl-],,,,,,
3871,53872,N-(2-chloro-6-methylphenyl)-2-(prop-2-enylamino)acetamide,CC1=C(C(=CC=C1)Cl)NC(=O)CNCC=C,,,,,,
3872,53873,Benzyl-[(2-chloro-6-methyl-phenyl)carbamoylmethyl]azanium chloride,CC1=C(C(=CC=C1)Cl)NC(=O)C[NH2+]CC2=CC=CC=C2.[Cl-],,,,,,
3873,53874,2-(benzylamino)-N-(2-chloro-6-methylphenyl)acetamide,CC1=C(C(=CC=C1)Cl)NC(=O)CNCC2=CC=CC=C2,,,,,,
3874,53875,N-Benzyl-6'-chloro-2-(diethylamino)-o-acetotoluidide hydrochloride,CC[NH+](CC)CC(=O)N(CC1=CC=CC=C1)C2=C(C=CC=C2Cl)C.[Cl-],,,,,,
3875,53876,N-benzyl-N-(2-chloro-6-methylphenyl)-2-(diethylamino)acetamide,CCN(CC)CC(=O)N(CC1=CC=CC=C1)C2=C(C=CC=C2Cl)C,,,,,,
3876,53877,2-(Benzyl(3-(diethylamino)propyl)amino)-6'-chloro-o-acetotoluidide dihydrochloride,CC[NH+](CC)CCC[NH+](CC1=CC=CC=C1)CC(=O)NC2=C(C=CC=C2Cl)C.[Cl-].[Cl-],,,,,,
3877,53878,2-[benzyl-[3-(diethylamino)propyl]amino]-N-(2-chloro-6-methylphenyl)acetamide,CCN(CC)CCCN(CC1=CC=CC=C1)CC(=O)NC2=C(C=CC=C2Cl)C,,,,,,
3878,53879,Benzyl-[3-(diethylazaniumyl)propyl]-[2-(2-methylanilino)-2-oxoethyl]azanium dichloride,CC[NH+](CC)CCC[NH+](CC1=CC=CC=C1)CC(=O)NC2=CC=CC=C2C.[Cl-].[Cl-],,,,,,
3879,53880,2-[benzyl-[3-(diethylamino)propyl]amino]-N-(2-methylphenyl)acetamide,CCN(CC)CCCN(CC1=CC=CC=C1)CC(=O)NC2=CC=CC=C2C,,,,,,
3880,53881,6'-Chloro-2-(p-chlorobenzyl(2-(diethylamino)ethyl)amino)-o-acetototuidide dihydrochloride,CC[NH+](CC)CC[NH+](CC1=CC=C(C=C1)Cl)CC(=O)NC2=C(C=CC=C2Cl)C.[Cl-].[Cl-],,,,,,
3881,53882,N-(2-chloro-6-methylphenyl)-2-[(4-chlorophenyl)methyl-[2-(diethylamino)ethyl]amino]acetamide,CCN(CC)CCN(CC1=CC=C(C=C1)Cl)CC(=O)NC2=C(C=CC=C2Cl)C,,,,,,
3882,53883,"6'-Chloro-2-(cyclohexylamino)-o-acetotoluidide, hydrochloride",CC1=C(C(=CC=C1)Cl)NC(=O)C[NH2+]C2CCCCC2.[Cl-],,,,,,
3883,53884,N-(2-chloro-6-methylphenyl)-2-(cyclohexylamino)acetamide,CC1=C(C(=CC=C1)Cl)NC(=O)CNC2CCCCC2,,,,,,
3884,53885,"6'-Chloro-2-(N-cyclohexyl-N-methylamino)-o-acetotoluidide, hydrochloride",CC1=C(C(=CC=C1)Cl)NC(=O)C[NH+](C)C2CCCCC2.[Cl-],,,,,,
3885,53886,N-(2-chloro-6-methylphenyl)-2-[cyclohexyl(methyl)amino]acetamide,CC1=C(C(=CC=C1)Cl)NC(=O)CN(C)C2CCCCC2,,,,,,
3886,53887,"6'-Chloro-2-(dibutylamino)-o-acetotoluidide, hydrochloride",CCCC[NH+](CCCC)CC(=O)NC1=C(C=CC=C1Cl)C.[Cl-],,,,,,
3887,53888,N-(2-chloro-6-methylphenyl)-2-(dibutylamino)acetamide,CCCCN(CCCC)CC(=O)NC1=C(C=CC=C1Cl)C,,,,,,
3888,53889,4'-Chloro-2-(2-(diethylamino)ethyl)methylamino-o-acetotoluidide dihydrochloride,CC[NH+](CC)CC[NH+](C)CC(=O)NC1=C(C=C(C=C1)Cl)C.[Cl-].[Cl-],,,,,,
3889,53890,N-(4-chloro-2-methylphenyl)-2-[2-(diethylamino)ethyl-methylamino]acetamide,CCN(CC)CCN(C)CC(=O)NC1=C(C=C(C=C1)Cl)C,,,,,,
3890,53891,5'-Chloro-2-(2-(diethylamino)ethyl)methylamino-o-acetotoluidide dihydrochloride,CC[NH+](CC)CC[NH+](C)CC(=O)NC1=C(C=CC(=C1)Cl)C.[Cl-].[Cl-],,,,,,
3891,53892,N-(5-chloro-2-methylphenyl)-2-[2-(diethylamino)ethyl-methylamino]acetamide,CCN(CC)CCN(C)CC(=O)NC1=C(C=CC(=C1)Cl)C,,,,,,
3892,53893,6'-Chloro-2-(2-(diethylamino)ethyl)methylamino-m-acetotoluidide dihydrochloride,CC[NH+](CC)CC[NH+](C)CC(=O)NC1=C(C=CC(=C1)C)Cl.[Cl-].[Cl-],,,,,,
3893,53894,N-(2-chloro-5-methylphenyl)-2-[2-(diethylamino)ethyl-methylamino]acetamide,CCN(CC)CCN(C)CC(=O)NC1=C(C=CC(=C1)C)Cl,,,,,,
3894,53895,"Acetanilide, 3'-chloro-2-(diethylamino)-2'-methyl-, hydrochloride",CC[NH+](CC)CC(=O)NC1=C(C(=CC=C1)Cl)C.[Cl-],,,,,,
3895,53896,N-(3-chloro-2-methylphenyl)-2-(diethylamino)acetamide,CCN(CC)CC(=O)NC1=C(C(=CC=C1)Cl)C,,,,,,
3896,53897,"Acetanilide, 4'-chloro-2-(diethylamino)-2'-methyl-, hydrochloride",CC[NH+](CC)CC(=O)NC1=C(C=C(C=C1)Cl)C.[Cl-],,,,,,
3897,53898,N-(4-chloro-2-methylphenyl)-2-(diethylamino)acetamide,CCN(CC)CC(=O)NC1=C(C=C(C=C1)Cl)C,,,,,,
3898,53899,"Acetanilide, 3'-chloro-2-(diethylamino)-6'-methyl-, hydrochloride",CC[NH+](CC)CC(=O)NC1=C(C=CC(=C1)Cl)C.[Cl-],,,,,,
3899,53900,N-(5-Chloro-2-methylphenyl)-2-(diethylamino)acetamide,CCN(CC)CC(=O)NC1=C(C=CC(=C1)Cl)C,,,,,,
3900,53901,"Acetanilide, 2'-chloro-2-(diethylamino)-5'-methyl-, hydrochloride",CC[NH+](CC)CC(=O)NC1=C(C=CC(=C1)C)Cl.[Cl-],,,,,,
3901,53902,N-(2-Chloro-5-methylphenyl)-2-(diethylamino)acetamide,CCN(CC)CC(=O)NC1=C(C=CC(=C1)C)Cl,,,,,,
3902,53903,"Acetanilide, 2'-chloro-2-(diethylamino)-6'-methyl-, hydrochloride",CC[NH+](CC)CC(=O)NC1=C(C=CC=C1Cl)C.[Cl-],,,,,,
3903,53904,N-(2-chloro-6-methylphenyl)-2-(diethylamino)acetamide,CCN(CC)CC(=O)NC1=C(C=CC=C1Cl)C,,,,,,
3904,53905,6'-Chloro-2-(diethylamino)-N-methyl-o-acetotoluidide hydrochloride,CC[NH+](CC)CC(=O)N(C)C1=C(C=CC=C1Cl)C.[Cl-],,,,,,
3905,53906,N-(2-chloro-6-methylphenyl)-2-(diethylamino)-N-methylacetamide,CCN(CC)CC(=O)N(C)C1=C(C=CC=C1Cl)C,,,,,,
3906,53907,"4'-Chloro-2-(diethylamino)-3'-trifluoromethylacetanilide, hydrochloride",CC[NH+](CC)CC(=O)NC1=CC(=C(C=C1)Cl)C(F)(F)F.[Cl-],,,,,,
3907,53908,N-[4-chloro-3-(trifluoromethyl)phenyl]-2-(diethylamino)acetamide,CCN(CC)CC(=O)NC1=CC(=C(C=C1)Cl)C(F)(F)F,,,,,,
3908,53909,"2'-Chloro-2-(diethylamino)-5'-trifluoromethylacetanilide, hydrochloride",CC[NH+](CC)CC(=O)NC1=C(C=CC(=C1)C(F)(F)F)Cl.[Cl-],,,,,,
3909,53910,N-[2-chloro-5-(trifluoromethyl)phenyl]-2-(diethylamino)acetamide,CCN(CC)CC(=O)NC1=C(C=CC(=C1)C(F)(F)F)Cl,,,,,,
3910,53911,"6'-Chloro-2-(diisopropylamino)-o-acetotoluidide, hydrochloride",CC1=C(C(=CC=C1)Cl)NC(=O)C[NH+](C(C)C)C(C)C.[Cl-],,,,,,
3911,53912,N-(2-chloro-6-methylphenyl)-2-[di(propan-2-yl)amino]acetamide,CC1=C(C(=CC=C1)Cl)NC(=O)CN(C(C)C)C(C)C,,,,,,
3912,53913,"6'-Chloro-2-(dimethylamino)-o-acetotoluidide, hydrochloride",CC1=C(C(=CC=C1)Cl)NC(=O)C[NH+](C)C.[Cl-],,,,,,
3913,53914,"Acetamide, N-(2-chloro-6-methylphenyl)-, 2-(N,N-dimethylamino)-",CC1=C(C(=CC=C1)Cl)NC(=O)CN(C)C,,,,,,
3914,53915,6'-Chloro-2-(dimethylamino)-N-methyl-o-acetotoluidide hydrochloride,CC1=C(C(=CC=C1)Cl)N(C)C(=O)C[NH+](C)C.[Cl-],,,,,,
3915,53916,N-(2-chloro-6-methylphenyl)-2-(dimethylamino)-N-methylacetamide,CC1=C(C(=CC=C1)Cl)N(C)C(=O)CN(C)C,,,,,,
3916,53917,"6'-Chloro-2-(dipropylamino)-o-acetotoluidide, hydrochloride",CCC[NH+](CCC)CC(=O)NC1=C(C=CC=C1Cl)C.[Cl-],,,,,,
3917,53918,N-(2-chloro-6-methylphenyl)-2-(dipropylamino)acetamide,CCCN(CCC)CC(=O)NC1=C(C=CC=C1Cl)C,,,,,,
3918,53919,"2'-Chloro-2-(ethylamino)-6'-methylacetanilide, hydrochloride",CC[NH2+]CC(=O)NC1=C(C=CC=C1Cl)C.[Cl-],,,,,,
3919,53920,N-(2-chloro-6-methylphenyl)-2-(ethylamino)acetamide,CCNCC(=O)NC1=C(C=CC=C1Cl)C,,,,,,
3920,53921,"2'-Chloro-2-(isopropylamino)-6'-methylacetanilide, hydrochloride",CC1=C(C(=CC=C1)Cl)NC(=O)C[NH2+]C(C)C.[Cl-],,,,,,
3921,53922,N-(2-chloro-6-methylphenyl)-2-(propan-2-ylamino)acetamide,CC1=C(C(=CC=C1)Cl)NC(=O)CNC(C)C,,,,,,
3922,53923,"2'-Chloro-6'-methyl-2-(methylamino)acetanilide, hydrochloride",CC1=C(C(=CC=C1)Cl)NC(=O)C[NH2+]C.[Cl-],,,,,,
3923,53924,N-(2-chloro-6-methylphenyl)-2-(methylamino)acetamide,CC1=C(C(=CC=C1)Cl)NC(=O)CNC,,,,,,
3924,53925,"6'-Chloro-2-(2-methylpiperidino)-o-acetotoluidide, hydrochloride",CC1CCCC[NH+]1CC(=O)NC2=C(C=CC=C2Cl)C.[Cl-],,,,,,
3925,53926,N-(2-chloro-6-methylphenyl)-2-(2-methylpiperidin-1-yl)acetamide,CC1CCCCN1CC(=O)NC2=C(C=CC=C2Cl)C,,,,,,
3926,53927,"4-Morpholineacetamide, N-(2-chloro-6-methylphenyl)-, monohydrochloride",CC1=C(C(=CC=C1)Cl)NC(=O)C[NH+]2CCOCC2.[Cl-],,,,,,
3927,53928,N-(2-chloro-6-methylphenyl)-2-morpholin-4-ylacetamide,CC1=C(C(=CC=C1)Cl)NC(=O)CN2CCOCC2,,,,,,
3928,53929,"6'-Chloro-2-piperidino-o-acetotoluidide, hydrochloride",CC1=C(C(=CC=C1)Cl)NC(=O)C[NH+]2CCCCC2.[Cl-],,,,,,
3929,53930,N-(2-chloro-6-methylphenyl)-2-piperidin-1-ylacetamide,CC1=C(C(=CC=C1)Cl)NC(=O)CN2CCCCC2,,,,,,
3930,53931,"2'-Chloro-6'-methyl-2-(propylamino)acetanilide, hydrochloride",CCC[NH2+]CC(=O)NC1=C(C=CC=C1Cl)C.[Cl-],,,,,,
3931,53932,N-(2-chloro-6-methylphenyl)-2-(propylamino)acetamide,CCCNCC(=O)NC1=C(C=CC=C1Cl)C,,,,,,
3932,53933,"Acetanilide, 2',6'-dibromo-2-(diethylamino)-4'-methyl-, hydrochloride",CC[NH+](CC)CC(=O)NC1=C(C=C(C=C1Br)C)Br.[Cl-],,,,,,
3933,53934,"N-(2,6-dibromo-4-methylphenyl)-2-(diethylamino)acetamide",CCN(CC)CC(=O)NC1=C(C=C(C=C1Br)C)Br,,,,,,
3934,53935,diethyl-[2-(N-ethyl-2-methylanilino)-2-oxoethyl]azanium chloride,CC[NH+](CC)CC(=O)N(CC)C1=CC=CC=C1C.[Cl-],,,,,,
3935,53936,2-(diethylamino)-N-ethyl-N-(2-methylphenyl)acetamide,CCN(CC)CC(=O)N(CC)C1=CC=CC=C1C,,,,,,
3936,53937,"Acetamide, 2-((2-(diethylamino)ethyl)methylamino)-N-(2-methylphenyl)-, dihydrochloride",CC[NH+](CC)CC[NH+](C)CC(=O)NC1=CC=CC=C1C.[Cl-].[Cl-],,,,,,
3937,53938,2-{[2-(Diethylamino)ethyl](methyl)amino}-N-(2-methylphenyl)ethanimidic acid,CCN(CC)CCN(C)CC(=O)NC1=CC=CC=C1C,,,,,,
3938,53939,2-(Diethylamino)-N-methyl-o-acetotoluidide hydrochloride,CC[NH+](CC)CC(=O)N(C)C1=CC=CC=C1C.[Cl-],,,,,,
3939,53940,NoName_4200,CCN(CC)CC(=O)N(C)C1=CC=CC=C1C,,,,,,
3940,53941,"2-(Benzyl(3-(diethylamino)propyl)amino)-2',6'-acetoxylidide dihydrochloride",CC[NH+](CC)CCC[NH+](CC1=CC=CC=C1)CC(=O)NC2=C(C=CC=C2C)C.[Cl-].[Cl-],,,,,,
3941,53942,"2-[benzyl-[3-(diethylamino)propyl]amino]-N-(2,6-dimethylphenyl)acetamide",CCN(CC)CCCN(CC1=CC=CC=C1)CC(=O)NC2=C(C=CC=C2C)C,,,,,,
3942,53943,"N-Butyl-2-(ethylamino)-2',6'-acetoxylidide hydrochloride",CCCCN(C1=C(C=CC=C1C)C)C(=O)C[NH2+]CC.[Cl-],,,,,,
3943,53944,"N-butyl-N-(2,6-dimethylphenyl)-2-(ethylamino)acetamide",CCCCN(C1=C(C=CC=C1C)C)C(=O)CNCC,,,,,,
3944,53945,"2-(p-Chlorobenzyl(2-(diethylamino)ethyl)amino)-2',6'-acetoxylidide dihydrochloride",CC[NH+](CC)CC[NH+](CC1=CC=C(C=C1)Cl)CC(=O)NC2=C(C=CC=C2C)C.[Cl-].[Cl-],,,,,,
3945,53946,"2-[(4-chlorophenyl)methyl-[2-(diethylamino)ethyl]amino]-N-(2,6-dimethylphenyl)acetamide",CCN(CC)CCN(CC1=CC=C(C=C1)Cl)CC(=O)NC2=C(C=CC=C2C)C,,,,,,
3946,53947,"2',6'-Acetoxylidide, 2-(dibutylamino)-, hydrochloride",CCCC[NH+](CCCC)CC(=O)NC1=C(C=CC=C1C)C.[Cl-],,,,,,
3947,53948,"2-(dibutylamino)-N-(2,6-dimethylphenyl)acetamide",CCCCN(CCCC)CC(=O)NC1=C(C=CC=C1C)C,,,,,,
3948,53949,"N-(2-(Diethylamino)ethyl)-2',6'-acetoxylidide, hydrochloride",CC[NH+](CC)CCN(C1=C(C=CC=C1C)C)C(=O)C.[Cl-],,,,,,
3949,53950,"2-(2-(Diethylamino)ethyl)methylamino-2',6'-acetoxylidide dihydrochloride",CC[NH+](CC)CC[NH+](C)CC(=O)NC1=C(C=CC=C1C)C.[Cl-].[Cl-],,,,,,
3950,53951,"2-[2-(diethylamino)ethyl-methylamino]-N-(2,6-dimethylphenyl)acetamide",CCN(CC)CCN(C)CC(=O)NC1=C(C=CC=C1C)C,,,,,,
3951,53952,"Acetanilide, 2-(diethylamino)-3',5'-dimethyl-, hydrochloride",CC[NH+](CC)CC(=O)NC1=CC(=CC(=C1)C)C.[Cl-],,,,,,
3952,53953,"2-(diethylamino)-N-(3,5-dimethylphenyl)acetamide",CCN(CC)CC(=O)NC1=CC(=CC(=C1)C)C,,,,,,
3953,53954,"2-(Diethylamino)-N-methyl-2',6'-acetoxylidide hydrochloride",CC[NH+](CC)CC(=O)N(C)C1=C(C=CC=C1C)C.[Cl-],,,,,,
3954,53955,"2-(diethylamino)-N-(2,6-dimethylphenyl)-N-methylacetamide",CCN(CC)CC(=O)N(C)C1=C(C=CC=C1C)C,,,,,,
3955,53956,"2-(Diisopropylamino)-2',6'-acetoxylidide, hydrochloride",CC1=C(C(=CC=C1)C)NC(=O)C[NH+](C(C)C)C(C)C.[Cl-],,,,,,
3956,53957,"N-(2,6-dimethylphenyl)-2-[di(propan-2-yl)amino]acetamide",CC1=C(C(=CC=C1)C)NC(=O)CN(C(C)C)C(C)C,,,,,,
3957,53958,"2-(2,6-Dimethylpiperidino)-2',6'-acetoxylidide, hydrochloride",CC1CCCC([NH+]1CC(=O)NC2=C(C=CC=C2C)C)C.[Cl-],,,,,,
3958,53959,"N-(2,6-dimethylphenyl)-2-(2,6-dimethylpiperidin-1-yl)acetamide",CC1CCCC(N1CC(=O)NC2=C(C=CC=C2C)C)C,,,,,,
3959,53960,"1-Piperidineacetamide, N-(2,6-dimethylphenyl)-2-methyl-, monohydrochloride",CC1CCCC[NH+]1CC(=O)NC2=C(C=CC=C2C)C.[Cl-],,,,,,
3960,53961,"N-(2,6-dimethylphenyl)-2-(2-methylpiperidin-1-yl)acetamide",CC1CCCCN1CC(=O)NC2=C(C=CC=C2C)C,,,,,,
3961,53962,"1-Piperidineacetamide, N-(2,6-dimethylphenyl)-, monohydrochloride",CC1=C(C(=CC=C1)C)NC(=O)C[NH+]2CCCCC2.[Cl-],,,,,,
3962,53963,"1-Piperidineacetamide, N-(2,6-dimethylphenyl)-",CC1=C(C(=CC=C1)C)NC(=O)CN2CCCCC2,,,,,,
3963,53964,"6'-Chloro-2-(2,6-dimethylpiperidino)-o-acetotoluidide, hydrochloride",CC1CCCC([NH+]1CC(=O)NC2=C(C=CC=C2Cl)C)C.[Cl-],,,,,,
3964,53965,"N-(2-chloro-6-methylphenyl)-2-(2,6-dimethylpiperidin-1-yl)acetamide",CC1CCCC(N1CC(=O)NC2=C(C=CC=C2Cl)C)C,,,,,,
3965,53966,"beta-ALANINE, N-(3-AMINO-2,4,6-TRIIODOBENZOYL)-N-PHENYL-, CALCIUM SALT",C1=CC=C(C=C1)N(CCC(=O)[O-])C(=O)C2=C(C(=C(C=C2I)I)N)I.C1=CC=C(C=C1)N(CCC(=O)[O-])C(=O)C2=C(C(=C(C=C2I)I)N)I.[Ca+2],,,,,,
3966,53967,"1-Pentyn-3-ol, 3-methyl-, allophanate",CCC(C)(C#C)OC(=O)NC(=O)N,,,,,,
3967,53968,"Barbituric acid, 5-allyl-1-benzyl-3-(2-(diethylmethylammonio)ethyl)-5-isopropyl-, iodide",CC[N+](C)(CC)CCN1C(=O)C(C(=O)N(C1=O)CC2=CC=CC=C2)(CC=C)C(C)C.[I-],,,,,,
3968,53969,"2-(3-Benzyl-2,4,6-trioxo-5-propan-2-yl-5-prop-2-enyl-1,3-diazinan-1-yl)ethyl-diethyl-methylazanium",CC[N+](C)(CC)CCN1C(=O)C(C(=O)N(C1=O)CC2=CC=CC=C2)(CC=C)C(C)C,,,,,,
3969,53970,"Barbituric acid, 5,5-diallyl-1-benzyl-3-(2-(diethylmethylammonio)ethyl)-, iodide",CC[N+](C)(CC)CCN1C(=O)C(C(=O)N(C1=O)CC2=CC=CC=C2)(CC=C)CC=C.[I-],,,,,,
3970,53971,"2-[3-Benzyl-2,4,6-trioxo-5,5-bis(prop-2-enyl)-1,3-diazinan-1-yl]ethyl-diethyl-methylazanium",CC[N+](C)(CC)CCN1C(=O)C(C(=O)N(C1=O)CC2=CC=CC=C2)(CC=C)CC=C,,,,,,
3971,53972,"4,4'-Biphenylenebis(2-oxoethylene)bis(triethylammonium) dibromide",CC[N+](CC)(CC)C(=O)CC1=CC=C(C=C1)C2=CC=C(C=C2)CC(=O)[N+](CC)(CC)CC.[Br-].[Br-],,,,,,
3972,53973,"Ammonium, 4,4'-biphenylenebis(3-oxopropylene)bis(dimethyl(2-hydroxyethyl)-, dibromide",C[N+](C)(CCO)C(=O)CCC1=CC=C(C=C1)C2=CC=C(C=C2)CCC(=O)[N+](C)(C)CCO.[Br-].[Br-],,,,,,
3973,53974,2-Hydroxyethyl-[3-[4-[4-[3-[2-hydroxyethyl(dimethyl)azaniumyl]-3-oxopropyl]phenyl]phenyl]propanoyl]-dimethylazanium,C[N+](C)(CCO)C(=O)CCC1=CC=C(C=C1)C2=CC=C(C=C2)CCC(=O)[N+](C)(C)CCO,,,,,,
3974,53975,"Ammonium, 7,14-diethyl-7,14-dimethyl-7,14-diazoniaeicosylenebis(diethylmethyl-, tetraiodide",CC[N+](C)(CC)CCCCCC[N+](C)(CC)CCCCCC[N+](C)(CC)CCCCCC[N+](C)(CC)CC.[I-].[I-].[I-].[I-],,,,,,
3975,53976,6-[Diethyl(methyl)azaniumyl]hexyl-[6-[6-[diethyl(methyl)azaniumyl]hexyl-ethyl-methylazaniumyl]hexyl]-ethyl-methylazanium,CC[N+](C)(CC)CCCCCC[N+](C)(CC)CCCCCC[N+](C)(CC)CCCCCC[N+](C)(CC)CC,,,,,,
3976,53977,"Ammonium, 7,14-diethyl-7,14-dipropyl-7,14-diazoniaeicosylenebis(diethylpropyl-, tetraiodide",CCC[N+](CC)(CC)CCCCCC[N+](CC)(CCC)CCCCCC[N+](CC)(CCC)CCCCCC[N+](CC)(CC)CCC.[I-].[I-].[I-].[I-],,,,,,
3977,53978,6-[Diethyl(propyl)azaniumyl]hexyl-[6-[6-[diethyl(propyl)azaniumyl]hexyl-ethyl-propylazaniumyl]hexyl]-ethyl-propylazanium,CCC[N+](CC)(CC)CCCCCC[N+](CC)(CCC)CCCCCC[N+](CC)(CCC)CCCCCC[N+](CC)(CC)CCC,,,,,,
3978,53979,"2-(2,2-Dicyclopentylacetyl)oxyethyl-diethyl-methylazanium bromide",CC[N+](C)(CC)CCOC(=O)C(C1CCCC1)C2CCCC2.[Br-],,,,,,
3979,53980,"2-(2,2-Dicyclopentylacetyl)oxyethyl-diethyl-methylazanium",CC[N+](C)(CC)CCOC(=O)C(C1CCCC1)C2CCCC2,,,,,,
3980,53981,"Ammonium, diethylmethyl(2-(10-phenothiazinyl)ethyl)-, iodide",CC[N+](C)(CC)CCN1C2=CC=CC=C2SC3=CC=CC=C31.[I-],,,,,,
3981,53982,Diethyl-methyl-(2-phenothiazin-10-ylethyl)azanium,CC[N+](C)(CC)CCN1C2=CC=CC=C2SC3=CC=CC=C31,,,,,,
3982,53983,Diethylmethyl(3-(10-phenothiazinyl)propyl)ammonium iodide,CC[N+](C)(CC)CCCN1C2=CC=CC=C2SC3=CC=CC=C31.[I-],,,,,,
3983,53984,Diethyl-methyl-(3-phenothiazin-10-ylpropyl)azanium,CC[N+](C)(CC)CCCN1C2=CC=CC=C2SC3=CC=CC=C31,,,,,,
3984,53985,"Ammonium, (2-(diphenylmethoxy)ethyl)triethyl-, iodide",CC[N+](CC)(CC)CCOC(C1=CC=CC=C1)C2=CC=CC=C2.[I-],,,,,,
3985,53986,2-Benzhydryloxyethyl(triethyl)azanium,CC[N+](CC)(CC)CCOC(C1=CC=CC=C1)C2=CC=CC=C2,,,,,,
3986,53987,(m-Hydroxyphenyl)-trimethylammonium methylsulfate di-sec-butylphosphate,CCC(C)OP(=O)(OC1=CC=CC(=C1)[N+](C)(C)C)OC(C)CC.COS(=O)(=O)[O-],,,,,,
3987,53988,[3-Di(butan-2-yloxy)phosphoryloxyphenyl]-trimethylazanium,CCC(C)OP(=O)(OC1=CC=CC(=C1)[N+](C)(C)C)OC(C)CC,,,,,,
3988,53989,"AMMONIUM, (m-HYDROXYPHENYL)TRIMETHYL-, METHYLSULFATE, DIISOPROPYLPHOSPHATE",CC(C)OP(=O)(OC1=CC=CC(=C1)[N+](C)(C)C)OC(C)C.COS(=O)(=O)[O-],,,,,,
3989,53990,[3-Di(propan-2-yloxy)phosphoryloxyphenyl]-trimethylazanium,CC(C)OP(=O)(OC1=CC=CC(=C1)[N+](C)(C)C)OC(C)C,,,,,,
3990,53991,"AMMONIUM, (m-HYDROXYPHENYL)TRIMETHYL-, METHYLSULFATE, DIMETHYLPHOSPHATE",C[N+](C)(C)C1=CC(=CC=C1)OP(=O)(OC)OC.COS(=O)(=O)[O-],,,,,,
3991,53992,(3-Dimethoxyphosphoryloxyphenyl)-trimethylazanium,C[N+](C)(C)C1=CC(=CC=C1)OP(=O)(OC)OC,,,,,,
3992,53993,"7,7,16,16-Tetraethyl-7,16-diazoniadocosylenebis(triethylammonium) tetraiodide",CC[N+](CC)(CC)CCCCCC[N+](CC)(CC)CCCCCCCC[N+](CC)(CC)CCCCCC[N+](CC)(CC)CC.[I-].[I-].[I-].[I-],,,,,,
3993,53994,8-[Diethyl-[6-(triethylazaniumyl)hexyl]azaniumyl]octyl-diethyl-[6-(triethylazaniumyl)hexyl]azanium,CC[N+](CC)(CC)CCCCCC[N+](CC)(CC)CCCCCCCC[N+](CC)(CC)CCCCCC[N+](CC)(CC)CC,,,,,,
3994,53995,"9,9,18,18-Tetraethyl-9,18-diazoniahexacosylenebis(triethylammonium) tetraiodide",CC[N+](CC)(CC)CCCCCCCC[N+](CC)(CC)CCCCCCCC[N+](CC)(CC)CCCCCCCC[N+](CC)(CC)CC.[I-].[I-].[I-].[I-],,,,,,
3995,53996,8-[Diethyl-[8-(triethylazaniumyl)octyl]azaniumyl]octyl-diethyl-[8-(triethylazaniumyl)octyl]azanium,CC[N+](CC)(CC)CCCCCCCC[N+](CC)(CC)CCCCCCCC[N+](CC)(CC)CCCCCCCC[N+](CC)(CC)CC,,,,,,
3996,53997,"Ammonium, 7,7,18,18-tetraethyl-7,18-diazoniatetracosylenebis(triethyl-, tetraiodide",CC[N+](CC)(CC)CCCCCC[N+](CC)(CC)CCCCCCCCCC[N+](CC)(CC)CCCCCC[N+](CC)(CC)CC.[I-].[I-].[I-].[I-],,,,,,
3997,53998,10-[Diethyl-[6-(triethylazaniumyl)hexyl]azaniumyl]decyl-diethyl-[6-(triethylazaniumyl)hexyl]azanium,CC[N+](CC)(CC)CCCCCC[N+](CC)(CC)CCCCCCCCCC[N+](CC)(CC)CCCCCC[N+](CC)(CC)CC,,,,,,
3998,53999,"Ammonium, 9,9,16,16-tetraethyl-9,16-diazoniatetracosylenebis(triethyl-, tetraiodide",CC[N+](CC)(CC)CCCCCCCC[N+](CC)(CC)CCCCCC[N+](CC)(CC)CCCCCCCC[N+](CC)(CC)CC.[I-].[I-].[I-].[I-],,,,,,
3999,54000,6-[Diethyl-[8-(triethylazaniumyl)octyl]azaniumyl]hexyl-diethyl-[8-(triethylazaniumyl)octyl]azanium,CC[N+](CC)(CC)CCCCCCCC[N+](CC)(CC)CCCCCC[N+](CC)(CC)CCCCCCCC[N+](CC)(CC)CC,,,,,,
4000,54001,CID 54001,CC(C[NH3+])C1(C2=CC=CC=C2C(C3=CC=CC=C31)(C)C)O.C(=CC(=O)[O-])C(=O)O,,,,,,
4001,54002,"9-(1-Aminopropan-2-yl)-10,10-dimethylanthracen-9-ol",CC(CN)C1(C2=CC=CC=C2C(C3=CC=CC=C31)(C)C)O,,,,,,
4002,54003,"1,1-Diphenyl-2-methyl-3-(1-azetidinyl)propanol hydrobromide",CC(C[NH+]1CCC1)C(C2=CC=CC=C2)(C3=CC=CC=C3)O.[Br-],,,,,,
4003,54004,"alpha,alpha-Diphenyl-beta-methyl-1-azetidine-1-propanol",CC(CN1CCC1)C(C2=CC=CC=C2)(C3=CC=CC=C3)O,,,,,,
4004,54005,11-methyl-11H-benzo[b]fluorene,CC1C2=CC=CC=C2C3=CC4=CC=CC=C4C=C13,,,,,,
4005,54006,"Acetamide, N-(3-chloro-2-methylphenyl)-2-((2-(diethylamino)ethyl)methylamino)-, dihydrochloride",CC[NH+](CC)CC[NH+](C)CC(=O)NC1=C(C(=CC=C1)Cl)C.[Cl-].[Cl-],,,,,,
4006,54007,N-(3-Chloro-2-methylphenyl)-2-{[2-(diethylamino)ethyl](methyl)amino}ethanimidic acid,CCN(CC)CCN(C)CC(=O)NC1=C(C(=CC=C1)Cl)C,,,,,,
4007,54008,(4-Biphenylcarbonylmethyl)dimethyl(2-hydroxyethyl)ammonium bromide,C[N+](C)(CCO)CC(=O)C1=CC=C(C=C1)C2=CC=CC=C2.[Br-],,,,,,
4008,54009,2-Hydroxyethyl-dimethyl-[2-oxo-2-(4-phenylphenyl)ethyl]azanium,C[N+](C)(CCO)CC(=O)C1=CC=C(C=C1)C2=CC=CC=C2,,,,,,
4009,54010,"Ammonium, 4,4'-biphenylenebis(2-oxoethylene)bis(diethyl(3-hydroxypropyl)-, dibromide",CC[N+](CC)(CCCO)C(=O)CC1=CC=C(C=C1)C2=CC=C(C=C2)CC(=O)[N+](CC)(CC)CCCO.[Br-].[Br-],,,,,,
4010,54011,[2-[4-[4-[2-[Diethyl(3-hydroxypropyl)azaniumyl]-2-oxoethyl]phenyl]phenyl]acetyl]-diethyl-(3-hydroxypropyl)azanium,CC[N+](CC)(CCCO)C(=O)CC1=CC=C(C=C1)C2=CC=C(C=C2)CC(=O)[N+](CC)(CC)CCCO,,,,,,
4011,54012,Trimethyl(2-phenothiazin-10-ylethyl)ammonium iodide,C[N+](C)(C)CCN1C2=CC=CC=C2SC3=CC=CC=C31.[I-],,,,,,
4012,54013,Trimethyl(2-phenothiazin-10-ylethyl)azanium,C[N+](C)(C)CCN1C2=CC=CC=C2SC3=CC=CC=C31,,,,,,
4013,54014,"Ammonium, 11,11,18,18-tetraethyl-11,18-diazoniaoctacosylenebis(triethyl-, tetraiodide",CC[N+](CC)(CC)CCCCCCCCCC[N+](CC)(CC)CCCCCC[N+](CC)(CC)CCCCCCCCCC[N+](CC)(CC)CC.[I-].[I-].[I-].[I-],,,,,,
4014,54015,6-[Diethyl-[10-(triethylazaniumyl)decyl]azaniumyl]hexyl-diethyl-[10-(triethylazaniumyl)decyl]azanium,CC[N+](CC)(CC)CCCCCCCCCC[N+](CC)(CC)CCCCCC[N+](CC)(CC)CCCCCCCCCC[N+](CC)(CC)CC,,,,,,
4015,54016,"3',5'-Dicarboxy-1,2',6'-trimethyl-4,4'-bipyridinium iodide diethyl ester",CCOC(=O)C1=C(N=C(C(=C1C2=CC=[N+](C=C2)C)C(=O)OCC)C)C.[I-],,,,,,
4016,54017,"Diethyl 2,6-dimethyl-4-(1-methylpyridin-1-ium-4-yl)pyridine-3,5-dicarboxylate",CCOC(=O)C1=C(N=C(C(=C1C2=CC=[N+](C=C2)C)C(=O)OCC)C)C,,,,,,
4017,54018,"2-(Diethylamino)ethyl 2,4-diphenylbutyrate",CCN(CC)CCOC(=O)C(CCC1=CC=CC=C1)C2=CC=CC=C2,,,,,,
4018,54019,6'-Chloro-3-(diethylamino)-o-butyrotoluidide hydrochloride,CC[NH+](CC)C(C)CC(=O)NC1=C(C=CC=C1Cl)C.[Cl-],,,,,,
4019,54020,N-(2-chloro-6-methylphenyl)-3-(diethylamino)butanamide,CCN(CC)C(C)CC(=O)NC1=C(C=CC=C1Cl)C,,,,,,
4020,54021,6'-Chloro-2-(propylamino)-o-butyrotoluidide hydrochloride,CCC[NH2+]C(CC)C(=O)NC1=C(C=CC=C1Cl)C.[Cl-],,,,,,
4021,54022,N-(2-chloro-6-methylphenyl)-2-(propylamino)butanamide,CCCNC(CC)C(=O)NC1=C(C=CC=C1Cl)C,,,,,,
4022,54023,"3-(Diethylamino)-2',6'-butyroxylidide hydrochloride",CC[NH+](CC)C(C)CC(=O)NC1=C(C=CC=C1C)C.[Cl-],,,,,,
4023,54024,"3-(diethylamino)-N-(2,6-dimethylphenyl)butanamide",CCN(CC)C(C)CC(=O)NC1=C(C=CC=C1C)C,,,,,,
4024,54025,"N-(2-(Diethylamino)ethyl)carbamic acid, 6-chloro-o-tolyl ester hydrochloride",CC[NH+](CC)CCNC(=O)OC1=C(C=CC=C1Cl)C.[Cl-],,,,,,
4025,54026,(2-chloro-6-methylphenyl) N-[2-(diethylamino)ethyl]carbamate,CCN(CC)CCNC(=O)OC1=C(C=CC=C1Cl)C,,,,,,
4026,54027,N-(2-(Diethylamino)ethyl)carbamic acid mesityl ester hydrochloride,CC[NH+](CC)CCNC(=O)OC1=C(C=C(C=C1C)C)C.[Cl-],,,,,,
4027,54028,"(2,4,6-trimethylphenyl) N-[2-(diethylamino)ethyl]carbamate",CCN(CC)CCNC(=O)OC1=C(C=C(C=C1C)C)C,,,,,,
4028,54029,"N-(2-(Diethylamino)ethyl)carbamic acid, 2,6-xylyl ester hydrochloride",CC[NH+](CC)CCNC(=O)OC1=C(C=CC=C1C)C.[Cl-],,,,,,
4029,54030,"(2,6-dimethylphenyl) N-[2-(diethylamino)ethyl]carbamate",CCN(CC)CCNC(=O)OC1=C(C=CC=C1C)C,,,,,,
4030,54031,"Carbamic acid, dimethyl-, 2-ethyl-5-methyl-3-pyrazolyl ester",CCN1C(=CC(=N1)C)OC(=O)N(C)C,,,,,,
4031,54032,"N-(2-Piperidinoethyl)carbamic acid, 6-chloro-o-tolyl ester, hydrochloride",CC1=C(C(=CC=C1)Cl)OC(=O)NCC[NH+]2CCCCC2.[Cl-],,,,,,
4032,54033,(2-chloro-6-methylphenyl) N-(2-piperidin-1-ylethyl)carbamate,CC1=C(C(=CC=C1)Cl)OC(=O)NCCN2CCCCC2,,,,,,
4033,54034,"N-(2-Piperidinoethyl)carbamic acid, mesityl ester, hydrochloride",CC1=CC(=C(C(=C1)C)OC(=O)NCC[NH+]2CCCCC2)C.[Cl-],,,,,,
4034,54035,"(2,4,6-trimethylphenyl) N-(2-piperidin-1-ylethyl)carbamate",CC1=CC(=C(C(=C1)C)OC(=O)NCCN2CCCCC2)C,,,,,,
4035,54036,"N-(2-(Piperidino)ethyl)carbamic acid, 2,6-xylyl ester hydrochloride",CC1=C(C(=CC=C1)C)OC(=O)NCC[NH+]2CCCCC2.[Cl-],,,,,,
4036,54037,"(2,6-dimethylphenyl) N-(2-piperidin-1-ylethyl)carbamate",CC1=C(C(=CC=C1)C)OC(=O)NCCN2CCCCC2,,,,,,
4037,54038,"N-(2-Pyrrolidinylethyl)carbamic acid, 6-chloro-o-tolyl ester, hydrochloride",CC1=C(C(=CC=C1)Cl)OC(=O)NCC[NH+]2CCCC2.[Cl-],,,,,,
4038,54039,(2-chloro-6-methylphenyl) N-(2-pyrrolidin-1-ylethyl)carbamate,CC1=C(C(=CC=C1)Cl)OC(=O)NCCN2CCCC2,,,,,,
4039,54040,"N-(2-Pyrrolidinylethyl)carbamic acid, mesityl ester, hydrochloride",CC1=CC(=C(C(=C1)C)OC(=O)NCC[NH+]2CCCC2)C.[Cl-],,,,,,
4040,54041,"(2,4,6-trimethylphenyl) N-(2-pyrrolidin-1-ylethyl)carbamate",CC1=CC(=C(C(=C1)C)OC(=O)NCCN2CCCC2)C,,,,,,
4041,54042,"N-(2-(Pyrrolidinyl)ethyl)carbamic acid, 2,6-xylyl ester hydrochloride",CC1=C(C(=CC=C1)C)OC(=O)NCC[NH+]2CCCC2.[Cl-],,,,,,
4042,54043,"(2,6-dimethylphenyl) N-(2-pyrrolidin-1-ylethyl)carbamate",CC1=C(C(=CC=C1)C)OC(=O)NCCN2CCCC2,,,,,,
4043,54044,"2,4'-Bipyridinium, 1',4'-dihydro-3',5'-dicarboxy-1,2',6'-trimethyl-, iodide, diethyl ester",CCOC(=O)C1=C(NC(=C(C1C2=CC=CC=[N+]2C)C(=O)OCC)C)C.[I-],,,,,,
4044,54045,"Diethyl 2,6-dimethyl-4-(1-methylpyridin-1-ium-2-yl)-1,4-dihydropyridine-3,5-dicarboxylate",CCOC(=O)C1=C(NC(=C(C1C2=CC=CC=[N+]2C)C(=O)OCC)C)C,,,,,,
4045,54046,"1H-Indole-7-carboxamide, 2,3-dihydro-2-oxo-3,3-diphenyl-",C1=CC=C(C=C1)C2(C3=CC=CC(=C3NC2=O)C(=O)N)C4=CC=CC=C4,,,,,,
4046,54047,"5-[3-(5-Bromo-2,4-dihydroxyphenyl)-3-oxoprop-1-enyl]-2-hydroxybenzoic acid",C1=CC(=C(C=C1C=CC(=O)C2=CC(=C(C=C2O)O)Br)C(=O)O)O,,,,,,
4047,54048,Agn-PC-0jkzy2,CC1(COP(=S)(OC1)N(C(C)(C)C)SN(C)C(=O)F)C,,,,,,
4048,54049,Ristianol phosphate,C1=CN=CC=C1CSCCO.OP(=O)(O)O,,,,,,
4049,54050,Ristianol,C1=CN=CC=C1CSCCO,,,,,,
4050,54051,Trichloro-2-cyclobuten-1-one,C1(C(=C(C1=O)Cl)Cl)Cl,,,,,,
4051,54052,Vanilol,CC(C)NCC(COC1=C(C=C(C=C1)C(=O)OC)OC)O,,,,,,
4052,54053,"Barbituric acid, 5-allyl-1-benzyl-3-(2-(diethylamino)ethyl)-5-isopropyl-, hydrochloride",CC[NH+](CC)CCN1C(=O)C(C(=O)N(C1=O)CC2=CC=CC=C2)(CC=C)C(C)C.[Cl-],,,,,,
4053,54054,5-Allyl-1-benzyl-3-[2-(diethylamino)ethyl]-5-isopropylbarbituric acid,CCN(CC)CCN1C(=O)C(C(=O)N(C1=O)CC2=CC=CC=C2)(CC=C)C(C)C,,,,,,
4054,54055,"Barbituric acid, 5-allyl-1-benzyl-3-(2-(dimethylamino)ethyl)-5-isopropyl-, hydrochloride",CC(C)C1(C(=O)N(C(=O)N(C1=O)CC2=CC=CC=C2)CC[NH+](C)C)CC=C.[Cl-],,,,,,
4055,54056,5-Allyl-1-benzyl-3-[2-(dimethylamino)ethyl]-5-isopropylbarbituric acid,CC(C)C1(C(=O)N(C(=O)N(C1=O)CC2=CC=CC=C2)CCN(C)C)CC=C,,,,,,
4056,54057,"Barbituric acid, 5-allyl-1-benzyl-3-(2-(dimethylamino)ethyl)-5-phenyl-, hydrochloride",C[NH+](C)CCN1C(=O)C(C(=O)N(C1=O)CC2=CC=CC=C2)(CC=C)C3=CC=CC=C3.[Cl-],,,,,,
4057,54058,5-Allyl-1-benzyl-3-[2-(dimethylamino)ethyl]-5-phenylbarbituric acid,CN(C)CCN1C(=O)C(C(=O)N(C1=O)CC2=CC=CC=C2)(CC=C)C3=CC=CC=C3,,,,,,
4058,54059,"Barbituric acid, 5-allyl-1-benzyl-3-(2-morpholinoethyl)-5-isopropyl-, hydrochloride",CC(C)C1(C(=O)N(C(=O)N(C1=O)CC2=CC=CC=C2)CC[NH+]3CCOCC3)CC=C.[Cl-],,,,,,
4059,54060,5-Allyl-1-benzyl-3-(2-morpholinoethyl)-5-isopropylbarbituric acid,CC(C)C1(C(=O)N(C(=O)N(C1=O)CC2=CC=CC=C2)CCN3CCOCC3)CC=C,,,,,,
4060,54061,"Barbituric acid, 5-allyl-1-benzyl-3-(2-piperidinoethyl)-5-isopropyl-, hydrobromide",CC(C)C1(C(=O)N(C(=O)N(C1=O)CC2=CC=CC=C2)CC[NH+]3CCCCC3)CC=C.[Br-],,,,,,
4061,54062,5-Allyl-1-benzyl-3-(2-piperidinoethyl)-5-isopropylbarbituric acid,CC(C)C1(C(=O)N(C(=O)N(C1=O)CC2=CC=CC=C2)CCN3CCCCC3)CC=C,,,,,,
4062,54063,N-(2-Aminoethyl)-o-isopropoxybenzamide hydrochloride,CC(C)OC1=CC=CC=C1C(=O)NCC[NH3+].[Cl-],,,,,,
4063,54064,N-(2-Aminoethyl)-2-isopropyloxybenzamide,CC(C)OC1=CC=CC=C1C(=O)NCCN,,,,,,
4064,54065,N-(3-Aminopropyl)-o-butoxybenzamide hydrochloride,CCCCOC1=CC=CC=C1C(=O)NCCC[NH3+].[Cl-],,,,,,
4065,54066,N-(3-aminopropyl)-2-butoxybenzamide,CCCCOC1=CC=CC=C1C(=O)NCCCN,,,,,,
4066,54067,N-(3-Aminopropyl)-o-ethoxybenzamide hydrochloride,CCOC1=CC=CC=C1C(=O)NCCC[NH3+].[Cl-],,,,,,
4067,54068,N-(3-aminopropyl)-2-ethoxybenzamide,CCOC1=CC=CC=C1C(=O)NCCCN,,,,,,
4068,54069,N-(3-Aminopropyl)-o-isopropoxybenzamide hydrochloride,CC(C)OC1=CC=CC=C1C(=O)NCCC[NH3+].[Cl-],,,,,,
4069,54070,N-(3-Aminopropyl)-2-isopropyloxybenzamide,CC(C)OC1=CC=CC=C1C(=O)NCCCN,,,,,,
4070,54071,N-(3-Aminopropyl)-o-methoxybenzamide hydrochloride,COC1=CC=CC=C1C(=O)NCCC[NH3+].[Cl-],,,,,,
4071,54072,N-(3-aminopropyl)-2-methoxybenzamide,COC1=CC=CC=C1C(=O)NCCCN,,,,,,
4072,54073,CID 54073,CCCOC1=CC=CC=C1C(=O)NCCC[NH3+].[Cl-],,,,,,
4073,54074,N-(3-aminopropyl)-2-propoxybenzamide,CCCOC1=CC=CC=C1C(=O)NCCCN,,,,,,
4074,54075,N-(3-(Bis(2-hydroxyethyl)amino)propyl)-o-ethoxybenzamide hydrochloride,CCOC1=CC=CC=C1C(=O)NCCC[NH+](CCO)CCO.[Cl-],,,,,,
4075,54076,N-[3-[bis(2-hydroxyethyl)amino]propyl]-2-ethoxybenzamide,CCOC1=CC=CC=C1C(=O)NCCCN(CCO)CCO,,,,,,
4076,54077,N-(3-(Bis(2-hydroxyethyl)amino)propyl)-o-isopentoxybenzamide hydrochloride,CC(C)CCOC1=CC=CC=C1C(=O)NCCC[NH+](CCO)CCO.[Cl-],,,,,,
4077,54078,N-[3-[bis(2-hydroxyethyl)amino]propyl]-2-(3-methylbutoxy)benzamide,CC(C)CCOC1=CC=CC=C1C(=O)NCCCN(CCO)CCO,,,,,,
4078,54079,N-(3-(Bis(2-hydroxyethyl)amino)propyl)benzamide hydrochloride,CCCCOC1=CC=CC=C1C(=O)NCCC[NH+](CCO)CCO.[Cl-],,,,,,
4079,54080,2-Butoxy-N-[3-[bis(2-hydroxyethyl)amino]propyl]benzamide,CCCCOC1=CC=CC=C1C(=O)NCCCN(CCO)CCO,,,,,,
4080,54081,o-Butoxy-N-(5-(diethylamino)-2-pentyl)benzamide hydrochloride,CCCCOC1=CC=CC=C1C(=O)NC(C)CCC[NH+](CC)CC.[Cl-],,,,,,
4081,54082,2-Butoxy-N-[4-(diethylamino)-1-methylbutyl]benzamide,CCCCOC1=CC=CC=C1C(=O)NC(C)CCCN(CC)CC,,,,,,
4082,54083,o-Butoxy-N-(3-(diethylamino)propyl)benzamide hydrochloride,CCCCOC1=CC=CC=C1C(=O)NCCC[NH+](CC)CC.[Cl-],,,,,,
4083,54084,2-butoxy-N-[3-(diethylamino)propyl]benzamide,CCCCOC1=CC=CC=C1C(=O)NCCCN(CC)CC,,,,,,
4084,54085,"BENZAMIDE, o-BUTOXY-N-(3-MORPHOLINOPROPYL)-",CCCCOC1=CC=CC=C1C(=O)NCCCN2CCOCC2,,,,,,
4085,54086,"N-(2-(Diethylamino)ethyl)-2,4,6-trimethylbenzamide hydrochloride",CC[NH+](CC)CCNC(=O)C1=C(C=C(C=C1C)C)C.[Cl-],,,,,,
4086,54087,"N-[2-(Diethylamino)ethyl]-2,4,6-trimethylbenzamide",CCN(CC)CCNC(=O)C1=C(C=C(C=C1C)C)C,,,,,,
4087,54088,o-Ethoxy-N-(3-morpholinopropyl)benzamide,CCOC1=CC=CC=C1C(=O)NCCCN2CCOCC2,,,,,,
4088,54089,"1-Pyrrolidineacetamide, N-acetyl-N-(2-chloro-6-methylphenyl)-, monohydrochloride",CC1=C(C(=CC=C1)Cl)N(C(=O)C)C(=O)CN2CCCC2.Cl,,,,,,
4089,54090,N-acetyl-N-(2-chloro-6-methylphenyl)-2-pyrrolidin-1-ylacetamide,CC1=C(C(=CC=C1)Cl)N(C(=O)C)C(=O)CN2CCCC2,,,,,,
4090,54091,"5-(2-Amino-1-methylethyl)-5H-dibenzo(a,d)cyclohepten-5-ol hydrochloride",CC(C[NH3+])C1(C2=CC=CC=C2C=CC3=CC=CC=C31)O.[Cl-],,,,,,
4091,54092,"2-(1-Aminopropan-2-yl)tricyclo[9.4.0.03,8]pentadeca-1(15),3,5,7,9,11,13-heptaen-2-ol",CC(CN)C1(C2=CC=CC=C2C=CC3=CC=CC=C31)O,,,,,,
4092,54093,"5H-Dibenzo(a,d)cyclohepten-5-ol, 5-(2-(diethylamino)-1-methylethyl)-, hydrochloride",CC[NH+](CC)CC(C)C1(C2=CC=CC=C2C=CC3=CC=CC=C31)O.[Cl-],,,,,,
4093,54094,"2-[1-(Diethylamino)propan-2-yl]tricyclo[9.4.0.03,8]pentadeca-1(15),3,5,7,9,11,13-heptaen-2-ol",CCN(CC)CC(C)C1(C2=CC=CC=C2C=CC3=CC=CC=C31)O,,,,,,
4094,54095,"10,11-Dihydro-5-(2-(diethylamino)-1-methylethyl)-5H-dibenzo(a,d)cyclohepten-5-ol HCl",CC[NH+](CC)CC(C)C1(C2=CC=CC=C2CCC3=CC=CC=C31)O.[Cl-],,,,,,
4095,54096,"2-[1-(Diethylamino)propan-2-yl]tricyclo[9.4.0.03,8]pentadeca-1(15),3,5,7,11,13-hexaen-2-ol",CCN(CC)CC(C)C1(C2=CC=CC=C2CCC3=CC=CC=C31)O,,,,,,
4096,54097,"10,11-Dihydro-5-(1-methyl-2-(pyrrolidinyl)ethyl)-5H-dibenzo(a,d)cyclohepten-5-ol HBr",C[NH+]1CCCC1CCC2(C3=CC=CC=C3CCC4=CC=CC=C42)O.[Br-],,,,,,
4097,54098,"10,11-Dihydro-5-[2-(1-methyl-2-pyrrolidinyl)ethyl]-5H-dibenzo[a,d]cyclohepten-5-ol",CN1CCCC1CCC2(C3=CC=CC=C3CCC4=CC=CC=C42)O,,,,,,
4098,54099,"5H-Dibenzo(b,e)(1,4)diazepin-11-one, 10,11-dihydro-6-chloro-10-(2-(dimethylamino)ethyl)-",CN(C)CCN1C2=C(C(=CC=C2)Cl)NC3=CC=CC=C3C1=O,,,,,,
4099,54100,"5H-Dibenzo(b,e)(1,4)diazepin-11-one, 10,11-dihydro-10-(2-(dimethylamino)ethyl)-7-methoxy-",CN(C)CCN1C2=C(C=C(C=C2)OC)NC3=CC=CC=C3C1=O,,,,,,
4100,54101,"5H-Dibenzo(b,e)(1,4)diazepin-11-one, 10,11-dihydro-10-(2-(dimethylamino)ethyl)-5-methyl-7-methylthio-, hydrochloride",CN1C2=CC=CC=C2C(=O)N(C3=C1C=C(C=C3)SC)CC[NH+](C)C.[Cl-],,,,,,
4101,54102,"5-[2-(Dimethylamino)ethyl]-11-methyl-2-methylsulfanylbenzo[b][1,4]benzodiazepin-6-one",CN1C2=CC=CC=C2C(=O)N(C3=C1C=C(C=C3)SC)CCN(C)C,,,,,,
4102,54103,"5H-Dibenzo(b,e)(1,4)diazepin-11-one, 10,11-dihydro-10-(2-(dimethylamino)ethyl)-8-trifluoromethyl-, hydrochloride",C[NH+](C)CCN1C2=C(C=CC(=C2)C(F)(F)F)NC3=CC=CC=C3C1=O.[Cl-],,,,,,
4103,54104,"Dibenzo(b,f)(1,4)thiazepin-11-one, 10,11-dihydro-7-chloro-10-(2-(dimethylamino)ethyl)-, hydrochloride",C[NH+](C)CCN1C2=C(C=C(C=C2)Cl)SC3=CC=CC=C3C1=O.[Cl-],,,,,,
4104,54105,"7-Chloro-10-(2-(dimethylamino)ethyl)dibenzo(b,f)(1,4)thiazepin-11(10H)-one",CN(C)CCN1C2=C(C=C(C=C2)Cl)SC3=CC=CC=C3C1=O,,,,,,
4105,54106,"Dibenz(b,f)(1,4)oxazepin-11-one, 10,11-dihydro-7-chloro-10-(2-(dimethylamino)ethyl)-, hydrochloride",C[NH+](C)CCN1C2=C(C=C(C=C2)Cl)OC3=CC=CC=C3C1=O.[Cl-],,,,,,
4106,54107,"2-Chloro-5-[2-(dimethylamino)ethyl]benzo[b][1,4]benzoxazepin-6-one",CN(C)CCN1C2=C(C=C(C=C2)Cl)OC3=CC=CC=C3C1=O,,,,,,
4107,54108,"1,3,2-Dioxaphospholan-2-amine, N,N-bis(2-chloroethyl)-, 2-oxide",C1COP(=O)(O1)N(CCCl)CCCl,,,,,,
4108,54109,"1,3,2-Dioxaphosphanane, 2-(bis(2-chloroethyl)amino)-, 2-oxide",C1CCCOP(=O)(OCC1)N(CCCl)CCCl,,,,,,
4109,54110,"1,3,2-Dioxaphosphepane, 2-(bis(2-chloroethyl)amino)-, 2-oxide",C1CCOP(=O)(OC1)N(CCCl)CCCl,,,,,,
4110,54111,"1,3,2-Dioxaphosphocane, 2-(bis(2-chloroethyl)amino)-, 2-oxide",C1CCOP(=O)(OCC1)N(CCCl)CCCl,,,,,,
4111,54112,"1,3,2-Dioxaphospholane, 2-(bis(2-chloroethyl)amino)-, 2-sulfide",C1COP(=S)(O1)N(CCCl)CCCl,,,,,,
4112,54113,"1,3,2-Dioxaphosphorinane, 2-(bis(2-chloroethyl)amino)-, 2-sulfide",C1COP(=S)(OC1)N(CCCl)CCCl,,,,,,
4113,54114,"2-(Bis(2-chloroethyl)amino)-4,5,6-trimethyl-1,3,2-dioxaphosphorinane 2-oxide",CC1C(OP(=O)(OC1C)N(CCCl)CCCl)C,,,,,,
4114,54115,"4-(3,4-Dimethoxyphenyl)-4,5,5-trimethyl-1,3-dioxolan-2-one",CC1(C(OC(=O)O1)(C)C2=CC(=C(C=C2)OC)OC)C,,,,,,
4115,54116,CID 54116,C[C@H]1[C@@H](C(=O)N1S(=O)(=O)[O-])NC(=O)C(=NOC(C)(C)C(=O)O)C2=CSC(=N2)[NH3+],,,,,,
4116,54117,"2-[[1-(2-amino-4-thiazolyl)-2-[[(2S,3S)-2-methyl-4-oxo-1-sulfo-3-azetidinyl]amino]-2-oxoethylidene]amino]oxy-2-methylpropanoic acid",C[C@H]1[C@@H](C(=O)N1S(=O)(=O)O)NC(=O)C(=NOC(C)(C)C(=O)O)C2=CSC(=N2)N,['Cayston is indicated for the suppressive therapy of chronic pulmonary infections due to Pseudomonas aeruginosa in patients with cystic fibrosis (CF) aged 6 years and older.'],,['Substances that inhibit the growth or reproduction of BACTERIA. (See all compounds classified as Anti-Bacterial Agents.)'],,,
4117,54118,CID 54118,C[C@@H]1CC[C@]2(CCCCO2)O[C@@H]1[C@@H](C)C[C@@H]([C@@H]3C(=C)[C@H]([C@H]4[C@H](O3)CC[C@]5(O4)CC[C@@H](O5)C=C[C@@H](C)[C@@H]6CC(=C[C@@]7(O6)C(CC[C@H](O7)C[C@](C)(C(=O)O)O)O)C)O)O,,,,,,
4118,54119,CID 54119,CC(C(=O)NCC(=O)[O-])SC(=O)C1=CC=CS1.[Na+],,,,,,
4119,54120,Stepronin,CC(C(=O)NCC(=O)O)SC(=O)C1=CC=CS1,['Strepronin is a mucolytic (expectorant) drug.'],['The drug promotes drainage of mucus from the lungs by thinning the mucus and lubricating the irritated respiratory tract'],"['Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of INTERLEUKINS and other CYTOKINES are emerging. (See all compounds classified as Immunosuppressive Agents.)', 'Agents used in the prophylaxis or therapy of VIRUS DISEASES. Some of the ways they may act include preventing viral replication by inhibiting viral DNA polymerase; binding to specific cell-surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking late stages of virus assembly. (See all compounds classified as Antiviral Agents.)', 'Agents that increase mucous excretion. Mucolytic agents, that is drugs that liquefy mucous secretions, are also included here. (See all compounds classified as Expectorants.)']",,,
4120,54121,N-(3-(Bis(2-hydroxyethyl)amino)propyl)-o-propoxybenzamide hydrochloride,CCCOC1=CC=CC=C1C(=O)NCCC[NH+](CCO)CCO.[Cl-],,,,,,
4121,54122,N-[3-[bis(2-hydroxyethyl)amino]propyl]-2-propoxybenzamide,CCCOC1=CC=CC=C1C(=O)NCCCN(CCO)CCO,,,,,,
4122,54123,"2,2',2''-Nitrilotriethanol tricarbamate",C(COC(=O)N)N(CCOC(=O)N)CCOC(=O)N,,,,,,
4123,54124,9-(1-(Pyrrolidinyl)-2-propyl)-9-fluorenol hydrochloride,CC(C[NH+]1CCCC1)C2(C3=CC=CC=C3C4=CC=CC=C42)O.[Cl-],,,,,,
4124,54125,9-(1-Pyrrolidin-1-ylpropan-2-yl)fluoren-9-ol,CC(CN1CCCC1)C2(C3=CC=CC=C3C4=CC=CC=C42)O,,,,,,
4125,54126,3-Benzyl-4-(2-diethylaminoethoxy)-2(5H)furanone,CCN(CC)CCOC1=C(C(=O)OC1)CC2=CC=CC=C2,,,,,,
4126,54127,"2(5H)Furanone, 3-benzyl-4-(N-(2-(dimethylamino)ethyl)-N-phenylamino)-",CN(C)CCN(C1=C(C(=O)OC1)CC2=CC=CC=C2)C3=CC=CC=C3,,,,,,
4127,54128,CID 54128,CCCCC1=C(OCC1=O)O,,,,,,
4128,54129,CID 54129,C1CCC(CC1)C2=C(OCC2=O)O,,,,,,
4129,54130,"2(5H)Furanone, 4-(N-(2-dimethylaminoethyl)-N-phenylamino)-3-methyl-",CC1=C(COC1=O)N(CCN(C)C)C2=CC=CC=C2,,,,,,
4130,54131,CID 54131,CCCCCCCCC1C(=O)C=C(O1)O,,,,,,
4131,54132,CID 54132,C1C(=O)C(=C(O1)O)CCCC2=CC=CC=C2,,,,,,
4132,54133,"Carbamic acid, methylnitroso-, 2,2-dimethyl-3-oxo-2,3-dihydro-7-benzofuranyl ester",CC1(C(=O)C2=C(O1)C(=CC=C2)OC(=O)N(C)N=O)C,,,,,,
4133,54134,N-Benzyldodecanamide,CCCCCCCCCCCC(=O)NCC1=CC=CC=C1,,,,,,
4134,54135,"1-Methyl-N-(2,6-xylyl)isonipecotamide hydrochloride",CC1=C(C(=CC=C1)C)NC(=O)C2CC[NH+](CC2)C.[Cl-],,,,,,
4135,54136,"N-(2,6-dimethylphenyl)-1-methylpiperidine-4-carboxamide",CC1=C(C(=CC=C1)C)NC(=O)C2CCN(CC2)C,,,,,,
4136,54137,N-[[1-(3-isoquinolin-2-ium-2-ylpropyl)pyridin-1-ium-4-yl]methylidene]hydroxylamine;dibromide,C1=CC=C2C=[N+](C=CC2=C1)CCC[N+]3=CC=C(C=C3)C=NO.[Br-].[Br-],,,,,,
4137,54138,N-[[1-(3-isoquinolin-2-ium-2-ylpropyl)pyridin-1-ium-4-yl]methylidene]hydroxylamine,C1=CC=C2C=[N+](C=CC2=C1)CCC[N+]3=CC=C(C=C3)C=NO,,,,,,
4138,54139,CID 54139,CC[NH+](CC)CC[NH2+]C(C)CC1(OC2=CC=CC=C2O1)C.C(=CC(=O)[O-])C(=O)O.C(=CC(=O)[O-])C(=O)O,,,,,,
4139,54140,"N',N'-diethyl-N-[1-(2-methyl-1,3-benzodioxol-2-yl)propan-2-yl]ethane-1,2-diamine",CCN(CC)CCNC(C)CC1(OC2=CC=CC=C2O1)C,,,,,,
4140,54141,"1,3-Benzodioxole, 5,6-DI(hydroxymethyl)-",C1OC2=C(O1)C=C(C(=C2)CO)CO,,,,,,
4141,54142,"2-Methyl-2-(methylamino)-1,3-benzodioxole hydrochloride",CC1(OC2=CC=CC=C2O1)[NH2+]C.[Cl-],,,,,,
4142,54143,"N,2-dimethyl-1,3-benzodioxol-2-amine",CC1(OC2=CC=CC=C2O1)NC,,,,,,
4143,54144,"2-Methyl-2-(2-(3-piperidinopropoxy)ethyl)-1,3-benzodioxole hydrobromide",CC1(OC2=CC=CC=C2O1)CCOCCC[NH+]3CCCCC3.[Br-],,,,,,
4144,54145,"1-[3-[2-(2-Methyl-1,3-benzodioxol-2-yl)ethoxy]propyl]piperidine",CC1(OC2=CC=CC=C2O1)CCOCCCN3CCCCC3,,,,,,
4145,54146,CID 54146,C1CC(=NC1)NN=CC2=CC=C(O2)[N+](=O)[O-],,,,,,
4146,54147,"2-Furancarboxylic acid, 2-(3,4-dihydro-2H-pyrrol-5-YL)hydrazide",C1CC(=NC1)NNC(=O)C2=CC=CO2,,,,,,
4147,54148,CID 54148,C1CC(=NC1)N=NC(=O)C2=CC=C(O2)N(O)O,,,,,,
4148,54149,"N'-(3,4-dihydro-2H-pyrrol-5-yl)benzohydrazide",C1CC(=NC1)NNC(=O)C2=CC=CC=C2,,,,,,
4149,54150,CID 54150,CCCCCCCCCCCCCCCCC(C(=O)O)C(CC(=O)[O-])(C(=O)O)O.[Na+],,,,,,
4150,54151,"Glycine, 2-phenyl-, decyl ester, hydrochloride, D,L-",CCCCCCCCCCOC(=O)C(C1=CC=CC=C1)[NH3+].[Cl-],,,,,,
4151,54152,Decyl 2-amino-2-phenylacetate,CCCCCCCCCCOC(=O)C(C1=CC=CC=C1)N,,,,,,
4152,54153,(3-(Diethylamino)propyl) 2-phenylheptanoate hydrochloride,CCCCCC(C1=CC=CC=C1)C(=O)OCCC[NH+](CC)CC.[Cl-],,,,,,
4153,54154,3-(Diethylamino)propyl 2-phenylheptanoate,CCCCCC(C1=CC=CC=C1)C(=O)OCCCN(CC)CC,,,,,,
4154,54155,2-(Diethylamino)ethyl alpha-phenyl-beta-methylcaproate hydrochloride,CCCC(C)C(C1=CC=CC=C1)C(=O)OCC[NH+](CC)CC.[Cl-],,,,,,
4155,54156,2-(Diethylamino)ethyl 3-methyl-2-phenylhexanoate,CCCC(C)C(C1=CC=CC=C1)C(=O)OCCN(CC)CC,,,,,,
4156,54157,2-(Diethylamino)ethyl 2-phenylhexanoate,CCCCC(C1=CC=CC=C1)C(=O)OCCN(CC)CC,,,,,,
4157,54158,Mebrofenin,CC1=CC(=C(C(=C1NC(=O)CN(CC(=O)O)CC(=O)O)C)Br)C,,,,,,
4158,54159,4-Biphenylcarbamic acid,C1=CC=C(C=C1)C2=CC=C(C=C2)NC(=O)O,,,,,,
4159,54160,9-Bicyclo[6.1.0]non-4-enylazanium;methanesulfonate,CS(=O)(=O)[O-].C1CC2C(C2[NH3+])CCC=C1,,,,,,
4160,54161,(4Z)-bicyclo[6.1.0]non-4-en-9-amine,C/1CC2C(C2N)CC/C=C1,,,,,,
4161,54162,3-[6-(Methylsulfanyl)-4-oxoquinazolin-3(4H)-yl]prop-2-enoic acid,CSC1=CC2=C(C=C1)N=CN(C2=O)C=CC(=O)O,,,,,,
4162,54163,"5-[(3,4-Dimethoxyphenyl)methylidene]-3-(2-methoxy-4-nitrophenyl)-2-methylimidazol-4-one",CC1=NC(=CC2=CC(=C(C=C2)OC)OC)C(=O)N1C3=C(C=C(C=C3)[N+](=O)[O-])OC,,,,,,
4163,54164,"Benzofurazan, 7-(3-(diethylamino)propylamino)-4-nitro-, 1-oxide",CCN(CC)CCCNC1=CC=C(C2=NO[N+](=C12)[O-])[N+](=O)[O-],,,,,,
4164,54165,2-(2-(Dibutylamino)ethoxy)ethyl p-aminobenzoate hydrochloride,CCCC[NH+](CCCC)CCOCCOC(=O)C1=CC=C(C=C1)N.[Cl-],,,,,,
4165,54166,2-[2-(Dibutylamino)ethoxy]ethyl 4-aminobenzoate,CCCCN(CCCC)CCOCCOC(=O)C1=CC=C(C=C1)N,,,,,,
4166,54167,"p-Aminobenzoic acid, 5-(diethylamino)-2-pentyl ester, hydrochloride",CC[NH+](CC)CCCC(C)OC(=O)C1=CC=C(C=C1)N.[Cl-],,,,,,
4167,54168,5-(Diethylamino)pentan-2-yl 4-aminobenzoate,CCN(CC)CCCC(C)OC(=O)C1=CC=C(C=C1)N,,,,,,
4168,54169,p-Aminobenzoic acid 2-(2-(dimethylamino)ethoxy)ethyl ester hydrochloride,C[NH+](C)CCOCCOC(=O)C1=CC=C(C=C1)N.[Cl-],,,,,,
4169,54170,2-[2-(Dimethylamino)ethoxy]ethyl 4-aminobenzoate,CN(C)CCOCCOC(=O)C1=CC=C(C=C1)N,,,,,,
4170,54171,p-Aminobenzoic acid 2-(2-(dipropylamino)ethoxy)ethyl ester hydrochloride,CCC[NH+](CCC)CCOCCOC(=O)C1=CC=C(C=C1)N.[Cl-],,,,,,
4171,54172,2-[2-(Dipropylamino)ethoxy]ethyl 4-aminobenzoate,CCCN(CCC)CCOCCOC(=O)C1=CC=C(C=C1)N,,,,,,
4172,54173,"Benzoic acid, 2-butoxy-4-(butylamino)-, 2-(dimethylamino)ethyl ester",CCCCNC1=CC(=C(C=C1)C(=O)OCCN(C)C)OCCCC,,,,,,
4173,54174,"Benzoic acid, 4-butoxy-, 2-(ethyl(2-hydroxyethyl)amino)ethyl ester",CCCCOC1=CC=C(C=C1)C(=O)OCCN(CC)CCO,,,,,,
4174,54175,p-Butoxybenzoic acid 2-(ethyl(2-hydroxyethyl)amino)ethyl ester hydrochloride,CCCCOC1=CC=C(C=C1)C(=O)OCC[NH+](CC)CCO.[Cl-],,,,,,
4175,54176,"BENZOIC ACID, p-(N-BUTYL-2-(BUTYLAMINO)ACETAMIDO)-, BUTYL ESTER, HYDROCHLORIDE",CCCC[NH2+]CC(=O)N(CCCC)C1=CC=C(C=C1)C(=O)OCCCC.[Cl-],,,,,,
4176,54177,Butyl 4-[butyl-[2-(butylamino)acetyl]amino]benzoate,CCCCNCC(=O)N(CCCC)C1=CC=C(C=C1)C(=O)OCCCC,,,,,,
4177,54178,"BENZOIC ACID, p-(N-BUTYL-2-(PIPERIDINO)ACETAMIDO)-, BUTYL ESTER, HYDROCHLORIDE",CCCCN(C1=CC=C(C=C1)C(=O)OCCCC)C(=O)C[NH+]2CCCCC2.[Cl-],,,,,,
4178,54179,Butyl 4-[butyl-(2-piperidin-1-ylacetyl)amino]benzoate,CCCCN(C1=CC=C(C=C1)C(=O)OCCCC)C(=O)CN2CCCCC2,,,,,,
4179,54180,"BENZOIC ACID, p-((2-DIBUTYLAMINOETHOXY)METHYL)-, 2-(DIBUTYLAMINO)ETHYL ESTER",CCCCN(CCCC)CCOCC1=CC=C(C=C1)C(=O)OCCN(CCCC)CCCC,,,,,,
4180,54181,"BENZOIC ACID, p-((3-DIBUTYLAMINOPROPOXY)METHYL)-, 3-(DIBUTYLAMINO)PROPYL ESTER",CCCCN(CCCC)CCCOCC1=CC=C(C=C1)C(=O)OCCCN(CCCC)CCCC,,,,,,
4181,54182,"BENZOIC ACID, p-((3-DIBUTYLAMINOPROPOXY)METHYL)-, ETHYL ESTER",CCCCN(CCCC)CCCOCC1=CC=C(C=C1)C(=O)OCC,,,,,,
4182,54183,"BENZOIC ACID, p-((2-DIETHYLAMINOETHOXY)METHYL)-, BUTYL ESTER",CCCCOC(=O)C1=CC=C(C=C1)COCCN(CC)CC,,,,,,
4183,54184,"BENZOIC ACID, p-((2-DIETHYLAMINOETHOXY)METHYL)-, 3-(DIBUTYLAMINO)PROPYL ESTER",CCCCN(CCCC)CCCOC(=O)C1=CC=C(C=C1)COCCN(CC)CC,,,,,,
4184,54185,"BENZOIC ACID, p-((2-DIETHYLAMINOETHOXY)METHYL)-, ETHYL ESTER",CCN(CC)CCOCC1=CC=C(C=C1)C(=O)OCC,,,,,,
4185,54186,2-Diethylamino-3-hydroxy-3-phenylpropyl benzoate,CCN(CC)C(COC(=O)C1=CC=CC=C1)C(C2=CC=CC=C2)O,,,,,,
4186,54187,"BENZOIC ACID, p-(DIETHYLAMINOMETHYL)-, 3-(DIBUTYLAMINO)PROPYL ESTER",CCCCN(CCCC)CCCOC(=O)C1=CC=C(C=C1)CN(CC)CC,,,,,,
4187,54188,"Benzoic acid, 3-(diethylamino)methyl-4-hydroxy-, ethyl ester",CCN(CC)CC1=C(C=CC(=C1)C(=O)OCC)O,,,,,,
4188,54189,"BENZOIC ACID, p-(2-(DIETHYLAMINO)PROPOXY)METHYL-, ETHYL ESTER",CCN(CC)CCCOCC1=CC=C(C=C1)C(=O)OCC,,,,,,
4189,54190,"Benzoic acid, 4-hydroxy-3-morpholinomethyl-, ethyl ester",CCOC(=O)C1=CC(=C(C=C1)O)CN2CCOCC2,,,,,,
4190,54191,"5-[2-(4-Cyanophenyl)hydrazinylidene]-6-oxo-5,6-dihydronaphthalene-2-sulfonic acid",C1=CC(=CC=C1C#N)N=NC2=C(C=CC3=C2C=CC(=C3)S(=O)(=O)O)O,,,,,,
4191,54192,"8-[(2,5-Disulfophenyl)azo]-7-hydroxy-1,3-naphthalenedisulfonic acid",C1=CC(=C(C2=C(C=C(C=C21)S(=O)(=O)O)S(=O)(=O)O)N=NC3=C(C=CC(=C3)S(=O)(=O)O)S(=O)(=O)O)O,,,,,,
4192,54193,"8-[[4-(2-Aminoethyl)phenyl]azo]-7-hydroxy-1,3-naphthalenedisulfonic acid",C1=CC(=CC=C1CCN)N=NC2=C(C=CC3=CC(=CC(=C32)S(=O)(=O)O)S(=O)(=O)O)O,,,,,,
4193,54194,"4-[[4-(Ethylamino)-1-naphthyl]azo]-5-hydroxy-2,7-naphthalenedisulfonic acid",CCNC1=CC=C(C2=CC=CC=C21)N=NC3=C4C(=CC(=C3)S(=O)(=O)O)C=C(C=C4O)S(=O)(=O)O,,,,,,
4194,54195,"3-[(4-Nitrophenyl)diazenyl]-6-phenyldiazenylnaphthalene-2,7-disulfonic acid",C1=CC=C(C=C1)N=NC2=C(C=C3C=C(C(=CC3=C2)N=NC4=CC=C(C=C4)[N+](=O)[O-])S(=O)(=O)O)S(=O)(=O)O,,,,,,
4195,54196,"(6R,7R)-7-[[2-(2-amino-1,3-thiazol-4-yl)-2-(2-carboxypropan-2-yloxyimino)acetyl]amino]-8-oxo-3-(pyridin-1-ium-1-ylmethyl)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate;pentahydrate",CC(C)(C(=O)O)ON=C(C1=CSC(=N1)N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C[N+]4=CC=CC=C4)C(=O)[O-].O.O.O.O.O,,,['Substances that inhibit the growth or reproduction of BACTERIA. (See all compounds classified as Anti-Bacterial Agents.)'],,,
4196,54197,"(6R,7R)-7-[[2-(2-amino-4-thiazolyl)-2-(2-carboxypropan-2-yloxyimino)-1-oxoethyl]amino]-8-oxo-3-(1-pyridin-1-iumylmethyl)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid",CC(C)(C(=O)O)ON=C(C1=CSC(=N1)N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C[N+]4=CC=CC=C4)C(=O)O,,,,,,
4197,54198,2-Amino-4-nitrobenzenemethanol,C1=CC(=C(C=C1[N+](=O)[O-])N)CO,,,,,,
4198,54199,CID 54199,C1=CC(=O)C=CC1=CC2=C(N(C(=O)N(C2=O)C3=CC(=C(C=C3)C(=O)[O-])[N+](=O)[O-])C4=CC(=C(C=C4)C(=O)[O-])[N+](=O)[O-])O.[K+].[K+],,,,,,
4199,54200,"Benzoic acid, 4,4'-(dihydro-5-((4-methoxyphenyl)methylene)-2,4,6-trioxo-1,3(2H,4H)-pyrimidinediyl)bis(2-nitro-, dipotassium salt",COC1=CC=C(C=C1)C=C2C(=O)N(C(=O)N(C2=O)C3=CC(=C(C=C3)C(=O)[O-])[N+](=O)[O-])C4=CC(=C(C=C4)C(=O)[O-])[N+](=O)[O-].[K+].[K+],,,,,,
4200,54201,"4-[3-(4-Carboxy-3-nitrophenyl)-5-[(4-methoxyphenyl)methylidene]-2,4,6-trioxo-1,3-diazinan-1-yl]-2-nitrobenzoic acid",COC1=CC=C(C=C1)C=C2C(=O)N(C(=O)N(C2=O)C3=CC(=C(C=C3)C(=O)O)[N+](=O)[O-])C4=CC(=C(C=C4)C(=O)O)[N+](=O)[O-],,,,,,
4201,54202,"Benzoic acid, 4,4'-(5-(3,4-dimethoxybenzylidene)-2,4,6-trioxohexahydropyrimidin-1,3-diyl)bis(2-nitro-, dipotassium salt",COC1=C(C=C(C=C1)C=C2C(=O)N(C(=O)N(C2=O)C3=CC(=C(C=C3)C(=O)[O-])[N+](=O)[O-])C4=CC(=C(C=C4)C(=O)[O-])[N+](=O)[O-])OC.[K+].[K+],,,,,,
4202,54203,"4-[3-(4-Carboxy-3-nitrophenyl)-5-[(3,4-dimethoxyphenyl)methylidene]-2,4,6-trioxo-1,3-diazinan-1-yl]-2-nitrobenzoic acid",COC1=C(C=C(C=C1)C=C2C(=O)N(C(=O)N(C2=O)C3=CC(=C(C=C3)C(=O)O)[N+](=O)[O-])C4=CC(=C(C=C4)C(=O)O)[N+](=O)[O-])OC,,,,,,
4203,54204,Bermoprofen,CC1=CC2=C(C=C1)OC3=C(C=C(C=C3)C(C)C(=O)O)C(=O)C2,,,,,,
4204,54205,"Benzoic acid, 4,4'-(5-benzylidene-2,4,6-trioxohexahydropyrimidin-1,3-diyl)bis(2-nitro-, dipotassium salt",C1=CC=C(C=C1)C=C2C(=O)N(C(=O)N(C2=O)C3=CC(=C(C=C3)C(=O)[O-])[N+](=O)[O-])C4=CC(=C(C=C4)C(=O)[O-])[N+](=O)[O-].[K+].[K+],,,,,,
4205,54206,"4-[5-Benzylidene-3-(4-carboxy-3-nitrophenyl)-2,4,6-trioxo-1,3-diazinan-1-yl]-2-nitrobenzoic acid",C1=CC=C(C=C1)C=C2C(=O)N(C(=O)N(C2=O)C3=CC(=C(C=C3)C(=O)O)[N+](=O)[O-])C4=CC(=C(C=C4)C(=O)O)[N+](=O)[O-],,,,,,
4206,54207,"N'-(4-Bromo-3,5-dimethylphenyl)-N,N-dimethylu*",CC1=CC(=CC(=C1Br)C)NC(=O)N(C)C,,,,,,
4207,54208,(4-Phenoxyphenyl)urea,C1=CC=C(C=C1)OC2=CC=C(C=C2)NC(=O)N,,,,,,
4208,54209,(4-Fluoro-3-methylphenyl)urea,CC1=C(C=CC(=C1)NC(=O)N)F,,,,,,
4209,54210,(4-Bromo-3-methylphenyl)urea,CC1=C(C=CC(=C1)NC(=O)N)Br,,,,,,
4210,54211,"BENZ(a)ANTHRACENE, 12-BROMOMETHYL-",C1=CC=C2C(=C1)C=CC3=CC4=CC=CC=C4C(=C32)CBr,,,,,,
4211,54212,"Carbamic acid, (1,4,5,6-tetrahydro-5-phenyl-2-pyrimidinyl)-, methyl ester",COC(=O)NC1=NCC(CN1)C2=CC=CC=C2,,,,,,
4212,54213,"Carbamic acid, (1,4,5,6-tetrahydro-5-(3-methoxyphenyl)-2-pyrimidinyl)-, methyl ester",COC1=CC=CC(=C1)C2CNC(=NC2)NC(=O)OC,,,,,,
4213,54214,Ethyl 2-(3-(4-chlorophenyl)propyl)oxirane-2-carboxylate,CCOC(=O)C1(CO1)CCCC2=CC=C(C=C2)Cl,,,,,,
4214,54215,"Ethyl 2-(3-(alpha,alpha,alpha-trifluoro-m-tolyl)propyl)oxirane-2-carboxylate",CCOC(=O)C1(CO1)CCCC2=CC(=CC=C2)C(F)(F)F,,,,,,
4215,54216,Ethyl 2-(5-phenylpentyl)oxirane-2-carboxylate,CCOC(=O)C1(CO1)CCCCCC2=CC=CC=C2,,,,,,
4216,54217,Ethyl 2-(5-(4-chlorophenyl)pentyl)oxiran-2-carboxylate,CCOC(=O)C1(CO1)CCCCCC2=CC=C(C=C2)Cl,,,['Substances which lower blood glucose levels. (See all compounds classified as Hypoglycemic Agents.)'],,,
4217,54218,CID 54218,C1C(O1)(CCCCCC2=CC=CC=C2)C(=O)[O-].[Na+],,,,,,
4218,54219,2-(5-phenylpentyl)oxirane-2-carboxylic Acid,C1C(O1)(CCCCCC2=CC=CC=C2)C(=O)O,,,,,,
4219,54220,CID 54220,C1C(O1)(CCCCCC2=CC=C(C=C2)Cl)C(=O)[O-].[Na+],,,,,,
4220,54221,Clomoxir,C1C(O1)(CCCCCC2=CC=C(C=C2)Cl)C(=O)O,,,,,,
4221,54222,Ethyl 2-(3-(4-fluorophenyl)propyl)oxirane-2-carboxylate,CCOC(=O)C1(CO1)CCCC2=CC=C(C=C2)F,,,,,,
4222,54223,"Ethyl 2-(3-(3,4-dichlorophenyl)propyl)oxirane-2-carboxylate",CCOC(=O)C1(CO1)CCCC2=CC(=C(C=C2)Cl)Cl,,,,,,
4223,54224,Ethyl 2-(7-(4-chlorophenyl)heptyl)oxirane-2-carboxylate,CCOC(=O)C1(CO1)CCCCCCCC2=CC=C(C=C2)Cl,,,,,,
4224,54225,"2H-1,4-Benzoxazine-6-acetic acid, 2-oxo-3-phenyl-, methyl ester",COC(=O)CC1=CC2=C(C=C1)OC(=O)C(=N2)C3=CC=CC=C3,,,,,,
4225,54226,"2H-1,4-Benzoxazine-6-acetic acid, 3-(4-chlorophenyl)-2-oxo-, methyl ester",COC(=O)CC1=CC2=C(C=C1)OC(=O)C(=N2)C3=CC=C(C=C3)Cl,,,,,,
4226,54227,"2H-1,4-Benzoxazine-6-acetic acid, 3-(4-fluorophenyl)-2-oxo-, methyl ester",COC(=O)CC1=CC2=C(C=C1)OC(=O)C(=N2)C3=CC=C(C=C3)F,,,,,,
4227,54228,"2H-1,4-Benzoxazine-6-acetic acid, 3-(4-methylphenyl)-2-oxo-, methyl ester",CC1=CC=C(C=C1)C2=NC3=C(C=CC(=C3)CC(=O)OC)OC2=O,,,,,,
4228,54229,"2H-1,4-Benzoxazine-6-acetic acid, 3-(4-methoxyphenyl)-2-oxo-, methyl ester",COC1=CC=C(C=C1)C2=NC3=C(C=CC(=C3)CC(=O)OC)OC2=O,,,,,,
4229,54230,"alpha-Methyl-2-oxo-3-phenyl-2H-1,4-benzoxazine-6-acetic acid methyl ester",CC(C1=CC2=C(C=C1)OC(=O)C(=N2)C3=CC=CC=C3)C(=O)OC,,,,,,
4230,54231,"3-(4-Chlorophenyl)-alpha-methyl-2-oxo-2H-1,4-benzoxazine-6-acetic acid methyl ester",CC(C1=CC2=C(C=C1)OC(=O)C(=N2)C3=CC=C(C=C3)Cl)C(=O)OC,,,,,,
4231,54232,"3-(4-Bromophenyl)-alpha-methyl-2-oxo-2H-1,4-benzoxazine-6-acetic acid methyl ester",CC(C1=CC2=C(C=C1)OC(=O)C(=N2)C3=CC=C(C=C3)Br)C(=O)OC,,,,,,
4232,54233,"3-(4-Fluorophenyl)-alpha-methyl-2-oxo-2H-1,4-benzoxazine-6-acetic acid methyl ester",CC(C1=CC2=C(C=C1)OC(=O)C(=N2)C3=CC=C(C=C3)F)C(=O)OC,,,,,,
4233,54234,"alpha-Methyl-3-(4-methylphenyl)-2-oxo-2H-1,4-benzoxazine-6-acetic acid methyl ester",CC1=CC=C(C=C1)C2=NC3=C(C=CC(=C3)C(C)C(=O)OC)OC2=O,,,,,,
4234,54235,"3-(4-Methoxyphenyl)-alpha-methyl-2-oxo-2H-1,4-benzoxazine-6-acetic acid methyl ester",CC(C1=CC2=C(C=C1)OC(=O)C(=N2)C3=CC=C(C=C3)OC)C(=O)OC,,,,,,
4235,54236,"2H-1,4-Benzoxazine-6-acetic acid, 3-(4-bromophenyl)-2-oxo-, methyl ester",COC(=O)CC1=CC2=C(C=C1)OC(=O)C(=N2)C3=CC=C(C=C3)Br,,,,,,
4236,54237,1-((2-Furyldimethylsilyl)methyl)hexahydro-1H-azepine hydrochloride,C[Si](C)(C[NH+]1CCCCCC1)C2=CC=CO2.[Cl-],,,,,,
4237,54238,Hexahydro-1-[[(2-furanyl)dimethylsilyl]methyl]-1H-azepine,C[Si](C)(CN1CCCCCC1)C2=CC=CO2,,,,,,
4238,54239,1-(2-(2-Furyldimethylsilyl)ethyl)hexahydro-1H-azepine hydrochloride,C[Si](C)(CC[NH+]1CCCCCC1)C2=CC=CO2.[Cl-],,,,,,
4239,54240,Hexahydro-1-[2-[(2-furanyl)dimethylsilyl]ethyl]-1H-azepine,C[Si](C)(CCN1CCCCCC1)C2=CC=CO2,,,,,,
4240,54241,1-(3-(2-Furyldimethylsilyl)propyl)hexahydro-1H-azepine hydrochloride,C[Si](C)(CCC[NH+]1CCCCCC1)C2=CC=CO2.[Cl-],,,,,,
4241,54242,Hexahydro-1-[3-[(2-furanyl)dimethylsilyl]propyl]-1H-azepine,C[Si](C)(CCCN1CCCCCC1)C2=CC=CO2,,,,,,
4242,54243,1-((2-Thienyldimethylsilyl)methyl)hexahydro-1H-azepine hydrochloride,C[Si](C)(C[NH+]1CCCCCC1)C2=CC=CS2.[Cl-],,,,,,
4243,54244,Hexahydro-1-[[(2-thienyl)dimethylsilyl]methyl]-1H-azepine,C[Si](C)(CN1CCCCCC1)C2=CC=CS2,,,,,,
4244,54245,1-(2-(2-Thienyldimethylsilyl)ethyl)hexahydro-1H-azepine hydrochloride,C[Si](C)(CC[NH+]1CCCCCC1)C2=CC=CS2.[Cl-],,,,,,
4245,54246,Hexahydro-1-[2-[(2-thienyl)dimethylsilyl]ethyl]-1H-azepine,C[Si](C)(CCN1CCCCCC1)C2=CC=CS2,,,,,,
4246,54247,1-(3-(Dimethyl(2-thienyl)silyl)propyl)hexahydro-1H-azepine hydrochloride,C[Si](C)(CCC[NH+]1CCCCCC1)C2=CC=CS2.[Cl-],,,,,,
4247,54248,Hexahydro-1-[3-[dimethyl(2-thienyl)silyl]propyl]-1H-azepine,C[Si](C)(CCCN1CCCCCC1)C2=CC=CS2,,,,,,
4248,54249,"3-Acetylaconitine, hydrobromide",CC[NH+]1CC2([C@H]3C(C4[C@@H]1C3([C@@H]5C[C@]6(C([C@@H]5[C@@]4(C(C6OC)O)OC(=O)C)OC(=O)C7=CC=CC=C7)O)C(CC2OC(=O)C)OC)OC)COC.[Br-],,,,,,
4249,54250,"[(2R,3R,5R,8R,10R,17S)-8,14-diacetyloxy-11-ethyl-5,7-dihydroxy-6,16,18-trimethoxy-13-(methoxymethyl)-11-azahexacyclo[7.7.2.12,5.01,10.03,8.013,17]nonadecan-4-yl] benzoate",CCN1CC2([C@H]3C(C4[C@@H]1C3([C@@H]5C[C@]6(C([C@@H]5[C@@]4(C(C6OC)O)OC(=O)C)OC(=O)C7=CC=CC=C7)O)C(CC2OC(=O)C)OC)OC)COC,,,,,,
4250,54251,CID 54251,C1=CC=C(C=C1)CC(C2=CC=CC=C2)C3=NN=C(O3)S,,,,,,
4251,54252,CID 54252,COC1=CC=C(C=C1)CC(C2=CC=CC=C2)C3=NN=C(O3)S,,,,,,
4252,54253,"ACETIC ACID, 2-((5-(alpha-PHENYLPHENETHYL)-1,3,4-OXADIAZOL-2-YL)THIO)-",C1=CC=C(C=C1)C(CC2=NN=C(O2)SCC(=O)O)C3=CC=CC=C3,,,,,,
4253,54254,"ACETIC ACID, 2-((5-(p-METHOXY-alpha-PHENYLPHENETHYL)-1,3,4-OXADIAZOL-2-YL)THIO)-",COC1=CC=C(C=C1)C(CC2=NN=C(O2)SCC(=O)O)C3=CC=CC=C3,,,,,,
4254,54255,CID 54255,CC1=C(C=CC(=C1)OCCC2=NN=C(O2)S)Cl,,,,,,
4255,54256,CID 54256,CC1=CC(=CC=C1)OC(C)(C)C2=NN=C(O2)S,,,,,,
4256,54257,CID 54257,CC(C)(C1=NN=C(O1)S)OC2=CC=C(C=C2)Cl,,,,,,
4257,54258,CID 54258,CC1=C(C=CC(=C1)OC(C)(C)C2=NN=C(O2)S)Cl,,,,,,
4258,54259,Amorolfine hydrochloride,CCC(C)(C)C1=CC=C(C=C1)CC(C)CN2C[C@H](O[C@H](C2)C)C.Cl,,,"['Substances that destroy fungi by suppressing their ability to grow or reproduce. They differ from FUNGICIDES, INDUSTRIAL because they defend against fungi present in human or animal tissues. (See all compounds classified as Antifungal Agents.)']",,,
4259,54260,Amorolfine,CCC(C)(C)C1=CC=C(C=C1)CC(C)CN2C[C@H](O[C@H](C2)C)C,,,"['Substances that destroy fungi by suppressing their ability to grow or reproduce. They differ from FUNGICIDES, INDUSTRIAL because they defend against fungi present in human or animal tissues. (See all compounds classified as Antifungal Agents.)']",,,
4260,54261,CID 54261,COC1=CC=C(C=C1)CC(C2=CC=C(C=C2)OC)C3=NN=C(O3)S,,,,,,
4261,54262,"5-amino-2,3-dihydroxy-N-[1-(8-hydroxy-1-oxo-3,4-dihydroisochromen-3-yl)-3-methylbutyl]hexanediamide",CC(C)CC(C1CC2=C(C(=CC=C2)O)C(=O)O1)NC(=O)C(C(CC(C(=O)N)N)O)O,,,,,,
4262,54263,"L-N-(p-(3,3-Dimethyltriazeno)phenyl)-N-(9-fluorenylacetyl)alanine ethyl ester",CCOC(=O)C(C)N(C1=CC=C(C=C1)N=NN(C)C)C(=O)CC2C3=CC=CC=C3C4=CC=CC=C24,,,,,,
4263,54264,"Acetamide, N-(3-(3-(4-phenyl-1-piperazinyl)propoxy)phenyl)-",CC(=O)NC1=CC(=CC=C1)OCCCN2CCN(CC2)C3=CC=CC=C3,,,,,,
4264,54265,"6-Chloro-5-(methanesulfonyl)pyrimidine-2,4-diamine",CS(=O)(=O)C1=C(N=C(N=C1Cl)N)N,,,,,,
4265,54266,"1-(3,4-Dimethoxyphenyl)-2-[3,5-dimethyl-4-(methylsulfanyl)phenoxy]propane-1,3-diol",CC1=CC(=CC(=C1SC)C)OC(CO)C(C2=CC(=C(C=C2)OC)OC)O,,,,,,
4266,54267,Monobutyltin,CCCC[Sn+3],,,,,,
4267,54268,N-Acetyl-S-2-chloroethyl-L-cysteine methyl ester,CC(=O)NC(CSCCCl)C(=O)OC,,,,,,
4268,54269,L-N-Acetyl-3-((2-chloro-1-methylpropyl)thio)alanine methyl ester,CC(C(C)Cl)SCC(C(=O)OC)NC(=O)C,,,,,,
4269,54270,N-Acetyl-S-2-iodoethyl-L-cysteine methyl ester,CC(=O)NC(CSCCI)C(=O)OC,,,,,,
4270,54271,"7,12-Dihydroxymethylbenz(a)anthracene-3,4-diol",C1=CC=C2C(=C1)C(=C3C=CC4=C(C3=C2CO)C=CC(=C4O)O)CO,,,,,,
4271,54272,"BENZ(a)ANTHRACENE-3,4-DIOL, 7-(HYDROXYMETHYL)-12-METHYL-",CC1=C2C3=C(C=CC2=C(C4=CC=CC=C14)CO)C(=C(C=C3)O)O,,,,,,
4272,54273,"BENZ(a)ANTHRACENE-3,4-DIOL, 12-(HYDROXYMETHYL)-7-METHYL-",CC1=C2C=CC3=C(C2=C(C4=CC=CC=C14)CO)C=CC(=C3O)O,,,,,,
4273,54274,but-2-enedioic acid;N-(1-methylpyrrolidin-2-ylidene)-N'-phenylmorpholine-4-carboximidamide,CN1CCCC1=NC(=NC2=CC=CC=C2)N3CCOCC3.C(=CC(=O)O)C(=O)O,,,,,,
4274,54275,N-(1-methylpyrrolidin-2-ylidene)-N'-phenylmorpholine-4-carboximidamide,CN1CCCC1=NC(=NC2=CC=CC=C2)N3CCOCC3,,,,,,
4275,54276,CID 54276,CCC#C[C@H](C)C1(C(=O)NC(=NC1=O)S)CC=C,,,,,,
4276,54277,CID 54277,C1=CC=C2C(=C1)C(=CC=N2)CN=C([NH3+])N.[Cl-],,,,,,
4277,54278,1-(Quinolin-4-ylmethyl)guanidine,C1=CC=C2C(=C1)C(=CC=N2)CN=C(N)N,,,,,,
4278,54279,CID 54279,CC1=NC2=CC=CC=C2C(=C1)CN=C([NH3+])N.[Cl-],,,,,,
4279,54280,4-Guanidinomethylquinaldine,CC1=NC2=CC=CC=C2C(=C1)CN=C(N)N,,,,,,
4280,54281,CID 54281,C1=CC=C(C=C1)C2=NC3=CC=CC=C3C(=C2)CN=C([NH3+])N.[Cl-],,,,,,
4281,54282,4-Guanidinomethyl-2-phenylquinoline,C1=CC=C(C=C1)C2=NC3=CC=CC=C3C(=C2)CN=C(N)N,,,,,,
4282,54283,CID 54283,C1=CC=C(C=C1)[NH+]=C(C2=CC=NC3=CC=CC=C23)[NH3+].[Cl-].[Cl-],,,,,,
4283,54284,4-(N'-phenylamidino) quinoline,C1=CC=C(C=C1)N=C(C2=CC=NC3=CC=CC=C23)N,,,,,,
4284,54285,6-Methyl-4-(N'-phenylamidino)quinoline dihydrochloride,CC1=CC2=C(C=CN=C2C=C1)C(=[NH2+])[NH2+]C3=CC=CC=C3.[Cl-].[Cl-],,,,,,
4285,54286,6-methyl-N'-phenylquinoline-4-carboximidamide,CC1=CC2=C(C=CN=C2C=C1)C(=NC3=CC=CC=C3)N,,,,,,
4286,54287,6-Bromo-4-(N'-phenylamidino)quinaldine dihydrochloride,CC1=CC(=C2C=C(C=CC2=N1)Br)C(=[NH2+])[NH2+]C3=CC=CC=C3.[Cl-].[Cl-],,,,,,
4287,54288,6-bromo-2-methyl-N'-phenylquinoline-4-carboximidamide,CC1=CC(=C2C=C(C=CC2=N1)Br)C(=NC3=CC=CC=C3)N,,,,,,
4288,54289,Hydrocinchonidine sulfate,CCC1C[NH+]2CCC1C[C@@H]2[C@H](C3=CC=NC4=CC=CC=C34)O.OS(=O)(=O)[O-],,,,,,
4289,54290,(S)-[(2R)-5-ethyl-1-azabicyclo[2.2.2]octan-2-yl]-quinolin-4-ylmethanol,CCC1CN2CCC1C[C@@H]2[C@H](C3=CC=NC4=CC=CC=C34)O,,,,,,
4290,54291,"3,4-Epoxy-1,2,3,4-tetrahydrodibenzo(a,i)pyrene",C1CC2=C(C=C3C=CC4=CC5=CC=CC=C5C6=C4C3=C2C=C6)C7C1O7,,,,,,
4291,54292,"1,2-Epoxy-1,2,3,4-tetrahydrodibenzo(a,h)pyrene",C1CC2=C(C=C3C=CC4=C5C3=C2C=CC5=CC6=CC=CC=C46)C7C1O7,,,,,,
4292,54293,1-((Decylthio)methyl)-3-methyl-1H-imidazolium chloride,CCCCCCCCCCSCN1C=C[N+](=C1)C.[Cl-],,,,,,
4293,54294,1-(Decylsulfanylmethyl)-3-methylimidazol-3-ium,CCCCCCCCCCSCN1C=C[N+](=C1)C,,,,,,
4294,54295,"1-Hexanaminium, N,N-bis(2-hydroxyethyl)-N-((octylthio)methyl)-, chloride (1:1)",CCCCCCCCSC[N+](CCCCCC)(CCO)CCO.[Cl-],,,,,,
4295,54296,"N,N-Bis(2-hydroxyethyl)-N-[(octylthio)methyl]-1-hexanaminium",CCCCCCCCSC[N+](CCCCCC)(CCO)CCO,,,,,,
4296,54297,"1-Hexanaminium, N-((dodecylthio)methyl)-N,N-bis(2-hydroxyethyl)-, chloride",CCCCCCCCCCCCSC[N+](CCCCCC)(CCO)CCO.[Cl-],,,,,,
4297,54298,"N,N-Bis(2-hydroxyethyl)-N-[(dodecylthio)methyl]-1-hexanaminium",CCCCCCCCCCCCSC[N+](CCCCCC)(CCO)CCO,,,,,,
4298,54299,"1-Dodecanaminium, N,N-bis(2-hydoxyethyl)-N-((octylthio)methyl)-, chloride",CCCCCCCCCCCC[N+](CCO)(CCO)CSCCCCCCCC.[Cl-],,,,,,
4299,54300,"N,N-Bis(2-hydroxyethyl)-N-[(octylthio)methyl]-1-dodecanaminium",CCCCCCCCCCCC[N+](CCO)(CCO)CSCCCCCCCC,,,,,,
4300,54301,"1-Dodecanaminium, N-((decylthio)methyl)-N,N-bis(1-hydroxyethyl)-, chloride",CCCCCCCCCCCC[N+](CCO)(CCO)CSCCCCCCCCCC.[Cl-],,,,,,
4301,54302,"N,N-Bis(2-hydroxyethyl)-N-[(decylthio)methyl]-1-dodecanaminium",CCCCCCCCCCCC[N+](CCO)(CCO)CSCCCCCCCCCC,,,,,,
4302,54303,"2-(1-Imidazolyl)-5',6',7',8'-tetrahydro-1'-acetonaphthone hydrochloride",C1CCC2=C(C1)C=CC=C2C(=O)C[NH+]3C=CN=C3.[Cl-],,,,,,
4303,54304,"2-Imidazol-1-yl-1-(5,6,7,8-tetrahydronaphthalen-1-yl)ethanone",C1CCC2=C(C1)C=CC=C2C(=O)CN3C=CN=C3,,,,,,
4304,54305,4'-Chloro-2-(1-imidazolyl)-1'-acetonaphthone hydrochloride,C1=CC=C2C(=C1)C(=CC=C2Cl)C(=O)C[NH+]3C=CN=C3.[Cl-],,,,,,
4305,54306,1-(4-Chloronaphthalen-1-yl)-2-(1h-imidazol-1-yl)ethanone,C1=CC=C2C(=C1)C(=CC=C2Cl)C(=O)CN3C=CN=C3,,,,,,
4306,54307,"INDOLE, 3-((tert-BUTYLAMINO)ACETYL)-, HYDROCHLORIDE, HYDRATE",CC(C)(C)[NH2+]CC(=O)C1=CNC2=CC=CC=C21.[Cl-],,,,,,
4307,54308,2-(tert-butylamino)-1-(1H-indol-3-yl)ethanone,CC(C)(C)NCC(=O)C1=CNC2=CC=CC=C21,,,,,,
4308,54309,CID 54309,CCN(CC)CCNC=C1C2=CC(=C(C=C2C(NC1=O)C3=CC=CC=C3)OC)OC,,,,,,
4309,54310,CID 54310,COC1=C(C=C2C(=C1)CC[NH2+]C2=NN)OC.[Cl-],,,,,,
4310,54311,"1-Hydrazino-6,7-dimethoxy-3,4-dihydroisoquinoline",COC1=C(C=C2C(=C1)CCN=C2NN)OC,,,,,,
4311,54312,"(+,-)-3-alpha,4-beta-Dihydroxy-1-alpha,2-alpha-epoxy-1,2,3,4-tetrahydrodibenzo(a,i)pyrene",C1=CC=C2C3=C4C(=CC2=C1)C=CC5=CC6=C([C@H]7[C@H](O7)[C@@H]([C@H]6O)O)C(=C54)C=C3,,,,,,
4312,54313,"5-[(3aS,5R,6aS)-5-hydroxy-4-[(3S)-3-hydroxy-4-methyloct-1-en-6-ynyl]-3,3a,4,5,6,6a-hexahydro-1H-pentalen-2-ylidene]pentanoic acid",CC#CCC(C)[C@@H](C=CC1[C@@H](C[C@H]2[C@@H]1CC(=CCCCC(=O)O)C2)O)O,"['Treatment of patients with primary pulmonary hypertension, classified as New York Heart Association functional class III, to improve exercise capacity and symptoms.']",,"['Drugs used to cause dilation of the blood vessels. (See all compounds classified as Vasodilator Agents.)', 'Drugs or agents which antagonize or impair any mechanism leading to blood platelet aggregation, whether during the phases of activation and shape change or following the dense-granule release reaction and stimulation of the prostaglandin-thromboxane system. (See all compounds classified as Platelet Aggregation Inhibitors.)']",,,
4313,54314,N-((4-Methoxyphenyl)methylene)-4-(4-phenyl-1-piperazinyl)benzenamine,COC1=CC=C(C=C1)C=NC2=CC=C(C=C2)N3CCN(CC3)C4=CC=CC=C4,,,,,,
4314,54315,N-((2-Methoxyphenyl)methylene)-4-(4-phenyl-1-piperazinyl)benzenamine,COC1=CC=CC=C1C=NC2=CC=C(C=C2)N3CCN(CC3)C4=CC=CC=C4,,,,,,
4315,54316,N-((4-(Phenylmethoxy)phenyl)methylene)-4-(4-phenyl-1-piperazinyl)benzenamine,C1CN(CCN1C2=CC=CC=C2)C3=CC=C(C=C3)N=CC4=CC=C(C=C4)OCC5=CC=CC=C5,,,,,,
4316,54317,N-((4-Methoxyphenyl)methylene)-4-(4-(2-methylphenyl)-1-piperazinyl)benzenamine,CC1=CC=CC=C1N2CCN(CC2)C3=CC=C(C=C3)N=CC4=CC=C(C=C4)OC,,,,,,
4317,54318,N-((2-Methoxyphenyl)methylene)-4-(4-(2-methylphenyl)-1-piperazinyl)benzenamine,CC1=CC=CC=C1N2CCN(CC2)C3=CC=C(C=C3)N=CC4=CC=CC=C4OC,,,,,,
4318,54319,"N-((4,5-Dimethoxy-2-nitrophenyl)methylene)-4-(4-(2-methylphenyl)-1-piperazinyl)benzenamine",CC1=CC=CC=C1N2CCN(CC2)C3=CC=C(C=C3)N=CC4=CC(=C(C=C4[N+](=O)[O-])OC)OC,,,,,,
4319,54320,N-((2-Methoxyphenyl)methylene)-4-(4-(4-methylphenyl)-1-piperazinyl)benzenamine,CC1=CC=C(C=C1)N2CCN(CC2)C3=CC=C(C=C3)N=CC4=CC=CC=C4OC,,,,,,
4320,54321,"N-((3,5-Dichlorophenyl)methylene)-4-(4-(4-methylphenyl)-1-piperazinyl)benzenamine",CC1=CC=C(C=C1)N2CCN(CC2)C3=CC=C(C=C3)N=CC4=CC(=CC(=C4)Cl)Cl,,,,,,
4321,54322,"N-((4,5-Dimethoxy-2-nitrophenyl)methylene)-4-(4-(4-methylphenyl)-1-piperazinyl)benzenamine",CC1=CC=C(C=C1)N2CCN(CC2)C3=CC=C(C=C3)N=CC4=CC(=C(C=C4[N+](=O)[O-])OC)OC,,,,,,
4322,54323,"3-Isoquinolinecarboxamide, N-(2-(dimethylamino)ethyl)-1-methoxy-4-phenyl-",CN(C)CCNC(=O)C1=C(C2=CC=CC=C2C(=N1)OC)C3=CC=CC=C3,,,,,,
4323,54324,"N-[3-(diethylamino)propyl]-2-methyl-1-oxo-4-phenyl-1,2-dihydroisoquinoline-3-carboxamide",CCN(CC)CCCNC(=O)C1=C(C2=CC=CC=C2C(=O)N1C)C3=CC=CC=C3,,,,,,
4324,54325,"Dodecylamine, chloroacetate",CCCCCCCCCCCC[NH3+].C(C(=O)[O-])Cl,,,,,,
4325,54326,"Tetradecylamine, chloroacetate",CCCCCCCCCCCCCCN.C(C(=O)O)Cl,,,,,,
4326,54327,"Aziridine, 1-((4-nitrophenoxy)acetyl)-",C1CN1C(=O)COC2=CC=C(C=C2)[N+](=O)[O-],,,,,,
4327,54328,"AZIRIDINE, 1-((p-TOLYLOXY)ACETYL)-",CC1=CC=C(C=C1)OCC(=O)N2CC2,,,,,,
4328,54329,"Aziridine, 1-((1-naphthyloxy)acetyl)-",C1CN1C(=O)COC2=CC=CC3=CC=CC=C32,,,,,,
4329,54330,"AZIRIDINE, 1-((m-TOLYLOXY)ACETYL)-",CC1=CC(=CC=C1)OCC(=O)N2CC2,,,,,,
4330,54331,Monuril,C[C@H]1[C@H](O1)P(=O)(O)[O-].C(C(CO)(CO)[NH3+])O,,,['Substances that inhibit the growth or reproduction of BACTERIA. (See all compounds classified as Anti-Bacterial Agents.)'],,,
4331,54332,1-(m-Hydroxyphenyl)-2-benzylaminoethanol hydrochloride,C1=CC=C(C=C1)C[NH2+]CC(C2=CC(=CC=C2)O)O.[Cl-],,,,,,
4332,54333,1-(3-Hydroxyphenyl)-2-benzylaminoethanol,C1=CC=C(C=C1)CNCC(C2=CC(=CC=C2)O)O,,,,,,
4333,54334,alpha-(p-Aminophenyl)-beta-dimethylaminoethanol,CN(C)CC(C1=CC=C(C=C1)N)O,,,,,,
4334,54335,1-(5-Bromo-2-(2-hydroxy-3-((1-methylethyl)amino)propoxy)phenyl)ethanone,CC(C)NCC(COC1=C(C=C(C=C1)Br)C(=O)C)O,,,,,,
4335,54336,"Ethanone, 1-(5-bromo-2-(2-(1-pyrrolidinyl)ethoxy)phenyl)-",CC(=O)C1=C(C=CC(=C1)Br)OCCN2CCCC2,,,,,,
4336,54337,"1,2,3,4,6,7-Hexachlorodibenzofuran",C1=CC(=C(C2=C1C3=C(O2)C(=C(C(=C3Cl)Cl)Cl)Cl)Cl)Cl,,,,,,
4337,54338,Antipyrene,CP(=O)(NC#SN)NS#CN,,,,,,
4338,54339,Fanetizole,C1=CC=C(C=C1)CCNC2=NC(=CS2)C3=CC=CC=C3,,,,,,
4339,54340,CID 54340,CC(=CC(=O)O)C=CC=CCC1=CC2=C(C=C1)C(CCC2(C)C)(C)C,,,,,,
4340,54341,alpha-Methyl-p-(methylnitrosoamino)benzyl alcohol,CC(C1=CC=C(C=C1)N(C)N=O)O,,,,,,
4341,54342,"1H,3H-Naphtho(1,8-cd)pyran-1,3-dione, methyl-",CC1=C2C3=C(C=CC=C3C(=O)OC2=O)C=C1,,,,,,
4342,54343,Daltroban,C1=CC(=CC=C1CCNS(=O)(=O)C2=CC=C(C=C2)Cl)CC(=O)O,,,"['Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of INTERLEUKINS and other CYTOKINES are emerging. (See all compounds classified as Immunosuppressive Agents.)', 'Drugs or agents which antagonize or impair any mechanism leading to blood platelet aggregation, whether during the phases of activation and shape change or following the dense-granule release reaction and stimulation of the prostaglandin-thromboxane system. (See all compounds classified as Platelet Aggregation Inhibitors.)']",,,
4343,54344,CID 54344,CC(=O)NC1=CC=C(C=C1)OC(=O)C2=CC=C(C=C2)N=C([NH3+])N.[Cl-],,,,,,
4344,54345,N-Myristoyloxy-N-acetyl-2-amino-7-iodofluorene,CCCCCCCCCCCCCC(=O)ON(C1=CC2=C(C=C1)C3=C(C2)C=C(C=C3)I)C(=O)C,,,,,,
4345,54346,"1,1-Bis(p-chlorophenyl)-2-chloro-1,2-epoxyethane",C1=CC(=CC=C1C2(C(O2)Cl)C3=CC=C(C=C3)Cl)Cl,,,,,,
4346,54347,Ethyl 4-amino-3-phenylbutanoate,CCOC(=O)CC(CN)C1=CC=CC=C1,,,,,,
4347,54348,"Ethanaminium, 2-amino-N,N-diethyl-2-oxo-N-(2-oxo-2-((2,4,6-trimethylphenyl)amino)ethyl)-, chloride",CC[N+](CC)(CC(=O)N)CC(=O)NC1=C(C=C(C=C1C)C)C.[Cl-],,,,,,
4348,54349,"(Carbamoylmethyl)diethyl(((2,4,6-trimethylphenyl)carbamoyl)methyl)ammonium",CC[N+](CC)(CC(=O)N)CC(=O)NC1=C(C=C(C=C1C)C)C,,,,,,
4349,54350,((Diethylcarbamoyl)methyl)diethyl((mesitylcarbamoyl)methyl)ammonium chloride,CCN(CC)C(=O)C[N+](CC)(CC)CC(=O)NC1=C(C=C(C=C1C)C)C.[Cl-],,,,,,
4350,54351,N-Ethyl-N-[(diethylcarbamoyl)methyl]-N-[(mesitylcarbamoyl)methyl]ethanaminium,CCN(CC)C(=O)C[N+](CC)(CC)CC(=O)NC1=C(C=C(C=C1C)C)C,,,,,,
4351,54352,Bis((mesitylcarbamoyl)methyl)diethylammonium chloride,CC[N+](CC)(CC(=O)NC1=C(C=C(C=C1C)C)C)CC(=O)NC2=C(C=C(C=C2C)C)C.[Cl-],,,,,,
4352,54353,"N,N-Bis[(mesitylcarbamoyl)methyl]-N-ethylethanaminium",CC[N+](CC)(CC(=O)NC1=C(C=C(C=C1C)C)C)CC(=O)NC2=C(C=C(C=C2C)C)C,,,,,,
4353,54354,"Ethanaminium, N,N-diethyl-N-(2-((2-methoxyphenyl)amino)-2-oxoethyl)-2-oxo-2-((2,4,6-trimethylphenyl)amino)-, chloride",CC[N+](CC)(CC(=O)NC1=CC=CC=C1OC)CC(=O)NC2=C(C=C(C=C2C)C)C.[Cl-],,,,,,
4354,54355,"Ammonium, diethyl(((o-methoxyphenyl)carbamoyl)methyl)(((2,4,6-trimethylphenyl)carbamoyl)methyl)-",CC[N+](CC)(CC(=O)NC1=CC=CC=C1OC)CC(=O)NC2=C(C=C(C=C2C)C)C,,,,,,
4355,54356,Methylfluorenone,CC1=C2C3=CC=CC=C3C(=O)C2=CC=C1,,,,,,
4356,54357,"Indole-2,3-dione, 1-benzyl-5-bromo-",C1=CC=C(C=C1)CN2C3=C(C=C(C=C3)Br)C(=O)C2=O,,,,,,
4357,54358,"3-Chloro-4,5-dihydroxybenzoic acid",C1=C(C=C(C(=C1O)O)Cl)C(=O)O,,,,,,
4358,54359,Savoxepin,C1CCC(C1)CN2CCC3=C(CC2)C4=C(C=CC(=C4)C#N)OC5=CC=CC=C35,,,,,,
4359,54360,Azelastine hydrochloride,CN1CCCC(CC1)N2C(=O)C3=CC=CC=C3C(=N2)CC4=CC=C(C=C4)Cl.Cl,,,"['A class of non-sedating drugs that bind to but do not activate histamine receptors (DRUG INVERSE AGONISM), thereby blocking the actions of histamine or histamine agonists. These antihistamines represent a heterogenous group of compounds with differing chemical structures, adverse effects, distribution, and metabolism. Compared to the early (first generation) antihistamines, these non-sedating antihistamines have greater receptor specificity, lower penetration of BLOOD-BRAIN BARRIER, and are less likely to cause drowsiness or psychomotor impairment. (See all compounds classified as Histamine H1 Antagonists, Non-Sedating.)', 'Agents that are used to treat allergic reactions. Most of these drugs act by preventing the release of inflammatory mediators or inhibiting the actions of released mediators on their target cells. (From AMA Drug Evaluations Annual, 1994, p475) (See all compounds classified as Anti-Allergic Agents.)', 'Agents that cause an increase in the expansion of a bronchus or bronchial tubes. (See all compounds classified as Bronchodilator Agents.)', 'Compounds that bind to and inhibit that enzymatic activity of LIPOXYGENASES. Included under this category are inhibitors that are specific for lipoxygenase subtypes and act to reduce the production of LEUKOTRIENES. (See all compounds classified as Lipoxygenase Inhibitors.)']",,,
4360,54361,Digoxigenin-beta-tetraacetyl-D-glucoside,CC(=O)OCC1[C@H](C(C([C@@H](O1)O[C@H]2CC[C@]3([C@@H](C2)CCC4C3C[C@H]([C@]5([C@@]4(CC[C@@H]5C6=CC(=O)OC6)O)C)O)C)OC(=O)C)OC(=O)C)OC(=O)C,,,,,,
4361,54362,"(6R,7R)-7-[[2-(2-amino-4-thiazolyl)-2-(carboxymethoxyimino)-1-oxoethyl]amino]-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid",C=CC1=C(N2[C@@H]([C@@H](C2=O)NC(=O)C(=NOCC(=O)O)C3=CSC(=N3)N)SC1)C(=O)O,,,['Substances that inhibit the growth or reproduction of BACTERIA. (See all compounds classified as Anti-Bacterial Agents.)'],,,
4362,54363,"9-Chloro-11,15-dihydroxy-16,16-dimethylprosta-5,13-dien-1-oic acid",CCCCC(C)(C)C(C=CC1C(CC(C1CC=CCCCC(=O)O)Cl)O)O,,,,,,
4363,54364,"N-Cyclohexylbutane-1,4-diamine",C1CCC(CC1)NCCCCN,,,,,,
4364,54365,"beta-ALANINE, N-(4-HYDROXYBUTYL)-N-NITROSO-, METHYL ESTER, ACETATE",CC(=O)OCCCCN(CCC(=O)OC)N=O,,,,,,
4365,54366,CID 54366,C1CN(CCC1C(=O)C2=CC=C(C=C2)F)CCN3C(=O)C4=CC=CC=C4N=C3S.[C@@H]([C@H](C(=O)O)O)(C(=O)O)O,,,,,,
4366,54367,CID 54367,C1CN(CCC1C(=O)C2=CC=C(C=C2)F)CCN3C(=O)C4=CC=CC=C4N=C3S,,,,,,
4367,54368,Piritrexim isethionate,CC1=C2C(=NC(=NC2=NC=C1CC3=C(C=CC(=C3)OC)OC)N)N.C(CS(=O)(=O)O)O,,,,,,
4368,54369,Piritrexim,CC1=C2C(=NC(=NC2=NC=C1CC3=C(C=CC(=C3)OC)OC)N)N,,,"['Inhibitors of the enzyme, dihydrofolate reductase (TETRAHYDROFOLATE DEHYDROGENASE), which converts dihydrofolate (FH2) to tetrahydrofolate (FH4). They are frequently used in cancer chemotherapy. (From AMA, Drug Evaluations Annual, 1994, p2033) (See all compounds classified as Folic Acid Antagonists.)', 'Substances that inhibit or prevent the proliferation of NEOPLASMS. (See all compounds classified as Antineoplastic Agents.)']",,,
4369,54370,CID 54370,CCCCN=C(N=C(NC1=CC=CC=C1)S)S,,,,,,
4370,54371,"Glycine, N-(((ethoxymethylphosphinyl)thio)acetyl)-, ethyl ester, (R)-",CCOC(=O)CNC(=O)CSP(=O)(C)OCC,,,,,,
4371,54372,Bromopentachloroethane,C(C(Cl)(Cl)Br)(Cl)(Cl)Cl,,,,,,
4372,54373,H-DL-Phe-DL-Cys(1)-DL-Phe-DL-Trp-DL-Lys-DL-xiThr-DL-Cys(1)-Thr-ol.2CH3CO2H,C[C@H]([C@@H](CO)NC(=O)C1CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)C(C)O)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=CC=C4)NC(=O)C(CC5=CC=CC=C5)N)O.CC(=O)O.CC(=O)O,,,,,,
4373,54374,H-DL-Phe-DL-Cys(1)-DL-Phe-DL-Trp-DL-Lys-DL-xiThr-DL-Cys(1)-Thr-ol,C[C@H]([C@@H](CO)NC(=O)C1CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)C(C)O)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=CC=C4)NC(=O)C(CC5=CC=CC=C5)N)O,,,,,,
4374,54375,"(1R,4R)-4-(3,4-dichlorophenyl)-N-methyl-1,2,3,4-tetrahydronaphthalen-1-amine",CN[C@@H]1CC[C@@H](C2=CC=CC=C12)C3=CC(=C(C=C3)Cl)Cl,,,,,,
4375,54376,"10-(Methylamino)-11H-indeno(1,2-b)quinolin-11-one",CNC1=C2C(=NC3=CC=CC=C31)C4=CC=CC=C4C2=O,,,,,,
4376,54377,"Bicyclo(5.1.0)octane-2-amine, hydrochloride",C1CCC(C2CC2C1)[NH3+].[Cl-],,,,,,
4377,54378,Bicyclo[5.1.0]octan-2-amine,C1CCC(C2CC2C1)N,,,,,,
4378,54379,N-Bicyclo(3.1.0)hex-2-ylethylamine oxalate,CC[NH2+]C1CCC2C1C2.C(=O)(C(=O)[O-])O,,,,,,
4379,54380,N-ethylbicyclo[3.1.0]hexan-2-amine,CCNC1CCC2C1C2,,,,,,
4380,54381,N-Bicyclo(3.1.0)hex-3-yl-anthranilic acid,C1C2C1CC(C2)NC3=CC=CC=C3C(=O)O,,,,,,
4381,54382,"Cyclopropanecarboxylic acid, 3-[(1Z)-2-chloro-3,3,3-trifluoro-1-propenyl]-2,2-dimethyl-, (2,3,5,6-tetrafluoro-4-methylphenyl)methyl ester, (1R,3R)-rel-",CC1=C(C(=C(C(=C1F)F)COC(=O)C2C(C2(C)C)C=C(C(F)(F)F)Cl)F)F,,,,"['In both rats and dogs, when given either 1 or 10 mg/kg, most of the radioactivity was found in the feces unchanged and most urinary metabolites were conjugated. Approximately 30% of the administered dose was absorbed and excreted in the urine in both species. Single doses in both rats and dogs were excreted within 48 hours, 50-65% in feces and 20-30% in the urine. In rats, a biliary fistula experiment suggested that the radioactivity measured in the feces may be partially due to biliary excretion. Studies also suggest that oxidation precedes the ester body cleavage.']","['In a study with rat fat, half of the radioactive residues could be attributed to the parent and the remaining residues consisted of a mixture of fatty acid esters of hydroxylated parent metabolites.', 'Species susceptibility to pyrethroid ester toxicity would appear to be highly dependent on the nature of the tissue esterase, the level of activity detected, the substrate specificity, and rate of hydrolysis encountered in target and nontarget species. The microsomal monoxygenase system found in the tissues of almost all species is extensively involved in the detoxification of every pyrethroid ester in mammals and of some of these agents in insect and fish species. /Pyrethroid esters/']","['In rats, the half-life in the liver is 4.8 days, in the fat is 13.3 days and in the blood is 10.6 days.']"
4382,54383,"DIBENZ(a,h)ACRIDINE, 14-METHYL-",CC1=C2C=CC3=CC=CC=C3C2=NC4=C1C5=CC=CC=C5C=C4,,,,,,
4383,54384,Levocabastine hydrochloride,C[C@@H]1CN(CC[C@@]1(C2=CC=CC=C2)C(=O)O)C3CCC(CC3)(C#N)C4=CC=C(C=C4)F.Cl,,,"['A class of non-sedating drugs that bind to but do not activate histamine receptors (DRUG INVERSE AGONISM), thereby blocking the actions of histamine or histamine agonists. These antihistamines represent a heterogenous group of compounds with differing chemical structures, adverse effects, distribution, and metabolism. Compared to the early (first generation) antihistamines, these non-sedating antihistamines have greater receptor specificity, lower penetration of BLOOD-BRAIN BARRIER, and are less likely to cause drowsiness or psychomotor impairment. (See all compounds classified as Histamine H1 Antagonists, Non-Sedating.)']",,,
4384,54385,Levocabastine,C[C@@H]1CN(CC[C@@]1(C2=CC=CC=C2)C(=O)O)C3CCC(CC3)(C#N)C4=CC=C(C=C4)F,['As an ophthalmic for the temporary relief of the signs and symptoms of seasonal allergic conjunctivitis. Also used as a nasal spray for allergic rhinitis.'],['Levocabastine is a selective histamine H1-receptor antagonist exerting inhibitory effects on the release of chemical mediators from mast cells and on the chemotaxis of polymorphonuclear leukocytes and eosinophils. Both histamine and antigens induced conjunctivitis can be inhibited by levocabastine. Levocabastine can also reduce symptoms of allergic rhinitis by preventing an increase in vascular permeability of nasal mucosa.'],"['A class of non-sedating drugs that bind to but do not activate histamine receptors (DRUG INVERSE AGONISM), thereby blocking the actions of histamine or histamine agonists. These antihistamines represent a heterogenous group of compounds with differing chemical structures, adverse effects, distribution, and metabolism. Compared to the early (first generation) antihistamines, these non-sedating antihistamines have greater receptor specificity, lower penetration of BLOOD-BRAIN BARRIER, and are less likely to cause drowsiness or psychomotor impairment. (See all compounds classified as Histamine H1 Antagonists, Non-Sedating.)']","['After instillation in the eye, levocabastine is systemically absorbed, albeit at low levels.']",['Mostly unchanged. 10 to 20% is metabolized to the acylglucuronide of levocabastine.'],['36 hours (after oral administration)']
4385,54386,"Bicyclo(5.1.0)oct-2-ene-8-amine, succinate",C1CC=CC2C(C1)C2[NH3+].C(CC(=O)[O-])C(=O)O,,,,,,
4386,54387,Bicyclo[5.1.0]oct-2-en-8-amine,C1CC=CC2C(C1)C2N,,,,,,
4387,54388,"Bicyclo(6.1.0)nonane-2-amine, hydrochloride",C1CCC2CC2C(CC1)[NH3+].[Cl-],,,,,,
4388,54389,Bicyclo[6.1.0]nonan-2-amine,C1CCC2CC2C(CC1)N,,,,,,
4389,54390,"Benzanilide, 3'-chloro-N-(2-((2-(dimethylamino)ethyl)carbamoyl)ethyl)-",CN(C)CCNC(=O)CCN(C1=CC(=CC=C1)Cl)C(=O)C2=CC=CC=C2,,,,,,
4390,54391,CID 54391,CCOC1=CC=C(C=C1)N(CCC(=O)NCC[NH+](C)C)C(=O)C2=CC=CC=C2.C1=CC=C(C(=C1)C(=O)[O-])O,,,,,,
4391,54392,N-[3-[2-(dimethylamino)ethylamino]-3-oxopropyl]-N-(4-ethoxyphenyl)benzamide,CCOC1=CC=C(C=C1)N(CCC(=O)NCCN(C)C)C(=O)C2=CC=CC=C2,,,,,,
4392,54393,"Benzanilide, 3'-chloro-N-(2-((2-(diethylamino)ethyl)carbamoyl)ethyl)-",CCN(CC)CCNC(=O)CCN(C1=CC(=CC=C1)Cl)C(=O)C2=CC=CC=C2,,,,,,
4393,54394,CID 54394,C[NH+](C)CCNC(=O)CCN(C1=CC(=CC=C1)Cl)C(=O)C2=CC=C(C=C2)OC.C1=CC=C(C(=C1)C(=O)[O-])O,,,,,,
4394,54395,3'-Chloro-N-[2-[[2-(dimethylamino)ethyl]carbamoyl]ethyl]-4-methoxybenzanilide,CN(C)CCNC(=O)CCN(C1=CC(=CC=C1)Cl)C(=O)C2=CC=C(C=C2)OC,,,,,,
4395,54396,CID 54396,CC[NH+](CC)CCNC(=O)CCN(C1=CC(=CC=C1)Cl)C(=O)C2=CC=C(C=C2)OC.C1=CC=C(C(=C1)C(=O)[O-])O,,,,,,
4396,54397,3'-Chloro-N-[2-[[2-(diethylamino)ethyl]carbamoyl]ethyl]-4-methoxybenzanilide,CCN(CC)CCNC(=O)CCN(C1=CC(=CC=C1)Cl)C(=O)C2=CC=C(C=C2)OC,,,,,,
4397,54398,CID 54398,CC[NH+](CC)CCNC(=O)C(C)N(C1=CC=C(C=C1)OCC)C(=O)C2=CC=CC=C2Cl.C1=CC=C(C(=C1)C(=O)[O-])O,,,,,,
4398,54399,2-Chloro-N-[1-[[2-(diethylamino)ethyl]carbamoyl]ethyl]-4'-ethoxybenzanilide,CCN(CC)CCNC(=O)C(C)N(C1=CC=C(C=C1)OCC)C(=O)C2=CC=CC=C2Cl,,,,,,
4399,54400,beta-Phenylhippuric acid 2-(diethylamino)ethyl ester hydrochloride,CC[NH+](CC)CCOC(=O)CN(C1=CC=CC=C1)C(=O)C2=CC=CC=C2.[Cl-],,,,,,
4400,54401,2-(diethylamino)ethyl 2-(N-benzoylanilino)acetate,CCN(CC)CCOC(=O)CN(C1=CC=CC=C1)C(=O)C2=CC=CC=C2,,,,,,
4401,54402,CID 54402,C[NH+](C)CCOC(=O)CCN(C1=CC(=CC=C1)Cl)C(=O)C2=CC=CC=C2.C(=CC(=O)[O-])C(=O)O,,,,,,
4402,54403,2-(dimethylamino)ethyl 3-(N-benzoyl-3-chloroanilino)propanoate,CN(C)CCOC(=O)CCN(C1=CC(=CC=C1)Cl)C(=O)C2=CC=CC=C2,,,,,,
4403,54404,"ALANINE, N-BENZOYL-N-(p-CHLOROPHENYL)-2-METHYL-, 2-(DIETHYLAMINO)ETHYL ESTER",CCN(CC)CCOC(=O)C(C)(C)N(C1=CC=C(C=C1)Cl)C(=O)C2=CC=CC=C2,,,,,,
4404,54405,Brimonidine tartrate,C1CN=C(N1)NC2=C(C3=NC=CN=C3C=C2)Br.[C@@H]([C@H](C(=O)O)O)(C(=O)O)O,['Mirvaso is indicated for the symptomatic treatment of facial erythema of rosacea in adult patients.'],,"['Compounds that bind to and activate ADRENERGIC ALPHA-2 RECEPTORS. (See all compounds classified as Adrenergic alpha-2 Receptor Agonists.)', 'Drugs used in the treatment of acute or chronic vascular HYPERTENSION regardless of pharmacological mechanism. Among the antihypertensive agents are DIURETICS; (especially DIURETICS, THIAZIDE); ADRENERGIC BETA-ANTAGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; GANGLIONIC BLOCKERS; and VASODILATOR AGENTS. (See all compounds classified as Antihypertensive Agents.)']",,,
4405,54406,CID 54406,C[C@H]1CC2C3CCC4=CC(=O)C=CC4[C@]3([C@H](CC2([C@]1(C(=O)SC)OC(=O)C)C)O)F,,,,,,
4406,54407,"ALANINE, N-BENZOYL-N-(p-CHLOROPHENYL)-2-METHYL-, 2-(DIMETHYLAMINO)ETHYL ESTER",CC(C)(C(=O)OCCN(C)C)N(C1=CC=C(C=C1)Cl)C(=O)C2=CC=CC=C2,,,,,,
4407,54408,"ETHYLENEDIAMINE, N,N-DIETHYL-N'-(o-TOLYL)-",CCN(CC)CCNC1=CC=CC=C1C,,,,,,
4408,54409,CID 54409,CCCNCC(COC1=CC2=C(C=C1)C(=O)C=C(O2)C3=CC=CC=C3)O.C(=CC(=O)O)C(=O)O,,,,,,
4409,54410,Flavodilol,CCCNCC(COC1=CC2=C(C=C1)C(=O)C=C(O2)C3=CC=CC=C3)O,,,,,,
4410,54411,CID 54411,C1CCC2C(C2[NH3+])C=CC1.C(CC(=O)[O-])C(=O)O,,,,,,
4411,54412,CID 54412,C1CCC2C(C2N)C=CC1,,,,,,
4412,54413,"4-Amino-2-[4,6-diamino-3-[3-amino-6-(aminomethyl)-5-hydroxyoxan-2-YL]oxy-2-hydroxycyclohexyl]oxy-6-(hydroxymethyl)oxane-3,5-diol sulfate",C1C(C(C(C(C1N)OC2C(C(C(C(O2)CO)O)N)O)O)OC3C(CC(C(O3)CN)O)N)N.OS(=O)(=O)O,,,,,,
4413,54414,"4,6-Isoquinolinediol, 1,2,3,4-tetrahydro-2-(phenylmethyl)-1-(3,4,5-trimethoxyphenyl)-, hydrochloride, hydrate (3:3:1)",COC1=CC(=CC(=C1OC)OC)C2C3=C(C=C(C=C3)O)C(C[NH+]2CC4=CC=CC=C4)O.[Cl-],,,,,,
4414,54415,"2-benzyl-1-(3,4,5-trimethoxyphenyl)-3,4-dihydro-1H-isoquinoline-4,6-diol",COC1=CC(=CC(=C1OC)OC)C2C3=C(C=C(C=C3)O)C(CN2CC4=CC=CC=C4)O,,,,,,
4415,54416,"4,6-Isoquinolinediol, 1,2,3,4-tetrahydro-1-(4-hydroxy-3-methoxyphenyl)-, hexanedioate, hydrate (4:2:1)",COC1=C(C=CC(=C1)C2C3=C(C=C(C=C3)O)C(C[NH2+]2)O)O.C(CCC(=O)[O-])CC(=O)O,,,,,,
4416,54417,"1-(4-Hydroxy-3-methoxyphenyl)-1,2,3,4-tetrahydroisoquinoline-4,6-diol",COC1=C(C=CC(=C1)C2C3=C(C=C(C=C3)O)C(CN2)O)O,,,,,,
4417,54418,"1,2,3,4-Tetrahydro-2-(phenylmethyl)-4,6-isoquinolinediol hydrochloride",C1C(C2=C(C[NH+]1CC3=CC=CC=C3)C=CC(=C2)O)O.[Cl-],,,,,,
4418,54419,"2-benzyl-3,4-dihydro-1H-isoquinoline-4,6-diol",C1C(C2=C(CN1CC3=CC=CC=C3)C=CC(=C2)O)O,,,,,,
4419,54420,"Phthalimide, N-(4-(2-morpholinoethoxy)phenyl)-",C1COCCN1CCOC2=CC=C(C=C2)N3C(=O)C4=CC=CC=C4C3=O,,,,,,
4420,54421,"Phthalimide, N-(4-(3-morpholinopropoxy)phenyl)-",C1COCCN1CCCOC2=CC=C(C=C2)N3C(=O)C4=CC=CC=C4C3=O,,,,,,
4421,54422,"Malononitrile, (1-methylpyrrol-2-ylmethylene)-",CN1C=CC=C1C=C(C#N)C#N,,,,,,
4422,54423,"1-[3-(1,3-dimethyl-3,7-dihydro-1H-purine-2,6-dion-7-yl)-2-hydroxypropyl]-4-(3-phenylthio-propyl)piperazine hydrochloride",CN1C2=C(C(=O)N(C1=O)C)N(C=N2)CC(CN3CCN(CC3)CCCSC4=CC=CC=C4)O.Cl,,,,,,
4423,54424,Tazifylline,CN1C2=C(C(=O)N(C1=O)C)N(C=N2)CC(CN3CCN(CC3)CCCSC4=CC=CC=C4)O,,,,,,
4424,54425,4-Pyridinecarboxylic acid 2-(2-thienylmethylene)hydrazide,C1=CSC(=C1)C=NNC(=O)C2=CC=NC=C2,,,,,,
4425,54426,"1-Benzoyl-3-phenyl-1,2,4-triazole",C1=CC=C(C=C1)C2=NN(C=N2)C(=O)C3=CC=CC=C3,,,,,,
4426,54427,"Ethanone, 1-phenyl-2-(3-phenyl-1H-1,2,4-triazol-1-yl)-",C1=CC=C(C=C1)C2=NN(C=N2)CC(=O)C3=CC=CC=C3,,,,,,
4427,54428,"Carbamic acid, (2-(2-hydroxy-3-((1-methylethyl)amino)propoxy)phenyl)-, butyl ester, monohydrochloride",CCCCOC(=O)NC1=CC=CC=C1OCC(C[NH2+]C(C)C)O.[Cl-],,,,,,
4428,54429,Butyl N-[2-[2-hydroxy-3-(propan-2-ylamino)propoxy]phenyl]carbamate,CCCCOC(=O)NC1=CC=CC=C1OCC(CNC(C)C)O,,,,,,
4429,54430,"Carbamic acid, (2-(3-((1,1-dimethylethyl)amino)-2-hydroxypropoxy)phenyl)-, butyl ester, monohydrochloride",CCCCOC(=O)NC1=CC=CC=C1OCC(C[NH2+]C(C)(C)C)O.[Cl-],,,,,,
4430,54431,N-[2-[3-(tert-Butylamino)-2-hydroxypropoxy]phenyl]carbamic acid butyl ester,CCCCOC(=O)NC1=CC=CC=C1OCC(CNC(C)(C)C)O,,,,,,
4431,54432,"Carbamic acid, (3-(2-hydroxy-3-((1-methylethyl)amino)propoxy)phenyl)-, butyl ester, monohydrochloride",CCCCOC(=O)NC1=CC(=CC=C1)OCC(C[NH2+]C(C)C)O.[Cl-],,,,,,
4432,54433,Butyl N-[3-[2-hydroxy-3-(propan-2-ylamino)propoxy]phenyl]carbamate,CCCCOC(=O)NC1=CC(=CC=C1)OCC(CNC(C)C)O,,,,,,
4433,54434,"Carbamic acid, (3-(3-((1,1-dimethylethyl)amino)-2-hydroxypropoxy)phenyl)-, butyl ester, monohydrochloride",CCCCOC(=O)NC1=CC(=CC=C1)OCC(C[NH2+]C(C)(C)C)O.[Cl-],,,,,,
4434,54435,N-[3-[3-(tert-Butylamino)-2-hydroxypropoxy]phenyl]carbamic acid butyl ester,CCCCOC(=O)NC1=CC(=CC=C1)OCC(CNC(C)(C)C)O,,,,,,
4435,54436,"Carbamic acid, (4-(2-hydroxy-3-((1-methylethyl)amino)propoxy)phenyl)-, butyl ester, monohydrochloride",CCCCOC(=O)NC1=CC=C(C=C1)OCC(C[NH2+]C(C)C)O.[Cl-],,,,,,
4436,54437,"Carbamic acid, (4-(2-hydroxy-3-((1-methylethyl)amino)propoxy)phenyl)-, butyl ester",CCCCOC(=O)NC1=CC=C(C=C1)OCC(CNC(C)C)O,,,,,,
4437,54438,"Carbamic acid, (4-(3-((1,1-dimethylethyl)amino)-2-hydroxypropoxy)phenyl)-, butyl ester, monohydrochloride",CCCCOC(=O)NC1=CC=C(C=C1)OCC(C[NH2+]C(C)(C)C)O.[Cl-],,,,,,
4438,54439,butyl N-[4-[3-(tert-butylamino)-2-hydroxypropoxy]phenyl]carbamate,CCCCOC(=O)NC1=CC=C(C=C1)OCC(CNC(C)(C)C)O,,,,,,
4439,54440,CID 54440,CC[NH+](CC)CCN(C1=CC=CC=C1C)C(=O)C2=CC(=C(C(=C2)OC)OC)OC.C(=CC(=O)[O-])C(=O)O,,,,,,
4440,54441,"Benzamide, N-(2-(diethylamino)ethyl)-3,4,5-trimethoxy-N-(2-methylphenyl)-",CCN(CC)CCN(C1=CC=CC=C1C)C(=O)C2=CC(=C(C(=C2)OC)OC)OC,,,,,,
4441,54442,"5-Benzofurancarboxylic acid, 4,7-dimethoxy-6-hydroxy-, 2-(diethylamino)ethyl ester, hydrochloride",CC[NH+](CC)CCOC(=O)C1=C(C2=C(C(=C1O)OC)OC=C2)OC.[Cl-],,,,,,
4442,54443,"2-(Diethylamino)ethyl 6-hydroxy-4,7-dimethoxy-1-benzofuran-5-carboxylate",CCN(CC)CCOC(=O)C1=C(C2=C(C(=C1O)OC)OC=C2)OC,,,,,,
4443,54444,Agn-PC-0JL06W,CC1(C2CC3=C(C1(CCN2)O)C=C(C=C3)O)C,,,,,,
4444,54445,Castanospermine,C1CN2C[C@@H]([C@H]([C@@H]([C@H]2[C@H]1O)O)O)O,,,"['Anti-inflammatory agents that are non-steroidal in nature. In addition to anti-inflammatory actions, they have analgesic, antipyretic, and platelet-inhibitory actions. They act by blocking the synthesis of prostaglandins by inhibiting cyclooxygenase, which converts arachidonic acid to cyclic endoperoxides, precursors of prostaglandins. Inhibition of prostaglandin synthesis accounts for their analgesic, antipyretic, and platelet-inhibitory actions; other mechanisms may contribute to their anti-inflammatory effects. (See all compounds classified as Anti-Inflammatory Agents, Non-Steroidal.)', 'Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of INTERLEUKINS and other CYTOKINES are emerging. (See all compounds classified as Immunosuppressive Agents.)', 'Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. (See all compounds classified as Enzyme Inhibitors.)', 'Compounds that inhibit or block the activity of GLYCOSIDE HYDROLASES such as ALPHA-AMYLASES and ALPHA-GLUCOSIDASES. (See all compounds classified as Glycoside Hydrolase Inhibitors.)']",,,
4445,54446,CID 54446,CC1=CC=C(C=C1)C=C2C(=O)N(C(=N2)S)C,,,,,,
4446,54447,CID 54447,CC1=CC=C(C=C1)C=C2C(=O)N(C(=N2)[SeH])C,,,,,,
4447,54448,CID 54448,CN1C(=O)C(=CC2=CC=C(C=C2)Cl)N=C1S,,,,,,
4448,54449,CID 54449,CN1C(=O)C(=CC2=CC=C(C=C2)Cl)N=C1[SeH],,,,,,
4449,54450,"2-[4-[(4-Chlorophenyl)methylidene]-2,5-dioxoimidazolidin-1-yl]acetic acid",C1=CC(=CC=C1C=C2C(=O)N(C(=O)N2)CC(=O)O)Cl,,,,,,
4450,54451,CID 54451,C1=CC(=CC=C1C=C2C(=O)N(C(=N2)S)CC(=O)O)Cl,,,,,,
4451,54452,CID 54452,C1=CC(=CC=C1C=C2C(=O)N(C(=N2)[SeH])CC(=O)O)Cl,,,,,,
4452,54453,"ACETOPHENONE, 2,2-DI-p-TOLUIDINO-",CC1=CC=C(C=C1)NC(C(=O)C2=CC=CC=C2)NC3=CC=C(C=C3)C,,,,,,
4453,54454,Simvastatin,CCC(C)(C)C(=O)O[C@H]1C[C@H](C=C2[C@H]1[C@H]([C@H](C=C2)C)CC[C@@H]3C[C@H](CC(=O)O3)O)C,"['Simvastatin is indicated for the treatment of hyperlipidemia to reduce elevated total cholesterol (total-C), low-density lipoprotein cholesterol (LDL‑C), apolipoprotein B (Apo B), and triglycerides (TG), and to increase high-density lipoprotein cholesterol (HDL-C).  This includes the treatment of primary hyperlipidemia (Fredrickson type IIa, heterozygous familial and nonfamilial), mixed dyslipidemia (Fredrickson type IIb), hypertriglyceridemia (Fredrickson type IV hyperlipidemia), primary dysbetalipoproteinemia (Fredrickson type III hyperlipidemia), homozygous familial hypercholesterolemia (HoFH) as an adjunct to other lipid-lowering treatments, as well as adolescent patients with Heterozygous Familial Hypercholesterolemia (HeFH).  Simvastatin is also indicated to reduce the risk of cardiovascular morbidity and mortality including myocardial infarction, stroke, and the need for revascularization procedures. It is primarily used in patients at high risk of coronary events because of existing coronary heart disease, diabetes, peripheral vessel disease, history of stroke or other cerebrovascular disease.  Prescribing of statin medications is considered standard practice following any cardiovascular events and for people with a moderate to high risk of development of CVD. Statin-indicated conditions include diabetes mellitus, clinical atherosclerosis (including myocardial infarction, acute coronary syndromes, stable angina, documented coronary artery disease, stroke, trans ischemic attack (TIA), documented carotid disease, peripheral artery disease, and claudication), abdominal aortic aneurysm, chronic kidney disease, and severely elevated LDL-C levels.']","[""Simvastatin is an oral antilipemic agent which inhibits HMG-CoA reductase. It is used to lower total cholesterol, low density lipoprotein-cholesterol (LDL-C), apolipoprotein B (apoB), non-high density lipoprotein-cholesterol (non-HDL-C), and trigleride (TG) plasma concentrations while increasing HDL-C concentrations. High LDL-C, low HDL-C and high TG concentrations in the plasma are associated with increased risk of atherosclerosis and cardiovascular disease. The total cholesterol to HDL-C ratio is a strong predictor of coronary artery disease and high ratios are associated with higher risk of disease. Increased levels of HDL-C are associated with lower cardiovascular risk. By decreasing LDL-C and TG and increasing HDL-C, rosuvastatin reduces the risk of cardiovascular morbidity and mortality.  Elevated cholesterol levels, and in particular, elevated low-density lipoprotein (LDL) levels, are an important risk factor for the development of CVD. Use of statins to target and reduce LDL levels has been shown in a number of landmark studies to significantly reduce the risk of development of CVD and all-cause mortality. Statins are considered a cost-effective treatment option for CVD due to their evidence of reducing all-cause mortality including fatal and non-fatal CVD as well as the need for surgical revascularization or angioplasty following a heart attack. Evidence has shown that even for low-risk individuals (with <10% risk of a major vascular event occurring within 5 years) statins cause a 20%-22% relative reduction in major cardiovascular events (heart attack, stroke, coronary revascularization, and coronary death) for every 1 mmol/L reduction in LDL without any significant side effects or risks.  **Skeletal Muscle Effects**  Simvastatin occasionally causes myopathy manifested as muscle pain, tenderness or weakness with creatine kinase (CK) above ten times the upper limit of normal (ULN). Myopathy sometimes takes the form of rhabdomyolysis with or without acute renal failure secondary to myoglobinuria, and rare fatalities have occurred. Predisposing factors for myopathy include advanced age (≥65 years), female gender, uncontrolled hypothyroidism, and renal impairment. Chinese patients may also be at increased risk for myopathy. In most cases, muscle symptoms and CK increases resolved when treatment was promptly discontinued.  In a clinical trial database of 41,413 patients, the incidence of myopathy was approximately 0.03% and 0.08% at 20 and 40 mg/day, respectively, while the risk of myopathy with simvastatin 80 mg (0.61%) was disproportionately higher than that observed at the lower doses. It's therefore recommended that the 80mg dose of simvastatin should be used only in patients who have been taking simvastatin 80 mg chronically (e.g., for 12 months or more) without evidence of muscle toxicity. As well, patients already stabilized on simvastatin 80mg should be monitored closely for evidence of muscle toxicity; if they need to be initiated on an interacting drug that is contraindicated or is associated with a dose cap for simvastatin, that patient should be switched to an alternative statin with less potential for the drug-drug interaction.  The risk of myopathy during treatment with simvastatin may be increased with concurrent administration of interacting drugs such as [fenofibrate], [niacin], [gemfibrozil], [cyclosporine], and strong inhibitors of the CYP3A4 enzyme.  Cases of myopathy, including rhabdomyolysis, have been reported with HMG-CoA reductase inhibitors coadministered with [colchicine], and caution should therefore be exercised when prescribing these two medications together.  **Liver Enzyme Abnormalities**  Persistent increases (to more than 3X the ULN) in serum transaminases have occurred in approximately 1% of patients who received simvastatin in clinical studies. When drug treatment was interrupted or discontinued in these patients, the transaminase levels usually fell slowly to pretreatment levels. The increases were not associated with jaundice or other clinical signs or symptoms.  In the Scandinavian Simvastatin Survival Study (4S), the number of patients with more than one transaminase elevation to >3 times the ULN, over the course of the study, was not significantly different between the simvastatin and placebo groups (14 [0.7%] vs. 12 [0.6%]). The frequency of single elevations of ALT to 3 times the ULN was significantly higher in the simvastatin group in the first year of the study (20 vs. 8, p=0.023), but not thereafter. In the HPS (Heart Protection Study), in which 20,536 patients were randomized to receive simvastatin 40 mg/day or placebo, the incidences of elevated transaminases (>3X ULN confirmed by repeat test) were 0.21% (n=21) for patients treated with simvastatin and 0.09% (n=9) for patients treated with placebo.   **Endocrine Effects**  Increases in HbA1c and fasting serum glucose levels have been reported with HMG-CoA reductase inhibitors, including simvastatin.  Although cholesterol is the precursor of all steroid hormones, studies with simvastatin have suggested that this agent has no clinical effect on steroidogenesis. Simvastatin caused no increase in biliary lithogenicity and, therefore, would not be expected to increase the incidence of gallstones.""]","['Compounds that inhibit HYDROXYMETHYLGLUTARYL COA REDUCTASES. They have been shown to directly lower CHOLESTEROL synthesis. (See all compounds classified as Hydroxymethylglutaryl-CoA Reductase Inhibitors.)', 'Substances that lower the levels of certain LIPIDS in the BLOOD. They are used to treat HYPERLIPIDEMIAS. (See all compounds classified as Hypolipidemic Agents.)', 'Substances used to lower plasma cholesterol levels. (See all compounds classified as Anticholesteremic Agents.)']","['Peak plasma concentrations of both active and total inhibitors were attained within 1.3 to 2.4 hours post-dose. While the recommended therapeutic dose range is 10 to 40 mg/day, there was no substantial deviation from linearity of AUC with an increase in dose to as high as 120 mg. Relative to the fasting state, the plasma profile of inhibitors was not affected when simvastatin was administered immediately before a test meal.  In a pharmacokinetic study of 17 healthy Chinese volunteers, the major PK parameters were as follows: Tmax 1.44 hours, Cmax 9.83 ug/L, t1/2 4.85 hours, and AUC 40.32ug·h/L.  Simvastatin undergoes extensive first-pass extraction in the liver, the target organ for the inhibition of HMG-CoA reductase and the primary site of action. This tissue selectivity (and consequent low systemic exposure) of orally administered simvastatin has been shown to be far greater than that observed when the drug is administered as the enzymatically active form, i.e. as the open hydroxyacid.  In animal studies, after oral dosing, simvastatin achieved substantially higher concentrations in the liver than in non-target tissues. However, because simvastatin undergoes extensive first-pass metabolism, the bioavailability of the drug in the systemic system is low.  In a single-dose study in nine healthy subjects, it was estimated that less than 5% of an oral dose of simvastatin reached the general circulation in the form of active inhibitors.  Genetic differences in the OATP1B1 (Organic-Anion-Transporting Polypeptide 1B1) hepatic transporter encoded by the SCLCO1B1 gene (Solute Carrier Organic Anion Transporter family member 1B1) have been shown to impact simvastatin pharmacokinetics. Evidence from pharmacogenetic studies of the c.521T>C single nucleotide polymorphism (SNP) showed that simvastatin plasma concentrations were increased on average 3.2-fold for individuals homozygous for 521CC compared to homozygous 521TT individuals. The 521CC genotype is also associated with a marked increase in the risk of developing myopathy, likely secondary to increased systemic exposure. Other statin drugs impacted by this polymorphism include [rosuvastatin], [pitavastatin], [atorvastatin], [lovastatin], and [pravastatin].  For patients known to have the above-mentioned c.521CC OATP1B1 genotype, a maximum daily dose of 20mg of simvastatin is recommended to avoid adverse effects from the increased exposure to the drug, such as muscle pain and risk of rhabdomyolysis.  Evidence has also been obtained with other statins such as [rosuvastatin] that concurrent use of statins and inhibitors of Breast Cancer Resistance Protein (BCRP) such as elbasvir and grazoprevir increased the plasma concentration of these statins. Further evidence is needed, however a dose adjustment of simvastatin may be necessary. Other statin drugs impacted by this polymorphism include [fluvastatin] and [atorvastatin].', 'Following an oral dose of 14C-labeled simvastatin in man, 13% of the dose was excreted in urine and 60% in feces.', 'Rat studies indicate that when radiolabeled simvastatin was administered, simvastatin-derived radioactivity crossed the blood-brain barrier.', 'Both simvastatin and its beta-hydroxyacid metabolite are highly bound (approximately 95%) to human plasma proteins. Rat studies indicate that when radiolabeled simvastatin was administered, simvastatin-derived radioactivity crossed the blood-brain barrier.', '/MILK/ It is not known whether simvastatin is distributed into human breast milk ... .', 'Following an oral dose of (14)C-labeled simvastatin in man, 13% of the dose was excreted in urine and 60% in feces. Plasma concentrations of total radioactivity (simvastatin plus (14)C-metabolites) peaked at 4 hours and declined rapidly to about 10% of peak by 12 hours postdose. Since simvastatin undergoes extensive first-pass extraction in the liver, the availability of the drug to the general circulation is low (<5%).', 'Absorption, distribution and excretion of (14)C-simvastatin were studied in male rats after 21-day consecutive daily oral administration at the dose of 10 mg/kg. Plasma levels of (14C)simvastatin at 1hr after each administration did not increase during and after repeated administration. The radioactivity levels-time curve after the final administration was similar to that after the first dosing. The cumulative excretion of radioactivity in urine and feces accounted for 9.0% and 91.4% of the total dose, respectively, within 96hr after the final administration. After the final administration, radioactivity was concentrated in the gastrointestinal tracts, liver and kidney. The distribution pattern was similar to that observed after the single administration. There was no accumulation of the drug and its metabolites in the tissues of rats after the consecutive oral administration of (14)C-simvastatin. Foeto-placental transfer and excretion of radioactivity into milk were studied in pregnant and lactating rats after single oral administration of (14)C-simvastatin. Whole body autoradiograms of rats on day 12 and 18 of gestation showed low distribution and rapid elimination of radioactivity from the fetus. On day 18 of gestation, the concentration of radioactivity in the placenta, amniotic fluid and fetal tissues were nearly equal to or less than those in the maternal plasma. The amount of radioactivity transferred into a fetus was about 0.02% of the oral dose. The concentrations of radioactivity in the milk were about 20-54% of those in maternal plasma.', 'For more Absorption, Distribution and Excretion (Complete) data for Simvastatin (6 total), please visit the HSDB record page.']","[""Simvastatin is administered as the inactive lactone derivative that is then metabolically activated to its β-hydroxyacid form by a combination of spontaneous chemical conversion and enzyme-mediated hydrolysis by nonspecific carboxyesterases in the intestinal wall, liver, and plasma. Oxidative metabolism in the liver is primarily mediated by CYP3A4 and CYP3A5, with the remaining metabolism occurring through CYP2C8 and CYP2C9.  The major active metabolites of simvastatin are β-hydroxyacid metabolite and its 6'-hydroxy, 6'-hydroxymethyl, and 6'-exomethylene derivatives.  Polymorphisms in the CYP3A5 gene have been shown to affect the disposition of simvastatin and may provide a plausible explanation for interindividual variability of simvastatin disposition and pharmacokinetics."", ""The major active metabolites of simvastatin present in human plasma are the beta-hydroxyacid of simvastatin and its 6'-hydroxy, 6'-hydroxymethyl, and 6'-exomethylene derivatives."", ""Simvastatin has known human metabolites that include 3', 5'-Dihydrodiol, 6'-alpha-Hydroxysimvastatin, and 6'-exomethylene.""]",['4.85 hours']
4454,54455,"1,2,3,4-Tetrahydro-1-methyl-6,7-isoquinolinediol hydrochloride",CC1C2=CC(=C(C=C2CC[NH2+]1)O)O.[Cl-],,,,,,
4455,54456,"1-Methyl-1,2,3,4-tetrahydroisoquinoline-6,7-diol",CC1C2=CC(=C(C=C2CCN1)O)O,,,,,,
4456,54457,"3-(1-Butyl-1,2,3,6-tetrahydro-4-pyridinyl)-5-chloro-1H-indole hydrochloride",CCCC[NH+]1CCC(=CC1)C2=CNC3=C2C=C(C=C3)Cl.[Cl-],,,,,,
4457,54458,"3-(1-butyl-3,6-dihydro-2H-pyridin-4-yl)-5-chloro-1H-indole",CCCCN1CCC(=CC1)C2=CNC3=C2C=C(C=C3)Cl,,,,,,
4458,54459,Idazoxan,C1CN=C(N1)C2COC3=CC=CC=C3O2,,,['Drugs that bind to and block the activation of ADRENERGIC ALPHA-2 RECEPTORS. (See all compounds classified as Adrenergic alpha-2 Receptor Antagonists.)'],,,
4459,54460,"Carbamic acid, methylnitroso-, 1,2-ethanediyl ester",CN(C(=O)OCCOC(=O)N(C)N=O)N=O,,,,,,
4460,54461,CID 54461,C1C(=O)N(C(=O)N1N=CC2=CC=C(O2)C3=CC(=C(C=C3)Cl)Cl)C(=O)CC[NH3+].[Cl-],,,,,,
4461,54462,"3-(3-Aminopropanoyl)-1-[[5-(3,4-dichlorophenyl)furan-2-yl]methylideneamino]imidazolidine-2,4-dione",C1C(=O)N(C(=O)N1N=CC2=CC=C(O2)C3=CC(=C(C=C3)Cl)Cl)C(=O)CCN,,,,,,
4462,54463,CID 54463,C1C(=O)N(C(=O)N1N=CC2=CC=C(O2)C3=CC(=C(C=C3)F)Cl)C(=O)CC[NH3+].[Cl-],,,,,,
4463,54464,CID 54464,C1C(=O)N(C(=O)N1N=CC2=CC=C(O2)C3=CC(=C(C=C3)F)Cl)C(=O)CCN,,,,,,
4464,54465,CID 54465,C1C(=O)N(C(=O)N1N=CC2=CC=C(O2)C3=CC(=C(C=C3)Cl)C(F)(F)F)C(=O)CC[NH3+].[Cl-],,,,,,
4465,54466,CID 54466,C1C(=O)N(C(=O)N1N=CC2=CC=C(O2)C3=CC(=C(C=C3)Cl)C(F)(F)F)C(=O)CCN,,,,,,
4466,54467,N-Butyl-2-(7-chloro-4-quinolylamino)acetamide monohydrochloride,CCCCNC(=O)C[NH2+]C1=C2C=CC(=CC2=NC=C1)Cl.[Cl-],,,,,,
4467,54468,N-butyl-2-[(7-chloroquinolin-4-yl)amino]acetamide,CCCCNC(=O)CNC1=C2C=CC(=CC2=NC=C1)Cl,,,,,,
4468,54469,N-tert-Butyl-2-(7-chloro-4-quinolylamino)acetamide monohydrochloride,CC(C)(C)NC(=O)C[NH2+]C1=C2C=CC(=CC2=NC=C1)Cl.[Cl-],,,,,,
4469,54470,"2-[(7-Chloro-4-quinolinyl)amino]-N-(1,1-dimethylethyl)acetamide",CC(C)(C)NC(=O)CNC1=C2C=CC(=CC2=NC=C1)Cl,,,,,,
4470,54471,Fengabine,CCCCN=C(C1=CC=CC=C1Cl)C2=C(C=CC(=C2)Cl)O,,,,,,
4471,54472,5-(2-Hydroxy-3-iodopropyl)-5-phenylbarbituric acid,C1=CC=C(C=C1)C2(C(=O)NC(=O)NC2=O)CC(CI)O,,,,,,
4472,54473,Bromopropyzamide,CC(C)(C#C)NC(=O)C1=CC=C(C=C1)Br,,,,,,
4473,54474,Fluoropropyzamide,CC(C)(C#C)NC(=O)C1=CC=C(C=C1)F,,,,,,
4474,54475,Isopropylpropyzamide,CC(C)C1=CC=C(C=C1)C(=O)NC(C)(C)C#C,,,,,,
4475,54476,N-4-Pyridinyl-2H-1-benzopyran-3-carboxamide,C1C(=CC2=CC=CC=C2O1)C(=O)NC3=CC=NC=C3,,,,,,
4476,54477,Remoxipride,CCN1CCC[C@H]1CNC(=O)C2=C(C=CC(=C2OC)Br)OC,['Remoxipride is an atypical antipsychotic once used for the treatment of schizophrenia.'],['Remoxipride is a weak selective dopamine D<sub>2</sub> receptor antagonist that was once used in the treatment of schizophrenia. It has a moderate therapeutic index and duration of action. Remoxipride was withdrawn due to deaths associated with aplastic anemia.'],"['Agents that control agitated psychotic behavior, alleviate acute psychotic states, reduce psychotic symptoms, and exert a quieting effect. They are used in SCHIZOPHRENIA; senile dementia; transient psychosis following surgery; or MYOCARDIAL INFARCTION; etc. These drugs are often referred to as neuroleptics alluding to the tendency to produce neurological side effects, but not all antipsychotics are likely to produce such effects. Many of these drugs may also be effective against nausea, emesis, and pruritus. (See all compounds classified as Antipsychotic Agents.)', 'Drugs that bind to but do not activate DOPAMINE RECEPTORS, thereby blocking the actions of dopamine or exogenous agonists. Many drugs used in the treatment of psychotic disorders (ANTIPSYCHOTIC AGENTS) are dopamine antagonists, although their therapeutic effects may be due to long-term adjustments of the brain rather than to the acute effects of blocking dopamine receptors. Dopamine antagonists have been used for several other clinical purposes including as ANTIEMETICS, in the treatment of Tourette syndrome, and for hiccup. Dopamine receptor blockade is associated with NEUROLEPTIC MALIGNANT SYNDROME. (See all compounds classified as Dopamine Antagonists.)']","['Remoxipride is approximately 90% bioavailable. In patients with normal creatinine clearance, remoxipride reaches a C<sub>max</sub> of 5.5 ± 1.1 µmol/L, with a T<sub>max</sub> of 0.8 ± 0.2 h, and an AUC of 39 ± 9 µmol\\*h/L. In patients with moderate renal impairment, remoxipride reaches a C<sub>max</sub> of 7.7 ± 2.7 µmol/L, with a T<sub>max</sub> of 0.9 ± 0.4 h, and an AUC of 63 ± 34 µmol\\*h/L. In patients with severe renal impairment, remoxipride reaches a C<sub>max</sub> of 9.3 ± 2.3 µmol/L, with a T<sub>max</sub> of 1.4 ± 0.9 h, and an AUC of 123 ± 60 µmol\\*h/L.', 'A dose of remoxipride is 89% recovered in the urine and 7% in the feces. 10-40% of a dose of remoxipride is recovered in the urine as the unchanged parent drug.', 'The volume of distribution of remoxipride in patients with normal creatinine clearance is 44.3 ± 8.3 L, in patients with moderate renal impairment is 37.4 ± 16.2 L, and in patients with severe renal impairment is 30.2 ± 9.4 L.', 'The renal clearance of remoxipride in patients with normal creatinine clearance is 23.6 ± 7.0 mL/min, in patients with moderate renal impairment is 9.3 ± 3.8 mL/min, and in patients with severe renal impairment is 3.7 ± 2.9 mL/min. The systemic plasma clearance of remoxipride is 120 mL/min.']","['Remoxipride can be N-dealkylated to FLA 853, oxidized to FLA 850, or N-deethylated to FLA 838. FLA 838 can be oxidized to NCL 118 which is further hydroxylated to NCM 009. FLA 850 can be N-deethylated to NCL 118 or hydroxylated to NCM 001. NCM 001 is further N-deethylated to NCM 009. None of these metabolites have measurable activity on dopamine D<sub>2</sub> receptors.']","['The half life of remoxipride in patients with normal creatinine clearance is 5.1 ± 1.6 h, in patients with moderate renal impairment is 6.1 ± 2.6 h, and in patients with severe renal impairment is 9.9 ± 3.8 h.']"
4477,54478,"7,12-Dimethyl-3,9-diacetoxybenz(a)anthracene",CC1=C2C=CC3=C(C2=C(C4=C1C=C(C=C4)OC(=O)C)C)C=CC(=C3)OC(=O)C,,,,,,
4478,54479,"BENZ(a)ANTHRACENE-3,9-DIOL, 12-METHYL-",CC1=C2C(=CC3=C1C=CC(=C3)O)C=CC4=C2C=CC(=C4)O,,,,,,
4479,54480,"BENZ(a)ANTHRACENE-3,9-DIOL, 7-METHYL-",CC1=C2C=C(C=CC2=CC3=C1C=CC4=C3C=CC(=C4)O)O,,,,,,
4480,54481,"Carbanilic acid, o-(methoxymethyl)-, 2-(1-pyrrolidinyl)ethyl ester, oxalate (1:1)",COCC1=CC=CC=C1NC(=O)OCC[NH+]2CCCC2.C(=O)(C(=O)[O-])O,,,,,,
4481,54482,2-pyrrolidin-1-ylethyl N-[2-(methoxymethyl)phenyl]carbamate,COCC1=CC=CC=C1NC(=O)OCCN2CCCC2,,,,,,
4482,54483,"CARBANILIC ACID, o-(ETHOXYMETHYL)-, 2-(1-PYRROLIDINYL)ETHYL ESTER, OXALATE (1:1)",CCOCC1=CC=CC=C1NC(=O)OCC[NH+]2CCCC2.C(=O)(C(=O)[O-])O,,,,,,
4483,54484,2-pyrrolidin-1-ylethyl N-[2-(ethoxymethyl)phenyl]carbamate,CCOCC1=CC=CC=C1NC(=O)OCCN2CCCC2,,,,,,
4484,54485,o-(Butoxymethyl)carbanilic acid 2-(1-pyrrolidinyl)ethyl ester hydrochloride,CCCCOCC1=CC=CC=C1NC(=O)OCC[NH+]2CCCC2.[Cl-],,,,,,
4485,54486,2-pyrrolidin-1-ylethyl N-[2-(butoxymethyl)phenyl]carbamate,CCCCOCC1=CC=CC=C1NC(=O)OCCN2CCCC2,,,,,,
4486,54487,"Carbanilic acid, o-((hexyloxy)methyl)-, 2-(1-pyrrolidinyl)ethyl ester, oxalate (1:1)",CCCCCCOCC1=CC=CC=C1NC(=O)OCC[NH+]2CCCC2.C(=O)(C(=O)[O-])O,,,,,,
4487,54488,2-pyrrolidin-1-ylethyl N-[2-(hexoxymethyl)phenyl]carbamate,CCCCCCOCC1=CC=CC=C1NC(=O)OCCN2CCCC2,,,,,,
4488,54489,m-(Ethoxymethyl)carbanilic acid 2-(1-pyrrolidinyl)ethyl ester hydrochloride,CCOCC1=CC(=CC=C1)NC(=O)OCC[NH+]2CCCC2.[Cl-],,,,,,
4489,54490,2-pyrrolidin-1-ylethyl N-[3-(ethoxymethyl)phenyl]carbamate,CCOCC1=CC(=CC=C1)NC(=O)OCCN2CCCC2,,,,,,
4490,54491,m-(Propoxymethyl)carbanilic acid 2-(1-pyrrolidinyl)ethyl ester hydrochloride,CCCOCC1=CC(=CC=C1)NC(=O)OCC[NH+]2CCCC2.[Cl-],,,,,,
4491,54492,2-pyrrolidin-1-ylethyl N-[3-(propoxymethyl)phenyl]carbamate,CCCOCC1=CC(=CC=C1)NC(=O)OCCN2CCCC2,,,,,,
4492,54493,m-(Butoxymethyl)carbanilic acid 2-(1-pyrrolidinyl)ethyl ester hydrochloride,CCCCOCC1=CC(=CC=C1)NC(=O)OCC[NH+]2CCCC2.[Cl-],,,,,,
4493,54494,2-pyrrolidin-1-ylethyl N-[3-(butoxymethyl)phenyl]carbamate,CCCCOCC1=CC(=CC=C1)NC(=O)OCCN2CCCC2,,,,,,
4494,54495,"Carbanilic acid, m-((pentyloxy)methyl)-, 2-(1-pyrrolidinyl)ethyl ester, hydrochloride",CCCCCOCC1=CC(=CC=C1)NC(=O)OCC[NH+]2CCCC2.[Cl-],,,,,,
4495,54496,2-pyrrolidin-1-ylethyl N-[3-(pentoxymethyl)phenyl]carbamate,CCCCCOCC1=CC(=CC=C1)NC(=O)OCCN2CCCC2,,,,,,
4496,54497,"Carbanilic acid, m-((hexyloxy)methyl)-, 2-(1-pyrrolidinyl)ethyl ester, hydrochloride",CCCCCCOCC1=CC(=CC=C1)NC(=O)OCC[NH+]2CCCC2.[Cl-],,,,,,
4497,54498,m-(Hexyloxymethyl)carbanilic acid 2-pyrrolizinoethyl ester,CCCCCCOCC1=CC(=CC=C1)NC(=O)OCCN2CCCC2,,,,,,
4498,54499,"CARBANILIC ACID, o-(METHOXYMETHYL)-, 2-PIPERIDINOETHYL ESTER, OXALATE (1:1)",COCC1=CC=CC=C1NC(=O)OCC[NH+]2CCCCC2.C(=O)(C(=O)[O-])O,,,,,,
4499,54500,"Phneylcarbanilic acid, 2-methoxymethyl,2-(1-pipe",COCC1=CC=CC=C1NC(=O)OCCN2CCCCC2,,,,,,
4500,54501,"CARBANILIC ACID, o-(ETHOXYMETHYL)-, 2-PIPERIDINOETHYL ESTER, OXALATE (1:1)",CCOCC1=CC=CC=C1NC(=O)OCC[NH+]2CCCCC2.C(=O)(C(=O)[O-])O,,,,,,
4501,54502,[2-(Ethoxymethyl)phenyl]carbamic acid 2-(1-piperidinyl)ethyl ester,CCOCC1=CC=CC=C1NC(=O)OCCN2CCCCC2,,,,,,
4502,54503,"CARBANILIC ACID, o-(PROPOXYMETHYL)-, 2-PIPERIDINOETHYL ESTER, OXALATE (1:1)",CCCOCC1=CC=CC=C1NC(=O)OCC[NH+]2CCCCC2.C(=O)(C(=O)[O-])O,,,,,,
4503,54504,"2-PrOMe-carbanilic acid,2(1-piperidinyl)ethyl es",CCCOCC1=CC=CC=C1NC(=O)OCCN2CCCCC2,,,,,,
4504,54505,2-Piperidinoethyl o-(butoxymethyl)carbanilate hydrochloride,CCCCOCC1=CC=CC=C1NC(=O)OCC[NH+]2CCCCC2.[Cl-],,,,,,
4505,54506,N-[2-(Butoxymethyl)phenyl]carbamic acid 2-piperidinoethyl ester,CCCCOCC1=CC=CC=C1NC(=O)OCCN2CCCCC2,,,,,,
4506,54507,o-((Pentyloxy)methyl)carbanilic acid 2-piperidinoethyl ester hydrochloride,CCCCCOCC1=CC=CC=C1NC(=O)OCC[NH+]2CCCCC2.[Cl-],,,,,,
4507,54508,N-[2-(Pentyloxymethyl)phenyl]carbamic acid 2-piperidinoethyl ester,CCCCCOCC1=CC=CC=C1NC(=O)OCCN2CCCCC2,,,,,,
4508,54509,2-Piperidinoethyl m-(ethoxymethyl)carbanilate hydrochloride,CCOCC1=CC(=CC=C1)NC(=O)OCC[NH+]2CCCCC2.[Cl-],,,,,,
4509,54510,2-piperidin-1-ylethyl N-[3-(ethoxymethyl)phenyl]carbamate,CCOCC1=CC(=CC=C1)NC(=O)OCCN2CCCCC2,,,,,,
4510,54511,m-(Propoxymethyl)carbanilic acid 2-piperidinoethyl ester hydrochloride,CCCOCC1=CC(=CC=C1)NC(=O)OCC[NH+]2CCCCC2.[Cl-],,,,,,
4511,54512,2-piperidin-1-ylethyl N-[3-(propoxymethyl)phenyl]carbamate,CCCOCC1=CC(=CC=C1)NC(=O)OCCN2CCCCC2,,,,,,
4512,54513,2-Piperidinoethyl m-(butoxymethyl)carbanilate hydrochloride,CCCCOCC1=CC(=CC=C1)NC(=O)OCC[NH+]2CCCCC2.[Cl-],,,,,,
4513,54514,N-[3-(Butoxymethyl)phenyl]carbamic acid 2-piperidinoethyl ester,CCCCOCC1=CC(=CC=C1)NC(=O)OCCN2CCCCC2,,,,,,
4514,54515,"CARBANILIC ACID, m-((PENTYLOXY)METHYL)-, 2-PIPERIDINOETHYL ESTER, HYDROCHLORIDE",CCCCCOCC1=CC(=CC=C1)NC(=O)OCC[NH+]2CCCCC2.[Cl-],,,,,,
4515,54516,N-[3-[(Pentyloxy)methyl]phenyl]carbamic acid 2-piperidinoethyl ester,CCCCCOCC1=CC(=CC=C1)NC(=O)OCCN2CCCCC2,,,,,,
4516,54517,"CARBANILIC ACID, m-((HEXYLOXY)METHYL)-, 2-PIPERIDINOETHYL ESTER, HYDROCHLORIDE",CCCCCCOCC1=CC(=CC=C1)NC(=O)OCC[NH+]2CCCCC2.[Cl-],,,,,,
4517,54518,"3-Hexyloxymethylcarbanilic acid,2-(1-piperidinyl",CCCCCCOCC1=CC(=CC=C1)NC(=O)OCCN2CCCCC2,,,,,,
4518,54519,o-(Methoxymethyl)carbanilic acid 2-(hexahydro-1H-azepin-1-yl)ethyl ester hydrochloride,COCC1=CC=CC=C1NC(=O)OCC[NH+]2CCCCCC2.[Cl-],,,,,,
4519,54520,2-(azepan-1-yl)ethyl N-[2-(methoxymethyl)phenyl]carbamate,COCC1=CC=CC=C1NC(=O)OCCN2CCCCCC2,,,,,,
4520,54521,"Carbanilic acid, o-(ethoxymethyl)-, 2-(hexahydro-1H-azepin-1-yl)ethyl ester, oxalate (1:1)",CCOCC1=CC=CC=C1NC(=O)OCC[NH+]2CCCCCC2.C(=O)(C(=O)[O-])O,,,,,,
4521,54522,2-(azepan-1-yl)ethyl N-[2-(ethoxymethyl)phenyl]carbamate,CCOCC1=CC=CC=C1NC(=O)OCCN2CCCCCC2,,,,,,
4522,54523,2-(Hexahydro-1H-azepin-1-yl)ethyl o-(butoxymethyl)carbanilate hydrochloride,CCCCOCC1=CC=CC=C1NC(=O)OCC[NH+]2CCCCCC2.[Cl-],,,,,,
4523,54524,2-(azepan-1-yl)ethyl N-[2-(butoxymethyl)phenyl]carbamate,CCCCOCC1=CC=CC=C1NC(=O)OCCN2CCCCCC2,,,,,,
4524,54525,o-((Pentyloxy)methyl)carbanilic acid 2-(hexahydro-1H-azepin-1-yl)ethyl ester hydrochloride,CCCCCOCC1=CC=CC=C1NC(=O)OCC[NH+]2CCCCCC2.[Cl-],,,,,,
4525,54526,2-(azepan-1-yl)ethyl N-[2-(pentoxymethyl)phenyl]carbamate,CCCCCOCC1=CC=CC=C1NC(=O)OCCN2CCCCCC2,,,,,,
4526,54527,2-(Hexahydro-1H-azepin-1-yl)ethyl o-((hexyloxy)methyl)carbanilate hydrochloride,CCCCCCOCC1=CC=CC=C1NC(=O)OCC[NH+]2CCCCCC2.[Cl-],,,,,,
4527,54528,2-(azepan-1-yl)ethyl N-[2-(hexoxymethyl)phenyl]carbamate,CCCCCCOCC1=CC=CC=C1NC(=O)OCCN2CCCCCC2,,,,,,
4528,54529,2-(Hexahydro-1H-azepin-1-yl)ethyl m-(ethoxymethyl)carbanilate hydrochloride,CCOCC1=CC(=CC=C1)NC(=O)OCC[NH+]2CCCCCC2.[Cl-],,,,,,
4529,54530,2-(azepan-1-yl)ethyl N-[3-(ethoxymethyl)phenyl]carbamate,CCOCC1=CC(=CC=C1)NC(=O)OCCN2CCCCCC2,,,,,,
4530,54531,m-(Propoxymethyl)carbanilic acid 2-(hexahydro-1H-azepin-1-yl)ethyl ester hydrochloride,CCCOCC1=CC(=CC=C1)NC(=O)OCC[NH+]2CCCCCC2.[Cl-],,,,,,
4531,54532,2-(azepan-1-yl)ethyl N-[3-(propoxymethyl)phenyl]carbamate,CCCOCC1=CC(=CC=C1)NC(=O)OCCN2CCCCCC2,,,,,,
4532,54533,2-(Hexahydro-2H-azepin-1-yl)ethyl m-(butoxymethyl)carbanilate hydrochloride,CCCCOCC1=CC(=CC=C1)NC(=O)OCC[NH+]2CCCCCC2.[Cl-],,,,,,
4533,54534,2-(azepan-1-yl)ethyl N-[3-(butoxymethyl)phenyl]carbamate,CCCCOCC1=CC(=CC=C1)NC(=O)OCCN2CCCCCC2,,,,,,
4534,54535,"Carbanilic acid, m-((pentyloxy)methyl)-, 2-(hexahydro-1H-azepin-1-yl)ethyl ester, hydrochloride",CCCCCOCC1=CC(=CC=C1)NC(=O)OCC[NH+]2CCCCCC2.[Cl-],,,,,,
4535,54536,2-(azepan-1-yl)ethyl N-[3-(pentoxymethyl)phenyl]carbamate,CCCCCOCC1=CC(=CC=C1)NC(=O)OCCN2CCCCCC2,,,,,,
4536,54537,"Carbanilic acid, m-((hexyloxy)methyl)-, 2-(hexahydro-1H-azepin-1-yl)ethyl ester, hydrochloride",CCCCCCOCC1=CC(=CC=C1)NC(=O)OCC[NH+]2CCCCCC2.[Cl-],,,,,,
4537,54538,2-(azepan-1-yl)ethyl N-[3-(hexoxymethyl)phenyl]carbamate,CCCCCCOCC1=CC(=CC=C1)NC(=O)OCCN2CCCCCC2,,,,,,
4538,54539,Dimethylnitrophenanthrene,CC1=CC(=C2C=CC3=C(C2=C1)C=C(C=C3)[N+](=O)[O-])C,,,,,,
4539,54540,Methylnitrochrysene,CC1=CC(=CC2=C1C=CC3=C2C=CC4=CC=CC=C43)[N+](=O)[O-],,,,,,
4540,54541,2-Piperidinoethyl o-((hexyloxy)methyl)carbanilate hydrochloride,CCCCCCOCC1=CC=CC=C1NC(=O)OCC[NH+]2CCCCC2.[Cl-],,,,,,
4541,54542,o-(Hexyloxymethyl)carbanilic acid 2-piperidinoethyl ester,CCCCCCOCC1=CC=CC=C1NC(=O)OCCN2CCCCC2,,,,,,
4542,54543,1-Methyl-3-nitroanthracene,CC1=CC(=CC2=CC3=CC=CC=C3C=C12)[N+](=O)[O-],,,,,,
4543,54544,1-Methyl-3-nitrophenanthrene,CC1=CC(=CC2=C1C=CC3=CC=CC=C32)[N+](=O)[O-],,,,,,
4544,54545,"Anthracene, dimethylnitro-",CC1=CC(=C(C2=CC3=CC=CC=C3C=C12)C)[N+](=O)[O-],,,,,,
4545,54546,"2,6-Bis(3,4,5-trimethoxybenzoylaminomethyl)pyridine",COC1=CC(=CC(=C1OC)OC)C(=O)NCC2=NC(=CC=C2)CNC(=O)C3=CC(=C(C(=C3)OC)OC)OC,,,,,,
4546,54547,"7-[[2-(2-Amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-3-(methoxymethyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid",COCC1=C(N2C(C(C2=O)NC(=O)C(=NOC)C3=CSC(=N3)N)SC1)C(=O)O,,,,,,
4547,54548,"(3R,4S,5S,6R,7R,9R,11S,12R,13S,14R)-6-[4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-14-ethyl-7,12,13-trihydroxy-4-(5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl)oxy-10-(2-methoxyethoxymethoxyimino)-3,5,7,9,11,13-hexamethyl-oxacyclotetradecan-2-one",CC[C@@H]1[C@@]([C@@H]([C@H](C(=NOCOCCOC)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)OC2CC(C(C(O2)C)O)(C)OC)C)OC3C(C(CC(O3)C)N(C)C)O)(C)O)C)C)O)(C)O,,,['Substances that inhibit the growth or reproduction of BACTERIA. (See all compounds classified as Anti-Bacterial Agents.)'],,,
4548,54549,"1,3,8-Tribromodibenzo-P-dioxin",C1=CC2=C(C=C1Br)OC3=C(O2)C=C(C=C3Br)Br,,,,,,
4549,54550,Eclazolast,CCOCCOC(=O)C1=NC2=C(O1)C=CC(=C2)Cl,,,,,,
4550,54551,Nitronaphthoquinone,C1=CC2=C(C=C1[N+](=O)[O-])C(=O)C=CC2=O,,,,,,
4551,54552,"1-Methyl-9-hydroxy-1,2,3,9a-tetrahydro-1-azafluorene hydrochloride",C[NH+]1CCC=C2C1C(C3=CC=CC=C23)O.[Cl-],,,,,,
4552,54553,"1-Methyl-2,3,9,9a-tetrahydroindeno[2,3-b]pyridin-9-ol",CN1CCC=C2C1C(C3=CC=CC=C23)O,,,,,,
4553,54554,"1-Methyl-9-benzoyloxy-1,2,3,9a-tetrahydro-1-azafluorene hydrochloride",C[NH+]1CCC=C2C1C(C3=CC=CC=C23)OC(=O)C4=CC=CC=C4.[Cl-],,,,,,
4554,54555,"(1-Methyl-2,3,9,9a-tetrahydroindeno[2,3-b]pyridin-9-yl) benzoate",CN1CCC=C2C1C(C3=CC=CC=C23)OC(=O)C4=CC=CC=C4,,,,,,
4555,54556,"Carbanilic acid, o-(propoxymethyl)-, 2-(1-pyrrolidinyl)ethyl ester, oxalate (1:1)",CC.CCCOCC1=CC=CC=C1NC(=O)OCC.C[NH+]1CCCC1.C(=O)(C(=O)[O-])O,,,,,,
4556,54557,ethyl N-[2-(propoxymethyl)phenyl]carbamate,CCCOCC1=CC=CC=C1NC(=O)OCC,,,,,,
4557,54558,"Benzoic acid, 4-((2-amino-1,4-dihydro-6-hydroxy-4-oxo-5-pyrimidinyl)methyl)-",C1=CC(=CC=C1CC2=C(N=C(NC2=O)N)O)C(=O)O,,,,,,
4558,54559,CID 54559,C1=CC(=CC=C1N=C(N=C(N)S)S)Cl,,,,,,
4559,54560,"Carbamic acid, methylnitroso-2,5-dioxo-1-pyrrolidinyl ester",CN(C(=O)ON1C(=O)CCC1=O)N=O,,,,,,
4560,54561,"Carbamic acid, (2-chloroethyl)nitroso-, 2,5-dioxo-1-pyrrolidinyl ester",C1CC(=O)N(C1=O)OC(=O)N(CCCl)N=O,,,,,,
4561,54562,Quinpirole,CCCN1CCC[C@H]2[C@H]1CC3=C(C2)NN=C3,,,['Drugs that bind to and activate dopamine receptors. (See all compounds classified as Dopamine Agonists.)'],,,
4562,54563,2-Phenylbutyric acid 3-quinuclidinyl ester hydrochloride,CCC(C1=CC=CC=C1)C(=O)OC2C[NH+]3CCC2CC3.[Cl-],,,,,,
4563,54564,1-Azabicyclo[2.2.2]octan-3-yl 2-phenylbutanoate,CCC(C1=CC=CC=C1)C(=O)OC2CN3CCC2CC3,,,,,,
4564,54565,Benzo(cd)pyrenone,C1CC2CC3CCCC4C3C5C2C(C1)CC(=O)C5C(=O)C4,,,,,,
4565,54566,Argininebutyrate,CCCC(=O)O.C(C[C@@H](C(=O)O)N)CN=C(N)N,,,,,,
4566,54567,Fezolamine,CN(C)CCCN1C=C(C(=N1)C2=CC=CC=C2)C3=CC=CC=C3,,,,,,
4567,54568,5-(2-(Dimethylamino)ethoxy)-7H-benzo(c)fluoren-7-one hydrochloride,C[NH+](C)CCOC1=CC2=C(C3=CC=CC=C31)C4=CC=CC=C4C2=O.[Cl-],,,,,,
4568,54569,Benflurone,CN(C)CCOC1=CC2=C(C3=CC=CC=C31)C4=CC=CC=C4C2=O,,,['Substances that inhibit or prevent the proliferation of NEOPLASMS. (See all compounds classified as Antineoplastic Agents.)'],,,
4569,54570,"trans-3-Phenyl-1,4-benzodioxan-2-carboxylic acid 2-(diethylamino)ethyl ester citrate",CC[NH+](CC)CCOC(=O)[C@H]1[C@@H](OC2=CC=CC=C2O1)C3=CC=CC=C3.C(C(=O)[O-])C(CO)(C(=O)O)C(=O)O,,,,,,
4570,54571,"2-(diethylamino)ethyl (2S,3R)-2-phenyl-2,3-dihydro-1,4-benzodioxine-3-carboxylate",CCN(CC)CCOC(=O)[C@H]1[C@@H](OC2=CC=CC=C2O1)C3=CC=CC=C3,,,,,,
4571,54572,"N-(2-(Diethylamino)ethyl)-3-phenyl-1,4-benzodioxan-2-methylamine dihydrochloride",CC[NH+](CC)CC[NH2+]C[C@H]1[C@@H](OC2=CC=CC=C2O1)C3=CC=CC=C3.[Cl-].[Cl-],,,,,,
4572,54573,"N',N'-diethyl-N-[[(2S,3S)-3-phenyl-2,3-dihydro-1,4-benzodioxin-2-yl]methyl]ethane-1,2-diamine",CCN(CC)CCNC[C@H]1[C@@H](OC2=CC=CC=C2O1)C3=CC=CC=C3,,,,,,
4573,54574,CID 54574,C1[C@@H](N(C2=C(N1)NC(=NC2=O)N)C=O)CNC3=CC=C(C=C3)C(=O)N[C@H](CCC(=O)[O-])C(=O)[O-].[Ca+2],,,,,,
4574,54575,CID 54575,C1C(N(C2=C(N1)NC(=NC2=O)N)C=O)CNC3=CC=C(C=C3)C(=O)N[C@H](CCC(=O)O)C(=O)O,,,,,,
4575,54576,"(+)-Chrysene-1-alpha,2-beta-diol-3-alpha,4-alpha-epoxide 1",C1=CC=C2C(=C1)C=CC3=C2C=CC4=C3[C@@H]5[C@@H](O5)[C@@H]([C@H]4O)O,,,,,,
4576,54577,"(-)-Chrysene-1-alpha,2-beta-diol-3-beta,4-beta-epoxide 2",C1=CC=C2C(=C1)C=CC3=C2C=CC4=C3[C@H]5[C@H](O5)[C@@H]([C@H]4O)O,,,,,,
4577,54578,"7H-Dibenz(DE,J)anthracen-7-one",C1=CC=C2C(=C1)C=CC3=C2C(=O)C4=CC=CC5=C4C3=CC=C5,,,,,,
4578,54579,"3,17-Dihydroxy-4,17-dimethyl-4,5-epoxyandrost-2-ene-2-carbonitrile",C[C@@]1(CCC2C1(CCC3C2CC[C@]45C3(CC(=C([C@]4(O5)C)O)C#N)C)C)O,,,,,,
4579,54580,Fluticasone propiponate,CCC(=O)O[C@@]1([C@@H](C[C@@H]2[C@@]1(C[C@@H]([C@]3(C2C[C@@H](C4=CC(=O)C=C[C@@]43C)F)F)O)C)C)C(=O)SCF,,,,,,
4580,54581,"17-{[(Chloromethyl)sulfanyl]carbonyl}-6,9-difluoro-11-hydroxy-16-methyl-3-oxoandrosta-1,4-dien-17-yl propanoate",CCC(=O)O[C@@]1([C@@H](C[C@@H]2[C@@]1(C[C@@H]([C@]3(C2C[C@@H](C4=CC(=O)C=C[C@@]43C)F)F)O)C)C)C(=O)SCCl,,,,,,
4581,54582,"2-(2,2-Dimethyl-1,3,6,2-dioxazasilocan-6-yl)ethyl pyridine-3-carboxylate",C[Si]1(OCCN(CCO1)CCOC(=O)C2=CN=CC=C2)C,,,,,,
4582,54583,"2-(2,2-Dimethyl-1,3,6,2-dioxazasilocan-6-yl)ethyl pyridine-4-carboxylate",C[Si]1(OCCN(CCO1)CCOC(=O)C2=CC=NC=C2)C,,,,,,
4583,54584,N-(2-Hydroxyethyl)-N-carboxymethylnitrosamine,C(CO)N(CC(=O)O)N=O,,,,,,
4584,54585,Balsalazide,C1=CC(=CC=C1C(=O)NCCC(=O)O)N=NC2=CC(=C(C=C2)O)C(=O)O,['For the treatment of mildly to moderately active ulcerative colitis.'],"['Balsalazide is a prodrug that has little or no pharmacologic activity until it is enzymatically cleaved in the colon to produce mesalamine (5-aminosalicylic acid), an anti inflammatory drug indicated for the treatment of mildly to moderately active ulcerative colitis. Balsalazide disodium is delivered intact to the colon where it is cleaved by bacterial azoreduction to release equimolar quantities of mesalamine, which is the therapeutically active portion of the molecule, and the intert 4-aminobenzoyl-(beta)-alanine. As a result, the spectrum of pharmacologic activity of balsalazide is similar to that of mesalamine.']","['Anti-inflammatory agents that are non-steroidal in nature. In addition to anti-inflammatory actions, they have analgesic, antipyretic, and platelet-inhibitory actions. They act by blocking the synthesis of prostaglandins by inhibiting cyclooxygenase, which converts arachidonic acid to cyclic endoperoxides, precursors of prostaglandins. Inhibition of prostaglandin synthesis accounts for their analgesic, antipyretic, and platelet-inhibitory actions; other mechanisms may contribute to their anti-inflammatory effects. (See all compounds classified as Anti-Inflammatory Agents, Non-Steroidal.)', 'Drugs used for their effects on the gastrointestinal system, as to control gastric acidity, regulate gastrointestinal motility and water flow, and improve digestion. (See all compounds classified as Gastrointestinal Agents.)']","['Low and variable, intact balsalazide is poorly absorbed systemically.', 'The products of the azoreduction of this compound, 5-ASA and 4-aminobenzoyl-ß-alanine, and their N-acetylated metabolites have been identified in plasma, urine and feces. Following single-dose administration of 2.25 g COLAZAL (three 750 mg capsules) under fasting conditions in healthy subjects, mean urinary recovery of balsalazide, 5-ASA, and N-Ac-5-ASA was 0.20%, 0.22% and 10.2%, respectively.']","['Cleaved in the colon via bacterial azoreduction to 5&ndash;aminosalicylic acid (5&ndash;ASA) and 4&ndash;aminobenzoyl-beta-alanine, the inactive carrier moiety.']",['Half-life could not be determined.']
4585,54586,"2-[[4-[1-(2,4-Diaminopteridin-6-yl)butan-2-yl]benzoyl]amino]pentanedioic acid",CCC(CC1=CN=C2C(=N1)C(=NC(=N2)N)N)C3=CC=C(C=C3)C(=O)NC(CCC(=O)O)C(=O)O,,,"['Substances that inhibit or prevent the proliferation of NEOPLASMS. (See all compounds classified as Antineoplastic Agents.)', 'Inhibitors of the enzyme, dihydrofolate reductase (TETRAHYDROFOLATE DEHYDROGENASE), which converts dihydrofolate (FH2) to tetrahydrofolate (FH4). They are frequently used in cancer chemotherapy. (From AMA, Drug Evaluations Annual, 1994, p2033) (See all compounds classified as Folic Acid Antagonists.)']",,,
4586,54587,Trimethylsilylethylthioethylamine,C[Si](C)(C)CCSCCN,,,,,,
4587,54588,"Benzofuran, 5-chloro-2-(diethylaminomethyl)-3-phenyl-",CCN(CC)CC1=C(C2=C(O1)C=CC(=C2)Cl)C3=CC=CC=C3,,,,,,
4588,54589,"Benzofuran, 5-bromo-2-(diethylaminomethyl)-3-phenyl-",CCN(CC)CC1=C(C2=C(O1)C=CC(=C2)Br)C3=CC=CC=C3,,,,,,
4589,54590,"Carbamic acid, (2-chloroethyl)nitroso-, cyclohexyl ester",C1CCC(CC1)OC(=O)N(CCCl)N=O,,,,,,
4590,54591,N-(2-Benzyl-1-methylcyclopentyl)formamide,CC1(CCCC1CC2=CC=CC=C2)NC=O,,,,,,
4591,54592,Tris(propylenediamine)tungstatoiron pentahydrate,CC(C[NH-])[NH-].CC(C[NH-])[NH-].CC(C[NH-])[NH-].[O-][W](=O)(=O)[O-].[Fe+2],,,,,,
4592,54593,"Iron, (ethanedioato(2-)-O,O')bis(1-butanamine)-",CCCCN.CCCCN.C(=O)(C(=O)[O-])[O-].[Fe+2],,,,,,
4593,54594,"Iron, (ethanedioato(2-)-O,O')bis(methanamine)-",CN.CN.C(=O)(C(=O)[O-])[O-].[Fe+2],,,,,,
4594,54595,Tetra(piperidine)oxalatoiron,C1CCNCC1.C1CCNCC1.C1CCNCC1.C1CCNCC1.C(=O)(C(=O)[O-])[O-].[Fe+2],,,,,,
4595,54596,"Iron, (ethanedioato(2-)-O,O')bis(3-methoxybenzenamine-N)-",COC1=CC=CC(=C1)N.COC1=CC=CC(=C1)N.C(=O)(C(=O)[O-])[O-].[Fe+2],,,,,,
4596,54597,"Iron, (1,2-benzenediamine-N,N')(ethanedioato(2-)-O,O')-",C1=CC=C(C(=C1)N)N.C(=O)(C(=O)[O-])[O-].[Fe+2],,,,,,
4597,54598,"2-[2,3-Dichloro-4-(3-oxo-3-thiophen-2-ylprop-1-enyl)phenoxy]acetic acid",C1=CSC(=C1)C(=O)C=CC2=C(C(=C(C=C2)OCC(=O)O)Cl)Cl,,,,,,
4598,54599,3-Monoacetyldigoxigenin,CC(=O)O[C@H]1CC[C@]2([C@@H](C1)CCC3C2C[C@H]([C@]4([C@@]3(CC[C@@H]4C5=CC(=O)OC5)O)C)O)C,,,,,,
4599,54600,4-Dimethylamino-1-phenyl-1-(p-chlorobenzoylamino)butane hydrochloride,C[NH+](C)CCCC(C1=CC=CC=C1)NC(=O)C2=CC=C(C=C2)Cl.[Cl-],,,,,,
4600,54601,4-Chloro-N-[alpha-[3-(dimethylamino)propyl]benzyl]benzamide,CN(C)CCCC(C1=CC=CC=C1)NC(=O)C2=CC=C(C=C2)Cl,,,,,,
4601,54602,p-Amino-N-(alpha-(3-(dimethylamino)propyl)benzyl)benzamide hydrochloride,C[NH+](C)CCCC(C1=CC=CC=C1)NC(=O)C2=CC=C(C=C2)N.[Cl-],,,,,,
4602,54603,4-Amino-N-[alpha-[3-(dimethylamino)propyl]benzyl]benzamide,CN(C)CCCC(C1=CC=CC=C1)NC(=O)C2=CC=C(C=C2)N,,,,,,
4603,54604,N-(alpha-(3-(Dimethylamino)propyl)benzyl)-m-nitro-benzamide hydrochloride,C[NH+](C)CCCC(C1=CC=CC=C1)NC(=O)C2=CC(=CC=C2)[N+](=O)[O-].[Cl-],,,,,,
4604,54605,N-[4-(dimethylamino)-1-phenylbutyl]-3-nitrobenzamide,CN(C)CCCC(C1=CC=CC=C1)NC(=O)C2=CC(=CC=C2)[N+](=O)[O-],,,,,,
4605,54606,N-(alpha-(3-(Dimethylamino)propyl)benzyl)acetamide hydrochloride,CC(=O)NC(CCCN(C)C)C1=CC=CC=C1.Cl,,,,,,
4606,54607,N-[4-(dimethylamino)-1-phenylbutyl]acetamide,CC(=O)NC(CCCN(C)C)C1=CC=CC=C1,,,,,,
4607,54608,"Ketone, (1,2,4-benzotriazin-3-YL)methyl 1-pyrrolidinyl",C1CCN(C1)C(=O)CC2=CC3=C(C=CC=N3)N=N2,,,,,,
4608,54609,"N-Propyl-1,2,4-benzotriazine-3-acetamide",CCCNC(=O)CC1=NC2=CC=CC=C2N=N1,,,,,,
4609,54610,CID 54610,CC1=C2C(=C(C3=CC=CC=C13)COS(=O)(=O)[O-])C=CC4=CC=CC=C42.[Na+],,,,,,
4610,54611,7-Hydroxymethyl-12-methylbenz[a]anthracene sulfate,CC1=C2C(=C(C3=CC=CC=C13)COS(=O)(=O)O)C=CC4=CC=CC=C42,,,,,,
4611,54612,"(5-Methyl-2-oxo-1,3-dioxolan-4-yl)methyl 6-[(2-amino-2-phenylacetyl)amino]-3,3-dimethyl-7-oxo-4-thia-1-azoniabicyclo[3.2.0]heptane-2-carboxylate;chloride",CC1C(OC(=O)O1)COC(=O)C2C(SC3[NH+]2C(=O)C3NC(=O)C(C4=CC=CC=C4)N)(C)C.[Cl-],,,,,,
4612,54613,"(5-Methyl-2-oxo-1,3-dioxolan-4-yl)methyl 6-[(2-amino-2-phenylacetyl)amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate",CC1C(OC(=O)O1)COC(=O)C2C(SC3N2C(=O)C3NC(=O)C(C4=CC=CC=C4)N)(C)C,,,,,,
4613,54614,"BENZ(a)ANTHRACENE-3,4-DIOL, 3,4-DIHYDRO-12-METHYL-, trans-",CC1=C2C(=CC3=CC=CC=C13)C=CC4=C2C=C[C@H]([C@@H]4O)O,,,,,,
4614,54615,"Isonicotinic acid, 2-(6,8-dioxo-5,6,7,8-tetrahydropyrimido(4,5-e)-as-triazin-3-yl)hydrazide, dihydrate",C1=CN=CC=C1C(=O)NNN2C=NC3=NC(=O)NC(=O)C3=N2.O.O,,,,,,
4615,54616,"N'-(6,8-dioxopyrimido[4,5-e][1,2,4]triazin-2-yl)pyridine-4-carbohydrazide",C1=CN=CC=C1C(=O)NNN2C=NC3=NC(=O)NC(=O)C3=N2,,,,,,
4616,54617,"Malononitrile, (5,7-dimethyl-6,8-dioxo-5,6,7,8-tetrahydropyrimido(4,5-e)-as-triazin-3-yl)-",CN1C2=C(C(=O)N(C1=O)C)N=NC(=N2)C(C#N)C#N,,,,,,
4617,54618,N-(p-(2-(Diisopropylamino)ethoxy)phenyl)-N'-ethyl-benzamidine dihydrobromide,CC[NH+]=C(C1=CC=CC=C1)NC2=CC=C(C=C2)OCC[NH+](C(C)C)C(C)C.[Br-].[Br-],,,,,,
4618,54619,N-[4-[2-(Diisopropylamino)ethoxy]phenyl]-N'-ethylbenzamidine,CCN=C(C1=CC=CC=C1)NC2=CC=C(C=C2)OCCN(C(C)C)C(C)C,,,,,,
4619,54620,CID 54620,CC(C)[NH+](CCOC1=CC=C(C=C1)NC(=[NH+]CC=C)C2=CC=CC=C2)C(C)C.[Br-].[Br-],,,,,,
4620,54621,"BENZAMIDINE, N'-ALLYL-N-(p-(2-(DIISOPROPYLAMINO)ETHOXY)PHENYL)-",CC(C)N(CCOC1=CC=C(C=C1)NC(=NCC=C)C2=CC=CC=C2)C(C)C,,,,,,
4621,54622,"Benzamidine, N'-benzyl-N-(p-(2-(diisopropylamino)ethoxy)phenyl)-, dihydrochloride",CC(C)[NH+](CCOC1=CC=C(C=C1)NC(=[NH+]CC2=CC=CC=C2)C3=CC=CC=C3)C(C)C.[Cl-].[Cl-],,,,,,
4622,54623,N'-Benzyl-N-[4-[2-(diisopropylamino)ethoxy]phenyl]benzamidine,CC(C)N(CCOC1=CC=C(C=C1)NC(=NCC2=CC=CC=C2)C3=CC=CC=C3)C(C)C,,,,,,
4623,54624,N-(p-(2-(Diisopropylamino)ethoxy)phenyl)-N'-phenyl-benzamidine dihydrobromide,CC(C)[NH+](CCOC1=CC=C(C=C1)[NH+]=C(C2=CC=CC=C2)NC3=CC=CC=C3)C(C)C.[Br-].[Br-],,,,,,
4624,54625,N-[4-[2-(Diisopropylamino)ethoxy]phenyl]-N'-phenylbenzamidine,CC(C)N(CCOC1=CC=C(C=C1)N=C(C2=CC=CC=C2)NC3=CC=CC=C3)C(C)C,,,,,,
4625,54626,"Benzamidine, N-(p-((2-(diisopropylamino)ethyl)thio)phenyl)-N'-phenyl-, dihydrochloride",CC(C)[NH+](CCSC1=CC=C(C=C1)[NH+]=C(C2=CC=CC=C2)NC3=CC=CC=C3)C(C)C.[Br-].[Br-],,,,,,
4626,54627,N-[4-[[2-(Diisopropylamino)ethyl]thio]phenyl]-N'-phenylbenzamidine,CC(C)N(CCSC1=CC=C(C=C1)N=C(C2=CC=CC=C2)NC3=CC=CC=C3)C(C)C,,,,,,
4627,54628,"Benzamidine, N-(m-(2-(diisopropylamino)ethoxy)phenyl)-N'-phenyl-, dihydrochloride",CC(C)[NH+](CCOC1=CC=CC(=C1)NC(=[NH+]C2=CC=CC=C2)C3=CC=CC=C3)C(C)C.[Cl-].[Cl-],,,,,,
4628,54629,N-[3-[2-(Diisopropylamino)ethoxy]phenyl]-N'-phenylbenzamidine,CC(C)N(CCOC1=CC=CC(=C1)NC(=NC2=CC=CC=C2)C3=CC=CC=C3)C(C)C,,,,,,
4629,54630,"Benzamidine, N-(o-(2-(diisopropylamino)ethoxy)phenyl)-N'-phenyl-, dihydrochloride",CC(C)[NH+](CCOC1=CC=CC=C1[NH+]=C(C2=CC=CC=C2)NC3=CC=CC=C3)C(C)C.[Cl-].[Cl-],,,,,,
4630,54631,N-[2-[2-(Diisopropylamino)ethoxy]phenyl]-N'-phenylbenzamidine,CC(C)N(CCOC1=CC=CC=C1N=C(C2=CC=CC=C2)NC3=CC=CC=C3)C(C)C,,,,,,
4631,54632,"Benzamidine, N-(p-(3-(diisopropylamino)propoxy)phenyl)-N'-phenyl-, dihydrobromide",CC(C)[NH+](CCCOC1=CC=C(C=C1)[NH+]=C(C2=CC=CC=C2)NC3=CC=CC=C3)C(C)C.[Br-].[Br-],,,,,,
4632,54633,N-[4-[3-(Diisopropylamino)propoxy]phenyl]-N'-phenylbenzamidine,CC(C)N(CCCOC1=CC=C(C=C1)N=C(C2=CC=CC=C2)NC3=CC=CC=C3)C(C)C,,,,,,
4633,54634,N-(p-(2-(Dimethylamino)ethoxy)phenyl)-N'-phenyl-benzamidine dihydrobromide,C[NH+](C)CCOC1=CC=C(C=C1)[NH+]=C(C2=CC=CC=C2)NC3=CC=CC=C3.[Br-].[Br-],,,,,,
4634,54635,N-[4-[2-(Dimethylamino)ethoxy]phenyl]-N'-phenylbenzamidine,CN(C)CCOC1=CC=C(C=C1)N=C(C2=CC=CC=C2)NC3=CC=CC=C3,,,,,,
4635,54636,N-(p-(2-(Dibutylamino)ethoxy)phenyl)-N'-phenyl-benzamidine dihydrochloride,CCCC[NH+](CCCC)CCOC1=CC=C(C=C1)[NH+]=C(C2=CC=CC=C2)NC3=CC=CC=C3.[Cl-].[Cl-],,,,,,
4636,54637,N-[4-[2-(Dibutylamino)ethoxy]phenyl]-N'-phenylbenzamidine,CCCCN(CCCC)CCOC1=CC=C(C=C1)N=C(C2=CC=CC=C2)NC3=CC=CC=C3,,,,,,
4637,54638,N-(p-(3-(Dibutylamino)propoxy)phenyl)-N'-phenyl-benzamidine dihydrochloride,CCCC[NH+](CCCC)CCCOC1=CC=C(C=C1)[NH+]=C(C2=CC=CC=C2)NC3=CC=CC=C3.[Cl-].[Cl-],,,,,,
4638,54639,N-[4-[3-(Dibutylamino)propoxy]phenyl]-N'-phenylbenzamidine,CCCCN(CCCC)CCCOC1=CC=C(C=C1)N=C(C2=CC=CC=C2)NC3=CC=CC=C3,,,,,,
4639,54640,"Benzamidine, N-(p-(2-(benzylmethylamino)ethoxy)phenyl)-N'-phenyl-, dihydrobromide, hydrate",C[NH+](CCOC1=CC=C(C=C1)[NH+]=C(C2=CC=CC=C2)NC3=CC=CC=C3)CC4=CC=CC=C4.[Br-].[Br-],,,,,,
4640,54641,N-[4-[2-[Benzyl(methyl)amino]ethoxy]phenyl]-N'-phenylbenzamidine,CN(CCOC1=CC=C(C=C1)N=C(C2=CC=CC=C2)NC3=CC=CC=C3)CC4=CC=CC=C4,,,,,,
4641,54642,N-(p-(2-Morpholinoethoxy)phenyl)-N'-phenyl-benzamidine dihydrobromide,C1COCC[NH+]1CCOC2=CC=C(C=C2)[NH+]=C(C3=CC=CC=C3)NC4=CC=CC=C4.[Br-].[Br-],,,,,,
4642,54643,N-[4-(2-Morpholinoethoxy)phenyl]-N'-phenylbenzamidine,C1COCCN1CCOC2=CC=C(C=C2)N=C(C3=CC=CC=C3)NC4=CC=CC=C4,,,,,,
4643,54644,N'-Phenyl-N-(p-(2-piperidinoethoxy)phenyl)benzamidine dihydrobromide,C1CC[NH+](CC1)CCOC2=CC=C(C=C2)[NH+]=C(C3=CC=CC=C3)NC4=CC=CC=C4.[Br-].[Br-],,,,,,
4644,54645,N'-Phenyl-N-[4-(2-piperidinoethoxy)phenyl]benzamidine,C1CCN(CC1)CCOC2=CC=C(C=C2)N=C(C3=CC=CC=C3)NC4=CC=CC=C4,,,,,,
4645,54646,"Benzamidine, N-(p-(2-(diisopropylamino)ethoxy)phenyl)-N'-(p-methoxyphenyl)-, dihydrochloride",CC(C)[NH+](CCOC1=CC=C(C=C1)[NH+]=C(C2=CC=CC=C2)NC3=CC=C(C=C3)OC)C(C)C.[Cl-].[Cl-],,,,,,
4646,54647,N-[4-[2-(Diisopropylamino)ethoxy]phenyl]-N'-(4-methoxyphenyl)benzamidine,CC(C)N(CCOC1=CC=C(C=C1)N=C(C2=CC=CC=C2)NC3=CC=C(C=C3)OC)C(C)C,,,,,,
4647,54648,"Benzamidine, N-(p-(3-(diisopropylamino)propoxy)phenyl)-N'-(p-methoxyphenyl)-, dihydrochloride",CC(C)[NH+](CCCOC1=CC=C(C=C1)[NH+]=C(C2=CC=CC=C2)NC3=CC=C(C=C3)OC)C(C)C.[Cl-].[Cl-],,,,,,
4648,54649,N-[4-[3-(Diisopropylamino)propoxy]phenyl]-N'-(4-methoxyphenyl)benzamidine,CC(C)N(CCCOC1=CC=C(C=C1)N=C(C2=CC=CC=C2)NC3=CC=C(C=C3)OC)C(C)C,,,,,,
4649,54650,"Benzamidine, N'-(p-chlorophenyl)-N-(p-(2-(diisopropylamino)ethoxy)phenyl)-, dihydrochloride",CC(C)[NH+](CCOC1=CC=C(C=C1)NC(=[NH+]C2=CC=C(C=C2)Cl)C3=CC=CC=C3)C(C)C.[Cl-].[Cl-],,,,,,
4650,54651,"Benzamidine, N'-(p-chlorophenyl)-N-(p-(2-(diisopropylamino)ethoxy)phenyl)-",CC(C)N(CCOC1=CC=C(C=C1)NC(=NC2=CC=C(C=C2)Cl)C3=CC=CC=C3)C(C)C,,,,,,
4651,54652,"Benzamidine, N'-(p-chlorophenyl)-N-(p-(3-(diisopropylamino)propoxy)phenyl)-, dihydrochloride",CC(C)[NH+](CCCOC1=CC=C(C=C1)NC(=[NH+]C2=CC=C(C=C2)Cl)C3=CC=CC=C3)C(C)C.[Cl-].[Cl-],,,,,,
4652,54653,N'-(4-Chlorophenyl)-N-[4-[3-(diisopropylamino)propoxy]phenyl]benzamidine,CC(C)N(CCCOC1=CC=C(C=C1)NC(=NC2=CC=C(C=C2)Cl)C3=CC=CC=C3)C(C)C,,,,,,
4653,54654,"Benzamidine, N'-(3,4-dichlorophenyl)-N-(p-(2-(diisopropylamino)ethoxy)phenyl)-, dihydrochloride",CC(C)[NH+](CCOC1=CC=C(C=C1)[NH+]=C(C2=CC=CC=C2)NC3=CC(=C(C=C3)Cl)Cl)C(C)C.[Cl-].[Cl-],,,,,,
4654,54655,"N'-(3,4-Dichlorophenyl)-N-[4-[2-(diisopropylamino)ethoxy]phenyl]benzamidine",CC(C)N(CCOC1=CC=C(C=C1)N=C(C2=CC=CC=C2)NC3=CC(=C(C=C3)Cl)Cl)C(C)C,,,,,,
4655,54656,"Benzamidine, N-(p-(2-(diisopropylamino)ethoxy)phenyl)-N'-(p-fluorophenyl)-, dihydrobromide",CC(C)[NH+](CCOC1=CC=C(C=C1)NC(=[NH+]C2=CC=C(C=C2)F)C3=CC=CC=C3)C(C)C.[Br-].[Br-],,,,,,
4656,54657,N-[4-[2-(Diisopropylamino)ethoxy]phenyl]-N'-(4-fluorophenyl)benzamidine,CC(C)N(CCOC1=CC=C(C=C1)NC(=NC2=CC=C(C=C2)F)C3=CC=CC=C3)C(C)C,,,,,,
4657,54658,"Benzamidine, N-(p-(2-(diisopropylamino)ethoxy)phenyl)-N'-(alpha,alpha,alpha-fluoro-m-tolyl)-,dihydrochloride",CC(C)[NH+](CCOC1=CC=C(C=C1)[NH+]=C(C2=CC=CC=C2)NC3=CC=CC(=C3)C(F)(F)F)C(C)C.[Br-].[Br-],,,,,,
4658,54659,N-[4-[2-(Diisopropylamino)ethoxy]phenyl]-N'-[3-(trifluoromethyl)phenyl]benzamidine,CC(C)N(CCOC1=CC=C(C=C1)N=C(C2=CC=CC=C2)NC3=CC=CC(=C3)C(F)(F)F)C(C)C,,,,,,
4659,54660,"Benzamidine, 4-chloro-N-(p-(2-(diisopropylamino)ethoxy)phenyl)-N'-phenyl-, dihydrochloride",CC(C)[NH+](CCOC1=CC=C(C=C1)[NH+]=C(C2=CC=C(C=C2)Cl)NC3=CC=CC=C3)C(C)C.[Cl-].[Cl-],,,,,,
4660,54661,4-Chloro-N-[4-[2-(diisopropylamino)ethoxy]phenyl]-N'-phenylbenzamidine,CC(C)N(CCOC1=CC=C(C=C1)N=C(C2=CC=C(C=C2)Cl)NC3=CC=CC=C3)C(C)C,,,,,,
4661,54662,"Benzamidine, N-(p-(2-(diisopropylamino)ethoxy)phenyl)-4-methoxy-N'-phenyl-, dihydrochloride",CC(C)[NH+](CCOC1=CC=C(C=C1)[NH+]=C(C2=CC=C(C=C2)OC)NC3=CC=CC=C3)C(C)C.[Cl-].[Cl-],,,,,,
4662,54663,N-[4-[2-(Diisopropylamino)ethoxy]phenyl]-4-methoxy-N'-phenylbenzamidine,CC(C)N(CCOC1=CC=C(C=C1)N=C(C2=CC=C(C=C2)OC)NC3=CC=CC=C3)C(C)C,,,,,,
4663,54664,"p-(2-(Diisopropylamino)ethyl)-N,N'-diphenyl-benzamidine dihydrochloride",CC(C)[NH+](CCC1=CC=C(C=C1)C(=[NH+]C2=CC=CC=C2)NC3=CC=CC=C3)C(C)C.[Cl-].[Cl-],,,,,,
4664,54665,"4-[2-(Diisopropylamino)ethyl]-N,N'-diphenylbenzamidine",CC(C)N(CCC1=CC=C(C=C1)C(=NC2=CC=CC=C2)NC3=CC=CC=C3)C(C)C,,,,,,
4665,54666,"BENZAMIDINE, N-(p-(2-(METHYLPHENYLAMINO)ETHOXY)PHENYL)-N'-PHENYL-",CN(CCOC1=CC=C(C=C1)N=C(C2=CC=CC=C2)NC3=CC=CC=C3)C4=CC=CC=C4,,,,,,
4666,54667,"Unk-DL-Ala-D-Oic(3aS,7aS)-OH.Cl-",CCOC(=O)C(CCC1=CC=CC=C1)[NH2+]C(C)C(=O)N2[C@H]3CCCC[C@H]3C[C@@H]2C(=O)O.[Cl-],,,,,,
4667,54668,"Unk-DL-Ala-D-Oic(3aS,7aS)-OH",CCOC(=O)C(CCC1=CC=CC=C1)NC(C)C(=O)N2[C@H]3CCCC[C@H]3C[C@@H]2C(=O)O,,,,,,
4668,54669,3-Methoxy-4-nitrosoazobenzene,COC1=C(C=CC(=C1)N=NC2=CC=CC=C2)N=O,,,,,,
4669,54670,"2,5-Dimethoxy-4-nitroazobenzene",COC1=CC(=C(C=C1N=NC2=CC=CC=C2)OC)[N+](=O)[O-],,,,,,
4670,54671,2-Methoxy-4-nitrosoazobenzene,COC1=C(C=CC(=C1)N=O)N=NC2=CC=CC=C2,,,,,,
4671,54672,(1-Methyl-3-piperidinyl)methyl (4-chlorophenoxy)acetate hydrochloride,C[NH+]1CCCC(C1)COC(=O)COC2=CC=C(C=C2)Cl.[Cl-],,,,,,
4672,54673,(4-Chlorophenoxy)acetic acid (1-methyl-3-piperidinyl)methyl ester,CN1CCCC(C1)COC(=O)COC2=CC=C(C=C2)Cl,,,,,,
4673,54674,6-(1-Phenylprop-1-en-1-yl)-1-(propane-2-sulfonyl)-1H-benzimidazol-2-amine,CC=C(C1=CC=CC=C1)C2=CC3=C(C=C2)N=C(N3S(=O)(=O)C(C)C)N,,,,,,
4674,54675,N-{[({4-[(3-Aminopropyl)amino]butyl}imino)(hydroxy)methoxy]methyl}-7-carbamimidamido-3-hydroxyheptanimidic acid,C(CCN=C(N)N)CC(CC(=O)NCOC(=O)NCCCCNCCCN)O,,,,,,
4675,54676,(+-)-trans-9-Oxaergoline hydrochloride,C1COC2C([NH2+]1)CC3=CNC4=CC=CC2=C34.[Cl-],,,,,,
4676,54677,"3-Oxa-6,11-diazatetracyclo[7.6.1.02,7.012,16]hexadeca-1(16),9,12,14-tetraene",C1COC2C(N1)CC3=CNC4=CC=CC2=C34,,,,,,
4677,54678,(+-)-trans-6-n-Propyl-9-oxaergoline hydrochloride,CCC[NH+]1CCOC2C1CC3=CNC4=CC=CC2=C34.[Cl-],,,,,,
4678,54679,"6-Propyl-3-oxa-6,11-diazatetracyclo[7.6.1.02,7.012,16]hexadeca-1(16),9,12,14-tetraene",CCCN1CCOC2C1CC3=CNC4=CC=CC2=C34,,,,,,
4679,54680,"1,2-Propanediol, 3-(o-tolyloxy)-, methylcarbamate",CC1=CC=CC=C1OCC(COC(=O)NC)O,,,,,,
4680,54681,"1-(1,3-Dihydro-5,6-dimethoxy-3-oxoisobenzofuran-1-yl)cinnolin-4(1H)-one",COC1=C(C=C2C(=C1)C(OC2=O)N3C4=CC=CC=C4C(=O)C=N3)OC,,,,,,
4681,54682,"6,7-Dimethoxy-1-(1,3-dihydro-4,5-dimethoxy-3-oxoisobenzofuran-1-yl)cinnolin-4(1H)-one",COC1=C(C2=C(C=C1)C(OC2=O)N3C4=CC(=C(C=C4C(=O)C=N3)OC)OC)OC,,,,,,
4682,54683,"methyl 7-[(1R,2R,3R)-3-hydroxy-2-(4-hydroxy-4-methyloct-1-enyl)-5-oxocyclopentyl]hept-4-enoate",CCCCC(C)(CC=C[C@H]1[C@@H](CC(=O)[C@@H]1CCC=CCCC(=O)OC)O)O,,,,,,
4683,54684,"2-[cyclopentyl-[(2R)-3-(2,2-dimethylpropanoylsulfanyl)-2-methylpropanoyl]amino]acetic acid",C[C@@H](CSC(=O)C(C)(C)C)C(=O)N(CC(=O)O)C1CCCC1,,,,,,
4684,54685,CID 54685,CC[C@H](C(=O)O[C@H]1CC[C@]2([C@@H](C1)CCC3C2CC[C@]4([C@@]3(CC[C@@H]4C5=CC(=O)OC5)O)C)C)N,,,,,,
4685,54686,CID 54686,CC[C@@H](C(=O)O[C@H]1CC[C@]2([C@@H](C1)CCC3C2CC[C@]4([C@@]3(CC[C@@H]4C5=CC(=O)OC5)O)C)C)N,,,,,,
4686,54687,Pravastatin,CC[C@H](C)C(=O)O[C@H]1C[C@@H](C=C2[C@H]1[C@H]([C@H](C=C2)C)CC[C@H](C[C@H](CC(=O)O)O)O)O,"['Pravastatin is indicated for primary prevention of coronary events hypercholesterolemic patients without clinical evidence of coronary heart disease. Its use includes the reduction of risk on myocardial infarction, undergoing myocardial revascularization procedures and cardiovascular mortality.  As well, pravastatin can be used as a secondary prevention agent for cardiovascular events in patients with clinically evident coronary heart disease. This indication includes the reduction of risk of total mortality by reducing coronary death, myocardial infarction, undergoing myocardial revascularization procedures, stroke, and stroke/transient ischemic attack as well as to slow the progression of coronary atherosclerosis.  The term cardiovascular events correspond to all the incidents that can produce damage to the heart muscle including the interruption of blood flow.  As adjunctive therapy to diet, pravastatin is used in:  - Patients with primary hypercholesterolemia and mixed dyslipidemias including hyperlipidemia type IIa and IIb. - Patients with elevated serum triglycerides including type IV hyperlipidemia. - Patients with heterozygous familial hypercholesterolemia in patients over 8 years of age with low-density lipoprotein (LDL) cholesterol higher than 190 mg/dl after diet modifications or LDL levels higher than 160 mg/dl and familial history of premature cardiovascular diseases or at least two cardiovascular risk factors.  In patients that do not respond adequately to diet, pravastatin is used to treat patients with primary dysbetalipoproteinemia (type III hyperlipidemia).   Dyslipidemia is defined as an elevation of plasma cholesterol, triglycerides or both as well as to the presence of low levels of high-density lipoprotein. This condition represents an increased risk for the development of atherosclerosis.']","['The action of pravastatin on the 3-hydroxy-3-methyl-glutaryl-coenzyme A (HMG-CoA) reductase produces an increase in the expression of hepatic LDL receptors which in order decreases the plasma levels of LDL cholesterol.  The effect of pravastatin has been shown to significantly reduce the circulating total cholesterol, LDL cholesterol, and apolipoprotein B. As well, it modestly reduces very low-density-lipoproteins (VLDL) cholesterol and triglycerides while increasing the level of high-density lipoprotein (HDL) cholesterol and apolipoprotein A.  In clinical trials with patients with a history of myocardial infarction or angina with high total cholesterol, pravastatin decreased the level of total cholesterol by 18%, decreased of LDL by 27%, decreased of triglycerides by 6% and increased of high-density lipoprotein (HDL) by 4%. As well, there was reported a decrease in risk of death due to coronary disease of 24%.   When coadministered with [cholestyramine], pravastatin can reduce by 50% the levels of LDL and slow the progression of atherosclerosis and the risk of myocardial infarction and death.']","['Substances used to lower plasma cholesterol levels. (See all compounds classified as Anticholesteremic Agents.)', 'Compounds that inhibit HYDROXYMETHYLGLUTARYL COA REDUCTASES. They have been shown to directly lower CHOLESTEROL synthesis. (See all compounds classified as Hydroxymethylglutaryl-CoA Reductase Inhibitors.)']","['Pravastatin is absorbed 60-90 min after oral administration and it presents a low bioavailability of 17%. This low bioavailability can be presented due to the polar nature of pravastatin which produces a high range of first-pass metabolism and incomplete absorption.  Pravastatin is rapidly absorbed from the upper part of the small intestine via proton-coupled carrier-mediated transport to be later taken up in the livery by the sodium-independent bile acid transporter. The reported time to reach the peak serum concentration in the range of 30-55 mcg/L is of 1-1.5 hours with an AUC ranging from 60-90 mcg.h/L.', 'From the administered dose of pravastatin, about 70% is eliminated in the feces while about 20% is obtained in the urine.  When pravastatin is administered intravenously, approximately 47% of the administered dose is eliminated via the urine with 53% of the dose eliminated either via biotransformation of biliary.', 'The reported steady-state volume of distribution of pravastatin is reported to be of 0.5 L/kg. This pharmacokinetic parameter in children was found to range from 31-37 ml/kg.', 'The reported clearance rate of pravastatin ranges from 6.3-13.5 ml.min/kg in adults while in children it has been reported to be of 4-11 L/min.', '/MILK/ In lactating rats, up to 7 times higher levels of pravastatin are present in the breast milk than in the maternal plasma, which corresponds to exposure 2 times the MRHD of 80 mg/day based on body surface area (mg/sq m).', 'In pregnant rats, pravastatin crosses the placenta and is found in fetal tissue at 30% of the maternal plasma levels following administration of a single dose of 20 mg/day orally on gestation day 18, which corresponds to exposure 2 times the MRHD of 80 mg daily based on body surface area (mg/ssq m).', 'Low levels of radioactivity were found in the fetuses of rats dosed orally with radiolabeled pravastatin sodium.', 'Dogs are unique as compared to all other species tested, including man, in that they have a much greater systemic exposure to pravastatin. Pharmacokinetic data from a study in dogs at a dose of 1.1 mg/kg (comparable to a 40 mg dose in humans) showed that the elimination of pravastatin is slower in dogs than in humans. Absolute bioavailability is two times greater in dogs compared to humans and estimated renal and hepatic extraction of pravastatin are about one-tenth and onehalf, respectively, than those in humans. When concentrations of pravastatin in plasma or serum of rats, dogs, rabbits, monkeys and humans were compared, the exposure in dogs was dramatically higher, based on both CMAX and AUC. The mean AUC value in man at a therapeutic dose of 40 mg is approximately 100 times less than that in the dog at the no-effect dose of 12.5 mg/kg, and approximately 180 times lower than that in dogs at the threshold dose of 25 mg/kg for cerebral hemorrhage.', 'For more Absorption, Distribution and Excretion (Complete) data for Pravastatin (23 total), please visit the HSDB record page.']","[""After initial administration, pravastatin undergoes extensive first-pass extraction in the liver. However, pravastatin's metabolism is not related to the activity of the cytochrome P-450 isoenzymes and its processing is performed in a minor extent in the liver. Therefore, this drug is highly exposed to peripheral tissues.   The metabolism of pravastatin is ruled mainly by the presence of glucuronidation reactions with very minimal intervention of CYP3A enzymes. After metabolism, pravastatin does not produce active metabolites. This metabolism is mainly done in the stomach followed by a minor portion of renal and hepatic processing.  The major metabolite formed as part of pravastatin metabolism is the 3-alpha-hydroxy isomer. The activity of this metabolite is very clinically negligible."", 'The major biotransformation pathways for pravastatin are: (a) isomerization to 6-epi pravastatin and the 3a-hydroxyisomer of pravastatin (SQ 31,906) and (b) enzymatic ring hydroxylation to SQ 31,945. The 3a-hydroxyisomeric metabolite (SQ 31,906) has 1/10 to 1/40 the HMG-CoA reductase inhibitory activity of the parent compound. Pravastatin undergoes extensive first-pass extraction in the liver (extraction ratio 0.66).']","['The reported elimination half-life of pravastatin is reported to be of 1.8 hours.', 'Following single dose oral administration of (14)C-pravastatin, the radioactive elimination half life for pravastatin is 1.8 hours in humans.', 'In a two-way crossover study, eight healthy male subjects each received an intravenous and an oral dose of (14)C-pravastatin sodium. ... The estimated average plasma elimination half-life of pravastatin was 0.8 and 1.8 hr for the intravenous and oral routes, respectively. ...']"
4687,54688,Biaxin XL,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)OC2CC(C(C(O2)C)O)(C)OC)C)OC3C(C(CC(O3)C)N(C)C)O)(C)OC)C)C)O)(C)O,,,,,,
4688,54689,CID 54689,CC1(C[C@@H]1C(=O)NC(=CCCCCSC[C@H](C(=O)O)N)C(=O)[O-])C.[Na+],,,,,,
4689,54690,"(Z)-7-[(2S)-2-amino-3-hydroxy-3-oxopropyl]sulfanyl-2-[[(1S)-2,2-dimethylcyclopropanecarbonyl]amino]hept-2-enoic acid",CC1(C[C@@H]1C(=O)NC(=CCCCCSC[C@H](C(=O)O)N)C(=O)O)C,,,,,,
4690,54691,CID 54691,C[C@H](C(=O)O[C@H]1CC[C@]2([C@@H](C1)CCC3C2CC[C@]4([C@@]3(CC[C@@H]4C5=CC(=O)OC5)O)C)C)N,,,,,,
4691,54692,CID 54692,CC[C@H](C)C(=O)O[C@H]1C[C@@H](C=C2[C@H]1[C@H]([C@H](C=C2)C)CC[C@H](C[C@H](CC(=O)[O-])O)O)O.[Na+],,,,,,
4692,54693,CID 54693,CC[C@H](C)C(=O)O[C@H]1CC(C=C2[C@H]1C([C@H](C=C2)C)CC[C@H](C[C@H](CC(=O)O)O)O)O,,,,,,
4693,54694,"3,4-Dihydro-6,7-dimethoxy-1-(3,4-dimethoxyphenethyl)isoquinoline hydrochloride",COC1=C(C=C(C=C1)CCC2=[NH+]CCC3=CC(=C(C=C32)OC)OC)OC.[Cl-],,,,,,
4694,54695,"1-(3,4-Dimethoxyphenethyl)-6,7-dimethoxy-3,4-dihydroisoquinoline",COC1=C(C=C(C=C1)CCC2=NCCC3=CC(=C(C=C32)OC)OC)OC,,,,,,
4695,54696,"Butyric acid, 4-(benzoyl(((4,5-dihydro-1H-imidazol-2-yl)(2-hydroxyethyl)amino)methyl)amino)-",C1CN=C(N1)N(CCO)CN(CCCC(=O)O)C(=O)C2=CC=CC=C2,,,,,,
4696,54697,"Butyric acid, 4-(benzoyl(((4,5-dihydro-1H-imidazol-2-yl)(3-hydroxypropyl)amino)methyl)amino)-",C1CN=C(N1)N(CCCO)CN(CCCC(=O)O)C(=O)C2=CC=CC=C2,,,,,,
4697,54698,"4-(Benzoyl(((4,5-dihydro-1H-imidazol-2-yl)(1-hydroxybutyl)amino)methyl)amino)butyric acid",CCCC(N(CN(CCCC(=O)O)C(=O)C1=CC=CC=C1)C2=NCCN2)O,,,,,,
4698,54699,"4-(Benzoyl(((4,5-dihydro-1H-imidazol-2-yl)(2-hydroxybutyl)amino)methyl)amino)butyric acid",CCC(CN(CN(CCCC(=O)O)C(=O)C1=CC=CC=C1)C2=NCCN2)O,,,,,,
4699,54700,"Butyric acid, 4-(benzoyl((cyclohexyl(4,5-dihydro-1H-imidazol-2-yl)amino)methyl)amino)-",C1CCC(CC1)N(CN(CCCC(=O)O)C(=O)C2=CC=CC=C2)C3=NCCN3,,,,,,
4700,54701,"Butyric acid, 4-(benzoyl((cyclopentyl(4,5-dihydro-1H-imidazol-2-yl)amino)methyl)amino)-",C1CCC(C1)N(CN(CCCC(=O)O)C(=O)C2=CC=CC=C2)C3=NCCN3,,,,,,
4701,54702,"1H-Benz(de)isoquinoline-1,3(2H)-dione, 2-(2-(diethylamino)ethyl)-5-methoxy-",CCN(CC)CCN1C(=O)C2=CC=CC3=CC(=CC(=C32)C1=O)OC,,,,,,
4702,54703,"Naphthalimide, 3-butoxy-N-(2-(diethylamino)ethyl)-",CCCCOC1=CC2=C3C(=C1)C=CC=C3C(=O)N(C2=O)CCN(CC)CC,,,,,,
4703,54704,"Benzamide, N-((antipyrinylcarbamoyl)methyl)-",CC1=C(C(=O)N(N1C)C2=CC=CC=C2)NC(=O)CNC(=O)C3=CC=CC=C3,,,,,,
4704,54705,N-(1-(Antipyrinylcarbamoyl)ethyl)benzamide,CC1=C(C(=O)N(N1C)C2=CC=CC=C2)NC(=O)C(C)NC(=O)C3=CC=CC=C3,,,,,,
4705,54706,N-(1-(Antipyrinylcarbamoyl)propyl)benzamide,CCC(C(=O)NC1=C(N(N(C1=O)C2=CC=CC=C2)C)C)NC(=O)C3=CC=CC=C3,,,,,,
4706,54707,N-(1-(Antipyrinylcarbamoyl)-2-methylpropyl)benzamide,CC1=C(C(=O)N(N1C)C2=CC=CC=C2)NC(=O)C(C(C)C)NC(=O)C3=CC=CC=C3,,,,,,
4707,54708,N-(1-(Antipyrinylcarbamoyl)pentyl)benzamide,CCCCC(C(=O)NC1=C(N(N(C1=O)C2=CC=CC=C2)C)C)NC(=O)C3=CC=CC=C3,,,,,,
4708,54709,N-(1-(Antipyrinylcarbamoyl)-3-methylbutyl)benzamide,CC1=C(C(=O)N(N1C)C2=CC=CC=C2)NC(=O)C(CC(C)C)NC(=O)C3=CC=CC=C3,,,,,,
4709,54710,"N-(1,5-dimethyl-3-oxo-2-phenylpyrazol-4-yl)-2-(1,3-dioxoisoindol-2-yl)propanamide",CC1=C(C(=O)N(N1C)C2=CC=CC=C2)NC(=O)C(C)N3C(=O)C4=CC=CC=C4C3=O,,,,,,
4710,54711,"N-Antipyrinyl-1,3-dioxo-alpha-ethyl-2-isoindolineacetamide",CCC(C(=O)NC1=C(N(N(C1=O)C2=CC=CC=C2)C)C)N3C(=O)C4=CC=CC=C4C3=O,,,,,,
4711,54712,"N-Antipyrinyl-1,3-dioxo-alpha-isopropyl-2-isoindolineacetamide",CC1=C(C(=O)N(N1C)C2=CC=CC=C2)NC(=O)C(C(C)C)N3C(=O)C4=CC=CC=C4C3=O,,,,,,
4712,54713,"N-Antipyrinyl-alpha-benzyl-1,3-dioxo-2-isoindolineacetamide",CC1=C(C(=O)N(N1C)C2=CC=CC=C2)NC(=O)C(CC3=CC=CC=C3)N4C(=O)C5=CC=CC=C5C4=O,,,,,,
4713,54714,"BENZAMIDE, N-ANTIPYRINYL-p-IODO-",CC1=C(C(=O)N(N1C)C2=CC=CC=C2)NC(=O)C3=CC=C(C=C3)I,,,,,,
4714,54715,"BENZAMIDE, N-ANTIPYRINYL-o-IODO-N-ISOPROPYL-",CC1=C(C(=O)N(N1C)C2=CC=CC=C2)N(C(C)C)C(=O)C3=CC=CC=C3I,,,,,,
4715,54716,"BENZAMIDE, N-ANTIPYRINYL-m-IODO-N-ISOPROPYL-",CC1=C(C(=O)N(N1C)C2=CC=CC=C2)N(C(C)C)C(=O)C3=CC(=CC=C3)I,,,,,,
4716,54717,"BENZAMIDE, N-ANTIPYRINYL-p-IODO-N-ISOPROPYL-",CC1=C(C(=O)N(N1C)C2=CC=CC=C2)N(C(C)C)C(=O)C3=CC=C(C=C3)I,,,,,,
4717,54718,"5-Acetyl-3,3-diphenyl-1-(morpholinomethyl)-2-indolinone",CC(=O)C1=CC2=C(C=C1)N(C(=O)C2(C3=CC=CC=C3)C4=CC=CC=C4)CN5CCOCC5,,,,,,
4718,54719,"2-Indolinone, 3,3-diphenyl-5-methoxy-1-(piperidinomethyl)-",COC1=CC2=C(C=C1)N(C(=O)C2(C3=CC=CC=C3)C4=CC=CC=C4)CN5CCCCC5,,,,,,
4719,54720,Propylmercury;propylmercury(1+);sulfanide,CCC[Hg].CCC[Hg+].[SH-],,,,,,
4720,54721,Propylmercury(1+),CCC[Hg+],,,,,,
4721,54722,Propylmercury,CCC[Hg],,,,,,
4722,54723,Butylmercury;butylmercury(1+);sulfanide,CCCC[Hg].CCCC[Hg+].[SH-],,,,,,
4723,54724,Butylmercury(1+),CCCC[Hg+],,,,,,
4724,54725,"ACETIC ACID, (p-(2H-INDAZOL-2-YL)PHENYL)-",C1=CC2=CN(N=C2C=C1)C3=CC=C(C=C3)CC(=O)O,,,,,,
4725,54726,"ACETIC ACID, (3-CHLORO-p-(2H-INDAZOL-2-YL)PHENYL)-",C1=CC2=CN(N=C2C=C1)C3=C(C=C(C=C3)CC(=O)O)Cl,,,,,,
4726,54727,"BUTYRIC ACID, 4-(p-(2H-INDAZOL-2-YL)PHENYL)-",C1=CC2=CN(N=C2C=C1)C3=CC=C(C=C3)CCCC(=O)O,,,,,,
4727,54728,2-(p-(2H-Indazol-2-yl)phenyl)butyric acid,CCC(C1=CC=C(C=C1)N2C=C3C=CC=CC3=N2)C(=O)O,,,,,,
4728,54729,3-(p-(2H-Indazol-2-yl)phenyl)-2-butanone,CC(C1=CC=C(C=C1)N2C=C3C=CC=CC3=N2)C(=O)C,,,,,,
4729,54730,"BENZOIC ACID, p-(2H-INDAZOL-2-YL)-",C1=CC2=CN(N=C2C=C1)C3=CC=C(C=C3)C(=O)O,,,,,,
4730,54731,"BENZONITRILE, o-(2H-INDAZOL-2-YL)-",C1=CC=C(C(=C1)C#N)N2C=C3C=CC=CC3=N2,,,,,,
4731,54732,1-Nitrocoronene,C1=CC2=C3C4=C1C=CC5=C4C6=C7C3=C(C=C2)C=CC7=C(C=C6C=C5)[N+](=O)[O-],,,,,,
4732,54733,"BENZO(ghi)PERYLENE, 5-NITRO-",C1=CC2=C3C(=C1)C4=C5C(=C(C=C4)[N+](=O)[O-])C=CC6=C5C3=C(C=C2)C=C6,,,,,,
4733,54734,"Benzyl 2,2-dimethyloctanoate",CCCCCCC(C)(C)C(=O)OCC1=CC=CC=C1,,,,,,
4734,54735,"Benzyl-2,2,4,4-tetramethylpentanoate",CC(C)(C)CC(C)(C)C(=O)OCC1=CC=CC=C1,,,,,,
4735,54736,O-Demethylencainide,CN1CCCCC1CCC2=CC=CC=C2NC(=O)C3=CC=C(C=C3)O,,,"['Agents used for the treatment or prevention of cardiac arrhythmias. They may affect the polarization-repolarization phase of the action potential, its excitability or refractoriness, or impulse conduction or membrane responsiveness within cardiac fibers. Anti-arrhythmia agents are often classed into four main groups according to their mechanism of action: sodium channel blockade, beta-adrenergic blockade, repolarization prolongation, or calcium channel blockade. (See all compounds classified as Anti-Arrhythmia Agents.)']",,"['O-demethylencainide has known human metabolites that include N,O-didemethylencainide.']",
4736,54737,Modecainide,CN1CCCCC1CCC2=CC=CC=C2NC(=O)C3=CC(=C(C=C3)O)OC,,,"['Agents used for the treatment or prevention of cardiac arrhythmias. They may affect the polarization-repolarization phase of the action potential, its excitability or refractoriness, or impulse conduction or membrane responsiveness within cardiac fibers. Anti-arrhythmia agents are often classed into four main groups according to their mechanism of action: sodium channel blockade, beta-adrenergic blockade, repolarization prolongation, or calcium channel blockade. (See all compounds classified as Anti-Arrhythmia Agents.)']",,,
4737,54738,Imazapyr,CC(C)C1(C(=O)NC(=N1)C2=C(C=CC=N2)C(=O)O)C,,,"['Pesticides used to destroy unwanted vegetation, especially various types of weeds, grasses (POACEAE), and woody plants. Some plants develop HERBICIDE RESISTANCE. (See all compounds classified as Herbicides.)']","['In rats, following oral admin, ... 87% of the dose was excreted in the urine and feces within 24 hr. In muscle and fat tissues and blood, residual levels were <0.01 mg/kg at both 24 & 192 hr.', 'Following foliar application, residues in plants decline rapidly in the first 24 hr. The major residue in plants is the parent compound.', 'Imazapyr, (unlabeled, 99.5% ai, (14)C-labeled at the 6-carbon on the pyridine ring, 93.4% ai), was administered to Sprague Dawley rats (5/sex/dose) as a single gavage dose of approximately 9.5 mg/kg or 924 mg/kg or as 14-daily doses of unlabeled followed by a single labeled dose of 9.26 mg/kg. Excretion via expired air was examined in a pilot study where two male and two female rats were given a single gavage dose of 10 mg/kg labeled imazapyr. Corn oil was used as the vehicle for all oral treatments. An additional study with five male and five female rats that received 9.94 mg/kg imazapyr by intravenous injection was also done. No sex-related differences in absorption were apparent. Within 48 hours of treatment, > 90% of the administered dose was recovered in the excreta suggesting that elimination of the labeled test material was rapid. No specific sequestering tissues or organs were identified. Seven days after treatment, essentially all the test material had been eliminated. The overall recovery of administered radioactivity for the single low-dose, multiple low-dose, and intravenous dose groups was similar and ranged from 92.1-107.7%, indicating acceptable mass balance. For the oral treatment groups, 68-81% of the administered test material was recovered in the urine and cage wash samples collected within 4 hours of treatment. Essentially all of the remainder was recovered in the feces with <0.2% of the administered dose remaining in the carcass/tissues. Rats that received the test material by intravenous injection excreted 87-95% of the administered dose in the urine and approximately 6% into the feces. This suggests that 15-28% of the administered dose recovered in the feces represents unabsorbed material.']","['Imazapyr, (unlabeled, 99.5% ai, (14)C-labeled at the 6-carbon on the pyridine ring, 93.4% ai). was administered to Sprague Dawley rats (5/sex/dose) as a single gavage dose of approximately 9.5 mg/kg or 924 mg/kg or as 14-daily doses of unlabeled followed by a single labeled dose of 9.26 mg/kg. Excretion via expired air was examined in a pilot study where two male and two female rats were given a single gavage dose of 10 mg/kg labeled imazapyr. Corn oil was used as the vehicle for all oral treatments. An additional study with five male and five female rats that received 9.94 mg/kg imazapyr by intravenous injection was also done. Metabolite characterization studies show that essentially all of the test material was excreted unchanged. Two minor metabolites CL 252,974 (2-((1-carbamoyl-1,2-dimethylpropyl)- carbamoyl)-nicotinic acid) and CL 60,032 (2-carbamoyl-nicotinic acid) were detected in the urine or feces of treated rats; however, their contribution combined was < 0.5% of the administered dose. Up to 12 additional unidentified metabolites were isolated, but they constituted < 3% of the administered dose. Based on the results, ... what limited metabolism of imazapyr occurs, proceeds through hydrolysis to form the 2-carbonyl derivatives: CL 252,974 and CL 60,032.']",
4738,54739,Imazaquin,CC(C)C1(C(=O)NC(=N1)C2=NC3=CC=CC=C3C=C2C(=O)O)C,,,"['Pesticides used to destroy unwanted vegetation, especially various types of weeds, grasses (POACEAE), and woody plants. Some plants develop HERBICIDE RESISTANCE. (See all compounds classified as Herbicides.)']","['Following oral administration, almost all was excreted in the urine as the unchanged compound within 2 days. No accumulation in blood or tissues.']",,
4739,54740,Imazethapyr,CCC1=CC(=C(N=C1)C2=NC(C(=O)N2)(C)C(C)C)C(=O)O,,,"['Pesticides used to destroy unwanted vegetation, especially various types of weeds, grasses (POACEAE), and woody plants. Some plants develop HERBICIDE RESISTANCE. (See all compounds classified as Herbicides.)']","['In rats, following oral administration, 92% was excreted in the urine and 5% in the feces within 24 hr. Residue levels in blood, liver, kidney, muscle, and fat tissues were <0.01 ppm after 48 hr.']","['In a rat metabolism study, almost 100% of the administered radiolabeled test material /imazethapyr/ was recovered in the excreta within 96 hours (89-95% in the urine and 6-11% in the feces). Greater than 95% of the oral dose was excreted in the first 31 hours. The major residue in both urine and feces was the parent compound. Approximately 2% of the oral dose was metabolized and excreted as CL 288511 (1-hydroxy ethyl derivative of imazethapyr). A high percentage of the administered material was excreted in the urine as the unmodified parent compound (> 97%) and a very small amount as CL 288511. In the high dose group, the unmodified parent compound was the major fecal component in both sexes, particularly at 12 hours or less. CL 288511 was the major metabolite. One unknown metabolite was also found in significant quantities. In the low dose group, six components were found in the feces: parent compound, CL 288511, the unknown previously mentioned and three minor unknowns.', 'Rapidly metabolized in non-susceptible plants (50% loss in soyabeans in 1.6 days).']",
4740,54741,CID 54741,CN1CCN(CC1)C2=NC3=CC=CC=C3SC4=NC=CN24.C(=CC(=O)O)C(=O)O,,,,,,
4741,54742,Pentiapine,CN1CCN(CC1)C2=NC3=CC=CC=C3SC4=NC=CN24,,,,,,
4742,54743,"Urea, N'-(4-chlorophenyl)-N-((beta-D-glucopyranosyloxy)methyl)-N-methoxy-",CON(COC1C(C(C(C(O1)CO)O)O)O)C(=O)NC2=CC=C(C=C2)Cl,,,,,,
4743,54744,para-Imazamethabenz methyl,CC1=CC(=C(C=C1)C(=O)OC)C2=NC(C(=O)N2)(C)C(C)C,,,,,,
4744,54745,Fluroxypyr-meptyl,CCCCCCC(C)OC(=O)COC1=NC(=C(C(=C1Cl)N)Cl)F,,,,,,
4745,54746,Cabergoline,CCNC(=O)N(CCCN(C)C)C(=O)[C@@H]1C[C@H]2[C@@H](CC3=CNC4=CC=CC2=C34)N(C1)CC=C,"['For the treatment of hyperprolactinemic disorders, either idiopathic or due to prolactinoma (prolactin-secreting adenomas). May also be used to manage symptoms of Parkinsonian Syndrome as monotherapy during initial symptomatic management or as an adjunct to levodopa therapy during advanced stages of disease.']","['Cabergoline stimulates centrally-located dopaminergic receptors resulting in a number of pharmacologic effects. Five dopamine receptor types from two dopaminergic subfamilies have been identified. The dopaminergic D1 receptor subfamily consists of D<sub>1</sub> and D<sub>5</sub> subreceptors, which are associated with dyskinesias. The dopaminergic D2 receptor subfamily consists of D<sub>2</sub>, D<sub>3</sub> and D<sub>4</sub> subreceptors, which are associated with improvement of symptoms of movement disorders. Thus, agonist activity specific for D2 subfamily receptors, primarily D<sub>2</sub> and D<sub>3</sub> receptor subtypes, are the primary targets of dopaminergic antiparkinsonian agents. It is thought that postsynaptic D2 stimulation is primarily responsible for the antiparkinsonian effect of dopamine agonists, while presynaptic D2 stimulation confers neuroprotective effects. This semisynthetic ergot derivative exhibits potent agonist activity on dopamine D<sub>2</sub>- and D<sub>3</sub>-receptors. It also exhibits: agonist activity (in order of decreasing binding affinities) on 5-hydroxytryptamine (5-HT)<sub>2B</sub>, 5-HT<sub>2A</sub>, 5-HT<sub>1D</sub>, dopamine D<sub>4</sub>, 5-HT<sub>1A</sub>, dopamine D<sub>1</sub>, 5-HT<sub>1B</sub> and 5-HT<sub>2C</sub> receptors and antagonist activity on &alpha;<sub>2B</sub>, &alpha;<sub>2A</sub>, and &alpha;<sub>2C</sub> receptors. Parkinsonian Syndrome manifests when approximately 80% of dopaminergic activity in the nigrostriatal pathway of the brain is lost. As this striatum is involved in modulating the intensity of coordinated muscle activity (e.g. movement, balance, walking), loss of activity may result in dystonia (acute muscle contraction), Parkinsonism (including symptoms of bradykinesia, tremor, rigidity, and flattened affect), akathesia (inner restlessness), tardive dyskinesia (involuntary muscle movements usually associated with long-term loss of dopaminergic activity), and neuroleptic malignant syndrome, which manifests when complete blockage of nigrostriatal dopamine occurs. High dopaminergic activity in the mesolimbic pathway of the brain causes hallucinations and delusions; these side effects of dopamine agonists are manifestations seen in patients with schizophrenia who have overractivity in this area of the brain. The hallucinogenic side effects of dopamine agonists may also be due to 5-HT<sub>2A</sub> agonism. The tuberoinfundibular pathway of the brain originates in the hypothalamus and terminates in the pituitary gland. In this pathway, dopamine inhibits lactotrophs in anterior pituitary from secreting prolactin. Increased dopaminergic activity in the tuberoinfundibular pathway inhibits prolactin secretion.']","['Agents used in the treatment of Parkinson&apos;s disease. The most commonly used drugs act on the dopaminergic system in the striatum and basal ganglia or are centrally acting muscarinic antagonists. (See all compounds classified as Antiparkinson Agents.)', 'Drugs that bind to and activate dopamine receptors. (See all compounds classified as Dopamine Agonists.)']","['First-pass effect is seen, however the absolute bioavailability is unknown.', 'After oral dosing of radioactive cabergoline to five healthy volunteers, approximately 22% and 60% of the dose was excreted within 20 days in the urine and feces, respectively. Less than 4% of the dose was excreted unchanged in the urine.', 'renal cl=0,008 L/min']","['Hepatic. Cabergoline is extensively metabolized, predominately via hydrolysis of the acylurea bond of the urea moiety. Cytochrome P-450 mediated metabolism appears to be minimal. The main metabolite identified in urine is 6-allyl-8b-carboxy-ergoline (4-6% of dose). Three other metabolites were identified urine (less than 3% of dose).']",['The elimination half-life is estimated from urinary data of 12 healthy subjects to range between 63 to 69 hours.']
4746,54747,Caracemide,CC(=O)N(C(=O)NC)OC(=O)NC,,,,,,
4747,54748,3-(3-(2-Chloroethyl)-3-nitrosoureido)-3-deoxyallose,C(CCl)N(C(=O)NC1[C@@H](C(O[C@H](C1O)O)CO)O)N=O,,,,,,
4748,54749,Losulazine hydrochloride,C1CN(CCN1C(=O)C2=CC=C(C=C2)NC3=C4C=CC(=CC4=NC=C3)C(F)(F)F)S(=O)(=O)C5=CC=C(C=C5)F.Cl,,,,,,
4749,54750,Losulazine,C1CN(CCN1C(=O)C2=CC=C(C=C2)NC3=C4C=CC(=CC4=NC=C3)C(F)(F)F)S(=O)(=O)C5=CC=C(C=C5)F,,,,,,
4750,54751,CID 54751,C1CC(=O)CC1CCC(=CCC(C(=O)O)N2CCOCC2)OCC3=CC=C(C=C3)C4=CC=CC=C4,,,,,,
4751,54752,CID 54752,CN(C)[C@H]1CCCC[C@@H]1NC(=O)C2=CC=C(C=C2)Br.C(=CC(=O)O)C(=O)O,,,,,,
4752,54753,Bromadoline,CN(C)[C@H]1CCCC[C@@H]1NC(=O)C2=CC=C(C=C2)Br,,,,,,
4753,54754,"3-Iodo-2-propynyl 2,4-dichlorophenylcarbamate",C1=CC(=C(C=C1Cl)Cl)NC(=O)OCC#CI,,,,,,
4754,54755,"Methyl 4-[(5-methyl-1,3,4-thiadiazol-2-yl)amino]-4-oxobut-2-enoate",CC1=NN=C(S1)NC(=O)C=CC(=O)OC,,,,,,
4755,54756,"Naphthalene, 5-ethyl-1,2,3,4-tetrahydro-",CCC1=CC=CC2=C1CCCC2,,,,,,
4756,54757,alpha-Ethyl-6-fluoro-1H-indole-3-ethanamine hydrochloride,CCC(CC1=CNC2=C1C=CC(=C2)F)[NH3+].[Cl-],,,,,,
4757,54758,1-(6-fluoro-1H-indol-3-yl)butan-2-amine,CCC(CC1=CNC2=C1C=CC(=C2)F)N,,,,,,
4758,54759,"N-(Glycylglycyl)-N-methyl-2',5-dichloro-2-amino-benzophenone hydrate",CN(C1=C(C=C(C=C1)Cl)C(=O)C2=CC=CC=C2Cl)C(=O)CNC(=O)CN.O,,,,,,
4759,54760,Lorzafone,CN(C1=C(C=C(C=C1)Cl)C(=O)C2=CC=CC=C2Cl)C(=O)CNC(=O)CN,,,,,,
4760,54761,(Z)-dec-3-enyl acetate,CCCCCCC=CCCOC(=O)C,,,,,,
4761,54762,"1,8-Dichlorodibenzofuran",C1=CC2=C(C(=C1)Cl)C3=C(O2)C=CC(=C3)Cl,,,,,,
4762,54763,"calcium;5-[(3aS,4S,5S,6aR)-5-hydroxy-4-[(3R)-3-hydroxyoct-1-enyl]-6a-methyl-1,3,3a,4,5,6-hexahydropentalen-2-ylidene]pentanoate",CCCCC[C@H](C=C[C@H]1[C@@H]2CC(=CCCCC(=O)[O-])C[C@@]2(C[C@@H]1O)C)O.CCCCC[C@H](C=C[C@H]1[C@@H]2CC(=CCCCC(=O)[O-])C[C@@]2(C[C@@H]1O)C)O.[Ca+2],,,,,,
4763,54764,"5-[(3aS,4S,5S,6aR)-5-hydroxy-4-[(3R)-3-hydroxyoct-1-enyl]-6a-methyl-1,3,3a,4,5,6-hexahydropentalen-2-ylidene]pentanoic acid",CCCCC[C@H](C=C[C@H]1[C@@H]2CC(=CCCCC(=O)O)C[C@@]2(C[C@@H]1O)C)O,,,,,,
4764,54765,Bambuterol hydrochloride,CC(C)(C)NCC(C1=CC(=CC(=C1)OC(=O)N(C)C)OC(=O)N(C)C)O.Cl,,,['Agents that cause an increase in the expansion of a bronchus or bronchial tubes. (See all compounds classified as Bronchodilator Agents.)'],,,
4765,54766,Bambuterol,CC(C)(C)NCC(C1=CC(=CC(=C1)OC(=O)N(C)C)OC(=O)N(C)C)O,['For the prevention and reversal of bronchospasm in patients 12 years of age and older with asthma and reversible bronchospasm associated with bronchitis and emphysema.'],"['Bambuterol is a long acting beta2-adrenoceptor agonist used in the treatment of asthma. It is a prodrug of terbutaline. Bambuterol causes smooth muscle relaxation, resulting in dilation of bronchial passages.']",['Agents that cause an increase in the expansion of a bronchus or bronchial tubes. (See all compounds classified as Bronchodilator Agents.)'],['Bioavailability is 20% following oral administration.'],"['Hepatic, extensive. Further metabolized to terbutaline by plasma cholinesterase.']",['13 hours for bambuterol and 21 hours for the primary active metabolite terbutaline.']
4766,54767,CID 54767,C1=CC=C2C(=C1)C(=CC(=N2)C=NN=C(N)N)C(=O)O.O,,,,,,
4767,54768,CID 54768,C1=CC=C2C(=C1)C(=CC(=N2)C=NN=C(N)N)C(=O)O,,,,,,
4768,54769,CID 54769,C1=CC2=C(C=C(N=C2C=C1Cl)C=NN=C(N)N)C(=O)O,,,,,,
4769,54770,CID 54770,C1=CC2=C(C=C(N=C2C=C1Cl)C=NN=C(N)S)C(=O)O,,,,,,
4770,54771,CID 54771,CNN=CC1=CC(=C2C=CC(=CC2=N1)Cl)C(=O)O,,,,,,
4771,54772,CID 54772,C1=CC2=C(C=C(N=C2C=C1Cl)C=N[NH2+]CCOS(=O)(=O)[O-])C(=O)O,,,,,,
4772,54773,CID 54773,C1=CC2=C(C=C(N=C2C=C1Cl)C=NNCCOS(=O)(=O)O)C(=O)O,,,,,,
4773,54774,CID 54774,C1=CC2=C(C=C(N=C2C=C1Cl)C=NO)C(=O)O,,,,,,
4774,54775,"Methanesulfonic acid--2,2'-azanediylbis[1-(2,3-dihydro-1,4-benzodioxin-2-yl)ethan-1-ol] (1/1)",CS(=O)(=O)O.C1[C@H](OC2=CC=CC=C2O1)C(CNCC([C@@H]3COC4=CC=CC=C4O3)O)O,,,,,,
4775,54776,"1-[(3S)-2,3-dihydro-1,4-benzodioxin-3-yl]-2-[[2-[(3S)-2,3-dihydro-1,4-benzodioxin-3-yl]-2-hydroxyethyl]amino]ethanol",C1[C@H](OC2=CC=CC=C2O1)C(CNCC([C@@H]3COC4=CC=CC=C4O3)O)O,,,,,,
4776,54777,CID 54777,CCCCC1(C(=O)NC(=O)NC1=O)C2=CCCCCCC2,,,,,,
4777,54778,Clomazone,CC1(CON(C1=O)CC2=CC=CC=C2Cl)C,,,,"[""Sprague-Dawley (CD, Crl (SD)Br) rats of both sexes were dosed with 3, 5, or 900 mg/kg of Methylene 14C-Labeled FMC 57020 (2[(2'-chlorophenyl)-14C-methyl]-4,4-dimethyl-3-isoxazolidinone; radiopurity: 99.8%; specific activity: 26.81 mCi/mmol). In Study A, two rats/sex were orally dosed by gavage with 5 mg/kg of the test material and expired air was collected for up to 24 hours. In the remaining studies, 5 animals/sex/group were dosed. In Studies B and C, the animals received a single oral dose of 5 and 900 mg/kg of the test material, respectively. In Study D, each animal was dosed intravenously with 3 mg/kg of the test material. In Study E, the animals received 14 doses, once per day for 2 weeks, of unlabeled FMC 57020 (purity: 99.0%). In Study B, C, D and E, urine and feces samples were collected periodically for 7 days. After 7 days, the animals were euthanized and radioactivity in the tissues was determined. Excretion of radiolabeled CO2 constituted less than 0.01% of the recovered dose. The primary pathway of excretion was in the urine with a range of 63.4 to 82.9% of the administered dose in the urine. Recovery in the feces ranged from 15.1 to 38.7% of the administered dose. At 7 days post-dose, aggregate residue levels in the tissues and carcass ranged from 0.08 to 0.17% of the administered dose. The amount dosed or frequency of the dosing did not affect the excretory profile.""]","['Four Sprague-Dawley rats/sex were treated by oral gavage with a single dose of 50 mg/kg of a mixture of Methylene-14C FMC 57020 (specific activity: 26.85 mCi/mmol, radiochemical purity: 99.3%) and Carbonyl-14C FMC 57020 (specific activity: 27.98 mCi/mmol, radiochemical purity: 99.3%). Radiolabeled compounds were recovered from the urine and feces samples and analyzed... in order to identify various metabolites of the test material. Twelve metabolites were recovered and identified. Hydroxylation of the phenyl and/or isoxazolidinone rings was the most common alteration of the parent compound which was observed with some evidence of glucuronide and sulfate conjugation.']",
4778,54779,N-Nitrosothialdine,CC1N(C(SC(S1)C)C)N=O,,,,,,
4779,54780,CID 54780,CC1=CC=C(C=C1)OCC(CNCCNC(=O)N2CCOCC2)O.C(=CC(=O)O)C(=O)O,,,,,,
4780,54781,CID 54781,CC1=CC=C(C=C1)OCC(CNCCNC(=O)N2CCOCC2)O,,,,,,
4781,54782,"Ethyl 3,4-dihydro-4-(4-(2-methoxyphenyl)-1-piperazinyl)-2H-1-benzopyran-6-carboxylate",CCOC(=O)C1=CC2=C(C=C1)OCCC2N3CCN(CC3)C4=CC=CC=C4OC,,,,,,
4782,54783,"2H-1-Benzopyran-6-methanol, 3,4-dihydro-4-(4-(2-methoxyphenyl)-1-piperazinyl)-, dihydrochloride",COC1=CC=CC=C1N2CCN(CC2)C3CC4=C(C=CC(=C4)CO)OC3.Cl.Cl,,,,,,
4783,54784,"[3-[4-(2-methoxyphenyl)piperazin-1-yl]-3,4-dihydro-2H-chromen-6-yl]methanol",COC1=CC=CC=C1N2CCN(CC2)C3CC4=C(C=CC(=C4)CO)OC3,,,,,,
4784,54785,"1-(3,4-Dimethoxyphenyl)-2-(4-nitrophenoxy)propane-1,3-diol",COC1=C(C=C(C=C1)C(C(CO)OC2=CC=C(C=C2)[N+](=O)[O-])O)OC,,,,,,
4785,54786,"2-(((1R,2R,3AS,9AS)-2-hydroxy-1-((S)-3-hydroxyoctyl)-2,3,3a,4,9,9a-hexahydro-1h-",CCCCC[C@H](CC[C@@H]1[C@H](C[C@@H]2[C@H]1CC3=C(C2)C(=CC=C3)OCC(=O)O)O)O,,,,,,
4786,54787,5-Amino-1-acenaphthenol,C1C(C2=CC=CC3=C(C=CC1=C32)N)O,,,,,,
4787,54788,"cis-1,2-Dihydroxy-5-nitroacenaphthene",C1=CC2=C(C=CC3=C2C(=C1)[C@H]([C@@H]3O)O)[N+](=O)[O-],,,,,,
4788,54789,(2-p-Tolyloxyethyl)hydrazine hydrochloride,CC1=CC=C(C=C1)OCCN[NH3+].[Cl-],,,,,,
4789,54790,1-(2-(p-Tolyloxy)ethyl)hydrazine,CC1=CC=C(C=C1)OCCNN,,,,,,
4790,54791,(1H-Indol-5-yl)methanamine,C1=CC2=C(C=CN2)C=C1CN,,,,,,
4791,54792,CID 54792,C[NH+](C)CCCC1C2=CC=CC=C2OC3=CC=CC=C3O1.C(=CC(=O)[O-])C(=O)O,,,,,,
4792,54793,"3-(6H-benzo[b][1,4]benzodioxepin-6-yl)-N,N-dimethylpropan-1-amine",CN(C)CCCC1C2=CC=CC=C2OC3=CC=CC=C3O1,,,,,,
4793,54794,"3,6-Anhydro-1,4-dideoxy-4-methyl-5-O-methylhex-2-ulose",CC1C(COC1C(=O)C)OC,,,,,,
4794,54795,"Cyclopropanecarboxylic acid, 2,2,3,3-tetramethyl-, 5-cyclopropyl-1-methyl-4-oxo-6-oxabicyclo(3.1.0)hex-2-yl ester",CC1(C(C1(C)C)C(=O)OC2CC(=O)C3(C2(O3)C)C4CC4)C,,,,,,
4795,54796,"2-(1-Benzylindazol-3-yl)oxyacetate;2,6-bis(azaniumyl)hexanoate",C1=CC=C(C=C1)CN2C3=CC=CC=C3C(=N2)OCC(=O)[O-].C(CC[NH3+])CC(C(=O)[O-])[NH3+],,,,,,
4796,54797,Zofenopril(1-),C[C@H](CSC(=O)C1=CC=CC=C1)C(=O)N2C[C@H](C[C@H]2C(=O)[O-])SC3=CC=CC=C3,,,,,,
4797,54798,"(2S,4S)-1-[3-(Benzoylthio)-2-methyl-1-oxopropyl]-4-(phenylthio)-2-pyrrolidinecarboxylic acid",CC(CSC(=O)C1=CC=CC=C1)C(=O)N2C[C@H](C[C@H]2C(=O)O)SC3=CC=CC=C3,,,,,,
4798,54799,"5,3',4'-Trihydroxy-3,6,7,8-tetramethoxyflavone",COC1=C(C(=C2C(=C1O)C(=O)C(=C(O2)C3=CC(=C(C=C3)O)O)OC)OC)OC,,,,,,
4799,54800,N-(4-((6-Methoxy-8-quinolinyl)amino)pentyl)octanamide,CCCCCCCC(=O)NCCCC(C)NC1=C2C(=CC(=C1)OC)C=CC=N2,,,,,,
4800,54801,Dazopride,CCN1CC(CN1CC)NC(=O)C2=CC(=C(C=C2OC)N)Cl,,,,,,
4801,54802,"5-(3,5-Dibromo-2-hydroxyphenyl)-3-(1-piperidinylmethyl)-1,3,4-oxadiazole-2(3H)-thione",C1CCN(CC1)CN2C(=S)OC(=N2)C3=C(C(=CC(=C3)Br)Br)O,,,,,,
4802,54803,Mergocriptine,CC1=C2C[C@@H]3C(=C[C@H](CN3C)C(=O)N[C@]4(C(=O)N5[C@H](C(=O)N6CCC[C@H]6[C@@]5(O4)O)CC(C)C)C(C)C)C7=C2C(=CC=C7)N1,,,,,,
4803,54804,"7-[[(2R)-2-amino-2-carboxyethyl]thio]-2-[[[(1S)-2,2-dimethylcyclopropyl]-oxomethyl]amino]-2-heptenoic acid",CC1(C[C@@H]1C(=O)NC(=CCCCCSC[C@@H](C(=O)O)N)C(=O)O)C,,,,,,
4804,54805,"6-Hydroxy-7,7-dimethyl-4,7-dihydro-3H-1,2,5-dithiazepine-4-carboxylic acid",CC1(C(=O)NC(CSS1)C(=O)O)C,,,,,,
4805,54806,"N-Nitroso-2,2,2-trifluoroethyl-ethylamine",CCN(CC(F)(F)F)N=O,,,,,,
4806,54807,"4,9-Dioxo-5,10-diazatetradecane",CCCCNC(=O)CCCNC(=O)CCC,,,,,,
4807,54808,"chloromethyl (10R,11S,13S,17R)-17-ethoxycarbonyloxy-11-hydroxy-10,13-dimethyl-3-oxo-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthrene-17-carboxylate",CCOC(=O)O[C@@]1(CCC2[C@@]1(C[C@@H](C3C2CCC4=CC(=O)C=C[C@]34C)O)C)C(=O)OCCl,,,,,,
4808,54809,4-Nitrobenzo[a]pyren-1-ol,C1=CC=C2C3=C4C(=CC2=C1)C=C(C5=C4C(=C(C=C5)O)C=C3)[N+](=O)[O-],,,,,,
4809,54810,"Benzo(a)pyren-1-ol, 6-nitro-",C1=CC=C2C(=C1)C=C3C=C(C4=CC=CC5=CC(=C2C3=C54)O)[N+](=O)[O-],,,,,,
4810,54811,"N-Ethyl-9-oxo-2,4,6,8-tetraphenyl-3,7-diazabicyclo(3.3.1)nonane-3-carboxamide",CCNC(=O)N1C(C2C(NC(C(C1C3=CC=CC=C3)C2=O)C4=CC=CC=C4)C5=CC=CC=C5)C6=CC=CC=C6,,,,,,
4811,54812,"N-Butyl-9-oxo-2,4,6,8-tetraphenyl-3,7-diazabicyclo(3.3.1)nonane-3-carboxamide",CCCCNC(=O)N1C(C2C(NC(C(C1C3=CC=CC=C3)C2=O)C4=CC=CC=C4)C5=CC=CC=C5)C6=CC=CC=C6,,,,,,
4812,54813,"N-tert-Butyl-9-oxo-2,4,6,8-tetraphenyl-3,7-diazabicyclo(3.3.1)nonane-3-carboxamide",CC(C)(C)NC(=O)N1C(C2C(NC(C(C1C3=CC=CC=C3)C2=O)C4=CC=CC=C4)C5=CC=CC=C5)C6=CC=CC=C6,,,,,,
4813,54814,"N-Cyclohexyl-9-oxo-2,4,6,8-tetraphenyl-3,7-diazabicyclo(3.3.1)nonane-3-carboxamide",C1CCC(CC1)NC(=O)N2C(C3C(NC(C(C2C4=CC=CC=C4)C3=O)C5=CC=CC=C5)C6=CC=CC=C6)C7=CC=CC=C7,,,,,,
4814,54815,"N-Ethyl-5-methyl-9-oxo-2,4,6,8-tetraphenyl-3,7-diazabicyclo(3.3.1)nonane-3-carboxamide",CCNC(=O)N1C(C2C(NC(C(C1C3=CC=CC=C3)(C2=O)C)C4=CC=CC=C4)C5=CC=CC=C5)C6=CC=CC=C6,,,,,,
4815,54816,"N-Butyl-5-methyl-9-oxo-2,4,6,8-tetraphenyl-3,7-diazabicyclo(3.3.1)nonane-3-carboxamide",CCCCNC(=O)N1C(C2C(NC(C(C1C3=CC=CC=C3)(C2=O)C)C4=CC=CC=C4)C5=CC=CC=C5)C6=CC=CC=C6,,,,,,
4816,54817,"N-tert-Butyl-5-methyl-9-oxo-2,4,6,8-tetraphenyl-3,7-diazabicyclo(3.3.1)nonane-3-carboxamide",CC12C(NC(C(C1=O)C(N(C2C3=CC=CC=C3)C(=O)NC(C)(C)C)C4=CC=CC=C4)C5=CC=CC=C5)C6=CC=CC=C6,,,,,,
4817,54818,"N-Cyclohexyl-5-methyl-9-oxo-2,4,6,8-tetraphenyl-3,7-diazabicyclo(3.3.1)nonane-3-carboxamide",CC12C(NC(C(C1=O)C(N(C2C3=CC=CC=C3)C(=O)NC4CCCCC4)C5=CC=CC=C5)C6=CC=CC=C6)C7=CC=CC=C7,,,,,,
4818,54819,CID 54819,CCN=C(N1C(C2C(NC(C(C1C3=CC=CC=C3)C2=O)C4=CC=CC=C4)C5=CC=CC=C5)C6=CC=CC=C6)S,,,,,,
4819,54820,CID 54820,C=CCN=C(N1C(C2C(NC(C(C1C3=CC=CC=C3)C2=O)C4=CC=CC=C4)C5=CC=CC=C5)C6=CC=CC=C6)S,,,,,,
4820,54821,CID 54821,C1=CC=C(C=C1)CN=C(N2C(C3C(NC(C(C2C4=CC=CC=C4)C3=O)C5=CC=CC=C5)C6=CC=CC=C6)C7=CC=CC=C7)S,,,,,,
4821,54822,CID 54822,CCN=C(N1C(C2C(NC(C(C1C3=CC=CC=C3)(C2=O)C)C4=CC=CC=C4)C5=CC=CC=C5)C6=CC=CC=C6)S,,,,,,
4822,54823,CID 54823,CC12C(NC(C(C1=O)C(N(C2C3=CC=CC=C3)C(=NCC=C)S)C4=CC=CC=C4)C5=CC=CC=C5)C6=CC=CC=C6,,,,,,
4823,54824,CID 54824,CC12C(NC(C(C1=O)C(N(C2C3=CC=CC=C3)C(=NCC4=CC=CC=C4)S)C5=CC=CC=C5)C6=CC=CC=C6)C7=CC=CC=C7,,,,,,
4824,54825,"3,7-Diazabicyclo(3.3.1)nonane-3-carboxamide, N-ethyl-9-oxo-2,4,6,8-tetrakis(p-methoxyphenyl)-",CCNC(=O)N1C(C2C(NC(C(C1C3=CC=C(C=C3)OC)C2=O)C4=CC=C(C=C4)OC)C5=CC=C(C=C5)OC)C6=CC=C(C=C6)OC,,,,,,
4825,54826,CID 54826,CCN=C(N1C(C2C(NC(C(C1C3=CC=C(C=C3)OC)C2=O)C4=CC=C(C=C4)OC)C5=CC=C(C=C5)OC)C6=CC=C(C=C6)OC)S,,,,,,
4826,54827,"N-Ethyl-9-oxo-2,4,6,8-tetrakis(o-chlorophenyl)-3,7-diazabicyclo(3.3.1)nonane-3-carboxamide",CCNC(=O)N1C(C2C(NC(C(C1C3=CC=CC=C3Cl)C2=O)C4=CC=CC=C4Cl)C5=CC=CC=C5Cl)C6=CC=CC=C6Cl,,,,,,
4827,54828,CID 54828,CCN=C(N1C(C2C(NC(C(C1C3=CC=CC=C3Cl)C2=O)C4=CC=CC=C4Cl)C5=CC=CC=C5Cl)C6=CC=CC=C6Cl)S,,,,,,
4828,54829,"N-Ethyl-9-oxo-2,4,6,8-tetrakis(p-chlorophenyl)-3,7-diazabicyclo(3.3.1)nonane-3-carboxamide",CCNC(=O)N1C(C2C(NC(C(C1C3=CC=C(C=C3)Cl)C2=O)C4=CC=C(C=C4)Cl)C5=CC=C(C=C5)Cl)C6=CC=C(C=C6)Cl,,,,,,
4829,54830,CID 54830,CCN=C(N1C(C2C(NC(C(C1C3=CC=C(C=C3)Cl)C2=O)C4=CC=C(C=C4)Cl)C5=CC=C(C=C5)Cl)C6=CC=C(C=C6)Cl)S,,,,,,
4830,54831,CID 54831,CCN(CC)C1=CC=C(C=C1)N=NC2=CC=CC=C2C(=O)[O-].[Na+],,,,,,
4831,54832,Ethyl red,CCN(CC)C1=CC=C(C=C1)N=NC2=CC=CC=C2C(=O)O,,,,,,
4832,54833,Amflutizole,C1=CC(=CC(=C1)C(F)(F)F)C2=NSC(=C2N)C(=O)O,,,,,,
4833,54834,Ludaconitine diacetate,CCN1CC2([C@H]3C(C4[C@@H]1C3([C@@H]5C[C@@]6([C@H](C[C@]4([C@H]5C6OC(=O)C7=CC=CC=C7)OC(=O)C)OC)O)C(CC2OC(=O)C)OC)OC)COC,,,,,,
4834,54835,Diacetylindaconitine,CCN1CC2([C@H]3C(C4[C@@H]1C3([C@@H]5C[C@@]6([C@H](C[C@]4([C@H]5C6OC(=O)C7=CC=CC=C7)OC(=O)C)OC)OC(=O)C)C(CC2OC(=O)C)OC)OC)COC,,,,,,
4835,54836,alpha-(4-Chlorophenyl)-3-methyl-2-benzofuranmethanol,CC1=C(OC2=CC=CC=C12)C(C3=CC=C(C=C3)Cl)O,,,,,,
4836,54837,alpha-(4-Chlorophenyl)-7-methoxy-alpha-methyl-2-benzofuranmethanol,CC(C1=CC=C(C=C1)Cl)(C2=CC3=C(O2)C(=CC=C3)OC)O,,,,,,
4837,54838,6-(2-(4-(4-Fluorophenyl)-1-piperazinyl)propionyl)-3-methylbenzoxazolinone,CC(C(=O)C1=CC2=C(C=C1)N(C(=O)O2)C)N3CCN(CC3)C4=CC=C(C=C4)F,,,,,,
4838,54839,3-(Dichloroamino)-3-methylbutanoic acid,CC(C)(CC(=O)O)N(Cl)Cl,,,,,,
4839,54840,Atomoxetine hydrochloride,CC1=CC=CC=C1O[C@H](CCNC)C2=CC=CC=C2.Cl,['Treatment of Attention Deficit Hyperactivity Disorder (ADHD)'],,"['Drugs that block the transport of adrenergic transmitters into axon terminals or into storage vesicles within terminals. The tricyclic antidepressants (ANTIDEPRESSIVE AGENTS, TRICYCLIC) and amphetamines are among the therapeutically important drugs that may act via inhibition of adrenergic transport. Many of these drugs also block transport of serotonin. (See all compounds classified as Adrenergic Uptake Inhibitors.)']",,,
4840,54841,Atomoxetine,CC1=CC=CC=C1O[C@H](CCNC)C2=CC=CC=C2,['Atomoxetine is indicated for the treatment of attention deficit hyperactivity disorder (ADHD) in children and adults.'],"[""Atomoxetine is a selective norepinephrine (NE) reuptake inhibitor used for the treatment of attention deficit hyperactivity disorder (ADHD). Atomoxetine has been shown to specifically increase norepinephrine and dopamine within the prefrontal cortex, which results in improved ADHD symptoms.  Due to atomoxetine's noradrenergic activity, it also has effects on the cardiovascular system such as increased blood pressure and tachycardia. Sudden deaths, stroke, and myocardial infarction have been reported in patients taking atomoxetine at usual doses for ADHD. Atomoxetine should be used with caution in patients whose underlying medical conditions could be worsened by increases in blood pressure or heart rate such as certain patients with hypertension, tachycardia, or cardiovascular or cerebrovascular disease. It should not be used in patients with severe cardiac or vascular disorders whose condition would be expected to deteriorate if they experienced clinically important increases in blood pressure or heart rate. Although the role of atomoxetine in these cases is unknown, consideration should be given to not treating patients with clinically significant cardiac abnormalities. Patients who develop symptoms such as exertional chest pain, unexplained syncope, or other symptoms suggestive of cardiac disease during atomoxetine treatment should undergo a prompt cardiac evaluation.  In general, particular care should be taken in treating ADHD in patients with comorbid bipolar disorder because of concern for possible induction of a mixed/manic episode in patients at risk for bipolar disorder. Treatment emergent psychotic or manic symptoms, e.g., hallucinations, delusional thinking, or mania in children and adolescents without a prior history of psychotic illness or mania can be caused by atomoxetine at usual doses. If such symptoms occur, consideration should be given to a possible causal role of atomoxetine, and discontinuation of treatment should be considered.  Atomoxetine capsules increased the risk of suicidal ideation in short-term studies in children and adolescents with Attention-Deficit/Hyperactivity Disorder (ADHD). All pediatric patients being treated with atomoxetine  should be monitored appropriately and observed closely for clinical worsening, suicidality, and unusual changes in behavior, especially during the initial few months of a course of drug therapy, or at times of dose changes, either increases or decreases.  Postmarketing reports indicate that atomoxetine can cause severe liver injury. Although no evidence of liver injury was detected in clinical trials of about 6000 patients, there have been rare cases of clinically significant liver injury that were considered probably or possibly related to atomoxetine use in postmarketing experience. Rare cases of liver failure have also been reported, including a case that resulted in a liver transplant. Atomoxetine should be discontinued in patients with jaundice or laboratory evidence of liver injury, and should not be restarted. Laboratory testing to determine liver enzyme levels should be done upon the first symptom or sign of liver dysfunction (e.g., pruritus, dark urine, jaundice, right upper quadrant tenderness, or unexplained “flu like” symptoms).""]","['Drugs that block the transport of adrenergic transmitters into axon terminals or into storage vesicles within terminals. The tricyclic antidepressants (ANTIDEPRESSIVE AGENTS, TRICYCLIC) and amphetamines are among the therapeutically important drugs that may act via inhibition of adrenergic transport. Many of these drugs also block transport of serotonin. (See all compounds classified as Adrenergic Uptake Inhibitors.)']","['The pharmacokinetic profile of atomoxetine is highly dependent on cytochrome P450 2D6 genetic polymorphisms of the individual. A large fraction of the population (up to 10% of Caucasians and 2% of people of African descent and 1% of Asians) are poor metabolizers (PMs) of CYP2D6 metabolized drugs. These individuals have reduced activity in this pathway resulting in 10-fold higher AUCs, 5-fold higher peak plasma concentrations, and slower elimination (plasma half-life of 21.6 hours) of atomoxetine compared with people with normal CYP2D6 activity.  Atomoxetine is rapidly absorbed after oral administration, with absolute bioavailability of about 63% in extensive metabolizers (EMs) and 94% in poor metabolizers (PMs). Mean maximal plasma concentrations (Cmax) are reached approximately 1 to 2 hours after dosing with a maximal concentration of 350 ng/ml with an AUC of 2 mcg.h/ml.', 'Atomoxetine is excreted primarily as 4-hydroxyatomoxetine-O-glucuronide, mainly in the urine (greater than 80% of the dose) and to a lesser extent in the feces (less than 17% of the dose). Only a small fraction (less than 3%) of the atomoxetine dose is excreted as unchanged atomoxetine, indicating extensive biotransformation.', 'The reported volume of distribution of oral atomoxetine was 1.6-2.6 L/kg. The steady-state volume of distribution of intravenous atomoxetine was approximately 0.85 L/kg.', 'The clearance rate of atomoxetine depends the CYP2D6 genetic polymorphisms of the individual and can range of 0.27-0.67 L.h/kg.', 'Steady-state volume of distribution (intravenous administration): 8.5 L/kg. Atomexetine distributes primarily into total body water; volume of distribution is similar across patient weight range after normalizing for body weight.', 'Atomoxetine is rapidly absorbed after oral administration, with absolute bioavailability of about 63% in extensive metabolizers and 94% in poor metabolizers. Maximal plasma concentrations (Cmax) are reached approximately 1 to 2 hours after dosing.', '/MILK/ Atomoxetine and/or its metabolites are distributed into milk in rats; it is not known whether the drug is distributed into milk in humans.', '... Atomoxetine has high aqueous solubility and biological membrane permeability that facilitates its rapid and complete absorption after oral administration. Absolute oral bioavailability ranges from 63 to 94%, which is governed by the extent of its first-pass metabolism. Three oxidative metabolic pathways are involved in the systemic clearance of atomoxetine: aromatic ring-hydroxylation, benzylic hydroxylation and N-demethylation. Aromatic ring-hydroxylation results in the formation of the primary oxidative metabolite of atomoxetine, 4-hydroxyatomoxetine, which is subsequently glucuronidated and excreted in urine. The formation of 4-hydroxyatomoxetine is primarily mediated by the polymorphically expressed enzyme cytochrome P450 (CYP) 2D6. This results in two distinct populations of individuals: those exhibiting active metabolic capabilities (CYP2D6 extensive metabolizers) and those exhibiting poor metabolic capabilities (CYP2D6 poor metabolizers) for atomoxetine. The oral bioavailability and clearance of atomoxetine are influenced by the activity of CYP2D6; nonetheless, plasma pharmacokinetic parameters are predictable in extensive and poor metabolizer patients. After single oral dose, atomoxetine reaches maximum plasma concentration within about 1-2 hours of administration. In extensive metabolizers, atomoxetine has a plasma half-life of 5.2 hours, while in poor metabolizers, atomoxetine has a plasma half-life of 21.6 hours. The systemic plasma clearance of atomoxetine is 0.35 and 0.03 L/h/kg in extensive and poor metabolizers, respectively. Correspondingly, the average steady-state plasma concentrations are approximately 10-fold higher in poor metabolizers compared with extensive metabolizers. Upon multiple dosing there is plasma accumulation of atomoxetine in poor metabolizers, but very little accumulation in extensive metabolizers. The volume of distribution is 0.85 L/kg, indicating that atomoxetine is distributed in total body water in both extensive and poor metabolizers. Atomoxetine is highly bound to plasma albumin (approximately 99% bound in plasma). Although steady-state concentrations of atomoxetine in poor metabolizers are higher than those in extensive metabolizers following administration of the same mg/kg/day dosage, the frequency and severity of adverse events are similar regardless of CYP2D6 phenotype.Atomoxetine administration does not inhibit or induce the clearance of other drugs metabolized by CYP enzymes. In extensive metabolizers, potent and selective CYP2D6 inhibitors reduce atomoxetine clearance; however, administration of CYP inhibitors to poor metabolizers has no effect on the steady-state plasma concentrations of atomoxetine.', 'For more Absorption, Distribution and Excretion (Complete) data for ATOMOXETINE (8 total), please visit the HSDB record page.']","['Atomoxetine undergoes biotransformation primarily through the cytochrome P450 2D6 (CYP2D6) enzymatic pathway. People with reduced activity in the CYP2D6 pathway (also known as poor metabolizers or PMs) have higher plasma concentrations of atomoxetine compared with people with normal activity (also known as extensive metabolizers, or EMs). For PMs, the AUC of atomoxetine at steady-state is approximately 10-fold higher and Cmax is about 5-fold greater than for EMs.   The major oxidative metabolite formed regardless of CYP2D6 status is 4-hydroxy-atomoxetine, which is rapidly glucuronidated. 4-Hydroxyatomoxetine is equipotent to atomoxetine as an inhibitor of the norepinephrine transporter, but circulates in plasma at much lower concentrations (1% of atomoxetine concentration in EMs and 0.1% of atomoxetine concentration in PMs).   In individuals that lack CYP2D6 activity, 4-hydroxyatomoxetine is still the primary metabolite, but is formed by several other cytochrome P450 enzymes and at a slower rate. Another minor metabolite, N-Desmethyl-atomoxetine is formed by CYP2C19 and other cytochrome P450 enzymes, but has much less pharmacological activity than atomoxetine and lower plasma concentrations (5% of atomoxetine concentration in EMs and 45% of atomoxetine concentration in PMs).', 'Atomoxetine is metabolized primarily through the CYP2D6 enzymatic pathway. People with reduced activity in this pathway (PMs) have higher plasma concentrations of atomoxetine compared with people with normal activity (EMs). For PMs, AUC of atomoxetine is approximately 10-fold and Css, max is about 5-fold greater than EMs. Laboratory tests are available to identify CYP2D6 PMs.', 'The major oxidative metabolite formed, regardless of CYP2D6 status, is 4-hydroxyatomoxetine, which is glucuronidated. 4-Hydroxyatomoxetine is equipotent to atomoxetine as an inhibitor of the norepinephrine transporter but circulates in plasma at much lower concentrations (1% of atomoxetine concentration in extensive metabolizers (EMs) and 0.1% of atomoxetine concentration in PMs). 4-Hydroxyatomoxetine is primarily formed by CYP2D6, but in PMs, 4-hydroxyatomoxetine is formed at a slower rate by several other cytochrome P450 enzymes. N-Desmethylatomoxetine is formed by CYP2C19 and other cytochrome P450 enzymes, but has substantially less pharmacological activity compared with atomoxetine and circulates in plasma at lower concentrations (5% of atomoxetine concentration in EMs and 45% of atomoxetine concentration in poor metabolizers (PMs)).', 'The role of the polymorphic cytochrome p450 2D6 (CYP2D6) in the pharmacokinetics of atomoxetine hydrochloride [(-)-N-methyl-gamma-(2-methylphenoxy)benzenepropanamine hydrochloride; LY139603] has been documented following both single and multiple doses of the drug. In this study, the influence of the CYP2D6 polymorphism on the overall disposition and metabolism of a 20-mg dose of (14)C-atomoxetine was evaluated in CYP2D6 extensive metabolizer (EM; n = 4) and poor metabolizer (PM; n = 3) subjects under steady-state conditions. Atomoxetine was well absorbed from the gastrointestinal tract and cleared primarily by metabolism with the preponderance of radioactivity being excreted into the urine. In EM subjects, the majority of the radioactive dose was excreted within 24 hr, whereas in PM subjects the majority of the dose was excreted by 72 hr. The biotransformation of atomoxetine was similar in all subjects undergoing aromatic ring hydroxylation, benzylic oxidation, and N-demethylation with no CYP2D6 phenotype-specific metabolites. The primary oxidative metabolite of atomoxetine was 4-hydroxyatomoxetine, which was subsequently conjugated forming 4-hydroxyatomoxetine-O-glucuronide. Due to the absence of CYP2D6 activity, the systemic exposure to radioactivity was prolonged in PM subjects (t(1/2) = 62 hr) compared with EM subjects (t(1/2) = 18 hr). In EM subjects, atomoxetine (t(1/2) = 5 hr) and 4-hydroxyatomoxetine-O-glucuronide (t(1/2) = 7 hr) were the principal circulating species, whereas atomoxetine (t(1/2) = 20 hr) and N-desmethylatomoxetine (t(1/2) = 33 hr) were the principal circulating species in PM subjects. Although differences were observed in the excretion and relative amounts of metabolites formed, the primary difference observed between EM and PM subjects was the rate at which atomoxetine was biotransformed to 4-hydroxyatomoxetine.', 'Atomoxetine is excreted primarily as 4-hydroxyatomoxetine-O-glucuronide, mainly in the urine (greater than 80% of the dose) and to a lesser extent in the feces (less than 17% of the dose). Only a small fraction of the Strattera dose is excreted as unchanged atomoxetine (less than 3% of the dose), indicating extensive biotransformation.', 'For more Metabolism/Metabolites (Complete) data for ATOMOXETINE (8 total), please visit the HSDB record page.']","['The reported half-life depends on the CYP2D6 genetic polymorphisms of the individual and can range from 3 to 5.6 hours.', 'The plasma elimination half life in normal (extensive) metabolizers is about 5 hours. In person who are poor metabolizers (7% of whites and 2% of blacks), the drug plasma levels are much higher and the plasma elimination half life is 24 hours.', 'Mean apparent plasma clearance of atomoxetine after oral administration in adult extensive metabolizers (EMs) is 0.35 L/hr/kg and the mean half-life is 5.2 hours. Following oral administration of atomoxetine to poor metabolizers (PMs), mean apparent plasma clearance is 0.03 L/hr/kg and mean half-life is 21.6 hours. For PMs, AUC of atomoxetine is approximately 10-fold and Css, max is about 5-fold greater than EMs. The elimination half-life of 4-hydroxyatomoxetine is similar to that of N-desmethylatomoxetine (6 to 8 hours) in EM subjects, while the half-life of N-desmethylatomoxetine is much longer in PM subjects (34 to 40 hours).', '... In extensive metabolizers, atomoxetine has a plasma half-life of 5.2 hours, while in poor metabolizers, atomoxetine has a plasma half-life of 21.6 hours. ...', '... Twenty-one cytochrome P450 2D6 extensive metabolizer patients participated in these single-dose and steady-state pharmacokinetic evaluations. Atomoxetine was rapidly absorbed, with peak plasma concentrations occurring 1 to 2 hours after dosing. Half-life averaged 3.12 and 3.28 hours after a single dose and at steady state, respectively. ...']"
4841,54842,"1-Propanaminium, N,N,N-trimethyl-3-oxo-3-(2-(trimethylammonio)ethoxy)-, diiodide",C[N+](C)(C)CCC(=O)OCC[N+](C)(C)C.[I-].[I-],,,,,,
4842,54843,"N-[3-Oxo-3-[2-(trimethylaminio)ethoxy]propyl]-N,N-dimethylmethanaminium",C[N+](C)(C)CCC(=O)OCC[N+](C)(C)C,,,,,,
4843,54844,"1,2,3,6,9-Pentachlorodibenzo-p-dioxin",C1=CC(=C2C(=C1Cl)OC3=CC(=C(C(=C3O2)Cl)Cl)Cl)Cl,,,,,,
4844,54845,"1,2,4,6,7-Pentachlorodibenzo-p-dioxin",C1=CC(=C(C2=C1OC3=C(O2)C(=CC(=C3Cl)Cl)Cl)Cl)Cl,,,,,,
4845,54846,"1,2,4,6,9-Pentachlorodibenzo-p-dioxin",C1=CC(=C2C(=C1Cl)OC3=C(O2)C(=C(C=C3Cl)Cl)Cl)Cl,,,,,,
4846,54847,"1,2,4,7,9-Pentachlorodibenzo-p-dioxin",C1=C(C=C(C2=C1OC3=C(O2)C(=C(C=C3Cl)Cl)Cl)Cl)Cl,,,,,,
4847,54848,"1,2,4,8,9-Pentachlorodibenzo-p-dioxin",C1=CC(=C(C2=C1OC3=C(O2)C(=C(C=C3Cl)Cl)Cl)Cl)Cl,,,,,,
4848,54849,7-Nitronaphthalen-2-ol,C1=CC(=CC2=C1C=CC(=C2)O)[N+](=O)[O-],,,,,,
4849,54850,"N,N-Dimethyl-11H-dibenz(b,f)-1,4-oxathiepin-11-ethanamine oxalate",C[NH+](C)CCC1C2=CC=CC=C2OC3=CC=CC=C3S1.C(=O)(C(=O)[O-])O,,,,,,
4850,54851,"2-(11H-dibenzo[b,f][1,4]oxathiepin-11-yl)-N,N-dimethylethanamine",CN(C)CCC1C2=CC=CC=C2OC3=CC=CC=C3S1,,,,,,
4851,54852,"11H-Dibenz(b,f)-1,4-oxathiepin-11-propanamine, N,N-dimethyl-, ethanedioate, hydrate (2:2:1)",C[NH+](C)CCCC1C2=CC=CC=C2OC3=CC=CC=C3S1.C(=O)(C(=O)[O-])O,,,,,,
4852,54853,"3-(6H-benzo[b][1,5]benzoxathiepin-6-yl)-N,N-dimethylpropan-1-amine",CN(C)CCCC1C2=CC=CC=C2OC3=CC=CC=C3S1,,,,,,
4853,54854,"2-Chloro-N,N-dimethyl-11H-dibenz(b,f)-1,4-oxathiepin-11-propanamine oxalate",C[NH+](C)CCCC1C2=C(C=CC(=C2)Cl)OC3=CC=CC=C3S1.C(=O)(C(=O)[O-])O,,,,,,
4854,54855,"3-(8-chloro-6H-benzo[b][1,5]benzoxathiepin-6-yl)-N,N-dimethylpropan-1-amine",CN(C)CCCC1C2=C(C=CC(=C2)Cl)OC3=CC=CC=C3S1,,,,,,
4855,54856,"N-Methyl-11H-dibenz(b,f)-1,4-oxathiepin-11-ethanamine ethanedioate",C[NH2+]CCC1C2=CC=CC=C2OC3=CC=CC=C3S1.C(=O)(C(=O)[O-])O,,,,,,
4856,54857,"2-(11H-dibenzo[b,f][1,4]oxathiepin-11-yl)-N-methylethanamine",CNCCC1C2=CC=CC=C2OC3=CC=CC=C3S1,,,,,,
4857,54858,"N-Methyl-11H-dibenz(b,f)-1,4-oxathiepin-11-propanamine oxalate",C[NH2+]CCCC1C2=CC=CC=C2OC3=CC=CC=C3S1.C(=O)(C(=O)[O-])O,,,,,,
4858,54859,"3-(11h-Dibenzo[b,f][1,4]oxathiepin-11-yl)-n-methylpropan-1-amine",CNCCCC1C2=CC=CC=C2OC3=CC=CC=C3S1,,,,,,
4859,54860,4'-Acetamidochalcone oxide,CC(=O)NC1=CC=C(C=C1)C(=O)[C@@H]2[C@H](O2)C3=CC=CC=C3,,,,,,
4860,54861,"6,11-Dihydrodibenzo(b,e)thiepin-11-methanamine hydrochloride",C1C2=CC=CC=C2C(C3=CC=CC=C3S1)C[NH3+].[Cl-],,,,,,
4861,54862,"6,11-Dihydrobenzo[c][1]benzothiepin-11-ylmethanamine",C1C2=CC=CC=C2C(C3=CC=CC=C3S1)CN,,,,,,
4862,54863,"6,11-Dihydro-4-methoxydibenzo(b,e)thiepin-11-methanamine hydrochloride",COC1=CC=CC2=C1SCC3=CC=CC=C3C2C[NH3+].[Cl-],,,,,,
4863,54864,"(4-Methoxy-6,11-dihydrobenzo[c][1]benzothiepin-11-yl)methanamine",COC1=CC=CC2=C1SCC3=CC=CC=C3C2CN,,,,,,
4864,54865,"11-(Methylaminomethyl)-6,11-dihydrodibenzo(b,e)thiepin hydrochloride",C[NH2+]CC1C2=CC=CC=C2CSC3=CC=CC=C13.[Cl-],,,,,,
4865,54866,"1-(6,11-dihydrobenzo[c][1]benzothiepin-11-yl)-N-methylmethanamine",CNCC1C2=CC=CC=C2CSC3=CC=CC=C13,,,,,,
4866,54867,"4-Methoxy-11-(methylaminomethyl)-6,11-dihydrodibenzo(b,e)thiepin hydrochloride",C[NH2+]CC1C2=C(C(=CC=C2)OC)SCC3=CC=CC=C13.[Cl-],,,,,,
4867,54868,"1-(4-methoxy-6,11-dihydrobenzo[c][1]benzothiepin-11-yl)-N-methylmethanamine",CNCC1C2=C(C(=CC=C2)OC)SCC3=CC=CC=C13,,,,,,
4868,54869,"11-(Dimethylaminomethyl)-6,11-dihydrodibenzo(b,e)thiepin hydrochloride",C[NH+](C)CC1C2=CC=CC=C2CSC3=CC=CC=C13.[Cl-],,,,,,
4869,54870,"1-(6,11-dihydrobenzo[c][1]benzothiepin-11-yl)-N,N-dimethylmethanamine",CN(C)CC1C2=CC=CC=C2CSC3=CC=CC=C13,,,,,,
4870,54871,"4-Methoxy-11-(dimethylaminomethyl)-6,11-dihydrodibenzo(b,e)thiepin hydrochloride",C[NH+](C)CC1C2=C(C(=CC=C2)OC)SCC3=CC=CC=C13.[Cl-],,,,,,
4871,54872,"1-(4-methoxy-6,11-dihydrobenzo[c][1]benzothiepin-11-yl)-N,N-dimethylmethanamine",CN(C)CC1C2=C(C(=CC=C2)OC)SCC3=CC=CC=C13,,,,,,
4872,54873,"1,3-DITHIOLANE, 2-(m-TOLYL)-",CC1=CC(=CC=C1)C2SCCS2,,,,,,
4873,54874,"1,3-DITHIOLANE, 2-(m-METHOXYPHENYL)-",COC1=CC=CC(=C1)C2SCCS2,,,,,,
4874,54875,"1,3-DITHIOLANE, 2-(m-BROMOPHENYL)-",C1CSC(S1)C2=CC(=CC=C2)Br,,,,,,
4875,54876,N-octadec-9-enylacetamide,CCCCCCCCC=CCCCCCCCCNC(=O)C,,,,,,
4876,54877,Isopropylantipyrine mixed with ethenzamide and caffeine monohydrate (3:5:1),CCOC1=CC=CC=C1C(=O)N.CC1=C(C(=O)N(N1C)C2=CC=CC=C2)C(C)C.CN1C=NC2=C1C(=O)N(C(=O)N2C)C,,,,,,
4877,54878,4-Aminobenzo(a)pyrene,C1=CC=C2C3=C4C(=CC2=C1)C=C(C5=CC=CC(=C54)C=C3)N,,,,,,
4878,54879,11-Aminobenzo(a)pyrene,C1=CC=C2C(=C1)C=C3C=CC4=C5C3=C2C(=CC5=CC=C4)N,,,,,,
4879,54880,12-Aminobenzo(a)pyrene,C1=CC=C2C(=C1)C=C3C=CC4=C5C3=C2C=C(C5=CC=C4)N,,,,,,
4880,54881,3-Methoxy-4'-methylbenzophenone,CC1=CC=C(C=C1)C(=O)C2=CC(=CC=C2)OC,,,,,,
4881,54882,"Chloroacetic acid hexahydro-2,6-dioxo-5-methyl-5-nitro-4-pyrimidinyl ester",CC1(C(NC(=O)NC1=O)OC(=O)CCl)[N+](=O)[O-],,,,,,
4882,54883,"Dichloroacetic acid hexahydro-2,6-dioxo-5-methyl-5-nitro-4-pyrimidinyl ester",CC1(C(NC(=O)NC1=O)OC(=O)C(Cl)Cl)[N+](=O)[O-],,,,,,
4883,54884,"(4-Amino-3,5-dichlorophenyl)glycolic acid",C1=C(C=C(C(=C1Cl)N)Cl)C(C(=O)O)O,,,,,,
4884,54885,CID 54885,CC1=NN(N=N1)CC2=C(N3[C@@H]([C@@H](C3=O)NC(=O)C(=NOC)C4=CSC(=N4)N)SC2)C(=O)OCOC(=O)C(C)(C)C,,,['Substances that inhibit the growth or reproduction of BACTERIA. (See all compounds classified as Anti-Bacterial Agents.)'],,,
4885,54886,Benfuracarb,CCOC(=O)CCN(C(C)C)SN(C)C(=O)OC1=CC=CC2=C1OC(C2)(C)C,,,,,,
4886,54887,"Carbamic acid, 5-amino-1,2-dihydro-3-(((4-methoxyphenyl)methylamino)methyl)pyrido(3,4-b)pyrazin-7-yl-, ethyl ester",CCOC(=O)NC1=NC(=C2C(=C1)NCC(=N2)CNCC3=CC=C(C=C3)OC)N,,,,,,
4887,54888,"Carbamic acid, 5-amino-1,2-dihydro-3-phenylpyrido(3,4-b)pyrazin-7-yl-, ethyl ester",CCOC(=O)NC1=NC(=C2C(=C1)NCC(=N2)C3=CC=CC=C3)N,,,,,,
4888,54889,Moexipril hydrochloride,CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](C)C(=O)N2CC3=CC(=C(C=C3C[C@H]2C(=O)O)OC)OC.Cl,,,"['Drugs used in the treatment of acute or chronic vascular HYPERTENSION regardless of pharmacological mechanism. Among the antihypertensive agents are DIURETICS; (especially DIURETICS, THIAZIDE); ADRENERGIC BETA-ANTAGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; GANGLIONIC BLOCKERS; and VASODILATOR AGENTS. (See all compounds classified as Antihypertensive Agents.)', 'A class of drugs whose main indications are the treatment of hypertension and heart failure. They exert their hemodynamic effect mainly by inhibiting the renin-angiotensin system. They also modulate sympathetic nervous system activity and increase prostaglandin synthesis. They cause mainly vasodilation and mild natriuresis without affecting heart rate and contractility. (See all compounds classified as Angiotensin-Converting Enzyme Inhibitors.)']",,,
4889,54890,"2-[(2S)-2-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]propanoyl]-6,7-dimethoxy-3,4-dihydro-1H-isoquinoline-3-carboxylic acid",CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](C)C(=O)N2CC3=CC(=C(C=C3CC2C(=O)O)OC)OC,,,,,,
4890,54891,Quinapril hydrochloride,CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](C)C(=O)N2CC3=CC=CC=C3C[C@H]2C(=O)O.Cl,,,"['A class of drugs whose main indications are the treatment of hypertension and heart failure. They exert their hemodynamic effect mainly by inhibiting the renin-angiotensin system. They also modulate sympathetic nervous system activity and increase prostaglandin synthesis. They cause mainly vasodilation and mild natriuresis without affecting heart rate and contractility. (See all compounds classified as Angiotensin-Converting Enzyme Inhibitors.)', 'Drugs used in the treatment of acute or chronic vascular HYPERTENSION regardless of pharmacological mechanism. Among the antihypertensive agents are DIURETICS; (especially DIURETICS, THIAZIDE); ADRENERGIC BETA-ANTAGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; GANGLIONIC BLOCKERS; and VASODILATOR AGENTS. (See all compounds classified as Antihypertensive Agents.)', 'Agents that affect the rate or intensity of cardiac contraction, blood vessel diameter, or blood volume. (See all compounds classified as Cardiovascular Agents.)']","['Absorption (bioavailability) of quinapril is 60%; time to peak serum concn is 2 hr; half-life (elimination) is 2 hr; protein binding is 97%; metabolism is in the liver. /from table/ /Salt not specified/', 'Quinapril is rapidly absorbed (peak concns are achieved in 1 hr, but the peak may be delayed after food), & its rate but not extent of oral absorption (60%) may be reduced by food. Quinapril is metabolized to quinaprilat & to other minor metabolites, & quinaprilat is excreted in the urine (61%) & the feces (37%). Peak concns of quinaprilat in plasma are achieved in about 2 hr. Conversion of quinapril to quinaprilat is reduced in patients with diminished liver function. The initial half-life of quinaprilat is about 2 hr; a prolonged terminal half-life of about 25 hr may be due to high-affinity binding of the drug to tissue ACE. /Salt not specified/']","['Cleavage of the ester moiety by hepatic esterases transforms quinapril hydrochloride, a prodrug, into quinaprilat, an ACE inhibitor that in vitro is about as potent as benazeprilat. ... Quinapril is metabolized to quinaprilat & to other minor metabolites ... .']",['The initial half-life of /the metabolite/ quinaprilat is about 2 hr; a prolonged terminal half-life of about 25 hr may be due to high-affinity binding of the drug to tissue ACE. /Salt not specified/']
4891,54892,Quinapril,CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](C)C(=O)N2CC3=CC=CC=C3C[C@H]2C(=O)O,['Quinapril is indicated for the treatment of hypertension and as an adjunct therapy in the treatment of heart failure. Quinapril in combination with hydrochlorothiazide is indicated for the treatment of hypertension.'],['Quinapril is a prodrug of an angiotensin converting enzyme (ACE) inhibitor used in the treatment of hypertension or adjunct in the treatment of heart failure. Quinapril has a wide therapeutic window and a long duration of action as it is given in doses of 10-80mg once daily.'],"['A class of drugs whose main indications are the treatment of hypertension and heart failure. They exert their hemodynamic effect mainly by inhibiting the renin-angiotensin system. They also modulate sympathetic nervous system activity and increase prostaglandin synthesis. They cause mainly vasodilation and mild natriuresis without affecting heart rate and contractility. (See all compounds classified as Angiotensin-Converting Enzyme Inhibitors.)', 'Agents that affect the rate or intensity of cardiac contraction, blood vessel diameter, or blood volume. (See all compounds classified as Cardiovascular Agents.)', 'Drugs used in the treatment of acute or chronic vascular HYPERTENSION regardless of pharmacological mechanism. Among the antihypertensive agents are DIURETICS; (especially DIURETICS, THIAZIDE); ADRENERGIC BETA-ANTAGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; GANGLIONIC BLOCKERS; and VASODILATOR AGENTS. (See all compounds classified as Antihypertensive Agents.)']","['Quinapril if 50-80% bioavailable. Quinapril has a T<sub>max</sub> of <1 hour, while quinaprilat has a T<sub>max</sub> of 2.5h. The C<sub>max</sub> of quinaprilat is highly variable but reaches 1526ng/mL with an AUC of 2443ng\\*h/mL in healthy males given a 10mg dose. A high fat meal reduces the absorption of quinapril by 25-30%.', 'Quinaprilat is up to 96% eliminated in the urine. The eliminated metabolites PD109488 and PD113413 account for approximately 6% of a dose of quinapril each. A small fraction of the dose recovered in the urine is accounted for by unmetabolized quinapril.', 'The mean volume of distribution of quinaprilat is 13.9L.', 'The clearance of quinaprilat is 68mL/min.']","['Quinapril is de-esterified to the active quinaprilat or dehydrated to form the inactive PD109488. PD109488 can undergo O-deethylation to form another inactive metabolite, PD113413.']",['The active metabolite quinaprilat has an elimination half life of 2.3 hours.']
4892,54893,"2-Benzoxazolinone, 3-methyl-6-((4-(alpha,alpha,alpha-trifluoro-m-tolyl)-4-piperazinyl)acetyl)-",CN1C2=C(C=C(C=C2)C(=O)CN3CCN(CC3)C4=CC=CC(=C4)C(F)(F)F)OC1=O,,,,,,
4893,54894,"Benzamide, 2-methoxy-5-(methylsulfonyl)-N-(2-(4-(alpha,alpha,alpha-trifluoro-m-tolyl)-1-piperazinyl)ethyl)-",COC1=C(C=C(C=C1)S(=O)(=O)C)C(=O)NCCN2CCN(CC2)C3=CC=CC(=C3)C(F)(F)F,,,,,,
4894,54895,"Benzamide, 2-methoxy-5-sulfamoyl-N-(2-(4-(alpha,alpha,alpha-trifluoro-m-tolyl)-1-piperazinyl)ethyl)-",COC1=C(C=C(C=C1)S(=O)(=O)N)C(=O)NCCN2CCN(CC2)C3=CC=CC(=C3)C(F)(F)F,,,,,,
4895,54896,6-(2-(4-(2-Methoxyphenyl)-1-piperazinyl)propionyl)-3-methylbenzoxazolinone,CC(C(=O)C1=CC2=C(C=C1)N(C(=O)O2)C)N3CCN(CC3)C4=CC=CC=C4OC,,,,,,
4896,54897,Alpidem,CCCN(CCC)C(=O)CC1=C(N=C2N1C=C(C=C2)Cl)C3=CC=C(C=C3)Cl,,,"['Agents that alleviate ANXIETY, tension, and ANXIETY DISORDERS, promote sedation, and have a calming effect without affecting clarity of consciousness or neurologic conditions. ADRENERGIC BETA-ANTAGONISTS are commonly used in the symptomatic treatment of anxiety but are not included here. (See all compounds classified as Anti-Anxiety Agents.)']",,,
4897,54898,"Butyl(1,2,3,4-tetrahydroacridin-4-yl)azanium;chloride",CCCC[NH2+]C1CCCC2=CC3=CC=CC=C3N=C12.[Cl-],,,,,,
4898,54899,"N-butyl-1,2,3,4-tetrahydroacridin-4-amine",CCCCNC1CCCC2=CC3=CC=CC=C3N=C12,,,,,,
4899,54900,Raloxifene hydrochloride,C1CCN(CC1)CCOC2=CC=C(C=C2)C(=O)C3=C(SC4=C3C=CC(=C4)O)C5=CC=C(C=C5)O.Cl,"['Optruma is indicated for the treatment and prevention of osteoporosis in post-menopausal women. A significant reduction in the incidence of vertebral, but not hip fractures has been demonstrated. When determining the choice of Optruma or other therapies, including oestrogens, for an individual postmenopausal woman, consideration should be given to menopausal symptoms, effects on uterine and breast tissues, and cardiovascular risks and benefits (see section 5. 1).']",,"['A structurally diverse group of compounds distinguished from ESTROGENS by their ability to bind and activate ESTROGEN RECEPTORS but act as either an agonist or antagonist depending on the tissue type and hormonal milieu. They are classified as either first generation because they demonstrate estrogen agonist properties in the ENDOMETRIUM or second generation based on their patterns of tissue specificity. (Horm Res 1997;48:155-63) (See all compounds classified as Selective Estrogen Receptor Modulators.)', 'Agents that inhibit BONE RESORPTION and/or favor BONE MINERALIZATION and BONE REGENERATION. They are used to heal BONE FRACTURES and to treat METABOLIC BONE DISEASES such as OSTEOPOROSIS. (See all compounds classified as Bone Density Conservation Agents.)', 'Compounds which inhibit or antagonize the action or biosynthesis of estrogenic compounds. (See all compounds classified as Estrogen Antagonists.)']",,,
4900,54901,"Cyclopropanecarboxylic acid, 3-[(1Z)-2-chloro-3,3,3-trifluoro-1-propenyl]-2,2-dimethyl-, (2-methyl[1,1'-biphenyl]-3-yl)methyl ester, (1R,3R)-rel-",CC1=C(C=CC=C1C2=CC=CC=C2)COC(=O)C3C(C3(C)C)C=C(C(F)(F)F)Cl,,,,"['Male and female rats were treated with (14)C-bifenthrin labeled in the acid or alcohol moiety at single oral doses of 4 and 35 mg/kg. (14)C was rapidly excreted into feces and urine, and the excretion rates of the (14)C to feces and urine were 66-83% and 13-25%, respectively. Highest residues were found in the fat, with values of slightly more than 1 ppm after low-dose administration and 8 and 16 ppm in males and females, respectively, after application of the high dose. Residue levels in other organs were in most cases <0.2 ppm after low-dose administration and <1 ppm after high-dose administration.', 'The tissue residues /of rats/ were examined after oral administration of (14)C-bifenthrin at 0.5 mg/kg/day for 70 days. The peak (14)C concentrations on an average were 9.6 ppm in fat, 1.7 ppm in skin, 0.4 ppm in liver, 0.3 ppm in kidney, 1.7 ppm in ovaries, 3.2 ppm in sciatic nerve, 0.06 ppm in whole blood, and 0.06 ppm in plasma. Analyses were extended for an additional 85 days following cessation of dosing (depuration phase). Half-lives of 51 days (fat), 50 days (skin), 19 days (liver), 28 days (kidney), and 40 days (ovaries and sciatic nerve) were estimated from (14)C-depuration. Analysis of the fat revealed that the parent chemical accounted for a majority (65-85%) of the (14)C-residues in fat.', 'Pyrethrins are absorbed through intact skin when applied topically. /Pyrethrins/', '... The pharmacokinetics of bifenthrin in the rat after oral, inhalation and intravenous administration is described. Pyrethroid acute toxicity via oral and inhalation routes is also presented. Groups of male rats were dosed by oral gavage at 3.1 mg/kg in 1 mL/kg of corn oil (the critical, acute, oral benchmark dose lower limit, BMDL) and at an equivalent dose by inhalation (0.018 mg/L) for 4 hr. At 2, 4, 6, 8 and 12 hr after dosing initiation, blood plasma and brain bifenthrin concentrations were measured. The maximum concentrations of bifenthrin in plasma were 361 ng/mL or 0.853 uM (oral) and 232 ng/mL or 0.548 uM (inhalation), and in brain they were 83 and 73 ng/g. The area under the concentration versus time curve (AUC) values were 1969 h ng/mL (plasma) and 763 h ng/mL (brain) following oral gavage dosing, and 1584 h ng/mL (plasma) and 619 h ng/mL (brain) after inhalation. Intravenous dosing resulted in apparent terminal half-life (t1/2 ) values of 13.4 h (plasma) and 11.1 h (brain) and in AUC0-infinity values of 454 and 1566 h ng/mL for plasma and brain. Clearance from plasma was 37 mL/min/kg. Peak plasma and brain concentrations were generally a little higher after oral dosing (by ca 14%). Inhalation administration of bifenthrin did not cause increases in exposure in plasma or brain by avoiding first-pass effects in the liver. The elimination t1/2 was comparable with other pyrethroids and indicated little bioaccumulation potential. ...', '... This study evaluated the oral disposition and bioavailability of bifenthrin in the adult male Long-Evans rat. In the disposition study, rats were administered bifenthrin (0.3 or 3 mg/kg) by oral gavage and serially sacrificed (0.25 hr to 21 days). Blood, liver, brain and adipose tissue were removed. In the bioavailability study, blood was collected serially from jugular vein cannulated rats (0.25 to 24 hr) following oral (0.3 or 3 mg/kg) or intravenous (0.3 mg/kg) administration of bifenthrin. Tissues were extracted and analyzed for bifenthrin by high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS). Bifenthrin concentration in blood and liver peaked 1-2-hr post-oral administration and were approximately 90 ng/mL (or g) and 1000 ng/mL (or g) for both tissues at 0.3 and 3 mg/kg, respectively. Bifenthrin was rapidly cleared from both blood and liver. Brain concentrations peaked at 4-6 hr and were lower than in blood at both doses (12 and 143 ng/g). Bifenthrin in adipose tissue peaked at the collected time points of 8 (157 ng/g) and 24 (1145 ng/g) hr for the 0.3 and 3 mg/kg doses, respectively and was retained 21 days post-oral administration. Following intravenous administration, the blood bifenthrin concentration decreased bi-exponentially, with a distribution half-life of 0.2 hr and an elimination half-life of 8 hr. Bifenthrin bioavailability was approximately 30%. These disposition and kinetic bifenthrin data may decrease uncertainties in the risk assessment for this pyrethroid insecticide.']","[""Male and female rats were treated with (14)C-bifenthrin labeled in the acid or alcohol moiety at single oral doses of 4 and 35 mg/kg. (14)C was rapidly excreted into feces and urine, and the excretion rates of the (14)C to feces and urine were 66-83% and 13-25%, respectively. ... The major fecal metabolites possessed intact ester linkage hydroxylated in the acid or alcohol moiety such as hydroxymethyl-bifenthrin, 4'-OH-bifenthrin, and 3'- or 4'-OH-hydroxymethyl bifenthrin. Ester-cleaved products derived from mono- and dihydroxylated parent compounds were also detected. On the other hand, the majority of urinary metabolites were ester-cleaved products such as 4'-OH-BPacid (4'-hydroxy-2-methyl-3-phenylbenzoic acid), BPacid (2-methyl-3-phenylbenzoic acid), 4'-OH-BPalcohol (4'-hydroxy-2-methyl-3-phenylbenzyl alcohol), dimethoxy-BPacid, 4'-methoxy BPacid, dimethoxy BPalcohol, BPalcohol, TFPacid [3-(2-chloro-3,3,3-trifluoro-1-propenyl-2,2-dimethyl-cyclopropanecarboxylic acid], cis- and trans-hydroxymethyl TFPacid. The major metabolic pathways are considered to be hydrolysis of ester linkage, oxidation at the methyl group of the acid moiety and at the 3'- and 4'-positions of the phenyl group, and O-methylation. The conjugation reactions are considered to take place; however, detailed information is not available."", 'Fastest breakdown is seen with primary alcohol esters of trans-substituted acids since they undergo rapid hydrolytic and oxidative attack. For all secondary alcohol esters and for primary alcohol cis-substituted cyclopropanecarboxylates, oxidative attack is predominant. /Pyrethroids/', 'Pyrethrins are reportedly inactivated in the GI tract following ingestion. In animals, pyrethrins are rapidly metabolized to water soluble, inactive compounds. /Pyrethrins/', ""Bifenthrin, a pyrethroid pesticide, is estrogenic in vivo in fishes. However, bifenthrin is documented to be anti-estrogenic in vitro, in the ER-CALUX (estrogen receptor) cell line. We investigated whether metabolite formation is the reason for this incongruity. We exposed Menidia beryllina (inland silversides) to 10 ng/L bifenthrin, 10 ng/L 4-hydroxy bifenthrin, and 10 ng/L bifenthrin with 25 ug/L piperonyl butoxide (PBO) - a P450 inhibitor. Metabolite-exposed juveniles had significantly higher estrogen-mediated protein levels (choriogenin) than bifenthrin/PBO-exposed, while bifenthrinalone was intermediate (not significantly different from either). This suggests that metabolites are the main contributors to bifenthrin's in vivo estrogenicity."", 'Synthetic pyrethroids are generally metabolized in mammals through ester hydrolysis, oxidation, and conjugation, and there is no tendency to accumulate in tissues. In the environment, synthetic pyrethroids are fairly rapidly degraded in soil and in plants. Ester hydrolysis and oxidation at various sites on the molecule are the major degradation processes. /Pyrethroids/']","['The tissue residues /of rats/ were examined after oral administration of (14)C-bifenthrin at 0.5 mg/kg/day for 70 days. ... Analyses were extended for an additional 85 days following cessation of dosing (depuration phase). Half-lives of 51 days (fat), 50 days (skin), 19 days (liver), 28 days (kidney), and 40 days (ovaries and sciatic nerve) were estimated from (14)C-depuration.', '... Intravenous dosing resulted in apparent terminal half-life (t1/2 ) values of 13.4 hr (plasma) and 11.1 hr (brain) ... .', '... Following intravenous administration, the blood bifenthrin concentration decreased bi-exponentially, with a distribution half-life of 0.2 hr and an elimination half-life of 8 hr. ...']"
4901,54902,2-Chloro-4-hydroxy-3-methoxybenzaldehyde,COC1=C(C=CC(=C1Cl)C=O)O,,,,,,
4902,54903,"Acridinium, 9-(4-(dimethylamino)phenyl)-10-phenyl-, thiocyanate",CN(C)C1=CC=C(C=C1)C2=C3C=CC=CC3=[N+](C4=CC=CC=C42)C5=CC=CC=C5.C(#N)[S-],,,,,,
4903,54904,"N,N-dimethyl-4-(10-phenylacridin-10-ium-9-yl)aniline",CN(C)C1=CC=C(C=C1)C2=C3C=CC=CC3=[N+](C4=CC=CC=C42)C5=CC=CC=C5,,,,,,
4904,54905,"6-Benzothiazolamine, 2-((2-methylpropyl)thio)-N-((5-phenyl-1H-tetrazol-1-yl)methyl)-",CC(C)CSC1=NC2=C(S1)C=C(C=C2)NCN3C(=NN=N3)C4=CC=CC=C4,,,,,,
4905,54906,"6-Benzothiazolamine, N-((5-phenyl-1H-tetrazol-1-YL)methyl)-2-(2-propenylthio)-",C=CCSC1=NC2=C(S1)C=C(C=C2)NCN3C(=NN=N3)C4=CC=CC=C4,,,,,,
4906,54907,"6-Benzothiazolamine, 2-(ethylthio)-N-((5-(4-nitrophenyl)-1H-tetrazol-1-yl)methyl)-",CCSC1=NC2=C(S1)C=C(C=C2)NCN3C(=NN=N3)C4=CC=C(C=C4)[N+](=O)[O-],,,,,,
4907,54908,"6-Benzothiazolamine, N-((5-(3,4-dichlorophenyl)-1H-tetrazol-1-yl)methyl)-2-(ethylthio)-",CCSC1=NC2=C(S1)C=C(C=C2)NCN3C(=NN=N3)C4=CC(=C(C=C4)Cl)Cl,,,,,,
4908,54909,Cicletanine hydrochloride,CC1=NC=C2C(OCC2=C1O)C3=CC=C(C=C3)Cl.Cl,,,"['Agents that promote the excretion of urine through their effects on kidney function. (See all compounds classified as Diuretics.)', 'Drugs used in the treatment of acute or chronic vascular HYPERTENSION regardless of pharmacological mechanism. Among the antihypertensive agents are DIURETICS; (especially DIURETICS, THIAZIDE); ADRENERGIC BETA-ANTAGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; GANGLIONIC BLOCKERS; and VASODILATOR AGENTS. (See all compounds classified as Antihypertensive Agents.)', 'Agents used for the treatment or prevention of cardiac arrhythmias. They may affect the polarization-repolarization phase of the action potential, its excitability or refractoriness, or impulse conduction or membrane responsiveness within cardiac fibers. Anti-arrhythmia agents are often classed into four main groups according to their mechanism of action: sodium channel blockade, beta-adrenergic blockade, repolarization prolongation, or calcium channel blockade. (See all compounds classified as Anti-Arrhythmia Agents.)']",,,
4909,54910,Cicletanine,CC1=NC=C2C(OCC2=C1O)C3=CC=C(C=C3)Cl,,,"['Agents used for the treatment or prevention of cardiac arrhythmias. They may affect the polarization-repolarization phase of the action potential, its excitability or refractoriness, or impulse conduction or membrane responsiveness within cardiac fibers. Anti-arrhythmia agents are often classed into four main groups according to their mechanism of action: sodium channel blockade, beta-adrenergic blockade, repolarization prolongation, or calcium channel blockade. (See all compounds classified as Anti-Arrhythmia Agents.)', 'Drugs used in the treatment of acute or chronic vascular HYPERTENSION regardless of pharmacological mechanism. Among the antihypertensive agents are DIURETICS; (especially DIURETICS, THIAZIDE); ADRENERGIC BETA-ANTAGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; GANGLIONIC BLOCKERS; and VASODILATOR AGENTS. (See all compounds classified as Antihypertensive Agents.)', 'Agents that promote the excretion of urine through their effects on kidney function. (See all compounds classified as Diuretics.)']",,,
4910,54911,Nefazodone hydrochloride,CCC1=NN(C(=O)N1CCOC2=CC=CC=C2)CCCN3CCN(CC3)C4=CC(=CC=C4)Cl.Cl,,,"['Drugs that bind to but do not activate SEROTONIN 5-HT2 RECEPTORS, thereby blocking the actions of SEROTONIN or SEROTONIN 5-HT2 RECEPTOR AGONISTS. Included under this heading are antagonists for one or more specific 5-HT2 receptor subtypes. (See all compounds classified as Serotonin 5-HT2 Receptor Antagonists.)', 'Drugs that selectively block or suppress the plasma membrane transport of SEROTONIN and NORADRENALINE into axon terminals and are used as ANTIDEPRESSIVE AGENTS. (See all compounds classified as Serotonin and Noradrenaline Reuptake Inhibitors.)', 'A structurally and mechanistically diverse group of drugs that are not tricyclics or monoamine oxidase inhibitors. The most clinically important appear to act selectively on serotonergic systems, especially by inhibiting serotonin reuptake. (See all compounds classified as Antidepressive Agents, Second-Generation.)']",,,
4911,54912,"3-Chloro-12,13-dimethoxy-5,9,10,14b-tetrahydroisoquino(2,1-d)(1,4)benzodiazepin-6(7H)-one",COC1=C(C=C2C3C4=C(C=C(C=C4)Cl)NC(=O)CN3CCC2=C1)OC,,,,,,
4912,54913,"6-(4-Bromophenyl)-3-chloro-12,13-dimethoxy-7,9,10,14b-tetrahydroisoquinolino[2,1-d][1,4]benzodiazepine",COC1=C(C=C2C3C4=C(C=C(C=C4)Cl)N=C(CN3CCC2=C1)C5=CC=C(C=C5)Br)OC,,,,,,
4913,54914,"3-Chloro-12,13-dimethoxy-6-(p-tolyl)-7,9,10,14b-tetrahydroisoquino(2,1-d)(1,4)benzodiazepine",CC1=CC=C(C=C1)C2=NC3=C(C=CC(=C3)Cl)C4C5=CC(=C(C=C5CCN4C2)OC)OC,,,,,,
4914,54915,"6-(4-Biphenylyl)-2,3,4,12,13-pentamethoxy-9,10-dihydro-7H-isoquino(2,1-d)(1,4)benzodiazepine",COC1=C(C=C2C3C4=CC(=C(C(=C4N=C(CN3CCC2=C1)C5=CC=C(C=C5)C6=CC=CC=C6)OC)OC)OC)OC,,,,,,
4915,54916,"6-(4-Bromophenyl)-2,3,4,12,13-pentamethoxy-7,9,10,14b-tetrahydroisoquinolino[2,1-d][1,4]benzodiazepine",COC1=C(C=C2C3C4=CC(=C(C(=C4N=C(CN3CCC2=C1)C5=CC=C(C=C5)Br)OC)OC)OC)OC,,,,,,
4916,54917,"7H-Isoquino(2,1-d)(1,4)benzodiazepin-8-ium, 9,10-dihydro-6-(4-biphenylyl)-3-chloro-12,13-dimethoxy-, bromide",COC1=C(C=C2C(=C1)CC[N+]3=C2C4=C(C=C(C=C4)Cl)N=C(C3)C5=CC=C(C=C5)C6=CC=CC=C6)OC.[Br-],,,,,,
4917,54918,"3-chloro-12,13-dimethoxy-6-(4-phenylphenyl)-9,10-dihydro-7H-isoquinolino[2,1-d][1,4]benzodiazepin-8-ium",COC1=C(C=C2C(=C1)CC[N+]3=C2C4=C(C=C(C=C4)Cl)N=C(C3)C5=CC=C(C=C5)C6=CC=CC=C6)OC,,,,,,
4918,54919,"7H-Isoquino(2,1-d)(1,4)benzodiazepin-8-ium, 9,10-dihydro-3-chloro-12,13-dimethoxy-6-(p-methoxyphenyl)-, bromide",COC1=CC=C(C=C1)C2=NC3=C(C=CC(=C3)Cl)C4=[N+](C2)CCC5=CC(=C(C=C54)OC)OC.[Br-],,,,,,
4919,54920,"3-chloro-12,13-dimethoxy-6-(4-methoxyphenyl)-9,10-dihydro-7H-isoquinolino[2,1-d][1,4]benzodiazepin-8-ium",COC1=CC=C(C=C1)C2=NC3=C(C=CC(=C3)Cl)C4=[N+](C2)CCC5=CC(=C(C=C54)OC)OC,,,,,,
4920,54921,"7H-Isoquino(2,1-d)(1,4)benzodiazepin-8-ium, 9,10-dihydro-3-chloro-12,13-dimethoxy-6-(p-tolyl)-, bromide",CC1=CC=C(C=C1)C2=NC3=C(C=CC(=C3)Cl)C4=[N+](C2)CCC5=CC(=C(C=C54)OC)OC.[Br-],,,,,,
4921,54922,"3-chloro-12,13-dimethoxy-6-(4-methylphenyl)-9,10-dihydro-7H-isoquinolino[2,1-d][1,4]benzodiazepin-8-ium",CC1=CC=C(C=C1)C2=NC3=C(C=CC(=C3)Cl)C4=[N+](C2)CCC5=CC(=C(C=C54)OC)OC,,,,,,
4922,54923,"7H-Isoquino(2,1-d)(1,4)benzodiazepin-8-ium, 9,10-dihydro-6-(p-bromophenyl)-3-chloro-12,13-dimethoxy-, bromide",COC1=C(C=C2C(=C1)CC[N+]3=C2C4=C(C=C(C=C4)Cl)N=C(C3)C5=CC=C(C=C5)Br)OC.[Br-],,,,,,
4923,54924,"6-(4-bromophenyl)-3-chloro-12,13-dimethoxy-9,10-dihydro-7H-isoquinolino[2,1-d][1,4]benzodiazepin-8-ium",COC1=C(C=C2C(=C1)CC[N+]3=C2C4=C(C=C(C=C4)Cl)N=C(C3)C5=CC=C(C=C5)Br)OC,,,,,,
4924,54925,"2,4-Dihydroxy-5-[3-(2-hydroxyphenyl)prop-2-enoyl]benzoic acid",C1=CC=C(C(=C1)C=CC(=O)C2=CC(=C(C=C2O)O)C(=O)O)O,,,,,,
4925,54926,"5-[3-(3-Carboxy-4-hydroxyphenyl)prop-2-enoyl]-2,4-dihydroxybenzoic acid",C1=CC(=C(C=C1C=CC(=O)C2=CC(=C(C=C2O)O)C(=O)O)C(=O)O)O,,,,,,
4926,54927,Diethyldithiocarbamic acid 1-(ethylnitrosamino)ethyl ester,CCN(CC)C(=S)SC(C)N(CC)N=O,,,,,,
4927,54928,Diethyldithiocarbamic acid 1-nitroso-2-pyrrolidinyl ester,CCN(CC)C(=S)SC1CCCN1N=O,,,,,,
4928,54929,5-Benzylacyclouridine,C1=CC=C(C=C1)CC2=CN(C(=O)NC2=O)COCCO,,,['Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. (See all compounds classified as Enzyme Inhibitors.)'],,,
4929,54930,"Piperidine, 1-(3-(1,3-benzodioxol-5-yl)-1-oxo-2-propenyl)-",C1CCN(CC1)C(=O)C=CC2=CC3=C(C=C2)OCO3,,,,,,
4930,54931,"Hexacyclo[9.2.1.02,10.03,8.04,6.05,9]tetradecane;methylcyclohexane;tricyclo[5.2.1.02,6]decane",CC1CCCCC1.C1CC2C3CCC(C3)C2C1.C1CC2CC1C3C2C4C5C3C6C4C6C5,,,,,,
4931,54932,(+-)-N-(4-(Dimethylamino)-1-methyl-2-butynyl)-N-methylacetamide,CC(C#CCN(C)C)N(C)C(=O)C,,,,,,
4932,54933,"ANILINE, N,N-BIS(2-CHLOROETHYL)-p-HEXYLOXY-",CCCCCCOC1=CC=C(C=C1)N(CCCl)CCCl,,,,,,
4933,54934,"trans-2,3-Dihydroxy-2,3-dihydrofluoranthene",C1=CC=C2C(=C1)C3=C4C2=C[C@H]([C@@H](C4=CC=C3)O)O,,,,,,
4934,54935,"1,4,6,8-Tetrachlorodibenzofuran",C1=CC(=C2C(=C1Cl)C3=C(O2)C(=CC(=C3)Cl)Cl)Cl,,,,,,
4935,54936,"1,6,8-Trichlorodibenzofuran",C1=CC2=C(C(=C1)Cl)C3=C(O2)C(=CC(=C3)Cl)Cl,,,,,,
4936,54937,"1,4,6-Trichlorodibenzofuran",C1=CC2=C(C(=C1)Cl)OC3=C(C=CC(=C23)Cl)Cl,,,,,,
4937,54938,"(2R)-1-[(2R,4R)-5-ethoxy-2,4-dimethyl-5-oxopentanoyl]-2,3-dihydroindole-2-carboxylic acid",CCOC(=O)[C@H](C)C[C@@H](C)C(=O)N1[C@H](CC2=CC=CC=C21)C(=O)O,,,,,,
4938,54939,"2-((3-Bromo-2,6-dimethoxybenzamido)methyl)-1-ethylpyrrolidine hydrochloride",CC[NH+]1CCCC1CNC(=O)C2=C(C=CC(=C2OC)Br)OC.[Cl-],,,,,,
4939,54940,(S)-Remoxipride,CCN1CCCC1CNC(=O)C2=C(C=CC(=C2OC)Br)OC,,,,,,
4940,54941,"2-((3,5-Dichloro-2,6-dimethoxybenzamido)methyl)-1-ethylpyrrolidine",CCN1CCCC1CNC(=O)C2=C(C(=CC(=C2OC)Cl)Cl)OC,,,,,,
4941,54942,"2-((3-Bromo-5-chloro-2,6-dimethoxybenzamido)methyl)-1-ethylpyrrolidine",CCN1CCCC1CNC(=O)C2=C(C(=CC(=C2OC)Br)Cl)OC,,,,,,
4942,54943,"2-((2,6-Diethoxybenzamido)methyl)-1-ethylpyrrolidine hydrochloride",CC[NH+]1CCCC1CNC(=O)C2=C(C=CC=C2OCC)OCC.[Cl-],,,,,,
4943,54944,"2,6-diethoxy-N-[(1-ethylpyrrolidin-2-yl)methyl]benzamide",CCN1CCCC1CNC(=O)C2=C(C=CC=C2OCC)OCC,,,,,,
4944,54945,"(S)-(-)-2-((3-Bromo-2,6-diethoxybenzamido)methyl)-1-ethylpyrrolidine hydrochloride",CC[NH+]1CCC[C@H]1CNC(=O)C2=C(C=CC(=C2OCC)Br)OCC.[Cl-],,,,,,
4945,54946,"3-bromo-2,6-diethoxy-N-[[(2S)-1-ethylpyrrolidin-2-yl]methyl]benzamide",CCN1CCC[C@H]1CNC(=O)C2=C(C=CC(=C2OCC)Br)OCC,,,,,,
4946,54947,"2,6-Diisopropoxy-N-(1-ethyl-2-pyrrolidinylmethyl)benzamide hydrochloride",CC[NH+]1CCCC1CNC(=O)C2=C(C=CC=C2OC(C)C)OC(C)C.[Cl-],,,,,,
4947,54948,"2,6-Diisopropoxy-N-[(1-ethyl-2-pyrrolidinyl)methyl]benzamide",CCN1CCCC1CNC(=O)C2=C(C=CC=C2OC(C)C)OC(C)C,,,,,,
4948,54949,Trimetrexate glucuronate,CC1=C(C=CC2=C1C(=NC(=N2)N)N)CNC3=CC(=C(C(=C3)OC)OC)OC.C(=O)[C@@H]([C@H]([C@@H]([C@@H](C(=O)O)O)O)O)O,,,,,,
4949,54950,CID 54950,C(=O)[C@@H](C(C([C@@H](C(=O)O)O)O)O)O,,,,,,
4950,54951,"3,5-Dibromo-2,6-dimethoxy-N-(1-ethyl-2-pyrrolidinylmethyl)benzamide hydrochloride",CC[NH+]1CCCC1CNC(=O)C2=C(C(=CC(=C2OC)Br)Br)OC.[Cl-],,,,,,
4951,54952,"N-[(1-Ethyl-2-pyrrolidinyl)methyl]-2,6-dimethoxy-3,5-dibromobenzamide",CCN1CCCC1CNC(=O)C2=C(C(=CC(=C2OC)Br)Br)OC,,,,,,
4952,54953,CID 54953,CS(=O)(=O)[O-].CS(=O)(=O)[O-].C1=CC(=CC=C1C(=O)OC2=CC3=C(C=C2)C=C(C=C3)C(=N)[NH3+])N=C([NH3+])N,,,,,,
4953,54954,"BENZ(c)ACRIDINE-8,9-DIOL, 8,9-DIHYDRO-7-METHYL-, trans-",CC1=C2C=CC3=CC=CC=C3C2=NC4=C1[C@@H]([C@H](C=C4)O)O,,,,,,
4954,54955,"(S)-(-)-2-((3-Chloro-2,6-dimethoxybenzamido)methyl)-1-ethylpyrrolidine hydrochloride",CC[NH+]1CCC[C@H]1CNC(=O)C2=C(C=CC(=C2OC)Cl)OC.[Cl-],,,,,,
4955,54956,"3-Chloro-N-(1-ethyl-pyrrolidin-2-ylmethyl)-2,6-dimethoxy-benzamide",CCN1CCC[C@H]1CNC(=O)C2=C(C=CC(=C2OC)Cl)OC,,,,,,
4956,54957,"Acetamide, N-(2-(trifluoromethyl)-5-benzimidazolyl)-",CC(=O)NC1=CC2=C(C=C1)N=C(N2)C(F)(F)F,,,,,,
4957,54958,CID 54958,C1=CC=C2C(=C1)N=C(N=N2)CC(=O)[O-].[Na+],,,,,,
4958,54959,"1,2,4-Benzotriazine-3-acetic acid",C1=CC=C2C(=C1)N=C(N=N2)CC(=O)O,,,,,,
4959,54960,Bensulfuron-methyl,COC1=CC(=NC(=N1)NC(=O)NS(=O)(=O)CC2=CC=CC=C2C(=O)OC)OC,,,,,,
4960,54961,Tampramine,CN(C)CCCN1C2=CC=CC=C2C(=NC3=C1N=CC=C3)C4=CC=CC=C4,,,,,,
4961,54962,"2-Imidazolidinethione, 1,3-dipropyl-",CCCN1CCN(C1=S)CCC,,,,,,
4962,54963,"6-(methylamino)hexane-1,2,3,4,5-pentol;5-methyl-6-(2-methylpropyl)-4-oxo-3H-thieno[2,3-d]pyrimidine-2-carboxylic acid",CC1=C(SC2=C1C(=O)NC(=N2)C(=O)O)CC(C)C.CNCC(C(C(C(CO)O)O)O)O,,,,,,
4963,54964,Tiprinast,CC1=C(SC2=C1C(=O)NC(=N2)C(=O)O)CC(C)C,,,,,,
4964,54965,Eproxindine,CCN(CC)CC(CNC(=O)C1=C(C2=CC=CC=C2N1C3=CC=CC=C3)OC)O,,,,,,
4965,54966,Anipamil,CCCCCCCCCCCCC(CCCN(C)CCC1=CC(=CC=C1)OC)(C#N)C2=CC(=CC=C2)OC,,,['A class of drugs that act by selective inhibition of calcium influx through cellular membranes. (See all compounds classified as Calcium Channel Blockers.)'],,,
4966,54967,"Methyl 4-(acetyloxy)-15-[5-ethyl-8-(methoxycarbonyl)-1,4,5,6,7,8,9,10-octahydro-2H-3,7-methanoazacycloundecino[5,4-b]indol-8-yl]-1-formyl-3-hydroxy-16-methoxy-6,7-didehydroaspidospermidine-3-carboxylate",CC[C@H]1CC2CN(C1)CCC3=C(C[C@]2(C4=C(C=C5C(=C4)[C@]67CCN8[C@H]6[C@@](C=CC8)([C@H]([C@@]([C@@H]7N5C=O)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)NC9=CC=CC=C39,,,,,,
4967,54968,CID 54968,CC1=CC(=NC=N1)C=CN(C)C,,,,,,
4968,54969,"[2-(2,6-Dimethoxy-5-nitropyrimidin-4-yl)ethenyl]dimethylamine",CN(C)C=CC1=C(C(=NC(=N1)OC)OC)[N+](=O)[O-],,,,,,
4969,54970,"2-[4,6-bis(trichloromethyl)-1,3,5-triazin-2-yl]-N,N-dimethylethenamine",CN(C)C=CC1=NC(=NC(=N1)C(Cl)(Cl)Cl)C(Cl)(Cl)Cl,,,,,,
4970,54971,"2-(4,6-diphenyl-1,3,5-triazin-2-yl)-N,N-dimethylethenamine",CN(C)C=CC1=NC(=NC(=N1)C2=CC=CC=C2)C3=CC=CC=C3,,,,,,
4971,54972,"Carbamic acid, (2-(3-((1,1-dimethylethyl)amino)-2-hydroxypropoxy)phenyl)-, ethyl ester, monohydrochloride",CCOC(=O)NC1=CC=CC=C1OCC(C[NH2+]C(C)(C)C)O.[Cl-],,,,,,
4972,54973,N-[2-[3-(tert-Butylamino)-2-hydroxypropoxy]phenyl]carbamic acid ethyl ester,CCOC(=O)NC1=CC=CC=C1OCC(CNC(C)(C)C)O,,,,,,
4973,54974,"Carbamic acid, (3-(2-hydroxy-3-((1-methylethyl)amino)propoxy)phenyl)-, ethyl ester, monohydrochloride",CCOC(=O)NC1=CC(=CC=C1)OCC(C[NH2+]C(C)C)O.[Cl-],,,,,,
4974,54975,"Carbamic acid, (3-(2-hydroxy-3-((1-methylethyl)amino)propoxy)phenyl)-, ethyl ester",CCOC(=O)NC1=CC(=CC=C1)OCC(CNC(C)C)O,,,,,,
4975,54976,"Carbamic acid, (3-(3-((1,1-dimethylethyl)amino)-2-hydroxypropoxy)phenyl)-, ethyl ester, monohydrochloride",CCOC(=O)NC1=CC(=CC=C1)OCC(C[NH2+]C(C)(C)C)O.[Cl-],,,,,,
4976,54977,"Carbamic acid, (3-(3-hydroxy-3-((1-methylethyl)amino)-2-hydroxypropoxy)phenyl)-, ethyl ester",CCOC(=O)NC1=CC(=CC=C1)OCC(CNC(C)(C)C)O,,,,,,
4977,54978,"Carbamic acid, (4-(2-hydroxy-3-((1-methylethyl)amino)propoxy)phenyl)-, ethyl ester, monohydrochloride",CCOC(=O)NC1=CC=C(C=C1)OCC(C[NH2+]C(C)C)O.[Cl-],,,,,,
4978,54979,Ethyl (4-(2-hydroxy-3-((1-methylethyl)amino)propoxy)phenyl)carbamate,CCOC(=O)NC1=CC=C(C=C1)OCC(CNC(C)C)O,,,,,,
4979,54980,"Carbamic acid, (4-(3-((1,1-dimethylethyl)amino)-2-hydroxypropoxy)phenyl)-, ethyl ester, monohydrochloride",CCOC(=O)NC1=CC=C(C=C1)OCC(C[NH2+]C(C)(C)C)O.[Cl-],,,,,,
4980,54981,ethyl N-[4-[3-(tert-butylamino)-2-hydroxypropoxy]phenyl]carbamate,CCOC(=O)NC1=CC=C(C=C1)OCC(CNC(C)(C)C)O,,,,,,
4981,54982,6-Methyl-N-(1H-tetrazol-5-yl)-2-pyridinecarboxamide,CC1=NC(=CC=C1)C(=O)NC2N=NN=N2,,,,,,
4982,54983,"BENZO(ghi)PERYLENE, 5,8-DINITRO-",C1=CC2=C3C4=C1C=CC5=C4C(=C(C=C5)[N+](=O)[O-])C6=C3C(=C(C=C6)[N+](=O)[O-])C=C2,,,,,,
4983,54984,"BENZO(ghi)PERYLENE, 5,10-DINITRO-",C1=CC2=C3C4=C1C=CC5=C(C=CC(=C54)C6=C3C(=C(C=C6)[N+](=O)[O-])C=C2)[N+](=O)[O-],,,,,,
4984,54985,"1,2,2,3,3-Pentachlorobutane",CC(C(CCl)(Cl)Cl)(Cl)Cl,,,,,,
4985,54986,"N,N'-Diacetyldianisidine",CC(=O)NC1=C(C=C(C=C1)C2=CC(=C(C=C2)NC(=O)C)OC)OC,,,,,,
4986,54987,CID 54987,CCCC=CC=CC(=O)O[C@H]1C(=CC(=O)OC)C[C@H]2CC(OC(=O)C[C@@H](CC3CC(C([C@@](O3)(CC4CC(=CC(=O)OC)C[C@@H](O4)C=CC([C@@]1(O2)O)(C)C)O)(C)C)OC(=O)C)O)[C@@H](C)O,,,,,,
4987,54988,"Aniline, N,N-dimethyl-4,4'-methylenedi-",CN(C)C1=CC=C(C=C1)CC2=CC=C(C=C2)N,,,,,,
4988,54989,"N-Nitroso-4,4,4-trifluorobutyl-butylamine",CCCCN(CCCC(F)(F)F)N=O,,,,,,
4989,54990,"N-Nitroso-bis-(4,4,4-trifluoro-n-butyl)amine",C(CC(F)(F)F)CN(CCCC(F)(F)F)N=O,,,,,,
4990,54991,Cupreidine 6'-acetate,CC(=O)OC1=CC2=C(C=CN=C2C=C1)C(C3CC4CCN3CC4C=C)O,,,,,,
4991,54992,[4-[(5-Ethenyl-1-azabicyclo[2.2.2]octan-2-yl)-hydroxymethyl]quinolin-6-yl] 3-methylbutanoate,CC(C)CC(=O)OC1=CC2=C(C=CN=C2C=C1)C(C3CC4CCN3CC4C=C)O,,,,,,
4992,54993,"1,2-Anhydro-6-bromomannitol",C=C(C(C(C(CBr)O)O)O)O,,,,,,
4993,54994,"Indol-6-OL, 4-chloro-2-(2,6-dichloro-4-hydroxyphenyl)-1-methyl-",CN1C(=CC2=C1C=C(C=C2Cl)O)C3=C(C=C(C=C3Cl)O)Cl,,,,,,
4994,54995,"Indol-6-OL, 4-chloro-2-(2,6-dichloro-4-hydroxyphenyl)-1-ethyl-",CCN1C(=CC2=C1C=C(C=C2Cl)O)C3=C(C=C(C=C3Cl)O)Cl,,,,,,
4995,54996,"Acetamide, 2-(1H-benzimidazol-2-ylthio)-N-(2,3-dimethylphenyl)-",CC1=C(C(=CC=C1)NC(=O)CSC2=NC3=CC=CC=C3N2)C,,,,,,
4996,54997,"2-(1H-Benzimidazol-2-ylthio)-N-(2,4,6-trimethylphenyl)acetamide",CC1=CC(=C(C(=C1)C)NC(=O)CSC2=NC3=CC=CC=C3N2)C,,,,,,
4997,54998,"Acetamide, 2-(1H-benzimidazol-2-ylthio)-N-(2-methoxyphenyl)-",COC1=CC=CC=C1NC(=O)CSC2=NC3=CC=CC=C3N2,,,,,,
4998,54999,"Acetamide, 2-(1H-benzimidazol-2-ylthio)-N-(3-methoxyphenyl)-",COC1=CC=CC(=C1)NC(=O)CSC2=NC3=CC=CC=C3N2,,,,,,
4999,55000,"Oxalic acid, bis(2-benzylhydrazide)",C1=CC=C(C=C1)CNNC(=O)C(=O)NNCC2=CC=CC=C2,,,,,,
5000,55001,CID 55001,CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@H](C)C(=O)N(CC(=O)O)C2CC3=CC=CC=C3C2.Cl,,,,,,
5001,55002,"2-[2,3-dihydro-1H-inden-2-yl-[(2R)-2-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]propanoyl]amino]acetic acid",CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@H](C)C(=O)N(CC(=O)O)C2CC3=CC=CC=C3C2,,,,,,
5002,55003,N-Acetylmuramyl-alanyl-isoglutaminyl-alanyl-sn-glycero-3-phosphoethanolamine,CCCCCCCCCCCCCCCC(=O)OCC(COP(=O)(O)OCCNC(=O)C(C)NC(=O)CCC(C(=O)N)NC(=O)C(C)NC(=O)C(C)OC(C(C=O)NC(=O)C)C(C(CO)O)O)OC(=O)CCCCCCCCCCCCCCC,,,"['Substances that augment, stimulate, activate, potentiate, or modulate the immune response at either the cellular or humoral level. The classical agents (Freund&apos;s adjuvant, BCG, Corynebacterium parvum, et al.) contain bacterial antigens. Some are endogenous (e.g., histamine, interferon, transfer factor, tuftsin, interleukin-1). Their mode of action is either non-specific, resulting in increased immune responsiveness to a wide variety of antigens, or antigen-specific, i.e., affecting a restricted type of immune response to a narrow group of antigens. The therapeutic efficacy of many biological response modifiers is related to their antigen-specific immunoadjuvanticity. (See all compounds classified as Adjuvants, Immunologic.)', 'Biologically active substances whose activities affect or play a role in the functioning of the immune system. (See all compounds classified as Immunologic Factors.)']",,,
5003,55004,Bromochloroacetonitrile,C(#N)C(Cl)Br,,,,"['Approximately 13% of a single oral dose to rats of 116 mg/kg bw of bromochloroacetonitrile was excreted in urine within 24 hr as thiocyanate, the product of released cyanide metabolized by rhodanese.']","['When administered orally to rats, the haloacetonitriles (HAN) were metabolized to cyanide and excreted in the urine as thiocyanate. The extent of thiocyanate excretion was chloroacetonitrile (CAN) greater than bromochloroacetonitrile (BCAN) greater than dichloroacetonitrile (DCAN)  greater than dibromoacetonitrile (DBAN)  much greater than trichloroacetonitrile (TCAN).']",
5004,55005,N-methyl-N-(1-methyl-4-pyrrolidino-2-butynyl)acetamide,CC(C#CCN1CCCC1)N(C)C(=O)C,,,,,,
5005,55006,"2,3,4,5,6-Pentachlorostyrene",C=CC1=C(C(=C(C(=C1Cl)Cl)Cl)Cl)Cl,,,,,,
5006,55007,Cyclopenta(ghi)picen-6-one,C1=CC=C2C3=C4C(=CC2=C1)C(=O)C5=CC6=CC=CC=C6C(=C54)C=C3,,,,,,
5007,55008,Ilmofosine,CCCCCCCCCCCCCCCCSCC(COC)COP(=O)([O-])OCC[N+](C)(C)C,,,['Substances that inhibit or prevent the proliferation of NEOPLASMS. (See all compounds classified as Antineoplastic Agents.)'],,,
5008,55009,"4-Hydroxy-7-(methoxymethyl)-N,N,N-trimethyl-4-oxo-3,5-dioxa-9-thia-4lambda~5~-phosphapentacosan-1-aminium",CCCCCCCCCCCCCCCCSCC(COC)COP(=O)(O)OCC[N+](C)(C)C,,,,,,
5009,55010,"2-(1-Methylbutyl)-1,3-dithiolane",CCCC(C)C1SCCS1,,,,,,
5010,55011,"2-(p-Fluorophenyl)-1,3-dithiolane",C1CSC(S1)C2=CC=C(C=C2)F,,,,,,
5011,55012,"1,3-DITHIOLANE, 2-(p-BROMOPHENYL)-",C1CSC(S1)C2=CC=C(C=C2)Br,,,,,,
5012,55013,"2-(m-Fluorophenyl)-1,3-dithiolane",C1CSC(S1)C2=CC(=CC=C2)F,,,,,,
5013,55014,"2-(m-Chlorophenyl)-1,3-dithiolane",C1CSC(S1)C2=CC(=CC=C2)Cl,,,,,,
5014,55015,"1,3-DITHIOLANE, 2-(o-CHLOROPHENYL)-",C1CSC(S1)C2=CC=CC=C2Cl,,,,,,
5015,55016,"2-(3,4-Dichlorophenyl)-1,3-dithiolane",C1CSC(S1)C2=CC(=C(C=C2)Cl)Cl,,,,,,
5016,55017,"2-(2,4-Dichlorophenyl)-1,3-dithiolane",C1CSC(S1)C2=C(C=C(C=C2)Cl)Cl,,,,,,
5017,55018,"1,3-Dithiolane, 2-(2,4-xylyl)-",CC1=CC(=C(C=C1)C2SCCS2)C,,,,,,
5018,55019,"2-(1-Methylbutyl)-4-methyl-1,3-dithiolane",CCCC(C)C1SCC(S1)C,,,,,,
5019,55020,"2-(1-Methylbutyl)-1,3-dithiolane-4-methanol",CCCC(C)C1SCC(S1)CO,,,,,,
5020,55021,"2-(alpha-Methylbenzyl)-1,3-dithiolane",CC(C1SCCS1)C2=CC=CC=C2,,,,,,
5021,55022,"4-Methyl-2-(p-tolyl)-1,3-dithiolane",CC1CSC(S1)C2=CC=C(C=C2)C,,,,,,
5022,55023,"2-(alpha-Methylbenzyl)-4-methyl-1,3-dithiolane",CC1CSC(S1)C(C)C2=CC=CC=C2,,,,,,
5023,55024,CID 55024,CC1=CC(=C(C=C1)C=CC2SCCS2)C,,,,,,
5024,55025,"1,3-Dithiolane, 2-phenyl-2-(2-thienyl)-",C1CSC(S1)(C2=CC=CC=C2)C3=CC=CS3,,,,,,
5025,55026,2-(p-Chlorophenyl)-1-methylimidazolidine,CN1CCNC1C2=CC=C(C=C2)Cl,,,,,,
5026,55027,1-Methyl-2-(p-tolyl)imidazolidine,CC1=CC=C(C=C1)C2NCCN2C,,,,,,
5027,55028,"2-(3,4-Dichlorophenyl)-1-methylimidazolidine",CN1CCNC1C2=CC(=C(C=C2)Cl)Cl,,,,,,
5028,55029,"IMIDAZOLIDINE, 1,3-DIMETHYL-2-(p-FLUOROPHENYL)-",CN1CCN(C1C2=CC=C(C=C2)F)C,,,,,,
5029,55030,"IMIDAZOLIDINE, 2-(p-(DIMETHYLAMINO)PHENYL)-1,3-DIMETHYL-",CN1CCN(C1C2=CC=C(C=C2)N(C)C)C,,,,,,
5030,55031,"2-(p-(Diethylamino)phenyl)-1,3-dimethylimidazolidine",CCN(CC)C1=CC=C(C=C1)C2N(CCN2C)C,,,,,,
5031,55032,"Imidazolidine, 2-(3,4-dichlorophenyl)-1,3-dimethyl-",CN1CCN(C1C2=CC(=C(C=C2)Cl)Cl)C,,,,,,
5032,55033,"IMIDAZOLIDINE, 1,3-DIMETHYL-2-(4-METHOXY-m-TOLYL)-",CC1=C(C=CC(=C1)C2N(CCN2C)C)OC,,,,,,
5033,55034,"2-(3,4-Dichlorophenyl)-1,3-oxathiolane",C1CSC(O1)C2=CC(=C(C=C2)Cl)Cl,,,,,,
5034,55035,p-(3-Methyl-2-oxazolidinyl)benzonitrile,CN1CCOC1C2=CC=C(C=C2)C#N,,,,,,
5035,55036,"2-{4-[2-(3,4-Dimethoxyphenyl)-2-hydroxyethyl]piperazin-1-yl}cyclohepta-2,4,6-trien-1-one",COC1=C(C=C(C=C1)C(CN2CCN(CC2)C3=CC=CC=CC3=O)O)OC,,,,,,
5036,55037,"1,2-Dihydroacenaphthylene-4-carbonitrile",C1CC2=C3C1=CC=CC3=CC(=C2)C#N,,,,,,
5037,55038,Pyrenecarbonitrile,C1=CC2=C3C(=C1)C=CC4=C3C(=CC(=C4)C#N)C=C2,,,,,,
5038,55039,"3-Azaspiro(5.5)undecane, 3-(2,6-diamino-4-pyrimidinyl)-, 1'-oxide, dihydrochloride",C1CCC2(CC1)CC[NH+](CC2)C3=NC(=[N+](C(=C3)N)O)N.[Cl-].[Cl-],,,,,,
5039,55040,"6-(3-Azaspiro[5.5]undecan-3-yl)-3-hydroxypyrimidin-3-ium-2,4-diamine",C1CCC2(CC1)CCN(CC2)C3=NC(=[N+](C(=C3)N)O)N,,,,,,
5040,55041,"9-(2,6-Diamino-4-pyrimidinyl)-1,5-dioxa-9-azaspiro(5.5)undecane 1'-oxide",C1COC2(CCN(CC2)C3=NC(=N)N(C(=C3)N)O)OC1,,,,,,
5041,55042,"6-(1,4-Dioxa-8-azaspiro[4.5]decan-8-yl)-3-hydroxy-2-iminopyrimidin-4-amine",C1CN(CCC12OCCO2)C3=NC(=N)N(C(=C3)N)O,,,,,,
5042,55043,"1,4-Dioxa-8-azaspiro(4.5)decane, 8-(2,6-diamino-4-pyrimidinyl)-2-methyl-, 1'-oxide",CC1COC2(O1)CCN(CC2)C3=NC(=N)N(C(=C3)N)O,,,,,,
5043,55044,"1,4-Dioxa-8-azaspiro(4.5)decane, 2-(allyloxymethyl)-8-(2,6-diamino-4-pyrimidinyl)-, 1-oxide",C=CCOCC1COC2(O1)CCN(CC2)C3=NC(=N)N(C(=C3)N)O,,,,,,
5044,55045,"1,4-Dithia-8-azaspiro(4.5)decane, 8-(2,6-diamino-4-pyrimidinyl)-, 1'-oxide, hydrochloride",C1C[NH+](CCC12SCCS2)C3=NC(=N)N(C(=C3)N)O.[Cl-],,,,,,
5045,55046,"6-(1,4-Dithia-8-azaspiro[4.5]decan-8-yl)-3-hydroxy-2-iminopyrimidin-4-amine",C1CN(CCC12SCCS2)C3=NC(=N)N(C(=C3)N)O,,,,,,
5046,55047,"(8S)-7-[(2S)-2-[[(2R)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]propanoyl]-1,4-dithia-7-azaspiro[4.4]nonane-8-carboxylic acid",CCOC(=O)[C@@H](CCC1=CC=CC=C1)N[C@@H](C)C(=O)N2CC3(C[C@H]2C(=O)O)SCCS3,,,,,,
5047,55048,"2,3-Dihydro-2,3-dihydroxyfluoranthene",C1=CC=C2C(=C1)C3=C4C2=CC(C(C4=CC=C3)O)O,,,,,,
5048,55049,"2-Methyl-4,5-dihydro-4,5-fluoranthenediol",CC1=CC2=C3C(=CC(C(C3=C1)O)O)C4=CC=CC=C42,,,,,,
5049,55050,"3-Methyl-4,5-dihydro-4,5-fluoranthenediol",CC1=C2C(C(C=C3C2=C(C=C1)C4=CC=CC=C43)O)O,,,,,,
5050,55051,"1,12-Carbonylperylene",C1=CC2=C3C(=C1)C4=CC=CC5=C4C6=C(C=C5)C(=O)C(=C36)C=C2,,,,,,
5051,55052,"2-Chloro-5-methylsulfanylpyrimidine-4,6-diamine;6-chloro-5-methylsulfanylpyrimidine-2,4-diamine",CSC1=C(N=C(N=C1N)Cl)N.CSC1=C(N=C(N=C1Cl)N)N,,,,,,
5052,55053,"cis-2-Ethoxy-3,5,5-trimethyl-1,2-oxaphospholan-3-ol 2-sulfide",CCOP1(=S)C(CC(O1)(C)C)(C)O,,,,,,
5053,55054,"1,2,3-Trichlorodibenzofuran",C1=CC=C2C(=C1)C3=C(C(=C(C=C3O2)Cl)Cl)Cl,,,,,,
5054,55055,"(6-ethyl-3a-methyl-7-oxo-2,3,4,5,8,9,9a,9b-octahydro-1H-cyclopenta[a]naphthalen-3-yl) acetate",CCC1=C2CCC3(C(C2CCC1=O)CCC3OC(=O)C)C,,,,,,
5055,55056,O-(N-Phthalimido)acetophenone,CC(=O)C1=CC=CC=C1N2C(=O)C3=CC=CC=C3C2=O,,,,,,
5056,55057,"2,2,3,4,5,5-Hexachlorohexane",CC(C(C(C(C)(Cl)Cl)Cl)Cl)(Cl)Cl,,,,,,
5057,55058,"1,2,2,5,5,6-Hexachlorohexane",C(CC(CCl)(Cl)Cl)C(CCl)(Cl)Cl,,,,,,
5058,55059,"1,1,4,4-Tetrachloro-2,3-dichloromethyl-2-butene",C(C(=C(C(Cl)Cl)C(Cl)Cl)C(Cl)Cl)(Cl)Cl,,,,,,
5059,55060,CID 55060,CC(C(=C(C(C)(Cl)Cl)Cl)Cl)(Cl)Cl,,,,,,
5060,55061,"1,3-Dichloroallene",C(=C=CCl)Cl,,,,,,
5061,55062,"3,4-Dichlorohexa-1,5-diene",C=CC(C(C=C)Cl)Cl,,,,,,
5062,55063,Perchlorohexane,C(C(C(C(Cl)(Cl)Cl)(Cl)Cl)(Cl)Cl)(C(C(Cl)(Cl)Cl)(Cl)Cl)(Cl)Cl,,,,,,
5063,55064,"3-Chlorohexa-1,2,5-triene",C=CCC(=C=C)Cl,,,,,,
5064,55065,CID 55065,CC=CCCC#CCl,,,,,,
5065,55066,CID 55066,C=CC(=C(C=C)Cl)Cl,,,,,,
5066,55067,"2-Trichloromethyl-3,3,3-trichloropropene",C=C(C(Cl)(Cl)Cl)C(Cl)(Cl)Cl,,,,,,
5067,55068,"1,3,3,3-Tetrachloro-2-(trichloromethyl)prop-1-ene",C(=C(C(Cl)(Cl)Cl)C(Cl)(Cl)Cl)Cl,,,,,,
5068,55069,"1,1-Dichloro-2,3-bis(trichloromethyl)propene",C(C(=C(Cl)Cl)C(Cl)(Cl)Cl)C(Cl)(Cl)Cl,,,,,,
5069,55070,"4,4-Dichloro-1,2-butadiene",C=C=CC(Cl)Cl,,,,,,
5070,55071,"4,4-Dichloro-1-butyne",C#CCC(Cl)Cl,,,,,,
5071,55072,"4,4,4-Trichloro-1-butyne",C#CCC(Cl)(Cl)Cl,,,,,,
5072,55073,"1,4-Dichloro-1,2-butadiene",C(C=C=CCl)Cl,,,,,,
5073,55074,"1,4-Dichloro-1-butyne",C(CCl)C#CCl,,,,,,
5074,55075,"1-Butyne, 1,4,4-trichloro-",C(=CCl)C=C(Cl)Cl,,,,,,
5075,55076,1-Hexachlorobutyne,C(#CCl)C(C(Cl)(Cl)Cl)(Cl)Cl,,,,,,
5076,55077,CID 55077,CC(=CCl)CCC(=CCl)C,,,,,,
5077,55078,"3,4-Dichloro-2,5-dimethyl-1,5-hexadiene",CC(=C)C(C(C(=C)C)Cl)Cl,,,,,,
5078,55079,"2,5-Dimethyl-3,3,4,4-tetrachloro-1,5-hexadiene",CC(=C)C(C(C(=C)C)(Cl)Cl)(Cl)Cl,,,,,,
5079,55080,"2,5-Bis(chloromethyl)-1,5-hexadiene",C=C(CCC(=C)CCl)CCl,,,,,,
5080,55081,"3,4-Dichloro-2,5-bis(chloromethyl)hexa-1,5-diene",C=C(CCl)C(C(C(=C)CCl)Cl)Cl,,,,,,
5081,55082,"3,3,4,4-Tetrachloro-2,5-bis(chloromethyl)hexa-1,5-diene",C=C(CCl)C(C(C(=C)CCl)(Cl)Cl)(Cl)Cl,,,,,,
5082,55083,"1,6-Dichloro-2,5-dimethylhexa-1,3,5-triene",CC(=CCl)C=CC(=CCl)C,,,,,,
5083,55084,"3,4-Dichloro-2,5-bis(chloromethyl)hexa-1,3,5-triene",C=C(CCl)C(=C(C(=C)CCl)Cl)Cl,,,,,,
5084,55085,"2,5-Bis(chloromethyl)hexa-1,3,5-triene",C=C(CCl)C=CC(=C)CCl,,,,,,
5085,55086,"3,4-Dichloro-2,5-bis(dichloromethyl)hexa-1,3,5-triene",C=C(C(Cl)Cl)C(=C(C(=C)C(Cl)Cl)Cl)Cl,,,,,,
5086,55087,CID 55087,C=C(C(=C(C(=C)C(Cl)(Cl)Cl)Cl)Cl)C(Cl)(Cl)Cl,,,,,,
5087,55088,"1,3,5-Tris(2,2-dichloroethyl)benzene",C1=C(C=C(C=C1CC(Cl)Cl)CC(Cl)Cl)CC(Cl)Cl,,,,,,
5088,55089,"1,3,5-Tris(2,2,2-trichloroethyl)benzene",C1=C(C=C(C=C1CC(Cl)(Cl)Cl)CC(Cl)(Cl)Cl)CC(Cl)(Cl)Cl,,,,,,
5089,55090,CID 55090,CCC=CCCC(=CCl)Cl,,,,,,
5090,55091,"1,2-Bis(1,2-dichloroethyl)cyclobutane",C1CC(C1C(CCl)Cl)C(CCl)Cl,,,,,,
5091,55092,"1,4-Dichloro-4-(1-chloroethenyl)cyclohexene",C=C(C1(CCC(=CC1)Cl)Cl)Cl,,,,,,
5092,55093,"1,3,4-Trichloro-1-(1,1,2-trichloroethyl)cyclohexane",C1CC(CC(C1Cl)Cl)(C(CCl)(Cl)Cl)Cl,,,,,,
5093,55094,CID 55094,C1CC(=CCC=C(C1)Cl)Cl,,,,,,
5094,55095,Bis(2-chloro-3-butenyl) ether,C=CC(COCC(C=C)Cl)Cl,,,,,,
5095,55096,"1,1'-Oxybis-3-buten-2-OL",C=CC(COCC(C=C)O)O,,,,,,
5096,55097,"2,2'-Oxybis-3-buten-1-OL",C=CC(CO)OC(CO)C=C,,,,,,
5097,55098,"1,1,2,2,3,3-Hexachlorobutane",CC(C(C(Cl)Cl)(Cl)Cl)(Cl)Cl,,,,,,
5098,55099,"1,1,1,2,2,3,3-Heptachlorobutane",CC(C(C(Cl)(Cl)Cl)(Cl)Cl)(Cl)Cl,,,,,,
5099,55100,"2,3,3,4,4,4-Hexachlorobut-1-ene",C=C(C(C(Cl)(Cl)Cl)(Cl)Cl)Cl,,,,,,
5100,55101,"3,3-Dichloropropanol",C(CO)C(Cl)Cl,,,,,,
5101,55102,"1,3,6,9-Tetrachlorodibenzofuran",C1=CC(=C2C(=C1Cl)C3=C(O2)C=C(C=C3Cl)Cl)Cl,,,,,,
5102,55103,"1,2,3,6-Tetrachlorodibenzofuran",C1=CC2=C(C(=C1)Cl)OC3=CC(=C(C(=C23)Cl)Cl)Cl,,,,,,
5103,55104,"1,2,3,7-Tetrachlorodibenzofuran",C1=CC2=C(C=C1Cl)OC3=CC(=C(C(=C23)Cl)Cl)Cl,,,,,,
5104,55105,"1,2,3,9-Tetrachlorodibenzofuran",C1=CC2=C(C(=C1)Cl)C3=C(C(=C(C=C3O2)Cl)Cl)Cl,,,,,,
5105,55106,"1,2,4,9-Tetrachlorodibenzofuran",C1=CC2=C(C(=C1)Cl)C3=C(O2)C(=CC(=C3Cl)Cl)Cl,,,,,,
5106,55107,"1,2,7,9-Tetrachlorodibenzofuran",C1=CC(=C(C2=C1OC3=C2C(=CC(=C3)Cl)Cl)Cl)Cl,,,,,,
5107,55108,"1,3,4,6-Tetrachlorodibenzofuran",C1=CC2=C(C(=C1)Cl)OC3=C2C(=CC(=C3Cl)Cl)Cl,,,,,,
5108,55109,"1,3,4,9-Tetrachlorodibenzofuran",C1=CC2=C(C(=C1)Cl)C3=C(O2)C(=C(C=C3Cl)Cl)Cl,,,,,,
5109,55110,"1,4,7,8-Tetrachlorodibenzofuran",C1=CC(=C2C(=C1Cl)C3=CC(=C(C=C3O2)Cl)Cl)Cl,,,,,,
5110,55111,"2,3,4,7-Tetrachlorodibenzofuran",C1=CC2=C(C=C1Cl)OC3=C(C(=C(C=C23)Cl)Cl)Cl,,,,,,
5111,55112,"2,3,4,8-Tetrachlorodibenzofuran",C1=CC2=C(C=C1Cl)C3=CC(=C(C(=C3O2)Cl)Cl)Cl,,,,,,
5112,55113,"1,6,7,8-Tetrachlorodibenzofuran",C1=CC2=C(C(=C1)Cl)C3=CC(=C(C(=C3O2)Cl)Cl)Cl,,,,,,
5113,55114,"1,2,8-Trichlorodibenzofuran",C1=CC2=C(C=C1Cl)C3=C(O2)C=CC(=C3Cl)Cl,,,,,,
5114,55115,"1,4,6,7,8-Pentachlorodibenzofuran",C1=CC(=C2C(=C1Cl)C3=CC(=C(C(=C3O2)Cl)Cl)Cl)Cl,,,,,,
5115,55116,"1,3,4,6,7-Pentachlorodibenzofuran",C1=CC(=C(C2=C1C3=C(O2)C(=C(C=C3Cl)Cl)Cl)Cl)Cl,,,,,,
5116,55117,"1,2,7-Trichlorodibenzofuran",C1=CC2=C(C=C1Cl)OC3=C2C(=C(C=C3)Cl)Cl,,,,,,
5117,55118,"1,2,9-Trichlorodibenzofuran",C1=CC2=C(C(=C1)Cl)C3=C(O2)C=CC(=C3Cl)Cl,,,,,,
5118,55119,"1,3,6-Trichlorodibenzofuran",C1=CC2=C(C(=C1)Cl)OC3=C2C(=CC(=C3)Cl)Cl,,,,,,
5119,55120,"1,3,9-Trichlorodibenzofuran",C1=CC2=C(C(=C1)Cl)C3=C(O2)C=C(C=C3Cl)Cl,,,,,,
5120,55121,"1,4,7-Trichlorodibenzofuran",C1=CC2=C(C=C1Cl)OC3=C(C=CC(=C23)Cl)Cl,,,,,,
5121,55122,"2,4,7-Trichlorodibenzofuran",C1=CC2=C(C=C1Cl)OC3=C2C=C(C=C3Cl)Cl,,,,,,
5122,55123,"3,4,6-Trichlorodibenzofuran",C1=CC2=C(C(=C1)Cl)OC3=C2C=CC(=C3Cl)Cl,,,,,,
5123,55124,"3,4,7-Trichlorodibenzofuran",C1=CC2=C(C=C1Cl)OC3=C2C=CC(=C3Cl)Cl,,,,,,
5124,55125,"2,6,7-Trichlorodibenzofuran",C1=CC2=C(C=C1Cl)C3=C(O2)C(=C(C=C3)Cl)Cl,,,,,,
5125,55126,"1,6,7-Trichlorodibenzofuran",C1=CC2=C(C3=C(O2)C(=C(C=C3)Cl)Cl)C(=C1)Cl,,,,,,
5126,55127,"1,2,3,4,6-Pentachlorodibenzofuran",C1=CC2=C(C(=C1)Cl)OC3=C2C(=C(C(=C3Cl)Cl)Cl)Cl,,,,,,
5127,55128,"1,2,3,4,7-Pentachlorodibenzofuran",C1=CC2=C(C=C1Cl)OC3=C2C(=C(C(=C3Cl)Cl)Cl)Cl,,,,,,
5128,55129,"1,2,3,4,9-Pentachlorodibenzofuran",C1=CC2=C(C(=C1)Cl)C3=C(O2)C(=C(C(=C3Cl)Cl)Cl)Cl,,,,,,
5129,55130,"1,2,4,6,7-Pentachlorodibenzofuran",C1=CC(=C(C2=C1C3=C(O2)C(=CC(=C3Cl)Cl)Cl)Cl)Cl,,,,,,
5130,55131,"1,2,3,6,8-Pentachlorodibenzofuran",C1=C(C=C(C2=C1C3=C(C(=C(C=C3O2)Cl)Cl)Cl)Cl)Cl,,,,,,
5131,55132,"1,2,3,6,9-Pentachlorodibenzofuran",C1=CC(=C2C(=C1Cl)C3=C(C(=C(C=C3O2)Cl)Cl)Cl)Cl,,,,,,
5132,55133,"1,2,3,7,9-Pentachlorodibenzofuran",C1=C(C=C(C2=C1OC3=CC(=C(C(=C32)Cl)Cl)Cl)Cl)Cl,,,,,,
5133,55134,"1,2,3,8,9-Pentachlorodibenzofuran",C1=CC(=C(C2=C1OC3=CC(=C(C(=C32)Cl)Cl)Cl)Cl)Cl,,,,,,
5134,55135,"1,3,4,6,8-Pentachlorodibenzofuran",C1=C(C=C(C2=C1C3=C(O2)C(=C(C=C3Cl)Cl)Cl)Cl)Cl,,,,,,
5135,55136,"1,2,6,8-Tetrachlorodibenzofuran",C1=CC(=C(C2=C1OC3=C2C=C(C=C3Cl)Cl)Cl)Cl,,,,,,
5136,55137,"1,2,4,7-Tetrachlorodibenzofuran",C1=CC2=C(C=C1Cl)OC3=C2C(=C(C=C3Cl)Cl)Cl,,,,,,
5137,55138,Fosmethilan,CCCC(=O)N(CSP(=S)(OC)OC)C1=CC=CC=C1Cl,,,,,,
5138,55139,"Ethyl 4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-3,6-dihydro-1(2H)-pyridinecarboxylate",CCOC(=O)N1CCC(=CC1)N2C3=CC=CC=C3NC2=O,,,,,,
5139,55140,2-(Dimethylamino)-6-phenylchromone,CN(C)C1=CC(=O)C2=C(O1)C=CC(=C2)C3=CC=CC=C3,,,,,,
5140,55141,"Chromone, 2-(ethylmethylamino)-6-phenyl-",CCN(C)C1=CC(=O)C2=C(O1)C=CC(=C2)C3=CC=CC=C3,,,,,,
5141,55142,2-(Dimethylamino)-8-phenylchromone,CN(C)C1=CC(=O)C2=C(O1)C(=CC=C2)C3=CC=CC=C3,,,,,,
5142,55143,2-(Diethylamino)-8-phenyl-4H-1-benzopyran-4-one,CCN(CC)C1=CC(=O)C2=C(O1)C(=CC=C2)C3=CC=CC=C3,,,,,,
5143,55144,"Chromone, 2-(ethylmethylamino)-8-phenyl-",CCN(C)C1=CC(=O)C2=C(O1)C(=CC=C2)C3=CC=CC=C3,,,,,,
5144,55145,S-Vinyl-DL-homocysteine,C=CSCCC(C(=O)O)N,,,,,,
5145,55146,"Carbamic acid, (4-phenyl-4-piperidyl)methyl-, ethyl ester",CCOC(=O)NCC1(CCNCC1)C2=CC=CC=C2,,,,,,
5146,55147,"3-Ethyl-2,6-dimethyl-4,4a,5,6,7,8,8a,9-octahydro-1H-pyrrolo[2,3-g]isoquinolin-4-ol",CCC1=C(NC2=C1C([C@@H]3CN(CC[C@H]3C2)C)O)C,,,,,,
5147,55148,"DIBENZO(b,f)THIEPIN, 3-METHOXY-10-METHYL-11-PHENYL-",CC1=C(C2=C(C=C(C=C2)OC)SC3=CC=CC=C13)C4=CC=CC=C4,,,,,,
5148,55149,"DIBENZ(b,f)OXEPINE, 3-(ALLYLOXY)-10-ETHYL-11-PHENYL-",CCC1=C(C2=C(C=C(C=C2)OCC=C)OC3=CC=CC=C31)C4=CC=CC=C4,,,,,,
5149,55150,"2H-1-Benzopyran-3-carboxamide, N-(2-phenylethyl)-",C1C(=CC2=CC=CC=C2O1)C(=O)NCCC3=CC=CC=C3,,,,,,
5150,55151,"2H-1-Benzopyran-3-carboxamide, N-3-pyridinyl-",C1C(=CC2=CC=CC=C2O1)C(=O)NC3=CN=CC=C3,,,,,,
5151,55152,"2H-1-Benzopyran-3-carboxamide, N,N-diethyl-",CCN(CC)C(=O)C1=CC2=CC=CC=C2OC1,,,,,,
5152,55153,N-(2-Hydroxy-2-phenylethyl)-2H-1-benzopyran-3-carboxamide,C1C(=CC2=CC=CC=C2O1)C(=O)NCC(C3=CC=CC=C3)O,,,,,,
5153,55154,"2H-1-Benzopyran-3-carboxamide, N-(2-(diethylamino)ethyl)-",CCN(CC)CCNC(=O)C1=CC2=CC=CC=C2OC1,,,,,,
5154,55155,"2H-1-Benzopyran-3-carboxamide, N-butyl-",CCCCNC(=O)C1=CC2=CC=CC=C2OC1,,,,,,
5155,55156,"2H-1-Benzopyran-3-carboxamide, 6-chloro-",C1C(=CC2=C(O1)C=CC(=C2)Cl)C(=O)N,,,,,,
5156,55157,"2H-1-Benzopyran-3-carboxamide, 6,8-dichloro-",C1C(=CC2=C(O1)C(=CC(=C2)Cl)Cl)C(=O)N,,,,,,
5157,55158,"2H-1-Benzopyran-3-carboxamide, 8-methoxy-",COC1=CC=CC2=C1OCC(=C2)C(=O)N,,,,,,
5158,55159,"2H-1-Benzopyran-3-carboxamide, N-(2-(3,4-dimethoxyphenyl)ethyl)-8-methoxy-",COC1=C(C=C(C=C1)CCNC(=O)C2=CC3=C(C(=CC=C3)OC)OC2)OC,,,,,,
5159,55160,N-(2-Phenylethyl)-2H-1-benzopyran-3-methanamine hydrochloride,C[NH+](CCC1=CC=CC=C1)C2=CC3=CC=CC=C3OC2.[Cl-],,,,,,
5160,55161,N-methyl-N-(2-phenylethyl)-2H-chromen-3-amine,CN(CCC1=CC=CC=C1)C2=CC3=CC=CC=C3OC2,,,,,,
5161,55162,"N,N-Diethyl-2H-1-benzopyran-3-methanamine hydrochloride",CC[N+](C)(CC)C1C=CC2=CC=CC=C2O1.[Cl-],,,,,,
5162,55163,2H-chromen-2-yl-diethyl-methylazanium,CC[N+](C)(CC)C1C=CC2=CC=CC=C2O1,,,,,,
5163,55164,CID 55164,CCN(CC)CCNC(=O)C(C1=CC=CC=C1)[NH2+]C2=CC(=CC=C2)Cl.C(=CC(=O)[O-])C(=O)O,,,,,,
5164,55165,2-(3-chloroanilino)-N-[2-(diethylamino)ethyl]-2-phenylacetamide,CCN(CC)CCNC(=O)C(C1=CC=CC=C1)NC2=CC(=CC=C2)Cl,,,,,,
5165,55166,3-(p-Chloroanilino)-N-(2-(dimethylamino)ethyl)-2-phenylacetamide,CN(C)CCNC(=O)C(C1=CC=CC=C1)NC2=CC=C(C=C2)Cl,,,,,,
5166,55167,2-(p-Chloroanilino)-N-(2-(diethylamino)ethyl)-2-phenylacetamide,CCN(CC)CCNC(=O)C(C1=CC=CC=C1)NC2=CC=C(C=C2)Cl,,,,,,
5167,55168,CID 55168,CC[NH+](CC)CCNC(=O)C(C1=CC=CC=C1)NC2=CC=C(C=C2)Cl.C(=CC(=O)[O-])C(=O)O,,,,,,
5168,55169,CID 55169,C[NH+](C)CCOC(=O)C(C1=CC=CC=C1)NC2=CC=CC=C2.C(=CC(=O)[O-])C(=O)O,,,,,,
5169,55170,2-(Dimethylamino)ethyl 2-anilino-2-phenylacetate,CN(C)CCOC(=O)C(C1=CC=CC=C1)NC2=CC=CC=C2,,,,,,
5170,55171,CID 55171,CC[NH+](CC)CCOC(=O)C(C1=CC=CC=C1)NC2=CC=CC=C2.C(=CC(=O)[O-])C(=O)O,,,,,,
5171,55172,2-(Diethylamino)ethyl 2-anilino-2-phenylacetate,CCN(CC)CCOC(=O)C(C1=CC=CC=C1)NC2=CC=CC=C2,,,,,,
5172,55173,CID 55173,CCOC1=CC=C(C=C1)NC(C2=CC=CC=C2)C(=O)OCC[NH+](C)C.C1=CC=C(C(=C1)C(=O)[O-])O,,,,,,
5173,55174,2-(Dimethylamino)ethyl 2-(4-ethoxyanilino)-2-phenylacetate,CCOC1=CC=C(C=C1)NC(C2=CC=CC=C2)C(=O)OCCN(C)C,,,,,,
5174,55175,(2-(2-Hydroxy-3-((1-methylethyl)amino)propoxy)phenyl)carbamic acid ethyl ester,CCOC(=O)NC1=CC=CC=C1OCC(CNC(C)C)O,,,,,,
5175,55176,2-Butyl-4-chloro-5-formylimidazole,CCCCC1=NC(=C(N1)Cl)C=O,,,,,,
5176,55177,"Ketone, 4-phenyl-4-piperidyl piperidino, hydrochloride",C1CCN(CC1)C(=O)C2CC[NH+](CC2)C3=CC=CC=C3.[Cl-],,,,,,
5177,55178,(1-Phenylpiperidin-4-yl)-piperidin-1-ylmethanone,C1CCN(CC1)C(=O)C2CCN(CC2)C3=CC=CC=C3,,,,,,
5178,55179,"cis-5,6-Dihydro-5,6-dihydroxy-12-methylbenz(a)acridine",CC1=C2C3=CC=CC=C3[C@H]([C@H](C2=NC4=CC=CC=C14)O)O,,,,,,
5179,55180,"BENZ(c)ACRIDINE, 3-METHOXY-7-METHYL-",CC1=C2C=CC3=C(C2=NC4=CC=CC=C14)C=CC(=C3)OC,,,,,,
5180,55181,4-Acetoxy-7-methylbenz(c)acridine,CC1=C2C=CC3=C(C2=NC4=CC=CC=C14)C=CC=C3OC(=O)C,,,,,,
5181,55182,Cetirizine hydrochloride,C1CN(CCN1CCOCC(=O)O)C(C2=CC=CC=C2)C3=CC=C(C=C3)Cl.Cl.Cl,,,"['A class of non-sedating drugs that bind to but do not activate histamine receptors (DRUG INVERSE AGONISM), thereby blocking the actions of histamine or histamine agonists. These antihistamines represent a heterogenous group of compounds with differing chemical structures, adverse effects, distribution, and metabolism. Compared to the early (first generation) antihistamines, these non-sedating antihistamines have greater receptor specificity, lower penetration of BLOOD-BRAIN BARRIER, and are less likely to cause drowsiness or psychomotor impairment. (See all compounds classified as Histamine H1 Antagonists, Non-Sedating.)', 'Agents that are used to treat allergic reactions. Most of these drugs act by preventing the release of inflammatory mediators or inhibiting the actions of released mediators on their target cells. (From AMA Drug Evaluations Annual, 1994, p475) (See all compounds classified as Anti-Allergic Agents.)']",,,
5182,55183,1-Methyl-2-(3-indolylmethyl)-4-gamma-(p-fluorobenzoyl)propylpiperazine,CN1CCN(CC1CC2=CNC3=CC=CC=C32)CCCC(=O)C4=CC=C(C=C4)F,,,,,,
5183,55184,"Butyrophenone, 4'-fluoro-4-(methyl(2-(1,2,3,4-tetrahydro-9H-pyrido(3,4-b)indol-2-yl)ethyl)amino)-",CN(CCCC(=O)C1=CC=C(C=C1)F)CCN2CCC3=C(C2)NC4=CC=CC=C34,,,,,,
5184,55185,CID 55185,CC[C@@H]1[C@@]([C@@H]([C@H](N(C[C@@H](C[C@@]([C@@H](C([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)O)C)C)C)O)(C)O,,,['Substances that inhibit the growth or reproduction of BACTERIA. (See all compounds classified as Anti-Bacterial Agents.)'],"['Biliary excretion of azithromycin, predominantly as unchanged drug is a major route of elimination following oral administration.', 'Azithromycin is rapidly absorbed from the GI tract after oral administration; absorption of the drug is incomplete but exceeds that of erythromycin. The absolute oral bioavailability of azithromycin is reported to be approximately 34-52% with single doses of 500 mg to 1.2 g administered as various oral dosage forms. Limited evidence indicates that the low bioavailability of zithromycin results from incomplete GI absorption rather acid degradation of the drug or extensive first-pss metabolism.', 'Azithromycin appears to be distributed into most body tissues and fluids after oral or IV administration. The extensive tissue uptake of azithromycin has been attributed to cellular uptake of this basic antibiotic into relatively acidic lysosomes as a result of iron trapping and to an energy-dependent pathway associated with the nucleoside transport system.', 'Because of rapid distribution into tissues and high intracellular concentrations of azithromycin, tissue concentrations of the drug generally exceed plasma concentrations by 10- to 100-fold following single dose administration; with multiple dosing, the tissue-to-plasma ratio increases.', 'For more Absorption, Distribution and Excretion (Complete) data for AZITHROMYCIN (10 total), please visit the HSDB record page.']","['The principal route of biotransformation involves N-demethylation of the desosamine sugar or at the 9a position on the macrolide ring. Other metabolic pathways include O-demethylation and hydrolysis and/or hydroxylation of the cladinose and desosamine sugar moieties and the macrolide ring. Up to 10 metabolites of azithromycin have been identified, and all are microbiologically inactive. While short-term administration of azithromycin produces hepatic accumulation of the drug and increases azithromycin demethylase activity, current evidence indicates that hepatic cytochrome p450 induction of inactivation via cytochrome-metabolite complex formation does not occur. In contrast to erythromycin, azithromycin does not inhibit its own metabolism via this pathway.']","['An elimination half-life of 54.5 hours has been reported in children 4 months to 15 years of age receiving single or multiple oral doses of azithromycin.', 'Plasma azithromycin concentrations following a single 500-mg oral or IV dose decline in a polyphasic manner with a terminal elimination half-life averaging 68 hours. The high values for apparent steady-state volume of distribution (31.3-33.3 L/kg) and plasma clearance (630 mL/minute, 10.18 mL/minute per kg) of azithromycin suggest that the prolonged half-life is related to extensive uptake and subsequent release of the drug from tissues. The average tissue half-life of azithromycin is estimated to be 1-4 days. The half-life of the drug in peripheral leukocytes ranges from 34-57 hours.']"
5185,55186,(2S)-1-[(2S)-6-amino-2-[[(1R)-1-carboxy-3-phenylpropyl]amino]hexanoyl]pyrrolidine-2-carboxylic acid;dihydrate,C1C[C@H](N(C1)C(=O)[C@H](CCCCN)N[C@H](CCC2=CC=CC=C2)C(=O)O)C(=O)O.O.O,,,,,,
5186,55187,"Lisinopril R,S,S-isomer",C1C[C@H](N(C1)C(=O)[C@H](CCCCN)N[C@H](CCC2=CC=CC=C2)C(=O)O)C(=O)O,,,,,,
5187,55188,"[(9R,10S,11S,13S,14S,16R,17R)-9-chloro-17-(2-chloroacetyl)-11-hydroxy-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl] furan-2-carboxylate",C[C@@H]1C[C@H]2C3CCC4=CC(=O)C=C[C@@]4([C@]3([C@H](C[C@@]2([C@]1(C(=O)CCl)OC(=O)C5=CC=CO5)C)O)Cl)C,,,,,,
5188,55189,4-Hydroperoxynon-2-enal,CCCCCC(C=CC=O)OO,,,,,,
5189,55190,Gepirone hydrochloride,CC1(CC(=O)N(C(=O)C1)CCCCN2CCN(CC2)C3=NC=CC=N3)C.Cl,,,"['Agents that alleviate ANXIETY, tension, and ANXIETY DISORDERS, promote sedation, and have a calming effect without affecting clarity of consciousness or neurologic conditions. ADRENERGIC BETA-ANTAGONISTS are commonly used in the symptomatic treatment of anxiety but are not included here. (See all compounds classified as Anti-Anxiety Agents.)', 'Mood-stimulating drugs used primarily in the treatment of affective disorders and related conditions. Several MONOAMINE OXIDASE INHIBITORS are useful as antidepressants apparently as a long-term consequence of their modulation of catecholamine levels. The tricyclic compounds useful as antidepressive agents (ANTIDEPRESSIVE AGENTS, TRICYCLIC) also appear to act through brain catecholamine systems. A third group (ANTIDEPRESSIVE AGENTS, SECOND-GENERATION) is a diverse group of drugs including some that act specifically on serotonergic systems. (See all compounds classified as Antidepressive Agents.)', 'Endogenous compounds and drugs that bind to and activate SEROTONIN RECEPTORS. Many serotonin receptor agonists are used as ANTIDEPRESSANTS; ANXIOLYTICS; and in the treatment of MIGRAINE DISORDERS. (See all compounds classified as Serotonin Receptor Agonists.)']",,,
5190,55191,Gepirone,CC1(CC(=O)N(C(=O)C1)CCCCN2CCN(CC2)C3=NC=CC=N3)C,,,"['Agents that alleviate ANXIETY, tension, and ANXIETY DISORDERS, promote sedation, and have a calming effect without affecting clarity of consciousness or neurologic conditions. ADRENERGIC BETA-ANTAGONISTS are commonly used in the symptomatic treatment of anxiety but are not included here. (See all compounds classified as Anti-Anxiety Agents.)', 'Mood-stimulating drugs used primarily in the treatment of affective disorders and related conditions. Several MONOAMINE OXIDASE INHIBITORS are useful as antidepressants apparently as a long-term consequence of their modulation of catecholamine levels. The tricyclic compounds useful as antidepressive agents (ANTIDEPRESSIVE AGENTS, TRICYCLIC) also appear to act through brain catecholamine systems. A third group (ANTIDEPRESSIVE AGENTS, SECOND-GENERATION) is a diverse group of drugs including some that act specifically on serotonergic systems. (See all compounds classified as Antidepressive Agents.)', 'Endogenous compounds and drugs that bind to and activate SEROTONIN RECEPTORS. Many serotonin receptor agonists are used as ANTIDEPRESSANTS; ANXIOLYTICS; and in the treatment of MIGRAINE DISORDERS. (See all compounds classified as Serotonin Receptor Agonists.)']",,"['Gepirone has known human metabolites that include 1-[4-[4-(5-Hydroxypyrimidin-2-yl)piperazin-1-yl]butyl]-4,4-dimethylpiperidine-2,6-dione, 2-(1-piperazinyl)pyrimidine, 3-Hydroxy-1-[4-[4-(5-hydroxypyrimidin-2-yl)piperazin-1-yl]butyl]-4,4-dimethylpiperidine-2,6-dione, and 3-Hydroxygepirone.']",
5191,55192,"Benzophenone, 2-hydroxy-4-(pentyloxy)-",CCCCCOC1=CC(=C(C=C1)C(=O)C2=CC=CC=C2)O,,,,,,
5192,55193,"3,4-Dihydro-N-(2-(3,4-dimethoxyphenyl)ethyl)-2H-1-benzopyran-3-amine",COC1=C(C=C(C=C1)CCNC2CC3=CC=CC=C3OC2)OC,,,,,,
5193,55194,"2-Chloro-N,N,11-trimethyl-11H-dibenz(b,e)(1,4)oxathiepin-11-propanamine oxalate",CC1(C2=C(C=CC(=C2)Cl)OC3=CC=CC=C3S1)CCC[NH+](C)C.C(=O)(C(=O)[O-])O,,,,,,
5194,55195,"3-(8-chloro-6-methylbenzo[b][1,5]benzoxathiepin-6-yl)-N,N-dimethylpropan-1-amine",CC1(C2=C(C=CC(=C2)Cl)OC3=CC=CC=C3S1)CCCN(C)C,,,,,,
5195,55196,"Butane-1,2,3-triyl trinitrate",CC(C(CO[N+](=O)[O-])O[N+](=O)[O-])O[N+](=O)[O-],,,,,,
5196,55197,CID 55197,CN1C2=CC=CC=C2C(=O)C(=C1O)C(=O)N(C)C3=CC=CC=C3,,,,,,
5197,55198,"4-Hydroxymethyl-3,3,4-trimethyl-1,2-dioxetane",CC1(C(OO1)(C)CO)C,,,,,,
5198,55199,"7H-Indolo(3,4-gh)(1,4)benzoxazine, 4,5,5a,6,6a,8,9,10a-octahydro-7-propyl-, (+-)-, (5a-RS(5a-alpha,6a-beta,10a-alpha))-",CCCN1CCO[C@@H]2[C@@H]1C[C@@H]3CNC4=CC=CC2=C34,,,,,,
5199,55200,"7H-Indolo(3,4-gh)(1,4)benzoxazine, 4,6,6a,8,9,10a-hexahydro-5-bromo-7-methyl-, oxalate, (+-)-(6-ars,10-ars)-",CN1CCOC2C1CC3=C([NH2+]C4=CC=CC2=C34)Br.C(=O)(C(=O)[O-])O,,,,,,
5200,55201,"10-Bromo-6-methyl-3-oxa-6,11-diazatetracyclo[7.6.1.02,7.012,16]hexadeca-1(16),9,12,14-tetraene",CN1CCOC2C1CC3=C(NC4=CC=CC2=C34)Br,,,,,,
5201,55202,N-Nitroso-N-(p-methoxybenzyl)methylamine,CN(CC1=CC=C(C=C1)OC)N=O,,,,,,
5202,55203,N-Nitroso-N-(p-fluorobenzyl)methylamine,CN(CC1=CC=C(C=C1)F)N=O,,,,,,
5203,55204,"BENZYLAMINE, p-CHLORO-N-METHYL-N-NITROSO-",CN(CC1=CC=C(C=C1)Cl)N=O,,,,,,
5204,55205,N-Nitroso-N-(p-cyanobenzyl)methylamine,CN(CC1=CC=C(C=C1)C#N)N=O,,,,,,
5205,55206,"BENZYLAMINE, N-METHYL-p-NITRO-N-NITROSO-",CN(CC1=CC=C(C=C1)[N+](=O)[O-])N=O,,,,,,
5206,55207,"ANILINE, N-(o-(2-(DIETHYLAMINO)ETHOXY)BENZYLIDENE)-",CCN(CC)CCOC1=CC=CC=C1C=NC2=CC=CC=C2,,,,,,
5207,55208,"Ammonium, allyldiethyl(((2,4,6-trimethylphenyl)carbamoyl)methyl)-",CC[N+](CC)(CC=C)CC(=O)NC1=C(C=C(C=C1C)C)C,,,,,,
5208,55209,"Ammonium, diethyl(2-propynyl)(((2,4,6-trimethylphenyl)carbamoyl)methyl)-",CC[N+](CC)(CC#C)CC(=O)NC1=C(C=C(C=C1C)C)C,,,,,,
5209,55210,"Ammonium, benzyldiethyl(((2,4,6-trimethylphenyl)carbamoyl)methyl)-",CC[N+](CC)(CC1=CC=CC=C1)CC(=O)NC2=C(C=C(C=C2C)C)C,,,,,,
5210,55211,"AMMONIUM, (o-CHLOROBENZYL)DIETHYL(((2,4,6-TRIMETHYLPHENYL)CARBAMOYL)METHYL)-",CC[N+](CC)(CC1=CC=CC=C1Cl)CC(=O)NC2=C(C=C(C=C2C)C)C,,,,,,
5211,55212,(2R)-2-amino-3-sulfanylpropanoate;iron,C([C@@H](C(=O)[O-])N)S.[Fe],,,,,,
5212,55213,"2-((m-Chloroanilino)methyl)-6,7-dimethoxy-1-(3-indolylmethyl)-1,2,3,4-tetrahydroisoquinoline",COC1=C(C=C2C(N(CCC2=C1)CNC3=CC(=CC=C3)Cl)CC4=CNC5=CC=CC=C54)OC,,,,,,
5213,55214,"6,7-Dimethoxy-1-(3-indolylmethyl)-2-((o-toluidino)methyl)-1,2,3,4-tetrahydroisoquinoline",CC1=CC=CC=C1NCN2CCC3=CC(=C(C=C3C2CC4=CNC5=CC=CC=C54)OC)OC,,,,,,
5214,55215,"6,7-Dimethoxy-1-(3-indolylmethyl)-2-((2-pyridylamino)methyl)-1,2,3,4-tetrahydroisoquinoline",COC1=C(C=C2C(N(CCC2=C1)CNC3=CC=CC=N3)CC4=CNC5=CC=CC=C54)OC,,,,,,
5215,55216,Raclopride authentic,CCN1CCC[C@@H]1CNC(=O)C2=C(C(=CC(=C2OC)Cl)Cl)O,,,,,,
5216,55217,"Benzamide, 3-ethyl-N-((1-ethyl-2-pyrrolidinyl)methyl)-2-hydroxy-6-methoxy-, (S)-",CCC1=C(C(=C(C=C1)OC)C(=O)NC[C@@H]2CCCN2CC)O,,,,,,
5217,55218,1-(Phenylthio)cyclopropanecarboxylic acid 2-(diethylamino)ethyl ester hydrochloride,CC[NH+](CC)CCOC(=O)C1(CC1)SC2=CC=CC=C2.[Cl-],,,,,,
5218,55219,2-(Diethylamino)ethyl 1-phenylsulfanylcyclopropane-1-carboxylate,CCN(CC)CCOC(=O)C1(CC1)SC2=CC=CC=C2,,,,,,
5219,55220,"BENZO(b)NAPHTHO(1,2-d)THIOPHENE, 1-METHYL-",CC1=C2C(=CC=C1)C=CC3=C2C4=CC=CC=C4S3,,,,,,
5220,55221,"BENZO(b)NAPHTHO(1,2-d)THIOPHENE, 3-METHYL-",CC1=CC2=C(C=C1)C3=C(C=C2)SC4=CC=CC=C43,,,,,,
5221,55222,"6,7-Dimethoxy-1-(3-indolylmethyl)-2-((p-toluidino)methyl)-1,2,3,4-tetrahydroisoquinoline",CC1=CC=C(C=C1)NCN2CCC3=CC(=C(C=C3C2CC4=CNC5=CC=CC=C54)OC)OC,,,,,,
5222,55223,Tucaresol,C1=CC(=C(C(=C1)OCC2=CC=C(C=C2)C(=O)O)C=O)O,,,,,,
5223,55224,"ACETAMIDINE, N'-(p-ISOPROPOXYPHENYL)-N-PHENYL-",CC(C)OC1=CC=C(C=C1)N=C(C)NC2=CC=CC=C2,,,,,,
5224,55225,"ACETAMIDINE, N,N'-BIS(p-ISOPROPOXYPHENYL)-",CC(C)OC1=CC=C(C=C1)NC(=NC2=CC=C(C=C2)OC(C)C)C,,,,,,
5225,55226,"ACETAMIDINE, N-(p-ETHOXYPHENYL)-N'-(p-ISOPROPOXYPHENYL)-",CCOC1=CC=C(C=C1)NC(=NC2=CC=C(C=C2)OC(C)C)C,,,,,,
5226,55227,"ACETAMIDINE, N'-(o-ETHOXYPHENYL)-N-(o-ISOPROPOXYPHENYL)-",CCOC1=CC=CC=C1NC(=NC2=CC=CC=C2OC(C)C)C,,,,,,
5227,55228,"ACETAMIDINE, N-(o-ISOPROPOXYPHENYL)-N'-(p-ISOPROPOXYPHENYL)-",CC(C)OC1=CC=C(C=C1)NC(=NC2=CC=CC=C2OC(C)C)C,,,,,,
5228,55229,"ACETAMIDINE, N-(p-ISOPROPOXYPHENYL)-N'-2-NAPHTHYL-",CC(C)OC1=CC=C(C=C1)N=C(C)NC2=CC3=CC=CC=C3C=C2,,,,,,
5229,55230,"N-[3-(dimethylamino)propyl]-N-(2,6-dimethylphenyl)-3-(3,4,5-trimethoxyphenyl)prop-2-enamide",CC1=C(C(=CC=C1)C)N(CCCN(C)C)C(=O)C=CC2=CC(=C(C(=C2)OC)OC)OC,,,,,,
5230,55231,"N-(3-(Dimethylamino)-2-methylpropyl)-2',6'-dimethyl-2-phenylacetanilide",CC1=C(C(=CC=C1)C)N(CC(C)CN(C)C)C(=O)CC2=CC=CC=C2,,,,,,
5231,55232,"Benzaldehyde, 2-(3-(4-phenyl-1-piperazinyl)propoxy)-",C1CN(CCN1CCCOC2=CC=CC=C2C=O)C3=CC=CC=C3,,,,,,
5232,55233,"Benzaldehyde, 3-(3-(4-phenyl-1-piperazinyl)propoxy)-",C1CN(CCN1CCCOC2=CC=CC(=C2)C=O)C3=CC=CC=C3,,,,,,
5233,55234,"Benzaldehyde, 4-(3-(4-phenyl-1-piperazinyl)propoxy)-",C1CN(CCN1CCCOC2=CC=C(C=C2)C=O)C3=CC=CC=C3,,,,,,
5234,55235,"2(1H)-Naphthalenone, 3,4-dihydro-6-(3-(4-phenyl-1-piperazinyl)propoxy)-, dihydrochloride",C1CC2=C(C=CC(=C2)OCCCN3CCN(CC3)C4=CC=CC=C4)C(=O)C1.Cl.Cl,,,,,,
5235,55236,"6-[3-(4-phenylpiperazin-1-yl)propoxy]-3,4-dihydro-2H-naphthalen-1-one",C1CC2=C(C=CC(=C2)OCCCN3CCN(CC3)C4=CC=CC=C4)C(=O)C1,,,,,,
5236,55237,"2(1H)-Naphthalenone, 3,4-dihydro-7-(3-(4-phenyl-1-piperazinyl)propoxy)-",C1CC2=C(C=C(C=C2)OCCCN3CCN(CC3)C4=CC=CC=C4)C(=O)C1,,,,,,
5237,55238,"Benzaldehyde, 3-(3-(4-(4-methoxyphenyl)-1-piperazinyl)propoxy)-",COC1=CC=C(C=C1)N2CCN(CC2)CCCOC3=CC=CC(=C3)C=O,,,,,,
5238,55239,"Benzaldehyde, 4-(3-(4-(4-methoxyphenyl)-1-piperazinyl)propoxy)-",COC1=CC=C(C=C1)N2CCN(CC2)CCCOC3=CC=C(C=C3)C=O,,,,,,
5239,55240,"Benzaldehyde, 3-(3-(4-(4-chlorophenyl)-1-piperazinyl)propoxy)-",C1CN(CCN1CCCOC2=CC=CC(=C2)C=O)C3=CC=C(C=C3)Cl,,,,,,
5240,55241,"Benzaldehyde, 3-(3-(4-(3-(trifluoromethyl)phenyl)-1-piperazinyl)propoxy)-, dihydrochloride",C1CN(CCN1CCCOC2=CC=CC(=C2)C=O)C3=CC=CC(=C3)C(F)(F)F.Cl.Cl,,,,,,
5241,55242,3-[3-[4-[3-(Trifluoromethyl)phenyl]piperazin-1-yl]propoxy]benzaldehyde,C1CN(CCN1CCCOC2=CC=CC(=C2)C=O)C3=CC=CC(=C3)C(F)(F)F,,,,,,
5242,55243,"Benzaldehyde, 4-(3-(4-(3-(trifluoromethyl)phenyl)-1-piperazinyl)propoxy)-",C1CN(CCN1CCCOC2=CC=C(C=C2)C=O)C3=CC=CC(=C3)C(F)(F)F,,,,,,
5243,55244,"2-Chloro-3-propoxy-1,4-naphthoquinone",CCCOC1=C(C(=O)C2=CC=CC=C2C1=O)Cl,,,,,,
5244,55245,Mifepristone,CC#C[C@@]1(CC[C@@H]2[C@@]1(C[C@@H](C3=C4CCC(=O)C=C4CC[C@@H]23)C5=CC=C(C=C5)N(C)C)C)O,"[""For the medical termination of intrauterine pregnancy through 49 days' pregnancy. Also indicated to control hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type 2 diabetes mellitus or glucose intolerance and are not candidates for surgery or have had unsuccessful surgery.""]","[""Mifepristone is a synthetic steroid with antiprogestational effects indicated for the medical termination of intrauterine pregnancy through 49 days' pregnancy. Doses of 1 mg/kg or greater of mifepristone have been shown to antagonize the endometrial and myometrial effects of progesterone in women. During pregnancy, the compound sensitizes the myometrium to the contraction-inducing activity of prostaglandins. Mifepristone also exhibits antiglucocorticoid and weak antiandrogenic activity. The activity of the glucocorticoid dexamethasone in rats was inhibited following doses of 10 to 25 mg/kg of mifepristone. Doses of 4.5 mg/kg or greater in human beings resulted in a compensatory elevation of adrenocorticotropic hormone (ACTH) and cortisol.""]","['Oral contraceptives which owe their effectiveness to synthetic preparations. (See all compounds classified as Contraceptives, Oral, Synthetic.)', 'Chemical compounds that cause LUTEOLYSIS or degeneration of the CORPUS LUTEUM. (See all compounds classified as Luteolytic Agents.)', 'Postcoital contraceptives which owe their effectiveness to synthetic preparations. (See all compounds classified as Contraceptives, Postcoital, Synthetic.)', 'Steroidal compounds with abortifacient activity. (See all compounds classified as Abortifacient Agents, Steroidal.)', 'Chemical compounds that induce menstruation either through direct action on the reproductive organs or through indirect action by relieving another condition of which amenorrhea is a secondary result. (From Dorland, 27th ed) (See all compounds classified as Menstruation-Inducing Agents.)', 'Chemical substances which inhibit the function of the endocrine glands, the biosynthesis of their secreted hormones, or the action of hormones upon their specific sites. (See all compounds classified as Hormone Antagonists.)']","['The absolute bioavailability of a 20 mg oral dose is 69%', 'Fecal: 83%; Renal: 9%.', 'The absolute bioavailability of oral mifepristone is 69%.', 'Protein binding: Very high (98%); predominantly to albumin and alpha1- acid glycoprotein.', 'Time to peak concentration: 90 minutes after a 600 mg oral dose.', 'Peak plasma concentration: 1.98 mg/L following a single 600 mg oral dose.', 'Fecal; 83% of a 600 mg dose over 11 days. Renal; 9% of a 600 mg dose over 11 days.']","['Hepatic. Hepatic, by Cytochrome P450 3A4 isoenzyme to the N-monodemethylated metabolite (RU 42 633); RU 42 698, which results from the loss of two methyl groups from position 11 beta; and RU 42 698, which results from terminal hydroxylation of the 17&ndash;propynyl chain.', 'Hepatic, by Cytochrome P450 3A4 isoenzyme to the N-monodemethylated metabolite (RU 42 633); RU 42 698, which results from terminal  hydroxylation of the 17-propynyl chain.', 'Mifepristone has known human metabolites that include 17alpha-hydroxymifepristone and Monodemethylated mifepristone.']","['18 hours', 'Terminal: 18 hours; begins slowly and becomes more rapid with time.']"
5245,55246,Methyl((2-(2-pyridinyl)ethoxy)sulfinyl)carbamic acid 3-methylphenyl ester,CC1=CC(=CC=C1)OC(=O)N(C)S(=O)OCCC2=CC=CC=N2,,,,,,
5246,55247,Methyl((2-pyridinylmethoxy)sulfinyl)carbamic acid 3-methylphenyl ester,CC1=CC(=CC=C1)OC(=O)N(C)S(=O)OCC2=CC=CC=N2,,,,,,
5247,55248,"Carbamic acid, methyl((2-pyridinylmethoxy)sulfinyl)-, 3-(1-methylethyl)phenyl ester",CC(C)C1=CC(=CC=C1)OC(=O)N(C)S(=O)OCC2=CC=CC=N2,,,,,,
5248,55249,Methyl((2-(2-pyridinyl)ethoxy)sulfinyl)carbamic acid 3-(1-methylethyl)phenyl ester,CC(C)C1=CC(=CC=C1)OC(=O)N(C)S(=O)OCCC2=CC=CC=N2,,,,,,
5249,55250,"Carbamic acid, methyl((3-(3-pyridinyl)propoxy)sulfinyl)-, 3-(1-methylethyl)phenyl ester",CC(C)C1=CC(=CC=C1)OC(=O)N(C)S(=O)OCCCC2=CN=CC=C2,,,,,,
5250,55251,Xenalipin,C1=CC=C(C(=C1)C2=CC=C(C=C2)C(F)(F)F)C(=O)O,,,,,,
5251,55252,"Diethyl-[2-[4-(7-methoxy-2,2-dimethyl-3-phenyl-3,4-dihydrochromen-4-yl)phenoxy]ethyl]azanium;chloride",CC[NH+](CC)CCOC1=CC=C(C=C1)C2C(C(OC3=C2C=CC(=C3)OC)(C)C)C4=CC=CC=C4.[Cl-],,,,,,
5252,55253,"N,N-diethyl-2-[4-(7-methoxy-2,2-dimethyl-3-phenyl-3,4-dihydrochromen-4-yl)phenoxy]ethanamine",CCN(CC)CCOC1=CC=C(C=C1)C2C(C(OC3=C2C=CC(=C3)OC)(C)C)C4=CC=CC=C4,,,,,,
5253,55254,"2-[4-(7-Methoxy-2,2-dimethyl-3-phenyl-3,4-dihydrochromen-4-yl)phenoxy]ethyl-dimethylazanium;chloride",CC1(C(C(C2=C(O1)C=C(C=C2)OC)C3=CC=C(C=C3)OCC[NH+](C)C)C4=CC=CC=C4)C.[Cl-],,,,,,
5254,55255,"2-[4-(7-methoxy-2,2-dimethyl-3-phenyl-3,4-dihydrochromen-4-yl)phenoxy]-N,N-dimethylethanamine",CC1(C(C(C2=C(O1)C=C(C=C2)OC)C3=CC=C(C=C3)OCCN(C)C)C4=CC=CC=C4)C,,,,,,
5255,55256,Desciclovir,C1=C2C(=NC(=N1)N)N(C=N2)COCCO,,,['Agents used in the prophylaxis or therapy of VIRUS DISEASES. Some of the ways they may act include preventing viral replication by inhibiting viral DNA polymerase; binding to specific cell-surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking late stages of virus assembly. (See all compounds classified as Antiviral Agents.)'],,,
5256,55257,"L-Alanine, 2-(2-oxo-2-(10H-phenothiazin-10-YL)ethyl)hydrazide",C[C@@H](C(=O)NNCC(=O)N1C2=CC=CC=C2SC3=CC=CC=C31)N,,,,,,
5257,55258,"1,2-Dihydroacenaphthylenecarboxaldehyde",C1CC2=C3C1=CC=CC3=CC(=C2)C=O,,,,,,
5258,55259,"Benzenamine, 4-((4-fluorophenyl)tellurinyl)-N,N-dimethyl-",CN(C)C1=CC=C(C=C1)[Te](=O)C2=CC=C(C=C2)F,,,,,,
5259,55260,N-Acetyl-2-chloropyrrole,CC(=O)N1C=CC=C1Cl,,,,,,
5260,55261,1-Acetyl-2-bromopyrrole,CC(=O)N1C=CC=C1Br,,,,,,
5261,55262,Navuridine,C1[C@@H]([C@H](O[C@H]1N2C=CC(=O)NC2=O)CO)N=[N+]=[N-],,,,,,
5262,55263,Piroximone,CCC1=C(NC(=O)N1)C(=O)C2=CC=NC=C2,,,"['Agents that have a strengthening effect on the heart or that can increase cardiac output. They may be CARDIAC GLYCOSIDES; SYMPATHOMIMETICS; or other drugs. They are used after MYOCARDIAL INFARCT; CARDIAC SURGICAL PROCEDURES; in SHOCK; or in congestive heart failure (HEART FAILURE). (See all compounds classified as Cardiotonic Agents.)', 'Drugs or agents which antagonize or impair any mechanism leading to blood platelet aggregation, whether during the phases of activation and shape change or following the dense-granule release reaction and stimulation of the prostaglandin-thromboxane system. (See all compounds classified as Platelet Aggregation Inhibitors.)', 'Compounds which inhibit or antagonize the biosynthesis or actions of phosphodiesterases. (See all compounds classified as Phosphodiesterase Inhibitors.)']",,,
5263,55264,CID 55264,COC(=O)C1=CC=C(C=C1)NC(=O)C2=CC=C(C=C2)NC3=C4C=C(C=CC4=NC3=O)Cl,,,,,,
5264,55265,CID 55265,CCOC(=O)C1=CC=C(C=C1)NC(=O)C2=CC=C(C=C2)NC3=C4C=C(C=CC4=NC3=O)Cl,,,,,,
5265,55266,CID 55266,CCCOC(=O)C1=CC=C(C=C1)NC(=O)C2=CC=C(C=C2)NC3=C4C=C(C=CC4=NC3=O)Cl,,,,,,
5266,55267,CID 55267,CCCCOC(=O)C1=CC=C(C=C1)NC(=O)C2=CC=C(C=C2)NC3=C4C=C(C=CC4=NC3=O)Cl,,,,,,
5267,55268,"Benzoic acid, 4-((4-((5-chloro-1,2-dihydro-1-methyl-2-oxo-3H-indol-3-ylidene)amino)benzoyl)amino)-, ethyl ester",CCOC(=O)C1=CC=C(C=C1)NC(=O)C2=CC=C(C=C2)N=C3C4=C(C=CC(=C4)Cl)N(C3=O)C,,,,,,
5268,55269,"Benzoic acid, 4-((4-((5-chloro-1,2-dihydro-1-methyl-2-oxo-3H-indol-3-ylidene)amino)benzoyl)amino)-, propyl ester",CCCOC(=O)C1=CC=C(C=C1)NC(=O)C2=CC=C(C=C2)N=C3C4=C(C=CC(=C4)Cl)N(C3=O)C,,,,,,
5269,55270,"Benzoic acid, 4-((4-((5-chloro-1,2-dihydro-1-methyl-2-oxo-3H-indol-3-ylidene)amino)benzoyl)amino)-, butyl ester",CCCCOC(=O)C1=CC=C(C=C1)NC(=O)C2=CC=C(C=C2)N=C3C4=C(C=CC(=C4)Cl)N(C3=O)C,,,,,,
5270,55271,"Benzoic acid, 4-((4-((5-chloro-1,2-dihydro-1-(4-morpholinylmethyl)-2-oxo-3H-indol-3-ylidene)amino)benzoyl)amino)-, methyl ester",COC(=O)C1=CC=C(C=C1)NC(=O)C2=CC=C(C=C2)N=C3C4=C(C=CC(=C4)Cl)N(C3=O)CN5CCOCC5,,,,,,
5271,55272,"Benzoic acid, 4-((4-((5-chloro-1,2-dihydro-2-oxo-1-(1-piperidinylmethyl)-3H-indol-3-ylidene)amino)benzoyl)amino)-, methyl ester",COC(=O)C1=CC=C(C=C1)NC(=O)C2=CC=C(C=C2)N=C3C4=C(C=CC(=C4)Cl)N(C3=O)CN5CCCCC5,,,,,,
5272,55273,"Benzoic acid, 4-((4-((5-chloro-1,2-dihydro-1-(4-morpholinylmethyl)-2-oxo-3H-indol-3-ylidene)amino)benzoyl)amino)-, ethyl ester",CCOC(=O)C1=CC=C(C=C1)NC(=O)C2=CC=C(C=C2)N=C3C4=C(C=CC(=C4)Cl)N(C3=O)CN5CCOCC5,,,,,,
5273,55274,"Benzoic acid, 4-((4-((5-chloro-1,2-dihydro-2-oxo-1-(1-piperidinylmethyl)-3H-indol-3-ylidene)amino)benzoyl)amino)-, ethyl ester",CCOC(=O)C1=CC=C(C=C1)NC(=O)C2=CC=C(C=C2)N=C3C4=C(C=CC(=C4)Cl)N(C3=O)CN5CCCCC5,,,,,,
5274,55275,"Benzoic acid, 4-((4-((5-chloro-1,2-dihydro-1-(4-morpholinylmethyl)-2-oxo-3H-indol-3-ylidene)amino)benzoyl)amino)-, propyl ester",CCCOC(=O)C1=CC=C(C=C1)NC(=O)C2=CC=C(C=C2)N=C3C4=C(C=CC(=C4)Cl)N(C3=O)CN5CCOCC5,,,,,,
5275,55276,"Benzoic acid, 4-((4-((5-chloro-1,2-dihydro-2-oxo-1-(1-piperidinylmethyl)-3H-indol-3-ylidene)amino)benzoyl)amino)-, propyl ester",CCCOC(=O)C1=CC=C(C=C1)NC(=O)C2=CC=C(C=C2)N=C3C4=C(C=CC(=C4)Cl)N(C3=O)CN5CCCCC5,,,,,,
5276,55277,"Benzoic acid, 4-((4-((5-chloro-1,2-dihydro-1-(4-morpholinylmethyl)-2-oxo-3H-indol-3-ylidene)amino)benzoyl)amino)-, butyl ester",CCCCOC(=O)C1=CC=C(C=C1)NC(=O)C2=CC=C(C=C2)N=C3C4=C(C=CC(=C4)Cl)N(C3=O)CN5CCOCC5,,,,,,
5277,55278,"Benzoic acid, 4-((4-((5-chloro-1,2-dihydro-2-oxo-1-(1-piperidinylmethyl)-3H-indol-3-ylidene)amino)benzoyl)amino)-, butyl ester",CCCCOC(=O)C1=CC=C(C=C1)NC(=O)C2=CC=C(C=C2)N=C3C4=C(C=CC(=C4)Cl)N(C3=O)CN5CCCCC5,,,,,,
5278,55279,5-Hydroxychrysene,C1=CC=C2C(=C1)C=CC3=C2C(=CC4=CC=CC=C34)O,,,,,,
5279,55280,"Benzoic acid, 4-((4-((5-chloro-1,2-dihydro-1-methyl-2-oxo-3H-indol-3-ylidene)amino)benzoyl)amino)-, methyl ester",CN1C2=C(C=C(C=C2)Cl)C(=NC3=CC=C(C=C3)C(=O)NC4=CC=C(C=C4)C(=O)OC)C1=O,,,,,,
5280,55281,Netivudine,CC#CC1=CN(C(=O)NC1=O)[C@H]2[C@H]([C@@H]([C@H](O2)CO)O)O,,,['Agents used in the prophylaxis or therapy of VIRUS DISEASES. Some of the ways they may act include preventing viral replication by inhibiting viral DNA polymerase; binding to specific cell-surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking late stages of virus assembly. (See all compounds classified as Antiviral Agents.)'],,,
5281,55282,Methyl((3-(2-pyridinyl)propoxy)sulfinyl)carbamic acid 3-methylphenyl ester,CC1=CC(=CC=C1)OC(=O)N(C)S(=O)OCCCC2=CC=CC=N2,,,,,,
5282,55283,Itraconazole,CCC(C)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OC[C@H]5CO[C@](O5)(CN6C=NC=N6)C7=C(C=C(C=C7)Cl)Cl,"['For the treatment of the following fungal infections in immunocompromised and non-immunocompromised patients: pulmonary and extrapulmonary blastomycosis, histoplasmosis, aspergillosis, and onychomycosis.']","['Itraconazole is an imidazole/triazole type antifungal agent. Itraconazole is a highly selective inhibitor of fungal cytochrome P-450 sterol C-14 &alpha;-demethylation via the inhibition of the enzyme cytochrome P450 14&alpha;-demethylase. This enzyme converts lanosterol to ergosterol, and is required in fungal cell wall synthesis. The subsequent loss of normal sterols correlates with the accumulation of 14 &alpha;-methyl sterols in fungi and may be partly responsible for the fungistatic activity of fluconazole. Mammalian cell demethylation is much less sensitive to fluconazole inhibition. Itraconazole exhibits <i>in vitro</i> activity against <i>Cryptococcus neoformans</i> and <i>Candida spp.</i> Fungistatic activity has also been demonstrated in normal and immunocompromised animal models for systemic and intracranial fungal infections due to <i>Cryptococcus neoformans</i> and for systemic infections due to <i>Candida albicans</i>.']","['Compounds that specifically inhibit STEROL 14-DEMETHYLASE. A variety of azole-derived ANTIFUNGAL AGENTS act through this mechanism. (See all compounds classified as 14-alpha Demethylase Inhibitors.)', 'Substances that destroy fungi by suppressing their ability to grow or reproduce. They differ from FUNGICIDES, INDUSTRIAL because they defend against fungi present in human or animal tissues. (See all compounds classified as Antifungal Agents.)', 'Drugs and compounds which inhibit or antagonize the biosynthesis or actions of CYTOCHROME P-450 CYP3A. (See all compounds classified as Cytochrome P-450 CYP3A Inhibitors.)']","['The absolute oral bioavailability of itraconazole is 55%, and is maximal when taken with a full meal.', 'Itraconazole is metabolized predominately by the cytochrome P450 3A4 isoenzyme system (CYP3A4) in the liver, resulting in the formation of several metabolites, including hydroxyitraconazole, the major metabolite. Fecal excretion of the parent drug varies between 3-18% of the dose. Renal excretion of the parent drug is less than 0.03% of the dose. About 40% of the dose is excreted as inactive metabolites in the urine. No single excreted metabolite represents more than 5% of a dose.', '796 ± 185 L', '381 +/- 95 mL/minute [IV administration]', 'The pharmacokinetics of itraconazole after intravenous administration and its absolute oral bioavailability from an oral solution were studied in a randomized crossover study in 6 healthy male volunteers. The observed absolute oral bioavailability of itraconazole was 55%.', 'The oral bioavailability of itraconazole is maximal when itraconazole capsules are taken with a full meal. The pharmacokinetics of itraconazole were studied in 6 healthy male volunteers who received, in a crossover design, single 100 mg doses of itraconazole as a polyethylene glycol capsule, with or without a full meal. The same 6 volunteers also received 50 mg or 200 mg with a full meal in a crossover design. In this study, only itraconazole plasma concentrations were measured. The respective pharmacokinetic parameters for itraconazole are presented in the table /provided/.', 'Steady-state concentrations were reached within 15 days following oral doses of 50 mg to 400 mg daily. Values given in the table below are data at steady-state from a pharmacokinetics study in which 27 healthy male volunteers took 200 mg itraconazole capsules b.i.d. (with a full meal) for 15 days [Table#7592]', 'Thirty healthy men received single 200 mg doses of itraconazole capsules under fasted conditions either 1) with water; 2) with water, after ranitidine 150 mg b.i.d. for 3 days; or 3) with cola, after ranitidine 150 mg b.i.d. for 3 days. When itraconazole capsules were administered after ranitidine pretreatment, itraconazole was absorbed to a lesser extent than when itraconazole capsules were administered alone, with decreases in AUC0-24 and Cmax of 39% +/- 37% and 42% +/- 39%, respectively. When itraconazole capsules were administered with cola after ranitidine pretreatment, itraconazole absorption was comparable to that observed when itraconazole capsules were administered alone.', 'For more Absorption, Distribution and Excretion (Complete) data for Itraconazole (11 total), please visit the HSDB record page.']","['Itraconazole is extensively metabolized by the liver into a large number of metabolites, including hydroxyitraconazole, the major metabolite. The main metabolic pathways are oxidative scission of the dioxolane ring, aliphatic oxidation at the 1-methylpropyl substituent, N-dealkylation of this 1-methylpropyl substituent, oxidative degradation of the piperazine ring and triazolone scission.', 'Itraconazole is metabolized predominantly by the cytochrome P450 3A4 isoenzyme system (CYP3A4), resulting in the formation of several metabolites, including hydroxyitraconazole, the major metabolite. Results of a pharmacokinetics study suggest that itraconazole may undergo saturable metabolism with multiple dosing.', 'Itraconazole (ITZ) is metabolized in vitro to three inhibitory metabolites: hydroxy-itraconazole (OH-ITZ), keto-itraconazole (keto-ITZ), and N-desalkyl-itraconazole (ND-ITZ). The goal of this study was to determine the contribution of these metabolites to drug-drug interactions caused by ITZ. Six healthy volunteers received 100 mg ITZ orally for 7 days, and pharmacokinetic analysis was conducted at days 1 and 7 of the study. The extent of CYP3A4 inhibition by ITZ and its metabolites was predicted using this data. ITZ, OH-ITZ, keto-ITZ, and ND-ITZ were detected in plasma samples of all volunteers. A 3.9-fold decrease in the hepatic intrinsic clearance of a CYP3A4 substrate was predicted using the average unbound steady-state concentrations (C(ss,ave,u)) and liver microsomal inhibition constants for ITZ, OH-ITZ, keto-ITZ, and ND-ITZ. Accounting for circulating metabolites of ITZ significantly improved the in vitro to in vivo extrapolation of CYP3A4 inhibition compared to a consideration of ITZ exposure alone.']",['21 hours']
5283,55284,"ANILINE, N,N-BIS(2-CHLOROETHYL)-p-PROPOXY-",CCCOC1=CC=C(C=C1)N(CCCl)CCCl,,,,,,
5284,55285,Dotarizine,C1CN(CCN1CCCC2(OCCO2)C3=CC=CC=C3)C(C4=CC=CC=C4)C5=CC=CC=C5,['Investigated for use/treatment in migraine and cluster headaches.'],,"['Drugs that bind to but do not activate serotonin receptors, thereby blocking the actions of serotonin or SEROTONIN RECEPTOR AGONISTS. (See all compounds classified as Serotonin Antagonists.)', 'A class of drugs that act by selective inhibition of calcium influx through cellular membranes. (See all compounds classified as Calcium Channel Blockers.)', 'Drugs used to cause dilation of the blood vessels. (See all compounds classified as Vasodilator Agents.)']",,,
5285,55286,2-[2-[(1-Carboxy-3-phenylpropyl)amino]propanoyl]pyrrolidine-1-carboxylic acid;dihydrate,CC(C(=O)C1CCCN1C(=O)O)NC(CCC2=CC=CC=C2)C(=O)O.O.O,,,,,,
5286,55287,2-[2-[(1-Carboxy-3-phenylpropyl)amino]propanoyl]pyrrolidine-1-carboxylic acid,CC(C(=O)C1CCCN1C(=O)O)NC(CCC2=CC=CC=C2)C(=O)O,,,,,,
5287,55288,"NAPHTHO(2,1-b)FURAN, METHOXY-2-NITRO-",COC1=C(OC2=C1C3=CC=CC=C3C=C2)[N+](=O)[O-],,,,,,
5288,55289,N-Formyl-p-nitrophenylhydroxylamine,C1=CC(=CC=C1N(C=O)O)[N+](=O)[O-],,,,,,
5289,55290,"1,2,7,8-Tetrabromodibenzofuran",C1=CC(=C(C2=C1OC3=CC(=C(C=C32)Br)Br)Br)Br,,,,,,
5290,55291,"1,2,8-Tribromodibenzofuran",C1=CC2=C(C=C1Br)C3=C(O2)C=CC(=C3Br)Br,,,,,,
5291,55292,"2,3,8-Tribromodibenzofuran",C1=CC2=C(C=C1Br)C3=CC(=C(C=C3O2)Br)Br,,,,,,
5292,55293,1-Chlorodibenzofuran,C1=CC=C2C(=C1)C3=C(O2)C=CC=C3Cl,,,,,,
5293,55294,"Acetic acid, ((6-methyl-2-benzothiazolyl)amino)oxo-, ethyl ester",CCOC(=O)C(=O)NC1=NC2=C(S1)C=C(C=C2)C,,,,,,
5294,55295,((6-Bromo-2-benzothiazolyl)amino)oxoacetic acid ethyl ester,CCOC(=O)C(=O)NC1=NC2=C(S1)C=C(C=C2)Br,,,,,,
5295,55296,Methyl 4-amino-3-phenylbutanoate,COC(=O)CC(CN)C1=CC=CC=C1,,,,,,
5296,55297,CID 55297,C[NH+](C)CCCC1(C2=CC=CC=C2CSC3=CC=CC=C31)C4=CC=CC=C4.C(=CC(=O)[O-])C(=O)O,,,,,,
5297,55298,"N,N-dimethyl-3-(11-phenyl-6H-benzo[c][1]benzothiepin-11-yl)propan-1-amine",CN(C)CCCC1(C2=CC=CC=C2CSC3=CC=CC=C31)C4=CC=CC=C4,,,,,,
5298,55299,CID 55299,C[NH+](C)CCCC1=CC2=C(C=C1)C(C3=CC=CC=C3CS2)C4=CC=CC=C4.C(=CC(=O)[O-])C(=O)O,,,,,,
5299,55300,"N,N-dimethyl-3-(11-phenyl-6,11-dihydrobenzo[c][1]benzothiepin-3-yl)propan-1-amine",CN(C)CCCC1=CC2=C(C=C1)C(C3=CC=CC=C3CS2)C4=CC=CC=C4,,,,,,
5300,55301,2-(Butylamino)-3'-chlorobutyranilide,CCCCNC(CC)C(=O)NC1=CC(=CC=C1)Cl,,,,,,
5301,55302,"Ether, 2-chloroethyl 2,3-dichloroallyl",C(CCl)OCC(=CCl)Cl,,,,,,
5302,55303,"[(2R,3R,5R,6S,8R,10R,17S)-4,5,7,8-tetraacetyloxy-11-ethyl-6,16,18-trimethoxy-13-(methoxymethyl)-11-azahexacyclo[7.7.2.12,5.01,10.03,8.013,17]nonadecan-14-yl] acetate",CCN1CC2([C@H]3C(C4[C@@H]1C3([C@@H]5C[C@@]6([C@H](C([C@]4([C@H]5C6OC(=O)C)OC(=O)C)OC(=O)C)OC)OC(=O)C)C(CC2OC(=O)C)OC)OC)COC,,,,,,
5303,55304,Suricainide,CCN(CC)CCNC(=O)N(CCS(=O)(=O)C1=CC=CC=C1)C(C)C,,,,,,
5304,55305,Iofetamine hydrochloride,CC(C)NC(C)CC1=CC=C(C=C1)I.Cl,,,,,,
5305,55306,"2-Methyl-2-(2-thienyl)-1,3-dithiolane",CC1(SCCS1)C2=CC=CS2,,,,,,
5306,55307,2-Amino-4-boronobenzoic acid,B(C1=CC(=C(C=C1)C(=O)O)N)(O)O,,,,,,
5307,55308,"Glycine, N,N'-1,2-ethanediylbis(N-((2-hydroxyphenyl)methyl)-, dimethyl ester",COC(=O)CN(CCN(CC1=CC=CC=C1O)CC(=O)OC)CC2=CC=CC=C2O,,,,,,
5308,55309,6'-Methoxycinchonan-9-ol--hydrogen chloride (1/2),COC1=CC2=C(C=CN=C2C=C1)[C@@H]([C@H]3CC4CCN3C[C@@H]4C=C)O.Cl.Cl,,,,,,
5309,55310,"[(1S,2R,3S,4S,5R,6S)-2,3,5-trihydroxy-4,6-diphosphonooxycyclohexyl] dihydrogen phosphate",[C@@H]1([C@H]([C@@H]([C@H]([C@@H]([C@H]1OP(=O)(O)O)O)OP(=O)(O)O)OP(=O)(O)O)O)O,,,,,,
5310,55311,2-(4-Morpholinyl)ethyl benzo(b)thiophene-3-carboxylate hydrochloride,C1COCC[NH+]1CCOC(=O)C2=CSC3=CC=CC=C32.[Cl-],,,,,,
5311,55312,2-Morpholin-4-ylethyl 1-benzothiophene-3-carboxylate,C1COCCN1CCOC(=O)C2=CSC3=CC=CC=C32,,,,,,
5312,55313,"Benzo(b)thiophene-3-carboxylic acid, 2-(dimethylamino)-2-methylpropyl ester, hydrochloride",CC(C)(COC(=O)C1=CSC2=CC=CC=C21)[NH+](C)C.[Cl-],,,,,,
5313,55314,[2-(Dimethylamino)-2-methylpropyl] 1-benzothiophene-3-carboxylate,CC(C)(COC(=O)C1=CSC2=CC=CC=C21)N(C)C,,,,,,
5314,55315,N-(2-(Diethylamino)ethyl)benzo(b)thiophene-3-carboxamide hydrochloride,CC[NH+](CC)CCNC(=O)C1=CSC2=CC=CC=C21.[Cl-],,,,,,
5315,55316,N-[2-(diethylamino)ethyl]-1-benzothiophene-3-carboxamide,CCN(CC)CCNC(=O)C1=CSC2=CC=CC=C21,,,,,,
5316,55317,Ferrous orotate,C1=C(NC(=O)NC1=O)C(=O)[O-].C1=C(NC(=O)NC1=O)C(=O)[O-].[Fe+2],,,,,,
5317,55318,"Dibenzo(b,f)thiepin-2-sulfonamide, 10,11-dihydro-7-fluoro-11-(4-(2-hydroxyethyl)-1-piperazinyl)-N,N-dimethyl-, hydrochloride, hydrate (1:2:1)",CN(C)S(=O)(=O)C1=CC2=C(C=C1)SC3=C(CC2N4CCN(CC4)CCO)C=CC(=C3)F.Cl.Cl,,,,,,
5318,55319,"9-fluoro-5-[4-(2-hydroxyethyl)piperazin-1-yl]-N,N-dimethyl-5,6-dihydrobenzo[b][1]benzothiepine-3-sulfonamide",CN(C)S(=O)(=O)C1=CC2=C(C=C1)SC3=C(CC2N4CCN(CC4)CCO)C=CC(=C3)F,,,,,,
5319,55320,"(1R,14R)-14-(ethylsulfanyl)-1-fluoro-17-hydroxy-2,15-dimethyl-14-(methylsulfanyl)tetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadeca-3,6-dien-5-one",CCS[C@@]1(CCC2C1(CC([C@]3(C2CCC4=CC(=O)C=CC43C)F)O)C)SC,,,,,,
5320,55321,CID 55321,CCCCCC(C=CC1C(C(CC1=O)O)CCOCCCC(=O)O)O,,,,,,
5321,55322,"1,2,3-Trichlorooctane",CCCCCC(C(CCl)Cl)Cl,,,,,,
5322,55323,7-[5-Hydroxy-2-(3-hydroxy-5-phenyloct-1-enyl)-3-oxocyclopentyl]hept-5-enoic acid,CCCC(CC(C=CC1C(C(CC1=O)O)CC=CCCCC(=O)O)O)C2=CC=CC=C2,,,,,,
5323,55324,Cefpimizole sodium,C1C(=C(N2[C@H](S1)[C@@H](C2=O)NC(=O)[C@H](C3=CC=CC=C3)NC(=O)C4=C(NC=N4)C(=O)O)C(=O)[O-])C[N+]5=CC=C(C=C5)CCS(=O)(=O)[O-].[Na+],,,['Substances that inhibit the growth or reproduction of BACTERIA. (See all compounds classified as Anti-Bacterial Agents.)'],,,
5324,55325,"(6R,7R)-7-[[(2S)-2-[(5-carboxy-1H-imidazole-4-carbonyl)amino]-2-phenylacetyl]amino]-8-oxo-3-[[4-(2-sulfoethyl)pyridin-1-ium-1-yl]methyl]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid",C1C(=C(N2[C@H](S1)[C@@H](C2=O)NC(=O)[C@H](C3=CC=CC=C3)NC(=O)C4=C(NC=N4)C(=O)O)C(=O)O)C[N+]5=CC=C(C=C5)CCS(=O)(=O)O,,,,,,
5325,55326,2-Methyl-4'-phenylbenzophenone,CC1=CC=CC=C1C(=O)C2=CC=C(C=C2)C3=CC=CC=C3,,,,,,
5326,55327,"1,2,5-Trichloro-3,4-dimethoxybenzene",COC1=C(C(=C(C=C1Cl)Cl)Cl)OC,,,,,,
5327,55328,"ACETIC ACID, THIO-, S,S'-(2-HYDROXYTRIMETHYLENE) ESTER, p-TOLUENESULFONATE",CC1=CC=C(C=C1)S(=O)(=O)OC(CSC(=O)C)CSC(=O)C,,,,,,
5328,55329,Pinacidil monohydrate,CC(C(C)(C)C)N=C(NC#N)NC1=CC=NC=C1.O,,,"['Drugs used in the treatment of acute or chronic vascular HYPERTENSION regardless of pharmacological mechanism. Among the antihypertensive agents are DIURETICS; (especially DIURETICS, THIAZIDE); ADRENERGIC BETA-ANTAGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; GANGLIONIC BLOCKERS; and VASODILATOR AGENTS. (See all compounds classified as Antihypertensive Agents.)', 'Agents that affect ION PUMPS; ION CHANNELS; ABC TRANSPORTERS; and other MEMBRANE TRANSPORT PROTEINS. (See all compounds classified as Membrane Transport Modulators.)', 'Drugs used to cause dilation of the blood vessels. (See all compounds classified as Vasodilator Agents.)']",,,
5329,55330,"5,5-Diethyl-1-isopropylbarbituric acid",CCC1(C(=O)NC(=O)N(C1=O)C(C)C)CC,,,,,,
5330,55331,Moexiprilat,C[C@@H](C(=O)N1CC2=CC(=C(C=C2C[C@H]1C(=O)O)OC)OC)N[C@@H](CCC3=CC=CC=C3)C(=O)O,,,,,,
5331,55332,"Benzo(b)thiophene-2-carboxylic acid, 4,5,6,7-tetrahydro-3-(2-hydroxy-3-((1-methylethyl)amino)propoxy)-, ethyl ester",CCOC(=O)C1=C(C2=C(S1)CCCC2)OCC(CNC(C)C)O,,,,,,
5332,55333,"Benzo(b)thiophene-2-carboxylic acid, 4,5,6,7-tetrahydro-2-(3-((1,1-dimethylethyl)amino)-2-hydroxypropoxy)-, ethyl ester, hydrochloride",CCOC(=O)C1=C(C2=C(S1)CCCC2)OCC(C[NH2+]C(C)(C)C)O.[Cl-],,,,,,
5333,55334,"Ethyl 3-[3-(tert-butylamino)-2-hydroxypropoxy]-4,5,6,7-tetrahydro-1-benzothiophene-2-carboxylate",CCOC(=O)C1=C(C2=C(S1)CCCC2)OCC(CNC(C)(C)C)O,,,,,,
5334,55335,cis-1-Phenyl-2-(1-pyrrolidinylmethyl)cyclopropanecarboxylic acid ethyl ester hydrochloride,CCOC(=O)[C@@]1(C[C@@H]1C[NH+]2CCCC2)C3=CC=CC=C3.[Cl-],,,,,,
5335,55336,"ethyl (1R,2S)-1-phenyl-2-(pyrrolidin-1-ylmethyl)cyclopropane-1-carboxylate",CCOC(=O)[C@@]1(C[C@@H]1CN2CCCC2)C3=CC=CC=C3,,,,,,
5336,55337,(Z)-2-((Methylamino)methyl)-1-phenylcyclopropanecarboxylic acid ethyl ester hydrochloride,CCOC(=O)[C@@]1(C[C@@H]1C[NH2+]C)C2=CC=CC=C2.[Cl-],,,,,,
5337,55338,CID 55338,CCOC(=O)[C@@]1(CC1CNC)C2=CC=CC=C2,,,,,,
5338,55339,"Cyclopropanecarboxylic acid, 1-phenyl-2-(((phenylmethyl)amino)methyl)-, ethyl ester, (Z)-, monohydrochloride",CCOC(=O)[C@@]1(C[C@@H]1C[NH2+]CC2=CC=CC=C2)C3=CC=CC=C3.[Cl-],,,,,,
5339,55340,"ethyl (1R,2S)-2-[(benzylamino)methyl]-1-phenylcyclopropane-1-carboxylate",CCOC(=O)[C@@]1(C[C@@H]1CNCC2=CC=CC=C2)C3=CC=CC=C3,,,,,,
5340,55341,CID 55341,CCOC(=O)[C@@]1(C[C@@H]1C[NH+](C(C)C)C(C)C)C2=CC=CC=C2.C(=CC(=O)[O-])C(=O)O,,,,,,
5341,55342,"ethyl (1R,2S)-2-[[di(propan-2-yl)amino]methyl]-1-phenylcyclopropane-1-carboxylate",CCOC(=O)[C@@]1(C[C@@H]1CN(C(C)C)C(C)C)C2=CC=CC=C2,,,,,,
5342,55343,"Cyclopropanecarboxylic acid, 2-((methyl(2-phenylethyl)amino)methyl)-1-phenyl-, ethyl ester, hydrochloride, cis-",CCOC(=O)[C@@]1(C[C@@H]1C[NH+](C)CCC2=CC=CC=C2)C3=CC=CC=C3.[Cl-],,,,,,
5343,55344,CID 55344,CCOC(=O)[C@@]1(CC1CN(C)CCC2=CC=CC=C2)C3=CC=CC=C3,,,,,,
5344,55345,"Cyclopropanecarboxylic acid, 2-((butylmethylamino)methyl)-1-phenyl-, ethyl ester, monohydrochloride, cis-",CCCC[NH+](C)C[C@H]1C[C@@]1(C2=CC=CC=C2)C(=O)OCC.[Cl-],,,,,,
5345,55346,"ethyl (1R,2S)-2-[[butyl(methyl)amino]methyl]-1-phenylcyclopropane-1-carboxylate",CCCCN(C)C[C@H]1C[C@@]1(C2=CC=CC=C2)C(=O)OCC,,,,,,
5346,55347,(Z)-2-((Dimethylamino)methyl)-1-phenylcyclopropanecarboxylic acid methyl ester hydrochloride,C[NH+](C)C[C@H]1C[C@@]1(C2=CC=CC=C2)C(=O)OC.[Cl-],,,,,,
5347,55348,"methyl (1R,2S)-2-[(dimethylamino)methyl]-1-phenylcyclopropane-1-carboxylate",CN(C)C[C@H]1C[C@@]1(C2=CC=CC=C2)C(=O)OC,,,,,,
5348,55349,CID 55349,CCCOC(=O)[C@@]1(C[C@@H]1C[NH+](C)C)C2=CC=CC=C2.C(=CC(=O)[O-])C(=O)O,,,,,,
5349,55350,"propyl (1R,2S)-2-[(dimethylamino)methyl]-1-phenylcyclopropane-1-carboxylate",CCCOC(=O)[C@@]1(C[C@@H]1CN(C)C)C2=CC=CC=C2,,,,,,
5350,55351,(Z)-Isopropyl 1-phenyl-2-((dimethylamino)methyl)cyclopropanecarboxylate hydrochloride,CC(C)OC(=O)[C@@]1(C[C@@H]1C[NH+](C)C)C2=CC=CC=C2.[Cl-],,,,,,
5351,55352,"propan-2-yl (1R,2S)-2-[(dimethylamino)methyl]-1-phenylcyclopropane-1-carboxylate",CC(C)OC(=O)[C@@]1(C[C@@H]1CN(C)C)C2=CC=CC=C2,,,,,,
5352,55353,CID 55353,C[NH+](C)C[C@H]1C[C@@]1(C2=CC=CC=C2)C(=O)OCC=C.C(=CC(=O)[O-])C(=O)O,,,,,,
5353,55354,CID 55354,CN(C)CC1C[C@@]1(C2=CC=CC=C2)C(=O)OCC=C,,,,,,
5354,55355,"Cyclopropanecarboxylic acid, 1-(p-chlorophenyl)-2-((dimethylamino)methyl)-, ethyl ester, (Z)-, monohydrochloride",CCOC(=O)[C@@]1(C[C@@H]1C[NH+](C)C)C2=CC=C(C=C2)Cl.[Cl-],,,,,,
5355,55356,"ethyl (1R,2S)-1-(4-chlorophenyl)-2-[(dimethylamino)methyl]cyclopropane-1-carboxylate",CCOC(=O)[C@@]1(C[C@@H]1CN(C)C)C2=CC=C(C=C2)Cl,,,,,,
5356,55357,"Cyclopropanecarboxylic acid, 2-((dimethylamino)methyl)-1-(p-methoxyphenyl)-, ethyl ester, (Z)-, monohydrochloride",CCOC(=O)[C@@]1(C[C@@H]1C[NH+](C)C)C2=CC=C(C=C2)OC.[Cl-],,,,,,
5357,55358,"ethyl (1R,2S)-2-[(dimethylamino)methyl]-1-(4-methoxyphenyl)cyclopropane-1-carboxylate",CCOC(=O)[C@@]1(C[C@@H]1CN(C)C)C2=CC=C(C=C2)OC,,,,,,
5358,55359,"Cyclopropanecarboxylic acid, 2-((dimethylamino)methyl)-1-(p-fluorophenyl)-, ethyl ester, (Z)-, monohydrochloride",CCOC(=O)[C@@]1(C[C@@H]1C[NH+](C)C)C2=CC=C(C=C2)F.[Cl-],,,,,,
5359,55360,"ethyl (1R,2S)-2-[(dimethylamino)methyl]-1-(4-fluorophenyl)cyclopropane-1-carboxylate",CCOC(=O)[C@@]1(C[C@@H]1CN(C)C)C2=CC=C(C=C2)F,,,,,,
5360,55361,Gusperimus trihydrochloride,C(CCCN=C(N)N)CCC(=O)NC(C(=O)NCCCCNCCCN)O.Cl.Cl.Cl,,,"['Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of INTERLEUKINS and other CYTOKINES are emerging. (See all compounds classified as Immunosuppressive Agents.)', 'Chemical substances, produced by microorganisms, inhibiting or preventing the proliferation of neoplasms. (See all compounds classified as Antibiotics, Antineoplastic.)', 'Substances which lower blood glucose levels. (See all compounds classified as Hypoglycemic Agents.)', 'Drugs used to protect against ionizing radiation. They are usually of interest for use in radiation therapy but have been considered for other purposes, e.g. military. (See all compounds classified as Radiation-Protective Agents.)']",,,
5361,55362,Gusperimus,C(CCCN=C(N)N)CCC(=O)NC(C(=O)NCCCCNCCCN)O,,,"['Chemical substances, produced by microorganisms, inhibiting or preventing the proliferation of neoplasms. (See all compounds classified as Antibiotics, Antineoplastic.)', 'Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of INTERLEUKINS and other CYTOKINES are emerging. (See all compounds classified as Immunosuppressive Agents.)', 'Substances which lower blood glucose levels. (See all compounds classified as Hypoglycemic Agents.)', 'Drugs used to protect against ionizing radiation. They are usually of interest for use in radiation therapy but have been considered for other purposes, e.g. military. (See all compounds classified as Radiation-Protective Agents.)']",,,
5362,55363,Nitrosoalanylalanine,C[C@@H](C(=O)O)NC(=O)C(C)NN=O,,,,,,
5363,55364,"1-Oxaspiro(4.5)dec-3-ene-4-carboxylic acid, 3-methyl-2-oxo-, 2-(diethylamino)ethyl ester, hydrochloride",CC[NH+](CC)CCOC(=O)C1=C(C(=O)OC2(C1)CCCC2)C.[Cl-],,,,,,
5364,55365,2-(Diethylamino)ethyl 8-methyl-7-oxo-6-oxaspiro[4.5]dec-8-ene-9-carboxylate,CCN(CC)CCOC(=O)C1=C(C(=O)OC2(C1)CCCC2)C,,,,,,
5365,55366,"1-Oxaspiro(4.5)dec-3-ene-4-carboxylic acid, 3-methyl-2-oxo-, 3-(dimethylamino)propyl ester, hydrochloride",CC1=C(CC2(CCCC2)OC1=O)C(=O)OCCC[NH+](C)C.[Cl-],,,,,,
5366,55367,3-(Dimethylamino)propyl 8-methyl-7-oxo-6-oxaspiro[4.5]dec-8-ene-9-carboxylate,CC1=C(CC2(CCCC2)OC1=O)C(=O)OCCCN(C)C,,,,,,
5367,55368,Copper gamma-aminobutyratopantothenate,CC(C)(CO)C(C(=O)NCCC(=O)O)O.C(CC(=O)O)CN.[Cu],,,,,,
5368,55369,N-D-(+)-Pantothenoyl-gamma-aminobutyric acid,CC(C)(CO)[C@H](C(=O)NCCC(=O)NCCCC(=O)O)O,,,,,,
5369,55370,CID 55370,B1(OCP(=O)(CO1)C2=CC=CC=C2)C3=CC=CC=C3.CCCC[O-].[Na+],,,,,,
5370,55371,"2,5-Diphenyl-1,3,5lambda5,2-dioxaphosphaborinane 5-oxide",B1(OCP(=O)(CO1)C2=CC=CC=C2)C3=CC=CC=C3,,,,,,
5371,55372,"1,1'-(Phenylphosphinothioylidene)bis(1-butanol)",CCCC(O)P(=S)(C1=CC=CC=C1)C(CCC)O,,,,,,
5372,55373,"Benzenamine, N,N',N''-(phosphinidynetris(methylene))tris(4-methyl-",CC1=CC=C(C=C1)NCP(CNC2=CC=C(C=C2)C)CNC3=CC=C(C=C3)C,,,,,,
5373,55374,"Benzenamine, N,N'-((phenylborylene)bis(methylene))bis-",B(CNC1=CC=CC=C1)(CNC2=CC=CC=C2)C3=CC=CC=C3,,,,,,
5374,55375,"Benzenamine, N,N'-((phenylphosphinylidene)bis(methylene))bis(4-methyl-",CC1=CC=C(C=C1)NCP(=O)(CNC2=CC=C(C=C2)C)C3=CC=CC=C3,,,,,,
5375,55376,CID 55376,CN1CCN(CC1)CC(=O)C2=CC=C(C=C2)C3CCCC3.C(=CC(=O)O)C(=O)O.C(=CC(=O)O)C(=O)O,,,,,,
5376,55377,1-(4-Cyclopentylphenyl)-2-(4-methylpiperazin-1-yl)ethanone,CN1CCN(CC1)CC(=O)C2=CC=C(C=C2)C3CCCC3,,,,,,
5377,55378,CID 55378,CC[NH+](CC)CC(=O)C1=CC=C(C=C1)C2CCCC2.C(=CC(=O)[O-])C(=O)O,,,,,,
5378,55379,1-(4-Cyclopentylphenyl)-2-(diethylamino)ethanone,CCN(CC)CC(=O)C1=CC=C(C=C1)C2CCCC2,,,,,,
5379,55380,CID 55380,C[NH+](CC1=CC=CC=C1)CC(=O)C2=CC=C(C=C2)C3CCCC3.C(=CC(=O)[O-])C(=O)O,,,,,,
5380,55381,2-[Benzyl(methyl)amino]-1-(4-cyclopentylphenyl)ethanone,CN(CC1=CC=CC=C1)CC(=O)C2=CC=C(C=C2)C3CCCC3,,,,,,
5381,55382,CID 55382,CC(C)[NH+](CC1=CC=CC=C1)CC(=O)C2=CC=C(C=C2)C3CCCC3.C(=CC(=O)[O-])C(=O)O,,,,,,
5382,55383,2-[Benzyl(propan-2-yl)amino]-1-(4-cyclopentylphenyl)ethanone,CC(C)N(CC1=CC=CC=C1)CC(=O)C2=CC=C(C=C2)C3CCCC3,,,,,,
5383,55384,CID 55384,C1CC[NH+](CC1)CC(=O)C2=CC=C(C=C2)C3CCCC3.C(=CC(=O)[O-])C(=O)O,,,,,,
5384,55385,1-(4-Cyclopentylphenyl)-2-piperidin-1-ylethanone,C1CCN(CC1)CC(=O)C2=CC=C(C=C2)C3CCCC3,,,,,,
5385,55386,CID 55386,C1CCC(C1)C2=CC=C(C=C2)C(=O)C[NH+]3CCOCC3.C(=CC(=O)[O-])C(=O)O,,,,,,
5386,55387,1-(4-Cyclopentylphenyl)-2-morpholin-4-ylethanone,C1CCC(C1)C2=CC=C(C=C2)C(=O)CN3CCOCC3,,,,,,
5387,55388,CID 55388,C1CCC(C1)C2=CC=C(C=C2)C(=O)CN3CCN(CC3)CCO.C(=CC(=O)O)C(=O)O.C(=CC(=O)O)C(=O)O,,,,,,
5388,55389,1-(4-Cyclopentylphenyl)-2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanone,C1CCC(C1)C2=CC=C(C=C2)C(=O)CN3CCN(CC3)CCO,,,,,,
5389,55390,Pirmagrel,C1=CC2=CN=CN2C(=C1)CCCCCC(=O)O,,,"['Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of INTERLEUKINS and other CYTOKINES are emerging. (See all compounds classified as Immunosuppressive Agents.)', 'Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. (See all compounds classified as Enzyme Inhibitors.)']",,,
5390,55391,"5-(Phenylmethyl)-2,4,6-triphenyl-1,3,5-dioxaphosphorinane 5-oxide",C1=CC=C(C=C1)CP2(=O)C(OC(OC2C3=CC=CC=C3)C4=CC=CC=C4)C5=CC=CC=C5,,,,,,
5391,55392,"4,4'-(1,2-Diethylethylene)di(m-cresol)",CCC(C1=C(C=C(C=C1)O)C)C(CC)C2=C(C=C(C=C2)O)C,,,,,,
5392,55393,"Acetamide, N-(1,3-dimethyl-4-(o-fluorobenzoyl)-5-pyrazolyl)-2-((3-(2-methylpiperidino)propyl)amino)-",CC1CCCCN1CCCNCC(=O)NC2=C(C(=NN2C)C)C(=O)C3=CC=CC=C3F,,,,,,
5393,55394,CID 55394,CC1CCCC[NH+]1CCC[NH2+]CC(=O)NC2=C(C(=NN2C)C)C(=O)C3=CC=CC=C3F.C(=CC(=O)[O-])C(=O)O.C(=CC(=O)[O-])C(=O)O,,,,,,
5394,55395,Pentachloro-3-butenoic acid,C(=C(Cl)Cl)(C(C(=O)O)(Cl)Cl)Cl,,,,,,
5395,55396,"(1,1'-BIPHENYL)-4-BUTANOIC ACID, alpha,gamma-DIOXO-",C1=CC=C(C=C1)C2=CC=C(C=C2)C(=O)CC(=O)C(=O)O,,,,,,
5396,55397,Quinpirole hydrochloride,CCCN1CCC[C@H]2[C@H]1CC3=C(C2)NN=C3.Cl,,,['Drugs that bind to and activate dopamine receptors. (See all compounds classified as Dopamine Agonists.)'],,,
5397,55398,"Benzoic acid, 4,4'-((6-(diethylamino)-1,3,5-triazine-2,4-diyl)bis(oxy))bis-, bis(2-(dimethylamino)ethyl) ester",CCN(CC)C1=NC(=NC(=N1)OC2=CC=C(C=C2)C(=O)OCCN(C)C)OC3=CC=C(C=C3)C(=O)OCCN(C)C,,,,,,
5398,55399,"Benzoic acid, 4,4'-((6-(diethylamino)-1,3,5-triazine-2,4-diyl)bis(oxy))bis-, bis(2-(diethylamino)ethyl) ester",CCN(CC)CCOC(=O)C1=CC=C(C=C1)OC2=NC(=NC(=N2)N(CC)CC)OC3=CC=C(C=C3)C(=O)OCCN(CC)CC,,,,,,
5399,55400,"Benzoic acid, 4,4'-((6-(diethylamino)-1,3,5-triazine-2,4-diyl)bis(oxy))bis-, bis(3-(diethylamino)-1,2-dimethylpropyl) ester",CCN(CC)CC(C)C(C)OC(=O)C1=CC=C(C=C1)OC2=NC(=NC(=N2)N(CC)CC)OC3=CC=C(C=C3)C(=O)OC(C)C(C)CN(CC)CC,,,,,,
5400,55401,"Benzoic acid, 4,4'-((6-(diphenylamino)-1,3,5-triazine-2,4-diyl)bis(oxy))bis-, bis(2-(diethylamino)ethyl) ester",CCN(CC)CCOC(=O)C1=CC=C(C=C1)OC2=NC(=NC(=N2)N(C3=CC=CC=C3)C4=CC=CC=C4)OC5=CC=C(C=C5)C(=O)OCCN(CC)CC,,,,,,
5401,55402,"Benzoic acid, 4,4'-((6-(diphenylamino)-1,3,5-triazine-2,4-diyl)bis(oxy))bis-, bis(3-(diethylamino)-1,2-dimethylpropyl) ester",CCN(CC)CC(C)C(C)OC(=O)C1=CC=C(C=C1)OC2=NC(=NC(=N2)N(C3=CC=CC=C3)C4=CC=CC=C4)OC5=CC=C(C=C5)C(=O)OC(C)C(C)CN(CC)CC,,,,,,
5402,55403,"Benzoic acid, 4,4'-((6-methoxy-1,3,5-triazine-2,4-diyl)bis(oxy))bis-, bis(2-(dimethylamino)ethyl) ester",CN(C)CCOC(=O)C1=CC=C(C=C1)OC2=NC(=NC(=N2)OC)OC3=CC=C(C=C3)C(=O)OCCN(C)C,,,,,,
5403,55404,"Benzoic acid, 4,4'-((6-methoxy-1,3,5-triazine-2,4-diyl)bis(oxy))bis-, bis(2-(diethylamino)ethyl) ester",CCN(CC)CCOC(=O)C1=CC=C(C=C1)OC2=NC(=NC(=N2)OC)OC3=CC=C(C=C3)C(=O)OCCN(CC)CC,,,,,,
5404,55405,"Benzoic acid, 4,4'-((6-methoxy-1,3,5-triazine-2,4-diyl)bis(oxy))bis-, bis(3-(diethylamino)-1,2-dimethylpropyl) ester",CCN(CC)CC(C)C(C)OC(=O)C1=CC=C(C=C1)OC2=NC(=NC(=N2)OC)OC3=CC=C(C=C3)C(=O)OC(C)C(C)CN(CC)CC,,,,,,
5405,55406,"DIBENZ(b,f)OXEPINE, 7-(2-(DIMETHYLAMINO)ETHOXY)-11-ETHYL-10-PHENYL-",CCC1=C(C2=C(C=C(C=C2)OCCN(C)C)OC3=CC=CC=C31)C4=CC=CC=C4,,,,,,
5406,55407,"DIBENZO(b,f)THIEPIN, 7-(2-(DIMETHYLAMINO)ETHOXY)-11-ETHYL-10-PHENYL-",CCC1=C(C2=C(C=C(C=C2)OCCN(C)C)SC3=CC=CC=C31)C4=CC=CC=C4,,,,,,
5407,55408,CID 55408,CCC1=C(C2=C(C=C(C=C2)OCCN(C)C)SCC3=CC=CC=C31)C4=CC=CC=C4,,,,,,
5408,55409,"DIBENZO(b,f)THIEPIN, 3-(ALLYLOXY)-10-ETHYL-11-PHENYL-",CCC1=C(C2=C(C=C(C=C2)OCC=C)SC3=CC=CC=C31)C4=CC=CC=C4,,,,,,
5409,55410,"2-Ethyl-3-phenyl-7-prop-2-enoxytricyclo[10.4.0.04,9]hexadeca-1(16),2,4(9),5,7,12,14-heptaene",CCC1=C(C2=C(CCC3=CC=CC=C31)C=C(C=C2)OCC=C)C4=CC=CC=C4,,,,,,
5410,55411,CID 55411,CCC1=C(C2=C(C=C(C=C2)OCC=C)SCC3=CC=CC=C31)C4=CC=CC=C4,,,,,,
5411,55412,"Benzenamine, 2-(3-(4-phenyl-1-piperazinyl)propoxy)-",C1CN(CCN1CCCOC2=CC=CC=C2N)C3=CC=CC=C3,,,,,,
5412,55413,"Benzenamine, 3-(3-(4-phenyl-1-piperazinyl)propoxy)-",C1CN(CCN1CCCOC2=CC=CC(=C2)N)C3=CC=CC=C3,,,,,,
5413,55414,"Benzenamine, 4-(3-(4-phenyl-1-piperazinyl)propoxy)-",C1CN(CCN1CCCOC2=CC=C(C=C2)N)C3=CC=CC=C3,,,,,,
5414,55415,"Benzenamine, 4-(3-(4-(3-methoxyphenyl)-1-piperazinyl)propoxy)-",COC1=CC=CC(=C1)N2CCN(CC2)CCCOC3=CC=C(C=C3)N,,,,,,
5415,55416,"Benzenamine, 4-(3-(4-(4-methoxyphenyl)-1-piperazinyl)propoxy)-",COC1=CC=C(C=C1)N2CCN(CC2)CCCOC3=CC=C(C=C3)N,,,,,,
5416,55417,"Benzenamine, 4-(3-(4-(4-chlorophenyl)-1-piperazinyl)propoxy)-",C1CN(CCN1CCCOC2=CC=C(C=C2)N)C3=CC=C(C=C3)Cl,,,,,,
5417,55418,"Benzenamine, 4-(3-(4-(3-(trifluoromethyl)phenyl)-1-piperazinyl)propoxy)-, dihydrochloride",C1CN(CC[NH+]1CCCOC2=CC=C(C=C2)[NH3+])C3=CC=CC(=C3)C(F)(F)F.[Cl-].[Cl-],,,,,,
5418,55419,4-[3-[4-[3-(Trifluoromethyl)phenyl]piperazin-1-yl]propoxy]aniline,C1CN(CCN1CCCOC2=CC=C(C=C2)N)C3=CC=CC(=C3)C(F)(F)F,,,,,,
5419,55420,"Acetamide, N-(2-(3-(4-phenyl-1-piperazinyl)propoxy)phenyl)-",CC(=O)NC1=CC=CC=C1OCCCN2CCN(CC2)C3=CC=CC=C3,,,,,,
5420,55421,"Acetamide, N-(4-(3-(4-(2-methoxyphenyl)-1-piperazinyl)propoxy)phenyl)-",CC(=O)NC1=CC=C(C=C1)OCCCN2CCN(CC2)C3=CC=CC=C3OC,,,,,,
5421,55422,"Acetamide, N-(4-(3-(4-(3-methoxyphenyl)-1-piperazinyl)propoxy)phenyl)-",CC(=O)NC1=CC=C(C=C1)OCCCN2CCN(CC2)C3=CC(=CC=C3)OC,,,,,,
5422,55423,"Acetamide, N-(4-(3-(4-(4-methoxyphenyl)-1-piperazinyl)propoxy)phenyl)-",CC(=O)NC1=CC=C(C=C1)OCCCN2CCN(CC2)C3=CC=C(C=C3)OC,,,,,,
5423,55424,"Acetamide, N-(4-(3-(4-(3-(trifluoromethyl)phenyl)-1-piperazinyl)propoxy)phenyl)-",CC(=O)NC1=CC=C(C=C1)OCCCN2CCN(CC2)C3=CC=CC(=C3)C(F)(F)F,,,,,,
5424,55425,"2H-1,4-Benzoxazin-3-amine, N-(3-(3-(4-phenyl-1-piperazinyl)propoxy)phenyl)-, tetrahydrochloride",C1CN(CCN1CCCOC2=CC=C(C=C2)NC3=NC4=CC=CC=C4OC3)C5=CC=CC=C5.Cl.Cl.Cl.Cl,,,,,,
5425,55426,"2H-1,4-Benzoxazin-3-amine, N-(4-(3-(4-phenyl-1-piperazinyl)propoxy)phenyl)-",C1CN(CCN1CCCOC2=CC=C(C=C2)NC3=NC4=CC=CC=C4OC3)C5=CC=CC=C5,,,,,,
5426,55427,"3H-1-Benzazepin-2-amine, 4,5-dihydro-N-(4-(3-(4-phenyl-1-piperazinyl)propoxy)phenyl)-",C1CC2=CC=CC=C2N=C(C1)NC3=CC=C(C=C3)OCCCN4CCN(CC4)C5=CC=CC=C5,,,,,,
5427,55428,"Butanoic acid, 4-((4-((((methylamino)oxacetyl)amino)sulfonyl)phenyl)amino)-4-oxo-, methyl ester",CNN(C(=O)C=O)S(=O)(=O)C1=CC=C(C=C1)NC(=O)CCC(=O)OC,,,,,,
5428,55429,"Butanoic acid, 4-((4-((((methylamino)oxacetyl)amino)sulfonyl)phenyl)amino)-4-oxo-",CNC(=O)C(=O)NS(=O)(=O)C1=CC=C(C=C1)NC(=O)CCC(=O)O,,,,,,
5429,55430,"Butanoic acid, 4-((4-(((aminooxacetyl)amino)sulfonyl)phenyl)amino)-4-oxo-, hydrazide",C1=CC(=CC=C1NC(=O)CCC(=O)NN)S(=O)(=O)NC(=O)C(=O)N,,,,,,
5430,55431,"Pyrido(3,4-c)psoralen",C1=CN=CC2=C1C3=C(C=C4C(=C3)C=CO4)OC2=O,,,,,,
5431,55432,"7-Methylpyrido(3,4-c)psoralen",CC1=C2C(=CC3=C1OC(=O)C4=C3C=CN=C4)C=CO2,,,,,,
5432,55433,2-(o-Chlorophenyl)-2-(triethylsiloxy)acetic acid ethyl ester,CCOC(=O)C(C1=CC=CC=C1Cl)O[Si](CC)(CC)CC,,,,,,
5433,55434,2-(o-Methoxyphenyl)-2-(triethylsiloxy)acetic acid ethyl ester,CCOC(=O)C(C1=CC=CC=C1OC)O[Si](CC)(CC)CC,,,,,,
5434,55435,2-Mesityl-2-(triethylsiloxy)acetic acid ethyl ester,CCOC(=O)C(C1=C(C=C(C=C1C)C)C)O[Si](CC)(CC)CC,,,,,,
5435,55436,2-(o-Chlorophenyl)-2-(dibutylethylsiloxy)acetic acid ethyl ester,CCCC[Si](CC)(CCCC)OC(C1=CC=CC=C1Cl)C(=O)OCC,,,,,,
5436,55437,2-(Dibutylethylsiloxy)-2-(o-tolyl)acetic acid ethyl ester,CCCC[Si](CC)(CCCC)OC(C1=CC=CC=C1C)C(=O)OCC,,,,,,
5437,55438,2-(Dibutylethylsiloxy)-2-(o-methoxyphenyl)acetic acid ethyl ester,CCCC[Si](CC)(CCCC)OC(C1=CC=CC=C1OC)C(=O)OCC,,,,,,
5438,55439,2-(Dibutylethylsiloxy)-2-mesitylacetic acid ethyl ester,CCCC[Si](CC)(CCCC)OC(C1=C(C=C(C=C1C)C)C)C(=O)OCC,,,,,,
5439,55440,2-(o-Chlorophenyl)-2-(triisobutylsiloxy)acetic acid ethyl ester,CCOC(=O)C(C1=CC=CC=C1Cl)O[Si](CC(C)C)(CC(C)C)CC(C)C,,,,,,
5440,55441,2-(o-Tolyl)-2-(triisobutylsiloxy)acetic acid ethyl ester,CCOC(=O)C(C1=CC=CC=C1C)O[Si](CC(C)C)(CC(C)C)CC(C)C,,,,,,
5441,55442,2-(o-Methoxyphenyl)-2-(triisobutylsiloxy)acetic acid ethyl ester,CCOC(=O)C(C1=CC=CC=C1OC)O[Si](CC(C)C)(CC(C)C)CC(C)C,,,,,,
5442,55443,2-Mesityl-2-(triisobutylsiloxy)acetic acid ethyl ester,CCOC(=O)C(C1=C(C=C(C=C1C)C)C)O[Si](CC(C)C)(CC(C)C)CC(C)C,,,,,,
5443,55444,"Glycine, N-(4-(butylnitrosoamino)-1-oxobutyl)-",CCCCN(CCCC(=O)NCC(=O)O)N=O,,,,,,
5444,55445,3-(1-Propyl-3-piperidinyl)phenol,CCCN1CCCC(C1)C2=CC(=CC=C2)O,,,"['Agents used in the treatment of Parkinson&apos;s disease. The most commonly used drugs act on the dopaminergic system in the striatum and basal ganglia or are centrally acting muscarinic antagonists. (See all compounds classified as Antiparkinson Agents.)', 'Drugs that bind to and activate dopamine receptors. (See all compounds classified as Dopamine Agonists.)']",,,
5445,55446,N-Methyl-N-(3-oxo-3-phenylpropyl)glycine hydrochloride,C[NH+](CCC(=O)C1=CC=CC=C1)CC(=O)O.[Cl-],,,,,,
5446,55447,2-[Methyl-(3-oxo-3-phenylpropyl)amino]acetic acid,CN(CCC(=O)C1=CC=CC=C1)CC(=O)O,,,,,,
5447,55448,N-(3-(4-Bromophenyl)-3-oxopropyl)-N-methylglycine hydrochloride,C[NH+](CCC(=O)C1=CC=C(C=C1)Br)CC(=O)O.[Cl-],,,,,,
5448,55449,"Acetic acid, 2-[3-(4-bromophenyl)-3-oxopropyl](methyl)amino-",CN(CCC(=O)C1=CC=C(C=C1)Br)CC(=O)O,,,,,,
5449,55450,"Glycine, N-(3-(4-chlorophenyl)-3-oxopropyl)-N-methyl-, ethyl ester, hydrochloride",CCOC(=O)C[NH+](C)CCC(=O)C1=CC=C(C=C1)Cl.[Cl-],,,,,,
5450,55451,Ethyl 2-[[3-(4-chlorophenyl)-3-oxopropyl]-methylamino]acetate,CCOC(=O)CN(C)CCC(=O)C1=CC=C(C=C1)Cl,,,,,,
5451,55452,"Glycine, N-(3-(1,1'-biphenyl)-4-yl-3-oxopropyl)-N-methyl-, ethyl ester, hydrochloride",CCOC(=O)C[NH+](C)CCC(=O)C1=CC=C(C=C1)C2=CC=CC=C2.[Cl-],,,,,,
5452,55453,[(3-Biphenyl-4-yl-3-oxo-propyl)-methyl-amino]-acetic acid ethyl ester,CCOC(=O)CN(C)CCC(=O)C1=CC=C(C=C1)C2=CC=CC=C2,,,,,,
5453,55454,"N-(3-(1,1'-Biphenyl)-4-yl-3-oxopropyl)glycine ethyl ester hydrochloride",CCOC(=O)C[NH2+]CCC(=O)C1=CC=C(C=C1)C2=CC=CC=C2.[Cl-],,,,,,
5454,55455,Ethyl 2-[[3-oxo-3-(4-phenylphenyl)propyl]amino]acetate,CCOC(=O)CNCCC(=O)C1=CC=C(C=C1)C2=CC=CC=C2,,,,,,
5455,55456,Tauromustine,CN(C)S(=O)(=O)CCNC(=O)N(CCCl)N=O,,,['Substances that inhibit or prevent the proliferation of NEOPLASMS. (See all compounds classified as Antineoplastic Agents.)'],,"['Tauromustine has known human metabolites that include Ethanesulfonamide, 2-((((2-chloroethyl)amino)carbonyl)amino)-N,N-dimethyl- and Ethanesulfonamide, 2-((((2-chloroethyl)nitrosoamino)carbonyl)amino)-N-methyl-.']",
5456,55457,"3,5-Dibromo-4-methylphenol",CC1=C(C=C(C=C1Br)O)Br,,,,,,
5457,55458,"Phenol, 3,5-dibromo-2-chloro-4-methyl-",CC1=C(C=C(C(=C1Br)Cl)O)Br,,,,,,
5458,55459,"1-Methyl-4-(2-(3,4,5-trimethoxyphenyl)ethyl)hexahydro-1H-1,4-diazepine dihydrochloride",C[NH+]1CCC[NH+](CC1)CCC2=CC(=C(C(=C2)OC)OC)OC.[Cl-].[Cl-],,,,,,
5459,55460,"1-Methyl-4-[2-(3,4,5-trimethoxyphenyl)ethyl]-1,4-diazepane",CN1CCCN(CC1)CCC2=CC(=C(C(=C2)OC)OC)OC,,,,,,
5460,55461,"1H-1,4-Diazepine, hexahydro-1,4-bis(2-(3,4,5-trimethoxyphenyl)ethyl)-, dihydrochloride",COC1=CC(=CC(=C1OC)OC)CC[NH+]2CCC[NH+](CC2)CCC3=CC(=C(C(=C3)OC)OC)OC.[Cl-].[Cl-],,,,,,
5461,55462,"1,4-Bis[2-(3,4,5-trimethoxyphenyl)ethyl]-1,4-diazepane",COC1=CC(=CC(=C1OC)OC)CCN2CCCN(CC2)CCC3=CC(=C(C(=C3)OC)OC)OC,,,,,,
5462,55463,Neflumozide,C1CN(CCC1N2C3=CC=CC=C3NC2=O)CCCC4=NOC5=C4C=CC(=C5)F,,,,,,
5463,55464,Quinacainol,CC(C)(C)C1=NC2=CC=CC=C2C(=C1)C(CCC3CCNCC3)O,,,,,,
5464,55465,3-(4-Nitrophenoxy)prop-2-enal,C1=CC(=CC=C1[N+](=O)[O-])OC=CC=O,,,,,,
5465,55466,Magnevist,CNC[C@@H]([C@H]([C@@H]([C@@H](CO)O)O)O)O.CNC[C@@H]([C@H]([C@@H]([C@@H](CO)O)O)O)O.C(CN(CC(=O)O)CC(=O)[O-])N(CCN(CC(=O)O)CC(=O)[O-])CC(=O)[O-].[Gd+3],,,['Substances used to allow enhanced visualization of tissues. (See all compounds classified as Contrast Media.)'],,,
5466,55467,2-Chloro-1-methyl-5-nitro-1H-imidazole,CN1C(=CN=C1Cl)[N+](=O)[O-],,,,,,
5467,55468,CID 55468,C1CN(CCC1N2CCNC2=O)CC[C@@H]3COC4=CC=CC=C4O3.C(=CC(=O)O)C(=O)O,,,,,,
5468,55469,"1-[1-[2-[(3R)-2,3-dihydro-1,4-benzodioxin-3-yl]ethyl]piperidin-4-yl]imidazolidin-2-one",C1CN(CCC1N2CCNC2=O)CC[C@@H]3COC4=CC=CC=C4O3,,,,,,
5469,55470,"Acetic acid, ((4-chlorophenyl)thio)-, compd. with 2,2',2''-nitrilotris(ethanol) (1:1)",C1=CC(=CC=C1SCC(=O)O)Cl.C(CO)N(CCO)CCO,,,,,,
5470,55471,(4-Chlorophenylthio)acetic acid,C1=CC(=CC=C1SCC(=O)O)Cl,,,,,,
5471,55472,Lavoltidine succinate,CN1C(=NC(=N1)CO)NCCCOC2=CC=CC(=C2)CN3CCCCC3.CN1C(=NC(=N1)CO)NCCCOC2=CC=CC(=C2)CN3CCCCC3.C(CC(=O)O)C(=O)O,,,,,,
5472,55473,Lavoltidine,CN1C(=NC(=N1)CO)NCCCOC2=CC=CC(=C2)CN3CCCCC3,,,"['Drugs that selectively bind to but do not activate histamine H2 receptors, thereby blocking the actions of histamine. Their clinically most important action is the inhibition of acid secretion in the treatment of gastrointestinal ulcers. Smooth muscle may also be affected. Some drugs in this class have strong effects in the central nervous system, but these actions are not well understood. (See all compounds classified as Histamine H2 Antagonists.)']",,,
5473,55474,"Anthranilic acid, N-benzoyl-3,5-diiodo-",C1=CC=C(C=C1)C(=O)NC2=C(C=C(C=C2I)I)C(=O)O,,,,,,
5474,55475,"Benzoic acid, 3-formamido-2,4,6-triiodo-",C1=C(C(=C(C(=C1I)NC=O)I)C(=O)O)I,,,,,,
5475,55476,"Benzoic acid, 3-benzamido-2,4,6-triiodo-",C1=CC=C(C=C1)C(=O)NC2=C(C=C(C(=C2I)C(=O)O)I)I,,,,,,
5476,55477,"Benzoic acid, 3-hexanamido-2,4,6-triiodo-",CCCCCC(=O)NC1=C(C=C(C(=C1I)C(=O)O)I)I,,,,,,
5477,55478,"Benzoic acid, 3-lauramido-2,4,6-triiodo-",CCCCCCCCCCCC(=O)NC1=C(C=C(C(=C1I)C(=O)O)I)I,,,,,,
5478,55479,"Benzoic acid, 4-acetamido-3,5-diiodo-",CC(=O)NC1=C(C=C(C=C1I)C(=O)O)I,,,,,,
5479,55480,"[(1S,2R)-2-(Diethylcarbamoyl)-2-phenylcyclopropyl]methylazanium;chloride",CCN(CC)C(=O)[C@@]1(C[C@@H]1C[NH3+])C2=CC=CC=C2.[Cl-],,,,,,
5480,55481,"(1R)-2-(aminomethyl)-N,N-diethyl-1-phenylcyclopropane-1-carboxamide",CCN(CC)C(=O)[C@@]1(CC1CN)C2=CC=CC=C2,['Treatment of stroke'],,"['Drugs that selectively block or suppress the plasma membrane transport of SEROTONIN and NORADRENALINE into axon terminals and are used as ANTIDEPRESSIVE AGENTS. (See all compounds classified as Serotonin and Noradrenaline Reuptake Inhibitors.)', 'Mood-stimulating drugs used primarily in the treatment of affective disorders and related conditions. Several MONOAMINE OXIDASE INHIBITORS are useful as antidepressants apparently as a long-term consequence of their modulation of catecholamine levels. The tricyclic compounds useful as antidepressive agents (ANTIDEPRESSIVE AGENTS, TRICYCLIC) also appear to act through brain catecholamine systems. A third group (ANTIDEPRESSIVE AGENTS, SECOND-GENERATION) is a diverse group of drugs including some that act specifically on serotonergic systems. (See all compounds classified as Antidepressive Agents.)']",,,
5481,55482,Temelastine,CC1=NC=C(C=C1)CC2=CN=C(NC2=O)NCCCCC3=NC=C(C=C3C)Br,,,"['Drugs that selectively bind to but do not activate histamine H1 receptors, thereby blocking the actions of endogenous histamine. Included here are the classical antihistaminics that antagonize or prevent the action of histamine mainly in immediate hypersensitivity. They act in the bronchi, capillaries, and some other smooth muscles, and are used to prevent or allay motion sickness, seasonal rhinitis, and allergic dermatitis and to induce somnolence. The effects of blocking central nervous system H1 receptors are not as well understood. (See all compounds classified as Histamine H1 Antagonists.)']",,,
5482,55483,Dopexamine,C1=CC=C(C=C1)CCNCCCCCCNCCC2=CC(=C(C=C2)O)O,,,"['Drugs that selectively bind to and activate beta-adrenergic receptors. (See all compounds classified as Adrenergic beta-Agonists.)', 'Drugs that bind to and activate dopamine receptors. (See all compounds classified as Dopamine Agonists.)', 'Drugs used to cause dilation of the blood vessels. (See all compounds classified as Vasodilator Agents.)']",,,
5483,55484,"NAPHTHO(2,1-b)FURAN, 6,7,8,9-TETRAHYDRO-2-NITRO-",C1CCC2=C(C1)C=CC3=C2C=C(O3)[N+](=O)[O-],,,,,,
5484,55485,"NAPHTHO(2,3-b)FURAN, 5,6,7,8-TETRAHYDRO-2-NITRO-",C1CCC2=C(C1)C=C3C=C(OC3=C2)[N+](=O)[O-],,,,,,
5485,55486,"NAPHTHO(2,1-b)FURAN, 6,7,8,9-TETRAHYDRO-1-METHYL-2-NITRO-",CC1=C(OC2=C1C3=C(CCCC3)C=C2)[N+](=O)[O-],,,,,,
5486,55487,"2-Nitro-3-methyl-5,6,7,8-tetrahydronaphtho(2,3-b)furan",CC1=C(OC2=C1CC3CCC=CC3=C2)[N+](=O)[O-],,,,,,
5487,55488,"NAPHTHO(1,2-b)FURAN, 6,7,8,9-TETRAHYDRO-3-METHYL-2-NITRO-",CC1=C(OC2=C1C=CC3=C2CCCC3)[N+](=O)[O-],,,,,,
5488,55489,"NAPHTHO(1,2-b)FURAN, 6,7,8,9-TETRAHYDRO-2-NITRO-",C1CCC2=C(C1)C=CC3=C2OC(=C3)[N+](=O)[O-],,,,,,
5489,55490,"2,3-Dichlorofluoranthene",C1=CC=C2C(=C1)C3=CC=CC4=C3C2=CC(=C4Cl)Cl,,,,,,
5490,55491,"Acetic acid, (2-(2,3,5,6-tetrachlorophenoxy)phenyl)-",C1=CC=C(C(=C1)CC(=O)O)OC2=C(C(=CC(=C2Cl)Cl)Cl)Cl,,,,,,
5491,55492,Amifloxacin,CNN1C=C(C(=O)C2=CC(=C(C=C21)N3CCN(CC3)C)F)C(=O)O,,,"['Substances that inhibit the growth or reproduction of BACTERIA. (See all compounds classified as Anti-Bacterial Agents.)', 'Compounds that inhibit the activity of DNA TOPOISOMERASE II. Included in this category are a variety of ANTINEOPLASTIC AGENTS which target the eukaryotic form of topoisomerase II and ANTIBACTERIAL AGENTS which target the prokaryotic form of topoisomerase II. (See all compounds classified as Topoisomerase II Inhibitors.)']",,,
5492,55493,3-(2-Hydroxybenzoyl)acrylic acid,C1=CC=C(C(=C1)C(=O)C=CC(=O)O)O,,,,,,
5493,55494,"3-Chloro-1-((2,4-dimethylphenyl)methyl)-4-(1H-indol-3-yl)-2-azetidinone",CC1=CC(=C(C=C1)CN2C(C(C2=O)Cl)C3=CNC4=CC=CC=C43)C,,,,,,
5494,55495,3-Chloro-4-(1H-indol-3-yl)-1-((4-methoxyphenyl)methyl)-2-azetidinone,COC1=CC=C(C=C1)CN2C(C(C2=O)Cl)C3=CNC4=CC=CC=C43,,,,,,
5495,55496,3-Chloro-4-(1H-indol-3-yl)-1-(phenylmethyl)-2-azetidinone,C1=CC=C(C=C1)CN2C(C(C2=O)Cl)C3=CNC4=CC=CC=C43,,,,,,
5496,55497,"(S)-N-(5,6,7,9-Tetrahydro-9-oxo-1,2,3,10-tetramethoxybenzo(a)heptalen-7-yl)butyramide",CCCC(=O)N[C@H]1CCC2=CC(=C(C(=C2C3=CC=C(C(=O)C=C13)OC)OC)OC)OC,,,,,,
5497,55498,"ethyl N-(1,2,3,10-tetramethoxy-9-oxo-6,7-dihydro-5H-benzo[a]heptalen-7-yl)carbamate",CCOC(=O)NC1CCC2=CC(=C(C(=C2C3=CC=C(C(=O)C=C13)OC)OC)OC)OC,,,,,,
5498,55499,CID 55499,CN1CC[NH+](CC1)[C@@H]2[C@@H](C3=CC=CC=C3SC4=C2C=C(C=C4)Cl)O.C(=CC(=O)[O-])C(=O)[O-],,,,,,
5499,55500,"(5S,6R)-3-chloro-5-(4-methylpiperazin-1-yl)-5,6-dihydrobenzo[b][1]benzothiepin-6-ol",CN1CCN(CC1)[C@@H]2[C@@H](C3=CC=CC=C3SC4=C2C=C(C=C4)Cl)O,,,,,,
5500,55501,CID 55501,CC1CCC(CC1)C2[C@@H](C3=CC=CC=C3SC4=C2C=C(C=C4)Cl)O.C(=CC(=O)[O-])C(=O)O,,,,,,
5501,55502,"(6S)-3-chloro-5-(4-methylcyclohexyl)-5,6-dihydrobenzo[b][1]benzothiepin-6-ol",CC1CCC(CC1)C2[C@@H](C3=CC=CC=C3SC4=C2C=C(C=C4)Cl)O,,,,,,
5502,55503,"[(2R,3R,5R,6S,8R,10R,17S)-5,7,14-trihydroxy-6,8,16,18-tetramethoxy-13-(methoxymethyl)-11-methyl-11-azahexacyclo[7.7.2.12,5.01,10.03,8.013,17]nonadecan-4-yl] benzoate",CN1CC2([C@H]3C(C4[C@@H]1C3([C@@H]5C[C@@]6([C@H](C([C@]4([C@H]5C6OC(=O)C7=CC=CC=C7)OC)O)OC)O)C(CC2O)OC)OC)COC,,,,,,
5503,55504,"BENZ(c)ACRIDIN-9-OL, 7-METHYL-",CC1=C2C=CC3=CC=CC=C3C2=NC4=C1C=C(C=C4)O,,,,,,
5504,55505,"BENZ(c)ACRIDIN-11-OL, 7-METHYL-",CC1=C2C=CC=C(C2=NC3=C1C=CC4=CC=CC=C43)O,,,,,,
5505,55506,"NAPHTHO(2,1-b)FURAN-7-OL, 2-NITRO-, ACETATE (ester)",CC(=O)OC1=CC2=C(C=C1)C3=C(C=C2)OC(=C3)[N+](=O)[O-],,,,,,
5506,55507,"NAPHTHO(2,1-b)FURAN-7-OL, 2-NITRO-",C1=CC2=C(C=CC3=C2C=C(O3)[N+](=O)[O-])C=C1O,,,,,,
5507,55508,"NAPHTHO(2,1-b)FURAN, 1-METHYL-2-NITRO-",CC1=C(OC2=C1C3=CC=CC=C3C=C2)[N+](=O)[O-],,,,,,
5508,55509,"ETHANONE, 1-(1-METHYL-5-NITRONAPHTHO(2,1-b)FURAN-2-YL)-",CC1=C(OC2=C1C3=CC=CC=C3C(=C2)[N+](=O)[O-])C(=O)C,,,,,,
5509,55510,"7-Methoxy-1-methyl-2-nitronaphtho[2,1-B]furan",CC1=C(OC2=C1C3=C(C=C2)C=C(C=C3)OC)[N+](=O)[O-],,,,,,
5510,55511,"NAPHTHO(2,3-b)FURAN, 3-METHYL-2-NITRO-",CC1=C(OC2=CC3=CC=CC=C3C=C12)[N+](=O)[O-],,,,,,
5511,55512,"NAPHTHO(1,2-b)FURAN, 3-METHYL-2-NITRO-",CC1=C(OC2=C1C=CC3=CC=CC=C32)[N+](=O)[O-],,,,,,
5512,55513,"2-((S)-3-((R)-1-ethoxy-1-oxo-4-phenylbutan-2-ylamino)-2-oxo-2,3,4,5-tetrahydro-1H-benzo[b]azepin-1-yl)acetic acid hydrochloride",CCOC(=O)[C@@H](CCC1=CC=CC=C1)N[C@H]2CCC3=CC=CC=C3N(C2=O)CC(=O)O.Cl,,,,,,
5513,55514,"rel-(1S,3R)-BenazeprilHydrochloride",CCOC(=O)[C@@H](CCC1=CC=CC=C1)N[C@H]2CCC3=CC=CC=C3N(C2=O)CC(=O)O,,,,,,
5514,55515,"Carbamic acid, (ethoxythio)methyl-, 2,3-dihydro-2,2-dimethyl-7-benzofuranyl ester",CCOSN(C)C(=O)OC1=CC=CC2=C1OC(C2)(C)C,,,,,,
5515,55516,"Carbamic acid, methyl((1-methylethoxy)thio)-, 2,3-dihydro-2,2-dimethyl-7-benzofuranyl ester",CC(C)OSN(C)C(=O)OC1=CC=CC2=C1OC(C2)(C)C,,,,,,
5516,55517,"Carbamic acid, ((hexyloxy)thio)methyl-, 2,3-dihydro-2,2-dimethyl-7-benzofuranyl ester",CCCCCCOSN(C)C(=O)OC1=CC=CC2=C1OC(C2)(C)C,,,,,,
5517,55518,"Carbamic acid, ((cyclohexyloxy)thio)methyl-, 2,3-dihydro-2,2-dimethyl-7-benzofuranyl ester",CC1(CC2=C(O1)C(=CC=C2)OC(=O)NCSOC3CCCCC3)C,,,,,,
5518,55519,"Carbamic acid, methyl((phenylmethoxy)thio)-, 2,3-dihydro-2,2-dimethyl-7-benzofuranyl ester",CC1(CC2=C(O1)C(=CC=C2)OC(=O)N(C)SOCC3=CC=CC=C3)C,,,,,,
5519,55520,"Carbamic acid, ((dodecyloxy)thio)methyl-, 2,3-dihydro-2,2-dimethyl-7-benzofuranyl ester",CCCCCCCCCCCCOSN(C)C(=O)OC1=CC=CC2=C1OC(C2)(C)C,,,,,,
5520,55521,"Carbamic acid, methyl((phenylmethoxy)thio)-, 3-(1-methylethyl)phenyl ester",CC(C)C1=CC(=CC=C1)OC(=O)N(C)SOCC2=CC=CC=C2,,,,,,
5521,55522,"Carbamic acid, ((hexyloxy)dithio)methyl-, 2,3-dihydro-2,2-dimethyl-7-benzofuranyl ester",CCCCCCOSSN(C)C(=O)OC1=CC=CC2=C1OC(C2)(C)C,,,,,,
5522,55523,"Carbamic acid, (methoxydithio)methyl-, 2,3-dihydro-2,2-dimethyl-7-benzofuranyl ester",CC1(CC2=C(O1)C(=CC=C2)OC(=O)N(C)SSOC)C,,,,,,
5523,55524,"Carbamic acid, ((1-ethylpropoxy)thio)methyl-, 2,3-dihydro-2,2-dimethyl-7-benzofuranyl ester",CCC(CC)OSN(C)C(=O)OC1=CC=CC2=C1OC(C2)(C)C,,,,,,
5524,55525,"Carbamic acid, ((1,1-dimethylethoxy)thio)methyl-, 2,3-dihydro-2,2-dimethyl-7-benzofuranyl ester",CC1(CC2=C(O1)C(=CC=C2)OC(=O)NCSOC(C)(C)C)C,,,,,,
5525,55526,"Carbamic acid, methyl((octyloxy)thio)-, 2,3-dihydro-2,2-dimethyl-7-benzofuranyl ester",CCCCCCCCOSN(C)C(=O)OC1=CC=CC2=C1OC(C2)(C)C,,,,,,
5526,55527,"Carbamic acid, ((decyloxy)thio)methyl-, 2,3-dihydro-2,2-dimethyl-7-benzofuranyl ester",CCCCCCCCCCOSCNC(=O)OC1=CC=CC2=C1OC(C2)(C)C,,,,,,
5527,55528,"Carbamic acid, (((4-(1,1-dimethylethyl)phenyl)methoxy)thio)methyl-, 2,3-dihydro-2,2-dimethyl-7-benzofuranyl ester",CC1(CC2=C(O1)C(=CC=C2)OC(=O)NCSOCC3=CC=C(C=C3)C(C)(C)C)C,,,,,,
5528,55529,"Carbamic acid, methyl((octadecyloxy)thio)-, 2,3-dihydro-2,2-dimethyl-7-benzofuranyl ester",CCCCCCCCCCCCCCCCCCOSN(C)C(=O)OC1=CC=CC2=C1OC(C2)(C)C,,,,,,
5529,55530,N-(2-Methyl-3-(1-pyrrolidinyl)propyl)-3-phenyl-5-isoxazolamine,CC(CNC1=CC(=NO1)C2=CC=CC=C2)CN3CCCC3,,,,,,
5530,55531,N-(1-Methyl-3-(1-pyrrolidinyl)propyl)-3-phenyl-5-isoxazolamine,CC(CCN1CCCC1)NC2=CC(=NO2)C3=CC=CC=C3,,,,,,
5531,55532,"cis-2-Methoxy-3,5,5-trimethyl-1,2-oxaphospholan-3-ol 2-oxide",CC1(CC(P(=O)(O1)OC)(C)O)C,,,,,,
5532,55533,"N-(2-Diethylaminoethyl)-2,4,5-trichlorophenoxyacetamide hydrochloride",CC[NH+](CC)CCNC(=O)COC1=C(C=CC(=C1Cl)Cl)Cl.[Cl-],,,,,,
5533,55534,"N-[2-(diethylamino)ethyl]-2-(2,3,6-trichlorophenoxy)acetamide",CCN(CC)CCNC(=O)COC1=C(C=CC(=C1Cl)Cl)Cl,,,,,,
5534,55535,"N-(3-(4-(2-Tolyl)piperazino)propyl)-4-bromo-3,5-dimethylphenoxyacetamide dihydrochloride",CC1=CC=CC=C1N2CCN(CC2)CCCNC(=O)COC3=CC(=C(C(=C3)C)Br)C.Cl.Cl,,,,,,
5535,55536,"2-(4-bromo-3,5-dimethylphenoxy)-N-[3-[4-(2-methylphenyl)piperazin-1-yl]propyl]acetamide",CC1=CC=CC=C1N2CCN(CC2)CCCNC(=O)COC3=CC(=C(C(=C3)C)Br)C,,,,,,
5536,55537,"2-(4-Bromo-3,5-dimethylphenoxy)-N-(2-(diethylamino)ethyl)acetamide hydrochloride",CC[NH+](CC)CCNC(=O)COC1=CC(=C(C(=C1)C)Br)C.[Cl-],,,,,,
5537,55538,"2-(4-bromo-3,5-dimethylphenoxy)-N-[2-(diethylamino)ethyl]acetamide",CCN(CC)CCNC(=O)COC1=CC(=C(C(=C1)C)Br)C,,,,,,
5538,55539,"N-(2-(4-Morpholinyl)ethyl)-2-(2,4,5-trichlorophenoxy)acetamide hydrochloride",C1COCC[NH+]1CCNC(=O)COC2=C(C=CC(=C2Cl)Cl)Cl.[Cl-],,,,,,
5539,55540,"N-(2-morpholin-4-ylethyl)-2-(2,3,6-trichlorophenoxy)acetamide",C1COCCN1CCNC(=O)COC2=C(C=CC(=C2Cl)Cl)Cl,,,,,,
5540,55541,"N-(3-(4-Morpholinyl)propyl)-2-(2,4,5-trichlorophenoxy)acetamide hydrochloride",C1COCC[NH+]1CCCNC(=O)COC2=CC(=C(C=C2Cl)Cl)Cl.[Cl-],,,,,,
5541,55542,"N-(3-morpholin-4-ylpropyl)-2-(2,4,5-trichlorophenoxy)acetamide",C1COCCN1CCCNC(=O)COC2=CC(=C(C=C2Cl)Cl)Cl,,,,,,
5542,55543,"Acetamide, N-(3-(4-morpholinyl)propyl)-2-(2,4,6-trimethylphenoxy)-, hydrochloride, hydrate (1:1:1)",CC1=CC(=C(C(=C1)C)OCC(=O)NCCC[NH+]2CCOCC2)C.[Cl-],,,,,,
5543,55544,"N-(3-morpholin-4-ylpropyl)-2-(2,4,6-trimethylphenoxy)acetamide",CC1=CC(=C(C(=C1)C)OCC(=O)NCCCN2CCOCC2)C,,,,,,
5544,55545,"Acetamide, N-(3-(4-methyl-1-piperazinyl)propyl)-2-(2,4,5-trichlorophenoxy)-, hydrochloride, hydrate (1:2:1)",CN1CCN(CC1)CCCNC(=O)COC2=CC(=C(C=C2Cl)Cl)Cl.Cl.Cl,,,,,,
5545,55546,"N-[3-(4-methylpiperazin-1-yl)propyl]-2-(2,4,5-trichlorophenoxy)acetamide",CN1CCN(CC1)CCCNC(=O)COC2=CC(=C(C=C2Cl)Cl)Cl,,,,,,
5546,55547,"Acetamide, N-(3-(4-methyl-1-piperazinyl)propyl)-2-(2,4,6-trimethylphenoxy)-, hydrochloride, hydrate (1:2:2)",CC1=CC(=C(C(=C1)C)OCC(=O)NCCCN2CCN(CC2)C)C.Cl.Cl,,,,,,
5547,55548,"N-[3-(4-methylpiperazin-1-yl)propyl]-2-(2,4,6-trimethylphenoxy)acetamide",CC1=CC(=C(C(=C1)C)OCC(=O)NCCCN2CCN(CC2)C)C,,,,,,
5548,55549,"Acetamide, 2-(4-bromo-3,5-dimethylphenoxy)-N-(3-(4-methyl-1-piperazinyl)propyl)-, hydrochloride, hydrate (1:2:1)",CC1=CC(=CC(=C1Br)C)OCC(=O)NCCCN2CCN(CC2)C.Cl.Cl,,,,,,
5549,55550,"2-(4-bromo-3,5-dimethylphenoxy)-N-[3-(4-methylpiperazin-1-yl)propyl]acetamide",CC1=CC(=CC(=C1Br)C)OCC(=O)NCCCN2CCN(CC2)C,,,,,,
5550,55551,"Acetamide, N-(3-(4-(2-methylphenyl)-1-piperazinyl)propyl)-2-(2,4,5-trichlorophenoxy)-, monohydrochloride",CC1=CC=CC=C1N2CC[NH+](CC2)CCCNC(=O)COC3=CC(=C(C=C3Cl)Cl)Cl.[Cl-],,,,,,
5551,55552,"N-[3-[4-(2-methylphenyl)piperazin-1-yl]propyl]-2-(2,4,5-trichlorophenoxy)acetamide",CC1=CC=CC=C1N2CCN(CC2)CCCNC(=O)COC3=CC(=C(C=C3Cl)Cl)Cl,,,,,,
5552,55553,"Acetamide, N-(3-(4-(2-methylphenyl)-1-piperazinyl)propyl)-2-(2,4,6-trimethylphenoxy)-, hydrochloride, hydrate (1:2:1)",CC1=CC=CC=C1N2CCN(CC2)CCCNC(=O)COC3=C(C=C(C=C3C)C)C.Cl.Cl,,,,,,
5553,55554,"N-[3-[4-(2-methylphenyl)piperazin-1-yl]propyl]-2-(2,4,6-trimethylphenoxy)acetamide",CC1=CC=CC=C1N2CCN(CC2)CCCNC(=O)COC3=C(C=C(C=C3C)C)C,,,,,,
5554,55555,"Acetic acid, (2,4,6-trimethylphenoxy)-, 1,4-piperazinediyldi-2,1-ethanediyl ester, dihydrochloride",CC1=CC(=C(C(=C1)C)OCC(=O)OCCN2CCN(CC2)CCOC(=O)COC3=C(C=C(C=C3C)C)C)C.Cl.Cl,,,,,,
5555,55556,"2-[4-[2-[2-(2,4,6-Trimethylphenoxy)acetyl]oxyethyl]piperazin-1-yl]ethyl 2-(2,4,6-trimethylphenoxy)acetate",CC1=CC(=C(C(=C1)C)OCC(=O)OCCN2CCN(CC2)CCOC(=O)COC3=C(C=C(C=C3C)C)C)C,,,,,,
5556,55557,"Acetic acid, (2,4,5-trichlorophenoxy)-, 1,4-piperazinediyldi-3,1-propanediyl ester, dihydrochloride",C1CN(CCN1CCCOC(=O)COC2=CC(=C(C=C2Cl)Cl)Cl)CCCOC(=O)COC3=CC(=C(C=C3Cl)Cl)Cl.Cl.Cl,,,,,,
5557,55558,"3-[4-[3-[2-(2,4,5-Trichlorophenoxy)acetyl]oxypropyl]piperazin-1-yl]propyl 2-(2,4,5-trichlorophenoxy)acetate",C1CN(CCN1CCCOC(=O)COC2=CC(=C(C=C2Cl)Cl)Cl)CCCOC(=O)COC3=CC(=C(C=C3Cl)Cl)Cl,,,,,,
5558,55559,"Acetic acid, (2,4,6-trimethylphenoxy)-, 1,4-piperazinediyldi-3,1-propanediyl ester, dihydrochloride",CC1=CC(=C(C(=C1)C)OCC(=O)OCCCN2CCN(CC2)CCCOC(=O)COC3=C(C=C(C=C3C)C)C)C.Cl.Cl,,,,,,
5559,55560,"3-[4-[3-[2-(2,4,6-Trimethylphenoxy)acetyl]oxypropyl]piperazin-1-yl]propyl 2-(2,4,6-trimethylphenoxy)acetate",CC1=CC(=C(C(=C1)C)OCC(=O)OCCCN2CCN(CC2)CCCOC(=O)COC3=C(C=C(C=C3C)C)C)C,,,,,,
5560,55561,"BENZO(a)PYRENE, 10-(CHLOROMETHYL)-",C1=CC2=C3C(=C1)C=CC4=C5C(=CC(=C43)C=C2)C=CC=C5CCl,,,,,,
5561,55562,"1H-Indole-3-acetic acid, 1-(4-chlorobenzoyl)-5-methoxy-2-methyl-, 2-[(2-carboxyphenoxy)carbonyl]phenyl ester",CC1=C(C2=C(N1C(=O)C3=CC=C(C=C3)Cl)C=CC(=C2)OC)CC(=O)OC4=CC=CC=C4C(=O)OC5=CC=CC=C5C(=O)O,,,,,,
5562,55563,4-Heptadecylphenol,CCCCCCCCCCCCCCCCCC1=CC=C(C=C1)O,,,,,,
5563,55564,"2H-1,4-Benzoxazine-6-acetic acid, 3-(4-chlorophenyl)-",C1C(=NC2=C(O1)C=CC(=C2)CC(=O)O)C3=CC=C(C=C3)Cl,,,,,,
5564,55565,"2H-1,4-Benzoxazine-6-acetic acid, 3-(4-bromophenyl)-",C1C(=NC2=C(O1)C=CC(=C2)CC(=O)O)C3=CC=C(C=C3)Br,,,,,,
5565,55566,CID 55566,CC1=CC=C(C=C1)C2=NC3=C(C=CC(=C3)CC(=O)O)OC2=O,,,,,,
5566,55567,"disodium;2-[[1-(2-amino-1,3-thiazol-4-yl)-2-[[(2S,3S)-2-(carbamoyloxymethyl)-4-oxo-1-sulfonatoazetidin-3-yl]amino]-2-oxoethylidene]amino]oxyacetate",C1=C(N=C(S1)N)C(=NOCC(=O)[O-])C(=O)N[C@H]2[C@H](N(C2=O)S(=O)(=O)[O-])COC(=O)N.[Na+].[Na+],,,,,,
5567,55568,"2-((Z)-1-(2-aminothiazol-4-yl)-2-((2S,3S)-2-(carbamoyloxymethyl)-4-oxo-1-sulfoazetidin-3-ylamino)-2-oxoethylideneaminooxy)acetic acid",C1=C(N=C(S1)N)C(=NOCC(=O)O)C(=O)N[C@H]2[C@H](N(C2=O)S(=O)(=O)O)COC(=O)N,,,,,,
5568,55569,"Cyclohexene, 5-methyl-3-(1-methylethenyl)-",CC1CC=CC(C1)C(=C)C,,,,,,
5569,55570,1H-Benz(DE)anthracen-1-one,C1=CC=C2C(=C1)C=C3C=CC=C4C3=C2C(=O)C=C4,,,,,,
5570,55571,11H-Benz(BC)aceanthrylen-11-one,C1=CC=C2C(=C1)C=C3C=CC4=C5C3=C2C(=O)C5=CC=C4,,,,,,
5571,55572,4H-Cyclopenta(def)triphenylen-4-one,C1=CC=C2C3=C4C(=CC=C3)C(=O)C5=CC=CC(=C54)C2=C1,,,,,,
5572,55573,Starbld0027436,C1=CC=C2C3=C4C(=CC2=C1)C(=O)C5=CC=CC(=C54)C=C3,,,,,,
5573,55574,4H-Benzo(def)cyclopenta(mno)chrysen-4-one,C1=CC2=C3C(=C1)C=C4C5=C6C(=CC(=C35)C=C2)C=CC=C6C4=O,,,,,,
5574,55575,"9H-Indeno(2,1-C)phenanthren-9-one",C1=CC=C2C(=C1)C=CC3=C2C4=C(C=C3)C(=O)C5=CC=CC=C54,,,,,,
5575,55576,"8H-Indeno(2,1-A)anthracen-8-one",C1=CC=C2C=C3C(=CC2=C1)C=CC4=C3C5=CC=CC=C5C4=O,,,,,,
5576,55577,"7H-Indeno(2,1-A)phenanthren-7-one",C1=CC=C2C(=C1)C=CC3=C2C=CC4=C3C5=CC=CC=C5C4=O,,,,,,
5577,55578,CID 55578,CCCC(=O)SC1=NN=C(S1)N=C(NC2=CC=CC=C2C)S,,,,,,
5578,55579,CID 55579,CCCC(=O)SC1=NN=C(S1)N=C(NC2=CC=CC=C2OC)S,,,,,,
5579,55580,CID 55580,CCCC(=O)SC1=NN=C(S1)N=C(NC2=CC=C(C=C2)OC)S,,,,,,
5580,55581,CID 55581,CCCC(=O)SC1=NN=C(S1)N=C(NC2=CC=C(C=C2)Cl)S,,,,,,
5581,55582,Neurokinin A,CC(C)CC(C(=O)NC(CCSC)C(=O)N)NC(=O)CNC(=O)C(C(C)C)NC(=O)C(CC1=CC=CC=C1)NC(=O)C(CO)NC(=O)C(CC(=O)O)NC(=O)C(C(C)O)NC(=O)C(CCCCN)NC(=O)C(CC2=CN=CN2)N,,,"['Substances used for their pharmacological actions on any aspect of neurotransmitter systems. Neurotransmitter agents include agonists, antagonists, degradation inhibitors, uptake inhibitors, depleters, precursors, and modulators of receptor function. (See all compounds classified as Neurotransmitter Agents.)']",,,
5582,55583,Neurokinin beta,CC(C)CC(C(=O)NC(CCSC)C(=O)N)NC(=O)CNC(=O)C(C(C)C)NC(=O)C(CC1=CC=CC=C1)NC(=O)C(CC2=CC=CC=C2)NC(=O)C(CC(=O)O)NC(=O)C(CC3=CN=CN3)NC(=O)C(CCSC)NC(=O)C(CC(=O)O)N,,,"['Substances used for their pharmacological actions on any aspect of neurotransmitter systems. Neurotransmitter agents include agonists, antagonists, degradation inhibitors, uptake inhibitors, depleters, precursors, and modulators of receptor function. (See all compounds classified as Neurotransmitter Agents.)']",,,
5583,55584,"10,11-Dihydrodibenzo(b,f)thiepin-10-carboxylic acid",C1C(C2=CC=CC=C2SC3=CC=CC=C31)C(=O)O,,,,,,
5584,55585,"DIBENZO(b,f)THIEPIN-10-CARBOXYLIC ACID, 10,11-DIHYDRO-2-CHLORO-",C1CC2=C(C=C1Cl)C=C(C3=CC=CC=C3S2)C(=O)O,,,,,,
5585,55586,"cis-11-(3-Dimethylaminopropyl)-10,11-dihydrodibenzo(b,f)thiepin-10-carbonitrile oxalate",CN(C)CCCC1C(C2=CC=CC=C2SC3=CC=CC=C13)C#N.C(=O)(C(=O)[O-])O,,,,,,
5586,55587,"6-[3-(Dimethylamino)propyl]-5,6-dihydrobenzo[b][1]benzothiepine-5-carbonitrile",CN(C)CCCC1C(C2=CC=CC=C2SC3=CC=CC=C13)C#N,,,,,,
5587,55588,"10-(2-Dimethylaminoethyl)-10,11-dihydrodibenzo(b,f)thiepin-10-carbonitrile hydrogen oxalate",C[NH+](C)CCC1(CC2=CC=CC=C2SC3=CC=CC=C31)C#N.C(=O)(C(=O)[O-])O,,,,,,
5588,55589,5-[2-(dimethylamino)ethyl]-6H-benzo[b][1]benzothiepine-5-carbonitrile,CN(C)CCC1(CC2=CC=CC=C2SC3=CC=CC=C31)C#N,,,,,,
5589,55590,CID 55590,C[NH+](C)CCCC1(CC2=CC=CC=C2SC3=CC=CC=C31)C#N.C(=CC(=O)[O-])C(=O)O,,,,,,
5590,55591,5-[3-(dimethylamino)propyl]-6H-benzo[b][1]benzothiepine-5-carbonitrile,CN(C)CCCC1(CC2=CC=CC=C2SC3=CC=CC=C31)C#N,,,,,,
5591,55592,"Ethanone, 1-(2,4-bis(3-chloropropoxy)phenyl)-",CC(=O)C1=C(C=C(C=C1)OCCCCl)OCCCCl,,,,,,
5592,55593,"Ethanone, 1-(2,5-bis(3-chloropropoxy)phenyl)-",CC(=O)C1=C(C=CC(=C1)OCCCCl)OCCCCl,,,,,,
5593,55594,"Acetic acid, 2,2'-((4-acetyl-1,3-phenylene)bis(oxy))bis-, diethyl ester",CCOC(=O)COC1=CC(=C(C=C1)C(=O)C)OCC(=O)OCC,,,,,,
5594,55595,"Acetic acid, 2,2'-((2-acetyl-1,4-phenylene)bis(oxy))bis-, diethyl ester",CCOC(=O)COC1=CC(=C(C=C1)OCC(=O)OCC)C(=O)C,,,,,,
5595,55596,"Ethanone, 1-(2,4-bis(3-((1-methylethyl)amino)propoxy)phenyl)-",CC(C)NCCCOC1=CC(=C(C=C1)C(=O)C)OCCCNC(C)C,,,,,,
5596,55597,"Ethanone, 1-(2,5-bis(3-((1-methylethyl)amino)propoxy)phenyl)-",CC(C)NCCCOC1=CC(=C(C=C1)OCCCNC(C)C)C(=O)C,,,,,,
5597,55598,"Ethanone, 1-(2,6-bis(3-((1-methylethyl)amino)propoxy)phenyl)-",CC(C)NCCCOC1=C(C(=CC=C1)OCCCNC(C)C)C(=O)C,,,,,,
5598,55599,"Ethanone, 1-(2,4-bis(3-(4-methyl-1-piperazinyl)propoxy)phenyl)-",CC(=O)C1=C(C=C(C=C1)OCCCN2CCN(CC2)C)OCCCN3CCN(CC3)C,,,,,,
5599,55600,"Ethanone, 1-(2,5-bis(3-(4-methyl-1-piperazinyl)propoxy)phenyl)-",CC(=O)C1=C(C=CC(=C1)OCCCN2CCN(CC2)C)OCCCN3CCN(CC3)C,,,,,,
5600,55601,"Ethanone, 1-(2,6-bis(3-(4-methyl-1-piperazinyl)propoxy)phenyl)-",CC(=O)C1=C(C=CC=C1OCCCN2CCN(CC2)C)OCCCN3CCN(CC3)C,,,,,,
5601,55602,"Ethanone, 1-(2,4-bis(3-(4-phenyl-1-piperazinyl)propoxy)phenyl)-",CC(=O)C1=C(C=C(C=C1)OCCCN2CCN(CC2)C3=CC=CC=C3)OCCCN4CCN(CC4)C5=CC=CC=C5,,,,,,
5602,55603,"Ethanone, 1-(2,5-bis(3-(4-phenyl-1-piperazinyl)propoxy)phenyl)-",CC(=O)C1=C(C=CC(=C1)OCCCN2CCN(CC2)C3=CC=CC=C3)OCCCN4CCN(CC4)C5=CC=CC=C5,,,,,,
5603,55604,"Ethanone, 1-(2,6-bis(3-(4-phenyl-1-piperazinyl)propoxy)phenyl)-",CC(=O)C1=C(C=CC=C1OCCCN2CCN(CC2)C3=CC=CC=C3)OCCCN4CCN(CC4)C5=CC=CC=C5,,,,,,
5604,55605,"Ethanone, 1-(2,4-bis(3-(4-hydroxy-4-phenyl-1-piperidinyl)propoxy)phenyl)-",CC(=O)C1=C(C=C(C=C1)OCCCN2CCC(CC2)(C3=CC=CC=C3)O)OCCCN4CCC(CC4)(C5=CC=CC=C5)O,,,,,,
5605,55606,"Ethanone, 1-(2,5-bis(3-(4-hydroxy-4-phenyl-1-piperidinyl)propoxy)phenyl)-",CC(=O)C1=C(C=CC(=C1)OCCCN2CCC(CC2)(C3=CC=CC=C3)O)OCCCN4CCC(CC4)(C5=CC=CC=C5)O,,,,,,
5606,55607,"Ethanone, 1-(2,6-bis(3-(4-hydroxy-4-phenyl-1-piperidinyl)propoxy)phenyl)-",CC(=O)C1=C(C=CC=C1OCCCN2CCC(CC2)(C3=CC=CC=C3)O)OCCCN4CCC(CC4)(C5=CC=CC=C5)O,,,,,,
5607,55608,"Ethanone, 1-(2,4-bis(3-(3,6-dihydro-4-phenyl-1(2H)-pyridinyl)propoxy)phenyl)-",CC(=O)C1=C(C=C(C=C1)OCCCN2CCC(=CC2)C3=CC=CC=C3)OCCCN4CCC(=CC4)C5=CC=CC=C5,,,,,,
5608,55609,"Ethanone, 1-(2,5-bis(3-(3,6-dihydro-4-phenyl-1(2H)-pyridinyl)propoxy)phenyl)-",CC(=O)C1=C(C=CC(=C1)OCCCN2CCC(=CC2)C3=CC=CC=C3)OCCCN4CCC(=CC4)C5=CC=CC=C5,,,,,,
5609,55610,"1-(2,6-Bis(3-(3,6-dihydro-4-phenyl-1(2H)-pyridinyl)propoxy)phenyl)ethanone",CC(=O)C1=C(C=CC=C1OCCCN2CCC(=CC2)C3=CC=CC=C3)OCCCN4CCC(=CC4)C5=CC=CC=C5,,,,,,
5610,55611,"1-(2,4-Bis(2-hydroxy-3-((1-methylethyl)amino)propoxy)phenyl)ethanone",CC(C)NCC(COC1=CC(=C(C=C1)C(=O)C)OCC(CNC(C)C)O)O,,,,,,
5611,55612,"1-(2,5-Bis(2-hydroxy-3-((1-methylethyl)amino)propoxy)phenyl)ethanone",CC(C)NCC(COC1=CC(=C(C=C1)OCC(CNC(C)C)O)C(=O)C)O,,,,,,
5612,55613,"1-(2,6-Bis(2-hydroxy-3-((1-methylethyl)amino)propoxy)phenyl)ethanone",CC(C)NCC(COC1=C(C(=CC=C1)OCC(CNC(C)C)O)C(=O)C)O,,,,,,
5613,55614,"2,4-Bis((tert-butylamino)-2-hydroxypropoxy)acetophenone",CC(=O)C1=C(C=C(C=C1)OCC(CNC(C)(C)C)O)OCC(CNC(C)(C)C)O,,,,,,
5614,55615,"Ethanone, 1-(2,5-bis(3-((1,1-dimethylethyl)amino)-2-hydroxypropoxy)phenyl)-, dihydrochloride",CC(=O)C1=C(C=CC(=C1)OCC(C[NH2+]C(C)(C)C)O)OCC(C[NH2+]C(C)(C)C)O.[Cl-].[Cl-],,,,,,
5615,55616,"1-[2,5-Bis[3-(tert-butylamino)-2-hydroxypropoxy]phenyl]ethanone",CC(=O)C1=C(C=CC(=C1)OCC(CNC(C)(C)C)O)OCC(CNC(C)(C)C)O,,,,,,
5616,55617,"2,6-Bis((tert-butylamino)-2-hydroxypropoxy)acetophenone",CC(=O)C1=C(C=CC=C1OCC(CNC(C)(C)C)O)OCC(CNC(C)(C)C)O,,,,,,
5617,55618,"1-(2,4-Bis(2-hydroxy-3-(1-piperidinyl)propoxy)phenyl)ethanone",CC(=O)C1=C(C=C(C=C1)OCC(CN2CCCCC2)O)OCC(CN3CCCCC3)O,,,,,,
5618,55619,"1-(2,5-Bis(2-hydroxy-3-(1-piperidinyl)propoxy)phenyl)ethanone",CC(=O)C1=C(C=CC(=C1)OCC(CN2CCCCC2)O)OCC(CN3CCCCC3)O,,,,,,
5619,55620,"1-(2,6-Bis(2-hydroxy-3-(1-piperidinyl)propoxy)phenyl)ethanone",CC(=O)C1=C(C=CC=C1OCC(CN2CCCCC2)O)OCC(CN3CCCCC3)O,,,,,,
5620,55621,"Ethanone, 1-(2,4-bis(2-hydroxy-3-(4-morpholinyl)propoxy)phenyl)-, dihydrochloride",CC(=O)C1=C(C=C(C=C1)OCC(C[NH+]2CCOCC2)O)OCC(C[NH+]3CCOCC3)O.[Cl-].[Cl-],,,,,,
5621,55622,"1-[2,4-Bis(2-hydroxy-3-morpholin-4-ylpropoxy)phenyl]ethanone",CC(=O)C1=C(C=C(C=C1)OCC(CN2CCOCC2)O)OCC(CN3CCOCC3)O,,,,,,
5622,55623,"Ethanone, 1-(2,4-bis(2-hydroxy-3-(4-methyl-1-piperazinyl)propoxy)phenyl)-, tetrahydrochloride",CC(=O)C1=C(C=C(C=C1)OCC(CN2CCN(CC2)C)O)OCC(CN3CCN(CC3)C)O.Cl.Cl.Cl.Cl,,,,,,
5623,55624,"1-[2,4-Bis[2-hydroxy-3-(4-methylpiperazin-1-yl)propoxy]phenyl]ethanone",CC(=O)C1=C(C=C(C=C1)OCC(CN2CCN(CC2)C)O)OCC(CN3CCN(CC3)C)O,,,,,,
5624,55625,"Ethanone, 1-(2,5-bis(2-hydroxy-3-(4-methyl-1-piperazinyl)propoxy)phenyl)-, tetrahydrochloride",CC(=O)C1=C(C=CC(=C1)OCC(CN2CCN(CC2)C)O)OCC(CN3CCN(CC3)C)O.Cl.Cl.Cl.Cl,,,,,,
5625,55626,"1-[2,5-Bis[2-hydroxy-3-(4-methylpiperazin-1-yl)propoxy]phenyl]ethanone",CC(=O)C1=C(C=CC(=C1)OCC(CN2CCN(CC2)C)O)OCC(CN3CCN(CC3)C)O,,,,,,
5626,55627,"1-(2,6-Bis(2-hydroxy-3-(4-methyl-1-piperazinyl)propoxy)phenyl)ethanone tetrahydrochloride",CC(=O)C1=C(C=CC=C1OCC(CN2CCN(CC2)C)O)OCC(CN3CCN(CC3)C)O.Cl.Cl.Cl.Cl,,,,,,
5627,55628,"1-[2,6-Bis[2-hydroxy-3-(4-methylpiperazin-1-yl)propoxy]phenyl]ethanone",CC(=O)C1=C(C=CC=C1OCC(CN2CCN(CC2)C)O)OCC(CN3CCN(CC3)C)O,,,,,,
5628,55629,"1-(2,4-Bis(2-hydroxy-3-(4-phenyl-1-piperazinyl)propoxy)phenyl)ethanone",CC(=O)C1=C(C=C(C=C1)OCC(CN2CCN(CC2)C3=CC=CC=C3)O)OCC(CN4CCN(CC4)C5=CC=CC=C5)O,,,,,,
5629,55630,"1-(2,5-Bis(2-hydroxy-3-(4-phenyl-1-piperazinyl)propoxy)phenyl)ethanone",CC(=O)C1=C(C=CC(=C1)OCC(CN2CCN(CC2)C3=CC=CC=C3)O)OCC(CN4CCN(CC4)C5=CC=CC=C5)O,,,,,,
5630,55631,"1-(2,6-Bis(2-hydroxy-3-(4-phenyl-1-piperazinyl)propoxy)phenyl)ethanone",CC(=O)C1=C(C=CC=C1OCC(CN2CCN(CC2)C3=CC=CC=C3)O)OCC(CN4CCN(CC4)C5=CC=CC=C5)O,,,,,,
5631,55632,"Ethanone, 1-(2,5-bis(3-(4-(3-chlorophenyl)-1-piperazinyl)-2-hydroxypropoxy)phenyl)-, tetrahydrochloride",CC(=O)C1=C(C=CC(=C1)OCC(CN2CCN(CC2)C3=CC(=CC=C3)Cl)O)OCC(CN4CCN(CC4)C5=CC(=CC=C5)Cl)O.Cl.Cl.Cl.Cl,,,,,,
5632,55633,"1-[2,5-Bis[3-[4-(3-chlorophenyl)piperazin-1-yl]-2-hydroxypropoxy]phenyl]ethanone",CC(=O)C1=C(C=CC(=C1)OCC(CN2CCN(CC2)C3=CC(=CC=C3)Cl)O)OCC(CN4CCN(CC4)C5=CC(=CC=C5)Cl)O,,,,,,
5633,55634,"Ethanone, 1-(2,6-bis(3-(4-(3-chlorophenyl)-1-piperazinyl)-2-hydroxypropoxy)phenyl)-, tetrahydrochloride",CC(=O)C1=C(C=CC=C1OCC(CN2CCN(CC2)C3=CC(=CC=C3)Cl)O)OCC(CN4CCN(CC4)C5=CC(=CC=C5)Cl)O.Cl.Cl.Cl.Cl,,,,,,
5634,55635,"1-[2,6-Bis[3-[4-(3-chlorophenyl)piperazin-1-yl]-2-hydroxypropoxy]phenyl]ethanone",CC(=O)C1=C(C=CC=C1OCC(CN2CCN(CC2)C3=CC(=CC=C3)Cl)O)OCC(CN4CCN(CC4)C5=CC(=CC=C5)Cl)O,,,,,,
5635,55636,"1-(2,4-Bis(2-hydroxy-3-(4-hydroxy-4-phenyl-1-piperidinyl)propoxy)phenyl)ethanone",CC(=O)C1=C(C=C(C=C1)OCC(CN2CCC(CC2)(C3=CC=CC=C3)O)O)OCC(CN4CCC(CC4)(C5=CC=CC=C5)O)O,,,,,,
5636,55637,"Ethanone, 1-(2,5-bis(2-hydroxy-3-(4-hydroxy-4-phenyl-1-piperidinyl)propoxy)phenyl)-, dihydrochloride",CC(=O)C1=C(C=CC(=C1)OCC(C[NH+]2CCC(CC2)(C3=CC=CC=C3)O)O)OCC(C[NH+]4CCC(CC4)(C5=CC=CC=C5)O)O.[Cl-].[Cl-],,,,,,
5637,55638,"1-[2,5-Bis[2-hydroxy-3-(4-hydroxy-4-phenylpiperidin-1-yl)propoxy]phenyl]ethanone",CC(=O)C1=C(C=CC(=C1)OCC(CN2CCC(CC2)(C3=CC=CC=C3)O)O)OCC(CN4CCC(CC4)(C5=CC=CC=C5)O)O,,,,,,
5638,55639,"1-(2,6-Bis(2-hydroxy-3-(4-hydroxy-4-phenyl-1-piperidinyl)propoxy)phenyl)ethanone",CC(=O)C1=C(C=CC=C1OCC(CN2CCC(CC2)(C3=CC=CC=C3)O)O)OCC(CN4CCC(CC4)(C5=CC=CC=C5)O)O,,,,,,
5639,55640,"1-(2,4-Bis(3-(3,6-dihydro-4-phenyl-1(2H)-pyridinyl)-2-hydroxypropoxy)phenyl)ethanone",CC(=O)C1=C(C=C(C=C1)OCC(CN2CCC(=CC2)C3=CC=CC=C3)O)OCC(CN4CCC(=CC4)C5=CC=CC=C5)O,,,,,,
5640,55641,"1-(2,5-Bis(3-(3,6-dihydro-4-phenyl-1(2H)-pyridinyl)-2-hydroxypropoxy)phenyl)ethanone",CC(=O)C1=C(C=CC(=C1)OCC(CN2CCC(=CC2)C3=CC=CC=C3)O)OCC(CN4CCC(=CC4)C5=CC=CC=C5)O,,,,,,
5641,55642,"1-(2,6-Bis(3-(3,6-dihydro-4-phenyl-1(2H)-pyridinyl)-2-hydroxypropoxy)phenyl)ethanone",CC(=O)C1=C(C=CC=C1OCC(CN2CCC(=CC2)C3=CC=CC=C3)O)OCC(CN4CCC(=CC4)C5=CC=CC=C5)O,,,,,,
5642,55643,"Ethanone, 1-(2,4-bis(2-(acetyloxy)-3-(4-phenyl-1-piperazinyl)propoxy)phenyl)-, tetrahydrochloride",CC(=O)C1=C(C=C(C=C1)OCC(CN2CCN(CC2)C3=CC=CC=C3)OC(=O)C)OCC(CN4CCN(CC4)C5=CC=CC=C5)OC(=O)C.Cl.Cl.Cl.Cl,,,,,,
5643,55644,[1-[4-Acetyl-3-[2-acetyloxy-3-(4-phenylpiperazin-1-yl)propoxy]phenoxy]-3-(4-phenylpiperazin-1-yl)propan-2-yl] acetate,CC(=O)C1=C(C=C(C=C1)OCC(CN2CCN(CC2)C3=CC=CC=C3)OC(=O)C)OCC(CN4CCN(CC4)C5=CC=CC=C5)OC(=O)C,,,,,,
5644,55645,Quinagolida,CCCN1CC(CC2C1CC3=C(C2)C(=CC=C3)O)NS(=O)(=O)N(CC)CC,,,,,,
5645,55646,CID 55646,CC1C=CC(=O)OC1C=CC(=CC(C)CC=CC(=CC(C)C(=O)C(C)C(C(C)CC(=CC(=O)O)C)O)C)C,,,,,,
5646,55647,N-Demethylencainide,COC1=CC=C(C=C1)C(=O)NC2=CC=CC=C2CCC3CCCCN3,,,,,['N-demethylencainide is a known human metabolite of Encainide.'],
5647,55648,"2-(2,3-Dihydro-benzo[1,4]dioxin-2-YL)-ethylamine",C1C(OC2=CC=CC=C2O1)CCN,,,,,,
5648,55649,2-Azidoethylamine,C(CN=[N+]=[N-])N,,,,,,
5649,55650,CID 55650,CCC(CC)C1(C(=O)NC(=NC1=O)S)CC,,,,,,
5650,55651,Spiradoline mesylate,CN([C@H]1CC[C@@]2(CCCO2)C[C@@H]1N3CCCC3)C(=O)CC4=CC(=C(C=C4)Cl)Cl.CS(=O)(=O)O,,,,,,
5651,55652,Spiradoline,CN([C@H]1CC[C@@]2(CCCO2)C[C@@H]1N3CCCC3)C(=O)CC4=CC(=C(C=C4)Cl)Cl,,,"['Agents used for the treatment or prevention of cardiac arrhythmias. They may affect the polarization-repolarization phase of the action potential, its excitability or refractoriness, or impulse conduction or membrane responsiveness within cardiac fibers. Anti-arrhythmia agents are often classed into four main groups according to their mechanism of action: sodium channel blockade, beta-adrenergic blockade, repolarization prolongation, or calcium channel blockade. (See all compounds classified as Anti-Arrhythmia Agents.)', 'Agents that promote the excretion of urine through their effects on kidney function. (See all compounds classified as Diuretics.)', 'Compounds capable of relieving pain without the loss of CONSCIOUSNESS. (See all compounds classified as Analgesics.)']",,,
5652,55653,"2,3,5-Trinitronaphthalene",C1=CC2=CC(=C(C=C2C(=C1)[N+](=O)[O-])[N+](=O)[O-])[N+](=O)[O-],,,,,,
5653,55654,"(1)BENZOPYRANO(3,4-d)IMIDAZOL-4(1H)-ONE, 1-METHYL-",CN1C=NC2=C1C3=CC=CC=C3OC2=O,,,,,,
5654,55655,"(1)BENZOPYRANO(3,4-d)IMIDAZOL-4(1H)-ONE, 1-ETHYL-",CCN1C=NC2=C1C3=CC=CC=C3OC2=O,,,,,,
5655,55656,"(1)BENZOPYRANO(3,4-d)IMIDAZOL-4(1H)-ONE, 1-PROPYL-",CCCN1C=NC2=C1C3=CC=CC=C3OC2=O,,,,,,
5656,55657,"(1)BENZOPYRANO(3,4-d)IMIDAZOL-4(1H)-ONE, 1-(1-METHYLETHYL)-",CC(C)N1C=NC2=C1C3=CC=CC=C3OC2=O,,,,,,
5657,55658,"(1)BENZOPYRANO(3,4-d)IMIDAZOL-4(1H)-ONE, 1-BUTYL-",CCCCN1C=NC2=C1C3=CC=CC=C3OC2=O,,,,,,
5658,55659,"(1)BENZOPYRANO(3,4-d)IMIDAZOL-4(1H)-ONE, 1-CYCLOPENTYL-",C1CCC(C1)N2C=NC3=C2C4=CC=CC=C4OC3=O,,,,,,
5659,55660,"(1)BENZOPYRANO(3,4-d)IMIDAZOL-4(1H)-ONE, 1-CYCLOHEXYL-",C1CCC(CC1)N2C=NC3=C2C4=CC=CC=C4OC3=O,,,,,,
5660,55661,"(1)BENZOPYRANO(3,4-d)IMIDAZOL-4(1H)-ONE, 1-(PHENYLMETHYL)-",C1=CC=C(C=C1)CN2C=NC3=C2C4=CC=CC=C4OC3=O,,,,,,
5661,55662,"(1)BENZOPYRANO(3,4-d)IMIDAZOL-4(1H)-ONE, 1-PHENYL-",C1=CC=C(C=C1)N2C=NC3=C2C4=CC=CC=C4OC3=O,,,,,,
5662,55663,"Benzimidazole, 2-(((4,5-diphenyl-4H-1,2,4-triazol-3-yl)thio)methyl)-, hydrochloride",C1=CC=C(C=C1)C2=NN=C(N2C3=CC=CC=C3)SCC4=[NH+]C5=CC=CC=C5N4.[Cl-],,,,,,
5663,55664,"2-{[(4,5-diphenyl-4H-1,2,4-triazol-3-yl)sulfanyl]methyl}-1H-benzimidazole",C1=CC=C(C=C1)C2=NN=C(N2C3=CC=CC=C3)SCC4=NC5=CC=CC=C5N4,,,,,,
5664,55665,"Acridine, 2-ethoxy-6-nitro-9-((4-phenyl-5-(4-pyridinyl)-4H-1,2,4-triazol-3-yl)thio)-",CCOC1=CC2=C(C3=C(C=C(C=C3)[N+](=O)[O-])N=C2C=C1)SC4=NN=C(N4C5=CC=CC=C5)C6=CC=NC=C6,,,,,,
5665,55666,acetyloxymethyl (6R)-3-(carbamoyloxymethyl)-6-[(1S)-1-hydroxyethyl]-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylate,C[C@@H]([C@H]1C2N(C1=O)C(=C(S2)COC(=O)N)C(=O)OCOC(=O)C)O,,,,,,
5666,55667,"7-[(1R,2R,3S,5S)-3-hydroxy-5-[(4-phenylphenyl)methoxy]-2-piperidin-1-ylcyclopentyl]hept-4-enoic acid;hydrochloride",C1CCN(CC1)[C@H]2[C@H](C[C@@H]([C@@H]2CCC=CCCC(=O)O)OCC3=CC=C(C=C3)C4=CC=CC=C4)O.Cl,,,,,,
5667,55668,"7-[(1R,2R,3S,5S)-3-hydroxy-5-[(4-phenylphenyl)methoxy]-2-(1-piperidinyl)cyclopentyl]-4-heptenoic acid",C1CCN(CC1)[C@H]2[C@H](C[C@@H]([C@@H]2CCC=CCCC(=O)O)OCC3=CC=C(C=C3)C4=CC=CC=C4)O,,,,,,
5668,55669,3-(3-Nitrophenyl)acrylonitrile,C1=CC(=CC(=C1)[N+](=O)[O-])C=CC#N,,,,,,
5669,55670,"(+-)-2-Acetimido-1,5-dimethyl-3,3-diphenylpyrrolidine",CC1CC(C(=NC(=O)C)N1C)(C2=CC=CC=C2)C3=CC=CC=C3,,,,,,
5670,55671,"ACETIC ACID, (PROPYLTHIO)-, compd. with 2,2',2''-NITRILOTRIS(ETHANOL) (1:1)",CCCSCC(=O)O.C(CO)N(CCO)CCO,,,,,,
5671,55672,(Propylthio)acetic acid,CCCSCC(=O)O,,,,,,
5672,55673,"Acetic acid, ((2,2-dichlorovinyl)thio)-, compd. with 2,2',2''-nitrilotris(ethanol) (1:1)",C(CO)N(CCO)CCO.C(C(=O)O)SC=C(Cl)Cl,,,,,,
5673,55674,"Acetic acid, ((2,2-dichloroethenyl)thio)-",C(C(=O)O)SC=C(Cl)Cl,,,,,,
5674,55675,"Acetic acid, ((p-bromophenyl)thio)-, compd. with 2,2',2''-nitrilotris(ethanol) (1:1)",C1=CC(=CC=C1SCC(=O)[O-])Br.C(CO)[NH+](CCO)CCO,,,,,,
5675,55676,(4-Bromo-phenylsulfanyl)-acetic acid,C1=CC(=CC=C1SCC(=O)O)Br,,,,,,
5676,55677,"ACETIC ACID, ((p-CHLOROPHENYL)THIO)-, compd. with 2-AMINOETHANOL (1:1)",C1=CC(=CC=C1SCC(=O)O)Cl.C(CO)N,,,,,,
5677,55678,"ACETIC ACID, ((p-CHLOROPHENYL)THIO)-, compd. with 2,2'-IMINOBIS(ETHANOL) (1:1)",C1=CC(=CC=C1SCC(=O)O)Cl.C(CO)NCCO,,,,,,
5678,55679,"Acetic acid, ((p-chlorophenyl)sulfonyl)-, compd. with 2,2',2''-nitrilotris(ethanol) (1:1)",C1=CC(=CC=C1S(=O)(=O)CC(=O)O)Cl.C(CO)N(CCO)CCO,,,,,,
5679,55680,2-[(4-Chlorophenyl)Sulfonyl]Acetic Acid,C1=CC(=CC=C1S(=O)(=O)CC(=O)O)Cl,,,,,,
5680,55681,"ACETIC ACID, THIODI-, compd. with 2,2',2''-NITRILOTRIS(ETHANOL) (1:2)",C(CO)[NH+](CCO)CCO.C(CO)[NH+](CCO)CCO.C(C(=O)[O-])SCC(=O)[O-],,,,,,
5681,55682,"Acetic acid, (oxybis(p-phenylenethio))di-, compd. with 2,2',2''-nitrilotris(ethanol) (1:2)",C1=CC(=CC=C1OC2=CC=C(C=C2)SCC(=O)O)SCC(=O)O.C(CO)N(CCO)CCO.C(CO)N(CCO)CCO,,,,,,
5682,55683,Cambridge id 5210721,C1=CC(=CC=C1OC2=CC=C(C=C2)SCC(=O)O)SCC(=O)O,,,,,,
5683,55684,"Acetic acid, (thiobis(p-phenylenethio))di-, compd. with 2,2',2''-nitrilotris(ethanol) (1:2)",C1=CC(=CC=C1SCC(=O)O)SC2=CC=C(C=C2)SCC(=O)O.C(CO)N(CCO)CCO.C(CO)N(CCO)CCO,,,,,,
5684,55685,2-[4-[4-(Carboxymethylsulfanyl)phenyl]sulfanylphenyl]sulfanylacetic acid,C1=CC(=CC=C1SCC(=O)O)SC2=CC=C(C=C2)SCC(=O)O,,,,,,
5685,55686,"Acetic acid, (m-phenylenedithio)di-, compd. with 2,2',2''-nitrilotris(ethanol) (1:2)",C1=CC(=CC(=C1)SCC(=O)O)SCC(=O)O.C(CO)N(CCO)CCO.C(CO)N(CCO)CCO,,,,,,
5686,55687,2-[3-(Carboxymethylsulfanyl)phenyl]sulfanylacetic acid,C1=CC(=CC(=C1)SCC(=O)O)SCC(=O)O,,,,,,
5687,55688,"(2S,3aS,6aS)-1-((2R)-2-(((1S)-1-(Ethoxycarbonyl)-3-phenylpropyl)amino)propanoyl)octahydrocyclopenta(b)pyrrole-2-carboxylic acid",CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@H](C)C(=O)N2[C@H]3CCC[C@H]3C[C@H]2C(=O)O,,,,,,
5688,55689,Isomazole hydrochloride,COC1=C(C=CC(=C1)S(=O)C)C2=NC3=C(N2)C=NC=C3.Cl,,,"['Compounds which inhibit or antagonize the biosynthesis or actions of phosphodiesterases. (See all compounds classified as Phosphodiesterase Inhibitors.)', 'Agents that have a strengthening effect on the heart or that can increase cardiac output. They may be CARDIAC GLYCOSIDES; SYMPATHOMIMETICS; or other drugs. They are used after MYOCARDIAL INFARCT; CARDIAC SURGICAL PROCEDURES; in SHOCK; or in congestive heart failure (HEART FAILURE). (See all compounds classified as Cardiotonic Agents.)']",,,
5689,55690,Isomazole,COC1=C(C=CC(=C1)S(=O)C)C2=NC3=C(N2)C=NC=C3,,,"['Agents that have a strengthening effect on the heart or that can increase cardiac output. They may be CARDIAC GLYCOSIDES; SYMPATHOMIMETICS; or other drugs. They are used after MYOCARDIAL INFARCT; CARDIAC SURGICAL PROCEDURES; in SHOCK; or in congestive heart failure (HEART FAILURE). (See all compounds classified as Cardiotonic Agents.)', 'Compounds which inhibit or antagonize the biosynthesis or actions of phosphodiesterases. (See all compounds classified as Phosphodiesterase Inhibitors.)']",,,
5690,55691,"(+-)-3,4,5-Trimethoxybenzoic acid 3-quinuclidinyl ester",COC1=CC(=CC(=C1OC)OC)C(=O)OC2CN3CCC2CC3,,,,,,
5691,55692,"(+-)-10,11-Dihydro-5H-dibenzo(a,d)cycloheptene-5-carboxylic acid 3-quinuclidinyl ester",C1CN2CCC1C(C2)OC(=O)C3C4=CC=CC=C4CCC5=CC=CC=C35,,,,,,
5692,55693,(+-)-Diphenylfluoroacetic acid 3-quinuclidinyl ester,C1CN2CCC1C(C2)OC(=O)C(C3=CC=CC=C3)(C4=CC=CC=C4)F,,,,,,
5693,55694,"Ammonium, dimethyl(2-hydroxy-3-(1-naphthyloxy)propyl)(((2,6-xylyl)carbamoyl)methyl)-, chloride",CC1=C(C(=CC=C1)C)NC(=O)C[N+](C)(C)CC(COC2=CC=CC3=CC=CC=C32)O.[Cl-],,,,,,
5694,55695,"[2-(2,6-Dimethylanilino)-2-oxoethyl]-(2-hydroxy-3-naphthalen-1-yloxypropyl)-dimethylazanium",CC1=C(C(=CC=C1)C)NC(=O)C[N+](C)(C)CC(COC2=CC=CC3=CC=CC=C32)O,,,,,,
5695,55696,"Ammonium, (((p-chlorophenyl)carbamoyl)methyl)dimethyl(2-hydroxy-3-(1-naphthyloxy)propyl)-, chloride",C[N+](C)(CC(COC1=CC=CC2=CC=CC=C21)O)CC(=O)NC3=CC=C(C=C3)Cl.[Cl-],,,,,,
5696,55697,[2-(4-Chloroanilino)-2-oxoethyl]-(2-hydroxy-3-naphthalen-1-yloxypropyl)-dimethylazanium,C[N+](C)(CC(COC1=CC=CC2=CC=CC=C21)O)CC(=O)NC3=CC=C(C=C3)Cl,,,,,,
5697,55698,(p-Bromophenacyl)dimethyl(2-hydroxy-3-(1-naphthyloxy)propyl)ammonium bromide,C[N+](C)(CC(COC1=CC=CC2=CC=CC=C21)O)CC(=O)C3=CC=C(C=C3)Br.[Br-],,,,,,
5698,55699,[2-(4-Bromophenyl)-2-oxoethyl]-(2-hydroxy-3-naphthalen-1-yloxypropyl)-dimethylazanium,C[N+](C)(CC(COC1=CC=CC2=CC=CC=C21)O)CC(=O)C3=CC=C(C=C3)Br,,,,,,
5699,55700,"Ammonium, (carboxymethyl)dimethyl(2-hydroxy-3-(1-naphthyloxy)propyl)-, ethyl ester, bromide",CCOC(=O)C[N+](C)(C)CC(COC1=CC=CC2=CC=CC=C21)O.[Br-],,,,,,
5700,55701,(2-Ethoxy-2-oxoethyl)-(2-hydroxy-3-naphthalen-1-yloxypropyl)-dimethylazanium,CCOC(=O)C[N+](C)(C)CC(COC1=CC=CC2=CC=CC=C21)O,,,,,,
5701,55702,(o-Bromobenzyl)dimethyl(2-hydroxy-3-(1-naphthyloxy)propyl)ammonium bromide,C[N+](C)(CC1=CC=CC=C1Br)CC(COC2=CC=CC3=CC=CC=C32)O.[Br-],,,,,,
5702,55703,(2-Bromophenyl)methyl-(2-hydroxy-3-naphthalen-1-yloxypropyl)-dimethylazanium,C[N+](C)(CC1=CC=CC=C1Br)CC(COC2=CC=CC3=CC=CC=C32)O,,,,,,
5703,55704,"Ammonium, dimethyl(2-hydroxy-3-(1-naphthyloxy)propyl)((mesitylcarbamoyl)methyl)-, chloride",CC1=CC(=C(C(=C1)C)NC(=O)C[N+](C)(C)CC(COC2=CC=CC3=CC=CC=C32)O)C.[Cl-],,,,,,
5704,55705,[2-Hydroxy-3-(1-naphthoxy)propyl]-(2-keto-2-mesidino-ethyl)-dimethyl-ammonium;chloride,CC1=CC(=C(C(=C1)C)NC(=O)C[N+](C)(C)CC(COC2=CC=CC3=CC=CC=C32)O)C,,,,,,
5705,55706,N-(2-Hydroxy-3-diethylaminopropyl)diphenylacetamide hydrochloride,CC[NH+](CC)CC(CNC(=O)C(C1=CC=CC=C1)C2=CC=CC=C2)O.[Cl-],,,,,,
5706,55707,"N-[3-(diethylamino)-2-hydroxypropyl]-2,2-diphenylacetamide",CCN(CC)CC(CNC(=O)C(C1=CC=CC=C1)C2=CC=CC=C2)O,,,,,,
5707,55708,2-Demethylthiocolchicine,CC(=O)N[C@H]1CCC2=CC(=C(C(=C2C3=CC=C(C(=O)C=C13)SC)OC)O)OC,,,,,,
5708,55709,Dezaguanine mesylate,CS(=O)(=O)O.C1=C(NC(=O)C2=C1NC=N2)N,,,,,,
5709,55710,Dezaguanine,C1=C(NC(=O)C2=C1NC=N2)N,,,"['Antimetabolites that are useful in cancer chemotherapy. (See all compounds classified as Antimetabolites, Antineoplastic.)', 'Drugs that are chemically similar to naturally occurring metabolites, but differ enough to interfere with normal metabolic pathways. (From AMA Drug Evaluations Annual, 1994, p2033) (See all compounds classified as Antimetabolites.)']",,,
5710,55711,Allyldimethyl(2-hydroxy-3-(1-naphthyloxy)propyl)ammonium bromide,C[N+](C)(CC=C)CC(COC1=CC=CC2=CC=CC=C21)O.[Br-],,,,,,
5711,55712,(2-Hydroxy-3-naphthalen-1-yloxypropyl)-dimethyl-prop-2-enylazanium,C[N+](C)(CC=C)CC(COC1=CC=CC2=CC=CC=C21)O,,,,,,
5712,55713,"Benzamide, N-(3-(((4-bromophenyl)amino)methyl)-3-chloro-2-(3-hydroxy-4-methoxyphenyl)-4-oxo-1-azetidinyl)-2-hydroxy-",COC1=C(C=C(C=C1)C2C(C(=O)N2NC(=O)C3=CC=CC=C3O)(CNC4=CC=C(C=C4)Br)Cl)O,,,,,,
5713,55714,"Benzamide, N-(3-(((4-bromophenyl)amino)methyl)-3-chloro-2-oxo-4-(4-phenoxyphenyl)-1-azetidinyl)-2-hydroxy-",C1=CC=C(C=C1)OC2=CC=C(C=C2)C3C(C(=O)N3NC(=O)C4=CC=CC=C4O)(CNC5=CC=C(C=C5)Br)Cl,,,,,,
5714,55715,CID 55715,C1=CC(=CN=C1)CC2=CC3=C(C=C2)OC(=C3)C(=O)[O-].[Na+],,,,,,
5715,55716,Isopropylammonium nitrate,CC(C)[NH3+].[N+](=O)([O-])[O-],,,,,,
5716,55717,Disoxaril,CC1=NOC(=C1)CCCCCCCOC2=CC=C(C=C2)C3=NCCO3,,,['Agents used in the prophylaxis or therapy of VIRUS DISEASES. Some of the ways they may act include preventing viral replication by inhibiting viral DNA polymerase; binding to specific cell-surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking late stages of virus assembly. (See all compounds classified as Antiviral Agents.)'],,,
5717,55718,Napamezole,C1CC(=CC2=CC=CC=C21)CC3=NCCN3,,,,,,
5718,55719,Hexahydro-N-(1-phenylethyl)-1H-azepin-1-amine,CC(C1=CC=CC=C1)NN2CCCCCC2,,,,,,
5719,55720,Hexahydro-N-(1-methyl-2-phenylethyl)-1H-azepin-1-amine,CC(CC1=CC=CC=C1)NN2CCCCCC2,,,,,,
5720,55721,"1H-Azepin-1-amine, hexahydro-N-(2-phenylethyl)-",C1CCCN(CC1)NCCC2=CC=CC=C2,,,,,,
5721,55722,"BENZONITRILE, 4-(6-(1-PYRROLIDINYL)-1,2,4-TRIAZOLO(3,4-a)PHTHALAZIN-3-YL)-",C1CCN(C1)C2=CC=CC3=C2C=NN4C3=NN=C4C5=CC=C(C=C5)C#N,,,,,,
5722,55723,"Benzenamine, N,N-dimethyl-4-(6-(1-pyrrolidinyl)-1,2,4-triazolo(3,4-a)phthalazin-3-yl)-",CN(C)C1=CC=C(C=C1)C2=NN=C3N2N=CC4=C3C=CC=C4N5CCCC5,,,,,,
5723,55724,"Benzenamine, 3-chloro-N,N-dimethyl-4-(6-(1-pyrrolidinyl)-1,2,4-triazolo(3,4-a)phthalazin-3-yl)-",CN(C)C1=CC(=C(C=C1)C2=NN=C3N2N=CC4=C3C=CC=C4N5CCCC5)Cl,,,,,,
5724,55725,"BENZAMIDE, 4-(6-(1-PYRROLIDINYL)-1,2,4-TRIAZOLO(3,4-a)PHTHALAZIN-3-YL)-",C1CCN(C1)C2=CC=CC3=C2C=NN4C3=NN=C4C5=CC=C(C=C5)C(=O)N,,,,,,
5725,55726,"BENZOIC ACID, 4-(6-(1-PYRROLIDINYL)-1,2,4-TRIAZOLO(3,4-a)PHTHALAZIN-3-YL)-",C1CCN(C1)C2=CC=CC3=C2C=NN4C3=NN=C4C5=CC=C(C=C5)C(=O)O,,,,,,
5726,55727,"3-(4-(Dimethylamino)phenyl)-6-ethoxy-1,2,4-triazolo(3,4-a)phthalazine",CCOC1=CC=CC2=C1C=NN3C2=NN=C3C4=CC=C(C=C4)N(C)C,,,,,,
5727,55728,"BENZONITRILE, 4-(6-ETHOXY-1,2,4-TRIAZOLO(3,4-a)PHTHALAZIN-3-YL)-",CCOC1=CC=CC2=C1C=NN3C2=NN=C3C4=CC=C(C=C4)C#N,,,,,,
5728,55729,"3-(2-Chloro-4-(dimethylamino)phenyl)-6-ethoxy-1,2,4-triazolo(3,4-a)phthalazine",CCOC1=CC=CC2=C1C=NN3C2=NN=C3C4=C(C=C(C=C4)N(C)C)Cl,,,,,,
5729,55730,"1-BUTANOL, 4-((3-(4-METHOXYPHENYL)-1,2,4-TRIAZOLO(3,4-a)PHTHALAZIN-6-YL)OXY)-",COC1=CC=C(C=C1)C2=NN=C3N2N=C(C4=CC=CC=C43)OCCCCO,,,,,,
5730,55731,"1H-Indole-6-carboximidamide, 2-(3,4,5-trimethoxyphenyl)-",COC1=CC(=CC(=C1OC)OC)C2=CC3=C(N2)C=C(C=C3)C(=N)N,,,,,,
5731,55732,"1H-Benzimidazole-5-carboximidamide, 2-(1H-benzimidazol-2-ylamino)-",C1=CC=C2C(=C1)NC(=N2)NC3=NC4=C(N3)C=C(C=C4)C(=N)N,,,,,,
5732,55733,"1H-Indole-6-carboximidamide, 2,2'-(oxydi-4,1-phenylene)bis-",C1=CC(=CC=C1C2=CC3=C(N2)C=C(C=C3)C(=N)N)OC4=CC=C(C=C4)C5=CC6=C(N5)C=C(C=C6)C(=N)N,,,,,,
5733,55734,"6-(4,5-dihydro-1H-imidazol-2-yl)-2-[2-[6-(4,5-dihydro-1H-imidazol-2-yl)-1-benzothiophen-2-yl]ethenyl]-1H-indole",C1CN=C(N1)C2=CC3=C(C=C2)C=C(N3)C=CC4=CC5=C(S4)C=C(C=C5)C6=NCCN6,,,,,,
5734,55735,"1H-Indole-5-carboximidamide, 2-(4-(4-(aminoiminomethyl)phenoxy)phenyl)-",C1=CC(=CC=C1C2=CC3=C(N2)C=CC(=C3)C(=N)N)OC4=CC=C(C=C4)C(=N)N,,,,,,
5735,55736,CID 55736,CN1CCC[NH+](CC1)CCOC(=O)COC2=CC=C(C=C2)Cl.C(=CC(=O)[O-])C(=O)O,,,,,,
5736,55737,"2-(4-Methyl-1,4-diazepan-1-yl)ethyl 2-(4-chlorophenoxy)acetate",CN1CCCN(CC1)CCOC(=O)COC2=CC=C(C=C2)Cl,,,,,,
5737,55738,CID 55738,C[NH+]1CCC[NH+](CC1)CCCOC(=O)COC2=CC=C(C=C2)Cl.C(=CC(=O)[O-])C(=O)[O-],,,,,,
5738,55739,"3-(4-Methyl-1,4-diazepan-1-yl)propyl 2-(4-chlorophenoxy)acetate",CN1CCCN(CC1)CCCOC(=O)COC2=CC=C(C=C2)Cl,,,,,,
5739,55740,(4-Chlorophenoxy)acetic acid 2-(2-(hexahydro-1H-azepin-1-yl)ethyl)hydrazide hydrochloride,C1CCC[NH+](CC1)CCNNC(=O)COC2=CC=C(C=C2)Cl.[Cl-],,,,,,
5740,55741,N'-[2-(azepan-1-yl)ethyl]-2-(4-chlorophenoxy)acetohydrazide,C1CCCN(CC1)CCNNC(=O)COC2=CC=C(C=C2)Cl,,,,,,
5741,55742,(4-Chlorophenoxy)acetic acid 2-(3-(hexahydro-1H-azepin-1-yl)propyl)hydrazide hydrochloride,CCCCNNC(=O)COC1=CC=C(C=C1)Cl.C1CCC[NH2+]CC1.[Cl-],,,,,,
5742,55743,N'-butyl-2-(4-chlorophenoxy)acetohydrazide,CCCCNNC(=O)COC1=CC=C(C=C1)Cl,,,,,,
5743,55744,CID 55744,CC(C1=CC=CC=[N+]1[O-])NN=C(N2CCCCCC2)S,,,,,,
5744,55745,CID 55745,CC(C)[NH+]1CCC[NH+](CC1)CCOC(=O)COC2=CC=C(C=C2)Cl.C(=CC(=O)[O-])C(=O)[O-],,,,,,
5745,55746,"2-(4-Propan-2-yl-1,4-diazepan-1-yl)ethyl 2-(4-chlorophenoxy)acetate",CC(C)N1CCCN(CC1)CCOC(=O)COC2=CC=C(C=C2)Cl,,,,,,
5746,55747,S-(pentachlorobutadienyl)-l-cysteine,C([C@@H](C(=O)O)N)SC(=C(C(=C(Cl)Cl)Cl)Cl)Cl,,,,,,
5747,55748,Mitoflaxone,C1=CC=C(C=C1)C2=CC(=O)C3=CC=CC(=C3O2)CC(=O)O,,,"['Substances that augment, stimulate, activate, potentiate, or modulate the immune response at either the cellular or humoral level. The classical agents (Freund&apos;s adjuvant, BCG, Corynebacterium parvum, et al.) contain bacterial antigens. Some are endogenous (e.g., histamine, interferon, transfer factor, tuftsin, interleukin-1). Their mode of action is either non-specific, resulting in increased immune responsiveness to a wide variety of antigens, or antigen-specific, i.e., affecting a restricted type of immune response to a narrow group of antigens. The therapeutic efficacy of many biological response modifiers is related to their antigen-specific immunoadjuvanticity. (See all compounds classified as Adjuvants, Immunologic.)', 'Substances that inhibit or prevent the proliferation of NEOPLASMS. (See all compounds classified as Antineoplastic Agents.)']",,,
5748,55749,"4H-1-Benzopyran-8-acetic acid, 4-oxo-2-phenyl-, 2-(diethylamino)ethyl ester, hydrochloride",CC[NH+](CC)CCOC(=O)CC1=C2C(=CC=C1)C(=O)C=C(O2)C3=CC=CC=C3.[Cl-],,,,,,
5749,55750,"4H-1-Benzopyran-8-acetic acid, 4-oxo-2-phenyl-, 2-(diethylamino)ethyl ester",CCN(CC)CCOC(=O)CC1=C2C(=CC=C1)C(=O)C=C(O2)C3=CC=CC=C3,,,,,,
5750,55751,Tiospirone hydrochloride,C1CCC2(C1)CC(=O)N(C(=O)C2)CCCCN3CCN(CC3)C4=NSC5=CC=CC=C54.Cl,,,,,,
5751,55752,Tiospirone,C1CCC2(C1)CC(=O)N(C(=O)C2)CCCCN3CCN(CC3)C4=NSC5=CC=CC=C54,,,,,,
5752,55753,"6-{1-[4-(Ethanesulfonyl)phenyl]prop-1-en-2-yl}-1,1,4,4-tetramethyl-1,2,3,4-tetrahydronaphthalene",CCS(=O)(=O)C1=CC=C(C=C1)C=C(C)C2=CC3=C(C=C2)C(CCC3(C)C)(C)C,,,,,,
5753,55754,Ofornine,C1CCN(CC1)C(=O)C2=CC=CC=C2NC3=CC=NC=C3,,,,,,
5754,55755,"4-Butyl-1,2-dihydro-5-((3,4-methylenedioxybenzoyl)oxy)-1,2-diphenyl-3H-pyrazol-3-one",CCCCC1=C(N(N(C1=O)C2=CC=CC=C2)C3=CC=CC=C3)OC(=O)C4=CC5=C(C=C4)OCO5,,,,,,
5755,55756,3-[6-[1-(4-Methylphenyl)-3-pyrrolidin-1-ylprop-1-enyl]pyridin-2-yl]prop-2-enoic acid,CC1=CC=C(C=C1)C(=CCN2CCCC2)C3=CC=CC(=N3)C=CC(=O)O,,,"['A class of non-sedating drugs that bind to but do not activate histamine receptors (DRUG INVERSE AGONISM), thereby blocking the actions of histamine or histamine agonists. These antihistamines represent a heterogenous group of compounds with differing chemical structures, adverse effects, distribution, and metabolism. Compared to the early (first generation) antihistamines, these non-sedating antihistamines have greater receptor specificity, lower penetration of BLOOD-BRAIN BARRIER, and are less likely to cause drowsiness or psychomotor impairment. (See all compounds classified as Histamine H1 Antagonists, Non-Sedating.)']",,,
5756,55757,CID 55757,CC(C=CC1CC=CC(=O)O1)(C(CC(C=CC=CC=CCO)O)OP(=O)(O)[O-])O.[Na+],,,,,,
5757,55758,"Furfurylamine, N-propyl-, hydrochloride",CCC[NH2+]CC1=CC=CO1.[Cl-],,,,,,
5758,55759,N-(furan-2-ylmethyl)propan-1-amine,CCCNCC1=CC=CO1,,,,,,
5759,55760,"2,3,4,5-Tetrahydro-4-phenyl-1H-1,5-benzodiazepine-2-carboxylic acid",C1C(NC2=CC=CC=C2NC1C(=O)O)C3=CC=CC=C3,,,,,,
5760,55761,"1H-1,5-Benzodiazepine-2-carboxylic acid, 2,3,4,5-tetrahydro-4-phenyl-, methyl ester",COC(=O)C1CC(NC2=CC=CC=C2N1)C3=CC=CC=C3,,,,,,
5761,55762,"2,3,4,5-Tetrahydro-4-phenyl-1H-1,5-benzodiazepine-2-carboxylic acid ethyl ester",CCOC(=O)C1CC(NC2=CC=CC=C2N1)C3=CC=CC=C3,,,,,,
5762,55763,"1H-1,5-Benzodiazepine-2-carboxylic acid, 2,3,4,5-tetrahydro-4-methyl-, ethyl ester",CCOC(=O)C1CC(NC2=CC=CC=C2N1)C,,,,,,
5763,55764,"2H-1,5-Benzodiazepin-2-one, 1,3-dihydro-4-phenyl-, hydrazone",C1C(=NC2=CC=CC=C2N=C1NN)C3=CC=CC=C3,,,,,,
5764,55765,"7,7'-Oxybis(2,3,4,5-tetrahydro-4-phenyl-1H-1,5-benzodiazepine-2-carbonitrile)",C1C(NC2=C(C=C(C=C2)OC3=CC4=C(C=C3)NC(CC(N4)C5=CC=CC=C5)C#N)NC1C6=CC=CC=C6)C#N,,,,,,
5765,55766,"7,7'-Carbonylbis(2,3,4,5-tetrahydro-4-phenyl-1H-1,5-benzodiazepine-2-carbonitrile)",C1C(NC2=C(C=C(C=C2)C(=O)C3=CC4=C(C=C3)NC(CC(N4)C5=CC=CC=C5)C#N)NC1C6=CC=CC=C6)C#N,,,,,,
5766,55767,"2,3,4,5-Tetrahydro-4-methyl-1H-1,5-benzodiazepine-2-carboxaldehyde",CC1CC(NC2=CC=CC=C2N1)C=O,,,,,,
5767,55768,"(7,7'-Bi-1H-1,5-benzodiazepine)-2,2'-dicarbonitrile, 2,2',3,3',4,4',5,5'-octahydro-4,4'-dimethyl-",CC1CC(NC2=C(N1)C=C(C=C2)C3=CC4=C(C=C3)NC(CC(N4)C)C#N)C#N,,,,,,
5768,55769,"7,7'-Carbonylbis(2,3,4,5-tetrahydro-4-methyl-1H-1,5-benzodiazepine-2-carbonitrile)",CC1CC(NC2=C(N1)C=C(C=C2)C(=O)C3=CC4=C(C=C3)NC(CC(N4)C)C#N)C#N,,,,,,
5769,55770,"7,7'-Oxybis(2,3,4,5-tetrahydro-4-methyl-1H-1,5-benzodiazepine-2-carbonitrile)",CC1CC(NC2=C(N1)C=C(C=C2)OC3=CC4=C(C=C3)NC(CC(N4)C)C#N)C#N,,,,,,
5770,55771,1-(2-Benzylidenecyclohexyl)azetidine;butanedioic acid,C1CCC(=CC2=CC=CC=C2)C(C1)N3CCC3.C(CC(=O)O)C(=O)O,,,,,,
5771,55772,1-(2-Benzylidenecyclohexyl)azetidine,C1CCC(=CC2=CC=CC=C2)C(C1)N3CCC3,,,,,,
5772,55773,"Benzofuran, 3-methyl-2-nitro-",CC1=C(OC2=CC=CC=C12)[N+](=O)[O-],,,,,,
5773,55774,"11-(2-Dimethylaminoethyl)-6,11-dihydrodibenzo(b,e)thiepin-11-carbonitrile oxalate hemihydrate",C[NH+](C)CCC1(C2=CC=CC=C2CSC3=CC=CC=C31)C#N.C(=O)(C(=O)[O-])O,,,,,,
5774,55775,11-[2-(dimethylamino)ethyl]-6H-benzo[c][1]benzothiepine-11-carbonitrile,CN(C)CCC1(C2=CC=CC=C2CSC3=CC=CC=C31)C#N,,,,,,
5775,55776,"6,11-Dihydro-11-(3-(dimethylamino)propyl)dibenzo(b,e)thiepin-11-carbonitrile ethanedioate",C[NH+](C)CCCC1(C2=CC=CC=C2CSC3=CC=CC=C31)C#N.C(=O)(C(=O)[O-])O,,,,,,
5776,55777,11-[3-(dimethylamino)propyl]-6H-benzo[c][1]benzothiepine-11-carbonitrile,CN(C)CCCC1(C2=CC=CC=C2CSC3=CC=CC=C31)C#N,,,,,,
5777,55778,CID 55778,CCC(=[NH2+])C1(C2=CC=CC=C2CSC3=CC=CC=C31)CC[NH+](C)C.C(=CC(=O)[O-])C(=O)O.C(=CC(=O)[O-])C(=O)O,,,,,,
5778,55779,"N,N-dimethyl-2-(11-propanimidoyl-6H-benzo[c][1]benzothiepin-11-yl)ethanamine",CCC(=N)C1(C2=CC=CC=C2CSC3=CC=CC=C31)CCN(C)C,,,,,,
5779,55780,CID 55780,CN1CCN(CC1)CCCC2(C3=CC=CC=C3CSC4=CC=CC=C42)C#N.C(=CC(=O)O)C(=O)O.C(=CC(=O)O)C(=O)O,,,,,,
5780,55781,11-[3-(4-methylpiperazin-1-yl)propyl]-6H-benzo[c][1]benzothiepine-11-carbonitrile,CN1CCN(CC1)CCCC2(C3=CC=CC=C3CSC4=CC=CC=C42)C#N,,,,,,
5781,55782,2-Hydroxymethylfluoranthene,C1=CC=C2C(=C1)C3=CC=CC4=CC(=CC2=C43)CO,,,,,,
5782,55783,2-Phenylpropylidenemalononitrile,CC(C=C(C#N)C#N)C1=CC=CC=C1,,,,,,
5783,55784,Bemitradine,CCOCCC1=C(N=C(N2C1=NC=N2)N)C3=CC=CC=C3,,,,,,
5784,55785,"D-Alanine, 3-azido-",C(C(C(=O)O)N)N=[N+]=[N-],,,,,,
5785,55786,"5,9-Dimethyldibenzo(c,g)carbazole",CC1=CC2=C(C3=CC=CC=C13)C4=C(N2)C=C(C5=CC=CC=C54)C,,,,,,
5786,55787,Ledienosid [German],CC1[C@@H](C(C([C@@H](O1)O[C@H]2CC[C@@]3(C4CC[C@@]5([C@H](CC[C@@]5(C4CC[C@@]3(C2)O)O)C6=CC(=O)OC6)C)C)O)O)O,,,,,,
5787,55788,CID 55788,CC1=NC(=CC2=CC=CC=C2)C(=O)N1C3=CC=C(C=C3)C(=O)O,,,,,,
5788,55789,"BENZO(c)PHENANTHRENE-3,4-DIOL, 3,4-DIHYDRO-",C1=CC=C2C(=C1)C=CC3=C2C4=C(C=C3)C(C(C=C4)O)O,,,,,,
5789,55790,Pyrifenox,CON=C(CC1=CN=CC=C1)C2=C(C=C(C=C2)Cl)Cl,,,,,,
5790,55791,CID 55791,CC1=C2C=CC(=O)N=C2C=CN1,,,,,,
5791,55792,"1,3-Bis(morpholinomethyl)-5-methyl-3-phenyl-2-indolinone",CC1=CC2=C(C=C1)N(C(=O)C2(CN3CCOCC3)C4=CC=CC=C4)CN5CCOCC5,,,,,,
5792,55793,"1,3-Bis(piperidinomethyl)-3-(p-bromophenyl)-2-indolinone",C1CCN(CC1)CC2(C3=CC=CC=C3N(C2=O)CN4CCCCC4)C5=CC=C(C=C5)Br,,,,,,
5793,55794,"Benzoic acid, 4-((4-(((2-thioxo-3(2H)-benzothiazolyl)methyl)amino)benzoyl)amino)-, methyl ester",COC(=O)C1=CC=C(C=C1)NC(=O)C2=CC(=CC=C2)NCN3C4=CC=CC=C4SC3=S,,,,,,
5794,55795,"Benzoic acid, 4-((4-(((2-thioxo-3(2H)-benzothiazolyl)methyl)amino)benzoyl)amino)-, ethyl ester",CCOC(=O)C1=CC=C(C=C1)NC(=O)C2=CC(=CC=C2)NCN3C4=CC=CC=C4SC3=S,,,,,,
5795,55796,"Benzoic acid, 4,4'-((2-thioxo-1H-benzimidazole-1,3(2H)-diyl)bis(methyleneimino-4,1-phenylenecarbonylimino))bis-, diethyl ester",CCOC(=O)C1=CC=C(C=C1)NC(=O)C2=CC=C(C=C2)NCN3C4=CC=CC=C4N(C3=S)CNC5=CC=C(C=C5)C(=O)NC6=CC=C(C=C6)C(=O)OCC,,,,,,
5796,55797,"Benzoic acid, 4-((4-(((2-oxo-3(2H)-benzoxazolyl)methyl)amino)benzoyl)amino)-, ethyl ester, hydrate",CCOC(=O)C1=CC=C(C=C1)NC(=O)C2=CC(=CC=C2)NCN3C4=CC=CC=C4OC3=O.O,,,,,,
5797,55798,"Ethyl 4-[[3-[(2-oxo-1,3-benzoxazol-3-yl)methylamino]benzoyl]amino]benzoate",CCOC(=O)C1=CC=C(C=C1)NC(=O)C2=CC(=CC=C2)NCN3C4=CC=CC=C4OC3=O,,,,,,
5798,55799,CID 55799,C1=CC(=CN=NC(=O)C2=CC=C(C=C2)NC(=O)C3=CC=C(C=C3)N(O)O)C(=O)C=C1,,,,,,
5799,55800,"AMMONIUM, (p-PHENYLENEDIMETHYLENE)BIS(DODECYLDIETHYL-, DIBROMIDE",CCCCCCCCCCCC[N+](CC)(CC)CC1=CC=C(C=C1)C[N+](CC)(CC)CCCCCCCCCCCC.[Br-].[Br-],,,,,,
5800,55801,p-Xylylenebis(dodecyldiethylaminium),CCCCCCCCCCCC[N+](CC)(CC)CC1=CC=C(C=C1)C[N+](CC)(CC)CCCCCCCCCCCC,,,,,,
5801,55802,alpha-((Butylamino)methyl)-3-hydroxybenzyl alcohol hydrochloride,CCCC[NH2+]CC(C1=CC(=CC=C1)O)O.[Cl-],,,,,,
5802,55803,3-[2-(Butylamino)-1-hydroxyethyl]phenol,CCCCNCC(C1=CC(=CC=C1)O)O,,,,,,
5803,55804,alpha-((Dimethylamino)methyl)-3-hydroxybenzyl alcohol hydrochloride,C[NH+](C)CC(C1=CC(=CC=C1)O)O.[Cl-],,,,,,
5804,55805,(+)-Dimethylaminomethyl-3-oxyphenylcarbinol,CN(C)CC(C1=CC(=CC=C1)O)O,,,,,,
5805,55806,"Benzyl alcohol, 3-hydroxy-alpha-((((4-methoxyphenyl)methyl)amino)methyl)-, hydrochloride",COC1=C(C=C(C=C1)C[NH2+]CC(C2=CC(=CC=C2)O)O)O.[Cl-],,,,,,
5806,55807,5-[[[2-Hydroxy-2-(3-hydroxyphenyl)ethyl]amino]methyl]-2-methoxyphenol,COC1=C(C=C(C=C1)CNCC(C2=CC(=CC=C2)O)O)O,,,,,,
5807,55808,"Benzyl alcohol, alpha-((((3,4-dimethoxyphenyl)methyl)amino)methyl)-3-hydroxy-, hydrochloride",COC1=C(C=C(C=C1)C[NH2+]CC(C2=CC(=CC=C2)O)O)OC.[Cl-],,,,,,
5808,55809,"3-[2-[(3,4-Dimethoxyphenyl)methylamino]-1-hydroxyethyl]phenol",COC1=C(C=C(C=C1)CNCC(C2=CC(=CC=C2)O)O)OC,,,,,,
5809,55810,3-Hydroxy-alpha-((propylamino)methyl)benzyl alcohol hydrochloride,CCC[NH2+]CC(C1=CC(=CC=C1)O)O.[Cl-],,,,,,
5810,55811,3-[1-Hydroxy-2-(propylamino)ethyl]phenol,CCCNCC(C1=CC(=CC=C1)O)O,,,,,,
5811,55812,1-Methyl-2-diethylaminomethyl-3-ethoxycarbonyl-5-tosyloxyindole hydrochloride,CC[NH+](CC)CC1=C(C2=C(N1C)C=CC(=C2)OS(=O)(=O)C3=CC=C(C=C3)C)C(=O)OCC.[Cl-],,,,,,
5812,55813,Ethyl 2-(diethylaminomethyl)-1-methyl-5-(4-methylphenyl)sulfonyloxyindole-3-carboxylate,CCN(CC)CC1=C(C2=C(N1C)C=CC(=C2)OS(=O)(=O)C3=CC=C(C=C3)C)C(=O)OCC,,,,,,
5813,55814,Benzyl-[[3-ethoxycarbonyl-1-methyl-5-(4-methylphenyl)sulfonyloxyindol-2-yl]methyl]azanium;chloride,CCOC(=O)C1=C(N(C2=C1C=C(C=C2)OS(=O)(=O)C3=CC=C(C=C3)C)C)C[NH2+]CC4=CC=CC=C4.[Cl-],,,,,,
5814,55815,Ethyl 2-[(benzylamino)methyl]-1-methyl-5-(4-methylphenyl)sulfonyloxyindole-3-carboxylate,CCOC(=O)C1=C(N(C2=C1C=C(C=C2)OS(=O)(=O)C3=CC=C(C=C3)C)C)CNCC4=CC=CC=C4,,,,,,
5815,55816,"Indole-3-carboxylic acid, 5-hydroxy-1-methyl-2-(morpholinomethyl)-, ethyl ester, p-toluenesulfonate (ester), hydrochloride",CCOC(=O)C1=C(N(C2=C1C=C(C=C2)OS(=O)(=O)C3=CC=C(C=C3)C)C)C[NH+]4CCOCC4.[Cl-],,,,,,
5816,55817,Ethyl 1-methyl-5-{[(4-methylphenyl)sulfonyl]oxy}-2-(morpholin-4-ylmethyl)-1h-indole-3-carboxylate,CCOC(=O)C1=C(N(C2=C1C=C(C=C2)OS(=O)(=O)C3=CC=C(C=C3)C)C)CN4CCOCC4,,,,,,
5817,55818,"Indole-3-carboxylic acid, 5-hydroxy-2-(morpholinomethyl)-1-phenyl-, ethyl ester, p-toluenesulfonate (ester), hydrochloride",CCOC(=O)C1=C(N(C2=C1C=C(C=C2)OS(=O)(=O)C3=CC=C(C=C3)C)C4=CC=CC=C4)C[NH+]5CCOCC5.[Cl-],,,,,,
5818,55819,Ethyl 5-(4-methylphenyl)sulfonyloxy-2-(morpholin-4-ylmethyl)-1-phenylindole-3-carboxylate,CCOC(=O)C1=C(N(C2=C1C=C(C=C2)OS(=O)(=O)C3=CC=C(C=C3)C)C4=CC=CC=C4)CN5CCOCC5,,,,,,
5819,55820,"Indole-3-carboxylic acid, 5-hydroxy-2-((4-methyl-1-piperazinyl)methyl)-1-phenyl-, ethyl ester, p-toluenesulfonate (ester), hydrochloride",CCOC(=O)C1=C(N(C2=C1C=C(C=C2)OS(=O)(=O)C3=CC=C(C=C3)C)C4=CC=CC=C4)C[NH+]5CCN(CC5)C.[Cl-],,,,,,
5820,55821,Ethyl 5-(4-methylphenyl)sulfonyloxy-2-[(4-methylpiperazin-1-yl)methyl]-1-phenylindole-3-carboxylate,CCOC(=O)C1=C(N(C2=C1C=C(C=C2)OS(=O)(=O)C3=CC=C(C=C3)C)C4=CC=CC=C4)CN5CCN(CC5)C,,,,,,
5821,55822,"Indole-3-carboxylic acid, 6-bromo-5-hydroxy-2-(morpholinomethyl)-1-(p-tolyl)-, ethyl ester, acetate (ester), hydrochloride",CCOC(=O)C1=C(N(C2=CC(=C(C=C21)OC(=O)C)Br)C3=CC=C(C=C3)C)C[NH+]4CCOCC4.[Cl-],,,,,,
5822,55823,Ethyl 5-acetyloxy-6-bromo-1-(4-methylphenyl)-2-(morpholin-4-ylmethyl)indole-3-carboxylate,CCOC(=O)C1=C(N(C2=CC(=C(C=C21)OC(=O)C)Br)C3=CC=C(C=C3)C)CN4CCOCC4,,,,,,
5823,55824,"Indole-3-carboxylic acid, 6-bromo-5-hydroxy-1-(p-methoxyphenyl)-2-(morpholinomethyl)-, ethyl ester, acetate (ester), hydrochloride",CCOC(=O)C1=C(N(C2=CC(=C(C=C21)OC(=O)C)Br)C3=CC=C(C=C3)OC)C[NH+]4CCOCC4.[Cl-],,,,,,
5824,55825,Ethyl 5-acetyloxy-6-bromo-1-(4-methoxyphenyl)-2-(morpholin-4-ylmethyl)indole-3-carboxylate,CCOC(=O)C1=C(N(C2=CC(=C(C=C21)OC(=O)C)Br)C3=CC=C(C=C3)OC)CN4CCOCC4,,,,,,
5825,55826,1-Phenyl-2-morpholinomethyl-3-ethoxycarbonyl-5-hydroxy-6-bromoindole hydrochloride,CCOC(=O)C1=C(N(C2=CC(=C(C=C21)O)Br)C3=CC=CC=C3)C[NH+]4CCOCC4.[Cl-],,,,,,
5826,55827,ethyl 6-bromo-5-hydroxy-2-(morpholin-4-ylmethyl)-1-phenyl-1H-indole-3-carboxylate,CCOC(=O)C1=C(N(C2=CC(=C(C=C21)O)Br)C3=CC=CC=C3)CN4CCOCC4,,,,,,
5827,55828,"ethyl 4,6-bis(dimethylaminomethyl)-5-hydroxy-2-methyl-1H-indole-3-carboxylate",CCOC(=O)C1=C(NC2=C1C(=C(C(=C2)CN(C)C)O)CN(C)C)C,,,,,,
5828,55829,"ethyl 4,6-bis[(dimethylamino)methyl]-5-hydroxy-1,2-dimethyl-1H-indole-3-carboxylate",CCOC(=O)C1=C(N(C2=C1C(=C(C(=C2)CN(C)C)O)CN(C)C)C)C,,,,,,
5829,55830,1-Methylindoline,CN1CCC2=CC=CC=C21,,,,,,
5830,55831,CID 55831,CC#CCC(C)C(C=CC1C(CC2C1C3=CC=CC(=C3O2)CCCC(=O)[O-])O)O.[Na+],,,,,,
5831,55832,"Acetic acid, (3-butoxy-2,4,6-triiodophenoxy)-",CCCCOC1=C(C(=C(C=C1I)I)OCC(=O)O)I,,,,,,
5832,55833,Desacetylravidomycin,C[C@@H]1[C@H]([C@H]([C@@H]([C@H](O1)C2=C3C(=C(C=C2)O)C(=CC4=C3OC(=O)C5=C4C(=CC(=C5)C=C)OC)OC)O)N(C)C)O,,,,,,
5833,55834,"Benzofuran-2,4(3H,5H)-dione, tetrahydro-3a-methyl-6-(1-methylethenyl)-, (3ar,6R,7ar)-",CC(=C1CC2C(CC(=O)O2)(C(=O)C1)C)C,,,,,,
5834,55835,"Benzofuran-2,4(3H,5H)-dione, tetrahydro-3a-methyl-6-(1-methylethyl)-, (3ar,6R)-",CC(C)C1CC2C(CC(=O)O2)(C(=O)C1)C,,,,,,
5835,55836,"(3aS,4R,6S,7aR)-hexahydro-4-hydroxy-3a-methyl-6-(1-methylethenyl)benzofuran-2(3H)-one",CC(=C)C1CC(C2(CC(=O)OC2C1)C)O,,,,,,
5836,55837,"p-MENTHAN-3-ONE, 2-PIPERIDINOMETHYL-, HYDROCHLORIDE",CC1CCC(C(=O)C1C[NH+]2CCCCC2)C(C)C.[Cl-],,,,,,
5837,55838,3-Methyl-2-(piperidin-1-ylmethyl)-6-propan-2-ylcyclohexan-1-one,CC1CCC(C(=O)C1CN2CCCCC2)C(C)C,,,,,,
5838,55839,2-(Diethylamino)-N-(4-(2-methoxyethyl)-3-methyl-5-isoxazolyl)-3-methylbutyramide,CCN(CC)C(C(C)C)C(=O)NC1=C(C(=NO1)C)CCOC,,,,,,
5839,55840,"Isoxazole, 4-(2-butoxyethyl)-5-(2-(diethylamino)acetamido)-3-methyl-",CCCCOCCC1=C(ON=C1C)NC(=O)CN(CC)CC,,,,,,
5840,55841,"1-Nitro-7,8,9,10-tetrahydrobenzo(a)pyrene",C1CCC2=C(C1)C=C3C=CC4=C5C3=C2C=CC5=C(C=C4)[N+](=O)[O-],,,,,,
5841,55842,"3-Nitro-7,8,9,10-tetrahydrobenzo(a)pyrene",C1CCC2=C(C1)C=C3C=CC4=C(C=CC5=C4C3=C2C=C5)[N+](=O)[O-],,,,,,
5842,55843,2-Benzamido-3-methylbut-2-enoic acid,CC(=C(C(=O)O)NC(=O)C1=CC=CC=C1)C,,,,,,
5843,55844,"ISOXAZOLE, 5-(p-AMINOBENZAMIDO)-3,4-DIMETHYL-",CC1=C(ON=C1C)NC(=O)C2=CC=C(C=C2)N,,,,,,
5844,55845,"Isoxazole, 5-(2-(dimethylamino)acetamido)-4-(2-ethoxyethyl)-3-methyl-",CCOCCC1=C(ON=C1C)NC(=O)CN(C)C,,,,,,
5845,55846,(4-(2-Cyclopenten-1-yl)phenoxy)acetic acid,C1CC(C=C1)C2=CC=C(C=C2)OCC(=O)O,,,,,,
5846,55847,N-(p-Ethoxyphenyl)formohydroxamic acid,CCOC1=CC=C(C=C1)NC(=O)O,,,,,,
5847,55848,"1H-Indeno(1,2-b)pyridine, 2,3,4,4a,5,9b-hexahydro-5-phenyl-1-propyl-, (4a-alpha,5-beta,9b-alpha)-",CCCN1CCC[C@@H]2[C@H]1C3=CC=CC=C3[C@@H]2C4=CC=CC=C4,,,,,,
5848,55849,"(+)-2,3,4,4a,5,9b-Hexahydro-5-(4-aminophenyl)-1H-indeno(1,2-b)pyridine",C1C[C@H]2[C@@H](C3=CC=CC=C3[C@H]2NC1)C4=CC=C(C=C4)N,,,,,,
5849,55850,"4-[(4aS,5R,9bS)-1-methyl-2,3,4,4a,5,9b-hexahydroindeno[1,2-b]pyridin-5-yl]aniline",CN1CCC[C@@H]2[C@H]1C3=CC=CC=C3[C@H]2C4=CC=C(C=C4)N,,,,,,
5850,55851,"3-[(4aS,5S,9bS)-2,3,4,4a,5,9b-hexahydro-1H-indeno[1,2-b]pyridin-5-yl]aniline",C1C[C@H]2[C@H](C3=CC=CC=C3[C@H]2NC1)C4=CC(=CC=C4)N,,,,,,
5851,55852,"5-[(4aS,5R,9bS)-2,3,4,4a,5,9b-hexahydro-1H-indeno[1,2-b]pyridin-5-yl]-2-methylaniline",CC1=C(C=C(C=C1)[C@H]2[C@@H]3CCCN[C@@H]3C4=CC=CC=C24)N,,,,,,
5852,55853,"Benzenamine, 4-(2,3,4,4a,5,9b-hexahydro-7-methoxy-1H-indeno(1,2-b)pyridin-5-yl)-, (4a-alpha,5-beta,9b-alpha)-",COC1=CC2=C(C=C1)[C@@H]3[C@H]([C@@H]2C4=CC=C(C=C4)N)CCCN3,,,,,,
5853,55854,"1H-Indeno(1,2-b)pyridin-7-ol, 2,3,4,4a,5,9b-hexahydro-5-(4-aminophenyl)-, (4a-alpha,5-alpha,9b-alpha)-",C1C[C@H]2[C@@H](C3=C([C@H]2NC1)C=CC(=C3)O)C4=CC=C(C=C4)N,,,,,,
5854,55855,"(4aS,5S,9bS)-5-(4-aminophenyl)-2,3,4,4a,5,9b-hexahydro-1H-indeno[1,2-b]pyridin-7-ol",C1C[C@H]2[C@H](C3=C([C@H]2NC1)C=CC(=C3)O)C4=CC=C(C=C4)N,,,,,,
5855,55856,"1H-Indeno(1,2-b)pyridin-7-ol, 2,3,4,4a,5,9b-hexahydro-7-methoxy-5-(4-methylphenyl)-, (4a-alpha,5-beta,9b-alpha)-",CC1=CC=C(C=C1)[C@@H]2[C@@H]3CCCN[C@@H]3C4=C2C=C(C=C4)OC,,,,,,
5856,55857,"1H-Indeno(1,2-b)pyridin-7-ol, 2,3,4,4a,5,9b-hexahydro-5-(4-methylphenyl)-, (4a-alpha,5-alpha,9b-alpha)-",CC1=CC=C(C=C1)[C@H]2[C@@H]3CCCN[C@@H]3C4=C2C=C(C=C4)O,,,,,,
5857,55858,"1H-Indeno(1,2-b)pyridin-7-ol, 2,3,4,4a,5,9b-hexahydro-5-(4-methylphenyl)-, (4a-alpha,5-beta,9b-alpha)-",CC1=CC=C(C=C1)[C@@H]2[C@@H]3CCCN[C@@H]3C4=C2C=C(C=C4)O,,,,,,
5858,55859,"1H-Indeno(1,2-b)pyridin-7-ol, 2,3,4,4a,5,9b-hexahydro-5-(3-amino-4-methylphenyl)-, (4a-alpha,5-beta,9b-alpha)-",CC1=C(C=C(C=C1)[C@@H]2[C@@H]3CCCN[C@@H]3C4=C2C=C(C=C4)O)N,,,,,,
5859,55860,"1H-Indeno(1,2-b)pyridin-7-ol, 2,3,4,4a,5,9b-hexahydro-5-(4-(1-methylethyl)phenyl)-, (4a-alpha,5-alpha,9b-alpha)-",CC(C)C1=CC=C(C=C1)[C@H]2[C@@H]3CCCN[C@@H]3C4=C2C=C(C=C4)O,,,,,,
5860,55861,"1H-Indeno(1,2-b)pyridin-7-ol, 2,3,4,4a,5,9b-hexahydro-5-(4-(1-methylethyl)phenyl)-, (4a-alpha,5-beta,9b-alpha)-",CC(C)C1=CC=C(C=C1)[C@@H]2[C@@H]3CCCN[C@@H]3C4=C2C=C(C=C4)O,,,,,,
5861,55862,"Benzenamine, N,N-dimethyl-4-(2,3,4,4a,5,9b-hexahydro-7-methoxy-1H-indeno(1,2-b)pyridin-5-yl)-, (4a-alpha,5-beta,9b-alpha)-",CN(C)C1=CC=C(C=C1)[C@H]2[C@@H]3CCCN[C@@H]3C4=C2C=C(C=C4)OC,,,,,,
5862,55863,"1H-Indeno(1,2-b)pyridin-7-ol, 2,3,4,4a,5,9b-hexahydro-5-(4-(dimethylamino)phenyl)-, (4a-alpha,5-beta,9b-alpha)-",CN(C)C1=CC=C(C=C1)[C@@H]2[C@@H]3CCCN[C@@H]3C4=C2C=C(C=C4)O,,,,,,
5863,55864,"1H-Indeno(1,2-b)pyridin-7-ol, 2,3,4,4a,5,9b-hexahydro-1-methyl-5-(4-methylphenyl)-, (4a-alpha,5-alpha,9b-alpha)-",CC1=CC=C(C=C1)[C@H]2[C@@H]3CCCN([C@@H]3C4=C2C=C(C=C4)O)C,,,,,,
5864,55865,"Benzenamine, 4-(2,3,4,4a,5,9b-hexahydro-7,8-dimethoxy-1H-indeno(1,2-b)pyridin-5-yl)-, (4a-alpha,5-beta,9b-alpha)-",COC1=C(C=C2[C@@H]3[C@@H](CCCN3)[C@@H](C2=C1)C4=CC=C(C=C4)N)OC,,,,,,
5865,55866,"1H-Indeno(1,2-b)pyridine, 2,3,4,4a,5,9b-hexahydro-5-(2-(trifluoromethyl)phenyl)-, (4a-alpha,5-beta,9b-alpha)-",C1C[C@H]2[C@H](C3=CC=CC=C3[C@H]2NC1)C4=CC=CC=C4C(F)(F)F,,,,,,
5866,55867,"1H-Indeno(1,2-b)pyridine, 2,3,4,4a,5,9b-hexahydro-5-(4-pyridinyl)-, (4a-alpha,5-alpha,9b-alpha)-",C1C[C@H]2[C@@H](C3=CC=CC=C3[C@H]2NC1)C4=CC=NC=C4,,,,,,
5867,55868,"dl-N-Methyl-N-allyl-1,2-diphenylethylamine hydrochloride",C[NH+](CC=C)C(CC1=CC=CC=C1)C2=CC=CC=C2.[Cl-],,,,,,
5868,55869,"N-(1,2-diphenylethyl)-N-methylprop-2-en-1-amine",CN(CC=C)C(CC1=CC=CC=C1)C2=CC=CC=C2,,,,,,
5869,55870,"trans-10,11-Dihydro-10,11-dihydroxy-7-methylbenz(c)acridine",CC1=C2C=CC3=CC=CC=C3C2=NC4=C1C=C[C@H]([C@@H]4O)O,,,,,,
5870,55871,"trans-1,2-Dihydro-1,2-dihydroxy-7-methylbenz(c)acridine",CC1=C2C=CC3=C(C2=NC4=CC=CC=C14)[C@@H]([C@H](C=C3)O)O,,,,,,
5871,55872,"Carbamodithioic acid, diethyl-, (1-((benzoylamino)methyl)-1H-benzimidazol-2-yl)methyl ester",CCN(CC)C(=S)SCC1=NC2=CC=CC=C2N1CNC(=O)C3=CC=CC=C3,,,,,,
5872,55873,"Carbamodithioic acid, diethyl-, (1-(2-naphthalenylmethyl)-1H-benzimidazol-2-yl)methyl ester",CCN(CC)C(=S)SCC1=NC2=CC=CC=C2N1CC3=CC4=CC=CC=C4C=C3,,,,,,
5873,55874,"Carbamodithioic acid, diethyl-, (1-((2,5-dihydroxyphenyl)methyl)-1H-benzimidazol-2-yl)methyl ester",CCN(CC)C(=S)SCC1=NC2=CC=CC=C2N1CC3=C(C=CC(=C3)O)O,,,,,,
5874,55875,"1H-Indeno(1,2-b)pyridine, 2,3,4,4a,5,9b-hexahydro-5-phenyl-1-propyl-, (4a-alpha,5-alpha,9b-alpha)-",CCCN1CCC[C@@H]2[C@H]1C3=CC=CC=C3[C@H]2C4=CC=CC=C4,,,,,,
5875,55876,"4-[(4aS,5S,9bS)-1-methyl-2,3,4,4a,5,9b-hexahydroindeno[1,2-b]pyridin-5-yl]aniline",CN1CCC[C@@H]2[C@H]1C3=CC=CC=C3[C@@H]2C4=CC=C(C=C4)N,,,,,,
5876,55877,"5-[(4aS,5S,9bS)-2,3,4,4a,5,9b-hexahydro-1H-indeno[1,2-b]pyridin-5-yl]-2-methylaniline",CC1=C(C=C(C=C1)[C@@H]2[C@@H]3CCCN[C@@H]3C4=CC=CC=C24)N,,,,,,
5877,55878,"Benzenamine, 4-(2,3,4,4a,5,9b-hexahydro-7-methoxy-1H-indeno(1,2-b)pyridin-5-yl)-, (4a-alpha,5-alpha,9b-alpha)-",COC1=CC2=C(C=C1)[C@@H]3[C@H]([C@H]2C4=CC=C(C=C4)N)CCCN3,,,,,,
5878,55879,"1H-Indeno(1,2-b)pyridin-7-ol, 2,3,4,4a,5,9b-hexahydro-5-(3-amino-4-methylphenyl)-, (4a-alpha,5-alpha,9b-alpha)-",CC1=C(C=C(C=C1)[C@H]2[C@@H]3CCCN[C@@H]3C4=C2C=C(C=C4)O)N,,,,,,
5879,55880,"1H-Indeno(1,2-b)pyridin-7-ol, 2,3,4,4a,5,9b-hexahydro-1-methyl-5-(4-methylphenyl)-, (4a-alpha,5-beta,9b-alpha)-",CC1=CC=C(C=C1)[C@@H]2[C@@H]3CCCN([C@@H]3C4=C2C=C(C=C4)O)C,,,,,,
5880,55881,"N-(1,5-dimethyl-3-oxo-2-phenylpyrazol-4-yl)-3-phenylprop-2-enamide",CC1=C(C(=O)N(N1C)C2=CC=CC=C2)NC(=O)C=CC3=CC=CC=C3,,,,,,
5881,55882,"Benzyl alcohol, p-chloro-alpha-(2-(alpha-methylphenethylamino)ethyl)-, hydrochloride",C[NH+](CCC1=CC=CC=C1)CCC(C2=CC=C(C=C2)Cl)O.[Cl-],,,,,,
5882,55883,1-(4-Chlorophenyl)-3-[methyl(2-phenylethyl)amino]propan-1-ol,CN(CCC1=CC=CC=C1)CCC(C2=CC=C(C=C2)Cl)O,,,,,,
5883,55884,Flestolol sulfate,CC(C)(CNC(=O)N)NCC(COC(=O)C1=CC=CC=C1F)O.OS(=O)(=O)O,,,"['Drugs that bind to but do not activate beta-adrenergic receptors thereby blocking the actions of beta-adrenergic agonists. Adrenergic beta-antagonists are used for treatment of hypertension, cardiac arrhythmias, angina pectoris, glaucoma, migraine headaches, and anxiety. (See all compounds classified as Adrenergic beta-Antagonists.)']",,,
5884,55885,Flestolol,CC(C)(CNC(=O)N)NCC(COC(=O)C1=CC=CC=C1F)O,,,"['Drugs that bind to but do not activate beta-adrenergic receptors thereby blocking the actions of beta-adrenergic agonists. Adrenergic beta-antagonists are used for treatment of hypertension, cardiac arrhythmias, angina pectoris, glaucoma, migraine headaches, and anxiety. (See all compounds classified as Adrenergic beta-Antagonists.)']",,,
5885,55886,Trospectomycin,CCCC[C@@H]1CC(=O)[C@]2([C@@H](O1)O[C@@H]3[C@H]([C@@H]([C@@H]([C@@H]([C@H]3O2)NC)O)NC)O)O,,,,,,
5886,55887,CID 55887,CCCC[C@@H](C=CC1[C@@H](CC2=C1C=C(N2C3=CC=CC=C3)CCCCC(=O)[O-])O)O.[K+],,,,,,
5887,55888,CID 55888,CCCC[C@@H](C=CC1[C@@H](CC2=C1C=C(N2C3=CC=CC=C3)CCCCC(=O)O)O)O,,,,,,
5888,55889,Tetradecylamine oxalate,CCCCCCCCCCCCCC[NH3+].C(=O)(C(=O)[O-])O,,,,,,
5889,55890,CID 55890,CCC(=O)OC(C(C)C)OP(=O)(CCCCC1=CC=CC=C1)CC(=O)N2C[C@@H](C[C@H]2C(=O)[O-])C3CCCCC3.[Na+],,,,,,
5890,55891,Fosinopril,CCC(=O)OC(C(C)C)OP(=O)(CCCCC1=CC=CC=C1)CC(=O)N2C[C@@H](C[C@H]2C(=O)O)C3CCCCC3,,,"['Drugs used in the treatment of acute or chronic vascular HYPERTENSION regardless of pharmacological mechanism. Among the antihypertensive agents are DIURETICS; (especially DIURETICS, THIAZIDE); ADRENERGIC BETA-ANTAGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; GANGLIONIC BLOCKERS; and VASODILATOR AGENTS. (See all compounds classified as Antihypertensive Agents.)', 'A class of drugs whose main indications are the treatment of hypertension and heart failure. They exert their hemodynamic effect mainly by inhibiting the renin-angiotensin system. They also modulate sympathetic nervous system activity and increase prostaglandin synthesis. They cause mainly vasodilation and mild natriuresis without affecting heart rate and contractility. (See all compounds classified as Angiotensin-Converting Enzyme Inhibitors.)']",,,
5891,55892,Fluorene-1-carbonyl azide,C1C2=CC=CC=C2C3=C1C(=CC=C3)C(=O)N=[N+]=[N-],,,,,,
5892,55893,CID 55893,C1C2=CC=CC=C2C3=C1C(=CC=C3)C(=O)N[N+]#N,,,,,,
5893,55894,"3H-1,2-Dithiole, 3,3,4,5-tetrachloro-",C1(=C(SSC1(Cl)Cl)Cl)Cl,,,,,,
5894,55895,"[(7R,8S)-11-(Dimethylaminomethylideneamino)-7-methoxy-12-methyl-10,13-dioxo-2,5-diazatetracyclo[7.4.0.02,7.04,6]trideca-1(9),11-dien-8-yl]methyl carbamate",CC1=C(C(=O)C2=C(C1=O)N3CC4C([C@@]3([C@@H]2COC(=O)N)OC)N4)N=CN(C)C,,,,,,
5895,55896,2-Methyl-6-methylene-2-octyl acetate,CCC(=C)CCCC(C)COC(=O)C,,,,,,
5896,55897,"2-Phenyl-1,3-dithiolane 1-oxide",C1CS(=O)C(S1)C2=CC=CC=C2,,,,,,
5897,55898,"Methyl 1,6-diazabicyclo[3.1.0]hexane-5-carboxylate",COC(=O)C12CCCN1N2,,,,,,
5898,55899,"N-Methyl-1,6-diazabicyclo(3.1.0)hexane-5-carboxamide",CNC(=O)C12CCCN1N2,,,,,,
5899,55900,"Benzamide, 3,5-diethyl-N-((1-ethyl-2-pyrrolidinyl)methyl)-2-hydroxy-6-methoxy-, (S)-, monomethanesulfonate (salt)",CCC1=CC(=C(C(=C1O)C(=O)NC[C@@H]2CCC[NH+]2CC)OC)CC.CS(=O)(=O)[O-],,,,,,
5900,55901,"3,5-Diethyl-N-(1-ethyl-pyrrolidin-2-ylmethyl)-2-hydroxy-6-methoxy-benzamide",CCC1=CC(=C(C(=C1O)C(=O)NC[C@@H]2CCCN2CC)OC)CC,,,,,,
5901,55902,CID 55902,CCOC(=O)C1=CC=C(C=C1)OC(=O)C2=CC=C(C=C2)N=C([NH3+])N.[Cl-],,,,,,
5902,55903,4'-Carboethoxyphenyl 4-guanidinobenzoate,CCOC(=O)C1=CC=C(C=C1)OC(=O)C2=CC=C(C=C2)N=C(N)N,,,,,,
5903,55904,CID 55904,C1=CC2=C(C(=C1)OC(=O)C3=CC=C(C=C3)[NH+]=C(N)N)N=CC=C2.[Cl-],,,,,,
5904,55905,Quinolin-8-yl 4-(diaminomethylideneamino)benzoate,C1=CC2=C(C(=C1)OC(=O)C3=CC=C(C=C3)N=C(N)N)N=CC=C2,,,,,,
5905,55906,2'-Carbomethoxyphenyl 4-guanidinobenzoate,COC(=O)C1=CC=CC=C1OC(=O)C2=CC=C(C=C2)N=C(N)N,,,,,,
5906,55907,p-Guanidinobenzoic acid 4-allyl-2-methoxyphenyl ester,COC1=C(C=CC(=C1)CC=C)OC(=O)C2=CC=C(C=C2)N=C(N)N,,,,,,
5907,55908,"Benzoic acid, 4-((aminoiminomethyl)amino)-, 4-hexyl-3-hydroxyphenyl ester",CCCCCCC1=C(C=C(C=C1)OC(=O)C2=CC=C(C=C2)N=C(N)N)O,,,,,,
5908,55909,"1,3-Dihydro-1,3-dimethyl-7-nitro-5-phenyl-2H-1,4-benzodiazepin-2-one",CC1C(=O)N(C2=C(C=C(C=C2)[N+](=O)[O-])C(=N1)C3=CC=CC=C3)C,,,,,,
5909,55910,1-Indolyl-3-isopropylmethylpropargylamine hydrobromide hydrate,CC(CC1=CNC2=CC=CC=C21)[NH+](C)CC#C.[Br-],,,,,,
5910,55911,"1H-Indole-3-ethanamine, N,alpha-dimethyl-N-2-propynyl-",CC(CC1=CNC2=CC=CC=C21)N(C)CC#C,,,,,,
5911,55912,"p-ACETOPHENETIDIDE, 2-DIMETHYLAMINO-N-(DIMETHYLCARBAMOYLMETHYL)-",CCOC1=CC=C(C=C1)N(CC(=O)N(C)C)C(=O)CN(C)C,,,,,,
5912,55913,"cis-2-Propoxy-3,5,5-trimethyl-1,2-oxaphospholan-3-ol 2-oxide",CCCOP1(=O)C(CC(O1)(C)C)(C)O,,,,,,
5913,55914,"Adenosine, 2-bromo-2'-deoxy-",C1[C@@H](O[C@@H](C1O)CO)N2C=NC3=C(N=C(N=C32)Br)N,,,,,,
5914,55915,(3-Ethyl-7-methyl-3-aza-7-azoniabicyclo[3.3.1]nonan-9-yl) 4-chlorobenzoate;chloride,CCN1CC2C[NH+](CC(C1)C2OC(=O)C3=CC=C(C=C3)Cl)C.[Cl-],,,,,,
5915,55916,"3-Ethyl-7-methyl-3,7-diazabicyclo[3.3.1]nonan-9-yl 4-chlorobenzoate",CCN1CC2CN(CC(C1)C2OC(=O)C3=CC=C(C=C3)Cl)C,,,,,,
5916,55917,Imazodan hydrochloride,C1CC(=O)NN=C1C2=CC=C(C=C2)N3C=CN=C3.Cl,,,"['Agents that have a strengthening effect on the heart or that can increase cardiac output. They may be CARDIAC GLYCOSIDES; SYMPATHOMIMETICS; or other drugs. They are used after MYOCARDIAL INFARCT; CARDIAC SURGICAL PROCEDURES; in SHOCK; or in congestive heart failure (HEART FAILURE). (See all compounds classified as Cardiotonic Agents.)', 'Compounds which inhibit or antagonize the biosynthesis or actions of phosphodiesterases. (See all compounds classified as Phosphodiesterase Inhibitors.)']",,,
5917,55918,Imazodan,C1CC(=O)NN=C1C2=CC=C(C=C2)N3C=CN=C3,,,"['Agents that have a strengthening effect on the heart or that can increase cardiac output. They may be CARDIAC GLYCOSIDES; SYMPATHOMIMETICS; or other drugs. They are used after MYOCARDIAL INFARCT; CARDIAC SURGICAL PROCEDURES; in SHOCK; or in congestive heart failure (HEART FAILURE). (See all compounds classified as Cardiotonic Agents.)', 'Compounds which inhibit or antagonize the biosynthesis or actions of phosphodiesterases. (See all compounds classified as Phosphodiesterase Inhibitors.)']",,,
5918,55919,CID 55919,CC1=NC(=O)C(=C(N1)NCC2=CN=CC=C2)C#N.Cl,,,,,,
5919,55920,CID 55920,CC1=NC(=O)C(=C(N1)NCC2=CN=CC=C2)C#N,,,,,,
5920,55921,"5,6,7,8-Tetrahydro-3-hydroxy-4-(1-iminoethyl)-2-propylisoquinolin-1(2H)-one",CCCN1C(=C2CCCCC2=C(C1=O)C(=N)C)O,,,,,,
5921,55922,"5,6,7,8-Tetrahydro-3-hydroxy-4-(1-iminomethyl)-2-methylisoquinolin-1(2H)-one",CC(=N)C1=C2CCCCC2=C(N(C1=O)C)O,,,,,,
5922,55923,"2-Ethyl-3-hydroxy-4-(1-iminoethyl)-5,6,7,8-tetrahydroisoquinolin-1(2H)-one",CCN1C(=C2CCCCC2=C(C1=O)C(=N)C)O,,,,,,
5923,55924,"5,6,7,8-Tetrahydro-2-butyl-3-hydroxy-4-(1-iminoethyl)isoquinolin-1(2H)-one",CCCCN1C(=C2CCCCC2=C(C1=O)C(=N)C)O,,,,,,
5924,55925,"5,6,7,8-Tetrahydro-2-hexyl-3-hydroxy-4-(1-iminoethyl)isoquinolin-1(2H)-one",CCCCCCN1C(=C2CCCCC2=C(C1=O)C(=N)C)O,,,,,,
5925,55926,"2,5,6,7,8,9-Hexahydro-2-ethyl-3-hydroxy-4-(1-iminoethyl)-1H-cyclohepta(c)pyridin-1-one",CCN1C(=C2CCCCCC2=C(C1=O)C(=N)C)O,,,,,,
5926,55927,"1-Ethoxy-4-(1-iminoethyl)-5,6,7,8-tetrahydro-cyclohexa(c)pyridin-3-ol",CCOC1=C2CCCCC2=C(C(=O)N1)C(=N)C,,,,,,
5927,55928,"3-Isoquinolinol, 5,6,7,8-tetrahydro-4-(1-iminoethyl)-1-propoxy-",CCCOC1=C2CCCCC2=C(C(=O)N1)C(=N)C,,,,,,
5928,55929,"3-Isoquinolinol, 5,6,7,8-tetrahydro-4-(1-iminoethyl)-1-isopropoxy-",CC(C)OC1=C2CCCCC2=C(C(=O)N1)C(=N)C,,,,,,
5929,55930,"3-Isoquinolinol, 5,6,7,8-tetrahydro-1-(hexyloxy)-4-(1-iminoethyl)-",CCCCCCOC1=C2CCCCC2=C(C(=O)N1)C(=N)C,,,,,,
5930,55931,"6,7,8,9-Tetrahydro-4-(1-iminoethyl)-1-isopropoxy-5H-cyclohepta(c)pyridin-3-ol",CC(C)OC1=C2CCCCCC2=C(C(=O)N1)C(=N)C,,,,,,
5931,55932,"Benzofuran, 5-methoxy-2-(5-nitro-2-furanyl)-",COC1=CC2=C(C=C1)OC(=C2)C3=CC=C(O3)[N+](=O)[O-],,,,,,
5932,55933,CID 55933,CC1=C2C(=NC(=O)N(C2=O)N=CC3=CC=C(C=C3)O)SN1,,,,,,
5933,55934,"Benzimidazole, 5-ethyl-2-(trifluoromethyl)-",CCC1=CC2=C(C=C1)N=C(N2)C(F)(F)F,,,,,,
5934,55935,methyl 2-(trifluoromethyl)-1H-benzimidazole-5-carboxylate,COC(=O)C1=CC2=C(C=C1)N=C(N2)C(F)(F)F,,,,,,
5935,55936,"Benzimidazole-5-carboxamide, 2-(trifluoromethyl)-",C1=CC2=C(C=C1C(=O)N)NC(=N2)C(F)(F)F,,,,,,
5936,55937,"Benzimidazole, 4,6-difluoro-2-(trifluoromethyl)-",C1=C(C=C(C2=C1NC(=N2)C(F)(F)F)F)F,,,,,,
5937,55938,"Benzimidazole, 5-chloro-4-fluoro-2-(trifluoromethyl)-",C1=CC(=C(C2=C1NC(=N2)C(F)(F)F)F)Cl,,,,,,
5938,55939,"Benzimidazole, 6-chloro-4-fluoro-2-(trifluoromethyl)-",C1=C(C=C(C2=C1NC(=N2)C(F)(F)F)F)Cl,,,,,,
5939,55940,"Benzimidazole, 4-chloro-6-fluoro-2-(trifluoromethyl)-",C1=C(C=C(C2=C1NC(=N2)C(F)(F)F)Cl)F,,,,,,
5940,55941,"Benzimidazole, 4-bromo-6-fluoro-2-(trifluoromethyl)-",C1=C(C=C(C2=C1NC(=N2)C(F)(F)F)Br)F,,,,,,
5941,55942,"Benzimidazole, 4-bromo-6-chloro-2-(trifluoromethyl)-",C1=C(C=C(C2=C1NC(=N2)C(F)(F)F)Br)Cl,,,,,,
5942,55943,"Benzimidazole, 4-chloro-6-iodo-2-(trifluoromethyl)-",C1=C(C=C(C2=C1NC(=N2)C(F)(F)F)Cl)I,,,,,,
5943,55944,"Benzimidazole, 5-chloro-4-methoxy-2-(trifluoromethyl)-",COC1=C(C=CC2=C1N=C(N2)C(F)(F)F)Cl,,,,,,
5944,55945,"Benzimidazole, 5-chloro-4-methyl-2-(trifluoromethyl)-",CC1=C(C=CC2=C1N=C(N2)C(F)(F)F)Cl,,,,,,
5945,55946,"Benzimidazole, 4-bromo-5-methyl-2-(trifluoromethyl)-",CC1=C(C2=C(C=C1)NC(=N2)C(F)(F)F)Br,,,,,,
5946,55947,"BENZIMIDAZOLE, 4-BROMO-6-tert-BUTYL-2-(TRIFLUOROMETHYL)-",CC(C)(C)C1=CC2=C(C(=C1)Br)N=C(N2)C(F)(F)F,,,,,,
5947,55948,"Benzimidazole-4-carbonitrile, 6-chloro-2-(trifluoromethyl)-",C1=C(C=C2C(=C1C#N)N=C(N2)C(F)(F)F)Cl,,,,,,
5948,55949,"Benzimidazole, 2,4-bis(trifluoromethyl)-6-chloro-",C1=C(C=C2C(=C1C(F)(F)F)N=C(N2)C(F)(F)F)Cl,,,,,,
5949,55950,CID 55950,C1=CC(=C2C(=C1[N+](=O)[O-])NC(=N2)C(F)(F)F)Cl,,,,,,
5950,55951,"Benzimidazole-4,7-diol, 2-(trifluoromethyl)-",C1=CC(=C2C(=C1O)NC(=N2)C(F)(F)F)O,,,,,,
5951,55952,"Benzimidazole, 5,6-dimethoxy-2-(trifluoromethyl)-",COC1=C(C=C2C(=C1)NC(=N2)C(F)(F)F)OC,,,,,,
5952,55953,"Benzimidazole, 4,7-dimethoxy-2-(trifluoromethyl)-",COC1=C2C(=C(C=C1)OC)N=C(N2)C(F)(F)F,,,,,,
5953,55954,"Benzimidazole, 6-bromo-4,5-dichloro-2-(trifluoromethyl)-",C1=C2C(=C(C(=C1Br)Cl)Cl)N=C(N2)C(F)(F)F,,,,,,
5954,55955,"Benzimidazole, 5-bromo-4,6-dichloro-2-(trifluoromethyl)-",C1=C2C(=C(C(=C1Cl)Br)Cl)N=C(N2)C(F)(F)F,,,,,,
5955,55956,"Benzimidazole, 4,6-dichloro-5-methoxy-2-(trifluoromethyl)-",COC1=C(C=C2C(=C1Cl)N=C(N2)C(F)(F)F)Cl,,,,,,
5956,55957,"Carbamic acid, ethyl-, 5,6-dichloro-2-(trifluoromethyl)-4-benzimidazolyl ester",CCNC(=O)OC1=C2C(=CC(=C1Cl)Cl)NC(=N2)C(F)(F)F,,,,,,
5957,55958,"Carbamic acid, dimethyl-, 5,6-dichloro-2-(trifluoromethyl)-4-benzimidazolyl ester",CN(C)C(=O)OC1=C2C(=CC(=C1Cl)Cl)NC(=N2)C(F)(F)F,,,,,,
5958,55959,"Benzimidazole, 6-bromo-5-chloro-4-methyl-2-(trifluoromethyl)-",CC1=C2C(=CC(=C1Cl)Br)NC(=N2)C(F)(F)F,,,,,,
5959,55960,"Benzimidazole, 5,6-dimethyl-4-nitro-2-(trifluoromethyl)-",CC1=CC2=C(C(=C1C)[N+](=O)[O-])N=C(N2)C(F)(F)F,,,,,,
5960,55961,6-Chloro-5-methyl-4-nitro-2-(trifluoromethyl)benzimidazole,CC1=C(C=C2C(=C1[N+](=O)[O-])N=C(N2)C(F)(F)F)Cl,,,,,,
5961,55962,6-Bromo-5-methyl-4-nitro-2-(trifluoromethyl)benzimidazole,CC1=C(C=C2C(=C1[N+](=O)[O-])N=C(N2)C(F)(F)F)Br,,,,,,
5962,55963,"Benzimidazole, 6-fluoro-4,5,7-tribromo-2-(trifluoromethyl)-",C12=C(C(=C(C(=C1Br)F)Br)Br)N=C(N2)C(F)(F)F,,,,,,
5963,55964,"Benzimidazole, 4-bromo-5,7-dichloro-6-fluoro-2-(trifluoromethyl)-",C12=C(C(=C(C(=C1Br)Cl)F)Cl)N=C(N2)C(F)(F)F,,,,,,
5964,55965,"Benzimidazole, 5-amino-4,6,7-trichloro-2-(trifluoromethyl)-",C1(=C(C2=C(C(=C1Cl)Cl)NC(=N2)C(F)(F)F)Cl)N,,,,,,
5965,55966,"Benzamide, N-(5,6,7-trichloro-2-(trifluoromethyl)-4-benzimidazolyl)-",C1=CC=C(C=C1)C(=O)NC2=C(C(=C(C3=C2NC(=N3)C(F)(F)F)Cl)Cl)Cl,,,,,,
5966,55967,"Benzimidazole, 4-(dimethylamino)-5,6,7-trichloro-2-(trifluoromethyl)-",CN(C)C1=C(C(=C(C2=C1NC(=N2)C(F)(F)F)Cl)Cl)Cl,,,,,,
5967,55968,"Benzimidazole, 5,6-dichloro-4,7-dimethoxy-2-(trifluoromethyl)-",COC1=C(C(=C(C2=C1NC(=N2)C(F)(F)F)OC)Cl)Cl,,,,,,
5968,55969,"Benzimidazole, 4,7-dichloro-5,6-dimethoxy-2-(trifluoromethyl)-",COC1=C(C2=C(C(=C1OC)Cl)N=C(N2)C(F)(F)F)Cl,,,,,,
5969,55970,"Anthranilic acid, N-(2-anilino-4-pyrimidinyl)-",C1=CC=C(C=C1)NC2=NC=CC(=N2)NC3=CC=CC=C3C(=O)O,,,,,,
5970,55971,"ethyl 2-(trifluoromethyl)-1H-1,3-benzodiazole-5-carboxylate",CCOC(=O)C1=CC2=C(C=C1)N=C(N2)C(F)(F)F,,,,,,
5971,55972,"Benzimidazole, 6-bromo-4-chloro-2-(trifluoromethyl)-",C1=C(C=C(C2=C1NC(=N2)C(F)(F)F)Cl)Br,,,,,,
5972,55973,"Benzimidazole, 4-bromo-5-chloro-6-fluoro-2-(trifluoromethyl)-",C1=C2C(=C(C(=C1F)Cl)Br)N=C(N2)C(F)(F)F,,,,,,
5973,55974,"3-Isoxazolecarboxylic acid, 5-methyl-, 2-methylhydrazide",CC1=CC(=NO1)C(=O)NNC,,,,,,
5974,55975,CID 55975,CC1=C(C(=O)/C(=C\2/C(=O)C(=C(C(=O)C2=O)C)[O-])/C(=C1O)O)O.[K+],,,,,,
5975,55976,CID 55976,CC1=C(C(=O)/C(=C\2/C(=O)C(=C(C(=O)C2=O)C)[O-])/C(=C1O)O)O.[Na+],,,,,,
5976,55977,Thiotropocin,C1=CC(=O)C2=C(C(=C1)S)SOC2=O,,,,,,
5977,55978,N-Methyl-N-(2-chloroethyl)-beta-alanine hydrochloride,C[NH+](CCC(=O)O)CCCl.[Cl-],,,,,,
5978,55979,3-[2-Chloroethyl(methyl)amino]propanoic acid,CN(CCC(=O)O)CCCl,,,,,,
5979,55980,"Diethylamine, N-(2-chloroethoxy)-2,2'-dichloro-",C(CCl)N(CCCl)OCCCl,,,,,,
5980,55981,Decachloroquaterphenyl,C1=C(C(=CC(=C1Cl)C2=CC(=C(C=C2Cl)Cl)Cl)Cl)C3=CC(=C(C=C3Cl)C4=CC(=C(C=C4Cl)Cl)Cl)Cl,,,,,,
5981,55982,Octachloroquaterphenyl,C1=CC(=C(C=C1Cl)C2=CC(=C(C=C2Cl)C3=C(C=C(C(=C3)Cl)C4=C(C=CC(=C4)Cl)Cl)Cl)Cl)Cl,,,,,,
5982,55983,Hexachloroquaterphenyl,C1=CC(=CC(=C1)Cl)C2=CC(=C(C=C2Cl)C3=C(C=C(C(=C3)Cl)C4=CC(=CC=C4)Cl)Cl)Cl,,,,,,
5983,55984,4-Dimethylamino-5-nitro-2-methoxy-N-(2-diethylaminoethyl)benzamide hydrochloride,CC[NH+](CC)CCNC(=O)C1=CC(=C(C=C1OC)N(C)C)[N+](=O)[O-].[Cl-],,,,,,
5984,55985,N-[2-(Diethylamino)ethyl]-4-(dimethylamino)-2-methoxy-5-nitrobenzamide,CCN(CC)CCNC(=O)C1=CC(=C(C=C1OC)N(C)C)[N+](=O)[O-],,,,,,
5985,55986,"Acetic acid, ((5-((2-methylphenyl)amino)-1,3,4-thiadiazol-2-yl)thio)-, 2-(2-methoxyphenyl)hydrazide",CC1=CC=CC=C1NC2=NN=C(S2)SCC(=O)NNC3=CC=CC=C3OC,,,,,,
5986,55987,"Acetic acid, ((5-((2-methylphenyl)amino)-1,3,4-thiadiazol-2-yl)thio)-, 2-(2-methylphenyl)hydrazide",CC1=CC=CC=C1NC2=NN=C(S2)SCC(=O)NNC3=CC=CC=C3C,,,,,,
5987,55988,"Acetic acid, ((5-((4-methylphenyl)amino)-1,3,4-thiadiazol-2-yl)thio)-, 2-(2-methylphenyl)hydrazide",CC1=CC=C(C=C1)NC2=NN=C(S2)SCC(=O)NNC3=CC=CC=C3C,,,,,,
5988,55989,CID 55989,CC1=CC=C(C=C1)NC2=NN=C(S2)SCC(=O)N=NC3=C(C=C(C=C3)N(O)O)[N+](=O)[O-],,,,,,
5989,55990,"Acetic acid, ((2,4,6-triiodo-3-pyridyl)oxy)-",C1=C(C(=C(N=C1I)I)OCC(=O)O)I,,,,,,
5990,55991,CID 55991,CC1=CC=CC=C1NC2=NN=C(S2)SCC(=O)N=NC3=C(C=C(C=C3)N(O)O)[N+](=O)[O-],,,,,,
5991,55992,"2,3,4,5-Tetrahydro-2-methyl-4-oxo-1H-1,5-benzodiazepine-1-carboxamide",CC1CC(=O)NC2=CC=CC=C2N1C(=O)N,,,,,,
5992,55993,(-)-Nomifensine,CN1C[C@H](C2=C(C1)C(=CC=C2)N)C3=CC=CC=C3,,,,,,
5993,55994,Cioteronel,CCC(CCCCC1CCC2C1CC(=O)C2)OC,,,,,,
5994,55995,"Butyronitrile, 4,4'-(methylimino)DI-",CN(CCCC#N)CCCC#N,,,,,,
5995,55996,"Diethylamine, N-(2-bromoethoxy)-2,2'-dichloro-",C(CCl)N(CCCl)OCCBr,,,,,,
5996,55997,CID 55997,C1=CC(=CC=C1OC2=CN=C(C=C2)C(=O)O)Cl.C1=CC(=CC=C1OC2=CN=C(C=C2)C(=O)O)Cl.O.[AlH3],,,,,,
5997,55998,"Picolinic acid, 5-(p-chlorophenoxy)-",C1=CC(=CC=C1OC2=CN=C(C=C2)C(=O)O)Cl,,,,,,
5998,55999,"Acetamide, N-(8-(dimethylamino)-3-methyl-2-phenazinyl)-2-(methylnitrosoamino)-",CC1=CC2=NC3=C(C=C(C=C3)N(C)C)N=C2C=C1NC(=O)CN(C)N=O,,,,,,
5999,56000,CID 56000,C1=CC(=CC=C1C=C2C(=O)N(C(=S)S2)CNC3=CC=C(C=C3)C(=O)O)O,,,,,,
6000,56001,CID 56001,COC1=C(C=CC(=C1)C=C2C(=O)N(C(=S)S2)CNC3=CC=C(C=C3)C(=O)O)O,,,,,,
6001,56002,"Benzamide, N-(4-((4-phenyl-1-piperazinyl)carbonyl)phenyl)-",C1CN(CCN1C2=CC=CC=C2)C(=O)C3=CC=C(C=C3)NC(=O)C4=CC=CC=C4,,,,,,
6002,56003,"Benzamide, 3,4-dimethoxy-N-(4-((4-phenyl-1-piperazinyl)carbonyl)phenyl)-",COC1=C(C=C(C=C1)C(=O)NC2=CC=C(C=C2)C(=O)N3CCN(CC3)C4=CC=CC=C4)OC,,,,,,
6003,56004,"Benzamide, N-(4-((4-phenyl-1-piperazinyl)carbonyl)phenyl)-3,4,5-trimethoxy-",COC1=CC(=CC(=C1OC)OC)C(=O)NC2=CC=C(C=C2)C(=O)N3CCN(CC3)C4=CC=CC=C4,,,,,,
6004,56005,"Benzamide, 3,4-dimethoxy-N-(4-((4-(4-methylphenyl)-1-piperazinyl)carbonyl)phenyl)-",CC1=CC=C(C=C1)N2CCN(CC2)C(=O)C3=CC=C(C=C3)NC(=O)C4=CC(=C(C=C4)OC)OC,,,,,,
6005,56006,"Benzamide, N-(4-((4-(4-chlorophenyl)-1-piperazinyl)carbonyl)phenyl)-3,4-dimethoxy-",COC1=C(C=C(C=C1)C(=O)NC2=CC=C(C=C2)C(=O)N3CCN(CC3)C4=CC=C(C=C4)Cl)OC,,,,,,
6006,56007,"Benzamide, N-(4-((4-(4-chlorophenyl)-1-piperazinyl)carbonyl)phenyl)-3,4,5-trimethoxy-",COC1=CC(=CC(=C1OC)OC)C(=O)NC2=CC=C(C=C2)C(=O)N3CCN(CC3)C4=CC=C(C=C4)Cl,,,,,,
6007,56008,Fareston,CN(C)CCOC1=CC=C(C=C1)C(=C(CCCl)C2=CC=CC=C2)C3=CC=CC=C3.C(C(=O)O)C(CC(=O)O)(C(=O)O)O,['First line hormone treatment of hormone-dependent metastatic breast cancer in postmenopausal patients.'],,"['Antineoplastic agents that are used to treat hormone-sensitive tumors. Hormone-sensitive tumors may be hormone-dependent, hormone-responsive, or both. A hormone-dependent tumor regresses on removal of the hormonal stimulus, by surgery or pharmacological block. Hormone-responsive tumors may regress when pharmacologic amounts of hormones are administered regardless of whether previous signs of hormone sensitivity were observed. The major hormone-responsive cancers include carcinomas of the breast, prostate, and endometrium; lymphomas; and certain leukemias. (From AMA Drug Evaluations Annual 1994, p2079) (See all compounds classified as Antineoplastic Agents, Hormonal.)', 'Agents that inhibit BONE RESORPTION and/or favor BONE MINERALIZATION and BONE REGENERATION. They are used to heal BONE FRACTURES and to treat METABOLIC BONE DISEASES such as OSTEOPOROSIS. (See all compounds classified as Bone Density Conservation Agents.)', 'A structurally diverse group of compounds distinguished from ESTROGENS by their ability to bind and activate ESTROGEN RECEPTORS but act as either an agonist or antagonist depending on the tissue type and hormonal milieu. They are classified as either first generation because they demonstrate estrogen agonist properties in the ENDOMETRIUM or second generation based on their patterns of tissue specificity. (Horm Res 1997;48:155-63) (See all compounds classified as Selective Estrogen Receptor Modulators.)']",,,
6008,56009,Rolafagrel,C1CC(=CC2=C1C=CC(=C2)C(=O)O)N3C=CN=C3,,,,,,
6009,56010,"N-Acetyl-S-(1,2,3,4,4-pentachlorobutadienyl)-L-cysteine",CC(=O)N[C@@H](CSC(=C(C(=C(Cl)Cl)Cl)Cl)Cl)C(=O)O,,,,,,
6010,56011,CID 56011,C[C@@]1([C@@H](N2C(S1(=O)=O)CC2=O)C(=O)[O-])CN3C=CN=N3.[Na+],,,,,,
6011,56012,"(2S,3S)-3-methyl-4,4,7-trioxo-3-(triazol-1-ylmethyl)-4lambda6-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid",C[C@@]1([C@@H](N2C(S1(=O)=O)CC2=O)C(=O)O)CN3C=CN=N3,,,,,,
6012,56013,"Allylamine, 2-bromo-N-butyl-",CCCCNCC(=C)Br,,,,,,
6013,56014,N-(2-Chloroethyl)-N-methyl-beta-alanine methyl ester hydrochloride,C[NH+](CCC(=O)OC)CCCl.[Cl-],,,,,,
6014,56015,Methyl 3-[2-chloroethyl(methyl)amino]propanoate,CN(CCC(=O)OC)CCCl,,,,,,
6015,56016,Iopentol,CC(=O)N(CC(COC)O)C1=C(C(=C(C(=C1I)C(=O)NCC(CO)O)I)C(=O)NCC(CO)O)I,,,['Substances used to allow enhanced visualization of tissues. (See all compounds classified as Contrast Media.)'],,,
6016,56017,"Benzeneethanamine, N-(2-(3,4-dimethoxyphenyl)ethyl)-3,4-dimethoxy-N-methyl-, hydrochloride",C[NH+](CCC1=CC(=C(C=C1)OC)OC)CCC2=CC(=C(C=C2)OC)OC.[Cl-],,,,,,
6017,56018,Hept-3-enal,CCCC=CCC=O,,,,,,
6018,56019,4-Hydroxy-4-methyl-2-hexynoic acid,CCC(C)(C#CC(=O)O)O,,,,,,
6019,56020,"3,4-Epoxybutyramide",C1C(O1)CC(=O)N,,,,,,
6020,56021,"3-Isoquinolinecarboxamide, N-(2-(dimethylamino)ethyl)-1-methoxy-4-methyl-",CC1=C(N=C(C2=CC=CC=C12)OC)C(=O)NCCN(C)C,,,,,,
6021,56022,"3-Isoquinolinecarboxamide, 1-chloro-N-(2-(dimethylamino)ethyl)-4-methyl-",CC1=C(N=C(C2=CC=CC=C12)Cl)C(=O)NCCN(C)C,,,,,,
6022,56023,CID 56023,CC1CC2=C(C=C(C(=C2C(=O)O1)O)C(=O)NC(CC3=CC=CC=C3)C(=O)[O-])Cl.[Na+],,,,,,
6023,56024,CID 56024,CC1CC2=C(C=C(C(=C2C(=O)O1)O)C(=O)NC(CC3=CC=CC=C3)C(=O)[O-])Cl.[K+],,,,,,
6024,56025,"Acetone, hydrazone, N-(N,N-bis(2-chloroethyl)sulfamoyl)-",CC(=NNS(=O)(=O)N(CCCl)CCCl)C,,,,,,
6025,56026,1-Bromohept-1-ene,CCCCCC=CBr,,,,,,
6026,56027,"Diethylamine, 2,2'-dichloro-N-ethoxy-",CCON(CCCl)CCCl,,,,,,
6027,56028,"Barbituric acid, 5-(2-bromoallyl)-5-methyl-",CC1(C(=O)NC(=O)NC1=O)CC(=C)Br,,,,,,
6028,56029,2-[2-Hydroxy-1-(5-nitro-2-furanyl)ethylidene]hydrazinecarboxamide,C1=C(OC(=C1)[N+](=O)[O-])C(=NNC(=O)N)CO,,,,,,
6029,56030,"Glycine, N-(4,5-dichloro-2-nitrophenyl)-",C1=C(C(=CC(=C1Cl)Cl)[N+](=O)[O-])NCC(=O)O,,,,,,
6030,56031,Detomidine hydrochloride,CC1=C(C(=CC=C1)CC2=CN=CN2)C.Cl,,,"['Compounds that bind to and activate ADRENERGIC ALPHA-2 RECEPTORS. (See all compounds classified as Adrenergic alpha-2 Receptor Agonists.)', 'Drugs used to induce drowsiness or sleep or to reduce psychological excitement or anxiety. (See all compounds classified as Hypnotics and Sedatives.)', 'Compounds capable of relieving pain without the loss of CONSCIOUSNESS. (See all compounds classified as Analgesics.)']",,,
6031,56032,Detomidine,CC1=C(C(=CC=C1)CC2=CN=CN2)C,"['Used as a large animal sedative, primarily in horses.']",,"['Compounds capable of relieving pain without the loss of CONSCIOUSNESS. (See all compounds classified as Analgesics.)', 'Compounds that bind to and activate ADRENERGIC ALPHA-2 RECEPTORS. (See all compounds classified as Adrenergic alpha-2 Receptor Agonists.)', 'Drugs used to induce drowsiness or sleep or to reduce psychological excitement or anxiety. (See all compounds classified as Hypnotics and Sedatives.)']",,,
6032,56033,"N,N'-Ethylenebis(2-(o-hydroxyphenyl)glycine) dimethyl ester",COC(=O)C(C1=CC=CC=C1O)NCCNC(C2=CC=CC=C2O)C(=O)OC,,,,,,
6033,56034,Bromotetrachlorobenzene,C1=C(C(=C(C(=C1Cl)Cl)Br)Cl)Cl,,,,,,
6034,56035,"3,3'-Iminodibutyronitrile",CC(CC#N)NC(C)CC#N,,,,,,
6035,56036,"Isothiazole, 5-(2-(dimethylamino)acetamido)-3-methyl-",CC1=NSC(=C1)NC(=O)CN(C)C,,,,,,
6036,56037,"(5-((4,6-Dimethyl-2-pyrimidinyl)thio)pentyl)triethylammonium bromide",CC[N+](CC)(CC)CCCCCSC1=NC(=CC(=N1)C)C.[Br-],,,,,,
6037,56038,"5-(4,6-Dimethylpyrimidin-2-yl)sulfanylpentyl-triethylazanium",CC[N+](CC)(CC)CCCCCSC1=NC(=CC(=N1)C)C,,,,,,
6038,56039,"Benzenamine, N-(6-((4,6-dimethyl-2-pyrimidinyl)thio)hexyl)-",CC1=CC(=NC(=N1)SCCCCCCNC2=CC=CC=C2)C,,,,,,
6039,56040,"1H-Indole-2-methanaminium, 5,5'-methylenebis(N,N,N-trimethyl-, bis(methyl sulfate)",C[N+](C)(C)CC1=CC2=C(N1)C=CC(=C2)CC3=CC4=C(C=C3)NC(=C4)C[N+](C)(C)C.COS(=O)(=O)[O-].COS(=O)(=O)[O-],,,,,,
6040,56041,trimethyl-[[5-[[2-[(trimethylazaniumyl)methyl]-1H-indol-5-yl]methyl]-1H-indol-2-yl]methyl]azanium,C[N+](C)(C)CC1=CC2=C(N1)C=CC(=C2)CC3=CC4=C(C=C3)NC(=C4)C[N+](C)(C)C,,,,,,
6041,56042,"3,3'-Di(trimethylammoniummethyl)-1,2-(5,5'-diindolyl)ethane diiodide",C[N+](C)(C)CC1=CNC2=C1C=C(C=C2)CCC3=CC4=C(C=C3)NC=C4C[N+](C)(C)C.[I-].[I-],,,,,,
6042,56043,trimethyl-[[5-[2-[3-[(trimethylazaniumyl)methyl]-1H-indol-5-yl]ethyl]-1H-indol-3-yl]methyl]azanium,C[N+](C)(C)CC1=CNC2=C1C=C(C=C2)CCC3=CC4=C(C=C3)NC=C4C[N+](C)(C)C,,,,,,
6043,56044,(m-Bromobenzyl)guanidine,C1=CC(=CC(=C1)Br)CN=C(N)N,,,,,,
6044,56045,"Formamide, N-(6-hydroxy-3-nitroso-7-oxo-1,3,5-cycloheptatrien-1-YL)-",C1=CC(=O)C(=C(C=C1N=O)NC=O)O,,,,,,
6045,56046,2-[Bis(2-chloroethyl)sulfamoylhydrazinylidene]-3-oxobutane,CC(=NNS(=O)(=O)N(CCCl)CCCl)C(=O)C,,,,,,
6046,56047,"2-Amino-2-methylpropane-1,3-diol aspartate",CC(CO)(CO)N.C(C(C(=O)O)N)C(=O)O,,,,,,
6047,56048,"3-Isoxazolecarboxylic acid, 5-methyl-, 2-ethylhydrazide",CCNNC(=O)C1=NOC(=C1)C,,,,,,
6048,56049,"Carbamic acid, (3-hydroxypropyl)-, isopropyl ester, carbamate",CC(C)OC(=O)NCCCOC(=O)N,,,,,,
6049,56050,"N-Isobutyl-1,4-butanediamine",CC(C)CNCCCCN,,,,,,
6050,56051,Zaltidine,CC1=NC=C(N1)C2=CSC(=N2)N=C(N)N,,,,,,
6051,56052,Ractopamine,CC(CCC1=CC=C(C=C1)O)NCC(C2=CC=C(C=C2)O)O,,,['Drugs that selectively bind to and activate beta-adrenergic receptors. (See all compounds classified as Adrenergic beta-Agonists.)'],"['/The authors/ investigated the detection, confirmation, and metabolism of the beta-adrenergic agonist ractopamine administered as Paylean to the horse. ... Based on the quantitation ions for ractopamine standards extracted from urine, standard curves showed a linear response for ractopamine concentrations between 10 and 100 ng/mL with a correlation coefficient r > 0.99, whereas standards in the concentration range of 10-1000 ng/mL were fit to a second-order regression curve with r > 0.99. ... Urine concentration of parent ractopamine 24 h post-dose was measured at 360 ng/mL by GC-MS after oral administration of 300 mg. Urinary metabolites were identified by electrospray ionization (+) tandem quadrupole mass spectrometry and were shown to include glucuronide, methyl, and mixed methyl-glucuronide conjugates', 'In a bioavailability study that complied with good laboratory practice (GLP), groups of five male and five female rats were given [14C]ractopamine as a single oral dose at 0.5, 2.0, or 20 mg/kg bw by gavage. The amount of radiolabel was quantified in samples of plasma and whole blood collected for 24 hr after dosing. Comparison of the area under the curve (AUC) of concentration-time for plasma and whole blood indicated that the bioavailability of (14)C-ractopamine was proportional to dose for males and females at doses up to 2.0 mg/kg bw. Increasing the dose to 20 mg/kg bw resulted in an increase in AUC versus dose in males and, to a more pronounced degree, in females. The absolute bioavailability of (14)C-ractopamine in rats cannot be determined from the results of this study since (14)C-ractopamine was not administered intravenously for comparison of oral and intravenous AUC values.', 'Experiments were conducted to determine the total residues remaining in ocular tissues of cattle and turkeys after oral administration of (14)C-ractopamine HCl. Twelve cattle were intraruminally dosed with 0.9 mg /kg/d of (14C-)ractopamine HCl for 7 d. Four cattle each were slaughtered with withdrawal periods of 48, 96, and 144 hr. Radioactive residues were not detectable in whole-eye homogenates from the cattle. Eight male and eight female turkeys per treatment received either 7.5, 22.5, or 30 ppm dietary (14)C-ractopamine HCl (0.33, 1.02, and 1.36 mg/kg/d; treatment groups 1, 2, and 3, respectively) for 7 d, and the birds were slaughtered with a 0-d withdrawal period. Eyes were dissected into retina/choroid/schlera (RCS), cornea/iris (CI), and aqueous humor (AH) fractions. Residues in RCS, CI, and AH of treatment 1 turkeys were not detectable. Residues in AH were < 0.02 ppm in treatment groups 2 and 3. Mean residues in RCS ranged from 0.15 to 0.26 ppm, and mean CI residues ranged from <0.09 to 0.17 ppm for treatment groups 2 and 3, respectively.', 'Ractopamine HCl is a beta-adrenergic leanness-enhancing agent recently approved for use in swine. Depletion of ractopamine in tissues, and elimination of ractopamine and its metabolites in urine, is of interest for the detection of off-label use. The objectives of this study were to measure the residues of ractopamine in livers and kidneys of cattle (n = 6), sheep (n = 6), and ducks (n = 9) after treatment with dietary ractopamine for seven (sheep, ducks) or eight (cattle) consecutive days and to measure the depletion of ractopamine from urine of cattle and sheep. Two cattle and sheep and three ducks were each slaughtered with withdrawal periods of 0, 3, and 7 day. Urine samples were collected daily from cattle and sheep. Tissue ractopamine concentrations were determined using the regulatory method (FDA approved) for ractopamine in swine tissues. Ractopamine residues in urine samples were measured before and after hydrolysis of conjugates. Analysis was performed with HPLC using fluorescence detection after liquid- (hydrolyzed samples) and(or) solid-phase extraction. No residues were detected in duck tissues. Liver residues in sheep averaged 24.0 and 2.6 ppb after 0- and 3-day withdrawal periods, respectively. Sheep liver residues after a 7-day withdrawal period were less than the limit of quantification (2.5 ppb). Sheep kidney residues were 65.1 and undetectable at 0- and at 3- and 7-day, withdrawal periods, respectively. Cattle liver residues were 9.3, 2.5, and undetectable after 0-, 3-, and 7-day withdrawal periods, respectively; kidney residues were 97.5, 3.4, and undetectable at the same respective withdrawal periods. Concentrations of parent ractopamine in sheep urine were 9.8+ or - 3.3 ppb on withdrawal d 0 and were below the LOQ (5 ppb) beyond the 2-day withdrawal period. After the hydrolysis of conjugates, ractopamine concentrations were 5,272 + or - 1,361 ppb on withdrawal d 0 and 178 + or - 78 ppb on withdrawal d 7. Ractopamine concentrations in cattle urine ranged from 164+ or - 61.7 ng/mL (withdrawal d 0) to below the LOQ (50 ppb) on withdrawal day 4. After the hydrolysis of conjugates in cattle urine, ractopamine concentrations were 4,129+ or - 2,351 ppb (withdrawal day 0) to below the LOQ (withdrawal d 6). These data indicate that after the hydrolysis of conjugates, ractopamine should be detectable in urine of sheep as long as 7 day after the last exposure to ractopamine and as long as 5 day after withdrawal in cattle.', 'For more Absorption, Distribution and Excretion (Complete) data for RACTOPAMINE (16 total), please visit the HSDB record page.']","['In urine, only a minor fraction of radioactivity recovered was parent ractopamine. Swine excreted about 4-16% of the parent compound in the urine after a single oral dose of ractopamine. After repeated doses, the amount of unchanged drug increased to 36-85% of total radioactivity in the urine collected on day 4 of a 4-day dosing regimen. In rats injected with (14)C-ractopamine at 9 mg/kg bw intraperitoneally, parent drug represented 22.6% of total urinary radioactivity while only 1.9% of radioactivity was associated with unchanged ractopamine after an oral dose of 9.9 mg/kg bw. The greater proportion of parent drug in the urine after parenteral administration than after oral administration suggests that liver and intestine play an important role in the biotransformation of ractopamine after oral administration. Therefore, although well absorbed from the gastrointestinal tract, the systemic availability of parent ractopamine is reduced, owing to a significant first-pass metabolism.', ""In the bile of rats dosed orally with (14)C-ractopamine, at least seven different crude metabolite fractions were partitioned chromatographically. Four of the crude metabolite fractions representing 76% of biliary radioactivity were isolated and identified with a sulfate-ester/glucuronic acid diconjugate of ractopamine as the main metabolite (46% of total biliary radioactivity). A further 6% of radioactivity was identified as a monosulfate conjugate and 25% as monoglucuronides of ractopamine. The site of sulfation was established at the C-10' phenol (aromatic ring attached to carbinol). The sulfate conjugation was not stereospecific. The major site of glucuronidation was the C-10 phenol (phenol attached to the nitrogen substituent)."", 'After a withdrawal of 6 hr (rats, dogs) or 12hr (swine, cattle), unchanged ractopamine represented 40, 14, 52, and 13-16% of the total extractable and identifiable residues in the rat, dog, pig, and cattle livers, respectively, and 21, 29, 28-30, and 14% in the kidneys, respectively. After a withdrawal of 24 hr and 72 hr, parent ractopamine represented 14.1% and 3.6% in liver, and 27.5% and 3% of total residues in kidney, respectively, in swine. The remaining residue was found to comprise conjugates of ractopamine. The chromatographic profiles of the (14)C-labelled residue extracts of rat, dog, pig, and cattle liver were qualitatively similar. The laboratory animals had generally a higher percentage of metabolites as residues. Studies in rats and dogs showed that urine from animals dosed with (14)C-ractopamine contained the same four glucuronide metabolites of ractopamine as in pigs. It is concluded that the dogs and rats used in the toxicological studies were exposed to the same metabolites as those found in the edible tissues of pigs and cattle.', 'In studies in rats, dogs, pigs, and cattle fed (14)C-ractopamine, a fourth metabolite was identified as a glucuronic acid diconjugate. The conjugation of the hydroxyl groups in both the aromatic ring attached to the carbinol and the phenol attached to the nitrogen substituent was not stereospecific.', 'For more Metabolism/Metabolites (Complete) data for RACTOPAMINE (8 total), please visit the HSDB record page.']","['Elimination 1/2 life = 6-7 hours; [HSDB]', 'The elimination half-life was about 6-7 hr.', 'The results of a study in six healthy male human volunteers receiving a single oral dose of 40 mg of ractopamine hydrochloride indicate a similar profile of pharmacokinetics and biotransformation in humans and animals. ... The half-life in plasma was about 4 hr.']"
6052,56053,"Methyl 4-oxo-4-(1,3,4-thiadiazol-2-ylamino)but-2-enoate",COC(=O)C=CC(=O)NC1=NN=CS1,,,,,,
6053,56054,"N'-(1,3,4-thiadiazol-2-yl)but-2-enediamide",C1=NN=C(S1)NC(=O)C=CC(=O)N,,,,,,
6054,56055,"N-methyl-N'-(1,3,4-thiadiazol-2-yl)but-2-enediamide",CNC(=O)C=CC(=O)NC1=NN=CS1,,,,,,
6055,56056,"4-Oxo-4-(1,3,4-thiadiazol-2-ylamino)but-2-enoic acid",C1=NN=C(S1)NC(=O)C=CC(=O)O,,,,,,
6056,56057,CID 56057,CCC1=NN=C(S1)NC(=O)C=CC(=O)OC,,,,,,
6057,56058,CID 56058,CC(C)CC1=NN=C(S1)NC(=O)C=CC(=O)OC,,,,,,
6058,56059,CID 56059,CCCCC1=NN=C(S1)NC(=O)C=CC(=O)OC,,,,,,
6059,56060,"1-Chloro-2,3-dimethoxybenzene",COC1=C(C(=CC=C1)Cl)OC,,,,,,
6060,56061,"1,2-Dichloro-3,4-dimethoxybenzene",COC1=C(C(=C(C=C1)Cl)Cl)OC,,,,,,
6061,56062,"1,5-Dichloro-2,3-dimethoxybenzene",COC1=C(C(=CC(=C1)Cl)Cl)OC,,,,,,
6062,56063,"1,4-Dichloro-2,3-dimethoxybenzene",COC1=C(C=CC(=C1OC)Cl)Cl,,,,,,
6063,56064,CID 56064,C1CN(C(=O)N1)N=CC(=O)C2=CC=C(O2)[N+](=O)[O-],,,,,,
6064,56065,"Glycine, N-(N,N-bis(2-chloroethyl)sulfamoyl)-, ethyl ester",CCOC(=O)CNS(=O)(=O)N(CCCl)CCCl,,,,,,
6065,56066,"5-[[[(1R,2R)-2-hydroxy-3-phenoxycyclopentyl]amino]methyl]-2-methyl-6,7-dihydro-5H-1-benzothiophen-4-one",CC1=CC2=C(S1)CCC(C2=O)CN[C@@H]3CCC([C@@H]3O)OC4=CC=CC=C4,,,,,,
6066,56067,CID 56067,C[C@H]1C[C@H]2[C@@H]3CC[C@@]([C@]3(C[C@@H]([C@@H]2[C@@]4(C1=CC(=O)C=C4)C)O)C)(C(=O)COC(=O)CCCCCCC(=O)N(C)CCS(=O)(=O)[O-])O.[Na+],,,,,,
6067,56068,Methylprednisolone 21-suleptanic acid ester,C[C@H]1C[C@H]2[C@@H]3CC[C@@]([C@]3(C[C@@H]([C@@H]2[C@@]4(C1=CC(=O)C=C4)C)O)C)(C(=O)COC(=O)CCCCCCC(=O)N(C)CCS(=O)(=O)O)O,,,,,,
6068,56069,(R)-Bicalutamide,C[C@](CS(=O)(=O)C1=CC=C(C=C1)F)(C(=O)NC2=CC(=C(C=C2)C#N)C(F)(F)F)O,,,,,,
6069,56070,"Diselenide, bis(2,2-diethoxyethyl)-",CCOC(C[Se][Se]CC(OCC)OCC)OCC,,,,,,
6070,56071,"Hydrazinesulfonamide, N,N-bis(2-chloroethyl)-",C(CCl)N(CCCl)S(=O)(=O)NN,,,,,,
6071,56072,"Butyronitrile, 4,4'-iminodi-",C(CC#N)CNCCCC#N,,,,,,
6072,56073,3-hydroxy-N-[(5-nitrofuran-2-yl)methylideneamino]butanamide,CC(CC(=O)NN=CC1=CC=C(O1)[N+](=O)[O-])O,,,,,,
6073,56074,"Barbituric acid, 5-(2-bromoallyl)-5-ethyl-",CCC1(C(=O)NC(=O)NC1=O)CC(=C)Br,,,,,,
6074,56075,"4,5-Bis(allyloxy)-2-imidazolidinone",C=CCOC1C(NC(=O)N1)OCC=C,,,,,,
6075,56076,"alpha,4-Dimethyl-2,5-dioxo-4-imidazolidineacetic acid ethyl ester",CCOC(=O)C(C)C1(C(=O)NC(=O)N1)C,,,,,,
6076,56077,Chlorothioacetic acid S-2-aminoethyl ester hydrochloride,C(CSC(=O)CCl)[NH3+].[Cl-],,,,,,
6077,56078,S-(2-aminoethyl) 2-chloroethanethioate,C(CSC(=O)CCl)N,,,,,,
6078,56079,"Ethene;2-methylidene-1,3-dioxepane",C=C.C=C1OCCCCO1,,,,,,
6079,56080,"2-Methylene-1,3-dioxepane",C=C1OCCCCO1,,,,,,
6080,56081,3-Methyl-2-methoxybenzamide,CC1=C(C(=CC=C1)C(=O)N)OC,,,,,,
6081,56082,"Carbonodithioic acid, S-(2-(2,3-dihydro-3-oxo-4H-1,4-benzoxazin-4-yl)-2-oxoethyl) O-(2-methylpropyl) ester",CC(C)COC(=S)SCC(=O)N1C(=O)COC2=CC=CC=C21,,,,,,
6082,56083,"Carbonodithioic acid, S-(2-(2,3-dihydro-3-oxo-4H-1,4-benzoxazin-4-yl)-2-oxoethyl) O-(3-methylbutyl) ester",CC(C)CCOC(=S)SCC(=O)N1C(=O)COC2=CC=CC=C21,,,,,,
6083,56084,"Carbamodithioic acid, diethyl-, 2-(2,3-dihydro-3-oxo-4H-1,4-benzoxazin-4-yl)-2-oxoethyl ester",CCN(CC)C(=S)SCC(=O)N1C(=O)COC2=CC=CC=C21,,,,,,
6084,56085,"1H-Isoindole-1,3(2H)-dione, 3a,4,7,7a-tetrahydro-2-(3-(4-(2-methylphenyl)-1-piperazinyl)propyl)-, dihydrochloride",CC1=CC=CC=C1N2CCN(CC2)CCCN3C(=O)C4CC=CCC4C3=O.Cl.Cl,,,,,,
6085,56086,"2-[3-[4-(2-Methylphenyl)piperazin-1-yl]propyl]-3a,4,7,7a-tetrahydroisoindole-1,3-dione",CC1=CC=CC=C1N2CCN(CC2)CCCN3C(=O)C4CC=CCC4C3=O,,,,,,
6086,56087,"1H-Isoindole-1,3(2H)-dione, 3a,4,7,7a-tetrahydro-2-(3-(4-(4-methylphenyl)-1-piperazinyl)propyl)-, dihydrochloride",CC1=CC=C(C=C1)N2CCN(CC2)CCCN3C(=O)C4CC=CCC4C3=O.Cl.Cl,,,,,,
6087,56088,"2-[3-[4-(4-Methylphenyl)piperazin-1-yl]propyl]-3a,4,7,7a-tetrahydroisoindole-1,3-dione",CC1=CC=C(C=C1)N2CCN(CC2)CCCN3C(=O)C4CC=CCC4C3=O,,,,,,
6088,56089,"1H-Isoindole-1,3(2H)-dione, 3a,4,7,7a-tetrahydro-2-(3-(4-(2-chlorophenyl)-1-piperazinyl)propyl)-, dihydrochloride",C1CN(CCN1CCCN2C(=O)C3CC=CCC3C2=O)C4=CC=CC=C4Cl.Cl.Cl,,,,,,
6089,56090,"2-[3-[4-(2-Chlorophenyl)piperazin-1-yl]propyl]-3a,4,7,7a-tetrahydroisoindole-1,3-dione",C1CN(CCN1CCCN2C(=O)C3CC=CCC3C2=O)C4=CC=CC=C4Cl,,,,,,
6090,56091,"3-Azabicyclo(3.2.1)octane-2,4-dione, 1,8,8-trimethyl-3-(3-(4-(2-methylphenyl)-1-piperazinyl)propyl)-, dihydrochloride",CC1=CC=CC=C1C2CNCCN2CCCN3C(=O)C4CCC(C3=O)(C4(C)C)C.Cl.Cl,,,,,,
6091,56092,"1,8,8-Trimethyl-3-[3-[2-(2-methylphenyl)piperazin-1-yl]propyl]-3-azabicyclo[3.2.1]octane-2,4-dione",CC1=CC=CC=C1C2CNCCN2CCCN3C(=O)C4CCC(C3=O)(C4(C)C)C,,,,,,
6092,56093,"3-Azabicyclo(3.2.1)octane-2,4-dione, 1,8,8-trimethyl-3-(3-(4-(4-methylphenyl)-1-piperazinyl)propyl)-, dihydrochloride",CC1=CC=C(C=C1)N2CCN(CC2)CCCN3C(=O)C4CCC(C3=O)(C4(C)C)C.Cl.Cl,,,,,,
6093,56094,"1,8,8-Trimethyl-3-[3-[4-(4-methylphenyl)piperazin-1-yl]propyl]-3-azabicyclo[3.2.1]octane-2,4-dione",CC1=CC=C(C=C1)N2CCN(CC2)CCCN3C(=O)C4CCC(C3=O)(C4(C)C)C,,,,,,
6094,56095,"3-Azabicyclo(3.2.1)octane-2,4-dione, 3-(3-(4-(2-chlorophenyl)-1-piperazinyl)propyl)-1,8,8-trimethyl-, dihydrochloride",CC1(C2CCC1(C(=O)N(C2=O)CCCN3CCN(CC3)C4=CC=CC=C4Cl)C)C.Cl.Cl,,,,,,
6095,56096,"3-[3-[4-(2-Chlorophenyl)piperazin-1-yl]propyl]-1,8,8-trimethyl-3-azabicyclo[3.2.1]octane-2,4-dione",CC1(C2CCC1(C(=O)N(C2=O)CCCN3CCN(CC3)C4=CC=CC=C4Cl)C)C,,,,,,
6096,56097,"3-Azabicyclo(3.2.1)octane-2,4-dione, 3-(3-(4-(3-chlorophenyl)-1-piperazinyl)propyl)-1,8,8-trimethyl-, dihydrochloride",CC1(C2CCC1(C(=O)N(C2=O)CCCN3CCN(CC3)C4=CC=C(C=C4)Cl)C)C.Cl.Cl,,,,,,
6097,56098,"3-[3-[4-(4-Chlorophenyl)piperazin-1-yl]propyl]-1,8,8-trimethyl-3-azabicyclo[3.2.1]octane-2,4-dione",CC1(C2CCC1(C(=O)N(C2=O)CCCN3CCN(CC3)C4=CC=C(C=C4)Cl)C)C,,,,,,
6098,56099,"Isoxazole, 5-(2-(dimethylamino)acetamido)-3-methyl-",CC1=NOC(=C1)NC(=O)CN(C)C,,,,,,
6099,56100,CID 56100,CC1=NC(=CC2=CC=CC=C2)C(=O)N1C3=CC=CC=C3C4=NC5=CC=CC=C5N4,,,,,,
6100,56101,3-[2-(1H-benzimidazol-2-yl)phenyl]-5-[(4-methoxyphenyl)methylidene]-2-methylimidazol-4-one,CC1=NC(=CC2=CC=C(C=C2)OC)C(=O)N1C3=CC=CC=C3C4=NC5=CC=CC=C5N4,,,,,,
6101,56102,CID 56102,CC1=NC(=CC2=CC(=C(C=C2)OC)OC)C(=O)N1C3=CC=CC=C3C4=NC5=CC=CC=C5N4,,,,,,
6102,56103,CID 56103,CC1=NC(=CC2=CC=CC=C2)C(=O)N1C3=CC=CC(=C3)C4=NC5=CC=CC=C5N4,,,,,,
6103,56104,CID 56104,CC1=NC(=CC2=CC=C(C=C2)OC)C(=O)N1C3=CC=CC(=C3)C4=NC5=CC=CC=C5N4,,,,,,
6104,56105,CID 56105,CC1=NC(=CC2=CC(=C(C=C2)OC)OC)C(=O)N1C3=CC=CC(=C3)C4=NC5=CC=CC=C5N4,,,,,,
6105,56106,"1H-BENZOTRIAZOLE, compd. with CYCLOHEXANAMINE (1:1)",C1CCC(CC1)N.C1=CC2=NNN=C2C=C1,,,,,,
6106,56107,"4,5-Dipropoxy-2-imidazolidinone",CCCOC1C(NC(=O)N1)OCCC,,,,,,
6107,56108,Oxodipine,CCOC(=O)C1=C(NC(=C(C1C2=C3C(=CC=C2)OCO3)C(=O)OC)C)C,,,['A class of drugs that act by selective inhibition of calcium influx through cellular membranes. (See all compounds classified as Calcium Channel Blockers.)'],,['Oxodipine has known human metabolites that include Oxodipine(m1) and Oxodipine(m2).'],
6108,56109,(2-Benzothiazolylamino)oxoacetic acid,C1=CC=C2C(=C1)N=C(S2)NC(=O)C(=O)O,,,,,,
6109,56110,CID 56110,CC[N+](C)(CC)CCSP(=O)OCCN(C)C.COS(=O)(=O)[O-],,,,,,
6110,56111,CID 56111,CC[N+](C)(CC)CCSP(=O)OCCN(C)C,,,,,,
6111,56112,N-((1-Ethyl-2-pyrrolidinyl)methyl)-2-methoxy-5-(N-methylmethanesulfonamido)benzamide,CCN1CCCC1CNC(=O)C2=C(C=CC(=C2)N(C)S(=O)(=O)C)OC,,,,,,
6112,56113,N-((1-Ethyl-2-pyrrolidinyl)methyl)-2-methoxy-5-((dimethylsulfamoyl)methylamino)benzamide,CCN1CCCC1CNC(=O)C2=C(C=CC(=C2)NCS(=O)(=O)N(C)C)OC,,,,,,
6113,56114,"Benzamide, 5-(((dimethylamino)sulfonyl)methylamino)-N-((1-ethyl-2-pyrrolidinyl)methyl)-2-methoxy-4-methyl-",CCN1CCCC1CNC(=O)C2=C(C=C(C(=C2)NCS(=O)(=O)N(C)C)C)OC,,,,,,
6114,56115,"Benzamide, 4-chloro-5-(((dimethylamino)sulfonyl)methylamino)-N-((1-ethyl-2-pyrrolidinyl)methyl)-2-methoxy-",CCN1CCCC1CNC(=O)C2=CC(=C(C=C2OC)Cl)NCS(=O)(=O)N(C)C,,,,,,
6115,56116,"2-[5-(1,3-Benzodioxol-5-yl)penta-2,4-dienoylamino]acetic acid",C1OC2=C(O1)C=C(C=C2)C=CC=CC(=O)NCC(=O)O,,,,,,
6116,56117,"2-[5-(1,3-Benzodioxol-5-yl)penta-2,4-dienoylamino]-2-methylpropanoic acid",CC(C)(C(=O)O)NC(=O)C=CC=CC1=CC2=C(C=C1)OCO2,,,,,,
6117,56118,CID 56118,CCC(C)[C@@H](C(=O)O)NC(=O)C=CC=CC1=CC2=C(C=C1)OCO2,,,,,,
6118,56119,CID 56119,C1OC2=C(O1)C=C(C=C2)C=CC=CC(=O)NC(C3=CC=CC=C3)C(=O)O,,,,,,
6119,56120,"Glycine, N-(4,5-dichloro-2-nitrophenyl)-, ethyl ester",CCOC(=O)CNC1=CC(=C(C=C1[N+](=O)[O-])Cl)Cl,,,,,,
6120,56121,2-(o-Iodophenoxy)butyric acid,CCC(C(=O)O)OC1=CC=CC=C1I,,,,,,
6121,56122,2-(p-Iodophenoxy)butyric acid,CCC(C(=O)O)OC1=CC=C(C=C1)I,,,,,,
6122,56123,"2-(3,6-Dichloro-2,4-diiodophenoxy)butyric acid",CCC(C(=O)O)OC1=C(C(=C(C=C1Cl)I)Cl)I,,,,,,
6123,56124,CID 56124,C1=C(C=C(C(=C1I)OCC=CC(=O)O)I)I,,,,,,
6124,56125,CID 56125,C(C(C(=O)OS(=O)(=O)[O-])N)S.[Na+],,,,,,
6125,56126,Cysteinsulphonic acid,C(C(C(=O)OS(=O)(=O)O)N)S,,,,,,
6126,56127,"2-(2,3,4,5-Tetraiodophenoxy)butyric acid",CCC(C(=O)O)OC1=CC(=C(C(=C1I)I)I)I,,,,,,
6127,56128,"2-(2,3,5,6-Tetraiodophenoxy)butyric acid",CCC(C(=O)O)OC1=C(C(=CC(=C1I)I)I)I,,,,,,
6128,56129,"2-(2,4,5-Triiodophenoxy)butyric acid",CCC(C(=O)O)OC1=CC(=C(C=C1I)I)I,,,,,,
6129,56130,"2-(3,4,5-Triiodophenoxy)butyric acid",CCC(C(=O)O)OC1=CC(=C(C(=C1)I)I)I,,,,,,
6130,56131,"Butyric acid, 4-(2,4,5-triiodophenoxy)-",C1=C(C(=CC(=C1I)I)I)OCCCC(=O)O,,,,,,
6131,56132,CID 56132,CC1[C@H](C(=O)N1OCC(=O)OCC(=O)OC(C)(C)C)NC(=O)C(=NOC)C2=CSC(=N2)N,,,,,,
6132,56133,"N-Cyclopentyl-1,4-butanediamine",C1CCC(C1)NCCCCN,,,,,,
6133,56134,5-(2-Aminopropan-2-yl)-2-methylcyclohexan-1-amine,CC1CCC(CC1N)C(C)(C)N,,,,,,
6134,56135,"N-Cyclohexyl-N'-methyl-1,3-propanediamine",CNCCCNC1CCCCC1,,,,,,
6135,56136,gamma-Methyl-1-piperazinepropanamine,CC(CCN)N1CCNCC1,,,,,,
6136,56137,2-[(6-Amino-3-methylhexyl)amino]ethan-1-ol,CC(CCCN)CCNCCO,,,,,,
6137,56138,"Ethanol, 2-((1,1-dimethyl-2-((1-methylethyl)amino)ethyl)amino)-",CC(C)NCC(C)(C)NCCO,,,,,,
6138,56139,"Ethanol, 2-((2-(dimethylamino)-1,1-dimethylethyl)amino)-",CC(C)(CN(C)C)NCCO,,,,,,
6139,56140,N-(3-(Dimethylamino)propyl)alanine,CC(C(=O)O)NCCCN(C)C,,,,,,
6140,56141,N-(2-(Dimethylamino)ethyl)alanine,CC(C(=O)O)NCCN(C)C,,,,,,
6141,56142,N-(3-(Cyclohexylamino)propyl)alanine,CC(C(=O)O)NCCCNC1CCCCC1,,,,,,
6142,56143,N-(3-(Cyclohexylamino)propyl)-2-methylalanine,CC(C)(C(=O)O)NCCCNC1CCCCC1,,,,,,
6143,56144,N-(2-Amino-2-methylpropyl)-2-methylalanine,CC(C)(CNC(C)(C)C(=O)O)N,,,,,,
6144,56145,N-(3-(2-Methyl-1-piperidinyl)propyl)alanine,CC1CCCCN1CCCNC(C)C(=O)O,,,,,,
6145,56146,"Butanoic acid, 3-((3-(2-methyl-1-piperidinyl)propyl)amino)-",CC1CCCCN1CCCNC(C)CC(=O)O,,,,,,
6146,56147,"ACETAMIDE, 2-(p-CHLOROANILINO)-N,N-DIMETHYL-",CN(C)C(=O)CNC1=CC=C(C=C1)Cl,,,,,,
6147,56148,2-(3-Iodophenoxy)butanoic acid,CCC(C(=O)O)OC1=CC(=CC=C1)I,,,,,,
6148,56149,"2-(2,4-Diiodophenoxy)butyric acid",CCC(C(=O)O)OC1=C(C=C(C=C1)I)I,,,,,,
6149,56150,"2-(2,5-Diiodophenoxy)butyric acid",CCC(C(=O)O)OC1=C(C=CC(=C1)I)I,,,,,,
6150,56151,"2-(3,4-Diiodophenoxy)butyric acid",CCC(C(=O)O)OC1=CC(=C(C=C1)I)I,,,,,,
6151,56152,"2-(3,5-Diiodophenoxy)butyric acid",CCC(C(=O)O)OC1=CC(=CC(=C1)I)I,,,,,,
6152,56153,"Butyric acid, 4-(2,4-diiodophenoxy)-",C1=CC(=C(C=C1I)I)OCCCC(=O)O,,,,,,
6153,56154,"ANILINE, o-METHOXY-N-(2-OXAZOLINYL)-",COC1=CC=CC=C1NC2=NCCO2,,,,,,
6154,56155,"ETHYLAMINE, 2-((p-CHLOROPHENYL)THIO)-N,N-DIMETHYL-",CN(C)CCSC1=CC=C(C=C1)Cl,,,,,,
6155,56156,"2-Norbornanamine, N,3-dimethyl-, hydrochloride",CC1C2CCC(C2)C1[NH2+]C.[Cl-],,,,,,
6156,56157,"N,3-dimethylbicyclo[2.2.1]heptan-2-amine",CC1C2CCC(C2)C1NC,,,,,,
6157,56158,N(sup 6)-(Methoxycarbonyl)-N(sup 6)-nitroso-L-lysine,COC(=O)N(CCCC[C@@H](C(=O)O)N)N=O,,,,,,
6158,56159,N(sup 6)-((2-Chloroethoxy)carbonyl)-N(sup 6)-nitroso-L-lysine,C(CCN(C(=O)OCCCl)N=O)C[C@@H](C(=O)O)N,,,,,,
6159,56160,Chlorimuron-ethyl,CCOC(=O)C1=CC=CC=C1S(=O)(=O)NC(=O)NC2=NC(=CC(=N2)Cl)OC,,,,"['The compound /chlorimuron-ethyl/ is absorbed from the gastrointestinal tract and is eliminated equally in urine and feces with a biological half-life of about 50 hours. Chlorimuron-ethyl is distributed throughout the body, with the largest portions found in the liver.']","['Chlorimuron-ethyl was ...extensively metabolized by both male and female rats at the low and high dose. Excretion was monitored up to 168 hrs and the elimination of radioactivity was equal via the urine and feces for the low and high dose. The half-life is 50 hrs. /Five/... major metabolites .../were found/.', ""(14)C Chlorimuron ethyl was readily absorbed by the roots of young intact corn seedlings and through the cut ends of excised leaves, but it was not readily absorbed by intact leaves. Under the conditions employed, (14)C-chlorimuron ethyl was metabolized at a moderate rate in both intact roots and excised leaves (ca 2.4 nmol/g fresh weight tissue/hr). Based upon HPLC analysis, (14)C-chlorimuron ethyl appeared to be metabolized by similar routes in both the roots and leaves. (14)C Chlorimuron ethyl and 10 radioactive metabolites were detected in the roots of corn 7 hr following herbicide treatment. (14)C-Chlorimuron ethyl and the following metabolites, listed in approximate order of their abundance, were isolated and characterized: chlorimuron ethyl (N-(4-chloro-6-methoxypyrimidine-2-yl)-N'-(2-ethoxycarbonylbenzene-sulfonyl)urea; N-(4-chloro-5-hydroxy-6-methoxypyrimidine-2-yl)-N'-(2-ethoxy carbonylbenzenesulfonyl)urea, 2-ethoxycarbonylbenzene sulfonamide, N-(4-(S-glutathionyl)-6-methoxypyrimidine-2-yl)-N'-(2-etho xycarbonyl benzenesulfonyl)urea, N-(4-(S-glutathionyl)-5-hydroxy-6-methoxypyrimidine-2-yl)- N'-(2- ethoxycarbonylbenzenesulfonyl)urea, N-(4-chloro-5-(O-beta-D-glucosyl)-6-methoxypyrimidine-2-yl)-N'ethoxy carbonylbenzenesulfonyl)urea, and N-(4-(S-cysteinyl)-6-methoxypyrimidine-2-yl)-N'-(2-ethoxycarbonyl- benzenesulfonyl)urea. Chlorimuron ethyl and these metabolites were purified by HPLC and were characterized by fast atom bombardment mass spectrometry. In addition to fast atom bombardment mass spectrometry, the following methods were used in the characterization of some metabolites: synthesis, hydrolysis with beta-glucosidase, analysis of hydrolysis products, electron impact MS, and proton nuclear magnetic resonance (400 MH).""]",['About 50 hours']
6160,56161,"1,3-Dichloro-2-methoxy-5-(2,4,6-trichlorophenoxy)benzene",COC1=C(C=C(C=C1Cl)OC2=C(C=C(C=C2Cl)Cl)Cl)Cl,,,,,,
6161,56162,"2,6-Dichloro-4-(2,4,6-trichlorophenoxy)phenol",C1=C(C=C(C(=C1Cl)O)Cl)OC2=C(C=C(C=C2Cl)Cl)Cl,,,,,,
6162,56163,N-methoxy-N-methyl-2-phenoxyacetamide,CN(C(=O)COC1=CC=CC=C1)OC,,,,,,
6163,56164,"5-Chloro-1,2-dimethyl-4-nitro-1H-imidazole",CC1=NC(=C(N1C)Cl)[N+](=O)[O-],,,,,,
6164,56165,"4-Chloro-1,2-dimethyl-5-nitro-1H-imidazole",CC1=NC(=C(N1C)[N+](=O)[O-])Cl,,,,,,
6165,56166,CID 56166,COC(=O)C=CCOC1=C(C(=C(C=C1I)I)I)I,,,,,,
6166,56167,"Barbituric acid, 5-(2-bromoallyl)-5-propyl-",CCCC1(C(=O)NC(=O)NC1=O)CC(=C)Br,,,,,,
6167,56168,"Benzoic acid, 4,4'-((5-chloro-2-thioxo-1H-benzimidazole-1,3(2H)-diyl)bis(methyleneimino)bis-",C1=CC(=CC=C1C(=O)O)NCN2C3=C(C=C(C=C3)Cl)N(C2=S)CNC4=CC=C(C=C4)C(=O)O,,,,,,
6168,56169,"ACETAMIDE, N-METHYL-N,N'-p-PHENYLENEBIS(2,2-DICHLORO-",CN(C1=CC=C(C=C1)NC(=O)C(Cl)Cl)C(=O)C(Cl)Cl,,,,,,
6169,56170,4'-((Dicyanomethyl)azo)acetanilide,CC(=O)NC1=CC=C(C=C1)N=NC(C#N)C#N,,,,,,
6170,56171,CID 56171,CCN(CC)CCON=C(C)C1=CC2=C(C=C1)OCC(=O)N2C,,,,,,
6171,56172,CID 56172,CC(=NOCCN1CCOCC1)C2=CC3=C(C=C2)OCC(=O)N3C,,,,,,
6172,56173,CID 56173,CCN1C(=O)COC2=C1C=C(C=C2)C(=NOCC#C)C,,,,,,
6173,56174,CID 56174,CCN1C(=O)COC2=C1C=C(C=C2)C(=NOCC(=O)O)C,,,,,,
6174,56175,CID 56175,CCN1C(=O)COC2=C1C=C(C=C2)C(=NOCCN(CC)CC)C,,,,,,
6175,56176,CID 56176,CN1C(=O)CSC2=C1C=C(C=C2)CC=NOCC#C,,,,,,
6176,56177,CID 56177,CCN1C(=O)CSC2=C1C=C(C=C2)C(=NOCC(=O)O)C,,,,,,
6177,56178,CID 56178,CCN1C(=O)CSC2=C1C=C(C=C2)C(=NOCC(=O)OCCN(CC)CC)C,,,,,,
6178,56179,"4H-1,4-Benzoxazine-4-acetic acid, 6-acetyl-2,3-dihydro-3-oxo-, ethyl ester",CCOC(=O)CN1C(=O)COC2=C1C=C(C=C2)C(=O)C,,,,,,
6179,56180,"4H-1,4-Benzoxazine-4-acetic acid, 6-acetyl-2,3-dihydro-3-oxo-",CC(=O)C1=CC2=C(C=C1)OCC(=O)N2CC(=O)O,,,,,,
6180,56181,"6-Acetyl-2,3-dihydro-3-oxo-4H-1,4-benzoxazine-4-acetic acid methyl ester",CC(=O)C1=CC2=C(C=C1)OCC(=O)N2CC(=O)OC,,,,,,
6181,56182,"4H-1,4-Benzoxazine-4-acetic acid, 6-acetyl-2,3-dihydro-3-oxo-, 2-(diethylamino)ethyl ester",CCN(CC)CCOC(=O)CN1C(=O)COC2=C1C=C(C=C2)C(=O)C,,,,,,
6182,56183,"6-Acetyl-2,3-dihydro-alpha-methyl-3-oxo-4H-1,4-benzoxazine-4-acetic acid ethyl ester",CCOC(=O)C(C)N1C(=O)COC2=C1C=C(C=C2)C(=O)C,,,,,,
6183,56184,"6-Acetyl-2,3-dihydro-alpha-methyl-3-oxo-4H-1,4-benzoxazine-4-acetic acid",CC(C(=O)O)N1C(=O)COC2=C1C=C(C=C2)C(=O)C,,,,,,
6184,56185,4-(4-Chlorophenyl)-3-methylbut-3-enoic acid,CC(=CC1=CC=C(C=C1)Cl)CC(=O)O,,,,,,
6185,56186,"3-Benzofuranmethylamine, 2-ethyl-",CCC1=C(C2=CC=CC=C2O1)CN,,,,,,
6186,56187,2-(But-2-en-1-yloxy)benzamide,CC=CCOC1=CC=CC=C1C(=O)N,,,,,,
6187,56188,"2,3-Dihydro-2-isopropyl-4H-1,3-benzoxazin-4-one",CC(C)C1NC(=O)C2=CC=CC=C2O1,,,,,,
6188,56189,Ethyl 3-[bis(2-chloroethyl)sulfamoylhydrazinylidene]butanoate,CCOC(=O)CC(=NNS(=O)(=O)N(CCCl)CCCl)C,,,,,,
6189,56190,"Isothiazole, 5-(2-(diethylamino)acetamido)-3-methyl-",CCN(CC)CC(=O)NC1=CC(=NS1)C,,,,,,
6190,56191,"Isoxazole, 5-(2-(diethylamino)acetamido)-3-methyl-",CCN(CC)CC(=O)NC1=CC(=NO1)C,,,,,,
6191,56192,2-Ethoxy-3-methylbenzamide,CCOC1=C(C=CC=C1C(=O)N)C,,,,,,
6192,56193,"N,N-Bis(2-chloroethyl)-N',N'-bis(carboxymethyl)ethylenediamine dihydrochloride",C(C[NH+](CC(=O)O)CC(=O)O)[NH+](CCCl)CCCl.[Cl-].[Cl-],,,,,,
6193,56194,2-[2-[Bis(2-chloroethyl)amino]ethyl-(carboxymethyl)amino]acetic acid,C(CN(CC(=O)O)CC(=O)O)N(CCCl)CCCl,,,,,,
6194,56195,"4,5-Bis(but-2-enoxy)imidazolidin-2-one",CC=CCOC1C(NC(=O)N1)OCC=CC,,,,,,
6195,56196,"4,5-Bis(3-butenyloxy)-2-imidazolidinone",C=CCCOC1C(NC(=O)N1)OCCC=C,,,,,,
6196,56197,1-(2-Propynyl)cyclopentanol carbamate,C#CCC1CCCC1OC(=O)N,,,,,,
6197,56198,"ACETAMIDE, 2-(p-CHLORO-N-METHYLANILINO)-N,N-DIMETHYL-",CN(C)C(=O)CN(C)C1=CC=C(C=C1)Cl,,,,,,
6198,56199,alpha-Methyl-beta-phenyl-1-aziridineethanol,CC(C(C1=CC=CC=C1)N2CC2)O,,,,,,
6199,56200,beta-Methyl-alpha-phenyl-1-aziridineethanol,CC(C(C1=CC=CC=C1)O)N2CC2,,,,,,
6200,56201,"2,3-Dihydro-2-ethyl-3-benzofuranmethylamine",CCC1C(C2=CC=CC=C2O1)CN,,,,,,
6201,56202,"N,N-Dimethyl-1,4-benzodioxan-2-methylamine",CN(C)CC1COC2=CC=CC=C2O1,,,,,,
6202,56203,"Carbamic acid, methyl-, 3-phenylpropyl ester",CNC(=O)OCCCC1=CC=CC=C1,,,,,,
6203,56204,"GUANIDINE, (m-METHYLBENZYL)-",CC1=CC(=CC=C1)CN=C(N)N,,,,,,
6204,56205,Difloxacin hydrochloride,CN1CCN(CC1)C2=C(C=C3C(=C2)N(C=C(C3=O)C(=O)O)C4=CC=C(C=C4)F)F.Cl,,,,,,
6205,56206,Difloxacin,CN1CCN(CC1)C2=C(C=C3C(=C2)N(C=C(C3=O)C(=O)O)C4=CC=C(C=C4)F)F,['* Chickens: :'],,,,,
6206,56207,Sarafloxacin hydrochloride,C1CN(CCN1)C2=C(C=C3C(=C2)N(C=C(C3=O)C(=O)O)C4=CC=C(C=C4)F)F.Cl,,,,,,
6207,56208,Sarafloxacin,C1CN(CCN1)C2=C(C=C3C(=C2)N(C=C(C3=O)C(=O)O)C4=CC=C(C=C4)F)F,,,,"['(14)C-Sarafloxacin was orally administered to six laying hens for five consecutive days. Eggs were collected for 15 days after the initial drug treatment. Egg yolk and egg albumen were separated and assayed for total radioactive residues (TRR) using a combustion oxidizer and scintillation counting techniques. Radioactivity was detected in egg yolk and egg albumen on the second day of dosing and reached a maximum at 24 hr after drug withdrawal. Thereafter, the sarafloxacin TRR levels in egg albumen declined rapidly and were undetectable 2 days after the last dose, whereas the levels in egg yolk declined at a much slower rate and were undetectable 7 days after drug withdrawal. In both the egg albumen and yolk, HPLC analysis indicated that the parent sarafloxacin was the major component.', 'Pharmacokinetics of sarafloxacin, a fluoroquinolone antibiotic, was determined in pigs and broilers after intravenous (i.v.), intramuscular (i.m.), or oral (p.o.) administration at a single dose of 5 (pigs) or 10 mg/kg (broilers). Plasma concentration profiles were analysed by a noncompartmental pharmacokinetic method. Following i.v., i.m. and p.o. doses, the elimination half-lives were 3.37 +/- 0.46, 4.66 +/- 1.34, 7.20 +/- 1.92 (pigs) and 2.53 +/- 0.82, 6.81 +/- 2.04, 3.89 +/- 1.19 hR (broilers), respectively. After i.m. and p.o. doses, bioavailabilities (F) were 81.8 +/- 9.8 and 42.6 +/- 8.2% (pigs) and 72.1 +/- 8.1 and 59.6 +/- 13.8% (broilers), respectively. Steady-state distribution volumes (Vd(ss)) of 1.92 +/- 0.27 and 3.40 +/- 1.26 L/kg and total body clearances (ClB) of 0.51 +/- 0.03 and 1.20 +/- 0.20 L/kg/hr were determined in pigs and broilers, respectively. Areas under the curve (AUC), mean residence times (MRT), and mean absorption times (MAT) were also determined. Sarafloxacin was demonstrated to be more rapidly absorbed, more extensively distributed, and more quickly eliminated in broilers than in pigs. Based on the single-dose pharmacokinetic parameters determined, multiple dosage regimens were recommended as: a dosage of 10 mg/kg given intramuscularly every 12 hr in pigs, or administered orally every 8 hr in broilers, can maintain effective plasma concentrations with bacteria infections, in which MIC90 are <0.25 ug/mL.', 'The absorption, metabolism, and excretion of (14)C-labelled sarafloxacin was studied in three-month-old female New Zealand white rabbits. Two groups of three animals per group were treated orally by gavage with 10 mg/kg bw of (14)C-sarafloxacin base. A third group of three animals received the same dose by intravenous administration. Blood samples were collected 1, 3, 6, 12, and 24 hr after oral administration from animals in one of the groups, and urine and feces were collected daily for five days from animals in the other groups. ... Within five days of oral administration, about 11% of the dose was eliminated in the urine and about 79% in the feces. Urinary excretion after intravenous administration indicated that about 16% of the oral dose had been systemically absorbed.', 'Five groups of 18 Sprague-Dawley rats of each sex were treated with sarafloxacin as follows: One group received a single intravenous dose of 20 mg/kg bw; three groups received a single oral dose of 20, 75, or 275 mg/kg bw; and animals in the fifth group received an oral dose of 1000 mg/kg bw daily for 14 consecutive days. Blood samples were collected from four rats in each group just before treatment and 0.5, 1, 2, 4, 6, 8, 12, and 24 hr after treatment on day 1 for the groups receiving the single dose and on days 1 and 14 for the 14-day treatment group. Plasma and urine samples were assayed for sarafloxacin base by high-performance liquid chromatography. ... A comparison of the 0 to infinity area under the concentration time curve (AUC) after a single intravenous or oral dose of 20 mg/kg bw sarafloxacin indicated that its bioavailability was about 12%. A plot of the AUC against dose was linear up to 275 mg/kg bw but deviated from linearity at 1000 mg/kg bw.', 'For more Absorption, Distribution and Excretion (Complete) data for SARAFLOXACIN (8 total), please visit the HSDB record page.']","[""The pharmacokinetics and metabolism of sarafloxacin were studied in two groups of six volunteers given a single oral dose of 100 or 200 mg sarafloxacin and two groups of five volunteers given a single oral dose of 400 or 800 mg. ... The metabolism of sarafloxacin appears to involve mainly oxidative degradation of the piperazinyl substituent, first producing 3'-oxo-sarafloxacin. Subsequent oxidation produces an ethylene diamine-substituted quinolone, which in turn is oxidized to an aminoquinolone. The plasma concentrations of the ethylene diamine-substituted quinolone parallel those of the parent drug, but the average AUC for the quinolone was consistently only about 6% that of sarafloxacin. The concentration of the aminoquinolone in plasma and  urine was considerably lower than that of the ethylene diamine-substituted quinolone. Owing to its weak fluorescence, 3'-oxo-sarafloxacin was not detected in plasma. In urine, the major drug-related peak was sarafloxacin, accounting for 75-80% of all urinary metabolites. After sarafloxacin, the predominant metabolite in urine was tentatively identified as 3'-oxo-sarafloxacin, which occurred at concentrations that were typically one-third to one-fourth those of sarafloxacin. The total urinary recovery of parent drug plus metabolites was low and dose-dependent, decreasing from 24 to 10% as the dose increased from 100 to 800 mg. The extent of the decrease was similar to that in the dose-normalized AUC. Collectively, the aminoquinolone, the ethylene diamine-substituted quinolone, and their conjugates accounted for < 7% of the urinary excretion."", '... /Dogs (breed, sex, and number not stated) were given an oral or intravenous dose of 10 mg/kg bw dose of (14)C-sarafloxacin base./ ... About 79% of the 10 mg/kg bw dose of (14)C-sarafloxacin base was excreted as unmetabolized parent drug in urine and faeces. In bile, the unchanged parent drug and its glucuronide were found in about equal proportions', 'To investigate the microbial biotransformation of veterinary fluoroquinolones, Mucor ramannianus was grown in sucrose/peptone broth with sarafloxacin for 18 days. Cultures were extracted with ethyl acetate and extracts were analyzed by liquid chromatography. The two metabolites (26% and 15% of the A280, respectively) were identified by mass and 1H nuclear magnetic resonance spectra as N-acetylsarafloxacin and desethylene-N-acetylsarafloxacin. The biological formation of desethylene-N-acetylsarafloxacin has not been previously observed.']","['A single oral dose of 100, 200, 400, or 800 mg sarafloxacin was administered to 22 healthy male volunteers ranging in age from 20 to 39 years. ... The average terminal phase half-lives were 9, 9, 10, and 11 hr at the 100, 200, 400, and 800 mg doses, respectively.', 'Pharmacokinetics of sarafloxacin, a fluoroquinolone antibiotic, was determined in pigs and broilers after intravenous (i.v.), intramuscular (i.m.), or oral (p.o.) administration at a single dose of 5 (pigs) or 10 mg/kg (broilers). ... Following i.v., i.m. and p.o. doses, the elimination half-lives were 3.37 +/- 0.46, 4.66 +/- 1.34, 7.20 +/- 1.92 (pigs) and 2.53 +/- 0.82, 6.81 +/- 2.04, 3.89 +/- 1.19 hR (broilers), respectively. ...', 'The pharmacokinetics of sarafloxacin applied by oral gavage at a dose of 15 mg/kg bw was studied in eel (Anguilla anguilla) at water temperature of 24 degrees C. ... The distribution rate constant (alpha) was 0.085 hr(-1) (r=0.972), and the half-life (t(1,2alpha)) was 8.15 hr. The elimination rate constant (beta) was 0.023 hr(-1) (r=0.909), and the half-life (t(1/2beta)) was 30.13 hr. ...']"
6208,56209,9-(3-Diethylamino-2-hydroxypropyl)carbazole,CCN(CC)CC(CN1C2=CC=CC=C2C3=CC=CC=C31)O,,,,,,
6209,56210,alpha-(1-Piperidinylmethyl)-9H-carbazole-9-ethanol,C1CCN(CC1)CC(CN2C3=CC=CC=C3C4=CC=CC=C42)O,,,,,,
6210,56211,alpha-((Hexahydro-1H-azepin-1-yl)methyl)-9H-carbazole-9-ethanol,C1CCCN(CC1)CC(CN2C3=CC=CC=C3C4=CC=CC=C42)O,,,,,,
6211,56212,alpha-(4-Morpholinylmethyl)-9H-carbazole-9-ethanol,C1COCCN1CC(CN2C3=CC=CC=C3C4=CC=CC=C42)O,,,,,,
6212,56213,"Isoxazole, 5-(2-(dimethylamino)acetamido)-4-(2-methoxyethyl)-3-methyl-",CC1=NOC(=C1CCOC)NC(=O)CN(C)C,,,,,,
6213,56214,CID 56214,CC(C)CCCC(C)CC(=NN)C,,,,,,
6214,56215,CID 56215,CCC(CCO)C(=O)NN=CC1=CC=C(O1)[N+](=O)[O-],,,,,,
6215,56216,1-(2-Propynyl)cycloheptanol carbamate,C#CCC1CCCCCC1OC(=O)N,,,,,,
6216,56217,(1-Methyl-2-(2-norbornyl)ethyl)hydrazine,CC(CC1CC2CCC1C2)NN,,,,,,
6217,56218,"Acetic acid, 2-cyclooctylhydrazide",CC(=O)NNC1CCCCCCC1,,,,,,
6218,56219,"Carbamic acid, (3-hydroxypropyl)-, ethyl ester, propylcarbamate",CCCNC(=O)OCCCNC(=O)OCC,,,,,,
6219,56220,"2-(3,5-Diiodo-2-methoxyphenoxy)butyric acid",CCC(C(=O)O)OC1=C(C(=CC(=C1)I)I)OC,,,,,,
6220,56221,"2-(3,5-Diiodo-4-methoxyphenoxy)butyric acid",CCC(C(=O)O)OC1=CC(=C(C(=C1)I)OC)I,,,,,,
6221,56222,"1,2,3,4-Tetrahydro-2-isoquinolineacetonitrile",C1CN(CC2=CC=CC=C21)CC#N,,,,,,
6222,56223,"2-Norbornanamine, 3,3-dimethyl-N-ethyl-, hydrochloride",CC[NH2+]C1C2CCC(C2)C1(C)C.[Cl-],,,,,,
6223,56224,"N-ethyl-3,3-dimethylbicyclo[2.2.1]heptan-2-amine",CCNC1C2CCC(C2)C1(C)C,,,,,,
6224,56225,cis-2-Ethyldecahydro-5-isoquinolinol,CCN1CCC2[C@H](CCCC2C1)O,,,,,,
6225,56226,"1,6-Dibromodibenzo-P-dioxin",C1=CC2=C(C(=C1)Br)OC3=C(O2)C(=CC=C3)Br,,,,,,
6226,56227,3-(2-Methylpropoxy)prop-2-enal,CC(C)COC=CC=O,,,,,,
6227,56228,3-Oxoprop-1-enyl benzoate,C1=CC=C(C=C1)C(=O)OC=CC=O,,,,,,
6228,56229,"1,4-Butanediamine, N-isopentyl-",CC(C)CCNCCCCN,,,,,,
6229,56230,CID 56230,CCOC1=CC=C(C=C1)N2C(=O)CC(=O)N=C2S,,,,,,
6230,56231,"3-ISOXAZOLECARBOXYLIC ACID, 5-METHYL-, 2-(o-CHLOROBENZYL)HYDRAZIDE",CC1=CC(=NO1)C(=O)NNCC2=CC=CC=C2Cl,,,,,,
6231,56232,"BARBITURIC ACID, 5-(o-CHLOROPHENYL)-5-ETHYL-",CCC1(C(=O)NC(=O)NC1=O)C2=CC=CC=C2Cl,,,,,,
6232,56233,"Butanoic acid, 4-((1-(cyanomethyl)-2-pyrrolidinylidene)amino)-, monohydrochloride",C1CC(=[N+](C1)CC#N)NCCCC(=O)O.[Cl-],,,,,,
6233,56234,"4-[[1-(cyanomethyl)-3,4-dihydro-2H-pyrrol-1-ium-5-yl]amino]butanoic acid",C1CC(=[N+](C1)CC#N)NCCCC(=O)O,,,,,,
6234,56235,"Acetamide, N,N-dimethyl-2-(N-methylanilino)-",CN(C)C(=O)CN(C)C1=CC=CC=C1,,,,,,
6235,56236,"ACETIC ACID, 2-(p-METHOXY-alpha-METHYLBENZYL)HYDRAZIDE",CC(C1=CC=C(C=C1)OC)NNC(=O)C,,,,,,
6236,56237,Lonapalene,CC(=O)OC1=C(C(=C(C2=C1C=CC(=C2)Cl)OC(=O)C)OC)OC,,,,,,
6237,56238,"1H-Benzimidazole, 5-chloro-2-(4-methoxyphenyl)-, hemihydrate",COC1=CC=C(C=C1)C2=NC3=C(N2)C=C(C=C3)Cl.COC1=CC=C(C=C1)C2=NC3=C(N2)C=C(C=C3)Cl.O,,,,,,
6238,56239,5-chloro-2-(4-methoxyphenyl)-1H-benzimidazole,COC1=CC=C(C=C1)C2=NC3=C(N2)C=C(C=C3)Cl,,,,,,
6239,56240,"Ethanone, 1-(2-phenyl-1H-benzimidazol-5-YL)-",CC(=O)C1=CC2=C(C=C1)N=C(N2)C3=CC=CC=C3,,,,,,
6240,56241,"[cyano-(3-phenoxyphenyl)methyl] (1R,3R)-3-(2-chloro-3,3,3-trifluoroprop-1-enyl)-2,2-dimethylcyclopropane-1-carboxylate",CC1([C@H]([C@H]1C(=O)OC(C#N)C2=CC(=CC=C2)OC3=CC=CC=C3)C=C(C(F)(F)F)Cl)C,,,,,,
6241,56242,1-[4-amino-5-(3-methoxyphenyl)-2-methyl-1H-pyrrol-3-yl]ethanone,CC1=C(C(=C(N1)C2=CC(=CC=C2)OC)N)C(=O)C,,,,,,
6242,56243,"Ethanone, 1-(4-amino-5-(4-methoxy-3-methylphenyl)-2-methyl-1H-pyrrol-3-YL)-",CC1=C(C=CC(=C1)C2=C(C(=C(N2)C)C(=O)C)N)OC,,,,,,
6243,56244,"Ethanone, 1-(4-amino-5-(3-fluorophenyl)-2-methyl-1H-pyrrol-3-YL)-",CC1=C(C(=C(N1)C2=CC(=CC=C2)F)N)C(=O)C,,,,,,
6244,56245,"1-[4-amino-5-(3,4-dimethoxyphenyl)-2-methyl-1H-pyrrol-3-yl]ethanone",CC1=C(C(=C(N1)C2=CC(=C(C=C2)OC)OC)N)C(=O)C,,,,,,
6245,56246,"1-[4-amino-5-(3,4-dichlorophenyl)-2-methyl-1H-pyrrol-3-yl]ethanone",CC1=C(C(=C(N1)C2=CC(=C(C=C2)Cl)Cl)N)C(=O)C,,,,,,
6246,56247,"Ethanone, 1-(4-hydroxy-2-methyl-5-phenyl-1H-pyrrol-3-YL)-",CC1=C(C(=C(N1)C2=CC=CC=C2)O)C(=O)C,,,,,,
6247,56248,1-(4-Methoxy-2-methyl-5-phenyl-1H-pyrrol-3-yl)ethanone,CC1=C(C(=C(N1)C2=CC=CC=C2)OC)C(=O)C,,,,,,
6248,56249,1-[4-amino-5-(2-chlorophenyl)-2-methyl-1H-pyrrol-3-yl]ethanone,CC1=C(C(=C(N1)C2=CC=CC=C2Cl)N)C(=O)C,,,,,,
6249,56250,"Ethanone, 1-(4-amino-5-(2-methoxyphenyl)-2-methyl-1H-pyrrol-3-YL)-",CC1=C(C(=C(N1)C2=CC=CC=C2OC)N)C(=O)C,,,,,,
6250,56251,"1-(2,4-Dimethyl-5-phenyl-1H-pyrrol-3-yl)ethanone",CC1=C(NC(=C1C(=O)C)C)C2=CC=CC=C2,,,,,,
6251,56252,"Ethanone, 1-(4-amino-5-(4-hydroxy-3-methoxyphenyl)-2-methyl-1H-pyrrol-3-yl)-, monohydrochloride",CC1=C(C(=C(N1)C2=CC(=C(C=C2)O)OC)[NH3+])C(=O)C.[Cl-],,,,,,
6252,56253,1-[4-amino-5-(4-hydroxy-3-methoxyphenyl)-2-methyl-1H-pyrrol-3-yl]ethanone,CC1=C(C(=C(N1)C2=CC(=C(C=C2)O)OC)N)C(=O)C,,,,,,
6253,56254,"Ethanone, 1-(4-amino-5-(3-bromophenyl)-2-methyl-1H-pyrrol-3-yl)-, monohydrochloride",CC1=C(C(=C(N1)C2=CC(=CC=C2)Br)[NH3+])C(=O)C.[Cl-],,,,,,
6254,56255,1-[4-amino-5-(3-bromophenyl)-2-methyl-1H-pyrrol-3-yl]ethanone,CC1=C(C(=C(N1)C2=CC(=CC=C2)Br)N)C(=O)C,,,,,,
6255,56256,"Ethylamine, 2,2'-((dimethylsilylene)dithio)bis-",C[Si](C)(SCCN)SCCN,,,,,,
6256,56257,CID 56257,CC1=CC=C(C=C1)C=C(C)CC(=O)O,,,,,,
6257,56258,CID 56258,C1C(=O)N=C(N1N=CC2=NC=C(O2)C3=CC=C(C=C3)Br)[O-].[Na+],,,,,,
6258,56259,"1-[[5-(4-Bromophenyl)-1,3-oxazol-2-yl]methylideneamino]imidazolidine-2,4-dione",C1C(=O)NC(=O)N1N=CC2=NC=C(O2)C3=CC=C(C=C3)Br,,,,,,
6259,56260,Antineoplaston A10,C1CC(=O)NC(=O)[C@H]1NC(=O)CC2=CC=CC=C2,,,,,,
6260,56261,"1,2,3,4,6,9-Hexachlorodibenzofuran",C1=CC(=C2C(=C1Cl)C3=C(O2)C(=C(C(=C3Cl)Cl)Cl)Cl)Cl,,,,,,
6261,56262,"1,2,3,4,7,9-Hexachlorodibenzofuran",C1=C(C=C(C2=C1OC3=C2C(=C(C(=C3Cl)Cl)Cl)Cl)Cl)Cl,,,,,,
6262,56263,1-(4-Butoxyphenyl)ethanamine,CCCCOC1=CC=C(C=C1)C(C)N,,,,,,
6263,56264,1-(2-Propynyl)cyclooctanol carbamate,C#CCC1CCCCCCC1OC(=O)N,,,,,,
6264,56265,"alpha-((Methylamino)methyl)-3,4,5-trimethoxy-benzyl alcohol hydrochloride",C[NH2+]CC(C1=CC(=C(C(=C1)OC)OC)OC)O.[Cl-],,,,,,
6265,56266,"2-(Methylamino)-1-(3,4,5-trimethoxyphenyl)ethanol",CNCC(C1=CC(=C(C(=C1)OC)OC)OC)O,,,,,,
6266,56267,CID 56267,CC(=NN(CCCl)CCCl)C(=NN(CCCl)CCCl)C,,,,,,
6267,56268,"2-Azaspiro(4.5)decane-1,3-dione, 2-allyl-",C=CCN1C(=O)CC2(C1=O)CCCCC2,,,,,,
6268,56269,"Carbamic acid, dimethyl-, 3-phenylpropyl ester",CN(C)C(=O)OCCCC1=CC=CC=C1,,,,,,
6269,56270,"Acetanilide, 4'-divinylsulfamoyl-",CC(=O)NC1=CC=C(C=C1)S(=O)(=O)N(C=C)C=C,,,,,,
6270,56271,"BARBITURIC ACID, 5-(p-BROMOPHENYL)-5-ETHYL-",CCC1(C(=O)NC(=O)NC1=O)C2=CC=C(C=C2)Br,,,,,,
6271,56272,"N-Acetyl-4,4'-methylenebis(2-chloroaniline)",CC(=O)NC1=C(C=C(C=C1)CC2=CC(=C(C=C2)N)Cl)Cl,,,,,,
6272,56273,Basf 43915; orf 18704;rwj 18704,CC1=C(C(CCC1)(C)C)C=CC(=CC=CC2=CC=C(C=C2)C(=O)O)C,,,,,,
6273,56274,"CARBAMIC ACID, (3-(p-CHLOROPHENYL)-1,2,4-OXADIAZOL-5-YL)METHYL ESTER",C1=CC(=CC=C1C2=NOC(=N2)COC(=O)N)Cl,,,,,,
6274,56275,CID 56275,C1=CC=C2C(=C1)C(=C3C=CC=CC3=N2)NN=CC4=CC(=CC=C4)[N+](=O)[O-],,,,,,
6275,56276,"9-{[(4-Nitrophenyl)methylidene]hydrazinylidene}-9,10-dihydroacridine",C1=CC=C2C(=C1)C(=C3C=CC=CC3=N2)NN=CC4=CC=C(C=C4)[N+](=O)[O-],,,,,,
6276,56277,"Benzoic acid, 4-(allyloxy)-3,5-diiodo-",C=CCOC1=C(C=C(C=C1I)C(=O)O)I,,,,,,
6277,56278,"Coumarin, 3-glyoxyloyl-",C1=CC=C2C(=C1)C=C(C(=O)O2)C(=O)C=O,,,,,,
6278,56279,"N,O-Diethyl-2-phenoxyacetohydroxamic acid",CCN(C(=O)COC1=CC=CC=C1)OCC,,,,,,
6279,56280,Cepacin B,C#CC#CC=C=CC1C(O1)C2C(O2)C(C3CCC(=O)O3)O,,,,,,
6280,56281,"5-(3-Hydroxy-4-oxododeca-1,6,7-trien-9,11-diynyl)oxolan-2-one",C#CC#CC=C=CCC(=O)C(C=CC1CCC(=O)O1)O,,,,,,
6281,56282,CID 56282,CC(=CC(=O)NN=CC1=CC=C(O1)[N+](=O)[O-])C,,,,,,
6282,56283,"2-methyl-N-[(5-nitrofuran-2-yl)methylideneamino]-1,3-dioxolane-2-carboxamide",CC1(OCCO1)C(=O)NN=CC2=CC=C(O2)[N+](=O)[O-],,,,,,
6283,56284,"2-Norbornanamine, 3,3-dimethyl-N-propyl-, hydrochloride",CCC[NH2+]C1C2CCC(C2)C1(C)C.[Cl-],,,,,,
6284,56285,"3,3-dimethyl-N-propylbicyclo[2.2.1]heptan-2-amine",CCCNC1C2CCC(C2)C1(C)C,,,,,,
6285,56286,3-(1-(2-Norbornyl)ethyl)carbazic acid ethyl ester,CCOC(=O)NNC(C)C1CC2CCC1C2,,,,,,
6286,56287,"BARBITURIC ACID, 5-ALLYL-5-(p-IODOPHENYL)-",C=CCC1(C(=O)NC(=O)NC1=O)C2=CC=C(C=C2)I,,,,,,
6287,56288,5-(p-Chlorophenyl)-3-(2-hydroxyethyl)-5-methylhydantoin,CC1(C(=O)N(C(=O)N1)CCO)C2=CC=C(C=C2)Cl,,,,,,
6288,56289,(2-Guanidinoethyl)trimethylammonium iodide hydriodide,C[N+](C)(C)CC[NH+]=C(N)N.[I-].[I-],,,,,,
6289,56290,2-(Diaminomethylideneamino)ethyl-trimethylazanium,C[N+](C)(C)CCN=C(N)N,,,,,,
6290,56291,N-(1-thiophen-2-ylpropylideneamino)pyridine-3-carboxamide,CCC(=NNC(=O)C1=CN=CC=C1)C2=CC=CS2,,,,,,
6291,56292,"Oxalic acid, 2-ethylhydrazide 2-isopropylhydrazide",CCNNC(=O)C(=O)NNC(C)C,,,,,,
6292,56293,Fibrostatin A,CC1=CC(=O)C2=CC(=C(C(=C2C1=O)O)CSC[C@@H](C(=O)O)NC(=O)C)OC,,,,,,
6293,56294,Fibrostatin E,CC(=O)N[C@@H](CSCC1=C(C=C2C(=O)C=C(C(=O)C2=C1O)CO)OC)C(=O)O,,,,,,
6294,56295,"L-Cysteine, N-acetyl-S-((5,8-dihydro-3,6-dimethoxy-5,8-dioxo-1-hydroxy-7-(hydroxymethyl)-2-naphthalenyl)methyl)-",CC(=O)N[C@@H](CSCC1=C(C=C2C(=C1O)C(=O)C(=C(C2=O)OC)CO)OC)C(=O)O,,,,,,
6295,56296,Fibrostatin C,CC(=O)N[C@@H](CSCC1=C(C=C2C(=C1O)C(=O)C=C(C2=O)OC)OC)C(=O)O,,,,,,
6296,56297,Fibrostatin B,CC1=C(C(=O)C2=CC(=C(C(=C2C1=O)O)CSC[C@@H](C(=O)O)NC(=O)C)OC)OC,,,,,,
6297,56298,"Acetamide, N-(alpha,alpha-dimethylbenzyl)-2-(propylamino)-",CCCNCC(=O)NC(C)(C)C1=CC=CC=C1,,,,,,
6298,56299,N-Benzyl-N-(2-chloroethyl)-beta-alanine hydrochloride,C1=CC=C(C=C1)C[NH+](CCC(=O)O)CCCl.[Cl-],,,,,,
6299,56300,3-[Benzyl(2-chloroethyl)amino]propanoic acid,C1=CC=C(C=C1)CN(CCC(=O)O)CCCl,,,,,,
6300,56301,CID 56301,CC=NN(C1=CC=NC=C1)C(=O)C2=CC=NC=C2,,,,,,
6301,56302,N-(1-pyridin-3-ylethylideneamino)pyridine-3-carboxamide,CC(=NNC(=O)C1=CN=CC=C1)C2=CN=CC=C2,,,,,,
6302,56303,"Carbamic acid, (3-hydroxypropyl)-, hexyl ester, carbamate",CCCCCCOC(=O)NCCCOC(=O)N,,,,,,
6303,56304,CID 56304,C=CC1=C(N2[C@@H]([C@@H](C2=O)NC(=C(C3=CSC(=N3)N)N=O)O)SC1)C(=O)O,,,,,,
6304,56305,"Acetanilide, 3'-carbamoyl-4'-hydroxy-5'-methyl-",CC1=CC(=CC(=C1O)C(=O)N)NC(=O)C,,,,,,
6305,56306,5-(p-Bromophenyl)-5-ethyl-3-(2-hydroxyethyl)hydantoin,CCC1(C(=O)N(C(=O)N1)CCO)C2=CC=C(C=C2)Br,,,,,,
6306,56307,5-(p-Chlorophenyl)-5-ethyl-3-(2-hydroxyethyl)hydantoin,CCC1(C(=O)N(C(=O)N1)CCO)C2=CC=C(C=C2)Cl,,,,,,
6307,56308,"N,N'-Ethylenebis(N-(2-chloroethyl)glycine) dihydrochloride",C(C[NH+](CCCl)CC(=O)O)[NH+](CCCl)CC(=O)O.[Cl-].[Cl-],,,,,,
6308,56309,"2,2'-(Ethane-1,2-diylbis((2-chloroethyl)azanediyl))diacetic acid",C(CN(CCCl)CC(=O)O)N(CCCl)CC(=O)O,,,,,,
6309,56310,"Benzoic acid, 4-(allyloxy)-3,5-dichloro-, allyl ester",C=CCOC1=C(C=C(C=C1Cl)C(=O)OCC=C)Cl,,,,,,
6310,56311,CID 56311,CN(C)C1C(=O)N=C(N(C1=O)C2=CC=C(C=C2)OC)S,,,,,,
6311,56312,Boranylformic acid;methanamine,BC(=O)O.CN,,,,,,
6312,56313,"BARBITURIC ACID, 5-ALLYL-5-(p-BROMOPHENYL)-",C=CCC1(C(=O)NC(=O)NC1=O)C2=CC=C(C=C2)Br,,,,,,
6313,56314,"BARBITURIC ACID, 5-ALLYL-5-(o-CHLOROPHENYL)-",C=CCC1(C(=O)NC(=O)NC1=O)C2=CC=CC=C2Cl,,,,,,
6314,56315,"BARBITURIC ACID, 5-ALLYL-5-(p-CHLOROPHENYL)-",C=CCC1(C(=O)NC(=O)NC1=O)C2=CC=C(C=C2)Cl,,,,,,
6315,56316,"Coumarin, 3-glyoxyloyl-8-methoxy-",COC1=CC=CC2=C1OC(=O)C(=C2)C(=O)C=O,,,,,,
6316,56317,"2-Norbornanamine, N-butyl-3,3-dimethyl-, hydrochloride",CCCC[NH2+]C1C2CCC(C2)C1(C)C.[Cl-],,,,,,
6317,56318,"N-butyl-3,3-dimethylbicyclo[2.2.1]heptan-2-amine",CCCCNC1C2CCC(C2)C1(C)C,,,,,,
6318,56319,N-(1-(Dimethylcarbamoyl)ethyl)acetanilide,CC(C(=O)N(C)C)N(C1=CC=CC=C1)C(=O)C,,,,,,
6319,56320,"o-ACETOTOLUIDIDE, N-(DIMETHYLCARBAMOYLMETHYL)-",CC1=CC=CC=C1N(CC(=O)N(C)C)C(=O)C,,,,,,
6320,56321,"p-ACETOTOLUIDIDE, N-(DIMETHYLCARBAMOYLMETHYL)-",CC1=CC=C(C=C1)N(CC(=O)N(C)C)C(=O)C,,,,,,
6321,56322,"o-ACETANISIDIDE, N-(DIMETHYLCARBAMOYLMETHYL)-",CC(=O)N(CC(=O)N(C)C)C1=CC=CC=C1OC,,,,,,
6322,56323,"p-ACETANISIDIDE, N-(DIMETHYLCARBAMOYLMETHYL)-",CC(=O)N(CC(=O)N(C)C)C1=CC=C(C=C1)OC,,,,,,
6323,56324,"BENZOIC ACID, p-((DIMETHYLCARBAMOYLMETHYL)AMINO)-, ETHYL ESTER",CCOC(=O)C1=CC=C(C=C1)NCC(=O)N(C)C,,,,,,
6324,56325,alpha-(1-(Methyl(2-propynyl)amino)ethyl)benzyl alcohol hydrochloride,CC(C(C1=CC=CC=C1)O)[NH+](C)CC#C.[Cl-],,,,,,
6325,56326,2-[Methyl(prop-2-ynyl)amino]-1-phenylpropan-1-ol,CC(C(C1=CC=CC=C1)O)N(C)CC#C,,,,,,
6326,56327,"Ethanol, 2-(((2-ethyl-3-benzofuranyl)methyl)amino)-",CCC1=C(C2=CC=CC=C2O1)CNCCO,,,,,,
6327,56328,"[(2S,5R)-5-(6-aminopurin-9-yl)-4-fluorooxolan-2-yl]methanol",C1[C@H](O[C@H](C1F)N2C=NC3=C(N=CN=C32)N)CO,,,,,,
6328,56329,Cilazapril monohydrate,CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@H]2CCCN3CCC[C@H](N3C2=O)C(=O)O.O,,,"['A class of drugs whose main indications are the treatment of hypertension and heart failure. They exert their hemodynamic effect mainly by inhibiting the renin-angiotensin system. They also modulate sympathetic nervous system activity and increase prostaglandin synthesis. They cause mainly vasodilation and mild natriuresis without affecting heart rate and contractility. (See all compounds classified as Angiotensin-Converting Enzyme Inhibitors.)', 'Drugs used in the treatment of acute or chronic vascular HYPERTENSION regardless of pharmacological mechanism. Among the antihypertensive agents are DIURETICS; (especially DIURETICS, THIAZIDE); ADRENERGIC BETA-ANTAGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; GANGLIONIC BLOCKERS; and VASODILATOR AGENTS. (See all compounds classified as Antihypertensive Agents.)']",,,
6329,56330,Cilazapril,CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@H]2CCCN3CCC[C@H](N3C2=O)C(=O)O,['Cilazapril is an ACE inhibtor class drug used in the treatment of hypertension and heart failure.'],"['Cilazapril inhibits the production angiotensin II. By doing so, it decreases sodium and water reabsorption (via aldosterone) and it decreases vasoconstriction. The combined effect of this is a decrease in vascular resistance, and therefore, blood pressure. The absolute bioavailability of cilazaprilat after oral administration of cilazapril is 57% based on urinary recovery data. (The absolute bioavailability of cilazaprilat after oral administration of cilazaprilat is 19%.) Ingestion of food immediately before the administration of cilazapril reduces the average peak plasma concentration of cilazaprilat by 29%, delays the peak by one hour and reduces the bioavailability of cilazaprilat by 14%. These pharmacokinetic changes have little influence on plasma ACE inhibition.']","['A class of drugs whose main indications are the treatment of hypertension and heart failure. They exert their hemodynamic effect mainly by inhibiting the renin-angiotensin system. They also modulate sympathetic nervous system activity and increase prostaglandin synthesis. They cause mainly vasodilation and mild natriuresis without affecting heart rate and contractility. (See all compounds classified as Angiotensin-Converting Enzyme Inhibitors.)', 'Drugs used in the treatment of acute or chronic vascular HYPERTENSION regardless of pharmacological mechanism. Among the antihypertensive agents are DIURETICS; (especially DIURETICS, THIAZIDE); ADRENERGIC BETA-ANTAGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; GANGLIONIC BLOCKERS; and VASODILATOR AGENTS. (See all compounds classified as Antihypertensive Agents.)']","['Maximum plasma concentrations of cilazaprilat are reached within two hours after administration of cilazapril.', 'Cilazaprilat is eliminated unchanged by the kidneys. The total urinary recovery of cilazaprilat after intravenous administration of 2.5 mg is 91%.', 'Total clearance is 12.3 L/h and renal clearance is 10.8 L/h. The total urinary recovery of cilazaprilat following the oral administration of 2.5 mg cilazapril is 52.6%.']",,['Half-lives for the periods 1 to 4 hours and 1 to 7 days after the intravenous administration of 2.5 mg cilazaprilat are 0.90 and 46.2 hours respectively.']
6330,56331,"2-Azaspiro(4.4)nonane-1,3-dione, 2-propyl-",CCCN1C(=O)CC2(C1=O)CCCC2,,,,,,
6331,56332,alpha-(1-Aminoethyl)-2-methoxy-5-methylbenzyl alcohol hydrochloride,CC1=CC(=C(C=C1)OC)C(C(C)[NH3+])O.[Cl-],,,,,,
6332,56333,2-Amino-1-(2-methoxy-5-methylphenyl)propan-1-ol,CC1=CC(=C(C=C1)OC)C(C(C)N)O,,,,,,
6333,56334,CID 56334,CN(C)C1=CC=C(C=C1)C=NNS(=O)(=O)N(CCCl)CCCl,,,,,,
6334,56335,N-Benzyl-N-(2-chloroethyl)-beta-alanine methyl ester hydrochloride,COC(=O)CC[NH+](CCCl)CC1=CC=CC=C1.[Cl-],,,,,,
6335,56336,"beta-Alanine, N-benzyl-N-(2-chloroethyl)-, methyl ester",COC(=O)CCN(CCCl)CC1=CC=CC=C1,,,,,,
6336,56337,2-(Methyl(2-oxo-3-bornyl)amino)acetamide,CC1(C2CCC1(C(=O)C2CNCC(=O)N)C)C,,,,,,
6337,56338,Fosphenytoin sodium,C1=CC=C(C=C1)C2(C(=O)N(C(=O)N2)COP(=O)([O-])[O-])C3=CC=CC=C3.[Na+].[Na+],,,"['A class of drugs that act by inhibition of sodium influx through cell membranes. Blockade of sodium channels slows the rate and amplitude of initial rapid depolarization, reduces cell excitability, and reduces conduction velocity. (See all compounds classified as Sodium Channel Blockers.)', 'Drugs used to prevent SEIZURES or reduce their severity. (See all compounds classified as Anticonvulsants.)']",,,
6338,56339,Fosphenytoin,C1=CC=C(C=C1)C2(C(=O)N(C(=O)N2)COP(=O)(O)O)C3=CC=CC=C3,"['Fosphenytoin is indicated for the treatment of generalized tonic-clonic status epilepticus and for the prevention and treatment of seizures occurring during neurosurgery in adult patients. It can also be substituted, short-term, for oral phenytoin in patients aged two years and older when oral phenytoin administration is not possible.']","['Fosphenytoin is a water-soluble phenytoin prodrug used for the treatment of epileptic seizures. Following parenteral administration of fosphenytoin, fosphenytoin is converted to the anticonvulsant phenytoin by endogenous phosphatases. Each 1.5 mg of fosphenytoin sodium is equivalent to 1.0mg of phenytoin sodium (PE equivalents); care should be taken to calculate the dose required in PE equivalents properly. Serious adverse effects such as Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS), Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis (SJS/TEN), and hematopoietic complications may occur and indicate an alternate antiepileptic should be used. Withdrawal of fosphenytoin sodium may precipitate seizures and should be done gradually.']","['Drugs used to prevent SEIZURES or reduce their severity. (See all compounds classified as Anticonvulsants.)', 'A class of drugs that act by inhibition of sodium influx through cell membranes. Blockade of sodium channels slows the rate and amplitude of initial rapid depolarization, reduces cell excitability, and reduces conduction velocity. (See all compounds classified as Sodium Channel Blockers.)']","['Fosphenytoin at 15 to 20 mg PE/kg infused at 100 to 150 mg PE/min intravenously yields free plasma phenytoin concentrations similar to an equivalent dose of phenytoin sodium administered at 50 mg/min. Single intravenous administration of fosphenytoin shows a linear increase in mean maximum total phenytoin concentration while the mean maximum unbound phenytoin concentrations increase with both dose and infusion rate. Fosphenytoin is rapidly converted to phenytoin following intravenous administration with a half-life of 15 minutes; if administered intramuscularly, the peak plasma phenytoin concentration is not reached until three hours.', 'Phenytoin derived from fosphenytoin administration is excreted in the urine primarily as 5-(p-hydroxyphenyl)-5-phenylhydantoin and its glucuronide. There is little unchanged phenytoin (1%–5% of the administered dose), and essentially no fosphenytoin recovered in urine.', 'The volume of distribution of fosphenytoin increases with dose and rate, ranging between 4.3 and 10.8 L.', 'Bioavailability from either intravenous or intramuscular route is essentially 100%.', '/Fosphenytoin is/ most likely distributed in humans to heart, kidneys, small intestine, liver, lungs, spleen, where it is hydrolyzed by phosphatases to phenytoin. Predominately distributed in the central (plasma) compartment.', 'The volume of distribution ranges from 4.3 to 10.8 liters, and increases with increasing dose and administration rate of fosphenytoin.', 'Protein binding is very high (95 to 99%); degree of binding is saturable, with the result that the percent bound decreases as the total plasma fosphenytoin concentration increases.', 'For more Absorption, Distribution and Excretion (Complete) data for FOSPHENYTOIN (10 total), please visit the HSDB record page.']","['Fosphenytoin is metabolized, likely by phosphatases, to phenytoin, phosphate, and formaldehyde; the formaldehyde is subsequently converted into formate. The phenytoin produced is metabolized hepatically by CYP2C9 and, to a lesser extent, by CYP2C19.', 'Fosphenytoin undergoes rapid hydrolysis to phenytoin. ... Conversion of fosphenytoin also yields two additional metabolites, phosphate and formaldehyde. Formaldehyde is subsequently converted to formate, which in turn is metabolized via a folate-dependent mechanism. ... Phosphatase enzymes probably play a major role in the conversion of fosphenytoin to phenytoin.', 'This investigation was undertaken to identify the structure of a novel immunoreactive metabolite derived from fosphenytoin that has been hypothesized previously as present in sera from renally impaired patients receiving this prodrug. The metabolite was isolated from uremic sera using solid-phase extraction and HPLC. Structural analysis was performed using HPLC-tandem mass spectrometry, nuclear magnetic resonance (NMR), deuterium exchange, and chemical derivatization. Immunoreactivity was evaluated using a fluorescence polarization immunoassay. The metabolite had a parent ion at m/z 457 in the negative-ion mode and fragmented to yield the m/z 251 of phenytoin, as well as other mass fragments of phenytoin. Mass fragments associated with glucuronic acid were also present. The chromatographic peak corresponding to this metabolite demonstrated immunoreactivity sufficient to lead to falsely increased reported values for phenytoin immunoassays. The observed immunoreactivity was also proportional to the relative concentration of the metabolite in collected fractions. Analysis by NMR indicated the presence of phenyl groups with chemical shifts identical to those of phenytoin, as well as the presence of a methylene bridge, which was consistent with the same methylene bridge present on the phosphate ester of fosphenytoin. Comparative analysis of serum samples from renally impaired patients receiving phenytoin vs fosphenytoin using multiple reaction monitoring quantification demonstrated that this metabolite was associated with fosphenytoin administration. A unique immunoreactive oxymethylglucuronide metabolite derived from fosphenytoin has been isolated from sera from uremic patients receiving this prodrug.', 'Fosphenytoin sodium is a hydantoin-derivative anticonvulsant. Fosphenytoin sodium, a water-soluble phosphate ester of phenytoin, is a prodrug and has little, if any, anticonvulsant activity until hydrolyzed in vivo to phenytoin. Pharmacologic effects of fosphenytoin include those of phenytoin.']","['Fosphenytoin has a conversion half-life of approximately 15 minutes. The resulting phenytoin has a wide range of mean total half-life values (12 to 28.9 hours), with longer half-life times at higher administered doses.', 'A single dose of fosphenytoin (250 mg over a period of 30 min) was administered to subjects with hepatic cirrhosis (n = 4), renal disease requiring maintenance hemodialysis (n = 4), and healthy controls (n = 4).  The half-life of fosphenytoin was 4.5, 9.2, and 9.5 min for the three groups, respectively.', 'The conversion half-life /of fosphenytoin/ to phenytoin ranges from 8 to 15 minutes. This value is independent of dose, infusion rate, or plasma concentration of either fosphenytoin or phenytoin. The elimination half-life of fosphenytoin after intravenous or intramuscular injection is also independent of dose.']"
6339,56340,"Acridine, 9-((4-aminobutyl)amino)-",C1=CC=C2C(=C1)C(=C3C=CC=CC3=N2)NCCCCN,,,,,,
6340,56341,"BENZ(c)ACRIDINE, 10,11-DIHYDRO-7-METHYL-",CC1=C2C=CC3=CC=CC=C3C2=NC4=C1C=CCC4,,,,,,
6341,56342,"BENZ(c)ACRIDINE, 8,9-DIHYDRO-7-METHYL-",CC1=C2C=CC3=CC=CC=C3C2=NC4=C1CCC=C4,,,,,,
6342,56343,"BENZ(c)ACRIDINE, 3,4-DIHYDRO-7-METHYL-",CC1=C2C=CC3=C(C2=NC4=CC=CC=C14)C=CCC3,,,,,,
6343,56344,"BENZ(c)ACRIDINE, 1,2-DIHYDRO-7-METHYL-",CC1=C2C=CC3=C(C2=NC4=CC=CC=C14)CCC=C3,,,,,,
6344,56345,"trans-3,4-Dihydro-3,4-dihydroxy-7-methylbenz(c)acridine",CC1=C2C=CC3=C(C2=NC4=CC=CC=C14)C=C[C@H]([C@@H]3O)O,,,,,,
6345,56346,2-chloro-N-(2-chloroethyl)-N-(1-phenylethylideneamino)ethanamine,CC(=NN(CCCl)CCCl)C1=CC=CC=C1,,,,,,
6346,56347,"4,5-Bis(pentyloxy)-2-imidazolidinone",CCCCCOC1C(NC(=O)N1)OCCCCC,,,,,,
6347,56348,CID 56348,CC=NN(C1=CC=CC(=N1)C)C(=O)C2=CC=NC=C2,,,,,,
6348,56349,CID 56349,CC1=NC(=CC=C1)CC=NNC(=O)C2=CN=CC=C2,,,,,,
6349,56350,"2,3-Dihydro-N,2-diethyl-3-benzofuranmethylamine",CCC1C(C2=CC=CC=C2O1)CNCC,,,,,,
6350,56351,"2-Azaspiro(4.6)undecane-1,3-dione, 2-allyl-",C=CCN1C(=O)CC2(C1=O)CCCCCC2,,,,,,
6351,56352,"Carbamic acid, isopropyl-, 3-phenylpropyl ester",CC(C)NC(=O)OCCCC1=CC=CC=C1,,,,,,
6352,56353,"Carbamic acid, propyl-, 3-phenylpropyl ester",CCCNC(=O)OCCCC1=CC=CC=C1,,,,,,
6353,56354,p-Ethoxybenzoic acid 2-(ethylamino)ethyl ester hydrochloride,CC[NH2+]CCOC(=O)C1=CC=C(C=C1)OCC.[Cl-],,,,,,
6354,56355,2-(Ethylamino)ethyl 4-ethoxybenzoate,CCNCCOC(=O)C1=CC=C(C=C1)OCC,,,,,,
6355,56356,Bis(2-chloroethyl)ethoxymethylammonium iodide,CCO[N+](C)(CCCl)CCCl.[I-],,,,,,
6356,56357,Bis(2-chloroethyl)-ethoxy-methylazanium,CCO[N+](C)(CCCl)CCCl,,,,,,
6357,56358,Diethyl(2-guanidinoethyl)methylammonium iodide hydriodide,CC[N+](C)(CC)CC[NH+]=C(N)N.[I-].[I-],,,,,,
6358,56359,2-(Diaminomethylideneamino)ethyl-diethyl-methylazanium,CC[N+](C)(CC)CCN=C(N)N,,,,,,
6359,56360,(3-Cyanopropyl)trimethylammonium iodide,C[N+](C)(C)CCCC#N.[I-],,,,,,
6360,56361,3-Cyanopropyltrimethylaminium,C[N+](C)(C)CCCC#N,,,,,,
6361,56362,(2-Cyanoethyl)(2-hydroxyethyl)dimethylammonium bromide,C[N+](C)(CCC#N)CCO.[Br-],,,,,,
6362,56363,2-Cyanoethyl-(2-hydroxyethyl)-dimethylazanium,C[N+](C)(CCC#N)CCO,,,,,,
6363,56364,"1-Chloro-3,5,8,8-tetramethyl-3-azabicyclo(3.2.1)octane hydrochloride",CC1(C2(CCC1(C[NH+](C2)C)Cl)C)C.[Cl-],,,,,,
6364,56365,"1-Chloro-3,5,8,8-tetramethyl-3-azabicyclo[3.2.1]octane",CC1(C2(CCC1(CN(C2)C)Cl)C)C,,,,,,
6365,56366,CID 56366,CC[NH+](CC)CC1=C2C(=CC=C(O2)O)C=C(C1=O)O.[Cl-],,,,,,
6366,56367,CID 56367,CCN(CC)CC1=C2C(=CC=C(O2)O)C=C(C1=O)O,,,,,,
6367,56368,"Acetic acid, (3-(hexyloxy)-2,4,6-triiodophenoxy)-",CCCCCCOC1=C(C(=C(C=C1I)I)OCC(=O)O)I,,,,,,
6368,56369,"NAPHTHO(2,1-b)FURAN-1-ACETIC ACID, 2-NITRO-",C1=CC=C2C(=C1)C=CC3=C2C(=C(O3)[N+](=O)[O-])CC(=O)O,,,,,,
6369,56370,"NAPHTHO(2,1-b)FURAN-7-CARBOXYLIC ACID, 2-NITRO-",C1=CC2=C(C=CC3=C2C=C(O3)[N+](=O)[O-])C=C1C(=O)O,,,,,,
6370,56371,"NAPHTHO(2,1-b)FURAN-7-ACETIC ACID, 2-NITRO-, METHYL ESTER",COC(=O)CC1=CC2=C(C=C1)C3=C(C=C2)OC(=C3)[N+](=O)[O-],,,,,,
6371,56372,"ACETIC ACID, ((2-NITRONAPHTHO(2,1-b)FURAN-7-YL)OXY)-, ETHYL ESTER",CCOC(=O)COC1=CC=CC2=C1C=CC3=C2C=C(O3)[N+](=O)[O-],,,,,,
6372,56373,"NAPHTHO(2,1-b)FURAN-1-ACETIC ACID, 2-NITRO-, METHYL ESTER",COC(=O)CC1=C(OC2=C1C3=CC=CC=C3C=C2)[N+](=O)[O-],,,,,,
6373,56374,"NAPHTHO(2,1-b)FURAN-7-ACETIC ACID, 2-NITRO-",C1=CC2=C(C=CC3=C2C=C(O3)[N+](=O)[O-])C=C1CC(=O)O,,,,,,
6374,56375,2-(diethylamino)-1-(1H-indol-3-yl)ethanone,CCN(CC)CC(=O)C1=CNC2=CC=CC=C21,,,,,,
6375,56376,CID 56376,CN(C)CCC1C(=O)N=C(N(C1=O)C2=CC=C(C=C2)Cl)S,,,,,,
6376,56377,"Acetanilide, 2'-bromo-2-(diethylamino)-5'-ethyl-",CCC1=CC(=C(C=C1)Br)NC(=O)CN(CC)CC,,,,,,
6377,56378,(p-Iodophenoxy)acetic acid 2-(diethylamino)ethyl ester hydrochloride,CC[NH+](CC)CCOC(=O)COC1=CC=C(C=C1)I.[Cl-],,,,,,
6378,56379,2-(Diethylamino)ethyl 2-(4-iodophenoxy)acetate,CCN(CC)CCOC(=O)COC1=CC=C(C=C1)I,,,,,,
6379,56380,CID 56380,C1=CC=C(C(=C1)CN=C(N)N[NH3+])Cl.[I-],,,,,,
6380,56381,N-[(2-Chlorophenyl)methyl]hydrazinecarboximidamide,C1=CC=C(C(=C1)CN=C(N)NN)Cl,,,,,,
6381,56382,"BUTYRIC ACID, 4-(p-(BIS(2-CHLOROETHYL)AMINO)PHENOXY)-",C1=CC(=CC=C1N(CCCl)CCCl)OCCCC(=O)O,,,,,,
6382,56383,"2,3-Dihydro-2-ethyl-N-(2-methoxyethyl)-3-benzofuranmethylamine",CCC1C(C2=CC=CC=C2O1)CNCCOC,,,,,,
6383,56384,"1,2,3,4-Tetrahydro-6,7-dimethoxy-2-propylisoquinoline hydrochloride",CCC[NH+]1CCC2=CC(=C(C=C2C1)OC)OC.[Cl-],,,,,,
6384,56385,"6,7-Dimethoxy-2-propyl-1,2,3,4-tetrahydroisoquinoline",CCCN1CCC2=CC(=C(C=C2C1)OC)OC,,,,,,
6385,56386,p-Ethoxybenzoic acid 2-(isopropylamino)ethyl ester hydrochloride,CCOC1=CC=C(C=C1)C(=O)OCC[NH2+]C(C)C.[Cl-],,,,,,
6386,56387,4-Ethoxybenzoic acid 2-(isopropylamino)ethyl ester,CCOC1=CC=C(C=C1)C(=O)OCCNC(C)C,,,,,,
6387,56388,"N,O-Dimethyl-2-(2-methoxy-4-propylphenoxy)acetohydroxamic acid",CCCC1=CC(=C(C=C1)OCC(=O)N(C)OC)OC,,,,,,
6388,56389,"Isoxazole, 4-(2-butoxyethyl)-5-(2-(dimethylamino)acetamido)-3-methyl-",CCCCOCCC1=C(ON=C1C)NC(=O)CN(C)C,,,,,,
6389,56390,"Isoxazole, 5-(2-(diethylamino)acetamido)-4-(2-ethoxyethyl)-3-methyl-",CCN(CC)CC(=O)NC1=C(C(=NO1)C)CCOCC,,,,,,
6390,56391,alpha-((2-(Isopropylmethylamino)ethoxy)methyl)benzyl alcohol hydrochloride,CC(C)[NH+](C)CCOCC(C1=CC=CC=C1)O.[Cl-],,,,,,
6391,56392,alpha-((2-(Isopropylmethylamino)ethoxy)methyl)benzyl alcohol,CC(C)N(C)CCOCC(C1=CC=CC=C1)O,,,,,,
6392,56393,N-(2-Oxo-3-bornyl)alanine methyl ester hydrochloride,CC(C(=O)OC)[NH2+]C1C2CCC(C1=O)(C2(C)C)C.[Cl-],,,,,,
6393,56394,"Methyl 2-[(4,7,7-trimethyl-3-oxo-2-bicyclo[2.2.1]heptanyl)amino]propanoate",CC(C(=O)OC)NC1C2CCC(C1=O)(C2(C)C)C,,,,,,
6394,56395,Bis(2-chloroethyl)(2-chloroethoxy)methylammonium chloride,C[N+](CCCl)(CCCl)OCCCl.[Cl-],,,,,,
6395,56396,2-Chloroethoxy-bis(2-chloroethyl)-methylazanium,C[N+](CCCl)(CCCl)OCCCl,,,,,,
6396,56397,"4-[(5-Methyl-1,3,4-thiadiazol-2-yl)amino]-4-oxobut-2-enoic acid",CC1=NN=C(S1)NC(=O)C=CC(=O)O,,,,,,
6397,56398,"1,3,4,8-Tetrachlorodibenzofuran",C1=CC2=C(C=C1Cl)C3=C(O2)C(=C(C=C3Cl)Cl)Cl,,,,,,
6398,56399,"1,3,4,6,7,9-Hexachlorodibenzofuran",C1=C(C2=C(C(=C1Cl)Cl)OC3=C2C(=CC(=C3Cl)Cl)Cl)Cl,,,,,,
6399,56400,"1,2,3,6,7,9-Hexachlorodibenzofuran",C1=C2C(=C(C(=C1Cl)Cl)Cl)C3=C(O2)C(=C(C=C3Cl)Cl)Cl,,,,,,
6400,56401,"Oxalic acid, bis(2-propylhydrazide)",CCCNNC(=O)C(=O)NNCCC,,,,,,
6401,56402,(2-Aminopropanoylamino)-bis(2-chloroethyl)azanium bromide,CC(C(=O)N[NH+](CCCl)CCCl)N.[Br-],,,,,,
6402,56403,"2-amino-N',N'-bis(2-chloroethyl)propanehydrazide",CC(C(=O)NN(CCCl)CCCl)N,,,,,,
6403,56404,"2-(2-Propynyl)-2-azaspiro(4.4)nonane-1,3-dione",C#CCN1C(=O)CC2(C1=O)CCCC2,,,,,,
6404,56405,"2-(Dimethylamino)-N-(alpha-methyl-3,4-(methylenedioxy)phenethyl)acetamide",CC(CC1=CC2=C(C=C1)OCO2)NC(=O)CN(C)C,,,,,,
6405,56406,p-((1-(Dimethylcarbamoyl)ethyl)amino)benzoic acid ethyl ester,CCOC(=O)C1=CC=C(C=C1)NC(C)C(=O)N(C)C,,,,,,
6406,56407,CID 56407,CCC(=NNC(=O)C1=CC=NC=C1)C2=CC=C(S2)C,,,,,,
6407,56408,N-[1-(5-methylthiophen-2-yl)propylideneamino]pyridine-3-carboxamide,CCC(=NNC(=O)C1=CN=CC=C1)C2=CC=C(S2)C,,,,,,
6408,56409,(3-Guanidinopropyl)trimethylammonium iodide hydriodide,C[N+](C)(C)CCC[NH+]=C(N)N.[I-].[I-],,,,,,
6409,56410,3-(Diaminomethylideneamino)propyl-trimethylazanium,C[N+](C)(C)CCCN=C(N)N,,,,,,
6410,56411,"Oxalic acid, bis(2-isopropylhydrazide)",CCCNNC(=O)C(=O)NNC(C)C,,,,,,
6411,56412,"1,8,8-Trimethyl-3-azabicyclo(3.2.1)octane-3-methanol hydrochloride",CC1(C2CCC1(C[NH+](C2)CO)C)C.[Cl-],,,,,,
6412,56413,"(1,8,8-Trimethyl-3-azabicyclo[3.2.1]octan-3-yl)methanol",CC1(C2CCC1(CN(C2)CO)C)C,,,,,,
6413,56414,"Acetanilide, 2-dimethylamino-N-(dimethylcarbamoylmethyl)-",CN(C)CC(=O)N(CC(=O)N(C)C)C1=CC=CC=C1,,,,,,
6414,56415,"Acetamide, N-(3-chloro-9H-fluoren-2-YL)-",CC(=O)NC1=C(C=C2C(=C1)CC3=CC=CC=C32)Cl,,,,,,
6415,56416,5-(p-Aminobenzamido)-4-(2-methoxyethyl)-3-methylisoxazole,CC1=NOC(=C1CCOC)NC(=O)C2=CC=C(C=C2)N,,,,,,
6416,56417,CID 56417,CCOC1=CC=C(C=C1)N2C(=O)C(C(=O)N=C2S)N(C)C,,,,,,
6417,56418,5-(Dimethylamino)-1-(p-ethoxyphenyl)barbituric acid,CCOC1=CC=C(C=C1)N2C(=O)C(C(=O)NC2=O)N(C)C,,,,,,
6418,56419,(4-Guanidinobutyl)trimethylammonium iodide hydriodide,C[N+](C)(C)CCCC[NH+]=C(N)N.[I-].[I-],,,,,,
6419,56420,4-(Diaminomethylideneamino)butyl-trimethylazanium,C[N+](C)(C)CCCCN=C(N)N,,,,,,
6420,56421,2-Allyl-2-azaspiro(4.4)nonane hydrochloride,C=CC[NH+]1CCC2(C1)CCCC2.[Cl-],,,,,,
6421,56422,2-Prop-2-enyl-2-azaspiro[4.4]nonane,C=CCN1CCC2(C1)CCCC2,,,,,,
6422,56423,"2-Anilino-N,N-diethylbutyramide",CCC(C(=O)N(CC)CC)NC1=CC=CC=C1,,,,,,
6423,56424,"ACETAMIDE, 2-(p-BUTOXYANILINO)-N,N-DIMETHYL-",CCCCOC1=CC=C(C=C1)NCC(=O)N(C)C,,,,,,
6424,56425,N-(2-(Dimethylamino)propyl)carbanilic acid ethyl ester,CCOC(=O)N(CC(C)N(C)C)C1=CC=CC=C1,,,,,,
6425,56426,"1(2H)-Naphthalenone, 3,4-dihydro-2-((dimethylamino)methyl)-4-methyl-, hydrochloride",CC1CC(C(=O)C2=CC=CC=C12)C[NH+](C)C.[Cl-],,,,,,
6426,56427,"2-[(dimethylamino)methyl]-4-methyl-3,4-dihydro-2H-naphthalen-1-one",CC1CC(C(=O)C2=CC=CC=C12)CN(C)C,,,,,,
6427,56428,"Acetohydroxamic acid, 2-(4-allyl-2-methoxyphenoxy)-N,O-dimethyl-",CN(C(=O)COC1=C(C=C(C=C1)CC=C)OC)OC,,,,,,
6428,56429,4-Dimethylamino-butyronitrile hydrochloride,C[NH+](C)CCCC#N.[Cl-],,,,,,
6429,56430,4-(Dimethylamino)butyronitrile,CN(C)CCCC#N,,,,,,
6430,56431,N-(3-(4-Ethoxyphenyl)-3-oxopropyl)-N-methylglycine hydrochloride,CCOC1=CC=C(C=C1)C(=O)CC[NH+](C)CC(=O)O.[Cl-],,,,,,
6431,56432,2-((3-(4-Ethoxyphenyl)-3-oxopropyl)(methyl)amino)acetic acid,CCOC1=CC=C(C=C1)C(=O)CCN(C)CC(=O)O,,,,,,
6432,56433,"Glycine, N-(N-(3-oxo-3-phenylpropoxy)glycyl)-",C1=CC=C(C=C1)C(=O)CCNCC(=O)NCC(=O)O,,,,,,
6433,56434,"Glycine, N-(N-(3-(4-chlorophenyl)-3-oxopropyl)glycyl)-",C1=CC(=CC=C1C(=O)CCNCC(=O)NCC(=O)O)Cl,,,,,,
6434,56435,"Glycine, N-(3-(4-chlorophenyl)-3-oxopropyl)-N-methyl-",CN(CCC(=O)C1=CC=C(C=C1)Cl)CC(=O)O,,,,,,
6435,56436,"2(3H)-Benzoxazolone, 6-(2-(4-(2-methoxyphenyl)-1-piperazinyl)ethyl)-3-methyl-",CN1C2=C(C=C(C=C2)CCN3CCN(CC3)C4=CC=CC=C4OC)OC1=O,,,,,,
6436,56437,1-(Dichloroacetyl)-3-(5-nitro-2-thiazolyl)-2-imidazolidinone,C1CN(C(=O)N1C2=NC=C(S2)[N+](=O)[O-])C(=O)C(Cl)Cl,,,,,,
6437,56438,N-(1-Anthraquinonyl)-N'-methyloxamide,CNC(=O)C(=O)NC1=CC=CC2=C1C(=O)C3=CC=CC=C3C2=O,,,,,,
6438,56439,"Oxamide, N-(1-anthraquinonyl)-N'-butyl-",CCCCNC(=O)C(=O)NC1=CC=CC2=C1C(=O)C3=CC=CC=C3C2=O,,,,,,
6439,56440,N-(1-Anthraquinonyl)-N'-cyclohexyloxamide,C1CCC(CC1)NC(=O)C(=O)NC2=CC=CC3=C2C(=O)C4=CC=CC=C4C3=O,,,,,,
6440,56441,N-(1-Anthraquinonyl)-N'-benzyloxamide,C1=CC=C(C=C1)CNC(=O)C(=O)NC2=CC=CC3=C2C(=O)C4=CC=CC=C4C3=O,,,,,,
6441,56442,N-(2-Anthraquinonyl)-N'-methyloxamide,CNC(=O)C(=O)NC1=CC2=C(C=C1)C(=O)C3=CC=CC=C3C2=O,,,,,,
6442,56443,N-(2-Anthraquinonyl)-N'-isopropyloxamide,CC(C)NC(=O)C(=O)NC1=CC2=C(C=C1)C(=O)C3=CC=CC=C3C2=O,,,,,,
6443,56444,"Oxamide, N-(2-anthraquinonyl)-N'-benzyl-",C1=CC=C(C=C1)CNC(=O)C(=O)NC2=CC3=C(C=C2)C(=O)C4=CC=CC=C4C3=O,,,,,,
6444,56445,"Oxamide, N-(2-anthraquinonyl)-N'-(2-hydroxyethyl)-",C1=CC=C2C(=C1)C(=O)C3=C(C2=O)C=C(C=C3)NC(=O)C(=O)NCCO,,,,,,
6445,56446,2-(1H-Benzimidazol-2-yl)-N-((2-phenyl-1H-indol-3-yl)methylene)benzenamine,C1=CC=C(C=C1)C2=C(C3=CC=CC=C3N2)C=NC4=CC=CC=C4C5=NC6=CC=CC=C6N5,,,,,,
6446,56447,2-(1H-Benzimidazol-2-yl)-N-((2-(4-methylphenyl)-1H-indol-3-yl)methylene)benzenamine,CC1=CC=C(C=C1)C2=C(C3=CC=CC=C3N2)C=NC4=CC=CC=C4C5=NC6=CC=CC=C6N5,,,,,,
6447,56448,2-(1H-Benzimidazol-2-yl)-N-((2-(4-methoxyphenyl)-1H-indol-3-yl)methylene)benzenamine,COC1=CC=C(C=C1)C2=C(C3=CC=CC=C3N2)C=NC4=CC=CC=C4C5=NC6=CC=CC=C6N5,,,,,,
6448,56449,2-(1H-Benzimidazol-2-yl)-N-((2-(4-chlorophenyl)-1H-indol-3-yl)methylene)benzenamine,C1=CC=C2C(=C1)C(=C(N2)C3=CC=C(C=C3)Cl)C=NC4=CC=CC=C4C5=NC6=CC=CC=C6N5,,,,,,
6449,56450,3-(1H-Benzimidazol-2-yl)-N-((2-phenyl-1H-indol-3-yl)methylene)benzenamine,C1=CC=C(C=C1)C2=C(C3=CC=CC=C3N2)C=NC4=CC=CC(=C4)C5=NC6=CC=CC=C6N5,,,,,,
6450,56451,3-(1H-Benzimidazol-2-yl)-N-((2-(4-methylphenyl)-1H-indol-3-yl)methylene)benzenamine,CC1=CC=C(C=C1)C2=C(C3=CC=CC=C3N2)C=NC4=CC=CC(=C4)C5=NC6=CC=CC=C6N5,,,,,,
6451,56452,3-(1H-Benzimidazol-2-yl)-N-((2-(4-methoxyphenyl)-1H-indol-3-yl)methylene)benzenamine,COC1=CC=C(C=C1)C2=C(C3=CC=CC=C3N2)C=NC4=CC=CC(=C4)C5=NC6=CC=CC=C6N5,,,,,,
6452,56453,3-(1H-Benzimidazol-2-yl)-N-((2-(4-chlorophenyl)-1H-indol-3-yl)methylene)benzenamine,C1=CC=C2C(=C1)C(=C(N2)C3=CC=C(C=C3)Cl)C=NC4=CC=CC(=C4)C5=NC6=CC=CC=C6N5,,,,,,
6453,56454,4-(1H-Benzimidazol-2-yl)-N-((2-phenyl-1H-indol-3-yl)methylene)benzenamine,C1=CC=C(C=C1)C2=C(C3=CC=CC=C3N2)C=NC4=CC=C(C=C4)C5=NC6=CC=CC=C6N5,,,,,,
6454,56455,4-(1H-Benzimidazol-2-yl)-N-((2-(4-methylphenyl)-1H-indol-3-yl)methylene)benzenamine,CC1=CC=C(C=C1)C2=C(C3=CC=CC=C3N2)C=NC4=CC=C(C=C4)C5=NC6=CC=CC=C6N5,,,,,,
6455,56456,4-(1H-Benzimidazol-2-yl)-N-((2-(4-methoxyphenyl)-1H-indol-3-yl)methylene)benzenamine,COC1=CC=C(C=C1)C2=C(C3=CC=CC=C3N2)C=NC4=CC=C(C=C4)C5=NC6=CC=CC=C6N5,,,,,,
6456,56457,4-(1H-Benzimidazol-2-yl)-N-((2-(4-chlorophenyl)-1H-indol-3-yl)methylene)benzenamine,C1=CC=C2C(=C1)C(=C(N2)C3=CC=C(C=C3)Cl)C=NC4=CC=C(C=C4)C5=NC6=CC=CC=C6N5,,,,,,
6457,56458,N-[(5-methylfuran-2-yl)methylideneamino]pyridine-4-carboxamide,CC1=CC=C(O1)C=NNC(=O)C2=CC=NC=C2,,,,,,
6458,56459,"1,3-Diallyl-5-phenylhydantoin",C=CCN1C(C(=O)N(C1=O)CC=C)C2=CC=CC=C2,,,,,,
6459,56460,6-(2-(Cyclopropylamino)ethyl)-3-methyl-2(3H)-benzoxazolone hydrobromide,CN1C2=C(C=C(C=C2)CC[NH2+]C3CC3)OC1=O.[Br-],,,,,,
6460,56461,"6-[2-(Cyclopropylamino)ethyl]-3-methyl-1,3-benzoxazol-2-one",CN1C2=C(C=C(C=C2)CCNC3CC3)OC1=O,,,,,,
6461,56462,"2(3H)-Benzoxazolone, 6-(2-(4-(2-pyrimidinyl)-1-piperazinyl)ethyl)-",C1CN(CCN1CCC2=CC3=C(C=C2)NC(=O)O3)C4=NC=CC=N4,,,,,,
6462,56463,Pravadoline,CC1=C(C2=CC=CC=C2N1CCN3CCOCC3)C(=O)C4=CC=C(C=C4)OC,,,,,,
6463,56464,Allylhydroxypropylhomophthalimide,CC(CC(C=C)C1C2=CC=CC=C2C(=O)NC1=O)O,,,,,,
6464,56465,"Acetanilide, 4'-(allyloxy)-N-(dimethylcarbamoylmethyl)-",CC(=O)N(CC(=O)N(C)C)C1=CC=C(C=C1)OCC=C,,,,,,
6465,56466,N-Acetyl-N-(dimethylcarbamoylmethyl)anthranilic acid ethyl ester,CCOC(=O)C1=CC=CC=C1N(CC(=O)N(C)C)C(=O)C,,,,,,
6466,56467,"3-ISOXAZOLECARBOXYLIC ACID, 5-METHYL-, 2-(p-ISOPROPYLBENZYL)HYDRAZIDE",CC1=CC(=NO1)C(=O)NNCC2=CC=C(C=C2)C(C)C,,,,,,
6467,56468,CID 56468,CCN(CC)C1C(=O)N=C(N(C1=O)C2=CC=C(C=C2)OC)S,,,,,,
6468,56469,CID 56469,CC[NH+](CC)CC1=C2C(=C(C=C(O2)O)C)C=C(C1=O)O.[Cl-],,,,,,
6469,56470,CID 56470,CCN(CC)CC1=C2C(=C(C=C(O2)O)C)C=C(C1=O)O,,,,,,
6470,56471,"3-Isoxazolecarboxylic acid, 5-methyl-, 2-propylhydrazide",CCCNNC(=O)C1=NOC(=C1)C,,,,,,
6471,56472,"Isophthalamic acid, N-(2-(diethylamino)ethyl)-6-hydroxy-5-nitro-, methyl ester",CCN(CC)CCNC(=O)C1=C(C(=CC(=C1)C(=O)OC)[N+](=O)[O-])O,,,,,,
6472,56473,"Acetanilide, N-(dimethylcarbamoylmethyl)-4'-isopropoxy-",CC(C)OC1=CC=C(C=C1)N(CC(=O)N(C)C)C(=O)C,,,,,,
6473,56474,"Acetanilide, N-(dimethylcarbamoylmethyl)-2'-propoxy-",CCCOC1=CC=CC=C1N(CC(=O)N(C)C)C(=O)C,,,,,,
6474,56475,"Acetanilide, N-(dimethylcarbamoylmethyl)-4'-propoxy-",CCCOC1=CC=C(C=C1)N(CC(=O)N(C)C)C(=O)C,,,,,,
6475,56476,"3-Benzofuranmethylamine, 2-ethyl-N-(3-methoxypropyl)-",CCC1=C(C2=CC=CC=C2O1)CNCCCOC,,,,,,
6476,56477,"2,3-Dimethylbenzoic acid 2-(diethylamino)ethyl ester hydrochloride",CC[NH+](CC)CCOC(=O)C1=CC=CC(=C1C)C.[Cl-],,,,,,
6477,56478,"2-(Diethylamino)ethyl 2,3-dimethylbenzoate",CCN(CC)CCOC(=O)C1=CC=CC(=C1C)C,,,,,,
6478,56479,"2,5-Dimethylbenzoic acid 2-(diethylamino)ethyl ester hydrochloride",CC[NH+](CC)CCOC(=O)C1=C(C=CC(=C1)C)C.[Cl-],,,,,,
6479,56480,"2-(Diethylamino)ethyl 2,5-dimethylbenzoate",CCN(CC)CCOC(=O)C1=C(C=CC(=C1)C)C,,,,,,
6480,56481,p-Ethoxybenzoic acid 2-(butylamino)ethyl ester hydrochloride,CCCC[NH2+]CCOC(=O)C1=CC=C(C=C1)OCC.[Cl-],,,,,,
6481,56482,2-(Butylamino)ethyl 4-ethoxybenzoate,CCCCNCCOC(=O)C1=CC=C(C=C1)OCC,,,,,,
6482,56483,p-Ethoxybenzoic acid 2-(isobutylamino)ethyl ester hydrochloride,CCOC1=CC=C(C=C1)C(=O)OCC[NH2+]CC(C)C.[Cl-],,,,,,
6483,56484,2-(2-Methylpropylamino)ethyl 4-ethoxybenzoate,CCOC1=CC=C(C=C1)C(=O)OCCNCC(C)C,,,,,,
6484,56485,"N-(4-Phenoxyethyl-1-piperazinomethyl)-1,4-benzodioxan-2-carboxamide dihydrochloride",C1CN(CCN1CCOC2=CC=CC=C2)CNC(=O)C3COC4=CC=CC=C4O3.Cl.Cl,,,,,,
6485,56486,"N-[[4-(2-phenoxyethyl)piperazin-1-yl]methyl]-2,3-dihydro-1,4-benzodioxine-3-carboxamide",C1CN(CCN1CCOC2=CC=CC=C2)CNC(=O)C3COC4=CC=CC=C4O3,,,,,,
6486,56487,Rogletimide,CCC1(CCC(=O)NC1=O)C2=CC=NC=C2,,,,,,
6487,56488,"3-Benzofuranmethylamine, N,2-diethyl-",CCC1=C(C2=CC=CC=C2O1)CNCC,,,,,,
6488,56489,"Malonic acid, ethyl(piperidinomethyl)-, diethyl ester",CCOC(=O)C(C(C)CN1CCCCC1)C(=O)OCC,,,,,,
6489,56490,2-(Dimethylamino)-N-(4-(2-ethoxyethyl)-3-methyl-5-isoxazolyl)-3-methylbutyramide,CCOCCC1=C(ON=C1C)NC(=O)C(C(C)C)N(C)C,,,,,,
6490,56491,"NAPHTHO(2,1-b)FURAN, 6-BROMO-7-METHOXY-2-NITRO-",COC1=C(C2=C(C=C1)C3=C(C=C2)OC(=C3)[N+](=O)[O-])Br,,,,,,
6491,56492,"NAPHTHO(2,1-b)FURAN, 8,9-DIMETHOXY-2-NITRO-",COC1=C(C2=C(C=CC3=C2C=C(O3)[N+](=O)[O-])C=C1)OC,,,,,,
6492,56493,"NAPHTHO(2,1-b)FURAN, 9-BROMO-8-METHOXY-2-NITRO-",COC1=C(C2=C(C=CC3=C2C=C(O3)[N+](=O)[O-])C=C1)Br,,,,,,
6493,56494,Fluorodopa (18F),C1=C(C(=CC(=C1O)O)[18F])C[C@@H](C(=O)O)N,['Fluorodopa F 18 is indicated for use with positron emission tomography (PET) to visualize dopaminergic nerve terminals in the striatum for the evaluation of adult patients with suspected Parkinsonian syndromes (PS).'],,,"['Approximately 80% of the administered radioactivity is eliminated in the urine.', 'The agent is cleared from blood and tissue within 24 hours following administration.']","['Fluorodopa F 18 is decarboxylated by aromatic amino acid decarboxylase (AADC) in the striatum to fluorodopamine F 18. Fluorodopamine F 18 is then further metabolized by monoamine oxidase (MAO) to yield [18F] 6-fluoro-3,4-dihydroxyphenylacetic acid, then subsequently by COMT to yield [18F]6-fluorohomovanillic acid.']",['The plasma half-life following intravenous administration is approximately 1-3 hours.']
6494,56495,(2-(3-Guanidinopropoxy)ethyl)trimethylammonium iodide hydriodide,C[N+](C)(C)CCOCCC[NH+]=C(N)N.[I-].[I-],,,,,,
6495,56496,2-[3-(Diaminomethylideneamino)propoxy]ethyl-trimethylazanium,C[N+](C)(C)CCOCCCN=C(N)N,,,,,,
6496,56497,1-Methyl-3-piperidyl phenyl(propynyl)glycolate,CC#CC(C1=CC=CC=C1)(C(=O)OC2CCCN(C2)C)O,,,,,,
6497,56498,(1-Methyl-4-piperidyl)methyl phenyl(1-propynyl)glycolate hydrochloride,CC#CC(C1=CC=CC=C1)(C(=O)OCC2CC[NH+](CC2)C)O.[Cl-],,,,,,
6498,56499,(1-Methylpiperidin-4-yl)methyl 2-hydroxy-2-phenylpent-3-ynoate,CC#CC(C1=CC=CC=C1)(C(=O)OCC2CCN(CC2)C)O,,,,,,
6499,56500,3-alpha-Tropanyl phenyl (1-propynyl)glycolate,CC#CC(C1=CC=CC=C1)(C(=O)OC2CC3CCC(C2)N3C)O,,,,,,
6500,56501,2-Methyl-3-quinuclidyl phenyl(1-butynyl)glycolate,CCC#CC(C1=CC=CC=C1)(C(=O)OC2C(N3CCC2CC3)C)O,,,,,,
6501,56502,alpha-Isopropenylmandelic acid 1-methyl-4-pyridyl ester,CC(=C)C(C1=CC=CC=C1)(C(=O)OC2CCN(CC2)C)O,,,,,,
6502,56503,alpha-Isopropenylmandelic acid 3-quinuclidinyl ester,CC(=C)C(C1=CC=CC=C1)(C(=O)OC2CN3CCC2CC3)O,,,,,,
6503,56504,CID 56504,CCCCC=CC(C1=CC=CC=C1)(C(=O)OC2=NC3=CC=CC=C3C=C2)O,,,,,,
6504,56505,1-Methyl-4-piperidyl phenyl(propargyl)glycolate,CN1CCC(CC1)OC(=O)C(CC#C)(C2=CC=CC=C2)O,,,,,,
6505,56506,1-Methyl-4-piperidyl phenyl(1-butynyl)glycolate,CCC#CC(C1=CC=CC=C1)(C(=O)OC2CCN(CC2)C)O,,,,,,
6506,56507,1-Methyl-4-piperidyl phenyl(1-pentynyl)glycolate,CCCC#CC(C1=CC=CC=C1)(C(=O)OC2CCN(CC2)C)O,,,,,,
6507,56508,"3-Octynoic acid, 2-hydroxy-2-phenyl-, 1-methyl-4-piperidyl ester",CCCCC#CC(C1=CC=CC=C1)(C(=O)ON2CCC(CC2)C)O,,,,,,
6508,56509,"3-Nonynoic acid, 2-hydroxy-2-phenyl-, 1-methyl-4-piperidyl ester",CCCCCC#CC(C1=CC=CC=C1)(C(=O)OC2CCN(CC2)C)O,,,,,,
6509,56510,2-Hydroxy-2-phenyl-3-nonynoic acid 3-quinuclidinyl ester,CCCCCC#CC(C1=CC=CC=C1)(C(=O)OC2CN3CCC2CC3)O,,,,,,
6510,56511,alpha-(1-Propynyl)cyclopropaneglycolic acid 3-quinuclidinyl ester,CC#CC(C1CC1)(C(=O)OC2CN3CCC2CC3)O,,,,,,
6511,56512,alpha-(Phenylethynyl)mandelic acid 3-quinuclidinyl ester,C1CN2CCC1C(C2)OC(=O)C(C#CC3=CC=CC=C3)(C4=CC=CC=C4)O,,,,,,
6512,56513,1-Methyl-4-piperidyl phenyl(phenylethynyl) glycolate,CN1CCC(CC1)OC(=O)C(C#CC2=CC=CC=C2)(C3=CC=CC=C3)O,,,,,,
6513,56514,alpha-Ethynylmandelic acid 1-methyl-4-piperidyl ester,CN1CCC(CC1)OC(=O)C(C#C)(C2=CC=CC=C2)O,,,,,,
6514,56515,5-(p-Bromophenyl)-3-(2-hydroxyethyl)-5-methylhydantoin,CC1(C(=O)N(C(=O)N1)CCO)C2=CC=C(C=C2)Br,,,,,,
6515,56516,"4,5-Diisobutoxy-2-imidazolidinone",CC(C)COC1C(NC(=O)N1)OCC(C)C,,,,,,
6516,56517,"3,4-Dihydro-7-chloro-2-(piperidinomethyl)-1(2H)-naphthalenone hydrochloride",C1CC[NH+](CC1)CC2CCC3=C(C2=O)C=C(C=C3)Cl.[Cl-],,,,,,
6517,56518,"7-chloro-2-(piperidin-1-ylmethyl)-3,4-dihydro-2H-naphthalen-1-one",C1CCN(CC1)CC2CCC3=C(C2=O)C=C(C=C3)Cl,,,,,,
6518,56519,CID 56519,CCN(CC)CCC1C(=O)N=C(N(C1=O)C2=CC=C(C=C2)Cl)S,,,,,,
6519,56520,"N,N-Dimethyl-p-((o-ethylphenyl)azo)aniline",CCC1=CC=CC=C1N=NC2=CC=C(C=C2)N(C)C,,,,,,
6520,56521,CID 56521,CC1=C2C=C(C(=O)C(=C2OC(=C1)O)C[NH+]3CCCCC3)O.[Cl-],,,,,,
6521,56522,CID 56522,CC1=C2C=C(C(=O)C(=C2OC(=C1)O)CN3CCCCC3)O,,,,,,
6522,56523,N-methyl-3-[3-(trifluoromethyl)phenyl]prop-2-enamide,CNC(=O)C=CC1=CC(=CC=C1)C(F)(F)F,,,,,,
6523,56524,N-ethyl-3-[3-(trifluoromethyl)phenyl]prop-2-enamide,CCNC(=O)C=CC1=CC(=CC=C1)C(F)(F)F,,,,,,
6524,56525,CID 56525,C1=CC(=CC(=C1)C(F)(F)F)C=CC(=O)NCCO,,,,,,
6525,56526,CID 56526,CCC(CNC(=O)C=CC1=CC(=CC=C1)C(F)(F)F)O,,,,,,
6526,56527,"N,N-dimethyl-3-[3-(trifluoromethyl)phenyl]prop-2-enamide",CN(C)C(=O)C=CC1=CC(=CC=C1)C(F)(F)F,,,,,,
6527,56528,CID 56528,CC(=CC1=CC(=CC=C1)C(F)(F)F)C(=O)NC,,,,,,
6528,56529,(p-Bromophenoxy)acetic acid 2-(dimethylamino)ethyl ester hydrochloride,C[NH+](C)CCOC(=O)COC1=CC=C(C=C1)Br.[Cl-],,,,,,
6529,56530,2-(Dimethylamino)ethyl (4-bromophenoxy)acetate,CN(C)CCOC(=O)COC1=CC=C(C=C1)Br,,,,,,
6530,56531,"Oxalic acid, hydrazide 2-isopropylhydrazide",CC(C)NNC(=O)C(=O)NN,,,,,,
6531,56532,CID 56532,CC=CCOC1=C(C=CC=C1C(=O)N)C,,,,,,
6532,56533,"Benzamide, 3-methyl-2-((2-methylallyl)oxy)-",CC1=C(C(=CC=C1)C(=O)N)OCC(=C)C,,,,,,
6533,56534,"p-Ethoxybenzoic acid, 2-(methylamino)ethyl ester hydrochloride",CCOC1=CC=C(C=C1)C(=O)OCC[NH2+]C.[Cl-],,,,,,
6534,56535,2-(Methylamino)ethyl 4-ethoxybenzoate,CCOC1=CC=C(C=C1)C(=O)OCCNC,,,,,,
6535,56536,CID 56536,CC=NN(C1=CC=CC=N1)C(=O)C2=CC=NC=C2,,,,,,
6536,56537,"Acetamide, N,N-diethyl-2-(N-methylanilino)-",CCN(CC)C(=O)CN(C)C1=CC=CC=C1,,,,,,
6537,56538,"Carbanilic acid, N-(2-(dimethylamino)ethyl)-, ethyl ester",CCOC(=O)N(CCN(C)C)C1=CC=CC=C1,,,,,,
6538,56539,5-(p-(Bis(2-chloroethyl)amino)phenethyl)-5-methylhydantoin,CC1(C(=O)NC(=O)N1)CCC2=CC=C(C=C2)N(CCCl)CCCl,,,,,,
6539,56540,"Mandelic acid, alpha-isopropenyl-, (1-methyl-1,2,3,6-tetrahydro-4-pyridyl)methyl ester",CC(=C)C(C1=CC=CC=C1)(C(=O)OCC2=CCN(CC2)C)O,,,,,,
6540,56541,"Mandelic acid, alpha-(1-cyclopentenyl)-, (1-methyl-1,2,3,6-tetrahydro-4-pyridyl)methyl ester",CN1CCC(=CC1)COC(=O)C(C2=CCCC2)(C3=CC=CC=C3)O,,,,,,
6541,56542,"Mandelic acid, alpha-(3-methylbut-1-yn-3-en-1-yl)-, (1-methyl-1,2,3,6-tetrahydro-4-pyridyl)methyl ester",CC(=C)C#CC(C1=CC=CC=C1)(C(=O)OCC2=CCN(CC2)C)O,,,,,,
6542,56543,"Mandelic acid, alpha-cyclopropyl-, 2-(1-methyl-1,2,5,6-tetrahydro-4-pyridyl)ethyl ester",CN1CCC(=CC1)CCOC(=O)C(C2CC2)(C3=CC=CC=C3)O,,,,,,
6543,56544,"Mandelic acid, alpha-isopropyl-, 2-(1-methyl-1,2,3,6-tetrahydro-4-pyridyl)ethyl ester",CC(C)C(C1=CC=CC=C1)(C(=O)OCCC2=CCN(CC2)C)O,,,,,,
6544,56545,"Mandelic acid, alpha-cyclopentyl-, 1,4-dimethyl-1,2,5,6-tetrahydro-3-pyridylmethyl ester",CC1=C(CN(CC1)C)COC(=O)C(C2CCCC2)(C3=CC=CC=C3)O,,,,,,
6545,56546,"Ethyl 1,4-dimethyl-1,2,5,6-tetrahydronicotinate hydrochloride",CCOC(=O)C1=C(CC[NH+](C1)C)C.[Cl-],,,,,,
6546,56547,"ethyl 1,4-dimethyl-3,6-dihydro-2H-pyridine-5-carboxylate",CCOC(=O)C1=C(CCN(C1)C)C,,,,,,
6547,56548,2-Tropidinemethyl alpha-isopropyl-alpha-phenylglycolate,CC(C)C(C1=CC=CC=C1)(C(=O)OCC2=CCC3CCC2N3C)O,,,,,,
6548,56549,2-(1-Azabicyclo(2.2.2)oct-2-ene)methyl-alpha-isopropyl-alpha-phenylglycolate hydrochloride,CC(C)C(C1=CC=CC=C1)(C(=O)OCC2=C[NH+]3CCC2CC3)O.[Cl-],,,,,,
6549,56550,1-Azabicyclo[2.2.2]oct-2-en-3-ylmethyl 2-hydroxy-3-methyl-2-phenylbutanoate,CC(C)C(C1=CC=CC=C1)(C(=O)OCC2=CN3CCC2CC3)O,,,,,,
6550,56551,"1-AZABICYCLO(2.2.2)OCTENE-3-METHANOL, BENZILATE (ester)",C1CN2CCC1C(=C2)COC(=O)C(C3=CC=CC=C3)(C4=CC=CC=C4)O,,,,,,
6551,56552,"Mandelic acid, alpha-(1-cyclopentenyl)-, (1-azabicyclo(2.2.2)oct-2-en-3-yl)methyl ester",C1CC=C(C1)C(C2=CC=CC=C2)(C(=O)OCC3=CN4CCC3CC4)O,,,,,,
6552,56553,"Mandelic acid, alpha-isopropenyl-, (1-azabicyclo(2.2.2)oct-2-en-3-yl)methyl ester",CC(=C)C(C1=CC=CC=C1)(C(=O)OCC2=CN3CCC2CC3)O,,,,,,
6553,56554,CID 56554,CC(C)C(C1=CC=CC=C1)(C(=O)OCC=C2CN3CCC2CC3)O,,,,,,
6554,56555,"4-(1-Methyl-1,2,3,6-tetrahydropyridyl)methyl isopropylphenylglycolate hydrochloride",CC(C)C(C1=CC=CC=C1)(C(=O)OCC2=CC[NH+](CC2)C)O.[Cl-],,,,,,
6555,56556,"(1-methyl-3,6-dihydro-2H-pyridin-4-yl)methyl 2-hydroxy-3-methyl-2-phenylbutanoate",CC(C)C(C1=CC=CC=C1)(C(=O)OCC2=CCN(CC2)C)O,,,,,,
6556,56557,Lodelaben,CCCCCCCCCCCCCCCCCC(C1=CC(=C(C=C1)C(=O)O)Cl)O,,,,,,
6557,56558,"Acetanilide, 2'-butoxy-N-(dimethylcarbamoylmethyl)-",CCCCOC1=CC=CC=C1N(CC(=O)N(C)C)C(=O)C,,,,,,
6558,56559,"Acetanilide, 4'-butoxy-N-(dimethylcarbamoylmethyl)-",CCCCOC1=CC=C(C=C1)N(CC(=O)N(C)C)C(=O)C,,,,,,
6559,56560,p-(2-(Butylamino)propionamido)benzoic acid ethyl ester,CCCCNC(C)C(=O)NC1=CC=C(C=C1)C(=O)OCC,,,,,,
6560,56561,"Carbanilic acid, N-(2-(diethylcarbamoyl)ethyl)-, ethyl ester",CCN(CC)C(=O)CCN(C1=CC=CC=C1)C(=O)OCC,,,,,,
6561,56562,N-(1-Methyl-2-morpholinoethyl)carbanilic acid ethyl ester,CCOC(=O)N(C1=CC=CC=C1)C(C)CN2CCOCC2,,,,,,
6562,56563,"Butyranilide, 2'-bromo-4-(diethylamino)-5'-ethyl-",CCC1=CC(=C(C=C1)Br)NC(=O)CCCN(CC)CC,,,,,,
6563,56564,alpha-((2-(Hexahydro-1H-azepin-1-yl)ethoxy)methyl)benzyl alcohol,C1CCCN(CC1)CCOCC(C2=CC=CC=C2)O,,,,,,
6564,56565,"Acetohydroxamic acid, N,O-diethyl-2-(2-methoxy-4-propylphenoxy)-",CCCC1=CC(=C(C=C1)OCC(=O)N(CC)OCC)OC,,,,,,
6565,56566,3-Allyl-2-[2-(diethylamino)ethoxy]benzaldehyde,CCN(CC)CCOC1=C(C=CC=C1C=O)CC=C,,,,,,
6566,56567,"Acetohydroxamic acid, 2-(4-allyl-2-methoxyphenoxy)-N,O-diethyl-",CCN(C(=O)COC1=C(C=C(C=C1)CC=C)OC)OCC,,,,,,
6567,56568,3-(2-(Diethylamino)ethyl)-5-methyl-5-phenylhydantoin,CCN(CC)CCN1C(=O)C(NC1=O)(C)C2=CC=CC=C2,,,,,,
6568,56569,CID 56569,CCN(CC)C1C(=O)N=C(N(C1=O)C2=CC=C(C=C2)OCC)S,,,,,,
6569,56570,CID 56570,CCOC1=CC=C(C=C1)N2C(=O)C(C(=O)N=C2S)CCN(C)C,,,,,,
6570,56571,5-(Diethylamino)-1-(p-ethoxyphenyl)barbituric acid,CCN(CC)C1C(=O)NC(=O)N(C1=O)C2=CC=C(C=C2)OCC,,,,,,
6571,56572,3-Benzyl-7-methyloctanoic acid,CC(C)CCCC(CC1=CC=CC=C1)CC(=O)O,,,,,,
6572,56573,"3,7-Dimethyl-7-phenyloctanoic acid",CC(CCCC(C)(C)C1=CC=CC=C1)CC(=O)O,,,,,,
6573,56574,"N,N-Dimethyl-2-(N-(2-oxo-3-bornyl)acetamido)acetamide",CC(=O)N(CC(=O)N(C)C)C1C2CCC(C1=O)(C2(C)C)C,,,,,,
6574,56575,CID 56575,CC(=CC(=O)O)CCCC(C)(C)C1=CC=CC=C1,,,,,,
6575,56576,(3-Cyanopropyl)dimethylethylammonium iodide,CC[N+](C)(C)CCCC#N.[I-],,,,,,
6576,56577,3-Cyanopropyl-ethyl-dimethylazanium,CC[N+](C)(C)CCCC#N,,,,,,
6577,56578,"1,2,3,4-Tetrahydro-1-(4-methoxyphenyl)-6-isoquinolinol hydrochloride",COC1=CC=C(C=C1)C2C3=C(CC[NH2+]2)C=C(C=C3)O.[Cl-],,,,,,
6578,56579,"1-(4-Methoxyphenyl)-1,2,3,4-tetrahydroisoquinoline-6-ol",COC1=CC=C(C=C1)C2C3=C(CCN2)C=C(C=C3)O,,,,,,
6579,56580,"4,6-Isoquinolinediol, 1,2,3,4-tetrahydro-1-methyl-2-(phenylmethyl)-, hydrochloride, hydrate",CC1C2=C(C=C(C=C2)O)C(C[NH+]1CC3=CC=CC=C3)O.[Cl-],,,,,,
6580,56581,"2-benzyl-1-methyl-3,4-dihydro-1H-isoquinoline-4,6-diol",CC1C2=C(C=C(C=C2)O)C(CN1CC3=CC=CC=C3)O,,,,,,
6581,56582,"4,6-Isoquinolinediol, 1,2,3,4-tetrahydro-1-(2-hydroxyphenyl)-2-(phenylmethyl)-, hydrochloride",C1C(C2=C(C=CC(=C2)O)C([NH+]1CC3=CC=CC=C3)C4=CC=CC=C4O)O.[Cl-],,,,,,
6582,56583,"2-benzyl-1-(2-hydroxyphenyl)-3,4-dihydro-1H-isoquinoline-4,6-diol",C1C(C2=C(C=CC(=C2)O)C(N1CC3=CC=CC=C3)C4=CC=CC=C4O)O,,,,,,
6583,56584,"4,6-Isoquinolinediol, 1,2,3,4-tetrahydro-1-(4-hydroxyphenyl)-2-(phenylmethyl)-, hydrochloride",C1C(C2=C(C=CC(=C2)O)C([NH+]1CC3=CC=CC=C3)C4=CC=C(C=C4)O)O.[Cl-],,,,,,
6584,56585,"2-benzyl-1-(4-hydroxyphenyl)-3,4-dihydro-1H-isoquinoline-4,6-diol",C1C(C2=C(C=CC(=C2)O)C(N1CC3=CC=CC=C3)C4=CC=C(C=C4)O)O,,,,,,
6585,56586,"1,2,3,4-Tetrahydro-2-(phenylmethyl)-1-(4-pyridinyl)-4,6-isoquinolinediol",C1C(C2=C(C=CC(=C2)O)C(N1CC3=CC=CC=C3)C4=CC=NC=C4)O,,,,,,
6586,56587,"1,2,3,4-Tetrahydro-1-(2-hydroxyphenyl)-4,6-isoquinolinediol",C1C(C2=C(C=CC(=C2)O)C(N1)C3=CC=CC=C3O)O,,,,,,
6587,56588,"1,2,3,4-Tetrahydro-1-(4-hydroxyphenyl)-4,6-isoquinolinediol hexanedioate",C1C(C2=C(C=CC(=C2)O)C([NH2+]1)C3=CC=C(C=C3)O)O.C(CCC(=O)[O-])CC(=O)O,,,,,,
6588,56589,"1-(4-Hydroxyphenyl)-1,2,3,4-tetrahydroisoquinoline-4,6-diol",C1C(C2=C(C=CC(=C2)O)C(N1)C3=CC=C(C=C3)O)O,,,,,,
6589,56590,"1,2,3,4-Tetrahydro-1-(2-hydroxyphenyl)-2-methyl-4,6-isoquinolinediol HCl hydrate (2:2:3)",C[NH+]1CC(C2=C(C1C3=CC=CC=C3O)C=CC(=C2)O)O.[Cl-],,,,,,
6590,56591,"1-(2-hydroxyphenyl)-2-methyl-3,4-dihydro-1H-isoquinoline-4,6-diol",CN1CC(C2=C(C1C3=CC=CC=C3O)C=CC(=C2)O)O,,,,,,
6591,56592,"4,6-Isoquinolinediol, 1,2,3,4-tetrahydro-1-(4-methoxyphenyl)-2-methyl-, hydrochloride, hydrate (2:2:1)",C[NH+]1CC(C2=C(C1C3=CC=C(C=C3)OC)C=CC(=C2)O)O.[Cl-],,,,,,
6592,56593,"1-(4-methoxyphenyl)-2-methyl-3,4-dihydro-1H-isoquinoline-4,6-diol",CN1CC(C2=C(C1C3=CC=C(C=C3)OC)C=CC(=C2)O)O,,,,,,
6593,56594,"6-Isoquinolinol, 1,2,3,4-tetrahydro-4-chloro-1-(2-hydroxyphenyl)-2-(phenylmethyl)-, hydrochloride",C1C(C2=C(C=CC(=C2)O)C([NH+]1CC3=CC=CC=C3)C4=CC=CC=C4O)Cl.[Cl-],,,,,,
6594,56595,"2-benzyl-4-chloro-1-(2-hydroxyphenyl)-3,4-dihydro-1H-isoquinolin-6-ol",C1C(C2=C(C=CC(=C2)O)C(N1CC3=CC=CC=C3)C4=CC=CC=C4O)Cl,,,,,,
6595,56596,"1,2,3,4-Tetrahydro-1-(2-hydroxyphenyl)-6-isoquinolinol hydrochloride",C1C[NH2+]C(C2=C1C=C(C=C2)O)C3=CC=CC=C3O.[Cl-],,,,,,
6596,56597,"1-(2-Hydroxyphenyl)-1,2,3,4-tetrahydroisoquinolin-6-ol",C1CNC(C2=C1C=C(C=C2)O)C3=CC=CC=C3O,,,,,,
6597,56598,CID 56598,CC(=O)C=COCC[N+](C)(C)C.[I-],,,,,,
6598,56599,CID 56599,CC(=O)C=COCC[N+](C)(C)C,,,,,,
6599,56600,(2-(2-Cyanoethoxy)ethyl)trimethylammonium iodide,C[N+](C)(C)CCOCCC#N.[I-],,,,,,
6600,56601,2-(2-Cyanoethoxy)ethyl-trimethylazanium,C[N+](C)(C)CCOCCC#N,,,,,,
6601,56602,CID 56602,COC1=C(C(=C(C=C1)C(CN)O)C(=O)[O-])OC.[Na+],,,,,,
6602,56603,"6-(2-Amino-1-hydroxyethyl)-2,3-dimethoxybenzoic acid",COC1=C(C(=C(C=C1)C(CN)O)C(=O)O)OC,,,,,,
6603,56604,(2-Bromoethyl)(3-cyanopropyl)dimethylammonium bromide,C[N+](C)(CCCC#N)CCBr.[Br-],,,,,,
6604,56605,2-Bromoethyl-(3-cyanopropyl)-dimethylazanium,C[N+](C)(CCCC#N)CCBr,,,,,,
6605,56606,(2-Cyanoethyl)(2-hydroxyethyl)dimethylammonium bromide acetate,CC(=O)OCC[N+](C)(C)CCC#N.[Br-],,,,,,
6606,56607,2-Acetyloxyethyl-(2-cyanoethyl)-dimethylazanium,CC(=O)OCC[N+](C)(C)CCC#N,,,,,,
6607,56608,Diethyl(3-guanidinopropyl)methylammonium iodide hydriodide,CC[N+](C)(CC)CCC[NH+]=C(N)N.[I-].[I-],,,,,,
6608,56609,3-(Diaminomethylideneamino)propyl-diethyl-methylazanium,CC[N+](C)(CC)CCCN=C(N)N,,,,,,
6609,56610,"2-Norbornanamine, 3,3-diethyl-N-methyl-, hydrochloride",CCC1(C2CCC(C2)C1[NH2+]C)CC.[Cl-],,,,,,
6610,56611,"3,3-diethyl-N-methylbicyclo[2.2.1]heptan-2-amine",CCC1(C2CCC(C2)C1NC)CC,,,,,,
6611,56612,"2,4-Imidazolidinedione, 5-(3-(bis(2-chloroethyl)amino)phenyl)-",C1=CC(=CC(=C1)N(CCCl)CCCl)C2C(=O)NC(=O)N2,,,,,,
6612,56613,"BARBITURIC ACID, 5-ALLYL-5-(m-CHLOROPHENYL)-",C=CCC1(C(=O)NC(=O)NC1=O)C2=CC(=CC=C2)Cl,,,,,,
6613,56614,alpha-((2-(Dimethylamino)propoxy)methyl)benzyl alcohol,CC(COCC(C1=CC=CC=C1)O)N(C)C,,,,,,
6614,56615,"Isonicotinamide, N-(2-methyl-5-phenylpyrrol-1-YL)-",CC1=CC=C(N1NC(=O)C2=CC=NC=C2)C3=CC=CC=C3,,,,,,
6615,56616,"Isoxazole, 5-(2-(diethylamino)acetamido)-4-(2-methoxyethyl)-3-methyl-",CCN(CC)CC(=O)NC1=C(C(=NO1)C)CCOC,,,,,,
6616,56617,CID 56617,C[NH+]1CC2CC3=CC=CC=C3SC4=CC=CC(=C24)C1.C(=CC(=O)[O-])C(=O)O,,,,,,
6617,56618,"2-methyl-2,3,12,12a-tetrahydro-1H-[1]benzothiepino[4,3,2-de]isoquinoline",CN1CC2CC3=CC=CC=C3SC4=CC=CC(=C24)C1,,,,,,
6618,56619,CID 56619,C1C2C[NH2+]CC3=C2C(=CC=C3)SC4=CC=CC=C41.C(=CC(=O)[O-])C(=O)O,,,,,,
6619,56620,"2-Thia-12-azatetracyclo[8.7.1.03,8.014,18]octadeca-1(17),3,5,7,14(18),15-hexaene",C1C2CNCC3=C2C(=CC=C3)SC4=CC=CC=C41,,,,,,
6620,56621,"1H-Benzimidazole-2-methanamine, N-(5-(ethylthio)-1,3,4-thiadiazol-2-YL)-",CCSC1=NN=C(S1)N(C)C2=NC3=CC=CC=C3N2,,,,,,
6621,56622,"1H-Benzimidazole-2-methanamine, N-(5-(propylthio)-1,3,4-thiadiazol-2-YL)-",CCCSC1=NN=C(S1)N(C)C2=NC3=CC=CC=C3N2,,,,,,
6622,56623,"1H-Benzimidazole-2-methanamine, N-(5-(methylsulfonyl)-1,3,4-thiadiazol-2-YL)-",CN(C1=NC2=CC=CC=C2N1)C3=NN=C(S3)S(=O)(=O)C,,,,,,
6623,56624,"1H-Benzimidazole-2-methanamine, N-(5-(propylsulfonyl)-1,3,4-thiadiazol-2-YL)-",CCCS(=O)(=O)C1=NN=C(S1)N(C)C2=NC3=CC=CC=C3N2,,,,,,
6624,56625,"1H-Benzimidazole-2-methanamine, N-(5-(butylsulfonyl)-1,3,4-thiadiazol-2-YL)-",CCCCS(=O)(=O)C1=NN=C(S1)N(C)C2=NC3=CC=CC=C3N2,,,,,,
6625,56626,"1H-Benzimidazole-2-methanamine, N-(5-(ethylsulfonyl)-1,3,4-thiadiazol-2-YL)-",CCS(=O)(=O)C1=NN=C(S1)N(C)C2=NC3=CC=CC=C3N2,,,,,,
6626,56627,"7,8-Dichloro-10-(3-(diethylamino)-2-hydroxypropyl)isoalloxazines ulfate",CC[NH+](CC)CC(CN1C2=CC(=C(C=C2N=C3C1=NC(=O)NC3=O)Cl)Cl)O.OS(=O)(=O)[O-],,,,,,
6627,56628,"7,8-Dichloro-10-[3-(diethylamino)-2-hydroxypropyl]benzo[g]pteridine-2,4-dione",CCN(CC)CC(CN1C2=CC(=C(C=C2N=C3C1=NC(=O)NC3=O)Cl)Cl)O,,,,,,
6628,56629,"4,5-Bis(4-pentenyloxy)-2-imidazolidinone",C=CCCCOC1C(NC(=O)N1)OCCCC=C,,,,,,
6629,56630,Ethyl N-(2-(dimethylamino)-1-methylethyl)carbanilate,CCOC(=O)N(C1=CC=CC=C1)C(C)CN(C)C,,,,,,
6630,56631,"3-Benzofuranmethylamine, 2-ethyl-N-(2-methoxyethyl)-",CCC1=C(C2=CC=CC=C2O1)CNCCOC,,,,,,
6631,56632,2-Hydroxy-4-isopropoxybenzophenone,CC(C)OC1=CC(=C(C=C1)C(=O)C2=CC=CC=C2)O,,,,,,
6632,56633,"2-(Dimethylamino)-N-(3,4-dimethyl-5-isoxazolyl)butyramide picrate",CCC(C(=O)NC1=C(C(=NO1)C)C)[NH+](C)C.C1=C(C=C(C(=C1[N+](=O)[O-])[O-])[N+](=O)[O-])[N+](=O)[O-],,,,,,
6633,56634,"2-(dimethylamino)-N-(3,4-dimethyl-1,2-oxazol-5-yl)butanamide",CCC(C(=O)NC1=C(C(=NO1)C)C)N(C)C,,,,,,
6634,56635,"5-(2-(Diethylamino)acetamido)-3,4-dimethylisoxazole picrate",CC[NH+](CC)CC(=O)NC1=C(C(=NO1)C)C.C1C(CC(C(C1[N+](=O)[O-])[O-])[N+](=O)[O-])[N+](=O)[O-],,,,,,
6635,56636,"2-(diethylamino)-N-(3,4-dimethyl-1,2-oxazol-5-yl)acetamide",CCN(CC)CC(=O)NC1=C(C(=NO1)C)C,,,,,,
6636,56637,"2,4,6-Trinitrocyclohexan-1-ol",C1C(CC(C(C1[N+](=O)[O-])O)[N+](=O)[O-])[N+](=O)[O-],,,,,,
6637,56638,(p-Iodophenoxy)acetic acid 2-(dimethylamino)ethyl ester hydrochloride,C[NH+](C)CCOC(=O)COC1=CC=C(C=C1)I.[Cl-],,,,,,
6638,56639,2-(Dimethylamino)ethyl 2-(4-iodophenoxy)acetate,CN(C)CCOC(=O)COC1=CC=C(C=C1)I,,,,,,
6639,56640,2-Methyl-2-piperidinomethyl-1-tetralone,CC1(CCC2=CC=CC=C2C1=O)CN3CCCCC3,,,,,,
6640,56641,2-Piperidinomethyl-3-methyl-1-tetralone hydrochloride,CC1CC2=CC=CC=C2C(=O)C1C[NH+]3CCCCC3.[Cl-],,,,,,
6641,56642,"3-methyl-2-(piperidin-1-ylmethyl)-3,4-dihydro-2H-naphthalen-1-one",CC1CC2=CC=CC=C2C(=O)C1CN3CCCCC3,,,,,,
6642,56643,"3,4-Dihydro-7-methyl-2-(piperidinomethyl)-1(2H)-naphthalenone hydrochloride",CC1=CC2=C(CCC(C2=O)C[NH+]3CCCCC3)C=C1.[Cl-],,,,,,
6643,56644,"7-methyl-2-(piperidin-1-ylmethyl)-3,4-dihydro-2H-naphthalen-1-one",CC1=CC2=C(CCC(C2=O)CN3CCCCC3)C=C1,,,,,,
6644,56645,N-(4-(2-Butoxyethyl)-3-methyl-5-isoxazolyl)-2-(dimethylamino)-3-methylbutyramide,CCCCOCCC1=C(ON=C1C)NC(=O)C(C(C)C)N(C)C,,,,,,
6645,56646,"[(2,2,5-trimethyl-1,3-dithiolan-4-ylidene)amino] N-methylcarbamate",CC1C(=NOC(=O)NC)SC(S1)(C)C,,,,,,
6646,56647,"(1,4-dithian-2-ylideneamino) N-butanoyl-N-methylcarbamate",CCCC(=O)N(C)C(=O)ON=C1CSCCS1,,,,,,
6647,56648,(3-Cyanopropyl)dimethylpropylammonium iodide,CCC[N+](C)(C)CCCC#N.[I-],,,,,,
6648,56649,3-Cyanopropyl-dimethyl-propylazanium,CCC[N+](C)(C)CCCC#N,,,,,,
6649,56650,1-Methyl-1-(4-(2-oxo-1-pyrrolidinyl)-2-butynyl)aziridinium chloride,C[N+]1(CC1)CC#CCN2CCCC2=O.[Cl-],,,,,,
6650,56651,1-[4-(1-Methylaziridin-1-ium-1-yl)but-2-ynyl]pyrrolidin-2-one,C[N+]1(CC1)CC#CCN2CCCC2=O,,,,,,
6651,56652,(p-Bromophenoxy)acetic acid 2-(diethylamino)ethyl ester hydrochloride,CC[NH+](CC)CCOC(=O)COC1=CC=C(C=C1)Br.[Cl-],,,,,,
6652,56653,"Acetic acid, (4-bromophenoxy)-, 2-(diethylamino)ethyl ester",CCN(CC)CCOC(=O)COC1=CC=C(C=C1)Br,,,,,,
6653,56654,"4-Hydroxy-2-methyl-6,7,8-trimethoxytetrahydroisoquinoline hydrochloride",C[NH+]1CC(C2=CC(=C(C(=C2C1)OC)OC)OC)O.[Cl-],,,,,,
6654,56655,"2-Methyl-6,7,8-trimethoxy-1,2,3,4-tetrahydroisoquinoline-4-ol",CN1CC(C2=CC(=C(C(=C2C1)OC)OC)OC)O,,,,,,
6655,56656,5-(m-(Bis(2-chloroethyl)amino)phenyl)-3-methylhydantoin,CN1C(=O)C(NC1=O)C2=CC(=CC=C2)N(CCCl)CCCl,,,,,,
6656,56657,5-(m-(Bis(2-chloroethyl)amino)phenyl)-5-methylhydantoin,CC1(C(=O)NC(=O)N1)C2=CC(=CC=C2)N(CCCl)CCCl,,,,,,
6657,56658,"2H-1,4-Benzodiazepin-2-one, 1,3-dihydro-1-(1-methyl-4-piperidinyl)-5-phenyl-",CN1CCC(CC1)N2C(=O)CN=C(C3=CC=CC=C32)C4=CC=CC=C4,,,,,,
6658,56659,N-methoxy-1-[5-(4-methylphenyl)thiophen-2-yl]ethanimine,CC1=CC=C(C=C1)C2=CC=C(S2)C(=NOC)C,,,,,,
6659,56660,CID 56660,CCON=C(C)C1=CC=C(S1)C2=CC=C(C=C2)C,,,,,,
6660,56661,CID 56661,CCCON=C(C)C1=CC=C(S1)C2=CC=C(C=C2)C,,,,,,
6661,56662,CID 56662,CCN(CC)CCON=C(C)C1=CC=C(S1)C2=CC=C(C=C2)C,,,,,,
6662,56663,CID 56663,CC1=CC=C(C=C1)C2=CC=C(S2)C(=NOCCN3CCCC3)C,,,,,,
6663,56664,CID 56664,CC1=CC=C(C=C1)C2=CC=C(S2)C(=NOCCN3CCCCC3)C,,,,,,
6664,56665,CID 56665,CC1=CC=C(C=C1)C2=CC=C(S2)C(=NOCCN3CCOCC3)C,,,,,,
6665,56666,CID 56666,CCOC(=O)CON=C(C)C1=CC=C(S1)C2=CC=C(C=C2)C,,,,,,
6666,56667,CID 56667,CC1=CC=C(C=C1)C2=CC=C(S2)C(=NOCC3=CC=CC=C3)C,,,,,,
6667,56668,CID 56668,CCC1=CC=C(C=C1)C2=CC=C(S2)C(=NOC)C,,,,,,
6668,56669,CID 56669,CCC1=CC=C(C=C1)C2=CC=C(S2)C(=NOCC)C,,,,,,
6669,56670,CID 56670,CCCON=C(C)C1=CC=C(S1)C2=CC=C(C=C2)CC,,,,,,
6670,56671,CID 56671,CCCCON=C(C)C1=CC=C(S1)C2=CC=C(C=C2)CC,,,,,,
6671,56672,CID 56672,CCC1=CC=C(C=C1)C2=CC=C(S2)C(=NOCC=C)C,,,,,,
6672,56673,CID 56673,CCC1=CC=C(C=C1)C2=CC=C(S2)C(=NOCCN(CC)CC)C,,,,,,
6673,56674,CID 56674,CCC1=CC=C(C=C1)C2=CC=C(S2)C(=NOCCN3CCOCC3)C,,,,,,
6674,56675,CID 56675,CCC1=CC=C(C=C1)C2=CC=C(S2)C(=NOCC(=O)OCC)C,,,,,,
6675,56676,CID 56676,CCC1=CC=C(C=C1)C2=CC=C(S2)C(=NOCC(=O)O)C,,,,,,
6676,56677,CID 56677,CCC1=CC=C(C=C1)C2=CC=C(S2)C(=NOCC3=CC=CC=C3)C,,,,,,
6677,56678,CID 56678,CCN(CC)CCON=C(C)C1=CC=C(S1)C2=CC=C(C=C2)C(C)C,,,,,,
6678,56679,CID 56679,CCOC(=O)CON=C(C)C1=CC=C(S1)C2=CC=C(C=C2)C(C)C,,,,,,
6679,56680,CID 56680,CCN(CC)CCON=C(C)C1=CC=C(S1)C2=CC(=C(C=C2)C)C,,,,,,
6680,56681,CID 56681,CC1=C(C=C(C=C1)C2=CC=C(S2)C(=NOCC=C)C)C,,,,,,
6681,56682,CID 56682,CC1=C(C=C(C=C1)C2=CC=C(S2)CC=NOCC(=O)O)C,,,,,,
6682,56683,"N,N-Bis(2-chloroethyl)-4-(((4-(1H-imidazol-4-yl)phenyl)imino)methyl)benzenamine",C1=CC(=CC=C1C=NC2=CC=C(C=C2)C3=CN=CN3)N(CCCl)CCCl,,,,,,
6683,56684,CID 56684,C1=CC=C(C=C1)CN2C=C(N=C2)C3=CC=C(C=C3)[NH+]=CC4=CC=C(C=C4)[NH+](CCCl)CCCl.[Cl-].[Cl-],,,,,,
6684,56685,"N,N-Bis(2-chloroethyl)-4-[[[4-[1-(phenylmethyl)-1H-imidazol-4-yl]phenyl]imino]methyl]benzenamine",C1=CC=C(C=C1)CN2C=C(N=C2)C3=CC=C(C=C3)N=CC4=CC=C(C=C4)N(CCCl)CCCl,,,,,,
6685,56686,"alpha-Phenyl-1,4-benzodioxan-6-propylamine hydrochloride",C1COC2=C(O1)C=CC(=C2)CCC(C3=CC=CC=C3)[NH3+].[Cl-],,,,,,
6686,56687,"3-(2,3-Dihydro-1,4-benzodioxin-6-yl)-1-phenylpropan-1-amine",C1COC2=C(O1)C=CC(=C2)CCC(C3=CC=CC=C3)N,,,,,,
6687,56688,"1,4-Benzodioxin-6-propanamine, 2,3-dihydro-alpha-(4-chlorophenyl)-, hydrochloride",C1COC2=C(O1)C=CC(=C2)CCC(C3=CC=C(C=C3)Cl)[NH3+].[Cl-],,,,,,
6688,56689,"1-(4-Chlorophenyl)-3-(2,3-dihydro-1,4-benzodioxin-6-yl)propan-1-amine",C1COC2=C(O1)C=CC(=C2)CCC(C3=CC=C(C=C3)Cl)N,,,,,,
6689,56690,"1,4-Benzodioxin-6-propanamine, 2,3-dihydro-alpha-(4-fluorophenyl)-, hydrochloride",C1COC2=C(O1)C=CC(=C2)CCC(C3=CC=C(C=C3)F)[NH3+].[Cl-],,,,,,
6690,56691,"3-(2,3-Dihydro-1,4-benzodioxin-6-yl)-1-(4-fluorophenyl)propan-1-amine",C1COC2=C(O1)C=CC(=C2)CCC(C3=CC=C(C=C3)F)N,,,,,,
6691,56692,"1,4-Benzodioxin-6-propanamine, 2,3-dihydro-alpha-(4-methoxyphenyl)-, hydrochloride",COC1=CC=C(C=C1)C(CCC2=CC3=C(C=C2)OCCO3)[NH3+].[Cl-],,,,,,
6692,56693,"3-(2,3-Dihydro-1,4-benzodioxin-6-yl)-1-(4-methoxyphenyl)propan-1-amine",COC1=CC=C(C=C1)C(CCC2=CC3=C(C=C2)OCCO3)N,,,,,,
6693,56694,2-(Dimethylamino)-N-(4-(2-methoxyethyl)-3-methyl-5-isoxazolyl)-3-methylbutyramide,CC1=NOC(=C1CCOC)NC(=O)C(C(C)C)N(C)C,,,,,,
6694,56695,"ISOXAZOLE, 5-(p-AMINOBENZAMIDO)-4-(2-BUTOXYETHYL)-3-METHYL-",CCCCOCCC1=C(ON=C1C)NC(=O)C2=CC=C(C=C2)N,,,,,,
6695,56696,CID 56696,CCN(CC)CCC1C(=O)N=C(N(C1=O)C2=CC=C(C=C2)OC)S,,,,,,
6696,56697,"2-Diethylaminoethyl 2,3,5,6-tetramethylbenzoate hydrochloride",CC[NH+](CC)CCOC(=O)C1=C(C(=CC(=C1C)C)C)C.[Cl-],,,,,,
6697,56698,"2-(Diethylamino)ethyl 2,3,5,6-tetramethylbenzoate",CCN(CC)CCOC(=O)C1=C(C(=CC(=C1C)C)C)C,,,,,,
6698,56699,"Dma sol(2,4-D-mcpp-benazolin)",CC1=C(C=CC(=C1)Cl)OC(C)C(=O)O.C1=CC2=C(C(=C1)Cl)N(C(=O)S2)CC(=O)O.C1=CC(=C(C=C1Cl)Cl)OCC(=O)O,,,,,,
6699,56700,"3-ISOXAZOLECARBOXYLIC ACID, 5-METHYL-, 2-(m-(DIMETHYLAMINO)BENZYL)HYDRAZIDE",CC1=CC(=NO1)C(=O)NNCC2=CC(=CC=C2)N(C)C,,,,,,
6700,56701,"Oxalic acid, bis(2-butylhydrazide)",CCCCNNC(=O)C(=O)NNCCCC,,,,,,
6701,56702,"OXALIC ACID, BIS(2-sec-BUTYLHYDRAZIDE)",CCC(C)NNC(=O)C(=O)NNC(C)CC,,,,,,
6702,56703,"Oxalic acid, bis(2-isobutylhydrazide)",CC(C)CNNC(=O)C(=O)NNCC(C)C,,,,,,
6703,56704,Roxatidine acetate hydrochloride,CC(=O)OCC(=O)NCCCOC1=CC=CC(=C1)CN2CCCCC2.Cl,,,"['Drugs that selectively bind to but do not activate histamine H2 receptors, thereby blocking the actions of histamine. Their clinically most important action is the inhibition of acid secretion in the treatment of gastrointestinal ulcers. Smooth muscle may also be affected. Some drugs in this class have strong effects in the central nervous system, but these actions are not well understood. (See all compounds classified as Histamine H2 Antagonists.)']",,,
6704,56705,"Benzoic acid, 2-(((2-(((2,5-dihydro-2,2,5,5-tetramethyl-1H-pyrrol-3-yl)carbonyl)amino)ethyl)amino)carbonyl)-",CC1(C=C(C(N1)(C)C)C(=O)NCCNC(=O)C2=CC=CC=C2C(=O)O)C,,,,,,
6705,56706,"Benzoic acid, 2-(((3-(((2,5-dihydro-2,2,5,5-tetramethyl-1H-pyrrol-3-yl)carbonyl)amino)propyl)amino)carbonyl)-",CC1(C=C(C(N1)(C)C)C(=O)NCCCNC(=O)C2=CC=CC=C2C(=O)O)C,,,,,,
6706,56707,N-(1-Methyl-2-piperidinoethyl)carbanilic acid ethyl ester,CCOC(=O)N(C1=CC=CC=C1)C(C)CN2CCCCC2,,,,,,
6707,56708,"Acetanilide, N-(dimethylcarbamoylmethyl)-4'-(isopentyloxy)-",CC(C)CCOC1=CC=C(C=C1)N(CC(=O)N(C)C)C(=O)C,,,,,,
6708,56709,"BENZAMIDE, o-(2-ETHOXYETHOXY)-N-(2-(1-PYRROLIDINYL)ETHYL)-",CCOCCOC1=CC=CC=C1C(=O)NCCN2CCCC2,,,,,,
6709,56710,"Carbanilic acid, N-((diethylcarbamoyl)methyl)-2,6-dimethyl-, ethyl ester",CCN(CC)C(=O)CN(C1=C(C=CC=C1C)C)C(=O)OCC,,,,,,
6710,56711,((p-(Phenylazo)phenyl)azo)malononitrile,C1=CC=C(C=C1)N=NC2=CC=C(C=C2)N=NC(C#N)C#N,,,,,,
6711,56712,"1(2H)-Naphthalenone, 3,4-dihydro-4,7-dimethyl-2-(piperidinomethyl)-, hydrochloride",CC1CC(C(=O)C2=C1C=CC(=C2)C)C[NH+]3CCCCC3.[Cl-],,,,,,
6712,56713,"4,7-dimethyl-2-(piperidin-1-ylmethyl)-3,4-dihydro-2H-naphthalen-1-one",CC1CC(C(=O)C2=C1C=CC(=C2)C)CN3CCCCC3,,,,,,
6713,56714,"1(2H)-Naphthalenone, 3,4-dihydro-6,7-dimethoxy-2-(piperidinomethyl)-, hydrochloride",COC1=C(C=C2C(=C1)CCC(C2=O)C[NH+]3CCCCC3)OC.[Cl-],,,,,,
6714,56715,"6,7-dimethoxy-2-(piperidin-1-ylmethyl)-3,4-dihydro-2H-naphthalen-1-one",COC1=C(C=C2C(=C1)CCC(C2=O)CN3CCCCC3)OC,,,,,,
6715,56716,Fenthiaprop-ethyl,CCOC(=O)C(C)OC1=CC=C(C=C1)OC2=NC3=C(S2)C=C(C=C3)Cl,,,,,,
6716,56717,"Acetamide, N-(2-(diethylamino)ethyl)-2-(1-naphthyloxy)-",CCN(CC)CCNC(=O)COC1=CC=CC2=CC=CC=C21,,,,,,
6717,56718,CID 56718,CC(C)N1C2=CC=CC=C2C(=C1C=C[C@@H](C[C@@H](CC(=O)[O-])O)O)C3=CC=C(C=C3)F.[Na+],,,,,,
6718,56719,"(3S,5R)-7-[3-(4-fluorophenyl)-1-propan-2-yl-2-indolyl]-3,5-dihydroxy-6-heptenoic acid",CC(C)N1C2=CC=CC=C2C(=C1C=C[C@@H](C[C@@H](CC(=O)O)O)O)C3=CC=C(C=C3)F,,,,,,
6719,56720,"2-Imidazoline, 2-((4-methoxy-1-naphthyl)methyl)-",COC1=CC=C(C2=CC=CC=C21)CC3=NCCN3,,,,,,
6720,56721,3-(2-(Diethylamino)ethyl)-5-ethyl-5-phenylhydantoin,CCC1(C(=O)N(C(=O)N1)CCN(CC)CC)C2=CC=CC=C2,,,,,,
6721,56722,"2-(Dimethylamino)-N-(3,4-dimethyl-5-isoxazolyl)-3-methylbutyramide picrate",CC1=C(ON=C1C)NC(=O)C(C(C)C)[NH+](C)C.C1=C(C=C(C(=C1[N+](=O)[O-])[O-])[N+](=O)[O-])[N+](=O)[O-],,,,,,
6722,56723,"2-(dimethylamino)-N-(3,4-dimethyl-1,2-oxazol-5-yl)-3-methylbutanamide",CC1=C(ON=C1C)NC(=O)C(C(C)C)N(C)C,,,,,,
6723,56724,"Isonicotinic acid, 2-cyclooctylhydrazide, dihydrochloride",C1CCCC(CCC1)NNC(=O)C2=CC=NC=C2.Cl.Cl,,,,,,
6724,56725,CID 56725,C1CC[NH+](CC1)CC2=C3C(=CC=C(O3)O)C=C(C2=O)O.[Cl-],,,,,,
6725,56726,CID 56726,C1CCN(CC1)CC2=C3C(=CC=C(O3)O)C=C(C2=O)O,,,,,,
6726,56727,"Indole, 3-(2-(hydroxyamino)propyl)-, hydrochloride, (+-)-",CC(CC1=CNC2=CC=CC=C21)[NH2+]O.[Cl-],,,,,,
6727,56728,n-Hydroxy-1-(1h-indol-3-yl)propan-2-amine,CC(CC1=CNC2=CC=CC=C21)NO,,,,,,
6728,56729,Diethyl(4-guanidinobutyl)methylammonium iodide hydriodide,CC[N+](C)(CC)CCCC[NH+]=C(N)N.[I-].[I-],,,,,,
6729,56730,4-(Diaminomethylideneamino)butyl-diethyl-methylazanium,CC[N+](C)(CC)CCCCN=C(N)N,,,,,,
6730,56731,(2-Dimethylamino)ethyl 3-amino-4-chlorobenzoate monohydrochloride,C[NH+](C)CCOC(=O)C1=CC(=C(C=C1)Cl)N.[Cl-],,,,,,
6731,56732,Clormecaine,CN(C)CCOC(=O)C1=CC(=C(C=C1)Cl)N,,,,,,
6732,56733,CID 56733,C(C[NH3+])C(C(=O)O)SC(=N)[NH3+].[Br-].[Br-],,,,,,
6733,56734,4-Amino-2-carbamimidoylsulfanylbutanoic acid,C(CN)C(C(=O)O)SC(=N)N,,,,,,
6734,56735,"1H-Benzotriazole-1-ethanol, 5-ethoxy-",CCOC1=CC2=C(C=C1)N(N=N2)CCO,,,,,,
6735,56736,"1H-Benzotriazole-1-ethanol, 5-methoxy-6-nitro-",COC1=C(C=C2C(=C1)N=NN2CCO)[N+](=O)[O-],,,,,,
6736,56737,"1H-Benzotriazole-1-ethanol, 5-ethoxy-6-nitro-",CCOC1=C(C=C2C(=C1)N=NN2CCO)[N+](=O)[O-],,,,,,
6737,56738,"1,1-Dimethoxy-2-(2-methoxyethoxy)ethane",COCCOCC(OC)OC,,,,,,
6738,56739,"1,3(2H,4H)-Isoquinolinedione, 2,4,4-triallyl-",C=CCC1(C2=CC=CC=C2C(=O)N(C1=O)CC=C)CC=C,,,,,,
6739,56740,"BENZOIC ACID, p-(N-(DIMETHYLCARBAMOYLMETHYL)ACETAMIDO)-, ETHYL ESTER",CCOC(=O)C1=CC=C(C=C1)N(CC(=O)N(C)C)C(=O)C,,,,,,
6740,56741,CID 56741,C1=CC=C(C=C1)S(=O)(=O)NNC(=O)C=CC(=O)O,,,,,,
6741,56742,"Benzanilide, N-((diethylcarbamoyl)methyl)-",CCN(CC)C(=O)CN(C1=CC=CC=C1)C(=O)C2=CC=CC=C2,,,,,,
6742,56743,"2,3-Dihydro-2-ethyl-N-(3-methoxypropyl)-3-benzofuranmethylamine",CCC1C(C2=CC=CC=C2O1)CNCCCOC,,,,,,
6743,56744,"7-Hydroxy-7,8-dihydrobenzo(a)pyrene",C1C=CC2=C(C1O)C=C3C=CC4=C5C3=C2C=CC5=CC=C4,,,,,,
6744,56745,"4-[(Acridin-9-ylhydrazinylidene)methyl]benzene-1,3-diol",C1=CC=C2C(=C1)C(=C3C=CC=CC3=N2)NN=CC4=C(C=C(C=C4)O)O,,,,,,
6745,56746,2-[(Acridin-9-ylhydrazinylidene)methyl]-4-bromophenol,C1=CC=C2C(=C1)C(=C3C=CC=CC3=N2)NN=CC4=C(C=CC(=C4)Br)O,,,,,,
6746,56747,"3-ISOXAZOLECARBOXYLIC ACID, 5-METHYL-, 2-(p-(DIETHYLAMINO)BENZYL)HYDRAZIDE",CCN(CC)C1=CC=C(C=C1)CNNC(=O)C2=NOC(=C2)C,,,,,,
6747,56748,CID 56748,CCOC(=O)NC1=CC=C(C=C1)OCC(C)N2CCOCC2,,,,,,
6748,56749,CID 56749,CN(C)C1=CC=C(C=C1)C=NN(CCCl)CCCl,,,,,,
6749,56750,N-(4-(2-Butoxyethyl)-3-methyl-5-isoxazolyl)-2-(diethylamino)-3-methylbutyramide,CCCCOCCC1=C(ON=C1C)NC(=O)C(C(C)C)N(CC)CC,,,,,,
6750,56751,"N,2-Bis(piperidinomethyl)-2-ethyl-malonamic acid ethyl ester",CCC(CN1CCCCC1)(C(=O)NCN2CCCCC2)C(=O)OCC,,,,,,
6751,56752,"1(2H)-Naphthalenone, 3,4-dihydro-4,6,7-trimethyl-2-(piperidinomethyl)-, hydrochloride",CC1CC(C(=O)C2=C1C=C(C(=C2)C)C)C[NH+]3CCCCC3.[Cl-],,,,,,
6752,56753,"4,6,7-trimethyl-2-(piperidin-1-ylmethyl)-3,4-dihydro-2H-naphthalen-1-one",CC1CC(C(=O)C2=C1C=C(C(=C2)C)C)CN3CCCCC3,,,,,,
6753,56754,N-[[4-(dimethylamino)phenyl]methylideneamino]acridin-9-amine,CN(C)C1=CC=C(C=C1)C=NNC2=C3C=CC=CC3=NC4=CC=CC=C42,,,,,,
6754,56755,"N,N'-Bis(2-chloroethyl)-N,N'-bis(2-cyanoethyl)ethylenediamine hydrochloride",C(CN(CCCl)CC#N)[NH+](CCCl)CC#N.[Cl-],,,,,,
6755,56756,2-[2-Chloroethyl-[2-[2-chloroethyl(cyanomethyl)amino]ethyl]amino]acetonitrile,C(CN(CCCl)CC#N)N(CCCl)CC#N,,,,,,
6756,56757,Bis(3-cyanopropyl)dimethylammonium iodide,C[N+](C)(CCCC#N)CCCC#N.[I-],,,,,,
6757,56758,Bis(3-cyanopropyl)-dimethylazanium,C[N+](C)(CCCC#N)CCCC#N,,,,,,
6758,56759,o-(2-Butoxyethoxy)-N-(2-(1-pyrrolidinyl)ethyl)benzamide,CCCCOCCOC1=CC=CC=C1C(=O)NCCN2CCCC2,,,,,,
6759,56760,N-(2-(Diethylamino)ethyl)-2-ethyl-2-(piperidinomethyl)malonamic acid ethyl ester,CCC(CN1CCCCC1)(C(=O)NCCN(CC)CC)C(=O)OCC,,,,,,
6760,56761,"2-Naphthaleneglycolic acid, 5,6,7,8-tetrahydro-alpha-methyl-, 2-(diethylamino)ethyl ester, hydrochloride",CC[NH+](CC)CCOC(=O)C(C)(C1=CC2=C(CCCC2)C=C1)O.[Cl-],,,,,,
6761,56762,"2-(Diethylamino)ethyl 2-hydroxy-2-(5,6,7,8-tetrahydronaphthalen-2-yl)propanoate",CCN(CC)CCOC(=O)C(C)(C1=CC2=C(CCCC2)C=C1)O,,,,,,
6762,56763,"2-(Diethylamino)-N-(3,4-dimethyl-5-isoxazolyl)butyramide picrate",CCC(C(=O)NC1=C(C(=NO1)C)C)[NH+](CC)CC.C1=C(C=C(C(=C1[N+](=O)[O-])[O-])[N+](=O)[O-])[N+](=O)[O-],,,,,,
6763,56764,"2-(diethylamino)-N-(3,4-dimethyl-1,2-oxazol-5-yl)butanamide",CCC(C(=O)NC1=C(C(=NO1)C)C)N(CC)CC,,,,,,
6764,56765,"2-(Dimethylamino)-N-(3,4-dimethyl-5-isoxazolyl)hexanamide picrate",CCCCC(C(=O)NC1=C(C(=NO1)C)C)[NH+](C)C.C1=C(C=C(C(=C1[N+](=O)[O-])[O-])[N+](=O)[O-])[N+](=O)[O-],,,,,,
6765,56766,"2-(Dimethylamino)-N-(3,4-dimethyl-5-isoxazolyl)hexanamide",CCCCC(C(=O)NC1=C(C(=NO1)C)C)N(C)C,,,,,,
6766,56767,CID 56767,C[N+](C)(C)CC(=O)NN=CC(=O)C1=CC=C(O1)[N+](=O)[O-].[Cl-],,,,,,
6767,56768,"2-[2-[(5-Nitro-2-furoyl)methylene]hydrazino]-N,N,N-trimethyl-2-oxoethanaminium",C[N+](C)(C)CC(=O)NN=CC(=O)C1=CC=C(O1)[N+](=O)[O-],,,,,,
6768,56769,12-Chloromethylbenzo(a)pyrene,C1=CC=C2C(=C1)C=C3C=CC4=C5C3=C2C=C(C5=CC=C4)CCl,,,,,,
6769,56770,"BENZO(a)PYRENE, 4-(CHLOROMETHYL)-",C1=CC=C2C3=C4C(=CC2=C1)C=C(C5=CC=CC(=C54)C=C3)CCl,,,,,,
6770,56771,11-Chloromethylbenzo(a)pyrene,C1=CC=C2C(=C1)C=C3C=CC4=C5C3=C2C(=CC5=CC=C4)CCl,,,,,,
6771,56772,CID 56772,CC(C)[NH+]=C(N)N=C(N)[NH-].CC(C)[NH+]=C(N)N=C(N)[NH-].[O-]S(=O)(=O)[O-].[Cu+2],,,,,,
6772,56773,CID 56773,CC1=C(C(=CC=C1)C)OCCN=C(N)N[NH3+].[I-],,,,,,
6773,56774,"1-Amino-2-[2-(2,6-dimethylphenoxy)ethyl]guanidine",CC1=C(C(=CC=C1)C)OCCN=C(N)NN,,,,,,
6774,56775,"3-Methoxyestra-1,3,5(10)-trien-17-ol",CC12CCC3C(C1CCC2O)CCC4=C3C=CC(=C4)OC,,,,,,
6775,56776,"1,4-Dichlorodibenzofuran",C1=CC=C2C(=C1)C3=C(C=CC(=C3O2)Cl)Cl,,,,,,
6776,56777,"1,7-Dichlorodibenzofuran",C1=CC2=C(C3=C(O2)C=C(C=C3)Cl)C(=C1)Cl,,,,,,
6777,56778,"2,4-Bis(beta-diethylaminoethyl)thio-6H-pyrimidine dihydrochloride",CC[NH+](CC)CCSC1=NC(=NC=C1)SCC[NH+](CC)CC.[Cl-].[Cl-],,,,,,
6778,56779,"2-[2-[2-(diethylamino)ethylsulfanyl]pyrimidin-4-yl]sulfanyl-N,N-diethylethanamine",CCN(CC)CCSC1=NC(=NC=C1)SCCN(CC)CC,,,,,,
6779,56780,"3,4-Dichlorodibenzofuran",C1=CC=C2C(=C1)C3=C(O2)C(=C(C=C3)Cl)Cl,,,,,,
6780,56781,Phenoxyacetic acid alpha-(1-pyrrolidinylmethyl)benzyl ester hydrochloride,C1CC[NH+](C1)CC(C2=CC=CC=C2)OC(=O)COC3=CC=CC=C3.[Cl-],,,,,,
6781,56782,(1-Phenyl-2-pyrrolidin-1-ylethyl) 2-phenoxyacetate,C1CCN(C1)CC(C2=CC=CC=C2)OC(=O)COC3=CC=CC=C3,,,,,,
6782,56783,"Acetic acid, (2-bromoethoxy)diphenyl-, 2-(dimethylamino)ethyl ester",CN(C)CCOC(=O)C(C1=CC=CC=C1)(C2=CC=CC=C2)OCCBr,,,,,,
6783,56784,"Ammonium, bis(2-cyanoethyl)dimethyl-, iodide",C[N+](C)(CCC#N)CCC#N.[I-],,,,,,
6784,56785,Bis(2-cyanoethyl)-dimethylazanium,C[N+](C)(CCC#N)CCC#N,,,,,,
6785,56786,"3,9,9-Trimethyl-3-aza-9-azoniabicyclo(3.3.1)nonane iodide",CN1CC2CCCC(C1)[N+]2(C)C.[I-],,,,,,
6786,56787,"3,9,9-Trimethyl-3-aza-9-azoniabicyclo[3.3.1]nonane",CN1CC2CCCC(C1)[N+]2(C)C,,,,,,
6787,56788,"Oxalic acid, hydrazide 2-phenethylhydrazide",C1=CC=C(C=C1)CCNNC(=O)C(=O)NN,,,,,,
6788,56789,3-[Bis(2-chloroethyl)hydrazinylidene]butan-2-one,CC(=NN(CCCl)CCCl)C(=O)C,,,,,,
6789,56790,CID 56790,C1=C(C(=CC2=C1S(=O)(=O)N=C(S2)S)Cl)C(=O)O,,,,,,
6790,56791,"4,5-Dichlorocyclopent-3-ene-1,2-dione",C1=C(C(C(=O)C1=O)Cl)Cl,,,,,,
6791,56792,CID 56792,C1CCN(CC1)C(=O)NC(=O)C2=CC=CC=C2C=CC3=CC=NC=C3,,,,,,
6792,56793,"3,4-Dihydro-6-hydroxy-2-(piperidinomethyl)-1(2H)-naphthalenone hydrochloride",C1CC[NH+](CC1)CC2CCC3=C(C2=O)C=CC(=C3)O.[Cl-],,,,,,
6793,56794,"6-hydroxy-2-(piperidin-1-ylmethyl)-3,4-dihydro-2H-naphthalen-1-one",C1CCN(CC1)CC2CCC3=C(C2=O)C=CC(=C3)O,,,,,,
6794,56795,"3,4-Dihydro-4-methyl-2-(morpholinomethyl)-1(2H)-naphthalenone hydrochloride",CC1CC(C(=O)C2=CC=CC=C12)C[NH+]3CCOCC3.[Cl-],,,,,,
6795,56796,"4-methyl-2-(morpholin-4-ylmethyl)-3,4-dihydro-2H-naphthalen-1-one",CC1CC(C(=O)C2=CC=CC=C12)CN3CCOCC3,,,,,,
6796,56797,"3,4-Dihydro-7-methoxy-2-(piperidinomethyl)-1(2H)-naphthalenone hydrochloride",COC1=CC2=C(CCC(C2=O)C[NH+]3CCCCC3)C=C1.[Cl-],,,,,,
6797,56798,7-Methoxy-2-(1-piperidylmethyl)tetralin-1-one,COC1=CC2=C(CCC(C2=O)CN3CCCCC3)C=C1,,,,,,
6798,56799,2-(Diethylamino)-N-(4-(2-ethoxyethyl)-3-methyl-5-isoxazolyl)-3-methylbutyramide,CCN(CC)C(C(C)C)C(=O)NC1=C(C(=NO1)C)CCOCC,,,,,,
6799,56800,"3H-NAPHTHO(2,1-b)PYRAN-3-ONE, 8-METHOXY-2-NITRO-",COC1=CC2=C(C=C1)C3=C(C=C2)OC(=O)C(=C3)[N+](=O)[O-],,,,,,
6800,56801,Salmeterol xinafoate,C1=CC=C(C=C1)CCCCOCCCCCCNCC(C2=CC(=C(C=C2)O)CO)O.C1=CC=C2C(=C1)C=CC(=C2O)C(=O)O,,,"['Agents that cause an increase in the expansion of a bronchus or bronchial tubes. (See all compounds classified as Bronchodilator Agents.)', 'Compounds bind to and activate ADRENERGIC BETA-2 RECEPTORS. (See all compounds classified as Adrenergic beta-2 Receptor Agonists.)']",,,
6801,56802,2-Ethyl-2-phenyl-N-(3-(1-pyrrolidinyl)propyl)malonamic acid ethyl ester,CCC(C1=CC=CC=C1)(C(=O)NCCCN2CCCC2)C(=O)OCC,,,,,,
6802,56803,2-Ethyl-N-(piperidinoacetyl)-2-(piperidinomethyl)malonamic acid ethyl ester,CCC(CN1CCCCC1)(C(=O)NC(=O)CN2CCCCC2)C(=O)OCC,,,,,,
6803,56804,"2-(1,3-benzothiazol-2-ylsulfanyl)-N-[(4-methoxyphenyl)methylideneamino]acetamide",COC1=CC=C(C=C1)C=NNC(=O)CSC2=NC3=CC=CC=C3S2,,,,,,
6804,56805,"2-(1,3-benzothiazol-2-ylsulfanyl)-N-[(3-nitrophenyl)methylideneamino]acetamide",C1=CC=C2C(=C1)N=C(S2)SCC(=O)NN=CC3=CC(=CC=C3)[N+](=O)[O-],,,,,,
6805,56806,CID 56806,C1=CC=C2C(=C1)N=C(S2)SCC(=O)NN=CC3=C(C=CC(=C3)Br)O.O,,,,,,
6806,56807,"2-(1,3-benzothiazol-2-ylsulfanyl)-N-[(5-bromo-2-hydroxyphenyl)methylideneamino]acetamide",C1=CC=C2C(=C1)N=C(S2)SCC(=O)NN=CC3=C(C=CC(=C3)Br)O,,,,,,
6807,56808,"2-(1,3-benzothiazol-2-ylsulfanyl)-N-[[4-(diethylamino)phenyl]methylideneamino]acetamide",CCN(CC)C1=CC=C(C=C1)C=NNC(=O)CSC2=NC3=CC=CC=C3S2,,,,,,
6808,56809,"2-(1,3-benzothiazol-2-ylsulfanyl)-N-(cinnamylideneamino)acetamide",C1=CC=C(C=C1)C=CC=NNC(=O)CSC2=NC3=CC=CC=C3S2,,,,,,
6809,56810,CID 56810,C1=CC=C2C(=C1)C(C(=O)N2)C=NNC(=O)CSC3=NC4=CC=CC=C4S3,,,,,,
6810,56811,CID 56811,CN1C2=CC=CC=C2C(C1=O)C=NNC(=O)CSC3=NC4=CC=CC=C4S3,,,,,,
6811,56812,"1H-NAPHTH(1,2-d)IMIDAZOLE, 2-AMINO-",C1=CC=C2C(=C1)C=CC3=C2N=C(N3)N,,,,,,
6812,56813,"Benzanilide, N-((dimethylcarbamoyl)methyl)-",CN(C)C(=O)CN(C1=CC=CC=C1)C(=O)C2=CC=CC=C2,,,,,,
6813,56814,CID 56814,C1CN(CCN1CCO)CC2=C3C(=CC=C(O3)O)C=C(C2=O)O.Cl.Cl,,,,,,
6814,56815,CID 56815,C1CN(CCN1CCO)CC2=C3C(=CC=C(O3)O)C=C(C2=O)O,,,,,,
6815,56816,"(3,4,5-Trihydroxy-6-oxocyclohexen-1-yl)methyl but-2-enoate",CC=CC(=O)OCC1=CC(C(C(C1=O)O)O)O,,,,,,
6816,56817,"3-Methyl-5-ethyl-6-nonyn-5,9-diol",CCC(C)CC(CC)(C#CCCO)O,,,,,,
6817,56818,"Ethanol, 2-(N-methyl-N-(1-phenylcyclohexyl)amino)-",CN(CCO)C1(CCCCC1)C2=CC=CC=C2,,,,,,
6818,56819,N-(2-Piperidinopropyl)carbanilic acid ethyl ester,CCOC(=O)N(CC(C)N1CCCCC1)C2=CC=CC=C2,,,,,,
6819,56820,2-Ethyl-2-phenyl-N-(2-(1-pyrrolidinyl)ethyl)malonamic acid ethyl ester,CCC(C1=CC=CC=C1)(C(=O)NCCN2CCCC2)C(=O)OCC,,,,,,
6820,56821,"2-(Diethylamino)-N-(3,4-dimethyl-5-isoxazolyl)-3-methylbutyramide picrate",CC[NH+](CC)C(C(C)C)C(=O)NC1=C(C(=NO1)C)C.C1=C(C=C(C(=C1[N+](=O)[O-])[O-])[N+](=O)[O-])[N+](=O)[O-],,,,,,
6821,56822,"2-(diethylamino)-N-(3,4-dimethyl-1,2-oxazol-5-yl)-3-methylbutanamide",CCN(CC)C(C(C)C)C(=O)NC1=C(C(=NO1)C)C,,,,,,
6822,56823,"ACETOPHENONE, 2,2-BIS(p-NITROANILINO)-4'-METHOXY-",COC1=CC=C(C=C1)C(=O)C(NC2=CC=C(C=C2)[N+](=O)[O-])NC3=CC=C(C=C3)[N+](=O)[O-],,,,,,
6823,56824,N-(2-(Diethylamino)ethyl)naphthalimide hydrochloride,CC[NH+](CC)CCN1C(=O)C2=CC=CC3=C2C(=CC=C3)C1=O.[Cl-],,,,,,
6824,56825,"2-(2-Diethylaminoethyl)benzo[de]isoquinoline-1,3-dione",CCN(CC)CCN1C(=O)C2=CC=CC3=C2C(=CC=C3)C1=O,,,,,,
6825,56826,"2,3,6-Trichloro-4-(2,4,6-trichlorophenoxy)phenol",C1=C(C=C(C(=C1Cl)OC2=CC(=C(C(=C2Cl)Cl)O)Cl)Cl)Cl,,,,,,
6826,56827,CID 56827,CC1=C(C(=CC=C1)C(=O)N)OCC=CC2=CC=CC=C2,,,,,,
6827,56828,Phenoxyacetic acid alpha-((isopropylmethylamino)methyl)benzyl ester hydrochloride,CC(C)[NH+](C)CC(C1=CC=CC=C1)OC(=O)COC2=CC=CC=C2.[Cl-],,,,,,
6828,56829,[2-[Methyl(propan-2-yl)amino]-1-phenylethyl] 2-phenoxyacetate,CC(C)N(C)CC(C1=CC=CC=C1)OC(=O)COC2=CC=CC=C2,,,,,,
6829,56830,p-Ethoxybenzoic acid 2-(benzylmethylamino)ethyl ester hydrochloride,CCOC1=CC=C(C=C1)C(=O)OCC[NH+](C)CC2=CC=CC=C2.[Cl-],,,,,,
6830,56831,2-[Benzyl(methyl)amino]ethyl 4-ethoxybenzoate,CCOC1=CC=C(C=C1)C(=O)OCCN(C)CC2=CC=CC=C2,,,,,,
6831,56832,"Acetic acid, (2-cyanoethoxy)diphenyl-, 2-(dimethylamino)ethyl ester",CN(C)CCOC(=O)C(C1=CC=CC=C1)(C2=CC=CC=C2)OCCC#N,,,,,,
6832,56833,(3-Cyanopropyl)(2-hydroxyethyl)dimethylammonium bromide acetate,CC(=O)OCC[N+](C)(C)CCCC#N.[Br-],,,,,,
6833,56834,2-Acetyloxyethyl-(3-cyanopropyl)-dimethylazanium,CC(=O)OCC[N+](C)(C)CCCC#N,,,,,,
6834,56835,"copper;N'-[2-(2-aminoethylamino)ethyl]ethane-1,2-diamine;dichloride",C(CNCCNCCN)N.[Cl-].[Cl-].[Cu+2],,,,,,
6835,56836,5-Methyl-3-isoxazolecarboxylic acid 2-pentylhydrazide hydrochloride,CCCCC[NH2+]NC(=O)C1=NOC(=C1)C.[Cl-],,,,,,
6836,56837,5-Methyl-N'-pentylisoxazole-3-carbohydrazide,CCCCCNNC(=O)C1=NOC(=C1)C,,,,,,
6837,56838,"Aniline, 4,4'-pentamethylenedioxybis(3-chloro-, dihydrochloride",C1=CC(=C(C=C1[NH3+])Cl)OCCCCCOC2=C(C=C(C=C2)[NH3+])Cl.[Cl-].[Cl-],,,,,,
6838,56839,4-[5-(4-Amino-2-chlorophenoxy)pentoxy]-3-chloroaniline,C1=CC(=C(C=C1N)Cl)OCCCCCOC2=C(C=C(C=C2)N)Cl,,,,,,
6839,56840,p-Ethoxybenzoic acid 2-(benzylamino)ethyl ester hydrochloride,CCOC1=CC=C(C=C1)C(=O)OCC[NH2+]CC2=CC=CC=C2.[Cl-],,,,,,
6840,56841,2-(Benzylamino)ethyl 4-ethoxybenzoate,CCOC1=CC=C(C=C1)C(=O)OCCNCC2=CC=CC=C2,,,,,,
6841,56842,"2-(Diethylamino)-N-(3,4-dimethyl-5-isoxazolyl)hexanamide picrate",CCCCC(C(=O)NC1=C(C(=NO1)C)C)[NH+](CC)CC.C1=C(C=C(C(=C1[N+](=O)[O-])[O-])[N+](=O)[O-])[N+](=O)[O-],,,,,,
6842,56843,"2-(Diethylamino)-N-(3,4-dimethyl-5-isoxazolyl)hexanamide",CCCCC(C(=O)NC1=C(C(=NO1)C)C)N(CC)CC,,,,,,
6843,56844,N-(2-(Methylphenethylamino)propyl)carbanilic acid ethyl ester,CCOC(=O)N(CC(C)N(C)CCC1=CC=CC=C1)C2=CC=CC=C2,,,,,,
6844,56845,"BENZAMIDE, o-(4-BUTOXYBUTOXY)-N-(2-(1-PYRROLIDINYL)ETHYL)-",CCCCOCCCCOC1=CC=CC=C1C(=O)NCCN2CCCC2,,,,,,
6845,56846,p-(2-Cyclohexen-1-yloxy)benzoic acid 3-(2-methyl-1-pyrrolidinyl)propyl ester,CC1CCC[NH+]1CCCOC(=O)C2=CC=C(C=C2)OC3CCCC=C3.[Cl-],,,,,,
6846,56847,"Benzoic acid, 4-[(cyclohex-2-enyl)oxy]-, [3-(2-methylpyrrolidin-1-yl)propyl] ester",CC1CCCN1CCCOC(=O)C2=CC=C(C=C2)OC3CCCC=C3,,,,,,
6847,56848,"Decanamide, N-(5-acetamido-8-quinolylsulfonyl)-",CCCCCCCCCC(=O)NS(=O)(=O)C1=C2C(=C(C=C1)NC(=O)C)C=CC=N2,,,,,,
6848,56849,2-Cyclohexyl-3-hydroxynonanoic acid 2-(diethylamino)ethyl ester hydrochloride,CCCCCCC(C(C1CCCCC1)C(=O)OCC[NH+](CC)CC)O.[Cl-],,,,,,
6849,56850,2-(Diethylamino)ethyl 2-cyclohexyl-3-hydroxynonanoate,CCCCCCC(C(C1CCCCC1)C(=O)OCCN(CC)CC)O,,,,,,
6850,56851,1-(2-(Amino(hydroxyimino)methyl)ethyl)-4-phenylisonipecotic acid ethyl ester dihydrochloride,CCOC(=O)C1(CCN(CC1)CCC(=[NH2+])[NH3+])C2=CC=CC=C2.[Cl-].[Cl-],,,,,,
6851,56852,Ethyl 1-(3-amino-3-iminopropyl)-4-phenylpiperidine-4-carboxylate,CCOC(=O)C1(CCN(CC1)CCC(=N)N)C2=CC=CC=C2,,,,,,
6852,56853,CID 56853,CC(C)CN(CC[NH2+]C(=N)[NH3+])C(C)C.[O-]S(=O)(=O)[O-],,,,,,
6853,56854,2-[2-[2-Methylpropyl(propan-2-yl)amino]ethyl]guanidine,CC(C)CN(CCN=C(N)N)C(C)C,,,,,,
6854,56855,N-7-(2-(Nitrophenyldithio)ethyl)mitomycin C,CC1=C(C(=O)C2=C(C1=O)N3C[C@H]4[C@@H]([C@@]3([C@@H]2COC(=O)N)OC)N4)NCCSSC5=CC=C(C=C5)[N+](=O)[O-],,,,,,
6855,56856,Diethyl(5-guanidinopentyl)methylammonium iodide hydriodide,CC[N+](C)(CC)CCCCC[NH+]=C(N)N.[I-].[I-],,,,,,
6856,56857,5-(Diaminomethylideneamino)pentyl-diethyl-methylazanium,CC[N+](C)(CC)CCCCCN=C(N)N,,,,,,
6857,56858,"Caffeine, 8-((3-hydroxypropyl)amino)-",CN1C2=C(N=C1NCCCO)N(C(=O)N(C2=O)C)C,,,,,,
6858,56859,"Carbanilic acid, N-(2-(diethylcarbamoyl)ethyl)-2,6-dimethyl-, ethyl ester",CCN(CC)C(=O)CCN(C1=C(C=CC=C1C)C)C(=O)OCC,,,,,,
6859,56860,Diphenylacetic acid 4-(1-pyrrolidinyl)-2-butynyl ester hydrochloride,C1CC[NH+](C1)CC#CCOC(=O)C(C2=CC=CC=C2)C3=CC=CC=C3.[Cl-],,,,,,
6860,56861,"4-Pyrrolidin-1-ylbut-2-ynyl 2,2-diphenylacetate",C1CCN(C1)CC#CCOC(=O)C(C2=CC=CC=C2)C3=CC=CC=C3,,,,,,
6861,56862,1-(beta-Hydroxyphenethyl)-4-phenylisonipecotic acid ethyl ester hydrochloride,CCOC(=O)C1(CC[NH+](CC1)CC(C2=CC=CC=C2)O)C3=CC=CC=C3.[Cl-],,,,,,
6862,56863,Oxpheneridine,CCOC(=O)C1(CCN(CC1)CC(C2=CC=CC=C2)O)C3=CC=CC=C3,,,,,,
6863,56864,Diphenylacetic acid 4-(diethylamino)-2-butynyl ester hydrochloride,CC[NH+](CC)CC#CCOC(=O)C(C1=CC=CC=C1)C2=CC=CC=C2.[Cl-],,,,,,
6864,56865,"4-(Diethylamino)but-2-ynyl 2,2-diphenylacetate",CCN(CC)CC#CCOC(=O)C(C1=CC=CC=C1)C2=CC=CC=C2,,,,,,
6865,56866,1-Phenacyl-4-phenylisonipecotic acid ethyl ester hydrochloride,CCOC(=O)C1(CC[NH+](CC1)CC(=O)C2=CC=CC=C2)C3=CC=CC=C3.[Cl-],,,,,,
6866,56867,Ethyl 1-(2-oxo-2-phenylethyl)-4-phenyl-4-piperidinecarboxylate,CCOC(=O)C1(CCN(CC1)CC(=O)C2=CC=CC=C2)C3=CC=CC=C3,,,,,,
6867,56868,alpha-Cyclohexyl-1-hydroxycycloheptaneacetic acid 2-(diethylamino)ethyl ester hydrochloride,CC[NH+](CC)CCOC(=O)C(C1CCCCCC1)C2(CCCCC2)O.[Cl-],,,,,,
6868,56869,2-(Diethylamino)ethyl 2-cycloheptyl-2-(1-hydroxycyclohexyl)acetate,CCN(CC)CCOC(=O)C(C1CCCCCC1)C2(CCCCC2)O,,,,,,
6869,56870,"Isophthalamic acid, N-antipyrinyl-4-hydroxy-5-nitro-, isopropyl ester",CC1=C(C(=O)N(N1C)C2=CC=CC=C2)NC(=O)C3=CC(=C(C(=C3)[N+](=O)[O-])O)C(=O)OC(C)C,,,,,,
6870,56871,"Isophthalamic acid, N-antipyrinyl-4-hydroxy-5-nitro-, propyl ester",CCCOC(=O)C1=C(C(=CC(=C1)C(=O)NC2=C(N(N(C2=O)C3=CC=CC=C3)C)C)[N+](=O)[O-])O,,,,,,
6871,56872,"ACETAMIDE, N-BENZYL-2-(p-CHLOROPHENOXY)-N-(3-(DIETHYLAMINO)PROPYL)-",CCN(CC)CCCN(CC1=CC=CC=C1)C(=O)COC2=CC=C(C=C2)Cl,,,,,,
6872,56873,"Ethylenediamine, N-(p-chloro-alpha-methylbenzyl)-N',N'-dimethyl-N-phenyl-, hydrochloride",CC(C1=CC=C(C=C1)Cl)N(CC[NH+](C)C)C2=CC=CC=C2.[Cl-],,,,,,
6873,56874,"N'-[1-(4-chlorophenyl)ethyl]-N,N-dimethyl-N'-phenylethane-1,2-diamine",CC(C1=CC=C(C=C1)Cl)N(CCN(C)C)C2=CC=CC=C2,,,,,,
6874,56875,alpha-((2-(Dibutylamino)ethoxy)methyl)benzyl alcohol,CCCCN(CCCC)CCOCC(C1=CC=CC=C1)O,,,,,,
6875,56876,"Indole, 3-(2-aminopropyl)-5-fluoro-, hydrochloride",CC(CC1=CNC2=C1C=C(C=C2)F)[NH3+].[Cl-],,,,,,
6876,56877,"Benzamide, N-(2-oxo-2-(1-pyrrolidinyl)ethyl)-",C1CCN(C1)C(=O)CNC(=O)C2=CC=CC=C2,,,,,,
6877,56878,CID 56878,CC(=O)OC(CCN1CCN(CC1)C2=CC=CC=C2)C(=O)C3=CC=C(C=C3)F.C(=CC(=O)O)C(=O)O,,,,,,
6878,56879,[1-(4-Fluorophenyl)-1-oxo-4-(4-phenylpiperazin-1-yl)butan-2-yl] acetate,CC(=O)OC(CCN1CCN(CC1)C2=CC=CC=C2)C(=O)C3=CC=C(C=C3)F,,,,,,
6879,56880,"1,3-Dioxol-2-one, 4-(4-fluorophenyl)-5-(2-(4-(2-methoxyphenyl)-1-piperazinyl)ethyl)-, dihydrochloride",COC1=CC=CC=C1N2CCN(CC2)CCC3=C(OC(=O)O3)C4=CC=C(C=C4)F.Cl.Cl,,,,,,
6880,56881,"4-(4-Fluorophenyl)-5-[2-[4-(2-methoxyphenyl)piperazin-1-yl]ethyl]-1,3-dioxol-2-one",COC1=CC=CC=C1N2CCN(CC2)CCC3=C(OC(=O)O3)C4=CC=C(C=C4)F,,,,,,
6881,56882,"Carbostyril, 3,4-dihydro-1-(2-piperidinoethyl)-, picrate",C1CC[NH+](CC1)CCN2C(=O)CCC3=CC=CC=C32.C1=C(C=C(C(=C1[N+](=O)[O-])[O-])[N+](=O)[O-])[N+](=O)[O-],,,,,,
6882,56883,"1-(2-Piperidin-1-ylethyl)-3,4-dihydroquinolin-2-one",C1CCN(CC1)CCN2C(=O)CCC3=CC=CC=C32,,,,,,
6883,56884,4-Methoxy-alpha-(3-(4-(o-methoxyphenyl)-1-piperazinyl)propyl)benzyl alcohol,COC1=CC=C(C=C1)C(CCCN2CCN(CC2)C3=CC=CC=C3OC)O,,,,,,
6884,56885,CID 56885,CC=CC[C@@]1(CCC2C1(CCC3C2CCC4=CC(=O)CCC34)C)O,,,,,,
6885,56886,N-Hydroxy-N-1-pyrenylacetamide,CC(=O)N(C1=C2C=CC3=CC=CC4=C3C2=C(C=C4)C=C1)O,,,,,,
6886,56887,CID 56887,CCOC(=O)CC(=NNC1=[N+](C(=O)N(C(=O)C1)C)C)C.[Cl-],,,,,,
6887,56888,CID 56888,CCOC(=O)CC(=NNC1=[N+](C(=O)N(C(=O)C1)C)C)C,,,,,,
6888,56889,CID 56889,CCOC(=O)CC(=NN=C1C(C(=O)N(C(=O)N1C)C)N=O)C,,,,,,
6889,56890,2-(3-Piperidinopropyl)-1-tetralone,C1CCN(CC1)CCCC2CCC3=CC=CC=C3C2=O,,,,,,
6890,56891,3-(2-bromo-6H-benzo[c][1]benzothiepin-11-ylidene)propyl-dimethylazanium;chloride,C[NH+](C)CCC=C1C2=CC=CC=C2CSC3=C1C=C(C=C3)Br.[Cl-],,,,,,
6891,56892,"3-(2-bromo-6H-benzo[c][1]benzothiepin-11-ylidene)-N,N-dimethylpropan-1-amine",CN(C)CCC=C1C2=CC=CC=C2CSC3=C1C=C(C=C3)Br,,,,,,
6892,56893,9-((2-Chloroethyl)ethylaminomethyl)anthracene hydrochloride,CC[NH+](CCCl)CC1=C2C=CC=CC2=CC3=CC=CC=C31.[Cl-],,,,,,
6893,56894,N-(anthracen-9-ylmethyl)-2-chloro-N-ethylethanamine,CCN(CCCl)CC1=C2C=CC=CC2=CC3=CC=CC=C31,,,,,,
6894,56895,CID 56895,C[NH+](C)CCC=C1C2=CC=CC=C2CSC3=C1C=C(C=C3)Cl.[Cl-],,,,,,
6895,56896,CID 56896,CN(C)CCC=C1C2=CC=CC=C2CSC3=C1C=C(C=C3)Cl,,,,,,
6896,56897,"Aniline, 4,4'-(heptamethylenedioxy)DI-, dihydrochloride",C1=CC(=CC=C1[NH3+])OCCCCCCCOC2=CC=C(C=C2)[NH3+].[Cl-].[Cl-],,,,,,
6897,56898,"Benzenamine, 4,4'-(1,7-heptanediylbis(oxy))bis-",C1=CC(=CC=C1N)OCCCCCCCOC2=CC=C(C=C2)N,,,,,,
6898,56899,17-beta-(2-(Methylamino)-4-thiazolyl)androst-4-en-3-one,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2C4=CSC(=N4)NC)CCC5=CC(=O)CC[C@]35C,,,,,,
6899,56900,4-Piperidino-2-butynyl benzilic acid hydrochloride,C1CC[NH+](CC1)CC#CCOC(=O)C(C2=CC=CC=C2)(C3=CC=CC=C3)O.[Cl-],,,,,,
6900,56901,4-(Piperidin-1-yl)but-2-yn-1-yl hydroxy(diphenyl)acetate,C1CCN(CC1)CC#CCOC(=O)C(C2=CC=CC=C2)(C3=CC=CC=C3)O,,,,,,
6901,56902,"ETHANONE, 1-(1-ETHYL-5-NITRONAPHTHO(2,1-b)FURAN-2-YL)-",CCC1=C(OC2=C1C3=CC=CC=C3C(=C2)[N+](=O)[O-])C(=O)C,,,,,,
6902,56903,"ETHANONE, 1-(1-BUTYL-5-NITRONAPHTHO(2,1-b)FURAN-2-YL)-",CCCCC1=C(OC2=C1C3=CC=CC=C3C(=C2)[N+](=O)[O-])C(=O)C,,,,,,
6903,56904,"NAPHTHO(2,1-b)FURAN, 1-ETHYL-2-NITRO-",CCC1=C(OC2=C1C3=CC=CC=C3C=C2)[N+](=O)[O-],,,,,,
6904,56905,"NAPHTHO(2,1-b)FURAN, 1-BUTYL-2-NITRO-",CCCCC1=C(OC2=C1C3=CC=CC=C3C=C2)[N+](=O)[O-],,,,,,
6905,56906,"NAPHTHO(2,1-b)FURAN, 2-NITRO-1-UNDECYL-",CCCCCCCCCCCC1=C(OC2=C1C3=CC=CC=C3C=C2)[N+](=O)[O-],,,,,,
6906,56907,"NAPHTHO(2,1-b)FURAN, 1-(1-METHYLETHYL)-2-NITRO-",CC(C)C1=C(OC2=C1C3=CC=CC=C3C=C2)[N+](=O)[O-],,,,,,
6907,56908,"NAPHTHO(2,1-b)FURAN, 7-BROMO-1-METHYL-2-NITRO-",CC1=C(OC2=C1C3=C(C=C2)C=C(C=C3)Br)[N+](=O)[O-],,,,,,
6908,56909,"NAPHTHO(2,1-b)FURAN-1-ETHANOL, 2-NITRO-",C1=CC=C2C(=C1)C=CC3=C2C(=C(O3)[N+](=O)[O-])CCO,,,,,,
6909,56910,"NAPHTHO(2,1-b)FURAN, 2-NITRO-1-PHENYL-",C1=CC=C(C=C1)C2=C(OC3=C2C4=CC=CC=C4C=C3)[N+](=O)[O-],,,,,,
6910,56911,"2-Phenyl-1,3-dithiolane 1,3-dioxide",C1CS(=O)C(S1=O)C2=CC=CC=C2,,,,,,
6911,56912,"Dodecanamide, N-(8-ethoxy-5-quinolylsulfonyl)-",CCCCCCCCCCCC(=O)NS(=O)(=O)C1=C2C=CC=NC2=C(C=C1)OCC,,,,,,
6912,56913,CID 56913,CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C([N-]2)C=CC(=C3)OC.[Na+],,,,,,
6913,56914,N-(3-Pyridylmethyl)acetanilide hydrochloride,CC(=O)N(CC1=C[NH+]=CC=C1)C2=CC=CC=C2.[Cl-],,,,,,
6914,56915,N-phenyl-N-(pyridin-3-ylmethyl)acetamide,CC(=O)N(CC1=CN=CC=C1)C2=CC=CC=C2,,,,,,
6915,56916,"7,12-Dioxa-4-azonia-2-silatetradecan-14-aminium, 8,11-dioxo-N,N,2,2,4,4-hexamethyl-N-((trimethylsilyl)methyl)-, diiodide",C[N+](C)(CCOC(=O)CCC(=O)OCC[N+](C)(C)C[Si](C)(C)C)C[Si](C)(C)C.[I-].[I-],,,,,,
6916,56917,2-[4-[2-[Dimethyl(trimethylsilylmethyl)azaniumyl]ethoxy]-4-oxobutanoyl]oxyethyl-dimethyl-(trimethylsilylmethyl)azanium,C[N+](C)(CCOC(=O)CCC(=O)OCC[N+](C)(C)C[Si](C)(C)C)C[Si](C)(C)C,,,,,,
6917,56918,"10,15-Dioxa-7-azonia-3-silaheptadecan-17-aminium, 11,14-dioxo-N-(3-(dimethylethylsilyl)propyl)-N,N,3,3,7,7-hexamethyl-, diiodide",CC[Si](C)(C)CCC[N+](C)(C)CCOC(=O)CCC(=O)OCC[N+](C)(C)CCC[Si](C)(C)CC.[I-].[I-],,,,,,
6918,56919,3-[Ethyl(dimethyl)silyl]propyl-[2-[4-[2-[3-[ethyl(dimethyl)silyl]propyl-dimethylazaniumyl]ethoxy]-4-oxobutanoyl]oxyethyl]-dimethylazanium,CC[Si](C)(C)CCC[N+](C)(C)CCOC(=O)CCC(=O)OCC[N+](C)(C)CCC[Si](C)(C)CC,,,,,,
6919,56920,"10,15-Dioxa-7-azonia-3-silaheptadecan-17-aminium, N-(3-(diethylmethylsilyl)propyl)-11,14-dioxo-3-ethyl-N,N,3,7,7-pentamethyl-, diiodide",CC[Si](C)(CC)CCC[N+](C)(C)CCOC(=O)CCC(=O)OCC[N+](C)(C)CCC[Si](C)(CC)CC.[I-].[I-],,,,,,
6920,56921,3-[Diethyl(methyl)silyl]propyl-[2-[4-[2-[3-[diethyl(methyl)silyl]propyl-dimethylazaniumyl]ethoxy]-4-oxobutanoyl]oxyethyl]-dimethylazanium,CC[Si](C)(CC)CCC[N+](C)(C)CCOC(=O)CCC(=O)OCC[N+](C)(C)CCC[Si](C)(CC)CC,,,,,,
6921,56922,"3,8-Dioxa-11-azonia-15-silaoctadecan-1-aminium, 4,7-dioxo-N-(3-(dipropylmethylsilyl)propyl)-N,N,11,11,15-pentamethyl-15-propyl-, diiodide",CCC[Si](C)(CCC)CCC[N+](C)(C)CCOC(=O)CCC(=O)OCC[N+](C)(C)CCC[Si](C)(CCC)CCC.[I-].[I-],,,,,,
6922,56923,2-[4-[2-[Dimethyl-[3-[methyl(dipropyl)silyl]propyl]azaniumyl]ethoxy]-4-oxobutanoyl]oxyethyl-dimethyl-[3-[methyl(dipropyl)silyl]propyl]azanium,CCC[Si](C)(CCC)CCC[N+](C)(C)CCOC(=O)CCC(=O)OCC[N+](C)(C)CCC[Si](C)(CCC)CCC,,,,,,
6923,56924,"3,8-Dioxa-11-azonia-15-silanonadecan-1-aminium, 15-butyl-N-(3-(dibutylmethylsilyl)propyl)-4,7-dioxo-N,N,11,11,15-pentamethyl-, diiodide",CCCC[Si](C)(CCCC)CCC[N+](C)(C)CCOC(=O)CCC(=O)OCC[N+](C)(C)CCC[Si](C)(CCCC)CCCC.[I-].[I-],,,,,,
6924,56925,3-[Dibutyl(methyl)silyl]propyl-[2-[4-[2-[3-[dibutyl(methyl)silyl]propyl-dimethylazaniumyl]ethoxy]-4-oxobutanoyl]oxyethyl]-dimethylazanium,CCCC[Si](C)(CCCC)CCC[N+](C)(C)CCOC(=O)CCC(=O)OCC[N+](C)(C)CCC[Si](C)(CCCC)CCCC,,,,,,
6925,56926,2-[4-[2-[Dimethyl(3-triethylsilylpropyl)azaniumyl]ethoxy]-4-oxobutanoyl]oxyethyl-dimethyl-(3-triethylsilylpropyl)azanium diiodide,CC[Si](CC)(CC)CCC[N+](C)(C)CCOC(=O)CCC(=O)OCC[N+](C)(C)CCC[Si](CC)(CC)CC.[I-].[I-],,,,,,
6926,56927,2-[4-[2-[Dimethyl(3-triethylsilylpropyl)azaniumyl]ethoxy]-4-oxobutanoyl]oxyethyl-dimethyl-(3-triethylsilylpropyl)azanium,CC[Si](CC)(CC)CCC[N+](C)(C)CCOC(=O)CCC(=O)OCC[N+](C)(C)CCC[Si](CC)(CC)CC,,,,,,
6927,56928,"8,15-Dioxa-5-azonia-3-silaheptadecan-17-aminium, 3,3-diethyl-9,14-dioxo-N,N,5,5-tetramethyl-N-((triethylsilyl)methyl)-, diiodide",CC[Si](CC)(CC)C[N+](C)(C)CCOC(=O)CCCCC(=O)OCC[N+](C)(C)C[Si](CC)(CC)CC.[I-].[I-],,,,,,
6928,56929,2-[6-[2-[Dimethyl(triethylsilylmethyl)azaniumyl]ethoxy]-6-oxohexanoyl]oxyethyl-dimethyl-(triethylsilylmethyl)azanium,CC[Si](CC)(CC)C[N+](C)(C)CCOC(=O)CCCCC(=O)OCC[N+](C)(C)C[Si](CC)(CC)CC,,,,,,
6929,56930,"8,17-Dioxa-5-azonia-3-silanonadecan-19-aminium, 3,3-diethyl-9,16-dioxo-N,N,5,5-tetramethyl-N-((triethylsilyl)methyl)-, diiodide",CC[Si](CC)(CC)C[N+](C)(C)CCOC(=O)CCCCCCC(=O)OCC[N+](C)(C)C[Si](CC)(CC)CC.[I-].[I-],,,,,,
6930,56931,2-[8-[2-[Dimethyl(triethylsilylmethyl)azaniumyl]ethoxy]-8-oxooctanoyl]oxyethyl-dimethyl-(triethylsilylmethyl)azanium,CC[Si](CC)(CC)C[N+](C)(C)CCOC(=O)CCCCCCC(=O)OCC[N+](C)(C)C[Si](CC)(CC)CC,,,,,,
6931,56932,"8,18-Dioxa-5-azonia-3-silaeicosan-20-aminium, 3,3-diethyl-9,17-dioxo-N,N,5,5-tetramethyl-N-((triethylsilyl)methyl)-, diiodide",CC[Si](CC)(CC)C[N+](C)(C)CCOC(=O)CCCCCCCC(=O)OCC[N+](C)(C)C[Si](CC)(CC)CC.[I-].[I-],,,,,,
6932,56933,2-[9-[2-[Dimethyl(triethylsilylmethyl)azaniumyl]ethoxy]-9-oxononanoyl]oxyethyl-dimethyl-(triethylsilylmethyl)azanium,CC[Si](CC)(CC)C[N+](C)(C)CCOC(=O)CCCCCCCC(=O)OCC[N+](C)(C)C[Si](CC)(CC)CC,,,,,,
6933,56934,"8,19-Dioxa-5-azonia-3-silaheneicosan-21-aminium, 3,3-diethyl-9,18-dioxo-N,N,5,5-tetramethyl-N-((triethylsilyl)methyl)-, diiodide",CC[Si](CC)(CC)C[N+](C)(C)CCOC(=O)CCCCCCCCC(=O)OCC[N+](C)(C)C[Si](CC)(CC)CC.[I-].[I-],,,,,,
6934,56935,2-[10-[2-[Dimethyl(triethylsilylmethyl)azaniumyl]ethoxy]-10-oxodecanoyl]oxyethyl-dimethyl-(triethylsilylmethyl)azanium,CC[Si](CC)(CC)C[N+](C)(C)CCOC(=O)CCCCCCCCC(=O)OCC[N+](C)(C)C[Si](CC)(CC)CC,,,,,,
6935,56936,"1-Heptanaminium, N,N'-((1,4-dioxo-1,4-butanediyl)bis(oxy-2,1-ethanediyl))bis(N,N-dimethyl-, diiodide",CCCCCCC[N+](C)(C)CCOC(=O)CCC(=O)OCC[N+](C)(C)CCCCCCC.[I-].[I-],,,,,,
6936,56937,Heptyl-[2-[4-[2-[heptyl(dimethyl)azaniumyl]ethoxy]-4-oxobutanoyl]oxyethyl]-dimethylazanium,CCCCCCC[N+](C)(C)CCOC(=O)CCC(=O)OCC[N+](C)(C)CCCCCCC,,,,,,
6937,56938,CID 56938,CC[O-].C[C@]12CC[C@@H](C=C1CC[C@@H]3[C@@H]2CC[C@]4([C@H]3CC[C@@]4(C5=CSC(=N5)[NH3+])O)C)O,,,,,,
6938,56939,"(3S,8R,9S,10R,13S,14S,17R)-17-(2-amino-1,3-thiazol-4-yl)-10,13-dimethyl-1,2,3,6,7,8,9,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthrene-3,17-diol",C[C@]12CC[C@@H](C=C1CC[C@@H]3[C@@H]2CC[C@]4([C@H]3CC[C@@]4(C5=CSC(=N5)N)O)C)O,,,,,,
6939,56940,"2-(2-(Ethylthio)-1-methylethyl)-2-methyl-1,3-dioxolane",CCSCC(C)C1(OCCO1)C,,,,,,
6940,56941,"2-Methyl-2-(1-methyl-2-(propylthio)ethyl)-1,3-dioxolane",CCCSCC(C)C1(OCCO1)C,,,,,,
6941,56942,"2-(2-(Ethylthio)-1-methylethyl)-2-methyl-1,3-dioxolane-4-methanol",CCSCC(C)C1(OCC(O1)CO)C,,,,,,
6942,56943,"2-Methyl-2-(1-methyl-2-(propylthio)ethyl)-1,3-dioxolane-4-methanol",CCCSCC(C)C1(OCC(O1)CO)C,,,,,,
6943,56944,"2-Methyl-2-(1-methyl-2-ethylthioethyl)-4-dimethylaminomethoxymethyl-1,3-dioxolane",CCN(CC)COCC1COC(O1)(C)C(C)CSCC,,,,,,
6944,56945,"Ethanamine, N-ethyl-N-(((2-methyl-2-(1-methyl-2-(propylthio)ethyl)-1,3-dioxolan-4-yl)methoxy)methyl)-",CCCSCC(C)C1(OCC(O1)COCN(CC)CC)C,,,,,,
6945,56946,"Acetic acid, ((6-(1-piperidinyl)-4-pyrimidinyl)thio)-, methyl ester",COC(=O)CSC1=NC=NC(=C1)N2CCCCC2,,,,,,
6946,56947,"Acetic acid, ((6-(4-morpholinyl)-4-pyrimidinyl)thio)-, hydrazide",C1COCCN1C2=CC(=NC=N2)SCC(=O)NN,,,,,,
6947,56948,"Acetic acid, ((6-(1-piperidinyl)-4-pyrimidinyl)thio)-, hydrazide",C1CCN(CC1)C2=CC(=NC=N2)SCC(=O)NN,,,,,,
6948,56949,"Acetic acid, ((6-(dimethylamino)-4-pyrimidinyl)thio)-, (1-methylethylidene)hydrazide",CC(=NNC(=O)CSC1=NC=NC(=C1)N(C)C)C,,,,,,
6949,56950,"Acetic acid, ((6-(4-morpholinyl)-4-pyrimidinyl)thio)-, (1-methylethylidene)hydrazide",CC(=NNC(=O)CSC1=NC=NC(=C1)N2CCOCC2)C,,,,,,
6950,56951,"Acetic acid, ((6-(1-piperidinyl)-4-pyrimidinyl)thio)-, (1-methylethylidene)hydrazide",CC(=NNC(=O)CSC1=NC=NC(=C1)N2CCCCC2)C,,,,,,
6951,56952,CID 56952,C1=CC=C(C=C1)C2=C(OC(=CC3=CC=C(C=C3)F)C2=O)O,,,,,,
6952,56953,CID 56953,C1=CC=C(C=C1)C=C2C(=O)C(=C(O2)O)C3=CC=C(C=C3)F,,,,,,
6953,56954,CID 56954,C1=CC(=CC=C1C=C2C(=O)C(=C(O2)O)C3=CC=C(C=C3)Cl)Cl,,,,,,
6954,56955,"2,6-Dimethyl-4-propoxy-benzoic acid 2-methyl-2-(1-pyrrolidinyl)propyl ester",CCCOC1=CC(=C(C(=C1)C)C(=O)OCC(C)(C)[NH+]2CCCC2)C.[Cl-],,,,,,
6955,56956,"(2-Methyl-2-pyrrolidin-1-ylpropyl) 2,6-dimethyl-4-propoxybenzoate",CCCOC1=CC(=C(C(=C1)C)C(=O)OCC(C)(C)N2CCCC2)C,,,,,,
6956,56957,Diphenylacetic acid beta-(dimethylamino)phenethyl ester hydrochloride,C[NH+](C)C(COC(=O)C(C1=CC=CC=C1)C2=CC=CC=C2)C3=CC=CC=C3.[Cl-],,,,,,
6957,56958,"[2-(Dimethylamino)-2-phenylethyl] 2,2-diphenylacetate",CN(C)C(COC(=O)C(C1=CC=CC=C1)C2=CC=CC=C2)C3=CC=CC=C3,,,,,,
6958,56959,Ranolazine,CC1=C(C(=CC=C1)C)NC(=O)CN2CCN(CC2)CC(COC3=CC=CC=C3OC)O,"['Ranolazine is indicated for the treatment of chronic angina. It can be used alone or in conjunction with nitrates, beta-blockers, angiotensin receptor blockers, anti-platelet drugs, calcium channel blockers, lipid-lowering drugs, and ACE inhibitors.  Ranolazine has also been used off-label for the treatment of certain arrhythmias, including ventricular tachycardia, however, this use is not strongly  supported by scientific evidence. Ranolazine has also been studied for the treatment of acute coronary syndrome, microvascular coronary dysfunction, arrhythmia, and glycemic control, which are not yet approved indications.']","['Ranolazine exerts both antianginal and ischemic effects independent from lowering heart rate or blood pressure. It blocks IKr, the rapid portion of the delayed rectifier potassium current, and prolongs the QTc interval in a dose-dependent fashion. The Ikr is important for cardiac repolarization. Ranolazine exerts its therapeutic effects without negative chronotropic, dromotropic, or inotropic actions neither at rest, nor during exercise.']","['A class of drugs that act by inhibition of sodium influx through cell membranes. Blockade of sodium channels slows the rate and amplitude of initial rapid depolarization, reduces cell excitability, and reduces conduction velocity. (See all compounds classified as Sodium Channel Blockers.)', 'Agents that affect the rate or intensity of cardiac contraction, blood vessel diameter, or blood volume. (See all compounds classified as Cardiovascular Agents.)']","['The time to reach peak serum concentration is quite variable but has been observed to be in the range of 2-6 hours, with steady-state within 3 days. The FDA indicates a Tmax of 3-5 hours. The average steady-state Cmax is about 2600 ng/mL. Absorption of ranolazine is not significantly affected by food consumption. The bioavailability of ranolazine taken in the tablet form compared to that from a solution of ranolazine is about 76%.', 'From the administered dose, about 3/4 of the dose is excreted renally, while 1/4 of the dose is excreted in the feces. An estimated 5% of an ingested dose is excreted as unchanged drug.', 'The mean apparent volume of distribution of ranolazine is reported to be 53.2 L and the average steady-state volume of distribution is estimated to range from 85 to 180 L.', 'The reported clearance rate of orally administered ranolazine is of 45 L/h when administered at a dose of 500 mg twice daily. The clearance rate of ranolazine is dose-dependent and renal impairment can increase ranolazine serum concentration by 40-50%.', 'Ranolazine is extensively metabolized in the gut and liver and its absorption is highly variable. For example, at a dose of 1000 mg twice daily, the mean steady-state Cmax was 2600 ng/mL with 95% confidence limits of 400 and 6100 ng/mL. The pharmacokinetics of the (+) R- and (-) S-enantiomers of ranolazine are similar in healthy volunteers. ... Steady state is generally achieved within 3 days of twice-daily dosing with ranolazine. At steady state over the dose range of 500 to 1000 mg twice daily, Cmax and AUC0-t increase slightly more than proportionally to dose, 2.2- and 2.4-fold, respectively. With twice-daily dosing, the trough:peak ratio of the ranolazine plasma concentration is 0.3 to 0.6. The pharmacokinetics of ranolazine is unaffected by age, gender, or food.', 'After oral administration of ranolazine, peak plasma concentrations of ranolazine are reached between 2 and 5 hours. After oral administration of (14)C-ranolazine as a solution, 73% of the dose is systemically available as ranolazine or metabolites. The bioavailability of ranolazine from ranolazine tablets relative to that from a solution of ranolazine is 76%. Because ranolazine is a substrate of P-gp, inhibitors of P-gp may increase the absorption of ranolazine.', 'Food (high-fat breakfast) has no important effect on the Cmax and AUC of ranolazine. Therefore, ranolazine may be taken without regard to meals. Over the concentration range of 0.25 to 10 ug/mL, ranolazine is approximately 62% bound to human plasma proteins.', 'It is not known whether ranolazine is distributed into milk.', 'For more Absorption, Distribution and Excretion (Complete) data for Ranolazine (7 total), please visit the HSDB record page.']","['Ranolazine is rapidly heavily metabolized in the liver an gastrointestinal tract through the activity of the CYP3A4 enzyme with minor contributions from CYP2D6. More than 40 ranolazine metabolites have been found in plasma and more than 100 metabolites have been identified in the urine.   Ranolazine and some of its metabolites are known to weakly inhibit CYP3A4. However, the activity of the metabolites of ranolazine has not been fully elucidated.', 'Ranolazine is extensively metabolized in the intestine and liver by the cytochrome P-450 (CYP) isoenzyme system, mainly by CYP3A and, to a lesser extent, CYP2D6. In vitro studies indicate that ranolazine also is a p-glycoprotein substrate. At least 4 metabolites of ranolazine have been identified. The pharmacologic activity of these metabolites has not been fully established.', 'Ranolazine is metabolized rapidly and extensively in the liver and intestine ... The pharmacologic activity of the metabolites has not been well characterized. After dosing to steady state with 500 mg to 1500 mg twice daily, the four most abundant metabolites in plasma have AUC values ranging from about 5 to 33% that of ranolazine...']","['The apparent terminal half-life of ranolazine is 7 hours.', '... Elimination half-life of ranolazine is 1.4-1.9 hours but is apparently prolonged, on average, to 7 hours for the ER formulation as a result of extended absorption (flip-flop kinetics). ...', '... The four most abundant metabolites in plasma ... display apparent half-lives ranging from 6 to 22 hours.']"
6959,56960,"Androst-4-ene-3-beta,17-alpha-diol, 17-beta-(2-(methylamino)-4-thiazolyl)-, monohydrate",C[C@]12CC[C@@H](C=C1CC[C@@H]3[C@@H]2CC[C@]4([C@H]3CC[C@@]4(C5=CSC(=N5)NC)O)C)O.O,,,,,,
6960,56961,CID 56961,C[C@]12CC[C@@H](C=C1CC[C@@H]3C2CC[C@]4(C3CC[C@@]4(C5=CSC(=N5)NC)O)C)O,,,,,,
6961,56962,"5H-DIBENZO(a,d)CYCLOHEPTEN-5-OL, 10,11-DIHYDRO-5-CYCLOHEXYL-",C1CCC(CC1)C2(C3=CC=CC=C3CCC4=CC=CC=C42)O,,,,,,
6962,56963,"7,12-Dimethylbenzo(k)fluoranthene",CC1=C2C3=CC=CC4=C3C(=CC=C4)C2=C(C5=CC=CC=C15)C,,,,,,
6963,56964,"BENZO(k)FLUORANTHENE, 2-METHYL-",CC1=CC2=C3C(=CC=C2)C4=CC5=CC=CC=C5C=C4C3=C1,,,,,,
6964,56965,17-beta-(2-(Ethylamino)-4-thiazolyl)-17-alpha-hydroxyandrost-4-en-3-one,CCNC1=NC(=CS1)[C@]2(CC[C@@H]3[C@@]2(CC[C@H]4[C@H]3CCC5=CC(=O)CC[C@]45C)C)O,,,,,,
6965,56966,"BENZOIC ACID, p-((METHYLCARBAMOYLMETHYL)AMINO)-, ETHYL ESTER",CCOC(=O)C1=CC=C(C=C1)NCC(=O)NC,,,,,,
6966,56967,2'-Chloro-2-(2-(dimethylamino)ethylthio)acetanilide hydrochloride,C[NH+](C)CCSCC(=O)NC1=CC=CC=C1Cl.[Cl-],,,,,,
6967,56968,N-(2-chlorophenyl)-2-[2-(dimethylamino)ethylsulfanyl]acetamide,CN(C)CCSCC(=O)NC1=CC=CC=C1Cl,,,,,,
6968,56969,6-Chlorochrysene,C1=CC=C2C(=C1)C=CC3=C2C=C(C4=CC=CC=C34)Cl,,,,,,
6969,56970,4-(2-Morpholinoethoxy)carbanilic acid 2-(heptyloxy)ethyl ester,CCCCCCCOCCOC(=O)NC1=CC=C(C=C1)OCCN2CCOCC2,,,,,,
6970,56971,Ipsapirone,C1CN(CCN1CCCCN2C(=O)C3=CC=CC=C3S2(=O)=O)C4=NC=CC=N4,,,"['Agents that alleviate ANXIETY, tension, and ANXIETY DISORDERS, promote sedation, and have a calming effect without affecting clarity of consciousness or neurologic conditions. ADRENERGIC BETA-ANTAGONISTS are commonly used in the symptomatic treatment of anxiety but are not included here. (See all compounds classified as Anti-Anxiety Agents.)', 'Endogenous compounds and drugs that bind to and activate SEROTONIN RECEPTORS. Many serotonin receptor agonists are used as ANTIDEPRESSANTS; ANXIOLYTICS; and in the treatment of MIGRAINE DISORDERS. (See all compounds classified as Serotonin Receptor Agonists.)']",,,
6971,56972,"Androst-4-en-3-one, 17alpha-hydroxy-17-(2-(isopropylamino)-4-thiazolyl)-",CC(C)NC1=NC(=CS1)[C@]2(CC[C@@H]3[C@@]2(CC[C@H]4[C@H]3CCC5=CC(=O)CC[C@]45C)C)O,,,,,,
6972,56973,"5-Ethyl-2,4-dihydro-4-(2-phenoxyethyl)-3H-1,2,4-triazol-3-one",CCC1=NNC(=O)N1CCOC2=CC=CC=C2,,,,,,
6973,56974,CID 56974,C1=NN=C(S1)NC(=O)CC(C(=O)O)S(=O)(=O)[O-].[Na+],,,,,,
6974,56975,"Butanoic acid, 4-oxo-2-sulfo-4-(1,3,4-thiadiazol-2-ylamino)-",C1=NN=C(S1)NC(=O)CC(C(=O)O)S(=O)(=O)O,,,,,,
6975,56976,CID 56976,CCC1=NN=C(S1)NC(=O)CC(C(=O)O)S(=O)(=O)[O-].[Na+],,,,,,
6976,56977,"4-[(5-Ethyl-1,3,4-thiadiazol-2-yl)amino]-4-oxo-2-sulfobutanoic acid",CCC1=NN=C(S1)NC(=O)CC(C(=O)O)S(=O)(=O)O,,,,,,
6977,56978,CID 56978,CCCC1=NN=C(S1)NC(=O)CC(C(=O)O)S(=O)(=O)[O-].[Na+],,,,,,
6978,56979,"4-Oxo-4-[(5-propyl-1,3,4-thiadiazol-2-yl)amino]-2-sulfobutanoic acid",CCCC1=NN=C(S1)NC(=O)CC(C(=O)O)S(=O)(=O)O,,,,,,
6979,56980,CID 56980,CC(C)C1=NN=C(S1)NC(=O)CC(C(=O)O)S(=O)(=O)[O-].[Na+],,,,,,
6980,56981,"4-Oxo-4-[(5-propan-2-yl-1,3,4-thiadiazol-2-yl)amino]-2-sulfobutanoic acid",CC(C)C1=NN=C(S1)NC(=O)CC(C(=O)O)S(=O)(=O)O,,,,,,
6981,56982,CID 56982,CCCCC1=NN=C(S1)NC(=O)CC(C(=O)O)S(=O)(=O)[O-].[Na+],,,,,,
6982,56983,"4-[(5-Butyl-1,3,4-thiadiazol-2-yl)amino]-4-oxo-2-sulfobutanoic acid",CCCCC1=NN=C(S1)NC(=O)CC(C(=O)O)S(=O)(=O)O,,,,,,
6983,56984,CID 56984,CCCC1=NN=C(S1)NC(=O)CC(C(=O)OC)S(=O)(=O)[O-].[Na+],,,,,,
6984,56985,"1-Methoxy-1,4-dioxo-4-[(5-propyl-1,3,4-thiadiazol-2-yl)amino]butane-2-sulfonic acid",CCCC1=NN=C(S1)NC(=O)CC(C(=O)OC)S(=O)(=O)O,,,,,,
6985,56986,CID 56986,CCCCC1=NN=C(S1)NC(=O)CC(C(=O)OC)S(=O)(=O)[O-].[Na+],,,,,,
6986,56987,"4-[(5-Butyl-1,3,4-thiadiazol-2-yl)amino]-1-methoxy-1,4-dioxobutane-2-sulfonic acid",CCCCC1=NN=C(S1)NC(=O)CC(C(=O)OC)S(=O)(=O)O,,,,,,
6987,56988,CID 56988,CC(C)C1=NN=C(S1)NC(=O)CC(C(=O)NC)S(=O)(=O)[O-].[Na+],,,,,,
6988,56989,"1-(Methylamino)-1,4-dioxo-4-[(5-propan-2-yl-1,3,4-thiadiazol-2-yl)amino]butane-2-sulfonic acid",CC(C)C1=NN=C(S1)NC(=O)CC(C(=O)NC)S(=O)(=O)O,,,,,,
6989,56990,CID 56990,CC(C)CC1=NN=C(S1)NC(=O)CC(C(=O)NC)S(=O)(=O)[O-].[Na+],,,,,,
6990,56991,"1-(Methylamino)-4-[[5-(2-methylpropyl)-1,3,4-thiadiazol-2-yl]amino]-1,4-dioxobutane-2-sulfonic acid",CC(C)CC1=NN=C(S1)NC(=O)CC(C(=O)NC)S(=O)(=O)O,,,,,,
6991,56992,"3-Azaspiro(5.5)undecane, 9-tert-butyl-3-(3-(dimethylamino)propyl)-, dihydrochloride",CC(C)(C)C1CCC2(CC1)CC[NH+](CC2)CCC[NH+](C)C.[Cl-].[Cl-],,,,,,
6992,56993,"3-(9-tert-butyl-3-azaspiro[5.5]undec-3-yl)-N,N-dimethyl-1-propanamine",CC(C)(C)C1CCC2(CC1)CCN(CC2)CCCN(C)C,,,,,,
6993,56994,trans-4-Bromo-1-phenyl-3-isochromanone,C1=CC=C(C=C1)C2C3=CC=CC=C3C(C(=O)O2)Br,,,,,,
6994,56995,"1-(N,N-Dimethylaminomethyl)-3-phenyl-1,3-dihydroisobenzofuran",CC1C2=CC=CC=C2C(O1)CN(C)C,,,,,,
6995,56996,CID 56996,C[N+](C)(C)CC(=O)NN=CC1=CC=C(O1)[N+](=O)[O-].[Cl-],,,,,,
6996,56997,Trimethyl-[2-[2-[(5-nitrofuran-2-yl)methylidene]hydrazinyl]-2-oxoethyl]azanium,C[N+](C)(C)CC(=O)NN=CC1=CC=C(O1)[N+](=O)[O-],,,,,,
6997,56998,"Caffeine, 8-((3-methoxypropyl)amino)-",CN1C2=C(N=C1NCCCOC)N(C(=O)N(C2=O)C)C,,,,,,
6998,56999,trans-4-Bromo-1-methyl-3-isochromanone,CC1C2=CC=CC=C2C(C(=O)O1)Br,,,,,,
6999,57000,"2-Imidazolidinone, 1-ethyl-4-phenyl-3-(phenylmethyl)-",CCN1CC(N(C1=O)CC2=CC=CC=C2)C3=CC=CC=C3,,,,,,
7000,57001,1-(1-Methylethyl)-4-phenyl-3-(phenylmethyl)-2-imidazolidinone,CC(C)N1CC(N(C1=O)CC2=CC=CC=C2)C3=CC=CC=C3,,,,,,
7001,57002,"5H-Dibenzo(a,d)cycloheptene-5-carboxylic acid, 10,11-dihydro-5-hydroxy-, (1-methyl-3-piperidyl) ester",CN1CCCC(C1)OC(=O)C2(C3=CC=CC=C3CCC4=CC=CC=C42)O,,,,,,
7002,57003,"1,2-Benzenediol, 4-(2-(N-propyl-N-(4-(3,4,5-trimethoxybenzoyloxy)butyl)amino)propyl)-",CCCN(CCCCOC(=O)C1=CC(=C(C(=C1)OC)OC)OC)C(C)CC2=CC(=C(C=C2)O)O,,,,,,
7003,57004,Eflornithine hydrochloride,C(CC(C(F)F)(C(=O)O)N)CN.Cl,['Treatment of facial hirsutism in women.'],,"['Agents destructive to the protozoal organisms belonging to the suborder TRYPANOSOMATINA. (See all compounds classified as Trypanocidal Agents.)', 'Substances that inhibit or prevent the proliferation of NEOPLASMS. (See all compounds classified as Antineoplastic Agents.)', 'Substances and drugs that inhibit or block the activity of ORNITHINE DECARBOXYLASE. (See all compounds classified as Ornithine Decarboxylase Inhibitors.)']",,,
7004,57005,Diethyl-[2-[(3-propoxyphenyl)carbamoyloxy]ethyl]azanium chloride,CCCOC1=CC=CC(=C1)NC(=O)OCC[NH+](CC)CC.[Cl-],,,,,,
7005,57006,2-(diethylamino)ethyl N-(3-propoxyphenyl)carbamate,CCCOC1=CC=CC(=C1)NC(=O)OCCN(CC)CC,,,,,,
7006,57007,"(17S)-17-hydroxy-13-methyl-17-propyl-1,2,4,6,7,8,9,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-3-one",CCC[C@@]1(CCC2C1(CCC3C2CCC4=C3CCC(=O)C4)C)O,,,,,,
7007,57008,2-Ethyl-N-(2-(hexahydro-1H-azepin-1-yl)ethyl)-2-phenyl-malonamic acid ethyl ester,CCC(C1=CC=CC=C1)(C(=O)NCCN2CCCCCC2)C(=O)OCC,,,,,,
7008,57009,2-Ethyl-2-phenyl-N-(3-piperidinopropyl)malonamic acid ethyl ester,CCC(C1=CC=CC=C1)(C(=O)NCCCN2CCCCC2)C(=O)OCC,,,,,,
7009,57010,"BENZILIC ACID, alpha-(1-PYRROLIDINYLMETHYL)BENZYL ESTER, HYDROCHLORIDE",C1CC[NH+](C1)CC(C2=CC=CC=C2)OC(=O)C(C3=CC=CC=C3)(C4=CC=CC=C4)O.[Cl-],,,,,,
7010,57011,"(1-Phenyl-2-pyrrolidin-1-ylethyl) 2-hydroxy-2,2-diphenylacetate",C1CCN(C1)CC(C2=CC=CC=C2)OC(=O)C(C3=CC=CC=C3)(C4=CC=CC=C4)O,,,,,,
7011,57012,"BENZILIC ACID, alpha-(MORPHOLINOMETHYL)BENZYL ESTER, HYDROCHLORIDE",C1COCC[NH+]1CC(C2=CC=CC=C2)OC(=O)C(C3=CC=CC=C3)(C4=CC=CC=C4)O.[Cl-],,,,,,
7012,57013,"(2-Morpholin-4-yl-1-phenylethyl) 2-hydroxy-2,2-diphenylacetate",C1COCCN1CC(C2=CC=CC=C2)OC(=O)C(C3=CC=CC=C3)(C4=CC=CC=C4)O,,,,,,
7013,57014,Diphenylacetic acid beta-(diethylamino)phenethyl ester hydrochloride,CC[NH+](CC)C(COC(=O)C(C1=CC=CC=C1)C2=CC=CC=C2)C3=CC=CC=C3.[Cl-],,,,,,
7014,57015,"[2-(Diethylamino)-2-phenylethyl] 2,2-diphenylacetate",CCN(CC)C(COC(=O)C(C1=CC=CC=C1)C2=CC=CC=C2)C3=CC=CC=C3,,,,,,
7015,57016,o-(3-Allyl-5-methyl-2-oxotetrahydro-3-furyl)benzoic acid 2-(diethylamino)ethyl ester,CCN(CC)CCOC(=O)C1=CC=CC=C1C2(CC(OC2=O)C)CC=C,,,,,,
7016,57017,17-beta-(2-(Butylamino)-4-thiazolyl)-17-alpha-hydroxy-androst-4-en-3-one,CCCCNC1=NC(=CS1)[C@]2(CC[C@@H]3[C@@]2(CC[C@H]4[C@H]3CCC5=CC(=O)CC[C@]45C)C)O,,,,,,
7017,57018,17-beta-(2-(sec-Butylamino)-4-thiazolyl)-17-alpha-hydroxyandrost-4-en-3-one,CCC(C)NC1=NC(=CS1)[C@]2(CC[C@@H]3[C@@]2(CC[C@H]4[C@H]3CCC5=CC(=O)CC[C@]45C)C)O,,,,,,
7018,57019,"17-beta-(2-(Butylamino)-4-thiazolyl)androst-4-ene-3-beta,17-alpha-diol dihydrate",CCCCNC1=NC(=CS1)[C@]2(CC[C@@H]3[C@@]2(CC[C@H]4[C@H]3CCC5=C[C@@H](CC[C@]45C)O)C)O.O.O,,,,,,
7019,57020,"(3R,8R,9S,10R,13S,14S,17R)-17-[2-(butylamino)-1,3-thiazol-4-yl]-10,13-dimethyl-1,2,3,6,7,8,9,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthrene-3,17-diol",CCCCNC1=NC(=CS1)[C@]2(CC[C@@H]3[C@@]2(CC[C@H]4[C@H]3CCC5=C[C@@H](CC[C@]45C)O)C)O,,,,,,
7020,57021,"2-(Bis(4-fluorophenyl)methoxy)-N,N-dimethylethanamine hydrochloride",C[NH+](C)CCOC(C1=CC=C(C=C1)F)C2=CC=C(C=C2)F.[Cl-],,,,,,
7021,57022,"2-[bis(4-fluorophenyl)methoxy]-N,N-dimethylethanamine",CN(C)CCOC(C1=CC=C(C=C1)F)C2=CC=C(C=C2)F,,,,,,
7022,57023,"Ethanamine, 2-((4-bromophenyl)(4-fluorophenyl)methoxy)-N,N-dimethyl-, hydrochloride",C[NH+](C)CCOC(C1=CC=C(C=C1)F)C2=CC=C(C=C2)Br.[Cl-],,,,,,
7023,57024,"2-[(4-bromophenyl)-(4-fluorophenyl)methoxy]-N,N-dimethylethanamine",CN(C)CCOC(C1=CC=C(C=C1)F)C2=CC=C(C=C2)Br,,,,,,
7024,57025,CID 57025,CC(=O)O[C@@H]1[C@@H](SC2=C(C=CC(=C2)Cl)N(C1=O)CCN(C)C)C3=CC=C(C=C3)OC.C(=CC(=O)O)C(=O)O,,,,,,
7025,57026,Clentiazem,CC(=O)O[C@@H]1[C@@H](SC2=C(C=CC(=C2)Cl)N(C1=O)CCN(C)C)C3=CC=C(C=C3)OC,,,"['Drugs used in the treatment of acute or chronic vascular HYPERTENSION regardless of pharmacological mechanism. Among the antihypertensive agents are DIURETICS; (especially DIURETICS, THIAZIDE); ADRENERGIC BETA-ANTAGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; GANGLIONIC BLOCKERS; and VASODILATOR AGENTS. (See all compounds classified as Antihypertensive Agents.)', 'Drugs or agents which antagonize or impair any mechanism leading to blood platelet aggregation, whether during the phases of activation and shape change or following the dense-granule release reaction and stimulation of the prostaglandin-thromboxane system. (See all compounds classified as Platelet Aggregation Inhibitors.)', 'A class of drugs that act by selective inhibition of calcium influx through cellular membranes. (See all compounds classified as Calcium Channel Blockers.)']",,,
7026,57027,"Oxalic acid, (2-(2-(benzylcarbamoyl)ethyl)hydrazide) hydrazide",C1=CC=C(C=C1)NC(=O)CCCNNC(=O)C(=O)NN,,,,,,
7027,57028,17-beta-(2-Amino-4-thiazolyl)-17-alpha-hydroxy-androst-4-en-3-one,C[C@]12CCC(=O)C=C1CC[C@@H]3[C@@H]2CC[C@]4([C@H]3CC[C@@]4(C5=CSC(=N5)N)O)C,,,,,,
7028,57029,CID 57029,CC1=C(C2=C(C=CC(=C2)F)N=C1C3=CC=C(C=C3)C4=CC=CC=C4F)C(=O)[O-].[Na+],,,,,,
7029,57030,Brequinar,CC1=C(C2=C(C=CC(=C2)F)N=C1C3=CC=C(C=C3)C4=CC=CC=C4F)C(=O)O,,,"['Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of INTERLEUKINS and other CYTOKINES are emerging. (See all compounds classified as Immunosuppressive Agents.)', 'Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. (See all compounds classified as Enzyme Inhibitors.)', 'Substances that inhibit or prevent the proliferation of NEOPLASMS. (See all compounds classified as Antineoplastic Agents.)']",,,
7030,57031,CID 57031,CCCC[NH2+]C1CCC2=C(C1)[NH+]=C[NH+]2CC.C(=CC(=O)[O-])C(=O)[O-],,,,,,
7031,57032,"N-butyl-1-ethyl-4,5,6,7-tetrahydrobenzimidazol-5-amine",CCCCNC1CCC2=C(C1)N=CN2CC,,,,,,
7032,57033,"N-phenyl-4,5,6,7-tetrahydro-3H-benzimidazol-5-amine",C1CC2=C(CC1NC3=CC=CC=C3)NC=N2,,,,,,
7033,57034,CID 57034,CCN1C=NC2=C1CCC(C2)N(C)C3CCCC3.C(=CC(=O)O)C(=O)O,,,,,,
7034,57035,"N-cyclopentyl-1-ethyl-N-methyl-4,5,6,7-tetrahydrobenzimidazol-5-amine",CCN1C=NC2=C1CCC(C2)N(C)C3CCCC3,,,,,,
7035,57036,CID 57036,CC[NH+]1C=[NH+]C2=C1CCC(C2)[NH2+]C3CCCC3.C(=CC(=O)[O-])C(=O)[O-],,,,,,
7036,57037,"N-cyclopentyl-1-ethyl-4,5,6,7-tetrahydrobenzimidazol-5-amine",CCN1C=NC2=C1CCC(C2)NC3CCCC3,,,,,,
7037,57038,"17-alpha-Hydroxy-17-beta-(2-(methylamino)-4-thiazolyl)androst-4-ene-3,11-dione",C[C@]12CCC(=O)C=C1CC[C@@H]3[C@@H]2C(=O)C[C@]4([C@H]3CC[C@@]4(C5=CSC(=N5)NC)O)C,,,,,,
7038,57039,17-alpha-Hydroxy-17-beta-(2-(N-methylanilino)-4-thiazolyl)androst-4-en-3-one,C[C@]12CCC(=O)C=C1CC[C@@H]3[C@@H]2CC[C@]4([C@H]3CC[C@@]4(C5=CSC(=N5)N(C)C6=CC=CC=C6)O)C,,,,,,
7039,57040,17-alpha-Hydroxy-17-beta-(2-(p-toluidino)-4-thiazolyl)androst-4-en-3-one,CC1=CC=C(C=C1)NC2=NC(=CS2)[C@]3(CC[C@@H]4[C@@]3(CC[C@H]5[C@H]4CCC6=CC(=O)CC[C@]56C)C)O,,,,,,
7040,57041,17-beta-(2-(p-Anisidino)-4-thiazolyl)-17-alpha-hydroxyandrost-4-en-3-one,C[C@]12CCC(=O)C=C1CC[C@@H]3[C@@H]2CC[C@]4([C@H]3CC[C@@]4(C5=CSC(=N5)NC6=CC=C(C=C6)OC)O)C,,,,,,
7041,57042,"Androst-4-ene-3-beta,17-alpha-diol, 17-beta-(2-(cyclohexylamino)-4-thiazolyl)-, monohydrate",C[C@]12CC[C@@H](C=C1CC[C@@H]3[C@@H]2CC[C@]4([C@H]3CC[C@@]4(C5=CSC(=N5)NC6CCCCC6)O)C)O.O,,,,,,
7042,57043,"(3S,8R,9S,10R,13S,14S,17R)-17-[2-(cyclohexylamino)-1,3-thiazol-4-yl]-10,13-dimethyl-1,2,3,6,7,8,9,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthrene-3,17-diol",C[C@]12CC[C@@H](C=C1CC[C@@H]3[C@@H]2CC[C@]4([C@H]3CC[C@@]4(C5=CSC(=N5)NC6CCCCC6)O)C)O,,,,,,
7043,57044,17-beta-(2-(Cyclohexylamino)-4-thiazolyl)-17-alpha-hydroxyandrost-4-en-3-one,C[C@]12CCC(=O)C=C1CC[C@@H]3[C@@H]2CC[C@]4([C@H]3CC[C@@]4(C5=CSC(=N5)NC6CCCCC6)O)C,,,,,,
7044,57045,17-beta-(2-Anilino-4-thiazolyl)-androst-4-en-3-one,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2C4=CSC(=N4)NC5=CC=CC=C5)CCC6=CC(=O)CC[C@]36C,,,,,,
7045,57046,17-beta-(2-Anilino-4-thiazolyl)-17-alpha-hydroxyandrost-4-en-3-one,C[C@]12CCC(=O)C=C1CC[C@@H]3[C@@H]2CC[C@]4([C@H]3CC[C@@]4(C5=CSC(=N5)NC6=CC=CC=C6)O)C,,,,,,
7046,57047,"3-Amino-4,6-dimethyldipyrido[1,2-A:3',2'-D]imidazole",CC1=CC=CN2C1=NC3=C(C(=CN=C32)N)C,,,,,,
7047,57048,"Ether, propyl thymyl",CCCOC1=C(C=CC(=C1)C)C(C)C,,,,,,
7048,57049,Isopropyl thymyl ether,CC1=CC(=C(C=C1)C(C)C)OC(C)C,,,,,,
7049,57050,Atamestane,CC1=CC(=O)C=C2[C@]1([C@H]3CC[C@]4([C@H]([C@@H]3CC2)CCC4=O)C)C,,,['Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. (See all compounds classified as Enzyme Inhibitors.)'],,,
7050,57051,"17-alpha-Hydroxy-17-beta-(2-(N-methylanilino)-4-thiazolyl)androst-4-ene-3,11-dione",C[C@]12CCC(=O)C=C1CC[C@@H]3[C@@H]2C(=O)C[C@]4([C@H]3CC[C@@]4(C5=CSC(=N5)N(C)C6=CC=CC=C6)O)C,,,,,,
7051,57052,(2-Hydroxyethyl)tripropylammonium chloride,CCC[N+](CCC)(CCC)CCO.[Cl-],,,,,,
7052,57053,(2-Hydroxyethyl)tripropylaminium,CCC[N+](CCC)(CCC)CCO,,,,,,
7053,57054,2-(6-(Bis(carboxymethyl)amino)-5-(2-(2-(bis(carboxymethyl)amino)-5-methylphenoxy)ethoxy)-2-benzofuranyl)-5-oxazolecarboxylic acid,CC1=CC(=C(C=C1)N(CC(=O)O)CC(=O)O)OCCOC2=C(C=C3C(=C2)C=C(O3)C4=NC=C(O4)C(=O)O)N(CC(=O)O)CC(=O)O,,,"['Chemicals that emit light after excitation by light. The wave length of the emitted light is usually longer than that of the incident light. Fluorochromes are substances that cause fluorescence in other substances, i.e., dyes used to mark or label other compounds with fluorescent tags. (See all compounds classified as Fluorescent Dyes.)', 'Substances that bind to and sequester CALCIUM ions. (See all compounds classified as Calcium Chelating Agents.)']",,,
7054,57055,5-Methoxy-3-methyl-2-nitrobenzofuran,CC1=C(OC2=C1C=C(C=C2)OC)[N+](=O)[O-],,,,,,
7055,57056,"(11R)-11-[4-(dimethylamino)phenyl]-17-hydroxy-17-(3-hydroxypropyl)-13-methyl-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-one",CC12C[C@@H](C3=C4CCC(=O)C=C4CCC3C1CCC2(CCCO)O)C5=CC=C(C=C5)N(C)C,,,,,,
7056,57057,17-alpha-Hydroxy-17-beta-(2-(methylamino)-4-thiazolyl)androst-4-en-3-one,C[C@]12CCC(=O)C=C1CC[C@@H]3[C@@H]2CC[C@]4([C@H]3CC[C@@]4(C5=CSC(=N5)NC)O)C,,,,,,
7057,57058,17-[(2-Hydroxyethyl)imino]androst-5-en-3-ol 3-acetate,CC(=O)OC1CC[C@@]2([C@H]3CC[C@]4([C@H]([C@@H]3CC=C2C1)CCC4=NCCO)C)C,,,,,,
7058,57059,17-beta-(2-(N-Ethylanilino)-4-thiazolyl)-17-alpha-hydroxyandrost-4-en-3-one,CCN(C1=CC=CC=C1)C2=NC(=CS2)[C@]3(CC[C@@H]4[C@@]3(CC[C@H]5[C@H]4CCC6=CC(=O)CC[C@]56C)C)O,,,,,,
7059,57060,"trans-1,2-Dihydro-1,2,9-trihydroxychrysene",C1=CC2=C(C=CC3=C2C=CC4=C3C=C(C=C4)O)[C@H]([C@@H]1O)O,,,,,,
7060,57061,Crisnatol mesylate,CC(CO)(CO)NCC1=CC2=C(C=CC3=CC=CC=C32)C4=CC=CC=C41.CS(=O)(=O)O,,,,,,
7061,57062,Crisnatol,CC(CO)(CO)NCC1=CC2=C(C=CC3=CC=CC=C32)C4=CC=CC=C41,,,,,,
7062,57063,"1-Benzoxepin-5(2H)-one, 3,4-dihydro-7-methyl-4-(piperidinomethyl)-, hydrochloride",CC1=CC2=C(C=C1)OCCC(C2=O)C[NH+]3CCCCC3.[Cl-],,,,,,
7063,57064,"7-methyl-4-(piperidin-1-ylmethyl)-3,4-dihydro-2H-1-benzoxepin-5-one",CC1=CC2=C(C=C1)OCCC(C2=O)CN3CCCCC3,,,,,,
7064,57065,"1-Benzoxepin-5(2H)-one, 3,4-dihydro-7-methyl-4-(morpholinomethyl)-, hydrochloride",CC1=CC2=C(C=C1)OCCC(C2=O)C[NH+]3CCOCC3.[Cl-],,,,,,
7065,57066,"7-methyl-4-(morpholin-4-ylmethyl)-3,4-dihydro-2H-1-benzoxepin-5-one",CC1=CC2=C(C=C1)OCCC(C2=O)CN3CCOCC3,,,,,,
7066,57067,"1-Benzoxepin-5(2H)-one, 3,4-dihydro-7-methyl-4-((4-methyl-1-piperazinyl)methyl)-, dihydrochloride",CC1=CC2=C(C=C1)OCCC(C2=O)CN3CCN(CC3)C.Cl.Cl,,,,,,
7067,57068,"7-methyl-4-[(4-methylpiperazin-1-yl)methyl]-3,4-dihydro-2H-1-benzoxepin-5-one",CC1=CC2=C(C=C1)OCCC(C2=O)CN3CCN(CC3)C,,,,,,
7068,57069,"1-Benzoxepin-5(2H)-one, 3,4-dihydro-7-methyl-4-((4-methylpiperidino)methyl)-, hydrochloride",CC1CC[NH+](CC1)CC2CCOC3=C(C2=O)C=C(C=C3)C.[Cl-],,,,,,
7069,57070,"7-methyl-4-[(4-methylpiperidin-1-yl)methyl]-3,4-dihydro-2H-1-benzoxepin-5-one",CC1CCN(CC1)CC2CCOC3=C(C2=O)C=C(C=C3)C,,,,,,
7070,57071,"1-Benzoxepin-5(2H)-one, 3,4-dihydro-7-methyl-4-((3-methylpiperidino)methyl)-, hydrochloride",CC1CCC[NH+](C1)CC2CCOC3=C(C2=O)C=C(C=C3)C.[Cl-],,,,,,
7071,57072,"7-methyl-4-[(3-methylpiperidin-1-yl)methyl]-3,4-dihydro-2H-1-benzoxepin-5-one",CC1CCCN(C1)CC2CCOC3=C(C2=O)C=C(C=C3)C,,,,,,
7072,57073,"7-Methyl-4-((4-phenylpiperidino)methyl)-3,4-dihydro-1-benzoxepin-5(2H)-one hydrochloride",CC1=CC2=C(C=C1)OCCC(C2=O)C[NH+]3CCC(CC3)C4=CC=CC=C4.[Cl-],,,,,,
7073,57074,"7-methyl-4-[(4-phenylpiperidin-1-yl)methyl]-3,4-dihydro-2H-1-benzoxepin-5-one",CC1=CC2=C(C=C1)OCCC(C2=O)CN3CCC(CC3)C4=CC=CC=C4,,,,,,
7074,57075,"1-Benzoxepin-5(2H)-one, 3,4-dihydro-7,8-dimethyl-4-(piperidinomethyl)-, hydrochloride",CC1=CC2=C(C=C1C)OCCC(C2=O)C[NH+]3CCCCC3.[Cl-],,,,,,
7075,57076,"7,8-dimethyl-4-(piperidin-1-ylmethyl)-3,4-dihydro-2H-1-benzoxepin-5-one",CC1=CC2=C(C=C1C)OCCC(C2=O)CN3CCCCC3,,,,,,
7076,57077,"1-Benzoxepin-5(2H)-one, 3,4-dihydro-7,8-dimethyl-4-(morpholinomethyl)-, hydrochloride",CC1=CC2=C(C=C1C)OCCC(C2=O)C[NH+]3CCOCC3.[Cl-],,,,,,
7077,57078,"7,8-dimethyl-4-(morpholin-4-ylmethyl)-3,4-dihydro-2H-1-benzoxepin-5-one",CC1=CC2=C(C=C1C)OCCC(C2=O)CN3CCOCC3,,,,,,
7078,57079,"1-Benzoxepin-5(2H)-one, 3,4-dihydro-7,8-dimethyl-4-((4-methyl-1-piperazinyl)methyl)-, dihydrochloride",CC1=CC2=C(C=C1C)OCCC(C2=O)CN3CCN(CC3)C.Cl.Cl,,,,,,
7079,57080,"7,8-dimethyl-4-[(4-methylpiperazin-1-yl)methyl]-3,4-dihydro-2H-1-benzoxepin-5-one",CC1=CC2=C(C=C1C)OCCC(C2=O)CN3CCN(CC3)C,,,,,,
7080,57081,"7-Methoxy-4-(piperidinomethyl)-3,4-dihydro-1-benzoxepin-5(2H)-one hydrochloride",COC1=CC2=C(C=C1)OCCC(C2=O)C[NH+]3CCCCC3.[Cl-],,,,,,
7081,57082,"7-methoxy-4-(piperidin-1-ylmethyl)-3,4-dihydro-2H-1-benzoxepin-5-one",COC1=CC2=C(C=C1)OCCC(C2=O)CN3CCCCC3,,,,,,
7082,57083,"Oxalic acid, bis(2-cyclopenylhydrazide)",C1CCC(C1)NNC(=O)C(=O)NNC2CCCC2,,,,,,
7083,57084,"Oxalic acid, bis(2-(1-cyclopropylethyl)hydrazide)",C1CC1CCNNC(=O)C(=O)NNCCC2CC2,,,,,,
7084,57085,"1-Benzoxepin-5(2H)-one, 3,4-dihydro-4-((hexahydro-1H-azepin-1-yl)methyl)-7-methyl-, hydrochloride",CC1=CC2=C(C=C1)OCCC(C2=O)C[NH+]3CCCCCC3.[Cl-],,,,,,
7085,57086,"4-(azepan-1-ylmethyl)-7-methyl-3,4-dihydro-2H-1-benzoxepin-5-one",CC1=CC2=C(C=C1)OCCC(C2=O)CN3CCCCCC3,,,,,,
7086,57087,"3-(p-Chlorophenyl)-5-((diethylamino)methyl)-1,2,4-oxadiazole hydrochloride",CC[NH+](CC)CC1=NC(=NO1)C2=CC=C(C=C2)Cl.[Cl-],,,,,,
7087,57088,"N-[[3-(4-chlorophenyl)-1,2,4-oxadiazol-5-yl]methyl]-N-ethylethanamine",CCN(CC)CC1=NC(=NO1)C2=CC=C(C=C2)Cl,,,,,,
7088,57089,"1-Chloro-3,3,5,8,8-pentamethyl-3-azoniabicyclo(3.2.1)octane iodide",CC1(C2(CCC1(C[N+](C2)(C)C)Cl)C)C.[I-],,,,,,
7089,57090,"1-Chloro-3,3,5,8,8-pentamethyl-3-azoniabicyclo[3.2.1]octane",CC1(C2(CCC1(C[N+](C2)(C)C)Cl)C)C,,,,,,
7090,57091,2-Ethyl-2-(piperidinomethyl)malonamic acid ethyl ester hydrochloride,CCC(C[NH+]1CCCCC1)(C(=O)N)C(=O)OCC.[Cl-],,,,,,
7091,57092,Ethyl 2-carbamoyl-2-(piperidin-1-ylmethyl)butanoate,CCC(CN1CCCCC1)(C(=O)N)C(=O)OCC,,,,,,
7092,57093,"2-Naphthaleneglycolic acid, 5,6,7,8-tetrahydro-alpha-phenyl-, 2-(diethylamino)ethyl ester, hydrochloride",CC[NH+](CC)CCOC(=O)C(C1=CC=CC=C1)(C2=CC3=C(CCCC3)C=C2)O.[Cl-],,,,,,
7093,57094,"2-(Diethylamino)ethyl 2-hydroxy-2-phenyl-2-(5,6,7,8-tetrahydronaphthalen-2-yl)acetate",CCN(CC)CCOC(=O)C(C1=CC=CC=C1)(C2=CC3=C(CCCC3)C=C2)O,,,,,,
7094,57095,17-((3-(1-Pyrrolidinyl)propyl)imino)androst-5-en-3-ol 3-acetate,CC(=O)OC1CC[C@@]2([C@H]3CC[C@]4([C@H]([C@@H]3CC=C2C1)CCC4=NCCCN5CCCC5)C)C,,,,,,
7095,57096,"N,N'-bis[(5-nitrofuran-2-yl)methylideneamino]oxamide",C1=C(OC(=C1)[N+](=O)[O-])C=NNC(=O)C(=O)NN=CC2=CC=C(O2)[N+](=O)[O-],,,,,,
7096,57097,Rodorubicin,CC[C@]1(C[C@@H](C2=C([C@H]1O[C@H]3C[C@@H]([C@@H]([C@@H](O3)C)O)N(C)C)C(=C4C(=C2O)C(=O)C5=C(C4=O)C=CC=C5O)O)O[C@H]6C[C@@H]([C@@H]([C@@H](O6)C)O[C@H]7C[C@H]8[C@@H]([C@@H](O7)C)O[C@H]9[C@@H](O8)CC(=O)[C@@H](O9)C)N(C)C)O,,,,,,
7097,57098,"1,3,4-Oxadiazole-2(3H)-thione, 5-(((2-ethyl-4-quinazolinyl)oxy)methyl)-3-((4-phenyl-1-piperazinyl)methyl)-",CCC1=NC2=CC=CC=C2C(=N1)OCC3=NN(C(=S)O3)CN4CCN(CC4)C5=CC=CC=C5,,,,,,
7098,57099,"1,3,4-Oxadiazole-2(3H)-thione, 5-(((2-ethyl-4-quinazolinyl)oxy)methyl)-3-((4-(4-methylphenyl)-1-piperazinyl)methyl)-",CCC1=NC2=CC=CC=C2C(=N1)OCC3=NN(C(=S)O3)CN4CCN(CC4)C5=CC=C(C=C5)C,,,,,,
7099,57100,"1,3,4-Oxadiazole-2(3H)-thione, 3-(4-morpholinylmethyl)-5-(((2-propyl-4-quinazolinyl)oxy)methyl)-",CCCC1=NC2=CC=CC=C2C(=N1)OCC3=NN(C(=S)O3)CN4CCOCC4,,,,,,
7100,57101,"1,3,4-Oxadiazole-2(3H)-thione, 3-(1-piperidinylmethyl)-5-(((2-propyl-4-quinazolinyl)oxy)methyl)-",CCCC1=NC2=CC=CC=C2C(=N1)OCC3=NN(C(=S)O3)CN4CCCCC4,,,,,,
7101,57102,"1,3,4-Oxadiazole-2(3H)-thione, 3-((4-phenyl-1-piperazinyl)methyl)-5-(((2-propyl-4-quinazolinyl)oxy)methyl)-",CCCC1=NC2=CC=CC=C2C(=N1)OCC3=NN(C(=S)O3)CN4CCN(CC4)C5=CC=CC=C5,,,,,,
7102,57103,"1,3,4-Oxadiazole-2(3H)-thione, 3-((4-(4-methylphenyl)-1-piperazinyl)methyl)-5-(((2-propyl-4-quinazolinyl)oxy)methyl)-",CCCC1=NC2=CC=CC=C2C(=N1)OCC3=NN(C(=S)O3)CN4CCN(CC4)C5=CC=C(C=C5)C,,,,,,
7103,57104,"1,3,4-Oxadiazole-2(3H)-thione, 5-(((2-methyl-4-quinazolinyl)oxy)methyl)-3-(4-morpholinylmethyl)-",CC1=NC2=CC=CC=C2C(=N1)OCC3=NN(C(=S)O3)CN4CCOCC4,,,,,,
7104,57105,"1,3,4-Oxadiazole-2(3H)-thione, 3-((4-(4-methylphenyl)-1-piperazinyl)methyl)-5-(((2-methyl-4-quinazolinyl)oxy)methyl)-",CC1=CC=C(C=C1)N2CCN(CC2)CN3C(=S)OC(=N3)COC4=NC(=NC5=CC=CC=C54)C,,,,,,
7105,57106,"1,3,4-Oxadiazole-2(3H)-thione, 5-(((2-ethyl-4-quinazolinyl)oxy)methyl)-3-(4-morpholinylmethyl)-",CCC1=NC2=CC=CC=C2C(=N1)OCC3=NN(C(=S)O3)CN4CCOCC4,,,,,,
7106,57107,"1,3,4-Oxadiazole-2(3H)-thione, 5-(((2-ethyl-4-quinazolinyl)oxy)methyl)-3-(1-piperidinylmethyl)-",CCC1=NC2=CC=CC=C2C(=N1)OCC3=NN(C(=S)O3)CN4CCCCC4,,,,,,
7107,57108,CID 57108,CCCC1=C(C=CC(=C1O)C(=O)C)OCCCCCOC2=C(C=C3CCC(OC3=C2)C(=O)[O-])C(=O)C.[Na+],,,,,,
7108,57109,Ablukast,CCCC1=C(C=CC(=C1O)C(=O)C)OCCCCCOC2=C(C=C3CCC(OC3=C2)C(=O)O)C(=O)C,,,,,,
7109,57110,"5H-Furo(3,2-g)(1)benzopyran-5-one, 9-(2-(diethylamino)-3-ethoxypropoxy)-4-hydroxy-7-methyl-, hydrochloride",CC[NH+](CC)C(COCC)COC1=C2C(=C(C3=C1OC=CC3=O)O)C=C(O2)C.[Cl-],,,,,,
7110,57111,"9-[2-(Diethylamino)-3-ethoxypropoxy]-4-hydroxy-2-methylfuro[3,2-g]chromen-5-one",CCN(CC)C(COCC)COC1=C2C(=C(C3=C1OC=CC3=O)O)C=C(O2)C,,,,,,
7111,57112,Lifibrol,CC(C)(C)C1=CC=C(C=C1)CCC(COC2=CC=C(C=C2)C(=O)O)O,,,,,,
7112,57113,"17-beta-(2-(Ethylamino)-4-thiazolyl)androst-4-ene-3-beta,17-alpha-diol",CCNC1=NC(=CS1)[C@]2(CC[C@@H]3[C@@]2(CC[C@H]4[C@H]3CCC5=C[C@H](CC[C@]45C)O)C)O,,,,,,
7113,57114,"17-beta-(2-(Propylamino)-4-thiazolyl)androst-4-ene-3-beta,17-alpha-diol",CCCNC1=NC(=CS1)[C@]2(CC[C@@H]3[C@@]2(CC[C@H]4[C@H]3CCC5=C[C@H](CC[C@]45C)O)C)O,,,,,,
7114,57115,"1-Naphthamide, N-(2-bromoethyl)-",C1=CC=C2C(=C1)C=CC=C2C(=O)NCCBr,,,,,,
7115,57116,"Indole, 3-(3-amino-2-butyl)-5-methoxy-, hydrochloride",CC(C1=CNC2=C1C=C(C=C2)OC)C(C)[NH3+].[Cl-],,,,,,
7116,57117,3-(5-methoxy-1H-indol-3-yl)butan-2-amine,CC(C1=CNC2=C1C=C(C=C2)OC)C(C)N,,,,,,
7117,57118,"OXALIC ACID, HYDRAZIDE 2-(alpha-METHYLPHENETHYL)HYDRAZIDE",CC(CC1=CC=CC=C1)NNC(=O)C(=O)NN,,,,,,
7118,57119,"17-beta-(2-(Isopropylamino)-4-thiazolyl)androst-4-ene-3-beta,17-alpha-diol",CC(C)NC1=NC(=CS1)[C@]2(CC[C@@H]3[C@@]2(CC[C@H]4[C@H]3CCC5=C[C@H](CC[C@]45C)O)C)O,,,,,,
7119,57120,"1H-Indolo(2,3-c)quinolin-1-one, 2,3,4,7-tetrahydro-3,3-dimethyl-6-(trifluoromethyl)-, monohydrochloride",CC1(CC2=C(C(=O)C1)C3=C(C(=N2)C(F)(F)F)[NH2+]C4=CC=CC=C43)C.[Cl-],,,,,,
7120,57121,CID 57121,CC1(CC2=C(C(=O)C1)C3=C4C=CC=CC4=NC3=C(N2)C(F)(F)F)C,,,,,,
7121,57122,"2,3,4,7-Tetrahydro-3,3-dimethyl-6-ethyl-1H-indolo(2,3-c)quinolin-1-one hydrochloride",CCC1=NC2=C(C(=O)CC(C2)(C)C)C3=C1[NH2+]C4=CC=CC=C43.[Cl-],,,,,,
7122,57123,CID 57123,CCC1=C2C(=C3C=CC=CC3=N2)C4=C(N1)CC(CC4=O)(C)C,,,,,,
7123,57124,"3-Isoxazolecarboxylic acid, 5-methyl-, 2-(p-methoxybenzyl)hydrazide, hydrochloride",CC1=CC(=NO1)C(=O)N[NH2+]CC2=CC=C(C=C2)OC.[Cl-],,,,,,
7124,57125,"N'-[(4-methoxyphenyl)methyl]-5-methyl-1,2-oxazole-3-carbohydrazide",CC1=CC(=NO1)C(=O)NNCC2=CC=C(C=C2)OC,,,,,,
7125,57126,5-Chloro-4-(3-(dimethylamino)propoxy)-m-anisidine hydrochloride,CN(C)CCCOC1=C(C=C(C=C1Cl)[NH3+])OC.[Cl-],,,,,,
7126,57127,3-Chloro-4-[3-(dimethylamino)propoxy]-5-methoxyaniline,CN(C)CCCOC1=C(C=C(C=C1Cl)N)OC,,,,,,
7127,57128,1-Phenethyl-2-(5-methyl-3-isoxazolylcarbonyl)hydrazine hydrochloride,CC1=CC(=NO1)C(=O)N[NH2+]CCC2=CC=CC=C2.[Cl-],,,,,,
7128,57129,"5-methyl-N'-(2-phenylethyl)-1,2-oxazole-3-carbohydrazide",CC1=CC(=NO1)C(=O)NNCCC2=CC=CC=C2,,,,,,
7129,57130,"5-((Diethylamino)methyl)-3-phenyl-1,2,4-oxadiazole hydrochloride",CC[NH+](CC)CC1=NC(=NO1)C2=CC=CC=C2.[Cl-],,,,,,
7130,57131,"N-ethyl-N-[(3-phenyl-1,2,4-oxadiazol-5-yl)methyl]ethanamine",CCN(CC)CC1=NC(=NO1)C2=CC=CC=C2,,,,,,
7131,57132,"1H-Indolo(2,3-c)quinolin-1-amine, 2,3,4,7-tetrahydro-3,3,6-trimethyl-, dihydrochloride",CC1=C2C(=C3C(CC(CC3=N1)(C)C)[NH3+])C4=CC=CC=C4[NH2+]2.[Cl-].[Cl-],,,,,,
7132,57133,CID 57133,CC1=C2C(=C3C=CC=CC3=N2)C4=C(N1)CC(CC4N)(C)C,,,,,,
7133,57134,CID 57134,CC1=C2C(=C3C(=N1)CC(CC3=NO)(C)C)C4=CC=CC=C4[NH2+]2.[Cl-],,,,,,
7134,57135,CID 57135,CC1=C2C(=C3C=CC=CC3=N2)C4=C(N1)CC(CC4=NO)(C)C,,,,,,
7135,57136,"1,2-CHRYSENEDIOL, 1,2-DIHYDRO-5-METHYL-, trans-(+-)-",CC1=CC2=CC=CC=C2C3=C1C4=C(C=C3)[C@H]([C@@H](C=C4)O)O,,,,,,
7136,57137,"1,2-CHRYSENEDIOL, 1,2-DIHYDRO-11-METHYL-, trans-(+-)-",CC1=CC2=C(C=C[C@H]([C@@H]2O)O)C3=C1C4=CC=CC=C4C=C3,,,,,,
7137,57138,"Estr-5(10)-ene-3,17-diol",CC12CCC3C(C1CCC2O)CCC4=C3CCC(C4)O,,,,,,
7138,57139,"5-Methylchrysene-1S,2R-diol-3R,4S-epoxide",CC1=CC2=CC=CC=C2C3=C1C4=C(C=C3)[C@@H]([C@H]([C@@H]5[C@H]4O5)O)O,,,"['Substances that increase the risk of NEOPLASMS in humans or animals. Both genotoxic chemicals, which affect DNA directly, and nongenotoxic chemicals, which induce neoplasms by other mechanism, are included. (See all compounds classified as Carcinogens.)']",,,
7139,57140,"(1S,2R,3S,4R)-5-Methyl-1,2,3,4-tetrahydro-3,4-epoxychrysene-1,2-diol",CC1=CC2=CC=CC=C2C3=C1C4=C(C=C3)[C@@H]([C@H]([C@H]5[C@@H]4O5)O)O,,,,,,
7140,57141,4-Methylsulfinylphenyloxooxazolidinylmethylacetamide,CC(=O)NC[C@H]1CN(C(=O)O1)C2=CC=C(C=C2)S(=O)C,,,,,,
7141,57142,CID 57142,CC(=O)NCC1CN(C(=O)O1)C2=CC=C(C=C2)[S+](C)O,,,,,,
7142,57143,"Oxalic acid, bis(2-(3-pentyl)hydrazide)",CCC(CC)NNC(=O)C(=O)NNC(CC)CC,,,,,,
7143,57144,Isovellerol,C[C@]12C[C@]1(C(=C[C@H]3[C@@H]2CC(C3)(C)C)CO)C=O,,,,,,
7144,57145,9-Hydroxyisovelleral,C[C@]12C[C@]1(C(=C[C@]3([C@@H]2CC(C3)(C)C)O)C=O)C=O,,,,,,
7145,57146,9-Hydroxyvelleral,C[C@H]1C=C(C(=C[C@]2([C@@H]1CC(C2)(C)C)O)C=O)C=O,,,,,,
7146,57147,"(4R)-4-[2-[di(propan-2-yl)amino]ethyl]-1-methyl-4-phenyl-5,6,7,8-tetrahydro-4aH-pyrido[1,2-c]pyrimidin-3-one",CC1=NC(=O)[C@](C2N1CCCC2)(CCN(C(C)C)C(C)C)C3=CC=CC=C3,,,,,,
7147,57148,"2,4,6-Cycloheptatrien-1-one, 5-nitroso-2,2'-hydrazodi-",C1=CC=C(C(=O)C=C1)NNC2=CC=C(C=CC2=O)N=O,,,,,,
7148,57149,"Androst-4-ene-3-beta,17-alpha-diol, 17-beta-(2-(p-toluidino)-4-thiazolyl)-, ethanolate",CC[O-].CC1=CC=C(C=C1)NC2=[NH+]C(=CS2)[C@]3(CC[C@@H]4[C@@]3(CC[C@H]5[C@H]4CCC6=C[C@H](CC[C@]56C)O)C)O,,,,,,
7149,57150,"(3S,8R,9S,10R,13S,14S,17R)-10,13-dimethyl-17-[2-(4-methylanilino)-1,3-thiazol-4-yl]-1,2,3,6,7,8,9,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthrene-3,17-diol",CC1=CC=C(C=C1)NC2=NC(=CS2)[C@]3(CC[C@@H]4[C@@]3(CC[C@H]5[C@H]4CCC6=C[C@H](CC[C@]56C)O)C)O,,,,,,
7150,57151,"3H-Pyrazol-3-one, 1,2-dihydro-1,5-dimethyl-4-(1-methylpropyl)-2-phenyl-",CCC(C)C1=C(N(N(C1=O)C2=CC=CC=C2)C)C,,,,,,
7151,57152,"17-beta-(2-Anilino-4-thiazolyl)androst-4-ene-3-beta,17-alpha-diol",C[C@]12CC[C@@H](C=C1CC[C@@H]3[C@@H]2CC[C@]4([C@H]3CC[C@@]4(C5=CSC(=N5)NC6=CC=CC=C6)O)C)O,,,,,,
7152,57153,"Carbazole, 9-(3-(4-methoxypiperidino)propyl)-",COC1CCN(CC1)CCCN2C3=CC=CC=C3C4=CC=CC=C42,,,,,,
7153,57154,N-(1-thiophen-2-ylheptylideneamino)pyridine-4-carboxamide,CCCCCCC(=NNC(=O)C1=CC=NC=C1)C2=CC=CS2,,,,,,
7154,57155,N-(1-thiophen-2-ylheptylideneamino)pyridine-3-carboxamide,CCCCCCC(=NNC(=O)C1=CN=CC=C1)C2=CC=CS2,,,,,,
7155,57156,N-Acetyl-N-(1-(dimethylcarbamoyl)ethyl)anthranilic acid ethyl ester,CCOC(=O)C1=CC=CC=C1N(C(C)C(=O)N(C)C)C(=O)C,,,,,,
7156,57157,p-(N-(1-(Dimethylcarbamoyl)ethyl)acetamido)benzoic acid ethyl ester,CCOC(=O)C1=CC=C(C=C1)N(C(C)C(=O)N(C)C)C(=O)C,,,,,,
7157,57158,4-Hydroxybenzyldimethylamine hydrochloride,CCCC1=CC(=CC(=C1O)CCC)C[NH+](C)C.[Cl-],,,,,,
7158,57159,"4-[(Dimethylamino)methyl]-2,6-dipropylphenol",CCCC1=CC(=CC(=C1O)CCC)CN(C)C,,,,,,
7159,57160,alpha-((3-(Diethylamino)propoxy)methyl)benzyl alcohol,CCN(CC)CCCOCC(C1=CC=CC=C1)O,,,,,,
7160,57161,"Benzanilide, 4-amino-2'-ethyl-6'-isopropyl-",CCC1=C(C(=CC=C1)C(C)C)NC(=O)C2=CC=C(C=C2)N,,,,,,
7161,57162,"Benzo(a)heptalene-7-carbamic acid, 5,6,7,9-tetrahydro-10-(methylthio)-9-oxo-1,2,3-trimethoxy-, butyl ester",CCCCOC(=O)NC1CCC2=CC(=C(C(=C2C3=CC=C(C(=O)C=C13)SC)OC)OC)OC,,,,,,
7162,57163,"Benzo(a)heptalene-7-carbamic acid, 5,6,7,9-tetrahydro-10-(methylthio)-9-oxo-1,2,3-trimethoxy-, vinyl ester",COC1=C(C(=C2C(=C1)CCC(C3=CC(=O)C(=CC=C32)SC)NC(=O)OC=C)OC)OC,,,,,,
7163,57164,"3-(Dichloromethyl)-2,4,4-trichloro-2-butenoic acid",C(C(=C(C(=O)O)Cl)C(Cl)Cl)(Cl)Cl,,,,,,
7164,57165,3-Chloro-4-(dichloromethyl)-5-methoxy-2(5H)-furanone,COC1C(=C(C(=O)O1)Cl)C(Cl)Cl,,,,,,
7165,57166,"3-[13-[1-[1-[8,12-Bis(2-carboxyethyl)-17-(1-hydroxyethyl)-3,7,13,18-tetramethyl-21,24-dihydroporphyrin-2-yl]ethoxy]ethyl]-18-(2-carboxyethyl)-8-(1-hydroxyethyl)-3,7,12,17-tetramethyl-22,23-dihydroporphyrin-2-yl]propanoic acid",CC1=C(C2=CC3=NC(=CC4=NC(=CC5=C(C(=C(N5)C=C1N2)C(C)OC(C)C6=C(C7=CC8=C(C(=C(N8)C=C9C(=C(C(=N9)C=C1C(=C(C(=N1)C=C6N7)C)CCC(=O)O)CCC(=O)O)C)C)C(C)O)C)C)C(=C4CCC(=O)O)C)C(=C3C)CCC(=O)O)C(C)O,,,,,,
7166,57167,CID 57167,C[C@@H]1[C@@H]([C@@H]([C@H](C(O1)O[C@H]2[C@@H](O[C@@H]([C@@H]([C@]2(C)O)O)C)OC3=CC=CC4=C3C5=C(OC6=C(C(=O)C=C7C6=C5C(=C4)OC7=O)O)O)N)OC)O,,,,,,
7167,57168,"17-beta-(2-(o-Toluidino)-4-thiazolyl)androst-4-ene-3-beta,17-alpha-diol",CC1=CC=CC=C1NC2=NC(=CS2)[C@]3(CC[C@@H]4[C@@]3(CC[C@H]5[C@H]4CCC6=C[C@H](CC[C@]56C)O)C)O,,,,,,
7168,57169,"(3S,8R,9S,10R,13S,14S,17R)-17-[2-(3-chloroanilino)-1,3-thiazol-4-yl]-10,13-dimethyl-1,2,3,6,7,8,9,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthrene-3,17-diol",C[C@]12CC[C@@H](C=C1CC[C@@H]3[C@@H]2CC[C@]4([C@H]3CC[C@@]4(C5=CSC(=N5)NC6=CC(=CC=C6)Cl)O)C)O,,,,,,
7169,57170,Diphenylacetic acid beta-piperidinophenethyl ester hydrochloride,C1CC[NH+](CC1)C(COC(=O)C(C2=CC=CC=C2)C3=CC=CC=C3)C4=CC=CC=C4.[Cl-],,,,,,
7170,57171,"(2-Phenyl-2-piperidin-1-ylethyl) 2,2-diphenylacetate",C1CCN(CC1)C(COC(=O)C(C2=CC=CC=C2)C3=CC=CC=C3)C4=CC=CC=C4,,,,,,
7171,57172,"BENZILIC ACID, alpha-(PIPERIDINOMETHYL)BENZYL ESTER, HYDROCHLORIDE",C1CC[NH+](CC1)CC(C2=CC=CC=C2)OC(=O)C(C3=CC=CC=C3)(C4=CC=CC=C4)O.[Cl-],,,,,,
7172,57173,"(1-Phenyl-2-piperidin-1-ylethyl) 2-hydroxy-2,2-diphenylacetate",C1CCN(CC1)CC(C2=CC=CC=C2)OC(=O)C(C3=CC=CC=C3)(C4=CC=CC=C4)O,,,,,,
7173,57174,"1,2-Dibromo-3-chlorobutane",CC(C(CBr)Br)Cl,,,,,,
7174,57175,"trans-1,2-Dihydroxy-anti-3,4-epoxy-1,2,3,4-tetrahydro-5-methylchrysene",CC1=CC2=CC=CC=C2C3=C1C4=C(C=C3)[C@@H]([C@@H]([C@H]5[C@@H]4O5)O)O,,,"['Substances that increase the risk of NEOPLASMS in humans or animals. Both genotoxic chemicals, which affect DNA directly, and nongenotoxic chemicals, which induce neoplasms by other mechanism, are included. (See all compounds classified as Carcinogens.)']",,,
7175,57176,"Chryseno(3,4-b)oxirene-1,2-diol, 1,2,2a,3a-tetrahydro-10-methyl-, (1-alpha,2-beta,2a-beta,3a-beta)-",CC1=CC2=C([C@@H]3[C@@H](O3)[C@@H]([C@H]2O)O)C4=C1C5=CC=CC=C5C=C4,,,,,,
7176,57177,"OXALIC ACID, 2-ISOPROPYLHYDRAZIDE 2-(alpha-METHYLPHENYL)HYDRAZIDE",CC(C)NNC(=O)C(=O)NNC(C)CC1=CC=CC=C1,,,,,,
7177,57178,CID 57178,CC1=C(C=C(C=C1)CCNN)C.C(=CC(=O)O)C(=O)O,,,,,,
7178,57179,"2-(3,4-Dimethylphenyl)ethylhydrazine",CC1=C(C=C(C=C1)CCNN)C,,,,,,
7179,57180,"(1-(3,4-Dimethyl-alpha-hydroxybenzyl)ethyl)trimethylammonium iodide",CC1=C(C=C(C=C1)COC(C)[N+](C)(C)C)C.[I-],,,,,,
7180,57181,"1-[(3,4-Dimethylphenyl)methoxy]ethyl-trimethylazanium",CC1=C(C=C(C=C1)COC(C)[N+](C)(C)C)C,,,,,,
7181,57182,"Benzoic acid, 3,4,5-tris(acetyloxy)-, 4-((1-oxohexadecyl)oxo)butyl ester",CCCCCCCCCCCCCCCC(=O)OCCCCOC(=O)C1=CC(=C(C(=C1)OC(=O)C)OC(=O)C)OC(=O)C,,,,,,
7182,57183,"Benzoic acid, 3,4,5-trimethoxy-, 1,2-ethanediyl ester",COC1=CC(=CC(=C1OC)OC)C(=O)OCCOC(=O)C2=CC(=C(C(=C2)OC)OC)OC,,,,,,
7183,57184,"Benzoic acid, 3,4,5-trimethoxy-, 1,4-butanediyl ester",COC1=CC(=CC(=C1OC)OC)C(=O)OCCCCOC(=O)C2=CC(=C(C(=C2)OC)OC)OC,,,,,,
7184,57185,4-(Decyloxy)-2-butanol,CCCCCCCCCCOCCC(C)O,,,,,,
7185,57186,"1-Butanol, 4-(decyloxy)-",CCCCCCCCCCOCCCCO,,,,,,
7186,57187,CID 57187,C1=C(OC(=C1)[N+](=O)[O-])C=NNC(=O)CC(=O)NN=CC2=CC=C(O2)[N+](=O)[O-],,,,,,
7187,57188,"o-ACETOPHENETIDIDE, N-(DIMETHYLCARBAMOYLMETHYL)-",CCOC1=CC=CC=C1N(CC(=O)N(C)C)C(=O)C,,,,,,
7188,57189,p-(2-(Dimethylamino)propionamido)benzoic acid ethyl ester hydrochloride,CCOC(=O)C1=CC=C(C=C1)NC(=O)C(C)[NH+](C)C.[Cl-],,,,,,
7189,57190,Ethyl 4-[2-(dimethylamino)propanoylamino]benzoate,CCOC(=O)C1=CC=C(C=C1)NC(=O)C(C)N(C)C,,,,,,
7190,57191,"9-Azabicyclo(3.3.1)nonan-3-OL, 9-benzyl-3-phenyl-",C1CC2CC(CC(C1)N2CC3=CC=CC=C3)OC4=CC=CC=C4,,,,,,
7191,57192,"Acetohydroxamic acid, 2-carvacryloxy-N,O-dimethyl-",CC1=C(C=C(C=C1)C(C)C)OCC(=O)N(C)OC,,,,,,
7192,57193,"Acetohydroxamic acid, N,O-dimethyl-2-thymyloxy-",CC1=CC(=C(C=C1)C(C)C)OCC(=O)N(C)OC,,,,,,
7193,57194,"Ammonium, (ethylimino)bis(trimethylene)bis(trimethyl-, diiodide",CCN(CCC[N+](C)(C)C)CCC[N+](C)(C)C.[I-].[I-],,,,,,
7194,57195,3-[Ethyl-[3-(trimethylazaniumyl)propyl]amino]propyl-trimethylazanium,CCN(CCC[N+](C)(C)C)CCC[N+](C)(C)C,,,,,,
7195,57196,2-Aza-1-hydroxypyrene,C1=CC2=C3C(=C1)C=CC4=C3C(=CNC4=O)C=C2,,,,,,
7196,57197,CID 57197,C1=CC=C(C(=C1)C=C2C(=O)N(C(=O)N2)C3=CC=CC=C3Cl)Cl,,,,,,
7197,57198,CID 57198,C1=CC=C(C(=C1)C=C2C(=O)N(C(=O)N2)C3=CC(=CC=C3)Cl)Cl,,,,,,
7198,57199,CID 57199,C1=CC=C(C(=C1)N2C(=O)C(=CC3=CC(=CC=C3)Cl)NC2=O)Cl,,,,,,
7199,57200,CID 57200,C1=CC=C(C(=C1)N2C(=O)C(=CC3=CC=C(C=C3)Cl)NC2=O)Cl,,,,,,
7200,57201,CID 57201,C1=CC(=CC(=C1)Cl)N2C(=O)C(=CC3=CC=C(C=C3)Cl)NC2=O,,,,,,
7201,57202,CID 57202,COC1=CC=CC=C1C=C2C(=O)N(C(=O)N2)C3=CC=CC=C3Cl,,,,,,
7202,57203,"3-(3-Chlorophenyl)-5-[(2-methoxyphenyl)methylidene]imidazolidine-2,4-dione",COC1=CC=CC=C1C=C2C(=O)N(C(=O)N2)C3=CC(=CC=C3)Cl,,,,,,
7203,57204,CID 57204,COC1=CC=CC=C1C=C2C(=O)N(C(=O)N2)C3=CC=C(C=C3)Cl,,,,,,
7204,57205,CID 57205,COC1=CC=CC(=C1)C=C2C(=O)N(C(=O)N2)C3=CC=CC=C3Cl,,,,,,
7205,57206,CID 57206,COC1=CC=CC(=C1)C=C2C(=O)N(C(=O)N2)C3=CC(=CC=C3)Cl,,,,,,
7206,57207,CID 57207,COC1=CC=CC(=C1)C=C2C(=O)N(C(=O)N2)C3=CC=C(C=C3)Cl,,,,,,
7207,57208,CID 57208,COC1=CC=C(C=C1)C=C2C(=O)N(C(=O)N2)C3=CC=CC=C3Cl,,,,,,
7208,57209,"3-(3-Chlorophenyl)-5-[(4-methoxyphenyl)methylidene]imidazolidine-2,4-dione",COC1=CC=C(C=C1)C=C2C(=O)N(C(=O)N2)C3=CC(=CC=C3)Cl,,,,,,
7209,57210,CID 57210,COC1=CC=C(C=C1)C=C2C(=O)N(C(=O)N2)C3=CC=C(C=C3)Cl,,,,,,
7210,57211,Thioacetic acid S-2-(2-aminoacetamido)ethyl ester hydrobromide,CC(=O)SCC[NH2+]C(=O)CN.[Br-],,,,,,
7211,57212,N-glycyl-S-acetylcys-teamine,CC(=O)SCCNC(=O)CN,,,,,,
7212,57213,"Glycine, thio-, S-2-acetamidoethyl ester, trifluoroacetate",CC(=O)NCCSC(=O)C[NH3+].C(=O)(C(F)(F)F)[O-],,,,,,
7213,57214,S-glycyl-N-acetyl-cysteamine,CC(=O)NCCSC(=O)CN,,,,,,
7214,57215,Thioacetic acid S-2-(2-aminopropionamido)ethyl ester hydrobromide,CC(C(=O)NCCSC(=O)C)[NH3+].[Br-],,,,,,
7215,57216,S-[2-(2-aminopropanoylamino)ethyl] ethanethioate,CC(C(=O)NCCSC(=O)C)N,,,,,,
7216,57217,Thioacetic acid S-2-(4-aminobutyramido)ethyl ester hydrobromide,CC(=O)SCC[NH2+]C(=O)CCCN.[Br-],,,,,,
7217,57218,S-[2-(4-aminobutanoylamino)ethyl] ethanethioate,CC(=O)SCCNC(=O)CCCN,,,,,,
7218,57219,S-Acetyl-N-glycylcysteamine,CC(=O)SCC[NH2+]C(=O)CN.C(=O)(C(F)(F)F)[O-],,,,,,
7219,57220,"Acetic acid, dichlorothio-, S-2-(2-aminoacetamido)ethyl ester, trifluoroacetate",C(CSC(=O)C(Cl)Cl)NC(=O)C[NH3+].C(=O)(C(F)(F)F)[O-],,,,,,
7220,57221,"S-[2-[(2-aminoacetyl)amino]ethyl] 2,2-dichloroethanethioate",C(CSC(=O)C(Cl)Cl)NC(=O)CN,,,,,,
7221,57222,"N,N'-(Dithiodiethylene)bis(2-aminoacetamide) dihydrobromide",C(CSSCCNC(=O)C[NH3+])NC(=O)C[NH3+].[Br-].[Br-],,,,,,
7222,57223,"2,2'-Dithiobis[N-glycylethaneamine]",C(CSSCCNC(=O)CN)NC(=O)CN,,,,,,
7223,57224,"N,N'-Bis(glycyl)cystamine bis(trifluoroacetate)",C(CSSCCNC(=O)C[NH3+])NC(=O)C[NH3+].C(=O)(C(F)(F)F)[O-].C(=O)(C(F)(F)F)[O-],,,,,,
7224,57225,Thioacetic acid S-2-(2-aminopropionamido)ethyl ester trifluoroacetate,CC(C(=O)NCCSC(=O)C)[NH3+].C(=O)(C(F)(F)F)[O-],,,,,,
7225,57226,(2-(p-Aminobenzamido)ethyl)diethylmethylammonium bromide,CC[N+](C)(CC)CCNC(=O)C1=CC=C(C=C1)N.[Br-],,,,,,
7226,57227,2-[(4-Aminobenzoyl)amino]ethyl-diethyl-methylazanium,CC[N+](C)(CC)CCNC(=O)C1=CC=C(C=C1)N,,,,,,
7227,57228,1-(4-Diethylaminoacetamido-2-diethylaminoacetamidomethylphenoxy)-n-octane dihydrochloride,CCCCCCCCOC1=C(C=C(C=C1)NC(=O)C[NH+](CC)CC)CNC(=O)C[NH+](CC)CC.[Cl-].[Cl-],,,,,,
7228,57229,2-(diethylamino)-N-[[5-[[2-(diethylamino)acetyl]amino]-2-octoxyphenyl]methyl]acetamide,CCCCCCCCOC1=C(C=C(C=C1)NC(=O)CN(CC)CC)CNC(=O)CN(CC)CC,,,,,,
7229,57230,"17-beta-(2-(N-Ethylanilino)-4-thiazolyl)androst-4-ene-3-beta,17-alpha-diol",CCN(C1=CC=CC=C1)C2=NC(=CS2)[C@]3(CC[C@@H]4[C@@]3(CC[C@H]5[C@H]4CCC6=C[C@H](CC[C@]56C)O)C)O,,,,,,
7230,57231,"3-(p-Chlorophenyl)-5-(3-(1-pyrrolidinyl)propyl)-1,2,4-oxadiazole hydrochloride",C1CC([NH2+]C1)CCCC2=NN=C(O2)C3=CC=C(C=C3)Cl.[Cl-],,,,,,
7231,57232,"2-(4-Chlorophenyl)-5-(3-pyrrolidin-2-ylpropyl)-1,3,4-oxadiazole",C1CC(NC1)CCCC2=NN=C(O2)C3=CC=C(C=C3)Cl,,,,,,
7232,57233,CID 57233,C1=CC=C(C=C1)OC2=CC=C(C=C2)C(=O)C(O)S(=O)(=O)[O-].[Na+],,,,,,
7233,57234,1-Hydroxy-2-oxo-2-(4-phenoxyphenyl)ethanesulfonic acid,C1=CC=C(C=C1)OC2=CC=C(C=C2)C(=O)C(O)S(=O)(=O)O,,,,,,
7234,57235,"1-Butanone, 1-(10-(3-morpholinopropyl)phenothiazin-2-YL)-",CCCC(=O)C1=CC2=C(C=C1)SC3=CC=CC=C3N2CCCN4CCOCC4,,,,,,
7235,57236,4-Oxo-4-(1-phenylpentoxy)but-2-enoic acid,CCCCC(C1=CC=CC=C1)OC(=O)C=CC(=O)O,,,,,,
7236,57237,17-alpha-Hydroxy-17-beta-(2-(o-toluidino)-4-thiazolyl)androst-4-en-3-one,CC1=CC=CC=C1NC2=NC(=CS2)[C@]3(CC[C@@H]4[C@@]3(CC[C@H]5[C@H]4CCC6=CC(=O)CC[C@]56C)C)O,,,,,,
7237,57238,p-(2-(Diethylamino)acetamido)benzoic acid ethyl ester hydrochloride,CC[NH+](CC)CC(=O)NC1=CC=C(C=C1)C(=O)OCC.[Cl-],,,,,,
7238,57239,Ethyl 4-[[2-(diethylamino)acetyl]amino]benzoate,CCN(CC)CC(=O)NC1=CC=C(C=C1)C(=O)OCC,,,,,,
7239,57240,N-(1-Dimethylcarbamoylethyl)-p-acetophenetidide,CCOC1=CC=C(C=C1)N(C(C)C(=O)N(C)C)C(=O)C,,,,,,
7240,57241,"Malononitrile, (cyano-(1,2,3,4-tetrahydro-6-quinolyl)methylene)-",C1CC2=C(C=CC(=C2)C(=C(C#N)C#N)C#N)NC1,,,,,,
7241,57242,Quinelorane,CCCN1CCC[C@H]2[C@H]1CC3=CN=C(N=C3C2)N,,,['Drugs that bind to and activate dopamine receptors. (See all compounds classified as Dopamine Agonists.)'],,,
7242,57243,N-((1-Methyl-3-piperidyl)methyl)acetanilide hydriodide,CC(=O)N(CC1CCC[NH+](C1)C)C2=CC=CC=C2.[I-],,,,,,
7243,57244,N-[(1-methylpiperidin-3-yl)methyl]-N-phenylacetamide,CC(=O)N(CC1CCCN(C1)C)C2=CC=CC=C2,,,,,,
7244,57245,"Cyanamide, (3,4-dihydro-2H-pyrrol-5-YL)-",C1CC(=NC1)NC#N,,,,,,
7245,57246,"Cyanamide, (3,4,5,6-tetrahydro-2-pyridinyl)-",C1CCN=C(C1)NC#N,,,,,,
7246,57247,"Cyanamide, (3,4,5,6-tetrahydro-2H-azepin-7-YL)-",C1CCC(=NCC1)NC#N,,,,,,
7247,57248,CID 57248,CN(C)C=C1CCN=C1NC#N,,,,,,
7248,57249,3-Dimethylaminomethylene-2-cyanoiminopiperidine,CN(C)C=C1CCCN=C1NC#N,,,,,,
7249,57250,CID 57250,CN(C)C=C1CCCCN=C1NC#N,,,,,,
7250,57251,"2',6'-Diethyl-2-(diethylamino)acetanilide hydrochloride",CCC1=C(C(=CC=C1)CC)NC(=O)C[NH+](CC)CC.[Cl-],,,,,,
7251,57252,Pinonicacid,CCC1=C(C(=CC=C1)CC)NC(=O)CN(CC)CC,,,,,,
7252,57253,"3,4-Dihydroxy-9-nitro-3,4-dihydroanthracene",C1=CC=C2C(=C1)C=C3[C@H]([C@@H](C=CC3=C2[N+](=O)[O-])O)O,,,,,,
7253,57254,"N,N-Dimethyl-2-(methyl(2-oxo-3-bornyl)amino)acetamide hydrochloride",CC1(C2CCC1(C(=O)C2N(C)CC(=O)N(C)C)C)C.Cl,,,,,,
7254,57255,"N,N-dimethyl-2-[methyl-(4,7,7-trimethyl-3-oxo-2-bicyclo[2.2.1]heptanyl)amino]acetamide",CC1(C2CCC1(C(=O)C2N(C)CC(=O)N(C)C)C)C,,,,,,
7255,57256,"Benzene, 1-methoxy-2,3,6-trichloro-4-(2,4,6-trichlorophenoxy)-",COC1=C(C=C(C(=C1Cl)Cl)OC2=C(C=C(C=C2Cl)Cl)Cl)Cl,,,,,,
7256,57257,"Benzene, 4-methoxy-1,2,3-trichloro-5-(2,4,6-trichlorophenoxy)-",COC1=C(C(=C(C=C1OC2=C(C=C(C=C2Cl)Cl)Cl)Cl)Cl)Cl,,,,,,
7257,57258,"Benzene, 1,2,3,5-tetrachloro-4-(2,3,5-trichloro-4-methoxyphenoxy)-",COC1=C(C=C(C(=C1Cl)Cl)OC2=C(C(=C(C=C2Cl)Cl)Cl)Cl)Cl,,,,,,
7258,57259,"Butyranilide, 4-(diethylamino)-3'-ethyl-",CCC1=CC(=CC=C1)NC(=O)CCCN(CC)CC,,,,,,
7259,57260,p-(2-(Diethylamino)propionamido)benzoic acid ethyl ester hydrochloride,CC[NH+](CC)C(C)C(=O)NC1=CC=C(C=C1)C(=O)OCC.[Cl-],,,,,,
7260,57261,Ethyl 4-[2-(diethylamino)propanoylamino]benzoate,CCN(CC)C(C)C(=O)NC1=CC=C(C=C1)C(=O)OCC,,,,,,
7261,57262,p-(2-(Butylamino)propionamido)benzoic acid ethyl ester hydrochloride,CCCC[NH2+]C(C)C(=O)NC1=CC=C(C=C1)C(=O)OCC.[Cl-],,,,,,
7262,57263,"p-ACETOPHENETIDIDE, N-(DIETHYLCARBAMOYLMETHYL)-",CCN(CC)C(=O)CN(C1=CC=C(C=C1)OCC)C(=O)C,,,,,,
7263,57264,4-((Dichloroacetyl)amino)-N-(2-(diethylamino)ethyl)benzamide hydrochloride,CC[NH+](CC)CCNC(=O)C1=CC=C(C=C1)NC(=O)C(Cl)Cl.[Cl-],,,,,,
7264,57265,"4-[(2,2-dichloroacetyl)amino]-N-[2-(diethylamino)ethyl]benzamide",CCN(CC)CCNC(=O)C1=CC=C(C=C1)NC(=O)C(Cl)Cl,,,,,,
7265,57266,"Benzamide, 3-chloro-5-ethyl-N-((1-ethyl-2-pyrrolidinyl)methyl)-6-hydroxy-2-methoxy-, monohydrochloride, (S)-",CCC1=CC(=C(C(=C1O)C(=O)NC[C@@H]2CCC[NH+]2CC)OC)Cl.[Cl-],,,"['Drugs that bind to but do not activate DOPAMINE RECEPTORS, thereby blocking the actions of dopamine or exogenous agonists. Many drugs used in the treatment of psychotic disorders (ANTIPSYCHOTIC AGENTS) are dopamine antagonists, although their therapeutic effects may be due to long-term adjustments of the brain rather than to the acute effects of blocking dopamine receptors. Dopamine antagonists have been used for several other clinical purposes including as ANTIEMETICS, in the treatment of Tourette syndrome, and for hiccup. Dopamine receptor blockade is associated with NEUROLEPTIC MALIGNANT SYNDROME. (See all compounds classified as Dopamine Antagonists.)']",,,
7266,57267,Eticlopride,CCC1=CC(=C(C(=C1O)C(=O)NC[C@@H]2CCCN2CC)OC)Cl,,,"['Drugs that bind to but do not activate DOPAMINE RECEPTORS, thereby blocking the actions of dopamine or exogenous agonists. Many drugs used in the treatment of psychotic disorders (ANTIPSYCHOTIC AGENTS) are dopamine antagonists, although their therapeutic effects may be due to long-term adjustments of the brain rather than to the acute effects of blocking dopamine receptors. Dopamine antagonists have been used for several other clinical purposes including as ANTIEMETICS, in the treatment of Tourette syndrome, and for hiccup. Dopamine receptor blockade is associated with NEUROLEPTIC MALIGNANT SYNDROME. (See all compounds classified as Dopamine Antagonists.)']",,,
7267,57268,2-(Diethylamino)ethyl phenethylcarbamate hydrochloride,CC[NH+](CC)CCOC(=O)NCCC1=CC=CC=C1.[Cl-],,,,,,
7268,57269,2-(diethylamino)ethyl N-(2-phenylethyl)carbamate,CCN(CC)CCOC(=O)NCCC1=CC=CC=C1,,,,,,
7269,57270,3-Bromo-4-(2-(diethylamino)ethoxy)-5-ethoxyacetanilide hydrochloride,CC[NH+](CC)CCOC1=C(C=C(C=C1Br)NC(=O)C)OCC.[Cl-],,,,,,
7270,57271,N-[3-bromo-4-[2-(diethylamino)ethoxy]-5-ethoxyphenyl]acetamide,CCN(CC)CCOC1=C(C=C(C=C1Br)NC(=O)C)OCC,,,,,,
7271,57272,"Decanamide, N-(8-ethoxy-5-quinolylsulfonyl)-",CCCCCCCCCC(=O)NS(=O)(=O)C1=C2C=CC=NC2=C(C=C1)OCC,,,,,,
7272,57273,1-Nitrosoindole-3-acetonitrile,C1=CC=C2C(=C1)C(=CN2N=O)CC#N,,,,,,
7273,57274,CID 57274,CC1=C(C=C(C=C1)Cl)NC(C2=CC=CC=C2)C(=O)NCC[NH+](C)C.C(=CC(=O)[O-])C(=O)O,,,,,,
7274,57275,2-(5-chloro-2-methylanilino)-N-[2-(dimethylamino)ethyl]-2-phenylacetamide,CC1=C(C=C(C=C1)Cl)NC(C2=CC=CC=C2)C(=O)NCCN(C)C,,,,,,
7275,57276,"Acetamide, N-(2-(diethylamino)ethyl)-2,2-diphenyl-N-(2-pyridylmethyl)-, hydrochloride",CC[NH+](CC)CCN(CC1=CC=CC=N1)C(=O)C(C2=CC=CC=C2)C3=CC=CC=C3.[Cl-],,,,,,
7276,57277,"N-[2-(diethylamino)ethyl]-2,2-diphenyl-N-(pyridin-2-ylmethyl)acetamide",CCN(CC)CCN(CC1=CC=CC=N1)C(=O)C(C2=CC=CC=C2)C3=CC=CC=C3,,,,,,
7277,57278,"Acetamide, N-(2-(diethylamino)ethyl)-2,2-diphenyl-N-(3-pyridylmethyl)-, hydrochloride",CC[NH+](CC)CCN(CC1=CN=CC=C1)C(=O)C(C2=CC=CC=C2)C3=CC=CC=C3.[Cl-],,,,,,
7278,57279,"N-[2-(diethylamino)ethyl]-2,2-diphenyl-N-(pyridin-3-ylmethyl)acetamide",CCN(CC)CCN(CC1=CN=CC=C1)C(=O)C(C2=CC=CC=C2)C3=CC=CC=C3,,,,,,
7279,57280,"Acetamide, N-(2-(diethylamino)ethyl)-2,2-diphenyl-N-(4-pyridylmethyl)-, hydrochloride",CC[NH+](CC)CCN(CC1=CC=NC=C1)C(=O)C(C2=CC=CC=C2)C3=CC=CC=C3.[Cl-],,,,,,
7280,57281,"N-[2-(diethylamino)ethyl]-2,2-diphenyl-N-(pyridin-4-ylmethyl)acetamide",CCN(CC)CCN(CC1=CC=NC=C1)C(=O)C(C2=CC=CC=C2)C3=CC=CC=C3,,,,,,
7281,57282,2-(Diethylamino)-N-methyl-N-(3-phenylpropyl)acetamide hydrochloride,CC[NH+](CC)CC(=O)N(C)CCCC1=CC=CC=C1.[Cl-],,,,,,
7282,57283,2-(diethylamino)-N-methyl-N-(3-phenylpropyl)acetamide,CCN(CC)CC(=O)N(C)CCCC1=CC=CC=C1,,,,,,
7283,57284,2-(Diethylamino)-N-methyl-N-(2-(p-tolyloxy)ethyl)acetamide hydrochloride,CC[NH+](CC)CC(=O)N(C)CCOC1=CC=C(C=C1)C.[Cl-],,,,,,
7284,57285,2-(diethylamino)-N-methyl-N-[2-(4-methylphenoxy)ethyl]acetamide,CCN(CC)CC(=O)N(C)CCOC1=CC=C(C=C1)C,,,,,,
7285,57286,2-(Diethylamino)-N-methyl-N-(1-(o-tolyloxy)-2-propyl)acetamide hydrochloride,CC[NH+](CC)CC(=O)N(C)C(C)COC1=CC=CC=C1C.[Cl-],,,,,,
7286,57287,2-(diethylamino)-N-methyl-N-[1-(2-methylphenoxy)propan-2-yl]acetamide,CCN(CC)CC(=O)N(C)C(C)COC1=CC=CC=C1C,,,,,,
7287,57288,"2-(Diethylamino)-N-methyl-N-(1-(2,4-xylyloxy)-2-propyl)acetamide hydrochloride",CC[NH+](CC)CC(=O)N(C)C(C)COC1=C(C=C(C=C1)C)C.[Cl-],,,,,,
7288,57289,"2-(diethylamino)-N-[1-(2,4-dimethylphenoxy)propan-2-yl]-N-methylacetamide",CCN(CC)CC(=O)N(C)C(C)COC1=C(C=C(C=C1)C)C,,,,,,
7289,57290,2-(Diethylamino)-N-(1-phenoxy-2-propyl)acetamide hydrochloride,CC[NH+](CC)CC(=O)NC(C)COC1=CC=CC=C1.[Cl-],,,,,,
7290,57291,2-(diethylamino)-N-(1-phenoxypropan-2-yl)acetamide,CCN(CC)CC(=O)NC(C)COC1=CC=CC=C1,,,,,,
7291,57292,2-(Diisopropylamino)-N-(2-norbornanyl)acetamide hydrochloride,CC(C)N(CC(=O)NC1CC2CCC1C2)C(C)C.Cl,,,,,,
7292,57293,N-(2-bicyclo[2.2.1]heptanyl)-2-[di(propan-2-yl)amino]acetamide,CC(C)N(CC(=O)NC1CC2CCC1C2)C(C)C,,,,,,
7293,57294,"Acetamide, 2-(dimethylamino)-N-(3-cyclohexyl-1,6-dimethyl-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl)-, hydrobromide",CC1=C(C(=O)N(C(=O)N1C)C2CCCCC2)[NH2+]C(=O)CN(C)C.[Br-],,,,,,
7294,57295,"N-(1-cyclohexyl-3,4-dimethyl-2,6-dioxopyrimidin-5-yl)-2-(dimethylamino)acetamide",CC1=C(C(=O)N(C(=O)N1C)C2CCCCC2)NC(=O)CN(C)C,,,,,,
7295,57296,"Acetamide, 2-(dimethylamino)-N-(2,4-dioxo-1,3,6-trimethyl-1,2,3,4-tetrahydro-5-pyrimidinyl)-",CC1=C(C(=O)N(C(=O)N1C)C)NC(=O)CN(C)C,,,,,,
7296,57297,Endo-2-(dimethylamino)-N-(2-norbornanyl)acetamide hydrochloride,CN(C)CC(=O)N[C@@H]1CC2CCC1C2.Cl,,,,,,
7297,57298,N-[(2R)-2-bicyclo[2.2.1]heptanyl]-2-(dimethylamino)acetamide,CN(C)CC(=O)N[C@@H]1CC2CCC1C2,,,,,,
7298,57299,CID 57299,CC12C[C@@H](C3=C4CCC(=O)C=C4CCC3C1CC[C@]2(C=CCO)O)C5=CC=C(C=C5)N(C)C,,,,,,
7299,57300,"(Z)-3-(1-(4-(2-(dimethylamino)ethoxy)phenyl)-2-phenylbut-1-enyl)phenol 2-hydroxypropane-1,2,3-tricarboxylate",CCC(=C(C1=CC=C(C=C1)OCCN(C)C)C2=CC(=CC=C2)O)C3=CC=CC=C3.C(C(=O)O)C(CC(=O)O)(C(=O)O)O,,,,,,
7300,57301,"2,2'-Hexamethylenebis(2-(2-chloroethyl)isoxazolidinium) diiodide",C1C[N+](OC1)(CCCCCC[N+]2(CCCO2)CCCl)CCCl.[I-].[I-],,,,,,
7301,57302,"2-(2-Chloroethyl)-2-[6-[2-(2-chloroethyl)-1,2-oxazolidin-2-ium-2-yl]hexyl]-1,2-oxazolidin-2-ium",C1C[N+](OC1)(CCCCCC[N+]2(CCCO2)CCCl)CCCl,,,,,,
7302,57303,o-Methoxycarbanilic acid 2-hydroxy-3-piperidinopropyl ester hydrochloride,COC1=CC=CC=C1NC(=O)OCC(C[NH+]2CCCCC2)O.[Cl-],,,,,,
7303,57304,(2-hydroxy-3-piperidin-1-ylpropyl) N-(2-methoxyphenyl)carbamate,COC1=CC=CC=C1NC(=O)OCC(CN2CCCCC2)O,,,,,,
7304,57305,Batrachotoxinin-A N-methylanthranilate,CC(C1=CC[C@@]23C1(C[C@H](C45C2=CC[C@H]6[C@@]4(CC[C@@](C6)(O5)O)C)O)CN(CCO3)C)OC(=O)C7=CC=CC=C7NC,,,,,,
7305,57306,"Acetamide, N-(2,6-dimethylphenyl)-2-(ethylpropylamino)-",CCCN(CC)CC(=O)NC1=C(C=CC=C1C)C,,,,,,
7306,57307,"N-[2-[2-[(2S,3S,5S,8S,10R,17R)-3,5,8-trihydroxy-4,6,16-trimethoxy-11-methyl-11-azoniahexacyclo[7.7.2.12,5.01,10.03,8.013,17]nonadecan-13-yl]acetyl]phenyl]acetamide;bromide",CC(=O)NC1=CC=CC=C1C(=O)CC23CCC(C45[C@@H]2CC([C@H]4[NH+](C3)C)[C@]6(CC([C@]7(C[C@@H]5[C@@]6(C7OC)O)O)OC)O)OC.[Br-],,,,,,
7307,57308,CID 57308,CC(=O)NC1=CC=CC=C1C(=O)CC23CCC(C45[C@@H]2CC(C4N(C3)C)[C@]6(CC([C@]7(C[C@@H]5[C@@]6(C7OC)O)O)OC)O)OC,,,,,,
7308,57309,"Acetohydroxamic acid, 2-carvacryloxy-N,O-diethyl-",CCN(C(=O)COC1=C(C=CC(=C1)C(C)C)C)OCC,,,,,,
7309,57310,"Acetohydroxamic acid, N,O-diethyl-2-thymyloxy-",CCN(C(=O)COC1=C(C=CC(=C1)C)C(C)C)OCC,,,,,,
7310,57311,"ACETOHYDROXAMIC ACID, 2-(o-VERATRAMIDO)-",COC1=C(C=C(C=C1)C(=O)NCC(=O)NO)OC,,,,,,
7311,57312,"Acetone, O-((1,3-benzodioxol-5-YL)carbamoyl)oxime",CC(=NOC(=O)NC1=CC2=C(C=C1)OCO2)C,,,,,,
7312,57313,(Bis(2-chloroethyl)amino)acetonitrile monohydrochloride,C(CCl)[NH+](CCCl)CC#N.[Cl-],,,,,,
7313,57314,2-[Bis(2-chloroethyl)amino]acetonitrile,C(CCl)N(CCCl)CC#N,,,,,,
7314,57315,"Acetonitrile, 2-(1-(3-(p-fluorobenzoyl)propyl)-4-piperidylidene)-2-phenyl-, hydrochloride",C1C[NH+](CCC1=C(C#N)C2=CC=CC=C2)CCCC(=O)C3=CC=C(C=C3)F.[Cl-],,,,,,
7315,57316,(1-(4-(4-Fluorophenyl)-4-oxobutyl)-4-piperidinylidene)(phenyl)acetonitrile hydrochloride,C1CN(CCC1=C(C#N)C2=CC=CC=C2)CCCC(=O)C3=CC=C(C=C3)F,,,,,,
7316,57317,CID 57317,CNC(=O)ON=C(CN=[N+]=[N-])C1=CC=CC=C1,,,,,,
7317,57318,"Acetophenone, 2-chlorodihydroxy-",C1=CC=C(C=C1)C(=O)C(O)(O)Cl,,,,,,
7318,57319,"ACETOPHENONE, alpha-(1-CHLORO-2,2,3,3,4,4-HEXAFLUOROCYCLOBUTYL)-",C1=CC=C(C=C1)C(=O)CC2(C(C(C2(F)F)(F)F)(F)F)Cl,,,,,,
7319,57320,"Acetophenone, 4'-((1-imidazolylcarbonyl)methyl)-2-(1-imidazolyl)-2',3',5',6'-tetramethyl-",CC1=C(C(=C(C(=C1CC(=O)N2C=CN=C2)C)C)C(=O)CN3C=CN=C3)C,,,,,,
7320,57321,"Acetophenone, 2-(1-imidazolyl)-, nitrate",C1=CC=C(C=C1)C(=O)C[NH+]2C=CN=C2.[N+](=O)([O-])[O-],,,,,,
7321,57322,16-Hydroxy-3-oxo-16-propylestr-4-en-17-yl acetate,CCC[C@@]1(CC2C3CCC4=CC(=O)CCC4C3CCC2([C@H]1OC(=O)C)C)O,,,,,,
7322,57323,"1H-AZEPINO(5,4,3-cd)INDOLE, 3,4-DIHYDRO-6-PHENYL-",C1CN=C(C2=C3C1=CNC3=CC=C2)C4=CC=CC=C4,,,,,,
7323,57324,"4-Hydroxy-3,3'-dinitrobiphenyl",C1=CC(=CC(=C1)[N+](=O)[O-])C2=CC(=C(C=C2)O)[N+](=O)[O-],,,,,,
7324,57325,"7,8-Dichloro-10-(3-(dimethylamino)propyl)isoalloxazine hydrochloride",C[NH+](C)CCCN1C2=CC(=C(C=C2N=C3C1=NC(=O)NC3=O)Cl)Cl.[Cl-],,,,,,
7325,57326,"7,8-Dichloro-10-[3-(dimethylamino)propyl]benzo[g]pteridine-2,4-dione",CN(C)CCCN1C2=CC(=C(C=C2N=C3C1=NC(=O)NC3=O)Cl)Cl,,,,,,
7326,57327,"6-amino-2-[[1-(carboxymethyl)-2-oxo-4,5-dihydro-3H-1-benzazepin-3-yl]amino]hexanoic acid",C1CC2=CC=CC=C2N(C(=O)C1NC(CCCCN)C(=O)O)CC(=O)O,,,,,,
7327,57328,"N,N'-Carbonylbis(2-ethyl-2-(piperidinomethyl)malonamic acid) diethyl ester 2HCl",CCC(C[NH+]1CCCCC1)(C(=O)NC(=O)NC(=O)C(CC)(C[NH+]2CCCCC2)C(=O)OCC)C(=O)OCC.[Cl-].[Cl-],,,,,,
7328,57329,Ethyl 2-[[2-ethoxycarbonyl-2-(piperidin-1-ylmethyl)butanoyl]carbamoylcarbamoyl]-2-(piperidin-1-ylmethyl)butanoate,CCC(CN1CCCCC1)(C(=O)NC(=O)NC(=O)C(CC)(CN2CCCCC2)C(=O)OCC)C(=O)OCC,,,,,,
7329,57330,"6-Nitro-4,5-dihydrobenzo(a)pyrene",C1CC2=C(C3=CC=CC=C3C4=C2C5=C(C=CC=C51)C=C4)[N+](=O)[O-],,,,,,
7330,57331,"Ethylamine, 2-chloro-N,N-dimethyl-, N-oxide",C[N+](C)(CCCl)[O-],,,,,,
7331,57332,"3-Methyl-3H-naphth(1,2-e)indol-10-ol",CN1C=CC2=C1C=CC3=C2C4=C(C=C3)C=CC(=C4)O,,,,,,
7332,57333,"1,2-Dihydro-3-methyl-3H-naphth(1,2-e)indol-10-ol",CC1CNC2=CC(=C3C=CC4=CC=CC=C4C3=C12)O,,,,,,
7333,57334,"3,4-Dihydro-7-hydroxy-1-(2-piperidinopropyl)carbostyril",CC(CN1C(=O)CCC2=C1C=C(C=C2)O)N3CCCCC3,,,,,,
7334,57335,p-(2-Piperidinopropionamido)benzoic acid ethyl ester,CCOC(=O)C1=CC=C(C=C1)NC(=O)C(C)N2CCCCC2,,,,,,
7335,57336,"1-Formyl-2,2-bis(2-chloroethyl)hydrazine",C(CCl)N(CCCl)NC=O,,,,,,
7336,57337,Delmopinol,CCCC(CCC)CCCC1COCCN1CCO,,,"['Agents that modify interfacial tension of water; usually substances that have one lipophilic and one hydrophilic group in the molecule; includes soaps, detergents, emulsifiers, dispersing and wetting agents, and several groups of antiseptics. (See all compounds classified as Surface-Active Agents.)', 'Solutions for rinsing the mouth, possessing cleansing, germicidal, or palliative properties. (From Boucher&apos;s Clinical Dental Terminology, 4th ed) (See all compounds classified as Mouthwashes.)']",,,
7337,57338,"7-Chloro-6-fluoro-1-(4-fluorophenyl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid",C1=CC(=CC=C1N2C=C(C(=O)C3=CC(=C(C=C32)Cl)F)C(=O)O)F,,,,,,
7338,57339,CID 57339,C1=CC=C2C=C(C=CC2=C1)OCCN[NH3+].C(=CC(=O)[O-])C(=O)O,,,,,,
7339,57340,"Hydrazine, [2-(2-naphthalenyloxy)ethyl]-",C1=CC=C2C=C(C=CC2=C1)OCCNN,,,,,,
7340,57341,"Oxalic acid, bis(2-methyl-2-phenylhydrazide)",CC1=CC=CC=C1NNC(=O)C(=O)NNC2=CC=CC=C2C,,,,,,
7341,57342,"Carbostyril, 3,4-dihydro-6-hydroxy-1-(2-piperidinoethyl)-",C1CCN(CC1)CCN2C(=O)CCC3=C2C=CC(=C3)O,,,,,,
7342,57343,"Carbostyril, 3,4-dihydro-7-hydroxy-1-(2-piperidinoethyl)-",C1CCN(CC1)CCN2C(=O)CCC3=C2C=C(C=C3)O,,,,,,
7343,57344,1-(2-Cyanoethyl)-4-phenylisonipecotic acid ethyl ester hydrochloride,CCOC(=O)C1(CC[NH+](CC1)CCC#N)C2=CC=CC=C2.[Cl-],,,,,,
7344,57345,Ethyl 1-(2-cyanoethyl)-4-phenylpiperidine-4-carboxylate,CCOC(=O)C1(CCN(CC1)CCC#N)C2=CC=CC=C2,,,,,,
7345,57346,"3,5-Dichloro-N-(1-ethylpyrrolidin-2-ylmethyl)-2-hydroxy-6-methoxybenzamide (+)-tartrate salt",CC[NH+]1CCC[C@H]1CNC(=O)C2=C(C(=CC(=C2OC)Cl)Cl)O.[C@@H]([C@H](C(=O)[O-])O)(C(=O)O)O,,,,,,
7346,57347,Flesinoxan,C1CN(CCN1CCNC(=O)C2=CC=C(C=C2)F)C3=C4C(=CC=C3)O[C@H](CO4)CO,,,"['Agents that alleviate ANXIETY, tension, and ANXIETY DISORDERS, promote sedation, and have a calming effect without affecting clarity of consciousness or neurologic conditions. ADRENERGIC BETA-ANTAGONISTS are commonly used in the symptomatic treatment of anxiety but are not included here. (See all compounds classified as Anti-Anxiety Agents.)', 'Mood-stimulating drugs used primarily in the treatment of affective disorders and related conditions. Several MONOAMINE OXIDASE INHIBITORS are useful as antidepressants apparently as a long-term consequence of their modulation of catecholamine levels. The tricyclic compounds useful as antidepressive agents (ANTIDEPRESSIVE AGENTS, TRICYCLIC) also appear to act through brain catecholamine systems. A third group (ANTIDEPRESSIVE AGENTS, SECOND-GENERATION) is a diverse group of drugs including some that act specifically on serotonergic systems. (See all compounds classified as Antidepressive Agents.)', 'Drugs used in the treatment of acute or chronic vascular HYPERTENSION regardless of pharmacological mechanism. Among the antihypertensive agents are DIURETICS; (especially DIURETICS, THIAZIDE); ADRENERGIC BETA-ANTAGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; GANGLIONIC BLOCKERS; and VASODILATOR AGENTS. (See all compounds classified as Antihypertensive Agents.)', 'Endogenous compounds and drugs that bind to and activate SEROTONIN RECEPTORS. Many serotonin receptor agonists are used as ANTIDEPRESSANTS; ANXIOLYTICS; and in the treatment of MIGRAINE DISORDERS. (See all compounds classified as Serotonin Receptor Agonists.)']",,,
7347,57348,"Benzo(b)phenanthridinium, 7,12-bis(acetyloxy)-5,6-dimethyl-2,3,9,10-tetramethoxy-, perchlorate",CC1=[N+](C2=C(C3=CC(=C(C=C3C(=C2C4=CC(=C(C=C14)OC)OC)OC(=O)C)OC)OC)OC(=O)C)C.[O-]Cl(=O)(=O)=O,,,,,,
7348,57349,"(7-Acetyloxy-2,3,9,10-tetramethoxy-5,6-dimethylbenzo[b]phenanthridin-6-ium-12-yl) acetate",CC1=[N+](C2=C(C3=CC(=C(C=C3C(=C2C4=CC(=C(C=C14)OC)OC)OC(=O)C)OC)OC)OC(=O)C)C,,,,,,
7349,57350,"Ethanone, 1-(9H-fluoren-2-YL)-2-(1H-imidazol-1-YL)-",C1C2=CC=CC=C2C3=C1C=C(C=C3)C(=O)CN4C=CN=C4,,,,,,
7350,57351,Methyl 10-(3-piperidinopropyl)phenothiazin-2-yl ketone,CC(=O)C1=CC2=C(C=C1)SC3=CC=CC=C3N2CCCN4CCCCC4,,,,,,
7351,57352,17-beta-(2-(N-Ethylanilino)-4-thiazolyl)androst-4-en-3-one,CCN(C1=CC=CC=C1)C2=NC(=CS2)[C@H]3CC[C@@H]4[C@@]3(CC[C@H]5[C@H]4CCC6=CC(=O)CC[C@]56C)C,,,,,,
7352,57353,17-beta-(2-(p-Ethoxyanilino)-4-thiazolyl)-17-alpha-hydroxyandrost-4-en-3-one,CCOC1=CC=C(C=C1)NC2=NC(=CS2)[C@]3(CC[C@@H]4[C@@]3(CC[C@H]5[C@H]4CCC6=CC(=O)CC[C@]56C)C)O,,,,,,
7353,57354,CID 57354,CCCCN=C(N=C(N)S)S,,,,,,
7354,57355,CID 57355,CC(C)CCCC(=CCOC1=C2C(=CC=C(O2)O)C=CC1=O)C,,,,,,
7355,57356,4-Amino-2-butoxy-N-(2-(diethylamino)ethyl)benzamide hydrochloride,CCCCOC1=C(C=CC(=C1)N)C(=O)NCC[NH+](CC)CC.[Cl-],,,,,,
7356,57357,4-Amino-2-butoxy-n-[2-(diethylamino)ethyl]benzamide,CCCCOC1=C(C=CC(=C1)N)C(=O)NCCN(CC)CC,,,,,,
7357,57358,4-(Aminomethyl)-6-methyl-2H-1-benzopyran-2-one hydrochloride,CC1=CC2=C(C=C1)OC(=O)C=C2C[NH3+].[Cl-],,,,,,
7358,57359,4-(Aminomethyl)-6-methyl-2h-chromen-2-one,CC1=CC2=C(C=C1)OC(=O)C=C2CN,,,,,,
7359,57360,4-(Aminomethyl)-7-methyl-2H-1-benzopyran-2-one hydrochloride,CC1=CC2=C(C=C1)C(=CC(=O)O2)C[NH3+].[Cl-],,,,,,
7360,57361,4-(Aminomethyl)-7-methyl-2h-chromen-2-one,CC1=CC2=C(C=C1)C(=CC(=O)O2)CN,,,,,,
7361,57362,"N,N'-Ethylenebis(2-(o-hydroxyphenyl)glycine) diethyl ester",CCOC(=O)C(C1=CC=CC=C1O)NCCNC(C2=CC=CC=C2O)C(=O)OCC,,,,,,
7362,57363,Finasteride,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2C(=O)NC(C)(C)C)CC[C@@H]4[C@@]3(C=CC(=O)N4)C,"['Finasteride is indicated for the treatment of symptomatic benign prostatic hyperplasia (BPH) in men with an enlarged prostate to improve symptoms, reduce the risk of acute urinary retention, and reduce the risk of the need for surgery including transurethral resection of the prostate (TURP) and prostatectomy. A combination product with [tadalafil] is also used for the symptomatic treatment of BPH for up to 26 weeks.  Finasteride is also indicated for the treatment of male pattern hair loss (androgenetic alopecia, hereditary alopecia, or common male baldness) in male patients.']","[""Finasteride is an antiandrogenic compound that works by suppressing the production of serum and intraprostatic dihydrotestosterone (DHT) in men via inhibiting the enzyme responsible for the biosynthesis of DHT. The maximum effect of a rapid reduction in serum DHT concentration is expected to be observed 8 hours following administration of the first dose. In a single man receiving a single oral dose of 5 mg finasteride for up to 4 years, there was a reduction in the serum DHT concentrations by approximately 70% and the median circulating level of testosterone increased by approximately 10-20% within the physiologic range. In a double-blind, placebo-controlled study, finasteride reduced intraprostatic DHT level by 91.4% but finasteride is not expected to decrease the DHT levels to castrate levels since circulating testosterone is also converted to DHT by the type 1 isoenzyme expressed in other tissues. It is expected that DHT levels return to normal within 14 days upon discontinuation of the drug. In a study of male patients with benign prostatic hyperplasia prior to prostatectomy, the treatment with finasteride resulted in an approximate 80% lower DHT content was measured in prostatic tissue removed at surgery compared to placebo. While finasteride reduces the size of the prostate gland by 20%, this may not correlate well with improvement in symptoms. The effects of finasteride are reported to be more pronounced in male patients with enlarged prostates (>25 mL) who are at the greatest risk of disease progression.  In phase III clinical studies, oral administration of finasteride in male patients with male pattern hair loss promoted hair growth and prevented further hair loss by 66% and 83% of the subjects, respectively, which lasted during two years' treatment. The incidences of these effects in treatment groups were significantly higher than that of the group receiving a placebo. Following finasteride administration, the levels of DHT in the scalp skin was shown to be reduced by more than 60%, indicating that the DHT found in scalp is derived from both local DHT production and circulating DHT. The effect of finasteride on scalp DHT is likely seen because of its effect on both local follicular DHT levels as well as serum DHT levels.. There is evidence from early clinical observations and controlled studies that finasteride may reduce bleeding of prostatic origin.""]","['Drugs used in the treatment of urological conditions and diseases such as URINARY INCONTINENCE and URINARY TRACT INFECTIONS. (See all compounds classified as Urological Agents.)', 'Drugs that inhibit 3-OXO-5-ALPHA-STEROID 4-DEHYDROGENASE. They are commonly used to reduce the production of DIHYDROTESTOSTERONE. (See all compounds classified as 5-alpha Reductase Inhibitors.)']","['Finasteride is well absorbed following oral administration and displays a slow accumulation phase after multiple dosing.[lablel] In healthy male subjects receiving oral finasteride, the mean oral bioavailability was 65% for 1 mg finasteride and 63% for 5 mg finasteride, and the values ranged from 26 to 170% for 1 mg dose and from 34 to 108% for 5 mg dose, respectively. It is reported that food intake does not affect the oral bioavailability of the drug. The peak plasma concentrations (Cmax) averaged 37 ng/mL (range, 27-49 ng/mL) and was reached 1-2 hours post administration. The AUC(0-24 hr) was 53 ngxhr/mL (range, 20-154 ngxhr/mL). The plasma concentrations and AUC are reported to be higher in elderly male patients aged 70 years or older.', 'In healthy subjects, about 32-46% of total oral dose of finasteride was excreted in the urine in the form of metabolites while about 51-64% of the dose was excreted in the feces. In patients with renal impairment, the extent of urinary excretion of finasteride is expected to be decreased while the fecal excretion is increased.', 'The volume of distribution is 76 L at steady state, ranging from 44 to 96 L. Finasteride has been shown to cross the blood brain barrier but does not appear to distribute preferentially to the CSF. It is not known whether finasteride is excreted in human milk.', 'In healthy young subjects (n=15), the mean plasma clearance of finasteride was 165 mL/min with the range between 70 and 279 mL/min.']","['Finasteride undergoes extensive hepatic metabolism predominantly mediated by the cytochrome P450 3A4 (CYP3A4) enzyme to form the t-butyl side chain monohydroxylated and monocarboxylic acid metabolites. Theses metabolites retain less than 20% of the pharmacological activity of the parent compound.', 'Finasteride has known human metabolites that include N-(1-Hydroxy-2-methylpropan-2-yl)-9a,11a-dimethyl-7-oxo-1,2,3,3a,3b,4,5,5a,6,9b,10,11-dodecahydroindeno[5,4-f]quinoline-1-carboxamide.']","['In healthy young subjects receiving finasteride, the mean elimination half-life in plasma was 6 hours ranging from 3 to 16 hours. In elderly patients over the age of 70 years, the half-life is prolonged to 8 hours.']"
7363,57364,Carmoxirole,C1CN(CC=C1C2=CC=CC=C2)CCCCC3=CNC4=C3C=C(C=C4)C(=O)O,,,,,,
7364,57365,Trimethylene glycol dinicotinate,C1=CC(=CN=C1)C(=O)OCCCOC(=O)C2=CN=CC=C2,,,,,,
7365,57366,3-(Morpholinomethyl)-5-(p-methoxyphenyl)-5-methylhydantoin hydrochloride,CC1(C(=O)N(C(=O)N1)C[NH+]2CCOCC2)C3=CC=C(C=C3)OC.[Cl-],,,,,,
7366,57367,"5-(4-Methoxyphenyl)-5-methyl-3-(morpholin-4-ylmethyl)imidazolidine-2,4-dione",CC1(C(=O)N(C(=O)N1)CN2CCOCC2)C3=CC=C(C=C3)OC,,,,,,
7367,57368,3-(Morpholinomethyl)-5-(p-ethoxyphenyl)-5-methylhydantoin hydrochloride,CCOC1=CC=C(C=C1)C2(C(=O)N(C(=O)N2)C[NH+]3CCOCC3)C.[Cl-],,,,,,
7368,57369,"5-(4-Ethoxyphenyl)-5-methyl-3-(morpholin-4-ylmethyl)imidazolidine-2,4-dione",CCOC1=CC=C(C=C1)C2(C(=O)N(C(=O)N2)CN3CCOCC3)C,,,,,,
7369,57370,3-(Morpholinomethyl)-5-(p-propoxyphenyl)-5-methylhydantoin hydrochloride,CCCOC1=CC=C(C=C1)C2(C(=O)N(C(=O)N2)C[NH+]3CCOCC3)C.[Cl-],,,,,,
7370,57371,"5-Methyl-3-(morpholin-4-ylmethyl)-5-(4-propoxyphenyl)imidazolidine-2,4-dione",CCCOC1=CC=C(C=C1)C2(C(=O)N(C(=O)N2)CN3CCOCC3)C,,,,,,
7371,57372,"2,4-Imidazolidinedione, 5-methyl-5-(4-(1-methylethoxy)phenyl)-3-(4-morpholinylmethyl)-, monohydrochloride",CC(C)OC1=CC=C(C=C1)C2(C(=O)N(C(=O)N2)C[NH+]3CCOCC3)C.[Cl-],,,,,,
7372,57373,"5-Methyl-3-(morpholin-4-ylmethyl)-5-(4-propan-2-yloxyphenyl)imidazolidine-2,4-dione",CC(C)OC1=CC=C(C=C1)C2(C(=O)N(C(=O)N2)CN3CCOCC3)C,,,,,,
7373,57374,3-(Morpholinomethyl)-5-(p-butoxyphenyl)-5-methylhydantoin hydrochloride,CCCCOC1=CC=C(C=C1)C2(C(=O)N(C(=O)N2)C[NH+]3CCOCC3)C.[Cl-],,,,,,
7374,57375,"5-(4-Butoxyphenyl)-5-methyl-3-(morpholin-4-ylmethyl)imidazolidine-2,4-dione",CCCCOC1=CC=C(C=C1)C2(C(=O)N(C(=O)N2)CN3CCOCC3)C,,,,,,
7375,57376,3-(Morpholinomethyl)-5-(p-isobutoxyphenyl)-5-methylhydantoin hydrochloride,CC(C)COC1=CC=C(C=C1)C2(C(=O)N(C(=O)N2)C[NH+]3CCOCC3)C.[Cl-],,,,,,
7376,57377,"5-Methyl-5-[4-(2-methylpropoxy)phenyl]-3-(morpholin-4-ylmethyl)imidazolidine-2,4-dione",CC(C)COC1=CC=C(C=C1)C2(C(=O)N(C(=O)N2)CN3CCOCC3)C,,,,,,
7377,57378,3-(Morpholinomethyl)-5-(p-pentyloxyphenyl)-5-methylhydantoin hydrochloride,CCCCCOC1=CC=C(C=C1)C2(C(=O)N(C(=O)N2)C[NH+]3CCOCC3)C.[Cl-],,,,,,
7378,57379,"5-Methyl-3-(morpholin-4-ylmethyl)-5-(4-pentoxyphenyl)imidazolidine-2,4-dione",CCCCCOC1=CC=C(C=C1)C2(C(=O)N(C(=O)N2)CN3CCOCC3)C,,,,,,
7379,57380,3-(Morpholinomethyl)-5-(p-isopentyloxyphenyl)-5-methylhydantoin hydrochloride,CC(C)CCOC1=CC=C(C=C1)C2(C(=O)N(C(=O)N2)C[NH+]3CCOCC3)C.[Cl-],,,,,,
7380,57381,"5-Methyl-5-[4-(3-methyl-butoxy)-phenyl]-3-morpholin-4-ylmethyl-imidazolidine-2,4-dione",CC(C)CCOC1=CC=C(C=C1)C2(C(=O)N(C(=O)N2)CN3CCOCC3)C,,,,,,
7381,57382,"1,3-Bis(morpholinomethyl)-5-(p-methoxyphenyl)-5-methylhydantoin",CC1(C(=O)N(C(=O)N1CN2CCOCC2)CN3CCOCC3)C4=CC=C(C=C4)OC,,,,,,
7382,57383,"1,3-Bis(morpholinomethyl)-5-(p-ethoxyphenyl)-5-methylhydantoin",CCOC1=CC=C(C=C1)C2(C(=O)N(C(=O)N2CN3CCOCC3)CN4CCOCC4)C,,,,,,
7383,57384,"1,3-Bis(morpholinomethyl)-5-(p-propoxyphenyl)-5-methylhydantoin",CCCOC1=CC=C(C=C1)C2(C(=O)N(C(=O)N2CN3CCOCC3)CN4CCOCC4)C,,,,,,
7384,57385,"1,3-Bis(morpholinomethyl)-5-(p-isopropoxyphenyl)-5-methylhydantoin",CC(C)OC1=CC=C(C=C1)C2(C(=O)N(C(=O)N2CN3CCOCC3)CN4CCOCC4)C,,,,,,
7385,57386,"1,3-Bis(morpholinomethyl)-5-(p-butoxyphenyl)-5-methylhydantoin",CCCCOC1=CC=C(C=C1)C2(C(=O)N(C(=O)N2CN3CCOCC3)CN4CCOCC4)C,,,,,,
7386,57387,"1,3-Bis(morpholinomethyl)-5-(p-isobutoxyphenyl)-5-methylhydantoin",CC(C)COC1=CC=C(C=C1)C2(C(=O)N(C(=O)N2CN3CCOCC3)CN4CCOCC4)C,,,,,,
7387,57388,"1,3-Bis(morpholinomethyl)-5-(p-pentyloxyphenyl)-5-methylhydantoin",CCCCCOC1=CC=C(C=C1)C2(C(=O)N(C(=O)N2CN3CCOCC3)CN4CCOCC4)C,,,,,,
7388,57389,"1,3-Bis(morpholinomethyl)-5-(isopentyloxyphenyl)-5-methylhydantoin",CC(C)CCOC1=CC=C(C=C1)C2(C(=O)N(C(=O)N2CN3CCOCC3)CN4CCOCC4)C,,,,,,
7389,57390,"1,3-Dimethyl-6-[2-[(5-nitrofuran-2-yl)methylidene]hydrazinyl]pyrimidine-2,4-dione",CN1C(=CC(=O)N(C1=O)C)NN=CC2=CC=C(O2)[N+](=O)[O-],,,,,,
7390,57391,"6-(2,3-Dichlorophenyl)-3-imino-2-propan-2-yl-1,2,4-triazin-5-amine;hydrochloride",CC(C)N1C(=N)N=C(C(=N1)C2=C(C(=CC=C2)Cl)Cl)N.Cl,,,,,,
7391,57392,Palatrigine,CC(C)N1C(=N)N=C(C(=N1)C2=C(C(=CC=C2)Cl)Cl)N,,,,,,
7392,57393,17-alpha-Hydroxy-17-beta-(2-(propylamino)-4-thiazolyl)androst-4-en-3-one,CCCNC1=NC(=CS1)[C@]2(CC[C@@H]3[C@@]2(CC[C@H]4[C@H]3CCC5=CC(=O)CC[C@]45C)C)O,,,,,,
7393,57394,N-Methyl-bis(2-chloropropyl)amine N-oxide hydrochloride,CC(C[N+](C)(CC(C)Cl)O)Cl.[Cl-],,,,,,
7394,57395,Bis(2-chloropropyl)-hydroxy-methylazanium,CC(C[N+](C)(CC(C)Cl)O)Cl,,,,,,
7395,57396,3-(Bis-(2-chloroethyl)amino)propionic acid hydrochloride,C(C[NH+](CCCl)CCCl)C(=O)O.[Cl-],,,,,,
7396,57397,3-[Bis(2-chloroethyl)amino]propanoic acid,C(CN(CCCl)CCCl)C(=O)O,,,,,,
7397,57398,N-(2-Chloroethyl)-N-(2-chloropropyl)glycine hydrochloride monohydrate,CC(C[NH+](CCCl)CC(=O)O)Cl.[Cl-],,,,,,
7398,57399,2-[2-Chloroethyl(2-chloropropyl)amino]acetic acid,CC(CN(CCCl)CC(=O)O)Cl,,,,,,
7399,57400,Centphenaquin,C1CCC2=C(C3=CC=CC=C3N=C2CC1)N4CCN(CC4)C5=CC=CC=C5.Cl.Cl,,,,,,
7400,57401,"7,8,9,10-Tetrahydro-11-(4-phenyl-1-piperazinyl)-6H-cyclohepta(b)quinoline",C1CCC2=C(C3=CC=CC=C3N=C2CC1)N4CCN(CC4)C5=CC=CC=C5,,,,,,
7401,57402,"Bis(2,3-epithiopropyl)disulfide",C1C(S1)CSSCC2CS2,,,,,,
7402,57403,"N,N-Bis(2-chloroethyl)glycine N-oxide hydrochloride",C(CCl)[N+](CCCl)(CC(=O)O)[O-].[Cl-],,,,,,
7403,57404,"N,N-bis(2-chloroethyl)-2-hydroxy-2-oxoethanamine oxide",C(CCl)[N+](CCCl)(CC(=O)O)[O-],,,,,,
7404,57405,Trichloroacetic acid 1-ethyl-1-methyl-2-propynyl ester,CCC(C)(C#C)OC(=O)C(Cl)(Cl)Cl,,,,,,
7405,57406,"Aniline, N-((methylthio)methyl)-",CSCNC1=CC=CC=C1,,,,,,
7406,57407,N-((Methylthio)methyl)-o-anisidine hydrochloride,COC1=CC=CC=C1[NH2+]CSC.[Cl-],,,,,,
7407,57408,2-methoxy-N-(methylsulfanylmethyl)aniline,COC1=CC=CC=C1NCSC,,,,,,
7408,57409,"Benzamide, 3,5-dibromo-N-((1-ethyl-2-pyrrolidinyl)methyl)-2-hydroxy-6-methoxy-, (S)-, monomethanesulfonate (salt)",CC[NH+]1CCC[C@H]1CNC(=O)C2=C(C(=CC(=C2OC)Br)Br)O.CS(=O)(=O)[O-],,,,,,
7409,57410,NoName_1292,CCN1CCCC1CNC(=O)C2=C(C(=CC(=C2OC)Br)Br)O,,,,,,
7410,57411,"Benzamide, 3-bromo-5-ethyl-N-((1-ethyl-2-pyrrolidinyl)methyl)-6-hydroxy-2-methoxy-, tartrate, hydrate (2:2:1)",CCC1=CC(=C(C(=C1O)C(=O)NCC2CCCN2CC)OC)Br.C(C(C(=O)O)O)(C(=O)O)O,,,,,,
7411,57412,5-bromo-3-ethyl-N-[(1-ethylpyrrolidin-2-yl)methyl]-2-hydroxy-6-methoxybenzamide,CCC1=CC(=C(C(=C1O)C(=O)NCC2CCCN2CC)OC)Br,,,,,,
7412,57413,CID 57413,C1=C(OC(=C1)N(O)O)N=NC(=O)CC#N,,,,,,
7413,57414,"N,N-Bis(2-chloroethyl)glycine ethyl ester hydrochloride",CCOC(=O)C[NH+](CCCl)CCCl.[Cl-],,,,,,
7414,57415,Ethyl 2-[bis(2-chloroethyl)amino]acetate,CCOC(=O)CN(CCCl)CCCl,,,,,,
7415,57416,"N,N-Bis(2-chloroethyl)glycine ethyl ester N-oxide hydrochloride",CCOC(=O)C[N+](CCCl)(CCCl)[O-].[Cl-],,,,,,
7416,57417,"N,N-bis(2-chloroethyl)-2-ethoxy-2-oxoethanamine oxide",CCOC(=O)C[N+](CCCl)(CCCl)[O-],,,,,,
7417,57418,"1,2,4-Benzotriazine-3-carboxylic acid, hydrazide",C1=CC=C2C(=C1)N=C(N=N2)C(=O)NN,,,,,,
7418,57419,"2,4-Dimethyl-2-propyl-1,3-dithiolane",CCCC1(SCC(S1)C)C,,,,,,
7419,57420,p-Methylsulphonylbenzylamine hydrochloride,CS(=O)(=O)C1=CC=C(C=C1)C[NH3+].[Cl-],,,,,,
7420,57421,4-(Methylsulfonyl)benzylamine,CS(=O)(=O)C1=CC=C(C=C1)CN,,,,,,
7421,57422,"Carbamic acid, 2-thenyl-, 2-hydroxyethyl ester",C1=CSC(=C1)CNC(=O)OCCO,,,,,,
7422,57423,"3-[(3S,5R,10S,11R,13R,14S,17R)-11,14-dihydroxy-3-[(2R,5R)-5-hydroxy-4-methoxy-6-methyloxan-2-yl]oxy-10,13-dimethyl-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthren-17-yl]-2H-furan-5-one",CC1[C@H](C(C[C@@H](O1)O[C@H]2CC[C@]3([C@@H](C2)CCC4C3[C@@H](C[C@]5([C@@]4(CC[C@@H]5C6=CC(=O)OC6)O)C)O)C)OC)O,,,,,,
7423,57424,"ETHYLAMINE, 2-((p-BUTOXY-alpha-PHENYLBENZYL)OXY)-N,N-DIMETHYL-",CCCCOC1=CC=C(C=C1)C(C2=CC=CC=C2)OCCN(C)C,,,,,,
7424,57425,CID 57425,C1=CC=C2C(=C1)C=CC3=C(C4=CC=CC=C4C(=C32)CO)COS(=O)(=O)[O-].[Na+],,,,,,
7425,57426,[12-(Hydroxymethyl)benzo[a]anthracen-7-yl]methyl hydrogen sulfate,C1=CC=C2C(=C1)C=CC3=C(C4=CC=CC=C4C(=C32)CO)COS(=O)(=O)O,,,,,,
7426,57427,3-Bromo-4-(2-(diethylamino)ethoxy)-5-ethoxyaniline hydrochloride,CCN(CC)CCOC1=C(C=C(C=C1Br)[NH3+])OCC.[Cl-],,,,,,
7427,57428,3-Bromo-4-[2-(diethylamino)ethoxy]-5-ethoxyaniline,CCN(CC)CCOC1=C(C=C(C=C1Br)N)OCC,,,,,,
7428,57429,5-Chloro-4-(3-(diethylamino)propoxy)-m-anisidine hydrochloride,CCN(CC)CCCOC1=C(C=C(C=C1Cl)[NH3+])OC.[Cl-],,,,,,
7429,57430,3-Chloro-4-[3-(diethylamino)propoxy]-5-methoxyaniline,CCN(CC)CCCOC1=C(C=C(C=C1Cl)N)OC,,,,,,
7430,57431,o-Ethoxycarbanilic acid 2-hydroxy-3-piperidinopropyl ester hydrochloride,CCOC1=CC=CC=C1NC(=O)OCC(C[NH+]2CCCCC2)O.[Cl-],,,,,,
7431,57432,(2-hydroxy-3-piperidin-1-ylpropyl) N-(2-ethoxyphenyl)carbamate,CCOC1=CC=CC=C1NC(=O)OCC(CN2CCCCC2)O,,,,,,
7432,57433,1-Methyl-4-acetyl-4-propionyloxypiperidine hydrochloride,CCC(=O)OC1(CC[NH+](CC1)C)C(=O)C.[Cl-],,,,,,
7433,57434,Propanoic acid 4-acetyl-1-methylpiperidin-4-yl ester,CCC(=O)OC1(CCN(CC1)C)C(=O)C,,,,,,
7434,57435,1-Methyl-4-acetyl-4-benzoyloxypiperidine hydrochloride,CC(=O)C1(CC[NH+](CC1)C)OC(=O)C2=CC=CC=C2.[Cl-],,,,,,
7435,57436,Benzoic acid 4-acetyl-1-methylpiperidin-4-yl ester,CC(=O)C1(CCN(CC1)C)OC(=O)C2=CC=CC=C2,,,,,,
7436,57437,"1,1-Diphenethylhydrazine hydrochloride",C1=CC=C(C=C1)CC[NH+](CCC2=CC=CC=C2)N.[Cl-],,,,,,
7437,57438,"1,1-Bis(2-phenylethyl)hydrazine",C1=CC=C(C=C1)CCN(CCC2=CC=CC=C2)N,,,,,,
7438,57439,CID 57439,CON=C(C1=CN=C(S1)N)C(=O)N[C@H]2C3N(C2=O)C(=C(CS3)C[N+]4=CC=CC5=C4CCC5)C(=O)[O-].OS(=O)(=O)O,,,,,,
7439,57440,CID 57440,CON=C(C1=CN=C(S1)N)C(=O)N[C@H]2C3N(C2=O)C(=C(CS3)C[N+]4=CC=CC5=C4CCC5)C(=O)O,,,,,,
7440,57441,"3-(o-Chlorobenzyl)-3,5,8,8-tetramethyl-3-azoniabicyclo(3.2.1)octane iodide",CC1(C2CCC1C[N+](C2)(C)CC3=CC=CC=C3Cl)C.[I-],,,,,,
7441,57442,"3-[(2-Chlorophenyl)methyl]-3,8,8-trimethyl-3-azoniabicyclo[3.2.1]octane",CC1(C2CCC1C[N+](C2)(C)CC3=CC=CC=C3Cl)C,,,,,,
7442,57443,"N-(4-(2-Diethylaminoethoxy)phenyl)-3,4,5-trimethoxybenzamide hydrochloride",CC[NH+](CC)CCOC1=CC=C(C=C1)NC(=O)C2=CC(=C(C(=C2)OC)OC)OC.[Cl-],,,,,,
7443,57444,"N-[4-[2-(Diethylamino)ethoxy]phenyl]-3,4,5-trimethoxybenzamide",CCN(CC)CCOC1=CC=C(C=C1)NC(=O)C2=CC(=C(C(=C2)OC)OC)OC,,,,,,
7444,57445,Diethyl(2-hydroxyethyl)methylammonium bromide alpha-(1-hydroxypropyl)cyclohexaneacetate,CCC(C(C1CCCCC1)C(=O)OCC[N+](C)(CC)CC)O.[Br-],,,,,,
7445,57446,2-(2-Cyclohexyl-3-hydroxypentanoyl)oxyethyl-diethyl-methylazanium,CCC(C(C1CCCCC1)C(=O)OCC[N+](C)(CC)CC)O,,,,,,
7446,57447,"p-BENZOPHENETIDIDE, N-(DIMETHYLCARBAMOYLMETHYL)-",CCOC1=CC=C(C=C1)N(CC(=O)N(C)C)C(=O)C2=CC=CC=C2,,,,,,
7447,57448,CID 57448,C1COP(=O)(N[C@H]1SCCS(=O)(=O)O)N(CCCl)CCCl.C(CCN)C[C@H](C(=O)O)N,,,,,,
7448,57449,D-Lysine,C(CCN)C[C@H](C(=O)O)N,,,,,,
7449,57450,CID 57450,C1COP(=O)(N[C@H]1SCCS(=O)(=O)O)N(CCCl)CCCl,,,,,,
7450,57451,1-(2-Methylpropyl)-5-phenyl-2-imidazolidinone,CC(C)CN1C(CNC1=O)C2=CC=CC=C2,,,,,,
7451,57452,5-(2-Chlorophenyl)-1-methyl-2-imidazolidinone,CN1C(CNC1=O)C2=CC=CC=C2Cl,,,,,,
7452,57453,1-Methyl-5-(4-methylphenyl)-2-imidazolidinone,CC1=CC=C(C=C1)C2CNC(=O)N2C,,,,,,
7453,57454,"Butyrophenone, 4-(4-methyl-1-piperazinyl)-, dihydrochloride",CN1CCN(CC1)CCCC(=O)C2=CC=CC=C2.Cl.Cl,,,,,,
7454,57455,4-(4-Methylpiperazin-1-yl)-1-phenylbutan-1-one,CN1CCN(CC1)CCCC(=O)C2=CC=CC=C2,,,,,,
7455,57456,"Butyrophenone, 4'-fluoro-4-(4-methyl-1-piperazinyl)-, dihydrochloride",CN1CCN(CC1)CCCC(=O)C2=CC=C(C=C2)F.Cl.Cl,,,,,,
7456,57457,1-(4-Fluorophenyl)-4-(4-methylpiperazin-1-yl)butan-1-one,CN1CCN(CC1)CCCC(=O)C2=CC=C(C=C2)F,,,,,,
7457,57458,5-Phenyl-1-propyl-2-imidazolidinone,CCCN1C(CNC1=O)C2=CC=CC=C2,,,,,,
7458,57459,CID 57459,C1=CC=C(C=C1)N=C(N=NC2=C(NC3=C2C=C(C=C3)CC(=O)O)O)S,,,,,,
7459,57460,"Acetic acid, dichloro-, 2,2-bis(2-chloroethyl)hydrazide",C(CCl)N(CCCl)NC(=O)C(Cl)Cl,,,,,,
7460,57461,1-(4-Chlorobenzyloxy)biguanide,C1=CC(=CC=C1CON=C(N)N=C(N)N)Cl,,,,,,
7461,57462,CID 57462,C(CCl)N(CCCl)NC(=NN(CCCl)CCCl)S,,,,,,
7462,57463,3-Methoxy-4-(methoxymethoxy)aniline,COCOC1=C(C=C(C=C1)N)OC,,,,,,
7463,57464,Diethylmethyl(((10-phenothiazinyl)carbonyl)methyl)ammonium iodide,CC[N+](C)(CC)CC(=O)N1C2=CC=CC=C2SC3=CC=CC=C31.[I-],,,,,,
7464,57465,Diethyl-methyl-(2-oxo-2-phenothiazin-10-ylethyl)azanium,CC[N+](C)(CC)CC(=O)N1C2=CC=CC=C2SC3=CC=CC=C31,,,,,,
7465,57466,"1H-Indole, 1-ethyl-3-(ethylthio)-",CCN1C=C(C2=CC=CC=C21)SCC,,,,,,
7466,57467,"N,N-Bis(2-chloroethyl)-N',N'-dicyclohexylethylenediamine dihydrochloride",C1CCC(CC1)[NH+](CC[NH+](CCCl)CCCl)C2CCCCC2.[Cl-].[Cl-],,,,,,
7467,57468,"N,N-bis(2-chloroethyl)-N',N'-dicyclohexylethane-1,2-diamine",C1CCC(CC1)N(CCN(CCCl)CCCl)C2CCCCC2,,,,,,
7468,57469,Imiquimod,CC(C)CN1C=NC2=C1C3=CC=CC=C3N=C2N,"['For the topical treatment of clinically typical, nonhyperkeratotic, nonhypertrophic actinic keratoses on the face or scalp in immunocompetent adults. Also indicated for the treatment of external genital and perianal warts/condyloma acuminata in individuals 12 years old and above.']","['Imiquimod is an immune response modifier that acts as a toll-like receptor 7 agonist. Imiquimod is commonly used topically to treat warts on the skin of the genital and anal areas. Imiquimod does not cure warts, and new warts may appear during treatment. Imiquimod does not fight the viruses that cause warts directly, however, it does help to relieve and control wart production. It is not used on warts inside the vagina, penis, or rectum. Imiquimod is also used to treat a skin condition of the face and scalp called actinic keratoses. Imiquimod can also be used to treat certain types of skin cancer called superficial basal cell carcinoma. Imiquimod is particularly useful on areas where surgery or other treatments may be difficult, complicated or otherwise undesirable, especially the face and lower legs.']","['Substances that augment, stimulate, activate, potentiate, or modulate the immune response at either the cellular or humoral level. The classical agents (Freund&apos;s adjuvant, BCG, Corynebacterium parvum, et al.) contain bacterial antigens. Some are endogenous (e.g., histamine, interferon, transfer factor, tuftsin, interleukin-1). Their mode of action is either non-specific, resulting in increased immune responsiveness to a wide variety of antigens, or antigen-specific, i.e., affecting a restricted type of immune response to a narrow group of antigens. The therapeutic efficacy of many biological response modifiers is related to their antigen-specific immunoadjuvanticity. (See all compounds classified as Adjuvants, Immunologic.)', 'Substances that inhibit or prevent the proliferation of NEOPLASMS. (See all compounds classified as Antineoplastic Agents.)', 'Agents that promote the production and release of interferons. They include mitogens, lipopolysaccharides, and the synthetic polymers Poly A-U and Poly I-C. Viruses, bacteria, and protozoa have been also known to induce interferons. (See all compounds classified as Interferon Inducers.)']","['Well absorbed through skin (as a cream)', 'Following topical application to the skin in adults with actinic keratosis (75-mg doses 3 times weekly for 16 weeks), 0.08-0.15% of the dose is eliminated in urine as unchanged drug and metabolites. Following topical application in patients with HPV warts, 0.11 or 2.41% of the dose is eliminated in urine as unchanged drug and metabolites in men or women, respectively.', 'Imiquimod is absorbed systemically following topical application to skin. In adults with actinic keratosis who received topical imiquimod 5% cream 3 times weekly for 16 weeks, mean peak serum concentrations at the end of week 16 were approximately 0.1, 0.2, or 3.5 ng/mL in those treated on the face (12.5-mg doses), scalp (25-mg doses), or hands/arms (75-mg doses), respectively. Systemic exposure appeared to depend more on the surface area of the application site than on the total applied dose. In patients with external genital and perianal human papillomavirus (HPV) warts who received topical imiquimod 5% cream (average dose 4.6 mg), mean peak serum concentrations were 0.4 ng/mL.']",,"['20 hours (topical dose), 2 hours (subcutaneous dose)', 'Studies using subcutaneous imiquimod indicate the drug has an apparent half-life of 2 hours. Following topical application, imiquimod appears to be retained in the skin for prolonged periods since the half-life is approximately 10 times greater than that reported following subcutaneous administration.']"
7469,57470,"Acetamide, N-sulfanilyl-N-((trichloromethyl)thio)-",CC(=O)N(SC(Cl)(Cl)Cl)S(=O)(=O)C1=CC=C(C=C1)N,,,,,,
7470,57471,CID 57471,CC(=O)NC1=CC(=C(C=C1)C=C[N+](=O)[O-])[N+](=O)[O-],,,,,,
7471,57472,2-(4-Bromophenyl)butanoic acid,CCC(C1=CC=C(C=C1)Br)C(=O)O,,,,,,
7472,57473,3-Cyclohexenylmethylenemalononitrile,C1CC(CC=C1)C=C(C#N)C#N,,,,,,
7473,57474,"CARBAMIC ACID, 3-(o-HYDROXYPHENYL)PROPYL ESTER",C1=CC=C(C(=C1)CCCOC(=O)N)O,,,,,,
7474,57475,"6-Naphthamide, 2-amino-",C1=CC2=C(C=CC(=C2)N)C=C1C(=O)N,,,,,,
7475,57476,"alpha,beta-Dichloroacrylic acid",C(=C(C(=O)O)Cl)Cl,,,,,,
7476,57477,CID 57477,C(C(=C(C(=O)C(=O)O)Cl)Cl)Cl,,,,,,
7477,57478,CID 57478,C(C(=C(C(=O)C(=O)O)Cl)Cl)(Cl)Cl,,,,,,
7478,57479,CID 57479,C(=C(C(Cl)(Cl)Cl)Cl)(C(=O)C(=O)O)Cl,,,,,,
7479,57480,"Benzoic acid, 2,3,6-trichloro-4,5-dihydroxy-",C1(=C(C(=C(C(=C1Cl)Cl)O)O)Cl)C(=O)O,,,,,,
7480,57481,CID 57481,C(=CC(Cl)(Cl)Cl)C(=O)C(=O)O,,,,,,
7481,57482,"1-Pentyn-3-ol, 3-methyl-, butyrate",CCCC(=O)OC(C)(CC)C#C,,,,,,
7482,57483,"Benzenamine, 4-(4-chlorophenoxy)-N-hydroxy-",C1=CC(=CC=C1NO)OC2=CC=C(C=C2)Cl,,,,,,
7483,57484,"2-({2-[({5-[(Dimethylamino)methyl]furan-2-yl}methyl)sulfanyl]ethyl}imino)-5-[(2-hydroxypyridin-3-yl)methyl]-1,2-dihydropyrimidin-4-ol",CN(C)CC1=CC=C(O1)CSCCNC2=NC=C(C(=O)N2)CC3=CC=CNC3=O,,,,,,
7484,57485,"8,8-Dimethoxy-2-phenyl-2,3,5,6,7,8-hexahydroimidazo[1,2-a]pyridine--hydrogen chloride (1/1)",COC1(CCCN2C1=N[C@H](C2)C3=CC=CC=C3)OC.Cl,,,,,,
7485,57486,"(2S)-8,8-dimethoxy-2-phenyl-3,5,6,7-tetrahydro-2H-imidazo[1,2-a]pyridine",COC1(CCCN2C1=N[C@H](C2)C3=CC=CC=C3)OC,,,,,,
7486,57487,Bikalm,CC1=CC=C(C=C1)C2=C(N3C=C(C=CC3=N2)C)CC(=O)N(C)C.[C@@H]([C@H](C(=O)O)O)(C(=O)O)O,,,"['Endogenous compounds and drugs that bind to and activate GABA-A RECEPTORS. (See all compounds classified as GABA-A Receptor Agonists.)', 'Drugs used to induce SLEEP, prevent SLEEPLESSNESS, or treat SLEEP INITIATION AND MAINTENANCE DISORDERS. (See all compounds classified as Sleep Aids, Pharmaceutical.)']","['A peak blood level of 200 ng/mL was reached 30 min after oral admin of 20 mg zolpidem. After oral admin zolpidem is rapidly & completely absorbed from the GI tract. Although some first-pass biotransformation of the drug results in a bioavailability of about 70%, after doses of 7-20 mg, zolpidem is 92% bound to plasma proteins. The apparent volume of distribution after a 5 mg iv dose was 0.5 L/kg. Brain concns reach one third to one half of those achieved in the plasma. Zolpidem is completely metabolized. <1% of an admin dose is excreted unchanged in the urine. Three metabolites have been identified but have no pharmacologic activity after an 8 mg iv dose. Systemic clearance of zolpidem was 0.26 L/kg/g & the elimination half-life was 1.5 hr. /Salt not specified/', 'The excretion of zolpidem in breast milk represents 0.004 to 0.019% of an admin dose. /Salt not specified/', 'Zolpidem is eliminated almost entirely by conversion to inactive products in the liver, largely through oxidation of the methyl groups on the phenyl & imidazopyridine rings to the corresponding carboxylic acids. Its half-life in plasma is approx 2 hr in individuals with normal hepatic blood flow or function. This value may be increased twofold or more in those with cirrhosis, & it also tends to be greater in older patients; adjustment of dosage often is necessary in both categories of patients. Although little or no unchanged zolpidem is found in the urine, the elimination of the drug is slower in patients with chronic renal insufficiency, largely owing to an incr in its apparent volume of distribution. /Salt not specified/', 'Solid dispersions & physical mixtures of Zolpidem in polyethylene glycol 4000 (PEG 4000) & 6000 (PEG 6000) were prepared with the aim to incr its aqueous solubility. ... Physical determinations/revealed/ no drug-polymer interactions ... Both solubility & dissolution rate of the drug in these formulations were increased. Each individual dissolution profile of PEG based formulation fitted Baker-Lonsdale & first order kinetic models. Finally, significant differences in ataxic induction time were observed between Zolpidem orally administered as suspension of drug alone & as solid dispersion or physical mixture. These formulations, indeed, showed almost 2- to 3-fold longer ataxic induction times suggesting that, in the presence of PEG, the intestinal membrane permeability is probably the rate-limiting factor of the absorption process. /Salt not specified/', 'For more Absorption, Distribution and Excretion (Complete) data for ZOLPIDEM TARTRATE (6 total), please visit the HSDB record page.']","['... Zopiclone & zolpidem are used primarily as hypnotics. Both are extensively metabolized; N-demethylation, N-oxidation, & decarboxylation of zopiclone occur, & zolpidem undergoes oxidation of methyl groups & hydroxylation of a position on the imidazolepyridine ring system. ... Since CYP3A4 has been reported to play an important role in metab of zolpidem, possible interactions with drugs which are substrates &/or inhibitors of that CYP isozyme should be considered. /Salt not specified/']","['Its half-life in plasma is approx 2 hr in individuals with normal hepatic blood flow or function. This value may be increased twofold or more in those with cirrhosis, & it also tends to be greater in older patients ... . /Salt not specified/', 'Nursing mothers: Studies in lactating mothers indicate that the half-life of zolpidem is similar to that in young normal volunteers (2.6 + or - 0.3 hr). /Salt not specified/', 'Carvedilol ... has a terminal half-life of 7-10 hr, but most of  the drug is eliminated with a half-life of about 2 hr.']"
7487,57488,"1,3-Dihydro-3-hydroxy-5-methyl-2H-indol-2-one",CC1=CC2=C(C=C1)NC(=O)C2O,,,,,,
7488,57489,"1,3-Dihydro-7-chloro-3-hydroxy-2H-indol-2-one",C1=CC2=C(C(=C1)Cl)NC(=O)C2O,,,,,,
7489,57490,"1,3-Dihydro-1-acetyl-3-hydroxy-2H-indol-2-one",CC(=O)N1C2=CC=CC=C2C(C1=O)O,,,,,,
7490,57491,3-(Pyridyl-2-methyl)-5-bromodioxindole,C1=CC=NC(=C1)CC2(C3=C(C=CC(=C3)Br)NC2=O)O,,,,,,
7491,57492,"1,3-Dihydro-3-(acetyloxy)-7-chloro-2H-indol-2-one",CC(=O)OC1C2=C(C(=CC=C2)Cl)NC1=O,,,,,,
7492,57493,"1,3-Dihydro-3-(1-oxopropoxy)-1-(1-oxopropyl)-2H-indol-2-one",CCC(=O)N1C2=CC=CC=C2C(C1=O)OC(=O)CC,,,,,,
7493,57494,"1,3-Dihydro-5-methyl-3-(1-oxopropoxy)-1-(1-oxopropyl)-2H-indol-2-one",CCC(=O)N1C2=C(C=C(C=C2)C)C(C1=O)OC(=O)CC,,,,,,
7494,57495,"Butanoic acid, 5-bromo-2,3-dihydro-2-oxo-1-(1-oxobutyl)-1H-indol-3-YL ester",CCCC(=O)N1C2=C(C=C(C=C2)Br)C(C1=O)OC(=O)CCC,,,,,,
7495,57496,"1,3-Dihydro-3-(acetyloxy)-5-bromo-2H-indol-2-one",CC(=O)OC1C2=C(C=CC(=C2)Br)NC1=O,,,,,,
7496,57497,Dichloro(dichloropropoxy)cyclohexane,CC(C(OC1CCC(CC1Cl)Cl)Cl)Cl,,,,,,
7497,57498,Trichloro-1-(dichloropropoxy)hexane,CC(C(C(CCOC(C(C)Cl)Cl)Cl)Cl)Cl,,,,,,
7498,57499,Tetrachloro-1-(dichloropropoxy)hexane,CC(C(C(C(COC(CCCl)Cl)Cl)Cl)Cl)Cl,,,,,,
7499,57500,Tetrachloro-1-(dichloropropoxy)nonane,CC(C(C(CCC(CCOC(CCCl)Cl)Cl)Cl)Cl)Cl,,,,,,
7500,57501,"Dichloro-1,6-bis(dichloropropoxy)hexane",CC(C(OCC(CCC(COC(C(C)Cl)Cl)Cl)Cl)Cl)Cl,,,,,,
7501,57502,"Trichloro-1,6-bis(dichloropropoxy)hexane",CC(C(OCCC(C(C(COC(C(C)Cl)Cl)Cl)Cl)Cl)Cl)Cl,,,,,,
7502,57503,"1,3-Dihydro-5-bromo-3-(1-oxopropoxy)-1-(1-oxopropyl)-2H-indol-2-one",CCC(=O)N1C2=C(C=C(C=C2)Br)C(C1=O)OC(=O)CC,,,,,,
7503,57504,Dimethylacridine,CC1=C2C(=CC=C1)C=C3C(=CC=CC3=N2)C,,,,,,
7504,57505,"1,2-Dichloro-1-(1,2-dichloropropoxy)propane",CC(C(OC(C(C)Cl)Cl)Cl)Cl,,,,,,
7505,57506,"Furfurylamine, N-ethyl-, hydrochloride",CC[NH2+]CC1=CC=CO1.[Cl-],,,,,,
7506,57507,N-(furan-2-ylmethyl)ethanamine,CCNCC1=CC=CO1,,,,,,
7507,57508,"Acetic acid, trichloro-, 2,2-bis(2-chloroethyl)hydrazide",C(CCl)N(CCCl)NC(=O)C(Cl)(Cl)Cl,,,,,,
7508,57509,CID 57509,CC=CC(=O)NC1CCC2=CC(=C(C(=C2C3=CC=C(C(=O)C=C13)OC)OC)OC)OC,,,,,,
7509,57510,CID 57510,CCCC=C1C(=O)N(C(S1)C2=CC=CC=C2OC)NC(=O)C3=CC=CC=C3O,,,,,,
7510,57511,CID 57511,COC1=C(C=C(C=C1)C2N(C(=O)C(=CC3=CC=CC=C3O)S2)NC(=O)C4=CC=CC=C4O)OC,,,,,,
7511,57512,CID 57512,CC1(N(C(=O)C(=CC2=CC=CC=C2O)S1)NC(=O)C3=CC=CC=C3O)C4=CC(=CC(=C4)OC)OC,,,,,,
7512,57513,Cyclodisone,C1COS(=O)(=O)CS(=O)(=O)O1,,,,,,
7513,57514,"N-(4-(((4-Oxo-2-(phenylimino)-3-thiazolidinyl)amino)carbonyl)phenyl)-3,4,5-trimethoxybenzamide",COC1=CC(=CC(=C1OC)OC)C(=O)NC2=CC=C(C=C2)C(=O)NN3C(=O)CSC3=NC4=CC=CC=C4,,,,,,
7514,57515,"Benzamide, N-(4-(((2-((4-bromophenyl)imino)-4-oxo-3-thiazolidinyl)amino)carbonyl)phenyl)-3,4,5-trimethoxy-",COC1=CC(=CC(=C1OC)OC)C(=O)NC2=CC=C(C=C2)C(=O)NN3C(=O)CSC3=NC4=CC=C(C=C4)Br,,,,,,
7515,57516,"Benzamide, N-(4-(((2-((4-chlorophenyl)imino)-4-oxo-3-thiazolidinyl)amino)carbonyl)phenyl)-3,4,5-trimethoxy-",COC1=CC(=CC(=C1OC)OC)C(=O)NC2=CC=C(C=C2)C(=O)NN3C(=O)CSC3=NC4=CC=C(C=C4)Cl,,,,,,
7516,57517,"Benzamide, N-(4-(((2-((4-methoxyphenyl)imino)-4-oxo-3-thiazolidinyl)amino)carbonyl)phenyl)-3,4,5-trimethoxy-",COC1=CC=C(C=C1)N=C2N(C(=O)CS2)NC(=O)C3=CC=C(C=C3)NC(=O)C4=CC(=C(C(=C4)OC)OC)OC,,,,,,
7517,57518,"Benzamide, N-(4-(((2-((4-methylphenyl)imino)-4-oxo-3-thiazolidinyl)amino)carbonyl)phenyl)-3,4,5-trimethoxy-",CC1=CC=C(C=C1)N=C2N(C(=O)CS2)NC(=O)C3=CC=C(C=C3)NC(=O)C4=CC(=C(C(=C4)OC)OC)OC,,,,,,
7518,57519,4-amino-N-(1-azabicyclo[2.2.2]octan-2-yl)-5-chloro-2-methoxybenzamide,COC1=CC(=C(C=C1C(=O)NC2CC3CCN2CC3)Cl)N,,,,,,
7519,57520,Rocastine,CN1CC(OC2=C(C1=S)C=CC=N2)CCN(C)C,,,,,,
7520,57521,"Benzamide, N-(4-(((2-((4-ethoxyphenyl)imino)-4-oxo-3-thiazolidinyl)amino)carbonyl)phenyl)-3,4,5-trimethoxy-",CCOC1=CC=C(C=C1)N=C2N(C(=O)CS2)NC(=O)C3=CC=C(C=C3)NC(=O)C4=CC(=C(C(=C4)OC)OC)OC,,,,,,
7521,57522,"O,O'-Di(4-bromobenzoyl)apomorphine",CN1CCC2=C3C1CC4=C(C3=CC=C2)C(=C(C=C4)OC(=O)C5=CC=C(C=C5)Br)OC(=O)C6=CC=C(C=C6)Br,,,,,,
7522,57523,"O,O'-Di(4-fluorobenzoyl)apomorphine",CN1CCC2=C3C1CC4=C(C3=CC=C2)C(=C(C=C4)OC(=O)C5=CC=C(C=C5)F)OC(=O)C6=CC=C(C=C6)F,,,,,,
7523,57524,"4H-Dibenzo(de,g)quinoline-10,11-diol, 5,6,6a,7-tetrahydro-6-methyl-, dibenzoate (ester)",CN1CCC2=C3C1CC4=C(C3=CC=C2)C(=C(C=C4)OC(=O)C5=CC=CC=C5)OC(=O)C6=CC=CC=C6,,,,,,
7524,57525,"NAPHTHO(1,8-bc)PYRAN-7,8-DIONE, 6,9-DIMETHYL-3-(4-METHYL-3-PENTENYL)-",CC1=C2C3=C(C=C1)C(=COC3=C(C(=O)C2=O)C)CCC=C(C)C,,,,,,
7525,57526,"3,4-Dihydro-1-(2-piperidinopropyl)carbostyril oxalate",CC(CN1C(=O)CCC2=CC=CC=C21)[NH+]3CCCCC3.C(=O)(C(=O)[O-])O,,,,,,
7526,57527,"[3-Hydroxy-6-[[9-hydroxy-2-[4-hydroxy-5-[(4-hydroxy-6-methyl-5-methylsulfanyloxan-2-yl)oxyamino]-3-[4-methoxy-5-(propan-2-ylamino)oxan-2-yl]oxy-6-methyloxan-2-yl]oxy-12-(methoxycarbonylamino)-13-[2-(methyltrisulfanyl)ethylidene]-11-oxo-10-bicyclo[7.3.1]trideca-1(12),5-dien-3,7-diynyl]oxy]-2-methyloxan-4-yl] 4,5-dimethoxy-2-(2-methoxyprop-2-enoylamino)benzoate",CC1C(C(C(C(O1)OC2C#CC=CC#CC3(C(C(=O)C(=C2C3=CCSSSC)NC(=O)OC)OC4CC(C(C(O4)C)O)OC(=O)C5=CC(=C(C=C5NC(=O)C(=C)OC)OC)OC)O)OC6CC(C(CO6)NC(C)C)OC)O)NOC7CC(C(C(O7)C)SC)O,,,,,,
7527,57528,"5,5'-Bis-trifluoromethyl-2,2'-dichlorobiphenyl",C1=CC(=C(C=C1C(F)(F)F)Cl)C2=C(C=C(C=C2)C(F)(F)F)Cl,,,,,,
7528,57529,"Ammonium, diethyl(2-hydroxyethyl)methyl-, nitrate, dicyclopentylacetate",CC[N+](C)(CC)CCOC(=O)C(C1CCCC1)C2CCCC2.[N+](=O)([O-])[O-],,,,,,
7529,57530,N-(2-(Dimethylamino)-1-methylethyl)benzanilide hydrochloride,CC(C[NH+](C)C)N(C1=CC=CC=C1)C(=O)C2=CC=CC=C2.[Cl-],,,,,,
7530,57531,N-[2-(Dimethylamino)-1-methylethyl]benzanilide,CC(CN(C)C)N(C1=CC=CC=C1)C(=O)C2=CC=CC=C2,,,,,,
7531,57532,Naxagolide hydrochloride,CCCN1CCO[C@H]2[C@H]1CCC3=C2C=C(C=C3)O.Cl,,,,,,
7532,57533,Naxagolide,CCCN1CCO[C@H]2[C@H]1CCC3=C2C=C(C=C3)O,,,['Drugs that bind to and activate dopamine receptors. (See all compounds classified as Dopamine Agonists.)'],,,
7533,57534,2-Methoxy-6-chloro-9-(3-(2-chloroethyl)mercaptopropylamino)acridine hydrochloride,COC1=CC2=C(C3=C(C=C(C=C3)Cl)N=C2C=C1)[NH2+]CCCSCCCl.[Cl-],,,,,,
7534,57535,6-chloro-N-[3-(2-chloroethylsulfanyl)propyl]-2-methoxyacridin-9-amine,COC1=CC2=C(C3=C(C=C(C=C3)Cl)N=C2C=C1)NCCCSCCCl,,,,,,
7535,57536,"MALONONITRILE, (m-CHLOROPHENYL)-",C1=CC(=CC(=C1)Cl)C(C#N)C#N,,,,,,
7536,57537,"1-Naphthalenol, 5,6,7,8-tetrahydro-6-[propyl[2-(2-thienyl)ethyl]amino]-",CCCN(CCC1=CC=CS1)C2CCC3=C(C2)C=CC=C3O,,,['Drugs that bind to and activate dopamine receptors. (See all compounds classified as Dopamine Agonists.)'],,,
7537,57538,"Acetic acid, chloro-, 2,2-bis(2-chloroethyl)hydrazide",C(CCl)N(CCCl)NC(=O)CCl,,,,,,
7538,57539,CID 57539,C1=CC=C(C=C1)C=NN(CCCl)CCCl,,,,,,
7539,57540,"Furfurylamine, N-phenyl-, hydrochloride",C1=CC=C(C=C1)[NH2+]CC2=CC=CO2.[Cl-],,,,,,
7540,57541,N-(2-Furylmethyl)-N-phenylamine,C1=CC=C(C=C1)NCC2=CC=CO2,,,,,,
7541,57542,"Barbituric acid, 5-methyl-5-(2-pyridylmethyl)-",CC1(C(=O)NC(=O)NC1=O)CC2=CC=CC=N2,,,,,,
7542,57543,CID 57543,C1=CC(=C(C=C1N)C2=CC=C(O2)N(O)O)C(=O)N=N,,,,,,
7543,57544,"Butyric acid, 2,3-dimercaptopropyl ester",CCCC(=O)OCC(CS)S,,,,,,
7544,57545,"(Ethylthio)acetic acid 2,3-dimercaptopropyl ester",CCSCC(=O)OCC(CS)S,,,,,,
7545,57546,"1,5-Dichloro-2,3,4-trimethoxybenzene",COC1=C(C(=C(C=C1Cl)Cl)OC)OC,,,,,,
7546,57547,"Benzylamine, N,N-bis(2-chloroethyl)-, N-oxide",C1=CC=C(C=C1)C[N+](CCCl)(CCCl)[O-],,,,,,
7547,57548,"Benzylamine, N,N-bis(2-chloroethyl)-, N-oxide, hydrochloride",C1=CC=C(C=C1)C[N+](CCCl)(CCCl)O.[Cl-],,,,,,
7548,57549,Benzyl-bis(2-chloroethyl)-hydroxyazanium,C1=CC=C(C=C1)C[N+](CCCl)(CCCl)O,,,,,,
7549,57550,"1-Hexylamine, N,N-bis(2-chloroethyl)-",CCCCCCN(CCCl)CCCl,,,,,,
7550,57551,"N,N-Bis(2-chloroethyl)-1-hexylamine hydrochloride",CCCCCC[NH+](CCCl)CCCl.[Cl-],,,,,,
7551,57552,"1-Aziridinepropionamide, N-benzyl-",C1CN1CCC(=O)NCC2=CC=CC=C2,,,,,,
7552,57553,"1-Aziridinepropionamide, N-(3,4-dichlorophenyl)-",C1CN1CCC(=O)NC2=CC(=C(C=C2)Cl)Cl,,,,,,
7553,57554,"N-(3,4-Dichlorophenyl)-2,2-dimethyl-1-aziridinepropionamide",CC1(CN1CCC(=O)NC2=CC(=C(C=C2)Cl)Cl)C,,,,,,
7554,57555,"N-(3,4-Dichlorophenyl)-2-methyl-1-aziridinepropionamide",CC1CN1CCC(=O)NC2=CC(=C(C=C2)Cl)Cl,,,,,,
7555,57556,"1-Aziridinepropionamide, N,N-diethyl-",CCN(CC)C(=O)CCN1CC1,,,,,,
7556,57557,"1-AZIRIDINEPROPIONAMIDE, N-(m-METHOXYBENZYL)-",COC1=CC=CC(=C1)CNC(=O)CCN2CC2,,,,,,
7557,57558,"1-AZIRIDINEPROPIONAMIDE, N-(p-METHOXYPHENYL)-",COC1=CC=C(C=C1)NC(=O)CCN2CC2,,,,,,
7558,57559,"1-AZIRIDINEPROPIONAMIDE, N,N'-(METHYLENEDI-p-PHENYLENE)BIS-",C1CN1CCC(=O)NC2=CC=C(C=C2)CC3=CC=C(C=C3)NC(=O)CCN4CC4,,,,,,
7559,57560,"1-Aziridinepropionamide, N-(1-naphthyl)-",C1CN1CCC(=O)NC2=CC=CC3=CC=CC=C32,,,,,,
7560,57561,"1-AZIRIDINEPROPIONAMIDE, N,N'-m-PHENYLENEBIS-",C1CN1CCC(=O)NC2=CC(=CC=C2)NC(=O)CCN3CC3,,,,,,
7561,57562,3-Phenylprop-2-enyl 3-(aziridin-1-yl)propanoate,C1CN1CCC(=O)OCC=CC2=CC=CC=C2,,,,,,
7562,57563,"1-Aziridinepropionic acid, cycloheptyl ester",C1CCCC(CC1)OC(=O)CCN2CC2,,,,,,
7563,57564,"1-Aziridinepropionic acid, cyclopentyl ester",C1CCC(C1)OC(=O)CCN2CC2,,,,,,
7564,57565,"1-Aziridinepropionic acid, cyclopropylmethyl ester",C1CC1COC(=O)CCN2CC2,,,,,,
7565,57566,"1-Aziridinepropionic acid, 2,2-dimethylpropyl ester",CC(C)(C)COC(=O)CCN1CC1,,,,,,
7566,57567,"Ethanediol, acrylate 1-aziridinepropionate",CC(OC(=O)CCN1CC1)OC(=O)C=C,,,,,,
7567,57568,"1-Aziridinepropanoic acid, 2-methylcyclohexyl ester",CC1CCCCC1OC(=O)CCN2CC2,,,,,,
7568,57569,"1-AZIRIDINEPROPIONIC ACID, METHYL ESTER, BENZOATE (salt)",COC(=O)CC[NH+]1CC1.C1=CC=C(C=C1)C(=O)[O-],,,,,,
7569,57570,"1-Aziridinepropionic acid, methyl ester compd. with m-nitroaniline and methanol, sodium salt",C[O-].COC(=O)CCN1CC1.C1=CC(=CC(=C1)[N+](=O)[O-])N.[Na+],,,,,,
7570,57571,"1-Aziridinepropanoic acid, 2-nitrobutyl ester",CCC(COC(=O)CCN1CC1)[N+](=O)[O-],,,,,,
7571,57572,"1-Aziridinepropionic acid, phenethyl ester",C1CN1CCC(=O)OCCC2=CC=CC=C2,,,,,,
7572,57573,"1-Aziridinepropionic acid, phenyl ester",C1CN1CCC(=O)OC2=CC=CC=C2,,,,,,
7573,57574,"1-Aziridinepropanoic acid, 3,3,5-trimethylcyclohexyl ester",CC1CC(CC(C1)(C)C)OC(=O)CCN2CC2,,,,,,
7574,57575,"Azirino(2',3':3,4)pyrrolo(1,2-a)indole-4,7-dione, 1,1a,2,8,8a,8b-hexahydro-1,5-dimethyl-8-(hydroxymethyl)-8a-methoxy-6-isopropoxy-, carbamate",CC1=C(C(=O)C2=C(C1=O)N3CC4C([C@@]3([C@@H]2COC(=O)N)OC)N4C)OC(C)C,,,,,,
7575,57576,"2,2-Dimethyl-6-hydroxy-2-azoniabicyclo(2.2.2)octane iodide",C[N+]1(CC2CCC1C(C2)O)C.[I-],,,,,,
7576,57577,"2,2-Dimethyl-2-azoniabicyclo[2.2.2]octan-6-ol",C[N+]1(CC2CCC1C(C2)O)C,,,,,,
7577,57578,Octahydro-1H-azonine-1-ethanol benzilate hydrochloride,C1CCCC[NH+](CCC1)CCOC(=O)C(C2=CC=CC=C2)(C3=CC=CC=C3)O.[Cl-],,,,,,
7578,57579,Octahydro-1H-azonine-1-ethanol diphenyl(hydroxy)acetate,C1CCCCN(CCC1)CCOC(=O)C(C2=CC=CC=C2)(C3=CC=CC=C3)O,,,,,,
7579,57580,"2-(1,8-Octamethyleneamino)propyl benzilate hydrochloride",CC(COC(=O)C(C1=CC=CC=C1)(C2=CC=CC=C2)O)[NH+]3CCCCCCCC3.[Cl-],,,,,,
7580,57581,Octahydro-beta-methyl-1H-azonine-1-ethanol diphenyl(hydroxy)acetate,CC(COC(=O)C(C1=CC=CC=C1)(C2=CC=CC=C2)O)N3CCCCCCCC3,,,,,,
7581,57582,"Barbituric acid, 5-allyl-5-(2-hydroxyallyl)-",C=CCC1(C(=O)NC(=O)NC1=O)CC(=C)O,,,,,,
7582,57583,CID 57583,CC(=CCC1(C(=O)NC(=NC1=O)[O-])CC=C)C.[Na+],,,,,,
7583,57584,"Barbituric acid, 5-allyl-5-(3-methyl-2-butenyl)-",CC(=CCC1(C(=O)NC(=O)NC1=O)CC=C)C,,,,,,
7584,57585,CID 57585,CCCCC1(C(=O)NC(=NC1=O)[O-])CC(=C)C.[Na+],,,,,,
7585,57586,(m-Chlorobenzyl)(2-(5-hydroxyindol-3-yl)ethyl)dimethylammonium bromide,C[N+](C)(CCC1=CNC2=C1C=C(C=C2)O)CC3=CC(=CC=C3)Cl.[Br-],,,,,,
7586,57587,(3-chlorophenyl)methyl-[2-(5-hydroxy-1H-indol-3-yl)ethyl]-dimethylazanium,C[N+](C)(CCC1=CNC2=C1C=C(C=C2)O)CC3=CC(=CC=C3)Cl,,,,,,
7587,57588,Benzyldiethyl(2-hydroxyethyl)ammonium bromide carbanilate,CC[N+](CC)(CCOC(=O)NC1=CC=CC=C1)CC2=CC=CC=C2.[Br-],,,,,,
7588,57589,"N-[2-(Carbanilinooxy)ethyl]-N,N-diethylbenzenemethanaminium",CC[N+](CC)(CCOC(=O)NC1=CC=CC=C1)CC2=CC=CC=C2,,,,,,
7589,57590,"3-(2,6-Diamino-4-hydroxy-3-pyridylazo)-2,4,6-triiodobenzoic acid",C1=C(C(=C(C(=C1I)N=NC2=C(NC(=CC2=O)N)N)I)C(=O)O)I,,,,,,
7590,57591,"Malononitrile, 5-bromovanillylidene-",COC1=C(C(=CC(=C1)C=C(C#N)C#N)Br)O,,,,,,
7591,57592,"Ethylenediamine, N,N,N',N'-tetrakis(2-chloroethyl)-, N,N'-dioxide",C(C[N+](CCCl)(CCCl)[O-])[N+](CCCl)(CCCl)[O-],,,,,,
7592,57593,"ETHYLAMINE, 2-(p-CHLOROPHENOXY)-N,N,1-TRIMETHYL-",CC(COC1=CC=C(C=C1)Cl)N(C)C,,,,,,
7593,57594,"Cyclohexanol, 1-(alpha-(2-(dimethylamino)ethoxy)-alpha-methoxybenzyl)-, oxalate",C[NH+](C)CCOC(C1=CC=CC=C1)(C2(CCCCC2)O)OC.C(=O)(C(=O)[O-])O,,,,,,
7594,57595,1-[alpha-Methoxy-alpha-(2-dimethylaminoethoxy)benzyl]cyclohexanol,CN(C)CCOC(C1=CC=CC=C1)(C2(CCCCC2)O)OC,,,,,,
7595,57596,"OXALIC ACID, BIS(2-(alpha-METHYLPHENETHYL)HYDRAZIDE)",CC(CC1=CC=CC=C1)NNC(=O)C(=O)NNC(C)CC2=CC=CC=C2,,,,,,
7596,57597,"Isoalloxazine, 7-chloro-8-methoxy-10-(2-pyrrolidinylethyl)-, acetate",CC(=O)[O-].COC1=C(C=C2C(=C1)N(C3=NC(=O)NC(=O)C3=N2)CC[NH+]4CCCC4)Cl,,,,,,
7597,57598,"7-Chloro-8-methoxy-10-(2-pyrrolidin-1-ylethyl)benzo[g]pteridine-2,4-dione",COC1=C(C=C2C(=C1)N(C3=NC(=O)NC(=O)C3=N2)CCN4CCCC4)Cl,,,,,,
7598,57599,"AMMONIUM, (m-PHENYLENEBIS(OXY(2-HYDROXYTRIMETHYLENE)))BIS(TRIMETHYL-, DIIODIDE",C[N+](C)(C)CC(COC1=CC(=CC=C1)OCC(C[N+](C)(C)C)O)O.[I-].[I-],,,,,,
7599,57600,[2-Hydroxy-3-[3-[2-hydroxy-3-(trimethylazaniumyl)propoxy]phenoxy]propyl]-trimethylazanium,C[N+](C)(C)CC(COC1=CC(=CC=C1)OCC(C[N+](C)(C)C)O)O,,,,,,
7600,57601,"Diethyl(3,3-diphenyl-3-hydroxypropyl)methylammonium iodide",CC[N+](C)(CC)CCC(C1=CC=CC=C1)(C2=CC=CC=C2)O.[I-],,,,,,
7601,57602,"Diethyl-(3-hydroxy-3,3-diphenyl-propyl)-methyl-ammonium",CC[N+](C)(CC)CCC(C1=CC=CC=C1)(C2=CC=CC=C2)O,,,,,,
7602,57603,"1,4-Benzodioxan, 7-benzoyl-2-(morpholinomethyl)-, hydrochloride",C1COCC[NH+]1CC2COC3=C(O2)C=C(C=C3)C(=O)C4=CC=CC=C4.[Cl-],,,,,,
7603,57604,"[3-(Morpholin-4-ylmethyl)-2,3-dihydro-1,4-benzodioxin-6-yl]-phenylmethanone",C1COCCN1CC2COC3=C(O2)C=C(C=C3)C(=O)C4=CC=CC=C4,,,,,,
7604,57605,"N,N-Bis(2-chloroethyl)-N',N'-dibenzylethylenediamine dihydrochloride",C1=CC=C(C=C1)C[NH+](CC[NH+](CCCl)CCCl)CC2=CC=CC=C2.[Cl-].[Cl-],,,,,,
7605,57606,"N',N'-dibenzyl-N,N-bis(2-chloroethyl)ethane-1,2-diamine",C1=CC=C(C=C1)CN(CCN(CCCl)CCCl)CC2=CC=CC=C2,,,,,,
7606,57607,3-(2-(p-(2-Imidazolin-2-ylamino)benzoyl)ethyl)-6-methyl-2-benzoxazolinone hydriodide,CC1=CC2=C(C=C1)N(C(=O)O2)CCC(=O)C3=CC=C(C=C3)NC4=NCC[NH2+]4.[I-],,,,,,
7607,57608,"3-[3-[4-(4,5-dihydro-1H-imidazol-2-ylamino)phenyl]-3-oxopropyl]-6-methyl-1,3-benzoxazol-2-one",CC1=CC2=C(C=C1)N(C(=O)O2)CCC(=O)C3=CC=C(C=C3)NC4=NCCN4,,,,,,
7608,57609,6-Chloro-3-(2-(p-(2-imidazolin-2-ylamino)benzoyl)ethyl)-2-benzoxazolinone hydriodide,C1CN=C([NH2+]1)NC2=CC=C(C=C2)C(=O)CCN3C4=C(C=C(C=C4)Cl)OC3=O.[I-],,,,,,
7609,57610,"6-chloro-3-[3-[4-(4,5-dihydro-1H-imidazol-2-ylamino)phenyl]-3-oxopropyl]-1,3-benzoxazol-2-one",C1CN=C(N1)NC2=CC=C(C=C2)C(=O)CCN3C4=C(C=C(C=C4)Cl)OC3=O,,,,,,
7610,57611,3-(2-(p-(2-Imidazolin-2-ylamino)benzoyl)ethyl)-6-nitro-2-benzoxazolinone hydriodide,C1CN=C([NH2+]1)NC2=CC=C(C=C2)C(=O)CCN3C4=C(C=C(C=C4)[N+](=O)[O-])OC3=O.[I-],,,,,,
7611,57612,"3-[3-[4-(4,5-dihydro-1H-imidazol-2-ylamino)phenyl]-3-oxopropyl]-6-nitro-1,3-benzoxazol-2-one",C1CN=C(N1)NC2=CC=C(C=C2)C(=O)CCN3C4=C(C=C(C=C4)[N+](=O)[O-])OC3=O,,,,,,
7612,57613,CID 57613,CC1=NC(=CC2=CC=CC=C2)C(=O)N1C3=NN=C(S3)C4=CC=CC=C4,,,,,,
7613,57614,CID 57614,CC1=NC(=CC2=CC(=C(C=C2)O)OC)C(=O)N1C3=CC=C(C=C3)C(=O)O,,,,,,
7614,57615,CID 57615,CC1=NC(=CN2C=CC3=CC=CC=C32)C(=O)N1C4=NN=C(S4)C5=CC=CC=C5,,,,,,
7615,57616,alpha-Methyl-alpha-(1-(methylamino)ethyl)benzyl alcohol hydrochloride,CC(C(C)(C1=CC=CC=C1)O)[NH2+]C.[Cl-],,,,,,
7616,57617,3-(Methylamino)-2-phenylbutan-2-ol,CC(C(C)(C1=CC=CC=C1)O)NC,,,,,,
7617,57618,"2,3-Bis(sulfanyl)propyl 4-methoxybenzoate",COC1=CC=C(C=C1)C(=O)OCC(CS)S,,,,,,
7618,57619,"2,4-Dimethyl-2-phenyl-1,3-dithiolane",CC1CSC(S1)(C)C2=CC=CC=C2,,,,,,
7619,57620,CID 57620,CC1=NC(=CC2=CC=C(C=C2)N(C)C)C(=O)N1C3=CC=C(C=C3)C(=O)O,,,,,,
7620,57621,"1,4-Benzodioxan, 7-(p-methoxybenzoyl)-2-(piperidinomethyl)-, hydrochloride",COC1=CC=C(C=C1)C(=O)C2=CC3=C(C=C2)OCC(O3)C[NH+]4CCCCC4.[Cl-],,,,,,
7621,57622,"(4-Methoxyphenyl)-[3-(piperidin-1-ylmethyl)-2,3-dihydro-1,4-benzodioxin-6-yl]methanone",COC1=CC=C(C=C1)C(=O)C2=CC3=C(C=C2)OCC(O3)CN4CCCCC4,,,,,,
7622,57623,9-(3-(4-Ethoxypiperidino)propyl)carbazole hydrochloride,CCOC1CC[NH+](CC1)CCCN2C3=CC=CC=C3C4=CC=CC=C42.[Cl-],,,,,,
7623,57624,9-[3-(4-Ethoxypiperidin-1-yl)propyl]carbazole,CCOC1CCN(CC1)CCCN2C3=CC=CC=C3C4=CC=CC=C42,,,,,,
7624,57625,"Ammonium, (1,4-piperazinediyldiethylene)bis(triethyl-, dibromide",CC[N+](CC)(CC)CCN1CCN(CC1)CC[N+](CC)(CC)CC.[Br-].[Br-],,,,,,
7625,57626,Triethyl-[2-[4-[2-(triethylazaniumyl)ethyl]piperazin-1-yl]ethyl]azanium,CC[N+](CC)(CC)CCN1CCN(CC1)CC[N+](CC)(CC)CC,,,,,,
7626,57627,"Barbituric acid, 5-methyl-5-((6-methyl-2-pyridyl)methyl)-",CC1=NC(=CC=C1)CC2(C(=O)NC(=O)NC2=O)C,,,,,,
7627,57628,"2-(p-Bromophenyl)-2-methyl-1,3-dioxolane-4-methanol",CC1(OCC(O1)CO)C2=CC=C(C=C2)Br,,,,,,
7628,57629,"Indole-3-glyoxylamide, N-(2-hydroxyethyl)-",C1=CC=C2C(=C1)C(=CN2)C(=O)C(=O)NCCO,,,,,,
7629,57630,CID 57630,C1=CC=C(C=C1)C=CC(=O)N(CC2=CC=CC=[NH+]2)C3=CC=CC=C3.[Cl-],,,,,,
7630,57631,CID 57631,C1=CC=C(C=C1)C=CC(=O)N(CC2=CC=CC=N2)C3=CC=CC=C3,,,,,,
7631,57632,CID 57632,C1=CC=C(C=C1)C=CC(=O)N(CC2=C[NH+]=CC=C2)C3=CC=CC=C3.[Cl-],,,,,,
7632,57633,CID 57633,C1=CC=C(C=C1)C=CC(=O)N(CC2=CN=CC=C2)C3=CC=CC=C3,,,,,,
7633,57634,Diethyl(2-hydroxyethyl)methylammonium bromide alpha-(1-hydroxybutyl)cyclohexaneacetate,CCCC(C(C1CCCCC1)C(=O)OCC[N+](C)(CC)CC)O.[Br-],,,,,,
7634,57635,2-(2-Cyclohexyl-3-hydroxyhexanoyl)oxyethyl-diethyl-methylazanium,CCCC(C(C1CCCCC1)C(=O)OCC[N+](C)(CC)CC)O,,,,,,
7635,57636,CID 57636,C1=CC=NC(=C1)CC(P(=O)(O)O)P(=O)(O)[O-].[Na+],,,,,,
7636,57637,Piridronic acid,C1=CC=NC(=C1)CC(P(=O)(O)O)P(=O)(O)O,,,,,,
7637,57638,"Hippuric acid, 3,5-diiodo-4-propoxy-",CCCOC1=C(C=C(C=C1I)C(=O)NCC(=O)O)I,,,,,,
7638,57639,"4-(Allyloxy)-3,5-dimethylbenzonitrile",CC1=CC(=CC(=C1OCC=C)C)C#N,,,,,,
7639,57640,Diethyl(2-hydroxyethyl)methylammonium bromide alpha-(1-hydroxycyclopentyl)cyclohexaneacetate,CC[N+](C)(CC)CCOC(=O)C(C1CCCCC1)C2(CCCC2)O.[Br-],,,,,,
7640,57641,2-[2-Cyclohexyl-2-(1-hydroxycyclopentyl)acetyl]oxyethyl-diethyl-methylazanium,CC[N+](C)(CC)CCOC(=O)C(C1CCCCC1)C2(CCCC2)O,,,,,,
7641,57642,N-(2-Bromoethyl)-p-phenylazobenzamide,C1=CC=C(C=C1)N=NC2=CC=C(C=C2)C(=O)NCCBr,,,,,,
7642,57643,p-Butylamino-N-(2-(diethylamino)ethyl)benzamide dihydrochloride,CCCC[NH2+]C1=CC=C(C=C1)C(=O)NCC[NH+](CC)CC.[Cl-].[Cl-],,,,,,
7643,57644,4-Butylamino-N-[2-(diethylamino)ethyl]benzamide,CCCCNC1=CC=C(C=C1)C(=O)NCCN(CC)CC,,,,,,
7644,57645,"Benzamide, N-(1,2-diazabicyclo(3.2.2)non-2-yl)-2-methoxy-5-sulfamoyl-, hemihydrate",COC1=C(C=C(C=C1)S(=O)(=O)N)C(=O)NN2CCC3CCN2CC3.COC1=C(C=C(C=C1)S(=O)(=O)N)C(=O)NN2CCC3CCN2CC3.O,,,,,,
7645,57646,"N-(1,2-diazabicyclo[3.2.2]nonan-2-yl)-2-methoxy-5-sulfamoylbenzamide",COC1=C(C=C(C=C1)S(=O)(=O)N)C(=O)NN2CCC3CCN2CC3,,,,,,
7646,57647,"N-(3-(1,2-Diazabicyclo(3.2.2)non-2-yl)propyl)-2-methoxy-5-sulfamoylbenzamide",COC1=C(C=C(C=C1)S(=O)(=O)N)C(=O)NCCCN2CCC3CCN2CC3,,,,,,
7647,57648,"N-(3-(1,2-Diazabicyclo(2.2.2)oct-3-yl)propyl)-2-methoxy-5-sulfamoylbenzamide",COC1=C(C=C(C=C1)S(=O)(=O)N)C(=O)NCCCC2C3CCN(N2)CC3,,,,,,
7648,57649,"N-[2-(4,4-dicyanobuta-1,3-dienyl)phenyl]benzamide",C1=CC=C(C=C1)C(=O)NC2=CC=CC=C2C=CC=C(C#N)C#N,,,,,,
7649,57650,"N-[2-(4,4-dicyanobuta-1,3-dienyl)-5-methylphenyl]benzamide",CC1=CC(=C(C=C1)C=CC=C(C#N)C#N)NC(=O)C2=CC=CC=C2,,,,,,
7650,57651,"4-(2-(Diethylamino)ethoxy)-3,5-dipropylbenzamide monohydrochloride",CCCC1=CC(=CC(=C1OCC[NH+](CC)CC)CCC)C(=O)N.[Cl-],,,,,,
7651,57652,"4-[2-(Diethylamino)ethoxy]-3,5-dipropylbenzamide",CCCC1=CC(=CC(=C1OCCN(CC)CC)CCC)C(=O)N,,,,,,
7652,57653,"BENZAMIDE, N-(2-(DIETHYLAMINO)ETHYL)-N,N'-o-PHENYLENEBIS-",CCN(CC)CCN(C1=CC=CC=C1NC(=O)C2=CC=CC=C2)C(=O)C3=CC=CC=C3,,,,,,
7653,57654,N-(2-Diethylaminoethyl)-N-(2-pyridylmethyl)benzamide hydrochloride,CC[NH+](CC)CCN(CC1=CC=CC=N1)C(=O)C2=CC=CC=C2.[Cl-],,,,,,
7654,57655,N-[2-(Diethylamino)ethyl]-N-(2-pyridinylmethyl)benzamide,CCN(CC)CCN(CC1=CC=CC=N1)C(=O)C2=CC=CC=C2,,,,,,
7655,57656,N-(2-Diethylaminoethyl)-N-(3-pyridylmethyl)benzamide hydrochloride,CC[NH+](CC)CCN(CC1=CN=CC=C1)C(=O)C2=CC=CC=C2.[Cl-],,,,,,
7656,57657,N-[2-(Diethylamino)ethyl]-N-(3-pyridinylmethyl)benzamide,CCN(CC)CCN(CC1=CN=CC=C1)C(=O)C2=CC=CC=C2,,,,,,
7657,57658,N-(2-Diethylaminoethyl)-N-(4-pyridylmethyl)benzamide hydrochloride,CC[NH+](CC)CCN(CC1=CC=NC=C1)C(=O)C2=CC=CC=C2.[Cl-],,,,,,
7658,57659,N-[2-(Diethylamino)ethyl]-N-(4-pyridinylmethyl)benzamide,CCN(CC)CCN(CC1=CC=NC=C1)C(=O)C2=CC=CC=C2,,,,,,
7659,57660,"4-Ethoxy-3,5-dipropylbenzamide",CCCC1=CC(=CC(=C1OCC)CCC)C(=O)N,,,,,,
7660,57661,"4-Hydroxy-3,5-dipropylbenzamide",CCCC1=CC(=CC(=C1O)CCC)C(=O)N,,,,,,
7661,57662,"4-Propoxy-3,5-dipropylbenzamide",CCCC1=CC(=CC(=C1OCCC)CCC)C(=O)N,,,,,,
7662,57663,"BENZAMIDE, o-HEPTYLOXY-",CCCCCCCOC1=CC=CC=C1C(=O)N,,,,,,
7663,57664,5-(2-Hydroxy-3-iodopropyl)-5-(1-methylbutyl)barbituric acid,CCCC(C)C1(C(=O)NC(=O)NC1=O)CC(CI)O,,,,,,
7664,57665,"2-(p-Methoxyphenyl)-2-methyl-1,3-dioxolane-4-methanol",CC1(OCC(O1)CO)C2=CC=C(C=C2)OC,,,,,,
7665,57666,CID 57666,CC1=CC=C(C=C1)C(C2=CC=CC=C2)OCC[NH+](C)C.C(=CC(=O)[O-])C(=O)O,,,,,,
7666,57667,2-Diethylaminoethyl p-ethoxy-N-phenylcarbanilate hydrochloride,CC[NH+](CC)CCOC(=O)N(C1=CC=CC=C1)C2=CC=C(C=C2)OCC.[Cl-],,,,,,
7667,57668,2-(diethylamino)ethyl N-(4-ethoxyphenyl)-N-phenylcarbamate,CCN(CC)CCOC(=O)N(C1=CC=CC=C1)C2=CC=C(C=C2)OCC,,,,,,
7668,57669,CID 57669,C1=CC=C(C(=C1)C=NNC(=O)C2=CC=C(C=C2)NC(=O)C3=CC=C(C=C3)Cl)O,,,,,,
7669,57670,4-[(4-chlorobenzoyl)amino]-N-[(4-methoxyphenyl)methylideneamino]benzamide,COC1=CC=C(C=C1)C=NNC(=O)C2=CC=C(C=C2)NC(=O)C3=CC=C(C=C3)Cl,,,,,,
7670,57671,CID 57671,COC1=C(C=CC(=C1)C=NNC(=O)C2=CC=C(C=C2)NC(=O)C3=CC=C(C=C3)Cl)O,,,,,,
7671,57672,CID 57672,COC1=CC=C(C=C1)C(=O)NC2=CC=C(C=C2)C(=O)NN=CC=CC3=CC=CC=C3,,,,,,
7672,57673,CID 57673,COC1=CC=C(C=C1)C(=O)NC2=CC=C(C=C2)C(=O)NN=CC3=CC=CC=C3[N+](=O)[O-],,,,,,
7673,57674,CID 57674,COC1=CC=C(C=C1)C(=O)NC2=CC=C(C=C2)C(=O)NN=CC3=CC=CO3,,,,,,
7674,57675,CID 57675,COC1=CC=C(C=C1)C=NNC(=O)C2=CC=C(C=C2)NC(=O)C3=CC(=C(C(=C3)OC)OC)OC,,,,,,
7675,57676,CID 57676,CN(C)C1=CC=C(C=C1)C=NNC(=O)C2=CC=C(C=C2)NC(=O)C3=CC(=C(C(=C3)OC)OC)OC,,,,,,
7676,57677,CID 57677,COC1=CC(=CC(=C1OC)OC)C(=O)NC2=CC=C(C=C2)C(=O)NN=CC3=CC=CO3,,,,,,
7677,57678,"4-[(4-chlorobenzoyl)amino]-N-[(3,4-dimethoxyphenyl)methylideneamino]benzamide",COC1=C(C=C(C=C1)C=NNC(=O)C2=CC=C(C=C2)NC(=O)C3=CC=C(C=C3)Cl)OC,,,,,,
7678,57679,CID 57679,CC1=CC=C(C=C1)C=NNC(=O)C2=CC=C(C=C2)NC(=O)C3=CC=C(C=C3)Cl,,,,,,
7679,57680,4-[(4-chlorobenzoyl)amino]-N-[[4-(dimethylamino)phenyl]methylideneamino]benzamide,CN(C)C1=CC=C(C=C1)C=NNC(=O)C2=CC=C(C=C2)NC(=O)C3=CC=C(C=C3)Cl,,,,,,
7680,57681,CID 57681,COC1=CC=C(C=C1)C(=O)NC2=CC=C(C=C2)C(=O)NN=CC3=CC(=C(C=C3)O)OC,,,,,,
7681,57682,CID 57682,COC1=CC=C(C=C1)C(=O)NC2=CC=C(C=C2)C(=O)NN=CC3=CC=CC=C3O,,,,,,
7682,57683,"N-[(3,4-dimethoxyphenyl)methylideneamino]-4-[(4-methoxybenzoyl)amino]benzamide",COC1=CC=C(C=C1)C(=O)NC2=CC=C(C=C2)C(=O)NN=CC3=CC(=C(C=C3)OC)OC,,,,,,
7683,57684,CID 57684,CC1=CC=C(C=C1)C=NNC(=O)C2=CC=C(C=C2)NC(=O)C3=CC(=C(C(=C3)OC)OC)OC,,,,,,
7684,57685,CID 57685,COC1=CC(=CC(=C1OC)OC)C(=O)NC2=CC=C(C=C2)C(=O)NN=CC3=CC=CC=C3[N+](=O)[O-],,,,,,
7685,57686,CID 57686,COC1=CC(=CC(=C1OC)OC)C(=O)NC2=CC=C(C=C2)C(=O)NN=CC=CC3=CC=CC=C3,,,,,,
7686,57687,4-[(4-chlorobenzoyl)amino]-N-(furan-2-ylmethylideneamino)benzamide,C1=COC(=C1)C=NNC(=O)C2=CC=C(C=C2)NC(=O)C3=CC=C(C=C3)Cl,,,,,,
7687,57688,4-[(4-chlorobenzoyl)amino]-N-[(3-nitrophenyl)methylideneamino]benzamide,C1=CC(=CC(=C1)[N+](=O)[O-])C=NNC(=O)C2=CC=C(C=C2)NC(=O)C3=CC=C(C=C3)Cl,,,,,,
7688,57689,CID 57689,C1=CC=C(C=C1)C=CC=NNC(=O)C2=CC=C(C=C2)NC(=O)C3=CC=C(C=C3)Cl,,,,,,
7689,57690,CID 57690,COC1=CC=C(C=C1)C=NNC(=O)C2=CC=C(C=C2)NC(=O)C3=CC=C(C=C3)OC,,,,,,
7690,57691,CID 57691,CN(C)C1=CC=C(C=C1)C=NNC(=O)C2=CC=C(C=C2)NC(=O)C3=CC=C(C=C3)OC,,,,,,
7691,57692,CID 57692,CC1=CC=C(C=C1)C=NNC(=O)C2=CC=C(C=C2)NC(=O)C3=CC=C(C=C3)OC,,,,,,
7692,57693,CID 57693,COC1=CC(=CC(=C1OC)OC)C(=O)NC2=CC=C(C=C2)C(=O)NN=CC3=CC=CC=C3O,,,,,,
7693,57694,CID 57694,COC1=CC(=CC(=C1OC)OC)C(=O)NC2=CC=C(C=C2)C(=O)NN=CC3=CC(=C(C=C3)O)OC,,,,,,
7694,57695,CID 57695,COC1=C(C=C(C=C1)C=NNC(=O)C2=CC=C(C=C2)NC(=O)C3=CC(=C(C(=C3)OC)OC)OC)OC,,,,,,
7695,57696,CID 57696,CC1=CC=CN2C1=NC=C(C2=O)C3=NN=N[N-]3.[K+],,,,,,
7696,57697,Pemirolast,CC1=CC=CN2C1=NC=C(C2=O)C3=NNN=N3,"['For the prevention of itching of the eyes caused by allergies such as hay fever, and allergic conjunctivitis']","['Pemirolast is used for the prophylactic treatment of itching of the eye associated with allergic conjunctivitis. Pemirolast potassium is a mast cell stabilizer that inhibits the <i>in vivo</i> Type I immediate hypersensitivity reaction. Pemirolast inhibits the antigen-induced release of inflammatory mediators (e.g., histamine, leukotriene C4, D4, E4) from human mast cells. Allergic reactions lead to cell-degranulation and the release of histamine (and other chemical mediators) from the mast cell or basophil. Once released, histamine can react with local or widespread tissues through histamine receptors. Histamine, acting on H<sub>1</sub>-receptors, produces pruritis and vasodilatation (allowing blood fluids to enter the area to cause swelling). Pemirolast is a histamine H1 antagonist. It competes with histamine for the normal H<sub>1</sub>-receptor sites on effector cells of blood vessels to provide effective, temporary relief of watery and itchy eyes.']","['Drugs that bind to but do not activate histamine receptors, thereby blocking the actions of histamine or histamine agonists. Classical antihistaminics block the histamine H1 receptors only. (See all compounds classified as Histamine Antagonists.)']","['Following topical administration, about 10-15% of the dose was excreted unchanged in the urine.', 'A mean peak plasma level of 4.7 ng/mL occurred after 2 weeks of administration. /Pemirolast potassium/', 'Elimination: Renal, 84 to 90% of dose eliminated within 24 hours, about 10 to 15% of the dose was excreted unchanged. /Pemirolast potassium/', 'Pemirolast potassium is excreted in the milk of lactating rats at concentrations higher than those in plasma. It is not known whether pemirolast potassium is excreted in human milk.', 'Topical ocular administration of one to two drops of Alamast ophthalmic solution in each eye four times daily in 16 healthy volunteers for two weeks resulted in detectable concentrations in the plasma. The mean (+/- SE) peak plasma level of 4.7 +/- 0.8 ng/mL occurred at 0.42 +/- 0.05 hours and the mean half-life was 4.5 +/- 0.2 hours. /Pemirolast potassium/']",['Hepatic (Ophthalmic)'],"['4.5 hours (Ophthalmic)', '...Mean half-life was 4.5 +/- 0.2 hours. /Pemirolast potassium/']"
7697,57698,"N-(2-Chloroethyl)-N-methyl-1,4-benzodioxan-2-ethylamine hydrochloride",C[NH+](CCC1COC2=CC=CC=C2O1)CCCl.[Cl-],,,,,,
7698,57699,"N-(2-chloroethyl)-2-(2,3-dihydro-1,4-benzodioxin-3-yl)-N-methylethanamine",CN(CCC1COC2=CC=CC=C2O1)CCCl,,,,,,
7699,57700,"1,4-Benzodioxan-2-ethylamine picrate",C1C(OC2=CC=CC=C2O1)CC[NH3+].C1=C(C=C(C(=C1[N+](=O)[O-])[O-])[N+](=O)[O-])[N+](=O)[O-],,,,,,
7700,57701,"1,3-Benzodioxan-8-methylamine, 6-chloro-N-(2-(diethylamino)ethyl)-",CCN(CC)CCNCC1=CC(=CC2=C1OCOC2)Cl,,,,,,
7701,57702,"N-(2-Chloroethyl)-6,7-dichloro-N-ethyl-1,4-benzodioxan-2-methylamine hydrochloride",CC[NH+](CCCl)CC1COC2=CC(=C(C=C2O1)Cl)Cl.[Cl-],,,,,,
7702,57703,"2-chloro-N-[(6,7-dichloro-2,3-dihydro-1,4-benzodioxin-3-yl)methyl]-N-ethylethanamine",CCN(CCCl)CC1COC2=CC(=C(C=C2O1)Cl)Cl,,,,,,
7703,57704,"8-Methoxy-2-ethylaminomethyl-1,4-benzodioxane hydrochloride",CC[NH2+]CC1COC2=C(O1)C(=CC=C2)OC.[Cl-],,,,,,
7704,57705,"N-[(5-methoxy-2,3-dihydro-1,4-benzodioxin-3-yl)methyl]ethanamine",CCNCC1COC2=C(O1)C(=CC=C2)OC,,,,,,
7705,57706,"N,N'-(1,1,4,4-Tetramethylhexamethylene)bis(1,4-benzodioxan-2-methylamine)",CC(C)(CCC(C)(C)NCC1COC2=CC=CC=C2O1)CCNCC3COC4=CC=CC=C4O3,,,,,,
7706,57707,"N-(2-Chloroethyl)-N-methyl-1,4-benzodioxan-2-propylamine hydrochloride",C[NH+](CCCC1COC2=CC=CC=C2O1)CCCl.[Cl-],,,,,,
7707,57708,"N-(2-chloroethyl)-3-(2,3-dihydro-1,4-benzodioxin-3-yl)-N-methylpropan-1-amine",CN(CCCC1COC2=CC=CC=C2O1)CCCl,,,,,,
7708,57709,"1,4-Benzodioxin, 6,7-dichloro-2-methyl-",CC1=COC2=CC(=C(C=C2O1)Cl)Cl,,,,,,
7709,57710,"1,3-Benzodioxole, 5-chloro-2-(2-(2-(diethylamino)ethoxy)ethyl)-2-methyl-, citrate",CC[NH+](CC)CCOCCC1(OC2=C(O1)C=C(C=C2)Cl)C.C(C(=O)[O-])C(CO)(C(=O)O)C(=O)O,,,,,,
7710,57711,"2-(2-(2-(Diethylamino)ethoxy)ethyl)-2,5-dimethyl-1,3-benzodioxole citrate",CC[NH+](CC)CCOCCC1(OC2=C(O1)C=C(C=C2)C)C.C(C(=O)O)C(CO)(C(=O)O)C(=O)[O-],,,,,,
7711,57712,"2-[2-(2,5-dimethyl-1,3-benzodioxol-2-yl)ethoxy]-N,N-diethylethanamine",CCN(CC)CCOCCC1(OC2=C(O1)C=C(C=C2)C)C,,,,,,
7712,57713,"1,3-Benzodioxole, 2-(2-(2-(diethylamino)ethoxy)ethyl)-4-methoxy-2-methyl-, citrate",CC[NH+](CC)CCOCCC1(OC2=C(O1)C(=CC=C2)OC)C.C(C(=O)O)C(CO)(C(=O)O)C(=O)[O-],,,,,,
7713,57714,"N,N-diethyl-2-[2-(4-methoxy-2-methyl-1,3-benzodioxol-2-yl)ethoxy]ethanamine",CCN(CC)CCOCCC1(OC2=C(O1)C(=CC=C2)OC)C,,,,,,
7714,57715,"1,3-Benzodioxole, 2-(2-(2-(diethylamino)ethoxy)ethyl)-2-methyl-, citrate",CC[NH+](CC)CCOCCC1(OC2=CC=CC=C2O1)C.C(C(=O)O)C(CO)(C(=O)O)C(=O)[O-],,,,,,
7715,57716,"N,N-diethyl-2-[2-(2-methyl-1,3-benzodioxol-2-yl)ethoxy]ethanamine",CCN(CC)CCOCCC1(OC2=CC=CC=C2O1)C,,,,,,
7716,57717,"1,3-Benzodioxole, 2-(2-(2-(diethylamino)ethoxy)ethyl)-2-phenyl-, citrate",CC[NH+](CC)CCOCCC1(OC2=CC=CC=C2O1)C3=CC=CC=C3.C(C(=O)O)C(CO)(C(=O)O)C(=O)[O-],,,,,,
7717,57718,"N,N-diethyl-2-[2-(2-phenyl-1,3-benzodioxol-2-yl)ethoxy]ethanamine",CCN(CC)CCOCCC1(OC2=CC=CC=C2O1)C3=CC=CC=C3,,,,,,
7718,57719,"1,3-Benzodioxole, 2-(2-(2-(diethylamino)ethylthio)ethyl)-2-methyl-, citrate",CC[NH+](CC)CCSCCC1(OC2=CC=CC=C2O1)C.C(C(=O)[O-])C(CO)(C(=O)O)C(=O)O,,,,,,
7719,57720,"Ethanamine, N,N-diethyl-2-((2-(2-methyl-1,3-benzodioxol-2-yl)ethyl)thio)-",CCN(CC)CCSCCC1(OC2=CC=CC=C2O1)C,,,,,,
7720,57721,"1,3-Benzodioxole, 2-(2-(3-(diethylamino)propoxy)ethyl)-2-methyl-, citrate",CC[NH+](CC)CCCOCCC1(OC2=CC=CC=C2O1)C.C(C(=O)O)C(CO)(C(=O)O)C(=O)[O-],,,,,,
7721,57722,"N,N-diethyl-3-[2-(2-methyl-1,3-benzodioxol-2-yl)ethoxy]propan-1-amine",CCN(CC)CCCOCCC1(OC2=CC=CC=C2O1)C,,,,,,
7722,57723,"1,3-Benzodioxole, 2-methyl-2-(2-(2-piperidinoethoxy)ethyl)-, citrate",CC1(OC2=CC=CC=C2O1)CCOCC[NH+]3CCCCC3.C(C(=O)O)C(CO)(C(=O)O)C(=O)[O-],,,,,,
7723,57724,"1-[2-[2-(2-Methyl-1,3-benzodioxol-2-yl)ethoxy]ethyl]piperidine",CC1(OC2=CC=CC=C2O1)CCOCCN3CCCCC3,,,,,,
7724,57725,"8,9-Dihydrobenzo[k]fluoranthene-8,9-diol",C1=CC2=C3C(=C1)C4=C(C3=CC=C2)C=C5C(C(C=CC5=C4)O)O,,,,,,
7725,57726,"2-Benzofuranylcarbamic acid, 2-(diethylamino)ethyl ester",CCN(CC)CCOC(=O)NC1=CC2=CC=CC=C2O1,,,,,,
7726,57727,"BENZ(a)ANTHRACEN-7-OL, 5-FLUORO-12-METHYL-, ACETATE",CC1=C2C3=CC=CC=C3C(=CC2=C(C4=CC=CC=C14)OC(=O)C)F,,,,,,
7727,57728,4-Amino-2-pentyloxybenzoic acid 2-(diethylamino)ethyl ester hydrochloride,CCCCCOC1=C(C=CC(=C1)N)C(=O)OCC[NH+](CC)CC.[Cl-],,,,,,
7728,57729,2-(Diethylamino)ethyl 4-amino-2-pentoxybenzoate,CCCCCOC1=C(C=CC(=C1)N)C(=O)OCCN(CC)CC,,,,,,
7729,57730,4-Amino-2-pentyloxythiobenzoic acid S-2-(diethylamino)ethyl ester hydrochloride,CCCCCOC1=C(C=CC(=C1)N)C(=O)SCC[NH+](CC)CC.[Cl-],,,,,,
7730,57731,S-[2-(diethylamino)ethyl] 4-amino-2-pentoxybenzenecarbothioate,CCCCCOC1=C(C=CC(=C1)N)C(=O)SCCN(CC)CC,,,,,,
7731,57732,5-Amino-2-(3-piperidinopropoxy)benzoic acid ethyl ester hydrochloride,CCOC(=O)C1=C(C=CC(=C1)N)OCCC[NH+]2CCCCC2.[Cl-],,,,,,
7732,57733,Ethyl 5-amino-2-(3-piperidin-1-ylpropoxy)benzoate,CCOC(=O)C1=C(C=CC(=C1)N)OCCCN2CCCCC2,,,,,,
7733,57734,2-Diethylaminoethyl 4-amino-3-propoxybenzoate hydrochloride,CCCOC1=C(C=CC(=C1)C(=O)OCC[NH+](CC)CC)N.[Cl-],,,,,,
7734,57735,2-(Diethylamino)ethyl 4-amino-3-propoxybenzoate,CCCOC1=C(C=CC(=C1)C(=O)OCCN(CC)CC)N,,,,,,
7735,57736,4-Amino-2-propoxybenzoic acid 3-(diethylamino)propyl ester dihydrochloride,CCCOC1=C(C=CC(=C1)[NH3+])C(=O)OCCC[NH+](CC)CC.[Cl-].[Cl-],,,,,,
7736,57737,3-(Diethylamino)propyl 4-amino-2-propoxybenzoate,CCCOC1=C(C=CC(=C1)N)C(=O)OCCCN(CC)CC,,,,,,
7737,57738,4-Amino-2-propoxy-benzoic acid 2-(dimethylamino)ethyl ester dihydrochloride,CCCOC1=C(C=CC(=C1)[NH3+])C(=O)OCC[NH+](C)C.[Cl-].[Cl-],,,,,,
7738,57739,2-(Dimethylamino)ethyl 4-amino-2-propoxybenzoate,CCCOC1=C(C=CC(=C1)N)C(=O)OCCN(C)C,,,,,,
7739,57740,4-Amino-2-propoxybenzoic acid 3-piperidinopropyl ester dihydrochloride,CCCOC1=C(C=CC(=C1)[NH3+])C(=O)OCCC[NH+]2CCCCC2.[Cl-].[Cl-],,,,,,
7740,57741,3-Piperidin-1-ylpropyl 4-amino-2-propoxybenzoate,CCCOC1=C(C=CC(=C1)N)C(=O)OCCCN2CCCCC2,,,,,,
7741,57742,4-Amino-2-propoxythiobenzoic acid S-(2-(diethylamino)ethyl) ester hydrogen phosphate,CCCOC1=C(C=CC(=C1)N)C(=O)SCC[NH+](CC)CC.OP(=O)(O)[O-],,,,,,
7742,57743,S-[2-(diethylamino)ethyl] 4-amino-2-propoxybenzenecarbothioate,CCCOC1=C(C=CC(=C1)N)C(=O)SCCN(CC)CC,,,,,,
7743,57744,"Benzoic acid, 2-(benzyloxy)-4-butylamino-, 2-(dimethylamino)ethyl ester",CCCCNC1=CC(=C(C=C1)C(=O)OCCN(C)C)OCC2=CC=CC=C2,,,,,,
7744,57745,CID 57745,CCCC1=CC(=CC(=C1OCC=CC)CCC)C(=O)O,,,,,,
7745,57746,"Benzoic acid, 2-butoxy-4-butylamino-, 3-piperidinopropyl ester",CCCCNC1=CC(=C(C=C1)C(=O)OCCCN2CCCCC2)OCCCC,,,,,,
7746,57747,3-Amino-2-hydroxypropyl p-(butylamino)benzoate hydrochloride,CCCCNC1=CC=C(C=C1)C(=O)OCC(C[NH3+])O.[Cl-],,,,,,
7747,57748,(3-Amino-2-hydroxypropyl) 4-(butylamino)benzoate,CCCCNC1=CC=C(C=C1)C(=O)OCC(CN)O,,,,,,
7748,57749,2-(Dimethylamino)ethyl p-(butylamino)benzoate hydrobromide,CCCCNC1=CC=C(C=C1)C(=O)OCC[NH+](C)C.[Br-],,,,,,
7749,57750,4-Butylamino-2-ethoxy-benzoic acid 3-piperidinopropyl ester dihydrochloride,CCCC[NH2+]C1=CC(=C(C=C1)C(=O)OCCC[NH+]2CCCCC2)OCC.[Cl-].[Cl-],,,,,,
7750,57751,3-Piperidin-1-ylpropyl 4-(butylamino)-2-ethoxybenzoate,CCCCNC1=CC(=C(C=C1)C(=O)OCCCN2CCCCC2)OCC,,,,,,
7751,57752,2-Hydroxy-3-morpholinopropyl p-(butylamino)benzoate hydrochloride,CCCCNC1=CC=C(C=C1)C(=O)OCC(C[NH+]2CCOCC2)O.[Cl-],,,,,,
7752,57753,(2-Hydroxy-3-morpholin-4-ylpropyl) 4-(butylamino)benzoate,CCCCNC1=CC=C(C=C1)C(=O)OCC(CN2CCOCC2)O,,,,,,
7753,57754,"Benzoic acid, p-(butylamino)-, 2-hydroxy-3-(phenylamino)propyl ester, hydrochloride",CCCCNC1=CC=C(C=C1)C(=O)OCC(CNC2=CC=CC=C2)O.[Cl-],,,,,,
7754,57755,(3-Anilino-2-hydroxypropyl) 4-(butylamino)benzoate,CCCCNC1=CC=C(C=C1)C(=O)OCC(CNC2=CC=CC=C2)O,,,,,,
7755,57756,"Benzoic acid, p-(butylamino)-, 2-hydroxy-3-(1-pyrrolidinyl)propyl ester, hydrochloride",CCCCNC1=CC=C(C=C1)C(=O)OCC(C[NH+]2CCCC2)O.[Cl-],,,,,,
7756,57757,(2-Hydroxy-3-pyrrolidin-1-ylpropyl) 4-(butylamino)benzoate,CCCCNC1=CC=C(C=C1)C(=O)OCC(CN2CCCC2)O,,,,,,
7757,57758,p-Butylaminobenzoic acid 3-piperidinopropyl ester hydrochloride,CCCCNC1=CC=C(C=C1)C(=O)OCCC[NH+]2CCCCC2.[Cl-],,,,,,
7758,57759,3-Piperidin-1-ylpropyl 4-(butylamino)benzoate,CCCCNC1=CC=C(C=C1)C(=O)OCCCN2CCCCC2,,,,,,
7759,57760,4-Butylamino-2-propoxy-benzoic acid 2-(diethylamino)ethyl ester dihydrochloride,CCCC[NH2+]C1=CC(=C(C=C1)C(=O)OCC[NH+](CC)CC)OCCC.[Cl-].[Cl-],,,,,,
7760,57761,2-(Diethylamino)ethyl 4-(butylamino)-2-propoxybenzoate,CCCCNC1=CC(=C(C=C1)C(=O)OCCN(CC)CC)OCCC,,,,,,
7761,57762,"4-(Carboxymethoxy)-3,5-dipropylbenzoic acid",CCCC1=CC(=CC(=C1OCC(=O)O)CCC)C(=O)O,,,,,,
7762,57763,"BENZOIC ACID, p-CHLORO-, 2-(p-(DIMETHYLAMINO)BENZYL)HYDRAZIDE",CN(C)C1=CC=C(C=C1)CNNC(=O)C2=CC=C(C=C2)Cl,,,,,,
7763,57764,"Cyclohexanemethanol, alpha-ethynyl-, benzoate",C#CC(C1CCCCC1)OC(=O)C2=CC=CC=C2,,,,,,
7764,57765,"Benzoic acid, 3,5-diallyl-4-hydroxy-",C=CCC1=CC(=CC(=C1O)CC=C)C(=O)O,,,,,,
7765,57766,"Benzoic acid, 3,5-diallyl-4-hydroxy-, ethyl ester",CCOC(=O)C1=CC(=C(C(=C1)CC=C)O)CC=C,,,,,,
7766,57767,"Benzoic acid, 3,5-diallyl-4-propoxy-",CCCOC1=C(C=C(C=C1CC=C)C(=O)O)CC=C,,,,,,
7767,57768,"4-(2-(Diethylamino)ethoxy)-3,5-dipropylbenzoic acid hydrochloride",CCCC1=CC(=CC(=C1OCC[NH+](CC)CC)CCC)C(=O)O.[Cl-],,,,,,
7768,57769,"4-[2-(Diethylamino)ethoxy]-3,5-dipropylbenzoic acid",CCCC1=CC(=CC(=C1OCCN(CC)CC)CCC)C(=O)O,,,,,,
7769,57770,"Benzoic acid, 3,5-dimethoxy-, 2-isopropylhydrazide",CC(C)NNC(=O)C1=CC(=CC(=C1)OC)OC,,,,,,
7770,57771,"BENZOIC ACID, 2-(p-(DIMETHYLAMINO)BENZYL)HYDRAZIDE",CN(C)C1=CC=C(C=C1)CNNC(=O)C2=CC=CC=C2,,,,,,
7771,57772,"Ethyl 3,5-dimethyl-4-propoxybenzoate",CCCOC1=C(C=C(C=C1C)C(=O)OCC)C,,,,,,
7772,57773,"Benzoic acid, 2,6-dimethyl-, 2-(1-pyrrolidinyl)ethyl ester",CC1=C(C(=CC=C1)C)C(=O)OCCN2CCCC2,,,,,,
7773,57774,"Benzoic acid, 4-(benzyloxy)-3,5-dipropyl-",CCCC1=CC(=CC(=C1OCC2=CC=CC=C2)CCC)C(=O)O,,,,,,
7774,57775,"FORMAMIDE, N-(5-(p-AMINOPHENOXY)PENTYL)-",C1=CC(=CC=C1N)OCCCCCNC=O,,,,,,
7775,57776,"Benzamide, p-amino-N-(3-(diethylamino)propyl)-N-(alpha-methylbenzyl)-, hydrochloride",CC[NH+](CC)CCCN(C(C)C1=CC=CC=C1)C(=O)C2=CC=C(C=C2)N.[Cl-],,,,,,
7776,57777,4-Amino-N-[3-(diethylamino)propyl]-N-(alpha-methylbenzyl)benzamide,CCN(CC)CCCN(C(C)C1=CC=CC=C1)C(=O)C2=CC=C(C=C2)N,,,,,,
7777,57778,"Benzamide, p-amino-N-(3-(diethylamino)propyl)-N-(p-methoxybenzyl)-, hydrochloride",CC[NH+](CC)CCCN(CC1=CC=C(C=C1)OC)C(=O)C2=CC=C(C=C2)N.[Cl-],,,,,,
7778,57779,4-Amino-n-[3-(diethylamino)propyl]-n-(4-methoxybenzyl)benzamide,CCN(CC)CCCN(CC1=CC=C(C=C1)OC)C(=O)C2=CC=C(C=C2)N,,,,,,
7779,57780,"1,4-Benzodioxan, 7-(p-methoxybenzoyl)-2-(morpholinomethyl)-, hydrochloride",COC1=CC=C(C=C1)C(=O)C2=CC3=C(C=C2)OCC(O3)C[NH+]4CCOCC4.[Cl-],,,,,,
7780,57781,"(4-Methoxyphenyl)-[3-(morpholin-4-ylmethyl)-2,3-dihydro-1,4-benzodioxin-6-yl]methanone",COC1=CC=C(C=C1)C(=O)C2=CC3=C(C=C2)OCC(O3)CN4CCOCC4,,,,,,
7781,57782,(+/-)-Lisofylline,CC(CCCCN1C(=O)C2=C(N=CN2C)N(C1=O)C)O,,,"['Anti-inflammatory agents that are non-steroidal in nature. In addition to anti-inflammatory actions, they have analgesic, antipyretic, and platelet-inhibitory actions. They act by blocking the synthesis of prostaglandins by inhibiting cyclooxygenase, which converts arachidonic acid to cyclic endoperoxides, precursors of prostaglandins. Inhibition of prostaglandin synthesis accounts for their analgesic, antipyretic, and platelet-inhibitory actions; other mechanisms may contribute to their anti-inflammatory effects. (See all compounds classified as Anti-Inflammatory Agents, Non-Steroidal.)', 'Substances that augment, stimulate, activate, potentiate, or modulate the immune response at either the cellular or humoral level. The classical agents (Freund&apos;s adjuvant, BCG, Corynebacterium parvum, et al.) contain bacterial antigens. Some are endogenous (e.g., histamine, interferon, transfer factor, tuftsin, interleukin-1). Their mode of action is either non-specific, resulting in increased immune responsiveness to a wide variety of antigens, or antigen-specific, i.e., affecting a restricted type of immune response to a narrow group of antigens. The therapeutic efficacy of many biological response modifiers is related to their antigen-specific immunoadjuvanticity. (See all compounds classified as Adjuvants, Immunologic.)', 'Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of INTERLEUKINS and other CYTOKINES are emerging. (See all compounds classified as Immunosuppressive Agents.)', 'Drugs used to potentiate the effectiveness of radiation therapy in destroying unwanted cells. (See all compounds classified as Radiation-Sensitizing Agents.)']",,,
7782,57783,"9,10-Dihydro-9,10-dihydroxybenzo(j)fluoranthene",C1=CC2=C3C(=C1)C4=C(C3=CC=C2)C5=C(C=C4)C(C(C=C5)O)O,,,,,,
7783,57784,1-Methyl-4-piperidyl 4-butylaminobenzoate methanesulfonate,CCCCNC1=CC=C(C=C1)C(=O)OC2CC[NH+](CC2)C.CS(=O)(=O)[O-],,,,,,
7784,57785,"Benzothiazole, 6-methoxy-2-(2-oxazolin-2-ylamino)-",COC1=CC2=C(C=C1)N=C(S2)NC3=NCCO3,,,,,,
7785,57786,"Benzothiazole, 2-(3,3,3-trifluoro-2-(trifluoromethyl)-1-propenyl)-",C1=CC=C2C(=C1)N=C(S2)C=C(C(F)(F)F)C(F)(F)F,,,,,,
7786,57787,"2,2,3-Trifluoro-7a-methyl-2,4,5,6,7-hexahydrobenzothiophene",CC12CCCCC1=C(C(S2)(F)F)F,,,,,,
7787,57788,"2,2,3,3-Tetrafluoro-3a-methyl-2,3,4,5,6,7-hexahydro-benzothiophene",CC12CCCCC1SC(C2(F)F)(F)F,,,,,,
7788,57789,"(6,7-dihydro-5H-1-benzothiophen-4-ylideneamino) N-methylcarbamate",CNC(=O)ON=C1CCCC2=C1C=CS2,,,,,,
7789,57790,"4H-(1)Benzothiopyrano(4,3-c)isoxazole-3-carboxamide, N-(2-(dimethylamino)ethyl)-6-fluoro-",CN(C)CCNC(=O)C1=C2CSC3=C(C2=NO1)C=CC=C3F,,,,,,
7790,57791,"m-ACETANISIDIDE, 2-CHLORO-N-(2-ETHOXYETHYL)-",CCOCCN(C1=CC(=CC=C1)OC)C(=O)CCl,,,,,,
7791,57792,4-Butylamino-2-propoxybenzoic acid 3-piperidinopropyl ester dihydrochloride,CCCC[NH2+]C1=CC(=C(C=C1)C(=O)OCCC[NH+]2CCCCC2)OCCC.[Cl-].[Cl-],,,,,,
7792,57793,3-Piperidin-1-ylpropyl 4-(butylamino)-2-propoxybenzoate,CCCCNC1=CC(=C(C=C1)C(=O)OCCCN2CCCCC2)OCCC,,,,,,
7793,57794,"3-Benzofurancarboxylic acid, 7-((dimethylamino)methyl)-6-hydroxy-2-methyl-, ethyl ester, tartrate",CCOC(=O)C1=C(OC2=C1C=CC(=C2CN(C)C)O)C.C(C(C(=O)O)O)(C(=O)O)O,,,,,,
7794,57795,Ethyl 7-[(dimethylamino)methyl]-6-hydroxy-2-methyl-1-benzofuran-3-carboxylate,CCOC(=O)C1=C(OC2=C1C=CC(=C2CN(C)C)O)C,,,,,,
7795,57796,"3-Benzofurancarboxylic acid, 4-((dimethylamino)methyl)-5-hydroxy-2-(p-tolylthio)-, ethyl ester, hydrochloride",CCOC(=O)C1=C(OC2=C1C(=C(C=C2)O)C[NH+](C)C)SC3=CC=C(C=C3)C.[Cl-],,,,,,
7796,57797,Ethyl 4-[(dimethylamino)methyl]-5-hydroxy-2-(4-methylphenyl)sulfanyl-1-benzofuran-3-carboxylate,CCOC(=O)C1=C(OC2=C1C(=C(C=C2)O)CN(C)C)SC3=CC=C(C=C3)C,,,,,,
7797,57798,"N,N-Diethyl-6-methoxy-3-phenyl-2-benzofuranmethylamine hydrochloride",CC[NH+](CC)CC1=C(C2=C(O1)C=C(C=C2)OC)C3=CC=CC=C3.[Cl-],,,,,,
7798,57799,N-ethyl-N-[(6-methoxy-3-phenyl-1-benzofuran-2-yl)methyl]ethanamine,CCN(CC)CC1=C(C2=C(O1)C=C(C=C2)OC)C3=CC=CC=C3,,,,,,
7799,57800,"5-Benzofuranol, 4-(benzylaminomethyl)-2-bromo-3-phenyl-",C1=CC=C(C=C1)CNCC2=C(C=CC3=C2C(=C(O3)Br)C4=CC=CC=C4)O,,,,,,
7800,57801,"5-Benzofuranol, 4-bromo-6-(diethylaminomethyl)-2-phenyl-",CCN(CC)CC1=CC2=C(C=C(O2)C3=CC=CC=C3)C(=C1O)Br,,,,,,
7801,57802,"4-Benzofuranol, 2,3-dihydro-2,2-dimethyl-, carbamate",CC1(CC2=C(O1)C=CC=C2OC(=O)N)C,,,,,,
7802,57803,"7-Benzofuranol, 2,3-dihydro-2,2-dimethyl-, N-hydroxycarbamate",CC1(CC2=C(O1)C(=CC=C2)OC(=O)NO)C,,,,,,
7803,57804,"Benzofuro(3,2-c)pyridine, 1,2,3,4-tetrahydro-2-(2-(dimethylamino)ethyl)-, dihydrochloride",C[NH+](C)CCC1CCC2=C(C1)C3=C(O2)C=C[NH+]=C3.[Cl-].[Cl-],,,,,,
7804,57805,"N,N-dimethyl-2-(6,7,8,9-tetrahydro-[1]benzofuro[3,2-c]pyridin-8-yl)ethanamine",CN(C)CCC1CCC2=C(C1)C3=C(O2)C=CN=C3,,,,,,
7805,57806,"Benzofuro(3,2-c)pyridine, 1,2,3,4-tetrahydro-2-(3-(dimethylamino)propyl)-, dihydrochloride",C[NH+](C)CCCC1CCC2=C(C1)C3=C(O2)C=C[NH+]=C3.[Cl-].[Cl-],,,,,,
7806,57807,"N,N-dimethyl-3-(6,7,8,9-tetrahydro-[1]benzofuro[3,2-c]pyridin-8-yl)propan-1-amine",CN(C)CCCC1CCC2=C(C1)C3=C(O2)C=CN=C3,,,,,,
7807,57808,"Benzoic acid, 3-allyl-4-hydroxy-5-propyl-, ethyl ester",CCCC1=C(C(=CC(=C1)C(=O)OCC)CC=C)O,,,,,,
7808,57809,"Benzoic acid, 4-(allyloxy)-3,5-diallyl-",C=CCC1=CC(=CC(=C1OCC=C)CC=C)C(=O)O,,,,,,
7809,57810,"Benzoic acid, 4-(allyloxy)-3,5-diallyl-, ethyl ester",CCOC(=O)C1=CC(=C(C(=C1)CC=C)OCC=C)CC=C,,,,,,
7810,57811,"Benzoic acid, 4-(allyloxy)-3,5-diisopropyl-, ethyl ester",CCOC(=O)C1=CC(=C(C(=C1)C(C)C)OCC=C)C(C)C,,,,,,
7811,57812,"Benzoic acid, 4-(allyloxy)-3,5-dimethyl-, ethyl ester",CCOC(=O)C1=CC(=C(C(=C1)C)OCC=C)C,,,,,,
7812,57813,"Benzoic acid, 4-(allyloxy)-3,5-dipropyl-",CCCC1=CC(=CC(=C1OCC=C)CCC)C(=O)O,,,,,,
7813,57814,"N-(4-Allyloxy-3,5-dipropylbenzoyl)-p-aminobenzoic acid",CCCC1=CC(=CC(=C1OCC=C)CCC)C(=O)NC2=CC=C(C=C2)C(=O)O,,,,,,
7814,57815,"Benzoic acid, 4-(allyloxy)-3,5-dipropyl-, 2-(diethylamino)ethyl ester, hydrochloride",CCCC1=CC(=CC(=C1OCC=C)CCC)C(=O)OCC[NH+](CC)CC.[Cl-],,,,,,
7815,57816,"2-(Diethylamino)ethyl 4-prop-2-enoxy-3,5-dipropylbenzoate",CCCC1=CC(=CC(=C1OCC=C)CCC)C(=O)OCCN(CC)CC,,,,,,
7816,57817,"Benzoic acid, 4-(allyloxy)-3,5-dipropyl-, ethyl ester",CCCC1=CC(=CC(=C1OCC=C)CCC)C(=O)OCC,,,,,,
7817,57818,"Benzoic acid, 4-(allyloxy)-3,5-dipropyl-, 2-hydroxyethyl ester",CCCC1=CC(=CC(=C1OCC=C)CCC)C(=O)OCCO,,,,,,
7818,57819,"Benzoic acid, 4-(allyloxy)-3,5-dipropyl-, methyl ester",CCCC1=CC(=CC(=C1OCC=C)CCC)C(=O)OC,,,,,,
7819,57820,4-Amino-2-(benzyloxy)-benzoic acid 2-(diethylamino)ethyl ester hydrochloride,CC[NH+](CC)CCOC(=O)C1=C(C=C(C=C1)N)OCC2=CC=CC=C2.[Cl-],,,,,,
7820,57821,2-(Diethylamino)ethyl 4-amino-2-phenylmethoxybenzoate,CCN(CC)CCOC(=O)C1=C(C=C(C=C1)N)OCC2=CC=CC=C2,,,,,,
7821,57822,"Benzoic acid, 4-amino-2-(benzyloxy)-, 3-(diethylamino)propyl ester",CCN(CC)CCCOC(=O)C1=C(C=C(C=C1)N)OCC2=CC=CC=C2,,,,,,
7822,57823,4-Amino-2-(benzyloxy)-benzoic acid 2-(dimethylamino)ethyl ester hydrogen phosphate,C[NH+](C)CCOC(=O)C1=C(C=C(C=C1)N)OCC2=CC=CC=C2.OP(=O)(O)[O-],,,,,,
7823,57824,2-(Dimethylamino)ethyl 4-amino-2-phenylmethoxybenzoate,CN(C)CCOC(=O)C1=C(C=C(C=C1)N)OCC2=CC=CC=C2,,,,,,
7824,57825,4-Amino-2-(benzyloxy)benzoic acid 3-piperidinopropyl ester hydrogen phosphate,C1CC[NH+](CC1)CCCOC(=O)C2=C(C=C(C=C2)N)OCC3=CC=CC=C3.OP(=O)(O)[O-],,,,,,
7825,57826,3-Piperidin-1-ylpropyl 4-amino-2-phenylmethoxybenzoate,C1CCN(CC1)CCCOC(=O)C2=C(C=C(C=C2)N)OCC3=CC=CC=C3,,,,,,
7826,57827,4-Amino-2-butoxy-benzoic acid 3-(diethylamino)propyl ester dihydrochloride,CCCCOC1=C(C=CC(=C1)[NH3+])C(=O)OCCC[NH+](CC)CC.[Cl-].[Cl-],,,,,,
7827,57828,3-(Diethylamino)propyl 4-amino-2-butoxybenzoate,CCCCOC1=C(C=CC(=C1)N)C(=O)OCCCN(CC)CC,,,,,,
7828,57829,"1,1-Dichloro-2-(3-methylbutoxy)cyclopropane",CC(C)CCOC1CC1(Cl)Cl,,,,,,
7829,57830,"2-(3-(Pyrrolidin-1-yl)propionyl)-1,2,3,4-tetrahydrobenzofuro(3,2-c)pyridine hydrochloride",C1CC[NH+](C1)CCC(=O)C2CCC3=C(C2)C4=C(O3)C=CN=C4.[Cl-],,,,,,
7830,57831,"3-Pyrrolidin-1-yl-1-(6,7,8,9-tetrahydro-[1]benzofuro[3,2-c]pyridin-8-yl)propan-1-one",C1CCN(C1)CCC(=O)C2CCC3=C(C2)C4=C(O3)C=CN=C4,,,,,,
7831,57832,"GLYCINE, N-(p-BUTOXYPHENYL)-",CCCCOC1=CC=C(C=C1)NCC(=O)O,,,,,,
7832,57833,3-(o-Methoxyphenoxy)-2-hydroxypropyl N-methylcarbamate,CNC(=O)OCC(COC1=CC=CC=C1OC)O,,,,,,
7833,57834,N-(2-Oxazolyl)-1-naphthylamine,C1=CC=C2C(=C1)C=CC=C2NC3=NC=CO3,,,,,,
7834,57835,"2-Methyl-3a,4,5,9b-tetrahydrobenzo[e]isoindole-1,3-dione",CN1C(=O)C2CCC3=CC=CC=C3C2C1=O,,,,,,
7835,57836,Benzyldiethyl(2-hydroxyethyl)ammonium bromide dibutylcarbamate,CCCCN(CCCC)C(=O)OCC[N+](CC)(CC)CC1=CC=CC=C1.[Br-],,,,,,
7836,57837,"N-[2-(Dibutylcarbamyloxy)ethyl]-N,N-diethylbenzenemethanaminium",CCCCN(CCCC)C(=O)OCC[N+](CC)(CC)CC1=CC=CC=C1,,,,,,
7837,57838,"BENZ(a)OXIRENO(c)ANTHRACENE, 11-METHYL-",CC1=C2C(=CC3=CC=CC=C13)C=CC4=C2C=CC5=C4O5,,,,,,
7838,57839,3-(beta-Hydroxy-beta-(4-aminophenyl)ethylamino)quinuclidine,C1CC2CC1CC2NC(C(C3=CC=C(C=C3)N)O)N,,,,,,
7839,57840,1-(4-Chlorophenyl)-2-(2-diethylaminoethylamino)ethanol,CCN(CC)CCNCC(C1=CC=C(C=C1)Cl)O,,,,,,
7840,57841,"BENZYL ALCOHOL, alpha-((2,2,3,3,4,4-HEXAFLUORO-1-HYDROXYCYCLOBUTYL)METHYL)-",C1=CC=C(C=C1)C(CC2(C(C(C2(F)F)(F)F)(F)F)O)O,,,,,,
7841,57842,"Benzyl alcohol, 3-methyl-2-(2-chloroethyl)ureido-",CC1=C(C(=CC=C1)CO)NC(=O)NCCCl,,,,,,
7842,57843,"BENZYL ALCOHOL, alpha-(1-PIPERIDINOCYCLOPENTYL)-, HYDROCHLORIDE",C1CC[NH+](CC1)C2(CCCC2)C(C3=CC=CC=C3)O.[Cl-],,,,,,
7843,57844,Phenyl-(1-piperidin-1-ylcyclopentyl)methanol,C1CCN(CC1)C2(CCCC2)C(C3=CC=CC=C3)O,,,,,,
7844,57845,"Benzylamine, 3-allyl-6-(2-(dimethylamino)ethoxy)-5-methoxy-",CN(C)CCOC1=C(C=C(C=C1OC)CC=C)CN,,,,,,
7845,57846,4-(4-Dimethylaminophenylazo)benzyl-bis(beta-chloroethyl)benzylamine,CN(C)C1=CC=C(C=C1)N=NC2=CC=C(C=C2)CN(CCCl)CCCl,,,,,,
7846,57847,"N,N-Bis(2-chloroethyl)-alpha-methylbenzylamine hydrochloride",CC(C1=CC=CC=C1)[NH+](CCCl)CCCl.[Cl-],,,,,,
7847,57848,"N,N-bis(2-chloroethyl)-1-phenylethanamine",CC(C1=CC=CC=C1)N(CCCl)CCCl,,,,,,
7848,57849,"BENZYLAMINE, p-CHLORO-N-ETHYL-N-(2-IODOETHYL)-",CCN(CCI)CC1=CC=C(C=C1)Cl,,,,,,
7849,57850,p-Chloro-N-ethyl-N-(2-iodoethyl)benzylamine hydriodide,CC[NH+](CCI)CC1=CC=C(C=C1)Cl.[I-],,,,,,
7850,57851,"3-(2-chlorophenyl)-N,N-diethyl-1-phenylpropan-1-amine",CCN(CC)C(CCC1=CC=CC=C1Cl)C2=CC=CC=C2,,,,,,
7851,57852,"BENZYLAMINE, alpha-(p-CHLOROPHENETHYL)-N,N-DIETHYL-",CCN(CC)C(CCC1=CC=C(C=C1)Cl)C2=CC=CC=C2,,,,,,
7852,57853,"3-(4-chlorophenyl)-N,N-dimethyl-1-phenylpropan-1-amine",CN(C)C(CCC1=CC=C(C=C1)Cl)C2=CC=CC=C2,,,,,,
7853,57854,"N,N-Diethyl-alpha-phenethylbenzylamine",CCN(CC)C(CCC1=CC=CC=C1)C2=CC=CC=C2,,,,,,
7854,57855,"BENZYLAMINE, alpha,alpha-DIMETHYL-N-(2-OXAZOLINYL)-",CC(C)(C1=CC=CC=C1)NC2=NCCO2,,,,,,
7855,57856,"BENZYLAMINE, alpha-ISOPROPYL-N-(2-OXAZOLINYL)-",CC(C)C(C1=CC=CC=C1)NC2=NCCO2,,,,,,
7856,57857,"8-[3-(4-Methyl-1-piperazinyl)propyl]-6,7,8,9-tetrahydro[1]benzofuro[3,2-c]pyridine trihydrochloride",CN1CCN(CC1)CCCC2CCC3=C(C2)C4=C(O3)C=CN=C4.Cl.Cl.Cl,,,,,,
7857,57858,"8-[3-(4-Methylpiperazin-1-yl)propyl]-6,7,8,9-tetrahydro-[1]benzofuro[3,2-c]pyridine",CN1CCN(CC1)CCCC2CCC3=C(C2)C4=C(O3)C=CN=C4,,,,,,
7858,57859,"N-methyl-3-(5-methyl-6-thia-4-azatricyclo[8.4.0.03,7]tetradeca-1(14),3(7),4,10,12-pentaen-2-ylidene)propan-1-amine",CC1=NC2=C(S1)CCC3=CC=CC=C3C2=CCCNC,,,,,,
7859,57860,CID 57860,CCC1=NC2=C(O1)CCC3=CC=CC=C3C2=CCCN(C)C,,,,,,
7860,57861,"N-methyl-3-(5-methyl-6-oxa-4-azatricyclo[8.4.0.03,7]tetradeca-1(14),3(7),4,10,12-pentaen-2-ylidene)propan-1-amine",CC1=NC2=C(O1)CCC3=CC=CC=C3C2=CCCNC,,,,,,
7861,57862,"1,4-Benzodioxan-2-carboxamide, N-(2-(diethylamino)ethyl)-3-phenyl-, (E)-",CCN(CC)CCNC(=O)[C@H]1[C@@H](OC2=CC=CC=C2O1)C3=CC=CC=C3,,,,,,
7862,57863,"1,4-Benzodioxan-2-carboxylic acid, 3-phenyl-, 2-(2-(diethylamino)ethoxy)ethyl ester, citrate, (E)-",CC[NH+](CC)CCOCCOC(=O)[C@H]1[C@@H](OC2=CC=CC=C2O1)C3=CC=CC=C3.C(C(=O)[O-])C(CO)(C(=O)O)C(=O)O,,,,,,
7863,57864,"2-[2-(diethylamino)ethoxy]ethyl (2S,3R)-2-phenyl-2,3-dihydro-1,4-benzodioxine-3-carboxylate",CCN(CC)CCOCCOC(=O)[C@H]1[C@@H](OC2=CC=CC=C2O1)C3=CC=CC=C3,,,,,,
7864,57865,"1,4-Benzodioxan-2-carboxylic acid, 3-phenyl-, 2-(2-morpholinoethoxy)ethyl ester, hydrochloride, (E)-",C1COCC[NH+]1CCOCCOC(=O)[C@H]2[C@@H](OC3=CC=CC=C3O2)C4=CC=CC=C4.[Cl-],,,,,,
7865,57866,CID 57866,C1COCCN1CCOCCOC(=O)[C@H]2C(OC3=CC=CC=C3O2)C4=CC=CC=C4,,,,,,
7866,57867,"2-(N-Methyl-N-(2-chloroethyl)aminomethyl)-1,4-benzodioxan hydrochloride",C[NH+](CCCl)CC1COC2=CC=CC=C2O1.[Cl-],,,,,,
7867,57868,"2-chloro-N-(2,3-dihydro-1,4-benzodioxin-3-ylmethyl)-N-methylethanamine",CN(CCCl)CC1COC2=CC=CC=C2O1,,,,,,
7868,57869,"3-Isoxazolecarboxylic acid, 5-methyl-, 2-heptylhydrazide",CCCCCCCNNC(=O)C1=NOC(=C1)C,,,,,,
7869,57870,"Ammonium, (4,6-dimethyl-m-phenylenebis(iminocarbonylmethylene))bis(diethylmethyl-, diiodide",CC[N+](C)(CC)CC(=O)NC1=CC(=C(C=C1C)C)NC(=O)C[N+](C)(CC)CC.[I-].[I-],,,,,,
7870,57871,"[2-[5-[[2-[Diethyl(methyl)azaniumyl]acetyl]amino]-2,4-dimethylanilino]-2-oxoethyl]-diethyl-methylazanium",CC[N+](C)(CC)CC(=O)NC1=CC(=C(C=C1C)C)NC(=O)C[N+](C)(CC)CC,,,,,,
7871,57872,CID 57872,C1=CC=C(C=C1)NC(=O)C2=CC=CC=C2OCC3=NN=C(O3)S,,,,,,
7872,57873,"2-Biphenylamine, N-(2-oxazolin-2-YL)-",C1COC(=N1)NC2=CC=CC=C2C3=CC=CC=C3,,,,,,
7873,57874,2-(2-Diethylaminoethyloxy)-3-phenylbenzamide,CCN(CC)CCOC1=C(C=CC=C1C(=O)N)C2=CC=CC=C2,,,,,,
7874,57875,CID 57875,C1CC[NH+](CC1)C2(CC[NH+](CC2)CCCN3C4=CC=CC=C4CCC5=CC=CC=C53)C(=O)N.C(=CC(=O)[O-])C(=O)[O-],,,,,,
7875,57876,"Benzoic acid, 3,5-dipropyl-4-(2-(diethylamino)ethoxy)-, ethyl ester, hydrochloride",CCCC1=CC(=CC(=C1OCC[NH+](CC)CC)CCC)C(=O)OCC.[Cl-],,,,,,
7876,57877,"Ethyl 4-[2-(diethylamino)ethoxy]-3,5-dipropylbenzoate",CCCC1=CC(=CC(=C1OCCN(CC)CC)CCC)C(=O)OCC,,,,,,
7877,57878,"4-Ethoxy-3,5-dipropylbenzoic acid",CCCC1=CC(=CC(=C1OCC)CCC)C(=O)O,,,,,,
7878,57879,"Ethyl 4-ethoxy-3,5-dipropylbenzoate",CCCC1=CC(=CC(=C1OCC)CCC)C(=O)OCC,,,,,,
7879,57880,"4-Hydroxy-3,5-dipropylbenzoic acid",CCCC1=CC(=CC(=C1O)CCC)C(=O)O,,,,,,
7880,57881,"3,5-Dipropyl-4-hydroxybenzoic acid ethyl ester",CCCC1=CC(=CC(=C1O)CCC)C(=O)OCC,,,,,,
7881,57882,"Ethyl 4-(diethylcarbamoyloxy)-3,5-dipropylbenzoate",CCCC1=CC(=CC(=C1OC(=O)N(CC)CC)CCC)C(=O)OCC,,,,,,
7882,57883,"4-Propoxy-3,5-dipropylbenzoic acid",CCCC1=CC(=CC(=C1OCCC)CCC)C(=O)O,,,,,,
7883,57884,"Benzoic acid, p-(ethylamino)-, 2-hydroxy-3-(1-pyrrolidinyl)propyl ester, hydrochloride",CCNC1=CC=C(C=C1)C(=O)OCC(C[NH+]2CCCC2)O.[Cl-],,,,,,
7884,57885,(2-Hydroxy-3-pyrrolidin-1-ylpropyl) 4-(ethylamino)benzoate,CCNC1=CC=C(C=C1)C(=O)OCC(CN2CCCC2)O,,,,,,
7885,57886,"BENZOIC ACID, o-(PHENYLHYDROXYARSINO)-",C1=CC=C(C=C1)[As](C2=CC=CC=C2C(=O)O)O,,,,,,
7886,57887,"Benzoic acid, p-(propylamino)-, 3-(benzylmethylamino)-2-hydroxypropyl ester, hydrochloride",CCCNC1=CC=C(C=C1)C(=O)OCC(C[NH+](C)CC2=CC=CC=C2)O.[Cl-],,,,,,
7887,57888,[3-[Benzyl(methyl)amino]-2-hydroxypropyl] 4-(propylamino)benzoate,CCCNC1=CC=C(C=C1)C(=O)OCC(CN(C)CC2=CC=CC=C2)O,,,,,,
7888,57889,"Benzoic acid, p-(propylamino)-, 3-(diethylamino)-2-hydroxypropyl ester, hydrochloride",CCCNC1=CC=C(C=C1)C(=O)OCC(C[NH+](CC)CC)O.[Cl-],,,,,,
7889,57890,[3-(Diethylamino)-2-hydroxypropyl] 4-(propylamino)benzoate,CCCNC1=CC=C(C=C1)C(=O)OCC(CN(CC)CC)O,,,,,,
7890,57891,"Benzoic acid, p-(propylamino)-, 2-hydroxy-3-(methylamino)propyl ester, hydrochloride",CCCNC1=CC=C(C=C1)C(=O)OCC(C[NH2+]C)O.[Cl-],,,,,,
7891,57892,[2-Hydroxy-3-(methylamino)propyl] 4-(propylamino)benzoate,CCCNC1=CC=C(C=C1)C(=O)OCC(CNC)O,,,,,,
7892,57893,"Benzoic acid, p-(propylamino)-, 2-hydroxy-3-morpholinopropyl ester, hydrochloride",CCCNC1=CC=C(C=C1)C(=O)OCC(C[NH+]2CCOCC2)O.[Cl-],,,,,,
7893,57894,(2-Hydroxy-3-morpholin-4-ylpropyl) 4-(propylamino)benzoate,CCCNC1=CC=C(C=C1)C(=O)OCC(CN2CCOCC2)O,,,,,,
7894,57895,"Benzoic acid, p-(propylamino)-, 2-hydroxy-3-piperidinopropyl ester, hydrochloride",C.CCCNC1=CC=C(C=C1)C(=O)OCC(C[NH+]2CCCCC2)O.[Cl-],,,,,,
7895,57896,(2-Hydroxy-3-piperidin-1-ylpropyl) 4-(propylamino)benzoate,CCCNC1=CC=C(C=C1)C(=O)OCC(CN2CCCCC2)O,,,,,,
7896,57897,"Benzoic acid, p-(propylamino)-, 2-hydroxy-3-(propylamino)propyl ester, hydrochloride",CCC[NH2+]CC(COC(=O)C1=CC=C(C=C1)NCCC)O.[Cl-],,,,,,
7897,57898,[2-Hydroxy-3-(propylamino)propyl] 4-(propylamino)benzoate,CCCNCC(COC(=O)C1=CC=C(C=C1)NCCC)O,,,,,,
7898,57899,"Benzoic acid, p-(propylamino)-, 2-hydroxy-3-(1-pyrrolidinyl)propyl ester, hydrochloride",CCCNC1=CC=C(C=C1)C(=O)OCC(C[NH+]2CCCC2)O.[Cl-],,,,,,
7899,57900,(2-Hydroxy-3-pyrrolidin-1-ylpropyl) 4-(propylamino)benzoate,CCCNC1=CC=C(C=C1)C(=O)OCC(CN2CCCC2)O,,,,,,
7900,57901,"Benzoic acid, 3,4,5-trimethoxy-, 2-(diphenylamino)ethyl ester",COC1=CC(=CC(=C1OC)OC)C(=O)OCCN(C2=CC=CC=C2)C3=CC=CC=C3,,,,,,
7901,57902,"Benzoic acid, 3,5-dipropyl-4-(2-methylallyl)-, ethyl ester",CCCC1=CC(=CC(=C1CC(=C)C)CCC)C(=O)OCC,,,,,,
7902,57903,"4-Chloro-1,1,1-trifluoro-4-(3-nitrophenyl)-2-(trifluoromethyl)-2-butanol",C1=CC(=CC(=C1)[N+](=O)[O-])C(CC(C(F)(F)F)(C(F)(F)F)O)Cl,,,,,,
7903,57904,"2-Butanol, 2-(N-(2-imidazolin-2-yl)-N-(2-(p-methoxyphenyl)-3-indolylmethyl)amino)-, hydriodide",CCC(C)([NH+](CC1=C(NC2=CC=CC=C21)C3=CC=C(C=C3)OC)C4=NCCN4)O.[I-],,,,,,
7904,57905,2-[N-(2-Imidazolin-2-yl)-N-[[2-(4-methoxyphenyl)-1H-indol-3-yl]methyl]amino]-2-butanol,CCC(C)(N(CC1=C(NC2=CC=CC=C21)C3=CC=C(C=C3)OC)C4=NCCN4)O,,,,,,
7905,57906,2-((3-(p-(Phenoxymethyl)phenyl)propyl)amino)-1-butanol,CCC(CO)NCCCC1=CC=C(C=C1)COC2=CC=CC=C2,,,,,,
7906,57907,"2-Butanol, 4-phenyl-1,1,1-trifluoro-2-trifluoromethyl-",C1=CC=C(C=C1)CCC(C(F)(F)F)(C(F)(F)F)O,,,,,,
7907,57908,2-(7-Chloro-4-quinolylamino)-1-piperidino-1-butanone monohydrochloride,CCC(C(=O)N1CCCCC1)[NH2+]C2=C3C=CC(=CC3=NC=C2)Cl.[Cl-],,,,,,
7908,57909,2-[(7-Chloroquinolin-4-yl)amino]-1-piperidin-1-ylbutan-1-one,CCC(C(=O)N1CCCCC1)NC2=C3C=CC(=CC3=NC=C2)Cl,,,,,,
7909,57910,CID 57910,CC=C(COC(=O)CI)OC(=O)CI,,,,,,
7910,57911,"1-(m-Chlorophenyl)-4,4,4-trifluoro-3-trifluoromethyl-2-buten-1-ol",C1=CC(=CC(=C1)Cl)C(C=C(C(F)(F)F)C(F)(F)F)O,,,,,,
7911,57912,"1-(o-Chlorophenyl)-4,4,4-trifluoro-3-(trifluoromethyl)-2-buten-1-ol",C1=CC=C(C(=C1)C(C=C(C(F)(F)F)C(F)(F)F)O)Cl,,,,,,
7912,57913,CID 57913,CC=C(CO)CSC,,,,,,
7913,57914,"1-(m-Nitrophenyl)-4,4,4-trifluoro-3-trifluoromethyl-2-buten-1-ol",C1=CC(=CC(=C1)[N+](=O)[O-])C(C=C(C(F)(F)F)C(F)(F)F)O,,,,,,
7914,57915,"1-(2-Thienyl)-4,4,4-trifluoro-3-trifluoromethyl-2-buten-1-ol",C1=CSC(=C1)C(C=C(C(F)(F)F)C(F)(F)F)O,,,,,,
7915,57916,"1-(9-Anthryl)-4,4,4-trifluoro-3-trifluoromethyl-2-buten-1-one",C1=CC=C2C(=C1)C=C3C=CC=CC3=C2C(=O)C=C(C(F)(F)F)C(F)(F)F,,,,,,
7916,57917,"4-Chloro-3-(chlorodifluoromethyl)-4,4-difluoro-1-(2-furyl)-2-buten-1-one",C1=COC(=C1)C(=O)C=C(C(F)(F)Cl)C(F)(F)Cl,,,,,,
7917,57918,CID 57918,CC[NH+](CC)C=CC(=O)C(C1=CC=CC=C1)C2=CC=CC=C2.C(=CC(=O)[O-])C(=O)O,,,,,,
7918,57919,"4-(Diethylamino)-1,1-diphenylbut-3-en-2-one",CCN(CC)C=CC(=O)C(C1=CC=CC=C1)C2=CC=CC=C2,,,,,,
7919,57920,CID 57920,CC[NH+](CC)C=CC(=O)C(C1=CC=CC=C1)C2=CC=CS2.C(=CC(=O)[O-])C(=O)O,,,,,,
7920,57921,4-(Diethylamino)-1-phenyl-1-thiophen-2-ylbut-3-en-2-one,CCN(CC)C=CC(=O)C(C1=CC=CC=C1)C2=CC=CS2,,,,,,
7921,57922,CID 57922,C1COCC[NH+]1C=CC(=O)C(C2=CC=CC=C2)C3=CC=CC=C3.[Cl-],,,,,,
7922,57923,"4-Morpholin-4-yl-1,1-diphenylbut-3-en-2-one",C1COCCN1C=CC(=O)C(C2=CC=CC=C2)C3=CC=CC=C3,,,,,,
7923,57924,CID 57924,C1CC[NH+](CC1)C=CC(=O)C(C2=CC=CC=C2)C3=CC=CC=C3.[Cl-],,,,,,
7924,57925,"1,1-Diphenyl-4-piperidin-1-ylbut-3-en-2-one",C1CCN(CC1)C=CC(=O)C(C2=CC=CC=C2)C3=CC=CC=C3,,,,,,
7925,57926,CID 57926,C1CC[NH+](C1)C=CC(=O)C(C2=CC=CC=C2)C3=CC=CC=C3.[Cl-],,,,,,
7926,57927,"1,1-Diphenyl-4-pyrrolidin-1-ylbut-3-en-2-one",C1CCN(C1)C=CC(=O)C(C2=CC=CC=C2)C3=CC=CC=C3,,,,,,
7927,57928,CID 57928,C1COCC[NH+]1C=CC(=O)C(C2=CC=CC=C2)C3=CC=CS3.[Cl-],,,,,,
7928,57929,CID 57929,C1COCCN1C=CC(=O)C(C2=CC=CC=C2)C3=CC=CS3,,,,,,
7929,57930,"2-BUTEN-1-ONE, 1,1'-p-PHENYLENEBIS(4,4,4-TRIFLUORO-3-TRIFLUOROMETHYL-",C1=CC(=CC=C1C(=O)C=C(C(F)(F)F)C(F)(F)F)C(=O)C=C(C(F)(F)F)C(F)(F)F,,,,,,
7930,57931,CID 57931,C1CC[NH+](CC1)C=CC(=O)C(C2=CC=CC=C2)C3=CC=CS3.[Cl-],,,,,,
7931,57932,1-Phenyl-4-piperidin-1-yl-1-thiophen-2-ylbut-3-en-2-one,C1CCN(CC1)C=CC(=O)C(C2=CC=CC=C2)C3=CC=CS3,,,,,,
7932,57933,CID 57933,C1CC[NH+](C1)C=CC(=O)C(C2=CC=CC=C2)C3=CC=CS3.[Cl-],,,,,,
7933,57934,CID 57934,C1CCN(C1)C=CC(=O)C(C2=CC=CC=C2)C3=CC=CS3,,,,,,
7934,57935,"4,4,4-Trifluoro-3-hydroxy-1-(2-thienyl)-3-(trifluoromethyl)-1-butanone oxime",C1=CSC(=C1)C(=NO)CC(C(F)(F)F)(C(F)(F)F)O,,,,,,
7935,57936,p-(1-Ethylpropoxy)-alpha-methylbenzylamine,CCC(CC)OC1=CC=C(C=C1)C(C)N,,,,,,
7936,57937,"1-Naphthylamine, decahydro-N-(2-oxazolin-2-YL)-",C1CCC2C(C1)CCCC2NC3=NCCO3,,,,,,
7937,57938,"2-(Dimethylamino)-N-(2,4-dioxo-1,3,6-trimethyl-1,2,3,4-tetrahydro-5-pyrimidinyl)butyramide",CCC(C(=O)NC1=C(N(C(=O)N(C1=O)C)C)C)N(C)C,,,,,,
7938,57939,"Cyclohexanemethanol, alpha-ethynyl-, butyrate",CCCC(=O)OC(C#C)C1CCCCC1,,,,,,
7939,57940,"N-Ethyl-N,1,5-trimethyl-4-hexenylamine",CCN(C)C(C)CCC=C(C)C,,,,,,
7940,57941,N-Isopentil-3-isogranatanina bromidrato [Italian],CC(C)CC[NH+]1CC2CCC(C1)CC2.[Br-],,,,,,
7941,57942,3-(3-Methylbutyl)-3-azabicyclo[3.2.2]nonane,CC(C)CCN1CC2CCC(C1)CC2,,,,,,
7942,57943,Iodoxamate sodium,C1=C(C(=C(C(=C1I)NC(=O)CCOCCOCCOCCOCCC(=O)NC2=C(C=C(C(=C2I)C(=O)[O-])I)I)I)C(=O)[O-])I.[Na+].[Na+],,,,,,
7943,57944,"Acetamide, 2,2'-(ethylenebis((2-chloroethyl)imino))bis-, dipicrate",C1=C(C=C(C(=C1[N+](=O)[O-])[O-])[N+](=O)[O-])[N+](=O)[O-].C1=C(C=C(C(=C1[N+](=O)[O-])[O-])[N+](=O)[O-])[N+](=O)[O-].C(C[NH+](CCCl)CC(=O)N)[NH+](CCCl)CC(=O)N,,,,,,
7944,57945,2-[2-[(2-Amino-2-oxoethyl)-(2-chloroethyl)amino]ethyl-(2-chloroethyl)amino]acetamide,C(CN(CCCl)CC(=O)N)N(CCCl)CC(=O)N,,,,,,
7945,57946,"2,3-Dihydro-5-chloro-2-oxo-3-(2-thienylcarbonyl)-1H-indole-1-carboxamide",C1=CSC(=C1)C(=O)C2C3=C(C=CC(=C3)Cl)N(C2=O)C(=O)N,,,,,,
7946,57947,p-(Cyclopentyloxy)-alpha-methylbenzylamine,CC(C1=CC=C(C=C1)OC2CCCC2)N,,,,,,
7947,57948,6'-Chloro-2-(2-(dimethylamino)ethylthio)-o-acetotoluidide hydrochloride,CC1=C(C(=CC=C1)Cl)NC(=O)CSCC[NH+](C)C.[Cl-],,,,,,
7948,57949,N-(2-chloro-6-methylphenyl)-2-[2-(dimethylamino)ethylsulfanyl]acetamide,CC1=C(C(=CC=C1)Cl)NC(=O)CSCCN(C)C,,,,,,
7949,57950,CID 57950,CC1(C2=CC(=C3CCC(=O)NN3)C=CC2=NC1=O)C,,,,,,
7950,57951,"N,N-dimethyl-[4-(2-pyrimidin-4-yl-vinyl)-phenyl]-amine",CN(C)C1=CC=C(C=C1)C=CC2=NC=NC=C2,,,,,,
7951,57952,Cibenzoline succinate,C1CN=C(N1)C2CC2(C3=CC=CC=C3)C4=CC=CC=C4.C(CC(=O)O)C(=O)O,,,"['Agents used for the treatment or prevention of cardiac arrhythmias. They may affect the polarization-repolarization phase of the action potential, its excitability or refractoriness, or impulse conduction or membrane responsiveness within cardiac fibers. Anti-arrhythmia agents are often classed into four main groups according to their mechanism of action: sodium channel blockade, beta-adrenergic blockade, repolarization prolongation, or calcium channel blockade. (See all compounds classified as Anti-Arrhythmia Agents.)']",,,
7952,57953,"4-Allyloxy-3,5-dipropylbenzamidine hydrochloride",CCCC1=CC(=CC(=C1OCC=C)CCC)C(=[NH2+])N.[Cl-],,,,,,
7953,57954,"4-Allyloxy-3,5-dipropylbenzamidine",CCCC1=CC(=CC(=C1OCC=C)CCC)C(=N)N,,,,,,
7954,57955,"Benzanilide, 2'-amino-N-(2-(diethylamino)ethyl)-4-methoxy-",CCN(CC)CCN(C1=CC=CC=C1N)C(=O)C2=CC=C(C=C2)OC,,,,,,
7955,57956,"Benzanilide, 4'-((bis(2-chloroethyl)amino)methyl)-",C1=CC=C(C=C1)C(=O)NC2=CC=C(C=C2)CN(CCCl)CCCl,,,,,,
7956,57957,"BENZ(a)ANTHRACENE, 5,6-EPOXY-7-(HYDROXYMETHYL)-12-METHYL-",CC1=C2C3=CC=CC=C3C4=C(C2=C(C5=CC=CC=C15)CO)O4,,,,,,
7957,57958,"Oxamide, N-(1-anthraquinonyl)-N'-(2-hydroxyethyl)-",C1=CC=C2C(=C1)C(=O)C3=C(C2=O)C(=CC=C3)NC(=O)C(=O)NCCO,,,,,,
7958,57959,N-(1-Anthraquinonyl)-N'-pentyloxamide,CCCCCNC(=O)C(=O)NC1=CC2=C(C=C1)C(=O)C3=CC=CC=C3C2=O,,,,,,
7959,57960,"8,9-Dihydroxy-10,11-epoxy-8,9-dihydrobenz(a)anthracene",C1=CC=C2C(=C1)C=CC3=CC4=C(C=C32)C5=C(O5)C(C4O)O,,,,,,
7960,57961,"8,9-Dihydro-8,9-dihydroxy-10,11-epoxy-7-methylbenz(a)anthracene",CC1=C2C=CC3=CC=CC=C3C2=CC4=C1C(C(C5=C4O5)O)O,,,,,,
7961,57962,2-(Bis(2-chloroethyl)amino)butyramide monohydrochloride,CCC(C(=O)N)[NH+](CCCl)CCCl.[Cl-],,,,,,
7962,57963,2-[Bis(2-chloroethyl)amino]butanamide,CCC(C(=O)N)N(CCCl)CCCl,,,,,,
7963,57964,"Butyramide, N-(2-bromoallyl)-",CCCC(=O)NCC(=C)Br,,,,,,
7964,57965,"Butyramide, 4-(nitrosocyanamido)-",C(CC(=O)N)CN(C#N)N=O,,,,,,
7965,57966,3-Hydroxy-4-(nitrosocyanamido)butyramide,C(C(CN(C#N)N=O)O)C(=O)N,,,,,,
7966,57967,CID 57967,CCC(COCCCCOC1=C(C=C(C(=C1I)NC(=O)C)I)I)C(=O)[O-].[Na+],,,,,,
7967,57968,"2-[4-(3-Acetamido-2,4,6-triiodophenoxy)butoxymethyl]butanoic acid",CCC(COCCCCOC1=C(C=C(C(=C1I)NC(=O)C)I)I)C(=O)O,,,,,,
7968,57969,CID 57969,CCC(C(=O)[O-])OCCOC1=C(C=C(C(=C1I)NC(=O)C)I)I.[Na+],,,,,,
7969,57970,"2-[2-(3-Acetamido-2,4,6-triiodophenoxy)ethoxy]butanoic acid",CCC(C(=O)O)OCCOC1=C(C=C(C(=C1I)NC(=O)C)I)I,,,,,,
7970,57971,CID 57971,CCC(COCCCOC1=C(C=C(C(=C1I)NC(=O)C)I)I)C(=O)[O-].[Na+],,,,,,
7971,57972,"2-[3-(3-Acetamido-2,4,6-triiodophenoxy)propoxymethyl]butanoic acid",CCC(COCCCOC1=C(C=C(C(=C1I)NC(=O)C)I)I)C(=O)O,,,,,,
7972,57973,"Butyric acid, 4-(bis(2-chloroethyl)amino)-, 2,4,6-trinitrobenzenesulfonate",C1=C(C=C(C(=C1[N+](=O)[O-])S(=O)(=O)[O-])[N+](=O)[O-])[N+](=O)[O-].C(CC(=O)O)C[NH+](CCCl)CCCl,,,,,,
7973,57974,4-[Bis(2-chloroethyl)amino]butanoic acid,C(CC(=O)O)CN(CCCl)CCCl,,,,,,
7974,57975,S-methyl 4-fluoro-2-hydroxybutanethioate,CSC(=O)C(CCF)O,,,,,,
7975,57976,"Butyric acid, 4-((4-hydroxybutyl)nitrosamino)-, methyl ester, acetate",CC(=O)OCCCCN(CCCC(=O)OC)N=O,,,,,,
7976,57977,2-(Hydroxymethyl)-2-phenylbutyric acid 3-quinuclidinyl ester hydrochloride,CCC(CO)(C1=CC=CC=C1)C(=O)OC2C[NH+]3CCC2CC3.[Cl-],,,,,,
7977,57978,1-Azabicyclo[2.2.2]octan-3-yl 2-(hydroxymethyl)-2-phenylbutanoate,CCC(CO)(C1=CC=CC=C1)C(=O)OC2CN3CCC2CC3,,,,,,
7978,57979,Di(2-acetoxy-n-propyl)amine,CC(CC(=O)O)CNCC(C)CC(=O)O,,,,,,
7979,57980,"Butyric acid, 2-((9-methoxy-7-methyl-5-oxo-3a,4,4a,8a,9,9a-hexahydro-5H-furo(3,2-g)(1)benzopyran-4-yl)oxy)-, 2-morpholinoethyl ester, hydrochloride",CCC(C(=O)OCC[NH+]1CCOCC1)OC2C3C=COC3C(C4C2C(=O)C=C(O4)C)OC.[Cl-],,,,,,
7980,57981,"2-Morpholin-4-ylethyl 2-[(9-methoxy-7-methyl-5-oxo-3a,4,4a,8a,9,9a-hexahydrofuro[3,2-g]chromen-4-yl)oxy]butanoate",CCC(C(=O)OCCN1CCOCC1)OC2C3C=COC3C(C4C2C(=O)C=C(O4)C)OC,,,,,,
7981,57982,"Butyric acid, 2-((9-methoxy-7-methyl-5-oxo-3a,4,4a,8a,9,9a-hexahydro-5H-furo(3,2-g)(1)benzopyran-4-yl)oxy)-, 2-piperidinoethyl ester, hydrochloride",CCC(C(=O)OCC[NH+]1CCCCC1)OC2C3C=COC3C(C4C2C(=O)C=C(O4)C)OC.[Cl-],,,,,,
7982,57983,"2-Piperidin-1-ylethyl 2-[(9-methoxy-7-methyl-5-oxo-3a,4,4a,8a,9,9a-hexahydrofuro[3,2-g]chromen-4-yl)oxy]butanoate",CCC(C(=O)OCCN1CCCCC1)OC2C3C=COC3C(C4C2C(=O)C=C(O4)C)OC,,,,,,
7983,57984,CID 57984,CCC(C(=O)[O-])OCCOC1=C(C=C(C(=C1I)N(C)C(=O)C)I)I.[Na+],,,,,,
7984,57985,"2-[2-[3-[Acetyl(methyl)amino]-2,4,6-triiodophenoxy]ethoxy]butanoic acid",CCC(C(=O)O)OCCOC1=C(C=C(C(=C1I)N(C)C(=O)C)I)I,,,,,,
7985,57986,CID 57986,CCC(C(=O)[O-])OC1=CC=CC=C1.[Na+],,,,,,
7986,57987,2-Phenoxybutanoic acid,CCC(C(=O)O)OC1=CC=CC=C1,,,,,,
7987,57988,"3-((2,3,5,6-Tetramethylphenyl)thio)butyric acid ethyl ester",CCOC(=O)CC(C)SC1=C(C(=CC(=C1C)C)C)C,,,,,,
7988,57989,"Butyronitrile, 4-(dimethylamino)-2-isopropyl-2-phenyl-, cyclohexane sulfamate",CC(C)C(CC[NH+](C)C)(C#N)C1=CC=CC=C1.C1CCC(CC1)NS(=O)(=O)[O-],,,,,,
7989,57990,"Butyronitrile, 2,2-diphenyl-4-(4-(3-hydroxymethyl-2-oxo-1-benzimidaizolinyl)piperidino)-",C1CN(CCC1N2C3=CC=CC=C3N(C2=O)CO)CCC(C#N)(C4=CC=CC=C4)C5=CC=CC=C5,,,,,,
7990,57991,"Butyronitrile, 4-fluoro-2-hydroxy-",C(CF)C(C#N)O,,,,,,
7991,57992,CID 57992,C1=CC=C(C=C1)C(=NO)CC(C(F)(F)Cl)(C(F)(F)Cl)O,,,,,,
7992,57993,"Butyrophenone, 4'-chloro-3-hydroxy-3'-nitro-4,4,4-trifluoro-3-trifluoromethyl-",C1=CC(=C(C=C1C(=O)CC(C(F)(F)F)(C(F)(F)F)O)[N+](=O)[O-])Cl,,,,,,
7993,57994,"Butyrophenone, 2-chloro-3-hydroxy-4,4,4-trifluoro-3-(trifluoromethyl)-",C1=CC=C(C=C1)C(=O)C(C(C(F)(F)F)(C(F)(F)F)O)Cl,,,,,,
7994,57995,"4-(3-Chlorophenyl)-1,1,1-trifluoro-4-hydroxyimino-2-(trifluoromethyl)butan-2-ol",C1=CC(=CC(=C1)Cl)C(=NO)CC(C(F)(F)F)(C(F)(F)F)O,,,,,,
7995,57996,"Butyrophenone, 3-chloro-3'-nitro-4,4,4-trifluoro-3-trifluoromethyl-",C1=CC(=CC(=C1)[N+](=O)[O-])C(=O)CC(C(F)(F)F)(C(F)(F)F)Cl,,,,,,
7996,57997,"Butyrophenone, 4'-(4-(p-chlorophenyl)-4-hydroxypiperidino)-4-(4-phenylpiperidino)-",C1CN(CCC1C2=CC=CC=C2)CCCC(=O)C3=CC=C(C=C3)N4CCC(CC4)(C5=CC=C(C=C5)Cl)O,,,,,,
7997,57998,"Ammonium, (1,5-naphthylenebis(iminocarbonylmethylene))bis((2-hydroxyethyl)dimethyl-, dibromide",C[N+](C)(CCO)CC(=O)NC1=CC=CC2=C1C=CC=C2NC(=O)C[N+](C)(C)CCO.[Br-].[Br-],,,,,,
7998,57999,2-Hydroxyethyl-[2-[[5-[[2-[2-hydroxyethyl(dimethyl)azaniumyl]acetyl]amino]naphthalen-1-yl]amino]-2-oxoethyl]-dimethylazanium,C[N+](C)(CCO)CC(=O)NC1=CC=CC2=C1C=CC=C2NC(=O)C[N+](C)(C)CCO,,,,,,
7999,58000,Ethyl 2-[2-(azocan-1-yl)ethylcarbamoyl]-2-phenylbutanoate,CCC(C1=CC=CC=C1)(C(=O)NCCN2CCCCCCC2)C(=O)OCC,,,,,,
8000,58001,p-Amino-N-benzyl-N-(2-(diethylamino)ethyl)benzamide hydrochloride,CC[NH+](CC)CCN(CC1=CC=CC=C1)C(=O)C2=CC=C(C=C2)N.[Cl-],,,,,,
8001,58002,4-amino-N-benzyl-N-[2-(diethylamino)ethyl]benzamide,CCN(CC)CCN(CC1=CC=CC=C1)C(=O)C2=CC=C(C=C2)N,,,,,,
8002,58003,"Butyramide, N-(4-butylcyclohexyl)-",CCCCC1CCC(CC1)NC(=O)CCC,,,,,,
8003,58004,Amiclenomycin,C1=CC(C=CC1CCC(C(=O)O)N)N,,,,,,
8004,58005,(2-(p-Amino-N-phenylbenzamido)ethyl)diethylmethylammonium bromide,CC[N+](C)(CC)CCN(C1=CC=CC=C1)C(=O)C2=CC=C(C=C2)N.[Br-],,,,,,
8005,58006,2-(N-(4-aminobenzoyl)anilino)ethyl-diethyl-methylazanium,CC[N+](C)(CC)CCN(C1=CC=CC=C1)C(=O)C2=CC=C(C=C2)N,,,,,,
8006,58007,Geigy G-35234,CCC(C)C1=CC=C(C=C1)OC(=O)NC,,,,,,
8007,58008,"2',4'-Dichloro-3-(diethylamino)butyranilide",CCN(CC)C(C)CC(=O)NC1=C(C=C(C=C1)Cl)Cl,,,,,,
8008,58009,"ACETAMIDE, N-(5-(p-AMINOPHENOXY)PENTYL)-",CC(=O)NCCCCCOC1=CC=C(C=C1)N,,,,,,
8009,58010,"Benzoic acid, 4-amino-2-ethoxy-, 2-(dimethylamino)ethyl ester",CCOC1=C(C=CC(=C1)N)C(=O)OCCN(C)C,,,,,,
8010,58011,2-(Dimethylamino)ethyl 4-amino-3-butoxybenzoate,CCCCOC1=C(C=CC(=C1)C(=O)OCCN(C)C)N,,,,,,
8011,58012,4-Amino-2-butoxy-benzoic acid 2-(dimethylamino)ethyl ester dihydrochloride,CCCCOC1=C(C=CC(=C1)[NH3+])C(=O)OCC[NH+](C)C.[Cl-].[Cl-],,,,,,
8012,58013,2-(Dimethylamino)ethyl 4-amino-2-butoxybenzoate,CCCCOC1=C(C=CC(=C1)N)C(=O)OCCN(C)C,,,,,,
8013,58014,4-Amino-2-butoxy-benzoic acid 3-piperidinopropyl ester hydrogen phosphate,CCCCOC1=C(C=CC(=C1)N)C(=O)OCCC[NH+]2CCCCC2.OP(=O)(O)[O-],,,,,,
8014,58015,3-Piperidin-1-ylpropyl 4-amino-2-butoxybenzoate,CCCCOC1=C(C=CC(=C1)N)C(=O)OCCCN2CCCCC2,,,,,,
8015,58016,3-Amino-4-butoxythiobenzoic acid S-(2-(diethylamino)ethyl) ester hydrochloride,CCCCOC1=C(C=C(C=C1)C(=O)SCC[NH+](CC)CC)N.[Cl-],,,,,,
8016,58017,S-[2-(diethylamino)ethyl] 3-amino-4-butoxybenzenecarbothioate,CCCCOC1=C(C=C(C=C1)C(=O)SCCN(CC)CC)N,,,,,,
8017,58018,4-Amino-2-butoxythiobenzoic acid S-(2-(diethylamino)ethyl) ester hydrochloride,CCCCOC1=C(C=CC(=C1)N)C(=O)SCC[NH+](CC)CC.[Cl-],,,,,,
8018,58019,S-[2-(diethylamino)ethyl] 4-amino-2-butoxybenzenecarbothioate,CCCCOC1=C(C=CC(=C1)N)C(=O)SCCN(CC)CC,,,,,,
8019,58020,3-Amino-4-chlorobenzoic acid 2-((diethylamino)ethyl) ester hydrochloride,CC[NH+](CC)CCOC(=O)C1=CC(=C(C=C1)Cl)N.[Cl-],,,,,,
8020,58021,2-(Diethylamino)ethyl 3-amino-4-chlorobenzoate,CCN(CC)CCOC(=O)C1=CC(=C(C=C1)Cl)N,,,,,,
8021,58022,p-Aminobenzoic acid (1-cyclohexylaminomethyl)-2-propyl ester,CC(CCNC1CCCCC1)OC(=O)C2=CC=C(C=C2)N,,,,,,
8022,58023,p-Aminobenzoic acid 2-(cyclohexylamino)propyl ester glycolate hydrate,CC(COC(=O)C1=CC=C(C=C1)N)[NH2+]C2CCCCC2.C(C(=O)[O-])O,,,,,,
8023,58024,p-Aminobenzoic acid 3-(diethylamino)propyl ester hydrogen phosphate,CC[NH+](CC)CCCOC(=O)C1=CC=C(C=C1)N.OP(=O)(O)[O-],,,,,,
8024,58025,4-Amino-2-ethoxy-benzoic acid 3-(diethylamino)propyl ester dihydrochloride,CC[NH+](CC)CCCOC(=O)C1=C(C=C(C=C1)[NH3+])OCC.[Cl-].[Cl-],,,,,,
8025,58026,3-(Diethylamino)propyl 4-amino-2-ethoxybenzoate,CCN(CC)CCCOC(=O)C1=C(C=C(C=C1)N)OCC,,,,,,
8026,58027,4-Amino-2-ethoxybenzoic acid 3-piperidinopropyl ester dihydrochloride,CCOC1=C(C=CC(=C1)[NH3+])C(=O)OCCC[NH+]2CCCCC2.[Cl-].[Cl-],,,,,,
8027,58028,3-Piperidin-1-ylpropyl 4-amino-2-ethoxybenzoate,CCOC1=C(C=CC(=C1)N)C(=O)OCCCN2CCCCC2,,,,,,
8028,58029,4-Amino-2-(hexyloxy)benzoic acid 2-(diethylamino)ethyl ester hydrochloride,CCCCCCOC1=C(C=CC(=C1)N)C(=O)OCC[NH+](CC)CC.[Cl-],,,,,,
8029,58030,2-(Diethylamino)ethyl 4-amino-2-hexoxybenzoate,CCCCCCOC1=C(C=CC(=C1)N)C(=O)OCCN(CC)CC,,,,,,
8030,58031,4-Amino-2-(hexyloxy)benzoic acid 3-piperidinopropyl ester hydrochloride,CCCCCCOC1=C(C=CC(=C1)N)C(=O)OCCC[NH+]2CCCCC2.[Cl-],,,,,,
8031,58032,3-Piperidin-1-ylpropyl 4-amino-2-hexoxybenzoate,CCCCCCOC1=C(C=CC(=C1)N)C(=O)OCCCN2CCCCC2,,,,,,
8032,58033,"5-Amino-2-(2-hydroxy-1,1,1,3,3,3-hexafluoro-2-propyl)benzoic acid",C1=CC(=C(C=C1N)C(=O)O)C(C(F)(F)F)(C(F)(F)F)O,,,,,,
8033,58034,p-Aminobenzoic acid 2-(methoxymethylamino)ethyl ester,CN(CCOC(=O)C1=CC=C(C=C1)N)OC,,,,,,
8034,58035,"(E)-N-(2,5-Dihydroxystyryl)formamide",C1=CC(=C(C=C1O)C=CNC=O)O,,,,,,
8035,58036,"N-(1-Mesityloxy-2-propyl)-N-methylcarbamic acid, 2-(diethylamino)ethyl ester, hydrochloride",CC[NH+](CC)CCOC(=O)N(C)C(C)COC1=C(C=C(C=C1C)C)C.[Cl-],,,,,,
8036,58037,"2-(diethylamino)ethyl N-methyl-N-[1-(2,4,6-trimethylphenoxy)propan-2-yl]carbamate",CCN(CC)CCOC(=O)N(C)C(C)COC1=C(C=C(C=C1C)C)C,,,,,,
8037,58038,2-(Diethylamino)ethyl (alpha-methylbenzyl)carbamate hydrochloride,CC[NH+](CC)CCOC(=O)NC(C)C1=CC=CC=C1.[Cl-],,,,,,
8038,58039,2-(diethylamino)ethyl N-(1-phenylethyl)carbamate,CCN(CC)CCOC(=O)NC(C)C1=CC=CC=C1,,,,,,
8039,58040,2-(Pyrrolidinyl)ethyl (alpha-methylbenzyl)carbamate hydrochloride,CC(C1=CC=CC=C1)NC(=O)OCC[NH+]2CCCC2.[Cl-],,,,,,
8040,58041,2-pyrrolidin-1-ylethyl N-(1-phenylethyl)carbamate,CC(C1=CC=CC=C1)NC(=O)OCCN2CCCC2,,,,,,
8041,58042,N-Methylcarbamic acid 6-(dimethylamino)thymyl ester hydrochloride,CC1=C(C(=C(C=C1)C(C)C)OC(=O)NC)[NH+](C)C.[Cl-],,,,,,
8042,58043,"Carbamic acid, N-methyl-N-(2-(5-methylthio-3-indolyl)ethyl)-, methyl ester",CN(CCC1=CNC2=C1C=C(C=C2)SC)C(=O)OC,,,,,,
8043,58044,"Carbamic acid, (1-methyl-5-nitro-2-imidazolyl)-, ethyl ester",CCOC(=O)NC1=NC=C(N1C)[N+](=O)[O-],,,,,,
8044,58045,Methylnitrosocarbamic acid p-((dimethylamino)methyleneamino)phenyl ester,CN(C)C=NC1=CC=C(C=C1)OC(=O)N(C)N=O,,,,,,
8045,58046,"Carbamic acid, methylnitroso-, 2,2-dimethyl-3-hydroxy-2,3-dihydro-7-benzofuranyl ester",CC1(C(C2=C(O1)C(=CC=C2)OC(=O)N(C)N=O)O)C,,,,,,
8046,58047,"o-(1,3-Dioxolan-2-yl)phenyl methylnitrosocarbamate",CN(C(=O)OC1=CC=CC=C1C2OCCO2)N=O,,,,,,
8047,58048,"CARBAMIC ACID, METHYLNITROSO-, alpha-(ETHYLTHIO)-o-TOLYL ESTER",CCSCC1=CC=CC=C1OC(=O)N(C)N=O,,,,,,
8048,58049,N-(3-Methylthiazolidin-2-ylidene)carbamic acid tert-butyl ester,CC(C)(C)OC(=O)N=C1N(CCS1)C,,,,,,
8049,58050,"Carbamic acid, N-methyl-N-(1-(3,5-xylyloxy)-2-propyl)-, 2-(diethylamino)ethyl ester, hydrochloride",CC[NH+](CC)CCOC(=O)N(C)C(C)COC1=CC(=CC(=C1)C)C.[Cl-],,,,,,
8050,58051,"2-(diethylamino)ethyl N-[1-(3,5-dimethylphenoxy)propan-2-yl]-N-methylcarbamate",CCN(CC)CCOC(=O)N(C)C(C)COC1=CC(=CC(=C1)C)C,,,,,,
8051,58052,"Carbamic acid, N-methyl-N-(1-(3,5-xylyloxy)-2-propyl)-, 2-(2-methylpiperidino)ethyl ester, hydrochloride",CC1CCCC[NH+]1CCOC(=O)N(C)C(C)COC2=CC(=CC(=C2)C)C.[Cl-],,,,,,
8052,58053,"2-(2-methylpiperidin-1-yl)ethyl N-[1-(3,5-dimethylphenoxy)propan-2-yl]-N-methylcarbamate",CC1CCCCN1CCOC(=O)N(C)C(C)COC2=CC(=CC(=C2)C)C,,,,,,
8053,58054,"Carbamic acid, N-methyl-N-(1-(3,5-xylyloxy)-2-propyl)-, 2-(pyrrolidinyl)ethyl ester, hydrochloride",CC1=CC(=CC(=C1)OCC(C)N(C)C(=O)OCC[NH+]2CCCC2)C.[Cl-],,,,,,
8054,58055,"2-pyrrolidin-1-ylethyl N-[1-(3,5-dimethylphenoxy)propan-2-yl]-N-methylcarbamate",CC1=CC(=CC(=C1)OCC(C)N(C)C(=O)OCCN2CCCC2)C,,,,,,
8055,58056,(2-Norbornen-5-yl)carbamic acid (diethylamino)methyl ester hydrochloride,CC[NH+](CC)COC(=O)NC1CC2CC1C=C2.[Cl-],,,,,,
8056,58057,diethylaminomethyl N-(2-bicyclo[2.2.1]hept-5-enyl)carbamate,CCN(CC)COC(=O)NC1CC2CC1C=C2,,,,,,
8057,58058,2-Piperidinoethyl phenethylcarbamate hydrochloride,C1CC[NH+](CC1)CCOC(=O)NCCC2=CC=CC=C2.[Cl-],,,,,,
8058,58059,2-piperidin-1-ylethyl N-(2-phenylethyl)carbamate,C1CCN(CC1)CCOC(=O)NCCC2=CC=CC=C2,,,,,,
8059,58060,"N-Phenylcarbamic acid, 2-(methyl(1-phenoxy-2-propyl)amino)ethyl ester, hydrochloride",CC(COC1=CC=CC=C1)[NH+](C)CCOC(=O)NC2=CC=CC=C2.[Cl-],,,,,,
8060,58061,2-[methyl(1-phenoxypropan-2-yl)amino]ethyl N-phenylcarbamate,CC(COC1=CC=CC=C1)N(C)CCOC(=O)NC2=CC=CC=C2,,,,,,
8061,58062,Benzyl N-(2-pyrrolidinylethyl)carbamate hydrochloride,C1CC[NH+](C1)CCNC(=O)OCC2=CC=CC=C2.[Cl-],,,,,,
8062,58063,benzyl N-(2-pyrrolidin-1-ylethyl)carbamate,C1CCN(C1)CCNC(=O)OCC2=CC=CC=C2,,,,,,
8063,58064,o-Chlorobenzyl N-(2-pyrrolidinylethyl)carbamate hydrochloride,C1CC[NH+](C1)CCNC(=O)OCC2=CC=CC=C2Cl.[Cl-],,,,,,
8064,58065,(2-chlorophenyl)methyl N-(2-pyrrolidin-1-ylethyl)carbamate,C1CCN(C1)CCNC(=O)OCC2=CC=CC=C2Cl,,,,,,
8065,58066,"2,4-Dimethylbenzyl N-(2-pyrrolidinylethyl)carbamate hydrochloride",CC1=CC(=C(C=C1)COC(=O)NCC[NH+]2CCCC2)C.[Cl-],,,,,,
8066,58067,"(2,4-dimethylphenyl)methyl N-(2-pyrrolidin-1-ylethyl)carbamate",CC1=CC(=C(C=C1)COC(=O)NCCN2CCCC2)C,,,,,,
8067,58068,"2,5-Dimethylbenzyl N-(2-pyrrolidinylethyl)carbamate hydrochloride",CC1=CC(=C(C=C1)C)COC(=O)NCC[NH+]2CCCC2.[Cl-],,,,,,
8068,58069,"(2,5-dimethylphenyl)methyl N-(2-pyrrolidin-1-ylethyl)carbamate",CC1=CC(=C(C=C1)C)COC(=O)NCCN2CCCC2,,,,,,
8069,58070,"2,6-Dimethylbenzyl N-(2-pyrrolidinylethyl)carbamate hydrochloride",CC1=C(C(=CC=C1)C)COC(=O)NCC[NH+]2CCCC2.[Cl-],,,,,,
8070,58071,"(2,6-dimethylphenyl)methyl N-(2-pyrrolidin-1-ylethyl)carbamate",CC1=C(C(=CC=C1)C)COC(=O)NCCN2CCCC2,,,,,,
8071,58072,p-Methylbenzyl N-(2-pyrrolidinylethyl)carbamate hydrochloride,CC1=CC=C(C=C1)COC(=O)NCC[NH+]2CCCC2.[Cl-],,,,,,
8072,58073,(4-methylphenyl)methyl N-(2-pyrrolidin-1-ylethyl)carbamate,CC1=CC=C(C=C1)COC(=O)NCCN2CCCC2,,,,,,
8073,58074,3-Phenylpropyl N-(2-pyrrolidinylethyl)carbamate hydrochloride,C1CC[NH+](C1)CCNC(=O)OCCCC2=CC=CC=C2.[Cl-],,,,,,
8074,58075,3-phenylpropyl N-(2-pyrrolidin-1-ylethyl)carbamate,C1CCN(C1)CCNC(=O)OCCCC2=CC=CC=C2,,,,,,
8075,58076,"CARBANILIC ACID, p-(9-ACRIDINYLAMINO)-",C1=CC=C2C(=C1)C(=C3C=CC=CC3=N2)NC4=CC=C(C=C4)NC(=O)O,,,,,,
8076,58077,o-Butoxy-N-phenyl-carbanilic acid 2-diethylaminoethyl ester hydrochloride,CCCCOC1=CC=CC=C1N(C2=CC=CC=C2)C(=O)OCC[NH+](CC)CC.[Cl-],,,,,,
8077,58078,(o-Butoxyphenyl)phenylcarbamic acid 2-(diethylamino)ethyl ester,CCCCOC1=CC=CC=C1N(C2=CC=CC=C2)C(=O)OCCN(CC)CC,,,,,,
8078,58079,p-Butoxy-N-phenyl-carbanilic acid 2-diethylaminoethyl ester hydrochloride,CCCCOC1=CC=C(C=C1)N(C2=CC=CC=C2)C(=O)OCC[NH+](CC)CC.[Cl-],,,,,,
8079,58080,(p-Butoxyphenyl)phenylcarbamic acid 2-(diethylamino)ethyl ester,CCCCOC1=CC=C(C=C1)N(C2=CC=CC=C2)C(=O)OCCN(CC)CC,,,,,,
8080,58081,2-(Pyrrolidinyl)ethyl 2-chlorocarbanilate hydrochloride,C1CC[NH+](C1)CCOC(=O)NC2=CC=CC=C2Cl.[Cl-],,,,,,
8081,58082,2-pyrrolidin-1-ylethyl N-(2-chlorophenyl)carbamate,C1CCN(C1)CCOC(=O)NC2=CC=CC=C2Cl,,,,,,
8082,58083,1-cyclohexylprop-2-ynyl N-phenylcarbamate,C#CC(C1CCCCC1)OC(=O)NC2=CC=CC=C2,,,,,,
8083,58084,"Carbanilic acid, 3,4-dichloro-N-nitroso-, methyl ester",COC(=O)N(C1=CC(=C(C=C1)Cl)Cl)N=O,,,,,,
8084,58085,"CHROMONE, 7-FLUORO-2-(3-(4-(o-METHOXYPHENYL)-1-PIPERAZINYL)PROPYL)-3-METHYL-",CC1=C(OC2=C(C1=O)C=CC(=C2)F)CCCN3CCN(CC3)C4=CC=CC=C4OC,,,,,,
8085,58086,CID 58086,CCCOC1=NC2=CC=CC=C2C(=C1)C=NOCCN(CC)CC,,,,,,
8086,58087,7-Chloro-2-[2-(5-nitro-2-furoyl)hydrazonomethyl]quinoline-4-carboxylic acid,C1=CC2=C(C=C(N=C2C=C1Cl)C=NNC(=O)C3=CC=C(O3)[N+](=O)[O-])C(=O)O,,,,,,
8087,58088,"4-Quinolinecarboxylicacid, 2-[(2-ethylhydrazinylidene)methyl]-",CCNN=CC1=NC2=CC=CC=C2C(=C1)C(=O)O,,,,,,
8088,58089,"Cinchoninic acid, 2-(10-(3-(4-methyl-1-piperazinyl)propyl)-2-phenothiazinyl)-, ethyl ester, dihydrochloride, hydrate",CCOC(=O)C1=CC(=NC2=CC=CC=C21)C3=CC4=C(C=C3)SC5=CC=CC=C5N4CCCN6CC[NH+](CC6)C.[Cl-],,,,,,
8089,58090,Ethyl 2-[10-[3-(4-methylpiperazin-1-yl)propyl]phenothiazin-2-yl]quinoline-4-carboxylate,CCOC(=O)C1=CC(=NC2=CC=CC=C21)C3=CC4=C(C=C3)SC5=CC=CC=C5N4CCCN6CCN(CC6)C,,,,,,
8090,58091,CID 58091,C1=CC=C2C(=C1)C(=CC(=N2)NN=C(N)S)C(=O)O,,,,,,
8091,58092,CID 58092,CSCC1=CC=CC=C1C=CC=O,,,,,,
8092,58093,3-(Bromoethynyl)-1-hepten-3-ol,CCCCC(C=C)(C#CBr)O,,,,,,
8093,58094,"Ethylamine, 2-(2,4,6-cycloheptatrienyl)-",CCNC1C=CC=CC=C1,,,,,,
8094,58095,"Anthracene, 1,2-diamino-",C1=CC=C2C=C3C(=CC2=C1)C=CC(=C3N)N,,,,,,
8095,58096,"3-Isoxazolecarboxylic acid, 5-methyl-, 2-nonylhydrazide",CCCCCCCCCNNC(=O)C1=NOC(=C1)C,,,,,,
8096,58097,Phenylacetic acid 1-ethyl-1-methyl-2-propynyl ester,CCC(C)(C#C)OC(=O)CC1=CC=CC=C1,,,,,,
8097,58098,"2,3-Dimethyl-6-morpholinomethyl-chromone hydrochloride",CC1=C(OC2=C(C1=O)C=C(C=C2)C[NH+]3CCOCC3)C.[Cl-],,,,,,
8098,58099,"2,3-Dimethyl-6-(morpholin-4-ylmethyl)chromen-4-one",CC1=C(OC2=C(C1=O)C=C(C=C2)CN3CCOCC3)C,,,,,,
8099,58100,alpha-Acetamido-N-isobutyl-beta-phenylacrylamide,CC(C)CNC(=O)C(=CC1=CC=CC=C1)NC(=O)C,,,,,,
8100,58101,2-methyl-3-phenyl-N-prop-2-enylprop-2-enamide,CC(=CC1=CC=CC=C1)C(=O)NCC=C,,,,,,
8101,58102,2-Cyano-3-(4-fluoro-phenyl)-acrylamide,C1=CC(=CC=C1C=C(C#N)C(=O)N)F,,,,,,
8102,58103,N-cyclopropyl-2-methyl-3-[3-(trifluoromethyl)phenyl]prop-2-enamide,CC(=CC1=CC(=CC=C1)C(F)(F)F)C(=O)NC2CC2,,,,,,
8103,58104,CID 58104,CC[NH+](CC)CCN(CC1=CC=[NH+]C=C1)C(=O)C=CC2=CC=CC=C2.[Cl-].[Cl-],,,,,,
8104,58105,CID 58105,CCN(CC)CCN(CC1=CC=NC=C1)C(=O)C=CC2=CC=CC=C2,,,,,,
8105,58106,2-Fluoro-3-phenylprop-2-enamide,C1=CC=C(C=C1)C=C(C(=O)N)F,,,,,,
8106,58107,2-Methyl-3-[3-(trifluoromethyl)phenyl]prop-2-enamide,CC(=CC1=CC(=CC=C1)C(F)(F)F)C(=O)N,,,,,,
8107,58108,3-phenyl-N-piperidin-1-ylprop-2-enamide,C1CCN(CC1)NC(=O)C=CC2=CC=CC=C2,,,,,,
8108,58109,CID 58109,C[NH+]1CCCCC1CN(C2=CC=CC=C2)C(=O)C=CC3=CC=CC=C3.[Cl-],,,,,,
8109,58110,CID 58110,CN1CCCCC1CN(C2=CC=CC=C2)C(=O)C=CC3=CC=CC=C3,,,,,,
8110,58111,CID 58111,C[NH+]1CCCC(C1)CN(C2=CC=CC=C2)C(=O)C=CC3=CC=CC=C3.[Cl-],,,,,,
8111,58112,CID 58112,CN1CCCC(C1)CN(C2=CC=CC=C2)C(=O)C=CC3=CC=CC=C3,,,,,,
8112,58113,CID 58113,C[NH+]1C2CCC1CC(C2)OC(=O)C(=CC3=CC=CC=C3)C4=CC=C(C=C4)N.[Cl-],,,,,,
8113,58114,CID 58114,CN1C2CCC1CC(C2)OC(=O)C(=CC3=CC=CC=C3)C4=CC=C(C=C4)N,,,,,,
8114,58115,CID 58115,C[NH+]1C2CCC1CC(C2)OC(=O)C(=CC3=CC=C(C=C3)Cl)C4=CC=CC=C4.[Cl-],,,,,,
8115,58116,CID 58116,CN1C2CCC1CC(C2)OC(=O)C(=CC3=CC=C(C=C3)Cl)C4=CC=CC=C4,,,,,,
8116,58117,CID 58117,CCC1=CC=C(C=C1)C(=CC2=CC=CC=C2)C(=O)OC3CC4CCC(C3)[NH+]4C.[Cl-],,,,,,
8117,58118,CID 58118,CCC1=CC=C(C=C1)C(=CC2=CC=CC=C2)C(=O)OC3CC4CCC(C3)N4C,,,,,,
8118,58119,CID 58119,CC(C)C[NH2+]C1=CC=CC(=C1)C(=CC2=CC=CC=C2)C(=O)OC3CC4CCC(C3)[NH+]4C.[Cl-].[Cl-],,,,,,
8119,58120,CID 58120,CC(C)CNC1=CC=CC(=C1)C(=CC2=CC=CC=C2)C(=O)OC3CC4CCC(C3)N4C,,,,,,
8120,58121,CID 58121,C[NH+]1C2CCC1CC(C2)OC(=O)C(=CC3=CC=CC=C3)C4=CC=C(C=C4)[N+](=O)[O-].[Cl-],,,,,,
8121,58122,CID 58122,CN1C2CCC1CC(C2)OC(=O)C(=CC3=CC=CC=C3)C4=CC=C(C=C4)[N+](=O)[O-],,,,,,
8122,58123,CID 58123,C[NH+]1C2CCC1CC(C2)OC(=O)C(=CC3=CC=CC=C3)C4=CC=CC=C4.[Cl-],,,,,,
8123,58124,CID 58124,CN1C2CCC1CC(C2)OC(=O)C(=CC3=CC=CC=C3)C4=CC=CC=C4,,,,,,
8124,58125,CID 58125,C1=CC=C(C(=C1)C=C(C#N)[N+](=O)[O-])Cl,,,,,,
8125,58126,"N-Butyl-2,3,3-trimethyl-2-norbornanamine",CCCCNC1(C2CCC(C2)C1(C)C)C,,,,,,
8126,58127,4'-Chloro-3-(diethylamino)butyranilide,CCN(CC)C(C)CC(=O)NC1=CC=C(C=C1)Cl,,,,,,
8127,58128,Diethyl(2-hydroxyethyl)methylammonium bromide alpha-cyclohexyl-1-hydroxycyclohexaneacetate,CC[N+](C)(CC)CCOC(=O)C(C1CCCCC1)C2(CCCCC2)O.[Br-],,,,,,
8128,58129,2-[2-Cyclohexyl-2-(1-hydroxycyclohexyl)acetyl]oxyethyl-diethyl-methylazanium,CC[N+](C)(CC)CCOC(=O)C(C1CCCCC1)C2(CCCCC2)O,,,,,,
8129,58130,5-Hydroxymethylchrysene sulfate,C1=CC=C2C(=C1)C=CC3=C2C(=CC4=CC=CC=C34)COS(=O)(=O)O,,,,,,
8130,58131,"1-(4-{Ethyl[1-(4-methoxyphenyl)propan-2-yl]amino}butanoyl)-n,n-dimethylpiperidine-4-carboxamide",CCN(CCCC(=O)N1CCC(CC1)C(=O)N(C)C)C(C)CC2=CC=C(C=C2)OC,,,,,,
8131,58132,"Indole-3-glyoxylamide, 1-ethyl-N,N,2-trimethyl-",CCN1C(=C(C2=CC=CC=C21)C(=O)C(=O)N(C)C)C,,,,,,
8132,58133,"MALEIMIDE, N-(5-(p-AMINOPHENOXY)PENTYL)-",C1=CC(=CC=C1N)OCCCCCN2C(=O)C=CC2=O,,,,,,
8133,58134,"1,3,2-Dioxaborinane, 6-tert-butyl-2-methoxy-4,4-bis(trifluoromethyl)-",B1(OC(CC(O1)(C(F)(F)F)C(F)(F)F)C(C)(C)C)OCC,,,,,,
8134,58135,19-O-Monoacetylbovosidol A,CC1[C@H](C(C([C@@H](O1)O[C@H]2CC[C@]3([C@@H](C2)CCC4C3CC[C@]5([C@@]4(CC[C@@H]5C6=COC(=O)C=C6)O)C)COC(=O)C)O)OC)O,,,,,,
8135,58136,"3-(Acetyloxy)-5,14,19-trihydroxybufa-20,22-dienolide",CC(=O)O[C@H]1CC[C@@]2(C3CC[C@@]4([C@H](CC[C@@]4(C3CC[C@@]2(C1)O)O)C5=COC(=O)C=C5)C)CO,,,,,,
8136,58137,"2-Amino-4-[4-(dimethylamino)phenyl]buta-1,3-di-ene-1,1,3-tricarbonitrile",CN(C)C1=CC=C(C=C1)C=C(C#N)C(=C(C#N)C#N)N,,,,,,
8137,58138,"1,4-Butanediamine, N,N'-bis(2-chloroethyl)-N,N'-dimethyl-",CN(CCCCN(C)CCCl)CCCl,,,,,,
8138,58139,"N,N'-Bis(2-chloroethyl)-N,N'-dimethyl-1,4-butanediamine N,N'-dioxide",C[N+](CCCC[N+](C)(CCCl)[O-])(CCCl)[O-],,,,,,
8139,58140,"1,3-Butanediol, 1-(2-furyl)-4,4,4-trifluoro-3-trifluoromethyl-",C1=COC(=C1)C(CC(C(F)(F)F)(C(F)(F)F)O)O,,,,,,
8140,58141,"p-Bis(4,4,4-trifluoro-1,3-dihydroxy-3-(trifluoromethyl)butyl)benzene",C1=CC(=CC=C1C(CC(C(F)(F)F)(C(F)(F)F)O)O)C(CC(C(F)(F)F)(C(F)(F)F)O)O,,,,,,
8141,58142,"2-[(3,4-Dichlorophenyl)methylidene]-1-phenylbutane-1,3-dione",CC(=O)C(=CC1=CC(=C(C=C1)Cl)Cl)C(=O)C2=CC=CC=C2,,,,,,
8142,58143,"1,3-Butanediol, 1-(p-fluorophenyl)-2-methyl-4,4,4-trifluoro-3-(trifluoromethyl)-, 3,4-dichlorocarbanilate",CC(C(C1=CC=C(C=C1)F)O)C(C(F)(F)F)(C(F)(F)F)OC(=O)NC2=CC(=C(C=C2)Cl)Cl,,,,,,
8143,58144,Indolophenanthridine,CN1CC2=CC=CC=C2[C@H]3[C@H]1CC4=CNC5=CC=CC3=C45,,,"['Agents used in the treatment of Parkinson&apos;s disease. The most commonly used drugs act on the dopaminergic system in the striatum and basal ganglia or are centrally acting muscarinic antagonists. (See all compounds classified as Antiparkinson Agents.)', 'Drugs that bind to and activate dopamine receptors. (See all compounds classified as Dopamine Agonists.)']",,,
8144,58145,"N-(2-Chloro-6-methylergoline-8-yl)-2,2-dimethylpropanamide",CC(C)(C)C(=O)N[C@H]1C[C@H]2[C@@H](CC3=C(NC4=CC=CC2=C34)Cl)N(C1)C,,,['Drugs that bind to and activate dopamine receptors. (See all compounds classified as Dopamine Agonists.)'],,,
8145,58146,(9-Acridyl)-spermine,C1=CC=C2C(=C1)C(=C3C=CC=CC3=N2)NCCCNCCCCNCCCN,,,,,,
8146,58147,"Ammonium, (4-methyl-m-phenylenebis(iminocarbonylmethylene))bis(diethylmethyl-, diiodide",CC[N+](C)(CC)CC(=O)NC1=CC(=C(C=C1)C)NC(=O)C[N+](C)(CC)CC.[I-].[I-],,,,,,
8147,58148,[2-[3-[[2-[Diethyl(methyl)azaniumyl]acetyl]amino]-4-methylanilino]-2-oxoethyl]-diethyl-methylazanium,CC[N+](C)(CC)CC(=O)NC1=CC(=C(C=C1)C)NC(=O)C[N+](C)(CC)CC,,,,,,
8148,58149,"(1)BENZOTHIOPYRANO(3,4-d)IMIDAZOL-4(1H)-ONE, 2-(1-PIPERIDINYLMETHYL)-",C1CCN(CC1)CC2=NC3=C(N2)C(=O)SC4=CC=CC=C43,,,,,,
8149,58150,"(1)BENZOTHIOPYRANO(3,4-d)IMIDAZOL-4(1H)-ONE, 1-METHYL-2-(1-PIPERIDINYLMETHYL)-",CN1C(=NC2=C1C3=CC=CC=C3SC2=O)CN4CCCCC4,,,,,,
8150,58151,"(1)BENZOTHIOPYRANO(3,4-d)IMIDAZOL-4(1H)-ONE, 1-BUTYL-2-(1-PIPERIDINYLMETHYL)-",CCCCN1C(=NC2=C1C3=CC=CC=C3SC2=O)CN4CCCCC4,,,,,,
8151,58152,2-ethyl-N-henicosylhex-2-en-1-imine,CCCCCCCCCCCCCCCCCCCCCN=CC(=CCCC)CC,,,,,,
8152,58153,"Vanillylamine, N-heptanoyl-, acetate",CCCCCCC(=O)NCC1=CC(=C(C=C1)OC(=O)C)OC,,,,,,
8153,58154,3-chloro-N-[(4-hydroxy-3-methoxyphenyl)methyl]but-2-enamide,CC(=CC(=O)NCC1=CC(=C(C=C1)O)OC)Cl,,,,,,
8154,58155,CID 58155,CC(=CC(=O)NC1=CC=C(C=C1)O)Cl,,,,,,
8155,58156,"Crotonanilide, 4'-hydroxy-3-methyl-",CC(=CC(=O)NC1=CC=C(C=C1)O)C,,,,,,
8156,58157,"Crotonophenone, 3'-fluorosulfonyl-4,4,4-trifluoro-3-trifluoromethyl-",C1=CC(=CC(=C1)S(=O)(=O)F)C(=O)C=C(C(F)(F)F)C(F)(F)F,,,,,,
8157,58158,1-Methyl-4-piperidyl cyclobutyl(1-propynyl)glycolate,CC#CC(C1CCC1)(C(=O)OC2CCN(CC2)C)O,,,,,,
8158,58159,"3-Pentynoic acid, 2-cyclobutyl-2-hydroxy-, 3-quinuclidinyl ester",CC#CC(C1CCC1)(C(=O)OC2CN3CCC2CC3)O,,,,,,
8159,58160,"Benzilic acid, 2,2-dimethyl-4-ethyl-3-piperidinocyclobutyl ester",CCC1C(C(C1OC(=O)C(C2=CC=CC=C2)(C3=CC=CC=C3)O)(C)C)N4CCCCC4,,,,,,
8160,58161,"7a,8a,9,10-Tetrahydro-7h-pyreno[1',2':5,6]cyclohepta[1,2-b]oxirene",C1CC2=C(CC3C1O3)C=C4C=CC5=C6C4=C2C=CC6=CC=C5,,,,,,
8161,58162,CID 58162,CCOC1=CC=C(C=C1)N(CC[NH+](C)C)C(=O)C2=CC=CC=C2.C(=CC(=O)[O-])C(=O)O,,,,,,
8162,58163,N-[2-(dimethylamino)ethyl]-N-(4-ethoxyphenyl)benzamide,CCOC1=CC=C(C=C1)N(CCN(C)C)C(=O)C2=CC=CC=C2,,,,,,
8163,58164,p-Amino-N-benzyl-N-(3-(diethylamino)propyl)benzamide hydrochloride,CC[NH+](CC)CCCN(CC1=CC=CC=C1)C(=O)C2=CC=C(C=C2)N.[Cl-],,,,,,
8164,58165,4-amino-N-benzyl-N-[3-(diethylamino)propyl]benzamide,CCN(CC)CCCN(CC1=CC=CC=C1)C(=O)C2=CC=C(C=C2)N,,,,,,
8165,58166,"CYCLOHEPTANECARBAMIC ACID, 3,3-BIS(p-FLUOROPHENYL)-1-PROPYNYL ESTER",C1CCCC(CC1)NC(=O)OC#CC(C2=CC=C(C=C2)F)C3=CC=C(C=C3)F,,,,,,
8166,58167,Camphechlor,C1C2C(C(C(C1(Cl)Cl)(C2(CCl)C(Cl)Cl)CCl)Cl)Cl,,,"['Pesticides designed to control insects that are harmful to man. The insects may be directly harmful, as those acting as disease vectors, or indirectly harmful, as destroyers of crops, food products, or textile fabrics. (See all compounds classified as Insecticides.)']",,,
8167,58168,alpha-Benzylcyclopropaneglycolic acid 3-quinuclidinyl ester,C1CC1C(CC2=CC=CC=C2)(C(=O)OC3CN4CCC3CC4)O,,,,,,
8168,58169,N-Bicyclo(3.1.0)hex-2-ylcyclopropylamine oxalate,C1CC1[NH2+]C2CCC3C2C3.C(=O)(C(=O)[O-])O,,,,,,
8169,58170,N-cyclopropylbicyclo[3.1.0]hexan-2-amine,C1CC1NC2CCC3C2C3,,,,,,
8170,58171,N-(2-Oxazolin-2-yl)-2-phenylcyclopropylamine,C1COC(=N1)NC2CC2C3=CC=CC=C3,,,,,,
8171,58172,"p-CYMEME-2-CARBOXYLIC ACID, 6-ALLYL-3-HYDROXY-",CC1=C(C(=C(C=C1CC=C)C(C)C)O)C(=O)O,,,,,,
8172,58173,"p-CYMENE-2-CARBOXYLIC ACID, 6-ALLYL-3-HYDROXY-, ALLYL ESTER",CC1=C(C(=C(C=C1CC=C)C(C)C)O)C(=O)OCC=C,,,,,,
8173,58174,"1,10-Bis(4-methylpiperazin-1-yl)decane-1,10-dione",CN1CCN(CC1)C(=O)CCCCCCCCC(=O)N2CCN(CC2)C,,,,,,
8174,58175,"3-Benzyl-9-methyl-3,9-diazabicyclo(3.3.1)nonane dihydrochloride",CN1C2CCCC1CN(C2)CC3=CC=CC=C3.Cl.Cl,,,,,,
8175,58176,"3-Benzyl-9-methyl-3,9-diazabicyclo[3.3.1]nonane",CN1C2CCCC1CN(C2)CC3=CC=CC=C3,,,,,,
8176,58177,"2-(alpha-Butylbenzylthio)-N,N-dimethylethylamine",CCCCC(C1=CC=CC=C1)SCCN(C)C,,,,,,
8177,58178,"Barbituric acid, 5-butyl-5-(2-piperidinoethyl)-",CCCCC1(C(=O)NC(=O)NC1=O)CCN2CCCCC2,,,,,,
8178,58179,"ISONICOTINIC ACID, 2-(p-(DIMETHYLAMINO)BENZYL)HYDRAZIDE",CN(C)C1=CC=C(C=C1)CNNC(=O)C2=CC=NC=C2,,,,,,
8179,58180,"FURFURYLAMINE, N-(o-METHOXY-alpha-METHYLPHENETHYL)-, HYDROCHLORIDE",CC(CC1=CC=CC=C1OC)[NH2+]CC2=CC=CO2.[Cl-],,,,,,
8180,58181,N-(furan-2-ylmethyl)-1-(2-methoxyphenyl)propan-2-amine,CC(CC1=CC=CC=C1OC)NCC2=CC=CO2,,,,,,
8181,58182,"FURFURYLAMINE, N-(3-(o-METHOXYPHENYL)PROPYL)-, HYDROCHLORIDE",COC1=CC=CC=C1CCC[NH2+]CC2=CC=CO2.[Cl-],,,,,,
8182,58183,N-(furan-2-ylmethyl)-3-(2-methoxyphenyl)propan-1-amine,COC1=CC=CC=C1CCCNCC2=CC=CO2,,,,,,
8183,58184,"1-Dicyclohexylamino-2,3-dichloropropane hydrochloride",C1CCC(CC1)[NH+](CC(CCl)Cl)C2CCCCC2.[Cl-],,,,,,
8184,58185,"N-cyclohexyl-N-(2,3-dichloropropyl)cyclohexanamine",C1CCC(CC1)N(CC(CCl)Cl)C2CCCCC2,,,,,,
8185,58186,"ACETAMIDE, N-(5-(p-AMINOPHENOXY)PENTYL)-2-CYANO-",C1=CC(=CC=C1N)OCCCCCNC(=O)CC#N,,,,,,
8186,58187,N-((5-Chloro-8-hydroxy-3-methyl-1-oxo-7-isochromanyl)carbonyl)cysteine,CC1CC2=C(C=C(C(=C2C(=O)O1)O)C(=O)NC(CS)C(=O)O)Cl,,,,,,
8187,58188,"3,4-Dihydro-7-hydroxy-1-(2-(methylphenethylamino)propyl)carbostyril oxalate",CC(CN1C(=O)CCC2=C1C=C(C=C2)O)[NH+](C)CCC3=CC=CC=C3.C(=O)(C(=O)[O-])O,,,,,,
8188,58189,"7-Hydroxy-1-[2-[methyl(2-phenylethyl)amino]propyl]-3,4-dihydroquinolin-2-one",CC(CN1C(=O)CCC2=C1C=C(C=C2)O)N(C)CCC3=CC=CC=C3,,,,,,
8189,58190,"1-Dibenzylamino-2,3-dichloropropane hydrochloride",C1=CC=C(C=C1)C[NH+](CC2=CC=CC=C2)CC(CCl)Cl.[Cl-],,,,,,
8190,58191,"N,N-dibenzyl-2,3-dichloropropan-1-amine",C1=CC=C(C=C1)CN(CC2=CC=CC=C2)CC(CCl)Cl,,,,,,
8191,58192,"3,3',4,4',5,5'-Hexamethoxydibenzylamine hydrochloride",COC1=CC(=CC(=C1OC)OC)C[NH2+]CC2=CC(=C(C(=C2)OC)OC)OC.[Cl-],,,,,,
8192,58193,"1-Dibutylamino-2,3-dichloropropane hydrochloride",CCCC[NH+](CCCC)CC(CCl)Cl.[Cl-],,,,,,
8193,58194,"N-butyl-N-(2,3-dichloropropyl)butan-1-amine",CCCCN(CCCC)CC(CCl)Cl,,,,,,
8194,58195,"DIBUTYLAMINE, N-(3-(p-(PHENOXYMETHYL)PHENYL)PROPYL)-",CCCCN(CCCC)CCCC1=CC=C(C=C1)COC2=CC=CC=C2,,,,,,
8195,58196,9-(Dibutyroamido)julolidine,CCCC(=O)N(C1=CCC2=C3C1CCNC3=CCC2)C(=O)CCC,,,,,,
8196,58197,2-Bromoethyl-(2-fluoroethyl)azanium chloride,C(CF)[NH2+]CCBr.[Cl-],,,,,,
8197,58198,2-bromo-N-(2-fluoroethyl)ethan-1-amine,C(CF)NCCBr,,,,,,
8198,58199,"1,4:5,8-Dimethanonaphthalene-2-propylamine, decahydro-3-aminomethyl-",C1CC2CC1C3C2C4CC3C(C4CN)CCCN,,,,,,
8199,58200,"2,2-Dimethyl-1,3-dioxa-6-aza-2-silacyclooctane-6-ethanol 2-methyl-3-phenoxypropionate",CC(COC1=CC=CC=C1)C(=O)OCCN2CCO[Si](OCC2)(C)C,,,,,,
8200,58201,"1,4-Dioxa-6-methyl-8-aza-8-(1-phenylcyclohexyl)spiro(4,5)decane hydrobromide",CC1C[NH+](CCC12OCCO2)C3(CCCCC3)C4=CC=CC=C4.[Br-],,,,,,
8201,58202,"6-Methyl-8-(1-phenylcyclohexyl)-1,4-dioxa-8-azaspiro[4.5]decane",CC1CN(CCC12OCCO2)C3(CCCCC3)C4=CC=CC=C4,,,,,,
8202,58203,"13,13-Dimethyl-4,11-dioxa-1,8-dithiadispiro(4.1.4.3)tetradecane",CC1(CC2(CC3(C1)OCCS3)OCCS2)C,,,,,,
8203,58204,"6-Methyl-2,2,4,4-tetra(trifluoromethyl)-1,3-dioxane",CC1CC(OC(O1)(C(F)(F)F)C(F)(F)F)(C(F)(F)F)C(F)(F)F,,,,,,
8204,58205,"1,5-Dimethyl-2,3,6,7-tetrahydro-1H,5H-biscyclopentapyrazine",CC1CCC2=C1N=C3CCC(C3=N2)C,,,,,,
8205,58206,"methyl 2-(N-((4-methoxy-6-methyl-1,3,5-triazin-2-yl)methylcarbamoyl)sulfamoyl)benzoate",CC1=NC(=NC(=N1)OC)CNC(=O)NS(=O)(=O)C2=CC=CC=C2C(=O)OC,,,,,,
8206,58207,"ETHANOL, 2-(ETHYL(3-(p-(PHENOXYMETHYL)PHENYL)PROPYL)AMINO)-",CCN(CCCC1=CC=C(C=C1)COC2=CC=CC=C2)CCO,,,,,,
8207,58208,"Ethanol, 2-(N-ethyl-N-(1-phenylcyclohexyl)methylamino)-",CCN(CCO)CC1(CCCCC1)C2=CC=CC=C2,,,,,,
8208,58209,2-(1-(1-Indolyl)ethoxy)ethanol,CC(N1C=CC2=CC=CC=C21)OCCO,,,,,,
8209,58210,2-[1-[3-(Trifluoromethyl)phenyl]propan-2-ylamino]ethyl 4-phenylbenzoate,CC(CC1=CC(=CC=C1)C(F)(F)F)NCCOC(=O)C2=CC=C(C=C2)C3=CC=CC=C3,,,,,,
8210,58211,2-(alpha-Methyl-m-trifluoromethylphenethylamino)ethanol succinate,CC(CC1=CC(=CC=C1)C(F)(F)F)NCCOC(=O)CCC(=O)O,,,,,,
8211,58212,"Butyrophenone, 4'-(dimethylamino)-4-(4-(alpha,alpha,alpha-trifluoro-p-tolyl)-4-hydroxypiperidino)-",CN(C)C1=CC=C(C=C1)C(=O)CCCN2CCC(CC2)(C3=CC=C(C=C3)C(F)(F)F)O,,,,,,
8212,58213,"Butyrophenone, 4'-fluoro-4-(3-hydroxy-3-phenyl-9-azabicyclo(3.3.1)non-9-YL)-",C1CC2CC(CC(C1)N2CCCC(=O)C3=CC=C(C=C3)F)(C4=CC=CC=C4)O,,,,,,
8213,58214,"Butyrophenone, 4'-fluoro-4-(4-(1-indolinyl)-1,2,5,6-tetrahydro-1-pyridyl)-",C1CN(CC=C1N2CCC3=CC=CC=C32)CCCC(=O)C4=CC=C(C=C4)F,,,,,,
8214,58215,Dicalcium;dichlorate;dichloride;hexahydrate,O.O.O.O.O.O.[O-]Cl(=O)=O.[O-]Cl(=O)=O.[Cl-].[Cl-].[Ca+2].[Ca+2],,,,,,
8215,58216,"Butyrophenone, 4'-fluoro-4-(methyl(1,2,3,4-tetrahydro-9H-pyrido(3,4-b)indol-2-ylmethyl)amino)-",CN(CCCC(=O)C1=CC=C(C=C1)F)CN2CCC3=C(C2)NC4=CC=CC=C34,,,,,,
8216,58217,"4'-Fluoro-4-(octahydrospiro(naphthalene-2(1H),4'-piperidin)-1'-yl)-butyrophenone HCl",C1CCC2CC3(CCC2C1)CC[NH+](CC3)CCCC(=O)C4=CC=C(C=C4)F.[Cl-],,,,,,
8217,58218,"1-(4-fluorophenyl)-4-spiro[2,3,4,4a,5,6,8,8a-octahydro-1H-naphthalene-7,4'-piperidine]-1'-ylbutan-1-one",C1CCC2CC3(CCC2C1)CCN(CC3)CCCC(=O)C4=CC=C(C=C4)F,,,,,,
8218,58219,"Butyrophenone, 4'-(4-hydroxypiperidino)-4-(4-hydroxy-4-(alpha,alpha,alpha-trifluoro-m-tolyl)piperidino)-",C1CN(CCC1O)C2=CC=C(C=C2)C(=O)CCCN3CCC(CC3)(C4=CC(=CC=C4)C(F)(F)F)O,,,,,,
8219,58220,"1,1,1-Trifluoro-4-phenyl-4-[[4,4,4-trifluoro-3-hydroxy-1-phenyl-3-(trifluoromethyl)butylidene]hydrazinylidene]-2-(trifluoromethyl)butan-2-ol",C1=CC=C(C=C1)C(=NN=C(CC(C(F)(F)F)(C(F)(F)F)O)C2=CC=CC=C2)CC(C(F)(F)F)(C(F)(F)F)O,,,,,,
8220,58221,"1,1,1-Trifluoro-4-hydroxyimino-4-phenyl-2-(trifluoromethyl)butan-2-ol",C1=CC=C(C=C1)C(=NO)CC(C(F)(F)F)(C(F)(F)F)O,,,,,,
8221,58222,"Butyrophenone, 3-hydroxy-4,4,4-trifluoro-3-(trifluoromethyl)-2',4',6'-trimethyl-",CC1=CC(=C(C(=C1)C)C(=O)CC(C(F)(F)F)(C(F)(F)F)O)C,,,,,,
8222,58223,9-(Bis(2-chloroethyl)amino)camphor hydrochloride,CC12CCC(C1(C)C[NH+](CCCl)CCCl)CC2=O.[Cl-],,,,,,
8223,58224,"7-[Bis(2-chloroethyl)aminomethyl]-1,7-dimethylbicyclo[2.2.1]heptan-2-one",CC12CCC(C1(C)CN(CCCl)CCCl)CC2=O,,,,,,
8224,58225,9-(Bis(2-chloroethyl)amino)camphor N-oxide hydrochloride,CC12CCC(C1(C)C[N+](CCCl)(CCCl)O)CC2=O.[Cl-],,,,,,
8225,58226,"Bis(2-chloroethyl)-[(1,7-dimethyl-2-oxo-7-bicyclo[2.2.1]heptanyl)methyl]-hydroxyazanium",CC12CCC(C1(C)C[N+](CCCl)(CCCl)O)CC2=O,,,,,,
8226,58227,"3,4-Dihydro-1-(2-(methylphenethylamino)propyl)carbostyril oxalate",CC(CN1C(=O)CCC2=CC=CC=C21)[NH+](C)CCC3=CC=CC=C3.C(=O)(C(=O)[O-])O,,,,,,
8227,58228,"1-[2-[Methyl(2-phenylethyl)amino]propyl]-3,4-dihydroquinolin-2-one",CC(CN1C(=O)CCC2=CC=CC=C21)N(C)CCC3=CC=CC=C3,,,,,,
8228,58229,"[(2R,5R,6S,8R,10R,17S)-11-ethyl-5,7,14-trihydroxy-6,8,16,18-tetramethoxy-13-(methoxymethyl)-11-azahexacyclo[7.7.2.12,5.01,10.03,8.013,17]nonadecan-4-yl] 4-methoxybenzoate",CCN1CC2([C@H]3C(C4[C@@H]1C3([C@@H]5C[C@@]6([C@H](C([C@]4(C5C6OC(=O)C7=CC=C(C=C7)OC)OC)O)OC)O)C(CC2O)OC)OC)COC,,,,,,
8229,58230,"[(2R,3R,5R,6S,8R,10R,17S)-8-ethoxy-11-ethyl-5,7,14-trihydroxy-6,16,18-trimethoxy-13-(methoxymethyl)-11-azahexacyclo[7.7.2.12,5.01,10.03,8.013,17]nonadecan-4-yl] 4-methoxybenzoate",CCN1CC2([C@H]3C(C4[C@@H]1C3([C@@H]5C[C@@]6([C@H](C([C@]4([C@H]5C6OC(=O)C7=CC=C(C=C7)OC)OCC)O)OC)O)C(CC2O)OC)OC)COC,,,,,,
8230,58231,"ETHANOL, 2-((3-(p-(PHENOXYMETHYL)PHENYL)PROPYL)AMINO)-",C1=CC=C(C=C1)COC2=CC=C(C=C2)CCCNCCO,,,,,,
8231,58232,"Butyrophenone, 4'-(1,3-dihydroxy-4,4,4-trifluoro-3-(trifluoromethyl)butyl)-3-hydroxy-4,4,4-trifluoro-3-(trifluoromethyl)-",C1=CC(=CC=C1C(CC(C(F)(F)F)(C(F)(F)F)O)O)C(=O)CC(C(F)(F)F)(C(F)(F)F)O,,,,,,
8232,58233,"2-Methyl-5-(gamma-(p-fluorobenzoyl)propyl)-1,2,3,4,5,6,7,8-octahydro-2,5-indolodiazocine",CC1CC2=C(CCNC(CN1)CCCC(=O)C3=CC=C(C=C3)F)C4=CC=CC=C4N2,,,,,,
8233,58234,"1-Chloro-2,3-butanedithiol",CC(C(CCl)S)S,,,,,,
8234,58235,"3-Chloro-1,2-butanedithiol",CC(C(CS)S)Cl,,,,,,
8235,58236,N-Methyl-bis(2-chloropropyl)amine hydrochloride,CC(C[NH+](C)CC(C)Cl)Cl.[Cl-],,,,,,
8236,58237,"N,N-bis(2-chloropropyl)-N-methylammonium chloride",CC(CN(C)CC(C)Cl)Cl,,,,,,
8237,58238,"Ethylenediamine, N,N-diethyl-N'-mesityl-",CCN(CC)CCNC1=C(C=C(C=C1C)C)C,,,,,,
8238,58239,"ACETAMIDE, N-(5-(p-AMINOPHENOXY)PENTYL)-2,2-DICHLORO-",C1=CC(=CC=C1N)OCCCCCNC(=O)C(Cl)Cl,,,,,,
8239,58240,alpha-(2-(Dimethylamino)ethyl)indole-3-methanol,CN(C)CCC(C1=CNC2=CC=CC=C21)O,,,,,,
8240,58241,"Carvacrylamine, N-(2-oxazolin-2-YL)-",CC1=C(C=C(C=C1)C(C)C)NC2=NCCO2,,,,,,
8241,58242,"Carbanilic acid, N-(dimethylcarbamoylmethyl)-, ethyl ester",CCOC(=O)N(CC(=O)N(C)C)C1=CC=CC=C1,,,,,,
8242,58243,"2-Ethyl-2-(p-methoxyphenyl)-1,3-dioxolane-4-methanol",CCC1(OCC(O1)CO)C2=CC=C(C=C2)OC,,,,,,
8243,58244,"Indole, 3-((4-ethylpiperidino)methyl)-",CCC1CCN(CC1)CC2=CNC3=CC=CC=C32,,,,,,
8244,58245,"Ammonium, sulfonylbis(hexamethylene)bis(triethyl-, diiodide",CC[N+](CC)(CC)CCCCCCS(=O)(=O)CCCCCC[N+](CC)(CC)CC.[I-].[I-],,,,,,
8245,58246,Triethyl-[6-[6-(triethylazaniumyl)hexylsulfonyl]hexyl]azanium,CC[N+](CC)(CC)CCCCCCS(=O)(=O)CCCCCC[N+](CC)(CC)CC,,,,,,
8246,58247,"AMMONIUM, (p-PHENYLENEBIS(OXY(2-HYDROXYTRIMETHYLENE)))BIS(TRIETHYL-, DIIODIDE",CC[N+](CC)(CC)CC(COC1=CC=C(C=C1)OCC(C[N+](CC)(CC)CC)O)O.[I-].[I-],,,,,,
8247,58248,Triethyl-[2-hydroxy-3-[4-[2-hydroxy-3-(triethylazaniumyl)propoxy]phenoxy]propyl]azanium,CC[N+](CC)(CC)CC(COC1=CC=C(C=C1)OCC(C[N+](CC)(CC)CC)O)O,,,,,,
8248,58249,"3-[(3S,5R,10S,13R,14S,16S,17R)-14,16-dihydroxy-3-[(2R,5R)-5-hydroxy-4-methoxy-6-methyloxan-2-yl]oxy-10,13-dimethyl-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthren-17-yl]-2H-furan-5-one",CC1[C@H](C(C[C@@H](O1)O[C@H]2CC[C@]3([C@@H](C2)CCC4C3CC[C@]5([C@@]4(C[C@@H]([C@@H]5C6=CC(=O)OC6)O)O)C)C)OC)O,,,,,,
8249,58250,Diethyl(2-hydroxyethyl)methylammonium bromide alpha-cyclohexyl-1-hydroxycyclooctaneacetate,CC[N+](C)(CC)CCOC(=O)C(C1CCCCC1)C2(CCCCCCC2)O.[Br-],,,,,,
8250,58251,2-[2-Cyclohexyl-2-(1-hydroxycyclooctyl)acetyl]oxyethyl-diethyl-methylazanium,CC[N+](C)(CC)CCOC(=O)C(C1CCCCC1)C2(CCCCCCC2)O,,,,,,
8251,58252,"Ammonium, diethyl(2-hydroxyethyl)methyl-, bromide, 2,3-dicyclohexyl-3-hydroxybutyrate",CC[N+](C)(CC)CCOC(=O)CC(C1CCCCC1)C(C2CCCCC2)O.[Br-],,,,,,
8252,58253,"2-(3,4-Dicyclohexyl-4-hydroxybutanoyl)oxyethyl-diethyl-methylazanium",CC[N+](C)(CC)CCOC(=O)CC(C1CCCCC1)C(C2CCCCC2)O,,,,,,
8253,58254,2-(9-Fluorenylamino)-2-oxazoline,C1COC(=N1)NC2C3=CC=CC=C3C4=CC=CC=C24,,,,,,
8254,58255,"4-(Cyclohexyloxy)-alpha,3-dimethylbenzylamine",CC1=C(C=CC(=C1)C(C)N)OC2CCCCC2,,,,,,
8255,58256,"N,N-Diethyl-N-methyl-2-(((1-(phenylthio)cyclobutyl)carbonyl)oxy)ethanaminium iodide",CC[N+](C)(CC)CCOC(=O)C1(CCC1)SC2=CC=CC=C2.[I-],,,,,,
8256,58257,Diethyl-methyl-[2-(1-phenylsulfanylcyclobutanecarbonyl)oxyethyl]azanium,CC[N+](C)(CC)CCOC(=O)C1(CCC1)SC2=CC=CC=C2,,,,,,
8257,58258,Rufloxacin,CN1CCN(CC1)C2=C(C=C3C4=C2SCCN4C=C(C3=O)C(=O)O)F,,,['Compounds that inhibit the activity of DNA TOPOISOMERASE II. Included in this category are a variety of ANTINEOPLASTIC AGENTS which target the eukaryotic form of topoisomerase II and ANTIBACTERIAL AGENTS which target the prokaryotic form of topoisomerase II. (See all compounds classified as Topoisomerase II Inhibitors.)'],,,
8258,58259,Benzilate ester of N-(beta-hydroxyethyl)norgranatane hydrochloride,C1CC2CCCC(C1)[NH+]2CCOC(=O)C(C3=CC=CC=C3)(C4=CC=CC=C4)O.[Cl-],,,,,,
8259,58260,"Fluoren-9-one, 2-azido-",C1=CC=C2C(=C1)C3=C(C2=O)C=C(C=C3)N=[N+]=[N-],,,,,,
8260,58261,CID 58261,C1=CC=C2C(=C1)C3=C(C2=O)C=C(C=C3)N[N+]#N,,,,,,
8261,58262,"Formamide, N-(2-bromoallyl)-",C=C(CNC=O)Br,,,,,,
8262,58263,"N'-(5-Acenaphthenyl)-N,N-dimethylformamidine",CN(C)C=NC1=CC=C2CCC3=C2C1=CC=C3,,,,,,
8263,58264,"N'-(9-Acridinyl)-N,N-dimethylformamidine",CN(C)C=NC1=C2C=CC=CC2=NC3=CC=CC=C31,,,,,,
8264,58265,"N'-(9-Acridinyl)-N,N'-dimethylformamidine methyl iodine",CN(C)C=NC1=C2C=CC=CC2=NC3=CC=CC=C31.CI,,,,,,
8265,58266,"4-(Dimethylamino)methyleneamino-2,1,3-benzothiadiazole",CN(C)C=NC1=CC=CC2=NSN=C21,,,,,,
8266,58267,"4-(Dimethylamino)methylene-2,1,3-benzothiadiazole and methyl iodide",CN(C)C=NC1=CC=CC2=NSN=C21.CI,,,,,,
8267,58268,"N'-(2-Benzyloxyethyl)-N,N-dimethylformamidine",CN(C)C=NCCOCC1=CC=CC=C1,,,,,,
8268,58269,3-Bromo-2-(dimethylamino)methyleneamino-9-fluorenone,CN(C)C=NC1=C(C=C2C3=CC=CC=C3C(=O)C2=C1)Br,,,,,,
8269,58270,"FORMAMIDINE, N'-(4-tert-BUTYL-1-CYCLOHEXYL)-N,N-DIMETHYL-",CC(C)(C)C1CCC(CC1)N=CN(C)C,,,,,,
8270,58271,"N'-Carvacryl-N,N-dimethylformamidine",CC1=C(C=C(C=C1)C(C)C)N=CN(C)C,,,,,,
8271,58272,"Formamidine, N'-(3-(2-chloro-10-phenothiazinyl)propyl)-N,N-dimethyl-, hydrochloride",CN(C)C=NCCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl.Cl,,,,,,
8272,58273,"N'-[3-(2-chlorophenothiazin-10-yl)propyl]-N,N-dimethylmethanimidamide",CN(C)C=NCCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl,,,,,,
8273,58274,"N'-(alpha-(4-Chlorophenyl)benzyl)-N,N-dimethylformamidine",CN(C)C=NC(C1=CC=CC=C1)C2=CC=C(C=C2)Cl,,,,,,
8274,58275,"N'-[4-cyano-5-(cyanomethyl)-2-phenylpyrazol-3-yl]-N,N-dimethylmethanimidamide",CN(C)C=NC1=C(C(=NN1C2=CC=CC=C2)CC#N)C#N,,,,,,
8275,58276,"N'-(10,11-Dihydro-5H-dibenzo(a,d)-5-cycloheptenyl)-N,N-dimethylformamidine",CN(C)C=NC1C2=CC=CC=C2CCC3=CC=CC=C13,,,,,,
8276,58277,"Formamidine, N,N-dimethyl-N'-(2-(1-aziridinyl)ethyl)-",CN(C)C=NCCN1CC1,,,,,,
8277,58278,"Formamidine, N'-4-(4H-1-benzothiopyranyl)-N,N-dimethyl-",CN(C)C=NC1C=CSC2=CC=CC=C12,,,,,,
8278,58279,"Formamidine, N'-(2-biphenylyl)-N,N-dimethyl-",CN(C)C=NC1=CC=CC=C1C2=CC=CC=C2,,,,,,
8279,58280,"N,N-Dimethyl-N'-(2-bromoallyl)formamidine",CN(C)C=NCC(=C)Br,,,,,,
8280,58281,"N'-(Dimethylaminoethyl)-N,N-dimethylformamidine",CN(C)CCN=CN(C)C,,,,,,
8281,58282,"2,3-Dimethyl-5-dimethylaminomethyleneaminoindole",CC1=C(NC2=C1C=C(C=C2)N=CN(C)C)C,,,,,,
8282,58283,"Formamidine, N,N-dimethyl-N'-diphenylmethyl-",CN(C)C=NC(C1=CC=CC=C1)C2=CC=CC=C2,,,,,,
8283,58284,"N'-(3-Fluoranthenyl)-N,N-dimethyl formamidine",CN(C)C=NC1=C2C=CC=C3C2=C(C=C1)C4=CC=CC=C43,,,,,,
8284,58285,9-(Dimethylamino)methyleneaminofluorene,CN(C)C=NC1C2=CC=CC=C2C3=CC=CC=C13,,,,,,
8285,58286,"N'-(4,4-Diethoxybutyl)-N,N-dimethylformamidine",CCOC(CCCN=CN(C)C)OCC,,,,,,
8286,58287,"N'-(azepan-1-yl)-N,N-dimethylmethanimidamide",CN(C)C=NN1CCCCCC1,,,,,,
8287,58288,1-(Dimethylamino)methyleneaminoindan,CN(C)C=NC1CCC2=CC=CC=C12,,,,,,
8288,58289,5-Dimethylaminomethyleneaminoisoquinoline,CN(C)C=NC1=CC=CC2=C1C=CN=C2,,,,,,
8289,58290,"N'-(5-methoxy-1,3-benzothiazol-2-yl)-N,N-dimethylmethanimidamide",CN(C)C=NC1=NC2=C(S1)C=CC(=C2)OC,,,,,,
8290,58291,"N'-(p-Methoxybenzyl)-N,N-dimethylformamidine",CN(C)C=NCC1=CC=C(C=C1)OC,,,,,,
8291,58292,4-(Dimethylamino)methyleneaminoquinaldine,CC1=NC2=CC=CC=C2C(=C1)N=CN(C)C,,,,,,
8292,58293,"Formamidine, N,N-dimethyl-N'-(1-(1-naphthyl)ethyl)-",CC(C1=CC=CC2=CC=CC=C21)N=CN(C)C,,,,,,
8293,58294,"Formamidine, N,N-dimethyl-N'-(2-(5-nitro-2-pyridinylamino)ethyl)-",CN(C)C=NCCNC1=NC=C(C=C1)[N+](=O)[O-],,,,,,
8294,58295,"Formamidine, N,N-dimethyl-N'-(3-(10-phenothiazinyl)propyl)-",CN(C)C=NCCCN1C2=CC=CC=C2SC3=CC=CC=C31,,,,,,
8295,58296,"N,N-Dimethyl-N'-((E)-2-phenylcyclopropyl)formamidine",CN(C)C=NC1CC1C2=CC=CC=C2,,,,,,
8296,58297,"N,N-Dimethyl-N'-(3-quinolinyl)formamidine",CN(C)C=NC1=CC2=CC=CC=C2N=C1,,,,,,
8297,58298,"Formamidine, N,N-dimethyl-N'-(1,2,3,4-tetrahydroacridin-9-YL)-",CN(C)C=NC1=C2CCCCC2=NC3=CC=CC=C31,,,,,,
8298,58299,"N,N-Dimethyl-N'-(5,6,7,8-tetrahydronaphth-1-yl)formamidine",CN(C)C=NC1=CC=CC2=C1CCCC2,,,,,,
8299,58300,"N,N-Dimethyl-N'-(2-tetrahydropyranylmethyl)-formamidine",CN(C)C=NCC1CCCCO1,,,,,,
8300,58301,"4-(Dimethylamino)methyleneamino-2,2,6,6-tetramethyl piperidine",CC1(CC(CC(N1)(C)C)N=CN(C)C)C,,,,,,
8301,58302,"N,N-Dimethyl-N'-(1-phenylcyclohexyl)formamidine",CN(C)C=NC1(CCCCC1)C2=CC=CC=C2,,,,,,
8302,58303,"N,N-Dimethyl-N'-(2-pyridylethyl)formamidine",CN(C)C=NCCC1=CC=CC=N1,,,,,,
8303,58304,CID 58304,CCOC1=CC=C(C=C1)N(CCC[NH+](C)C)C(=O)C2=CC=CC=C2.C(=CC(=O)[O-])C(=O)O,,,,,,
8304,58305,N-[3-(dimethylamino)propyl]-N-(4-ethoxyphenyl)benzamide,CCOC1=CC=C(C=C1)N(CCCN(C)C)C(=O)C2=CC=CC=C2,,,,,,
8305,58306,2-(Diethylamino)ethyl o-ethoxycarbanilate hydrochloride,CC[NH+](CC)CCOC(=O)NC1=CC=CC=C1OCC.[Cl-],,,,,,
8306,58307,2-(diethylamino)ethyl N-(2-ethoxyphenyl)carbamate,CCN(CC)CCOC(=O)NC1=CC=CC=C1OCC,,,,,,
8307,58308,"Carbanilic acid, N-nitroso-, isopropyl ester",CC(C)OC(=O)N(C1=CC=CC=C1)N=O,,,,,,
8308,58309,(5-methyl-2-propan-2-ylcyclohexyl) N-(dimethylaminomethylideneamino)carbamate,CC1CCC(C(C1)OC(=O)NN=CN(C)C)C(C)C,,,,,,
8309,58310,2-Acetyl-9-(3-(4-ethoxypiperidino)propyl)carbazole hydrochloride,CCOC1CC[NH+](CC1)CCCN2C3=CC=CC=C3C4=C2C=C(C=C4)C(=O)C.[Cl-],,,,,,
8310,58311,1-[9-[3-(4-Ethoxypiperidin-1-yl)propyl]carbazol-2-yl]ethanone,CCOC1CCN(CC1)CCCN2C3=CC=CC=C3C4=C2C=C(C=C4)C(=O)C,,,,,,
8311,58312,2-Acetyl-9-(3-(4-methoxypiperidino)propyl)carbazole hydrochloride,CC(=O)C1=CC2=C(C=C1)C3=CC=CC=C3N2CCC[NH+]4CCC(CC4)OC.[Cl-],,,,,,
8312,58313,1-[9-[3-(4-Methoxypiperidin-1-yl)propyl]carbazol-2-yl]ethanone,CC(=O)C1=CC2=C(C=C1)C3=CC=CC=C3N2CCCN4CCC(CC4)OC,,,,,,
8313,58314,"9-Methyl-1-methylamino-1,2,3,4,4a,9a-hexahydrocarbazole hydrochloride",C[NH2+]C1CCCC2C1N(C3=CC=CC=C23)C.[Cl-],,,,,,
8314,58315,"N,9-dimethyl-1,2,3,4,4a,9a-hexahydrocarbazol-1-amine",CNC1CCCC2C1N(C3=CC=CC=C23)C,,,,,,
8315,58316,9-(2-Piperidinoethyl)carbazole hydrochloride,C1CC[NH+](CC1)CCN2C3=CC=CC=C3C4=CC=CC=C42.[Cl-],,,,,,
8316,58317,"9-Benzyl-6-dimethylaminomethyl-1,2,3,4-tetrahydrocarbazole hydrochloride monohydrate",C[NH+](C)CC1=CC2=C(C=C1)N(C3=C2CCCC3)CC4=CC=CC=C4.[Cl-],,,,,,
8317,58318,"1-(9-benzyl-5,6,7,8-tetrahydrocarbazol-3-yl)-N,N-dimethylmethanamine",CN(C)CC1=CC2=C(C=C1)N(C3=C2CCCC3)CC4=CC=CC=C4,,,,,,
8318,58319,"Carbazole, 1,2,3,4-tetrahydro-6-(dimethylaminomethyl)-9-methyl-",CN1C2=C(CCCC2)C3=C1C=CC(=C3)CN(C)C,,,,,,
8319,58320,"Carbonic acid, ethyl 1-methyl-4-phenyl-4-piperidyl ester",CCOC(=O)OC1(CCN(CC1)C)C2=CC=CC=C2,,,,,,
8320,58321,Ethyl 3-quinuclidinyl carbonate,CCOC(=O)OC1CN2CCC1CC2,,,,,,
8321,58322,"Carbonic acid, 4-methoxycarbonyl-1-methyl-4-piperidyl phenyl ester",CN1CCC(CC1)(C(=O)OC)OC(=O)OC2=CC=CC=C2,,,,,,
8322,58323,"Carbonic acid, methyl 1-methyl-4-phenyl-4-piperidyl ester",CN1CCC(CC1)(C2=CC=CC=C2)OC(=O)OC,,,,,,
8323,58324,"Carbonic acid, 1-methyl-4-phenyl-4-piperidyl phenyl ester",CN1CCC(CC1)(C2=CC=CC=C2)OC(=O)OC3=CC=CC=C3,,,,,,
8324,58325,"Carbonic acid, 1-methyl-4-piperidyl phenyl ester",CN1CCC(CC1)OC(=O)OC2=CC=CC=C2,,,,,,
8325,58326,"Carbostyril, 3,4-dihydro-1-(2-(diethylamino)ethyl)-, picrate",CC[NH+](CC)CCN1C(=O)CCC2=CC=CC=C21.C1=C(C=C(C(=C1[N+](=O)[O-])[O-])[N+](=O)[O-])[N+](=O)[O-],,,,,,
8326,58327,"1-[2-(Diethylamino)ethyl]-3,4-dihydroquinolin-2-one",CCN(CC)CCN1C(=O)CCC2=CC=CC=C21,,,,,,
8327,58328,Panstrosid [German],CC1[C@@H](C(C([C@@H](O1)O[C@H]2CC[C@]3([C@@H](C2)C[C@H]4C5(C3[C@@H](C[C@]6([C@@]5(CC[C@@H]6C7=CC(=O)OC7)O)C)O)O4)C)O)OC)O,,,,,,
8328,58329,Desaroside,CC1[C@@H](C(C([C@@H](O1)O[C@H]2CC[C@]3([C@@H](C2)CCC4C3C(=O)C[C@]5([C@@]4(CC[C@@H]5C6=CC(=O)OC6)O)C)C)O)OC)O,,,,,,
8329,58330,Neriifolin-diacetat [German],CC1[C@H](C(C([C@@H](O1)O[C@H]2CC[C@]3([C@@H](C2)CCC4C3CC[C@]5([C@@]4(CC[C@@H]5C6=CC(=O)OC6)OC(=O)C)C)C)O)OC)OC(=O)C,,,,,,
8330,58331,"Ethylamine, 2-((8-allyl-6-chloro-1,4-benzodioxan-5-yl)oxy)-N-methyl-, hydrochloride",C[NH2+]CCOC1=C(C=C(C2=C1OCCO2)CC=C)Cl.[Cl-],,,,,,
8331,58332,"6-Chloro-5-(2-methylaminoethoxy)-8-allylbenzo-1,4-dioxane",CNCCOC1=C(C=C(C2=C1OCCO2)CC=C)Cl,,,,,,
8332,58333,"Isopropylamine, N-bicyclo(3.1.0)hex-2-yl-, oxalate",CC(C)[NH2+]C1CCC2C1C2.C(=O)(C(=O)[O-])O,,,,,,
8333,58334,N-propan-2-ylbicyclo[3.1.0]hexan-2-amine,CC(C)NC1CCC2C1C2,,,,,,
8334,58335,"ETHYLAMINE, 2-(alpha-(p-CHLOROPHENYL)-alpha-ETHYLBENZYLOXY)-N,N-DIMETHYL-",CCC(C1=CC=CC=C1)(C2=CC=C(C=C2)Cl)OCCN(C)C,,,,,,
8335,58336,O-Benzhydryldibutylaminoethanol hydrochloride,CCCC[NH+](CCCC)CCOC(C1=CC=CC=C1)C2=CC=CC=C2.[Cl-],,,,,,
8336,58337,N-(2-benzhydryloxyethyl)-N-butylbutan-1-amine,CCCCN(CCCC)CCOC(C1=CC=CC=C1)C2=CC=CC=C2,,,,,,
8337,58338,O-Trityldibutylaminoethanol hydrochloride,CCCC[NH+](CCCC)CCOC(C1=CC=CC=C1)(C2=CC=CC=C2)C3=CC=CC=C3.[Cl-],,,,,,
8338,58339,N-butyl-N-(2-trityloxyethyl)butan-1-amine,CCCCN(CCCC)CCOC(C1=CC=CC=C1)(C2=CC=CC=C2)C3=CC=CC=C3,,,,,,
8339,58340,"N,N-Diethyl-2-(3-methyl-1-naphthoxy)ethylamine hydrochloride",CC[NH+](CC)CCOC1=CC(=CC2=CC=CC=C21)C.[Cl-],,,,,,
8340,58341,"N,N-diethyl-2-(3-methylnaphthalen-1-yl)oxyethanamine",CCN(CC)CCOC1=CC(=CC2=CC=CC=C21)C,,,,,,
8341,58342,"Ethylamine, N,N-dimethyl-2-(11-methyl-9,10-ethanoanthracen-9(10H)-yloxy)-, hydrochloride",CC1CC2C3=CC=CC=C3C1(C4=CC=CC=C24)OCC[NH+](C)C.[Cl-],,,,,,
8342,58343,"N,N-dimethyl-2-[(15-methyl-1-tetracyclo[6.6.2.02,7.09,14]hexadeca-2,4,6,9,11,13-hexaenyl)oxy]ethanamine",CC1CC2C3=CC=CC=C3C1(C4=CC=CC=C24)OCCN(C)C,,,,,,
8343,58344,"Ethylamine, 2-(diphenylmethoxy)-N-(ethoxymethylene)-",CCOC=NCCOC(C1=CC=CC=C1)C2=CC=CC=C2,,,,,,
8344,58345,"Ethylamine, 2,2'-dithiobis-, calcium salt",C(CSSCCN)N.[Ca+2],,,,,,
8345,58346,"Ethylenediamine, N,N-bis(2-chloroethyl)-N'-cyclohexyl-N'-methyl-, dihydrochloride",C[NH+](CC[NH+](CCCl)CCCl)C1CCCCC1.[Cl-].[Cl-],,,,,,
8346,58347,"N',N'-bis(2-chloroethyl)-N-cyclohexyl-N-methylethane-1,2-diamine",CN(CCN(CCCl)CCCl)C1CCCCC1,,,,,,
8347,58348,"Ethylenediamine, N,N'-bis(2-chloroethyl)-N,N'-dimethyl-",CN(CCN(C)CCCl)CCCl,,,,,,
8348,58349,"N,N'-Bis(2-chloroethyl)-N,N'-dimethylethylenediamine N,N'-dioxide",C[N+](CC[N+](C)(CCCl)[O-])(CCCl)[O-],,,,,,
8349,58350,"N,N-Bis(2-chloroethyl)-N'-ethyl-N'-phenylethylenediamine dipicrate",CC[NH+](CC[NH+](CCCl)CCCl)C1=CC=CC=C1.C1=C(C=C(C(=C1[N+](=O)[O-])[O-])[N+](=O)[O-])[N+](=O)[O-].C1=C(C=C(C(=C1[N+](=O)[O-])[O-])[N+](=O)[O-])[N+](=O)[O-],,,,,,
8350,58351,"N',N'-bis(2-chloroethyl)-N-ethyl-N-phenylethane-1,2-diamine",CCN(CCN(CCCl)CCCl)C1=CC=CC=C1,,,,,,
8351,58352,"N,N'-Bis(1-ethyl-3-(p-methoxyphenyl)propyl)ethylenediamine dihydrobromide",CCC(CCC1=CC=C(C=C1)OC)[NH2+]CC[NH2+]C(CC)CCC2=CC=C(C=C2)OC.[Br-].[Br-],,,,,,
8352,58353,"N,N'-bis[1-(4-methoxyphenyl)pentan-3-yl]ethane-1,2-diamine",CCC(CCC1=CC=C(C=C1)OC)NCCNC(CC)CCC2=CC=C(C=C2)OC,,,,,,
8353,58354,"N,N'-Bis(1-(2-naphthyl)ethyl)ethylenediamine dihydrobromide",CC(C1=CC2=CC=CC=C2C=C1)[NH2+]CC[NH2+]C(C)C3=CC4=CC=CC=C4C=C3.[Br-].[Br-],,,,,,
8354,58355,"N,N'-bis(1-naphthalen-2-ylethyl)ethane-1,2-diamine",CC(C1=CC2=CC=CC=C2C=C1)NCCNC(C)C3=CC4=CC=CC=C4C=C3,,,,,,
8355,58356,"N,N-Diethyl-N',N'-diphenyl-ethylenediamine hydrochloride",CC[NH+](CC)CCN(C1=CC=CC=C1)C2=CC=CC=C2.[Cl-],,,,,,
8356,58357,"N,N-diethyl-N',N'-diphenylethane-1,2-diamine",CCN(CC)CCN(C1=CC=CC=C1)C2=CC=CC=C2,,,,,,
8357,58358,"N,N-Diethyl-N'-methyl-N'-(2-phenoxyethyl)ethylenediamine hydrochloride",CCN(CC)CC[NH+](C)CCOC1=CC=CC=C1.[Cl-],,,,,,
8358,58359,"N',N'-diethyl-N-methyl-N-(2-phenoxyethyl)ethane-1,2-diamine",CCN(CC)CCN(C)CCOC1=CC=CC=C1,,,,,,
8359,58360,"ETHYLENEDIAMINE, N,N-DIETHYL-N'-(3-(p-(PHENOXYMETHYL)PHENYL)PROPYL)-",CCN(CC)CCNCCCC1=CC=C(C=C1)COC2=CC=CC=C2,,,,,,
8360,58361,"ETHYLENEDIAMINE, N-(3-(p-(PHENOXYMETHYL)PHENYL)PROPYL)-",C1=CC=C(C=C1)OCC2=CC=C(C=C2)CCCNCCN,,,,,,
8361,58362,"Ethylenediamine, N,N,N',N'-tetracyclohexyl-, hydrobromide, hydrochloride",C1CCC(CC1)[NH+](CC[NH+](C2CCCCC2)C3CCCCC3)C4CCCCC4.[Cl-].[Br-],,,,,,
8362,58363,"N,N,N',N'-Tetracyclohexylethylenediamine",C1CCC(CC1)N(CCN(C2CCCCC2)C3CCCCC3)C4CCCCC4,,,,,,
8363,58364,Tetrakis(2-chloropropyl)ethylenediamine dihydrochloride,CC(C[NH+](CC[NH+](CC(C)Cl)CC(C)Cl)CC(C)Cl)Cl.[Cl-].[Cl-],,,,,,
8364,58365,"N,N,N',N'-tetrakis(2-chloropropyl)ethane-1,2-diamine",CC(CN(CCN(CC(C)Cl)CC(C)Cl)CC(C)Cl)Cl,,,,,,
8365,58366,"Nonylamine, 1-methyl-2-phenyl-",CCCCCCCC(C1=CC=CC=C1)C(C)N,,,,,,
8366,58367,"HEXYLAMINE, N-(3-(o-METHOXYPHENYL)PROPYL)-, HYDROCHLORIDE",CCCCCC[NH2+]CCCC1=CC=CC=C1OC.[Cl-],,,,,,
8367,58368,N-[3-(2-methoxyphenyl)propyl]hexan-1-amine,CCCCCCNCCCC1=CC=CC=C1OC,,,,,,
8368,58369,"Decanamide, N-(2-(diethylamino)ethyl)-",CCCCCCCCCC(=O)NCCN(CC)CC,,,,,,
8369,58370,"Ethylamine, 2-((1-cyclohexylcyclohexyl)oxy)-N,N-dimethyl-, hydrochloride",C[NH+](C)CCOC1(CCCCC1)C2CCCCC2.[Cl-],,,,,,
8370,58371,"2-(1-cyclohexylcyclohexyl)oxy-N,N-dimethylethanamine",CN(C)CCOC1(CCCCC1)C2CCCCC2,,,,,,
8371,58372,6-(Aminomethyl)-3-methyl-flavone hydrochloride,CC1=C(OC2=C(C1=O)C=C(C=C2)C[NH3+])C3=CC=CC=C3.[Cl-],,,,,,
8372,58373,"4h-1-Benzopyran-4-one,6-(aminomethyl)-3-methyl-2-phenyl-",CC1=C(OC2=C(C1=O)C=C(C=C2)CN)C3=CC=CC=C3,,,,,,
8373,58374,"Coumarilic acid, 3-(2-methylpiperidino)propyl ester, monohydrochloride",CC1CCCC[NH+]1CCCC2=C(OC3=CC=CC=C32)C(=O)O.[Cl-],,,,,,
8374,58375,3-[3-(2-Methylpiperidin-1-yl)propyl]-1-benzofuran-2-carboxylic acid,CC1CCCCN1CCCC2=C(OC3=CC=CC=C32)C(=O)O,,,,,,
8375,58376,"Coumarin, 3-amino-4-diethylamino-",CCN(CC)C1=C(C(=O)OC2=CC=CC=C21)N,,,,,,
8376,58377,CID 58377,C=C(CC(C1=CC=CC=C1)C2=C(OC3=CC=CC=C3C2=O)O)O,,,,,,
8377,58378,"Formamide, N-(1-adamantyl-1-butyl)-",CCCC(C12CC3CC(C1)CC(C3)C2)NC=O,,,,,,
8378,58379,"Formamide, N-(1-adamantyl-1-ethyl)-",CC(C12CC3CC(C1)CC(C3)C2)NC=O,,,,,,
8379,58380,N-(1-(1-Adamantyl)hexyl)formamide,CCCCCC(C12CC3CC(C1)CC(C3)C2)NC=O,,,,,,
8380,58381,"Formamide, N-(1-adamantyl-1-propyl)-",CCC(C12CC3CC(C1)CC(C3)C2)NC=O,,,,,,
8381,58382,"Furfurylamine, N-(2-oxazolinyl)-",C1COC(=N1)NCC2=CC=CO2,,,,,,
8382,58383,"5H-Furo(3,2-g)(1)benzopyran-5-one, 9-(3-(diethylamino)-2-hydroxypropyl)-4-hydroxy-7-methyl-, hydrochloride",CC[NH+](CC)CC(CC1=C2C(=C(C3=C1OC=CC3=O)O)C=C(O2)C)O.[Cl-],,,,,,
8383,58384,"9-[3-(Diethylamino)-2-hydroxypropyl]-4-hydroxy-2-methylfuro[3,2-g]chromen-5-one",CCN(CC)CC(CC1=C2C(=C(C3=C1OC=CC3=O)O)C=C(O2)C)O,,,,,,
8384,58385,"Ethylenediamine, N-allyl-N',N'-bis(2-chloroethyl)-N-methyl-, dipicrate",C[NH+](CC[NH+](CCCl)CCCl)CC=C.C1=C(C=C(C(=C1[N+](=O)[O-])[O-])[N+](=O)[O-])[N+](=O)[O-].C1=C(C=C(C(=C1[N+](=O)[O-])[O-])[N+](=O)[O-])[N+](=O)[O-],,,,,,
8385,58386,"N',N'-bis(2-chloroethyl)-N-methyl-N-prop-2-enylethane-1,2-diamine",CN(CCN(CCCl)CCCl)CC=C,,,,,,
8386,58387,Christyoside,CC1[C@@H](C(C([C@@H](O1)O[C@H]2CC[C@]3([C@H](C2)CCC4C3CC[C@]5([C@@]4(CC[C@@H]5C6=CC(=O)OC6)O)C)C=O)O)OC)O,,,,,,
8387,58388,"2-((Dicyclopentylacetyl)oxy)-N-butyl-N,N-diethylethanaminium bromide",CCCC[N+](CC)(CC)CCOC(=O)C(C1CCCC1)C2CCCC2.[Br-],,,,,,
8388,58389,"Butyl-[2-(2,2-dicyclopentylacetyl)oxyethyl]-diethylazanium",CCCC[N+](CC)(CC)CCOC(=O)C(C1CCCC1)C2CCCC2,,,,,,
8389,58390,Diethyl(2-hydroxyethyl)methylammonium bromide 2-cyclohexyl-3-hydroxynonanoate,CCCCCCC(C(C1CCCCC1)C(=O)OCC[N+](C)(CC)CC)O.[Br-],,,,,,
8390,58391,2-(2-Cyclohexyl-3-hydroxynonanoyl)oxyethyl-diethyl-methylazanium,CCCCCCC(C(C1CCCCC1)C(=O)OCC[N+](C)(CC)CC)O,,,,,,
8391,58392,"2-(alpha,2,4-Trimethylbenzylamino)-2-oxazoline",CC1=CC(=C(C=C1)C(C)NC2=NCCO2)C,,,,,,
8392,58393,"2-(alpha,2,5-Trimethylbenzylamino)-2-oxazoline",CC1=CC(=C(C=C1)C)C(C)NC2=NCCO2,,,,,,
8393,58394,"1-(3,4,5-trimethoxyphenyl)-N-[(3,4,5-trimethoxyphenyl)methyl]methanimine",COC1=CC(=CC(=C1OC)OC)CN=CC2=CC(=C(C(=C2)OC)OC)OC,,,,,,
8394,58395,CID 58395,C(CO)[NH+](CCO)C(=NC(=N)N)N.[Cl-],,,,,,
8395,58396,"1-carbamimidamido-N,N-bis(2-hydroxyethyl)methanimidamide",C(CO)N(CCO)C(=N)N=C(N)N,,,,,,
8396,58397,CID 58397,CC(=O)[O-].CC(=O)[O-].C1=CC(=CC=C1N=C(N)N=C(N)[NH2+]CCCCCCCCCC[NH2+]C(=NC(=NC2=CC=C(C=C2)Cl)N)N)Cl,,,,,,
8397,58398,2-[10-[[Amino-[[amino-(4-chloroanilino)methylidene]amino]methylidene]amino]decyl]-1-[amino-(4-chloroanilino)methylidene]guanidine,C1=CC(=CC=C1NC(=NC(=NCCCCCCCCCCN=C(N)N=C(N)NC2=CC=C(C=C2)Cl)N)N)Cl,,,,,,
8398,58399,CID 58399,CCCC[NH+](CCCC)C(=NC(=N)N)N.[Cl-],,,,,,
8399,58400,"N,N-dibutylimidodicarbonimidic diamide",CCCCN(CCCC)C(=N)N=C(N)N,,,,,,
8400,58401,CID 58401,CCCC[NH2+]C(=NC(=NCCCC)N)N.[Cl-],,,,,,
8401,58402,"1,5-Dibutylbiguanide",CCCCN=C(N)NC(=NCCCC)N,,,,,,
8402,58403,"1,1-Diamylbiguanide",CCCCCN(CCCCC)C(=N)N=C(N)N,,,,,,
8403,58404,"Biguanide, 1-dodecyl-, hemisulfate, hydrate",CCCCCCCCCCCCN=C(N)N=C(N)N.OS(=O)(=O)O,,,,,,
8404,58405,CID 58405,CCCCCCC[NH2+]C(=NC(=N)N)N.[Cl-],,,,,,
8405,58406,1-(Diaminomethylidene)-2-heptylguanidine,CCCCCCCN=C(N)N=C(N)N,,,,,,
8406,58407,(N'-carbamimidoylcarbamimidoyl)-octylazanium;chloride,CCCCCCCC[NH2+]C(=NC(=N)N)N.[Cl-],,,,,,
8407,58408,n-Octylbiguanide,CCCCCCCCN=C(N)N=C(N)N,,,,,,
8408,58409,CID 58409,CCCCN=C(N)N=C(N)[NH+](CCCC)CCCC.[Cl-],,,,,,
8409,58410,"1,1-dibutyl-2-(N'-butylcarbamimidoyl)guanidine",CCCCN=C(N)N=C(N)N(CCCC)CCCC,,,,,,
8410,58411,6-(Dipropylaminomethyl)-3-methyl-flavone hydrochloride,CCC[NH+](CCC)CC1=CC2=C(C=C1)OC(=C(C2=O)C)C3=CC=CC=C3.[Cl-],,,,,,
8411,58412,6-[(Dipropylamino)methyl]-3-methyl-2-phenylchromen-4-one,CCCN(CCC)CC1=CC2=C(C=C1)OC(=C(C2=O)C)C3=CC=CC=C3,,,,,,
8412,58413,(1-Ammoniopropan-2-yl)(propan-2-yl)ammoniumcarbothioate,CC(C)[NH+](C(C)C[NH3+])C(=O)[S-],,,,,,
8413,58414,N-(2-Amino-1-methylethyl)-N-isopropyl(thiocarbamic acid),CC(C)N(C(C)CN)C(=O)S,,,,,,
8414,58415,2-(Diethylamino)ethyl benzylcarbamate hydrochloride,CC[NH+](CC)CCOC(=O)NCC1=CC=CC=C1.[Cl-],,,,,,
8415,58416,2-(diethylamino)ethyl N-benzylcarbamate,CCN(CC)CCOC(=O)NCC1=CC=CC=C1,,,,,,
8416,58417,2-Piperidinoethyl benzylcarbamate hydrochloride,C1CC[NH+](CC1)CCOC(=O)NCC2=CC=CC=C2.[Cl-],,,,,,
8417,58418,2-piperidin-1-ylethyl N-benzylcarbamate,C1CCN(CC1)CCOC(=O)NCC2=CC=CC=C2,,,,,,
8418,58419,"Carbamic acid, (bis(1-aziridinyl)phosphinyl)-, 1-methoxy-2,2,6,6-tetramethyl-4-piperidyl ester",CC1(CC(CC(N1OC)(C)C)OC(=O)NP(=O)(N2CC2)N3CC3)C,,,,,,
8419,58420,CID 58420,CC1(CC(CC(N1OC)(C)C)CCOC(=O)NP(=O)(N2CC2)N3CC3)C,,,,,,
8420,58421,"Carbamic acid, (bis(2,2-dimethyl-1-aziridinyl)phosphinyl)-, 1-methoxy-2,2,6,6-tetramethyl-4-piperidyl ester",CC1(CN(CC(C1OC(=O)NP(=O)(N2CC2(C)C)N3CC3(C)C)(C)C)OC)C,,,,,,
8421,58422,"2-[(1-Methoxy-3,3,5,5-tetramethylpiperidin-4-yl)oxy]ethyl hydrogen [bis(2,2-dimethylaziridin-1-yl)phosphoryl]carbonimidate",CC1(CN(CC(C1OCCOC(=O)NP(=O)(N2CC2(C)C)N3CC3(C)C)(C)C)OC)C,,,,,,
8422,58423,naphthalen-1-yl N-(3-bromoprop-2-enyl)carbamate,C1=CC=C2C(=C1)C=CC=C2OC(=O)NCC=CBr,,,,,,
8423,58424,"Carbamic acid, 2-bromoethyl-, 1-naphthyl ester",C1=CC=C2C(=C1)C=CC=C2OC(=O)NCCBr,,,,,,
8424,58425,Benzyl N-(2-(diethylamino)ethyl)carbamate hydrochloride,CC[NH+](CC)CCNC(=O)OCC1=CC=CC=C1.[Cl-],,,,,,
8425,58426,benzyl N-[2-(diethylamino)ethyl]carbamate,CCN(CC)CCNC(=O)OCC1=CC=CC=C1,,,,,,
8426,58427,o-Chlorobenzyl N-(2-(diethylamino)ethyl)carbamate hydrochloride,CC[NH+](CC)CCNC(=O)OCC1=CC=CC=C1Cl.[Cl-],,,,,,
8427,58428,(2-chlorophenyl)methyl N-[2-(diethylamino)ethyl]carbamate,CCN(CC)CCNC(=O)OCC1=CC=CC=C1Cl,,,,,,
8428,58429,p-Chlorobenzyl N-(2-(diethylamino)ethyl)carbamate hydrochloride,CC[NH+](CC)CCNC(=O)OCC1=CC=C(C=C1)Cl.[Cl-],,,,,,
8429,58430,(4-chlorophenyl)methyl N-[2-(diethylamino)ethyl]carbamate,CCN(CC)CCNC(=O)OCC1=CC=C(C=C1)Cl,,,,,,
8430,58431,"2,4-Dimethylbenzyl N-(2-(diethylamino)ethyl)carbamate hydrochloride",CC[NH+](CC)CCNC(=O)OCC1=C(C=C(C=C1)C)C.[Cl-],,,,,,
8431,58432,"(2,4-dimethylphenyl)methyl N-[2-(diethylamino)ethyl]carbamate",CCN(CC)CCNC(=O)OCC1=C(C=C(C=C1)C)C,,,,,,
8432,58433,"2,5-Dimethylbenzyl N-(2-(diethylamino)ethyl)carbamate hydrochloride",CC[NH+](CC)CCNC(=O)OCC1=C(C=CC(=C1)C)C.[Cl-],,,,,,
8433,58434,"(2,5-dimethylphenyl)methyl N-[2-(diethylamino)ethyl]carbamate",CCN(CC)CCNC(=O)OCC1=C(C=CC(=C1)C)C,,,,,,
8434,58435,"2,6-Dimethylbenzyl N-(2-(diethylamino)ethyl)carbamate hydrochloride",CC[NH+](CC)CCNC(=O)OCC1=C(C=CC=C1C)C.[Cl-],,,,,,
8435,58436,"(2,6-dimethylphenyl)methyl N-[2-(diethylamino)ethyl]carbamate",CCN(CC)CCNC(=O)OCC1=C(C=CC=C1C)C,,,,,,
8436,58437,o-Methylbenzyl N-(2-(diethylamino)ethyl)carbamate hydrochloride,CC[NH+](CC)CCNC(=O)OCC1=CC=CC=C1C.[Cl-],,,,,,
8437,58438,(2-methylphenyl)methyl N-[2-(diethylamino)ethyl]carbamate,CCN(CC)CCNC(=O)OCC1=CC=CC=C1C,,,,,,
8438,58439,p-Methylbenzyl N-(2-(diethylamino)ethyl)carbamate hydrochloride,CC[NH+](CC)CCNC(=O)OCC1=CC=C(C=C1)C.[Cl-],,,,,,
8439,58440,(4-methylphenyl)methyl N-[2-(diethylamino)ethyl]carbamate,CCN(CC)CCNC(=O)OCC1=CC=C(C=C1)C,,,,,,
8440,58441,alpha-Methylbenzyl N-(2-(diethylamino)ethyl)carbamate hydrochloride,CC[NH+](CC)CCNC(=O)OC(C)C1=CC=CC=C1.[Cl-],,,,,,
8441,58442,1-phenylethyl N-[2-(diethylamino)ethyl]carbamate,CCN(CC)CCNC(=O)OC(C)C1=CC=CC=C1,,,,,,
8442,58443,Phenethyl N-(2-(diethylamino)ethyl)carbamate hydrochloride,CC[NH+](CC)CCNC(=O)OCCC1=CC=CC=C1.[Cl-],,,,,,
8443,58444,2-phenylethyl N-[2-(diethylamino)ethyl]carbamate,CCN(CC)CCNC(=O)OCCC1=CC=CC=C1,,,,,,
8444,58445,3-Phenylpropyl N-(2-(diethylamino)ethyl)carbamate hydrochloride,CC[NH+](CC)CCNC(=O)OCCCC1=CC=CC=C1.[Cl-],,,,,,
8445,58446,3-phenylpropyl N-[2-(diethylamino)ethyl]carbamate,CCN(CC)CCNC(=O)OCCCC1=CC=CC=C1,,,,,,
8446,58447,"Diethylcarbamic acid, 1,2-dimethyl-3-phenyl-3-pyrrolidinyl ester",CCN(CC)C(=O)OC1(CCN(C1C)C)C2=CC=CC=C2,,,,,,
8447,58448,Phenethyl N-(2-(dimethylamino)ethyl)carbamate hydrochloride,C[NH+](C)CCNC(=O)OCCC1=CC=CC=C1.[Cl-],,,,,,
8448,58449,2-phenylethyl N-[2-(dimethylamino)ethyl]carbamate,CN(C)CCNC(=O)OCCC1=CC=CC=C1,,,,,,
8449,58450,"Carbamic acid, (2-(dimethylamino)ethyl)-, phenethyl ester, monophosphate",C[NH+](C)CCNC(=O)OCCC1=CC=CC=C1.OP(=O)(O)[O-],,,,,,
8450,58451,"Carbamic acid, (3-(dimethylamino)propyl)-, 3-phenylpropyl ester, monophosphate",C[NH+](C)CCCNC(=O)OCCCC1=CC=CC=C1.OP(=O)(O)[O-],,,,,,
8451,58452,3-phenylpropyl N-[3-(dimethylamino)propyl]carbamate,CN(C)CCCNC(=O)OCCCC1=CC=CC=C1,,,,,,
8452,58453,2-Pyridyl dimethylcarbamate hydrochloride,CN(C)C(=O)OC1=CC=CC=[NH+]1.[Cl-],,,,,,
8453,58454,Pyridin-2-yl dimethylcarbamate,CN(C)C(=O)OC1=CC=CC=N1,,,,,,
8454,58455,"1,1-Diphenylbutylcarbamic acid 2-diethylaminoethyl ester hydrochloride",CCCC(C1=CC=CC=C1)(C2=CC=CC=C2)NC(=O)OCC[NH+](CC)CC.[Cl-],,,,,,
8455,58456,"2-(diethylamino)ethyl N-(1,1-diphenylbutyl)carbamate",CCCC(C1=CC=CC=C1)(C2=CC=CC=C2)NC(=O)OCCN(CC)CC,,,,,,
8456,58457,"1,1-Diphenylbutylcarbamic acid 2-dimethylaminoethyl ester hydrochloride",CCCC(C1=CC=CC=C1)(C2=CC=CC=C2)NC(=O)OCC[NH+](C)C.[Cl-],,,,,,
8457,58458,"2-(dimethylamino)ethyl N-(1,1-diphenylbutyl)carbamate",CCCC(C1=CC=CC=C1)(C2=CC=CC=C2)NC(=O)OCCN(C)C,,,,,,
8458,58459,"Carbamic acid, diphenyl-, 1-methyl-4-piperidyl ester",CN1CCC(CC1)OC(=O)N(C2=CC=CC=C2)C3=CC=CC=C3,,,,,,
8459,58460,CID 58460,C[NH+](C)CCSC(=O)N(C1=CC=CC=C1)C2=CC=CC=C2.C(=CC(=O)[O-])C(=O)O,,,,,,
8460,58461,S-[2-(dimethylamino)ethyl] diphenylthiocarbamate,CN(C)CCSC(=O)N(C1=CC=CC=C1)C2=CC=CC=C2,,,,,,
8461,58462,"Carbamic acid, N-(N-dodecylamidino)-",CCCCCCCCCCCCN=C(N)NC(=O)O,,,,,,
8462,58463,"N-Ethyl-N-(1-phenoxy-2-propyl)carbamic acid, 2-(diethylamino)ethyl ester hydrochloride",CC[NH+](CC)CCOC(=O)N(CC)C(C)COC1=CC=CC=C1.[Cl-],,,,,,
8463,58464,2-(diethylamino)ethyl N-ethyl-N-(1-phenoxypropan-2-yl)carbamate,CCN(CC)CCOC(=O)N(CC)C(C)COC1=CC=CC=C1,,,,,,
8464,58465,"N-Ethyl-N-(1-phenoxy-2-propyl)carbamic acid, 2-(2-methylpiperidino)ethyl ester hydrochloride",CCN(C(C)COC1=CC=CC=C1)C(=O)OCC[NH+]2CCCCC2C.[Cl-],,,,,,
8465,58466,2-(2-methylpiperidin-1-yl)ethyl N-ethyl-N-(1-phenoxypropan-2-yl)carbamate,CCN(C(C)COC1=CC=CC=C1)C(=O)OCCN2CCCCC2C,,,,,,
8466,58467,"Carbamic acid, N-ethyl-N-(1-(o-tolyloxy)-2-propyl)-, 2-(2-methylpiperidino)ethyl ester, hydrochloride",CCN(C(C)COC1=CC=CC=C1C)C(=O)OCC[NH+]2CCCCC2C.[Cl-],,,,,,
8467,58468,2-(2-methylpiperidin-1-yl)ethyl N-ethyl-N-[1-(2-methylphenoxy)propan-2-yl]carbamate,CCN(C(C)COC1=CC=CC=C1C)C(=O)OCCN2CCCCC2C,,,,,,
8468,58469,"Carbamic acid, N-ethyl-N-(1-(3,5-xylyloxy)-2-propyl)-, 2-(diethylamino)ethyl ester, hydrochloride",CC[NH+](CC)CCOC(=O)N(CC)C(C)COC1=CC(=CC(=C1)C)C.[Cl-],,,,,,
8469,58470,"2-(diethylamino)ethyl N-[1-(3,5-dimethylphenoxy)propan-2-yl]-N-ethylcarbamate",CCN(CC)CCOC(=O)N(CC)C(C)COC1=CC(=CC(=C1)C)C,,,,,,
8470,58471,"Carbamic acid, N-ethyl-N-(1-(3,5-xylyloxy)-2-propyl)-, 2-(2-methylpiperidino)ethyl ester, hydrochloride",CCN(C(C)COC1=CC(=CC(=C1)C)C)C(=O)OCC[NH+]2CCCCC2C.[Cl-],,,,,,
8471,58472,"2-(2-methylpiperidin-1-yl)ethyl N-[1-(3,5-dimethylphenoxy)propan-2-yl]-N-ethylcarbamate",CCN(C(C)COC1=CC(=CC(=C1)C)C)C(=O)OCCN2CCCCC2C,,,,,,
8472,58473,Propyl 2-(ethoxycarbonylamino)ethylsulfanylformate,CCCOC(=O)SCCNC(=O)OCC,,,,,,
8473,58474,"CARBAMIC ACID, N-MERCAPTO-N-METHYL-, m-ISOPROPYLPHENYL ESTER",CC(C)C1=CC(=CC=C1)OC(=O)N(C)S,,,,,,
8474,58475,"4-Butyl-1,5-dimethyl-2-phenylpyrazol-3-one",CCCCC1=C(N(N(C1=O)C2=CC=CC=C2)C)C,,,,,,
8475,58476,"AMMONIUM, (m-PHENYLENEBIS(OXY(2-HYDROXYTRIMETHYLENE)))BIS(TRIETHYL-, DIIODIDE",CC[N+](CC)(CC)CC(COC1=CC(=CC=C1)OCC(C[N+](CC)(CC)CC)O)O.[I-].[I-],,,,,,
8476,58477,Triethyl-[2-hydroxy-3-[3-[2-hydroxy-3-(triethylazaniumyl)propoxy]phenoxy]propyl]azanium,CC[N+](CC)(CC)CC(COC1=CC(=CC=C1)OCC(C[N+](CC)(CC)CC)O)O,,,,,,
8477,58478,"Oxalic acid, bis(2-(2-(benzylcarbamoyl)ethyl)hydrazide)",C1=CC=C(C=C1)CNC(=O)CCNNC(=O)C(=O)NNCCC(=O)NCC2=CC=CC=C2,,,,,,
8478,58479,"Carbamic acid, N-(1,3-benzodioxol-5-YL)-, 2-(2-pyridyl)ethyl ester",C1OC2=C(O1)C=C(C=C2)NC(=O)OCCC3=CC=CC=N3,,,,,,
8479,58480,5-(4-Methoxy-1-naphthyl)hydantoic acid ethyl ester,CCOC(=O)CNC(=O)NC1=CC=C(C2=CC=CC=C21)OC,,,,,,
8480,58481,"2-Phenylglycine 3,3,5-trimethylcyclohexyl ester",CC1CC(CC(C1)(C)C)OC(=O)C(C2=CC=CC=C2)N,,,,,,
8481,58482,CID 58482,C1=CC=C2C(=C1)C=CC=C2NC(=N[NH3+])N.[I-],,,,,,
8482,58483,1-(1-Naphthyl)-2-aminoguanidine,C1=CC=C2C(=C1)C=CC=C2N=C(N)NN,,,,,,
8483,58484,CID 58484,CC(C)(C)[NH2+]C(=NC1=NC=CS1)N.C(=CC(=O)[O-])C(=O)O,,,,,,
8484,58485,"2-Tert-butyl-1-(1,3-thiazol-2-yl)guanidine",CC(C)(C)N=C(N)NC1=NC=CS1,,,,,,
8485,58486,CID 58486,C1=CC=C(C=C1)C(C2=CC=CC=C2)N=C([NH3+])N.[Cl-],,,,,,
8486,58487,2-Benzhydrylguanidine,C1=CC=C(C=C1)C(C2=CC=CC=C2)N=C(N)N,,,,,,
8487,58488,"Guanidine, 3-dodecyl-1-nitro-",CCCCCCCCCCCCN=C(N)N[N+](=O)[O-],,,,,,
8488,58489,CID 58489,COC1=CC=C(C2=CC=CC=C21)C[NH2+]C(=N)[NH3+].[O-]S(=O)(=O)[O-],,,,,,
8489,58490,1-[(4-Methoxy-1-naphthyl)methyl]guanidine,COC1=CC=C(C2=CC=CC=C21)CN=C(N)N,,,,,,
8490,58491,Piperidino ethyl guanidine sulphate,C1CC[NH+](CC1)CC[NH2+]C(=N)N.[O-]S(=O)(=O)[O-],,,,,,
8491,58492,2-(2-Piperidin-1-ylethyl)guanidine,C1CCN(CC1)CCN=C(N)N,,,,,,
8492,58493,"7-Chloro-7,7-difluoro-6-trifluoromethylheptan-2,4-dion-6-ol",CC(=O)CC(=O)CC(C(F)(F)F)(C(F)(F)Cl)O,,,,,,
8493,58494,CID 58494,CCCCCC(C=NO)C(C(F)(F)F)(C(F)(F)F)O,,,,,,
8494,58495,"Heptanamide, 7-isopropylthio-",CC(C)SCCCCCCC(=O)N,,,,,,
8495,58496,CID 58496,CC(C)SCCCCCCC(=O)NC(=O)C1=CC(=C(C=C1)O)OC,,,,,,
8496,58497,"2,7-Bis(dimethylamino)-2,7-dimethyloctane",CC(C)(CCCCC(C)(C)N(C)C)N(C)C,,,,,,
8497,58498,"2,6-Dimethylcarbanilic acid 2-hydroxy-3-piperidinopropyl ester carbanilate hydrochloride",CC1=C(C(=CC=C1)C)NC(=O)OCC(C[NH+]2CCCCC2)OC(=O)NC3=CC=CC=C3.[Cl-],,,,,,
8498,58499,"[2-(phenylcarbamoyloxy)-3-piperidin-1-ylpropyl] N-(2,6-dimethylphenyl)carbamate",CC1=C(C(=CC=C1)C)NC(=O)OCC(CN2CCCCC2)OC(=O)NC3=CC=CC=C3,,,,,,
8499,58500,"2,2-Diphenyl-N-(3-pyridylmethyl)acetanilide hydrochloride",C1=CC=C(C=C1)C(C2=CC=CC=C2)C(=O)N(CC3=C[NH+]=CC=C3)C4=CC=CC=C4.[Cl-],,,,,,
8500,58501,"N,2,2-triphenyl-N-(pyridin-3-ylmethyl)acetamide",C1=CC=C(C=C1)C(C2=CC=CC=C2)C(=O)N(CC3=CN=CC=C3)C4=CC=CC=C4,,,,,,
8501,58502,"2,2-Diphenyl-N-(2-pyridylmethyl)acetanilide hydrochloride",C1=CC=C(C=C1)C(C2=CC=CC=C2)C(=O)N(CC3=CC=CC=[NH+]3)C4=CC=CC=C4.[Cl-],,,,,,
8502,58503,"N,2,2-triphenyl-N-(pyridin-2-ylmethyl)acetamide",C1=CC=C(C=C1)C(C2=CC=CC=C2)C(=O)N(CC3=CC=CC=N3)C4=CC=CC=C4,,,,,,
8503,58504,Sematilide hydrochloride,CCN(CC)CCNC(=O)C1=CC=C(C=C1)NS(=O)(=O)C.Cl,,,"['Agents used for the treatment or prevention of cardiac arrhythmias. They may affect the polarization-repolarization phase of the action potential, its excitability or refractoriness, or impulse conduction or membrane responsiveness within cardiac fibers. Anti-arrhythmia agents are often classed into four main groups according to their mechanism of action: sodium channel blockade, beta-adrenergic blockade, repolarization prolongation, or calcium channel blockade. (See all compounds classified as Anti-Arrhythmia Agents.)']",,,
8504,58505,Sematilide,CCN(CC)CCNC(=O)C1=CC=C(C=C1)NS(=O)(=O)C,,,"['Agents used for the treatment or prevention of cardiac arrhythmias. They may affect the polarization-repolarization phase of the action potential, its excitability or refractoriness, or impulse conduction or membrane responsiveness within cardiac fibers. Anti-arrhythmia agents are often classed into four main groups according to their mechanism of action: sodium channel blockade, beta-adrenergic blockade, repolarization prolongation, or calcium channel blockade. (See all compounds classified as Anti-Arrhythmia Agents.)']",,,
8505,58506,CID 58506,C1=CC=C(C=C1)C[NH+]=C(N)N=C(N)[NH-].C1=CC=C(C=C1)C[NH+]=C(N)N=C(N)[NH-].[O-]S(=O)(=O)[O-].[Cu+2],,,,,,
8506,58507,CID 58507,C[NH+]=C(N)N=C(N)[NH-].C[NH+]=C(N)N=C(N)[NH-].[O-]S(=O)(=O)[O-].[Cu+2],,,,,,
8507,58508,CID 58508,C1=CC=C(C=C1)CC[NH+]=C(N)N=C(N)[NH-].C1=CC=C(C=C1)CC[NH+]=C(N)N=C(N)[NH-].[O-]S(=O)(=O)[O-].[Cu+2],,,,,,
8508,58509,"8aH-CYCLOHEPTA(b)THIOPHENE, 2,4,5,6,7,8-HEXAHYDRO-2,2,3-TRIFLUORO-",C1CCC2C(=C(C(S2)(F)F)F)CC1,,,,,,
8509,58510,"2,2,3,3-Tetrafluorooctahydrocyclohepta(b)thiophene",C1CCC2C(CC1)SC(C2(F)F)(F)F,,,,,,
8510,58511,2-Cycloheptylamino-2-oxazoline,C1CCCC(CC1)NC2NC=CO2,,,,,,
8511,58512,"3,4-Bis(p-hydroxyphenyl)-2-hexanone",CCC(C1=CC=C(C=C1)O)C(C2=CC=C(C=C2)O)C(=O)C,,,,,,
8512,58513,"HEXA-3-YN-5-ENOIC ACID, 2-tert-BUTYL-2-HYDROXY-5-METHYL-, 3-QUINUCLIDINYL ESTER",CC(=C)C#CC(C(=O)OC1CN2CCC1CC2)(C(C)(C)C)O,,,,,,
8513,58514,2-Methyl-3-quinuclidyl isopropyl(3-methyl-but-1-yn-3-enyl)glycolate,CC1C(C2CCN1CC2)OC(=O)C(C#CC(=C)C)(C(C)C)O,,,,,,
8514,58515,"1,1,1-Trifluoro-2-(trifluoromethyl)-6-(2,6,6-trimethylcyclohexen-1-yl)hex-5-ene-2,4-diol",CC1=C(C(CCC1)(C)C)C=CC(CC(C(F)(F)F)(C(F)(F)F)O)O,,,,,,
8515,58516,1-Methyl-4-piperidyl isopropyl(3-methylbut-1-yn-3-enyl)glycolate,CC(C)C(C#CC(=C)C)(C(=O)OC1CCN(CC1)C)O,,,,,,
8516,58517,1-Azabicyclo[2.2.2]octan-3-yl 2-hydroxy-5-methyl-2-propan-2-ylhex-5-en-3-ynoate,CC(C)C(C#CC(=C)C)(C(=O)OC1CN2CCC1CC2)O,,,,,,
8517,58518,4-Hydroxy-4-methyl-2-hexynoic acid ammonium salt,CCC(C)(C#CC(=O)[O-])O.[NH4+],,,,,,
8518,58519,"Hippuric acid, 4-(allyloxy)-3,5-dipropyl-",CCCC1=CC(=CC(=C1OCC=C)CCC)C(=O)NCC(=O)O,,,,,,
8519,58520,"HYDANTOIN, 5,5-BIS(p-METHOXYPHENYL)-3-(2-PIPERIDINOETHYL)-, HEMISULFATE",COC1=CC=C(C=C1)C2(C(=O)N(C(=O)N2)CCN3CCCCC3)C4=CC=C(C=C4)OC.COC1=CC=C(C=C1)C2(C(=O)N(C(=O)N2)CCN3CCCCC3)C4=CC=C(C=C4)OC.OS(=O)(=O)O,,,,,,
8520,58521,Idanpramine,COC1=CC=C(C=C1)C2(C(=O)N(C(=O)N2)CCN3CCCCC3)C4=CC=C(C=C4)OC,,,,,,
8521,58522,"1-Imidazolidineacetic acid, 3-(4-methoxy-1-naphthyl)-2,4,5-trioxo-, ethyl ester",CCOC(=O)CN1C(=O)C(=O)N(C1=O)C2=CC=C(C3=CC=CC=C32)OC,,,,,,
8522,58523,"2-(2,4-Dichlorophenyl)-1-methylimidazolidine",CN1CCNC1C2=C(C=C(C=C2)Cl)Cl,,,,,,
8523,58524,CID 58524,CCOC1CN=C([NH+]1C2=CC=CC3=CC=CC=C32)S.[Br-],,,,,,
8524,58525,CID 58525,CCOC1CN=C(N1C2=CC=CC3=CC=CC=C32)S,,,,,,
8525,58526,"Imidazolidinetrione, 1-(2-bromoethyl)-3-(4-methoxy-1-naphthylmethyl)-",COC1=CC=C(C2=CC=CC=C21)CN3C(=O)C(=O)N(C3=O)CCBr,,,,,,
8526,58527,"Imidazolidinetrione, 3-(2-bromoethyl)-1-(1-naphthylmethyl)-",C1=CC=C2C(=C1)C=CC=C2CN3C(=O)C(=O)N(C3=O)CCBr,,,,,,
8527,58528,4-Ethoxy-1-naphthalen-1-ylimidazolidin-2-one,CCOC1CN(C(=O)N1)C2=CC=CC3=CC=CC=C32,,,,,,
8528,58529,"2-Imidazolidinone, 1-(3-methyl-2-pyridyl)-",CC1=C(N=CC=C1)N2CCNC2=O,,,,,,
8529,58530,CID 58530,C1CN(C(=N1)[NH3+])C2=CC=CC3=CC=CC=C32.C1CN(C(=N1)[NH3+])C2=CC=CC3=CC=CC=C32.[O-]S(=O)(=O)[O-],,,,,,
8530,58531,"1-Naphthalen-1-yl-4,5-dihydroimidazol-2-amine",C1CN(C(=N1)N)C2=CC=CC3=CC=CC=C32,,,,,,
8531,58532,2-(2-tert-Butylphenoxy)methyl-2-imidazoline hydrochloride,CC(C)(C)C1=CC=CC=C1OCC2=NCC[NH2+]2.[Cl-],,,,,,
8532,58533,"2-[(2-tert-butylphenoxy)methyl]-4,5-dihydro-1H-imidazole",CC(C)(C)C1=CC=CC=C1OCC2=NCCN2,,,,,,
8533,58534,"2-(4-Chloro-2,3-dimethylphenoxymethyl)-2-imidazoline hydrochloride",CC1=C(C=CC(=C1C)Cl)OCC2=NCC[NH2+]2.[Cl-],,,,,,
8534,58535,"2-[(4-chloro-2,3-dimethylphenoxy)methyl]-4,5-dihydro-1H-imidazole",CC1=C(C=CC(=C1C)Cl)OCC2=NCCN2,,,,,,
8535,58536,"2-Imidazoline, 2-((4-chloro-2,3,5-trimethylphenoxy)methyl)-",CC1=CC(=C(C(=C1Cl)C)C)OCC2=NCCN2,,,,,,
8536,58537,"2-(2,4-Dibromo-5,6,7,8-tetrahydro-1-naphthylamino)-2-imidazoline hydrobromide",C1CCC2=C(C1)C(=CC(=C2NC3=NCC[NH2+]3)Br)Br.[Br-],,,,,,
8537,58538,"N-(2,4-dibromo-5,6,7,8-tetrahydronaphthalen-1-yl)-4,5-dihydro-1H-imidazol-2-amine",C1CCC2=C(C1)C(=CC(=C2NC3=NCCN3)Br)Br,,,,,,
8538,58539,2-(4-Iodo-1-naphthylamino)-2-imidazoline hydrochloride,C1CN=C([NH2+]1)NC2=CC=C(C3=CC=CC=C32)I.[Cl-],,,,,,
8539,58540,"N-(4-iodonaphthalen-1-yl)-4,5-dihydro-1H-imidazol-2-amine",C1CN=C(N1)NC2=CC=C(C3=CC=CC=C32)I,,,,,,
8540,58541,"2-Imidazoline, 1-methyl-2-(thymyloxymethyl)-, hydrochloride",CC1=CC(=C(C=C1)C(C)C)OCC2=NCC[NH+]2C.[Cl-],,,,,,
8541,58542,"1-Methyl-2-[(5-methyl-2-propan-2-ylphenoxy)methyl]-4,5-dihydroimidazole",CC1=CC(=C(C=C1)C(C)C)OCC2=NCCN2C,,,,,,
8542,58543,"2-Imidazoline, 2-(1-naphthyloxy)methyl-, hydrochloride",C1CN=C([NH2+]1)COC2=CC=CC3=CC=CC=C32.[Cl-],,,,,,
8543,58544,"2-{[(Naphthalen-1-yl)oxy]methyl}-4,5-dihydro-1H-imidazole",C1CN=C(N1)COC2=CC=CC3=CC=CC=C32,,,,,,
8544,58545,"2-Imidazoline, 2-((5,6,7,8-tetrahydro-1-napthyloxy)methyl)-, hydrochloride",C1CCC2=C(C1)C=CC=C2OCC3=NCC[NH2+]3.[Cl-],,,,,,
8545,58546,"2-(5,6,7,8-tetrahydronaphthalen-1-yloxymethyl)-4,5-dihydro-1H-imidazole",C1CCC2=C(C1)C=CC=C2OCC3=NCCN3,,,,,,
8546,58547,"2-Imidazoline, 2-thymyloxyethylamino-, hydrochloride",CC1=CC(=C(C=C1)C(C)C)OCCNC2=NCC[NH2+]2.[Cl-],,,,,,
8547,58548,"N-[2-(5-methyl-2-propan-2-ylphenoxy)ethyl]-4,5-dihydro-1H-imidazol-2-amine",CC1=CC(=C(C=C1)C(C)C)OCCNC2=NCCN2,,,,,,
8548,58549,"5H-Dibenzo(a,d)cycloheptene-5-carboxylic acid, 10,11-dihydro-5-hydroxy-, 1-methyl-4-piperidyl ester",CN1CCC(CC1)OC(=O)C2(C3=CC=CC=C3CCC4=CC=CC=C42)O,,,,,,
8549,58550,"2-Benzyl-3-chloromethyl-1,2,3,4-tetrahydroisoquinoline hydrochloride",C1C([NH+](CC2=CC=CC=C21)CC3=CC=CC=C3)CCl.[Cl-],,,,,,
8550,58551,"2-benzyl-3-(chloromethyl)-3,4-dihydro-1H-isoquinoline",C1C(N(CC2=CC=CC=C21)CC3=CC=CC=C3)CCl,,,,,,
8551,58552,CID 58552,CC=C(C)C(=O)NC1=CC=C(C=C1)S(=O)(=O)C2=CC=C(C=C2)N,,,,,,
8552,58553,"ISONICOTINAMIDE, N-(5-(p-AMINOPHENOXY)PENTYL)-",C1=CC(=CC=C1N)OCCCCCNC(=O)C2=CC=NC=C2,,,,,,
8553,58554,"BENZYLAMINE, N-(3-(o-METHOXYPHENYL)PROPYL)-, HYDROCHLORIDE",COC1=CC=CC=C1CCC[NH2+]CC2=CC=CC=C2.[Cl-],,,,,,
8554,58555,N-benzyl-3-(2-methoxyphenyl)propan-1-amine,COC1=CC=CC=C1CCCNCC2=CC=CC=C2,,,,,,
8555,58556,"ANILINE, p-(5-PHENOXYPENTYLOXY)-",C1=CC=C(C=C1)OCCCCCOC2=CC=C(C=C2)N,,,,,,
8556,58557,"Indole-3-glyoxylamide, 1-butyl-N,N-dimethyl-",CCCCN1C=C(C2=CC=CC=C21)C(=O)C(=O)N(C)C,,,,,,
8557,58558,"Indole-3-glyoxylamide, N,N-diethyl-1,2-dimethyl-",CCN(CC)C(=O)C(=O)C1=C(N(C2=CC=CC=C21)C)C,,,,,,
8558,58559,"2-FURAMIDE, N-(5-(p-AMINOPHENOXY)PENTYL)-",C1=COC(=C1)C(=O)NCCCCCOC2=CC=C(C=C2)N,,,,,,
8559,58560,N-(o-(2-(Dimethylamino)ethoxy)benzylidene)aniline,CN(C)CCOC1=CC=CC=C1C=NC2=CC=CC=C2,,,,,,
8560,58561,"BENZAMIDE, N-(4-(p-AMINOPHENOXY)BUTYL)-",C1=CC=C(C=C1)C(=O)NCCCCOC2=CC=C(C=C2)N,,,,,,
8561,58562,"Barbituric acid, 5-ethyl-5-(4-methylpiperidino)-",CCC1(C(=O)NC(=O)NC1=O)N2CCC(CC2)C,,,,,,
8562,58563,2-(2-Piperidinoethyl)-1-tetralone,C1CCN(CC1)CCC2CCC3=CC=CC=C3C2=O,,,,,,
8563,58564,"BENZYLAMINE, o-(2-(DIMETHYLAMINO)ETHOXY)-N-PHENYL-",CN(C)CCOC1=CC=CC=C1CNC2=CC=CC=C2,,,,,,
8564,58565,1-(3-Indolylmethyl)nipecotic acid ethyl ester,CCOC(=O)C1CCCN(C1)CC2=CNC3=CC=CC=C32,,,,,,
8565,58566,"3,9-Diazabicyclo(3.3.1)nonane, 3-(3-(diethylamino)propyl)-9-methyl-, trihydrochloride",CCN(CC)CCCN1CC2CCCC(C1)N2C.Cl.Cl.Cl,,,,,,
8566,58567,"N,N-diethyl-3-(9-methyl-3,9-diazabicyclo[3.3.1]nonan-3-yl)propan-1-amine",CCN(CC)CCCN1CC2CCCC(C1)N2C,,,,,,
8567,58568,"3,9-Diazabicyclo(3.3.1)nonane, 9-methyl-3-(3-piperidinopropyl)-, trihydrochloride",CN1C2CCCC1CN(C2)CCCN3CCCCC3.Cl.Cl.Cl,,,,,,
8568,58569,"9-Methyl-3-(3-piperidin-1-ylpropyl)-3,9-diazabicyclo[3.3.1]nonane",CN1C2CCCC1CN(C2)CCCN3CCCCC3,,,,,,
8569,58570,CID 58570,CC=C(C)CN1CC2CCC(C1)N2CCCC=O,,,,,,
8570,58571,"DIBENZ(a,h)ACRIDINE, 8,9,10,11-TETRAHYDRO-14-METHYL-",CC1=C2C=CC3=C(C2=NC4=C1C5=CC=CC=C5C=C4)CCCC3,,,,,,
8571,58572,"DIBENZ(c,h)ACRIDINE, 1,2,3,4-TETRAHYDRO-7-METHYL-",CC1=C2C=CC3=CC=CC=C3C2=NC4=C1C=CC5=C4CCCC5,,,,,,
8572,58573,CID 58573,CN(C1CCCCC1)C(=O)CCCOC2=CC3=C(C=C2)NC4=NC(=O)CN4C3.O.OS(=O)(=O)O,,,,,,
8573,58574,CID 58574,CN(C1CCCCC1)C(=O)CCCOC2=CC3=C(C=C2)NC4=NC(=O)CN4C3,,,,,,
8574,58575,Bemarinone,CC1=C2C(=NC(=O)N1)C=CC(=C2OC)OC,,,,,,
8575,58576,"2-IMIDAZOLINE, 2-((6-tert-BUTYL-m-TOLYLOXY)METHYL)-, HYDROCHLORIDE",CC1=CC(=C(C=C1)C(C)(C)C)OCC2=NCC[NH2+]2.[Cl-],,,,,,
8576,58577,"2-[(2-tert-butyl-5-methylphenoxy)methyl]-4,5-dihydro-1H-imidazole",CC1=CC(=C(C=C1)C(C)(C)C)OCC2=NCCN2,,,,,,
8577,58578,2-((2-Isopropylphenylthio)methyl)-2-imidazoline hydrochloride,CC(C)C1=CC=CC=C1SCC2=NCC[NH2+]2.[Cl-],,,,,,
8578,58579,"2-[(2-propan-2-ylphenyl)sulfanylmethyl]-4,5-dihydro-1H-imidazole",CC(C)C1=CC=CC=C1SCC2=NCCN2,,,,,,
8579,58580,2-(Dipropylamino)-N-(2-norbornanyl)acetamide hydrochloride,CCCN(CCC)CC(=O)NC1CC2CCC1C2.Cl,,,,,,
8580,58581,N-(2-bicyclo[2.2.1]heptanyl)-2-(dipropylamino)acetamide,CCCN(CCC)CC(=O)NC1CC2CCC1C2,,,,,,
8581,58582,"ACETAMIDE, 2-(p-ETHOXYPHENYL)-N-VANILLYL-",CCOC1=CC=C(C=C1)CC(=O)NCC2=CC(=C(C=C2)O)OC,,,,,,
8582,58583,2-(Ethylmethylamino)-N-(2-norbornanyl)acetamide hydrochloride,CC[NH+](C)CC(=O)NC1CC2CCC1C2.[Cl-],,,,,,
8583,58584,N-(2-bicyclo[2.2.1]heptanyl)-2-[ethyl(methyl)amino]acetamide,CCN(C)CC(=O)NC1CC2CCC1C2,,,,,,
8584,58585,endo-2-(Ethylpropylamino)-N-(2-norbornanyl)acetamide hydrochloride,CCC[NH+](CC)CC(=O)NC1CC2CCC1C2.[Cl-],,,,,,
8585,58586,N-(2-bicyclo[2.2.1]heptanyl)-2-[ethyl(propyl)amino]acetamide,CCCN(CC)CC(=O)NC1CC2CCC1C2,,,,,,
8586,58587,2-(Isobutylamino)-N-(1-phenoxy-2-propyl)acetamide hydrochloride,CC(C)C[NH2+]CC(=O)NC(C)COC1=CC=CC=C1.[Cl-],,,,,,
8587,58588,2-(2-methylpropylamino)-N-(1-phenoxypropan-2-yl)acetamide,CC(C)CNCC(=O)NC(C)COC1=CC=CC=C1,,,,,,
8588,58589,N-(1-Mesityloxy-2-propyl)-N-methyl-2-(2-methylpiperidino)acetamide hydrochloride,CC1CCCC[NH+]1CC(=O)N(C)C(C)COC2=C(C=C(C=C2C)C)C.[Cl-],,,,,,
8589,58590,"N-methyl-2-(2-methylpiperidin-1-yl)-N-[1-(2,4,6-trimethylphenoxy)propan-2-yl]acetamide",CC1CCCCN1CC(=O)N(C)C(C)COC2=C(C=C(C=C2C)C)C,,,,,,
8590,58591,N-(m-Methoxyphenyl)-N-phenylacetamide,CC(=O)N(C1=CC=CC=C1)C2=CC(=CC=C2)OC,,,,,,
8591,58592,N-(1-Phenyl-2-propyl)-2-(2-methylpiperidino)acetamide hydrochloride,CC1CCCC[NH+]1CC(=O)NC(C)CC2=CC=CC=C2.[Cl-],,,,,,
8592,58593,2-(2-methylpiperidin-1-yl)-N-(1-phenylpropan-2-yl)acetamide,CC1CCCCN1CC(=O)NC(C)CC2=CC=CC=C2,,,,,,
8593,58594,"ACETAMIDE, N-METHYL-N-(2,3,6,7-TETRAHYDRO-1H,5H-BENZO(ij)QUINOLIZIN-9-YL)-",CC(=O)N(C)C1=CCC2=C3N1CCCC3=CCC2,,,,,,
8594,58595,"Acetamide, N-(1-naphthyl)-2-nitro-",C1=CC=C2C(=C1)C=CC=C2NC(=O)C[N+](=O)[O-],,,,,,
8595,58596,"Acetamide, 2-(N-nitro-N-(2,2,2-trinitroethyl)amino)-",C(C(=O)N)N(CC([N+](=O)[O-])([N+](=O)[O-])[N+](=O)[O-])[N+](=O)[O-],,,,,,
8596,58597,N-(2-Norbornanyl)-2-(propylamino)acetamide hydrochloride,CCC[NH2+]CC(=O)NC1CC2CCC1C2.[Cl-],,,,,,
8597,58598,N-(2-bicyclo[2.2.1]heptanyl)-2-(propylamino)acetamide,CCCNCC(=O)NC1CC2CCC1C2,,,,,,
8598,58599,N-(1-Phenoxy-2-propyl)-2-(2-methoxypiperidino)acetamide hydrochloride,CC1CCCC[NH+]1CC(=O)NC(C)COC2=CC=CC=C2.[Cl-],,,,,,
8599,58600,2-(2-methylpiperidin-1-yl)-N-(1-phenoxypropan-2-yl)acetamide,CC1CCCCN1CC(=O)NC(C)COC2=CC=CC=C2,,,,,,
8600,58601,"N'-(9-Acridinyl)-N,N-dimethylacetamidine",CC(=NC1=C2C=CC=CC2=NC3=CC=CC=C31)N(C)C,,,,,,
8601,58602,"N'-(2-(Benzyloxy)ethyl)-N,N-dimethylacetamidine",CC(=NCCOCC1=CC=CC=C1)N(C)C,,,,,,
8602,58603,"N'-(1,2,3,4-Tetrahydro-9-acridinyl)-N,N-dimethylformamidine",CC(=NC1=C2CCCCC2=NC3=CC=CC=C31)N(C)C,,,,,,
8603,58604,"Acetanilide, 3'-acetamido-4'-allyloxy-",CC(=O)NC1=CC(=C(C=C1)OCC=C)NC(=O)C,,,,,,
8604,58605,CID 58605,CC(=O)NC1=CC=C(C=C1)C2=NN=C(S2)[NH3+].[Cl-],,,,,,
8605,58606,"N-[4-(5-amino-1,3,4-thiadiazol-2-yl)phenyl]acetamide",CC(=O)NC1=CC=C(C=C1)C2=NN=C(S2)N,,,,,,
8606,58607,2-(Benzyl(2-(diethylamino)ethyl)amino)acetanilide dihydrochloride,CC[NH+](CC)CC[NH+](CC1=CC=CC=C1)CC(=O)NC2=CC=CC=C2.[Cl-].[Cl-],,,,,,
8607,58608,2-[benzyl-[2-(diethylamino)ethyl]amino]-N-phenylacetamide,CCN(CC)CCN(CC1=CC=CC=C1)CC(=O)NC2=CC=CC=C2,,,,,,
8608,58609,"Acetanilide, 3'-(2-(bis(2-bromoethyl)amino)ethyl)-4'-methoxy-",CC(=O)NC1=CC(=C(C=C1)OC)CCN(CCBr)CCBr,,,,,,
8609,58610,"Acetanilide, 3'-(2-(bis(2-chloroethyl)amino)ethyl)-4'-ethoxy-",CCOC1=C(C=C(C=C1)NC(=O)C)CCN(CCCl)CCCl,,,,,,
8610,58611,3-Chloro-4-(2-(diethylamino)ethoxy)-5-ethoxyacetanilide hydrochloride,CC[NH+](CC)CCOC1=C(C=C(C=C1Cl)NC(=O)C)OCC.[Cl-],,,,,,
8611,58612,N-[3-chloro-4-[2-(diethylamino)ethoxy]-5-ethoxyphenyl]acetamide,CCN(CC)CCOC1=C(C=C(C=C1Cl)NC(=O)C)OCC,,,,,,
8612,58613,6'-Chloro-2-(2-(diethylamino)ethoxy)acetanilide hydrochloride,CC[NH+](CC)CCOCC(=O)NC1=CC=CC=C1Cl.[Cl-],,,,,,
8613,58614,N-(2-chlorophenyl)-2-[2-(diethylamino)ethoxy]acetamide,CCN(CC)CCOCC(=O)NC1=CC=CC=C1Cl,,,,,,
8614,58615,2'-Chloro-2-((2-(diethylamino)ethyl)ethylamino)acetanilide dihydrochloride,CC[NH+](CC)CC[NH+](CC)CC(=O)NC1=CC=CC=C1Cl.[Cl-].[Cl-],,,,,,
8615,58616,Clodacaine,CCN(CC)CCN(CC)CC(=O)NC1=CC=CC=C1Cl,,,,,,
8616,58617,2'-Chloro-2-(2-(diethylamino)ethylthio)acetanilide hydrochloride,CC[NH+](CC)CCSCC(=O)NC1=CC=CC=C1Cl.[Cl-],,,,,,
8617,58618,N-(2-chlorophenyl)-2-[2-(diethylamino)ethylsulfanyl]acetamide,CCN(CC)CCSCC(=O)NC1=CC=CC=C1Cl,,,,,,
8618,58619,2'-Chloro-2-((2-(dimethylamino)ethyl)ethylamino)acetanilide dihydrochloride,CC[NH+](CC[NH+](C)C)CC(=O)NC1=CC=CC=C1Cl.[Cl-].[Cl-],,,,,,
8619,58620,N-(2-chlorophenyl)-2-[2-(dimethylamino)ethyl-ethylamino]acetamide,CCN(CCN(C)C)CC(=O)NC1=CC=CC=C1Cl,,,,,,
8620,58621,"Acetanilide, 2-chloro-4'-(2,3-dioxo-4-hexyl-1-piperazinyl)-N-ethyl-",CCCCCCN1CCN(C(=O)C1=O)C2=CC=C(C=C2)N(CC)C(=O)CCl,,,,,,
8621,58622,2'-Chloro-2-(ethyl(2-piperidinoethyl)amino)acetanilide dihydrochloride,CC[NH+](CC[NH+]1CCCCC1)CC(=O)NC2=CC=CC=C2Cl.[Cl-].[Cl-],,,,,,
8622,58623,N-(2-chlorophenyl)-2-[ethyl(2-piperidin-1-ylethyl)amino]acetamide,CCN(CCN1CCCCC1)CC(=O)NC2=CC=CC=C2Cl,,,,,,
8623,58624,o-Chloro-2-(methyl(2-(dimethylamino)ethyl)amino)acetanilide dihydrochloride,C[NH+](C)CC[NH+](C)CC(=O)NC1=CC=CC=C1Cl.[Cl-].[Cl-],,,,,,
8624,58625,N-(2-chlorophenyl)-2-[2-(dimethylamino)ethyl-methylamino]acetamide,CN(C)CCN(C)CC(=O)NC1=CC=CC=C1Cl,,,,,,
8625,58626,o-Chloro-2-(methyl(2-(piperidino)ethyl)amino)acetanilide dihydrochloride,C[NH+](CC[NH+]1CCCCC1)CC(=O)NC2=CC=CC=C2Cl.[Cl-].[Cl-],,,,,,
8626,58627,N-(2-chlorophenyl)-2-[methyl(2-piperidin-1-ylethyl)amino]acetamide,CN(CCN1CCCCC1)CC(=O)NC2=CC=CC=C2Cl,,,,,,
8627,58628,"ACETANILIDE, 4'-(p-CHLOROPHENYLTHIO)-2-(DIETHYLAMINO)-N-METHYL-, OXALATE",CC[NH+](CC)CC(=O)N(C)C1=CC=C(C=C1)SC2=CC=C(C=C2)Cl.C(=O)(C(=O)[O-])O,,,,,,
8628,58629,N-[4-(4-chlorophenyl)sulfanylphenyl]-2-(diethylamino)-N-methylacetamide,CCN(CC)CC(=O)N(C)C1=CC=C(C=C1)SC2=CC=C(C=C2)Cl,,,,,,
8629,58630,"2',6'-Dichloro-2-(2-(diethylamino)ethyl)thioacetanilide hydrochloride",CC[NH+](CC)CCSCC(=O)NC1=C(C=CC=C1Cl)Cl.[Cl-],,,,,,
8630,58631,"N-(2,6-dichlorophenyl)-2-[2-(diethylamino)ethylsulfanyl]acetamide",CCN(CC)CCSCC(=O)NC1=C(C=CC=C1Cl)Cl,,,,,,
8631,58632,2-(Diethylamino)-2'-ethylacetanilide hydrochloride,CCC1=CC=CC=C1NC(=O)C[NH+](CC)CC.[Cl-],,,,,,
8632,58633,2-(Diethylamino)-2'-ethylacetanilide,CCC1=CC=CC=C1NC(=O)CN(CC)CC,,,,,,
8633,58634,"2,2-Diphenyl-N-((1-methyl-3-piperidyl)methyl)acetanilide hydriodide",C[NH+]1CCCC(C1)CN(C2=CC=CC=C2)C(=O)C(C3=CC=CC=C3)C4=CC=CC=C4.[I-],,,,,,
8634,58635,"N-[(1-methylpiperidin-3-yl)methyl]-N,2,2-triphenylacetamide",CN1CCCC(C1)CN(C2=CC=CC=C2)C(=O)C(C3=CC=CC=C3)C4=CC=CC=C4,,,,,,
8635,58636,"N-(1-ethyl-2,2,6,6-tetramethylpiperidin-4-yl)-N-phenylacetamide",CCN1C(CC(CC1(C)C)N(C2=CC=CC=C2)C(=O)C)(C)C,,,,,,
8636,58637,CID 58637,CC(=O)NC1=CC=C(C=C1)S(=O)(=O)[N-]C2=CC=CC=N2.[Na+],,,,,,
8637,58638,"Acetamide, N-[4-[(2-pyridinylamino)sulfonyl]phenyl]-",CC(=O)NC1=CC=C(C=C1)S(=O)(=O)NC2=CC=CC=N2,,,,,"['Sulfapyridine, N-acetyl is a known human metabolite of Sulfapyridine.']",
8638,58639,CID 58639,CC(=O)NC1=C(C(=C(C=C1I)I)OCCOC(C2=CC=CC=C2)C(=O)[O-])I.[Na+],,,,,,
8639,58640,"2-[2-(3-Acetamido-2,4,6-triiodophenoxy)ethoxy]-2-phenylacetic acid",CC(=O)NC1=C(C(=C(C=C1I)I)OCCOC(C2=CC=CC=C2)C(=O)O)I,,,,,,
8640,58641,CID 58641,CC(=O)NC1=C(C(=C(C=C1I)I)OCCOCC(=O)[O-])I.[Na+],,,,,,
8641,58642,"2-[2-(3-Acetamido-2,4,6-triiodophenoxy)ethoxy]acetic acid",CC(=O)NC1=C(C(=C(C=C1I)I)OCCOCC(=O)O)I,,,,,,
8642,58643,CID 58643,CC1=CC=CC=C1C(C(=O)[O-])OCCOC2=C(C=C(C(=C2I)NC(=O)C)I)I.[Na+],,,,,,
8643,58644,"2-[2-(3-Acetamido-2,4,6-triiodophenoxy)ethoxy]-2-(2-methylphenyl)acetic acid",CC1=CC=CC=C1C(C(=O)O)OCCOC2=C(C=C(C(=C2I)NC(=O)C)I)I,,,,,,
8644,58645,CID 58645,CC1=CC=C(C=C1)C(C(=O)[O-])OCCOC2=C(C=C(C(=C2I)NC(=O)C)I)I.[Na+],,,,,,
8645,58646,"2-[2-(3-Acetamido-2,4,6-triiodophenoxy)ethoxy]-2-(4-methylphenyl)acetic acid",CC1=CC=C(C=C1)C(C(=O)O)OCCOC2=C(C=C(C(=C2I)NC(=O)C)I)I,,,,,,
8646,58647,N-Ethyl-N-(1-phenoxy-2-propyl)-2-(2-methylpiperidino)acetamide hydrochloride,CCN(C(C)COC1=CC=CC=C1)C(=O)C(C)[NH+]2CCCCC2.[Cl-],,,,,,
8647,58648,N-ethyl-N-(1-phenoxypropan-2-yl)-2-piperidin-1-ylpropanamide,CCN(C(C)COC1=CC=CC=C1)C(=O)C(C)N2CCCCC2,,,,,,
8648,58649,"2-Indolinone, 3-hydroxy-3-(2-aminopropyl)-",CC(CC1(C2=CC=CC=C2NC1=O)O)N,,,,,,
8649,58650,3-Hydroxy-3-(2-nitropropyl)-2-indolinone,CC(CC1(C2=CC=CC=C2NC1=O)O)[N+](=O)[O-],,,,,,
8650,58651,5-Hydroxy-alpha-methyltryptamine hydrochloride,CC(CC1=CNC2=C1C=C(C=C2)O)[NH3+].[Cl-],,,,,,
8651,58652,6-Hydroxy-5-methoxy-alpha-methyltryptamine hydrochloride,CC(CC1=CNC2=CC(=C(C=C21)OC)O)[NH3+].[Cl-],,,,,,
8652,58653,3-(2-aminopropyl)-5-methoxy-1H-indol-6-ol,CC(CC1=CNC2=CC(=C(C=C21)OC)O)N,,,,,,
8653,58654,2-(((p-(Bis(2-chloroethyl)amino)phenyl)imino)methyl)indol-3-ol,C1=CC=C2C(=C1)C(=C(N2)C=NC3=CC=C(C=C3)N(CCCl)CCCl)O,,,,,,
8654,58655,L-alpha-Aminomethyl-5-hydroxytryptamine dihydrochloride,C1=CC2=C(C=C1O)C(=CN2)CC(C[NH3+])[NH3+].[Cl-].[Cl-],,,,,,
8655,58656,"3-(2,3-diaminopropyl)-1H-indol-5-ol",C1=CC2=C(C=C1O)C(=CN2)CC(CN)N,,,,,,
8656,58657,"Isoalloxazine, 7-chloro-10-(3-(bis(2-hydroxyethyl)amino)propyl)-, sulfate",C1=CC2=C(C=C1Cl)N=C3C(=O)NC(=O)N=C3N2CCC[NH+](CCO)CCO.OS(=O)(=O)[O-],,,,,,
8657,58658,"10-[3-[Bis(2-hydroxyethyl)amino]propyl]-7-chlorobenzo[g]pteridine-2,4-dione",C1=CC2=C(C=C1Cl)N=C3C(=O)NC(=O)N=C3N2CCCN(CCO)CCO,,,,,,
8658,58659,7-Chloro-10-(3-(diethylamino)-2-hydroxypropyl)isoalloxazine sulfate,CC[NH+](CC)CC(CN1C2=C(C=C(C=C2)Cl)N=C3C1=NC(=O)NC3=O)O.OS(=O)(=O)[O-],,,,,,
8659,58660,"7-Chloro-10-[3-(diethylamino)-2-hydroxypropyl]benzo[g]pteridine-2,4-dione",CCN(CC)CC(CN1C2=C(C=C(C=C2)Cl)N=C3C1=NC(=O)NC3=O)O,,,,,,
8660,58661,7-Chloro-10-(4-(diethylamino)-1-methylbutyl)isoalloxazine sulfate,CC[NH+](CC)CCCC(C)N1C2=C(C=C(C=C2)Cl)N=C3C1=NC(=O)NC3=O.OS(=O)(=O)[O-],,,,,,
8661,58662,"7-Chloro-10-[5-(diethylamino)pentan-2-yl]benzo[g]pteridine-2,4-dione;sulfuric acid",CCN(CC)CCCC(C)N1C2=C(C=C(C=C2)Cl)N=C3C1=NC(=O)NC3=O,,,,,,
8662,58663,"Isoalloxazine, 7-chloro-10-(2-(dimethylamino)ethyl)-, sulfate",C[NH+](C)CCN1C2=C(C=C(C=C2)Cl)N=C3C1=NC(=O)NC3=O.OS(=O)(=O)[O-],,,,,,
8663,58664,"7-Chloro-10-[2-(dimethylamino)ethyl]benzo[g]pteridine-2,4-dione",CN(C)CCN1C2=C(C=C(C=C2)Cl)N=C3C1=NC(=O)NC3=O,,,,,,
8664,58665,7-Chloro-10-(4-(dimethylamino)-1-methylbutyl)isoalloxazine sulfate,CC(CCC[NH+](C)C)N1C2=C(C=C(C=C2)Cl)N=C3C1=NC(=O)NC3=O.OS(=O)(=O)[O-],,,,,,
8665,58666,"7-Chloro-10-[5-(dimethylamino)pentan-2-yl]benzo[g]pteridine-2,4-dione",CC(CCCN(C)C)N1C2=C(C=C(C=C2)Cl)N=C3C1=NC(=O)NC3=O,,,,,,
8666,58667,7-Chloro-10-(3-(dimethylamino)propyl)isoalloxazine hydrochloride,C[NH+](C)CCCN1C2=C(C=C(C=C2)Cl)N=C3C1=NC(=O)NC3=O.[Cl-],,,,,,
8667,58668,"7-Chloro-10-[3-(dimethylamino)propyl]benzo[g]pteridine-2,4-dione",CN(C)CCCN1C2=C(C=C(C=C2)Cl)N=C3C1=NC(=O)NC3=O,,,,,,
8668,58669,"Isoalloxazine, 7-chloro-10-(3-(N-ethyl-N-(2-hydroxyethyl)amino)propyl)-, hydrochloride",CC[NH+](CCCN1C2=C(C=C(C=C2)Cl)N=C3C1=NC(=O)NC3=O)CCO.[Cl-],,,,,,
8669,58670,"7-Chloro-10-[3-[ethyl(2-hydroxyethyl)amino]propyl]benzo[g]pteridine-2,4-dione",CCN(CCCN1C2=C(C=C(C=C2)Cl)N=C3C1=NC(=O)NC3=O)CCO,,,,,,
8670,58671,7-Chloro-10-(2-hydroxy-3-piperidinopropyl)isoalloxazine sulfate,C1CC[NH+](CC1)CC(CN2C3=C(C=C(C=C3)Cl)N=C4C2=NC(=O)NC4=O)O.OS(=O)(=O)[O-],,,,,,
8671,58672,"7-Chloro-10-(2-hydroxy-3-piperidin-1-ylpropyl)benzo[g]pteridine-2,4-dione",C1CCN(CC1)CC(CN2C3=C(C=C(C=C3)Cl)N=C4C2=NC(=O)NC4=O)O,,,,,,
8672,58673,"7,8-Dichloro-10-(4-(diethylamino)-1-methylbutyl)isoalloxazine hydrochloride",CC[NH+](CC)CCCC(C)N1C2=CC(=C(C=C2N=C3C1=NC(=O)NC3=O)Cl)Cl.[Cl-],,,,,,
8673,58674,"7,8-Dichloro-10-[5-(diethylamino)pentan-2-yl]benzo[g]pteridine-2,4-dione",CCN(CC)CCCC(C)N1C2=CC(=C(C=C2N=C3C1=NC(=O)NC3=O)Cl)Cl,,,,,,
8674,58675,"Isoalloxazine, 7,8-dichloro-10-(2-(dimethylamino)ethyl)-, sulfate",C[NH+](C)CCN1C2=CC(=C(C=C2N=C3C1=NC(=O)NC3=O)Cl)Cl.OS(=O)(=O)[O-],,,,,,
8675,58676,"7,8-Dichloro-10-[2-(dimethylamino)ethyl]benzo[g]pteridine-2,4-dione",CN(C)CCN1C2=CC(=C(C=C2N=C3C1=NC(=O)NC3=O)Cl)Cl,,,,,,
8676,58677,"Isoalloxazine, 6,7-dichloro-10-(3-(N-(2-hydroxyethyl)ethylamino)propyl)-, sulfate",CC[NH+](CCCN1C2=C(C(=C(C=C2)Cl)Cl)N=C3C1=NC(=O)NC3=O)CCO.OS(=O)(=O)[O-],,,,,,
8677,58678,"6,7-Dichloro-10-[3-[ethyl(2-hydroxyethyl)amino]propyl]benzo[g]pteridine-2,4-dione",CCN(CCCN1C2=C(C(=C(C=C2)Cl)Cl)N=C3C1=NC(=O)NC3=O)CCO,,,,,,
8678,58679,"Isoalloxazine, 6,7-dichloro-10-(3-(N-(2-hydroxyethyl)methylamino)propyl)-, sulfate",C[NH+](CCCN1C2=C(C(=C(C=C2)Cl)Cl)N=C3C1=NC(=O)NC3=O)CCO.OS(=O)(=O)[O-],,,,,,
8679,58680,"6,7-Dichloro-10-[3-[2-hydroxyethyl(methyl)amino]propyl]benzo[g]pteridine-2,4-dione",CN(CCCN1C2=C(C(=C(C=C2)Cl)Cl)N=C3C1=NC(=O)NC3=O)CCO,,,,,,
8680,58681,"Isoalloxazine, 10-(2-(diethylamino)ethyl)-8-methoxy-7-methyl-, sulfate",CCN(CC)CC[N+]1=C2C(=NC3=C1C=C(C=C3)OC)C(=O)NC(=O)N2C.OS(=O)(=O)[O-],,,,,,
8681,58682,"10-[2-(Diethylamino)ethyl]-8-methoxy-1-methylbenzo[g]pteridin-10-ium-2,4-dione",CCN(CC)CC[N+]1=C2C(=NC3=C1C=C(C=C3)OC)C(=O)NC(=O)N2C,,,,,,
8682,58683,"7,8-Dimethyl-10-(D-ribo-2,3,4,5-tetrahydroxypentyl)-4a,5-dihydroisoalloxazine",CC1=CC2=C(C=C1C)N(C3=NC(=O)NC(=O)C3N2)C[C@H]([C@H]([C@H](CO)O)O)O,,,,,,
8683,58684,"Isoalloxazine, 10-(2-(dimethylamino)ethyl)-, sulfate",C[NH+](C)CCN1C2=CC=CC=C2N=C3C1=NC(=O)NC3=O.OS(=O)(=O)[O-],,,,,,
8684,58685,"10-[2-(Dimethylamino)ethyl]benzo[g]pteridine-2,4-dione",CN(C)CCN1C2=CC=CC=C2N=C3C1=NC(=O)NC3=O,,,,,,
8685,58686,"Isobutyramide, N-(2-bromoallyl)-",CC(C)C(=O)NCC(=C)Br,,,,,,
8686,58687,CID 58687,C(C=CBr)N=C=O,,,,,,
8687,58688,"1,2-Dibromo-3-isocyanatoprop-1-ene",C(C(=CBr)Br)N=C=O,,,,,,
8688,58689,(alpha-(Hydroxymethyl)benzyl)trimethylammonium bromide diphenylacetate,C[N+](C)(C)C(COC(=O)C(C1=CC=CC=C1)C2=CC=CC=C2)C3=CC=CC=C3.[Br-],,,,,,
8689,58690,"[2-(2,2-Diphenylacetyl)oxy-1-phenylethyl]-trimethylazanium",C[N+](C)(C)C(COC(=O)C(C1=CC=CC=C1)C2=CC=CC=C2)C3=CC=CC=C3,,,,,,
8690,58691,2-(2-(Diethylamino)ethyl)thioacetanilide hydrochloride,CC[NH+](CC)CCSCC(=O)NC1=CC=CC=C1.[Cl-],,,,,,
8691,58692,2-[2-(diethylamino)ethylsulfanyl]-N-phenylacetamide,CCN(CC)CCSCC(=O)NC1=CC=CC=C1,,,,,,
8692,58693,CID 58693,C1=C2C(=CC(=C1Cl)Cl)N(C3=NC(=NC(=O)C3N2)[O-])CCO.[Na+],,,,,,
8693,58694,"7,8-Dichloro-10-(2-hydroxyethyl)-4a,5-dihydrobenzo[g]pteridine-2,4-dione",C1=C2C(=CC(=C1Cl)Cl)N(C3=NC(=O)NC(=O)C3N2)CCO,,,,,,
8694,58695,"Isoquinoline, 1,2,3,4-tetrahydro-6-methoxy-2-(2-piperidinoethyl)-, dihydrochloride",COC1=CC2=C(C[NH+](CC2)CC[NH+]3CCCCC3)C=C1.[Cl-].[Cl-],,,,,,
8695,58696,"6-methoxy-2-(2-piperidin-1-ylethyl)-3,4-dihydro-1H-isoquinoline",COC1=CC2=C(CN(CC2)CCN3CCCCC3)C=C1,,,,,,
8696,58697,"Isoquinoline, 1,2,3,4-tetrahydro-7-methoxy-2-(2-piperidinoethyl)-, dihydrochloride",COC1=CC2=C(CC[NH+](C2)CC[NH+]3CCCCC3)C=C1.[Cl-].[Cl-],,,,,,
8697,58698,"7-methoxy-2-(2-piperidin-1-ylethyl)-3,4-dihydro-1H-isoquinoline",COC1=CC2=C(CCN(C2)CCN3CCCCC3)C=C1,,,,,,
8698,58699,"2-(2-Oxazolin-2-yl)-1,2,3,4-tetrahydroisoquinoline hydrobromide",C1C[NH+](CC2=CC=CC=C21)C3=NCCO3.[Br-],,,,,,
8699,58700,"2-(4,5-Dihydro-1,3-oxazol-2-yl)-1,2,3,4-tetrahydroisoquinoline",C1CN(CC2=CC=CC=C21)C3=NCCO3,,,,,,
8700,58701,"1,2,3,4-Tetrahydro-2-(2-piperidinoethyl)isoquinoline dihydrochloride",C1CC[NH+](CC1)CC[NH+]2CCC3=CC=CC=C3C2.[Cl-].[Cl-],,,,,,
8701,58702,"2-(2-piperidin-1-ylethyl)-3,4-dihydro-1H-isoquinoline",C1CCN(CC1)CCN2CCC3=CC=CC=C3C2,,,,,,
8702,58703,"Isoquinolin-1-one, 1,2,3,4-tetrahydro-4,7,8-trihydroxy-, hydrochloride",C1C(C2=C(C(=C(C=C2)O)O)C(=O)[NH2+]1)O.[Cl-],,,,,,
8703,58704,"4,7,8-trihydroxy-3,4-dihydro-2H-isoquinolin-1-one",C1C(C2=C(C(=C(C=C2)O)O)C(=O)N1)O,,,,,,
8704,58705,1-Methyl-4-piperidyl 5-isothiazyl(phenyl)glycolate,CN1CCC(CC1)OC(=O)C(C2=CC=CC=C2)(C3=CC=NS3)O,,,,,,
8705,58706,"5-ISOTHIAZOLEGLYCOLIC ACID, alpha-PHENYL-, 3-QUINUCLIDINYL ESTER",C1CN2CCC1C(C2)OC(=O)C(C3=CC=CC=C3)(C4=CC=NS4)O,,,,,,
8706,58707,1-Bromoallylisothiocyanate,C=CC(N=C=S)Br,,,,,,
8707,58708,2-Bromoallyl isothiocyanate,C=C(CN=C=S)Br,,,,,,
8708,58709,1-Chloroallyl isothiocyanate,C=CC(N=C=S)Cl,,,,,,
8709,58710,"Isothiocyanic acid, 4-chloro-1-naphthyl ester",C1=CC=C2C(=C1)C(=CC=C2Cl)N=C=S,,,,,,
8710,58711,"1,2-Dibromo-3-isothiocyanatoprop-1-ene",C(C(=CBr)Br)N=C=S,,,,,,
8711,58712,"1,3,5-Triisothiocyanatobenzene",C1=C(C=C(C=C1N=C=S)N=C=S)N=C=S,,,,,,
8712,58713,"3-Isoxazolecarboxylic acid, 5-methyl-, 2-benzyl-2-(5-methyl-3-isoxazolylcarbonyl)hydrazide",CC1=CC(=NO1)C(=O)NN(CC2=CC=CC=C2)C(=O)C3=NOC(=C3)C,,,,,,
8713,58714,"3-Isoxazolecarboxylic acid, 5-methyl-, 2-butylhydrazide",CCCCNNC(=O)C1=NOC(=C1)C,,,,,,
8714,58715,"5-ISOXAZOLECARBOXYLIC ACID, 3-METHYL-, 2-(p-(DIMETHYLAMINO)BENZYL)HYDRAZIDE",CC1=NOC(=C1)C(=O)NNCC2=CC=C(C=C2)N(C)C,,,,,,
8715,58716,"2,2-Bis(2-chloroethyl)isoxazolidinium chloride",C1C[N+](OC1)(CCCl)CCCl.[Cl-],,,,,,
8716,58717,"2,2-Bis(2-chloroethyl)-1,2-oxazolidin-2-ium",C1C[N+](OC1)(CCCl)CCCl,,,,,,
8717,58718,"2,2-Bis(2-chloroethyl)isoxazolidinium iodide",C1C[N+](OC1)(CCCl)CCCl.[I-],,,,,,
8718,58719,2-(2-Chloroethyl)-2-methylisoxazolidinium iodide,C[N+]1(CCCO1)CCCl.[I-],,,,,,
8719,58720,2-(2-Chloroethyl)-2-methyl-isoxazolidinium halide,C[N+]1(CCCO1)CCCl,,,,,,
8720,58721,"2,2-Diethylisoxazolidinium chloride",CC[N+]1(CCCO1)CC.[Cl-],,,,,,
8721,58722,"2,2-Diethyl-1,2-oxazolidin-2-ium",CC[N+]1(CCCO1)CC,,,,,,
8722,58723,"3-Isoxazolidinone, 4,4'-(2,5-furylenebis(methyleneimino))-, calcium salt, tetrahydrate",C1C(C(=NO1)[O-])N=CC2=CC=C(O2)C=NC3CON=C3[O-].[Ca+2],,,,,,
8723,58724,"4-[[5-[(3-Oxo-1,2-oxazolidin-4-yl)iminomethyl]furan-2-yl]methylideneamino]-1,2-oxazolidin-3-one",C1C(C(=O)NO1)N=CC2=CC=C(O2)C=NC3CONC3=O,,,,,,
8724,58725,1-(trans-2-Phenylcyclopropylcarbonyl)-4-anilinopiperidine hydrochloride,C1CN(CCC1[NH2+]C2=CC=CC=C2)C(=O)C3CC3C4=CC=CC=C4.[Cl-],,,,,,
8725,58726,(4-Anilinopiperidin-1-yl)-(2-phenylcyclopropyl)methanone,C1CN(CCC1NC2=CC=CC=C2)C(=O)C3CC3C4=CC=CC=C4,,,,,,
8726,58727,"Ketone, 5-benzyloxy-3-indolyl 4-piperidyl",C1CNCCC1C(=O)C2=CNC3=C2C=C(C=C3)OCC4=CC=CC=C4,,,,,,
8727,58728,(alpha-(Hydroxymethyl)benzyl)trimethylammonium bromide benzilate,C[N+](C)(C)C(COC(=O)C(C1=CC=CC=C1)(C2=CC=CC=C2)O)C3=CC=CC=C3.[Br-],,,,,,
8728,58729,"[2-(2-Hydroxy-2,2-diphenylacetyl)oxy-1-phenylethyl]-trimethylazanium",C[N+](C)(C)C(COC(=O)C(C1=CC=CC=C1)(C2=CC=CC=C2)O)C3=CC=CC=C3,,,,,,
8729,58730,"Ammonium, (m-phenylenebis(oxy(2-hydroxytrimethylene)))bis(diethylmethyl-, diiodide",CC[N+](C)(CC)CC(COC1=CC(=CC=C1)OCC(C[N+](C)(CC)CC)O)O.[I-].[I-],,,,,,
8730,58731,[3-[3-[3-[Diethyl(methyl)azaniumyl]-2-hydroxypropoxy]phenoxy]-2-hydroxypropyl]-diethyl-methylazanium,CC[N+](C)(CC)CC(COC1=CC(=CC=C1)OCC(C[N+](C)(CC)CC)O)O,,,,,,
8731,58732,"ETHANONE, 1-(2-NITRONAPHTHO(2,1-b)FURAN-7-YL)-",CC(=O)C1=CC2=C(C=C1)C3=C(C=C2)OC(=C3)[N+](=O)[O-],,,,,,
8732,58733,"2-(2,6-dimethylphenyl)-4,5-dihydro-1H-imidazole",CC1=C(C(=CC=C1)C)C2=NCCN2,,,,,,
8733,58734,"4-Imidazolin-2-one, 1-cyclohexyl-3-methyl-",CN1C=CN(C1=O)C2CCCCC2,,,,,,
8734,58735,"3-Imidazolin-2-one, 1-(5-nitro-2-thiazolyl)-",C1C=NC(=O)N1C2=NC=C(S2)[N+](=O)[O-],,,,,,
8735,58736,"1-Propanaminium, 2,2-dimethyl-3-((3-methyl-2-phenylvaleryl)oxy)-N,N,N-trimethyl-, bromide",CCC(C)C(C1=CC=CC=C1)C(=O)OCC(C)(C)C[N+](C)(C)C.[Br-],,,,,,
8736,58737,"[2,2-Dimethyl-3-(3-methyl-2-phenylpentanoyl)oxypropyl]-trimethylazanium",CCC(C)C(C1=CC=CC=C1)C(=O)OCC(C)(C)C[N+](C)(C)C,,,,,,
8737,58738,Triethyl-[2-[4-(2-phenylethenyl)benzoyl]oxyethyl]azanium;iodide,CC[N+](CC)(CC)CCOC(=O)C1=CC=C(C=C1)C=CC2=CC=CC=C2.[I-],,,,,,
8738,58739,Triethyl-[2-[4-(2-phenylethenyl)benzoyl]oxyethyl]azanium,CC[N+](CC)(CC)CCOC(=O)C1=CC=C(C=C1)C=CC2=CC=CC=C2,,,,,,
8739,58740,"Ammonium, (2-hydroxyethyl)triethyl-, iodide, diphenylcarbamate",CC[N+](CC)(CC)CCOC(=O)N(C1=CC=CC=C1)C2=CC=CC=C2.[I-],,,,,,
8740,58741,"2-[[(Diphenylamino)carbonyl]oxy]-N,N,N-triethylethanaminium",CC[N+](CC)(CC)CCOC(=O)N(C1=CC=CC=C1)C2=CC=CC=C2,,,,,,
8741,58742,(2-Hydroxy-5-tert-pentylphenyl)trimethylammonium iodide dimethylcarbamate,CC(C)(C)CC1=CC(=C(C=C1)[N+](C)(C)C)OC(=O)N(C)C.[I-],,,,,,
8742,58743,"[2-(Dimethylcarbamoyloxy)-4-(2,2-dimethylpropyl)phenyl]-trimethylazanium",CC(C)(C)CC1=CC(=C(C=C1)[N+](C)(C)C)OC(=O)N(C)C,,,,,,
8743,58744,(p-Hydroxyphenyl)trimethylammonium iodide dimethyl carbamate (ester),CN(C)C(=O)OC1=CC=C(C=C1)[N+](C)(C)C.[I-],,,,,,
8744,58745,[4-(Dimethylcarbamoyloxy)phenyl]-trimethylazanium,CN(C)C(=O)OC1=CC=C(C=C1)[N+](C)(C)C,,,,,,
8745,58746,"Ammonium, (3-hydroxypropyl)triethyl-, bromide, 3-methyl-2-phenylvalerate",CC[N+](CC)(CC)CCCOC(=O)CC(C1=CC=CC=C1)C(C)C.[Br-],,,,,,
8746,58747,Triethyl-[3-(4-methyl-3-phenylpentanoyl)oxypropyl]azanium,CC[N+](CC)(CC)CCCOC(=O)CC(C1=CC=CC=C1)C(C)C,,,,,,
8747,58748,"Ammonium, 3-methoxyhexamethylenebis(trimethyl-, diiodide",C[N+](C)(C)CCCC(CC[N+](C)(C)C)OC.[I-].[I-],,,,,,
8748,58749,[3-Methoxy-6-(trimethylazaniumyl)hexyl]-trimethylazanium,C[N+](C)(C)CCCC(CC[N+](C)(C)C)OC,,,,,,
8749,58750,"Ammonium, (3-(3-nitroguanidino)propyl)trimethyl-, iodide",C[N+](C)(C)CCCN=C(N)N[N+](=O)[O-].[I-],,,,,,
8750,58751,3-[[Amino(nitramido)methylidene]amino]propyl-trimethylazanium,C[N+](C)(C)CCCN=C(N)N[N+](=O)[O-],,,,,,
8751,58752,"AMMONIUM, (p-PHENYLENEDIMETHYLENE)BIS(DIETHYL(2-HYDROXYETHYL)-, DIBROMIDE",CC[N+](CC)(CCO)CC1=CC=C(C=C1)C[N+](CC)(CC)CCO.[Br-].[Br-],,,,,,
8752,58753,[4-[[Diethyl(2-hydroxyethyl)azaniumyl]methyl]phenyl]methyl-diethyl-(2-hydroxyethyl)azanium,CC[N+](CC)(CCO)CC1=CC=C(C=C1)C[N+](CC)(CC)CCO,,,,,,
8753,58754,"AMMONIUM, (p-PHENYLENEDIMETHYLENE)BIS(ETHYL(2-HYDROXYETHYL)PROPYL-, DIBROMIDE",CCC[N+](CC)(CCO)CC1=CC=C(C=C1)C[N+](CC)(CCC)CCO.[Br-].[Br-],,,,,,
8754,58755,Ethyl-[[4-[[ethyl-(2-hydroxyethyl)-propylazaniumyl]methyl]phenyl]methyl]-(2-hydroxyethyl)-propylazanium,CCC[N+](CC)(CCO)CC1=CC=C(C=C1)C[N+](CC)(CCC)CCO,,,,,,
8755,58756,"AMMONIUM, (p-PHENYLENEDIMETHYLENE)BIS((2-HYDROXYETHYL)DIMETHYL-, DIBROMIDE",C[N+](C)(CCO)CC1=CC=C(C=C1)C[N+](C)(C)CCO.[Br-].[Br-],,,,,,
8756,58757,"N,N'-Bis(2-hydroxyethyl)-N,N,N',N'-tetramethyl-1,4-benzenebis(methanaminium)",C[N+](C)(CCO)CC1=CC=C(C=C1)C[N+](C)(C)CCO,,,,,,
8757,58758,"AMMONIUM, (p-PHENYLENEDIMETHYLENE)BIS(TRIBUTYL-, DIBROMIDE",CCCC[N+](CCCC)(CCCC)CC1=CC=C(C=C1)C[N+](CCCC)(CCCC)CCCC.[Br-].[Br-],,,,,,
8758,58759,"1,4-Bis(tributylaminiomethyl)benzene",CCCC[N+](CCCC)(CCCC)CC1=CC=C(C=C1)C[N+](CCCC)(CCCC)CCCC,,,,,,
8759,58760,"AMMONIUM, (p-PHENYLENEDIMETHYLENE)BIS(TRIPROPYL-, DIBROMIDE",CCC[N+](CCC)(CCC)CC1=CC=C(C=C1)C[N+](CCC)(CCC)CCC.[Br-].[Br-],,,,,,
8760,58761,Tripropyl-[[4-[(tripropylazaniumyl)methyl]phenyl]methyl]azanium,CCC[N+](CCC)(CCC)CC1=CC=C(C=C1)C[N+](CCC)(CCC)CCC,,,,,,
8761,58762,"Ammonium, 1,1,6,6-tetramethylhexamethylenebis(trimethyl-, diiodide",CC(C)(CCCCC(C)(C)[N+](C)(C)C)[N+](C)(C)C.[I-].[I-],,,,,,
8762,58763,"[2,7-Dimethyl-7-(trimethylazaniumyl)octan-2-yl]-trimethylazanium",CC(C)(CCCCC(C)(C)[N+](C)(C)C)[N+](C)(C)C,,,,,,
8763,58764,(2-(Triphenylmethoxy)ethyl)triethylammonium bromide,CC[N+](CC)(CC)CCOC(C1=CC=CC=C1)(C2=CC=CC=C2)C3=CC=CC=C3.[Br-],,,,,,
8764,58765,Triethyl(2-trityloxyethyl)azanium,CC[N+](CC)(CC)CCOC(C1=CC=CC=C1)(C2=CC=CC=C2)C3=CC=CC=C3,,,,,,
8765,58766,"Trimethyl-[2-oxo-2-[2-[(3,4,5-trimethoxyphenyl)methylidene]hydrazinyl]ethyl]azanium;chloride",C[N+](C)(C)CC(=O)NN=CC1=CC(=C(C(=C1)OC)OC)OC.[Cl-],,,,,,
8766,58767,"Trimethyl-[2-oxo-2-[2-[(3,4,5-trimethoxyphenyl)methylidene]hydrazinyl]ethyl]azanium",C[N+](C)(C)CC(=O)NN=CC1=CC(=C(C(=C1)OC)OC)OC,,,,,,
8767,58768,"Ammonium, trimethyl(3-((trimethylammonio)methyl)-5-indolyl)-, dichloride",C[N+](C)(C)CC1=CNC2=C1C=C(C=C2)[N+](C)(C)C.[Cl-].[Cl-],,,,,,
8768,58769,"Ammonium, (2-(10-undecenamido)ethyl)trimethyl-, iodide",C[N+](C)(C)CCNC(=O)CCCCCCCCC=C.[I-],,,,,,
8769,58770,"N,N,N-Trimethyl-2-[(10-undecenoyl)amino]ethanaminium",C[N+](C)(C)CCNC(=O)CCCCCCCCC=C,,,,,,
8770,58771,3-(1-Azabicyclo(2.2.2)oct-2-ene)methyl alpha-cyclopentyl-alpha-phenylglycolate hydrochloride,C1CCC(C1)C(C2=CC=CC=C2)(C(=O)OCC3=C[NH+]4CCC3CC4)O.[Cl-],,,,,,
8771,58772,1-Azabicyclo[2.2.2]oct-2-en-3-ylmethyl 2-cyclopentyl-2-hydroxy-2-phenylacetate,C1CCC(C1)C(C2=CC=CC=C2)(C(=O)OCC3=CN4CCC3CC4)O,,,,,,
8772,58773,alpha-Cyclopentylmandelic acid 1-benzyl-3-pyrrolidinyl ester,C1CCC(C1)C(C2=CC=CC=C2)(C(=O)OC3CCN(C3)CC4=CC=CC=C4)O,,,,,,
8773,58774,alpha-Cyclopentylmandelic acid 1-butyl-3-pyrrolidinyl ester hydrochloride,CCCC[NH+]1CCC(C1)OC(=O)C(C2CCCC2)(C3=CC=CC=C3)O.[Cl-],,,,,,
8774,58775,(1-Butylpyrrolidin-3-yl) 2-cyclopentyl-2-hydroxy-2-phenylacetate,CCCCN1CCC(C1)OC(=O)C(C2CCCC2)(C3=CC=CC=C3)O,,,,,,
8775,58776,alpha-Cyclopentylmandelic acid 1-cyclohexyl-3-pyrrolidinyl ester hydrochloride,C1CCC(CC1)[NH+]2CCC(C2)OC(=O)C(C3CCCC3)(C4=CC=CC=C4)O.[Cl-],,,,,,
8776,58777,(1-Cyclohexylpyrrolidin-3-yl) 2-cyclopentyl-2-hydroxy-2-phenylacetate,C1CCC(CC1)N2CCC(C2)OC(=O)C(C3CCCC3)(C4=CC=CC=C4)O,,,,,,
8777,58778,"1,3-Dimethyl-4-piperidyl phenylcyclopentylglycolate hydrochloride",CC1C[NH+](CCC1OC(=O)C(C2CCCC2)(C3=CC=CC=C3)O)C.[Cl-],,,,,,
8778,58779,"(1,3-Dimethylpiperidin-4-yl) 2-cyclopentyl-2-hydroxy-2-phenylacetate",CC1CN(CCC1OC(=O)C(C2CCCC2)(C3=CC=CC=C3)O)C,,,,,,
8779,58780,"2-(2,2-Dimethyl-1-pyrrolidinyl)ethyl alpha-cyclopentylmandelate hydrochloride",CC1(CCC[NH+]1CCOC(=O)C(C2CCCC2)(C3=CC=CC=C3)O)C.[Cl-],,,,,,
8780,58781,"2-(2,2-Dimethylpyrrolidin-1-yl)ethyl 2-cyclopentyl-2-hydroxy-2-phenylacetate",CC1(CCCN1CCOC(=O)C(C2CCCC2)(C3=CC=CC=C3)O)C,,,,,,
8781,58782,2-Ethyl-3-quinuclidyl alpha-cyclopentyl-alpha-phenylglycolate,CCC1C(C2CCN1CC2)OC(=O)C(C3CCCC3)(C4=CC=CC=C4)O,,,,,,
8782,58783,9-Methyl-3-beta-granatanyl phenylcyclopentylglycolate hydrochloride,C[NH+]1C2CCCC1CC(C2)OC(=O)C(C3CCCC3)(C4=CC=CC=C4)O.[Cl-],,,,,,
8783,58784,(9-Methyl-9-azabicyclo[3.3.1]nonan-3-yl) 2-cyclopentyl-2-hydroxy-2-phenylacetate,CN1C2CCCC1CC(C2)OC(=O)C(C3CCCC3)(C4=CC=CC=C4)O,,,,,,
8784,58785,9-Methyl-3-alpha-granatanyl phenylcyclopentylglycolate-p-toluene-sulfonate,CC1=CC=C(C=C1)S(=O)(=O)[O-].C[NH+]1C2CCCC1CC(C2)OC(=O)C(C3CCCC3)(C4=CC=CC=C4)O,,,,,,
8785,58786,2-(1-Methylpiperidine)methyl alpha-cyclopentyl-alpha-phenylglycolate hydrochloride,C[NH+]1CCCCC1COC(=O)C(C2CCCC2)(C3=CC=CC=C3)O.[Cl-],,,,,,
8786,58787,(1-Methylpiperidin-2-yl)methyl 2-cyclopentyl-2-hydroxy-2-phenylacetate,CN1CCCCC1COC(=O)C(C2CCCC2)(C3=CC=CC=C3)O,,,,,,
8787,58788,alpha-Cyclopentylmandelic acid (1-methyl-4-piperidyl)methyl ester hydrochloride,C[NH+]1CCC(CC1)COC(=O)C(C2CCCC2)(C3=CC=CC=C3)O.[Cl-],,,,,,
8788,58789,(1-Methylpiperidin-4-yl)methyl 2-cyclopentyl-2-hydroxy-2-phenylacetate,CN1CCC(CC1)COC(=O)C(C2CCCC2)(C3=CC=CC=C3)O,,,,,,
8789,58790,"Mandelic acid, alpha-cyclopentyl-, (1-methyl-3-pyrrolin-3-yl)methyl ester, hydrochloride",C[NH+]1CC=C(C1)COC(=O)C(C2CCCC2)(C3=CC=CC=C3)O.[Cl-],,,,,,
8790,58791,"(1-Methyl-2,5-dihydropyrrol-3-yl)methyl 2-cyclopentyl-2-hydroxy-2-phenylacetate",CN1CC=C(C1)COC(=O)C(C2CCCC2)(C3=CC=CC=C3)O,,,,,,
8791,58792,"alpha-Cyclopentylmandelic acid 2-(1-methyl-1,2,3,6-tetrahydro-4-pyridyl)ethyl ester HCl",C[NH+]1CCC(=CC1)CCOC(=O)C(C2CCCC2)(C3=CC=CC=C3)O.[Cl-],,,,,,
8792,58793,"2-(1-methyl-3,6-dihydro-2H-pyridin-4-yl)ethyl 2-cyclopentyl-2-hydroxy-2-phenylacetate",CN1CCC(=CC1)CCOC(=O)C(C2CCCC2)(C3=CC=CC=C3)O,,,,,,
8793,58794,2-(1-Azoniabicyclo[2.2.2]octan-3-ylidene)ethyl 2-cyclopentyl-2-hydroxy-2-phenylacetate;chloride,C1CCC(C1)C(C2=CC=CC=C2)(C(=O)OCC=C3C[NH+]4CCC3CC4)O.[Cl-],,,,,,
8794,58795,2-(1-Azabicyclo[2.2.2]octan-3-ylidene)ethyl 2-cyclopentyl-2-hydroxy-2-phenylacetate,C1CCC(C1)C(C2=CC=CC=C2)(C(=O)OCC=C3CN4CCC3CC4)O,,,,,,
8795,58796,"Mandelic acid, alpha-cyclopropyl-, (1-azabicyclo(2.2.2)oct-2-en-3-yl)methyl ester, hydrochloride",C1CC1C(C2=CC=CC=C2)(C(=O)OCC3=C[NH+]4CCC3CC4)O.[Cl-],,,,,,
8796,58797,1-Azabicyclo[2.2.2]oct-2-en-3-ylmethyl 2-cyclopropyl-2-hydroxy-2-phenylacetate,C1CC1C(C2=CC=CC=C2)(C(=O)OCC3=CN4CCC3CC4)O,,,,,,
8797,58798,cis-2-Methyl-3-quinuclidyl phenyl(cyclopropyl)glycolate (mixed isomers),CC1C(C2CCN1CC2)OC(=O)C(C3CC3)(C4=CC=CC=C4)O,,,,,,
8798,58799,"alpha-Cyclopropylmandelic acid (1-methyl-1,2,3,6-tetrahydro-4-pyridyl)methyl ester HCl",C[NH+]1CCC(=CC1)COC(=O)C(C2CC2)(C3=CC=CC=C3)O.[Cl-],,,,,,
8799,58800,"(1-methyl-3,6-dihydro-2H-pyridin-4-yl)methyl 2-cyclopropyl-2-hydroxy-2-phenylacetate",CN1CCC(=CC1)COC(=O)C(C2CC2)(C3=CC=CC=C3)O,,,,,,
8800,58801,"1-Methyl-4-piperidyl 3,4-dimethoxyphenyl(isopropenyl)glycolate",CC(=C)C(C1=CC(=C(C=C1)OC)OC)(C(=O)OC2CCN(CC2)C)O,,,,,,
8801,58802,"3-Quinuclidyl 3,4-dimethoxyphenyl(isopropenyl)glycolate",CC(=C)C(C1=CC(=C(C=C1)OC)OC)(C(=O)OC2CN3CCC2CC3)O,,,,,,
8802,58803,alpha-Isopropenylmandelic acid 2-methyl-3-quinuclidinyl ester,CC1C(C2CCN1CC2)OC(=O)C(C3=CC=CC=C3)(C(=C)C)O,,,,,,
8803,58804,"Mandelic acid, alpha-isopropenyl-, 1-methyl-1,2,5,6-tetrahydro-3-pyridylmethyl ester",CC(=C)C(C1=CC=CC=C1)(C(=O)OCC2=CN(CCC2)C)O,,,,,,
8804,58805,"1,2,2,6-Tetramethyl-4-piperidyl phenyl(isopropenyl)glycolate",CC1CC(CC(N1C)(C)C)OC(=O)C(C2=CC=CC=C2)(C(=C)C)O,,,,,,
8805,58806,"Mandelic acid, alpha-isopropyl-, 1,4-dimethyl-1,2,5,6-tetrahydro-3-pyridylmethyl ester, hydrochloride",CC1=C(C[NH+](CC1)C)COC(=O)C(C2=CC=CC=C2)(C(C)C)O.[Cl-],,,,,,
8806,58807,"(1,4-dimethyl-3,6-dihydro-2H-pyridin-5-yl)methyl 2-hydroxy-3-methyl-2-phenylbutanoate",CC1=C(CN(CC1)C)COC(=O)C(C2=CC=CC=C2)(C(C)C)O,,,,,,
8807,58808,(2-Methyl-1-azabicyclo[2.2.2]octan-3-yl) 2-hydroxy-3-methyl-2-phenylbutanoate,CC1C(C2CCN1CC2)OC(=O)C(C3=CC=CC=C3)(C(C)C)O,,,,,,
8808,58809,"Mandelic acid, alpha-isopropyl-, 1-methyl-1,2,5,6-tetrahydro-3-pyridylmethyl ester, hydrochloride",CC(C)C(C1=CC=CC=C1)(C(=O)OCC2=CCC[NH+](C2)C)O.[Cl-],,,,,,
8809,58810,"(1-methyl-3,6-dihydro-2H-pyridin-5-yl)methyl 2-hydroxy-3-methyl-2-phenylbutanoate",CC(C)C(C1=CC=CC=C1)(C(=O)OCC2=CCCN(C2)C)O,,,,,,
8810,58811,2-Pyridinemethyl alpha-isopropyl-alpha-phenylglycolate,CC(C)C(C1=CC=CC=C1)(C(=O)OCC2=CC=CC=N2)O,,,,,,
8811,58812,"MANDELIC ACID, alpha-ISOPROPYL-, 2-QUINUCLIDINYLMETHYL ESTER, HYDROCHLORIDE",CC(C)C(C1=CC=CC=C1)(C(=O)OCC2CC3CC[NH+]2CC3)O.[Cl-],,,,,,
8812,58813,1-Azabicyclo[2.2.2]octan-2-ylmethyl 2-hydroxy-3-methyl-2-phenylbutanoate,CC(C)C(C1=CC=CC=C1)(C(=O)OCC2CC3CCN2CC3)O,,,,,,
8813,58814,CID 58814,CC(C)C=CC(C1=CC=CC=C1)(C(=O)OC2CCN(CC2)C)O,,,,,,
8814,58815,1-Azabicyclo[2.2.2]octan-3-yl 2-hydroxy-5-methyl-2-phenylhex-3-enoate,CC(C)C=CC(C1=CC=CC=C1)(C(=O)OC2CN3CCC2CC3)O,,,,,,
8815,58816,(2-Methyl-1-azabicyclo[2.2.2]octan-3-yl) 2-hydroxy-5-methyl-2-phenylhex-5-en-3-ynoate,CC1C(C2CCN1CC2)OC(=O)C(C#CC(=C)C)(C3=CC=CC=C3)O,,,,,,
8816,58817,"MANDELIC ACID, alpha-(3-METHYLBUT-1-YN-3-ENYL)-, 3-QUINUCLIDINYL ESTER",CC(=C)C#CC(C1=CC=CC=C1)(C(=O)OC2CN3CCC2CC3)O,,,,,,
8817,58818,L-(+)-2-alpha-Tropanyl phenyl(3-methyl-3-buten-1-ynyl)glycolate,CC(=C)C#C[C@](C1=CC=CC=C1)(C(=O)OC2CCC3CCC2N3C)O,,,,,,
8818,58819,1-Methyl-4-piperidyl phenyl(3-methyl-1-pentynyl)glycolate,CCC(C)C#CC(C1=CC=CC=C1)(C(=O)OC2CCN(CC2)C)O,,,,,,
8819,58820,3-Quinuclidyl phenyl(3-methyl-1-pentynyl)glycolate A,CCC(C)C#CC(C1=CC=CC=C1)(C(=O)OC2CN3CCC2CC3)O,,,,,,
8820,58821,3-Quinuclidyl phenyl(1-pentynyl)glycolate,CCCC#CC(C1=CC=CC=C1)(C(=O)OC2CN3CCC2CC3)O,,,,,,
8821,58822,1-Methyl-4-piperidyl phenyl(2-phenylethyl)glycolate,CN1CCCC(C1)OC(=O)C(CCC2=CC=CC=C2)(C3=CC=CC=C3)O,,,,,,
8822,58823,3-Quinuclidyl phenyl(2-phenylethyl)glycolate,C1CN2CCC1C(C2)OC(=O)C(CCC3=CC=CC=C3)(C4=CC=CC=C4)O,,,,,,
8823,58824,(1-Methylpiperidin-4-yl) 2-hydroxy-2-phenylpent-3-enoate,CC=CC(C1=CC=CC=C1)(C(=O)OC2CCN(CC2)C)O,,,,,,
8824,58825,1-Azabicyclo[2.2.2]octan-3-yl 2-hydroxy-2-phenylpent-3-enoate,CC=CC(C1=CC=CC=C1)(C(=O)OC2CN3CCC2CC3)O,,,,,,
8825,58826,alpha-(1-Propynyl)mandelic acid 1-methyl-3-pyrrolidinyl ester,CC#CC(C1=CC=CC=C1)(C(=O)OC2CCN(C2)C)O,,,,,,
8826,58827,2-Methyl-3-quinuclidyl phenyl(1-propynyl)glycolate,CC#CC(C1=CC=CC=C1)(C(=O)OC2C(N3CCC2CC3)C)O,,,,,,
8827,58828,"MANDELIC ACID, alpha-(1-PROPYNYL)-, 3-QUINUCLIDINYL ESTER",CC#CC(C1=CC=CC=C1)(C(=O)OC2CN3CCC2CC3)O,,,,,,
8828,58829,"1-Methyl-4-piperidyl phenyl(3,3,3-trifluoropropynyl)glycolate",CN1CCC(CC1)OC(=O)C(C#CC(F)(F)F)(C2=CC=CC=C2)O,,,,,,
8829,58830,2-Monoiododibenzo-P-dioxin,C1=CC=C2C(=C1)OC3=C(O2)C=C(C=C3)I,,,,,,
8830,58831,"BENZOIC ACID, p-(5-(p-AMINOPHENOXY)PENTYLOXY)-, HYDROCHLORIDE",C1=CC(=CC=C1C(=O)O)OCCCCCOC2=CC=C(C=C2)[NH3+].[Cl-],,,,,,
8831,58832,4-[5-(4-Aminophenoxy)pentoxy]benzoic acid,C1=CC(=CC=C1C(=O)O)OCCCCCOC2=CC=C(C=C2)N,,,,,,
8832,58833,"Acetic acid, dicyclohexylethoxy-",CCOC(C1CCCCC1)(C2CCCCC2)C(=O)O,,,,,,
8833,58834,"Pyridine, 2,6-dimethyl-4-(alpha-(2-(dimethylamino)ethyl)benzyl)-",CC1=CC(=CC(=N1)C)C(CCN(C)C)C2=CC=CC=C2,,,,,,
8834,58835,2-ethoxyethyl N-[4-(2-morpholin-4-ylethoxy)phenyl]carbamate,CCOCCOC(=O)NC1=CC=C(C=C1)OCCN2CCOCC2,,,,,,
8835,58836,"AMMONIUM, (p-PHENYLENEDIMETHYLENE)BIS(BENZYLDIETHYL-, DIBROMIDE",CC[N+](CC)(CC1=CC=CC=C1)CC2=CC=C(C=C2)C[N+](CC)(CC)CC3=CC=CC=C3.[Br-].[Br-],,,,,,
8836,58837,Benzyl-[[4-[[benzyl(diethyl)azaniumyl]methyl]phenyl]methyl]-diethylazanium,CC[N+](CC)(CC1=CC=CC=C1)CC2=CC=C(C=C2)C[N+](CC)(CC)CC3=CC=CC=C3,,,,,,
8837,58838,2-Ethyl-N-(2-morpholinoethyl)-2-phenyl-malonamic acid ethyl ester,CCC(C1=CC=CC=C1)(C(=O)NCCN2CCOCC2)C(=O)OCC,,,,,,
8838,58839,2-Ethyl-N-(3-morpholinopropyl)-2-phenyl-malonamic acid ethyl ester,CCC(C1=CC=CC=C1)(C(=O)NCCCN2CCOCC2)C(=O)OCC,,,,,,
8839,58840,"Malonic acid, ((bis(2-chloroethyl)amino)methyl)nitro-, diethyl ester",CCOC(=O)C(CN(CCCl)CCCl)(C(=O)OCC)[N+](=O)[O-],,,,,,
8840,58841,"8-(3,3-Bis(ethoxycarbonyl)propyl)-3-methyl-4-oxo-1-phenyl-1,3,8-triazaspiro(4,5)decane HCl",CCOC(=O)C(CCN1CCC2(CC1)C[NH+](CN2C3=CC=CC=C3)C)C(=O)OCC.[Cl-],,,,,,
8841,58842,"Diethyl 2-[2-(3-methyl-1-phenyl-1,3,8-triazaspiro[4.5]decan-8-yl)ethyl]propanedioate",CCOC(=O)C(CCN1CCC2(CC1)CN(CN2C3=CC=CC=C3)C)C(=O)OCC,,,,,,
8842,58843,3-[1-(4-Methylphenyl)propoxy]-3-oxopropanoic acid,CCC(C1=CC=C(C=C1)C)OC(=O)CC(=O)O,,,,,,
8843,58844,"MALONONITRILE, (p-(p-CHLOROBENZYLTHIO)BENZYLIDENE)-",C1=CC(=CC=C1CSC2=CC=C(C=C2)C=C(C#N)C#N)Cl,,,,,,
8844,58845,"2-[3-(2,6-Dichlorophenyl)prop-2-enylidene]propanedinitrile",C1=CC(=C(C(=C1)Cl)C=CC=C(C#N)C#N)Cl,,,,,,
8845,58846,"(3,4-Dihydro-2,5-dimethyl-2H-pyran-2-yl)methylenemalononitrile",CC1=COC(CC1)(C)C=C(C#N)C#N,,,,,,
8846,58847,"Malononitrile, (N,N-diisopropylaminomethylene)-",CC(C)N(C=C(C#N)C#N)C(C)C,,,,,,
8847,58848,"(2,5-Dimethyl-6-ethoxy-tetrahydro-2H-pyran-2-yl)methylenemalononitrile",CCOC1C(CCC(O1)(C)C=C(C#N)C#N)C,,,,,,
8848,58849,"Malononitrile, 1-((hexahydro-1H-azepin-1-YL)methylene)-",C1CCCN(CC1)C=C(C#N)C#N,,,,,,
8849,58850,"Malononitrile, (2-hydroxy-1-(naphthylmethylene))-",C1=CC=C2C(=C1)C=CC(=C2C=C(C#N)C#N)O,,,,,,
8850,58851,"Malononitrile, (6-(2-hydroxy-3,3,3-trifluoro-2-trifluoromethylpropyl)-2-pyridylmethylene)-",C1=CC(=NC(=C1)C=C(C#N)C#N)CC(C(F)(F)F)(C(F)(F)F)O,,,,,,
8851,58852,"Malononitrile, (3-indolyl)propenylidene-",C1=CC=C2C(=C1)C(=CN2)CCC=C(C#N)C#N,,,,,,
8852,58853,"Malononitrile, (4-methoxy-2-methylphenyl)hydrazono-",CC1=C(C=CC(=C1)OC)NN=C(C#N)C#N,,,,,,
8853,58854,"Malononitrile, (1-methyl-4-piperidinyl)-, hydrochloride, dihydrate",C[NH+]1CCC(CC1)C(C#N)C#N.[Cl-],,,,,,
8854,58855,2-(1-Methylpiperidin-4-yl)propanedinitrile,CN1CCC(CC1)C(C#N)C#N,,,,,,
8855,58856,"Malononitrile, (5-nitro-1-naphthyl)methylene-",C1=CC(=C2C=CC=C(C2=C1)[N+](=O)[O-])C=C(C#N)C#N,,,,,,
8856,58857,"Malononitrile, (5-nitrovanillylidene)-",COC1=CC(=CC(=C1O)[N+](=O)[O-])C=C(C#N)C#N,,,,,,
8857,58858,"Malononitrile, (N-(2-oxazolin-2-yl)-N-(5,6,7,8-tetrahydro-1-naphthyl)aminomethyl)-",C1CCC2=C(C1)C=CC=C2N(CC(C#N)C#N)C3=NCCO3,,,,,,
8858,58859,"Malononitrile, (3-thenylidene)-",C1=CSC=C1C=C(C#N)C#N,,,,,,
8859,58860,"Malononitrile, (3,4,5-trimethoxyphenyl)hydrazono-",COC1=CC(=CC(=C1OC)OC)NN=C(C#N)C#N,,,,,,
8860,58861,"Mandelic acid, alpha-benzyl-, 2-(3-azabicyclo(3.2.2)non-3-yl)ethyl ester, hydrochloride",C1CC2CCC1C[NH+](C2)CCOC(=O)C(CC3=CC=CC=C3)(C4=CC=CC=C4)O.[Cl-],,,,,,
8861,58862,"2-(3-Azabicyclo[3.2.2]nonan-3-yl)ethyl 2-hydroxy-2,3-diphenylpropanoate",C1CC2CCC1CN(C2)CCOC(=O)C(CC3=CC=CC=C3)(C4=CC=CC=C4)O,,,,,,
8862,58863,2-(Diethylamino)ethyl benzylphenylglycolate hydrochloride,CC[NH+](CC)CCOC(=O)C(CC1=CC=CC=C1)(C2=CC=CC=C2)O.[Cl-],,,,,,
8863,58864,"2-(Diethylamino)ethyl 2-hydroxy-2,3-diphenylpropanoate",CCN(CC)CCOC(=O)C(CC1=CC=CC=C1)(C2=CC=CC=C2)O,,,,,,
8864,58865,2-(Dimethylamino)ethyl benzylphenylglycolate hydrochloride,C[NH+](C)CCOC(=O)C(CC1=CC=CC=C1)(C2=CC=CC=C2)O.[Cl-],,,,,,
8865,58866,"2-(Dimethylamino)ethyl 2-hydroxy-2,3-diphenylpropanoate",CN(C)CCOC(=O)C(CC1=CC=CC=C1)(C2=CC=CC=C2)O,,,,,,
8866,58867,1-Methyl-4-piperidyl benzylphenylglycolate hydrochloride,C[NH+]1CCC(CC1)OC(=O)C(CC2=CC=CC=C2)(C3=CC=CC=C3)O.[Cl-],,,,,,
8867,58868,"(1-Methylpiperidin-4-yl) 2-hydroxy-2,3-diphenylpropanoate",CN1CCC(CC1)OC(=O)C(CC2=CC=CC=C2)(C3=CC=CC=C3)O,,,,,,
8868,58869,alpha-Benzylmandelic acid (1-methyl-3-piperidyl)methyl ester,CN1CCCC(C1)COC(=O)C(CC2=CC=CC=C2)(C3=CC=CC=C3)O,,,,,,
8869,58870,alpha-Benzylmandelic acid 2-piperidinoethyl ester hydrochloride,C1CC[NH+](CC1)CCOC(=O)C(CC2=CC=CC=C2)(C3=CC=CC=C3)O.[Cl-],,,,,,
8870,58871,"2-Piperidin-1-ylethyl 2-hydroxy-2,3-diphenylpropanoate",C1CCN(CC1)CCOC(=O)C(CC2=CC=CC=C2)(C3=CC=CC=C3)O,,,,,,
8871,58872,alpha-Benzylmandelic acid 3-quinuclidinyl ester hydrochloride,C1C[NH+]2CCC1C(C2)OC(=O)C(CC3=CC=CC=C3)(C4=CC=CC=C4)O.[Cl-],,,,,,
8872,58873,"1-Azabicyclo[2.2.2]octan-3-yl 2-hydroxy-2,3-diphenylpropanoate",C1CN2CCC1C(C2)OC(=O)C(CC3=CC=CC=C3)(C4=CC=CC=C4)O,,,,,,
8873,58874,CID 58874,CCC=CC(C1=CC=CC=C1)(C(=O)OC2CCN(CC2)C)O,,,,,,
8874,58875,CID 58875,CCC=CC(C1=CC=CC=C1)(C(=O)OC2CN3CCC2CC3)O,,,,,,
8875,58876,3-Quinuclidyl phenyl(1-butynyl)glycolate,CCC#CC(C1=CC=CC=C1)(C(=O)OC2CN3CCC2CC3)O,,,,,,
8876,58877,8-Methyl-8-azabicyclo[3.2.1]oct-3-yl 2-hydroxy-2-phenyl-3-hexynoate,CCC#CC(C1=CC=CC=C1)(C(=O)OC2CC3CCC(C2)N3C)O,,,,,,
8877,58878,"Mandelic acid, alpha-cyclobutyl-, 1,4-dimethyl-1,2,3,6-tetrahydro-3-pyridylmethyl ester, hydrochloride",CC1=CC[NH+](CC1COC(=O)C(C2CCC2)(C3=CC=CC=C3)O)C.[Cl-],,,,,,
8878,58879,"(1,4-dimethyl-3,6-dihydro-2H-pyridin-3-yl)methyl 2-cyclobutyl-2-hydroxy-2-phenylacetate",CC1=CCN(CC1COC(=O)C(C2CCC2)(C3=CC=CC=C3)O)C,,,,,,
8879,58880,"Mandelic acid, alpha-cyclobutyl-, (1-methyl-1,2,3,6-tetrahydro-4-pyridyl)methyl ester, hydrochloride",C[NH+]1CCC(=CC1)COC(=O)C(C2CCC2)(C3=CC=CC=C3)O.[Cl-],,,,,,
8880,58881,"(1-methyl-3,6-dihydro-2H-pyridin-4-yl)methyl 2-cyclobutyl-2-hydroxy-2-phenylacetate",CN1CCC(=CC1)COC(=O)C(C2CCC2)(C3=CC=CC=C3)O,,,,,,
8881,58882,"MANDELIC ACID, alpha-(1-CYCLOPENTENYL)-, 1-METHYL-3-PYRROLIN-2-YLMETHYL ESTER",CN1CC=CC1COC(=O)C(C2=CCCC2)(C3=CC=CC=C3)O,,,,,,
8882,58883,2-Methyl-3-quinuclidinyl phenyl(1-cyclopentenyl)glycolate,CC1C(C2CCN1CC2)OC(=O)C(C3=CCCC3)(C4=CC=CC=C4)O,,,,,,
8883,58884,"Mandelic acid, alpha-(1-cyclopentenyl)-, (1-methyl-1,2,5,6-tetrahydro-3-pyridyl)methyl ester",CN1CCC=C(C1)COC(=O)C(C2=CCCC2)(C3=CC=CC=C3)O,,,,,,
8884,58885,"MANDELIC ACID, alpha-(1-CYCLOPENTENYL)-, 3-QUINUCLIDINYL ESTER",C1CC=C(C1)C(C2=CC=CC=C2)(C(=O)OC3CN4CCC3CC4)O,,,,,,
8885,58886,3-Hydroxy-2-phenylhexanoic acid 2-(diethylamino)ethyl ester hydrochloride,CCCC(C(C1=CC=CC=C1)C(=O)OCC[NH+](CC)CC)O.[Cl-],,,,,,
8886,58887,2-(Diethylamino)ethyl 3-hydroxy-2-phenylhexanoate,CCCC(C(C1=CC=CC=C1)C(=O)OCCN(CC)CC)O,,,,,,
8887,58888,"2-Naphthol, 1-((2,4-dimethylpiperidino)methyl)-",CC1CCN(C(C1)C)CC2=C(C=CC3=CC=CC=C32)O,,,,,,
8888,58889,"2-Naphthol, 1-((4-ethylpiperidino)methyl)-",CCC1CCN(CC1)CC2=C(C=CC3=CC=CC=C32)O,,,,,,
8889,58890,"ANILINE, p-(5-(p-TOLYLOXY)PENTYLOXY)-, HYDROCHLORIDE",CC1=CC=C(C=C1)OCCCCCOC2=CC=C(C=C2)[NH3+].[Cl-],,,,,,
8890,58891,4-[5-(4-Methylphenoxy)pentoxy]aniline,CC1=CC=C(C=C1)OCCCCCOC2=CC=C(C=C2)N,,,,,,
8891,58892,"BENZYL ALCOHOL, alpha-(4-(4-AMINO-2-METHOXYPHENOXY)BUTYL)-",COC1=C(C=CC(=C1)N)OCCCCC(C2=CC=CC=C2)O,,,,,,
8892,58893,"2-(Diethylamino)-N,N-diphenylacetamide",CCN(CC)CC(=O)N(C1=CC=CC=C1)C2=CC=CC=C2,,,,,,
8893,58894,"Malonic acid, 2-acetamido-2-((4,4-dimethyl-4H-1,3-benzothiazin-2-yl)methyl)-, diethyl ester",CCOC(=O)C(CC1=NC(C2=CC=CC=C2S1)(C)C)(C(=O)OCC)NC(=O)C,,,,,,
8894,58895,"Cyclopropanecarboxamide, N-((1-(1,4-benzodioxan-2-ylmethyl)-4-phenyl-4-piperidyl)methyl)-, hydrochloride",C1CC1C(=O)NCC2(CC[NH+](CC2)CC3COC4=CC=CC=C4O3)C5=CC=CC=C5.[Cl-],,,,,,
8895,58896,"N-[[1-(2,3-dihydro-1,4-benzodioxin-3-ylmethyl)-4-phenylpiperidin-4-yl]methyl]cyclopropanecarboxamide",C1CC1C(=O)NCC2(CCN(CC2)CC3COC4=CC=CC=C4O3)C5=CC=CC=C5,,,,,,
8896,58897,2-((2-Hydroxypropyl)amino)benzamide,CC(CNC1=CC=CC=C1C(=O)N)O,,,,,,
8897,58898,"Benzamide, 2-((2-butoxyethyl)amino)-",CCCCOCCNC1=CC=CC=C1C(=O)N,,,,,,
8898,58899,"Benzamide, 2-((2-butoxyethyl)amino)-5-chloro-",CCCCOCCNC1=C(C=C(C=C1)Cl)C(=O)N,,,,,,
8899,58900,"Benzamide, 5-chloro-2-((2-hydroxyethyl)amino)-",C1=CC(=C(C=C1Cl)C(=O)N)NCCO,,,,,,
8900,58901,Clazuril,C1=CC(=CC=C1C(C#N)C2=C(C=C(C=C2)N3C(=O)NC(=O)C=N3)Cl)Cl,,,,,,
8901,58902,"Benzeneacetonitrile, 2,6-dichloro-alpha-(4-chlorophenyl)-3-(4,5-dihydro-3,5-dioxo-1,2,4-triazin-2(3H)-yl)-",C1=CC(=CC=C1C(C#N)C2=C(C=CC(=C2Cl)N3C(=O)NC(=O)C=N3)Cl)Cl,,,,,,
8902,58903,"17-beta,19-Dihydroxyandrosta-1,4-dien-3-one 19-acetate",CC(=O)OC[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)CCC4=CC(=O)C=C[C@]34C,,,,,,
8903,58904,CID 58904,C[C@]12CC[C@@H](CC1=CC[C@@H]3[C@@H]2CC[C@]4([C@H]3CC[C@]4(C)O)C)OC(=O)CCC(=O)[O-].[Na+],,,,,,
8904,58905,"4-[[(3S,8R,9S,10R,13S,14S,17S)-17-hydroxy-10,13,17-trimethyl-1,2,3,4,7,8,9,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-3-yl]oxy]-4-oxobutanoic acid",C[C@]12CC[C@@H](CC1=CC[C@@H]3[C@@H]2CC[C@]4([C@H]3CC[C@]4(C)O)C)OC(=O)CCC(=O)O,,,,,,
8905,58906,CID 58906,C[C@]12CC[C@@H](CC1=CC[C@@H]3[C@@H]2CC[C@]4([C@H]3CC[C@]4(C)O)C)OC(=O)C5=CC=CC=C5C(=O)[O-].[Na+],,,,,,
8906,58907,"2-[[(3S,8R,9S,10R,13S,14S,17S)-17-hydroxy-10,13,17-trimethyl-1,2,3,4,7,8,9,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-3-yl]oxycarbonyl]benzoic acid",C[C@]12CC[C@@H](CC1=CC[C@@H]3[C@@H]2CC[C@]4([C@H]3CC[C@]4(C)O)C)OC(=O)C5=CC=CC=C5C(=O)O,,,,,,
8907,58908,4-Chloro-2-((p-chlorophenyl)thio)-N-(3-(dimethylamino)propyl)aniline hydrochloride,C[NH+](C)CCCNC1=C(C=C(C=C1)Cl)SC2=CC=C(C=C2)Cl.[Cl-],,,,,,
8908,58909,"N-[4-chloro-2-(4-chlorophenyl)sulfanylphenyl]-N',N'-dimethylpropane-1,3-diamine",CN(C)CCCNC1=C(C=C(C=C1)Cl)SC2=CC=C(C=C2)Cl,,,,,,
8909,58910,"Aniline, 2,5-dimethoxy-N-(2-oxazolin-2-YL)-",COC1=CC(=C(C=C1)OC)NC2=NCCO2,,,,,,
8910,58911,"ANILINE, p-ETHYL-N-(2-OXAZOLIN-2-YL)-",CCC1=CC=C(C=C1)NC2=NCCO2,,,,,,
8911,58912,"ANILINE, o-METHYLTHIO-N-(2-OXAZOLIN-2-YL)-",CSC1=CC=CC=C1NC2=NCCO2,,,,,,
8912,58913,"3,5-Dibromo-4-[2-(diethylamino)ethoxy]phenyl 2-(2,4,6-trimethylphenyl)-3-benzofuranyl ketone",CCN(CC)CCOC1=C(C=C(C=C1Br)C(=O)C2=C(OC3=CC=CC=C32)C4=C(C=C(C=C4C)C)C)Br,,,,,,
8913,58914,"4-[2-(Diethylamino)ethoxy]-3,5-diiodophenyl 2-(2,4,6-trimethylphenyl)-3-benzofuranyl ketone",CCN(CC)CCOC1=C(C=C(C=C1I)C(=O)C2=C(OC3=CC=CC=C32)C4=C(C=C(C=C4C)C)C)I,,,,,,
8914,58915,"4-[2-(Diethylamino)ethoxy]phenyl 2-(2,4,6-trimethylphenyl)-3-benzofuranyl ketone",CCN(CC)CCOC1=CC=C(C=C1)C(=O)C2=C(OC3=CC=CC=C32)C4=C(C=C(C=C4C)C)C,,,,,,
8915,58916,"Nitroso-4-acetyl-3,5-dimethylpiperazine",CC1CN(CC(N1N=O)C)C(=O)C,,,,,,
8916,58917,"Ketone, hydroxymethyl 3-benzyl-2-indolyl-",C1=CC=C(C=C1)CC2=C(NC3=CC=CC=C32)C(=O)CO,,,,,,
8917,58918,CID 58918,CC(=NN=C(C)C1=CNC2=CC=CC=C21)C3=CNC4=CC=CC=C43,,,,,,
8918,58919,"Ketone, methoxymethyl 3-benzyl-2-indolyl",COCC(=O)C1=C(C2=CC=CC=C2N1)CC3=CC=CC=C3,,,,,,
8919,58920,6-Acetylperimidine hydrochloride,CC(=O)C1=C2C=CC=C3C2=C(C=C1)[NH2+]C=N3.[Cl-],,,,,,
8920,58921,6-Acetyl-1H-perimidine,CC(=C1C=CC2=NC=NC3=CC=CC1=C23)O,,,,,,
8921,58922,9-Acetylperimidine hydrochloride,CC(=O)C1=C2C3=C(C=CC=C3[NH2+]C=N2)C=C1.[Cl-],,,,,,
8922,58923,1-Perimidin-4-ylideneethanol,CC(=C1C=CC2=C3C1=NC=NC3=CC=C2)O,,,,,,
8923,58924,2-Methylpiperidine beta-naphthoamide,CC1CCCCN1C(=O)C2=CC3=CC=CC=C3C=C2,,,,,,
8924,58925,3-(2-aminoethyl)-1H-indole-5-carbonitrile hydrochloride,C1=CC2=C(C=C1C#N)C(=CN2)CCN.Cl,,,,,,
8925,58926,3-(2-aminoethyl)-1H-indole-5-carbonitrile,C1=CC2=C(C=C1C#N)C(=CN2)CCN,,,,,,
8926,58927,3-[C-(azidomethyl)-N-hydroxycarbonimidoyl]-1H-indole-5-carbonitrile,C1=CC2=C(C=C1C#N)C(=CN2)C(=NO)CN=[N+]=[N-],,,,,,
8927,58928,"Indole-5-carbonitrile, 3-(diethylaminomethyl)-",CCN(CC)CC1=CNC2=C1C=C(C=C2)C#N,,,,,,
8928,58929,"Indole-5-carbonitrile, 3-(dipropylaminomethyl)-",CCCN(CCC)CC1=CNC2=C1C=C(C=C2)C#N,,,,,,
8929,58930,"Indole-5-carbonitrile, 3-(hexahydro-1H-azepinylethyl)-",C1CCCN(CC1)CCC2=CNC3=C2C=C(C=C3)C#N,,,,,,
8930,58931,3-(azepan-1-ylmethyl)-1H-indole-5-carbonitrile,C1CCCN(CC1)CC2=CNC3=C2C=C(C=C3)C#N,,,,,,
8931,58932,"Indole-5-carbonitrile, 3-(hexahydro-1(2H)-azocinylmethyl)-",C1CCCN(CCC1)CC2=CNC3=C2C=C(C=C3)C#N,,,,,,
8932,58933,"Indole-5-carbonitrile, 3-(4-methyl-1-piperazinylmethyl)-",CN1CCN(CC1)CC2=CNC3=C2C=C(C=C3)C#N,,,,,,
8933,58934,3-(Morpholinomethyl)-1H-indole-5-carbonitrile,C1COCCN1CC2=CNC3=C2C=C(C=C3)C#N,,,,,,
8934,58935,"Indole-5-carbonitrile, 3-(octahydro-1H-azonin-1-ylmethyl)-",C1CCCCN(CCC1)CC2=CNC3=C2C=C(C=C3)C#N,,,,,,
8935,58936,"Indole-5-carbonitrile, 3-(2-piperidinoethyl)-, hydrochloride",C1CCN(CC1)CCC2=CNC3=C2C=C(C=C3)C#N.Cl,,,,,,
8936,58937,3-(2-piperidin-1-ylethyl)-1H-indole-5-carbonitrile,C1CCN(CC1)CCC2=CNC3=C2C=C(C=C3)C#N,,,,,,
8937,58938,"N-(5,5-Dimethyl-2-oxotetrahydro-3-furyl)indole-3-carboxamide",CC1(CC(C(=O)O1)NC(=O)C2=CNC3=CC=CC=C32)C,,,,,,
8938,58939,"Indole, 5-chloro-3-(2-amino-3-methylbutyl)-",CC(C)C(CC1=CNC2=C1C=C(C=C2)Cl)N,,,,,,
8939,58940,"Indole, 3-((1-cyclopropylmethyl-2-piperidyl)methyl)-",C1CCN(C(C1)CC2=CNC3=CC=CC=C32)CC4CC4,,,,,,
8940,58941,"INDOLE, 1-(2-(DIMETHYLAMINO)ETHYL)-3-(p-ETHOXYBENZYL)-5-NITRO-",CCOC1=CC=C(C=C1)CC2=CN(C3=C2C=C(C=C3)[N+](=O)[O-])CCN(C)C,,,,,,
8941,58942,5-Dimethylamino-3-ethylindole hydrochloride,CCC1=CNC2=C1C=C(C=C2)[NH+](C)C.[Cl-],,,,,,
8942,58943,"3-ethyl-N,N-dimethyl-1H-indol-5-amine",CCC1=CNC2=C1C=C(C=C2)N(C)C,,,,,,
8943,58944,"Indole, 3-(2-(dimethylamino)ethyl)-, sulfosalicylate",C[NH+](C)CCC1=CNC2=CC=CC=C21.C1=CC(=C(C=C1S(=O)(=O)[O-])C(=O)O)O,,,,,,
8944,58945,"Indole, 5-((dimethylamino)methyl)-1-methyl-",CN1C=CC2=C1C=CC(=C2)CN(C)C,,,,,,
8945,58946,"N,N-Dimethyl-5-methoxy-alpha-methyltryptamine",CC(CC1=CNC2=C1C=C(C=C2)OC)N(C)C,,,,,,
8946,58947,CID 58947,C1OC2=C(O1)C=C(C=C2)NC(=O)ONC3=C4C=CC=CC4=NC3=O,,,,,,
8947,58948,"Indole, 2-(1,3-dithiolan-2-YL)-",C1CSC(S1)C2=CC3=CC=CC=C3N2,,,,,,
8948,58949,"2-INDOLEETHANOL, alpha,alpha-BIS(TRIFLUOROMETHYL)-",C1=CC=C2C(=C1)C=C(N2)CC(C(F)(F)F)(C(F)(F)F)O,,,,,,
8949,58950,3-(1-Ethyl-2-piperidyl)methylindole hydrochloride,CC[NH+]1CCCCC1CC2=CNC3=CC=CC=C32.[Cl-],,,,,,
8950,58951,3-[(1-ethylpiperidin-2-yl)methyl]-1H-indole,CCN1CCCCC1CC2=CNC3=CC=CC=C32,,,,,,
8951,58952,3-(azepan-1-ylmethyl)-5-nitro-1H-indole,C1CCCN(CC1)CC2=CNC3=C2C=C(C=C3)[N+](=O)[O-],,,,,,
8952,58953,"Indole, 3-(hexahydro-1(2H)-azocinylmethyl)-",C1CCCN(CCC1)CC2=CNC3=CC=CC=C32,,,,,,
8953,58954,"Indole, 3-(hexahydro-1(2H)-azocinylmethyl)-5-methoxy-",COC1=CC2=C(C=C1)NC=C2CN3CCCCCCC3,,,,,,
8954,58955,"Indole, 3-(hexahydro-1(2H)-azocinylmethyl)-5-nitro-",C1CCCN(CCC1)CC2=CNC3=C2C=C(C=C3)[N+](=O)[O-],,,,,,
8955,58956,"Indole, 3-(hexahydro-1(2H)-azocinylmethyl)-6-nitro-",C1CCCN(CCC1)CC2=CNC3=C2C=CC(=C3)[N+](=O)[O-],,,,,,
8956,58957,N-(n-Hexyl)-5-methoxy-alpha-methyltryptamine hydrochloride,CCCCCC[NH2+]CCCC1=CNC2=C1C=C(C=C2)OC.[Cl-],,,,,,
8957,58958,N-[3-(5-methoxy-1H-indol-3-yl)propyl]hexan-1-amine,CCCCCCNCCCC1=CNC2=C1C=C(C=C2)OC,,,,,,
8958,58959,5-Methylthio-N-hexyl-alpha-methyltryptamine,CCCCCCNCCCC1=CNC2=C1C=C(C=C2)SC,,,,,,
8959,58960,alpha-Aminomethyl-3-indolemethanol hydrochloride,C1=CC=C2C(=C1)C(=CN2)C(C[NH3+])O.[Cl-],,,,,,
8960,58961,2-amino-1-(1H-indol-3-yl)ethanol,C1=CC=C2C(=C1)C(=CN2)C(CN)O,,,,,,
8961,58962,"3-INDOLEMETHANOL, 5-NITRO-alpha-(TRIFLUOROMETHYL)-",C1=CC2=C(C=C1[N+](=O)[O-])C(=CN2)C(C(F)(F)F)O,,,,,,
8962,58963,3-Indolyl-4-piperidylcarbinol,C1CNCCC1C(C2=CNC3=CC=CC=C32)O,,,,,,
8963,58964,"Indole, 5-methoxy-3-(2-piperidylmethyl)-, hydrochloride",COC1=CC2=C(C=C1)NC=C2CC3CCCC[NH2+]3.[Cl-],,,,,,
8964,58965,5-methoxy-3-(piperidin-2-ylmethyl)-1H-indole,COC1=CC2=C(C=C1)NC=C2CC3CCCCN3,,,,,,
8965,58966,"Indole, 5-methoxy-3-(2-pyridylmethyl)-",COC1=CC2=C(C=C1)NC=C2CC3=CC=CC=N3,,,,,,
8966,58967,3-(1-Methyl-2-piperidyl)methylindole,CN1CCCCC1CC2=CNC3=CC=CC=C32,,,,,,
8967,58968,5-Nitro-3-morpholinoacetylindole,C1COCC[NH+]1CC(=O)C2=CNC3=C2C=C(C=C3)[N+](=O)[O-].[Cl-],,,,,,
8968,58969,2-morpholin-4-yl-1-(5-nitro-1H-indol-3-yl)ethanone,C1COCCN1CC(=O)C2=CNC3=C2C=C(C=C3)[N+](=O)[O-],,,,,,
8969,58970,6-nitro-3-(piperidin-1-ylmethyl)-1H-indole,C1CCN(CC1)CC2=CNC3=C2C=CC(=C3)[N+](=O)[O-],,,,,,
8970,58971,"Indole, 5-nitro-3-(trifluoroacetyl)-",C1=CC2=C(C=C1[N+](=O)[O-])C(=CN2)C(=O)C(F)(F)F,,,,,,
8971,58972,"Indole, 3-(2-(2-oxazolinylamino)ethyl)-",C1COC(=N1)NCCC2=CNC3=CC=CC=C32,,,,,,
8972,58973,"Indole, 3-(1-phenethyl-2-piperidylmethyl)-",C1CCN(C(C1)CC2=CNC3=CC=CC=C32)CCC4=CC=CC=C4,,,,,,
8973,58974,"NONANAMIDE, N-(p-CHLOROBENZYL)-",CCCCCCCCC(=O)NCC1=CC=C(C=C1)Cl,,,,,,
8974,58975,"N-(2,2-Dimethoxyethyl)-N-methylnonanamide",CCCCCCCCC(=O)N(C)CC(OC)OC,,,,,,
8975,58976,"N-(3,4-Dimethylbenzyl)nonanamide",CCCCCCCCC(=O)NCC1=CC(=C(C=C1)C)C,,,,,,
8976,58977,"Nonanamide, N-(2-furfuryl)-",CCCCCCCCC(=O)NCC1=CC=CO1,,,,,,
8977,58978,"NONANAMIDE, N-(m-METHOXYBENZYL)-",CCCCCCCCC(=O)NCC1=CC(=CC=C1)OC,,,,,,
8978,58979,"NONANAMIDE, N-(p-METHOXYBENZYL)-",CCCCCCCCC(=O)NCC1=CC=C(C=C1)OC,,,,,,
8979,58980,N-(2-Methoxyethyl)nonanamide,CCCCCCCCC(=O)NCCOC,,,,,,
8980,58981,N-(3-Methoxypropyl)nonanamide,CCCCCCCCC(=O)NCCCOC,,,,,,
8981,58982,"1,9-Nonanediamine, N,N'-bis(2-chloroethyl)-N,N'-dimethyl-",CN(CCCCCCCCCN(C)CCCl)CCCl,,,,,,
8982,58983,"N,N'-Bis(2-chloroethyl)-N,N'-dimethyl-1,9-nonanediamine N,N'-dioxide",C[N+](CCCCCCCCC[N+](C)(CCCl)[O-])(CCCl)[O-],,,,,,
8983,58984,"4,6-Nonanedione, 2,8-bis(trifluoromethyl)-2,8-dihydroxy-1,1,1,9,9,9-hexafluoro-",C(C(=O)CC(C(F)(F)F)(C(F)(F)F)O)C(=O)CC(C(F)(F)F)(C(F)(F)F)O,,,,,,
8984,58985,N-methoxy-N-methylnonanamide,CCCCCCCCC(=O)N(C)OC,,,,,,
8985,58986,"9-(2,2,3,3-Tetrafluorocyclobutyl)nonanoic acid",C1C(C(C1(F)F)(F)F)CCCCCCCCC(=O)O,,,,,,
8986,58987,"6-Benzyl-1,2,10-trimethoxy-6a-alpha-noraporphin-9-ol hydrochloride",COC1=C(C2=C3[C@H](CC4=C2C(=C(C=C4)O)OC)[NH+](CCC3=C1)CC5=CC=CC=C5)OC.[Cl-],,,,,,
8987,58988,"(6aS)-6-benzyl-1,2,11-trimethoxy-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinolin-10-ol",COC1=C(C2=C3[C@H](CC4=C2C(=C(C=C4)O)OC)N(CCC3=C1)CC5=CC=CC=C5)OC,,,,,,
8988,58989,"6a-alpha-Noraporphin-9-ol, 6-(2-(diethylamino)ethyl)-1,2,10-trimethoxy-, monohydrochloride",CCN(CC)CC[NH+]1CCC2=CC(=C(C3=C2[C@@H]1CC4=C3C(=C(C=C4)O)OC)OC)OC.[Cl-],,,,,,
8989,58990,"(6aS)-6-[2-(diethylamino)ethyl]-1,2,11-trimethoxy-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinolin-10-ol",CCN(CC)CCN1CCC2=CC(=C(C3=C2[C@@H]1CC4=C3C(=C(C=C4)O)OC)OC)OC,,,,,,
8990,58991,"6-(3-(Dimethylamino)propyl)-1,2,10-trimethoxy-6a-alpha-noraporphin-9-ol hydrochloride",CN(C)CCC[NH+]1CCC2=CC(=C(C3=C2[C@@H]1CC4=C3C(=C(C=C4)O)OC)OC)OC.[Cl-],,,,,,
8991,58992,"(6aS)-6-[3-(dimethylamino)propyl]-1,2,11-trimethoxy-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinolin-10-ol",CN(C)CCCN1CCC2=CC(=C(C3=C2[C@@H]1CC4=C3C(=C(C=C4)O)OC)OC)OC,,,,,,
8992,58993,"6a-alpha-Noraporphin-9-ol, 6-(2-morpholinoethyl)-1,2,10-trimethoxy-, monohydrochloride",COC1=C(C2=C3[C@H](CC4=C2C(=C(C=C4)O)OC)[NH+](CCC3=C1)CCN5CCOCC5)OC.[Cl-],,,,,,
8993,58994,"(6aS)-1,2,11-trimethoxy-6-(2-morpholin-4-ylethyl)-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinolin-10-ol",COC1=C(C2=C3[C@H](CC4=C2C(=C(C=C4)O)OC)N(CCC3=C1)CCN5CCOCC5)OC,,,,,,
8994,58995,"6a-alpha-Noraporphin-9-ol, 6-(2-piperidinoethyl)-1,2,10-trimethoxy-, monohydrochloride",COC1=C(C2=C3[C@H](CC4=C2C(=C(C=C4)O)OC)[NH+](CCC3=C1)CCN5CCCCC5)OC.[Cl-],,,,,,
8995,58996,"(6aS)-1,2,11-trimethoxy-6-(2-piperidin-1-ylethyl)-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinolin-10-ol",COC1=C(C2=C3[C@H](CC4=C2C(=C(C=C4)O)OC)N(CCC3=C1)CCN5CCCCC5)OC,,,,,,
8996,58997,"1-Methyl-1,2,3,9a-tetrahydro-1-azafluorene hydrochloride",C[NH+]1CCC=C2C1CC3=CC=CC=C32.[Cl-],,,,,,
8997,58998,"1-Methyl-1,2,3,9a-tetrahydro-1-azafluorene",CN1CCC=C2C1CC3=CC=CC=C32,,,,,,
8998,58999,5-Acetyl-beta-methyltryptamine hydrochloride,CC(CN)C1=CNC2=C1C=C(C=C2)C(=O)C.Cl,,,,,,
8999,59000,1-[3-(1-aminopropan-2-yl)-1H-indol-5-yl]ethanone,CC(CN)C1=CNC2=C1C=C(C=C2)C(=O)C,,,,,,
9000,59001,"Indole, 3-(1-allyl-2-piperidylmethyl)-",C=CCN1CCCCC1CC2=CNC3=CC=CC=C32,,,,,,
9001,59002,3-((1-Allyl-3-piperidyl)methyl)indole,C=CCN1CCCC(C1)CC2=CNC3=CC=CC=C32,,,,,,
9002,59003,"2,3-dimethyl-1H-indol-7-amine",CC1=C(NC2=C1C=CC=C2N)C,,,,,,
9003,59004,5-Methylthiotryptamine hydrochloride,CSC1=CC2=C(C=C1)NC=C2CC[NH3+].[Cl-],,,,,,
9004,59005,5-Methylmercapto-tryptamin,CSC1=CC2=C(C=C1)NC=C2CCN,,,,,,
9005,59006,5-Aminomethyl-3-benzyl indole hydrochloride,C1=CC=C(C=C1)CC2=CNC3=C2C=C(C=C3)C[NH3+].[Cl-],,,,,,
9006,59007,(3-benzyl-1H-indol-5-yl)methanamine,C1=CC=C(C=C1)CC2=CNC3=C2C=C(C=C3)CN,,,,,,
9007,59008,1-Methyl-3-(alpha-isopropylaminoethyl)indole,CC(C)C(CC1=CN(C2=CC=CC=C21)C)N,,,,,,
9008,59009,"Indole, 5-aminomethyl-3-phenethyl-",C1=CC=C(C=C1)CCC2=CNC3=C2C=C(C=C3)CN,,,,,,
9009,59010,"Indole, 3-(1-amino-2-propyl)-5-benzylthio-",CC(CN)C1=CNC2=C1C=C(C=C2)SCC3=CC=CC=C3,,,,,,
9010,59011,3-(2-Aminopropyl)-5-benzylthioindole hydrochloride,CC(CC1=CNC2=C1C=C(C=C2)SCC3=CC=CC=C3)[NH3+].[Cl-],,,,,,
9011,59012,1-(5-benzylsulfanyl-1H-indol-3-yl)propan-2-amine,CC(CC1=CNC2=C1C=C(C=C2)SCC3=CC=CC=C3)N,,,,,,
9012,59013,5-Dimethylamino-alpha-methyltryptamine hydrochloride,CC(CC1=CNC2=C1C=C(C=C2)[NH+](C)C)[NH3+].[Cl-].[Cl-],,,,,,
9013,59014,"3-(2-aminopropyl)-N,N-dimethyl-1H-indol-5-amine",CC(CC1=CNC2=C1C=C(C=C2)N(C)C)N,,,,,,
9014,59015,5-Ethoxy-alpha-methyltryptamine,CCOC1=CC2=C(C=C1)NC=C2CC(C)N,,,,,,
9015,59016,"Indole, 3-(1-amino-2-propyl)-5-methylthio-",CC(CN)C1=CNC2=C1C=C(C=C2)SC,,,,,,
9016,59017,6-Nitro-3-(hexamethyleneiminomethyl)indole hydrochloride,C1CCC[NH+](CC1)CC2=CNC3=C2C=CC(=C3)[N+](=O)[O-].[Cl-],,,,,,
9017,59018,3-(azepan-1-ylmethyl)-6-nitro-1H-indole,C1CCCN(CC1)CC2=CNC3=C2C=CC(=C3)[N+](=O)[O-],,,,,,
9018,59019,1-Benzyl-5-dimethylaminomethylindole hydrochloride,C[NH+](C)CC1=CC2=C(C=C1)N(C=C2)CC3=CC=CC=C3.[Cl-],,,,,,
9019,59020,"1-(1-benzylindol-5-yl)-N,N-dimethylmethanamine",CN(C)CC1=CC2=C(C=C1)N(C=C2)CC3=CC=CC=C3,,,,,,
9020,59021,"5-Benzyloxy-N,N-dimethyltryptamine oxalate",C[NH+](C)CCC1=CNC2=C1C=C(C=C2)OCC3=CC=CC=C3.C(=O)(C(=O)[O-])O,,,,,,
9021,59022,"1H-Indole-3-ethanamine, N,N'-dimethyl-5-(phenylmethoxy)-",CN(C)CCC1=CNC2=C1C=C(C=C2)OCC3=CC=CC=C3,,,,,,
9022,59023,"Indole, 5-benzyloxy-3-(4-piperidylmethyl)-",C1CNCCC1CC2=CNC3=C2C=C(C=C3)OCC4=CC=CC=C4,,,,,,
9023,59024,"Indole, 3-(1-benzyl-4-piperidylmethyl)-",C1CN(CCC1CC2=CNC3=CC=CC=C32)CC4=CC=CC=C4,,,,,,
9024,59025,"Indole, 3-(1-benzyl-2-piperidylmethyl)-, hydrochloride",C1CC[NH+](C(C1)CC2=CNC3=CC=CC=C32)CC4=CC=CC=C4.[Cl-],,,,,,
9025,59026,3-[(1-benzylpiperidin-2-yl)methyl]-1H-indole,C1CCN(C(C1)CC2=CNC3=CC=CC=C32)CC4=CC=CC=C4,,,,,,
9026,59027,CID 59027,CN(C)C=NC(C1=CC=C(C=C1)C2=CC=CC=C2)N=CN(C)C,,,,,,
9027,59028,"Formamidine, N'-(5,6,7,8-tetrahydronaphth-1-YL)-N,N,1-trimethyl-",CC(=NC1=CC=CC2=C1CCCC2)N(C)C,,,,,,
9028,59029,"Formamidinium, N,N''-hexamethylenebis(N,N,N-trimethyl-, diiodide",C[N+](C)(C)C=NCCCCCCN=C[N+](C)(C)C.[I-].[I-],,,,,,
9029,59030,Trimethyl-[6-[(trimethylazaniumyl)methylideneamino]hexyliminomethyl]azanium,C[N+](C)(C)C=NCCCCCCN=C[N+](C)(C)C,,,,,,
9030,59031,"N'-(5,6,7,8-Tetrahydro-1-naphthyl)-N,N,N-trimethylformamidinium iodide",C[N+](C)(C)C=NC1=CC=CC2=C1CCCC2.[I-],,,,,,
9031,59032,"Trimethyl(5,6,7,8-tetrahydronaphthalen-1-yliminomethyl)azanium",C[N+](C)(C)C=NC1=CC=CC2=C1CCCC2,,,,,,
9032,59033,"N-(5,5-Dimethyl-2-oxotetrahydro-3-furyl)-5-nitro-3-furamide",CC1(CC(C(=O)O1)NC(=O)C2=COC(=C2)[N+](=O)[O-])C,,,,,,
9033,59034,"Furan, 2,5-dimethyl-3-thiobenzoyl-",CC1=CC(=C(O1)C)C(=S)C2=CC=CC=C2,,,,,,
9034,59035,"Furan, 2,5-dimethyl-3-(thiofuroyl)-",CC1=CC(=C(O1)C)C(=S)C2=CC=CO2,,,,,,
9035,59036,2-(1-Morpholinomethyl)-4-(p-methylphenyl)furan hydrochloride,CC1=CC=C(C=C1)C2=COC(=C2)C[NH+]3CCOCC3.[Cl-],,,,,,
9036,59037,4-[[4-(4-Methylphenyl)furan-2-yl]methyl]morpholine,CC1=CC=C(C=C1)C2=COC(=C2)CN3CCOCC3,,,,,,
9037,59038,2-(1-Morpholinomethyl)-4-phenoxyfuran hydrochloride,C1COCC[NH+]1CC2=CC(=CO2)OC3=CC=CC=C3.[Cl-],,,,,,
9038,59039,4-[(4-Phenoxyfuran-2-yl)methyl]morpholine,C1COCCN1CC2=CC(=CO2)OC3=CC=CC=C3,,,,,,
9039,59040,4-Chloromethyl-3-phenyl-2(5H)-furanone,C1C(=C(C(=O)O1)C2=CC=CC=C2)CCl,,,,,,
9040,59041,3-Allyl-5-methyl-3-phenyldihydro-2(3H)-furanone,CC1CC(C(=O)O1)(CC=C)C2=CC=CC=C2,,,,,,
9041,59042,"2(3H)-Furanone, dihydro-5,5-bis(chlorodifluoromethyl)-3-hydroxy-3-methyl-",CC1(CC(OC1=O)(C(F)(F)Cl)C(F)(F)Cl)O,,,,,,
9042,59043,"2-Hydroxy-2-methyl-5,5-bis(trifluoromethyl)oxolan-3-one",CC1(C(=O)CC(O1)(C(F)(F)F)C(F)(F)F)O,,,,,,
9043,59044,"2(3H)-Furanone, dihydro-5,5-bis(trifluoromethyl)-3-hydroxy-4-pentyl-",CCCCCC1C(C(=O)OC1(C(F)(F)F)C(F)(F)F)O,,,,,,
9044,59045,"Dihydro-5,5-bis(trifluoromethyl)-2-hydroxy-2-phenyl-3(2H)-furanone",C1C(=O)C(OC1(C(F)(F)F)C(F)(F)F)(C2=CC=CC=C2)O,,,,,,
9045,59046,"N-[5,5-bis(trifluoromethyl)oxolan-3-ylidene]hydroxylamine",C1C(=NO)COC1(C(F)(F)F)C(F)(F)F,,,,,,
9046,59047,Dihydro-5-chlorodifluoromethyl-3-hydroxy-3-methyl-5-trifluoromethyl-2(3H)-furanone,CC1(CC(OC1=O)(C(F)(F)F)C(F)(F)Cl)O,,,,,,
9047,59048,"3-[3,3,3-Trifluoro-2-hydroxy-2-(trifluoromethyl)propyl]oxolan-2-one",C1COC(=O)C1CC(C(F)(F)F)(C(F)(F)F)O,,,,,,
9048,59049,"Furan, 2-(1-piperidinomethyl)-4-phenoxy-, tartrate",C1CCN(CC1)CC2=CC(=CO2)OC3=CC=CC=C3.[C@@H]([C@H](C(=O)O)O)(C(=O)O)O,,,,,,
9049,59050,1-[(4-Phenoxyfuran-2-yl)methyl]piperidine,C1CCN(CC1)CC2=CC(=CO2)OC3=CC=CC=C3,,,,,,
9050,59051,2-(1-Piperidinomethyl)-4-(p-methylphenoxy)furan tartrate,CC1=CC=C(C=C1)OC2=COC(=C2)CN3CCCCC3.[C@@H]([C@H](C(=O)O)O)(C(=O)O)O,,,,,,
9051,59052,1-[[4-(4-Methylphenoxy)furan-2-yl]methyl]piperidine,CC1=CC=C(C=C1)OC2=COC(=C2)CN3CCCCC3,,,,,,
9052,59053,"2-Oxaspiro(4.5)decane-3-acetic acid, 1-oxo-3-phenyl-, 1-methyl-4-piperidyl ester",CN1CCC(CC1)OC(=O)CC2(CCC3(CCCC3)C(=O)O2)C4=CC=CC=C4,,,,,,
9053,59054,"2-Oxaspiro(4.4)nonane-3-acetic acid, 1-oxo-1-phenyl-, 1-methyl-4-piperidyl ester",CN1CCC(CC1)OC(=O)CC2(CC3(CCCC3)C(=O)O2)C4=CC=CC=C4,,,,,,
9054,59055,"1-Oxo-3-phenyl-2-oxaspiro(4,4)nonane-3-acetic acid 3-quinuclidinyl ester",C1CCC2(C1)CC(OC2=O)(CC(=O)OC3CN4CCC3CC4)C5=CC=CC=C5,,,,,,
9055,59056,1-[3-(Diethylamino)propyl]-3-[(5-nitrofuran-2-yl)methylideneamino]urea,CCN(CC)CCCNC(=O)NN=CC1=CC=C(O1)[N+](=O)[O-],,,,,,
9056,59057,"1,18-Octadecanediamine, N,N'-bis(9-acridinyl)-",C1=CC=C2C(=C1)C(=C3C=CC=CC3=N2)NCCCCCCCCCCCCCCCCCCNC4=C5C=CC=CC5=NC6=CC=CC=C64,,,,,,
9057,59058,"N,N-Bis(2-chloroethyl)-1-octadecylamine hydrochloride",CCCCCCCCCCCCCCCCCC[NH+](CCCl)CCCl.[Cl-],,,,,,
9058,59059,"N,N-bis(2-chloroethyl)octadecan-1-amine",CCCCCCCCCCCCCCCCCCN(CCCl)CCCl,,,,,,
9059,59060,"2,7-Octanediamine, N,N'-bis(2-oxazolin-2-YL)-2,7-dimethyl-, dihydrobromide",CC(C)(CCCCC(C)(C)[NH2+]N1C=CCO1)[NH2+]N2C=CCO2.[Br-].[Br-],,,,,,
9060,59061,"2,7-dimethyl-2-N,7-N-bis(5H-1,2-oxazol-2-yl)octane-2,7-diamine",CC(C)(CCCCC(C)(C)NN1C=CCO1)NN2C=CCO2,,,,,,
9061,59062,"2,5-Octanedione, 7-hydroxy-8,8,8-trifluoro-7-trifluoromethyl-",CC(=O)CCC(=O)CC(C(F)(F)F)(C(F)(F)F)O,,,,,,
9062,59063,"7-Hydroxy-6-(1,1,1,3,3,3-hexafluoro-2-hydroxy-2-propyl)octanenitrile",CC(C(CCCCC#N)C(C(F)(F)F)(C(F)(F)F)O)O,,,,,,
9063,59064,N-methoxy-N-methyloctanamide,CCCCCCCC(=O)N(C)OC,,,,,,
9064,59065,"ANILINE, p-(5-PHENYLPENTYLOXY)-, METHANESULFONATE",CS(=O)(=O)[O-].C1=CC=C(C=C1)CCCCCOC2=CC=C(C=C2)[NH3+],,,,,,
9065,59066,4-(5-Phenylpentoxy)aniline,C1=CC=C(C=C1)CCCCCOC2=CC=C(C=C2)N,,,,,,
9066,59067,alpha-((Dimethylamino)methyl)-1-hexylindole-3-methanol,CCCCCCN1C=C(C2=CC=CC=C21)C(CN(C)C)O,,,,,,
9067,59068,"N,N-Diethyl-1-phenethylnipecotamide",CCN(CC)C(=O)C1CCCN(C1)CCC2=CC=CC=C2,,,,,,
9068,59069,2-propoxyethyl N-[4-(2-morpholin-4-ylethoxy)phenyl]carbamate,CCCOCCOC(=O)NC1=CC=C(C=C1)OCCN2CCOCC2,,,,,,
9069,59070,"o-CRESOL, 4-CYCLOHEXYL-alpha-PIPERIDINO-",C1CCC(CC1)C2=CC(=C(C=C2)O)CN3CCCCC3,,,,,,
9070,59071,"Isonipecotic acid, 1-(2-(ethylthio)ethyl)-4-phenyl-, ethyl ester",CCOC(=O)C1(CCN(CC1)CCSCC)C2=CC=CC=C2,,,,,,
9071,59072,"Anthranilic acid, N-(4-biphenylyl)-",C1=CC=C(C=C1)C2=CC=C(C=C2)NC3=CC=CC=C3C(=O)O,,,,,,
9072,59073,"NICOTINIC ACID, alpha-PHENYLBENZYL ESTER",C1=CC=C(C=C1)C(C2=CC=CC=C2)OC(=O)C3=CN=CC=C3,,,,,,
9073,59074,"Carbonic acid, (alpha-(1-((dimethylamino)methyl)ethyl)-2-thenyl) phenyl ester, hydrochloride",CC(C[NH+](C)C)C(C1=CC=CS1)OC(=O)OC2=CC=CC=C2.[Cl-],,,,,,
9074,59075,[3-(Dimethylamino)-2-methyl-1-thiophen-2-ylpropyl] phenyl carbonate,CC(CN(C)C)C(C1=CC=CS1)OC(=O)OC2=CC=CC=C2,,,,,,
9075,59076,Phenyl (alpha-(1-(piperidinomethyl)ethyl)-2-thenyl) carbonate hydrochloride,C.CC(C[NH+]1CCCCC1)C(C2=CC=CS2)OC(=O)OC3=CC=CC=C3.[Cl-],,,,,,
9076,59077,(2-Methyl-3-piperidin-1-yl-1-thiophen-2-ylpropyl) phenyl carbonate,CC(CN1CCCCC1)C(C2=CC=CS2)OC(=O)OC3=CC=CC=C3,,,,,,
9077,59078,"Carbonic acid, (alpha-(1-(morpholinomethyl)ethyl)-2-thenyl) phenyl ester, hydrochloride",CC(C[NH+]1CCOCC1)C(C2=CC=CS2)OC(=O)OC3=CC=CC=C3.[Cl-],,,,,,
9078,59079,(2-Methyl-3-morpholin-4-yl-1-thiophen-2-ylpropyl) phenyl carbonate,CC(CN1CCOCC1)C(C2=CC=CS2)OC(=O)OC3=CC=CC=C3,,,,,,
9079,59080,"Hexadecylamine, trifluorostannite",CCCCCCCCCCCCCCCC[NH3+].F[Sn-](F)F,,,,,,
9080,59081,"7-Chloro-1,1,1-trifluoro-2-(trifluoromethyl)heptane-2,4-diol",C(CC(CC(C(F)(F)F)(C(F)(F)F)O)O)CCl,,,,,,
9081,59082,"2,4-Heptanedione, 6-hydroxy-7,7,7-trifluoro-6-trifluoromethyl-",CC(=O)CC(=O)CC(C(F)(F)F)(C(F)(F)F)O,,,,,,
9082,59083,"3,6-Dimethyl-3-phenylheptanoic acid",CC(C)CCC(C)(CC(=O)O)C1=CC=CC=C1,,,,,,
9083,59084,2-Methyl-3-quinuclidyl-n-amyl(isopropenyl)glycolate B,CCCCCC(C(=C)C)(C(=O)OC1C(N2CCC1CC2)C)O,,,,,,
9084,59085,1-Azabicyclo[2.2.2]octan-3-yl 2-hydroxy-2-prop-1-en-2-ylheptanoate,CCCCCC(C(=C)C)(C(=O)OC1CN2CCC1CC2)O,,,,,,
9085,59086,1-Methyl-4-piperidyl-n-amyl-(isopropenyl)glycolate,CCCCCC(C(=C)C)(C(=O)OC1(CCNCC1)C)O,,,,,,
9086,59087,"Heptanoic acid, 2-hydroxy-2-(1-propynyl)-, 2-methyl-3-quinuclidinyl ester",CCCCCC(C#CC)(C(=O)OC1C(N2CCC1CC2)C)O,,,,,,
9087,59088,"Heptanoic acid, 2-hydroxy-2-(1-propynyl)-, 3-quinuclidinyl ester",CCCCCC(C#CC)(C(=O)OC1CN2CCC1CC2)O,,,,,,
9088,59089,"Heptanoic acid, 7-isopropylthio-",CC(C)SCCCCCCC(=O)O,,,,,,
9089,59090,"1,7-Dichloro-2,6-bis[chloro(difluoro)methyl]-1,1,7,7-tetrafluoro-2,6-dihydroxy-3-methylheptan-4-one",CC(C(=O)CC(C(F)(F)Cl)(C(F)(F)Cl)O)C(C(F)(F)Cl)(C(F)(F)Cl)O,,,,,,
9090,59091,"4-Heptanone, 2,6-bis(chlorodifluoromethyl)-1,7-dichloro-2,6-dihydroxy-1,1,7,7-tetrafluoro-",C(C(=O)CC(C(F)(F)Cl)(C(F)(F)Cl)O)C(C(F)(F)Cl)(C(F)(F)Cl)O,,,,,,
9091,59092,"4-Heptanone, 2,6-bis(chlorodifluoromethyl)-1,7-dichloro-2,6-dihydroxy-1,1,7,7-tetrafluoro-, oxime",C(C(=NO)CC(C(F)(F)Cl)(C(F)(F)Cl)O)C(C(F)(F)Cl)(C(F)(F)Cl)O,,,,,,
9092,59093,"3-Chloro-1,1,1,7,7,7-hexafluoro-2,6-dihydroxy-2,6-bis(trifluoromethyl)-4-heptanone",C(C(=O)C(C(C(F)(F)F)(C(F)(F)F)O)Cl)C(C(F)(F)F)(C(F)(F)F)O,,,,,,
9093,59094,"2,6-Bis(trifluoromethyl)-3-(2-chloroethyl)-2,6-dihydroxy-1,1,1,7,7,7-hexafluoro-4-heptanone",C(CCl)C(C(=O)CC(C(F)(F)F)(C(F)(F)F)O)C(C(F)(F)F)(C(F)(F)F)O,,,,,,
9094,59095,"2,6-Bis(trifluoromethyl)-1,7-dichloro-2,6-dihydroxy-1,1,7,7-tetrafluoro-4-heptanone",C(C(=O)CC(C(F)(F)F)(C(F)(F)Cl)O)C(C(F)(F)F)(C(F)(F)Cl)O,,,,,,
9095,59096,"4-Heptanone, 2,6-bis(trifluoromethyl)-1,7-dichloro-2,6-dihydroxy-1,1,7,7-tetrafluoro-, dimethylhydrazone",CN(C)N=C(CC(C(F)(F)F)(C(F)(F)Cl)O)CC(C(F)(F)F)(C(F)(F)Cl)O,,,,,,
9096,59097,"4-Heptanone, 2,6-bis(trifluoromethyl)-2,6-dihydroxy-1,1,1,7,7,7-hexafluoro-, azine",C(C(=NN=C(CC(C(F)(F)F)(C(F)(F)F)O)CC(C(F)(F)F)(C(F)(F)F)O)CC(C(F)(F)F)(C(F)(F)F)O)C(C(F)(F)F)(C(F)(F)F)O,,,,,,
9097,59098,"4-Heptanone, 2,6-bis(trifluoromethyl)-2,6-dihydroxy-1,1,1,7,7,7-hexafluoro-, bis(triethylamine)salt",CC[NH+](CC)CC.CC[NH+](CC)CC.C(C(=O)CC(C(F)(F)F)(C(F)(F)F)[O-])C(C(F)(F)F)(C(F)(F)F)[O-],,,,,,
9098,59099,"4-(Dimethylhydrazinylidene)-1,1,1,7,7,7-hexafluoro-2,6-bis(trifluoromethyl)heptane-2,6-diol",CN(C)N=C(CC(C(F)(F)F)(C(F)(F)F)O)CC(C(F)(F)F)(C(F)(F)F)O,,,,,,
9099,59100,"4-Heptanone, 2,6-bis(trifluoromethyl)-2,6-dihydroxy-1,1,1,7,7,7-hexafluoro-, oxime",C(C(=NO)CC(C(F)(F)F)(C(F)(F)F)O)C(C(F)(F)F)(C(F)(F)F)O,,,,,,
9100,59101,"1,1,1,7,7,7-Hexafluoro-2,6-dihydroxy-3-phenyl-2,6-bis(trifluoromethyl)-4-heptanone",C1=CC=C(C=C1)C(C(=O)CC(C(F)(F)F)(C(F)(F)F)O)C(C(F)(F)F)(C(F)(F)F)O,,,,,,
9101,59102,"4-Heptanone, 2,6-bis(trifluoromethyl)-2,6-dihydroxy-1,1,1,7,7,7-hexafluoro-, phenylhydrazone",C1=CC=C(C=C1)NN=C(CC(C(F)(F)F)(C(F)(F)F)O)CC(C(F)(F)F)(C(F)(F)F)O,,,,,,
9102,59103,"4-Heptanone, 7-chloro-2-hydroxy-1,1,1-trifluoro-2-trifluoromethyl-",C(CC(=O)CC(C(F)(F)F)(C(F)(F)F)O)CCl,,,,,,
9103,59104,"2-Chloro-1,1,1-trifluoro-6-methyl-2-(trifluoromethyl)heptan-4-one",CC(C)CC(=O)CC(C(F)(F)F)(C(F)(F)F)Cl,,,,,,
9104,59105,"1-Chloro-6-[chloro(difluoro)methyl]-1,1,7,7,7-pentafluoro-4-hydrazinylidene-2-(trifluoromethyl)heptane-2,6-diol",C(C(=NN)CC(C(F)(F)F)(C(F)(F)Cl)O)C(C(F)(F)F)(C(F)(F)Cl)O,,,,,,
9105,59106,"1,7-Difluoro-1,1,7,7-tetrafluoro-2,6-dihydroxy-2,6-bis(chlorodifluoromethyl)-4-heptanone",C(C(=O)CC(C(F)(F)Cl)(C(F)(Cl)Cl)O)C(C(F)(F)Cl)(C(F)(Cl)Cl)O,,,,,,
9106,59107,"Heptanonitrile, 7-(3-methyl-4-oxo-1-phenyl-1,3,8-triazaspiro(4.5)dec-8-YL)-",CN1CN(C2(C1=O)CCN(CC2)CCCCCCC#N)C3=CC=CC=C3,,,,,,
9107,59108,2-Hydroxy-6-(nitrosocyanamido)hexanamide,C(CCN(C#N)N=O)CC(C(=O)N)O,,,,,,
9108,59109,Dinoprost methoxyamine,CCCCCC(C=CC1C(CC(C1CC=CCCCC(=O)[O-])O)O)O.CO[NH3+],,,,,,
9109,59110,CID 59110,C[NH+](CCCCCC[NH+](C)CCCl)CCCl.[Cl-].[Cl-],,,,,,
9110,59111,"1,6-Hexanediamine, N,N'-bis(2-chloroethyl)-N,N'-dimethyl-",CN(CCCCCCN(C)CCCl)CCCl,,,,,,
9111,59112,"N,N'-Bis(2-chloroethyl)-N,N'-dimethyl-1,6-hexanediamine N,N'-dioxide",C[N+](CCCCCC[N+](C)(CCCl)[O-])(CCCl)[O-],,,,,,
9112,59113,2-Chloroallylhexaminium chloride,C=C(C[N+]12CN3CN(C1)CN(C3)C2)Cl.[Cl-],,,,,,
9113,59114,"1-(2-Chloroprop-2-enyl)-3,5,7-triaza-1-azoniatricyclo[3.3.1.13,7]decane",C=C(C[N+]12CN3CN(C1)CN(C3)C2)Cl,,,,,,
9114,59115,"N,N-Bis(2-chloroethyl)-1-heptylamine hydrochloride",CCCCCCC[NH+](CCCl)CCCl.[Cl-],,,,,,
9115,59116,"N,N-bis(2-chloroethyl)heptan-1-amine",CCCCCCCN(CCCl)CCCl,,,,,,
9116,59117,"Heptanoic acid, 2-hydroxy-2-(2-propynyl)-, 1-methyl-4-piperidyl ester",CCCCCC(CC#C)(C(=O)OC1(CCNCC1)C)O,,,,,,
9117,59118,"2,4-Hexanediol, 5,5-dimethyl-1,1,1-trifluoro-2-(trifluoromethyl)-4-acetate",CC(=O)OC(CC(C(F)(F)F)(C(F)(F)F)O)C(C)(C)C,,,,,,
9118,59119,"4-Methyl-6-phenyl-1,1,1-trifluoro-2-trifluoromethyl-2,4-hexanediol",CC(CCC1=CC=CC=C1)(CC(C(F)(F)F)(C(F)(F)F)O)O,,,,,,
9119,59120,"N-[(1S)-1-naphthalen-1-ylethyl]-4,5-dihydro-1,3-oxazol-2-amine",C[C@@H](C1=CC=CC2=CC=CC=C21)NC3=NCCO3,,,,,,
9120,59121,"Ethylamine, alpha-(1-naphthyl)-N-(2-oxazolin-2-yl)-",CC(C1=CC=CC2=CC=CC=C21)NC3=NCCO3,,,,,,
9121,59122,"3-(4-Bis(beta-chloroethyl)aminophenylazo)-1,5-naphthalenedisulfonic acid",C1=CC2=C(C=C(C=C2S(=O)(=O)O)N=NC3=CC=C(C=C3)N(CCCl)CCCl)C(=C1)S(=O)(=O)O,,,,,,
9122,59123,"1-NAPHTHALENEETHYLAMINE, beta-DIMETHYLAMINO-, DIHYDROBROMIDE",C[NH+](C)C(C[NH3+])C1=CC=CC2=CC=CC=C21.[Br-].[Br-],,,,,,
9123,59124,"N1,N1-Dimethyl-1-(naphthalen-1-yl)ethane-1,2-diamine",CN(C)C(CN)C1=CC=CC2=CC=CC=C21,,,,,,
9124,59125,3-(beta-Hydroxy-beta-(1-naphthyl)ethylamino)quinuclidine trihydrate,C1CN2CCC1C(C2)NCC(C3=CC4=CC=CC=C4C=C3)O.O.O.O,,,,,,
9125,59126,2-(1-Azabicyclo[2.2.2]octan-3-ylamino)-1-naphthalen-2-ylethanol,C1CN2CCC1C(C2)NCC(C3=CC4=CC=CC=C4C=C3)O,,,,,,
9126,59127,CID 59127,C1=CC=C2C=C(C=CC2=C1)COS(=O)(=O)[O-].[Na+],,,,,,
9127,59128,Naphthalen-2-ylmethyl hydrogen sulfate,C1=CC=C2C=C(C=CC2=C1)COS(=O)(=O)O,,,,,,
9128,59129,N-(2-Bromoethyl)-N-methylnaphthalene-1-methylamine,CN(CCBr)CC1=CC=CC2=CC=CC=C21,,,,,,
9129,59130,"1-Naphthalenemethylamine, N-(2-chloroethyl)-N-methyl-",CN(CCCl)CC1=CC=CC2=CC=CC=C21,,,,,,
9130,59131,4-Ethoxy-1-naphthalenemethylamine hydrobromide,CCOC1=CC=C(C2=CC=CC=C21)C[NH3+].[Br-],,,,,,
9131,59132,(4-Ethoxynaphthalen-1-yl)methanamine,CCOC1=CC=C(C2=CC=CC=C21)CN,,,,,,
9132,59133,"1-Naphthalenemethylamine, 4-ethoxy-N-(2-oxazolinyl)-",CCOC1=CC=C(C2=CC=CC=C21)CNC3=NCCO3,,,,,,
9133,59134,"1-Naphthalenemethylamine, N-(2-iodoethyl)-N-ethyl-",CCN(CCI)CC1=CC=CC2=CC=CC=C21,,,,,,
9134,59135,"1-Naphthalenemethylamine, N-(2-iodoethyl)-N-methyl-",CN(CCI)CC1=CC=CC2=CC=CC=C21,,,,,,
9135,59136,4-Isopropoxy-1-naphthalenemethylamine hydrobromide,CC(C)OC1=CC=C(C2=CC=CC=C21)C[NH3+].[Br-],,,,,,
9136,59137,(4-Propan-2-yloxynaphthalen-1-yl)methanamine,CC(C)OC1=CC=C(C2=CC=CC=C21)CN,,,,,,
9137,59138,"1-Naphthalenemethylamine, 4-methoxy-, acetate",CC(=O)[O-].COC1=CC=C(C2=CC=CC=C21)C[NH3+],,,,,,
9138,59139,"1-Naphthalenemethanamine, 4-methoxy-",COC1=CC=C(C2=CC=CC=C21)CN,,,,,,
9139,59140,4-Methoxy-N-(2-oxazolinyl)-1-naphthalenemethylamine hydrobromide,COC1=CC=C(C2=CC=CC=C21)C[NH2+]C3=NCCO3.[Br-],,,,,,
9140,59141,"N-[(4-methoxynaphthalen-1-yl)methyl]-4,5-dihydro-1,3-oxazol-2-amine",COC1=CC=C(C2=CC=CC=C21)CNC3=NCCO3,,,,,,
9141,59142,"1-Naphthalenemethylamine, N-(2-oxazolinyl)-4-propoxy-, hydrobromide",CCCOC1=CC=C(C2=CC=CC=C21)C[NH2+]C3=NCCO3.[Br-],,,,,,
9142,59143,"N-[(4-propoxynaphthalen-1-yl)methyl]-4,5-dihydro-1,3-oxazol-2-amine",CCCOC1=CC=C(C2=CC=CC=C21)CNC3=NCCO3,,,,,,
9143,59144,4-Propoxy-1-naphthalenemethylamine hydrobromide,CCCOC1=CC=C(C2=CC=CC=C21)C[NH3+].[Br-],,,,,,
9144,59145,(4-Propoxynaphthalen-1-yl)methanamine,CCCOC1=CC=C(C2=CC=CC=C21)CN,,,,,,
9145,59146,"2-(5,6,7,8-Tetrahydro-1-naphthalenemethylamino)-2-oxazoline",C1CCC2=C(C1)C=CC=C2CNC3=NCCO3,,,,,,
9146,59147,6-(4-Bis(beta-chloroethyl)aminophenylazo)-2-naphthalenesulfonic acid,C1=CC(=CC=C1N=NC2=CC3=C(C=C2)C=C(C=C3)S(=O)(=O)O)N(CCCl)CCCl,,,,,,
9147,59148,"2-(Dimethylaminomethylidene)-7-nitro-3,4-dihydronaphthalen-1-one",CN(C)C=C1CCC2=C(C1=O)C=C(C=C2)[N+](=O)[O-],,,,,,
9148,59149,"1(2H)-Naphthalenone, 3,4-dihydro-2-((4-methyl-1-piperazinyl)methyl)-, hydrochloride",C[NH+]1CCN(CC1)CC2CCC3=CC=CC=C3C2=O.[Cl-],,,,,,
9149,59150,"2-[(4-methylpiperazin-1-yl)methyl]-3,4-dihydro-2H-naphthalen-1-one",CN1CCN(CC1)CC2CCC3=CC=CC=C3C2=O,,,,,,
9150,59151,"Naphtho(2,3-b)-p-dioxin-2-methylamine, 2,3-dihydro-N-(2-chloroethyl)-N-methyl-, hydrochloride",C[NH+](CCCl)CC1COC2=CC3=CC=CC=C3C=C2O1.[Cl-],,,,,,
9151,59152,"2-chloro-N-(2,3-dihydrobenzo[g][1,4]benzodioxin-3-ylmethyl)-N-methylethanamine",CN(CCCl)CC1COC2=CC3=CC=CC=C3C=C2O1,,,,,,
9152,59153,"6-Bromo-2-nitronaphtho(2,1-b)furan",C1=CC2=C(C=CC3=C2C=C(O3)[N+](=O)[O-])C(=C1)Br,,,,,,
9153,59154,"NAPHTHO(1,2-b)FURAN, 2,3-DIHYDRO-2,2-DIFLUORO-3-DIFLUOROMETHYLENE-",C1=CC=C2C(=C1)C=CC3=C2OC(C3=C(F)F)(F)F,,,,,,
9154,59155,"6-Methoxy-2-nitronaphtho(2,1-b)furan",COC1=CC=CC2=C1C=CC3=C2C=C(O3)[N+](=O)[O-],,,,,,
9155,59156,"9-Methoxy-2-nitronaphtho(2,1-b)furan",COC1=CC=CC2=C1C3=C(C=C2)OC(=C3)[N+](=O)[O-],,,,,,
9156,59157,"1-NAPHTHOIC ACID, (m-CHLOROBENZOYL)HYDRAZIDE",C1=CC=C2C(=C1)C=CC=C2C(=O)NNC(=O)C3=CC(=CC=C3)Cl,,,,,,
9157,59158,"Indole-3-glyoxylamide, N,N,1,2-tetramethyl-",CC1=C(C2=CC=CC=C2N1C)C(=O)C(=O)N(C)C,,,,,,
9158,59159,"1,1,1,7,7,7-Hexafluoro-6-hydroxy-4-oxo-2,6-bis(trifluoromethyl)heptan-2-yl acetate",CC(=O)OC(CC(=O)CC(C(F)(F)F)(C(F)(F)F)O)(C(F)(F)F)C(F)(F)F,,,,,,
9159,59160,"Acridine, 9-(2-oxazolin-2-ylamino)-",C1COC(=N1)NC2=C3C=CC=CC3=NC4=CC=CC=C42,,,,,,
9160,59161,"Acridine, 9,9'-tetramethylenediiminobis(2-chloro-6-methoxy-",COC1=CC2=C(C=C1)C(=C3C=C(C=CC3=N2)Cl)NCCCCNC4=C5C=C(C=CC5=NC6=C4C=CC(=C6)OC)Cl,,,,,,
9161,59162,"Acridinium, 3,6-diamino-10-ethyl-, sulfate",CC[N+]1=C2C=C(C=CC2=CC3=C1C=C(C=C3)N)N.OS(=O)(=O)[O-],,,,,,
9162,59163,"10-Ethylacridin-10-ium-3,6-diamine",CC[N+]1=C2C=C(C=CC2=CC3=C1C=C(C=C3)N)N,,,,,,
9163,59164,"Acridinium, 3,6-diamino-10-pentyl-, sulfate",CCCCC[N+]1=C2C=C(C=CC2=CC3=C1C=C(C=C3)N)N.OS(=O)(=O)[O-],,,,,,
9164,59165,"10-Pentylacridin-10-ium-3,6-diamine",CCCCC[N+]1=C2C=C(C=CC2=CC3=C1C=C(C=C3)N)N,,,,,,
9165,59166,"2,3-Bis(furan-2-yl)prop-2-enamide",C1=COC(=C1)C=C(C2=CC=CO2)C(=O)N,,,,,,
9166,59167,CID 59167,CCOC(=O)C=CC(=O)NC1CC(OC1=O)(C)C,,,,,,
9167,59168,"Acridinium, 10-butyl-3,6-diamino-, sulfate",CCCC[N+]1=C2C=C(C=CC2=CC3=C1C=C(C=C3)N)N.OS(=O)(=O)[O-],,,,,,
9168,59169,"10-Butylacridin-10-ium-3,6-diamine",CCCC[N+]1=C2C=C(C=CC2=CC3=C1C=C(C=C3)N)N,,,,,,
9169,59170,"Acridinium, 3,6-diamino-10-methyl-, sulfate",C[N+]1=C2C=C(C=CC2=CC3=C1C=C(C=C3)N)N.OS(=O)(=O)[O-],,,,,,
9170,59171,2-((Diphenylmethyl)thio)ethyl nicotinate,C1=CC=C(C=C1)C(C2=CC=CC=C2)SCCOC(=O)C3=CN=CC=C3,,,,,,
9171,59172,2-(Hexadecylthio)ethyl nicotinate,CCCCCCCCCCCCCCCCSCCOC(=O)C1=CN=CC=C1,,,,,,
9172,59173,2-(Hexylthio)ethyl nicotinate,CCCCCCSCCOC(=O)C1=CN=CC=C1,,,,,,
9173,59174,"Nicotinic acid, 6-hydroxyhexyl ester",C1=CC(=CN=C1)C(=O)OCCCCCCO,,,,,,
9174,59175,"Nicotinic acid, 5-hydroxypentyl ester",C1=CC(=CN=C1)C(=O)OCCCCCO,,,,,,
9175,59176,"Nicotinic acid, 3-hydroxypropyl ester",C1=CC(=CN=C1)C(=O)OCCCO,,,,,,
9176,59177,alpha-Methylbenzyl nicotinate,CC(C1=CC=CC=C1)OC(=O)C2=CN=CC=C2,,,,,,
9177,59178,"Nicotinic acid, 2-(methylthio)ethyl ester",CSCCOC(=O)C1=CN=CC=C1,,,,,,
9178,59179,"Nicotinic acid, pentamethylene ester",C1=CC(=CN=C1)C(=O)OCCCCCOC(=O)C2=CN=CC=C2,,,,,,
9179,59180,"Nicotinic acid, 2-(pentylthio)ethyl ester",CCCCCSCCOC(=O)C1=CN=CC=C1,,,,,,
9180,59181,2-(Phenethylthio)ethyl nicotinate,C1=CC=C(C=C1)CCSCCOC(=O)C2=CN=CC=C2,,,,,,
9181,59182,CID 59182,C1=CC=C(C=C1)SC2=CC=C(C=C2)NC3=C(C=CC=N3)C(=O)[O-].[Na+],,,,,,
9182,59183,Ptpan,C1=CC=C(C=C1)SC2=CC=C(C=C2)NC3=C(C=CC=N3)C(=O)O,,,,,,
9183,59184,2-(Phenylthio)ethyl nicotinate,C1=CC=C(C=C1)SCCOC(=O)C2=CN=CC=C2,,,,,,
9184,59185,"Nicotinic acid, 2-(propylthio)ethyl ester",CCCSCCOC(=O)C1=CN=CC=C1,,,,,,
9185,59186,"Nicotinic acid, 2-((3-pyridylmethyl)thio)ethyl ester",C1=CC(=CN=C1)CSCCOC(=O)C2=CN=CC=C2,,,,,,
9186,59187,"3-Carbomethoxy-1-methyl-4-(2-methylpiperidino)-1,2,5,6-tetrahydropyridine HCl hydrate",CC1CCCCN1C2=C(C[NH+](CC2)C)C(=O)OC.[Cl-],,,,,,
9187,59188,"methyl 1-methyl-4-(2-methylpiperidin-1-yl)-3,6-dihydro-2H-pyridine-5-carboxylate",CC1CCCCN1C2=C(CN(CC2)C)C(=O)OC,,,,,,
9188,59189,4-(Pyridine-3-carbonyloxy)butyl pyridine-3-carboxylate,C1=CC(=CN=C1)C(=O)OCCCCOC(=O)C2=CN=CC=C2,,,,,,
9189,59190,"Nicotinic acid, 6-thiocyanatohexyl ester",C1=CC(=CN=C1)C(=O)OCCCCCCSC#N,,,,,,
9190,59191,"Nicotinic acid, 5-thiocyanatopentyl ester",C1=CC(=CN=C1)C(=O)OCCCCCSC#N,,,,,,
9191,59192,alpha-(m-Tolyl)benzyl nicotinate,CC1=CC(=CC=C1)C(C2=CC=CC=C2)OC(=O)C3=CN=CC=C3,,,,,,
9192,59193,alpha-(o-Tolyl)benzyl nicotinate,CC1=CC=CC=C1C(C2=CC=CC=C2)OC(=O)C3=CN=CC=C3,,,,,,
9193,59194,alpha-(p-Tolyl)benzyl nicotinate,CC1=CC=C(C=C1)C(C2=CC=CC=C2)OC(=O)C3=CN=CC=C3,,,,,,
9194,59195,6-(Pyridine-3-carbonyloxy)hexyl pyridine-3-carboxylate,C1=CC(=CN=C1)C(=O)OCCCCCCOC(=O)C2=CN=CC=C2,,,,,,
9195,59196,"ACETAMIDE, N-(5-(p-AMINOPHENOXY)PENTYL)-2-PHENYL-",C1=CC=C(C=C1)CC(=O)NCCCCCOC2=CC=C(C=C2)N,,,,,,
9196,59197,"BENZAMIDE, N-(5-(p-AMINOPHENOXY)PENTYL)-N-METHYL-",CN(CCCCCOC1=CC=C(C=C1)N)C(=O)C2=CC=CC=C2,,,,,,
9197,59198,"ACETAMIDE, N-(5-(p-AMINOPHENOXY)PENTYL)-2-PHENOXY-",C1=CC=C(C=C1)OCC(=O)NCCCCCOC2=CC=C(C=C2)N,,,,,,
9198,59199,3-(2-Methoxyphenyl)propyl-(3-phenylprop-2-enyl)azanium;chloride,COC1=CC=CC=C1CCC[NH2+]CC=CC2=CC=CC=C2.[Cl-],,,,,,
9199,59200,3-(2-methoxyphenyl)-N-(3-phenylprop-2-enyl)propan-1-amine,COC1=CC=CC=C1CCCNCC=CC2=CC=CC=C2,,,,,,
9200,59201,"ACETOPHENONE, 4'-(5-(p-AMINOPHENOXY)PENTYLOXY)-",CC(=O)C1=CC=C(C=C1)OCCCCCOC2=CC=C(C=C2)N,,,,,,
9201,59202,"Carbanilic acid, p-(2-morpholinoethoxy)-, 2-butoxyethyl ester, hydrochloride",CCCCOCCOC(=O)NC1=CC=C(C=C1)OCCN2CCOCC2.Cl,,,,,,
9202,59203,4-(2-Morpholinoethoxy)carbanilic acid 2-butoxyethyl ester,CCCCOCCOC(=O)NC1=CC=C(C=C1)OCCN2CCOCC2,,,,,,
9203,59204,"3-Methoxyestra-1(10),2,4-triene-17-thiol",CC12CCC3C(C1CC[C@H]2S)CCC4=C3C=CC(=C4)OC,,,,,,
9204,59205,4-Phenyl-4-piperidino-1-methylpiperidine dihydrochloride,C[NH+]1CCC(CC1)(C2=CC=CC=C2)[NH+]3CCCCC3.[Cl-].[Cl-],,,,,,
9205,59206,"1'-Methyl-4'-phenyl-1,4'-bipiperidine",CN1CCC(CC1)(C2=CC=CC=C2)N3CCCCC3,,,,,,
9206,59207,1-(4-Phenoxyphenyl)ethan-1-amine,CC(C1=CC=C(C=C1)OC2=CC=CC=C2)N,,,,,,
9207,59208,alpha-Ethoxy-alpha-phenyl-1-naphthaleneacetic acid,CCOC(C1=CC=CC=C1)(C2=CC=CC3=CC=CC=C32)C(=O)O,,,,,,
9208,59209,"2,2-Diphenyl-4-(1-methyl-2-piperidyl)-1,3-dioxolane",CN1CCCCC1C2COC(O2)(C3=CC=CC=C3)C4=CC=CC=C4,,,,,,
9209,59210,"alpha,alpha'-Dimethyl-2-methoxy-diphenethylamine hydrochloride",CC(CC1=CC=CC=C1)[NH2+]C(C)CC2=CC=CC=C2OC.[Cl-],,,,,,
9210,59211,N-[1-(2-methoxyphenyl)propan-2-yl]-1-phenylpropan-2-amine,CC(CC1=CC=CC=C1)NC(C)CC2=CC=CC=C2OC,,,,,,
9211,59212,"Diphenethylamine, o,o'-dimethoxy-N,alpha,alpha'-trimethyl-, hydrochloride, vinyl alcohol",CC(C[NH+](C)CC(C)C1=CC=CC=C1OC)C2=CC=CC=C2OC.C=CO.[Cl-],,,,,,
9212,59213,2-(2-methoxyphenyl)-N-[2-(2-methoxyphenyl)propyl]-N-methylpropan-1-amine,CC(CN(C)CC(C)C1=CC=CC=C1OC)C2=CC=CC=C2OC,,,,,,
9213,59214,"N-Methyl-bis(2,3-dichloropropyl)amine hydrochloride",C[NH+](CC(CCl)Cl)CC(CCl)Cl.[Cl-],,,,,,
9214,59215,"2,3-dichloro-N-(2,3-dichloropropyl)-N-methylpropan-1-amine",CN(CC(CCl)Cl)CC(CCl)Cl,,,,,,
9215,59216,"2,4-Dimethyl-2-isopropyl-1,3-dithiolane",CC1CSC(S1)(C)C(C)C,,,,,,
9216,59217,"4-Methyl-2-phenethyl-1,3-dithiolane",CC1CSC(S1)CCC2=CC=CC=C2,,,,,,
9217,59218,"3,5-Bis(ethylamino)-1,2-dithiolium chloride",CCNC1=CC(=[NH+]CC)SS1.[Cl-],,,,,,
9218,59219,CID 59219,CC(=NNC(=NC1=CC=CC=C1)S)CCCCCCCCC(=NNC(=NC2=CC=CC=C2)S)C,,,,,,
9219,59220,"Dodecanamide, N-(5-acetamido-8-quinolylsulfonyl)-",CCCCCCCCCCCC(=O)NS(=O)(=O)C1=C2C(=C(C=C1)NC(=O)C)C=CC=N2,,,,,,
9220,59221,"DODECANAMIDE, N-(o-BROMOBENZYL)-",CCCCCCCCCCCC(=O)NCC1=CC=CC=C1Br,,,,,,
9221,59222,"DODECANAMIDE, N-(p-BROMOBENZYL)-",CCCCCCCCCCCC(=O)NCC1=CC=C(C=C1)Br,,,,,,
9222,59223,"1,3-DITHIOLANE, 2-(4-METHOXY-o-TOLYL)-",CC1=C(C=CC(=C1)OC)C2SCCS2,,,,,,
9223,59224,"3,5-Bis(methylamino)-4-(2-(dimethylamino)ethyl)-1,2-dithiolium iodide hydriodide",CNC1=C(C(=[NH+]C)SS1)CC[NH+](C)C.[I-].[I-],,,,,,
9224,59225,4-[2-(dimethylamino)ethyl]-N-methyl-5-methyliminodithiol-3-amine,CNC1=C(C(=NC)SS1)CCN(C)C,,,,,,
9225,59226,"[(2S)-5-hydroxy-1,2,3,4-tetrahydronaphthalen-2-yl]-propyl-(2-thiophen-2-ylethyl)azanium;chloride",CCC[NH+](CCC1=CC=CS1)[C@H]2CCC3=C(C2)C=CC=C3O.[Cl-],,,,,,
9226,59227,Rotigotine,CCCN(CCC1=CC=CS1)[C@H]2CCC3=C(C2)C=CC=C3O,"[""For use/treatment in neurologic disorders and parkinson's disease as well as moderate-to-severe primary Restless Legs Syndrome.""]","[""Rotigotine is an agonist at all 5 dopamine receptor subtypes (D1-D5) but binds to the D3 receptor with the highest affinity. It is also an antagonist at α-2-adrenergic receptors and an agonist at the 5HT1A receptors. Rotigotine also inhibits dopamine uptake and prolactin secretion. There is no indication of a QT/QTc prolonging effect of Neupro in doses up to 24 mg/24 hours. The effects of Neupro at doses up to 24 mg/24 hours (supratherapeutic doses) on the QT/QTc interval was evaluated in a double-blind, randomized, placebo- and positive-controlled (moxifloxacin 400 mg IV, single dose) parallel-group trial with an overall treatment period of 52 days in male and female patients with advanced-stage Parkinson's disease. Assay sensitivity was confirmed by significant QTc prolongation by moxifloxacin.""]",['Drugs that bind to and activate dopamine receptors. (See all compounds classified as Dopamine Agonists.)'],"['Bioavailability varies depending on the application site. Differences in bioavailability were very small between the abdomen and hip (<1%). In contrast, the shoulder and thigh had a very large different in measured bioavailability (46%), with the shoulder showing the higher value.  Tmax, 8 mg dose = 15 - 18 hours (it take approximately 3 hours until rotigotine reaches detectable levels in the plasma). The peak concentration cannot be observered. Steady state is reached in 2-3 days.', 'Urine (71%), Fecal (23%). Most of rotigotine that is excreted in the urine is in the form of inactive conjugates. Unchanged drug made up less <1%.', 'The weight normalized apparent volume of distribution, (Vd/F), in humans is approximately 84 L/kg after repeated dose administration.', 'Results obtained with the patch administration in animals showed that the silicone based patch was superior to the acrylic based patch with respect to substance release. Following repeated dosing, 81 and 93 % substance was released from the silicone patch on the rat and monkey, respectively. The corresponding % release from the acrylic based patch was 28 and 22 %, respectively.', 'The weight normalized apparent volume of distribution (Vd/F) in humans is approximately 84 L/kg after repeated dose administration.  The binding of rotigotine to human plasma proteins is approximately 92% in vitro and 89.5% in vivo.', ""When single doses of 8 mg/24 hours are applied to the trunk, there is an average lag time of approximately 3 hours until drug is detected in plasma (range 1 to 8 hours). Tmax typically occurs between 15 to 18 hours post dose but can occur from 4 to 27 hours post dose. However, there is no characteristic peak concentration observed. Rotigotine displays dose-proportionality over a daily dose range of 1 mg/24 hours to 24 mg/24 hours. In the clinical studies of rotigotine effectiveness, the transdermal system application site was rotated from day to day (abdomen, thigh, hip, flank, shoulder, or upper arm) and the mean measured plasma concentrations of rotigotine were stable over the 6 months of maintenance treatment. Relative bioavailability for the different application sites at steady-state was evaluated in subjects with Parkinson's disease. In a single trial conducted in patients with early-stage Parkinson's disease, differences in bioavailability ranged from less than 1% (abdomen vs. hip) to 46% (shoulder vs. thigh) with shoulder application showing higher bioavailability."", 'Rotigotine is primarily excreted in urine (approximately 71%) as inactive conjugates of the parent compound and N-desalkyl metabolites. A smaller proportion is excreted in feces (approximately 23%). The major metabolites found in urine were rotigotine sulfate (16% to 22% of the absorbed dose), rotigotine glucuronide (11% to 15%), and N-despropyl-rotigotine sulfate metabolite (14% to 20%) and N-desthienylethyl-rotigotine sulfate metabolite (10% to 21%). Approximately 11% is renally eliminated as other metabolites. A small amount of unconjugated rotigotine is renally eliminated (less than 1% of the absorbed dose).', 'For more Absorption, Distribution and Excretion (Complete) data for ROTIGOTINE (9 total), please visit the HSDB record page.']","['Hepatic (CYP-mediated). Rotigotine is extensively and rapidly metabolized by conjugation and N-dealkylation. After intravenous dosing the predominant metabolites in human plasma are sulfate conjugates of rotigotine, glucuronide conjugates of rotigotine, sulfate conjugates of the N-despropyl-rotigotine and conjugates of N-desthienylethyl-rotigotine. Multiple CYP isoenzymes, sulfotransferases and two UDP-glucuronosyltransferases catalyze the metabolism of rotigotine.', 'CYP2C19 was found to be the major CYP isoform involved in the phase 1 metabolism of rotigotine. However, multiple CYP-isoforms appear to be capable of catalyzing the metabolism. In vitro studies suggest a low risk for drug-drug interactions with co-administered drugs which are substrates of CYP isoforms in vivo. Also, no induction of human liver CYP isoforms has been found. No potential for displacement of rotigotine by warfarin and vice versa was detected with human serum albumin in vitro. Rotigotine was found not to be a substrate for P-glycoprotein and does not modulate digoxin transport in vitro.', 'Following absorption rotigotine was rapidly metabolised. Three phase 1 metabolites showed pharmacological activity. However, pharmacokinetics of these metabolites were not required as their presence in plasma was too low. The major metabolite observed in animal hepatocytes, the glucuronide conjugate of rotigotine, was in vivo excreted into bile and only reached the blood system at low levels. Conjugates of the Ndealkylated metabolites were found to be the major metabolites in plasma. Following subcutaneous administration, the sulfate and the glucuronide conjugates of the SPM 9206 metabolite and the sulfate conjugates of the SPM 9257 and the sulfate of the desthienylethyl despropyl metabolite were found to be the major metabolites in plasma. In human plasma, the sulphate conjugates of rotigotine, the SPM 9206 and the SPM 9257 metabolite were found to be the major metabolites. All the human major metabolites found in plasma were also found in the plasma of the main toxicological species.', 'Rotigotine is extensively metabolized by conjugation and N-dealkylation. After intravenous dosing the predominant metabolites in human plasma are sulfate conjugates of rotigotine, glucuronide conjugates of rotigotine, sulfate conjugates of the N-despropyl-rotigotine and conjugates of N-desthienylethyl-rotigotine. Multiple CYP isoenzymes, sulfotransferases and two UDP-glucuronosyltransferases catalyze the metabolism of rotigotine.', 'Rotigotine is primarily excreted in urine (approximately 71%) as inactive conjugates of the parent compound and N-desalkyl metabolites. A smaller proportion is excreted in feces (approximately 23%). The major metabolites found in urine were rotigotine sulfate (16% to 22% of the absorbed dose), rotigotine glucuronide (11% to 15%), and N-despropyl-rotigotine sulfate metabolite (14% to 20%) and N-desthienylethyl-rotigotine sulfate metabolite (10% to 21%). Approximately 11% is renally eliminated as other metabolites. A small amount of unconjugated rotigotine is renally eliminated (less than 1% of the absorbed dose).']","['After removal of the patch, plasma levels decreased with a terminal half-life of 5 to 7 hours. The pharmacokinetic profile showed a biphasic elimination with an initial half-life of 3 hours.', 'After removal of the patch, plasma levels decreased with a terminal half-life of 5 to 7 hours. The pharmacokinetic profile showed a biphasic elimination with an initial half-life of 3 hours.', '... A single transdermal patch delivering 2 mg/24 hr rotigotine (patch content 4.5 mg) was applied to the ventral/lateral abdomen for 24 hr. ... The pharmacokinetic analysis included 48 subjects (24 Japanese, 24 Caucasian). ... The terminal half-life for unconjugated rotigotine was 5.3 hr in Japanese subjects and 5.7 hr in Caucasians; corresponding values for total rotigotine were 8.6 hr and 9.6 hr. ...']"
9227,59228,"2-Methyl-2-(1-methyl-2-butylthioethyl)-1,3-dioxolane",CCCCSCC(C)C1(OCCO1)C,,,,,,
9228,59229,"2-Methyl-2-(1-methyl-2-isoamylthioethyl)-1,3-dioxolane",CC(C)CCSCC(C)C1(OCCO1)C,,,,,,
9229,59230,"2-Methyl-2-(1-methyl-2-amylthioethyl)-1,3-dioxolane",CCCCCSCC(C)C1(OCCO1)C,,,,,,
9230,59231,CID 59231,CCC1=CC=CC2=C1C(CCC2)C[NH2+]CCC3=CC=CC=C3.C(=CC(=O)[O-])C(=O)O,,,,,,
9231,59232,"N-[(8-ethyl-1,2,3,4-tetrahydronaphthalen-1-yl)methyl]-2-phenylethanamine",CCC1=CC=CC2=C1C(CCC2)CNCCC3=CC=CC=C3,,,,,,
9232,59233,"4,5-Dihydro-N-propyl-3H-1-benzazepin-2-amine hydrochloride",CCC[NH2+]C1=NC2=CC=CC=C2CCC1.[Cl-],,,,,,
9233,59234,CID 59234,CCCNC1=NC2=CC=CC=C2CCC1,,,,,,
9234,59235,"4,5-Dihydro-N-butyl-3H-1-benzazepin-2-amine hydrochloride",CCCC[NH2+]C1=NC2=CC=CC=C2CCC1.[Cl-],,,,,,
9235,59236,CID 59236,CCCCNC1=NC2=CC=CC=C2CCC1,,,,,,
9236,59237,"4,5-Dihydro-N-(2-methylpropyl)-3H-1-benzazepin-2-amine hydrochloride",CC(C)C[NH2+]C1=NC2=CC=CC=C2CCC1.[Cl-],,,,,,
9237,59238,CID 59238,CC(C)CNC1=NC2=CC=CC=C2CCC1,,,,,,
9238,59239,(1-Methylpyrrolid-2-yl)methyl benzilate,CN1CCCC1COC(=O)C(C2=CC=CC=C2)(C3=CC=CC=C3)O,,,,,,
9239,59240,alpha-(2-(Dimethylamino)ethyl)-alpha-phenylindole-3-methanol,CN(C)CCC(C1=CC=CC=C1)(C2=CNC3=CC=CC=C32)O,,,,,,
9240,59241,"Butyramide, 4-diethylamino-2,2-diphenyl-",CCN(CC)CCC(C1=CC=CC=C1)(C2=CC=CC=C2)C(=O)N,,,,,,
9241,59242,"N-(2-(Dimethylamino)ethyl)-N,2-diphenylglycine ethyl ester",CCOC(=O)C(C1=CC=CC=C1)N(CCN(C)C)C2=CC=CC=C2,,,,,,
9242,59243,"Barbituric acid, 5-heptyl-5-(2-piperidinoethyl)-",CCCCCCCC1(C(=O)NC(=O)NC1=O)CCN2CCCCC2,,,,,,
9243,59244,CID 59244,C[NH+](C)CC(C1=CC=CC=C1)OC(=O)C=CC2=CC=CC=C2.[Cl-],,,,,,
9244,59245,"Ethanol, 2,2'-((3-methoxy-4-(octyloxy)phenyl)imino)DI-",CCCCCCCCOC1=C(C=C(C=C1)N(CCO)CCO)OC,,,,,,
9245,59246,"2-[(2,6-Dimethylphenyl)carbamoylmethoxy]ethyl-diethyl-azanium chloride",CC[NH+](CC)CCOCC(=O)NC1=C(C=CC=C1C)C.[Cl-],,,,,,
9246,59247,"2-[2-(diethylamino)ethoxy]-N-(2,6-dimethylphenyl)acetamide",CCN(CC)CCOCC(=O)NC1=C(C=CC=C1C)C,,,,,,
9247,59248,"2-(N'-(2-(Diethylamino)ethyl)acetamido)-2',6'-acetoxylidide hydrochloride",CC[NH+](CC)CCN(CC(=O)NC1=C(C=CC=C1C)C)C(=O)C.[Cl-],,,,,,
9248,59249,"2-[acetyl-[2-(diethylamino)ethyl]amino]-N-(2,6-dimethylphenyl)acetamide",CCN(CC)CCN(CC(=O)NC1=C(C=CC=C1C)C)C(=O)C,,,,,,
9249,59250,"2',6'-Dimethyl-2-(2-ethoxyethylamino)-acetanilide hydrochloride",CCOCC[NH2+]CC(=O)NC1=C(C=CC=C1C)C.[Cl-],,,,,,
9250,59251,"9-ACRIDANONE, 6-METHOXY-10-(p-TOLYLSULFONYL)-",CC1=CC=C(C=C1)S(=O)(=O)N2C3=CC=CC=C3C(=O)C4=C2C=C(C=C4)OC,,,,,,
9251,59252,(2-Benzilamidoethyl)diethylmethylammonium iodide,CC[N+](C)(CC)CCNC(=O)C(C1=CC=CC=C1)(C2=CC=CC=C2)O.[I-],,,,,,
9252,59253,"Diethyl-[2-[(2-hydroxy-2,2-diphenylacetyl)amino]ethyl]-methylazanium",CC[N+](C)(CC)CCNC(=O)C(C1=CC=CC=C1)(C2=CC=CC=C2)O,,,,,,
9253,59254,4-Amino-N-(2-(diethylamino)ethyl)benzanilide hydrochloride,CC[NH+](CC)CCN(C1=CC=CC=C1)C(=O)C2=CC=C(C=C2)N.[Cl-],,,,,,
9254,59255,4-Amino-N-[2-(diethylamino)ethyl]benzanilide,CCN(CC)CCN(C1=CC=CC=C1)C(=O)C2=CC=C(C=C2)N,,,,,,
9255,59256,"Heptanophenone, 7-(4-amino-2-methoxyphenoxy)-",COC1=C(C=CC(=C1)N)OCCCCCCC(=O)C2=CC=CC=C2,,,,,,
9256,59257,"Acridine, 2-methoxy-9-(4-quinazolinylthio)-",COC1=CC2=C(C3=CC=CC=C3N=C2C=C1)SC4=NC=NC5=CC=CC=C54,,,,,,
9257,59258,"Acridine, 2-ethoxy-9-(4-quinazolinylthio)-",CCOC1=CC2=C(C3=CC=CC=C3N=C2C=C1)SC4=NC=NC5=CC=CC=C54,,,,,,
9258,59259,"Acridine, 2-chloro-9-(4-quinazolinylthio)-",C1=CC=C2C(=C1)C(=C3C=C(C=CC3=N2)Cl)SC4=NC=NC5=CC=CC=C54,,,,,,
9259,59260,"Acridine, 4-methoxy-9-(4-quinazolinylthio)-",COC1=CC=CC2=C(C3=CC=CC=C3N=C21)SC4=NC=NC5=CC=CC=C54,,,,,,
9260,59261,"2,5,6-Trimethyl-7-pentylthiohept-1-en-3-yn-5-ol",CCCCCSCC(C)C(C)(C#CC(=C)C)O,,,,,,
9261,59262,"2,5,6-Trimethyl-7-isopentylthiohept-1-en-3-yn-5-ol",CC(C)CCSCC(C)C(C)(C#CC(=C)C)O,,,,,,
9262,59263,"2,5,6-Trimethyl-7-hexylthiohept-1-en-3-yn-5-ol",CCCCCCSCC(C)C(C)(C#CC(=C)C)O,,,,,,
9263,59264,"6-Hepten-4-YN-3-OL, 1-(heptylthio)-2,3,6-trimethyl-",CCCCCCCSCC(C)C(C)(C#CC(=C)C)O,,,,,,
9264,59265,"2,5,6-Trimethyl-7-octylthiohept-1-en-3-yn-5-ol",CCCCCCCCSCC(C)C(C)(C#CC(=C)C)O,,,,,,
9265,59266,"2,3,6-Trimethyl-1-nonylsulfanylhept-6-en-4-yn-3-ol",CCCCCCCCCSCC(C)C(C)(C#CC(=C)C)O,,,,,,
9266,59267,"1-(Decylthio)-2,3,6-trimethyl-6-hepten-4-yn-3-ol",CCCCCCCCCCSCC(C)C(C)(C#CC(=C)C)O,,,,,,
9267,59268,"Carbamimidothioic acid, 3-aminobutyl ester, dihydrobromide",C(CCSC(=[NH2+])N)C[NH3+].[Br-].[Br-],,,,,,
9268,59269,2-(4-Aminobutyl)isothiourea,C(CCSC(=N)N)CN,,,,,,
9269,59270,1-((p-((Bis(2-chloroethyl)amino)methyl)phenyl)azo)-2-naphthol,C1=CC=C2C(=C1)C=CC(=C2N=NC3=CC=C(C=C3)CN(CCCl)CCCl)O,,,,,,
9270,59271,"trans-1-(p-Aminobenzoyloxy)-2-dimethylamino-1,2,3,4-tetrahydronaphthalene hydrochloride",C[NH+](C)[C@H]1CCC2=CC=CC=C2[C@H]1OC(=O)C3=CC=C(C=C3)N.[Cl-],,,,,,
9271,59272,"[(1R,2S)-2-(dimethylamino)-1,2,3,4-tetrahydronaphthalen-1-yl] 4-aminobenzoate",CN(C)[C@H]1CCC2=CC=CC=C2[C@H]1OC(=O)C3=CC=C(C=C3)N,,,,,,
9272,59273,"4H-NAPHTHO(2,3-b)PYRAN-4-ONE, 2-DIETHYLAMINO-",CCN(CC)C1=CC(=O)C2=CC3=CC=CC=C3C=C2O1,,,,,,
9273,59274,"4H-NAPHTHO(2,3-b)PYRAN-4-ONE, 2-(ETHYLMETHYLAMINO)-",CCN(C)C1=CC(=O)C2=CC3=CC=CC=C3C=C2O1,,,,,,
9274,59275,"1-Naphthylamine, N-(5-amino-2-oxazolyl)-",C1=CC=C2C(=C1)C=CC=C2NC3=NC=C(O3)N,,,,,,
9275,59276,2-(2-Bromo-1-naphthylamino)-2-imidazoline hydrobromide,C1CN=C([NH2+]1)NC2=C(C=CC3=CC=CC=C32)Br.[Br-],,,,,,
9276,59277,"N-(2-bromonaphthalen-1-yl)-4,5-dihydro-1H-imidazol-2-amine",C1CN=C(N1)NC2=C(C=CC3=CC=CC=C32)Br,,,,,,
9277,59278,2-(4-Bromo-1-naphthylamino)-2-imidazoline hydrochloride,C1CN=C([NH2+]1)NC2=CC=C(C3=CC=CC=C32)Br.[Cl-],,,,,,
9278,59279,"N-(4-bromonaphthalen-1-yl)-4,5-dihydro-1H-imidazol-2-amine",C1CN=C(N1)NC2=CC=C(C3=CC=CC=C32)Br,,,,,,
9279,59280,"1-Naphthylamine, 4-chloro-N-(5,6-dihydro-4H-1,3-thiazin-2-YL)-",C1CN=C(SC1)NC2=CC=C(C3=CC=CC=C32)Cl,,,,,,
9280,59281,"2-(2,4-Dibromo-1-naphthylamino)-2-imidazoline hydrobromide",C1CN=C([NH2+]1)NC2=C(C=C(C3=CC=CC=C32)Br)Br.[Br-],,,,,,
9281,59282,"N-(2,4-dibromonaphthalen-1-yl)-4,5-dihydro-1H-imidazol-2-amine",C1CN=C(N1)NC2=C(C=C(C3=CC=CC=C32)Br)Br,,,,,,
9282,59283,"2-Imidazoline, 2-(2-bromo-5,6,7,8-tetrahydro-1-naphthylamino)-, hydrobromide",C1CCC2=C(C1)C=CC(=C2[NH2+]C3=NCCN3)Br.[Br-],,,,,,
9283,59284,"N-(2-bromo-5,6,7,8-tetrahydronaphthalen-1-yl)-4,5-dihydro-1H-imidazol-2-amine",C1CCC2=C(C1)C=CC(=C2NC3=NCCN3)Br,,,,,,
9284,59285,"1-Naphthylamine, 5,6,7,8-tetrahydro-N-(5,6-dihydro-4H-1,3-oxazin-2-YL)-",C1CCC2=C(C1)C=CC=C2NC3=NCCCO3,,,,,,
9285,59286,"1-Naphthylamine, 5,6,7,8-tetrahydro-N-(5,6-dihydro-4H-1,3-thiazin-2-YL)-",C1CCC2=C(C1)C=CC=C2NC3=NCCCS3,,,,,,
9286,59287,"4-Ethyl-2-(5,6,7,8-tetrahydro-1-naphthylamino)-2-oxazoline",CCC1COC(=N1)NC2=CC=CC3=C2CCCC3,,,,,,
9287,59288,"2-(5,6,7,8-Tetrahydro-1-naphthylamino)-2-imidazoline p-toluenesulfonate",CC1=CC=C(C=C1)S(=O)(=O)[O-].C1CCC2=C(C1)C=CC=C2NC3=NCC[NH2+]3,,,,,,
9288,59289,"1-Naphthylamine, 5,6,7,8-tetrahydro-2,3-dimethyl-N-(2-oxazolinyl)-",CC1=CC2=C(CCCC2)C(=C1C)NC3=NCCO3,,,,,,
9289,59290,AL-Dihydro-beta-antiarin [German],CC1[C@H](C(C([C@H](O1)O[C@H]2CC[C@@]3(C4C[C@H]([C@@]5([C@H](CC[C@@]5(C4CC[C@@]3(C2)O)O)C6=CC(=O)OC6)C)O)CO)O)O)O,,,,,,
9290,59291,"[(3S,5R,10S,12R,13S,14S,17R)-3,12,14-trihydroxy-10,13-dimethyl-17-(5-oxo-2H-furan-3-yl)-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthren-16-yl] acetate",CC(=O)OC1C[C@@]2(C3CC[C@@H]4C[C@H](CC[C@@]4(C3C[C@H]([C@@]2([C@H]1C5=CC(=O)OC5)C)O)C)O)O,,,,,,
9291,59292,"Carvacrol, 3-(2-(dimethylamino)ethoxy)-, hydrochloride",CC1=C(C(=C(C=C1)C(C)C)OCC[NH+](C)C)O.[Cl-],,,,,,
9292,59293,2-[2-(Dimethylamino)ethoxy]-6-methyl-3-(1-methylethyl)phenol,CC1=C(C(=C(C=C1)C(C)C)OCCN(C)C)O,,,,,,
9293,59294,"Carvacrol, 3-(2-(methylamino)ethoxy)-, hydrochloride",CC1=CC(=C(C=C1O)C(C)C)OCC[NH2+]C.[Cl-],,,,,,
9294,59295,"3,6,14-Trihydroxycard-20(22)-enolide",C[C@]12CCC3C([C@]1(CC[C@@H]2C4=CC(=O)OC4)O)CC([C@H]5[C@@]3(CC[C@@H](C5)O)C)O,,,,,,
9295,59296,Isopropylvinylputrescin,CC(C)C=CNCCCCN,,,,,,
9296,59297,4-(2-Morpholinoethoxy)carbanilic acid 2-(pentyloxy)ethyl ester,CCCCCOCCOC(=O)NC1=CC=C(C=C1)OCCN2CCOCC2,,,,,,
9297,59298,"ISONICOTINAMIDE, N-(3,3-BIS(p-CHLOROPHENYL)PROPYL)-",C1=CC(=CC=C1C(CCNC(=O)C2=CC=NC=C2)C3=CC=C(C=C3)Cl)Cl,,,,,,
9298,59299,"Aniline, 4,4'-(trimethylenedioxy)bis(N,N-dimethyl-",CN(C)C1=CC=C(C=C1)OCCCOC2=CC=C(C=C2)N(C)C,,,,,,
9299,59300,"ANILINE, N-ETHYL-p-(5-PHENYLPENTYLOXY)-, HYDROCHLORIDE",CC[NH2+]C1=CC=C(C=C1)OCCCCCC2=CC=CC=C2.[Cl-],,,,,,
9300,59301,N-ethyl-4-(5-phenylpentoxy)aniline,CCNC1=CC=C(C=C1)OCCCCCC2=CC=CC=C2,,,,,,
9301,59302,"ANILINE, p-(5-(p-ETHOXYPHENOXY)PENTYLOXY)-",CCOC1=CC=C(C=C1)OCCCCCOC2=CC=C(C=C2)N,,,,,,
9302,59303,CID 59303,COC1=CC(=CC(=C1OC)OC)NC(=O)OCCCN2CCN(CC2)C3=CC=CC=C3.C(=CC(=O)O)C(=O)O,,,,,,
9303,59304,"3-(4-phenylpiperazin-1-yl)propyl N-(3,4,5-trimethoxyphenyl)carbamate",COC1=CC(=CC(=C1OC)OC)NC(=O)OCCCN2CCN(CC2)C3=CC=CC=C3,,,,,,
9304,59305,"DODECANAMIDE, N-(p-CHLOROBENZYL)-",CCCCCCCCCCCC(=O)NCC1=CC=C(C=C1)Cl,,,,,,
9305,59306,"N-(3,4-Dichlorobenzyl)dodecanamide",CCCCCCCCCCCC(=O)NCC1=CC(=C(C=C1)Cl)Cl,,,,,,
9306,59307,"N-(3,4-Dimethylbenzyl)dodecanamide",CCCCCCCCCCCC(=O)NCC1=CC(=C(C=C1)C)C,,,,,,
9307,59308,"Adenine, 7,8-dihydro-N-benzyl-",C1NC2=C(N1)N=CN=C2NCC3=CC=CC=C3,,,,,,
9308,59309,N(sup 6)Benzyladenosine-5'-monophosphate diammonium salt,C1=CC=C(C=C1)CNC2=C3C(=NC=N2)N(C=N3)[C@H]4[C@@H]([C@@H]([C@H](O4)COP(=O)(O)O)O)O.N.N,,,,,,
9309,59310,Benzyl-adenosine monophosphate,C1=CC=C(C=C1)CNC2=C3C(=NC=N2)N(C=N3)[C@H]4[C@@H]([C@@H]([C@H](O4)COP(=O)(O)O)O)O,,,,,,
9310,59311,"N,N-Di-tert-butyl-beta-benzyloxyadipamide",CC(C)(C)NC(=O)CCC(CC(=O)NC(C)(C)C)OCC1=CC=CC=C1,,,,,,
9311,59312,"N,N-Bis(tert-butyl)-3-(2-nitrocyclohexyl)adipamide",CC(C)(C)N(C(=O)CC(CCC(=O)N)C1CCCCC1[N+](=O)[O-])C(C)(C)C,,,,,,
9312,59313,"N,N'-Di-tert-butyl-beta-(dimethylamino)adipamide",CC(C)(C)NC(=O)CCCC(C(=O)NC(C)(C)C)N(C)C,,,,,,
9313,59314,"N,N-Di-tert-butyl-beta-propoxyadipamide",CCCOC(CCC(=O)N)CC(=O)N(C(C)(C)C)C(C)(C)C,,,,,,
9314,59315,"3,5-Dimethoxybenzoic acid alpha-((diethylamino)methyl)benzyl ester",CCN(CC)CC(C1=CC=CC=C1)OC(=O)C2=CC(=CC(=C2)OC)OC,,,,,,
9315,59316,"N,N-Dimethyl-2-((alpha-(5,6,7,8-tetrahydro-2-naphthyl)benzyl)thio)ethylamine hydrochloride",C[NH+](C)CCSC(C1=CC=CC=C1)C2=CC3=C(CCCC3)C=C2.[Cl-],,,,,,
9316,59317,"N,N-dimethyl-2-[phenyl(5,6,7,8-tetrahydronaphthalen-2-yl)methyl]sulfanylethanamine",CN(C)CCSC(C1=CC=CC=C1)C2=CC3=C(CCCC3)C=C2,,,,,,
9317,59318,"Ethylenediamine, N-benzyl-N',N'-dimethyl-N-1-naphthyl-",CN(C)CCN(CC1=CC=CC=C1)C2=CC=CC3=CC=CC=C32,,,,,,
9318,59319,"Isonipecotic acid, 4-phenyl-1-phenylcarbamoyl-, ethyl ester",CCOC(=O)C1(CCN(CC1)C(=O)NC2=CC=CC=C2)C3=CC=CC=C3,,,,,,
9319,59320,"1-Adamantanamine citrate, monohydrate",C1C2CC3CC1CC(C2)(C3)N.C(C(=O)O)C(CC(=O)O)(C(=O)O)O.O,,,,,,
9320,59321,"1-Isonicotinoyl-2,2-bis(2-chloroethyl)hydrazine hydrochloride",C1=CN=CC=C1C(=O)N[NH+](CCCl)CCCl.[Cl-],,,,,,
9321,59322,"N',N'-bis(2-chloroethyl)pyridine-4-carbohydrazide",C1=CN=CC=C1C(=O)NN(CCCl)CCCl,,,,,,
9322,59323,"Isonipecotic acid, 1-acetonyl-4-phenyl-, ethyl ester",CCOC(=O)C1(CCN(CC1)CC(=O)C)C2=CC=CC=C2,,,,,,
9323,59324,"ISONIPECOTIC ACID, 1-((p-AMINOPHENYL)CARBAMOYL)-4-PHENYL-, ETHYL ESTER",CCOC(=O)C1(CCN(CC1)C(=O)NC2=CC=C(C=C2)N)C3=CC=CC=C3,,,,,,
9324,59325,"ISONIPECOTIC ACID, 1-((p-CHLOROPHENYL)CARBAMOYL)-4-PHENYL-, ETHYL ESTER",CCOC(=O)C1(CCN(CC1)C(=O)NC2=CC=C(C=C2)Cl)C3=CC=CC=C3,,,,,,
9325,59326,"Isonipecotic acid, 1-(2-(p-fluorobenzoyl)allyl)-4-phenyl-, ethyl ester, hydrochloride",CCOC(=O)C1(CC[NH+](CC1)CC(=C)C(=O)C2=CC=C(C=C2)F)C3=CC=CC=C3.[Cl-],,,,,,
9326,59327,Ethyl 1-[2-(4-fluorobenzoyl)prop-2-enyl]-4-phenylpiperidine-4-carboxylate,CCOC(=O)C1(CCN(CC1)CC(=C)C(=O)C2=CC=C(C=C2)F)C3=CC=CC=C3,,,,,,
9327,59328,"Isonipecotic acid, 1-(2-(p-fluorobenzoyl)ethyl)-4-phenyl-, ethyl ester, hydrochloride",CCOC(=O)C1(CC[NH+](CC1)CCC(=O)C2=CC=C(C=C2)F)C3=CC=CC=C3.[Cl-],,,,,,
9328,59329,Ethyl 1-[3-(4-fluorophenyl)-3-oxopropyl]-4-phenylpiperidine-4-carboxylate,CCOC(=O)C1(CCN(CC1)CCC(=O)C2=CC=C(C=C2)F)C3=CC=CC=C3,,,,,,
9329,59330,"Isonipecotic acid, 4-hydroxy-1-methyl-, diphenylmethyl ester",CN1CCC(CC1)(C(=O)OC(C2=CC=CC=C2)C3=CC=CC=C3)O,,,,,,
9330,59331,"Isonipecotic acid, 1-methyl-, diphenylmethyl ester",CN1CCC(CC1)C(=O)OC(C2=CC=CC=C2)C3=CC=CC=C3,,,,,,
9331,59332,"ISONIPECOTIC ACID, 1-METHYL-, 2-HYDROXY-3-(o-TOLYLOXY)PROPYL ESTER",CC1=CC=CC=C1OCCCOC(=O)C2CCN(C(C2)O)C,,,,,,
9332,59333,"Isonipecotic acid, 4-phenyl-1-(1-phenylcyclohexyl)-, ethyl ester, hydrobromide",CCOC(=O)C1(CC[NH+](CC1)C2(CCCCC2)C3=CC=CC=C3)C4=CC=CC=C4.[Br-],,,,,,
9333,59334,Ethyl 4-phenyl-1-(1-phenylcyclohexyl)piperidine-4-carboxylate,CCOC(=O)C1(CCN(CC1)C2(CCCCC2)C3=CC=CC=C3)C4=CC=CC=C4,,,,,,
9334,59335,"Isonipecotic acid, 4-phenyl-1-(p-(4-(4-phenyl-1,2,5,6-tetrahydro-1-pyridyl)butyryl)phenyl)-, ethyl ester",CCOC(=O)C1(CCN(CC1)C2=CC=C(C=C2)C(=O)CCCN3CCC(=CC3)C4=CC=CC=C4)C5=CC=CC=C5,,,,,,
9335,59336,"ISONIPECOTIC ACID, 4-PHENYL-1-p-TOLYLCARBAMOYL-, ETHYL ESTER",CCOC(=O)C1(CCN(CC1)C(=O)NC2=CC=C(C=C2)C)C3=CC=CC=C3,,,,,,
9336,59337,"Isophthalanilide, 4-hydroxy-2',2'',4',4'',5-pentachloro-",C1=CC(=C(C=C1Cl)Cl)NC(=O)C2=CC(=C(C(=C2)Cl)O)C(=O)NC3=C(C=C(C=C3)Cl)Cl,,,,,,
9337,59338,"Isoquino(2,1-d)(1,4)benzodiazepin-6(7H)-one, 5,9,10,14b-tetrahydro-2-chloro-12,13-dimethoxy-7-ethyl-",CCC1C(=O)NC2=C(C=C(C=C2)Cl)C3N1CCC4=CC(=C(C=C34)OC)OC,,,,,,
9338,59339,"12,13-Dimethoxy-10-nitro-7,9,10,14b-tetrahydro-5H-isoquino(2,1-d)(1,4)benzodiazepin-6-one",COC1=C(C=C2C3C4=CC=CC=C4NC(=O)CN3CC(C2=C1)[N+](=O)[O-])OC,,,,,,
9339,59340,"2-[(4-Chlorophenyl)(phenyl)methyl]-1,2,3,4-tetrahydroisoquinoline",C1CN(CC2=CC=CC=C21)C(C3=CC=CC=C3)C4=CC=C(C=C4)Cl,,,,,,
9340,59341,"N-Cyclopropyl-1,2,3,4-tetrahydroisoquinoline hydrochloride",C1CC1[NH+]2CCC3=CC=CC=C3C2.[Cl-],,,,,,
9341,59342,"2-cyclopropyl-3,4-dihydro-1H-isoquinoline",C1CC1N2CCC3=CC=CC=C3C2,,,,,,
9342,59343,"1,2,3,4-Tetrahydro-6,7-dimethoxy-2-(2-piperidinoethyl)isoquinoline dihydrochloride",COC1=C(C=C2C[NH+](CCC2=C1)CC[NH+]3CCCCC3)OC.[Cl-].[Cl-],,,,,,
9343,59344,"6,7-dimethoxy-2-(2-piperidin-1-ylethyl)-3,4-dihydro-1H-isoquinoline",COC1=C(C=C2CN(CCC2=C1)CCN3CCCCC3)OC,,,,,,
9344,59345,L-N-(1-Hydroxy-2-propyl)-1-(3-indolylmethyl)isonipecotamide,CC(CO)NC(=O)C1CCN(CC1)CC2=CNC3=CC=CC=C32,,,,,,
9345,59346,"Acetanilide, 2-chloro-N-(2-ethoxyethyl)-",CCOCCN(C1=CC=CC=C1)C(=O)CCl,,,,,,
9346,59347,"Acetanilide, 2-chloro-N-(3-methoxypropyl)-",COCCCN(C1=CC=CC=C1)C(=O)CCl,,,,,,
9347,59348,2-chloro-N-(3-methoxypropyl)-N-(2-methylphenyl)acetamide,CC1=CC=CC=C1N(CCCOC)C(=O)CCl,,,,,,
9348,59349,N-ethyl-4-[5-[4-(ethylamino)phenoxy]pentoxy]aniline,CCNC1=CC=C(C=C1)OCCCCCOC2=CC=C(C=C2)NCC,,,,,,
9349,59350,2-(1-methylpyrrolidin-2-yl)ethyl 9H-fluorene-9-carboxylate,CN1CCCC1CCOC(=O)C2C3=CC=CC=C3C4=CC=CC=C24,,,,,,
9350,59351,CID 59351,C1COCC[NH+]1CC(C2=CC=CC=C2)OC(=O)C=CC3=CC=CC=C3.[Cl-],,,,,,
9351,59352,CID 59352,C1COCCN1CC(C2=CC=CC=C2)OC(=O)C=CC3=CC=CC=C3,,,,,,
9352,59353,2-Ethyl-5-methylhexanamide,CCC(CCC(C)C)C(=O)N,,,,,,
9353,59354,"BENZAMIDE, N-(8-(p-AMINOPHENOXY)OCTYL)-",C1=CC=C(C=C1)C(=O)NCCCCCCCCOC2=CC=C(C=C2)N,,,,,,
9354,59355,Diphenylacetic acid 2-(1-ethyl-2-pyrrolidinyl)ethyl ester,CCN1CCCC1CCOC(=O)C(C2=CC=CC=C2)C3=CC=CC=C3,,,,,,
9355,59356,"2-Pyrrolidinepropanol, 1-methyl-, benzilate",CN1CCCC1CCCOC(=O)C(C2=CC=CC=C2)(C3=CC=CC=C3)O,,,,,,
9356,59357,CID 59357,CSC1=CC=C(C=C1)C(=O)C2=C3C(=CC(=C2)CC(=O)[O-])C=CO3.[Na+],,,,,,
9357,59358,Tifurac,CSC1=CC=C(C=C1)C(=O)C2=C3C(=CC(=C2)CC(=O)O)C=CO3,,,,,,
9358,59359,"Acetophenone, 4'-(4-phenyl-1,2,5,6-tetrahydro-1-pyridyl)-",CC(=O)C1=CC=C(C=C1)N2CCC(=CC2)C3=CC=CC=C3,,,,,,
9359,59360,2-(Benzyl(2-(diethylamino)ethyl)amino)-6'-chloro-o-acetotoluidide dihydrochloride,CC[NH+](CC)CC[NH+](CC1=CC=CC=C1)CC(=O)NC2=C(C=CC=C2Cl)C.[Cl-].[Cl-],,,,,,
9360,59361,"Acetamide, N-(2-chloro-6-methylphenyl)-2-[[2-(diethylamino)ethyl](phenylmethyl)amino]-",CCN(CC)CCN(CC1=CC=CC=C1)CC(=O)NC2=C(C=CC=C2Cl)C,,,,,,
9361,59362,2-(Benzyl(2-(diethylamino)ethyl)amino)-o-acetotoluidide dihydrochloride,CC[NH+](CC)CC[NH+](CC1=CC=CC=C1)CC(=O)NC2=CC=CC=C2C.[Cl-].[Cl-],,,,,,
9362,59363,2-{benzyl[2-(diethylamino)ethyl]amino}-N-(2-methylphenyl)acetamide,CCN(CC)CCN(CC1=CC=CC=C1)CC(=O)NC2=CC=CC=C2C,,,,,,
9363,59364,2-(Butyl(2-(diethylamino)ethyl)amino)-6'-chloro-o-acetotoluidide hydrochloride,CCCCN(CC[NH+](CC)CC)CC(=O)NC1=C(C=CC=C1Cl)C.[Cl-],,,,,,
9364,59365,2-[butyl-[2-(diethylamino)ethyl]amino]-N-(2-chloro-6-methylphenyl)acetamide,CCCCN(CCN(CC)CC)CC(=O)NC1=C(C=CC=C1Cl)C,,,,,,
9365,59366,6'-Chloro-2-(2-(diethylamino)ethoxy)-o-acetotoluidide hydrochloride,CC[NH+](CC)CCOCC(=O)NC1=C(C=CC=C1Cl)C.[Cl-],,,,,,
9366,59367,N-(2-chloro-6-methylphenyl)-2-[2-(diethylamino)ethoxy]acetamide,CCN(CC)CCOCC(=O)NC1=C(C=CC=C1Cl)C,,,,,,
9367,59368,6'-Chloro-2-(2-(diethylamino)ethyl)amino-o-acetotoluidide hydrochloride,CC[NH+](CC)CCNCC(=O)NC1=C(C=CC=C1Cl)C.[Cl-],,,,,,
9368,59369,N-(2-chloro-6-methylphenyl)-2-[2-(diethylamino)ethylamino]acetamide,CCN(CC)CCNCC(=O)NC1=C(C=CC=C1Cl)C,,,,,,
9369,59370,6'-Chloro-2-((2-(diethylamino)ethyl)ethylamino)-o-acetotoluidide hydrochloride,CC[NH+](CC)CCN(CC)CC(=O)NC1=C(C=CC=C1Cl)C.[Cl-],,,,,,
9370,59371,N-(2-chloro-6-methylphenyl)-2-[2-(diethylamino)ethyl-ethylamino]acetamide,CCN(CC)CCN(CC)CC(=O)NC1=C(C=CC=C1Cl)C,,,,,,
9371,59372,6'-Chloro-2-((2-(diethylamino)ethyl)isopropylamino)-o-acetotoluidide hydrochloride,CC[NH+](CC)CCN(CC(=O)NC1=C(C=CC=C1Cl)C)C(C)C.[Cl-],,,,,,
9372,59373,N-(2-chloro-6-methylphenyl)-2-[2-(diethylamino)ethyl-propan-2-ylamino]acetamide,CCN(CC)CCN(CC(=O)NC1=C(C=CC=C1Cl)C)C(C)C,,,,,,
9373,59374,6'-Chloro-2-((2-(diethylamino)ethyl)methylamino)-o-acetotoluidide hydrochloride,CC[NH+](CC)CCN(C)CC(=O)NC1=C(C=CC=C1Cl)C.[Cl-],,,,,,
9374,59375,N-(2-chloro-6-methylphenyl)-2-[2-(diethylamino)ethyl-methylamino]acetamide,CCN(CC)CCN(C)CC(=O)NC1=C(C=CC=C1Cl)C,,,,,,
9375,59376,6'-Chloro-2-((2-(diethylamino)ethyl)octylamino)-o-acetotoluidide hydrochloride,CCCCCCCCN(CC[NH+](CC)CC)CC(=O)NC1=C(C=CC=C1Cl)C.[Cl-],,,,,,
9376,59377,N-(2-chloro-6-methylphenyl)-2-[2-(diethylamino)ethyl-octylamino]acetamide,CCCCCCCCN(CCN(CC)CC)CC(=O)NC1=C(C=CC=C1Cl)C,,,,,,
9377,59378,6'-Chloro-2-((2-(diethylamino)ethyl)(2-phenoxyethyl)amino)-o-acetotoluidide hydrochloride,CC[NH+](CC)CCN(CCOC1=CC=CC=C1)CC(=O)NC2=C(C=CC=C2Cl)C.[Cl-],,,,,,
9378,59379,N-(2-chloro-6-methylphenyl)-2-[2-(diethylamino)ethyl-(2-phenoxyethyl)amino]acetamide,CCN(CC)CCN(CCOC1=CC=CC=C1)CC(=O)NC2=C(C=CC=C2Cl)C,,,,,,
9379,59380,6'-Chloro-2-((2-(diethylamino)ethyl)propylamino)-o-acetotoluidide hydrochloride,CCCN(CC[NH+](CC)CC)CC(=O)NC1=C(C=CC=C1Cl)C.[Cl-],,,,,,
9380,59381,N-(2-chloro-6-methylphenyl)-2-[2-(diethylamino)ethyl-propylamino]acetamide,CCCN(CCN(CC)CC)CC(=O)NC1=C(C=CC=C1Cl)C,,,,,,
9381,59382,6'-Chloro-2-(2-(diethylamino)ethylthio)-o-acetotoluidide hydrochloride,CC[NH+](CC)CCSCC(=O)NC1=C(C=CC=C1Cl)C.[Cl-],,,,,,
9382,59383,N-(2-chloro-6-methylphenyl)-2-[2-(diethylamino)ethylsulfanyl]acetamide,CCN(CC)CCSCC(=O)NC1=C(C=CC=C1Cl)C,,,,,,
9383,59384,6'-Chloro-2-(ethyl(2-phenoxyethyl)amino)-o-acetotoluidide hydrochloride,CC[NH+](CCOC1=CC=CC=C1)CC(=O)NC2=C(C=CC=C2Cl)C.[Cl-],,,,,,
9384,59385,N-(2-chloro-6-methylphenyl)-2-[ethyl(2-phenoxyethyl)amino]acetamide,CCN(CCOC1=CC=CC=C1)CC(=O)NC2=C(C=CC=C2Cl)C,,,,,,
9385,59386,"6'-Chloro-2-(2-furylmethyl)amino-o-acetotoluidide, hydrochloride",CC1=C(C(=CC=C1)Cl)NC(=O)C[NH2+]CC2=CC=CO2.[Cl-],,,,,,
9386,59387,N-(2-chloro-6-methylphenyl)-2-(furan-2-ylmethylamino)acetamide,CC1=C(C(=CC=C1)Cl)NC(=O)CNCC2=CC=CO2,,,,,,
9387,59388,"6'-Chloro-2-(isobutylamino)-o-acetotoluidide, hydrochloride",CC1=C(C(=CC=C1)Cl)NC(=O)C[NH2+]CC(C)C.[Cl-],,,,,,
9388,59389,N-(2-chloro-6-methylphenyl)-2-(2-methylpropylamino)acetamide,CC1=C(C(=CC=C1)Cl)NC(=O)CNCC(C)C,,,,,,
9389,59390,N-(2-chloro-6-methylphenyl)-2-pyrrolidin-1-ium-1-ylacetamide bromide,CC1=C(C(=CC=C1)Cl)NC(=O)C[NH+]2CCCC2.[Br-],,,,,,
9390,59391,N-(2-Chloro-6-methylphenyl)-1-pyrrolidineacetamide,CC1=C(C(=CC=C1)Cl)NC(=O)CN2CCCC2,,,,,,
9391,59392,2-(2-(Diethylamino)ethyl)thio-o-acetotoluidide hydrochloride,CC[NH+](CC)CCSCC(=O)NC1=CC=CC=C1C.[Cl-],,,,,,
9392,59393,2-[2-(diethylamino)ethylsulfanyl]-N-(2-methylphenyl)acetamide,CCN(CC)CCSCC(=O)NC1=CC=CC=C1C,,,,,,
9393,59394,"2-(Benzyl(2-(diethylamino)ethyl)amino)-2',6'-acetoxylidide dihydrochloride",CC[NH+](CC)CC[NH+](CC1=CC=CC=C1)CC(=O)NC2=C(C=CC=C2C)C.[Cl-].[Cl-],,,,,,
9394,59395,"2-[benzyl-[2-(diethylamino)ethyl]amino]-N-(2,6-dimethylphenyl)acetamide",CCN(CC)CCN(CC1=CC=CC=C1)CC(=O)NC2=C(C=CC=C2C)C,,,,,,
9395,59396,"1,3,4-OXADIAZOLE, 5-(o-CHLOROPHENYL)-2-(1-NAPHTHYL)-",C1=CC=C2C(=C1)C=CC=C2C3=NN=C(O3)C4=CC=CC=C4Cl,,,,,,
9396,59397,"1,3,4-Oxadiazole, 5-methyl-2-(1-naphthylamino)-",CC1=NN=C(O1)NC2=CC=CC3=CC=CC=C32,,,,,,
9397,59398,CID 59398,C1N(N=C(O1)[NH3+])CCC2=CC=CC=C2.[Cl-],,,,,,
9398,59399,"3-(2-phenylethyl)-2H-1,3,4-oxadiazol-5-amine",C1N(N=C(O1)N)CCC2=CC=CC=C2,,,,,,
9399,59400,"5-((Butylamino)methyl)-3-phenyl-delta(sup 4)-1,2,4-oxadiazoline hydrochloride",CCCCNCC1=NN(CO1)C2=CC=CC=C2.[Cl-],,,,,,
9400,59401,"N-[(3-phenyl-2H-1,3,4-oxadiazol-5-yl)methyl]butan-1-amine",CCCCNCC1=NN(CO1)C2=CC=CC=C2,,,,,,
9401,59402,CID 59402,C1CCN(C1)CCCC2=NNC(O2)C3=CC=C(C=C3)Cl.[Cl-],,,,,,
9402,59403,"2-(4-Chlorophenyl)-5-(3-pyrrolidin-1-ylpropyl)-2,3-dihydro-1,3,4-oxadiazole",C1CCN(C1)CCCC2=NNC(O2)C3=CC=C(C=C3)Cl,,,,,,
9403,59404,CID 59404,CCN(CC)CCC1=NNC(O1)C2=CC=C(C=C2)OC.[Cl-],,,,,,
9404,59405,"N,N-diethyl-2-[2-(4-methoxyphenyl)-2,3-dihydro-1,3,4-oxadiazol-5-yl]ethanamine",CCN(CC)CCC1=NNC(O1)C2=CC=C(C=C2)OC,,,,,,
9405,59406,"delta(sup 4)-1,2,4-Oxadiazoline, 5-(2-(diethylamino)ethyl)-3-phenyl-, hydrochloride",CCN(CC)CCC1=NNC(O1)C2=CC=CC=C2.[Cl-],,,,,,
9406,59407,"N,N-diethyl-2-(2-phenyl-2,3-dihydro-1,3,4-oxadiazol-5-yl)ethanamine",CCN(CC)CCC1=NNC(O1)C2=CC=CC=C2,,,,,,
9407,59408,"delta(sup 4)-1,2,4-Oxadiazoline, 5-(2-(diethylamino)ethyl)-3-(p-tolyl)-, hydrochloride",CCN(CC)CCC1=NNC(O1)C2=CC=C(C=C2)C.[Cl-],,,,,,
9408,59409,"N,N-diethyl-2-[2-(4-methylphenyl)-2,3-dihydro-1,3,4-oxadiazol-5-yl]ethanamine",CCN(CC)CCC1=NNC(O1)C2=CC=C(C=C2)C,,,,,,
9409,59410,"delta(sup 4)-1,2,4-Oxadiazoline, 5-((diethylamino)methyl)-3-phenyl-, hydrochloride",CCN(CC)CC1=NNC(O1)C2=CC=CC=C2.[Cl-],,,,,,
9410,59411,"N-ethyl-N-[(2-phenyl-2,3-dihydro-1,3,4-oxadiazol-5-yl)methyl]ethanamine",CCN(CC)CC1=NNC(O1)C2=CC=CC=C2,,,,,,
9411,59412,"delta(sup 4)-1,2,4-Oxadiazoline, 5-(3-(diethylamino)propyl)-3-(p-chlorophenyl)-, hydrochloride",CCN(CC)CCCC1=NNC(O1)C2=CC=C(C=C2)Cl.[Cl-],,,,,,
9412,59413,"3-[2-(4-chlorophenyl)-2,3-dihydro-1,3,4-oxadiazol-5-yl]-N,N-diethylpropan-1-amine",CCN(CC)CCCC1=NNC(O1)C2=CC=C(C=C2)Cl,,,,,,
9413,59414,"delta(sup 4)-1,2,4-Oxadiazoline, 5-(3-(diethylamino)propyl)-3-phenyl-, hydrochloride",CC[NH+](CC)CCCC1=CN(NO1)C2=CC=CC=C2.[Cl-],,,,,,
9414,59415,"N,N-diethyl-3-(3-phenyl-2H-oxadiazol-5-yl)propan-1-amine",CCN(CC)CCCC1=CN(NO1)C2=CC=CC=C2,,,,,,
9415,59416,"delta(sup 4)-1,2,4-Oxadiazoline, 5-((isopropylmethylamino)methyl)-3-phenyl-, hydrochloride",CC(C)[NH+](C)CC1=CN(NO1)C2=CC=CC=C2.[Cl-],,,,,,
9416,59417,N-methyl-N-[(3-phenyl-2H-oxadiazol-5-yl)methyl]propan-2-amine,CC(C)N(C)CC1=CN(NO1)C2=CC=CC=C2,,,,,,
9417,59418,"delta(sup 4)-1,2,4-Oxadiazoline, 3-(1-naphthyl)-5-(3-(1-pyrrolidinyl)propyl)-, hydrochloride",C1CC[NH+](C1)CCCC2=NC(NO2)C3=CC=CC4=CC=CC=C43.[Cl-],,,,,,
9418,59419,"3-Naphthalen-1-yl-5-(3-pyrrolidin-1-ylpropyl)-2,3-dihydro-1,2,4-oxadiazole",C1CCN(C1)CCCC2=NC(NO2)C3=CC=CC4=CC=CC=C43,,,,,,
9419,59420,"Oxalic acid, 2-hexyl-1-imidazolyl ester",CCCCCCC1=NC=CN1OC(=O)C(=O)O,,,,,,
9420,59421,CID 59421,CC1=C(C(=CC=C1)N)N(N=C2C(=CC=CC2=N)C)O,,,,,,
9421,59422,Methyl 2-acetamido-3-(2-bromo-1-fluoroethenyl)sulfanylpropanoate,CC(=O)NC(CSC(=CBr)F)C(=O)OC,,,,,,
9422,59423,N-Acetyl-S-(2-chloro-2-methylpropyl)-L-cysteine methyl ester,CC(=O)NC(CSCC(C)(C)Cl)C(=O)OC,,,,,,
9423,59424,N-beta-Carbethoxyethyladamantanamine hydrochloride,CCOC(=O)CCNC12CC3CC(C1)CC(C3)C2.Cl,,,,,,
9424,59425,Ethyl 3-(1-adamantylamino)propanoate,CCOC(=O)CCNC12CC3CC(C1)CC(C3)C2,,,,,,
9425,59426,3-(((3-Amino-4-hydroxyphenyl)phenylarsino)thio)alanine,C1=CC=C(C=C1)[As](C2=CC(=C(C=C2)O)N)SCC(C(=O)O)N,,,,,,
9426,59427,N-(Chloroacetyl)-N-(4-methylbenzene-1-sulfonyl)phenylalanine,CC1=CC=C(C=C1)S(=O)(=O)N(C(CC2=CC=CC=C2)C(=O)O)C(=O)CCl,,,,,,
9427,59428,"beta-ALANINE, N-(2-((5-DIAZO-4-OXOPENTYL)NITROAMINO)ETHYL)-N-NITRO-",C(CC(=O)C[N+]#N)CN(CCN(CCC(=O)[O-])[N+](=O)[O-])[N+](=O)[O-],,,,,,
9428,59429,5-[2-[2-Carboxyethyl(nitro)amino]ethyl-nitroamino]-2-oxopentane-1-diazonium,C(CC(=O)C[N+]#N)CN(CCN(CCC(=O)O)[N+](=O)[O-])[N+](=O)[O-],,,,,,
9429,59430,Ethyl 3-[[4-(dimethylaminodiazenyl)benzoyl]amino]propanoate,CCOC(=O)CCNC(=O)C1=CC=C(C=C1)N=NN(C)C,,,,,,
9430,59431,Ethyl 2-[[4-(dimethylaminodiazenyl)benzoyl]amino]-3-phenylpropanoate,CCOC(=O)C(CC1=CC=CC=C1)NC(=O)C2=CC=C(C=C2)N=NN(C)C,,,,,,
9431,59432,2-(N-Thiamorpholino)ethyl benzilate hydrochloride,C1CSCC[NH+]1CCOC(=O)C(C2=CC=CC=C2)(C3=CC=CC=C3)O.[Cl-],,,,,,
9432,59433,2-(4-Thiomorpholinyl)ethyl hydroxy(diphenyl)acetate,C1CSCCN1CCOC(=O)C(C2=CC=CC=C2)(C3=CC=CC=C3)O,,,,,,
9433,59434,5-Chloro-2-benzylaminomethyl benzimidazole dihydrochloride,C1=CC=C(C=C1)C[NH2+]CC2=[NH+]C3=C(N2)C=C(C=C3)Cl.[Cl-].[Cl-],,,,,,
9434,59435,"benzyl[(5-chloro-1H-1,3-benzodiazol-2-yl)methyl]amine",C1=CC=C(C=C1)CNCC2=NC3=C(N2)C=C(C=C3)Cl,,,,,,
9435,59436,"BENZIMIDAZOLE, 2-tert-BUTYL-1-(2-(DIETHYLAMINO)ETHYL)-",CCN(CC)CCN1C2=CC=CC=C2N=C1C(C)(C)C,,,,,,
9436,59437,"2,2'-(N-Butyliminodimethylene)bis(5,6-dichlorobenzimidazole) dihydrochloride",CCCC[NH+](CC1=[NH+]C2=CC(=C(C=C2N1)Cl)Cl)CC3=NC4=CC(=C(C=C4N3)Cl)Cl.[Cl-].[Cl-],,,,,,
9437,59438,"N,N-bis[(5,6-dichloro-1H-benzimidazol-2-yl)methyl]butan-1-amine",CCCCN(CC1=NC2=CC(=C(C=C2N1)Cl)Cl)CC3=NC4=CC(=C(C=C4N3)Cl)Cl,,,,,,
9438,59439,"BENZIMIDAZOLE, 2-tert-BUTYL-4,5,6-TRICHLORO-",CC(C)(C)C1=NC2=C(C(=C(C=C2N1)Cl)Cl)Cl,,,,,,
9439,59440,"Benzimidazole, 6-chloro-1-(2-(diethylamino)ethyl)-2-(p-methoxybenzyl)-, hydrochloride",CC[NH+](CC)CCN1C2=C(C=CC(=C2)Cl)N=C1CC3=CC=C(C=C3)OC.[Cl-],,,,,,
9440,59441,"2-[6-chloro-2-[(4-methoxyphenyl)methyl]benzimidazol-1-yl]-N,N-diethyl-ethanamine",CCN(CC)CCN1C2=C(C=CC(=C2)Cl)N=C1CC3=CC=C(C=C3)OC,,,,,,
9441,59442,5(or 6)Chloro-2-(p-methoxybenzyl)benzimidazole hydrochloride,COC1=CC=C(C=C1)CC2=[NH+]C3=C(N2)C=C(C=C3)Cl.[Cl-],,,,,,
9442,59443,5-Chloro-2-(4-methoxybenzyl)-1H-benzimidazole,COC1=CC=C(C=C1)CC2=NC3=C(N2)C=C(C=C3)Cl,,,,,,
9443,59444,2-Cyclohexylaminomethylbenzimidazole dihydrochloride,C1CCC(CC1)[NH2+]CC2=[NH+]C3=CC=CC=C3N2.[Cl-].[Cl-],,,,,,
9444,59445,N-(1H-benzimidazol-2-ylmethyl)cyclohexanamine,C1CCC(CC1)NCC2=NC3=CC=CC=C3N2,,,,,,
9445,59446,"5,6-Dichloro-2-pentafluoroethyl benzimidazole",C1=C2C(=CC(=C1Cl)Cl)N=C(N2)C(C(F)(F)F)(F)F,,,,,,
9446,59447,"Benzimidazole, 1-((2-(diethylamino)ethoxy)methyl)-, dioxalate",CC[NH+](CC)CCOC[N+]1=CNC2=CC=CC=C21.C(=O)(C(=O)[O-])O.C(=O)(C(=O)[O-])O,,,,,,
9447,59448,"2-(3H-benzimidazol-1-ium-1-ylmethoxy)-N,N-diethylethanamine",CCN(CC)CCOC[N+]1=CNC2=CC=CC=C21,,,,,,
9448,59449,"Benzimidazole, 1-(2-(diethylamino)ethyl)-2-(3,4-dimethoxybenzyl)-, dihydrochloride",CC[NH+](CC)CC[N+]1=C(NC2=CC=CC=C21)CC3=CC(=C(C=C3)OC)OC.[Cl-].[Cl-],,,,,,
9449,59450,"2-[2-[(3,4-dimethoxyphenyl)methyl]-3H-benzimidazol-1-ium-1-yl]-N,N-diethylethanamine",CCN(CC)CC[N+]1=C(NC2=CC=CC=C21)CC3=CC(=C(C=C3)OC)OC,,,,,,
9450,59451,"Benzimidazole, 1-(2-(diethylamino)ethyl)-2-(3-methoxybenzyl)-",CCN(CC)CCN1C2=CC=CC=C2N=C1CC3=CC(=CC=C3)OC,,,,,,
9451,59452,"Benzimidazole, 5,5'-dithiobis(6-chloro-2-(trifluoromethyl)-",C1=C2C(=CC(=C1Cl)SSC3=C(C=C4C(=C3)N=C(N4)C(F)(F)F)Cl)N=C(N2)C(F)(F)F,,,,,,
9452,59453,"Benzimidazole, 5,5'-dithiobis(2-(trifluoromethyl)-",C1=CC2=C(C=C1SSC3=CC4=C(C=C3)N=C(N4)C(F)(F)F)NC(=N2)C(F)(F)F,,,,,,
9453,59454,2-(Dodecylthiomethyl)-benzimidazole hydrochloride,CCCCCCCCCCCCSCC1=[NH+]C2=CC=CC=C2N1.[Cl-],,,,,,
9454,59455,2-(dodecylsulfanylmethyl)-1H-benzimidazole,CCCCCCCCCCCCSCC1=NC2=CC=CC=C2N1,,,,,,
9455,59456,"BENZIMIDAZOLE, 2-(p-ETHOXYBENZYL)-5-NITRO-",CCOC1=CC=C(C=C1)CC2=NC3=C(N2)C=C(C=C3)[N+](=O)[O-],,,,,,
9456,59457,2-Heptylaminomethylbenzimidazole dihydrochloride,CCCCCCC[NH2+]CC1=[NH+]C2=CC=CC=C2N1.[Cl-].[Cl-],,,,,,
9457,59458,N-(1H-benzimidazol-2-ylmethyl)heptan-1-amine,CCCCCCCNCC1=NC2=CC=CC=C2N1,,,,,,
9458,59459,"2,2'-(N-Methyliminodimethylene)bisbenzimidazole dihydrochloride",C[NH+](CC1=[NH+]C2=CC=CC=C2N1)CC3=NC4=CC=CC=C4N3.[Cl-].[Cl-],,,,,,
9459,59460,Bis(1H-benzimidazole-2-ylmethyl)methylamine,CN(CC1=NC2=CC=CC=C2N1)CC3=NC4=CC=CC=C4N3,,,,,,
9460,59461,"Indole, 3-(4-(dimethylamino)butyl)-1-phenyl-",CN(C)CCCCC1=CN(C2=CC=CC=C21)C3=CC=CC=C3,,,,,,
9461,59462,alpha-(2-(Dimethylamino)ethyl)-1-methyl-alpha-phenylindole-3-methanol,CN1C=C(C2=CC=CC=C21)C(CCN(C)C)(C3=CC=CC=C3)O,,,,,,
9462,59463,"o-BENZOTOLUIDIDE, N-(DIETHYLCARBAMOYLMETHYL)-",CCN(CC)C(=O)CN(C1=CC=CC=C1C)C(=O)C2=CC=CC=C2,,,,,,
9463,59464,"N-(2-(Diethylamino)ethyl)-N,2-diphenylglycine ethyl ester",CCN(CC)CCN(C1=CC=CC=C1)C(C2=CC=CC=C2)C(=O)OCC,,,,,,
9464,59465,1-Methyl-2-phenyl-alpha-(piperidinomethyl)indole-3-methanol,CN1C2=CC=CC=C2C(=C1C3=CC=CC=C3)C(CN4CCCCC4)O,,,,,,
9465,59466,"ANILINE, p-(5-(p-PHENOXYPHENOXY)PENTYLOXY)-",C1=CC=C(C=C1)OC2=CC=C(C=C2)OCCCCCOC3=CC=C(C=C3)N,,,,,,
9466,59467,"N,N-Dimethyl-2-((alpha-phenyl-p-(phenylthio)benzyl)thio)ethylamine",CN(C)CCSC(C1=CC=CC=C1)C2=CC=C(C=C2)SC3=CC=CC=C3,,,,,,
9467,59468,1-(o-Methoxy-alpha-methylphenethyl)-1-methylhydrazine hydrochloride,CC(CC1=CC=CC=C1OC)N[NH2+]C.[Cl-],,,,,,
9468,59469,1-[1-(2-Methoxyphenyl)propan-2-yl]-2-methylhydrazine,CC(CC1=CC=CC=C1OC)NNC,,,,,,
9469,59470,1-(o-Methoxy-alpha-methylphenethyl)-2-methylhydrazine hydrochloride,CC(CC1=CC=CC=C1OC)[NH2+]NC.[Cl-],,,,,,
9470,59471,"1-(o-Methoxy-alpha-methylphenethyl)-1,2,2-trimethylhydrazine hydrochloride",CC(CC1=CC=CC=C1OC)N(C)[NH+](C)C.[Cl-],,,,,,
9471,59472,"1-[1-(2-Methoxyphenyl)propan-2-yl]-1,2,2-trimethylhydrazine",CC(CC1=CC=CC=C1OC)N(C)N(C)C,,,,,,
9472,59473,2-((2-Methyl-2-naphthyl)hydrazino)-2-oxazoline,CN(C1=CC=CC2=CC=CC=C21)NC3N=CCO3,,,,,,
9473,59474,"[(3,4-Diethoxyphenyl)methylideneamino]-trimethylazanium;iodide",CCOC1=C(C=C(C=C1)C=N[N+](C)(C)C)OCC.[I-],,,,,,
9474,59475,"[(3,4-Diethoxyphenyl)methylideneamino]-trimethylazanium",CCOC1=C(C=C(C=C1)C=N[N+](C)(C)C)OCC,,,,,,
9475,59476,"Hydrazinium, dimethyl(3,4-dimethoxybenzyl)-, chloride",C[N+](C)(CC1=CC(=C(C=C1)OC)OC)N.[Cl-],,,,,,
9476,59477,"Amino-[(3,4-dimethoxyphenyl)methyl]-dimethyl-ammonium",C[N+](C)(CC1=CC(=C(C=C1)OC)OC)N,,,,,,
9477,59478,"Dimethyl(3,4-dimethylbenzyl)hydrazinium chloride",CC1=C(C=C(C=C1)C[N+](C)(C)N)C.[Cl-],,,,,,
9478,59479,"Amino-[(3,4-dimethylphenyl)methyl]-dimethyl-ammonium",CC1=C(C=C(C=C1)C[N+](C)(C)N)C,,,,,,
9479,59480,[(2-Hydroxy-3-methoxyphenyl)methylideneamino]-trimethylazanium;iodide,C[N+](C)(C)N=CC1=C(C(=CC=C1)OC)O.[I-],,,,,,
9480,59481,[(2-Hydroxy-3-methoxyphenyl)methylideneamino]-trimethylazanium,C[N+](C)(C)N=CC1=C(C(=CC=C1)OC)O,,,,,,
9481,59482,"[1-(3,4-Dimethylphenyl)ethylideneamino]-trimethylazanium;iodide",CC1=C(C=C(C=C1)C(=N[N+](C)(C)C)C)C.[I-],,,,,,
9482,59483,"2-(1-(3,4-Dimethylphenyl)ethylidene)-1,1,1-trimethyl-15-diazane",CC1=C(C=C(C=C1)C(=N[N+](C)(C)C)C)C,,,,,,
9483,59484,[(4-Hydroxy-3-methoxyphenyl)methylideneamino]-trimethylazanium;iodide,C[N+](C)(C)N=CC1=CC(=C(C=C1)O)OC.[I-],,,,,,
9484,59485,[(4-Hydroxy-3-methoxyphenyl)methylideneamino]-trimethylazanium,C[N+](C)(C)N=CC1=CC(=C(C=C1)O)OC,,,,,,
9485,59486,4-Amino-3-phenylbutanamide,C1=CC=C(C=C1)C(CC(=O)N)CN,,,,,,
9486,59487,1-(o-Methoxy-alpha-methylphenethyl)hydrazine hydrochloride,CC(CC1=CC=CC=C1OC)N[NH3+].[Cl-],,,,,,
9487,59488,1-(2-Methoxyphenyl)propan-2-ylhydrazine,CC(CC1=CC=CC=C1OC)NN,,,,,,
9488,59489,2-(Diethylamino)ethyl benzylcyclopropylglycolate,CCN(CC)CCOC(=O)C(CC1=CC=CC=C1)(C2CC2)O,,,,,,
9489,59490,3-(Dimethylamino)propyl benzylcyclopropylglycolate,CN(C)CCCOC(=O)C(CC1=CC=CC=C1)(C2CC2)O,,,,,,
9490,59491,1-Methyl-3-piperidyl benzylcyclopropylglycolate,CN1CCCC(C1)OC(=O)C(CC2=CC=CC=C2)(C3CC3)O,,,,,,
9491,59492,1-Methyl-4-piperidyl benzylcyclopropylglycolate,CN1CCC(CC1)OC(=O)C(CC2=CC=CC=C2)(C3CC3)O,,,,,,
9492,59493,Diethyl(2-hydroxyethyl)propylammonium bromide dicyclopentylacetate,CCC[N+](CC)(CC)CCOC(=O)C(C1CCCC1)C2CCCC2.[Br-],,,,,,
9493,59494,"2-(2,2-Dicyclopentylacetyl)oxyethyl-diethyl-propylazanium",CCC[N+](CC)(CC)CCOC(=O)C(C1CCCC1)C2CCCC2,,,,,,
9494,59495,endo-Diethylmethyl((2-norbornanylcarbamoyl)methyl)ammonium iodide,CC[N+](C)(CC)CC(=O)NC1CC2CCC1C2.[I-],,,,,,
9495,59496,[2-(2-Bicyclo[2.2.1]heptanylamino)-2-oxoethyl]-diethyl-methylazanium,CC[N+](C)(CC)CC(=O)NC1CC2CCC1C2,,,,,,
9496,59497,"Ammonium, diethylmethyl(2-(thymyloxy)ethyl)-, iodide",CC[N+](C)(CC)CCOC1=C(C=CC(=C1)C)C(C)C.[I-],,,,,,
9497,59498,Diethyl-methyl-[2-(5-methyl-2-propan-2-ylphenoxy)ethyl]azanium,CC[N+](C)(CC)CCOC1=C(C=CC(=C1)C)C(C)C,,,,,,
9498,59499,Diethylmethyl(9-xanthenylcarbamoylmethyl)ammonium bromide,CC[N+](C)(CC)CC(=O)NC1C2=CC=CC=C2OC3=CC=CC=C13.[Br-],,,,,,
9499,59500,diethyl-methyl-[2-oxo-2-(9H-xanthen-9-ylamino)ethyl]azanium,CC[N+](C)(CC)CC(=O)NC1C2=CC=CC=C2OC3=CC=CC=C13,,,,,,
9500,59501,"Diisopropyl(2-(2,2-diphenylethoxy)ethyl)methylammonium iodide",CC(C)[N+](C)(CCOCC(C1=CC=CC=C1)C2=CC=CC=C2)C(C)C.[I-],,,,,,
9501,59502,"2-(2,2-Diphenylethoxy)ethyl-methyl-di(propan-2-yl)azanium",CC(C)[N+](C)(CCOCC(C1=CC=CC=C1)C2=CC=CC=C2)C(C)C,,,,,,
9502,59503,"Ammonium, diisopropyl(2-diphenylmethoxyethyl)methyl-, iodide",CC(C)[N+](C)(CCOC(C1=CC=CC=C1)C2=CC=CC=C2)C(C)C.[I-],,,,,,
9503,59504,2-Benzhydryloxyethyl-methyl-di(propan-2-yl)azanium,CC(C)[N+](C)(CCOC(C1=CC=CC=C1)C2=CC=CC=C2)C(C)C,,,,,,
9504,59505,"Diisopropyl(2-(3,3-diphenylpropoxy)ethyl)methylammonium iodide",CC(C)[N+](C)(CCOCCC(C1=CC=CC=C1)C2=CC=CC=C2)C(C)C.[I-],,,,,,
9505,59506,"2-(3,3-Diphenylpropoxy)ethyl-methyl-di(propan-2-yl)azanium",CC(C)[N+](C)(CCOCCC(C1=CC=CC=C1)C2=CC=CC=C2)C(C)C,,,,,,
9506,59507,3-(p-Aminobenzamido)propyl-dimethyl-dodecyl ammonium bromide,CCCCCCCCCCCC[N+](C)(C)CCCNC(=O)C1=CC=C(C=C1)N.[Br-],,,,,,
9507,59508,3-[(4-Aminobenzoyl)amino]propyl-dodecyl-dimethylazanium,CCCCCCCCCCCC[N+](C)(C)CCCNC(=O)C1=CC=C(C=C1)N,,,,,,
9508,59509,3-(p-Nitrobenzamido)propyl-dimethyl-dodecyl ammonium bromide,CCCCCCCCCCCC[N+](C)(C)CCCNC(=O)C1=CC=C(C=C1)[N+](=O)[O-].[Br-],,,,,,
9509,59510,Dodecyl-dimethyl-[3-[(4-nitrobenzoyl)amino]propyl]azanium,CCCCCCCCCCCC[N+](C)(C)CCCNC(=O)C1=CC=C(C=C1)[N+](=O)[O-],,,,,,
9510,59511,Dimethyl(2-hydroxyethyl)methoxyammonium iodide 9-xanthenecarboxylate,C[N+](C)(CCOC(=O)C1C2=CC=CC=C2OC3=CC=CC=C13)OC.[I-],,,,,,
9511,59512,methoxy-dimethyl-[2-(9H-xanthene-9-carbonyloxy)ethyl]azanium,C[N+](C)(CCOC(=O)C1C2=CC=CC=C2OC3=CC=CC=C13)OC,,,,,,
9512,59513,Dimethyl (2-hydroxyethyl)-(2-phenothiazin-10-ylethyl)ammonium iodide,C[N+](C)(CCN1C2=CC=CC=C2SC3=CC=CC=C31)CCO.[I-],,,,,,
9513,59514,2-Hydroxyethyl-dimethyl-(2-phenothiazin-10-ylethyl)azanium,C[N+](C)(CCN1C2=CC=CC=C2SC3=CC=CC=C31)CCO,,,,,,
9514,59515,(2-(Diphenylmethoxy)ethyl)triethylammonium bromide,CC[N+](CC)(CC)CCOC(C1=CC=CC=C1)C2=CC=CC=C2.[Br-],,,,,,
9515,59516,(beta-Ethyl-beta-(hydroxymethyl)phenethyl)trimethylammonium iodide,CCC(C[N+](C)(C)C)(CO)C1=CC=CC=C1.[I-],,,,,,
9516,59517,[2-(Hydroxymethyl)-2-phenylbutyl]-trimethylazanium,CCC(C[N+](C)(C)C)(CO)C1=CC=CC=C1,,,,,,
9517,59518,[2-(Dimethylcarbamoyloxy)-5-ethylphenyl]-trimethylazanium iodide,CCC1=CC(=C(C=C1)OC(=O)N(C)C)[N+](C)(C)C.[I-],,,,,,
9518,59519,[2-(Dimethylcarbamoyloxy)-5-ethylphenyl]-trimethylazanium,CCC1=CC(=C(C=C1)OC(=O)N(C)C)[N+](C)(C)C,,,,,,
9519,59520,(4-(2-Furyl)pentyl)trimethylammonium iodide,CC(CCC[N+](C)(C)C)C1=CC=CO1.[I-],,,,,,
9520,59521,4-(Furan-2-yl)pentyl-trimethylazanium,CC(CCC[N+](C)(C)C)C1=CC=CO1,,,,,,
9521,59522,"AMMONIUM, (2-(p-ACETAMIDOPHENYL)THIOETHYL)DIETHYLMETHYL-, IODIDE",CC[N+](C)(CC)CCSC1=CC=C(C=C1)NC(=O)C.[I-],,,,,,
9522,59523,2-(4-Acetamidophenyl)sulfanylethyl-diethyl-methylazanium,CC[N+](C)(CC)CCSC1=CC=C(C=C1)NC(=O)C,,,,,,
9523,59524,1-(3-(Dimethylamino)propoxy)adamantane ethyl iodide,CC[N+](C)(C)CC(C)OC12CC3CC(C1)CC(C3)C2.[I-],,,,,,
9524,59525,2-(1-Adamantyloxy)propyl-ethyl-dimethylazanium,CC[N+](C)(C)CC(C)OC12CC3CC(C1)CC(C3)C2,,,,,,
9525,59526,"(2,1,3-Benzothia(S IV)diazol-5-yl)dimethyloctoxymethylammonium iodide",CCCCCCCCOC[N+](C)(C)C1=CC2=NSN=C2C=C1.[I-],,,,,,
9526,59527,"2,1,3-Benzothiadiazol-5-yl-dimethyl-(octoxymethyl)azanium",CCCCCCCCOC[N+](C)(C)C1=CC2=NSN=C2C=C1,,,,,,
9527,59528,Di(2-hydroxyethyl)benzyltridecylammonium chloride,CCCCCCCCCCCCC[N+](CCO)(CCO)CC1=CC=CC=C1.[Cl-],,,,,,
9528,59529,Benzyl-bis(2-hydroxyethyl)-tridecylazanium,CCCCCCCCCCCCC[N+](CCO)(CCO)CC1=CC=CC=C1,,,,,,
9529,59530,Di(2-hydroxyethyl)benzylundecylammonium chloride,CCCCCCCCCCC[N+](CCO)(CCO)CC1=CC=CC=C1.[Cl-],,,,,,
9530,59531,Benzyl-bis(2-hydroxyethyl)-undecylazanium,CCCCCCCCCCC[N+](CCO)(CCO)CC1=CC=CC=C1,,,,,,
9531,59532,(N-Benzyl-N-(2-pyridyl)aminoethyl)trimethylammonium iodide,C[N+](C)(C)CCN(CC1=CC=CC=C1)C2=CC=CC=N2.[I-],,,,,,
9532,59533,2-[Benzyl(pyridin-2-yl)amino]ethyl-trimethylazanium,C[N+](C)(C)CCN(CC1=CC=CC=C1)C2=CC=CC=N2,,,,,,
9533,59534,Undecylbis(beta-hydroxyethyl)methylammonium chloride,CCCCCCCCCCC[N+](C)(CCO)CCO.[Cl-],,,,,,
9534,59535,Bis(2-hydroxyethyl)-methyl-undecylazanium,CCCCCCCCCCC[N+](C)(CCO)CCO,,,,,,
9535,59536,"Ammonium, (2-bromoallyl)triethyl-, bromide",CC[N+](CC)(CC)CC(=C)Br.[Br-],,,,,,
9536,59537,"N-(2-Bromoallyl)-N,N-diethylethanaminium",CC[N+](CC)(CC)CC(=C)Br,,,,,,
9537,59538,"Ammonium, (((1-butyl-3,6-dimethyl-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl)carbamoyl)methyl)trimethyl-, bromide",CCCCN1C(=C(C(=O)N(C1=O)C)NC(=O)C[N+](C)(C)C)C.[Br-],,,,,,
9538,59539,"[2-[(1-Butyl-3,6-dimethyl-2,4-dioxopyrimidin-5-yl)amino]-2-oxoethyl]-trimethylazanium",CCCCN1C(=C(C(=O)N(C1=O)C)NC(=O)C[N+](C)(C)C)C,,,,,,
9539,59540,"ACETIC ACID, (PHENYLTHIO)-, compd. with 2,2',2''-NITRILOTRISETHANOL (1:1)",C1=CC=C(C=C1)SCC(=O)O.C(CO)N(CCO)CCO,,,,,,
9540,59541,(Phenylthio)acetic acid,C1=CC=C(C=C1)SCC(=O)O,,,,,,
9541,59542,"ACETIC ACID, (PHENYLSULFONYL)-, compd. with 2,2',2''-NITRILOTRISETHANOL (1:1)",C1=CC=C(C=C1)S(=O)(=O)CC(=O)O.C(CO)N(CCO)CCO,,,,,,
9542,59543,(Phenylsulfonyl)acetic acid,C1=CC=C(C=C1)S(=O)(=O)CC(=O)O,,,,,,
9543,59544,"Acetic acid, ((4-methylphenyl)thio)-, compd. with 2,2',2''-nitrilotris(ethanol) (1:1)",CC1=CC=C(C=C1)SCC(=O)[O-].C(CO)[NH+](CCO)CCO,,,,,,
9544,59545,2-[(4-Methylphenyl)sulfanyl]acetic acid,CC1=CC=C(C=C1)SCC(=O)O,,,,,,
9545,59546,"Acetic acid, ((4-nitrophenyl)thio)-, compd. with 2,2'',2'''-nitrilotris(ethanol) (1:1)",C1=CC(=CC=C1[N+](=O)[O-])SCC(=O)[O-].C(CO)[NH+](CCO)CCO,,,,,,
9546,59547,2-[(4-Nitrophenyl)sulfanyl]acetic acid,C1=CC(=CC=C1[N+](=O)[O-])SCC(=O)O,,,,,,
9547,59548,"Acetic acid, ((2,4-dichlorophenyl)sulfonyl)-, compd. with 2,2',2''-nitrilotrisethanol (1:1)",C1=CC(=C(C=C1Cl)Cl)S(=O)(=O)CC(=O)O.C(CO)N(CCO)CCO,,,,,,
9548,59549,"2-(2,4-Dichlorophenyl)sulfonylacetic acid",C1=CC(=C(C=C1Cl)Cl)S(=O)(=O)CC(=O)O,,,,,,
9549,59550,1-Isopropyl-2-(o-methoxy-alpha-methylphenethyl)hydrazine hydrochloride,CC(C)[NH2+]NC(C)CC1=CC=CC=C1OC.[Cl-],,,,,,
9550,59551,1-[1-(2-Methoxyphenyl)propan-2-yl]-2-propan-2-ylhydrazine,CC(C)NNC(C)CC1=CC=CC=C1OC,,,,,,
9551,59552,2-Bromoallylamine hydrobromide,C=C(C[NH3+])Br.[Br-],,,,,,
9552,59553,Di(2-hydroxyethyl)methyltridecyl ammonium chloride,CCCCCCCCCCCCC[N+](C)(CCO)CCO.[Cl-],,,,,,
9553,59554,Bis(2-hydroxyethyl)-methyl-tridecylazanium,CCCCCCCCCCCCC[N+](C)(CCO)CCO,,,,,,
9554,59555,(2-Carbanilino-1-methylethyl)diethylmethylammonium bromide,CC[N+](C)(CC)C(C)CC(=O)NC1=CC=CC=C1.[Br-],,,,,,
9555,59556,(4-Anilino-4-oxobutan-2-yl)-diethyl-methylazanium,CC[N+](C)(CC)C(C)CC(=O)NC1=CC=CC=C1,,,,,,
9556,59557,Benzyldimethyltridecylammonium chloroiodite,CCCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1.Cl[I-]Cl,,,,,,
9557,59558,CID 59558,Cl[I-]Cl,,,,,,
9558,59559,"Aniline, 3-(methylthio)-N-(2-oxazolin-2-YL)-",CSC1=CC=CC(=C1)NC2=NCCO2,,,,,,
9559,59560,2-(p-Phenylazoanilino)-2-oxazoline,C1COC(=N1)NC2=CC=C(C=C2)N=NC3=CC=CC=C3,,,,,,
9560,59561,"Aniline, N-(2-oxazolinyl)-2,3,5,6-tetramethyl-",CC1=CC(=C(C(=C1C)NC2=NCCO2)C)C,,,,,,
9561,59562,2-[(Dimethylhydrazinylidene)methyl]-6-methoxyphenol,CN(C)N=CC1=C(C(=CC=C1)OC)O,,,,,,
9562,59563,[(3-methoxyphenyl)methylideneamino] N-methylcarbamate,CNC(=O)ON=CC1=CC(=CC=C1)OC,,,,,,
9563,59564,4-Amino-o-anisic acid 2-(diethylamino)ethyl ester hydrogen phosphate,CC[NH+](CC)CCOC(=O)C1=C(C=C(C=C1)N)OC.OP(=O)(O)[O-],,,,,,
9564,59565,2-(Diethylamino)ethyl 4-amino-2-methoxybenzoate,CCN(CC)CCOC(=O)C1=C(C=C(C=C1)N)OC,,,,,,
9565,59566,4-Butylamino-o-anisic acid 2-(diethylamino)ethyl ester dihydrochloride,CC[NH+](CC)CCOC(=O)C1=C(C=C(C=C1)CCCC[NH3+])OC.[Cl-].[Cl-],,,,,,
9566,59567,2-(Diethylamino)ethyl 4-(4-aminobutyl)-2-methoxybenzoate,CCN(CC)CCOC(=O)C1=C(C=C(C=C1)CCCCN)OC,,,,,,
9567,59568,"Anthranilic acid, N-(N'-(2-bromoethyl)carbamoyl)-, methyl ester",COC(=O)C1=CC=CC=C1NC(=O)NCCBr,,,,,,
9568,59569,"6,7,8,8a-Tetrahydro-N-(2-oxazolin-2-yl)-5-acenaphthenamine",C1CC2CCC3=C2C(=C(C=C3)NC4=NCCO4)C1,,,,,,
9569,59570,2-[Bis(2-chloroethyl)amino]acetaldehyde,C(CCl)N(CCCl)CC=O,,,,,,
9570,59571,"2,2-dibutoxy-N,N-bis(2-chloroethyl)ethanamine",CCCCOC(CN(CCCl)CCCl)OCCCC,,,,,,
9571,59572,(Bis(2-chloroethyl)amino)acetaldehyde diethyl acetal hydrochloride,CCOC(C[NH+](CCCl)CCCl)OCC.[Cl-],,,,,,
9572,59573,"N,N-bis(2-chloroethyl)-2,2-diethoxyethanamine",CCOC(CN(CCCl)CCCl)OCC,,,,,,
9573,59574,(Bis(2-chloroethyl)amino)acetaldehyde dimethyl acetal hydrochloride,COC(C[NH+](CCCl)CCCl)OC.[Cl-],,,,,,
9574,59575,"N,N-bis(2-chloroethyl)-2,2-dimethoxyethanamine",COC(CN(CCCl)CCCl)OC,,,,,,
9575,59576,"N-(1,1-diethoxyethyl)-1-naphthalen-1-ylmethanimine",CCOC(C)(N=CC1=CC=CC2=CC=CC=C21)OCC,,,,,,
9576,59577,"Acetamide, N-(4-benzylcyclohexyl)-",CC(=O)NC1CCC(CC1)CC2=CC=CC=C2,,,,,,
9577,59578,"Acetamide, N-(2-bromoallyl)-N-butyl-",CCCCN(CC(=C)Br)C(=O)C,,,,,,
9578,59579,"Acetamide, N-(2-bromoallyl)-N-cyclohexyl-",CC(=O)N(CC(=C)Br)C1CCCCC1,,,,,,
9579,59580,"N-(2-Bromoallyl)-2,2-dichloroacetamide",C=C(CNC(=O)C(Cl)Cl)Br,,,,,,
9580,59581,"Acetamide, N-(2-bromoallyl)-N-methyl-",CC(=O)N(C)CC(=C)Br,,,,,,
9581,59582,"Acetamide, N-(2-bromoallyl)-2,2,2-trifluoro-",C=C(CNC(=O)C(F)(F)F)Br,,,,,,
9582,59583,"Acetamide, 2-bromo-N-(2-bromoallyl)-",C=C(CNC(=O)CBr)Br,,,,,,
9583,59584,"2-(sec-Butylamino)-N-methyl-N-(1-(2,4-xylyloxy)-2-propyl)acetamide hydrochloride dihydrate",CCC(C)[NH2+]CC(=O)N(C)C(C)COC1=C(C=C(C=C1)C)C.[Cl-],,,,,,
9584,59585,"2-(butan-2-ylamino)-N-[1-(2,4-dimethylphenoxy)propan-2-yl]-N-methylacetamide",CCC(C)NCC(=O)N(C)C(C)COC1=C(C=C(C=C1)C)C,,,,,,
9585,59586,2-(Butylamino)-N-(1-phenoxy-2-propyl)acetamide hydrochloride,CCCC[NH2+]CC(=O)NC(C)COC1=CC=CC=C1.[Cl-],,,,,,
9586,59587,2-(butylamino)-N-(1-phenoxypropan-2-yl)acetamide,CCCCNCC(=O)NC(C)COC1=CC=CC=C1,,,,,,
9587,59588,"N-(4-Butylcyclohexyl)-2,2-dichloroacetamide",CCCCC1CCC(CC1)NC(=O)C(Cl)Cl,,,,,,
9588,59589,"Acetamide, N-(2-chloroallyl)trifluoro-",C=C(CNC(=O)C(F)(F)F)Cl,,,,,,
9589,59590,2-(N-(2-Chloroethyl)-N-(2-chloropropyl)amino)acetamide monohydrochloride,CC(C[NH+](CCCl)CC(=O)N)Cl.[Cl-],,,,,,
9590,59591,2-[2-Chloroethyl(2-chloropropyl)amino]acetamide,CC(CN(CCCl)CC(=O)N)Cl,,,,,,
9591,59592,N-(1-(o-Chlorophenoxy)-2-propyl)-2-(diethylamino)-N-ethylacetamide hydrochloride,CC[NH+](CC)CC(=O)N(CC)C(C)COC1=CC=CC=C1Cl.[Cl-],,,,,,
9592,59593,N-[1-(2-chlorophenoxy)propan-2-yl]-2-(diethylamino)-N-ethylacetamide,CCN(CC)CC(=O)N(CC)C(C)COC1=CC=CC=C1Cl,,,,,,
9593,59594,N-(1-(o-Chlorophenoxy)-2-propyl)-2-(diethylamino)-N-methylacetamide hydrochloride,CC[NH+](CC)CC(=O)N(C)C(C)COC1=CC=CC=C1Cl.[Cl-],,,,,,
9594,59595,N-[1-(2-chlorophenoxy)propan-2-yl]-2-(diethylamino)-N-methylacetamide,CCN(CC)CC(=O)N(C)C(C)COC1=CC=CC=C1Cl,,,,,,
9595,59596,2-(m-Chlorophenyl)-N-(2-(dimethylamino)ethyl)-2-phenylacetamide,CN(C)CCNC(=O)C(C1=CC=CC=C1)C2=CC(=CC=C2)Cl,,,,,,
9596,59597,2-(7-Chloro-4-quinolylamino)-N-sec-butylacetamide monohydrochloride,CCC(C)NC(=O)C[NH2+]C1=C2C=CC(=CC2=NC=C1)Cl.[Cl-],,,,,,
9597,59598,N-butan-2-yl-2-[(7-chloroquinolin-4-yl)amino]acetamide,CCC(C)NC(=O)CNC1=C2C=CC(=CC2=NC=C1)Cl,,,,,,
9598,59599,Acetamido-cnu,CC(=O)NN(C(=O)NCCCl)N=O,,,,,,
9599,59600,"((2,3-Dimethyl-4-oxo-4H-1-benzopyran-6-yl)oxy)acetic acid ethyl ester",CCOC(=O)COC1=CC2=C(C=C1)OC(=C(C2=O)C)C,,,,,,
9600,59601,"Acetic acid, 2,2-diphenyl-, (4-hydroxy-1-methyl-4-piperidyl)methyl ester",CN1CCC(CC1)(COC(=O)C(C2=CC=CC=C2)C3=CC=CC=C3)O,,,,,,
9601,59602,Diphenylacetic acid beta-(4-methyl-1-piperazinyl)phenethyl ester hydrochloride,C[NH+]1CCN(CC1)C(COC(=O)C(C2=CC=CC=C2)C3=CC=CC=C3)C4=CC=CC=C4.[Cl-],,,,,,
9602,59603,"[2-(4-Methylpiperazin-1-yl)-2-phenylethyl] 2,2-diphenylacetate",CN1CCN(CC1)C(COC(=O)C(C2=CC=CC=C2)C3=CC=CC=C3)C4=CC=CC=C4,,,,,,
9603,59604,"4-{2-[(Diphenylacetyl)oxy]-1-phenylethyl}-1,1-dimethylpiperazin-1-ium bromide",C[N+]1(CCN(CC1)C(COC(=O)C(C2=CC=CC=C2)C3=CC=CC=C3)C4=CC=CC=C4)C.[Br-],,,,,,
9604,59605,"[2-(4,4-Dimethylpiperazin-4-ium-1-yl)-2-phenylethyl] 2,2-diphenylacetate",C[N+]1(CCN(CC1)C(COC(=O)C(C2=CC=CC=C2)C3=CC=CC=C3)C4=CC=CC=C4)C,,,,,,
9605,59606,CID 59606,CCN(C1=C(C(=C(C=C1I)I)OCCOC(C2=CC=CC=C2)C(=O)[O-])I)C(=O)C.[Na+],,,,,,
9606,59607,"2-[2-[3-[Acetyl(ethyl)amino]-2,4,6-triiodophenoxy]ethoxy]-2-phenylacetic acid",CCN(C1=C(C(=C(C=C1I)I)OCCOC(C2=CC=CC=C2)C(=O)O)I)C(=O)C,,,,,,
9607,59608,CID 59608,CCN(C1=C(C(=C(C=C1I)I)OCCOCC(=O)[O-])I)C(=O)C.[Na+],,,,,,
9608,59609,"2-[2-[3-[Acetyl(ethyl)amino]-2,4,6-triiodophenoxy]ethoxy]acetic acid",CCN(C1=C(C(=C(C=C1I)I)OCCOCC(=O)O)I)C(=O)C,,,,,,
9609,59610,"Acetic acid, ((2-ethyl-3-methyl-4-oxo-4H-1-benzopyran-7-YL)oxy)-, ethyl ester",CCC1=C(C(=O)C2=C(O1)C=C(C=C2)OCC(=O)OCC)C,,,,,,
9610,59611,3-(Dimethylamino)propyl (1-hydroxycyclopentyl)phenylacetate hydrochloride,C[NH+](C)CCCOC(=O)C(C1=CC=CC=C1)C2(CCCC2)O.[Cl-],,,,,,
9611,59612,3-(Dimethylamino)propyl 2-(1-hydroxycyclopentyl)-2-phenylacetate,CN(C)CCCOC(=O)C(C1=CC=CC=C1)C2(CCCC2)O,,,,,,
9612,59613,2-(1-Piperidyl)ethyl (1-hydroxycyclopentyl)phenylacetate hydrochloride,C1CC[NH+](CC1)CCOC(=O)C(C2=CC=CC=C2)C3(CCCC3)O.[Cl-],,,,,,
9613,59614,2-Piperidin-1-ylethyl 2-(1-hydroxycyclopentyl)-2-phenylacetate,C1CCN(CC1)CCOC(=O)C(C2=CC=CC=C2)C3(CCCC3)O,,,,,,
9614,59615,"Acetic acid, 2-(mercaptomethylthio)-, butyl ester, S-ester with O-methyl methylphosphonothioate",CCCCOC(=O)CSCSP(=O)(C)OC,,,,,,
9615,59616,CID 59616,CC(=O)N(C)C1=C(C(=C(C=C1I)I)OCCOC(C2=CC=CC=C2)C(=O)[O-])I.[Na+],,,,,,
9616,59617,"2-[2-[3-[Acetyl(methyl)amino]-2,4,6-triiodophenoxy]ethoxy]-2-phenylacetic acid",CC(=O)N(C)C1=C(C(=C(C=C1I)I)OCCOC(C2=CC=CC=C2)C(=O)O)I,,,,,,
9617,59618,CID 59618,CC(=O)N(C)C1=C(C(=C(C=C1I)I)OCCOCC(=O)[O-])I.[Na+],,,,,,
9618,59619,"2-[2-[3-[Acetyl(methyl)amino]-2,4,6-triiodophenoxy]ethoxy]acetic acid",CC(=O)N(C)C1=C(C(=C(C=C1I)I)OCCOCC(=O)O)I,,,,,,
9619,59620,CID 59620,C1=CC=C(C(=C1)O)SCC(=O)[O-].C1=CC=C(C(=C1)O)SCC(=O)[O-].O.O.O.O.[Ca+2].[SbH3].[SbH3],,,,,,
9620,59621,CID 59621,C1=CC=C(C(=C1)O)SCC(=O)[O-].C(CO)[NH2+]CCO.O.O.[SbH3],,,,,,
9621,59622,"Thioacetic acid, S-(alpha-nitromethyl-4-benzyloxy-3-methoxybenzyl) ester",CC(=O)SC(C[N+](=O)[O-])C1=CC(=C(C=C1)OCC2=CC=CC=C2)OC,,,,,,
9622,59623,"2,2,2-Triphenylacetic acid (2-morpholinoethyl) ester hydrochloride ethanoate",C1COCC[NH+]1CCOC(C(C2=CC=CC=C2)(C3=CC=CC=C3)C4=CC=CC=C4)O.[Cl-],,,,,,
9623,59624,"1-(2-Morpholin-4-ylethoxy)-2,2,2-triphenylethanol",C1COCCN1CCOC(C(C2=CC=CC=C2)(C3=CC=CC=C3)C4=CC=CC=C4)O,,,,,,
9624,59625,4-(4-Antipyrylazo)-1-phenyl-3-methyl-5-pyrazolone,CC1=C(C(=O)N(N1C)C2=CC=CC=C2)N=NC3=C(N(N(C3=O)C4=CC=CC=C4)C)C,,,,,,
9625,59626,"Aspartic acid, N-((2-chloroethyl)nitrosocarbamoyl)-, dimethyl ester, L-",COC(=O)C[C@@H](C(=O)OC)NC(=O)N(CCCl)N=O,,,,,,
9626,59627,"3-Benzyl-9,9-dimethyl-3-aza-9-azoniabicyclo(3.3.1)nonane iodide",C[N+]1(C2CCCC1CN(C2)CC3=CC=CC=C3)C.[I-],,,,,,
9627,59628,"3-Benzyl-9,9-dimethyl-3-aza-9-azoniabicyclo[3.3.1]nonane",C[N+]1(C2CCCC1CN(C2)CC3=CC=CC=C3)C,,,,,,
9628,59629,"3-Aza-9-azoniabicyclo(3.3.1)nonane, 3-(3-(diethylmethylammonio)propionyl)-9,9-dimethyl-, diiodide",CC[N+](C)(CC)CCC(=O)N1CC2CCCC(C1)[N+]2(C)C.[I-].[I-],,,,,,
9629,59630,"[3-(9,9-Dimethyl-3-aza-9-azoniabicyclo[3.3.1]nonan-3-yl)-3-oxopropyl]-diethyl-methylazanium",CC[N+](C)(CC)CCC(=O)N1CC2CCCC(C1)[N+]2(C)C,,,,,,
9630,59631,"3-Aza-9-azoniabicyclo(3.3.1)nonane, 3-(3-(diethylmethylammonio)propyl)-9,9-dimethyl-, diiodide",CC[N+](C)(CC)CCCN1CC2CCCC(C1)[N+]2(C)C.[I-].[I-],,,,,,
9631,59632,"3-(9,9-Dimethyl-3-aza-9-azoniabicyclo[3.3.1]nonan-3-yl)propyl-diethyl-methylazanium",CC[N+](C)(CC)CCCN1CC2CCCC(C1)[N+]2(C)C,,,,,,
9632,59633,"3-Aza-9-azoniabicyclo(3.3.1)nonane, 9,9-dimethyl-3-(2-(4-methylmorpholinio)ethyl)-, diiodide",C[N+]1(C2CCCC1CN(C2)CC[N+]3(CCOCC3)C)C.[I-].[I-],,,,,,
9633,59634,"4-[2-(9,9-Dimethyl-3-aza-9-azoniabicyclo[3.3.1]nonan-3-yl)ethyl]-4-methylmorpholin-4-ium",C[N+]1(C2CCCC1CN(C2)CC[N+]3(CCOCC3)C)C,,,,,,
9634,59635,"3-Aza-9-azoniabicyclo(3.3.1)nonane, 9,9-dimethyl-3-(3-(4-methylmorpholinio)propyl)-, diiodide",C[N+]1(C2CCCC1CN(C2)CCC[N+]3(CCOCC3)C)C.[I-].[I-],,,,,,
9635,59636,"4-[3-(9,9-Dimethyl-3-aza-9-azoniabicyclo[3.3.1]nonan-3-yl)propyl]-4-methylmorpholin-4-ium",C[N+]1(C2CCCC1CN(C2)CCC[N+]3(CCOCC3)C)C,,,,,,
9636,59637,"3-Aza-9-azoniabicyclo(3.3.1)nonane, 9,9-dimethyl-3-(3-(1-methylpiperidinio)propionyl)-, diiodide",C[N+]1(C2CCCC1CN(C2)C(=O)CC[N+]3(CCCCC3)C)C.[I-].[I-],,,,,,
9637,59638,"1-(9,9-Dimethyl-3-aza-9-azoniabicyclo[3.3.1]nonan-3-yl)-3-(1-methylpiperidin-1-ium-1-yl)propan-1-one",C[N+]1(C2CCCC1CN(C2)C(=O)CC[N+]3(CCCCC3)C)C,,,,,,
9638,59639,"3-Aza-9-azoniabicyclo(3.3.1)nonane, 9,9-dimethyl-3-(3-(1-methylpiperidinio)propyl)-, diiodide",C[N+]1(C2CCCC1CN(C2)CCC[N+]3(CCCCC3)C)C.[I-].[I-],,,,,,
9639,59640,"9,9-Dimethyl-3-[3-(1-methylpiperidin-1-ium-1-yl)propyl]-3-aza-9-azoniabicyclo[3.3.1]nonane",C[N+]1(C2CCCC1CN(C2)CCC[N+]3(CCCCC3)C)C,,,,,,
9640,59641,"9,9-Dimethyl-3-(3-(trimethylammonio)propyl)-3-aza-9-azoniabicyclo(3.3.1)nonane diiodide",C[N+]1(C2CCCC1CN(C2)CCC[N+](C)(C)C)C.[I-].[I-],,,,,,
9641,59642,"3-(9,9-Dimethyl-3-aza-9-azoniabicyclo[3.3.1]nonan-3-yl)propyl-trimethylazanium",C[N+]1(C2CCCC1CN(C2)CCC[N+](C)(C)C)C,,,,,,
9642,59643,"3-Aza-9-azoniabicyclo(3.3.1)nonane, 3,3'-pentamethylenebis(9,9-dimethyl-, diiodide",C[N+]1(C2CCCC1CN(C2)CCCCCN3CC4CCCC(C3)[N+]4(C)C)C.[I-].[I-],,,,,,
9643,59644,"3-[5-(9,9-Dimethyl-3-aza-9-azoniabicyclo[3.3.1]nonan-3-yl)pentyl]-9,9-dimethyl-3-aza-9-azoniabicyclo[3.3.1]nonane",C[N+]1(C2CCCC1CN(C2)CCCCCN3CC4CCCC(C3)[N+]4(C)C)C,,,,,,
9644,59645,3-Allyl-3-azabicyclo(3.3.1)nonane hydrobromide,C=CC[NH+]1CC2CCCC(C2)C1.[Br-],,,,,,
9645,59646,3-Prop-2-enyl-3-azabicyclo[3.3.1]nonane,C=CCN1CC2CCCC(C2)C1,,,,,,
9646,59647,3-Butyl-3-azabicyclo(3.3.1)nonane hydrobromide,CCCC[NH+]1CC2CCCC(C2)C1.[Br-],,,,,,
9647,59648,3-Butyl-3-azabicyclo[3.3.1]nonane,CCCCN1CC2CCCC(C2)C1,,,,,,
9648,59649,3-Methyl-3-azabicyclo(3.3.1)nonane hydrobromide,C[NH+]1CC2CCCC(C2)C1.[Br-],,,,,,
9649,59650,3-Methyl-3-azabicyclo[3.3.1]nonane,CN1CC2CCCC(C2)C1,,,,,,
9650,59651,"3-(2-Oxazolin-2-yl)-3-azabicyclo(3,2,2)nonane, hydrobromide",C1CC2CCC1C[NH+](C2)C3=NCCO3.[Br-],,,,,,
9651,59652,"3-(4,5-Dihydro-1,3-oxazol-2-yl)-3-azabicyclo[3.2.2]nonane",C1CC2CCC1CN(C2)C3=NCCO3,,,,,,
9652,59653,"9-Azabicyclo(3.3.1)nonan-3-OL, 9-(1,4-benzodioxan-2-ylmethyl)-3-phenyl-",C1CC2CC(CC(C1)N2CC3COC4=CC=CC=C4O3)(C5=CC=CC=C5)O,,,,,,
9653,59654,9-Benzyl-3-(4-methylphenoxy)-9-azabicyclo[3.3.1]nonane,CC1=CC=C(C=C1)OC2CC3CCCC(C2)N3CC4=CC=CC=C4,,,,,,
9654,59655,"9-Azabicyclo(3.3.1)nonan-3-ol, 9-(3-(2-(p-fluorophenyl)-1,3-dioxolan-2-yl)propyl)-3-phenyl-",C1CC2CC(CC(C1)N2CCCC3(OCCO3)C4=CC=C(C=C4)F)(C5=CC=CC=C5)O,,,,,,
9655,59656,"9-Azabicyclo(3.3.1)nonan-3-ol, 9-(3-(p-fluorophenylthio)propyl)-3-phenyl-, hydrochloride",C1CC2CC(CC(C1)[NH+]2CCCSC3=CC=C(C=C3)F)OC4=CC=CC=C4.[Cl-],,,,,,
9656,59657,9-[3-(4-Fluorophenyl)sulfanylpropyl]-3-phenoxy-9-azabicyclo[3.3.1]nonane,C1CC2CC(CC(C1)N2CCCSC3=CC=C(C=C3)F)OC4=CC=CC=C4,,,,,,
9657,59658,"3-Azahexanedial, 3-methyl-, tetraethylacetal",CCOC(CCN(C)CC(OCC)OCC)OCC,,,,,,
9658,59659,"2-Azaspiro(4,5)decane-1,3,4-trione, 2-(3',4',5'-trimethoxyphenyl)-",COC1=CC(=CC(=C1OC)OC)N2C(=O)C(=O)C3(C2=O)CCCCC3,,,,,,
9659,59660,"Aziridine, 1-(1-adamantyl)-, hydrochloride",C1CN1C23CC4CC(C2)CC(C4)C3.Cl,,,,,,
9660,59661,1-(1-Adamantyl)aziridine,C1CN1C23CC4CC(C2)CC(C4)C3,,,,,,
9661,59662,"1-Aziridinepropionamide, N-allyl-",C=CCNC(=O)CCN1CC1,,,,,,
9662,59663,CID 59663,CC1(C(=O)NC(=O)NC1=O)C2=CCCCCCC2,,,,,,
9663,59664,5-(2-Hydroxy-3-iodopropyl)-5-isopropylbarbituric acid,CC(C)C1(C(=O)NC(=O)NC1=O)CC(CI)O,,,,,,
9664,59665,"(benzylideneamino) N-(1,3-benzodioxol-5-yl)carbamate",C1OC2=C(O1)C=C(C=C2)NC(=O)ON=CC3=CC=CC=C3,,,,,,
9665,59666,CID 59666,CN(C)C1=CC=C(C=C1)C=N[NH+](CCCl)CCCl.[Cl-],,,,,,
9666,59667,"4-Allyloxy-3,5-dipropyl-N-(2-(1-pyrrolidinyl)ethyl)benzamide hydrochloride",CCCC1=CC(=CC(=C1OCC=C)CCC)C(=O)NCC[NH+]2CCCC2.[Cl-],,,,,,
9667,59668,"4-(Allyloxy)-3,5-dipropyl-N-[2-(1-pyrrolidinyl)ethyl]benzamide",CCCC1=CC(=CC(=C1OCC=C)CCC)C(=O)NCCN2CCCC2,,,,,,
9668,59669,CID 59669,CN(C1CC[NH+](C1)C2CCCCC2)C(=O)C3=CC=C(C=C3)N.C(=CC(=O)[O-])C(=O)O,,,,,,
9669,59670,AHR-5645B free base,CN(C1CCN(C1)C2CCCCC2)C(=O)C3=CC=C(C=C3)N,,,,,,
9670,59671,4-Amino-N-(2-(diethylamino)ethyl)-2-propoxy-benzamide hydrochloride,CCCOC1=C(C=CC(=C1)N)C(=O)NCC[NH+](CC)CC.[Cl-],,,,,,
9671,59672,4-Amino-n-[2-(diethylamino)ethyl]-2-propoxybenzamide,CCCOC1=C(C=CC(=C1)N)C(=O)NCCN(CC)CC,,,,,,
9672,59673,"BENZAMIDE, N-(o-AMINOPHENYL)-N-(2-(DIETHYLAMINO)ETHYL)-p-FLUORO-",CCN(CC)CCN(C1=CC=CC=C1N)C(=O)C2=CC=C(C=C2)F,,,,,,
9673,59674,N-(2-(1-Benzimidazolyl)ethyl)-p-methoxybenzamide hydrochloride,COC1=CC=C(C=C1)C(=O)NCC[NH+]2C=NC3=CC=CC=C32.[Cl-],,,,,,
9674,59675,n-[2-(1h-Benzimidazol-1-yl)ethyl]-4-methoxybenzamide,COC1=CC=C(C=C1)C(=O)NCCN2C=NC3=CC=CC=C32,,,,,,
9675,59676,"Benzamide, N-(2-bromoallyl)-",C=C(CC1=CC=CC=C1C(=O)N)Br,,,,,,
9676,59677,"N2-Carbamoyl-N2,N6-dinitroso-N6-aminomethyllysine ethyl ester",CCOC(=O)C(CCCCN(CN)N=O)N(C(=O)N)N=O,,,,,,
9677,59678,"N(sup 2)-Carbamoyl-N(sup 2),N(sup 6)-dinitroso-N(sup 6)-methylaminolysine",CNN(CCCCC(C(=O)O)N(C(=O)N)N=O)N=O,,,,,,
9678,59679,Diphenylacetic acid 2-(1-methyl-2-pyrrolidinyl)ethyl ester,CN1CCCC1CCOC(=O)C(C2=CC=CC=C2)C3=CC=CC=C3,,,,,,
9679,59680,CID 59680,CCN(CC)CC(C1=CC=CC=C1)OC(=O)C=CC2=CC=CC=C2,,,,,,
9680,59681,"Benzoic acid, 4-amino-2-methoxy-, 3-diethylaminopropyl ester, phosphate",CC[NH+](CC)CCCOC(=O)C1=C(C=C(C=C1)N)OC.OP(=O)(O)[O-],,,,,,
9681,59682,3-(Diethylamino)propyl 4-amino-2-methoxybenzoate,CCN(CC)CCCOC(=O)C1=C(C=C(C=C1)N)OC,,,,,,
9682,59683,"Acetic acid, ((2,3-dimethyl-4-oxo-4H-1-benzopyran-7-YL)oxy)-, ethyl ester",CCOC(=O)COC1=CC2=C(C=C1)C(=O)C(=C(O2)C)C,,,,,,
9683,59684,"3-Aza-9-azoniabicyclo(3.3.1)nonane, 3,3'-hexamethylenebis(9,9-dimethyl-, diiodide",C[N+]1(C2CCCC1CN(C2)CCCCCCN3CC4CCCC(C3)[N+]4(C)C)C.[I-].[I-],,,,,,
9684,59685,"3-[6-(9,9-Dimethyl-3-aza-9-azoniabicyclo[3.3.1]nonan-3-yl)hexyl]-9,9-dimethyl-3-aza-9-azoniabicyclo[3.3.1]nonane",C[N+]1(C2CCCC1CN(C2)CCCCCCN3CC4CCCC(C3)[N+]4(C)C)C,,,,,,
9685,59686,"CYCLOPROPANECARBOXAMIDE, N-(3-METHYLBUTYL)-2-(PHENOXYMETHYL)-, trans-",CC(C)CCNC(=O)[C@@H]1C[C@H]1COC2=CC=CC=C2,,,,,,
9686,59687,trans-2-(Phenoxymethyl)-N-propylcyclopropanecarboxamide,CCCNC(=O)[C@@H]1C[C@H]1COC2=CC=CC=C2,,,,,,
9687,59688,trans-N-(1-Methylethyl)-2-(phenoxymethyl)cyclopropanecarboxamide,CC(C)NC(=O)[C@@H]1C[C@H]1COC2=CC=CC=C2,,,,,,
9688,59689,"2-Azabicyclo(2.2.2)octan-6-OL, 2-methyl-, hydrochloride",C[NH+]1CC2CCC1C(C2)O.[Cl-],,,,,,
9689,59690,2-Methyl-2-azabicyclo[2.2.2]octan-6-ol,CN1CC2CCC1C(C2)O,,,,,,
9690,59691,Batanopride hydrochloride,CCN(CC)CCNC(=O)C1=CC(=C(C=C1OC(C)C(=O)C)N)Cl.Cl,,,,,,
9691,59692,Batanopride,CCN(CC)CCNC(=O)C1=CC(=C(C=C1OC(C)C(=O)C)N)Cl,,,,,,
9692,59693,Fadrozole,C1CC(N2C=NC=C2C1)C3=CC=C(C=C3)C#N,,,"['Antineoplastic agents that are used to treat hormone-sensitive tumors. Hormone-sensitive tumors may be hormone-dependent, hormone-responsive, or both. A hormone-dependent tumor regresses on removal of the hormonal stimulus, by surgery or pharmacological block. Hormone-responsive tumors may regress when pharmacologic amounts of hormones are administered regardless of whether previous signs of hormone sensitivity were observed. The major hormone-responsive cancers include carcinomas of the breast, prostate, and endometrium; lymphomas; and certain leukemias. (From AMA Drug Evaluations Annual 1994, p2079) (See all compounds classified as Antineoplastic Agents, Hormonal.)', 'Compounds that inhibit AROMATASE in order to reduce production of estrogenic steroid hormones. (See all compounds classified as Aromatase Inhibitors.)', 'Compounds which inhibit or antagonize the action or biosynthesis of estrogenic compounds. (See all compounds classified as Estrogen Antagonists.)']",,,
9693,59694,Fadrozole hydrochloride,C1CC(N2C=NC=C2C1)C3=CC=C(C=C3)C#N.Cl,,,"['Antineoplastic agents that are used to treat hormone-sensitive tumors. Hormone-sensitive tumors may be hormone-dependent, hormone-responsive, or both. A hormone-dependent tumor regresses on removal of the hormonal stimulus, by surgery or pharmacological block. Hormone-responsive tumors may regress when pharmacologic amounts of hormones are administered regardless of whether previous signs of hormone sensitivity were observed. The major hormone-responsive cancers include carcinomas of the breast, prostate, and endometrium; lymphomas; and certain leukemias. (From AMA Drug Evaluations Annual 1994, p2079) (See all compounds classified as Antineoplastic Agents, Hormonal.)', 'Compounds that inhibit AROMATASE in order to reduce production of estrogenic steroid hormones. (See all compounds classified as Aromatase Inhibitors.)', 'Compounds which inhibit or antagonize the action or biosynthesis of estrogenic compounds. (See all compounds classified as Estrogen Antagonists.)']",,,
9694,59695,"Butanoic acid, 4-((7,8-dihydro-7,7-dimethyl-4-methoxy-6H-pyrimido(4,5-b)(1,4)benzothiazin-9-yl)amino)-, monohydrobromide",CC1(CC(=C2C(=NC3=C(N=CN=C3S2)OC)C1)[NH2+]CCCC(=O)O)C.[Br-],,,,,,
9695,59696,CID 59696,CC1(CC(=C2C(=NC3=C(N=CN=C3S2)OC)C1)NCCCC(=O)O)C,,,,,,
9696,59697,"3,4,5-Trimethoxybenzoic acid alpha-((diethylamino)methyl)benzyl ester hydrochloride",CC[NH+](CC)CC(C1=CC=CC=C1)OC(=O)C2=CC(=C(C(=C2)OC)OC)OC.[Cl-],,,,,,
9697,59698,"[2-(Diethylamino)-1-phenylethyl] 3,4,5-trimethoxybenzoate",CCN(CC)CC(C1=CC=CC=C1)OC(=O)C2=CC(=C(C(=C2)OC)OC)OC,,,,,,
9698,59699,CID 59699,CCCCN(CCCC)CC(=NC1=C(C=C(C=C1C)C)C)S,,,,,,
9699,59700,"Carbamodithioic acid, diethyl-, 3-oxo-1-phenyl-3-(2-thienyl)-1-propenyl ester",CCN(CC)C(=S)SC(=CC(=O)C1=CC=CS1)C2=CC=CC=C2,,,,,,
9700,59701,"ACETIC ACID, NITRILOTRI-, DISODIUM SALT, IRON(II) chelate",C(C(=O)[O-])N(CC(=O)[O-])CC(=O)[O-].C(C(=O)[O-])N(CC(=O)[O-])CC(=O)[O-].[Na+].[Na+].[Na+].[Na+].[Fe+2],,,,,,
9701,59702,"Acrylic acid, 2-(dimethylaminomethyl)-3,3-DI-2-thienyl-, ethyl ester, picrate",CCOC(=O)C(=C(C1=CC=CS1)C2=CC=CS2)C[NH+](C)C.C1=C(C=C(C(=C1[N+](=O)[O-])[O-])[N+](=O)[O-])[N+](=O)[O-],,,,,,
9702,59703,"Ethyl 2-[(dimethylamino)methyl]-3,3-dithiophen-2-ylprop-2-enoate",CCOC(=O)C(=C(C1=CC=CS1)C2=CC=CS2)CN(C)C,,,,,,
9703,59704,"ACETANILIDE, 4'-(5-(p-(DIMETHYLAMINO)PHENOXY)PENTYLOXY)-N-ETHYL-",CCN(C1=CC=C(C=C1)OCCCCCOC2=CC=C(C=C2)N(C)C)C(=O)C,,,,,,
9704,59705,"ANILINE, N-METHYL-p-(8-PHENOXYOCTYLOXY)-",CNC1=CC=C(C=C1)OCCCCCCCCOC2=CC=CC=C2,,,,,,
9705,59706,"ETHANOL, 2,2'-((p-(5-PHENYLPENTYLOXY)PHENYL)IMINO)DI-",C1=CC=C(C=C1)CCCCCOC2=CC=C(C=C2)N(CCO)CCO,,,,,,
9706,59707,"2-Pyrrolidinemethanol, 1-propyl-, benzilate",CCCN1CCCC1CCOC(=O)C(C2=CC=CC=C2)(C3=CC=CC=C3)O,,,,,,
9707,59708,Etiracetam,CCC(C(=O)N)N1CCCC1=O,,,"['Drugs used to specifically facilitate learning or memory, particularly to prevent the cognitive deficits associated with dementias. These drugs act by a variety of mechanisms. (See all compounds classified as Nootropic Agents.)', 'Drugs used to prevent SEIZURES or reduce their severity. (See all compounds classified as Anticonvulsants.)']",,,
9708,59709,5'-(Pentahydrogen tetraphosphate)adenosine 5'-5'-ester with adenosine tetraammonium salt,C1=NC(=C2C(=N1)N(C=N2)[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(O)OP(=O)(O)OP(=O)(O)OP(=O)(O)OC[C@@H]4[C@H]([C@H]([C@@H](O4)N5C=NC6=C(N=CN=C65)N)O)O)O)O)N.N.N.N.N,,,,,,
9709,59710,"N-(2-(Diethylamino)ethyl)-N,2-diphenylglycine butyl ester",CCCCOC(=O)C(C1=CC=CC=C1)N(CCN(CC)CC)C2=CC=CC=C2,,,,,,
9710,59711,"ETHYLENEDIAMINE, N,N-DIETHYL-N'-(p-(5-PHENOXYPENTYLOXY)PHENYL)-",CCN(CC)CCNC1=CC=C(C=C1)OCCCCCOC2=CC=CC=C2,,,,,,
9711,59712,"2,4,3'-Trinitrobiphenyl",C1=CC(=CC(=C1)[N+](=O)[O-])C2=C(C=C(C=C2)[N+](=O)[O-])[N+](=O)[O-],,,,,,
9712,59713,"Indole, 1-phenyl-3-(4-piperidinobutyl)-",C1CCN(CC1)CCCCC2=CN(C3=CC=CC=C32)C4=CC=CC=C4,,,,,,
9713,59714,1-(2-(p-Carboxyphenoxy)ethyl)-4-phenylisonipecotic acid diethyl ester hydrobromide,CCOC(=O)C1=CC=C(C=C1)OCC[NH+]2CCC(CC2)(C3=CC=CC=C3)C(=O)OCC.[Br-],,,,,,
9714,59715,Ethyl 1-[2-(4-ethoxycarbonylphenoxy)ethyl]-4-phenylpiperidine-4-carboxylate,CCOC(=O)C1=CC=C(C=C1)OCCN2CCC(CC2)(C3=CC=CC=C3)C(=O)OCC,,,,,,
9715,59716,CID 59716,CC1(C(C(=O)N1OS(=O)(=O)[O-])NC(=O)C(=NOCC(=O)[O-])C2=CSC(=N2)N)C,,,,,,
9716,59717,"[[[(Z)-1-(2-Aminothiazol-4-yl)-2-[[(3S)-2,2-dimethyl-4-oxo-1-(sulfooxy)azetidin-3-yl]amino]-2-oxoethylidene]amino]oxy]acetic acid;[[[(Z)-1-(2-Aminothiazol-4-yl)-2-[[(3S)-2,2-dimethyl-4-oxo-1-(sulfooxy)azetidin-3-yl]amino]-2-oxoethylidene]amino]oxy]acetic acid",CC1(C(C(=O)N1OS(=O)(=O)O)NC(=O)C(=NOCC(=O)O)C2=CSC(=N2)N)C,,,,,,
9717,59718,1-(2-(Cyclohexyloxy)ethyl)-4-phenylisonipecotic acid ethyl ester hydrobromide,CCOC(=O)C1(CC[NH+](CC1)CCOC2CCCCC2)C3=CC=CC=C3.[Br-],,,,,,
9718,59719,Ethyl 1-(2-cyclohexyloxyethyl)-4-phenylpiperidine-4-carboxylate,CCOC(=O)C1(CCN(CC1)CCOC2CCCCC2)C3=CC=CC=C3,,,,,,
9719,59720,"BENZANILIDE, N-(5-(p-AMINOPHENOXY)PENTYL)-",C1=CC=C(C=C1)C(=O)N(CCCCCOC2=CC=C(C=C2)N)C3=CC=CC=C3,,,,,,
9720,59721,CID 59721,C1=CC=C(C=C1)C(=C2C=C(C=CC2=NC(=O)CCl)Cl)N=NC3=C(C=C(C=C3)N(O)O)[N+](=O)[O-],,,,,,
9721,59722,"2,3-Dimercaptopropyl p-chlorobenzoate",C1=CC(=CC=C1C(=O)OCC(CS)S)Cl,,,,,,
9722,59723,"2,3-Dimercaptopropyl o-chlorobenzoate",C1=CC=C(C(=C1)C(=O)OCC(CS)S)Cl,,,,,,
9723,59724,"AMMONIUM, HEXAMETHYLENEBIS(TRIMETHYL-, BIS(p-NITROBENZOATE)",C[N+](C)(C)CCCCCC[N+](C)(C)C.C1=CC(=CC=C1C(=O)[O-])[N+](=O)[O-].C1=CC(=CC=C1C(=O)[O-])[N+](=O)[O-],,,,,,
9724,59725,"Serine, 3-(7-oxo-4-oxa-1-azabicyclo(3.2.0)hept-3-yl)-N-L-valyl-",CC(C)[C@@H](C(=O)NC(C1CN2C(O1)CC2=O)C(C(=O)O)O)N,,,,,,
9725,59726,"Ammonium, (3-(p-amino-N-(p-methoxybenzyl)benzamido)propyl)diethylmethyl-, bromide",CC[N+](C)(CC)CCCN(CC1=CC=C(C=C1)OC)C(=O)C2=CC=C(C=C2)N.[Br-],,,,,,
9726,59727,3-[(4-Aminobenzoyl)-[(4-methoxyphenyl)methyl]amino]propyl-diethyl-methylazanium,CC[N+](C)(CC)CCCN(CC1=CC=C(C=C1)OC)C(=O)C2=CC=C(C=C2)N,,,,,,
9727,59728,"Ammonium, (3-(p-amino-N-(alpha-methylbenzyl)benzamido)propyl)diethylmethyl-, bromide",CC[N+](C)(CC)CCCN(C(C)C1=CC=CC=C1)C(=O)C2=CC=C(C=C2)N.[Br-],,,,,,
9728,59729,3-[(4-Aminobenzoyl)-(1-phenylethyl)amino]propyl-diethyl-methylazanium,CC[N+](C)(CC)CCCN(C(C)C1=CC=CC=C1)C(=O)C2=CC=C(C=C2)N,,,,,,
9729,59730,"3,4-Chrysenedione",C1=CC=C2C(=C1)C=CC3=C2C=CC4=C3C(=O)C(=O)C=C4,,,,,,
9730,59731,1-(2-(4-Biphenylyloxy)ethyl)-4-phenylisonipecotic acid ethyl ester hydrobromide,CCOC(=O)C1(CC[NH+](CC1)CCOC2=CC=C(C=C2)C3=CC=CC=C3)C4=CC=CC=C4.[Br-],,,,,,
9731,59732,Ethyl 4-phenyl-1-[2-(4-phenylphenoxy)ethyl]piperidine-4-carboxylate,CCOC(=O)C1(CCN(CC1)CCOC2=CC=C(C=C2)C3=CC=CC=C3)C4=CC=CC=C4,,,,,,
9732,59733,"3,4a-Dichloro-10a-[(3-chloro-2,2-dimethyl-6-methylidenecyclohexyl)methyl]-6,8-dihydroxy-2,2-dimethyl-3,4-dihydrobenzo[g]chromene-5,10-dione",CC1(C(CCC(=C)C1CC23C(=O)C4=C(C(=CC(=C4)O)O)C(=O)C2(CC(C(O3)(C)C)Cl)Cl)Cl)C,,,,,,
9733,59734,"AMMONIUM, (m-PHENYLENEBIS(IMINOCARBONYLMETHYLENE))BIS(DIETHYLMETHYL-, DIIODIDE",CC[N+](C)(CC)CC(=O)NC1=CC(=CC=C1)NC(=O)C[N+](C)(CC)CC.[I-].[I-],,,,,,
9734,59735,[2-[3-[[2-[Diethyl(methyl)azaniumyl]acetyl]amino]anilino]-2-oxoethyl]-diethyl-methylazanium,CC[N+](C)(CC)CC(=O)NC1=CC(=CC=C1)NC(=O)C[N+](C)(CC)CC,,,,,,
9735,59736,1-[4-(Cyclohexyloxy)phenyl]ethan-1-amine,CC(C1=CC=C(C=C1)OC2CCCCC2)N,,,,,,
9736,59737,"BENZAMIDE, N,N-BIS(5-(p-AMINOPHENOXY)PENTYL)-",C1=CC=C(C=C1)C(=O)N(CCCCCOC2=CC=C(C=C2)N)CCCCCOC3=CC=C(C=C3)N,,,,,,
9737,59738,"N-(2-(Diethylamino)ethyl)-N,2-diphenylglycine isopentyl ester",CCN(CC)CCN(C1=CC=CC=C1)C(C2=CC=CC=C2)C(=O)OCCC(C)C,,,,,,
9738,59739,"1-Piperazineacetamide, N-(2,3-dihydro-7-hydroxy-2,2,4,6-tetramethyl-1H-inden-1-yl)-4-(3-methoxyphenyl)-",CC1=CC(=C(C2=C1CC(C2NC(=O)CN3CCN(CC3)C4=CC(=CC=C4)OC)(C)C)O)C,,,"['Substances that eliminate free radicals. Among other effects, they protect PANCREATIC ISLETS against damage by CYTOKINES and prevent myocardial and pulmonary REPERFUSION INJURY. (See all compounds classified as Free Radical Scavengers.)']",,,
9739,59740,"NAPHTHO(2,1-b)FURAN, 2,6-DINITRO-7-METHOXY-",COC1=C(C2=C(C=C1)C3=C(C=C2)OC(=C3)[N+](=O)[O-])[N+](=O)[O-],,,,,,
9740,59741,Amino-[[6-[5-(hydrazinylmethylideneazaniumylmethyl)furan-2-carbonyl]oxynaphthalen-2-yl]methylidene]azanium;methanesulfonate,CS(=O)(=O)[O-].CS(=O)(=O)[O-].C1=CC2=C(C=CC(=C2)OC(=O)C3=CC=C(O3)C[NH+]=CNN)C=C1C=[NH+]N,,,,,,
9741,59742,(6-Methanehydrazonoylnaphthalen-2-yl) 5-[(hydrazinylmethylideneamino)methyl]furan-2-carboxylate,C1=CC2=C(C=CC(=C2)OC(=O)C3=CC=C(O3)CN=CNN)C=C1C=NN,,,,,,
9742,59743,Pazinaclone,C1CN(CCC12OCCO2)C(=O)CC3C4=CC=CC=C4C(=O)N3C5=NC6=C(C=C5)C=CC(=N6)Cl,,,,,,
9743,59744,"(8S,9S,10R,13S,14S,17S)-10,13-dimethyl-17-(3-phenylprop-2-enoyl)-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-3-one",C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2C(=O)C=CC4=CC=CC=C4)CCC5=CC(=O)CC[C@]35C,,,,,,
9744,59745,Letrazuril,C1=CC(=CC=C1C(C#N)C2=C(C=C(C=C2Cl)N3C(=O)NC(=O)C=N3)Cl)F,,,,,,
9745,59746,"Ammonium, hexamethylenebis(trimethyl-, dibenzoate",C[N+](C)(C)CCCCCC[N+](C)(C)C.C1=CC=C(C=C1)C(=O)[O-].C1=CC=C(C=C1)C(=O)[O-],,,,,,
9746,59747,"BENZAMIDE, N-(5-(p-((2-HYDROXYETHYL)AMINO)PHENOXY)PENTYL)-",C1=CC=C(C=C1)C(=O)NCCCCCOC2=CC=C(C=C2)NCCO,,,,,,
9747,59748,alpha-(m-Aminophenyl)-beta-dimethylaminoethanol,CN(C)CC(C1=CC(=CC=C1)N)O,,,,,,
9748,59749,"2-(Diethylamino)-N-(1,3-dimethyl-4-(o-fluorobenzoyl)-5-pyrazolyl)acetamide hydrochloride",CC[NH+](CC)CC(=O)NC1=C(C(=NN1C)C)C(=O)C2=CC=CC=C2F.[Cl-],,,,,,
9749,59750,Ccris 1810,CCN(CC)CC(=O)NC1=C(C(=NN1C)C)C(=O)C2=CC=CC=C2F,,,,,,
9750,59751,"N-(1-methyl-2-oxo-5-phenyl-3H-1,4-benzodiazepin-3-yl)-1H-indole-2-carboxamide",CN1C2=CC=CC=C2C(=NC(C1=O)NC(=O)C3=CC4=CC=CC=C4N3)C5=CC=CC=C5,,,,,,
9751,59752,"Acetamide, N-(acetyloxy)-N-(4-(2-chlorophenoxy)phenyl)-",CC(=O)N(C1=CC=C(C=C1)OC2=CC=CC=C2Cl)OC(=O)C,,,,,,
9752,59753,"Acetamide, N-(acetyloxy)-N-(4-(3-chlorophenoxy)phenyl)-",CC(=O)N(C1=CC=C(C=C1)OC2=CC(=CC=C2)Cl)OC(=O)C,,,,,,
9753,59754,"Acetamide, N-(acetyloxy)-N-(4-(4-chlorophenoxy)phenyl)-",CC(=O)N(C1=CC=C(C=C1)OC2=CC=C(C=C2)Cl)OC(=O)C,,,,,,
9754,59755,"2,6-Naphthalenedisulfonic acid, 3,7-di-tert-butyl-, compd. with 6-(dimethylamino)-4,4-diphenyl-3-hexanone",CCC(=O)C(CCN(C)C)(C1=CC=CC=C1)C2=CC=CC=C2.CC(C)(C)C1=CC2=CC(=CC(=C2C=C1S(=O)(=O)O)C(C)(C)C)S(=O)(=O)O,,,,,,
9755,59756,"3,8-Ditert-butylnaphthalene-2,6-disulfonic acid",CC(C)(C)C1=CC2=CC(=CC(=C2C=C1S(=O)(=O)O)C(C)(C)C)S(=O)(=O)O,,,,,,
9756,59757,Tepoxalin,CN(C(=O)CCC1=NN(C(=C1)C2=CC=C(C=C2)Cl)C3=CC=C(C=C3)OC)O,['Reduction of inflammation and relief of pain caused by acute and chronic musculoskeletal disorders.'],,"['Anti-inflammatory agents that are non-steroidal in nature. In addition to anti-inflammatory actions, they have analgesic, antipyretic, and platelet-inhibitory actions. They act by blocking the synthesis of prostaglandins by inhibiting cyclooxygenase, which converts arachidonic acid to cyclic endoperoxides, precursors of prostaglandins. Inhibition of prostaglandin synthesis accounts for their analgesic, antipyretic, and platelet-inhibitory actions; other mechanisms may contribute to their anti-inflammatory effects. (See all compounds classified as Anti-Inflammatory Agents, Non-Steroidal.)', 'Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of INTERLEUKINS and other CYTOKINES are emerging. (See all compounds classified as Immunosuppressive Agents.)']",,,
9757,59758,"1-(2-Hydroxy-4a,6a-dimethyl-4b,5,6,6a,7,8,9,9a,9b,10,11,11a-dodecahydro-4aH-indeno[5,4-f]quinolin-7-yl)-3-methylbutan-1-one",CC(C)CC(=O)C1CCC2C1(CCC3C2CCC4C3(C=CC(=O)N4)C)C,,,,,,
9758,59759,Benzyldiethyl(((10-phenothiazinyl)carbonyl)methyl)ammonium chloride,CC[N+](CC)(CC1=CC=CC=C1)CC(=O)N2C3=CC=CC=C3SC4=CC=CC=C42.[Cl-],,,,,,
9759,59760,Benzyl-diethyl-(2-oxo-2-phenothiazin-10-ylethyl)azanium,CC[N+](CC)(CC1=CC=CC=C1)CC(=O)N2C3=CC=CC=C3SC4=CC=CC=C42,,,,,,
9760,59761,DE(fluoro) chloroflezelastine,C1CC(CCN(C1)CCC2=CC=CC=C2)N3C(=O)C4=CC=CC=C4C(=N3)CC5=CC=C(C=C5)Cl,,,,,,
9761,59762,6-Methoxy-1-(2-nitroethenyl)naphthalen-2-ol,COC1=CC2=C(C=C1)C(=C(C=C2)O)C=C[N+](=O)[O-],,,,,,
9762,59763,"ACETIC ACID, ((2-NITRONAPHTHO(2,1-b)FURAN-7-YL)OXY)-",C1=CC2=C(C=CC3=C2C=C(O3)[N+](=O)[O-])C(=C1)OCC(=O)O,,,,,,
9763,59764,"NAPHTHO(2,1-b)FURAN, 7-METHYL-2-NITRO-",CC1=CC2=C(C=C1)C3=C(C=C2)OC(=C3)[N+](=O)[O-],,,,,,
9764,59765,(Diphenylphosphinyl)acetic acid hydrazide mono(di-2-propenylphosphinate),C=CCP(=O)(CC=C)[O-].C1=CC=C(C=C1)P(CC(=O)ON[NH3+])C2=CC=CC=C2,,,,,,
9765,59766,Diallylphosphinic acid,C=CCP(=O)(CC=C)O,,,,,,
9766,59767,Hydrazinyl 2-diphenylphosphanylacetate,C1=CC=C(C=C1)P(CC(=O)ONN)C2=CC=CC=C2,,,,,,
9767,59768,Esmolol,CC(C)NCC(COC1=CC=C(C=C1)CCC(=O)OC)O,"['For the rapid control of ventricular rate in patients with atrial fibrillation or atrial flutter in perioperative, postoperative, or other emergent circumstances where short term control of ventricular rate with a short-acting agent is desirable. Also used in noncompensatory sinus tachycardia where the rapid heart rate requires specific intervention.']",,['Drugs that bind to and block the activation of ADRENERGIC BETA-1 RECEPTORS. (See all compounds classified as Adrenergic beta-1 Receptor Antagonists.)'],"['Rapidly absorbed, steady-state blood levels for dosages from 50-300 &micro;g/kg/min (0.05-0.3 mg/kg/mm) are obtained within five minutes.', 'Consistent with the high rate of blood-based metabolism of esmolol hydrochloride, less than 2% of the drug is excreted unchanged in the urine. The acid metabolite has an elimination half-life of about 3.7 hours and is excreted in the urine with a clearance approximately equivalent to the glomerular filtration rate.  Excretion of the acid metabolite is significantly decreased in patients with renal disease, with the elimination half-life increased to about ten-fold that of normals, and plasma levels considerably elevated.', '20 L/kg/hr [Men]']",['Esmolol undergoes rapid hydrolysis of ester linkage which is catalyzed by esterases found in the cytosol of red blood cells (RBCs). The plasma cholinersterases or RBC membrane acetylcholinesterases are not involved in this metabolic reaction. Metabolism of the drug occurs mainly in RBCs to form a free acid metabolite (with 1/1500 the activity of esmolol) and methanol.'],['Rapid distribution half-life of about 2 minutes and an elimination half-life of about 9 minutes. The acid metabolite has an elimination half-life of about 3.7 hours.']
9768,59769,"4-Isoquinolinecarbonitrile, 5,6,7,8-tetrahydro-3-(2-hydroxy-3-(1-methylethyl)amino)propoxy)-,monohydrochloride",CC(C)[NH2+]CC(COC1=NC=C2CCCCC2=C1C#N)O.[Cl-],,,,,,
9769,59770,"3-[2-Hydroxy-3-(propan-2-ylamino)propoxy]-5,6,7,8-tetrahydroisoquinoline-4-carbonitrile",CC(C)NCC(COC1=NC=C2CCCCC2=C1C#N)O,,,,,,
9770,59771,Fenothiocarb sulfoxide,CN(C)C(=O)S(=O)CCCCOC1=CC=CC=C1,,,,,,
9771,59772,Sumatriptan succinate,CNS(=O)(=O)CC1=CC2=C(C=C1)NC=C2CCN(C)C.C(CC(=O)O)C(=O)O,,,"['Endogenous compounds and drugs that specifically stimulate SEROTONIN 5-HT1 RECEPTORS. Included under this heading are agonists for one or more of the specific 5-HT1 receptor subtypes. (See all compounds classified as Serotonin 5-HT1 Receptor Agonists.)', 'Drugs used to cause constriction of the blood vessels. (See all compounds classified as Vasoconstrictor Agents.)']",,,
9772,59773,"3,3-Difluorochlorambucil",C1=CC(=CC=C1CC(CC(=O)O)(F)F)N(CCCl)CCCl,,,,,,
9773,59774,Ondansetron hydrochloride dihydrate,CC1=NC=CN1CC2CCC3=C(C2=O)C4=CC=CC=C4N3C.O.O.Cl,,,"['Drugs used to prevent NAUSEA or VOMITING. (See all compounds classified as Antiemetics.)', 'Agents, usually topical, that relieve itching (pruritus). (See all compounds classified as Antipruritics.)', 'Drugs that bind to but do not activate SEROTONIN 5-HT3 RECEPTORS, thereby blocking the actions of SEROTONIN or SEROTONIN 5-HT3 RECEPTOR AGONISTS. (See all compounds classified as Serotonin 5-HT3 Receptor Antagonists.)']",,,
9774,59775,"2,2''-Bis(diethylamino)-4',4'''-biacetanilide dihydrochloride",CC[NH+](CC)CC(=O)NC1=CC=C(C=C1)C2=CC=C(C=C2)NC(=O)C[NH+](CC)CC.[Cl-].[Cl-],,,,,,
9775,59776,2-(diethylamino)-N-[4-[4-[[2-(diethylamino)acetyl]amino]phenyl]phenyl]acetamide,CCN(CC)CC(=O)NC1=CC=C(C=C1)C2=CC=C(C=C2)NC(=O)CN(CC)CC,,,,,,
9776,59777,"2,4-Dichlorobenzoic acid 2,3-dimercaptopropyl ester",C1=CC(=C(C=C1Cl)Cl)C(=O)OCC(CS)S,,,,,,
9777,59778,"Acridine, 2-ethoxy-6-nitro-9-(1H-1,2,4-triazol-3-ylthio)-",CCOC1=CC2=C(C3=C(C=C(C=C3)[N+](=O)[O-])N=C2C=C1)SC4=NC=NN4,,,,,,
9778,59779,"Acridine, 2-ethoxy-9-((5-methyl-1H-1,2,4-triazol-3-YL)thio)-6-nitro-",CCOC1=CC2=C(C3=C(C=C(C=C3)[N+](=O)[O-])N=C2C=C1)SC4=NNC(=N4)C,,,,,,
9779,59780,"2-((3,4-Dimethoxyphenyl)methyl)-1-azabicyclo(2.2.2)octan-3-one hydrochloride",COC1=C(C=C(C=C1)CC2C(=O)C3CC[NH+]2CC3)OC.[Cl-],,,,,,
9780,59781,"2-(3,4-Dimethoxybenzyl)-3-oxoquinuclidine",COC1=C(C=C(C=C1)CC2C(=O)C3CCN2CC3)OC,,,,,,
9781,59782,2-((4-Methoxyphenyl)methyl)-1-azabicyclo(2.2.2)octan-3-one hydrochloride,COC1=CC=C(C=C1)CC2C(=O)C3CC[NH+]2CC3.[Cl-],,,,,,
9782,59783,2-[(4-Methoxyphenyl)methyl]-1-azabicyclo[2.2.2]octan-3-one,COC1=CC=C(C=C1)CC2C(=O)C3CCN2CC3,,,,,,
9783,59784,"Acridine, 2-ethoxy-6-nitro-9-((5-phenyl-1H-1,2,4-triazol-3-YL)thio)-",CCOC1=CC2=C(C3=C(C=C(C=C3)[N+](=O)[O-])N=C2C=C1)SC4=NNC(=N4)C5=CC=CC=C5,,,,,,
9784,59785,CID 59785,O[SeH](=O)=O.[O-]S(=O)(=O)[O-].Cl.[Cu+2],,,,,,
9785,59786,Selenonic acid,O[SeH](=O)=O,,,,,,
9786,59787,CID 59787,C[NH+](C)CCOC1=CC=CC=C1C(=O)C=CC2=CC=CC=C2.C(C(=O)O)C(CO)(C(=O)O)C(=O)[O-],,,,,,
9787,59788,1-[2-[2-(Dimethylamino)ethoxy]phenyl]-3-phenylprop-2-en-1-one,CN(C)CCOC1=CC=CC=C1C(=O)C=CC2=CC=CC=C2,,,,,,
9788,59789,N-(6-Aminohexyl)-5-iodo-1-naphthalenesulfonamide,C1=CC2=C(C=CC=C2I)C(=C1)S(=O)(=O)NCCCCCCN,,,,,,
9789,59790,"1-Naphthalenesulfonamide, N-(7-aminoheptyl)-5-iodo-",C1=CC2=C(C=CC=C2I)C(=C1)S(=O)(=O)NCCCCCCCN,,,,,,
9790,59791,"1-Naphthalenesulfonamide, N-(9-aminononyl)-5-iodo-",C1=CC2=C(C=CC=C2I)C(=C1)S(=O)(=O)NCCCCCCCCCN,,,,,,
9791,59792,"1-Naphthalenesulfonamide, N-(10-aminodecyl)-5-iodo-",C1=CC2=C(C=CC=C2I)C(=C1)S(=O)(=O)NCCCCCCCCCCN,,,,,,
9792,59793,N-(12-Aminododecyl)-5-iodo-1-naphthalenesulfonamide,C1=CC2=C(C=CC=C2I)C(=C1)S(=O)(=O)NCCCCCCCCCCCCN,,,,,,
9793,59794,N-(2-Methyl-3-(1-pyrrolidinyl)propyl)-3-phenyl-N-(phenylmethyl)-5-isoxazolamine citrate,CC(C[NH+]1CCCC1)CN(CC2=CC=CC=C2)C3=CC(=NO3)C4=CC=CC=C4.C(C(=O)O)C(CC(=O)[O-])(C(=O)O)O,,,,,,
9794,59795,"N-benzyl-N-(2-methyl-3-pyrrolidin-1-ylpropyl)-3-phenyl-1,2-oxazol-5-amine",CC(CN1CCCC1)CN(CC2=CC=CC=C2)C3=CC(=NO3)C4=CC=CC=C4,,,,,,
9795,59796,CID 59796,CC(CCN(CC1=CC=CC=C1)C2=CC(=NO2)C3=CC=CC=C3)[NH+]4CCCC4.C(=CC(=O)[O-])C(=O)O,,,,,,
9796,59797,"N-benzyl-3-phenyl-N-(3-pyrrolidin-1-ylbutyl)-1,2-oxazol-5-amine",CC(CCN(CC1=CC=CC=C1)C2=CC(=NO2)C3=CC=CC=C3)N4CCCC4,,,,,,
9797,59798,Bidisomide,CC(C)N(CCC(CCN1CCCCC1)(C2=CC=CC=C2Cl)C(=O)N)C(=O)C,,,"['Agents used for the treatment or prevention of cardiac arrhythmias. They may affect the polarization-repolarization phase of the action potential, its excitability or refractoriness, or impulse conduction or membrane responsiveness within cardiac fibers. Anti-arrhythmia agents are often classed into four main groups according to their mechanism of action: sodium channel blockade, beta-adrenergic blockade, repolarization prolongation, or calcium channel blockade. (See all compounds classified as Anti-Arrhythmia Agents.)']",,,
9798,59799,"3-(3,5-Diamino-2-pyridylazo)-2,4,6-triiodobenzoic acid",C1=C(C=NC(=C1N)N=NC2=C(C=C(C(=C2I)C(=O)O)I)I)N,,,,,,
9799,59800,"3-(2,6-Diamino-3-pyridylazo)-2,4,6-triiodobenzoic acid",C1=CC(=NC(=C1N=NC2=C(C=C(C(=C2I)C(=O)O)I)I)N)N,,,,,,
9800,59801,alpha-(m-Aminophenyl)-beta-ethylmethylaminoethanol,CCN(C)CC(C1=CC(=CC=C1)N)O,,,,,,
9801,59802,"6,7-dichloro-5-(N,N-dimethylsulfamoyl)-2,3-dihydrobenzofuran-2-carboxylic acid",CN(C)S(=O)(=O)C1=C(C(=C2C(=C1)CC(O2)C(=O)O)Cl)Cl,,,,,,
9802,59803,1-(4-Isopropoxy-phenyl)-ethylamine,CC(C)OC1=CC=C(C=C1)C(C)N,,,,,,
9803,59804,"1-(2,4-Difluorophenyl)-6,7-difluoro-1,4-dihydro-4-oxoquinoline-3-carboxylic acid",C1=CC(=C(C=C1F)F)N2C=C(C(=O)C3=CC(=C(C=C32)F)F)C(=O)O,,,,,,
9804,59805,"Benzaldehyde, 4-hydroxy-3-methoxy-5-((5-phenyl-2H-tetrazol-2-YL)methyl)-",COC1=CC(=CC(=C1O)CN2N=C(N=N2)C3=CC=CC=C3)C=O,,,,,,
9805,59806,Thioacetic acid S-2-(3-aminopropionamido)ethyl ester hydrobromide,CC(=O)SCCNC(=O)CC[NH3+].[Br-],,,,,,
9806,59807,S-[2-(3-aminopropanoylamino)ethyl] ethanethioate,CC(=O)SCCNC(=O)CCN,,,,,,
9807,59808,"Acetic acid, chlorothio-, S-2-(2-aminoacetamido)ethyl ester, trifluoroacetate",C(CSC(=O)CCl)NC(=O)C[NH3+].C(=O)(C(F)(F)F)[O-],,,,,,
9808,59809,S-[2-[(2-aminoacetyl)amino]ethyl] 2-chloroethanethioate,C(CSC(=O)CCl)NC(=O)CN,,,,,,
9809,59810,"Acetic acid, trichlorothio-, S-2-(2-aminoacetamido)ethyl ester, trifluoroacetate",C(CSC(=O)C(Cl)(Cl)Cl)NC(=O)C[NH3+].C(=O)(C(F)(F)F)[O-],,,,,,
9810,59811,"S-[2-[(2-aminoacetyl)amino]ethyl] 2,2,2-trichloroethanethioate",C(CSC(=O)C(Cl)(Cl)Cl)NC(=O)CN,,,,,,
9811,59812,"N,N'-(Dithiodiethylene)bis(4-aminobutyramide) dihydrobromide",C(CC(=O)NCCSSCCNC(=O)CCC[NH3+])C[NH3+].[Br-].[Br-],,,,,,
9812,59813,4-amino-N-[2-[2-(4-aminobutanoylamino)ethyldisulfanyl]ethyl]butanamide,C(CC(=O)NCCSSCCNC(=O)CCCN)CN,,,,,,
9813,59814,Thioglycine S-2-acetamidoethyl ester hydrobromide,CC(=O)NCCSC(=O)C[NH3+].[Br-],,,,,,
9814,59815,"ACETAMIDE, N,N-DIMETHYL-2-(o-TOLUIDINO)-",CC1=CC=CC=C1NCC(=O)N(C)C,,,,,,
9815,59816,"ACETAMIDE, 2-(o-ANISIDINO)-N,N-DIMETHYL-",CN(C)C(=O)CNC1=CC=CC=C1OC,,,,,,
9816,59817,"Phenylacetic acid 2,3-dimercaptopropyl ester",C1=CC=C(C=C1)CC(=O)OCC(CS)S,,,,,,
9817,59818,Phellodendrine chloride,C[N+]12CCC3=CC(=C(C=C3[C@@H]1CC4=CC(=C(C=C4C2)OC)O)O)OC.[Cl-],,,,,,
9818,59819,"(13aS)-3,10-dimethoxy-7-methyl-6,8,13,13a-tetrahydro-5H-isoquinolino[2,1-b]isoquinolin-7-ium-2,11-diol",C[N+]12CCC3=CC(=C(C=C3[C@@H]1CC4=CC(=C(C=C4C2)OC)O)O)OC,,,,,,
9819,59820,"N'-(5-butyl-1,3,4-thiadiazol-2-yl)but-2-enediamide",CCCCC1=NN=C(S1)NC(=O)C=CC(=O)N,,,,,,
9820,59821,"N'-(5-propyl-1,3,4-thiadiazol-2-yl)but-2-enediamide",CCCC1=NN=C(S1)NC(=O)C=CC(=O)N,,,,,,
9821,59822,"N'-(5-methyl-1,3,4-thiadiazol-2-yl)but-2-enediamide",CC1=NN=C(S1)NC(=O)C=CC(=O)N,,,,,,
9822,59823,Sabeluzole,CN(C1CCN(CC1)CC(COC2=CC=C(C=C2)F)O)C3=NC4=CC=CC=C4S3,,,,,,
9823,59824,"m-ANISIDINE, 4-BUTOXY-",CCCCOC1=C(C=C(C=C1)N)OC,,,,,,
9824,59825,CID 59825,CCN(CC)C(=O)C1=CC=C(C=C1)NCN2C(=O)C(=CC3=CC=C(C=C3)OC)SC2=S,,,,,,
9825,59826,CID 59826,CCN(CC)C(=O)C1=CC=C(C=C1)NCN2C(=O)C(=CC3=CC=C(C=C3)Cl)SC2=S,,,,,,
9826,59827,CID 59827,C1C=C(C=C1OC(=[OH+])CCCCCCCCC(=[OH+])OC2=CC(C=C2)C3=CC=CC=C3)C4=CC=CC=C4.N.N,,,,,,
9827,59828,CID 59828,C1C=C(C=C1OC(=O)CCCCCCCCC(=O)OC2=CC(C=C2)C3=CC=CC=C3)C4=CC=CC=C4,,,,,,
9828,59829,alpha-(1-Aminoethyl)-alpha-methylbenzyl alcohol hydrochloride,CC(C(C)(C1=CC=CC=C1)O)[NH3+].[Cl-],,,,,,
9829,59830,3-Amino-2-phenylbutan-2-ol,CC(C(C)(C1=CC=CC=C1)O)N,,,,,,
9830,59831,1-(4-Ethoxyphenyl)ethanamine,CCOC1=CC=C(C=C1)C(C)N,,,,,,
9831,59832,"1H-1,5-Benzodiazepine-1-carboxaldehyde, 2,3,4,5-tetrahydro-4-oxo-",C1CN(C2=CC=CC=C2NC1=O)C=O,,,,,,
9832,59833,"3-methyl-4-oxo-2,3,4,5-tetrahydro-1H-1,5-benzodiazepine-1-carbaldehyde",CC1CN(C2=CC=CC=C2NC1=O)C=O,,,,,,
9833,59834,"1H-Azepine-1-ethanol, hexahydro-alpha-(((1-methylethyl)amino)methyl)-, dihydrochloride",CC(C)[NH2+]CC(C[NH+]1CCCCCC1)O.[Cl-].[Cl-],,,,,,
9834,59835,1-(Azepan-1-yl)-3-(propan-2-ylamino)propan-2-ol,CC(C)NCC(CN1CCCCCC1)O,,,,,,
9835,59836,3-Methoxy-4-propoxyaniline,CCCOC1=C(C=C(C=C1)N)OC,,,,,,
9836,59837,"Benzamide, 4-amino-2,6-dimethyl-N-(2-(4-(2-pyridinyl)-1-piperazinyl)ethyl)-, trihydrochloride, monohydrate",CC1=CC(=CC(=C1C(=O)NCCN2CCN(CC2)C3=CC=CC=N3)C)N.Cl.Cl.Cl,,,,,,
9837,59838,"4-amino-2,6-dimethyl-N-[2-(4-pyridin-2-ylpiperazin-1-yl)ethyl]benzamide",CC1=CC(=CC(=C1C(=O)NCCN2CCN(CC2)C3=CC=CC=N3)C)N,,,,,,
9838,59839,"Benzamide, 4-amino-N-(2-(4-(2-pyridinyl)-1-piperazinyl)ethyl)-2,3,5,6-tetramethyl-",CC1=C(C(=C(C(=C1C(=O)NCCN2CCN(CC2)C3=CC=CC=N3)C)C)N)C,,,,,,
9839,59840,"Benzamide, 2,6-dimethyl-4-nitro-N-(2-(4-(2-pyridinyl)-1-piperazinyl)ethyl)-, dihydrochloride",CC1=CC(=CC(=C1C(=O)NCCN2CCN(CC2)C3=CC=CC=N3)C)[N+](=O)[O-].Cl.Cl,,,,,,
9840,59841,"2,6-dimethyl-4-nitro-N-[2-(4-pyridin-2-ylpiperazin-1-yl)ethyl]benzamide",CC1=CC(=CC(=C1C(=O)NCCN2CCN(CC2)C3=CC=CC=N3)C)[N+](=O)[O-],,,,,,
9841,59842,"Benzamide, 4-nitro-N-(2-(4-(2-pyridinyl)-1-piperazinyl)ethyl)-2,3,5,6-tetramethyl-, dihydrochloride",CC1=C(C(=C(C(=C1C(=O)NCCN2CCN(CC2)C3=CC=CC=N3)C)C)[N+](=O)[O-])C.Cl.Cl,,,,,,
9842,59843,"2,3,5,6-tetramethyl-4-nitro-N-[2-(4-pyridin-2-ylpiperazin-1-yl)ethyl]benzamide",CC1=C(C(=C(C(=C1C(=O)NCCN2CCN(CC2)C3=CC=CC=N3)C)C)[N+](=O)[O-])C,,,,,,
9843,59844,CID 59844,CN1C(=NC(=O)C(=N1)[O-])SCC2=C(N3[C@@H]([C@@H](C3=O)NC(=O)C(=NOC)C4=CSC(=N4)N)SC2)C(=O)[O-].[Na+].[Na+],,,['Substances that inhibit the growth or reproduction of BACTERIA. (See all compounds classified as Anti-Bacterial Agents.)'],,,
9844,59845,"(6R,7S)-7-[[2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-3-[(2-methyl-5,6-dioxo-1H-1,2,4-triazin-3-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid",CN1C(=NC(=O)C(=O)N1)SCC2=C(N3[C@@H]([C@H](C3=O)NC(=O)C(=NOC)C4=CSC(=N4)N)SC2)C(=O)O,,,,,,
9845,59846,"Acetic acid, ((6-(aminosulfonyl)-2-benzothiazolyl)amino)oxo-, ethyl ester",CCOC(=O)C(=O)NC1=NC2=C(S1)C=C(C=C2)S(=O)(=O)N,,,,,,
9846,59847,"Acetic acid, (2-benzothiazolylamino)oxo-, methyl ester",COC(=O)C(=O)NC1=NC2=CC=CC=C2S1,,,,,,
9847,59848,"Acetic acid, ((6-methyl-2-benzothiazolyl)amino)oxo-, methyl ester",CC1=CC2=C(C=C1)N=C(S2)NC(=O)C(=O)OC,,,,,,
9848,59849,"Acetic acid, ((6-bromo-2-benzothiazolyl)amino)oxo-, methyl ester",COC(=O)C(=O)NC1=NC2=C(S1)C=C(C=C2)Br,,,,,,
9849,59850,"Acetic acid, ((6-nitro-2-benzothiazolyl)amino)oxo-, methyl ester",COC(=O)C(=O)NC1=NC2=C(S1)C=C(C=C2)[N+](=O)[O-],,,,,,
9850,59851,"6-Benzothiazolecarboxylic acid, 2-((methoxyoxoacetyl)amino)-, ethyl ester",CCOC(=O)C1=CC2=C(C=C1)N=C(S2)NC(=O)C(=O)OC,,,,,,
9851,59852,"Acetic acid, ((6-(aminosulfonyl)-2-benzothiazolyl)amino)oxo-, methyl ester",COC(=O)C(=O)NC1=NC2=C(S1)C=C(C=C2)S(=O)(=O)N,,,,,,
9852,59853,"Acetic acid, ((6-methyl-2-benzothiazolyl)amino)oxo-",CC1=CC2=C(C=C1)N=C(S2)NC(=O)C(=O)O,,,,,,
9853,59854,"Acetic acid, ((6-(aminosulfonyl)-2-benzothiazolyl)amino)oxo-",C1=CC2=C(C=C1S(=O)(=O)N)SC(=N2)NC(=O)C(=O)O,,,,,,
9854,59855,"Benzoic acid, p-butylamino-, 2-(2-(2-(2-(2-(2-(2-(2-(2-(2-(2-methoxyethoxy)ethoxy)ethoxy)ethoxy)ethoxy)ethoxy)ethoxy)ethoxy)ethoxy)ethoxy)ethyl ester",CCCCNC1=CC=C(C=C1)C(=O)OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOC,,,,,,
9855,59856,Cisconazole,C1=CC(=C(C(=C1)F)CO[C@H]2[C@H](SC3=C2C=C(C=C3)F)CN4C=CN=C4)F,,,,,,
9856,59857,"3-Chloro-5-((dimethylamino)methyl)-4,5-dimethyl-2(5H)-furanone",CC1=C(C(=O)OC1(C)CN(C)C)Cl,,,,,,
9857,59858,"3-Chloro-5-((hexahydro-1H-azepin-1-yl)methyl)-4,5-dimethyl-2(5H)-furanone",CC1=C(C(=O)OC1(C)CN2CCCCCC2)Cl,,,,,,
9858,59859,"3-Chloro-4,5-dimethyl-5-(4-morpholinylmethyl)-2(5H)-furanone",CC1=C(C(=O)OC1(C)CN2CCOCC2)Cl,,,,,,
9859,59860,"3-Bromo-5-((dimethylamino)methyl)-4,5-dimethyl-2(5H)-furanone",CC1=C(C(=O)OC1(C)CN(C)C)Br,,,,,,
9860,59861,"3-Bromo-4,5-dimethyl-5-(1-pyrrolidinylmethyl)-2(5H)-furanone",CC1=C(C(=O)OC1(C)CN2CCCC2)Br,,,,,,
9861,59862,"3-Bromo-5-((hexahydro-1H-azepin-1-yl)methyl)-4,5-dimethyl-2(5H)-furanone",CC1=C(C(=O)OC1(C)CN2CCCCCC2)Br,,,,,,
9862,59863,"3-Bromo-4,5-dimethyl-5-(4-morpholinylmethyl)-2(5H)-furanone",CC1=C(C(=O)OC1(C)CN2CCOCC2)Br,,,,,,
9863,59864,"Benzothiazole, 2-(4-butyl-3,5-dimethyl-1H-pyrazol-1-YL)-",CCCCC1=C(N(N=C1C)C2=NC3=CC=CC=C3S2)C,,,,,,
9864,59865,"Benzothiazole, 2-(4-butyl-3,5-dimethyl-1H-pyrazol-1-YL)-6-methyl-",CCCCC1=C(N(N=C1C)C2=NC3=C(S2)C=C(C=C3)C)C,,,,,,
9865,59866,"Benzothiazole, 2-(4-butyl-3,5-dimethyl-1H-pyrazol-1-YL)-6-chloro-",CCCCC1=C(N(N=C1C)C2=NC3=C(S2)C=C(C=C3)Cl)C,,,,,,
9866,59867,"7-{1-[4-(Hydroxymethyl)phenyl]prop-1-en-2-yl}-1,1,4,4-tetramethyl-1,2,3,4-tetrahydronaphthalen-2-ol",CC(=CC1=CC=C(C=C1)CO)C2=CC3=C(C=C2)C(CC(C3(C)C)O)(C)C,,,,,,
9867,59868,Dexpramipexole,CCCN[C@@H]1CCC2=C(C1)SC(=N2)N,,,"['Naturally occurring or synthetic substances that inhibit or retard oxidation reactions. They counteract the damaging effects of oxidation in animal tissues. (See all compounds classified as Antioxidants.)', 'Agents used in the treatment of Parkinson&apos;s disease. The most commonly used drugs act on the dopaminergic system in the striatum and basal ganglia or are centrally acting muscarinic antagonists. (See all compounds classified as Antiparkinson Agents.)', 'Drugs that bind to and activate dopamine receptors. (See all compounds classified as Dopamine Agonists.)']",,,
9868,59869,"Cyclopropa(c)pyrrolo(3,2-e)indol-4(5H)-one, 1,2,8,8a-tetrahydro-2-(1H-indol-2-ylcarbonyl)-7-methyl-, (+-)-",CC1=C2CC23C4=C(C(=O)CC3=N1)NC(C4)C(=O)C5=CC6=CC=CC=C6N5,,,,,,
9869,59870,"Chlordiazepoxide, nitrosated",CN=C1CN(C(=C2C=C(C=CC2=N1)Cl)C3=CC=CC=C3)O.N(=O)[O-].[Na+],,,,,,
9870,59871,"Acetamide, N-(4-(3-(4-(2-methoxyphenyl)-1-piperazinyl)propoxy)phenyl)-N-phenyl-",CC(=O)N(C1=CC=CC=C1)C2=CC=C(C=C2)OCCCN3CCN(CC3)C4=CC=CC=C4OC,,,,,,
9871,59872,"Benzenamine, 4-(3-(4-(2-methoxyphenyl)-1-piperazinyl)propoxy)-N-(1-methylethyl)-, trihydrochloride",CC(C)NC1=CC=C(C=C1)OCCCN2CCN(CC2)C3=CC=CC=C3OC.Cl.Cl.Cl,,,,,,
9872,59873,4-[3-[4-(2-methoxyphenyl)piperazin-1-yl]propoxy]-N-propan-2-ylaniline,CC(C)NC1=CC=C(C=C1)OCCCN2CCN(CC2)C3=CC=CC=C3OC,,,,,,
9873,59874,"1,4-Benzodioxin-2-methanamine, 2,3-dihydro-N-(4-(3-(4-(2-methoxyphenyl)-1-piperazinyl)propoxy)phenyl)-, trihydrochloride",COC1=CC=CC=C1N2CCN(CC2)CCCOC3=CC=C(C=C3)NCC4COC5=CC=CC=C5O4.Cl.Cl.Cl,,,,,,
9874,59875,"N-(2,3-dihydro-1,4-benzodioxin-3-ylmethyl)-4-[3-[4-(2-methoxyphenyl)piperazin-1-yl]propoxy]aniline",COC1=CC=CC=C1N2CCN(CC2)CCCOC3=CC=C(C=C3)NCC4COC5=CC=CC=C5O4,,,,,,
9875,59876,"Benzenamine, 4-(3-(4-(2-methoxyphenyl)-1-piperazinyl)propoxy)-N-methyl-, trihydrochloride, hydrate",CNC1=CC=C(C=C1)OCCCN2CCN(CC2)C3=CC=CC=C3OC.Cl.Cl.Cl,,,,,,
9876,59877,4-[3-[4-(2-methoxyphenyl)piperazin-1-yl]propoxy]-N-methylaniline,CNC1=CC=C(C=C1)OCCCN2CCN(CC2)C3=CC=CC=C3OC,,,,,,
9877,59878,"Benzenamine, N,N-dimethyl-4-(3-(4-(2-methoxyphenyl)-1-piperazinyl)propoxy)-, trihydrochloride",CN(C)C1=CC=C(C=C1)OCCCN2CCN(CC2)C3=CC=CC=C3OC.Cl.Cl.Cl,,,,,,
9878,59879,"4-[3-[4-(2-methoxyphenyl)piperazin-1-yl]propoxy]-N,N-dimethylaniline",CN(C)C1=CC=C(C=C1)OCCCN2CCN(CC2)C3=CC=CC=C3OC,,,,,,
9879,59880,"Benzenamine, 4-(3-(4-(2-methoxyphenyl)-1-piperazinyl)propoxy)-N-propyl-, trihydrochloride",CCCNC1=CC=C(C=C1)OCCCN2CCN(CC2)C3=CC=CC=C3OC.Cl.Cl.Cl,,,,,,
9880,59881,4-[3-[4-(2-methoxyphenyl)piperazin-1-yl]propoxy]-N-propylaniline,CCCNC1=CC=C(C=C1)OCCCN2CCN(CC2)C3=CC=CC=C3OC,,,,,,
9881,59882,"Benzenamine, 4-(3-(4-(2-methoxyphenyl)-1-piperazinyl)propoxy)-N-phenyl-, trihydrochloride",COC1=CC=CC=C1N2CCN(CC2)CCCOC3=CC=C(C=C3)NC4=CC=CC=C4.Cl.Cl.Cl,,,,,,
9882,59883,4-[3-[4-(2-methoxyphenyl)piperazin-1-yl]propoxy]-N-phenylaniline,COC1=CC=CC=C1N2CCN(CC2)CCCOC3=CC=C(C=C3)NC4=CC=CC=C4,,,,,,
9883,59884,"Isoquinolinium, 1-(2,2-bis(methylthio)ethenyl)-2-methyl-, iodide",C[N+]1=C(C2=CC=CC=C2C=C1)C=C(SC)SC.[I-],,,,,,
9884,59885,"1-[2,2-Bis(methylsulfanyl)ethenyl]-2-methylisoquinolin-2-ium",C[N+]1=C(C2=CC=CC=C2C=C1)C=C(SC)SC,,,,,,
9885,59886,"Acetamide, N-(((methylamino)carbonyl)oxy)-",CC(=O)NOC(=O)NC,,,,,,
9886,59887,"Benzamide, N-(hexahydro-1H-azepin-1-YL)-3,4,5-trimethoxy-",COC1=CC(=CC(=C1OC)OC)C(=O)NN2CCCCCC2,,,,,,
9887,59888,"m-ANISIDINE, 4-(PENTYLOXY)-",CCCCCOC1=C(C=C(C=C1)N)OC,,,,,,
9888,59889,N-(2-(Diethylamino)ethyl)-4-((1-oxobutyl)amino)benzamide hydrochloride,CCCC(=O)NC1=CC=C(C=C1)C(=O)NCC[NH+](CC)CC.[Cl-],,,,,,
9889,59890,4-(butanoylamino)-N-[2-(diethylamino)ethyl]benzamide,CCCC(=O)NC1=CC=C(C=C1)C(=O)NCCN(CC)CC,,,,,,
9890,59891,"Benzamide, 4-((chloroacetyl)amino)-N-(2-(diethylamino)ethyl)-, ethanedioate (1:1)",CC[NH+](CC)CCNC(=O)C1=CC=C(C=C1)NC(=O)CCl.C(=O)(C(=O)[O-])O,,,,,,
9891,59892,"Benzamide, 4-[(chloroacetyl)amino]-N-[2-(diethylamino)ethyl]-",CCN(CC)CCNC(=O)C1=CC=C(C=C1)NC(=O)CCl,,,,,,
9892,59893,"Benzamide, N-(2-(diethylamino)ethyl)-4-((2-methyl-1-oxopropyl)amino)-, ethanedioate (1:1)",CC[NH+](CC)CCNC(=O)C1=CC=C(C=C1)NC(=O)C(C)C.C(=O)(C(=O)[O-])O,,,,,,
9893,59894,N-[2-(diethylamino)ethyl]-4-(2-methylpropanoylamino)benzamide,CCN(CC)CCNC(=O)C1=CC=C(C=C1)NC(=O)C(C)C,,,,,,
9894,59895,"Benzamide, N-(2-(diethylamino)ethyl)-4-((2,2-dimethyl-1-oxopropyl)amino)-, ethanedioate (1:1)",CC[NH+](CC)CCNC(=O)C1=CC=C(C=C1)NC(=O)C(C)(C)C.C(=O)(C(=O)[O-])O,,,,,,
9895,59896,"N-[2-(diethylamino)ethyl]-4-(2,2-dimethylpropanoylamino)benzamide",CCN(CC)CCNC(=O)C1=CC=C(C=C1)NC(=O)C(C)(C)C,,,,,,
9896,59897,"4H-1-Benzopyran-4-one, 3-(2-amino-4-thiazolyl)-2-methyl-",CC1=C(C(=O)C2=CC=CC=C2O1)C3=CSC(=N3)N,,,,,,
9897,59898,"4H-1-Benzopyran-4-one, 3-(2-amino-4-thiazolyl)-2,6-dimethyl-",CC1=CC2=C(C=C1)OC(=C(C2=O)C3=CSC(=N3)N)C,,,,,,
9898,59899,"Carbamic acid, (((((4-chloro-2-methylphenyl)imino)methyl)methylamino)thio)methyl-, 2,3-dihydro-2,2-dimethyl-7-benzofuranyl ester",CC1=C(C=CC(=C1)Cl)N=CN(C)SCNC(=O)OC2=CC=CC3=C2OC(C3)(C)C,,,,,,
9899,59900,"Carbamic acid, (((((2,4-dimethylphenyl)imino)methyl)methylamino)thio)methyl-, 2,3-dihydro-2,2-dimethyl-7-benzofuranyl ester",CC1=CC(=C(C=C1)N=CN(C)SCNC(=O)OC2=CC=CC3=C2OC(C3)(C)C)C,,,,,,
9900,59901,"Carbamic acid, (((((4-chloro-2-methylphenyl)imino)methyl)methylamino)thio)methyl-, 3-(1-methylethyl)phenyl ester",CC1=C(C=CC(=C1)Cl)N=CN(C)SCNC(=O)OC2=CC=CC(=C2)C(C)C,,,,,,
9901,59902,4-(2-Methyloxiranyl)benzonitrile,CC1C(O1)C2=CC=C(C=C2)C#N,,,,,,
9902,59903,"Benzo(c)phenanthridinium, 11,12-bis(acetyloxy)-5,6-dimethyl-2,3,8,9-tetramethoxy-, perchlorate",CC1=[N+](C2=C(C3=CC(=C(C=C13)OC)OC)C(=C(C4=CC(=C(C=C42)OC)OC)OC(=O)C)OC(=O)C)C.[O-]Cl(=O)(=O)=O,,,,,,
9903,59904,"(11-Acetyloxy-2,3,8,9-tetramethoxy-5,6-dimethylbenzo[c]phenanthridin-5-ium-12-yl) acetate",CC1=[N+](C2=C(C3=CC(=C(C=C13)OC)OC)C(=C(C4=CC(=C(C=C42)OC)OC)OC(=O)C)OC(=O)C)C,,,,,,
9904,59905,"Ammonium, N-benzyl-N'-(o-chlorobenzyl)-N,N'-(oxalylbis(iminoethylene))bis(N,N-diethyl-, dichloride",CC[N+](CC)(CCNC(=O)C(=O)NCC[N+](CC)(CC)CC1=CC=CC=C1Cl)CC2=CC=CC=C2.[Cl-].[Cl-],,,,,,
9905,59906,Benzyl-[2-[[2-[2-[(2-chlorophenyl)methyl-diethylazaniumyl]ethylamino]-2-oxoacetyl]amino]ethyl]-diethylazanium,CC[N+](CC)(CCNC(=O)C(=O)NCC[N+](CC)(CC)CC1=CC=CC=C1Cl)CC2=CC=CC=C2,,,,,,
9906,59907,"Ketone, 10-(3-(4-(2-hydroxyethyl)piperidino)propyl)phenoxazin-2-YL methyl",CC(=O)C1=CC2=C(C=C1)OC3=CC=CC=C3N2CCCN4CCC(CC4)CCO,,,,,,
9907,59908,"Glycine, N-(2-(bis(carboxymethyl)amino)ethyl)-N-(hydroxymethyl)-",C(CN(CC(=O)O)CO)N(CC(=O)O)CC(=O)O,,,,,,
9908,59909,"2-Nitronaphtho(1,8-bc)pyran",C1=CC2=C3C(=C1)C=C(OC3=CC=C2)[N+](=O)[O-],,,,,,
9909,59910,"6-Methoxy-2-nitronaphtho(1,8-bc)pyran",COC1=C2C=CC=C3C2=C(C=C1)C=C(O3)[N+](=O)[O-],,,,,,
9910,59911,4-(4-Chlorophenylsulfonylcarbamoyl)benzoyl-valyl-prolyl-1-(1-trifluoroacetyl-2-methylprolyl)amide,CC(C)[C@@H](C(=O)NC(=O)[C@@H]1CCCN1C(C(C)C)C(=O)C(F)(F)F)NC(=O)C2=CC=C(C=C2)C(=O)NS(=O)(=O)C3=CC=C(C=C3)Cl,,,,,,
9911,59912,CID 59912,CCOC1=C(C=C2C(=C1)C=C(S2)C(=O)[O-])OCC.[Na+],,,,,,
9912,59913,Tibenelast,CCOC1=C(C=C2C(=C1)C=C(S2)C(=O)O)OCC,,,,,,
9913,59914,"Acetic acid, (2,4,5-trichlorophenoxy)-, 1,4-piperazinediyldi-2,1-ethanediyl ester, dihydrochloride",C1CN(CCN1CCOC(=O)COC2=CC(=C(C=C2Cl)Cl)Cl)CCOC(=O)COC3=CC(=C(C=C3Cl)Cl)Cl.Cl.Cl,,,,,,
9914,59915,"2-[4-[2-[2-(2,4,5-Trichlorophenoxy)acetyl]oxyethyl]piperazin-1-yl]ethyl 2-(2,4,5-trichlorophenoxy)acetate",C1CN(CCN1CCOC(=O)COC2=CC(=C(C=C2Cl)Cl)Cl)CCOC(=O)COC3=CC(=C(C=C3Cl)Cl)Cl,,,,,,
9915,59916,Piroxantrone,C1=CC(=NCCCN)C2=C(C3=C(C=CC(=O)C3=C4C2=C1N(N4)CCNCCO)O)O,,,['Substances that inhibit or prevent the proliferation of NEOPLASMS. (See all compounds classified as Antineoplastic Agents.)'],,,
9916,59917,"AMMONIUM, (OXALYLBIS(IMINOETHYLENE))BIS((o-CHLOROBENZYL)DIPROPYL-, DICHLORIDE",CCC[N+](CCC)(CCNC(=O)C(=O)NCC[N+](CCC)(CCC)CC1=CC=CC=C1Cl)CC2=CC=CC=C2Cl.[Cl-].[Cl-],,,,,,
9917,59918,(2-Chlorophenyl)methyl-[2-[[2-[2-[(2-chlorophenyl)methyl-dipropylazaniumyl]ethylamino]-2-oxoacetyl]amino]ethyl]-dipropylazanium,CCC[N+](CCC)(CCNC(=O)C(=O)NCC[N+](CCC)(CCC)CC1=CC=CC=C1Cl)CC2=CC=CC=C2Cl,,,,,,
9918,59919,"Cyclopropanecarboxamide, N,N-diethyl-2-((glycylamino)methyl)-1-phenyl-, (Z)-",CCN(CC)C(=O)[C@@]1(C[C@@H]1CNC(=O)CN)C2=CC=CC=C2,,,,,,
9919,59920,(Z)-Isopropyl 1-phenyl-2-(aminomethyl)cyclopropanecarboxylate hydrochloride,CC(C)OC(=O)[C@@]1(C[C@@H]1C[NH3+])C2=CC=CC=C2.[Cl-],,,,,,
9920,59921,CID 59921,CC(C)OC(=O)[C@@]1(CC1CN)C2=CC=CC=C2,,,,,,
9921,59922,"Cyclopropanecarboxylic acid, 2-(aminomethyl)-1-(p-chlorophenyl)-, 1-methylethyl ester, (Z)-, monohydrochloride",CC(C)OC(=O)[C@@]1(C[C@@H]1C[NH3+])C2=CC=C(C=C2)Cl.[Cl-],,,,,,
9922,59923,CID 59923,CC(C)OC(=O)[C@@]1(CC1CN)C2=CC=C(C=C2)Cl,,,,,,
9923,59924,"Cyclopropanecarboxylic acid, 2-(aminomethyl)-1-(4-methylphenyl)-, 1-methylethyl ester, (Z)-, monohydrochloride",CC1=CC=C(C=C1)[C@]2(C[C@@H]2C[NH3+])C(=O)OC(C)C.[Cl-],,,,,,
9924,59925,"propan-2-yl (1R,2S)-2-(aminomethyl)-1-(4-methylphenyl)cyclopropane-1-carboxylate",CC1=CC=C(C=C1)[C@]2(C[C@@H]2CN)C(=O)OC(C)C,,,,,,
9925,59926,(E)-2-(Aminomethyl)-1-phenylcyclopropanecarboxylic acid ethyl ester hydrochloride,CCOC(=O)[C@@]1(C[C@H]1C[NH3+])C2=CC=CC=C2.[Cl-],,,,,,
9926,59927,"ethyl (1R,2R)-2-(aminomethyl)-1-phenylcyclopropane-1-carboxylate",CCOC(=O)[C@@]1(C[C@H]1CN)C2=CC=CC=C2,,,,,,
9927,59928,(Z)-2-(Aminomethyl)-N-ethyl-1-phenylcyclopropanecarboxamide oxalate,CCNC(=O)[C@@]1(C[C@@H]1C[NH3+])C2=CC=CC=C2.C(=O)(C(=O)[O-])O,,,,,,
9928,59929,N-Desethyl Milnacipran,CCNC(=O)[C@@]1(C[C@@H]1CN)C2=CC=CC=C2,,,,,,
9929,59930,"Cyclopropanecarboxamide, 2-(aminomethyl)-1-(o-chlorophenyl)-N,N-diethyl-, (Z)-, hydrochloride",CCN(CC)C(=O)[C@@]1(C[C@@H]1C[NH3+])C2=CC=CC=C2Cl.[Cl-],,,,,,
9930,59931,"(1R)-2-(aminomethyl)-1-(2-chlorophenyl)-N,N-diethylcyclopropane-1-carboxamide",CCN(CC)C(=O)[C@@]1(CC1CN)C2=CC=CC=C2Cl,,,,,,
9931,59932,"(Z)-2-(Aminomethyl)-1-(m-chlorophenyl)-N,N-diethylcyclopropanecarboxamide hydrochloride",CCN(CC)C(=O)[C@@]1(C[C@@H]1C[NH3+])C2=CC(=CC=C2)Cl.[Cl-],,,,,,
9932,59933,"(1R)-2-(aminomethyl)-1-(3-chlorophenyl)-N,N-diethylcyclopropane-1-carboxamide",CCN(CC)C(=O)[C@@]1(CC1CN)C2=CC(=CC=C2)Cl,,,,,,
9933,59934,"(Z)-2-(Aminomethyl)-1-(p-chlorophenyl)-N,N-diethylcyclopropanecarboxamide hydrochloride",CCN(CC)C(=O)[C@@]1(C[C@@H]1C[NH3+])C2=CC=C(C=C2)Cl.[Cl-],,,,,,
9934,59935,"(1R)-2-(aminomethyl)-1-(4-chlorophenyl)-N,N-diethylcyclopropane-1-carboxamide",CCN(CC)C(=O)[C@@]1(CC1CN)C2=CC=C(C=C2)Cl,,,,,,
9935,59936,"(Z)-2-(Aminomethyl)-N,N-diethyl-1-(p-methylphenyl)cyclopropanecarboxamide hydrochloride",CCN(CC)C(=O)[C@@]1(C[C@@H]1C[NH3+])C2=CC=C(C=C2)C.[Cl-],,,,,,
9936,59937,"(1R,2S)-2-(aminomethyl)-N,N-diethyl-1-(4-methylphenyl)cyclopropane-1-carboxamide",CCN(CC)C(=O)[C@@]1(C[C@@H]1CN)C2=CC=C(C=C2)C,,,,,,
9937,59938,"(Z)-2-(Aminomethyl)-N,N-dipropyl-1-phenylcyclopropanecarboxamide oxalate",CCCN(CCC)C(=O)[C@@]1(C[C@@H]1C[NH3+])C2=CC=CC=C2.C(=O)(C(=O)[O-])O,,,,,,
9938,59939,CID 59939,CCCN(CCC)C(=O)[C@@]1(CC1CN)C2=CC=CC=C2,,,,,,
9939,59940,"(Z)-2-(Aminomethyl)-N,N-(1-methylethyl)-1-phenylcyclopropanecarboxamide hydrochloride",CC(C)N(C(C)C)C(=O)[C@@]1(C[C@@H]1C[NH3+])C2=CC=CC=C2.[Cl-],,,,,,
9940,59941,"(1R,2S)-2-(aminomethyl)-1-phenyl-N,N-di(propan-2-yl)cyclopropane-1-carboxamide",CC(C)N(C(C)C)C(=O)[C@@]1(C[C@@H]1CN)C2=CC=CC=C2,,,,,,
9941,59942,"(Z)-2-(Aminomethyl)-N,N-dibutyl-1-phenylcyclopropanecarboxamide oxalate",CCCCN(CCCC)C(=O)[C@@]1(C[C@@H]1C[NH3+])C2=CC=CC=C2.C(=O)(C(=O)[O-])O,,,,,,
9942,59943,CID 59943,CCCCN(CCCC)C(=O)[C@@]1(CC1CN)C2=CC=CC=C2,,,,,,
9943,59944,"Cyclopropanecarboxamide, N,N-diethyl-2-((methylamino)methyl)-1-phenyl-, (Z)-, oxalate",CCN(CC)C(=O)[C@@]1(C[C@@H]1C[NH2+]C)C2=CC=CC=C2.C(=O)(C(=O)[O-])O,,,,,,
9944,59945,"(1R,2S)-N,N-diethyl-2-(methylaminomethyl)-1-phenylcyclopropane-1-carboxamide",CCN(CC)C(=O)[C@@]1(C[C@@H]1CNC)C2=CC=CC=C2,,,,,,
9945,59946,"[(1R,2R)-2-(diethylcarbamoyl)-2-phenylcyclopropyl]methylazanium;chloride",CCN(CC)C(=O)[C@@]1(C[C@H]1C[NH3+])C2=CC=CC=C2.[Cl-],,,,,,
9946,59947,"(Z)-2-(Aminomethyl)-N,N-dimethyl-1-phenylcyclopropanecarboxamide hydrochloride",CN(C)C(=O)[C@@]1(C[C@@H]1C[NH3+])C2=CC=CC=C2.[Cl-],,,,,,
9947,59948,"(1R)-2-(aminomethyl)-N,N-dimethyl-1-phenylcyclopropane-1-carboxamide",CN(C)C(=O)[C@@]1(CC1CN)C2=CC=CC=C2,,,,,,
9948,59949,"(Z)-2-(Aminomethyl)-N,N-diethyl-1-(p-fluorophenyl)cyclopropanecarboxamide hydrochloride",CCN(CC)C(=O)[C@@]1(C[C@@H]1C[NH3+])C2=CC=C(C=C2)F.[Cl-],,,,,,
9949,59950,"(1R)-2-(aminomethyl)-N,N-diethyl-1-(4-fluorophenyl)cyclopropane-1-carboxamide",CCN(CC)C(=O)[C@@]1(CC1CN)C2=CC=C(C=C2)F,,,,,,
9950,59951,CID 59951,CC1=NC(=CC=C1)CC2(C(=O)NC(=NC2=O)S)C,,,,,,
9951,59952,1-Aza-2-hydroxypyrene,C1=CC2=C3C(=C1)C=CC4=C3C(=CC(=O)N4)C=C2,,,,,,
9952,59953,Diethyl-[2-[(2-pentoxyphenyl)carbamoyloxy]-3-pyrrolidin-1-ium-1-yl-propyl]ammonium; 2-hydroxy-2-oxo-acetate,CCCCCOC1=CC=CC=C1NC(=O)OC(C[NH+]2CCCC2)C[NH+](CC)CC.C(=O)(C(=O)[O-])O.C(=O)(C(=O)[O-])O,,,,,,
9953,59954,[1-(diethylamino)-3-pyrrolidin-1-ylpropan-2-yl] N-(2-pentoxyphenyl)carbamate,CCCCCOC1=CC=CC=C1NC(=O)OC(CN2CCCC2)CN(CC)CC,,,,,,
9954,59955,1-[3-(Diethylammonio)-2-({[3-(hexyloxy)phenyl]carbamoyl}oxy)propyl]pyrrolidinium dichloride,CCCCCCOC1=CC=CC(=C1)NC(=O)OC(C[NH+]2CCCC2)C[NH+](CC)CC.[Cl-].[Cl-],,,,,,
9955,59956,[1-(diethylamino)-3-pyrrolidin-1-ylpropan-2-yl] N-(3-hexoxyphenyl)carbamate,CCCCCCOC1=CC=CC(=C1)NC(=O)OC(CN2CCCC2)CN(CC)CC,,,,,,
9956,59957,"Carbamic acid, (2-butoxyphenyl)-, 1-ethyl-4-piperidinyl ester, monohydrochloride",CCCCOC1=CC=CC=C1NC(=O)OC2CC[NH+](CC2)CC.[Cl-],,,,,,
9957,59958,(1-ethylpiperidin-4-yl) N-(2-butoxyphenyl)carbamate,CCCCOC1=CC=CC=C1NC(=O)OC2CCN(CC2)CC,,,,,,
9958,59959,"Carbamic acid, (2-(pentyloxy)phenyl)-, 1-ethyl-4-piperidinyl ester, monohydrochloride",CCCCCOC1=CC=CC=C1NC(=O)OC2CC[NH+](CC2)CC.[Cl-],,,,,,
9959,59960,(1-ethylpiperidin-4-yl) N-(2-pentoxyphenyl)carbamate,CCCCCOC1=CC=CC=C1NC(=O)OC2CCN(CC2)CC,,,,,,
9960,59961,"Carbamic acid, (2-(hexyloxy)phenyl)-, 1-ethyl-4-piperidinyl ester, monohydrochloride",CCCCCCOC1=CC=CC=C1NC(=O)OC2CC[NH+](CC2)CC.[Cl-],,,,,,
9961,59962,(1-ethylpiperidin-4-yl) N-(2-hexoxyphenyl)carbamate,CCCCCCOC1=CC=CC=C1NC(=O)OC2CCN(CC2)CC,,,,,,
9962,59963,"Carbamic acid, (2-(heptyloxy)phenyl)-, 1-ethyl-4-piperidinyl ester, monohydrochloride",CCCCCCCOC1=CC=CC=C1NC(=O)OC2CC[NH+](CC2)CC.[Cl-],,,,,,
9963,59964,(1-ethylpiperidin-4-yl) N-(2-heptoxyphenyl)carbamate,CCCCCCCOC1=CC=CC=C1NC(=O)OC2CCN(CC2)CC,,,,,,
9964,59965,"Carbamic acid, (3-butoxyphenyl)-, 1-ethyl-4-piperidinyl ester, monohydrochloride",CCCCOC1=CC=CC(=C1)NC(=O)OC2CC[NH+](CC2)CC.[Cl-],,,,,,
9965,59966,(1-ethylpiperidin-4-yl) N-(3-butoxyphenyl)carbamate,CCCCOC1=CC=CC(=C1)NC(=O)OC2CCN(CC2)CC,,,,,,
9966,59967,"Carbamic acid, (3-(heptyloxy)phenyl)-, 1-ethyl-4-piperidinyl ester, monohydrochloride",CCCCCCCOC1=CC=CC(=C1)NC(=O)OC2CC[NH+](CC2)CC.[Cl-],,,,,,
9967,59968,(1-ethylpiperidin-4-yl) N-(3-heptoxyphenyl)carbamate,CCCCCCCOC1=CC=CC(=C1)NC(=O)OC2CCN(CC2)CC,,,,,,
9968,59969,"4-Piperidinol, 1-ethyl-, phenylcarbamate, monohydrochloride",CC[NH+]1CCC(CC1)OC(=O)NC2=CC=CC=C2.[Cl-],,,,,,
9969,59970,(1-ethylpiperidin-4-yl) N-phenylcarbamate,CCN1CCC(CC1)OC(=O)NC2=CC=CC=C2,,,,,,
9970,59971,"Carbamic acid, (2-butoxyphenyl)-, 1-propyl-4-piperidinyl ester, monohydrochloride",CCCCOC1=CC=CC=C1NC(=O)OC2CC[NH+](CC2)CCC.[Cl-],,,,,,
9971,59972,(1-propylpiperidin-4-yl) N-(2-butoxyphenyl)carbamate,CCCCOC1=CC=CC=C1NC(=O)OC2CCN(CC2)CCC,,,,,,
9972,59973,"Carbamic acid, (2-(pentyloxy)phenyl)-, 1-propyl-4-piperidinyl ester, monohydrochloride",CCCCCOC1=CC=CC=C1NC(=O)OC2CC[NH+](CC2)CCC.[Cl-],,,,,,
9973,59974,(1-propylpiperidin-4-yl) N-(2-pentoxyphenyl)carbamate,CCCCCOC1=CC=CC=C1NC(=O)OC2CCN(CC2)CCC,,,,,,
9974,59975,"Carbamic acid, (2-(hexyloxy)phenyl)-, 1-propyl-4-piperidinyl ester, monohydrochloride",CCCCCCOC1=CC=CC=C1NC(=O)OC2CC[NH+](CC2)CCC.[Cl-],,,,,,
9975,59976,[2-(Hexyloxy)phenyl]carbamic acid 1-propyl-4-piperidyl ester,CCCCCCOC1=CC=CC=C1NC(=O)OC2CCN(CC2)CCC,,,,,,
9976,59977,"Carbamic acid, (2-(heptyloxy)phenyl)-, 1-propyl-4-piperidinyl ester, monohydrochloride",CCCCCCCOC1=CC=CC=C1NC(=O)OC2CC[NH+](CC2)CCC.[Cl-],,,,,,
9977,59978,(1-propylpiperidin-4-yl) N-(2-heptoxyphenyl)carbamate,CCCCCCCOC1=CC=CC=C1NC(=O)OC2CCN(CC2)CCC,,,,,,
9978,59979,"Carbamic acid, (3-(pentyloxy)phenyl)-, 1-propyl-4-piperidinyl ester, monohydrochloride",CCCCCOC1=CC=CC(=C1)NC(=O)OC2CC[NH+](CC2)CCC.[Cl-],,,,,,
9979,59980,(1-propylpiperidin-4-yl) N-(3-pentoxyphenyl)carbamate,CCCCCOC1=CC=CC(=C1)NC(=O)OC2CCN(CC2)CCC,,,,,,
9980,59981,"Carbamic acid, (3-(heptyloxy)phenyl)-, 1-propyl-4-piperidinyl ester, monohydrochloride",CCCCCCCOC1=CC=CC(=C1)NC(=O)OC2CC[NH+](CC2)CCC.[Cl-],,,,,,
9981,59982,(1-propylpiperidin-4-yl) N-(3-heptoxyphenyl)carbamate,CCCCCCCOC1=CC=CC(=C1)NC(=O)OC2CCN(CC2)CCC,,,,,,
9982,59983,"Carbamic acid, (2-butoxyphenyl)-, 1-butyl-4-piperidinyl ester, monohydrochloride",CCCC[NH+]1CCC(CC1)OC(=O)NC2=CC=CC=C2OCCCC.[Cl-],,,,,,
9983,59984,(1-butylpiperidin-4-yl) N-(2-butoxyphenyl)carbamate,CCCCN1CCC(CC1)OC(=O)NC2=CC=CC=C2OCCCC,,,,,,
9984,59985,"Carbamic acid, (2-(pentyloxy)phenyl)-, 1-butyl-4-piperidinyl ester, monohydrochloride",CCCCCOC1=CC=CC=C1NC(=O)OC2CC[NH+](CC2)CCCC.[Cl-],,,,,,
9985,59986,(1-butylpiperidin-4-yl) N-(2-pentoxyphenyl)carbamate,CCCCCOC1=CC=CC=C1NC(=O)OC2CCN(CC2)CCCC,,,,,,
9986,59987,"Carbamic acid, (2-(hexyloxy)phenyl)-, 1-butyl-4-piperidinyl ester, monohydrochloride",CCCCCCOC1=CC=CC=C1NC(=O)OC2CC[NH+](CC2)CCCC.[Cl-],,,,,,
9987,59988,(1-butylpiperidin-4-yl) N-(2-hexoxyphenyl)carbamate,CCCCCCOC1=CC=CC=C1NC(=O)OC2CCN(CC2)CCCC,,,,,,
9988,59989,"Carbamic acid, (2-(heptyloxy)phenyl)-, 1-butyl-4-piperidinyl ester, monohydrochloride",CCCCCCCOC1=CC=CC=C1NC(=O)OC2CC[NH+](CC2)CCCC.[Cl-],,,,,,
9989,59990,(1-butylpiperidin-4-yl) N-(2-heptoxyphenyl)carbamate,CCCCCCCOC1=CC=CC=C1NC(=O)OC2CCN(CC2)CCCC,,,,,,
9990,59991,"Carbamic acid, (3-butoxyphenyl)-, 1-butyl-4-piperidinyl ester, monohydrochloride",CCCC[NH+]1CCC(CC1)OC(=O)NC2=CC(=CC=C2)OCCCC.[Cl-],,,,,,
9991,59992,(1-butylpiperidin-4-yl) N-(3-butoxyphenyl)carbamate,CCCCN1CCC(CC1)OC(=O)NC2=CC(=CC=C2)OCCCC,,,,,,
9992,59993,m-(Hexyloxy)carbanilic acid 1-butyl-4-piperidyl ester hydrochloride,CCCCCCOC1=CC=CC(=C1)NC(=O)OC2CC[NH+](CC2)CCCC.[Cl-],,,,,,
9993,59994,(1-butylpiperidin-4-yl) N-(3-hexoxyphenyl)carbamate,CCCCCCOC1=CC=CC(=C1)NC(=O)OC2CCN(CC2)CCCC,,,,,,
9994,59995,1-[2-{[(2-Butoxyphenyl)carbamoyl]oxy}-3-(diethylammonio)propyl]pyrrolidinium dichloride,CCCCOC1=CC=CC=C1NC(=O)OC(C[NH+]2CCCC2)C[NH+](CC)CC.[Cl-].[Cl-],,,,,,
9995,59996,[1-(diethylamino)-3-pyrrolidin-1-ylpropan-2-yl] N-(2-butoxyphenyl)carbamate,CCCCOC1=CC=CC=C1NC(=O)OC(CN2CCCC2)CN(CC)CC,,,,,,
9996,59997,Diethyl-[2-[(2-hexoxyphenyl)carbamoyloxy]-3-pyrrolidin-1-ium-1-ylpropyl]azanium;2-hydroxy-2-oxoacetate,CCCCCCOC1=CC=CC=C1NC(=O)OC(C[NH+]2CCCC2)C[NH+](CC)CC.C(=O)(C(=O)[O-])O.C(=O)(C(=O)[O-])O,,,,,,
9997,59998,[1-(diethylamino)-3-pyrrolidin-1-ylpropan-2-yl] N-(2-hexoxyphenyl)carbamate,CCCCCCOC1=CC=CC=C1NC(=O)OC(CN2CCCC2)CN(CC)CC,,,,,,
9998,59999,Diethyl-[2-[(2-heptoxyphenyl)carbamoyloxy]-3-pyrrolidin-1-ium-1-ylpropyl]azanium;2-hydroxy-2-oxoacetate,CCCCCCCOC1=CC=CC=C1NC(=O)OC(C[NH+]2CCCC2)C[NH+](CC)CC.C(=O)(C(=O)[O-])O.C(=O)(C(=O)[O-])O,,,,,,
9999,60000,[1-(diethylamino)-3-pyrrolidin-1-ylpropan-2-yl] N-(2-heptoxyphenyl)carbamate,CCCCCCCOC1=CC=CC=C1NC(=O)OC(CN2CCCC2)CN(CC)CC,,,,,,
